<SEC-DOCUMENT>0001213900-21-014576.txt : 20210310
<SEC-HEADER>0001213900-21-014576.hdr.sgml : 20210310
<ACCEPTANCE-DATETIME>20210310160705
ACCESSION NUMBER:		0001213900-21-014576
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		76
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210310
DATE AS OF CHANGE:		20210310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lantern Pharma Inc.
		CENTRAL INDEX KEY:			0001763950
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				463973463
		STATE OF INCORPORATION:			TX
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39318
		FILM NUMBER:		21729737

	BUSINESS ADDRESS:	
		STREET 1:		1920 MCKINNEY AVENUE
		STREET 2:		7TH FLOOR
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75201
		BUSINESS PHONE:		972-277-1136

	MAIL ADDRESS:	
		STREET 1:		1920 MCKINNEY AVENUE
		STREET 2:		7TH FLOOR
		CITY:			DALLAS
		STATE:			TX
		ZIP:			75201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Lantern Pharma
		DATE OF NAME CHANGE:	20190108
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>f10k2020_lanternpharma.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>FORM
10-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Mark
One)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>For
the fiscal year ended December 31, 2020</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">OR</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><U>Lantern
Pharma Inc.</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>001-39318</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>46-3973463</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or Other Jurisdiction<BR>
    of Incorporation)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission<BR>
    File Number)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer<BR>
    Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1920
    McKinney Avenue, 7th Floor<BR>
    Dallas, Texas</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>75201</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of Principal
    Executive Offices)</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(972)
277-1136</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">(<B>Registrant&rsquo;s
telephone number, including area code</B>)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Securities
registered pursuant to Section 12(b) of the Act: Common Stock</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title
    of each class</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading
    Symbol</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name
    of each exchange on which registered</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common Stock, $0.0001
    par value</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LTRN</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Nasdaq Stock
    Market</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes &#9744; No
&#9745;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes &#9744;
No &#9745;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes &#9745;&nbsp;No &#9744;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant
to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit such files). Yes &#9745;&nbsp;No</FONT>&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo;
&ldquo;smaller reporting company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 23%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large accelerated filer</FONT></TD>
    <TD STYLE="width: 27%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="width: 23%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated filer</FONT></TD>
    <TD STYLE="width: 27%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated filer</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9745;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller reporting company</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9745;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging growth company</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9745;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has filed a report on and attestation to its management&rsquo;s assessment of the effectiveness
of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. &#9744;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No
&#9745;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">State
the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price
at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day
of the registrant&rsquo;s most recently completed second fiscal quarter: $34,733,370.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of March 8, 2021, the registrant had 11,169,665 shares of common stock, $0.0001 par value per share outstanding.</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">DOCUMENTS
INCORPORATED BY REFERENCE</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 7pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">Portions
of the registrant&rsquo;s definitive proxy statement for the registrant&rsquo;s 2021 Annual Meeting of Stockholders to be filed
pursuant to Regulation 14A within 120 days of the registrant&rsquo;s year ended December 31, 2020 are incorporated herein by reference
into Part III of this Annual Report on Form 10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 7pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Table
of Contents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; width: 8%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 84%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 8%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><A HREF="#aa_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Forward Looking Statements</FONT></A></TD>
    <TD STYLE="text-align: center">ii</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#aa_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>PART 1</U>.</FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#aa_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.</FONT></A></TD>
    <TD><A HREF="#aa_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Business</FONT></A></TD>
    <TD STYLE="text-align: center">1</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#aa_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1A.</FONT></A></TD>
    <TD><A HREF="#aa_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Risk Factors</FONT></A></TD>
    <TD STYLE="text-align: center">65</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#aa_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1B.</FONT></A></TD>
    <TD><A HREF="#aa_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unresolved Staff Comments.</FONT></A></TD>
    <TD STYLE="text-align: center">112</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#aa_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</FONT></A></TD>
    <TD><A HREF="#aa_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Properties.</FONT></A></TD>
    <TD STYLE="text-align: center">112</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#aa_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</FONT></A></TD>
    <TD><A HREF="#aa_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings.</FONT></A></TD>
    <TD STYLE="text-align: center">112</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#aa_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</FONT></A></TD>
    <TD><A HREF="#aa_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosures.</FONT></A></TD>
    <TD STYLE="text-align: center">112</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#aa_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>PART II</U></FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#aa_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 5.</FONT></A></TD>
    <TD><A HREF="#aa_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Market for Registrant&rsquo;s Common Equity,
    Related Stockholder Matters and Issuer Purchases of Equity Securities.</FONT></A></TD>
    <TD STYLE="text-align: center">113</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#aa_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 6.</FONT></A></TD>
    <TD><A HREF="#aa_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Selected Financial Data.</FONT></A></TD>
    <TD STYLE="text-align: center">114</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#aa_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7.</FONT></A></TD>
    <TD><A HREF="#aa_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Management&rsquo;s Discussion and Analysis of
    Financial Condition and Results of Operations.</FONT></A></TD>
    <TD STYLE="text-align: center">115</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#aa_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 7A.</FONT></A></TD>
    <TD><A HREF="#aa_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quantitative and Qualitative Disclosures About
    Market Risk.</FONT></A></TD>
    <TD STYLE="text-align: center">125</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#aa_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 8.</FONT></A></TD>
    <TD><A HREF="#aa_014"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial Statements and Supplementary Data.</FONT></A></TD>
    <TD STYLE="text-align: center">F-1</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#aa_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9.</FONT></A></TD>
    <TD><A HREF="#aa_015"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Changes in and Disagreements with Accountants
    on Accounting and Financial Disclosure.</FONT></A></TD>
    <TD STYLE="text-align: center">126</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#aa_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9A.</FONT></A></TD>
    <TD><A HREF="#aa_016"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Controls and Procedures.</FONT></A></TD>
    <TD STYLE="text-align: center">126</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#aa_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 9B.</FONT></A></TD>
    <TD><A HREF="#aa_017"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other Information.</FONT></A></TD>
    <TD STYLE="text-align: center">126</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#aa_018"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>PART III</U></FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#aa_019"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 10.</FONT></A></TD>
    <TD><A HREF="#aa_019"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Directors, Executive Officers and Corporate
    Governance.</FONT></A></TD>
    <TD STYLE="text-align: center">127</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#aa_020"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 11.</FONT></A></TD>
    <TD><A HREF="#aa_020"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Executive Compensation.</FONT></A></TD>
    <TD STYLE="text-align: center">127</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#aa_021"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 12.</FONT></A></TD>
    <TD><A HREF="#aa_021"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security Ownership of Certain Beneficial Owners
    and Management and Related Stockholder Matters.</FONT></A></TD>
    <TD STYLE="text-align: center">127</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#aa_022"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 13.</FONT></A></TD>
    <TD><A HREF="#aa_022"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain Relationships and Related Transactions,
    and Director Independence.</FONT></A></TD>
    <TD STYLE="text-align: center">127</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#aa_023"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 14.</FONT></A></TD>
    <TD><A HREF="#aa_023"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principal Accountant Fees and Services.</FONT></A></TD>
    <TD STYLE="text-align: center">127</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#aa_024"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>PART IV</U></FONT></A></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#aa_025"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 15.</FONT></A></TD>
    <TD><A HREF="#aa_025"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exhibit and Financial Statement Schedules.</FONT></A></TD>
    <TD STYLE="text-align: center">128</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#aa_026"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 16.</FONT></A></TD>
    <TD><A HREF="#aa_026"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form 10&ndash;K Summary.</FONT></A></TD>
    <TD STYLE="text-align: center">129</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="aa_001"></A>SPECIAL
NOTE CONCERNING FORWARD-LOOKING STATEMENTS AND RISK FACTORS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
Annual Report on Form 10-K contains forward-looking statements that involve substantial risks and uncertainties. We make such
forward-looking statements pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act, Section
21E of the Securities Exchange Act of 1934, as amended, and other federal securities laws. All statements, other than statements
of historical fact, contained in this Annual Report on Form 10-K, including statements regarding our strategy, future preclinical
studies and clinical trials, future financial position, projected costs, prospects, plans and objectives of management, are forward-looking
statements. The words &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;contemplate,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;seek,&rdquo; &ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;plan,&rdquo; &ldquo;potential,&rdquo;
&ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;target,&rdquo; &ldquo;aim,&rdquo; &ldquo;should,&rdquo; &lsquo;will&rdquo;
&ldquo;would,&rdquo; or the negative of these words or other similar expressions are intended to identify forward-looking&nbsp;statements,
although not all forward-looking&nbsp;statements contain these words. Forward-looking statements reflect our current views with
respect to future events and are based on assumptions and subject to risks and uncertainties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
forward-looking statements in this Annual Report on Form 10-K include, among other things, statements relating to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential advantages
    of our RADR<SUP>&reg;</SUP> platform in identifying drug candidates and patient populations that are likely to respond to
    a drug candidate;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our strategic plans
    to advance the development of any of our drug candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our strategic plans
    to expand the number of data points that our RADR<SUP>&reg;</SUP>&nbsp;platform can access and analyze;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our research and
    development efforts of our internal drug discovery programs and the utilization of our RADR<SUP>&reg;</SUP>&nbsp;platform
    to streamline the drug development process;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the initiation,
    timing, progress, and results of our preclinical studies or clinical trials on any of our drug candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our intention to
    leverage artificial intelligence, machine learning and genomic data to streamline the drug development process and to identify
    patient populations that would likely respond to a drug candidate;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our plans to discover
    and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration
    with others;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectations
    regarding our ability to fund our operating expenses and capital expenditure requirements with our existing cash and cash
    equivalents;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to secure
    sufficient funding and alternative source of funding to support our existing and proposed preclinical studies and clinical
    trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our estimates regarding
    the potential market opportunity for our drug candidates we or any of our collaborators may in the future develop;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our anticipated
    growth strategies and our ability to manage the expansion of our business operations effectively;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectations
    related to future expenses and expenditures;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to keep
    up with rapidly changing technologies and evolving industry standards, including our ability to achieve technological advances;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the potential impact
    that COVID-19 may have on our business plans;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to source
    our needs for skilled labor in the fields of artificial intelligence, genomics, biology, oncology and drug development; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the impact of government
    laws and regulations on the development and commercialization of our drug candidates.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not actually
achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance
on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations
disclosed in the forward-looking&nbsp;statements we make. Factors that may cause actual results or events to differ materially
from current plans, intentions, and expectations include, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">We have a limited operating history and have never generated
any revenues other than from a prior research grant, which may make it difficult to evaluate the success of our business to date
and to assess our future viability;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">We have incurred significant operating losses since inception
and anticipate that we will continue to incur substantial operating losses for the foreseeable future and may never achieve or
maintain profitability;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">We will need substantial additional funding, and if we
are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our drug development programs or commercialization
efforts;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Our RADR<SUP>&reg; </SUP>platform may fail to help us discover
and develop additional potential drug candidates;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">We have limited experience in drug discovery and drug development
and may not receive regulatory approval to market our drug candidates;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Even if we are successful in completing all preclinical
studies and clinical trials, we may not be successful in commercializing one or more of our drug candidates; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">Those other risk factors listed under Part I, Item 1A. &ldquo;Risk
Factors,&rdquo; Part II, Item 7. &ldquo;Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations&rdquo;
and elsewhere in this Annual Report on Form 10-K.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These factors could
cause actual results or events to differ materially from the forward-statements that we make. Furthermore, we operate in a competitive
and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict
all risks and uncertainties that could have an impact on the forward-looking statements contained in this Annual Report on Form
10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">You
should read this Annual Report on Form 10-K and the documents that we file with the Securities and Exchange Commission, or the
SEC, with the understanding that our actual future results may be materially different from what we expect. These forward-looking
statements are based on management&rsquo;s current expectations. These statements are neither promises nor guarantees, but involve
known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements
to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
Factors that may cause actual results or events to differ materially from current plans, intentions, and expectations include,
among other things, those listed under Part I, Item 1A. &ldquo;Risk Factors,&rdquo; Part II, Item 7. &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations&rdquo; and elsewhere in this Annual Report on Form 10-K.
Given these uncertainties, you should not rely on these forward-looking statements as predictions of future events. The forward-looking
statements contained in this Annual Report on Form 10-K are made as of the date of this Annual Report on Form 10-K, and we do
not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise,
except as required by applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition, statements that &ldquo;we believe&rdquo; and similar statements reflect our beliefs and opinions on the relevant subject.
These statements are based upon information available to us as of the date of this Annual Report on Form 10-K, and while we believe
such information forms a reasonable basis for such statements, such information may be limited or incomplete. Our statements should
not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information.
These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Unless
the context requires otherwise, references to the &ldquo;Company,&rdquo; &ldquo;Lantern,&rdquo; &ldquo;we,&rdquo;
&ldquo;us,&rdquo; and &ldquo;our&rdquo; in this Annual Report on Form 10-K refer to Lantern Pharma Inc., a Delaware
corporation, and, where appropriate, its wholly-owned subsidiary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="aa_002"></A>PART
I</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><A NAME="aa_003"></A>Item
1. Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are a clinical stage biotechnology company, focused on leveraging artificial intelligence (&ldquo;A.I.&rdquo;), machine learning
and genomic data to streamline the drug development process and to identify the patients that will benefit from our targeted oncology
therapies. Our portfolio of therapies consists of small molecules that others have tried, but failed, to develop into an approved
commercialized drug, as well as new compounds that we are developing with the assistance of our proprietary A.I. platform and
our biomarker driven approach. Our A.I. platform, known as RADR<SUP>&reg;</SUP>, currently includes more than 1.2 billion data
points, and uses big data analytics (combining molecular data, drug efficacy data, data from historical studies, data from scientific
literature, phenotypic data from trials and publications, and mechanistic pathway data) and machine learning to rapidly uncover
biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may
benefit most from our compounds. This data-driven, genomically-targeted and biomarker-driven approach allows us to pursue a transformational
drug development strategy that identifies, rescues or develops, and advances potential small molecule drug candidates at what
we believe is a fraction of the time and cost associated with traditional cancer drug development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
strategy is to both develop new drug candidates using our RADR<SUP>&reg;</SUP> platform and other machine learning driven methodologies,
and to pursue the development of drug candidates that have undergone previous clinical trial testing or that may have been halted
in development or deprioritized because of insufficient clinical trial efficacy (i.e., a meaningful treatment benefit relevant
for the disease or condition under study as measured against the comparator treatment used in the relevant clinical testing) or
for strategic reasons by the owner or development team responsible for the compound. Importantly, these historical drug candidates
appear to have been well-tolerated in many instances, and often have considerable data from previous toxicity, tolerability and
ADME (absorption, distribution, metabolism, and excretion) studies that have been completed. Additionally, these drug candidates
may also have a body of existing data supporting the potential mechanism(s) by which they achieve their intended biologic effect,
but often require more targeted trials in a stratified group of patients to demonstrate statistically meaningful results. Our
dual approach to both develop de-novo, biomarker-guided drug candidates and &ldquo;rescue&rdquo; historical drug candidates by
leveraging A.I., recent advances in genomics, computational biology and cloud computing is emblematic of a new era in drug development
that is being driven by data-intensive approaches meant to de-risk development and accelerate the clinical trial process. In this
context, we intend to create a diverse portfolio of oncology drug candidates for further development towards regulatory and marketing
approval with the objective of establishing a leading A.I.-driven, methodology for treating the right patient with the right oncology
therapy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
key component of our strategy is to target specific cancer patient populations and treatment indications identified by leveraging
our RADR<SUP>&reg;</SUP> platform, a proprietary A.I. enabled engine created and owned by us. We believe the combination of our
therapeutic area expertise, our A.I. expertise, and our ability to identify and develop promising drug candidates through our
collaborative relationships with research institutions in selected areas of oncology gives us a significant competitive advantage.
Our RADR<SUP>&reg;</SUP> platform was developed and refined over the last four years and integrates millions of data points immediately
relevant for oncology drug development and patient response prediction using artificial intelligence and proprietary machine learning
algorithms. By identifying clinical candidates, together with relevant genomic and phenotypic data, we believe our approach will
help us design more efficient preclinical studies, and more targeted clinical trials, thereby accelerating our drug candidates&rsquo;
time to approval and eventually to market. Although we have not yet applied for or received regulatory or marketing approval for
any of our drug candidates, we believe our RADR<SUP>&reg;</SUP> platform has the ability to reduce the cost and time to bring
drug candidates to specifically targeted patient groups. We believe we have developed a sustainable and scalable biopharma business
model by combining a unique, oncology-focused big-data platform that leverages artificial intelligence along with active clinical
and preclinical programs that are being advanced in targeted cancer therapeutic areas to address today&rsquo;s treatment needs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 5; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Scientific
literature offers a definition for &ldquo;drug rescue&rdquo; as research involving abandoned small molecules and biologics that
have not been approved by the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;). These rescued molecular compounds are often
abandoned by pharmaceutical companies in the drug discovery or preclinical testing phase, typically because they do not prove
effective for the specific use for which they were developed. Some of these compounds may be useful in treating other diseases
for which they have not been tested. <I>See, </I>Hemphill, Thomas A., &ldquo;The NIH Promotes Drug Repurposing and Rescue,&rdquo;
Research Technology Management, v. 5, no. 5, pp. 6-8 (2012). Our use of the term &ldquo;rescue&rdquo;, &ldquo;drug rescue&rdquo;,
or &ldquo;drug rescuing&rdquo; refers to, &ldquo;&hellip;a system of developing new uses for chemical and biological entities
that previously were investigated in clinical studies but not further developed or submitted for regulatory approval, or had to
be removed from the market for safety reasons.&rdquo;, which is a definition we believe is recognized in the drug discovery, drug
development and pharmaceutical and biotechnology industries. <I>See</I>, Naylor, S. and Schonfeld J., &ldquo;Therapeutic Drug
Repurposing, Repositioning and Rescue,&rdquo; DDW (Drug Discovery World) Winter 2014, and Mucke, HAM, A New Journal for the Drug
Repurposing Community. Drug Repurposing, Rescue &amp; Repositioning 1, 3-4 (2014). The use of the term &ldquo;drug rescue,&rdquo;
&ldquo;rescuing,&rdquo; or words of similar meaning in this report should not be construed to mean that our RADR<SUP>&reg;</SUP>
platform has resolved all issues of safety and/or efficacy for any of our drug candidates. Issues of safety and efficacy for any
drug candidate may only be determined by the U.S. FDA or other applicable regulatory authorities in jurisdictions outside the
United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our current portfolio
consists of four compounds in active development: two drug candidates in clinical phases, one in preclinical studies, and one in
research optimization. All of these drug candidates are leveraging precision oncology, A.I. and genomic driven approaches to accelerate
and direct development efforts. We currently have two drug candidates in clinical development, LP-100 and LP-300, where we are
leveraging data from prior preclinical studies and clinical trials, along with insights generated from our A.I. platform, to target
the types of tumors and patient groups that would be most responsive to the drug. Both LP-100 and LP-300 showed promise in important
patient subgroups, but failed pivotal Phase III trials when the overall results did not meet the predefined clinical endpoints.
We believe that this was due to a lack of biomarker-driven patient stratification. Additionally, we have one new drug candidate,
LP-184, in preclinical development for two potentially distinct indications where we are leveraging machine learning and genomic
data to streamline the drug development process and to identify the patients and cancer subtypes that will best benefit from the
drug, if approved. As part of our antibody drug conjugate (ADC) program commenced in early 2021, we have initiated the optimization
and evaluation of an antibody drug conjugate aimed at leveraging our LP-184 molecule in combination with an antibody for select
solid tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
development strategy is to pursue an increasing number of oncology focused, molecularly targeted therapies where artificial intelligence
and genomic data can help us provide biological insights, reduce the risk associated with development efforts and help clarify
potential patient response. We plan on strategically evaluating these on a program-by-program basis as they advance into clinical
development, either to be done entirely by us or with out-licensing partners to maximize the commercial opportunity and reduce
the time it takes to bring the right drug to the right patient.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have out-licensed
our drug-candidate LP-100 to Allarity Therapeutics A/S (&ldquo;<I>Allarity Therapeutics&rdquo;), </I>a European biotechnology company.
LP-100 is in a Phase II clinical trial in metastatic, castration-resistant, prostate cancer (mCRPC) that is managed by Allarity
Therapeutics. Our second clinical-stage drug candidate in the rescue process is LP-300. LP-300 is a small molecule with cysteine
modifying activity on select proteins, which has an existing investigational new drug application (&ldquo;IND&rdquo;). We are in
the process of initiating discussions with the U.S. FDA to launch a future phase II clinical trial for LP-300 with a stratified
patient population of approximately 40 to 75 patients. Our new drug candidate, LP-184, is in a preclinical translational <I>ex
vivo</I> study using fresh human biopsies. LP-184 is a next generation alkylating agent with nanomolar potency that preferentially
damages DNA in cancer cells that overexpress certain biomarkers. LP-184 is in the fulvene class of compounds and has shown preliminary
preclinical indications of lower toxicity, longer half-life, and increased antitumor activity as compared to other compounds in
this drug class. Subject to regulatory clearance to move forward under a future IND application, we are planning a Phase I clinical
trial for LP-184 across multiple solid tumors that express a certain biomarker profile, and in glioblastoma to begin in late 2021
or early 2022. Our antibody drug conjugate (ADC) program is in early stage development and compound optimization for solid tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">LP-100
(Irofulven) is showing promise in solid tumors, primarily prostate cancer, where it is being advanced in an out-licensing transaction
with Allarity Therapeutics<I>, </I>after being in-licensed and developed by us. LP-100 has been well-tolerated, based on initial
observations from a phase II clinical trial in Europe in mCRPC. Continuing enrollment for this Phase II clinical trial has slowed
during the COVID-19 pandemic. Allarity Therapeutics has also stated that it is focusing its existing resources on other programs
that are currently higher priority for Allarity than LP-100. As of the date of this report, we are unable to forecast the timeline
for the completion of the Phase II clinical trial. Recently published data (also supported by prior publications on Irofulven)
indicates that tumors carrying mutations in ERCC2 and ERCC3 genes are likely to be sensitive to LP-100, and that the drug will
be synthetically lethal in these tumors, in a fashion similar to the activity of PARP inhibitors in BRCA deficient tumors. These
observations expand the potential treatment indications for LP-100 to include urothelial tumors, including bladder cancers, since
as many as 10% of bladder cancers carry ERCC2/ERCC3 mutations. These indications may represent a more rapid and efficient path
to potential approval of LP-100, and we are evaluating possibilities aimed at maximizing the value of these additional observations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Most
patients with metastatic prostate cancer present with localized cancer, for which the standard of care may include active observation,
radiation, surgery, and androgen deprivation/suppression therapy. Responses to such therapy can be transient and many patients
will develop a castration resistant prostate cancer (CRPC) and develop, or are at risk to develop, mCRPC which accumulates genomic
alterations including DNA repair deficits. Chemotherapeutic agents play a critical role in the management of both metastatic castration
sensitive and mCRPC. The frequent use of the chemotherapy drug docetaxel in treating metastatic androgen sensitive prostate cancers
exemplifies this role. Historical observations of potential anticancer activity of LP-100 in clinical studies with prostate cancer,
and evidence of sensitivity to LP-184 in prostate cancer cell lines along with the development of computational methods that integrate
gene expression signatures, support LP-184 as a drug candidate with potential for use in combination with androgen deprivation
therapy for metastatic prostate cancer that is castration sensitive as well as metastatic prostate cancer that is castration resistant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">LP-184
is a new small molecule drug candidate that in preliminary preclinical studies has demonstrated increased plasma stability, reduced
total body clearance, significantly longer half-life, and potentially greater tumor regression than other studied fulvene based
compounds. We estimate that a substantial number of patients each year who suffer from metastatic prostate cancer globally could
be eligible for potential treatment with LP-184, if approved. In addition, the observed nanomolar potency of LP-184 suggests that
it may have anticancer properties in a wide range of solid tumors as an alkylating agent that works by causing DNA damage in tumor
cells. Other indications for LP-184 in solid tumors are emerging as a result of early developmental and biomarker studies, including
ovarian, breast, liver, kidney, pancreatic and thyroid cancers, as well as certain glioblastomas.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on increased
    sensitivity in cell-lines and PDx models exhibiting DNA repair deficient genetic backgrounds, we believe that LP-184 could
    have potential for targeted treatment of DNA repair deficient hereditary breast and ovarian cancers, from which more than
    2.3 million patients suffer globally according to the Global Cancer Observatory. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on recent
    observations, we also believe that LP-184 could have potential as treatment (alone or in combination with other treatments)
    for glioblastoma, which is an aggressive type of cancer that accounts for more than half of all primary brain tumors. The
    American Association of Neurological Surgeons estimates that glioblastoma has an incidence of two to three per 100,000 adults
    per year and accounts for about 17% of all tumors of the brain (primary and metastatic). </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our A.I. platform
    RADR<SUP>&reg;</SUP> helped uncover genomic biomarkers that we believe indicate certain patients could be more responsive
    to therapy with LP-184.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Further
work on these biomarkers both <I>in-silico</I> and in preclinical studies will help to establish a genomic signature that may
accelerate our time to a clinical trial and help guide patient selection. We believe that the market for LP-184 as a molecularly-targeted
drug candidate could be significant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">LP-300
(disodium 2,2&rsquo;-dithio-bis-ethane sulfonate or dimesna) is a late-stage clinical drug candidate that was in-licensed by us
from BioNumerik Pharmaceuticals, Inc. (&ldquo;BioNumerik&rdquo;) in May 2016, and subsequently acquired by us in January of 2018.
Using our RADR<SUP>&reg;</SUP>platform as part of the drug rescue process, we have identified LP-300 for use in a more targeted
set of cancer patients who exhibit a biomarker profile that we believe correlates with non-or never smoking status but still have
a form of non-small cell lung cancer (NSCLC). LP-300, originally branded as Tavocept<SUP>&reg;</SUP>, is a molecular entity that
we believe may be capable of ameliorating the toxic side effects of chemotherapeutic drugs such as cisplatin, and it also appears
to act as a potential chemoenhancer. LP-300 has been studied in multiple randomized, controlled, multi-center non-small cell lung
cancer (NSCLC) trials that included administration of either paclitaxel and cisplatin and/or docetaxel and cisplatin. Since acquiring
LP-300 from BioNumerik, we have not yet conducted further clinical testing of LP-300. We are currently evaluating LP-300 for the
launch of a targeted phase II trial, in non or never smoking patients with NSCLC in combination with chemotherapy, under an existing
IND.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prior
clinical trials conducted by BioNumerik for LP-300 did not meet their primary clinical endpoints and at least one or more future
clinical trials that meet their pre-specified primary endpoints with statistical significance will be required before we can obtain
a regulatory marketing approval, if any, to commercialize LP-300. Prior clinical trial observations are not necessarily predictive
of the outcome of any future clinical trials we may conduct.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Retrospective
analyses of the results of a multi-country phase III lung cancer trial conducted by BioNumerik in subgroups of NSCLC adenocarcinoma
patients receiving LP-300, paclitaxel and cisplatin demonstrated substantial improvement in overall survival, particularly among
female never smokers, where a 13.6 month improvement in overall survival (p-value 0.0167, hazard ratio 0.367) in favor of LP-300
was observed, as compared to placebo in the subgroup of paclitaxel/cisplatin-treated patients. Similar retrospective findings
of increased overall survival in the subgroup of LP-300/paclitaxel/cisplatin treated female Asian patients with adenocarcinoma
of the lung were observed in a randomized, double-blind, placebo-controlled trial in Japan. We plan on advancing this drug candidate
for the never or non-smoker population of patients due to the following important market and clinical need factors:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As many as 40% of
    lung cancers either do not carry currently known targetable proteins or will progress despite initial therapy resulting in
    a dependence upon chemotherapeutic drug regimens in their treatment, and according to the Global Cancer Observatory, lung
    cancer is the second most common cancer with over 2 million cases globally.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Approximately 40%
    of all lung cancers are adenocarcinomas, with more than half of such lung adenocarcinomas occurring in women. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As many as 20% of
    people who die from lung cancer in the United States every year have never smoked or used any other form of tobacco. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With declining rates
    of smoking, especially in North America and Europe, the relative proportion of lung cancer patients who are never-smokers
    is increasing, and this does not appear to be confounded by passive smoking or misreported smoking status. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Women who have never
    smoked have a higher proportion of lung cancer than men who are lifelong never-smokers.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In the clinical
    research community, a greater focus is being placed on lung cancers that occur in the never-smoking population along with
    the recognition that such lung cancers might be a genetically distinct type of cancer with a different molecular profile than
    smoking-based lung cancers. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mechanistic studies
    indicate that LP-300 may work by disruption at binding sites of oncoproteins such as ALK, MET, ROS1 and EGFR which are more
    commonly altered in female non-smokers and Asian females than in any other groups.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Never-smokers have
    also been observed to be less responsive to therapies that stimulate or leverage the immune system such as checkpoint inhibitors
    or PD-1 and PL-L1 inhibitors. In a meta-analysis research publication of 1,981 patients by Drs. Li, Huang and Fu published
    in <I>OncoTargets and Therapy, June 26, 2018</I> which spanned 3 Phase III randomized, controlled clinical trials the authors
    observed that, &ldquo;&hellip;PD-1 inhibitors were more efficacious in smoking NSCLC patients compared with chemotherapy.
    No better survival of nonsmoking patients was observed in the treatment of PD-1 inhibitors than chemotherapy.&rdquo; </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are focused on advancing the development of LP-300 as a combination therapy for non or never-smokers with NSCLC adenocarcinoma
and potentially among non or never-smokers with a genomic signature that correlates with a higher potential of response to this
drug compound. We selected NSCLC in non- or never smokers as our lead proposed indication because it is a cancer with a growing
patient population, without effective treatment options, and LP-300 has shown an improvement in overall survival in this targeted
sub-group population in prior clinical studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>In
vitro</I> studies indicate that the target-specific effects of LP-300 potentially correlate to the covalent modification of accessible
cysteine residues important in protein function/structure. These could be involved in disruption/ blocking of cofactor binding
sites resulting in blocking of oncoproteins such as ALK, MET, ROS1, and EGFR that are more commonly altered in female non-smokers
than in any other group. Other potential mechanisms of action of LP-300 could include impact on stress induced oxidoreductases
thereby allowing LP-300 to exert its potential chemo-enhancing effects in the presence of chemotherapeutic agents such as cisplatin.
LP-300 is postulated to potentiate antitumor cytotoxicity of standard of care chemotherapy agents such as cisplatin. We believe
a key LP-300 related mechanism is likely to occur through the increase of tumor cell sensitivity to oxidative stress. Additionally,
via induction of NRF2 (also known as NFE2L2), LP-300 has the potential to provide protection of healthy cells against chemotherapy-associated
toxicity, and such protection potential was observed with LP-300 combination therapy in both prior nonclinical studies and clinical
trials</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
differential gene expression analysis of whole transcriptome profiling data from LP-300 treated versus untreated NSCLC adenocarcinoma
cells has been performed. Using a threshold of fold change &gt; 2 out of a set of 51 curated NRF2 (NFE2L2) target genes as well
as NRF2 itself, we observed the top significantly upregulated genes in response to LP-300 exposure. Based on our observations,
we believe these genes could include NFE2L2, NQO1, PHGDH, HMOX1, SLC7A11, SRXN1, SOX2, GPX2, GPX3, GPX4, GPX7, G6PD, SIRT1, ITGB2
and BCL2. Our analysis indicates that these genes preferentially map to the following biological signaling pathways: (i) detoxification
of reactive oxygen species; (ii) glutathione metabolism; and (iii) inflammatory response. We filed a patent application in March
of 2020 on this discovery.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
interaction network of selected genes along with the associated biological pathways is shown in the figure below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="image_001.jpg" ALT="" STYLE="width: 650px; height: 394px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
part of our overall growth strategy, we plan to grow our pipeline by identifying new drug candidates and pursuing potential indications
for both LP-184 and LP-300 while leveraging our RADR<SUP>&reg;</SUP> platform. We are also pursuing the identification and design
of potential combination therapies in cancer for our compounds by leveraging our RADR<SUP>&reg;</SUP> platform to analyze synergistic
genomic networks and biological pathways with other currently approved drugs. We intend to select our next clinical program in
the next twelve months.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have an extensive multi-national portfolio of intellectual property directed to our drug candidates, and to protect the targeted
use and development of our portfolio of compounds in specific patient populations and in specific therapeutic indications. In
addition, as our RADR<SUP>&reg;</SUP> platform and other machine learning driven methodologies progress and mature, we will continue
to evaluate additional ways to further protect these assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
of March 2021, we own or control over 70 active patents and patent applications across 14 patent families whose claims are directed
to our drug candidates and what we plan to do with our drug candidates. We have in-licensed or acquired patents from AF Chemicals,
and BioNumerik that are directed to the compounds, LP-100, LP-184 and LP-300. Additionally, we have also filed patent applications
to further enhance, and extend the use of these in-licensed compounds. Our 14 patent families are directed to our drug candidates,
their usage, manufacturing and other matters. These matters are essential to precision oncology and relate to: (a) uniquely powerful,
data-driven, biologically relevant biomarker signatures, (b) patient selection and stratification approaches that rely on prediction
of response derived from these signatures and, (c) the ability to develop novel, combination therapy approaches with existing
therapeutics.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our
Drug Candidate Pipeline</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">One
of the ways we are building our drug candidate pipeline is by in-licensing clinical stage drug candidates that may have been discontinued
for development. We use our RADR<SUP>&reg;</SUP> platform to assist in analyzing prior clinical research conducted by others to
identify small-molecule oncology drug candidates that have (i) a well-tolerated profile evidenced by completion of phase I clinical
trials, and (ii) demonstrated at least limited antitumor or anticancer activity in clinical trials. We intend to implement an
efficient and thorough workflow to advance the drug candidates in our pipeline as potential precision medicine treatments for
cancer. Our targeted development workflow includes preclinical studies where drug activity and associated gene signatures are
identified, in part through strategic collaborations with some of the top academic institutions and clinical translational centers
in the world. Using this collaborative approach, together with innovative observations from our RADR<SUP>&reg;</SUP> platform,
we intend to develop and add drug candidates to our pipeline with the objective of treating the right patient populations with
the right oncology therapies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
use our RADR<SUP>&reg; </SUP>platform to identify potential biomarkers for patient response to a drug candidate and we further
intend to validate the selected drug candidate and potential associated biomarkers by conducting small, focused early phase clinical
trials. We intend to create various exit opportunities between one to three years for each drug candidate that progresses successfully.
For each drug candidate that progresses, along with its newly identified biomarker diagnostic potential for drug response, we
intend to partner, out-license, or internally develop the drug.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
current pipeline of development programs involves three small molecule drug candidates: LP-100, LP-184 and LP-300.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_002.jpg" ALT="" STYLE="width: 650px; height: 323px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LP-100 (6-Hydroxymethylacylfulvene
    or irofulven</B>) LP-100 has been out-licensed to Allarity Therapeutics and is in a phase II clinical
    trial in AR-targeted and Docetaxel-Pretreated mCRPC Patients.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LP-300 (Sodium
    2,2&rsquo;-disulfanediyldiethanesulfonate) (Tavocept<SUP>&reg;</SUP>) </B>We are currently evaluating LP-300 for the launch
    of a phase II clinical trial, in combination with chemotherapy in non-smokers or never-smokers with NSCLC adenocarcinoma that
    have a unique biomarker profile.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LP-184</B>. <B>(hydroxyureamethylacylfulvene)&nbsp;</B>LP-184
    is a next generation alkylating agent with nanomolar potency that preferentially damages DNA in cancer cells that overexpress
    certain biomarkers. LP-184 is in preclinical development and is in the planning stages for a phase I clinical trial.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">LP-100
is currently being advanced by our licensee, Allarity Therapeutics. LP-184 and LP-300 are being advanced solely by us. There is
currently no active IND in the U.S. for LP-100 and LP-184. We currently have an existing IND in the U.S. for LP-300 that was transferred
to us as part of our in-licensing and agreement with BioNumerik to acquire the rights to the compound.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Additional
Portfolio Opportunities</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Based
on the recognition of antibody drug conjugates (ADCs) as a promising therapeutic approach for cancer treatment, and one that has
growing interest due to the potential to increase targeted cancer cell death, we have started reviewing our portfolio of small
molecules for their potential to be used as part of an ADC approach. ADCs can increase selectivity and maximize tumor cell death
and also minimize collateral toxicity. Our compounds LP-100 and LP-184 have the potential to be linked to antibodies (or peptides)
and used in potential additional indications or alongside other small molecules or immuno-oncology agents. We believe that LP-300
can also play a role in developing ADC constructs and increasing the potential to deliver targeted therapies. We are actively
researching and reviewing potential development pathways and partnerships that would enable us to develop an ADC complement to
our portfolio.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
last two years have seen five FDA approvals in the growing class of ADCs for therapeutic use. This has driven increased deal-making
and portfolio additions by large pharma companies. In addition to the acquisition of Immunomedics by Gilead, Merck acquired Velos
Bio in November of 2020 and NBE Therapeutics was acquired by Boehringer Ingelheim in December of 2020. It is notable that both
NBE and Velos, at the time of their acquisition, had just successfully completed Phase 1 trials using their ADC approach in specific
cancer subtypes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
December 30, 2020, we entered into an Evaluation and Limited Use Agreement (the &ldquo;Evaluation Agreement&rdquo;) with Califia
Pharma, Inc. (&ldquo;Califia&rdquo;). Califia&rsquo;s founder, Michael J. Kelner, M.D., is a widely published researcher with
recognized expertise in the areas of illudofulvene chemistry and antibody drug conjugates. Califia has developed novel transcriptional-coupled
repair inhibitors that have demonstrated potential for an improved therapeutic index compared to traditional ADC payloads.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
Evaluation Agreement provides for Lantern and Califia to collaborate on the in vitro and in vivo testing and evaluation of novel
Califia payloads conjugated to a Lantern targeting entity. The Evaluation Agreement also provides us with the right to negotiate
with Califia for exclusive license rights to use LP-184 and related analogs as the payload with an affinity drug conjugate or
small molecule drug conjugate targeting entity supplied by Lantern. We also have the right under the Evaluation Agreement to negotiate
for non-exclusive license rights to use a Lantern targeting entity with a payload and linker combination selected from novel specified
Califia payloads and linkers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">We
plan on increasing our focus on CNS (Central Nervous System) cancers based on the promising data that has been generated in experiments
conducted with LP-184. LP-184 has shown that it can cross the blood brain barrier (BBB) while leaving neuronal cells intact. This
unique profile has been validated in neuronal cell-plate assays, neuronal spheroids, and also in xenograft models and is now undergoing
further validation in a collaboration with an affiliate of the </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">Johns
Hopkins School of Medicine<FONT STYLE="background-color: white">. We have launched a program in GBM, and have uncovered several
additional CNS cancers we believe will be sensitive to LP-184 based on genomic profiling and biomarker analysis conducted with
our A.I. platform, RADR. We expect to focus additional resources on developing LP-184 as both monotherapy and combination therapy
in several rare and ultra-rate CNS and brain cancers.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Based
on the positive data regarding the blood brain barrier permeability for LP-184, we reviewed and analyzed a range of CNS cancers,
beyond GBM, that we believe to have the potential to be responsive to LP-184 and make an improvement in patient survival. One
of the CNS tumor types that was identified by RADR was ATRT, Atypical Teratoid Rhabdoid Tumor, which is a very rare, fast-growing
tumor of the brain and spinal cord. It usually occurs in children aged three years and younger, but can also occur in older children
and sometimes adults. However, the younger the patient the poorer the prognosis for survival. ATRT has no known approved targeted
therapies and there is no standard chemotherapy regimen. According to the NCI, approximately 90 percent of ATRTs are characterized
by a SMARCB1 mutation, which significantly reduces the ability of the surrounding cells to suppress the tumor. ATRT occurs in
about 50 to 60 children per year and less than 10 adults per year, although recent diagnosis has increased due to improved access
to cancer care and improved diagnostic methods. We believe that we can target this genetically defined subset of ultra-rare ATRT
cancers, and plan on pursuing this indication in collaborations with academic cancer centers and potentially pursuing orphan or
fast-track status if the additional data we obtain supports that this has the potential for changing the clinical outcome for
patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">We
have obtained initial cell line data regarding LP-184 and ATRT that we believe supports the potential for LP-184 to qualify in
the future for possible grant of a Rare Pediatric Disease Designation for use of LP-184 for ATRT. Additionally, we believe that
subject to LP-184 successfully completing required clinical trials and regulatory requirements, LP-184 for the rare disease indication
of ATRT may also potentially qualify for grant of a Rare Pediatric Disease Priority Review Voucher (&quot;PRV&quot;). Under Section
529 of the Federal Food, Drug, and Cosmetic Act, FDA will award a PRV to sponsors of rare pediatric disease product applications
that meet certain criteria. Under this program, a sponsor that receives approval for a drug or biologic for a rare pediatric disease
may qualify for a PRV that can be redeemed to receive expedited review of a subsequent product marketing application. A </FONT>PRV
may be redeemed by the company that initially receives it, or the PRV can be <FONT STYLE="background-color: white">sold to another
company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our
Precision Cancer Therapy Development Using Our Innovative </I>RADR<SUP>&reg;</SUP> <I>Platform</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Historically,
cancer treatment protocols include surgery, chemotherapy and radiation therapy. Treatments have been selected based on histologic
type and disease spread, irrespective of genetic differences among patients. With the advent of precision therapies, cancer treatments
increasingly target specific genes or mechanisms of action for a more personalized approach to patient care. This trend represents
a substantial advance in cancer treatment because tumor growth is highly dependent on genetic changes and the genetic profile
of the individual and the progression of the disease is highly variable amongst patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
RADR<SUP>&reg; </SUP>platform is core to our drug development approach for identifying the desired candidates to in-license and
develop. According to a recent article in JAMA (<I><U>Estimated Research and Development Investment Needed to Bring a New Medicine
to Market</U></I><U>, 2009-18</U>, <I>JAMA, March 3, 2020</I>) oncology drug development is costly, risky, and highly competitive
with an average success rate of 4% to 8% and average developmental costs of over $1 billion per successful drug. There is a critical
need to rescue clinical research on drugs that have failed clinical trials in order to provide additional possible therapies for
patients while reducing the overall cost of therapeutic development. Many drug failures within oncology may be attributed to the
heterogeneity of the tested patient population, even though there may be a strongly positive therapeutic impact on certain patient
subgroups within that population.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">As
data-centric and machine learning approaches begin to change the pace and scale of drug discovery and development, research and
development (&ldquo;R&amp;D&rdquo;) we believe efforts in large biopharma companies will begin to shift away from traditional
approaches towards new data and A.I.-centric approaches. According to Deloitte Consulting, in <I>Ten Years On | Measuring the
return from pharmaceutical innovation 2019,&nbsp;</I>&ldquo;decades of advances in science and technology have driven improvements
in health care outcomes and influenced stakeholder expectations of the role of the biopharmaceutical industry (biopharma). However,
the past decade has seen increasing pressures undermine the productivity&nbsp;of biopharma R&amp;D, leading to a decade of decline
in the return&nbsp;on investment. At the same time, innovative new treatments are changing the face of disease management. New
treatment modalities and an increasing understanding of precision medicine have led to the need for new R&amp;D models...&rdquo;
The Deloitte Consulting report further describes that R&amp;D costs will, &ldquo;shift from traditional discovery and trial execution
to a process driven by large datasets, advanced computing power and cloud storage&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; background-color: white">Analysts
estimate that this shift from traditional screening, and trial-based studies to leveraging in silico, data and A.I. methodologies
will drive a significant increase in the spending on A.I. by the biopharma and drug discovery community to approximately $4 billion
by 2021, increasing by about 40% annually from $730 Million in 2019 according to PMLive and Global Market Insights. As a result
of these trends and changes in the R&amp;D model in biopharma, we believe that we, and companies that are using data-centric and
A.I. centric approaches to drug discovery and development, are in an ideal position to benefit from this industry shift that has
the potential to help deliver drugs to the right patients faster, with a higher degree of personalization and a potentially lower
amount of average costs in the development cycle.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
drug rescue approach leverages substantial prior research and development investments in candidates that were withdrawn from development
prior to submission for FDA approval. The large volume of failed compounds, recent developments that permit increased access to
validated genomic and biomarker data, and the rapid evolution of AI technology creates an opportunity to efficiently capitalize
on these investments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
RADR<SUP>&reg; </SUP>platform is rapidly emerging as a robust and scalable platform for targeted cancer therapy development. Through
the use of AI and machine learning, RADR<SUP>&reg;</SUP> is designed to quickly identify and guide the development of compounds
that we can develop as potential oncology agents through either a process of drug rescue, drug repositioning or de-novo development.
RADR<SUP>&reg; </SUP>is being developed on a routine basis through an accumulation and curation of genomic and biomarker data
that is directly relevant to the measurement and classification drug-tumor interaction, and clinical datapoints related to patient
response and patient stratification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Predicting
optimal drug responses in cancer patients requires the identification and validation of predictive biomarkers. Our RADR<SUP>&reg;
</SUP>platform seeks to identify biomarkers to assist in selecting patients who have the highest likelihood to respond to our
drug candidates. For example, the targeted indications for our drug candidate LP-184 were chosen in part because they are known
to highly express the protein coding gene PTGR1. Our preclinical &ldquo;PRostate cancer Artificial Intelligence Study using <I>Ex
vivo</I> models&rdquo; or &ldquo;PRAISE&rdquo; trial and our planned clinical trial for LP-184 are intended to examine biomarkers
related to LP-184&rsquo;s molecular and cellular targets to identify those that may correlate with clinical observed anticancer
activity. This method of using and validating targeted biomarkers during development and then using these biomarkers during clinical
trials can lead to shortening of the development timeline and compression of costs associated with oncology drug development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Similarly,
we believe LP-300 targets molecular pathways that are more common in female non- or never smokers than in any other group and
also targets kinases involved in key signaling pathways involving enzymes critical for DNA synthesis and repair, such as Excision
Repair Cross-Complementation Group 1 (ERCC1), Ribonucleotide Reductase 1 (RNR1), Ribonucleotide Reductase 2 (RNR2), as well as
enzymes and proteins important in regulating cell redox status, such as Thioredoxin (TRX), Peroxiredoxin (PRX), Glutaredoxin (GRX),
and Protein Disulfide Isomerase (PDI). Our plan is to bring LP-300 into a targeted phase 2 clinical trial within the non- or never-smoker
sub-group that are identified with the adenocarcinoma sub-type of NSCLC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Our
RADR<SUP>&reg;</SUP> Platform</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">The
human genome consists of 19,000 to 20,000 protein coding genes. One input record derived from available data bases and analyzed
by our RADR<SUP>&reg; </SUP>platform consists of datapoints (expression values) from approximately 20,000 genes, another input
record type is drug sensitivity data (IC20, IC50), and other sets include key clinical parameters from HIPAA compliant patient
data and clinical histories. Our RADR<SUP>&reg;</SUP> platform uses a data-driven gene feature selection methodology that is a
combination of biology, informatics, and statistics &ndash; computational biology. The architecture and modules of our platform
are depicted in the image below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_003.jpg" ALT="" STYLE="width: 650px; height: 545px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>RADR<SUP>&reg;
</SUP>Platform Architecture and Modules</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
platform uses AI and machine learning to identify genes and genomic signatures believed to be highly correlated with drug sensitivity.
These statistically significant genes are furthered filtered in the pathway network and interaction analysis to identify genes
believed to be biologically relevant. Genes that make up this layer are either related to the molecule&rsquo;s mechanism of action
or heavily connected to each other in gene networks. Lastly, another inductive learning algorithm ranks these filtered genes based
on drug sensitivity by calculating the half maximal inhibiting concentration (IC<SUB>50</SUB>) of the correlated relationship.
In this way, our platform has the potential to predict drug sensitivity, classify a patient as responder or non-responder and
identify biomarkers for each drug-tumor combination.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We developed our platform
using primarily open-source third party supervised algorithms such as Neural Networks, Support Vector Machine, Random Forest, K-Nearest
Neighbors, Logistic Regression and Penalized Multivariate Regression. Each algorithm is trained with input data to predict drug
sensitivity (regressor models) and stratify patient response as responder or non-responder (classifier models). Model tuning and
optimization is then performed using a hyperparameter search algorithm in order to produce the predicted lowest cross validation
error. The models are then evaluated using traditional performance metrics such as accuracy, area under the curve, sensitivity,
specificity, precision, root mean square error and mean absolute error calculations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
feature reduction algorithm is then used to reduce the number of genes under analysis to a biomarker gene panel of less than approximately
50 genes. This set of genes is intended to carry the highest coefficient to predict drug sensitivity and the highest variable
importance in classifying a responder from a non-responder. Genes that do not help in predicting the output variable are eliminated
sequentially.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_004.jpg" ALT="" STYLE="width: 650px; height: 290px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Our
RADR<SUP>&reg;</SUP> Platform Workflow</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
RADR<SUP>&reg; </SUP>platform&rsquo;s proprietary workflow involves preliminary statistical analysis on approximately 18,000 features
typically from whole transcriptomic datasets reducing the set to approximately 2,000 features. This is followed by gene filtering
via biological and statistical methodologies yielding approximately 200 significant genes. Feature selection ensures that genes
that do not contribute to response prediction are excluded from the output dataset. The prediction component subsequently applies
an A.I.-driven reduction algorithm to the previously filtered genes generating a targeted set of typically less than 50 candidate
biomarkers predictive of response to a particular molecule.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">A
distinct and unique benefit of the RADR<SUP>&reg;</SUP> platform is its ability to integrate biological knowledge and data-driven
feature selection to generate hypothesis-free biomarker signatures. This can then aid in identifying novel targets for predictive
screening and drug development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our RADR<SUP>&reg; </SUP>platform is enabled through access
to, and analysis of, a number of key datasets: (i) publicly available databases (ii) data from commercial clinical studies and
trials and (iii) our proprietary data generated from <I>ex vivo</I> 3D tumor models specific to drug-tumor interactions. We incorporate
automated supervised machine learning strategies along with big data analytics, statistics and systems biology to facilitate identification
of new correlations of genetic biomarkers with drug activity. The value of the platform architecture is derived from its validation
through the analysis of over 1.2 billion oncology-specific clinical and preclinical data points, more than 140 drug-cancer interactions,
and over 55,000 patient records from five data bases, one of which is our internal data base. Our long-term objective is to collect
and analyze over ten billion oncology-specific clinical and preclinical data points to further enhance the prediction power of
our RADR<SUP>&reg;</SUP> platform. We use cancer cell line gene expression profiles and drug sensitivity data (IC50) as one of
its input types. In a population of 10 case studies our platform was able to distinguish responders from non-responders with an
average historical accuracy of over 80%. We have also used our platform to generate genetic signatures that we believe to have
applicability for the majority of FDA approved drug-tumor indications. External validation, through retrospective data analysis,
of patient datasets from 10 independent clinical studies achieved an average response prediction accuracy greater than 80%, and
internal analysis of 120 drug-tumor interactions in cell lines achieved an accuracy of greater than 85%.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_005.jpg" ALT="" STYLE="width: 650px; height: 360px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_006.jpg" ALT="" STYLE="width: 650px; height: 395px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
have developed our platform in a cloud environment that efficiently uses parallel processing to analyze patient stratification
and biomarker selection. Best software engineering practices are followed while designing and developing our platform&rsquo;s
architecture. Each component of the platform&rsquo;s architecture is unit tested and then integration tested to ensure functions
and programs are working as designed. In order to track modifications in the software, a version control system is in place. Detailed
documentation has been created to record the design and architecture of our platform.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
platform uses a simple user input and GUI based AI architecture that can be used in many pharmaceutical research areas such as
biomarker identification, patient stratification, drug rescue and reposition by bioinformaticians, clinicians and trained wet-lab
scientists.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_007.jpg" ALT=""><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Our
Strategy</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
mission is to bring the right cancer drugs to the right patients by transforming the drug development process through the use
of artificial intelligence and data-driven development approaches. Our proprietary A.I.-enabled, and precision oncology approach,
which focuses on developing our own pipeline of compounds by rescuing drug candidates that have previously failed and developing
new compounds that are targeted to specific biological activity and genomic pathways, has the potential, we believe, to bring
drugs to market faster, with lower costs, and with reduced risk, thereby enabling a change in the cost and availability of precision
cancer therapy. We work with leading research laboratories, translational medicine and cancer centers to develop our studies and
clinical trials for our portfolio, and actively update and improve our RADR<SUP>&reg;</SUP> platform to incorporate additional
biomarker data, patient outcome data, cancer drug efficacy studies and computational models that relate to oncology drug development
and prediction of patient response.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_008.jpg" ALT="" STYLE="width: 650px; height: 372px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">As
part of our growth strategy, we plan to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Pursue existing
    indications for both LP-184 and LP-300, leveraging our RADR<SUP>&reg;</SUP> platform to refine and optimize our trial design
    and biomarker signatures that correlate to potential patient response. </I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Expand our pipeline
    by identifying new drug candidates that have either been abandoned or have failed in late stage clinical trials, and have
    the potential to benefit from a precision medicine approach that leverages our expertise and A.I. platform.</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Identify and
    design potential combination therapy approaches to use our compounds in conjunction with currently approved drugs by leveraging
    our RADR<SUP>&reg;</SUP> platform to analyze and uncover synergistic mechanisms and biological pathways using genomics and
    machine learning. </I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Increase the
    number of data points powering our RADR<SUP>&reg;</SUP> A.I. platform from more than the current 1.2&nbsp;billion to approximately
    three billion by the end of 2021.</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Advance the algorithms,
    methodologies and models that underlie our computational and machine learning platform to improve the predictive power, and
    to develop additional capabilities that are focused on accelerating or de-risking oncology drug development.</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Pursue collaborations
    and partnerships with other biotech and pharma companies where our A.I. and precision oncology expertise can be used to de-risk
    or accelerate development programs and where our stockholders can receive a significant economic benefit.</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Continue to develop
    and patent intellectual property and advance our intellectual property portfolio associated with both fundamental patents
    and patents associated with precision, patient stratified, targeted therapies and genomic or biomarker signatures. </I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Select and launch
    our next clinical development program in the coming twelve months.</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LP-300</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>General
Overview</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">LP-300
is a cysteine-modifying molecular entity that works to modulate multiple cellular pathways simultaneously and is a potential combination
agent for targeted indications in NSCLC. LP-300 is a small molecule (molecular weight 326.4 Da) that was in-licensed from BioNumerik
Pharmaceuticals, Inc. in May 2016, and subsequently acquired by us in 2018. We are focused on repositioning LP-300 as a potential
combination therapy for non-smoking (or never-smoker) NSCLC patients with histologically defined adenocarcinoma. Since obtaining
LP-300 rights from BioNumerik, we have not yet conducted further clinical testing of LP-300. We are currently evaluating LP-300
for the launch of a phase II trial, in combination with chemotherapy under an existing IND. Prior clinical trials conducted by
BioNumerik for LP-300 did not meet their primary clinical endpoints, and at least one or more future clinical trials that meet
their pre-specified primary endpoints with statistical significance will be required before we can obtain a regulatory marketing
approval, if any, to commercialize LP-300. Safety and efficacy determinations are solely within the authority of the FDA in the
U.S. or other regulatory agencies in other jurisdictions. Currently there is no approved therapy specifically for the growing
indication of non-smokers (or never-smokers) with NSCLC, and female non- or never smokers appear to be uniquely responsive to
LP-300. With both chemosensitizing and chemoprotective activity, LP-300 has potential as a combination agent or adjuvant in front
line, second line or salvage therapy in newly diagnosed, relapsed, metastatic or advanced NSCLC for overall survival enhancement
and toxicity alleviation from primary chemotherapy or standard of care. We are currently in the early stages of defining a specific
biomarker signature that correlates with heightened sensitivity to LP-300. We believe that this signature may help accelerate
the clinical development of LP-300 and has the potential to guide patient selection for targeted clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">LP-300
has been administered in multiple clinical trials to more than 1,000 patients and has been generally well-tolerated.&nbsp; Retrospective
analyses of the results of a multi-country phase III lung cancer trial (study ID DMS32212R) in subgroups of adenocarcinoma patients
receiving LP-300, paclitaxel and cisplatin demonstrated substantial improvement in overall survival, particularly among female
never smokers, where a 13.6 month improvement in overall survival (p-value 0.0167, hazard ratio&nbsp;0.367) in favor of LP-300
was observed, as compared to placebo in the subgroup of paclitaxel/cisplatin-treated patients. Similar retrospective findings
of increased overall survival in the subgroup of LP-300/paclitaxel/cisplatin treated female Asian patients with adenocarcinoma
of the lung were observed in a randomized, double-blind, placebo-controlled trial in Japan. Prior historical clinical trial observations
are not necessarily predictive of the outcome of future trials. No assurances can be given that we will be successful in obtaining
marketing approval for LP-300. The chemical structure of LP-300 is depicted below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">LP-300
Chemical Structure</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_009.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on the subgroup observations of increased overall survival
described above, we believe LP-300 has potential for an orphan indication designation in treating non- or never smokers with advanced
NSCLC adenocarcinoma. Although orphan status has not previously been granted for non-smoking associated NSCLC, we believe pursuit
of this designation is supported by the unique observations regarding LP-300 and the growing recognition that non-smoking associated
NSCLC is a distinct disease type as compared to smoking associated NSCLC. Summarized below are some key findings from LP-300&rsquo;s
prior clinical trials:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>LP-300 targets molecular pathways that are more common in female non-smokers than in any other group.</B> Key mechanisms have been elucidated to support LP-300&rsquo;s role in the observed treatment benefits for females and never smokers noted in the Phase III NSCLC adenocarcinoma trial. The rationale for these observations includes the following: (1) Met/ALK &amp; EGFR alterations are more common in non-smokers, who are most commonly female and present with advanced stage adenocarcinoma; (2) laboratory data indicate that LP-300 targets both EGFR WT/mut+ and Met/ALK; and (3) a high percentage of adenocarcinoma patients are either EGFR mutants or Met/ALK positive.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>There are several key pathways in NSCLC adenocarcinoma whose targets are often overexpressed in females, and LP-300 modulates these pathways</B>. LP-300 targets the following key pathways: (1) kinases involved in key signaling pathways (ALK, ROS, MET); (2) enzymes critical for DNA synthesis and repair (ERCC1, RNR1, RNR2); and (3) enzymes and proteins important in regulating cell redox status (TRX, PRX, GRX, PDI). The alterations that are targeted and modulated by LP-300 are more likely in women with lung adenocarcinoma, especially non-smokers.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>LP-300 showed that females had a survival increase from 13 months to 25 months, based on a retrospective subgroup analysis of a Phase III NSCLC adenocarcinoma trial.&nbsp;&nbsp;</B>Results from a Phase III NSCLC adenocarcinoma trial exhibited an overall survival of 25.0 months, with a 2-year survival of 51.4%, in the subgroup of females with advanced adenocarcinoma of the lung receiving paclitaxel/cisplatin and LP-300. The observed results were statistically significant (p-value = 0.0477; HR=0.579) and were observed in a subgroup of 114 patients in retrospective analyses. Consistent statistically significant retrospective subgroup analysis results were observed in female NSCLC adenocarcinoma patients receiving paclitaxel/cisplatin and LP-300 in a prior LP-300 double-blind, placebo-controlled phase III trial conducted in Japan.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt"><B>LP-300 exhibits potential to reduce anemia and protect against chemotherapy-induced kidney toxicity, both of which are conditions that disproportionately affect females.</B>&nbsp; The LP-300 arm of the Phase III NSCLC adenocarcinoma trial also demonstrated the potential for LP-300 to protect against chemotherapy-induced kidney toxicity and anemia. These findings complement earlier clinical observations regarding LP-300&rsquo;s potential to protect against neuropathy and other chemotherapy-induced toxicities.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Background-Scope of Prior Phase III
NSCLC Adenocarcinoma Trial (LP-300)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LP-300 was studied
in a randomized, multi-center (trial locations in four US states and five European countries), double-blind and placebo-controlled
Phase III trial from 2010 to 2013 in patients with adenocarcinoma of the lung (the &ldquo;Phase III NSCLC adenocarcinoma trial&rdquo;).
The aim of the trial was to determine whether LP-300, combined with a standard combination of chemotherapy drugs, would increase
survival in patients with advanced NSCLC adenocarcinoma. The secondary aim of the trial was to determine if the chemoprotective
properties of LP-300 were effective in preventing or reducing common side-effects of cancer treatment, including kidney damage,
anemia, nausea and vomiting that can occur with these drug combinations. The trial enrolled NSCLC patients with newly diagnosed
or recurrent advanced (stage IIIB/IV) primary adenocarcinoma of the lung. Patients with confirmed histopathological diagnosis of
inoperable and measurable advanced primary adenocarcinoma (including bronchioalveolar cell carcinoma) of the lung, and no prior
systemic treatment for NSCLC including chemotherapy, immunotherapy, hormonal therapy, targeted therapies or investigational drugs,
were included in the trial. Overall survival was the primary outcome measure. Patients in the control arm received standard of
care (cisplatin and either paclitaxel or docetaxel) plus placebo, whereas patients in the treatment arm received standard of care
(cisplatin and either paclitaxel or docetaxel) plus LP-300. The primary results of the trial for patients receiving cisplatin and
paclitaxel are outlined in the table below. While the overall results of the Phase III NSCLC adenocarcinoma trial did not meet
the specified endpoint of the trial in increasing overall survival in all patients, when the data were retrospectively separated
by gender and smoking status, the trial data demonstrated that all never smokers, especially female never smokers, saw increased
survival with LP-300 combination treatment with paclitaxel and cisplatin. Furthermore, the LP-300 group in the phase III NSCLC
adenocarcinoma trial exhibited well-tolerated advantages relating to the potential to protect against chemotherapy-induced nephrotoxicity,
neuropathy and nausea along with reduced anemia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_010.jpg" ALT="Table&#10;&#10;Description automatically generated" STYLE="height: 210px; width: 624px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The figure below depicts
the survival curves for cisplatin/paclitaxel subgroups for the Phase III NSCLC adenocarcinoma trial that ended in 2013, as summarized.
The Kaplan Meier curves maintain consistent separation between treatment arms for the never smokers, females, and female never
smokers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><IMG SRC="image_011.jpg" ALT="" STYLE="height: 444px; width: 624px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Rationale Behind LP-300 Rescue
and Repositioning Efforts</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the results
from the prior Phase III NSCL adenocarcinoma trial, we are in the process of designing a new Phase II clinical trial to target
the population of non- or never smokers with adenocarcinoma that saw the greatest benefit in the previous Phase III trial. Although
the incidence of non-smokers with NSCLC is rising currently there is no approved therapy specifically for the growing indication
of non-smokers (or never-smokers) with NSCLC. Preclinical observations support that LP-300 preferentially modulates ALK and EGFR,
two commonly mutated genes in non-smokers with adenocarcinoma. Based on the findings from the previous Phase III NSCL adenocarcinoma
trial, it is possible that the benefits of combining LP-300 with standard of care chemotherapy could be further improved by identifying
additional molecular biomarkers in patients who respond well to LP-300 combination treatment. We continue to seek additional opportunities
for LP-300. Some of our considerations include a non- or never smoker population with a specific genetic signature that correlates
to increased LP-300 sensitivity. We believe that this may also qualify as an orphan (rare disease) designation being a defined
subset of NSCLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Clinical Translation Strategies</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have conducted discussions
with more than ten key opinion leaders (KOLs) in the US, UK and India who recognized non-smokers with NSCLC adenocarcinoma as a
unique population that could benefit from targeted precision oncology therapy. We intend to invite active participation and input
from clinical and regulatory experts including KOLs and FDA authorities to facilitate evaluation of parameters important for repositioning
our LP-300 program and conducting precision clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Disease Background and Opportunity
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Lung cancer remains
one of the most common and deadly cancers worldwide. Lung cancer accounts for 13% of all new cancer diagnoses but 24% of all cancer
deaths. Lung cancer kills more people annually than cancers of the breast, prostate, colon, liver, kidney, pancreatic, and melanoma
combined. The American Cancer Society&rsquo;s estimates for lung cancer in the US for 2019 are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Approximately 228,150 new cases of lung cancer (116,440 in men and 111,710 in women)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Approximately 142,670 deaths from lung cancer (76,650 in men and 66,020 in women)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The most common type
of lung cancer is called non-small cell lung cancer (&ldquo;NSCLC&rdquo;), which represents about 85% of all lung cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Lung adenocarcinoma,
a histological subtype of NSCLC that originates within the glands that line the lung, is the most common subtype of lung cancer
in the world inflicting approximately 50% to 65% of non-Asians and approximately 70% to 85% of Asians diagnosed with lung cancer.
According to the SEER Cancer Statistics Review (November 2018) published by the National Cancer Institute and other published literature,
60% to 65% of all new lung cancer diagnoses are among people who are former smokers or have never smoked, while 10-15% of new lung
cancer cases are among never-smokers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Over one-half of the
patients diagnosed with NSCLC in any given year will present with inoperable advanced (stage IV) disease, for which there is no
cure. Patients with stage IV NSCLC exhibit a median overall survival time of 8 to 10 months; approximately one-third of patients
will survive for year, and only 10% to 21% of those patients will survive for two years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Lung cancer is the
most common cause of global cancer-related mortality, leading to over a million deaths each year and adenocarcinoma is its most
common histological subtype. Worldwide, lung cancer occurred in approximately 2.1 million patients in 2018 and caused an estimated
1.8 million deaths. NSCLC is described as any type of epithelial lung cancer other than small cell lung cancer (&ldquo;SCLC&rdquo;).
The 5-year survival rate for NSCLC is 16%. Rapid advances in understanding the molecular pathogenesis of NSCLC have demonstrated
that NSCLC is a heterogeneous group of diseases. Although the initial treatment of localized disease is the same, the molecular
characterization of tumor tissue in patients with NSCLC serves as a guide to treatment both in those who present with metastatic
disease and in those who relapse after primary therapy. Molecularly targeted therapies have dramatically improved treatment for
patients whose tumors harbor somatically activated oncogenes such as mutant EGFR1 or translocated ALK, RET, or ROS1. Mutant BRAF
and ERBB2 are also investigational targets. Smoking is the major cause of lung adenocarcinoma but, as smoking rates decrease, proportionally
more cases occur in never-smokers (defined as less than 100 cigarettes in a lifetime). KRAS mutations in lung cancer cases are
nearly exclusive to smokers. KRAS, &ldquo;Kristen rat sarcoma viral oncogene homolog,&rdquo; is a protein involved in regulating
cell division. KRAS mutation is a gain-of-function mutation (i.e. somatic mutation turns RAS, a benign gene &ldquo;proto-oncogene&rdquo;
into KRAS, an oncogenic driver of many tumors). KRAS-mutated non-small cell lung cancer represents 20% to 25% of all NSCLC. There
are no current KRAS-mutated NSCLC-targeted therapies but there are targeted therapies for the indication by targeting downstream
pathways - for example mTOR inhibition. Tumor suppressor gene abnormalities, such as those in TP53, STK11, CDKN2A8, KEAP1, and
SMARCA4 are also common but are not currently clinically actionable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In reviewing lung cancer
incidence and mortality rates among never-smokers in the Journal of Clinical Oncology, Wakelee, H.A. et al. have reported that
the age-adjusted incidence rates of lung cancer among never-smokers aged 40 to 79 years from large population-based cohorts ranged
from 14.4 to 20.8 per 100,000 person-years in women and 4.8 to 13.7 per 100,000 person-years in men, supporting earlier observations
that women are more likely than men to have never smoking-associated lung cancer. The biology of lung cancer in never-smokers is
apparent in differential responses to epidermal growth factor receptor inhibitors and an increased prevalence of adenocarcinoma
histology in never-smokers. Lung cancer in never-smokers is an important public health issue needing further exploration of its
incidence patterns, etiology, and biology. Due to the fact that there are no known therapy options for this group, we believe that
aggressive development of therapy options is needed and is a high unmet clinical need.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below illustrates
the growing concern of lung cancer in nonsmokers and never-smokers, and is a sample of the recent literature on the topic of never-smokers
that the Company has used in assessing the potential patient and unmet clinical needs in this cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 20%; border-bottom: black 1.5pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Source</B></P></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 15%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Date of Study / Publication&nbsp;</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 63%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Illustrative Quote</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt"><B>American Cancer Society</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Oct. 31, 2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><I>&ldquo;As many as 20% of people who die from lung cancer in the United States every year have never smoked or used any other form of tobacco.&rdquo;</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Journal of Royal Society of Medicine</B></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Aug. 25, 2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><I>&ldquo;Globally, there is wide variation in the proportion of lung cancers in never-smokers, in the range of 10% to 25%. With declining rates of smoking, the relative proportion of lung cancers in never-smokers are increasing and this does not appear to be confounded by passive smoking or misreported smoking status.&rdquo;</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt"><B>Roswell Park</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Apr. 3, 2019</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><I>&ldquo;&hellip;15% of lung cancers are found in people who have never smoked.&rdquo;</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD><FONT STYLE="font-size: 10pt"><B>Cancer Research U.K.</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Nov. 16, 2018</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><I>&ldquo;Around 10-15% of the lung cancer patients I see have never smoked.&rdquo;</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt"><B>ASCO &ndash; The Asco Post</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Dec. 25, 2017</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><I>&ldquo;In the United States, about 20% of women with lung cancer are never-smokers, and about 7% of men with lung cancer are never-smokers.&rdquo;</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Clinical Cancer Research</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>September 2009<BR>
        Volume 15, Issue 18</I></B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">Sep. 15, 2009</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><I>&ldquo;The lung cancer death rates among never-smokers, although &ldquo;rare&rdquo; by conventional definitions (&lt;40,000 US deaths per year), is similar to the death rates from leukemia, and endometrial cancer in women and cancers of the esophagus, kidney, and liver in men in the United States, and may be even more important in other populations, including Chinese women</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2019 in the US,
9,034 cases of NSCLC adenocarcinoma cases are estimated to be diagnosed in female non-smokers, accounting for approximately 3.9%
of all lung cancer cases. With an estimated 120,000 globally projected adenocarcinoma cases of NSCLC in non-smoking females in
2019, this specific indication may possibly be classified as a rare disease. When attempting to explain some gender susceptibility
differences, research has demonstrated that women with NSCLC tend to be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Younger;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Asian;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">2-3 times more likely to be non-smokers;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">more likely to develop adenocarcinoma and;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">having metastatic disease.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The high rate of adenocarcinomas in non-smoking
women suggests the possible existence of other etiological factors in addition to smoking. Some factors that have been considered
include gender-specific genetic alterations and predispositions, passive smoke effects, different nicotine metabolism in women,
occupational exposure, diet, and chronic obstructive pulmonary disease. Based upon 2018 estimates published by Global Cancer Observatory
and 2019 estimates published by the American Cancer Society, below is an overview of relevant potential patient population and
market sizes that we believe LP-300 could address, if approved:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Lung cancer</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Global</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left">Total 2019 lung cancer estimated incidence (new cases)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">228,150</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">NSCLC adenocarcinoma incidence (~40% of all lung cancers)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">800,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">91,260</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Never-smokers estimate (~15% of adenocarcinoma)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">120,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">13,689</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Female never-smoker estimate (~66% of never-smokers with lung cancer are female)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">79,200</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,034</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total Patient Segment in New Lung Cancer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.0</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Limitations on Current Treatment</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Treatment of patients
with advanced NSCLC in the first-line setting usually includes chemotherapy (including taxanes, vinorelbine, or gemcitabine) in
combination with a platinum doublet (cisplatin or carboplatin). According to the clinical practice guidelines published by the
National Comprehensive Cancer Network, many of these combinations have reached a plateau in terms of overall response (&ge; 25%
to 35%), time to progression (four to six months), median survival time (eight to ten months), one-year survival rate (30% to 40%),
and two-year survival rate (10% to 15%) in patients with good performance status. Treatment remains palliative and is limited due
to inherent toxicities that may affect the quality of life resulting from treatment. Toxicities can be life-threatening or cause
treatment delays, thereby limiting the intensity of treatment delivered and affecting its efficacy. Common and serious chemotherapy-induced
toxicities, such as anemia, emesis, and peripheral neurotoxicity resulting from treatment with platinum and taxanes, and nephrotoxicity
due to cisplatin can result in treatment delays, dose modifications, and in severe cases, discontinuation of treatment. We believe
it is important to pursue the development of novel therapies and combinations thereof that can substantially improve patient survival
and quality of life by potentiating the antitumor activity of chemotherapy treatment while protecting against chemotherapy-induced
toxicity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Market Opportunity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Most non-smoker patients
with lung cancer are women, and adenocarcinoma is the most common type. Non-smoker patients with non-small-cell lung cancer (&ldquo;NSCLC&rdquo;)
generally have a better response to inhibitors of epidermal-growth-factor receptor (EGFR) tyrosine kinase, including without limitation
gefitinib and erlotinib, than do those with a history of tobacco smoking. Studies have identified differences in chromosomal aberrations,
genetic polymorphisms, gene mutations, and methylation status between lung cancer in non-smokers and tobacco-associated lung cancer.
These clinical and biological differences suggest that the two cancers have overlapping but unique pathways of carcinogenesis.
The EGFR mutation is one of the most important genetic change in lung cancer in people who have never smoked because it is more
common in lung cancer in never-smokers than in tobacco associated lung cancer and is associated with greater therapeutic benefit
from inhibitors of EGFR. Other alterations associated with never-smokers include mutations, fusions or amplifications in ALK, ROS1,
RET and MET genes. Based upon published articles in CA: Cancer Journal for Clinicians and Nature Review Cancer, incidence in never-smokers
is 10% to 15% of all lung cancers and globally, NSCLC in never-smokers comprises 15% to 20% of cases in men and greater than 50%
in women. In Asia, never-smokers with NSCLC are 60% to 80% women and 20% to 40% men.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are focused on advancing
LP-300 as a potential combination therapy for non- or never smoking NSCLC patients with adenocarcinoma by leveraging our A.I. platform
to help uncover the genomic and biomarker networks that are associated with response in the never-smoker and non-smoker groups.&nbsp;
Additionally, through our early, preclinical work to define a gene signature that correlates with heightened sensitivity to LP-300,
we believe there is potential to further expand the indication to include all NSCLC patients that have this identified genetic
profile in their cancer. Currently there is no approved therapy specifically for the growing indication of non-smokers (or never-smokers)
with NSCLC, and female non- or never smokers appear to be uniquely responsive to LP-300.&nbsp; If successful, LP-300 could provide
improved patient benefit in terms of improved survival, and secondarily through the concurrent prevention and mitigation of common
and serious chemotherapy-induced toxicities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>LP-300 Summary of Preclinical and Clinical
Studies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Through partnerships
and third-party outsourcing arrangements, we are conducting, or have conducted, the following preclinical studies on LP-300.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Cell line work with third party CROs</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A study was conducted
to assess whether LP-300 induces or suppresses specific biological pathways or functions that impact tumor cell proliferation,
survival or apoptosis.&nbsp; In this study, NSCLC cell lines were exposed to selected concentrations of LP-300 alone and in combination
with cisplatin, for defined duration.&nbsp; After exposure to the drugs in cell culture according to the chosen treatment conditions,
RNA was obtained and transcriptomic analysis was performed using a NovaSeq 6000 next-generation sequencing platform.&nbsp; Overall,
1.26 million data points were generated and analyzed from this study yielding differential gene expression profiles between LP-300
untreated versus treated samples.&nbsp; Key pathways that emerged as being regulated by LP-300 include redox homeostasis and NRF2/Antioxidant
Response Element signaling, among others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are working with
a preclinical and discovery focused CRO to generate supporting preclinical data on LP-300 anticancer activity profiles in various
molecular and demographic brackets of NSCLC cell line models.&nbsp; The goal of this study is to generate dose response curves
and associated IC<SUB>50</SUB> values for LP-300 alone as well as in combination with Cisplatin (standard of care agent) and selected
targeted therapy agents on up to 20 different NSCLC cell lines.&nbsp; Genetic backgrounds of NSCLC drivers and related oncogenes
in these cell lines are known, and will help to establish correlations between LP-300 cytotoxicity and specific markers.&nbsp;
We intend to evaluate the status of LP-300 as a chemosensitizing agent, whether LP-300 triggers catastrophic oxidative stress,
and understand specific transcriptional characteristics of tumors that are sensitive or resistant to LP-300 alone and in combination
with other treatments.&nbsp; From this ongoing study, we hope to develop information to assist in further stratifying patients
that would be key targets for future clinical trials.&nbsp; LP-300 could potentially be positioned to treat advanced NSCLC adenocarcinoma
not just in never-smokers but also based upon genetic alterations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Fox Chase Collaboration</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are engaged in discussions
with Fox Chase Cancer Center (&ldquo;FCCC&rdquo;) to identify opportunities for collaborative research, both preclinically and
clinically, for advancing LP-300. The objective is to develop studies to further elucidate the mechanism of action of LP-300, and
to pursue a Phase II clinical trial in never-smokers with NSCLC. Regarding preclinical studies, we intend to discuss appropriate
preclinical studies with cell lines, organoids or patient derived xenograft (PDX) models that are required to move forward to a
clinical trial. In pursuing the areas of LP-300 related cysteine modification of EGFR / FGFR and other drivers commonly altered
in never-smoking NSCLC, we plan on comparing LP-300 response in cell line models with EGFR exon 3 deletion, EGFR L858R/ T790M,
exon 19 or 21 deletions, and EGFR wild type among other genetic backgrounds. We are interested in prioritizing studies that will
progress towards a Phase II trial, including a PDX trial testing LP-300 in combination with selected tyrosine kinase inhibitors
(TKIs) in addition to cisplatin / paclitaxel as standard of care agents in relevant models and comparing never-smokers and nonsmokers
to smokers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Prior Completed Trials of LP-300</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Phase I</I>. LP-300
has been evaluated in five Phase I studies (DMS10001, BioNumerik, 09/1997 through 04/2004; DMS10002, BioNumerik, 12/1997 through
08/2001; DMS12209, ASKA Pharmaceutical, 04/2000 through 12/2001; DMS10011, BioNumerik, 02/2006 through 07/2006; and DMS12307, Baxter,
07/2002 through 07/2005) to determine the maximum tolerated dose (&ldquo;MTD&rdquo;), and to evaluate the safety, tolerability,
pharmacokinetics, and potential efficacy of LP-300 (alone or in combination with cisplatin, cisplatin/paclitaxel, or carboplatin/paclitaxel).
An MTD for LP-300 was not reached in any of the Phase I studies at dose levels of up to 41 g/m<SUP>2</SUP>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;Phase II.
</I>In a U.S. multi-center, randomized, open-label trial (n=160 patients) with advanced (Stage IIIB and IV) NSCLC treated with
LP-300 or no LP-300 (DMS22210/CALGB 30303, Cancer and Leukemia Group B, 08/2004 through 03/2007), although the overall population
did not meet the pre-specified primary endpoint, an analysis of a subgroup of patients with adenocarcinoma revealed that the difference
in the median overall survival period between the 2 treatment groups was statistically significant (LP-300 = 15.6 months, no LP-300
= 8.9 months; Log-rank p=0.0326), and the median overall survival for patients who received LP-300 was 6.7 months longer than that
of those who did not receive LP-300.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Phase III.</I> LP-300
has been evaluated in five Phase III studies: two in patients with metastatic breast cancer, with a primary endpoint examining
the ability to reduce platinum/taxane induced peripheral neuropathy, and three in patients with NSCLC or advanced primary lung
adenocarcinoma. (DMS32205R, ASKA Pharmaceutical, 08/2005 through 02/2008; DMS30203R, BioNumerik, 09/2001 through 10/2006; DMS30204R,
ASKA Pharmaceutical, 04/2003 through 03/2006; DMS32206R, Baxter, 10/2002 through 04/2006; and DMS32212R, BioNumerik, 04/2010 through
06/2013) Although the overall population did not meet the pre-specified primary endpoints in any of the trials, analysis of subgroups
of patients in one multi-country lung adenocarcinoma trial and one Japanese NSCLC trial revealed differences in the median overall
survival between the two treatment arms (with or without LP-300 treatment). The results from the two key lung cancer trials obtained
from retrospective analyses are described below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Multi-country, double-blind, randomized, multi-center &amp; placebo-controlled trial (n=540 patients) with advanced primary lung adenocarcinoma treated with LP-300 or Placebo &amp; paclitaxel or docetaxel with cisplatin (DMS32212R). (the Phase III NSCLC adenocarcinoma trial)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&Oslash;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Treatment with LP-300 nearly doubled the Overall Survival in women receiving paclitaxel/cisplatin (25.0-month median OS in LP-300 arm vs. 13.2-month OS in control arm) and the results in this subgroup were statistically significant (P-value = 0.0477; HR = 0.579)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&Oslash;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">For never smoking women with adenocarcinoma of the lung receiving paclitaxel/cisplatin, the Overall Survival in the LP-300 arm was more than double the control arm (27.0 months vs. 13.4 months, respectively) also being statistically significant in favor of LP-300 (P-value = 0.0167; HR = 0.367) and the 2-year survival was 72.4% in the LP-300 arm vs. 32.3% in the control arm.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Statistically significant subgroup analyses and trends from this LP-300 Phase III NSCLC adenocarcinoma trial support repositioning LP-300 for non- or never smokers with adenocarcinoma of the lung.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Randomized, double-blind, placebo-controlled and multi-center trial in patients with advanced NSCLC receiving paclitaxel &amp; cisplatin (Japan Trial) (DMS32205R). The Japan Trial observations support and complement observations in the multi-country Phase III NSCLC adenocarcinoma trial. The observations for the female adenocarcinoma patient population in the LP-300 multi-country Phase III NSCLC adenocarcinoma trial are consistent with observations made for the subgroup of females with adenocarcinoma of the lung receiving paclitaxel/cisplatin and LP-300 or placebo in the Japan Trial. Although the overall population in the Japanese trial did not meet the pre-specified primary endpoint, a retrospective analysis of the subgroup consisting of female patients with adenocarcinoma revealed that the difference in the median overall survival period between the two treatment arms in this subgroup was significant (P-value = 0.0456, HR = 0.376).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The LP-300 arm of the
multi-country Phase III NSCLC adenocarcinoma trial also demonstrated safety profile advantages in terms of the potential to protect
against chemotherapy-induced kidney toxicity and chemotherapy-induced anemia. These observations complemented earlier clinical
observations regarding LP-300&rsquo;s potential to protect against neuropathy and other chemotherapy-induced toxicities. Results
from these trials indicate that treatment with LP-300 may, in further clinical testing, lead to improved survival in female and
non- or never smoking patients with primary adenocarcinoma of the lung receiving cisplatin/paclitaxel combination chemotherapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Phase II and III LP-300 Adverse Events
Summary</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following summarizes
adverse events reported from a total of 1,712 patients enrolled in five randomized multi-center phase II and phase III studies
with chemotherapy, with or without LP-300. A total of 1,712 patients were enrolled in these studies, of which 856 patients received
LP-300 with chemotherapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>All Adverse Events (AEs)</I>. The most frequently-occurring adverse events in patients receiving LP-300 with chemotherapy were generally similar to patients receiving placebo or chemotherapy alone. These events included blood and lymphatic system disorders (myelosuppression manifested as anemia, leukopenia, lymphopenia, neutropenia, and thrombocytopenia; also including decreased hematocrit, hemoglobin, lymphocyte count, neutrophil count, red blood cell count, platelet count, and white blood cell count), with an incidence ranging from 12% to 83%; gastrointestinal disorders including constipation, abdominal pain, diarrhea, nausea, stomatitis, and vomiting, with an incidence ranging from 22% to 83%; general disorders and administrative site conditions including fatigue (ranging from 17% to 85%); infusion/injection site pain/reactions (ranging from&nbsp;12% to 18%); malaise (ranging from 16% to 28%); peripheral edema (ranging from 13% to 22%); pyrexia (ranging from 10% to 17%); infections and infestations disorders including nasopharyngitis (ranging from 11% to 16%); investigations including increased liver function tests including ALT, AST, and alkaline phosphatase (ranging from approximately 10% to 55%); increased blood lactate dehydrogenase (ranging from approximately 17% to 26%); increased blood urea or blood uric acid (ranging from approximately 11% to 32%); increased gamma-glutamyltransferase (ranging from approximately 23% to 33%); decreased total protein (ranging from approximately 12% to 21%); metabolic and nutritional disorders including weight decreased (ranging from 15% to 22%), anorexia (ranging from 14% to 82%), and hypomagnesemia (ranging from 22% to 30%); musculoskeletal and connective tissue disorders including arthralgia, back pain, and myalgia (ranging from 7% to 80%); nervous system disorders including dysgeusia (ranging from 12% to 22%), headache (ranging from 14% to 17%), and peripheral neuropathy (motor and sensory &ndash; ranging from 22% to 86%); psychiatric disorders including insomnia (ranging from 12% to 17%); respiratory, thoracic, and mediastinal disorders including dyspnea (ranging from 12% to 40%); skin and subcutaneous disorders including alopecia (ranging from&nbsp; 33% to 92%); rash (ranging from 22% to 29%); nail disorder/discoloration (10%); and vascular disorders including angiopathy (ranging from 64% to 69%) and flushing (ranging from 15% to 39%).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Treatment-Related Adverse Events.</I> Frequently occurring treatment-related AEs experienced by patients receiving LP-300 with chemotherapy included gastrointestinal disorders manifesting as nausea and vomiting (ranging from 12% to 67%, and 12% to 32%, respectively); fatigue (ranging from 22% to 82%); infusion/injection site pain/reactions (ranging from 11% to 18%); increased ALT (alanine aminotransferase) and gamma-glutamyltransferase (ranging from approximately 13% to 18%, and approximately 11% to 12%, respectively); peripheral neuropathy (motor and sensory &ndash; ranging from 14% to 54%); and vascular disorders including angiopathy (ranging from 60% to 69%), and flushing (ranging from 8% to 11%).&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><I>Serious Adverse Events (SAEs)</I>. 11% to 49% of patients receiving LP-300 with chemotherapy,
    and 7% to 42% of patients in control groups receiving chemotherapy alone experienced SAEs during randomized multicenter studies.
    Frequently-occurring SAEs in patients receiving LP-300 with chemotherapy included pneumonia, hypersensitivity or drug hypersensitivity,
    dyspnea, pyrexia and dehydration, diarrhea, anaphylactic shock or anaphylactic reactions, vomiting, disease progression, infection,
    bronchospasm, pleural effusion, pulmonary embolism, thrombosis, hemolysis, nausea, chills, fatigue, sudden death, neutropenic
    infection, sepsis, anorexia, neutropenia, febrile neutropenia, pneumonitis, rash, and hypotension. Multiple allergic reactions
    have been reported in clinical trials of LP-300, and some of these reactions have been severe. It is possible that patients
    could experience an allergic reaction that is life-threatening.&nbsp; Five reports of grade 3 or 4 hemolysis events with three
    fatal outcomes were reported in patients receiving LP-300 with chemotherapy in a study involving the weekly drug administration
    schedule.&nbsp;&nbsp;Two events of hemolysis were reported in a study involving drug administration every two weeks. No events
    of hemolysis were reported in studies using the three weeks schedule of administration, which is the administration schedule
    used for the multi-country Phase III NSCLC adenocarcinoma trial.&nbsp; &nbsp;</TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Treatment-Related Serious Adverse Events.</I> Approximately 7% of patients receiving LP-300 with chemotherapy experienced treatment-related SAEs during randomized multicenter studies. The most frequently-occurring treatment-related SAEs experienced by patients receiving LP-300 with chemotherapy were hypersensitivity or drug hypersensitivity (five and two patients, respectively) and neutropenia (six patients). Other treatment-related SAEs experienced by patients receiving LP-300 with chemotherapy included hemolysis, bronchospasm, febrile neutropenia, anemia, nausea, and pulmonary edema (three patients, each); chills, diarrhea, pyrexia, neutropenic infection, hyperglycemia, acute respiratory distress syndrome, pulmonary embolism, sudden death, infection, and rash (two patients, each); and angina pectoris, cardiac arrest, tachycardia, sudden hearing loss, abdominal pain, vomiting, adverse drug reaction, anaphylactic shock, <I>C. difficile </I>colitis, pneumonia, sepsis, chemical cystitis, thrombosis in device, dehydration, leukopenia, anorexia, atrial fibrillation, fatigue, weight decrease, muscle disorder, pain in extremity, dizziness, peripheral sensory neuropathy, dyspnea, hypotension, and thrombosis (one patient, each).&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Clinical Evidence of Toxicity Protection
by LP-300 </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The data from randomized
multicenter studies of LP-300 and chemotherapy demonstrates objective evidence of several instances where treatment with LP-300
appears to provide potential benefit in terms of preventing and mitigating chemotherapy-induced toxicities, particularly in studies
of LP-300 and chemotherapy in patients with advanced NSCLC. These data support that LP-300 has the potential to protect against
chemotherapy-induced toxicities, including gastrointestinal, renal, electrolyte disturbances, and anemia; and there is data supporting
the potential for LP-300 to protect against severe forms of these toxicities. In addition, treatment with LP-300 may protect against
severe platinum-induced hearing loss and dehydration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>LP-300 Mechanism of Action</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LP-300 is a water-soluble
disulfide compound that lacks a free thiol or sulfate moiety. We postulate this unique structure of LP-300 may allow it to potentiate
antitumor activity of certain types of cytotoxic chemotherapy, and exert chemoprotective effects, through distinct and interrelated
mechanisms. In plasma, the lack of a free thiol prevents untoward reactivity and drug-drug interactions, and thereby may allow
chemotherapeutic agents to retain their efficacy. Once inside the tumor cell, LP-300 is metabolized and may then potentiate antitumor
activity of cytotoxic certain types of chemotherapy. A significant fraction of LP-300 is taken up by the kidneys, where LP-300&rsquo;s
metabolites can interact with chemotherapy drugs, such as cisplatin, and potentially diminish the chemotherapy drug&rsquo;s ability
to cause organ damage. We believe the postulated mechanisms that can enhance tumor directed chemosensitivity include restoration
of apoptotic sensitivity thereby countering drug resistance; oxidative stress enhancement; anti-angiogenesis; decreased DNA synthesis
and gene expression; and decreased glutathione and precursors (limiting glutathione tumor-mediated drug resistance). When LP-300
accumulates in the kidneys it appears to reduce the toxicity of certain drugs, such as cisplatin, that are excreted through the
renal system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As depicted in the
model below, we believe LP-300 and its metabolites can modulate key components of the thioredoxin and glutaredoxin systems, which
are believed to be involved as major mechanisms of the potentially enhanced antitumor effects of LP-300 with chemotherapy. The
thioredoxin pathway is commonly upregulated in adenocarcinomas, and examination of primary lung tumors from non-smokers have shown
significantly increased gene expression of thioredoxin. Overexpression of thioredoxin in cancer cells has been postulated to lead
to resistance to apoptosis, increased cellular proliferation, increased gene expression, increased angiogenesis, increased conversion
of DNA into RNA, and resistance to oxidative stress induction. We believe the modulation of thioredoxin expression is important
for the observed increases in patient survival identified in retrospective analyses of certain subgroups of patients with primary
adenocarcinoma of the lung receiving LP-300 in conjunction with cisplatin and paclitaxel chemotherapy. Different glutaredoxin transcript
variants have been found to be elevated in transformed cells, and glutaredoxin isoforms (e.g., variants of glutaredoxin 2) have
been found to be elevated in NSCLC cell lines, lending evidence for potential roles of glutaredoxin in tumor progression.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe LP-300 and
its metabolites may potentiate the antitumor activity of chemotherapy by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(1) shifting the redox
balance and concentrations of reduced forms of thioredoxin and glutaredoxin to inactive oxidized forms of thioredoxin and glutaredoxin,
thereby restoring apoptotic sensitivity, increasing sensitivity to oxidative stress, inhibiting cell growth and angiogenesis, RNA
to DNA synthesis, and growth signaling, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">(2) forming thioredoxin
or glutaredoxin adducts, which as inactive forms lead to thioredoxin- and glutaredoxin-mediated reduction of downstream targets
in the cell that are important for tumor resistance to chemotherapy, angiogenesis and cell growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><IMG SRC="image_012.jpg" ALT="" STYLE="height: 374px; width: 624px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that LP-300
may potentiate antitumor activity of certain types of cytotoxic chemotherapy, and exert chemoprotective effects through several
distinct and interrelated mechanisms of action. LP-300 is a cysteine-modifying agent that appears to modulate multiple cellular
pathways simultaneously. Experimental data indicate that LP-300 modifies and/or modulates the following key pathways:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Kinases involved in key signaling pathways (EGFR, ALK, ROS, MET)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Enzymes critical for DNA synthesis and repair (ERCC1, RNR1, RNR2)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Enzymes and proteins important in regulating cell redox status (TRX, PRX, GRX, PDI)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following key mechanisms
have been observed to support our belief that LP-300 has potential to play an important role in the treatment of females and non-
or never smokers with NSCLC adenocarcinoma. We believe these mechanisms help to explain the retrospective subgroup observations
for females and never smokers receiving LP-300 together with cisplatin and paclitaxel in the Phase III NSCLC adenocarcinoma trial:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>LP-300 targets cysteine residues</I>. Computational and experimental data indicate that LP-300 demonstrates specificity towards cysteines. LP-300-mediated xenobiotic modulation of protein targets on cysteine results in distinct, (multi)target-specific effects correlated to the role of the cysteine residue(s) in the target.</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>LP-300 alone inhibits human ALK and stimulates the inhibitory effect of crizotinib on human ALK</I>. Alterations in ALK, along with MET, ROS1 &amp; PDGFRA are thought to underlie nearly 10% of NSCLC adenocarcinoma cancers. Liquid Chromatography (LC), Mass Spectrometry (MS) and X-ray structural data demonstrate that LP-300 covalently modifies human ALK on Cys1156 and Cys1235. Enzyme assay data demonstrates that LP-300 inhibits human ALK&rsquo;s kinase activity and stimulates the inhibitory effect of crizotinib on human ALK&rsquo;s kinase activity.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>LP-300 inhibits human MET kinase activity and stimulates Staurosporine inhibition of human MET kinase activity</I>. Mesenchymal Epithelial Transition Factor Kinase (MET) kinase mutations and amplification are an important, specific subset of NSCLC adenocarcinoma. Enzyme assays demonstrate that LP-300 inhibits human MET kinase activity and stimulates the inhibitory activity of staurosporine on human MET kinase.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>LP-300 inhibits EGFR kinase activity</I>. EGFR mutations are an important, specific subset of NSCLC adenocarcinoma, particularly in non-smoker females. Enzyme assays demonstrate that LP-300 inhibits EGFR kinase activity and potentiates the inhibitory effect of eErlotinib on wild type as well as mutant EGFR kinase activity.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>LP-300 modestly inhibits retinal rod outer segment kinase (ROS1) activity</I>. ROS1 chromosomal rearrangements are a recently identified class of mutations in NSCLC. Estimates of frequency of ROS1 rearrangements range from 1% to 2%. Experimental data are as follows:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&Oslash;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Enzyme activity data demonstrates that LP-300 has an effect on Human ROS1 activity when ROS1 is preincubated with LP-300. We hypothesize that pre-incubation allows slower reacting cysteine residues to be modulated by LP-300.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&Oslash;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on modeling studies, the cysteines on ROS1 appeared to be in less optimal orientations compared to cysteines in ALK.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 72px">&nbsp;</TD>
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Wingdings; font-size: 10pt">&Oslash;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">LP-300 appears not to impact ROS1 activity unless ROS1 and LP-300 are pre-incubated prior to kinase assays. Therefore, to see an effect <I>in vivo</I>, it may be necessary to administer LP-300 prior to LP-300&rsquo;s effects on ROS1 through preincubation of ROS1 and LP-300, suggesting slower xenobiotic modulation reactions. However, there are several possible explanations for the LP-300 effect on ROS1 and in the absence of an X-ray structure this remains a hypothesis.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>LP-300 modifies Ribonucleotide Reductase 1 and 2 (RNR1 and RNR2).</I> Selective, elevated expression of the RNR1 subunit is associated with gemcitabine resistance in NSCLC. RNR1/RNR2 are essential for DNA synthesis, DNA repair &amp; cell proliferation. RNR1/2 catalyzes the formation of deoxyribonucleotides needed for DNA synthesis, from ribonucleotides.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>LP-300 targets proteins that may result in protection against chemotherapy-induced nephrotoxicity and neuropathy</I>. The LP-300 derivative-cisplatin/paclitaxel conjugate is inactive and this conjugate is not a substrate for aminopeptidase/&gamma;-Glutamyl-transpeptidase (APN/GGT). These LP-300 heteroconjugates appear to cause potent inhibition of APN/GGT leading to suppression/bypass of renal APN/GGT xenobiotic metabolism pathways promoting protection against chemotherapy-induced nephrotoxicity. In addition, binding of the LP-300 derivative with reactive cisplatin/paclitaxel species, appears to inactivate the platinum-catalyzed microtubule hyper-polymerization. This action may serve to protect against chemotherapy-induced peripheral neuropathy.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>LP-300 modulates protein function in a way that may promote chemosensitization</I>. LP-300 appears to promote covalent oxidation of redox proteins Thioredoxin (TRX), Peroxiredoxin1 (PRX1) and Glutaredoxin (GRX). This action may keep these redox proteins in an inactive non-signaling state, which could enhance sensitivity to oxidative stress and apoptosis induced by concomitant chemotherapy.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Using various <I>in
vitro</I> experimental approaches, LP-300 has been observed to form adducts on cysteines of various protein targets such as those
listed below. For several of these targets, studies evaluating enzyme activity associated with the targets have demonstrated inhibition,
modulation or impairment of such activity. In addition, X-ray crystallographic studies support LP-300 derived adducts at specific
cysteines on these proteins.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Targeted Proteins Modified by LP-300</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 23%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Cellular Target of LP-300</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 76%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Cellular consequence of LP-300-modification and/or modulation</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Cellular thiol/disulfide balance</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">LP-300 and LP-300-derived mesna disulfide heteroconjugates are pharmacological surrogate/modulators of physiological thiols and disulfides (e.g., glutathione, cysteine, and homocysteine).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Gamma-Glutamyltranspeptidase Aminopeptidase N</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">LP-300 and LP-300-derived mesna disulfide heteroconjugates can inhibit gamma-glutamyltranspeptidase and aminopeptidase N enzyme activity.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Tubulin</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">LP-300 exerts direct and indirect protective interactions with tubulin.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Anaplastic Lymphoma Kinase (ALK)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">LP-300 disrupts/blocks ATP binding site resulting in inhibition of ALK kinase activity (vide infra).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 3pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mesenchymal Epithelial</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Transition (MET) Factor Kinase</P></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Modification of non-active site cysteine(s) resulting in enzyme inhibition (MET).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">ROS1 kinase</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">LP-300 xenobiotically modifies ROS1 kinase in a time dependent manner.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Redox Balance</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">LP-300 and LP-300-derived mesna disulfide heteroconjugates assist in the maintenance of cellular redox balance and support cellular defenses against oxidative insult.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Thioredoxin (Trx) Glutaredoxin (Grx)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">LP-300 modifies non-catalytic cysteines important in redox protein function/structure (Grx and Trx).</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">Thioredoxin (Trx) Glutaredoxin (Grx)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">LP-300 and/or LP-300-derived mesna disulfide heteroconjugates function as alternative substrates/inhibitors (Trx, Grx) resulting in impaired enzyme activity.</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-size: 10pt">Peroxiredoxin (Prx)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">LP-300 disrupts active site structure (Prx) resulting in impaired enzyme activity.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mechanistic evaluation
of LP-300 revealed that it has cysteine-modifying activity on select Receptor Tyrosine Kinases (RTKs) initiating proliferative
signaling such as ALK, EGFR, MET and ROS1. LP-300 may also serve as a potential chemosensitizer for certain combination chemotherapies
by inactivating proteins such as Thioredoxin (TRX), Glutaredoxin (GRX) and Peroxiredoxin (PRX) that are important in modulating
cellular redox status and in turn drug resistance. Higher levels of PRX gene expression have been shown to correlate significantly
with the absence of smoking history and with the female gender.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe well-tolerated
profile advantages of LP-300 are imparted through its chemoprotective action via production of inactive LP-300-chemotherapeutic
conjugates and preventing toxic taxane/platinum metabolites in the kidney, and targeting toxicity-inducing molecules and pathways
(e.g. APN, GGT, and Tubulin).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We plan to conduct
additional mechanism of action studies aimed at identifying and validating signaling molecules and pathways selectively triggered
by or responding to LP-300, as well as identifying additional potential drug combinations for clinical applications. Using female
non- or never smoker-derived lung adenocarcinoma cell lines that are sensitive to the combination of cisplatin, paclitaxel and
LP-300, we intend to analyze the induction of expressed genes in a time and concentration-dependent manner. Identification of a
pharmacodynamic biomarker that would be relevant at a lower dose of LP-300 could be a potentially valuable outcome of this investigation.
We intend to employ established cell lines with known genetic backgrounds as well as fresh patient tumor specimens as <I>in vitro
</I>or <I>ex vivo </I>model systems to perform drug response assays and genomic/ transcriptomic profiling. We believe these studies
may assist with determination of correlations between frequently occurring known driver mutations or resistance-related alterations
in ALK, EGFR, MET, ROS1 etc. and sensitivity to LP-300.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Planned Phase II Clinical Trial for
LP-300</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to conduct
a Phase II clinical trial of LP-300 in patients with adenocarcinoma NSCLC that are believed most likely to respond to treatment
based on the characteristics of the tumor being treated and other preclinical studies being conducted with CROs and key collaborators.
This proposed clinical trial will be subject to obtaining input from the FDA and other regulatory bodies, as well as approval by
investigators and Institutional Review Boards.&nbsp; We anticipate employing a combination therapy approach that includes a doublet
chemotherapy treatment. Our planned clinical trial of LP-300 may span over a two year period or more in either a single center
or in multi-center locations involving approximately 40 to 75 patients diagnosed with adenocarcinoma NSCLC with little to no history
of smoking and no prior chemotherapy treatment. We further anticipate that the primary objective of the study will be to investigate
the response to treatment with a recommended Phase II dose of LP-300 in combination with chemotherapy in non- or never smoking
patients with NSCLC.&nbsp; Secondary objectives may include (i) to assess the efficacy of LP-300 in combination with chemotherapy
in patients with NSCLC and non- or never smoking status, (ii) to assess the efficacy of LP-300 in combination with chemotherapy
in non-smoking females versus non-smoking males with NSCLC, (iii) to further investigate the safety and toxicity profile/tolerability
of the LP-300 and chemotherapy combination, and (iv) to investigate biomarkers correlated with potential efficacy of LP-300 in
paired tumor biopsies.&nbsp; We expect that the primary endpoint of the study will be overall survival with possible secondary
endpoints of (i) progression-free survival, (ii) objective response rate, (iii) identification of gene signatures correlated with
potential LP-300 efficacy from matched tumor tissue analysis, and (iv) protection against chemotherapy-induced nephrotoxicity.
We have contracted with Patheon API Services, Inc., a division of Thermo Fisher Scientific, Inc., to manufacture a sufficient quantity
of the active pharmaceutical ingredient for LP-300 to conduct a phase II trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our RADR<SUP>&reg;</SUP> Platform&rsquo;s
Approach to LP-300 Repositioning</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our RADR<SUP>&reg;
</SUP>platform is being implemented with the objective of uncovering insights from LP-300 rescued preclinical data as well as from
lung cancer clinical trial data regarding actionable bioinformatics, biomarkers, target population demographics and smoking history.
Differential expression analyses of RNAseq data on LP-300 pre- and post-exposure in selected NSCLC cell lines has revealed gene
sets that could be upregulated and downregulated in response to LP-300 treatments involving the mapping of genes performing cellular
redox functions, kinases involved in proliferating signaling, and apoptotic markers. We are currently in the early stages of defining
a specific biomarker signature that correlates with heightened sensitivity to LP-300. We believe that this signature may help accelerate
the clinical development of LP-300 and has the potential to guide patient selection for targeted clinical trials. We are also developing
a list of approved cancer drugs that, when used in combination with LP-300, may have potential to improve the overall benefit to
patients through either potentially greater anticancer properties or improved tolerability. We believe identifying such combinations
would be attractive to established pharmaceutical and biotech companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Acquisition of Tavocept<SUP>&reg;</SUP> (LP-300) Rights from
BioNumerik</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2018, we
entered into an Assignment Agreement (the &ldquo;Assignment Agreement&rdquo;) with BioNumerik Pharmaceuticals, Inc. (&ldquo;BioNumerik&rdquo;),
pursuant to which we acquired rights to domestic and international patents, trademarks and related technology and data relating
to LP-300 for human therapeutic treatment indications. Mr. Margrave, our Chief Financial Officer and Secretary, formerly served
as the President, Chief Administrative Officer, General Counsel and Secretary of BioNumerik and has a minority ownership interest
in BioNumerik. The Assignment Agreement replaced a License Agreement that was entered into between us and BioNumerik in May 2016.
We made upfront payments totaling $25,000 in connection with entry into the Assignment Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we commercialize
LP-300 internally, we will be required to pay to the BioNumerik-related payment recipients designated in the Assignment Agreement
a percentage royalty in the low double digits of cumulative net revenue up to $100 million, with incremental increases in the percentage
royalty for net cumulative revenue between $100 million and $250 million, $250 million and $500 million, and $500 million and $1
billion, with a percentage royalty payment that could exceed $200 million for net cumulative revenue in excess of $1 billion. In
addition, we have the right to first recover certain designated portions of patent costs and development and regulatory costs before
the payment of royalties described above. We are obligated to make royalty payments under the Assignment Agreement during the &ldquo;Agreement
Term<B>&rdquo; </B>that started on January 5, 2018 and continues (on a country-by-country and product-by-product basis) until the
later to occur of (i) five (5) years after the expiration of the last to expire Patent Rights, as defined in the Assignment Agreement,
in an applicable country in the Territory, as defined in the Assignment Agreement, and (ii) if no Patent Rights exist in such country,
fifteen (15) years after May 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
we enter into a third party transaction for LP-300, we are required to pay the BioNumerik-related payment recipients a specified
percentage of any upfront, milestone, and royalty amounts received by us from the transaction, after first recovering specified
direct costs incurred by us for the development of LP-300 that are not otherwise reimbursed from such third party transaction.
In addition, the Assignment Agreement provides that we will use commercially diligent efforts to develop LP-300 and make specified
regulatory filings and pay specified development and regulatory costs related to LP-300. The Assignment Agreement also provides
that we will provide TriviumVet DAC (&ldquo;TriviumVet&rdquo;) with (i) specified data and information generated by us with respect
to LP-300, and (ii) an exclusive license to use specified LP-300-related patent rights, trademark rights and related intellectual
property to support LP-300 development in non-human (animal) treatment indications. Under the Assignment Agreement, we are required
to pay all patent costs on covered patents related to LP-300. Patent costs paid by us with respect to LP-300 related patents amounted
to approximately $59,000 and $74,000 for the years ended December 31, 2018 and December 31, 2019, respectively. These patent costs
are fully recoverable at the time of any net revenue from LP-300, with up to 50% of net revenue amounts to be applied towards repayment
of patent costs until such costs are fully recovered. In addition to the recovery of patent costs, we have the right to recover
the $25,000 upfront payments made in connection with entry into the Assignment Agreement, which payments are recoverable prior
to making any royalty or third-party transaction sharing payments. We also have the right to recover all previously incurred LP-300
development and regulatory costs, with up to a mid-single digit percentage of net revenue amounts to be applied towards repayment
of development and regulatory costs until such costs are fully recovered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>LP-184</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>General Overview</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LP-184 (hydroxyureamethylacylfulvene)
is currently in preclinical development. LP-184 is a small molecule drug candidate that is a next generation alkylating agent that
preferentially damages DNA in cancer cells that overexpress certain biomarkers. It is from the fulvene class of compounds. LP-184
has nanomolar potency and it is a member of a new generation of acylfulvenes, a family of naturally-derived anticancer drug candidates.
Earlier generations of acylfulvenes showed great promise in preclinical studies, but were hampered in human clinical studies because
of the inability to deliver effective therapeutic doses due to unacceptable toxicities to normal cells. In preclinical studies,
LP-184 has shown significantly enhanced antitumor activity and substantially reduced toxicity as compared to earlier generation
acylfulvenes. In addition, we have used our RADR<SUP>&reg;</SUP> platform, together with work of collaborators, to develop a patient-specific
biomarker test we believe will be predictive of LP-184&rsquo;s anticancer activity in targeted patient populations. We plan on
using this test to facilitate patient selection in our planned Phase 1 clinical trial for LP-184. The chemical structure of LP-184
is depicted below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><IMG SRC="image_013.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">LP-184 Chemical Structure</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have conducted LP-184
preclinical studies using fresh biopsy material from patients with advanced prostate cancer, which we see as a potential LP-184
indication. In addition, we are also evaluating LP-184 in a number of solid tumors that overexpress certain biomarkers that have
been identified as correlating with potential response to LP-184. Preliminary analysis suggests that LP-184 is also expected to
be a pro-drug likely activated by the enzyme Prostaglandin Reductase&nbsp;1 (&ldquo;PTGR1&rdquo;). We believe LP-184&rsquo;s mechanism
of action is to alkylate DNA and protein macromolecules, form adducts, and arrest cells in the S-phase of the cell cycle.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In preclinical studies,
LP-184 has demonstrated tumor regression in a xenograft mouse model of multi-drug resistant lung adenocarcinoma without dose-limiting
toxicities. In mouse model studies, LP-184 further demonstrated favorable <I>in vivo</I> pharmacokinetic properties including increased
half-life, plasma stability and bioavailability with reduced total body clearance. Further preliminary results from mouse studies
reveal a better <I>in vivo</I> hematological profile for LP-184 with decreased neutropenia and thrombocytopenia events.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Using our RADR<SUP>&reg;
</SUP>platform, we have derived a 10-gene signature composed of candidate biomarkers determining sensitivity to LP-184. Genes from
this signature, such as PTGR1, were found to be implicated in the potential induction of bioactivation of LP-184. We believe LP-184
may be well positioned as a new drug candidate for individual patient genetic profiles identified as having DNA repair complex
deficiencies or other commonly prevalent gene signatures. LP-184 displayed less bone marrow toxicity in preclinical studies (dog
and mouse), had an improved pharmacokinetic profile (increased bioavailability as reflected by increased AUC), was stable in plasma,
and had an increased shelf life or stability in pharmaceutical grade material (sterile glass containers) for its class of compounds.
LP-184 retained selective cytotoxicity towards solid tumor derived cell lines <I>in vitro</I>. LP-184 can be synthesized from original
stock material (Illudin S) with additional steps.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe LP-184 is
a non-hormone, non-chemotherapy, next generation alkylating agent with nanomolar potency that preferentially damages DNA in cancer
cells that overexpress certain biomarkers indicated primarily in solid tumors such as those in prostate, pancreatic and ovarian
cancers. LP-184 was developed using combinatorial chemistry approaches. Based on screening against conventional therapies both
<I>in vitro</I> and <I>in vivo</I>, LP-184 cytotoxicity appears to be mediated through the Transcription Coupled Nucleotide Excision
Repair (TC-NER) pathway, via alkylation of DNA leading to cell cycle arrest in S phase. Additional cytotoxic effects on tumors
may include the generation of reactive oxygen species, chemical modification of various intracellular proteins, and induction of
the Mitogen Activated Protein Kinase (&ldquo;MAPK&rdquo;) pathway followed by apoptosis. A proposed model for the mechanism of
action of LP-184 is illustrated below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt"><IMG SRC="image_014.jpg" ALT="" STYLE="height: 368px; width: 624px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We anticipate that
the results from ongoing preclinical cell line studies will inform the targets for broader indications for LP-184 in solid tumors.
Our RADR<SUP>&reg;</SUP> platform has identified multiple solid tumor cancer indications that highly express PTGR1, including prostate,
ovarian, kidney, liver, lung, pancreatic and thyroid cancers. Our RADR<SUP>&reg;</SUP> platform will be employed to correlate results
from ongoing preclinical studies with gene expression data to attempt to determine the likely anticancer activity of LP-184 in
these cancer indications. Based on these results, we intend to conduct follow-up studies in patient derived xenografts (PDX) models
to further elucidate precise targets and potential patient groups for future LP-184 clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>LP-184 Biomarker Background Using Our RADR<SUP>&reg;</SUP>
platform </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LP-184 biomarker studies
are being conducted by us to investigate the validity of relevant biomarkers. An NCI-60 cell line panel is being used to obtain
gene expression data and sensitivity data (GI<SUB>50</SUB>). Determination of potential biomarkers for LP-184 target indications
is performed by correlation analysis between normalized gene expression and GI<SUB>50</SUB> values followed by biological and statistical
filtering. For further testing, we intend to acquire biopsy tissues (from prostate and ovarian cancer patients) to perform gene
expression analysis, predict potential drug response using Artificial Intelligence and machine learning and validate the results
experimentally by preclinical drug sensitivity testing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our RADR<SUP>&reg;</SUP>
platform was used to analyze our dataset on preclinical LP-184 sensitivity to and baseline gene expression profiles of 57 cell
lines from the NCI-60 panel. Panel A in the figure below highlights the comparison of LP-184 sensitivity prediction accuracy across
a range of biomarker numbers. Starting from greater than 18,000 genes, our RADR<SUP>&reg;</SUP> platform identified the 10 most
significant genes as predictive of response to LP-184 treatment. As depicted in panel B below, out of 18 cell lines included in
the blinded test set, our RADR<SUP>&reg;</SUP> platform correctly predicted all 10 out of the actual 10 sensitive cell lines. Panels
C and D show model performance metrics such as area under curve (AUC) and confusion matrix representation, respectively. Model
training was performed using an initial set of 66 genes derived from 39 cell lines from the NCI-60 dataset. Model testing was conducted
on 18 cell line records isolated as the blinded hold-out set.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that genes
from the 10 identified by our RADR<SUP>&reg;</SUP> platform have been shown to be functionally involved in the postulated mechanism
of action of LP-184, thereby reaffirming our belief in the utility and value of our RADR<SUP>&reg;</SUP> platform. We intend to
further extend and validate these cell line-derived preliminary biomarker analyses using LP-184 sensitivity and gene expression
data derived from fresh tumor biopsy samples. Our goal is to determine the molecular profiles of patient tumors that predict potential
drug response and to derive a diagnostic assay for stratifying patients. We believe that precision biomarker approaches increase
the likelihood that a treatment will be found to be effective in a relatively small phase II cohort by eliminating the most likely
non-responders and selecting the most likely responders. We anticipate that our RADR<SUP>&reg;</SUP> platform driven determination
of molecular profiles of tumor tissues that are sensitive to LP-184 will greatly assist with stratification of patients in a future
phase II clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><IMG SRC="image_015.jpg" ALT="" STYLE="height: 241px; width: 624px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As described above,
analysis of LP-184 using our RADR<SUP>&reg;</SUP> platform yielded a 10-gene pan-cancer signature of candidate biomarkers associated
with LP-184 sensitivity. We intend to further validate these preliminary biomarker analyses using LP-184 sensitivity and pre-treatment
gene expression data derived from <I>ex vivo</I> models of fresh tumor biopsy samples from selected cancer indications. Furthermore,
gene weightage analysis was performed using Garson&rsquo;s function to analyze the relative ranking of 10 genes in the LP-184 signature
associated with anticancer sensitivity. We believe that PTGR1 stands out as the gene with the highest relative importance for purposes
of determining LP-184 sensitivity.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><IMG SRC="image_016.jpg" ALT="" STYLE="height: 422px; width: 650px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The effect of gene
expression on the response variable was also studied across the identified LP-184 signature genes using the Lek&rsquo;s profile
function as depicted below. We believe that the high expression of PTGR1 is significantly correlated to a possible positive anticancer
response to LP-184. The Lek&rsquo;s profile method explores the relationship of the outcome variable and a predictor of interest,
while holding other predictors at constant values.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><IMG SRC="image_017.jpg" ALT="" STYLE="height: 395px; width: 650px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Numerous studies have
determined that PTGR1 expression is elevated in several tumor types, including prostate. Our RADR<SUP>&reg;</SUP> platform analyses
indicate that tumor cells with high PTGR1 expression may be more sensitive to DNA damaging drugs like LP-184. Independent studies
suggest that PTGR1 may be responsible for converting LP-184 to its active form. These two results support our belief that PTGR1
is the most prominent biomarker for predicting LP-184&rsquo;s potential anticancer activity in targeted tumor types. Clinical mapping
of PTGR1 expression profile was performed in independent historical datasets of unselected prostate cancer patients. Using our
RADR<SUP>&reg;</SUP> platform, we analyzed historical data from a total of 2,204 prostate cancer patients from 14 different studies
and identified that on average 30% of the patient population showed high PTGR1 expression, and 39% of the patient population showed
intermediate PTGR1 expression, representing a group of patients that has the potential to be at least partial responders to LP-184.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Disease Background for Prostate,
Ovarian and Liver Cancer</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Initial target patient
populations for LP-184 include advanced cancers of the prostate and ovary. Based on computational analysis of <I>in vitro</I> cell
line sensitivity data, we believe additional cancer types, including liver, kidney and thyroid, deserve further consideration as
target indications in which LP-184 is predicted to have potential anticancer activity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Prostate Cancer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prostate cancer is
the most commonly diagnosed cancer in men in the US and the second leading cause of cancer-related death in men in the US. The
American Cancer Society&rsquo;s estimates for prostate cancer in the United States for 2019 are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Approximately 174,650 new cases of prostate cancer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Approximately 31,620 deaths from prostate cancer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Approximately
50% of patients who die from prostate cancer have metastases at diagnosis. The survival gains over the last decade have been modest
with acceleration in life-extending drug development occurring in the last three years. Hormonal therapy works to reduce testosterone
levels in the body to a level equal to that seen if physical castration were to occur. However, hormonal therapy can become refractory
after one to three years and tumor growth may resume. This is referred to as Castration-Resistant Prostate Cancer (&ldquo;CRPC&rdquo;).
About 10 - 20 % of prostate cancer patients develop CRPC within five years. According to JP Morgan, in 2011, approximately 136,000
men were treated for CRPC. Typically, standard hormonal therapy involving Androgen Deprivation Therapy (ADT) was prescribed in
the past for all comer patients. Current prescribed regimens involve intensified therapy for most patients (docetaxel for high
volume disease, and Zytiga for low and high volume disease) whereas upcoming molecularly selected agents in addition to hormonal
therapy are used in an individualized approach to metastasis-directed or local therapy. Standard of care agents for prostate cancer
include without limitation (i) Androgen production suppressors, such as Leuprolide (Lupron, Eligard), Goserelin (Zoladex), Triptorelin
(Trelstar), Histrelin (Vantas), Abiraterone (Zytiga), (ii) Androgen signaling blockers, such as Flutamide (Eulexin), Bicalutamide
(Casodex), Nilutamide (Nilandron), and Enzalutamide (Xtandi), and (iii) chemotherapeutics such as docetaxel and cabazitaxel. Drug
classes of new small molecules in development include PARP inhibitors, PI3K inhibitors and DNA Damage Repair (DDR) inhibitors.
The PARP inhibitor rucaparib (Rubraca) has recently been approved by the FDA. The identification and characterization of new molecular
targets, agents exploiting new or non-parallel mechanisms of action, and the discovery of predictive biomarkers for mCRPC, are
three of the major unmet needs in the prostate cancer space in the era of precision medicine that we believe LP-184 may address.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>Ovarian Cancer
</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">According
to the American Cancer Society and other published sources, ovarian cancer is the second most common gynecologic cancer in the
US. Ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive
system. Ovarian cancer is the second most common gynecologic malignancy in developed countries, with an incidence of 9.4 per 100,000
women and a mortality rate of 5.1 per 100,000. In developing countries, it is the third most common gynecologic malignancy, with
an incidence of 5.0 per 100,000 and a mortality rate of 3.1 per 100,000. About 85% of ovarian cancer patients stop responding to
or relapse within two years after first line therapy. The American Cancer Society estimates for ovarian cancer in the US for 2019
are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Approximately 22,530 women will receive a new diagnosis of ovarian cancer.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Approximately 13,980 women will die from ovarian cancer.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">A
woman&rsquo;s lifetime risk of developing ovarian cancer is 1 in 75, and her chance of dying of the disease is 1 in 1004. The disease
typically presents at late stage when the 5-year relative survival rate is only 29%. Few cases (15%) are diagnosed with localized
tumor (stage 1) when the five-year survival rate is 92%. The overall five-year relative survival rate generally ranges between
30%&ndash;40% across the globe and has seen only modest increases (2%&ndash;4%) since 1995.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Carboplatin
in combination with paclitaxel has been the standard of care in the adjuvant and first-line settings for ovarian cancer, and, despite
all relevant efforts, improving upon this standard in clinical practice has proven extremely hard. Attempts to improve survival
and response rates using a triplet rather than the traditional doublet have failed to demonstrate any effective advantage. Prolonging
antineoplastic therapy after the conventional 5 to 6 cycles also was not reported to provide significantly better outcomes. Intraperitoneal
or dose-dense chemotherapy, and alternative platinum doublets, have been tested alongside targeted therapies such as bevacizumab,
pazopanib, nintedanib and PARP inhibitors (olaparib/ rucaparib) with limited success to date. At present, alternatives to standard
therapy do exist, but none has proven to be superior to conventional treatments, with the notable exception of carboplatin-paclitaxel
plus bevacizumab. In light of available data, none of the other options can be considered a &ldquo;new standard&rdquo; that fits
all. We believe that LP-184 has the potential to serve patient subgroups from multiple cancer types based on their gene signature
status in a tissue-agnostic manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>Liver Cancer</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">According
to estimates published by the American Cancer Society and other published sources, liver cancer incidence has more than tripled
since 1980. Liver cancer develops approximately three times more often in men than in women. Liver cancer death rates have increased
over 2% per year since 2007. The American Cancer Society&rsquo;s estimates for primary liver cancer (hepatocellular carcinoma)
and intrahepatic bile duct cancer (cholangiocarcinoma) in the US for 2019 are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Approximately 42,030 new cases (29,480 in men and 12,550 in women) will be diagnosed</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Approximately 31,780 people (21,600 men and 10,180 women) will die of these cancers</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Market Opportunity for LP-184</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are targeting a
set of indications for LP-184 based on combining the factors of predicted response, unmet clinical need and market opportunity.
These include prostate, ovarian and liver cancers. Below is an overview of relevant patient numbers and market sizes that we believe
LP-184 may potentially address, if approved, based upon published estimates by the Global Cancer Observatory and other published
sources:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Prostate cancer</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Global</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify; text-indent: -9pt; padding-left: 9pt">Total 2019 prostate cancer estimated incidence (new cases)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,300,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">174,650</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -9pt; padding-left: 9pt">CRPC incidence, ~20% of all prostate cancer</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">260,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">34,930</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; text-indent: -9pt; padding-left: 9pt">Metastatic CRPC incidence, ~80% of newly diagnosed CRPC</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">208,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,944</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; text-indent: -9pt; padding-left: 9pt">Patient fraction in target segment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Ovarian cancer</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Global</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Total 2019 ovarian cancer estimated incidence (new cases)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">300,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">22,530</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Estimated patients not responding to or relapsing within 2 years after first line therapy (85% of all ovarian cancers)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">255,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">19,150</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Patient fraction in target segment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">85</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">85</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Liver cancer</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Global</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">US</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Total 2019 liver cancer estimated incidence (new cases)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">841,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">42,030</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Estimated patients with hepatocellular carcinoma (75% of all liver cancers)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">630,750</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">31,522</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -9pt; padding-left: 9pt">Patient fraction in target segment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">75</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Summary of LP-184 Preclinical Studies
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Below is a summary
of preclinical studies conducted on LP-184:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>LP-184 screening studies using MV522
lung cancer line.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In cell line screening
studies, LP-184 retained toxicity against the MV522 lung cancer line but displayed reduced toxicity against the normal 8392 B cell
and CHRF 288-11 megakaryocyte lines (platelet precursors). From the NCI-60 cell line panel, LP-184 demonstrated increased tumor-killing
activities against a variety of cancer cell lines, notably prostate, ovarian, lung and renal cancers. These observations are summarized
below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Cell Line</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>LP-184 <BR>
IC<SUB>50 </SUB>(nM)</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">8392 Normal B Cells</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">&gt;100,000</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="width: 88%; text-align: justify">CHRF 288-11 Megakaryocytic Cells</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">8,800</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">PC3 Prostate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">140</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">DU145 Prostate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">OVCAR3 Ovarian</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">100</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">OVCAR5 Ovarian</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">45</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">A549 Lung</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">70</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">A498 Renal</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">25</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">MV522 Lung (multi-drug resistant)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">210</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In hematotoxicity studies,
animals were treated 3 times per week for 3 weeks with control (sterile saline), or LP-100 at 10 mg/kg (MTD), or LP-184 at 10 mg/kg
(80% MTD). N=6, mean + SD. LP-184 neutrophil and platelet results vs LP-100; p &lt;0.02. Based on these studies, we believe LP-184
shows potential for an enhanced <I>in vivo</I> hematological safety profile. LP-184 appears less toxic to normal blood cells than
LP-100. Studies in mice showing WBC differentials data indicated that LP-184 induces less thrombocytopenia and neutropenia than
LP-100. The tables and figure below summarize these observations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Groups of 6 mice treated 3X per week for 3 weeks with 10
mg/kg drug</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Analyte</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Control</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">LP-100</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">LP-184</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">White blood cell count*</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">4.57&plusmn;0.82</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.97&plusmn;0.44</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3.02&plusmn;0.67</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Neutrophil count*</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.61&plusmn;0.19</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.51&plusmn;0.03</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.03&plusmn;0.11</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: justify">Hemoglobin (g/dL)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">9.9</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">8.2</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">10.6</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Platelet count*</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">574&plusmn;127</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">384&plusmn;64</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">587&plusmn;149</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Cells per microliter</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In both human plasma
and in mice, LP-184 demonstrated a superior pharmacokinetic property profile compared to LP-100.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Pharmacokinetic property</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">LP-100</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">LP-184</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">Half life (h)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">0.1</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2.4</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">AUC (ng*h)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">695</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2200</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Cmax (ng/ml)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5650</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9730</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><IMG SRC="image_018.jpg" ALT="" STYLE="height: 396px; width: 450px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><IMG SRC="image_019.jpg" ALT="" STYLE="height: 396px; width: 450px"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Xenograft studies by Staake, et al.
2016</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In a preclinical animal
study by Staake MD, et al. of Hydroxyurea derivatives of irofulven with improved antitumor efficacy reported in Bioort Med Chem
Lett. 2016: 26(7): 1836-1838, LP-184 treatment indicated a greater tumor regression in a mouse model with human cancer than LP-100.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LP-184 was tested in
a variety of xenograft models including MV522 lung adenocarcinoma and was found to be superior to LP-100 in its ability to induce
tumor regression or complete tumor remission. As described in the following figure, treatment with LP-184 demonstrated substantial
regression of lung cancer tumors in mice treated with the 10 mg/kg and 20 mg/kg doses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_020.jpg" ALT="" STYLE="height: 411px; width: 550px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Glioblastoma</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Glioblastoma is a fast-growing,
aggressive type of CNS (Central Nervous System) tumor that forms on the supportive tissue of the brain. Glioblastoma is the most
common grade IV brain cancer. <FONT STYLE="background-color: white">The American Cancer Society estimates that approximately 23,890
brain and other nervous system cancers (13,590 men and 10,300 women) will occur in the U.S. in 2020. It also estimates that in
2020, approximately 18,020 deaths will occur from brain and other nervous system cancers. Approximately 240,000 new glioblastoma
cases are estimated to occur each year worldwide, with approximately 11,000 to 13,000 new glioblastoma cases estimated to occur
each year in the U.S. </FONT>Glioblastomas usually affect adults. Treating glioblastoma is very difficult due to the brain-blood
barrier and treatment often focuses primarily on relieving symptoms. <FONT STYLE="background-color: white">The standard treatment
for glioblastoma includes radiation and chemotherapy with temozolomide. Based on an article in the journal Genes and Diseases (<I>Temozolomide
resistance in glioblastoma multiforme</I>, Genes Dis., 2016 May 11;3(3):198-210) and other publications, at least fifty percent
of temozolomide treated patients do not respond to this treatment, and others often form resistance to temozolomide based regimens.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on recent observations
and a preclinical study, we believe that LP-184 could have potential as treatment (alone or in combination with other treatments)
for glioblastoma, which is an aggressive type of cancer that begins in the brain and accounts for more than half of all brain cancers.
Our A.I. platform has helped to uncover biomarkers that may make a patient more responsive to LP-184 for the treatment of glioblastoma
as well as LP-184 in combination with other approved therapies. We have filed a patent application on this discovery.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Ongoing and Planned Preclinical Studies
for LP-184</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For LP-184, we have
conducted and planned the following preclinical studies:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>Cell line sensitivity
studies.</I> We have partnered with a CRO to generate key preclinical data on LP-184 anticancer activity profiles in various cancer
types. The goal of this study is to generate dose response curves and associated IC<SUB>50</SUB> values for LP-184 as monotherapy
on 41 different cancer cell lines representing prostate, NSCLC, ovarian, liver, kidney and thyroid cancer indications. PTGR1 transcript
levels in these cell lines are generally known, and will help to determine correlations between LP-184 cytotoxicity and PTGR1 gene
expression. LP-184 sensitivity profiles in cell lines from various cancer types, including liver, NSCLC and ovarian, were compared
with publicly available data for standard of care chemotherapy agents cisplatin and pemetrexed that are commonly prescribed in
NSCLC. In this cell line panel, LP-184 showed nanomolar potency whereas cisplatin and pemetrexed were less effective. A representative
chart demonstrating the superior potency of LP-184 is depicted in the graph below. From this ongoing study, we hope to identify
tumor types in addition to prostate that would be key potential targets for future clinical trials. LP-184 could potentially be
positioned to treat tumors not just based upon tissue of origin or histology, but upon the PTGR1 expression status of the tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="image_021.jpg" ALT="" STYLE="height: 381px; width: 624px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have now demonstrated
LP184 activity in a panel of NSCLC cell lines. The data we have obtained support LP-184&rsquo;s potential as a candidate for lung
cancers that carry mutations in genes such as KEAP, which otherwise make such tumors refractory to alkylating agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">By utilizing wet lab
generated IC50 values across several tumor cell lines, including prostate, NSCLC, ovarian, liver, kidney and thyroid cancer, we
reaffirmed and validated our RADR generated signature as a robust predictive tool to assess sensitivity in tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have now confirmed
that the racemically pure negative isomer of LP-184 is several orders of magnitude superior to the positive enantiomer, while retaining
differential toxicity between tumor cells and normal cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are in the process
of translating the leads generated by our A.I. based in silico analysis to confirm the most optimal drug combinations that would
best enhance the efficacy of LP-184 and broaden potential indications of its utility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The strong antitumor
response of LP-184 observed in glioblastoma cell lines, prompted our further assessment of LP-184 as a candidate for glioblastoma
and other CNS tumors. Since CNS tumor effective agents require the ability to cross the blood brain barrier (BBB), we used in silico
analysis to determine the potential of LP-184 to penetrate BBB. Positive results from such analysis led us to partner with a CRO
to validate the ability of LP-184 to cross the BBB in a multicellular <I>in vitro</I> model. Based on this research, we believe
LP-184 is as efficacious as the standard of care Temozolomide in penetrating the BBB. These data have now led to a strategic collaboration
with investigators at <FONT STYLE="background-color: white">The Kennedy Krieger Institute, an affiliate of</FONT> the Johns Hopkins
School of Medicine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Strategic Academic Collaborations
for LP-184</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are or have been
involved in the following academic collaborations for LP-184:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Georgetown University</I>. We have entered into the second phase of our collaboration with Georgetown University. In the first phase, we confirmed the efficacy of LP-184 in a panel of prostate cancer organoid models. In the second phase, we will focus on wet lab validation of the leads generated by our A.I. models of the gene dependency of most sensitive prostate cancers. This project is intended to provide necessary experimental data for use of LP-184 in a personalized medicine approach to treating prostate cancer. Our gene correlation data has highlighted the deficiency of several pathways that hypothetically would allow LP-184 to be synthetically lethal in tumors with such disruptions. Our RADR analysis also indicates that as many as 20% of prostate cancers carry markers that will make these tumors highly sensitive to LP1-84. In Phase 2 or our collaboration with Georgetown, we are focusing on the development of gene specific isogenic engineered prostate cancer cell lines to dissect the pathways as well as extend the 2D and 3D prostate cancer studies to in vivo genomically defined prostate cancer PDXs. In addition, we have designed studies that will test LP-184 in combination with several other drugs that are known to inhibit pathways needed to repair damage to DNA caused by LP-184. The advantage of combining our DNA damaging agent along with a DNA damage repair inhibitor is that it is expected to substantially extend the tumor specific efficacy of LP-184, including prostate cancers that might otherwise not carry deficiencies in the DNA repair pathway. We expect that the drug sensitivity data and genomic data from these studies will further guide optimal positioning of LP-184.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Memorial Sloan Kettering Cancer Center</I>. We collaborated with the Memorial Sloan Kettering Cancer Center to evaluate LP-184 efficacy in preclinical models of cancer with defective DNA damage repair backgrounds, specifically ERCC3 mutations that are relatively common in hereditary breast and ovarian cancers. This study helped us in our efforts to (i) identify biomarkers (genomic, transcriptomic and/ or proteomic) associated with transcription-coupled nucleotide excision repair (TC-NER), the DNA repair pathway that acylfulvenes are known to target, and (ii) develop strategies for targeting vulnerabilities in this pathway during tumor growth (i.e. identify additional genetic backgrounds in this DNA repair pathway that can act with LP-184 in a synthetically lethal manner to inhibit tumor growth). Evidence from <I>in vitro</I> cell line work provided independent support for our belief in LP-184 anticancer activity in an engineered ERCC3 mutant breast cancer cell line model. The observed growth inhibition in this model fit well with the previously reported sensitivity range for LP-184 in the NCI-60 breast cancer cell line panel. This project provides a foundation to explore hereditary cancers with certain DNA damage repair deficiencies as potential indications for future LP-184 studies. An extrapolation of the results from this collaboration, when linked in the context of recent data and publications and other observations regarding acylfulvene mechanism of action, supports the potential for LP-184 to act as a synthetic lethal agent in tumors that carry mutations in ERCC3.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>The Research Institute of Fox Chase Cancer Center (&ldquo;FCCC&rdquo;)</I>. Our ongoing collaboration with FCCC has yielded results that strongly link LP-184 efficacy to the expression of PTGR1. PTGR1 was identified by our RADR analysis as the lead gene candidate, the expression of which is essential to LP-184 mediated cytotoxicity. Using CRISPR engineered cells, we have now demonstrated a total lack of activity in tumor cell lines where PTGR1 expression is artificially knocked out. These data continue to support our RADR based predictions and the strategies of using LP-184 for tumor indications based upon PTGR1 expression. Our RADR analysis has identified a multitude of tumors with a higher than required threshold of PTGR1 expression. We have further validated the activity of LP-184 in a panel of pancreatic cancer cell lines. Studies to evaluate the efficacy of LP-184 in pancreatic cancer PDX models and in xenografts are ongoing. Our intent is to use the results from these studies to support our filing for orphan drug designation for LP-184 for use in pancreatic cancers.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white"><I>Kennedy Krieger Institute and</I></FONT><I> <FONT STYLE="font-size: 10pt">the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.</FONT></I><FONT STYLE="font-size: 10pt"> We have initiated a new collaboration with <FONT STYLE="background-color: white">Kennedy Krieger Institute</FONT> and investigators at the Johns Hopkins School of Medicine. We sought this collaboration following multiple unique findings regarding LP-184, including: the efficacy of LP-184 in glioblastoma (GBM); a positive result suggesting the ability of LP-184 to penetrate the Blood Brain Barrier, in amounts similar to the GBM standard of care agent Temozolomide (TMZ); and LP-184&rsquo;s special ability to kill GBM cells irrespective of the methylation status of MGMT promoter. We believe there is an urgent unmet need for an effective therapy to treat GBM with unmethylated MGMT. Both wet lab data and RADR based gene correlations highlighted sensitivity of tumor cells that carry unmethylated MGMT to LP-184. We will seek to obtain additional data in an expanded panel of GBM tumor cell lines, neurospheres obtained from patient biopsies and evaluation of LP-184 in GBM xenografts in order to support an orphan drug designation for LP-184 for GBM. Early results from this collaboration continue to support the cytotoxicity of LP-184 in both GBM cell lines and neurospheres. Additional GBM <I>in vivo</I> studies involving animal xenografts are expected to be completed in the first quarter of 2021.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; background-color: white"><I>Clinical Trials and Research Innovation Center in Northern Ireland</I>. In 2019, we initiated a new collaboration with the Clinical Trials and Research Innovation Center in Northern Ireland (&ldquo;C-TRIC&rdquo;) on a novel preclinical ex-vivo study focused on determining gene signatures correlated with LP-184 anticancer activity in human fresh prostate tumor tissue biopsies. This study was paused due to the COVID-19 pandemic, including the impracticality of international travel and the reprioritization of projects due to the pandemic. We are collaborating with other studies in the U.S. and will evaluating recommencing the study with C-TRIC as more is learned following the end of the COVID-19 pandemic. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;<B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Ongoing pre-IND Enabling and Planned
IND Enabling Animal Studies </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We intend to obtain
toxicity data on fully synthetically produced (-) and (+) or R and S enantiomeric forms of LP-184 from cell line efficacy studies
as well as non-GLP dose range finding studies in rats. We expect to select the enantiomer with the most favorable safety and antitumor
profiles for continued analyses and further studies. Enantiomers are molecules that are non-superimposable mirror images of each
other. We have planned an animal study to determine the selection of the desired LP-184 enantiomer involving non-GLP dose range
finding in rats to compare toxicity of the enantiomers. Pursuant to the planned study, Sprague-Dawley rats will be given intravenous
(over 30 min) doses of the two compounds in sterile saline on Days 1 and 8, using a syringe pump or infusion pump. We anticipate
that the high dose will cause detectable toxicity to permit comparison between the two (+S) and (-R) enantiomers. Once an enantiomer
selection decision is made, we intend to conduct further IND-enabling animal studies involving some or all of the following: (i)
non-GLP dose range finding in rats, (ii) GLP analysis of toxicity in rats, (iii) non-GLP dose range finding in dogs, (iv) GLP analysis
of toxicity in dogs, (v) LC-MS/MS Method development for the determination of LP-184 levels in Rat and Dog Plasma, (vi) HPLC Method
development, (vii) Compatibility study of dose formulations and infusion systems (GLP), and (viii) Hemolytic potential (GLP).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Planned Phase I Clinical Trial for
LP-184</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Once regulatory clearance
has been obtained to move forward under a future IND and subject to any changes or modifications in the IND in response to comments
from the FDA, we intend to conduct a Phase I clinical trial to study LP-184 versus placebo in combination with neoadjuvant chemotherapy
for the treatment of late stage solid tumors expected to include ovarian, prostate and liver cancer with high expression of the
protein coding gene PTGR1 (Prostaglandin Reductase 1). We anticipate that the study will have a duration of 6 to 18 months and
be located in a single center or multiple centers. We intend to conduct the study in two phases. In Phase 1A, we intend to perform
a dose escalation using a standard 3 + 3 escalation strategy with a primary objective to assess the safety and toxicity profile
of LP-184 in patients with solid tumors using the NCI CTCAE v.4.03 and to determine the maximum tolerated dose (MTD). In Phase
IB we intend to perform a dose expansion involving treatment with LP-184 at the MTD in patients with metastatic solid tumors, with
a primary objective to assess the safety and toxicity profile of LP-184 at the targeted MTD in patients with advanced solid tumors.
Further planning and development of secondary objectives and primary and secondary endpoints are in process and will be subject
to FDA review and comment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>LP-100</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>General Overview</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LP-100 or
6-Hydroxymethylacylfulvene (or irofulven) exploits cancer cells&rsquo; deficiency in DNA repair mechanisms. We have
out-licensed LP-100 to Allarity Therapeutics. LP-100 is in a phase II clinical trial in androgen receptor (AR)-targeted and
Docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC) patients. We hold an exclusive license for the
development and commercialization of LP-100.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LP-100 shows multiple
cytotoxic effects on tumor cell biology such as DNA adduct formation, RNA polymerase stalling and redox protein modification. It
demonstrates enhanced sensitivity in DNA repair deficient (e.g. ERCC3 mutant or knockout) <I>in vitro</I> and <I>in vivo</I> models.
In historical testing, clinical antitumor activity for LP-100 was observed in approximately 10-12% of patients with multidrug resistant
advanced prostate cancer with notable resolution of bone metastases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>History of LP-100</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LP-100 belongs to the
family of compounds and small molecular entities (molecular weight &lt;330) that represent a class of anticancer agents derived
from fungal toxins called Illudins. Acylfulvenes were originally synthesized and developed by Drs. Michael J. Kelner and Trevor
C. McMorris at University of California at San Diego (&ldquo;UCSD&rdquo;). In 1987, Professor McMorris published the first preclinical
evaluation of the Illudins as anticancer agents and a library of hundreds of acylfulvene derivatives was created, many with significant
<I>in vitro</I> and <I>in vivo</I> antitumor activity and potentially improved selectivity for tumor cells versus normal cells.
The compound Illudin S was found to be highly cytotoxic against cancer cells, but demonstrated a poor therapeutic index. Better
understanding of the mechanism of action led to the development of a novel family of semisynthetic antitumor agents, or next-generation
acylfulvenes such as 6-hydroxymethylacylfulvene, now designated as LP-100. LP-100 is a semisynthetic derivative of Illudin S, one
of a series of sesquiterpene natural products (Illudins) isolated from the Lantern mushroom <I>Omphalotus illudens</I>. LP-100
was selected for further study based on its potential to demonstrate promising antitumor activity while maintaining a more favorable
therapeutic index, compared to previously studied Illudins. The chemical structure of LP-100 is depicted below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">LP-100 Chemical Structure</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt"><IMG SRC="image_022.jpg" ALT="" ></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Mechanism of Action</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LP-100 leads to rapid
inhibition of DNA synthesis and induction of DNA damage. LP-100 is a monofunctional covalent DNA binder that inhibits DNA synthesis
and replication, affects cell cycle and induces apoptosis. DNA repair of LP-100-induced lesions is mediated by components of the
transcription-coupled nucleotide excision repair (TC-NER) pathway. LP-100 produces damage to DNA that can only be repaired by the
TC-NER pathway. The DNA damage is unique, as two enzymes, RNA Polymerase III and Topoisomerase I (Topo 1), associated with the
TC-NER are displaced leading to irreversible inactivation of the repair pathway. Other conventional DNA damaging chemotherapeutic
agents, such as cisplatin, etoposide, doxorubicin and others, produce general damage that can be repaired by the Global Genome
Nucleotide Excision Repair (GG-NER) pathway. Tumor cells often develop multidrug resistance (MDR) making them impossible to kill
using conventional drugs. LP-100 appears to retain activity against MDR tumor cells regardless of the mechanism of resistance and
tumor cells appear less likely to become resistant to LP-100. Killing of MDR tumor cells by LP-100 reflects its unique mechanism
of disrupting the TC-NER pathway. Cell-based studies have demonstrated selective cytotoxicity of LP-100 towards a variety of solid
tumor cell lines. The tumor cells cannot recover from this damage, undergo S-phase arrest, and then irreversibly initiate both
caspase-dependent and &ndash;independent apoptosis pathways. LP-100 produces DNA damage and induces apoptotic DNA fragmentation
in several tumor cell lines. Normal diploid cells, in contrast, do not normally need repair by the TC-NER pathway unless exposed
to UV light. Treatment of mouse xenografts of human tumors with LP-100 results in tumor shrinkage. Synergistic or additive activity
is observed when LP-100 is combined with various traditional anticancer agents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LP-100 acts as a DNA
damaging agent by causing alkylation of DNA and adduct formation. It modulates the TC-NER DNA repair pathway further activating
the MAPK signaling cascade followed by apoptosis of target cells. Also, LP-100 induces RNA Polymerase II stalling in actively transcribed
regions, triggering cell death possibly due to collisions between transcriptional machinery and the replication fork. LP-100 is
not a substrate for drug efflux pumps, which helps to counteract chemoresistance to LP-100. Sensitivity to LP-100 is unlikely to
be influenced by common resistance-inducing phenomena observed for other DNA damaging agents like cisplatin. Antitumor activity
of LP-100 is independent of cellular p53 and p21 tumor suppressor gene status (such as loss of p53 or p21). LP-100 also produces
redox protein modifications by targeting key redox-controlling proteins TrxR/ GrxR. Distortion of the redox status of cellular
proteins serves as a pro-apoptotic stimulus in cancer cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>LP-100 Clinical Profile</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical studies of
LP-100 have been conducted in multiple solid tumor indications including prostate, ovarian, colorectal, pancreatic, thyroid, lung,
breast and gastric cancers. More than 38 Phase I or Phase II trials involving &gt; 1,300 patients have been conducted with LP-100.
In prior clinical trials, LP-100 showed activity and produced regression in a variety of cancers, but failed to meet required endpoints
for clinical trial success. Objective responses were reported for LP-100 single agent therapy in drug-resistant prostate (hormone
and taxotere refractory), ovarian (platinum resistant), pancreatic, sarcoma, kidney, endometrial, and lung cancers. LP-100 also
showed cancer treating potential when administered in combination with a variety of conventional chemotherapeutics including Camptosar,
GemZar, Taxotere, Xeloda, Cisplatin, and Oxaliplatin. In a study of patients who failed prior conventional therapies, two rounds
of LP-100 therapy led to rapid resolution of ovarian cancer metastasis. In a randomized Phase IIb study of patients with metastatic
hormone refractory taxotere-resistant prostate cancer, LP-100 was compared to mitoxantrone. A total of 138 patients were enrolled
and specified endpoints included overall survival, response rate, and safety assessment. The median one-year survival increased
from 22% in the mitoxantrone-treated control group to 41% in the LP-100-treated group. Median overall survival was 10.1 months
for treatment arm (LP-100 + Prednisone) and 7.4 months for control arm (Mitoxantrone + Prednisone), i.e. a 37% increase over standard
of care. Treatment was well-tolerated in all arms. The most frequent Grade 3&ndash;4 toxicities (as % of patients in treatment/control
arms) were asthenia (8%/0%), and vomiting (4%/0%). Grade 3&ndash;4 hematological events included neutropenia (22%/61%) and thrombocytopenia
(23%/4%).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2001, LP-100 received
FDA&rsquo;s fast track status and a Phase III international clinical trial for LP-100 in refractory pancreatic patients was started.
Clinical trials looked promising in shrinking tumors of drug-resistant pancreatic cancer. However, MGI Pharma stopped the Phase
III clinical trial because it was unlikely for the trial to reach its objective due to a greater than expected survival benefit
associated with the comparator agent (5-FU). In 2005, Phase II clinical trial results of LP-100 in women with recurrent and heavily
pre-treated ovarian cancer revealed retinal toxicity. This retinal damage was associated with dose and administration of drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">LP-100 has been well-tolerated,
based on initial observations from the phase II clinical trial in Europe that is being managed by Allarity Therapeutics in patients
with metastatic, castration-resistant, prostate cancer. This Phase II trial is aimed at evaluating the antitumor effect of LP-100
treatment in combination with Prednisolone in patients who have progressed on androgen receptor (AR)-targeted therapy and in docetaxel-pretreated
metastatic Castration-Resistant Prostate Cancer (mCRPC) patients. In this protocol, patients are screened using a LP-100-specific
response biomarker signature and eligible patients likely to respond to and benefit from treatment with LP-100 are recruited in
the trial. Allarity Therapeutics dosed the first patient in the trial in the fourth quarter of 2018. Continuing enrollment for
this Phase II clinical trial has slowed during the COVID-19 pandemic. Allarity Therapeutics has also stated that it is focusing
its existing resources on other programs that are currently higher priority for Allarity than LP-100. As of the date of this report,
we are unable to forecast the timeline for the completion of the Phase II clinical trial. Recently published data (also supported
by prior publications on (Irofulven) indicates that tumors carrying mutations in ERCC2 and ERCC3 genes are likely to be sensitive
to LP-100, and that the drug will be synthetically lethal in these tumors, in a fashion similar to the activity of PARP inhibitors
in BRCA deficient tumors. These observations expand the potential treatment indications for LP-100 to include urothelial tumors,
including bladder cancers, since as many as 10% of bladder cancers carry ERCC2/ERCC3 mutations. These indications may represent
a more rapid and efficient path to potential approval of LP-100, and we are evaluating possibilities aimed at maximizing the value
of these additional observations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>AF Chemicals</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">In </FONT>January 2015,
we entered into a Technology License Agreement to exclusively license global patent rights from AF Chemicals, LLC (&ldquo;AF Chemicals&rdquo;)
for the treatment of cancer in humans for the compounds LP-100 (Irofulven) and LP-184. In February 2016, we and AF Chemicals entered
into an Addendum (the &ldquo;Addendum&rdquo;) providing for additions and amendments to the Technology License Agreement. In December
2020, we and AF Chemicals entered into a Second Addendum (the &ldquo;Second Addendum&rdquo;) providing for further additions and
amendments to the Technology License Agreement. The Technology License Agreement, Addendum and Second Addendum are collectively
referred to as the &ldquo;AFC License Agreement&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Second Addendum
provides for us to make specified payments to AF Chemicals within 10 days after signing and by March 31, 2021. The Second Addendum
also provides that, from December 30, 2020 until January 15, 2025, we will have no obligation to pay annual licensing fees, development
diligence extension payments, or patent maintenance fee payments to AFC under the AFC License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of the Second
Addendum, we have agreed to apply for specified orphan drug designations for LP-184 in the US and EU. The Second Addendum also
amends and clarifies other provisions of the Technology License Agreement, and provides us with the ability to recover a portion
of initial payments made under the Second Addendum from sublicense fees or royalty payments that may be made to AFC by us or third
parties prior to January 15, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the AFC
License Agreement we made annual licensing fee payments relating to LP-184 to AF Chemicals in the amount of $30,000 during each
of the years ended December 31, 2020 and 2019. In addition, we are obligated to make milestone payments to AF Chemicals at the
time of an Investigational New Drug Application (&ldquo;IND&rdquo;) filing relating to LP-184 and also upon reaching additional
specified milestones in connection with the development and potential marketing approval of LP-184 in the United States, specified
countries in Europe, and other countries. We estimate that these payments could be as much as approximately $3,780,000 if all milestones
were achieved and LP-184 obtained marketing approval in multiple countries and for multiple therapeutic indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of a sublicense
of the LP-184 rights, we are obligated to pay AF Chemicals (a) low double digit percentage of the gross income and fees received
by us with respect to the United States in connection with such sublicense, and (b) a lower double digit percentage of the gross
income and fees received by us with respect to Europe and Japan in connection with such sublicense. We are obligated to pay royalties
under the AFC License Agreement for a term that expires upon the later of the expiration of the last patent licensed to us under
the agreement, and the last to expire orphan drug designation, if any, relating to our product candidate LP-184 or other specified
licensed technology under the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
AFC License Agreement also provides that we will pay AF Chemicals a royalty of at least very small single digit percentage of specified
net sales of LP-184 and other analogs. In addition, the AFC License Agreement contains specified time requirements for us to file
an IND, enroll patients in clinical trials, and file a potential NDA with respect to LP-184, with the ability for us to pay AF
Chemicals additional amounts ranging up to an amount in the low hundreds of thousands of dollars for each one, two, three and four
year extension to such development time requirements, with additional extensions beyond four years to be negotiated by us and AF
Chemicals. Pursuant to the Second Addendum, no additional payments of annual licensing fees or development diligence extension
payments are required to be made by us until January 15, 2025, at which time these obligations will resume. We will also be obligated
to make annual licensing fee payments to AF Chemicals relating to LP-100 beginning January 15, 2025, as described below under Allarity
Therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
AFC License Agreement has a term that expires upon the later of the expiration of the last patent licensed to us under the agreement,
and the last to expire orphan drug designation, if any, relating to our product candidate LP-184 or other specified licensed technology
under the agreement, unless sooner terminated. The AFC License Agreement may be sooner terminated by AF Chemicals if we fail to
make any payments required to be made under the agreement when due, upon a material breach of any other provision of the agreement
that is not cured within the time period specified, and upon our bankruptcy or insolvency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Allarity Therapeutics </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Allarity Therapeutics
has begun a Phase II trial of Irofulven in Denmark. With Allarity Therapeutics, we won a joint Massachusetts-Denmark grant to provide
matching funds for production of LP-100 in Massachusetts and clinical studies in Denmark. The clinical studies utilize Allarity
Therapeutics&rsquo; proprietary DRP<SUP>&reg;</SUP> biomarker screening of potential patients to select those most likely to respond
to the drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With our help, Allarity
Therapeutics has had cGMP LP-100 produced at Albany Molecular Research Inc., PCI Synthesis, a division of SEQENS CDMO and Piramal
Pharma Solutions (Lexington, KY USA). Allarity Therapeutics has used a proprietary DRP<SUP>&reg;</SUP> bioinformatics approach
to identify putative biomarkers that can predict which patients will respond based on gene expression profiles. Allarity Therapeutics
started a Phase II clinical trial in Denmark for treatment of castration-resistant metastatic prostate cancer, with the first patient
enrolled in the fourth quarter of 2018. The trial is over half way through enrollment for the first stage of the trial, although
enrollment has slowed during the COVID-19 pandemic. The trial is estimated to enroll up to approximately 27 patients. If the study
has a successful outcome, we anticipate that Allarity Therapeutics may out-license the drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Allarity Therapeutics Drug License and
Development Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2015, we licensed
various rights to LP-100 (Irofulven) to Allarity Therapeutics pursuant to a drug license and development agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the agreement,
Allarity Therapeutics is responsible for the development of LP-100 pursuant to a defined clinical development plan. The agreement
also provides for a joint development committee, including representatives from Allarity Therapeutics and us, to regularly discuss,
plan and inform the development of products under the agreement. In connection with the license under the agreement, Allarity Therapeutics
also agreed to directly pay to AF Chemicals on our behalf various specified amounts owed to AF Chemicals with respect to LP-100
under the AFC License Agreement, which amounts will then be deducted from payments to be made by Allarity Therapeutics to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Development Milestone Payments</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Pursuant
to the agreement, Allarity Therapeutics has agreed to make milestone payments to us in connection with the development of LP-100
by Allarity Therapeutics or its affiliates, or by a third party (a &ldquo;Program Acquirer&rdquo;) that assumes control of the
LP-100 development program from Allarity Therapeutics corresponding to: (i) initiation of treatment of first patient in a Phase
III clinical trial; (ii) first filing for regulatory approval in the EU; (iii) first filing for regulatory approval in the US;
(iv) first regulatory approval in the EU; and (v) first regulatory approval in the US. We and Allarity Therapeutics have also agreed
that a portion of these milestone payments will be paid directly to AF Chemicals to satisfy our obligations under the AFC License
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The above milestones
to be paid to us under the agreement are also subject to caps and floors providing that: the development milestones discussed above
for initiation of Phase III treatment and for the first filing for regulatory approval in the EU and the US shall not be less than
a specified percentage of the amount Allarity Therapeutics receives from a Program Acquirer upon the occurrence of a substantially
similar milestone; and the development milestones discussed above for first regulatory approval in the EU and the US shall not
be greater than a specified percentage of the amount Allarity Therapeutics receives from a Program Acquirer upon the occurrence
of a substantially similar milestone. With certain exceptions, the maximum aggregate amount of development milestone payments described
above to be paid by Allarity Therapeutics to us is $13,875,000 and to AF Chemicals is $7,125,000 for an aggregate total of $21,000,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the
above milestones, Allarity Therapeutics has agreed to pay us a specified percentage of any milestone payments Allarity Therapeutics
receives from a Program Acquirer that are different than the milestones described above, or a one-time payment in an amount in
the low seven figures, whichever is higher. AF Chemicals would also receive a portion of any amounts to be received by us pursuant
to this provision. The Allarity Therapeutics agreement also provides that development milestone payments (including the payments
described above) will be paid not more than once even if additional indications are developed for LP-100.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Alternate Payment Structure in Event
of Third Party Program Acquirer Agreement.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As an alternative to
the development milestone payments to be paid as discussed above, and without the $21 million payment limitation, Allarity Therapeutics
has agreed that we may select an alternate payment structure for all payments Allarity Therapeutics receives (other than royalty
payments which are described below) in the event Allarity Therapeutics enters into an agreement for LP-100 with a Program Acquirer
regarding a particular territory. We only have 15 days to make this selection from the date we receive notice from Allarity Therapeutics
that they have entered into an agreement with a Program Acquirer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we select the alternate
payment structure, then we would generally be entitled to receive a specified percentage of all amounts, other than royalty payments,
received by or on behalf of Allarity Therapeutics from the Program Acquirer, after subtraction of amounts paid or payable by Allarity
Therapeutics pursuant to the Program Acquirer agreement for taxes, other fees and payments to governmental authorities, and payments
made by the Program Acquirer to reimburse Allarity Therapeutics&rsquo; regulatory and other costs. Selection of the alternate payment
structure would not change our right to receive royalty payments from Allarity Therapeutics as described below. We have agreed
to obtain the consent of AF Chemicals prior to electing to receive payments pursuant to the alternate payment structure and no
assurances can be given that AF Chemicals would provide their consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Royalty Payments</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the
milestone payments described above, Allarity Therapeutics has agreed to pay us royalties based on annual incremental sales of product
derived from LP-100 in an amount equal to a low single digit percentage of annual sales of between $0 and $50 million, a slightly
higher single digit percentage of annual sales between $50 million and $150 million, a mid-level single digit percentage of annual
sales between $150 million and $300 million, and a slightly higher mid-level single digit percentage of annual sales in excess
of $300 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Royalties are subject
to a cap of a specified percentage of any royalty payment Allarity Therapeutics receives from a Program Acquirer. The royalty amounts
to be received by us may be subject to reduction in the event of generic competition, patent expiry, or if additional third-party
licenses are required to be obtained for the development, use or commercialization of LP-100. Royalties will generally be received
on a country by country basis until the later of: expiration of an applicable patent in a particular country; 10 years after the
first commercial sale in the country; expiration of the last to expire valid claim of a relevant patent covering the LP-100 related
product together with the use of the DRP<SUP>&reg;</SUP> biomarker, provided the product is approved only for use with the DRP
biomarker in the country; or expiration of any FDA (or any foreign equivalent) regulatory approval in each country that requires
use of the DRP<SUP>&reg;</SUP> biomarker as a companion diagnostic for the relevant product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Allarity Therapeutics
is obligated to pay royalties under the agreement on a country-by-country and product-by-product basis for a period that commences
with the first commercial sale of a product until the later of (i) the expiration of the last valid claim on the patent that covers
the product sold, or (ii) ten years after the first commercial sale of the covered product, or (iii) expiration of the last valid
claim covered by a patent using a DRP<SUP>&reg;</SUP> Biomarker as a companion diagnostic to the product sold, or (iv) on a country-by-country
basis when the regulatory approval of the DRP<SUP>&reg;</SUP> Biomarker as a companion diagnostic expires. However, the agreement
may be sooner terminated without cause by Allarity Therapeutics upon 120 days prior written notice, or immediately upon certain
regulatory actions that impede ongoing or future clinical trials, or upon written notice of a material breach of the agreement
by us that we do not cure within 60 days. We also have the right to terminate the agreement upon written notice of a material breach
of the agreement by Allarity Therapeutics that is not cured within 60 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Third Party Research and Development
Programs for Our Drug Candidates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Virtually all of our
developmental work is expected to be performed in contract labs in the near future, and most of it requires close collaboration
with these groups. Our strategic collaborations have specialized focus areas tailored to advancing our pipeline drug candidates
and provide expertise benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 39%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Collaborator</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 44%; border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-size: 10pt"><B>Focus Area</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 15%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Drug&nbsp;Candidate</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">National Cancer Institute (NCI)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Gene signature development and drug sensitivity prediction</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">LP-184</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Georgetown University</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Evaluation of drug efficacy and sensitivity in prostate and pancreatic cancer organoid models and engineered pancreatic cancer cell lines</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">LP-184</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Fox Chase Cancer Center (FCCC)</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom"><FONT STYLE="font-size: 10pt">Determination of drug efficacy in PDX tumor models</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">LP-300 &amp; LP-184</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Manufacturing Overview</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently
own or operate any manufacturing facilities or have any manufacturing personnel. We currently rely, and expect to continue to rely,
on third party contract manufacturing organizations (&ldquo;CMOs&rdquo;) for the manufacturing of our drug candidates for preclinical
uses, clinical trials as well as for commercial manufacturing if our drug candidates receive marketing approval. We require that
our CMOs produce bulk drug substances and finished drug products in accordance with current Good Manufacturing Practices (&ldquo;cGMPs&rdquo;)
and all other applicable laws and regulations. We maintain agreements with our manufacturers that include confidentiality and intellectual
property provisions to protect our proprietary rights related to our drug candidates. We have a CMO contracted to manufacture LP-184
for preclinical use. We obtain our supplies from these CMOs on a purchase order basis and do not have long-term supply arrangements
in place. We do not currently have arrangements in place for redundant supply. For all of our drug candidates, we intend to identify
and qualify additional manufacturers to provide the active pharmaceutical ingredient and fill-and-finish services prior to seeking
regulatory approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>LP-184 Manufacturing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have contracted
to Southwest Research Institute<SUP>&reg;</SUP> (&ldquo;SwRI<SUP>&reg;</SUP>&rdquo;) the development of a fully synthetic route
to (-) and (+) LP-184. The synthesis process involves development and optimization of novel chemistry via multiple intermediates
to produce (-) and (+) enantiomers of LP-184. We have contracted to SwRI<SUP>&reg;</SUP> the production of pre-GMP batch of the
desired enantiomer of fully synthetic LP-184. We intend to continue with the same supplier for manufacturing the GMP material intended
for IND-enabling animal studies as well as phase I clinical trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>LP-300 Manufacturing Plans</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the supply of LP-300
for our phase II and/or III clinical program, we have identified potential CMOs, and we believe GMP grade API material will be
readily available. We have contracted with Patheon API Services, Inc., a division of Thermo Fisher Scientific, Inc., to manufacture
a sufficient quantity of the active pharmaceutical ingredient for LP-300 to conduct a phase II trial. Our manufacturing process
and protocol for LP-300 have been well established and substantial progress towards process validation has been made from previous
campaigns that were undertaken by BioNumerik Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Commercialization</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We retain worldwide
commercialization rights for our key candidates with the exception of LP-100, which we have out-licensed to Allarity Therapeutics.
We plan to continue considering out-license and collaboration opportunities in order to maximize returns and pursue successful
development of our key candidates. We currently have no sales, marketing or product distribution capabilities. However, once we
have key candidates closer to FDA approval, we may build our own specialty sales force, partner with a larger pharmaceutical organization,
or out-license our drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are continually
evaluating out-license opportunities for our candidates at later stages of development in order to focus on identifying and licensing
additional drug candidates for novel indications and/or patient subpopulations with an oncology focus for expansion of our pipeline.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial plans
and strategy for each particular program may change as our programs advance, the markets change, we receive more clinical data,
and depending on availability of capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Intellectual Property</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
have an extensive multi-national portfolio of intellectual property rights directed to our drug candidates, and their targeted
use and development in specific patient populations and in specific therapeutic indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this
report, we own or control rights in over 70 active patents and patent applications across over 14 patent families whose claims
are directed to our drug candidates and what we plan to do with our drug candidates. We have in-licensed or acquired patents from
AF Chemicals, and BioNumerik directed to the compounds, LP-100, LP-184 and LP-300. Additionally, we have also filed patent applications
to further enhance and extend the use of these in-licensed compounds. Our patents are directed to our drug candidates, their usage,
manufacturing, and other matters. These matters are essential to precision oncology and relate to: (a) uniquely powerful, data-driven,
biologically relevant biomarker signatures, (b) patient selection and stratification approaches that rely on prediction of response
deriving from these signatures and, (c) the ability to develop novel, combination therapy approaches with existing approved therapeutics.
A recent application is directed to the use of LP-300 as a potential disulfide linker. We intend to pursue additional patent coverage
relating to the use of LP-300 as a potential linker or linking technology.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
rely on a combination of patents, trade secrets, copyrights, trademarks, license agreements, nondisclosure and other contractual
provisions and technical measures to protect our intellectual property rights in our novel drug candidates as well as our rescue
drug candidates. Additionally, we also rely on the patent applications, trade secrets, and other contractual provisions and technical
measures to protect the development of our genomic and biomarker signatures that help us in making predictions about the sensitivity
to our drug candidates, patient stratification approaches, and the development of potential combination therapies with our drug
candidates. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Intellectual
Property Portfolio by the Numbers</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
of March 2021, our intellectual property portfolio consisted of over 14 patent families covered by:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-size: 10pt">Over 50 issued patents across our portfolio of compounds in key, commercially important geographies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Over 20 pending patent applications, including three PCT applications;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">as well as two registered trademarks, two pending trademark registrations, and trademark applications in Japan, China, Europe, Canada and Australia.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
policy is to protect the proprietary technologies, inventions, and improvements that are commercially important to our business
in the United States, Europe, Japan and other key jurisdictions important to our business. &nbsp;We fully expect that additional
advances will come out of our ongoing work in developing biomarker signatures and patient stratification approaches and that these
advances will form the basis of additional intellectual property protection through new patent filings, trademarks, trade secrets,
and copyrights.&nbsp;We will continue to file patent applications and use trade secret laws to protect the uses&nbsp;of our genomic
and biomarker signatures, response prediction and patient stratification discoveries. We plan to rely on these intellectual property
advances to develop, strengthen, and maintain our proprietary position for novel therapeutics and novel formulations and uses of
existing and new compounds across multiple therapeutic areas. We also plan to rely on data exclusivity, market exclusivity and
patent term extensions when available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Patent Portfolio</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
have an extensive multi-national portfolio of intellectual property rights directed to our drug candidates, and their targeted
use and development in specific patient populations and in specific therapeutic indications. Our portfolio consists of 14 patent
families across issued patents and pending patent applications. For LP-100, we own and control two in-licensed patent families,
including issued US Patents, Japan Patents, and various issued EU Patents directed to LP-100. We have also filed seven patent applications
directed to our proprietary drug programs together with biomarkers and sensitivity parameters, two of which are being consolidated
into one application, and one additional patent application directed to our RADR<SUP>&reg;</SUP> platform. These filings include
patent applications directed to LP-300 and additional patent applications directed to new manufacturing methods for novel, synthetic
illudins, and gene signatures and biomarker profiles indicating sensitivity to LP-184 and use of LP-184 and novel synthetic illudins
in glioblastoma and CNS cancers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Our patent family directed to LP-100 has patents that expire in August 2026. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Our patent family directed to LP-184 has patents that expire in August 2026, and patent applications, if granted, that would expire as late as May 2040. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Our patent family directed to LP-300 has patents that expire in March 2028, and patent applications, if granted, that would expire as late as&nbsp;March 2040. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We typically file a
non-provisional patent application within 12 months of filing the corresponding provisional patent application. While we intend
to timely file non-provisional patent applications relating to our provisional patent applications, we cannot predict whether any
of our existing or future patent applications for our existing or future drug candidates will result in the issuance of patents
that effectively protect these candidates, or if any of our issued patents or if any of our licensor&rsquo;s issued patents will
effectively prevent others from commercializing competitive products. Patent protection for the composition of matter of the LP-300
compound itself is unavailable because the compound was first identified many years ago.&nbsp; For more information regarding the
risks related to our intellectual property, see <I>&ldquo;Risk Factors &ndash; Risks Related to Our Intellectual Property.&rdquo;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>RADR<SUP>&reg; </SUP>Platform</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not own or in-license
any patents on our RADR<SUP>&reg;</SUP> platform, but we have filed one patent application directed to our RADR<SUP>&reg; </SUP>platform
and rely on trade secrets and confidential procedures directed to protecting:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our A.I. and machine learning methodologies for our specific purposes in oncology drug development and drug rescue,</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our curation and normalization of select data from both public and proprietary data sources, and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our developing insights that can be modeled to cover biological processes as algorithms inside our RADR<SUP>&reg;</SUP> platform.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>LP-100</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our portfolio directed
to LP-100 consists of two families of in-licensed patents that were filed in 2006. The patents include European, Japanese and US
patents.&nbsp; US Patent No. 7655695 relates to acylfulvene analogs that are directed to tumor solid tumor growth inhibition.&nbsp;&nbsp;
The nominal expiration for our patents directed to LP-100 is August 2026 and does not account for any applicable patent term adjustments
or extensions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>LP-184&amp; other Novel, Synthetic
Illudin Derivatives </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our portfolio directed
to LP-184 consists of six families of patents and patent applications and includes three PCT applications.&nbsp; &nbsp;US Patent
No. 7655695 relates to acylfulvene analogs that are directed to solid tumor growth inhibition.&nbsp; The PCT applications filed
in 2019 are related to synthetic preparation methods, additional indications, and treatment of cancers using genomic stratification.
A provisional patent application filed in 2020 was directed to using LP-184 or other novel, synthetic illudin analogs or deriviatives
to treat glioblastoma or other CNS cancers as either a mono or combination therapy. A provisional patent application filed in 2020
was directed to using LP-184 or other novel, synthetic illudin analogs or derivatives to treat pancreatic cancer also as either
a mono or combination therapy. The nominal expiration for patents and patent applications directed to LP-184 ranges from 2026 to
as late as 2040 and does not account for any applicable patent term adjustments or extensions.&nbsp; We intend to nationalize our
patent applications in the US, Canada, EU, China, and Japan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have in-licensed
patents from AF Chemicals related to the composition of matter of LP-184. We have also developed additional intellectual property
for this class of compounds related to the development of novel synthetic routes and the preparation of certain illudin derivatives
having therapeutic value. Additionally, in April of 2020, we filed a provisional patent on the use of LP-184 and these novel synthetic
illudin derivatives in the treatment of glioblastoma and other CNS cancers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>LP-300</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our portfolio directed
to LP-300 consists of seven families of owned patents.&nbsp;&nbsp; A more recent PCT patent application filed in 2020 is directed
to treatment of non-small cell lung cancer (NSCLC) in nonsmokers and never smoking patients using disodium 2,2&rsquo;-dithio-bis-ethane
sulfonate (dimensa).&nbsp; The nominal expiration for NSCLC related patents and patent applications directed to LP-300 ranges from
2028 to as late as 2040 and does not account for any applicable patent term adjustments or extensions. We intend to nationalize
our patent applications in the US, Canada, EU, China, and Japan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We filed an additional
PCT application in March 2020 directed to LP-300 and its application to NSCLC, as well as biomarkers that correlate to heightened
response or sensitivity to LP-300. A recent application is directed to the use of LP-300 as a potential disulfide linker.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Confidentiality &amp; Trade Secrecy</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we enter into
non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research
and development output, such as our employees, collaborators, contract research organizations, contract manufacturers, consultants,
advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application
is filed, thereby jeopardizing our ability to seek patent protection. <FONT STYLE="background-color: white">These agreements provide
that all confidential information developed or made known during the course of an individual or entities&rsquo; relationship with
us must be kept confidential during and after the relationship. These agreements also provide that all inventions resulting from
work performed for us or relating to our business and conceived or completed during the period of employment or assignment, as
applicable, shall be our exclusive property. Third parties may also be able to develop substantially equivalent proprietary information,
platforms or compounds, or otherwise gain access to our trade secret</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Trademarks</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 30.95pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We
own various trademarks, applications and unregistered trademarks in the United States and other commercially important markets,
including our company name, our A.I. platform, and certain compounds in development. Our trademark portfolio is designed to protect
the brands for our Company, our A.I. platform and our portfolio of compounds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Other Intellectual Property</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our
intellectual property rights on the RADR<SUP>&reg;</SUP> platform are valuable and important to our business. We rely on a combination
of trademarks, copyrights, trade secrets, license agreements, confidentiality procedures, non-disclosure agreements, employee disclosure,
and invention assignment agreements, and other legal and contractual rights to establish and protect our proprietary rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Competition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
exist at the intersection of rapidly moving, global industries, namely, the biotechnology industry and the A.I. drug development
industry. This is a unique and rapidly moving category with a variety of business models being developed globally. The pharmaceutical
and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on
intellectual property. A.I. is disrupting and changing all industries, including the biotechnology industry. Although these are
competitive industries, we believe we are uniquely positioned due to our focus on oncology drug development, prediction of patient
response, use of computational biology, and the ability to both rescue and develop compounds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
face potential competition from many different sources, including major pharmaceutical and biotechnology companies, academic institutions
and governmental agencies, and public and private research institutions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Many
of the companies against which we may compete have significantly greater financial resources and expertise in research and development,
manufacturing, preclinical studies, conducting clinical trials, obtaining regulatory approvals and marketing approved products
than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements
with large and established companies. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may
result in even more resources being concentrated among a smaller number of our competitors. These competitors also compete with
us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient
registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
commercial opportunity could be reduced or eliminated if our competitors develop and commercialize medicines that are safer, more
effective, have fewer or less severe side effects, and are more convenient or less expensive than any medicines we may develop.
Our competitors also may obtain FDA or other regulatory approval for their medicines more rapidly than we may obtain approval for
ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition,
our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic
medicines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Any
drug candidates we successfully develop will compete with current and new therapies that may become available in the future. The
key competitive factors affecting the success of all of our drug candidates, if approved, are likely to be their efficacy, combinability,
safety profile, convenience, cost, the effectiveness of companion diagnostics in guiding the use of related therapeutics, if any,
the level of generic competition, level of promotional activity, intellectual property protection, and the availability of reimbursement
from government and other third-party payors. If any drug candidates under development are approved for the indications in which
we are currently planning clinical trials, they will compete with the drugs discussed below and will likely compete with other
drugs in development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Artificial
Intelligence and Drug Development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
believe our proprietary RADR<SUP>&reg;</SUP> platform gives us a significant competitive advantage by using AI to select and license
drugs with a well-tolerated safety profile to quickly and cost-effectively bring drugs to market. Recently, there has been an increase
in the use of AI for drug development that we face competition in both for developing new drugs and in biomarker development. This
includes competition to the pool of already existing drug candidates that may be eligible for patient stratification. Our competition
in AI-driven drug development for oncology includes, but is not limited to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Development of drug candidates</I></B>: A2A Pharmaceuticals, AI Therapeutics, Atomwise, Benevolent AI, Berg Health, BioXcel, Celsius Therapeutics, Exscientia, Gritstone Oncology, Deep Genomics; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B><I>Development of biomarkers and/or signatures for patient stratification and improved drug development</I></B>: Adaptive Biotechnologies, Concerto HealthAI, Datavant, Envisagenics, Erasca, and Genialis,.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Prostate
Cancer</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">New
agents are being actively developed to treat specific subtypes of prostate cancer. Our approach is to leverage A.I. and biomarker
data to discover subtypes of prostate cancer and treatments for those subtypes of cancer. We believe our approach and our compounds
take advantage of this improved characterization of prostate cancer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">There
are approved standard of care agents for treating solid tumor prostate cancer, but there are a lack of approved therapeutic options
for non-metastatic castration-resistant prostate cancer (&ldquo;nmCRPC&rdquo;) patients and castration-resistant disease in metastatic
hormone-na&iuml;ve prostate cancer (&ldquo;mHNPC&rdquo;). The competition we may face in regards to LP-100 and one of the indications
of LP-184, specifically mCRPC, includes without limitation the following drugs:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Astellas/Pfizer&rsquo;s Xtandi (enzalutamide) and Johnson &amp; Johnson&rsquo;s Zytiga (abiraterone acetate) and Clovis Oncology&rsquo;s Rubraca (rucaparib) are approved for treatment of metastatic castration-resistant prostate cancer (mCRPC). </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Xtandi Zytiga and Androgen Deprivation Therapy (&ldquo;ADT&rdquo;) to treat mHNPC and nmCRPC, respectively. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Pfizer has tested Talazoparib and Enzalutamide to treat mCRPC </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">BeiGene has used Pamiparib treat mCRPC </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Millennium Pharmaceuticals has used ADT and TAK-700, a hormonal therapy that inhibits 17,20 lyase activity of the CYP17A1 enzyme, to treat Metastatic Prostate Cancer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
believe LP-184 is unique and it has promise for use in an expanded set of proposed indications including ovarian cancer and hepatocellular
carcinoma and other indications where specific biomarker profiles indicate likely sensitivity to the treatment. We are not aware
of any drugs in development or approved that are specifically addressing this range of proposed biomarker profile targeted indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Non Small
Cell Lung Cancer (NSCLC)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
believe LP-300 may have an advantage to approved drugs on the market by serving as a well-tolerated agent in combination with multiple
existing standards of care drugs for the NSCLC patient population or female NSCLC patient population. LP-300 has shown potential
to alleviate adverse events associated with approved chemotherapeutics such as cisplatin and paclitaxel while also potentiating
their antitumor activities. LP-300 combined with cisplatin and/or paclitaxel has the potential to treat never-smoking NSCLC patients
with advanced adenocarcinoma. Due to its multi-modal mechanism of action and tolerability, LP-300 has the potential to be combined
with chemotherapy, targeted therapy and / or immunotherapy drugs.&nbsp; Beyond traditional chemotherapies, NSCLC treatments include
targeted small molecules and biologics, which include, without limitation, afatinib, brigatinib, ceritinib, crizotinib, pembrolizumab,
and ramucirumab that are used in specific NSCLC subtypes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Government Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Government authorities
in the United States at the federal, state and local level and in other countries regulate, among other things, the research, development,
testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution,
post-approval monitoring and reporting, marketing and export and import of drug and biological products. Generally, before a new
drug can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format
specific for each regulatory authority, submitted for review and approved by the regulatory authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>U.S. Drug Development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States,
the FDA regulates drugs under the Food, Drug, and Cosmetic Act (&ldquo;FDCA&rdquo;). Drugs also are subject to other federal, state
and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate
federal, state, local and foreign statutes and regulations requires the expenditure of substantial time and financial resources.
Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or
post-market may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions,
the FDA&rsquo;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters,
product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions,
fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement
action could have a material adverse effect on us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our drug candidates
are considered small molecule drugs and must be approved by the FDA through the NDA process before they may be legally marketed
in the United States. The process generally involves the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">completion of extensive preclinical studies in accordance with applicable regulations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">submission to the FDA of an IND, which must become effective before human clinical trials may begin;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">approval by an independent institutional review board (&ldquo;IRB&rdquo;), or ethics committee at each clinical trial site before each trial may be initiated;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, good clinical practice (&ldquo;GCP&rdquo;), requirements and other clinical trial-related regulations to establish substantial evidence of the safety and efficacy of the investigational product for each proposed indication;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">submission to the FDA of an NDA;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a determination by the FDA within 60 days of its receipt of an NDA to accept the filing for review;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">satisfactory completion of a FDA pre-approval inspection of the manufacturing facility or facilities where the drug will be produced to assess compliance with cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the drug or biologic&rsquo;s identity, strength, quality and purity;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">potential FDA audit of the preclinical study and/or clinical trial sites that generated the data in support of the NDA filing;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">FDA review and approval of the NDA, including consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug in the United States; and</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy (&ldquo;REMS&rdquo;), and the potential requirement to conduct post-approval studies.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The data required to
support an NDA are generated in two distinct developmental stages: preclinical studies and clinical trials. The preclinical and
clinical testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that
any approvals for any future drug candidates will be granted on a timely basis, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Preclinical Studies and IND</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Preclinical studies
generally involve laboratory evaluations of drug chemistry, formulation and stability, as well as studies to evaluate toxicity
in animals, which support subsequent clinical testing. The sponsor must submit the results of the preclinical studies, together
with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to
the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational product to humans,
and must become effective before human clinical trials may begin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Preclinical studies
include laboratory evaluation of product chemistry and formulation, as well as <I>in vitro</I> and animal studies to assess the
potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies
is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies. An IND sponsor must
submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data
or literature and plans for clinical studies, among other things, to the FDA as part of an IND. Some long-term preclinical testing,
such as animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. An IND automatically
becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one
or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve
any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing
clinical trials to commence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Clinical Trials</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The clinical stage
of development involves the administration of the investigational product to healthy volunteers or patients under the supervision
of qualified investigators, generally physicians not employed by or under the trial sponsor&rsquo;s control, in accordance with
GCP requirements, which include the requirement that all research subjects provide their informed consent for their participation
in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical
trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety and
assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND.
Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will
be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation
to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or
his or her legal representative, and must monitor the clinical trial until completed. There also are requirements governing the
reporting of ongoing clinical trials and completed clinical trial results to public registries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A sponsor who wishes
to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial
under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to
the FDA in support of an NDA. The FDA will accept a well-designed and well-conducted foreign clinical trial not conducted under
an IND if the trial was conducted in accordance with GCP requirements and the FDA is able to validate the data through an onsite
inspection, if deemed necessary, and the practice of medicine in the foreign country is consistent with the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials in
the United States generally are conducted in three sequential phases, known as Phase I, Phase II and Phase III, and may overlap.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Phase I clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to a single dose and then multiple doses of the drug candidate.</B>&nbsp;&nbsp;The primary purpose of these clinical trials is to assess the metabolism, pharmacologic action, tolerability and safety of the drug.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Phase II clinical trials involve studies in disease-affected patients to determine the dose and dosing schedule required to produce the desired benefits.</B>&nbsp;&nbsp;At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety risks are identified and a preliminary evaluation of efficacy is conducted.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Phase III clinical trials generally involve a large number of patients at multiple sites and are designed to provide the data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship</B> of the product and provide an adequate basis for product approval. These trials may include comparisons with placebo and/or other comparator treatments.&nbsp;&nbsp;The duration of treatment is often extended to mimic the actual use of a product during marketing.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Post-approval trials,
sometimes referred to as Phase IV clinical trials, are conducted after initial marketing approval. These trials are used to gain
additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may
mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Progress reports detailing
the results of the clinical trials, among other information, must be submitted at least annually to the FDA and written IND safety
reports must be submitted to the FDA and the investigators for serious and unexpected suspected adverse events, findings from other
studies suggesting a significant risk to humans exposed to the drug, findings from animal or <I>in vitro</I> testing that suggest
a significant risk for human subjects and any clinically important increase in the rate of a serious suspected adverse reaction
over that listed in the protocol or investigator brochure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Phase I, Phase II and
Phase III clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor may
suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients
are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its
institution if the clinical trial is not being conducted in accordance with the IRB&rsquo;s requirements or if the drug has been
associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of
qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides
authorization for whether a trial may move forward at designated check-points based on access to certain data from the trial. Concurrent
with clinical trials, companies usually complete additional animal safety studies and also must develop additional information
about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial
quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches
of our drug candidates. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted
to demonstrate that our drug candidates do not undergo unacceptable deterioration over their labeled shelf life.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>NDA Review Process</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following completion
of the clinical trials, data is analyzed to assess whether the investigational product is safe and effective for the proposed indicated
use or uses. The results of preclinical studies and clinical trials are then submitted to the FDA as part of an NDA, along with
proposed labeling, chemistry and manufacturing information to ensure product quality and other relevant data. In short, the NDA
is a request for approval to market the drug for one or more specified indications and must contain proof of safety and efficacy
for a drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;The application
must include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings. Data
may come from company-sponsored clinical trials intended to test the safety and efficacy of a product&rsquo;s use or from a number
of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be
sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of FDA.
FDA approval of an NDA must be obtained before a drug may be marketed in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Prescription
Drug User Fee Act (&ldquo;PDUFA&rdquo;), as amended, each NDA must be accompanied by a user fee. The FDA adjusts the PDUFA user
fees on an annual basis. According to the FDA&rsquo;s fiscal year 2019 fee schedule, effective through September 30, 2020, the
user fee for an application requiring clinical data, such as an NDA, was approximately $2.94 million. PDUFA also imposes an annual
program fee for each marketed human drug ($325,424 in 2020) and an annual establishment fee on facilities used to manufacture prescription
drugs. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first
application filed by a small business. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs,
unless the product also includes a non-orphan indication.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA reviews all
submitted NDAs before it accepts them for filing, and may request additional information rather than accepting the NDA for filing.
The FDA must make a decision on accepting an NDA for filing within 60 days of receipt. Once the submission is accepted for filing,
the FDA begins an in-depth review of the NDA. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has 10 months,
from the filing date, in which to complete its initial review of a new molecular-entity NDA and respond to the applicant, and six
months from the filing date of a new molecular-entity NDA designated for priority review. The FDA does not always meet its PDUFA
goal dates for standard and priority NDAs, and the review process is often extended by FDA requests for additional information
or clarification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before approving an
NDA, the FDA will conduct a pre-approval inspection of the manufacturing facilities for the new product to determine whether they
comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities
are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications.
The FDA also may audit data from clinical trials to ensure compliance with GCP requirements. Additionally, the FDA may refer applications
for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee, typically
a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should
be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it considers
such recommendations when making decisions on approval. The FDA likely will reanalyze the clinical trial data, which could result
in extensive discussions between the FDA and the applicant during the review process. After the FDA evaluates an NDA, it will issue
an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific
prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application
is complete and the application will not be approved in its present form. A Complete Response Letter usually describes all of the
specific deficiencies in the NDA identified by the FDA. The Complete Response Letter may require additional clinical data, additional
pivotal Phase 3 clinical trial(s) and/or other significant and time-consuming requirements related to clinical trials, preclinical
studies or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the NDA, addressing all of
the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA
may decide that the NDA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive
and the FDA may interpret data differently than we interpret the same data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Orphan Drugs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Orphan Drug
Act, the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which
is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals
in the United States and for which there is no reasonable expectation that the cost of developing and making the product available
in the United States for this type of disease or condition will be recovered from sales of the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Orphan drug designation
must be requested before submitting an NDA. After the FDA grants orphan drug designation, the identity of the therapeutic agent
and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten
the duration of the regulatory review and approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a product that has
orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation,
the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the
same drug for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing
of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety or providing a
major contribution to patient care or in instances of drug supply issues. However, competitors may receive approval of either a
different product for the same indication or the same product for a different indication but that could be used off-label in the
orphan indication. Orphan drug exclusivity also could block the approval of one of our products for seven years if a competitor
obtains approval before we do for the same product, as defined by the FDA, for the same indication we are seeking approval, or
if a drug candidate is determined to be contained within the scope of the competitor&rsquo;s product for the same indication or
disease. If one of our products designated as an orphan drug receives marketing approval for an indication broader than that which
is designated, it may not be entitled to orphan drug exclusivity. Orphan drug status in the European Union has similar, but not
identical, requirements and benefits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Expedited Development and Review
Programs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA has a fast
track program that is intended to expedite or facilitate the process for reviewing new drugs that meet certain criteria. Specifically,
new drugs are eligible for fast track designation if they are intended to treat a serious or life-threatening condition and preclinical
or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to
both the product and the specific indication for which it is being studied. The sponsor can request the FDA to designate the product
for fast track status any time before receiving NDA approval, but ideally no later than the pre-NDA meeting with the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any product submitted
to the FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended to expedite
development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it treats
a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared
to available therapies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A product may also
be eligible for accelerated approval, if it treats a serious or life-threatening condition and generally provides a meaningful
advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely
to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (&ldquo;IMM&rdquo;),
which is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require
that a sponsor of a drug or biologic receiving accelerated approval perform adequate and well-controlled post-marketing clinical
trials. If the FDA concludes that a drug or biologic shown to be effective can be safely used only if distribution or use is restricted,
it may require such post-marketing restrictions as it deems necessary to assure safe use of the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, a drug
may be eligible for designation as a breakthrough therapy if the product is intended, alone or in combination with one or more
other drugs or biologics, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the
product may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints.
The benefits of breakthrough therapy designation include the same benefits as fast track designation, plus intensive guidance from
the FDA to ensure an efficient drug development program. Fast track designation, priority review, accelerated approval and breakthrough
therapy designation do not change the standards for approval, but may expedite the development or approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Post-Approval Requirements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following approval
of a new product, the manufacturer and the approved product are subject to continuing regulation by the FDA, including, among other
things, monitoring and record-keeping requirements, requirements to report adverse experiences and comply with promotion and advertising
requirements, which include restrictions on promoting drugs for unapproved uses or patient populations, known as &ldquo;off-label
use,&rdquo; and limitations on industry-sponsored scientific and educational activities. Although physicians may prescribe legally
available drugs for off-label uses, manufacturers may not market or promote such uses. Prescription drug promotional materials
must be submitted to the FDA in conjunction with their first use. Further, if there are any modifications to the drug, including
changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA
approval of a new NDA or NDA supplement, which may require the development of additional data or preclinical studies and clinical
trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA may also place
other conditions on approvals including the requirement for REMS, to assure the safe use of the product. A REMS could include medication
guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries
and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution,
prescription or dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory standards or if problems
occur following initial marketing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA may withdraw
approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches
the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or
frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved
labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks or imposition
of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market, or product recalls;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">fines, warning letters, or holds on post-approval clinical studies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">refusal of the FDA to approve pending applications or supplements to approved applications;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">applications, or suspension or revocation of product license approvals;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">product seizure or detention, or refusal to permit the import or export of products; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">injunctions or the imposition of civil or criminal penalties.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA strictly regulates
marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved
indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and
regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses
may be subject to significant liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Other U.S. Regulatory Matters</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Manufacturing, sales,
promotion and other activities following product approval are also subject to regulation by numerous regulatory authorities in
the United States in addition to the FDA, including the Centers for Medicare &amp; Medicaid Services, other divisions of the Department
of Health and Human Services, the Department of Justice, the Drug Enforcement Administration, the Consumer Product Safety Commission,
the Federal Trade Commission, the Occupational Safety &amp; Health Administration, the Environmental Protection Agency, and state
and local governments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;For example,
in the United States, sales, marketing and scientific and educational programs also must comply with state and federal fraud and
abuse laws, false claims laws, transparency laws, government price reporting, and health information privacy and security laws.
These laws include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the federal Anti-Kickback Statute, which makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration that is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid.&nbsp;&nbsp;Moreover, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the federal false claims and civil monetary penalties laws, including the civil False Claims Act that can be enforced by private citizens through civil whistleblower or qui tam actions, prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the Federal Health Insurance Portability and Accountability Act of 1996 (&ldquo;HIPAA&rdquo;), prohibits, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and their implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&rsquo;s Health Insurance Program, with specific exceptions, to annually report to CMS information regarding payments and other transfers of value to physicians and teaching hospitals as well as information regarding ownership and investment interests held by physicians and their immediate family members; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, state laws that require biotechnology companies to comply with the biotechnology industry&rsquo;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, state laws that require biotechnology companies to report information on the pricing of certain drug products, and state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pricing and rebate
programs must also comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more
recent requirements in the ACA. If products are made available to authorized users of the Federal Supply Schedule of the General
Services Administration, additional laws and requirements apply. Products must meet applicable child-resistant packaging requirements
under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities also are potentially subject
to federal and state consumer protection and unfair competition laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The distribution of
pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage
and security requirements intended to prevent the unauthorized sale of pharmaceutical products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The failure to comply
with any of these laws or regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances,
failure to meet applicable regulatory requirements can result in significant civil, criminal and administrative penalties, including
damages, fines, disgorgement, individual imprisonment, exclusion from participation in government funded healthcare programs, such
as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits
and future earnings, injunctions, requests for recall, seizure of products, total or partial suspension of production, denial or
withdrawal of product approvals or refusal to allow a firm to enter into supply contracts, including government contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>U.S. Patent-Term Restoration and
Marketing Exclusivity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Depending upon the
timing, duration and specifics of FDA approval of any future drug candidates, some of our U.S. patents may be eligible for limited
patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits restoration of the patent term of up to five years
as compensation for patent term lost during product development and FDA regulatory review process. Patent-term restoration, however,
cannot extend the remaining term of a patent beyond a total of 14 years from the product&rsquo;s approval date. The patent-term
restoration period is generally one-half the time between the effective date of an IND or the issue date of the patent, whichever
is later, and the submission date of an NDA plus the time between the submission date of an NDA or the issue date of the patent,
whichever is later, and the approval of that application, except that the review period is reduced by any time during which the
applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension and the
application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA,
reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration
of patent term for our currently owned or licensed patents to add patent life beyond its current expiration date, depending on
the expected length of the clinical trials and other factors involved in the filing of the relevant NDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Market exclusivity
provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year
period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new
chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same
active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the
FDA may not accept for review an abbreviated new drug application (&ldquo;ANDA&rdquo;), or a 505(b)(2) NDA submitted by another
company for another version of such drug where the applicant does not own or have a legal right of reference to all the data required
for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or
non-infringement. The FDCA also provides three years of marketing exclusivity for a NDA, 505(b)(2) NDA or supplement to an existing
NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed
by the FDA to be essential to the approval of the application, for example, new indications, dosages or strengths of an existing
drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not
prohibit the FDA from approving ANDAs for drugs containing the original active agent. Five-year and three-year exclusivity will
not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or
obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate
safety and effectiveness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>European Union Drug Development</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Similar to the United
States, the various phases of preclinical and clinical research in the European Union are subject to significant regulatory controls.
Although the EU Clinical Trials Directive 2001/20/EC has sought to harmonize the EU clinical trials regulatory framework, setting
out common rules for the control and authorization of clinical trials in the EU, the EU Member States have transposed and applied
the provisions of the Directive differently. This has led to significant variations in the member state regimes. Under the current
regime, before a clinical trial can be initiated it must be approved in each of the EU countries where the trial is to be conducted
by two distinct bodies: the National Competent Authority (&ldquo;NCA&rdquo;), and one or more Ethics Committees (&ldquo;ECs&rdquo;).
Under the current regime all suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical
trial have to be reported to the NCA and ECs of the Member State where they occurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The EU clinical
trials legislation currently is undergoing a transition process mainly aimed at harmonizing and streamlining clinical-trial authorization,
simplifying adverse-event reporting procedures, improving the supervision of clinical trials and increasing their transparency.
Recently enacted Clinical Trials Regulation EU No 536/2014 ensures that the rules for conducting clinical trials in the EU will
be identical. In the meantime, Clinical Trials Directive 2001/20/EC continues to govern all clinical trials performed in the EU.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>European Union Drug Review and Approval</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the European Economic
Area (&ldquo;EEA&rdquo;), which is comprised of the 27 Member States of the European Union (including Norway and excluding Croatia),
Iceland and Liechtenstein, medicinal products can only be commercialized after obtaining a Marketing Authorization (&ldquo;MA&rdquo;).
There are two types of marketing authorizations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Community MA is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use (&ldquo;CHMP&rdquo;), of the EMA, and is valid throughout the entire territory of the EEA.&nbsp;&nbsp;The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products, advanced-therapy medicines such as gene-therapy, somatic cell-therapy or tissue-engineered medicines and medicinal products containing a new active substance indicated for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions and viral diseases.&nbsp;&nbsp;The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure.&nbsp;&nbsp;Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member States through the Mutual Recognition Procedure.&nbsp;&nbsp;If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure.&nbsp;&nbsp;Under the Decentralized Procedure an identical dossier is submitted to the competent authorities of each of the Member States in which the MA is sought, one of which is selected by the applicant as the Reference Member State (&ldquo;RMS&rdquo;).&nbsp;&nbsp;The competent authority of the RMS prepares a draft assessment report, a draft summary of the product characteristics (&ldquo;SPC&rdquo;), and a draft of the labeling and package leaflet, which are sent to the other Member States (referred to as the Member States Concerned) for their approval.&nbsp;&nbsp;If the Member States Concerned raise no objections, based on a potential serious risk to public health, to the assessment, SPC, labeling or packaging proposed by the RMS, the product is subsequently granted a national MA in all the Member States (i.e., in the RMS and the Member States Concerned).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the above described
procedures, before granting the MA, EMA or the competent authorities of the Member States of the EEA make an assessment of the
risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. Similar to
the U.S. patent term-restoration, Supplementary Protection Certificates (&ldquo;SPCs&rdquo;) serve as an extension to a patent
right in Europe for up to five years. SPCs apply to specific pharmaceutical products to offset the loss of patent protection due
to the lengthy testing and clinical trials these products require prior to obtaining regulatory marketing approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Coverage and Reimbursement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales of our products
will depend, in part, on the extent to which our products will be covered by third-party payors, such as government health programs,
commercial insurance, and managed healthcare organizations. There is significant uncertainty related to third-party payor coverage
and reimbursement of newly approved products. In the United States, for example, principal decisions about reimbursement for new
products are typically made by CMS. CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare,
and private third-party payors often follow CMS&rsquo;s decisions regarding coverage and reimbursement to a substantial degree.
However, no uniform policy of coverage and reimbursement for drug products exists. Accordingly, decisions regarding the extent
of coverage and amount of reimbursement to be provided for any of our products will be made on a payor-by-payor basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Increasingly, third-party
payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices
charged for medical products. Further, such payors are increasingly challenging the price, examining the medical necessity and
reviewing the cost effectiveness of medical drug candidates. There may be especially significant delays in obtaining coverage and
reimbursement for newly approved drugs. Third-party payors may limit coverage to specific drug candidates on an approved list,
known as a formulary, which might not include all FDA-approved drugs for a particular indication. We may need to conduct expensive
pharmaco-economic studies to demonstrate the medical necessity and cost effectiveness of our products. As a result, the coverage
determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support
for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, in most
foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing
drug pricing and reimbursement vary widely from country to country. For example, the European Union provides options for its member
states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and
to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product
or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product
on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical
products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in
the European Union do not follow price structures of the United States and generally prices tend to be significantly lower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Healthcare Reform</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The United States government,
state legislatures, and foreign governments have shown significant interest in implementing cost containment programs to limit
the growth of government-paid healthcare costs, including price-controls, restrictions on reimbursement, and requirements for substitution
of generic products for branded prescription drugs. For example, in March 2010, the Patient Protection and Affordable Care Act
of 2010, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, the &ldquo;ACA&rdquo;), was passed
which substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts
the U.S. pharmaceutical industry. The ACA contains provisions that may reduce the profitability of drug products through increased
rebates for drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts
for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies&rsquo; share of sales to federal health
care programs. The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national
rebate agreement with the HHS Secretary as a condition for states to receive federal matching funds for the manufacturer&rsquo;s
outpatient drugs furnished to Medicaid patients. The ACA made several changes to the Medicaid Drug Rebate Program, including increasing
pharmaceutical manufacturers&rsquo; rebate liability by raising the minimum basic Medicaid rebate on most branded prescription
drugs from 15.1% of average manufacturer price (&ldquo;AMP&rdquo;), to 23.1% of AMP and adding a new rebate calculation for &ldquo;line
extensions&rdquo; (i.e., new formulations, such as extended release formulations) of solid oral dosage forms of branded products,
as well as potentially impacting their rebate liability by modifying the statutory definition of AMP. The ACA also expanded the
universe of Medicaid utilization subject to drug rebates by requiring pharmaceutical manufacturers to pay rebates on Medicaid managed
care utilization and by enlarging the population potentially eligible for Medicaid drug benefits. The Centers for Medicare &amp;
Medicaid Services (&ldquo;CMS&rdquo;), have proposed to expand Medicaid rebate liability to the territories of the United States
as well. Additionally, for a drug product to receive federal reimbursement under the Medicaid or Medicare Part B programs or to
be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the
340B drug pricing program. The required 340B discount on a given product is calculated based on the AMP and Medicaid rebate amounts
reported by the manufacturer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some of the provisions
of the ACA have yet to be implemented, and there have been judicial and Congressional challenges to certain aspects of the ACA
Congress has recently considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has
not passed comprehensive repeal legislation, two bills affecting the implementation of certain taxes under the ACA have passed.
On December 22, 2017, the Tax Cuts and Jobs Act (the &ldquo;Tax Act&rdquo;) was enacted, which includes a provision repealing,
effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain
qualifying health coverage for all or part of a year that is commonly referred to as the &ldquo;individual mandate.&rdquo; The
Bipartisan Budget Act of 2018 (the &ldquo;BBA&rdquo;), among other things, amended the ACA, effective January 1, 2019, to close
the coverage gap in most Medicare Part D drug plans. In July 2018, CMS published a final rule permitting further collections and
payments to and from certain ACA-qualified health plans and health insurance issuers under the ACA risk adjustment program in response
to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. On December
14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &ldquo;individual
mandate&rdquo; was repealed by Congress as part of the Tax Act. On December 18, 2019, the United States Court of Appeal for the
Fifth Circuit ruled that the &ldquo;individual mandate&rdquo; of the ACA is unconstitutional, but remanded the case to the U.S.
District Court to reconsider whether the entire ACA is unconstitutional. The remanded case is still pending in the U.S. District
Court and other than on the application of the &ldquo;individual mandate,&rdquo; the ruling will have no immediate effect on the
remaining provisions of the ACA pending a decision on remand by the U.S. District Court. Consequently, it is unclear how this decision,
subsequent appeals, and other efforts to repeal and replace the ACA will impact the ACA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Other legislative changes
have been proposed and adopted in the United States since the ACA was enacted. These changes included aggregate reductions to Medicare
payments to providers of up to 2% per fiscal year, effective April 1, 2013, which, due to subsequent legislative amendments, will
stay in effect through 2027 unless additional congressional action is taken. In January 2013, President Obama signed into law the
American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers, and increased
the statute of limitations period for the government to recover overpayments to providers from three to five years. These new laws
may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers
for our drugs, if approved, and accordingly, our financial operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, there
has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products,
which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among
other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs,
and reform government program reimbursement methodologies for drug products. For example, At the state level, legislatures have
increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing,
including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure
and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, the
Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (&ldquo;MMA&rdquo;), established the Medicare Part D program
to provide a voluntary prescription drug benefit to Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in
prescription drug plans offered by private entities that provide coverage of outpatient prescription drugs. Unlike Medicare Part
A and B, Part D coverage is not standardized. While all Medicare drug plans must give at least a standard level of coverage set
by Medicare, Part D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can
develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription
drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily
all the drugs in each category or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed by
a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for products
for which we receive marketing approval. However, any negotiated prices for our products covered by a Part D prescription drug
plan likely will be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for
Medicare beneficiaries, private third-party payors often follow Medicare coverage policy and payment limitations in setting their
own payment rates.<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Employees</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this report, we employed a total of 15 professionals:
11 full-time and four part-time employees. None of our employees are represented by a labor union or covered under a collective
bargaining agreement. We believe that we maintain strong relations with our employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also engage outside
consultants to assist with research and development, clinical development and regulatory matters, business development, operations
and other functions from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>Human Capital Resources.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our employees drive
our mission and we place a high level of importance on employee engagement and corporate culture. Fostering and maintaining a strong,
healthy culture is a key strategic focus for us, and we regularly engage in independent third party surveys to gauge the satisfaction
and engagement of our team.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our compensation approach
is aimed at attracting, retaining, motivating and rewarding superior employees who operate in a highly competitive and technologically
challenging environment. The structure of our compensation aims to balance incentives for both short-term and long-term performance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Some examples of the benefits we offer include
medical insurance, dental insurance, vision insurance, and an unlimited paid-time off policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A substantial portion
of our employees are focused on leading and advancing our drug development, biology and data science efforts. As we progress our
product candidates and grow and expand our team, we intend to continue to place a significant focus on our human capital resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Available Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain a website
at www.lanternpharma.com. The contents of our website are not incorporated in, or otherwise to be regarded as part of, this Annual
Report on Form 10-K. We make available, free of charge on our website, access to our Annual Report on Form 10-K, our Quarterly
Reports on Form 10-Q, our Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a)
or 15(d) of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), as soon as reasonably practicable after
we file or furnish them electronically with the Securities and Exchange Commission (&ldquo;SEC&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Copies of our Annual
Report on Form 10-K, our Quarterly Reports on Form 10-Q, our Current Reports on Form 8-K and other filings we make with the SEC
are also available at the SEC&rsquo;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC
at 1-800-SEC-0330 for further information on the Public Reference Room. Our SEC filings are also available on the SEC&rsquo;s website
at www.sec.gov. Statements contained in this Annual Report on Form 10-K concerning the contents of any contract or any other documents
are not necessarily complete. If a contract or document has been filed as an exhibit to this Annual Report on Form 10-K, please
see the copy of the contract or document that has been filed. Each statement in this this Annual Report on Form 10-K relating to
a contract or document filed as an exhibit is qualified in all respects by the filed exhibit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="aa_004"></A>Item 1A. Risk Factors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An investment in our
common stock involves a high degree of risk. You should give careful consideration to the following risk factors, in addition to
general economic and business risks and the other information included in this Annual Report on Form 10-K, including our financial
statements and related notes, before deciding whether to invest in shares of our common stock. The occurrence of any of the adverse
developments described in the following risk factors could materially and adversely harm our business, financial condition, results
of operations or prospects. In that case, the trading price of our common stock could decline, and you may lose all or part of
your investment. Additional risks or uncertainties not presently known to us or that we currently deem immaterial may also materially
and adversely harm our business, financial condition, results of operations or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Financial Position
and Need for Capital </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have a limited operating history
and have never generated any revenues other than from research grants, which may make it difficult to evaluate the success of our
business to date and to assess our future viability. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were incorporated
in November 7, 2013, and to date have been largely focused on organizing and staffing our company, raising capital, developing
the RADR<SUP>&reg;</SUP> platform and acquiring the rights to, and advancing the development of, our drug candidates, including
conducting preclinical studies and early phase clinical trials on our drug candidates. We have not yet demonstrated an ability
to successfully complete clinical trials, obtain marketing approvals, manufacture drugs on a commercial scale, or arrange for a
third party to do so on our behalf, or conduct sales and marketing activities necessary for successful commercialization. Consequently,
predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history
or a history of successfully developing and commercializing drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect our financial
condition and operating results to continue to fluctuate from quarter to quarter and year to year due to a variety of factors,
many of which are beyond our control. We will need to eventually transition from a company with a research and development focus
to a company capable of undertaking commercial activities. We may encounter unforeseen expenses, difficulties, complications and
delays, and may not be successful in such a transition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have incurred significant operating
losses since inception and anticipate that we will continue to incur substantial operating losses for the foreseeable future and
may never achieve or maintain profitability. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since our inception,
we have incurred losses. Our net losses were $5,908,190 and $2,428,185 for the years ended December 31, 2020 and 2019, respectively.
We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. None of our current
drug candidates have been approved for marketing in the United States, or in any other jurisdiction, and may never receive such
approval. It could be several years, if ever, before we have a commercialized drug that generates significant revenues. As a result,
we are uncertain when or if we will achieve profitability and, if so, whether we will be able to sustain profitability. The net
losses we incur may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase
substantially as we:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">continue the development of our drug candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">initiate preclinical studies and clinical trials for any additional indications for our current drug candidates and any future drug candidates that we may pursue;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">continue to build our portfolio of drug candidates through the acquisition or in-license of additional drug candidates or technologies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">continue to develop, maintain, expand and protect our intellectual property portfolio;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">continue to develop, maintain, and expand our RADR<SUP>&reg;</SUP> platform;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">pursue regulatory approvals for our current and future drug candidates that successfully complete clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">ultimately establish a sales, marketing, distribution and other commercial infrastructure to commercialize any drug candidate for which we may obtain marketing approval;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">hire additional clinical, regulatory, scientific and accounting personnel; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">incur additional legal, accounting and other expenses in operating as a public company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To become and remain
profitable, we must develop and eventually commercialize one or more drug candidates with significant market potential or license
one or more of our drug candidates to an industry partner. This will require us to be successful in a range of challenging activities,
including completing clinical trials of our drug candidates, publishing our data and findings on our drug candidates with peer
reviewed publications, developing commercial scale manufacturing processes, obtaining marketing approval, manufacturing, marketing
and selling any current and future drug candidates for which we may obtain marketing approval, and satisfying any post-marketing
requirements. We are only in the preliminary stages of most of these activities and, in some cases, have not yet commenced certain
of these activities. We may never succeed in any or all of these activities and, even if we do, we may never generate sufficient
revenue to achieve profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because of the numerous
risks and uncertainties associated with drug development, we are unable to accurately predict the timing or amount of expenses
or when, or if, we will obtain marketing approval to commercialize any of our drug candidates. If we are required by the U.S. Food
and Drug Administration, or FDA, or other regulatory authorities such as the European Medicines Agency, or EMA, to perform studies
and trials in addition to those currently expected, or if there are any delays in the development, or in the completion of any
planned or future preclinical studies or clinical trials of our current or future drug candidates, our expenses could increase
and profitability could be further delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we do achieve
profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and
remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research
and development efforts, expand our business or continue our operations. A decline in the value of our company also could cause
investors to lose all or part of your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will need substantial additional
funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate our drug development
programs or commercialization efforts.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We anticipate that
our expenses will increase substantially as we continue to develop and begin and continue clinical trials with respect to LP-184,
LP-300 and our other drug candidates; seek to identify and develop additional drug candidates; acquire or in-license other drug
candidates or technologies; seek regulatory and marketing approvals for our drug candidates that successfully complete clinical
trials, if any; establish sales, marketing, distribution and other commercial infrastructure in the future to commercialize various
drugs for which we may obtain marketing approval, if any; require the manufacture of larger quantities of drug candidates for clinical
development and, potentially, commercialization; maintain, expand and protect our intellectual property portfolio; develop, maintain,
and expand our RADR<SUP>&reg;</SUP> platform; hire and retain additional personnel, such as clinical, quality control and scientific
personnel; add operational, financial and management information systems and personnel, including personnel to support our drug
development and help us comply with our obligations as a public company; and add equipment and physical infrastructure to support
our research and development programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will be required
to expend significant funds in order to advance the development of LP-184, LP-300 and our other drug candidates. In addition, while
we may seek one or more collaborators for future development of our current drug candidates or any future drug candidates that
we may develop for one or more indications, we may not be able to enter into a partnership or out-license for any of our drug candidates
for such indications on suitable terms, on a timely basis or at all. In any event, our existing cash, cash equivalents and other
capital resources will not be sufficient to fund all of the efforts that we plan to undertake or to fund the completion of development
of our drug candidates or our other preclinical studies. Accordingly, we will be required to obtain further funding through public
or private equity offerings, debt financings, collaborations and licensing arrangements or other sources. We do not have any committed
external source of funds. Further financing may not be available to us on acceptable terms, or at all. Our failure to raise capital
as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe our existing
cash and cash equivalents as of December 31, 2020, plus approximately $64,200,000 of net proceeds from our public offering of common
shares in January 2021, along with our anticipated expenditures and commitments for calendar year 2021, will enable us to fund
our operating expenses and capital expenditure requirements for at least 12 months from the filing of this Form 10-K for the year
ended December 31, 2020. Our estimate as to how long we expect our existing cash, cash equivalents and other capital resources
to be able to continue to fund our operations is based on assumptions that may prove to be wrong, and we could use our available
capital resources sooner than we currently expect. Further, changing circumstances, some of which may be beyond our control, could
cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner
than planned. Our future funding requirements, both short-term and long-term, will depend on many factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the scope, progress, timing, costs and results of preclinical studies and clinical trials of LP-184, LP-300 and our other drug candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the costs associated with maintaining, expanding and updating our RADR<SUP>&reg;</SUP> platform;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the costs, timing and outcome of seeking regulatory approvals;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our headcount growth and associated costs as we expand our research and development as well as potentially establish a commercial infrastructure;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the costs of our licensing or commercialization activities for any of our drug candidates that receive marketing approval to the extent such costs are not the responsibility of any future collaborators, including the costs and timing of establishing drug sales, marketing, distribution and manufacturing capabilities;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to enter into and the terms and timing of any collaborations, licensing agreements or other arrangements;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">revenue received from commercial sales, if any, of our current and future drug candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property rights and defending against intellectual property related claims;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the number of future drug candidates that we pursue and their development requirements;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">changes in regulatory policies or laws that may affect our operations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">changes in physician acceptance or medical society recommendations that may affect commercial efforts;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the costs of acquiring potential new drug candidates or technology;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the costs associated with purchasing data for our RADR<SUP>&reg;</SUP> platform;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the costs associated with maintaining and expanding our cybersecurity systems; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the costs of operating as a public company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to the Discovery and Development
of Drug Candidates</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have limited experience in drug
discovery and drug development and may not receive regulatory approval to market our drug candidates. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to the acquisition
of our drug candidates, we were not involved in and had no control over their preclinical and clinical development. In addition,
we rely upon the parties from whom we have acquired our drug candidates from to have conducted such research and development in
accordance with the applicable protocol, legal, regulatory and scientific standards, having accurately reported the results of
all clinical trials conducted prior to our acquisition of the applicable drug candidate, and having correctly collected the data
from these studies and trials. To the extent any of these has not occurred, our expected development time and costs may be increased,
which could adversely affect our prospects for marketing approval of, and receiving any future revenue from, these drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the near term, we
are dependent on our ability to advance the development of LP-184 and LP-300 and on the efforts of Allarity Therapeutics to advance
LP-100. If we are unable to initiate or complete the clinical development of, obtain marketing approval for or successfully commercialize
LP-184 and LP-300 and our other drug candidates, either alone or with a collaborator, or if we experience significant delays in
doing so, our business could be substantially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently do not
have any drugs that have received regulatory approval and may never be able to develop marketable drug candidates. We are investing
a significant portion of our efforts and financial resources in the advancement of LP-184, LP-300 and our other drug candidates
and in the development of our RADR<SUP>&reg;</SUP> platform. Our prospects are substantially dependent on our ability, or those
of any future collaborator, to develop, obtain marketing approval for and successfully commercialize drug candidates in one or
more disease indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The success of LP-184,
LP-300 and our other drug candidates will depend on several factors, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">following submission of an Investigational New Drug Application, or IND, with the FDA or any comparable foreign regulatory authority, receiving clearance for the conduct of clinical trials of drug candidates and proposed design of future clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">initiation, progress, timing, costs and results of clinical trials of our drug candidates and potential drug candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">establishment of a safety, tolerability and efficacy profile that is satisfactory to the FDA or any comparable foreign regulatory authority for marketing approval;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">adequate ongoing availability of quality data sources for our RADR<SUP>&reg;</SUP> platform and raw materials and drug product for clinical development and any commercial sales;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">obtaining and maintaining patent, trade secret protection and regulatory exclusivity, both in the United States and relevant global markets;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the performance of our future collaborators, if any;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the extent of any required post-marketing approval commitments to applicable regulatory authorities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">establishment of supply arrangements with third-party raw materials suppliers and manufacturers;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">establishment of arrangements with third-party manufacturers to obtain finished drug product that is appropriately packaged for sale;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">protection of our rights in our intellectual property portfolio;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">successful launch of commercial sales following any marketing approval;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a continued acceptable safety profile following any marketing approval;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">commercial acceptance by patients, the medical community and third-party payors; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to compete with other therapies.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many of these factors
are beyond our control, including the results of clinical trials, the time required for the FDA or any comparable foreign regulatory
authorities to review any regulatory submissions we may make, potential threats to our intellectual property rights and the manufacturing,
marketing and sales efforts of any future collaborator. If we are unable to develop, receive marketing approval for and successfully
commercialize LP-300 and LP-184 our other drug candidates, on our own or with any future collaborator or experience delays as a
result of any of these factors or otherwise, our business could be substantially harmed. The regulatory approval processes of the
FDA and comparable foreign authorities are lengthy, time consuming, expensive and inherently unpredictable, and if we are ultimately
unable to obtain regulatory approval for our drug candidates, our business will be substantially harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The time required to
obtain approval by the FDA and comparable foreign authorities is unpredictable but can take many years following the commencement
of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. The results
of preclinical studies and early clinical trials of our drug candidates may not be predictive of the results of later-stage clinical
trials. Drug candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having
progressed through preclinical studies and initial clinical trials. It is not uncommon for companies in the biotechnology and pharmaceutical
industries to suffer significant setbacks in advanced clinical trials due to nonclinical findings made while clinical studies were
underway and safety or efficacy observations made in clinical studies, including previously unreported adverse events. Our future
clinical trial results may not be successful, and notwithstanding any potential promising results in earlier studies, we cannot
be certain that we will not face similar setbacks. The historical failure rate for drug candidates in our industry is high. In
addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during
the course of a drug candidate&rsquo;s clinical development and may vary among jurisdictions. We have not obtained final regulatory
approval for any drug candidate and it is possible that none of our existing drug candidates or any drug candidates we may seek
to develop in the future will ever obtain regulatory approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our drug candidates could fail to receive
regulatory clearance or marketing approval for many reasons, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials, including, but not limited to, the use of genomic or biomarker signatures to identify patients that may respond to drug efficacy;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a drug candidate is safe and effective for its proposed indication;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">we may be unable to identify and recruit a sufficient number of patients with relevant genomic or biomarker signatures in order to conduct clinical trials on our drug candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the data collected from clinical trials of our drug candidates may not be sufficient to support the submission of a New Drug Application, or NDA, or other submission or to obtain regulatory approval in the United States or elsewhere;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not previously
completed all clinical trials for any of our drug candidates. Consequently, we may not have the necessary capabilities, including
adequate staffing, to successfully manage the execution and completion of any clinical trials we initiate in a way that leads to
our obtaining marketing approval for our drug candidates in a timely manner, or at all. This lengthy approval process as well as
the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our drug
candidates, which would significantly harm our business, results of operations and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, even if
we were to obtain approval, regulatory authorities may approve any of our drug candidates for fewer or more limited indications
than we request, may not approve the price we intend to charge for our drugs, may grant approval contingent on the performance
of costly post-marketing clinical trials, may approve a drug candidate with a label that does not include the labeling claims necessary
or desirable for the successful commercialization of that drug candidate or may restrict its distribution. Any of the foregoing
restrictions or requirements could materially harm the commercial prospects for our drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not previously
submitted a new drug application (an &ldquo;NDA&rdquo;) to the FDA or similar drug approval filings to comparable foreign authorities,
for any drug candidate, and we cannot be certain that any of our drug candidates will be successful in clinical trials or receive
regulatory approval. Further, our drug candidates may not receive regulatory approval even if they are successful in clinical trials.
If we do not receive regulatory approvals for our drug candidates, we may not be able to continue our operations. Even if we successfully
obtain regulatory approvals to market one or more of our drug candidates, our revenues will be dependent, in part, upon the size
of the markets in the territories for which we gain regulatory approval and have commercial rights. If the markets for patients
that we are targeting for our drug candidates are not as significant as we estimate, or if the price we charge for our drug candidate
is too high, we may not generate significant revenues from sales of such drugs, if approved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We plan to seek regulatory approval to commercialize
our drug candidates both in the United States and the European Union and in additional foreign countries. While the scope of regulatory
approval is similar in other countries, to obtain separate regulatory approval in many other countries we must comply with numerous
and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical
trials and possible limitations placed upon commercial sales, pricing and distribution of our drug candidates, and we cannot predict
success in these jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our business strategy to rescue previously
failed drug candidates may not be successful, and important issues relating to safety and efficacy remain to be resolved for all
of our drug candidates. Our strategy also involves risks and uncertainties that differ from other biotechnology companies that
focus solely on new drug candidates that do not have a history of failed clinical trials.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our drug candidate
portfolio includes small molecules that others have tried, but failed, to develop into an approved commercialized drug. Our strategy
to rescue previously failed drug candidates may not be successful, and the use of the term &ldquo;drug rescue,&rdquo; &ldquo;rescuing,&rdquo;
or words of similar meaning in this report should not be construed to mean that our RADR<SUP>&reg;</SUP> platform has resolved
all issues of safety and/or efficacy for any of our drug candidates. Issues of safety and efficacy for any drug candidate may only
be determined by the U.S. FDA or other applicable regulatory authorities in jurisdictions outside the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business strategy
includes a focus on leveraging A.I. to streamline the drug development process and to identify patients that will benefit from
drug candidates that other biotechnology or pharmaceutical companies have abandoned or shelved after initiating clinical trials
under an IND application filed with the FDA, including candidates that have failed to achieve statistical significance on the original
endpoints established in the clinical trials. We use our RADR<SUP>&reg;</SUP>platform to assess drug candidates together with big
data sources of information to both target and evaluate sub-populations and identify new therapeutic indices and gene signatures
that will potentially correlate with drug efficacy and patient response to treatment. While we have not yet successfully received
regulatory or marketing approval for any of our drug candidates, and while we believe that our approach has the potential to reduce
the cost and time of drug development through the identification and selection of patient populations more likely to respond to
therapy, our strategy involves risks and uncertainties that differ from other biotechnology companies that focus solely on new
drug candidates that do not have a history of failed clinical development. These risks and uncertainties include, but are not limited
to, the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The remaining term of the initial patents filed with respect to a rescued and repositioned drug candidate may be significantly less than the patent term for a newly discovered drug candidate;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Potential out-licensees, alliance partners and collaborators may view a rescued and repositioned drug candidate with more skepticism because of its history of failed clinical trials, thereby requiring a higher level of additional data and further explanations of mechanisms of action in order to overcome this skepticism and obtain commercially reasonable terms for future development or collaboration;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Key personnel and institutional knowledge relating to a rescued and repositioned drug candidate may no longer be available for us;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The current standard of care in the targeted therapeutic indication for the rescued and repositioned drug candidate may be different than the standard of care that existed during the candidate&rsquo;s last clinical trial, which will require more time and resources from us to reassess and redesign the regulatory development path for the rescued and repositioned drug candidate; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The rescued and repositioned drug candidate may be perceived to be in an &ldquo;older&rdquo; therapeutic focus area of oncology, thereby generating less enthusiasm and support compared to therapeutic focus areas of oncology that may be perceived as more recent.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We are dependent on Allarity Therapeutics for the
development of LP-100.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We, with the consent
of our licensor for LP-100, AF Chemicals, have entered into an agreement with Allarity Therapeutics in which we have granted an
exclusive, royalty-bearing license, with the right to sublicense, to develop LP-100. Allarity Therapeutics will be solely responsible
for the development of LP-100, including development of a comprehensive plan for a clinical trial program, but has the right to
assign all or part of the agreement to a third-party program acquirer. Under the agreement, we and AF Chemicals, are entitled to
receive certain specified milestone payments from Allarity Therapeutics subject to an overall aggregate maximum payment of $21
million U.S. dollars ($21,000,000) with certain exceptions. In addition to milestone payments, we are also entitled to receive
royalty payments based on incremental levels of annual sales of LP-100 products by Allarity Therapeutics or any third-party program
acquirer. As a result of the drug license and development agreement with Allarity Therapeutics, we are completely dependent on
Allarity Therapeutics for the development of LP-100. Allarity Therapeutics is managing a Phase II clinical trial of LP-100 in patients
with mCRPC. Continuing enrollment for this Phase II clinical trial has slowed during the COVID-19 pandemic. Allarity Therapeutics
has also stated that it is focusing its existing resources on other programs that are currently higher priority for Allarity than
LP-100. As of the date of this report, we are unable to forecast the timeline for the completion of the Phase II clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may depend on enrollment of patients
with specific genomic or biomarker signatures in our clinical trials in order for us to continue development of our drug candidates.
If we are unable to enroll patients with specific genomic or biomarker signatures in our clinical trials, our research, development
and commercialization efforts could be adversely affected. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The timely completion
of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number
of patients with genomic or biomarker signatures we have identified and who remain in the study until its conclusion. We may experience
difficulties in patient enrollment in our clinical trials for a variety of reasons. Patient enrollment is affected by many factors
including the size and nature of the patient population with the specific genomic or biomarker signature we have identified, the
proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, the size of
the patient population required for analysis of the trial&rsquo;s primary endpoints, the proximity of patients to study sites,
our ability to recruit clinical trial investigators with the appropriate competencies and experience, our ability to obtain and
maintain patient consents, the risk that patients enrolled in clinical trials will drop out of the trials before completion, and
competing clinical trials and clinicians&rsquo; and patients&rsquo; perceptions as to the potential advantages of the drug being
studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating.
We will compete with other pharmaceutical companies for clinical sites, physicians and the limited number of patients who fulfill
the stringent requirements for participation in oncology clinical trials. Also, due to the confidential nature of clinical trials,
we do not know how many of the eligible patients may be enrolled in competing studies and who are consequently not available to
us for our clinical trials. Our clinical trials may be delayed or terminated due to the inability to enroll enough patients. The
delay or inability to meet planned patient enrollment may result in increased costs and delay or termination of our trials, which
could have a harmful effect on our ability to develop drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Delays in clinical testing could
result in increased costs to us and delay our ability to generate revenue. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we are planning
for certain clinical trials relating to LP-300 and LP-184 and our other drug candidates, there can be no assurance that the FDA
will accept our proposed trial designs. We may experience delays in our clinical trials and we do not know whether planned clinical
trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, if at all. Clinical trials
can be delayed for a variety of reasons, including delays related to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">obtaining regulatory clearance to commence a trial;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">obtaining institutional review
board, or IRB, approval at each site;</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">recruiting suitable patients to participate in a trial;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">identifying clinical sites with adequate infrastructure (including data collection) to conduct the trial;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">clinical sites deviating from trial protocol or dropping out of a trial;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">addressing patient safety concerns that arise during the course of a trial;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">having patients complete a trial or return for post-treatment follow-up;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">adding a sufficient number of clinical trial sites; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">manufacturing sufficient quantities and quality of a drug candidate for use in clinical trials.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may also experience
numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing
approval or commercialize our drug candidates, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">we may receive feedback from regulatory authorities that requires us to modify the design of our clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">we may not have the ability to test patients for our clinical trials that require a specific genomic or biomarker signature in order to qualify for enrollment;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">clinical trials of our drug candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon drug development programs;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the number of patients required for clinical trials of our drug candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the cost of clinical trials of our drug candidates may be greater than we anticipate;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the supply or quality of our drug candidates or other materials necessary to conduct clinical trials of our drug candidates may be insufficient or inadequate;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">regulators may revise the requirements for approving our drug candidates, or such requirements may not be as we anticipate; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any future collaborators that conduct clinical trials may face any of the above issues, and may conduct clinical trials in ways they view as advantageous to themselves but that are suboptimal for us.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are required
to conduct additional clinical trials or other testing of our drug candidates beyond those that we currently contemplate, if we
are unable to successfully complete clinical trials of our drug candidates or other testing, if the results of these trials or
tests are not positive or are only modestly positive or if there are safety concerns, we may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">incur unplanned costs;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">be delayed in obtaining marketing approval for our drug candidates or not obtain marketing approval at all;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">obtain marketing approval in some countries and not in others;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">obtain marketing approval for indications or patient populations that are not as broad as intended or desired;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">obtain marketing approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">be subject to additional post-marketing testing requirements; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">have the drug removed from the market after obtaining marketing approval.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, we intend
to rely on CROs, cancer research centers and clinical trial sites to ensure the proper and timely conduct of our clinical trials
and we intend to have agreements governing their committed activities. They may not perform as required or we may face competition
from other clinical trials being conducted by other pharmaceutical companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We could encounter
delays if a clinical trial is suspended or terminated by us, by the Institutional Review Board or IRB of the institutions in which
such trials are being conducted, by the Data Safety Monitoring Board, or DSMB, for such trial or by the FDA or other regulatory
authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct
the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations
or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues
or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative
actions or lack of adequate funding to continue the clinical trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, conducting
clinical trials in foreign countries, as we may do for our current and future drug candidates, presents additional risks that may
delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to
clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens
associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we experience delays
in the completion of, or termination of, any clinical trial of our drug candidates, the commercial prospects of our drug candidates
will be harmed, and our ability to generate revenues from any of these drug candidates will be delayed. In addition, any delays
in completing our clinical trials will increase our costs, slow down our drug candidate development and approval process and jeopardize
our ability to commence drug sales and generate revenues. Any of these occurrences may harm our business, financial condition and
prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of
clinical trials may also ultimately lead to the denial of regulatory approval of our drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our drug candidates may cause undesirable
side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an
approved label, or result in significant negative consequences following marketing approval, if any. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Undesirable side effects
caused by our drug candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result
in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. The
clinical evaluation of LP-184 and our other drug candidates in patients is still in the early stages and it is possible that there
may be side effects associated with their use. In such an event, we, the FDA, the IRBs at the institutions in which our studies
are conducted, or the DSMB could suspend or terminate our clinical trials or the FDA or comparable foreign regulatory authorities
could order us to cease clinical trials or deny approval of our drug candidates for any or all targeted indications. Treatment-related
side effects could also affect patient recruitment or the ability of enrolled patients to complete the clinical trial or result
in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating
medical staff. We expect to have to train medical personnel using our drug candidates to understand the side effect profiles for
our clinical trials and upon any commercialization of any of our drug candidates. Inadequate training in recognizing or managing
the potential side effects of our drug candidates could result in patient injury or death. Any of these occurrences may harm our
business, financial condition and prospects significantly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Additionally, if one or more of our drug
candidates receives marketing approval, and we or others later identify undesirable side effects caused by such drugs, a number
of potentially significant negative consequences could result, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">regulatory authorities may withdraw approvals of such drugs;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">we may be required to recall a drug or change the way such a drug is administered to patients;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">additional restrictions may be imposed on the marketing or distribution of the particular drug or the manufacturing processes for the drug or any component thereof;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">regulatory authorities may require additional warnings on the label, such as a &ldquo;black box&rdquo; warning or contraindication;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">we may be required to implement Risk Evaluation and Mitigation Strategies, or REMS, or create a medication guide outlining the risks of such side effects for distribution to patients;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">we could be sued and held liable for harm caused to patients;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our drug may become less competitive; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our reputation may suffer.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of these events
could prevent us from achieving or maintaining market acceptance of the particular drug candidate or for particular indications
of a drug candidate, if approved, and could significantly harm our business, results of operations and prospects. Our approach
to the discovery and development of drug candidates based on our RADR<SUP>&reg;</SUP> platform is innovative and in the early stages
of development; and we do not know whether we will be able to develop any drugs of commercial value.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are leveraging our
RADR<SUP>&reg;</SUP> platform in an attempt to create a pipeline of drug candidates using biomarker identification and patient
stratification for the development of oncology drugs. While we believe that applying our RADR<SUP>&reg;</SUP> platform to drugs
that have failed, been abandoned or otherwise failed to meet clinical endpoints and then developing a precision oncology approach
that identifies the mechanism of action, potential combination drug usage and potentially responsive patient population is a powerful
strategy, our approach is both innovative and in the early stages of development. Because our approach is both innovative and in
the early stages of development, the cost and time needed to develop our drug candidates is difficult to predict, and our efforts
may not result in the successful discovery and development of commercially viable medicines. We may also be incorrect about the
effects of our drug candidates on the diseases of our defined patient populations, which may limit the utility of our approach
or the perception of the utility of our approach. Furthermore, our estimates of our defined patient populations available for study
and treatment may be lower than expected, which could adversely affect our ability to conduct clinical trials and may also adversely
affect the size of any market for medicines we may successfully commercialize. Our approach may not result in time savings, higher
success rates or reduced costs as we expect it to, and if not, we may not attract collaborators or develop new drugs as quickly
or cost effectively as expected and therefore we may not be able to commercialize our approach as originally expected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our RADR</I></B><I><SUP>&reg; </SUP><B>platform
may fail to help us discover and develop additional potential drug candidates.</B></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any drug discovery
or drug development that we are conducting using our RADR<SUP>&reg;</SUP> platform may not be successful in identifying compounds
that have commercial value or therapeutic utility. Our RADR<SUP>&reg;</SUP> platform may initially show promise in identifying
potential drug candidates, yet fail to yield viable drug candidates for clinical development or commercialization for a number
of reasons, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">research programs to identify new drug candidates will require substantial technical, financial and human resources, and we may be unsuccessful in our efforts to identify new drug candidates. If we are unable to identify suitable additional compounds for preclinical and clinical development, our ability to develop drug candidates and obtain product revenues in future periods could be compromised, which could result in significant harm to our financial position and adversely impact our stock price;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">compounds identified through our RADR<SUP>&reg;</SUP> platform may not demonstrate efficacy, safety or tolerability;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the data available for our RADR<SUP>&reg;</SUP> platform that seeks to correlate genomic or biomarker signatures with certain cancers may be influenced by the race of the patient which may limit the efficacy of our drug candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">potential drug candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to receive marketing approval and achieve market acceptance;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">competitors may develop alternative therapies that render our potential drug candidates non-competitive or less attractive; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a potential drug candidate may not be capable of being produced at an acceptable cost.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Any failure by us to comply with
existing regulations could harm our reputation and operating results. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will be subject
to extensive regulation by U.S. federal and state and foreign governments in each of the markets where we intend to sell LP-300
and LP-184 if and after they are approved. For example, we will have to adhere to all regulatory requirements including the FDA&rsquo;s
current GCPs, Good Laboratory Practice, or GLP, and GMP requirements. If we fail to comply with applicable regulations, including
FDA pre-or post- approval cGMP requirements, then the FDA or other foreign regulatory authorities could sanction us. Even if a
drug is FDA-approved, regulatory authorities may impose significant restrictions on a drug&rsquo;s indicated uses or marketing
or impose ongoing requirements for potentially costly post-marketing studies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any action against
us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses,
divert our management&rsquo;s attention from the operation of our business and damage our reputation. We will need to expend significant
resources on compliance efforts and such expenses are unpredictable and might adversely affect our results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA&rsquo;s and
other regulatory authorities&rsquo; policies may change and additional government regulations may be enacted that could prevent,
limit or delay regulatory approval of our drug candidates. For example, in December 2016, the 21st Century Cures Act, or Cures
Act, was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs and spur innovation,
but its ultimate implementation is unclear. If we are slow or unable to adapt to changes in existing requirements or the adoption
of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that
we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial
condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we cannot
predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive
action, either in the United States or abroad. If future legislation or administrative or executive actions impose restrictions
on FDA&rsquo;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively
impacted. In addition, if we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements
or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained
and we may not achieve or sustain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be subject to extensive regulations
outside the United States and may not obtain marketing approvals for drugs in Europe and other jurisdictions. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to regulations
in the United States, should we or our collaborators pursue marketing approvals for LP-184 and LP-300 and our other drug candidates
internationally, we and our collaborators will be subject to a variety of regulations in other jurisdictions governing, among other
things, clinical trials and any commercial sales and distribution of our drugs. Whether or not we, or our collaborators, obtain
applicable FDA regulatory clearance and marketing approval for a drug, we must obtain the requisite approvals from regulatory authorities
in foreign countries prior to the commencement of clinical trials or marketing of the drug in those countries. The requirements
and process governing the conduct of clinical trials, drug licensing, pricing and reimbursement vary from country to country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to pursue
marketing approvals for LP-184 and LP-300 and our other drug candidates in Europe and other jurisdictions outside the United States
with collaborative partners. The time and process required to obtain regulatory approvals and reimbursement in Europe and other
jurisdictions may be different from those in the United States regulatory and approval in one jurisdiction does not ensure approvals
in any other jurisdiction; however, negative regulatory decisions in any jurisdiction may have a negative impact on the regulatory
process in other jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, on June
23, 2016, the electorate in the United Kingdom voted in favor of leaving the European Union, commonly referred to as Brexit. On
March 29, 2017, the country formally notified the European Union of its intention to withdraw pursuant to Article 50 of the Lisbon
Treaty triggering a two-year period for the United Kingdom to formally leave the European Union. Following a series of extensions
to leave the European Union, on January 31, 2020, the United Kingdom officially left the European Union commencing a transition
period in which the United Kingdom is required to continue to follow all European Union rules and trading relationships, but will
no longer be represented in the European Parliament. During the transition period, the United Kingdom and the European Union will
engage in negotiations for new trade agreements and, among other things, the regulation of their pharmaceutical industries. Since
a significant proportion of the regulatory framework in the United Kingdom is derived from European Union directives and regulations,
the transition period could materially impact the regulatory regime with respect to the approval of our drug candidates in the
United Kingdom or the European Union. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of
Brexit or otherwise, would prevent us from commercializing our drug candidates in the United Kingdom and/or the European Union
and restrict our ability to generate revenue and achieve and sustain profitability. If any of these outcomes occur, we may be forced
to restrict or delay efforts to seek regulatory approval in the United Kingdom and/or European Union for our drug candidates, which
could materially and adversely affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are found in violation of federal
or state &ldquo;fraud and abuse&rdquo; laws, we may be required to pay a penalty and/or be suspended from participation in federal
or state health care programs, which may adversely affect our business, financial condition and results of operations. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States,
we will be subject to various federal and state health care &ldquo;fraud and abuse&rdquo; laws, including anti-kickback laws, false
claims laws and other laws intended to reduce fraud and abuse in federal and state health care programs, which could affect us,
particularly upon successful commercialization of our drugs in the United States. The federal Anti-Kickback Statute makes it illegal
for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit,
receive, offer or pay any remuneration that is intended to induce the referral of business, including the purchase, order or prescription
of a particular drug for which payment may be made under a federal health care program, such as Medicare or Medicaid. Under federal
government regulations, some arrangements, known as safe harbors, are deemed not to violate the federal Anti-Kickback Statute.
Although we seek to structure our business arrangements in compliance with all applicable requirements, these laws are broadly
written, and it is often difficult to determine precisely how the law will be applied in specific circumstances. Accordingly, it
is possible that our practices may be challenged under the federal Anti-Kickback Statute. False claims laws prohibit anyone from
knowingly and willfully presenting or causing to be presented for payment to third-party payers, including government payers, claims
for reimbursed drugs or services that are false or fraudulent, claims for items or services that were not provided as claimed,
or claims for medically unnecessary items or services. Cases have been brought under false claims laws alleging that off-label
promotion of pharmaceutical drugs or the provision of kickbacks has resulted in the submission of false claims to governmental
health care programs. Under the Health Insurance Portability and Accountability Act of 1996, we are prohibited from knowingly and
willfully executing a scheme to defraud any health care benefit program, including private payers, or knowingly and willfully falsifying,
concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with
the delivery of or payment for health care benefits, items or services. Violations of fraud and abuse laws may be punishable by
criminal and/or civil sanctions, including fines and/or exclusion or suspension from federal and state health care programs such
as Medicare and Medicaid and debarment from contracting with the U.S. government. In addition, private individuals have the ability
to bring actions on behalf of the government under the federal False Claims Act as well as under the false claims laws of several
states.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many states have adopted
laws similar to the federal anti-kickback statute, some of which apply to the referral of patients for health care services reimbursed
by any source, not just governmental payers. Neither the government nor the courts have provided definitive guidance on the application
of fraud and abuse laws to our business. Law enforcement authorities are increasingly focused on enforcing these laws, and if we
are found in violation of one of these laws, we could be required to pay a penalty and could be suspended or excluded from participation
in federal or state health care programs, and our business, results of operations and financial condition may be adversely affected.
We may be unable to maintain sufficient clinical trial liability insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our inability to obtain and retain
sufficient clinical trial liability insurance at an acceptable cost to protect against potential liability claims could prevent
or inhibit our ability to conduct clinical trials for drug candidates we develop. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently do not
have clinical trial liability insurance and would need to secure coverage before commencing patient enrollment for our clinical
trials in the United States or other jurisdictions. Any claim that may be brought against us could result in a court judgment or
settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance
coverage. We expect we will supplement our clinical trial coverage with product liability coverage in connection with the commercial
launch of LP-184 and LP-300 or other drug candidates we develop in the future; however, we may be unable to obtain such increased
coverage on acceptable terms or at all. If we are found liable in a clinical trial lawsuit or a product liability lawsuit in the
future, we will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or
that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The FDA and other regulatory agencies
actively enforce the laws and regulations prohibiting the promotion of off-label uses. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are found to
have improperly promoted off-label uses of our drugs or drug candidates, if approved, we may become subject to significant liability.
Such enforcement has become more common in the industry. The FDA and other regulatory agencies strictly regulate the promotional
claims that may be made about prescription drug products, such as our drug candidates, if approved. In particular, a drug may not
be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the drug&rsquo;s approved
labeling. If we receive marketing approval for our drug candidates for our proposed indications, physicians may nevertheless use
our drugs for their patients in a manner that is inconsistent with the approved label, if the physicians personally believe in
their professional medical judgment it could be used in such manner. However, if we are found to have promoted our drugs for any
off-label uses, the federal government could levy civil, criminal and/or administrative penalties, and seek fines against us. The
FDA or other regulatory authorities could also request that we enter into a consent decree or a corporate integrity agreement,
or seek a permanent injunction against us under which specified promotional conduct is monitored, changed or curtailed. If we cannot
successfully manage the promotion of our drug candidates, if approved, we could become subject to significant liability, which
would materially adversely affect our business and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We may not experience a faster development or regulatory
review or approval process with potential Fast Track designation.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a drug is intended
for the treatment of a serious condition and nonclinical or clinical data demonstrate the potential to address unmet medical need
for this condition, a drug sponsor may apply for FDA Fast Track designation. If we seek Fast Track designation for a drug candidate,
we may not receive it from the FDA. However, even if we receive Fast Track designation, Fast Track designation does not ensure
that we will receive marketing approval or that approval will be granted within any particular timeframe. We may not experience
a faster development or regulatory review or approval process with Fast Track designation compared to conventional FDA procedures.
In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from
our clinical development program. Fast Track designation alone does not guarantee qualification for the FDA&rsquo;s priority review
procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Commercialization of
Our Drug Candidates </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Even if we are successful in completing
all preclinical studies and clinical trials, we may not be successful in commercializing one or more of our drug candidates.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we complete
the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain
and may prevent us from obtaining approvals for the commercialization of some or all of our drug candidates. If we are not able
to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our drug candidates,
and our ability to generate revenue will be materially impaired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our drug candidates
and the activities associated with their development and commercialization, including their design, testing, manufacture, safety,
efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, export and import are subject
to comprehensive regulation by the FDA and other regulatory agencies in the United States and by the EMA and similar regulatory
authorities outside of the United States. Failure to obtain marketing approval for a drug candidate will prevent us from commercializing
the drug candidate. We have not submitted an application for or received marketing approval for any of our drug candidates in the
United States or in any other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have only limited
experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party clinical
research organizations or other third-party consultants or vendors to assist us in this process. Securing marketing approval requires
the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic
indication to establish the drug candidate&rsquo;s safety and efficacy. Securing marketing approval also requires the submission
of information about the drug manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities.
Our drug candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side
effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial
use. New cancer drugs frequently are indicated only for patient populations that have not responded to an existing therapy or have
relapsed. If any of our drug candidates receives marketing approval, the accompanying label may limit the approved use of our drug
in this way, which could limit sales of the drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The process of obtaining
marketing approvals, both in the United States and abroad, is expensive, may take many years, if approval is obtained at all, and
can vary substantially based upon a variety of factors, including the type, complexity and novelty of the drug candidates involved.
Changes in marketing approval policies during the development period, changes in or the enactment of additional statutes or regulations,
or changes in regulatory review for each submitted drug application, may cause delays in the approval or rejection of an application.
Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide
that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying
interpretations of the data obtained from preclinical studies and clinical trials could delay, limit or prevent marketing approval
of a drug candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments
that render the approved drug not commercially viable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If our drugs do not gain market acceptance, our business
will suffer because we might not be able to fund future operations. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A number of factors
may affect the market acceptance of our drugs or any other products we develop or acquire, including, among others:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the price of our drugs relative to other products for the same or similar treatments;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the perception by patients, physicians and other members of the health care community of the effectiveness and safety of our drugs for their indicated applications and treatments;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to fund our sales and marketing efforts; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the effectiveness of our sales and marketing efforts.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our drugs do not
gain market acceptance, we may not be able to fund future operations, including developing, testing and obtaining regulatory approval
for new drug candidates and expanding our sales and marketing efforts for our approved drugs, which would cause our business to
suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may rely on orphan drug status
to commercialize some of our drug candidates, and even if orphan drug status is approved, such approval may not confer marketing
exclusivity or other commercial advantages or expected commercial benefits. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may rely on orphan
drug exclusivity for our drug candidates. In the United States, orphan drug designation entitles a party to financial incentives
such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers. In addition, if a drug
that has orphan drug designation subsequently receives the first FDA marketing approval for the disease for which it has such designation,
the drug is entitled to orphan drug exclusivity. Orphan drug exclusivity in the United States provides that the FDA may not approve
any other applications, including a full NDA, to market the same drug for the same indication for seven years, and except in limited
circumstances the applicable exclusivity period is ten years in Europe. The European exclusivity period can be reduced to six years
if a drug no longer meets the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity
is no longer justified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we, or any
future collaborators, obtain orphan drug designation for a drug candidate, we, or they, may not be able to obtain or maintain orphan
drug exclusivity for that drug candidate. We may not be the first to obtain marketing approval of any drug candidate for which
we have obtained orphan drug designation for the orphan-designated indication due to the uncertainties associated with developing
pharmaceutical products, and it is possible that another company also holding orphan drug designation for the same drug candidate
will receive marketing approval for the same indication before we do. If that were to happen, our applications for that indication
may not be approved until the competing company&rsquo;s period of exclusivity expires. In addition, exclusive marketing rights
in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may
be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient
quantities of the drug to meet the needs of patients with the rare disease or condition. Further, even if we, or any future collaborators,
obtain orphan drug exclusivity for a drug, that exclusivity may not effectively protect the drug from competition because different
drugs with different active moieties may be approved for the same condition. Even after an orphan drug is approved, the FDA can
subsequently approve the same drug with the same active moiety for the same condition if the FDA concludes that the later drug
is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care or the manufacturer
of the drug with orphan exclusivity is unable to maintain sufficient drug quantity. Orphan drug designation neither shortens the
development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process,
nor does it prevent competitors from obtaining approval of the same drug candidate as ours for indications other than those in
which we have been granted orphan drug designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On August 3, 2017, the U.S. Congress passed
the FDA Reauthorization Act of 2017, or FDARA. FDARA, among other things, codified the FDA&rsquo;s preexisting regulatory interpretation,
to require that a drug sponsor demonstrate the clinical superiority of an orphan drug that is otherwise the same as a previously
approved drug for the same rare disease in order to receive orphan drug exclusivity. The new legislation reverses prior precedent
holding that the Orphan Drug Act unambiguously requires that the FDA recognize the orphan exclusivity period regardless of a showing
of clinical superiority. The FDA may further reevaluate the Orphan Drug Act and its regulations and policies. We do not know if,
when or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might
affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could
be adversely impacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>A Breakthrough Therapy designation
by the FDA for our drug candidates may not lead to a faster development or regulatory review or approval process, and it does not
increase the likelihood that our drug candidates will receive marketing approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may seek a breakthrough
therapy designation for some of our drug candidates. A breakthrough therapy is defined as a drug that is intended, alone or in
combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical
evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant
endpoints, such as substantial treatment effects observed early in clinical development. For drugs and biologics that have been
designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify
the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens.
Drugs designated as breakthrough therapies by the FDA are also eligible for accelerated approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Designation as a breakthrough
therapy is within the discretion of the FDA. Accordingly, even if we believe one of our drug candidates meets the criteria for
designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. Even if we receive
Breakthrough Therapy designation, the receipt of such designation for a drug candidate may not result in a faster development process,
review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval
by the FDA. In addition, even if one or more of our drug candidates qualify as breakthrough therapies, the FDA may later decide
that the drugs no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not
be shortened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>A Fast Track designation by the FDA
may not lead to a faster development or regulatory review or approval process.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may seek Fast Track
designation for some of our drug candidates. If a drug is intended for the treatment of a serious or life-threatening condition
and the drug demonstrates the potential to address unmet medical needs for this condition, the drug sponsor may apply for FDA Fast
Track designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular drug
candidate is eligible for this designation, we cannot assure you that the FDA would decide to grant it. Even if we do receive Fast
Track designation, we may not experience a faster development process, review or approval compared to conventional FDA procedures.
The FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical
development program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Failure to obtain marketing approval
in foreign jurisdictions would prevent our drug candidates from being marketed abroad.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to market
and sell our drugs in the European Union and many other foreign jurisdictions, we or our potential third-party collaborators must
obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies
among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required
to obtain FDA marketing approval. The regulatory approval process outside of the United States generally includes all of the risks
associated with obtaining FDA approval. In addition, in many countries outside of the United States, it is required that the drug
be approved for reimbursement before the drug can be approved for sale in that country. We or our potential third-party collaborators
may not obtain approvals from regulatory authorities outside of the United States on a timely basis, if at all. Approval by the
FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority
outside of the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA.
However, a failure or delay in obtaining regulatory approval in one country may have a negative effect on the regulatory process
in other countries. We may not be able to file for marketing approvals and may not receive necessary approvals to commercialize
our drugs in any market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>If we are required by the FDA to obtain approval of a
companion diagnostic in connection with approval of a therapeutic drug candidate, and we do not obtain or face delays in obtaining
FDA approval of a diagnostic device, we will not be able to commercialize the drug candidate and our ability to generate revenue
will be materially impaired.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to FDA guidance,
if the FDA determines that a companion diagnostic device is essential to the safe and effective use of a novel therapeutic drug
or indication, the FDA generally will not approve the therapeutic drug or new therapeutic drug indication if the companion diagnostic
is not also approved or cleared for that indication. Under the Federal Food, Drug, and Cosmetic Act, or FDCA, companion diagnostics
are regulated as medical devices, and the FDA has generally required companion diagnostics intended to select the patients who
will respond to cancer treatment to obtain Premarket Approval, or a PMA, for the diagnostic. The PMA process, including the gathering
of clinical and preclinical data and the submission to and review by the FDA, involves a rigorous premarket review during which
the applicant must prepare and provide the FDA with reasonable assurance of the device&rsquo;s safety and effectiveness and information
about the device and its components regarding, among other things, device design, manufacturing and labeling. A PMA is not guaranteed
and may take considerable time, and the FDA may ultimately respond to a PMA submission with a &ldquo;not approvable&rdquo; determination
based on deficiencies in the application and require additional clinical trial or other data that may be expensive and time-consuming
to generate and that can substantially delay approval. As a result, if we are required by the FDA to obtain approval of a companion
diagnostic for a therapeutic drug candidate, and we do not obtain or there are delays in obtaining FDA approval of a diagnostic
device, we may not be able to commercialize the drug candidate on a timely basis or at all and our ability to generate revenue
will be materially impaired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While it is possible
that one or more of our drug candidates may require a companion diagnostic to select the patients who will likely respond to a
cancer therapy involving one of our drug candidates that would require a PMA for the companion diagnostic as a condition to obtaining
marketing approval from the FDA, it is too early in our drug candidates development to identify which drug candidate, if any, would
require a PMA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Any drug candidate that we obtain
marketing approval for could be subject to post-marketing restrictions or withdrawal from the market and we may be subject to substantial
penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our drugs, when and
if any of them are approved. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any drug candidate
for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising
and promotional activities for such drug, will be subject to continual requirements of and review by the FDA and other regulatory
authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and
listing requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance
of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing
approval of a drug candidate is granted, the approval may be subject to limitations on the indicated uses for which the drug may
be marketed or to the conditions of approval, including the requirement to implement a REMS. New cancer drugs frequently are indicated
only for patient populations that have not responded to an existing therapy or have relapsed. If any of our drug candidates receives
marketing approval, the accompanying label may limit the approved use of our drug in this way, which could limit sales of the drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA may also impose
requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of the drug,
including the adoption and implementation of REMS. The FDA and other agencies, including the Department of Justice, or the DOJ,
closely regulate and monitor the post-approval marketing and promotion of drugs to ensure they are marketed and distributed only
for the approved indications and in accordance with the provisions of the approved labeling. The FDA and DOJ impose stringent restrictions
on manufacturers&rsquo; communications regarding off-label use, and if we do not market our drugs for their approved indications,
we may be subject to enforcement action for off-label marketing. Violations of the FDCA and other statutes, including the False
Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations and enforcement actions
alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, later
discovery of previously unknown adverse events or other problems with our drugs, manufacturers or manufacturing processes, or failure
to comply with regulatory requirements, may have various consequences, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">restrictions on such drugs, manufacturers or manufacturing processes;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">restrictions and warnings on the labeling or marketing of a drug;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">restrictions on drug distribution or use;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">requirements to conduct post-marketing studies or clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">warning letters or untitled letters;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">withdrawal of the drugs from the market;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">refusal to approve pending applications or supplements to approved applications that we submit;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">recall of drugs;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">fines, restitution or disgorgement of profits or revenues;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">suspension or withdrawal of marketing approvals;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">damage to relationships with any potential collaborators;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">unfavorable press coverage and damage to our reputation;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">refusal to permit the import or export of our drugs;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">drug seizure;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">injunctions or the imposition of civil or criminal penalties; or</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">litigation involving patients using our drugs.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Non-compliance with European Union
requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of drugs for the
pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the European Union&rsquo;s
requirements regarding the protection of personal information can also lead to significant penalties and sanctions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, manufacturers
of approved drugs and those manufacturers&rsquo; facilities are required to comply with extensive FDA requirements, including ensuring
that quality control and manufacturing procedures conform to cGMPs applicable to drug manufacturers or quality assurance standards
applicable to medical device manufacturers, which include requirements relating to quality control and quality assurance as well
as the corresponding maintenance of records and documentation and reporting requirements. We, any contract manufacturers we may
engage in the future, our future collaborators and their contract manufacturers will also be subject to other regulatory requirements,
including submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements
regarding the distribution of samples to clinicians, recordkeeping, and costly post-marketing studies or clinical trials and surveillance
to monitor the safety or efficacy of the drug such as the requirement to implement a REMS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We operate in a highly competitive
and rapidly changing industry</I>. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Biotechnological and
pharmaceutical drug development is highly competitive and subject to rapid and significant technological advancements. Our success
is highly dependent upon our ability to in-license, acquire, develop and obtain regulatory approval for new and innovative drugs
on a cost-effective basis and to market them successfully. In doing so, we face and will continue to face intense competition
from a variety of businesses, including large, fully integrated, well-established pharmaceutical companies who already possess
a large share of the market, specialty pharmaceutical and biopharmaceutical companies, academic institutions, government agencies
and other private and public research institutions in the United States, the European Union and other jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many of the companies
against which we are competing or against which we may compete in the future have significantly greater financial resources and
expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals
and marketing approved drugs than we do. These third parties compete with us in recruiting and retaining qualified scientific
and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring
technologies complementary to, or necessary for, our programs. Mergers and acquisitions in the pharmaceutical and biotechnology
industries could result in even more resources being concentrated among a small number of our competitors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competition may further
increase as a result of advances in the commercial applicability of technologies and greater availability of capital for investment
in these industries. Our competitors may succeed in developing, acquiring or licensing, on an exclusive basis, drugs that are
more effective or less costly than any drug candidate that we may develop.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Established pharmaceutical
and biotechnology companies may invest heavily to accelerate discovery and development of novel compounds or to in-license novel
compounds that could make our drug candidates less competitive. In addition, any new drug that competes with an approved drug
must demonstrate compelling advantages in efficacy, convenience, tolerability and safety in order to overcome price competition
and to be commercially successful. Accordingly, our competitors may succeed in obtaining patent protection, discovering, developing,
receiving FDA approval for or commercializing drugs before we do, which would have an adverse impact on our business and results
of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The availability of
our competitors&rsquo; drugs could limit the demand and the price we are able to charge for any drug candidate we commercialize,
if any. The inability to compete with existing or subsequently introduced drugs would harm our business, financial condition and
results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we are unable to develop satisfactory
sales and marketing capabilities, we may not succeed in commercializing LP-184 and LP-300 or any other drug candidate</I>.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have no experience
in marketing and selling drug products. We have not entered into arrangements for the sale and marketing of LP-184 and LP-300
or any other drug candidate. Typically, pharmaceutical companies would employ groups of sales representatives and associated sales
and marketing staff numbering in the hundreds to thousands of individuals to call on this large number of physicians and hospitals.
We may seek to collaborate with a third party to market our drugs or may seek to market and sell our drugs by ourselves. If we
seek to collaborate with a third party, we cannot be sure that a collaborative agreement can be reached on terms acceptable to
us. If we seek to market and sell our drugs directly, we will need to hire additional personnel skilled in marketing and sales.
We cannot be sure that we will be able to acquire, or establish third party relationships to provide, any or all of these marketing
and sales capabilities. The establishment of a direct sales force or a contract sales force or a combination direct and contract
sales force to market our drugs will be expensive and time-consuming and could delay any drug launch. Further, we can give no
assurances that we may be able to maintain a direct and/or contract sales force for any period of time or that our sales efforts
will be sufficient to generate or to grow our revenues or that our sales efforts will ever lead to profits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Even if we obtain regulatory approvals
to commercialize LP-184 and LP-300 or our other drug candidates, our drug candidates may not be accepted by physicians or the
medical community in general. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There can be no assurance
that LP-184 and LP-300 and our other drug candidates or any other drug candidate successfully developed by us, independently or
with partners, will be accepted by physicians, hospitals and other health care facilities. LP-184 and LP-300 and any future drug
candidates we develop will compete with a number of drugs manufactured and marketed by major pharmaceutical and biotech companies.
The degree of market acceptance of any drugs we develop depends on a number of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our demonstration of
the clinical efficacy and safety of LP-184 and LP-300 and our other drug candidates;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">timing of market approval
and commercial launch of LP-184 and LP-300 and our other drug candidates;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the clinical indication(s)
for which LP-184 and LP-300 and our other drug candidates are approved;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">drug label and package
insert requirements;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">advantages and disadvantages
of our drug candidates compared to existing</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">continued interest in
and growth of the market for anticancer or anti-agitation drugs;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">strength of sales, marketing,
and distribution support;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">drug pricing in absolute
terms and relative to alternative treatments;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">future changes in health
care laws, regulations, and medical policies; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">availability of reimbursement
codes and coverage in select jurisdictions, and future changes to reimbursement policies of government and third-party payors.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Significant uncertainty
exists as to the coverage and reimbursement status of any drug candidate for which we obtain regulatory approval. In the United
States and markets in other countries, sales of any drugs for which we receive regulatory approval for commercial sale will depend
in part on the availability of reimbursement from third-party payors. Third-party payors include government health administrative
authorities, managed care providers, private health insurers and other organizations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Healthcare reform measures could
hinder or prevent our drug candidates&rsquo; commercial success. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The U.S. government
and other governments have shown significant interest in pursuing healthcare reform. Any government-adopted reform measures could
adversely impact the pricing of healthcare drugs and services in the United States or internationally and the amount of reimbursement
available from governmental agencies or other third-party payors. The continuing efforts of the U.S. and foreign governments,
insurance companies, managed care organizations and other payors of health care services to contain or reduce health care costs
may adversely affect our ability to set prices for our drugs which we believe are fair, and our ability to generate revenues and
achieve and maintain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States,
some states have implemented, and other states are considering, pharmaceutical price controls or patient access constraints under
their Medicaid program. There have also been recent state legislative efforts that have generally focused on increasing transparency
around drug costs or limiting drug prices. In addition, the growth of large managed care organizations and prescription benefit
managers, as well as the prevalence of generic substitution, has hindered price increases for prescription drugs. Continued intense
public scrutiny of the price of drugs, together with government and payor dynamics, may limit the ability of producers and marketers
to set or adjust the price of products based on their value. Outside the United States, numerous major markets, including the
EU, Japan and China, have pervasive government involvement in funding healthcare, and, in that regard, fix the pricing and reimbursement
of pharmaceutical products. Consequently, our products generating will be subject to increasing government decision-making and
budgetary actions. There can be no assurance that new or proposed products will be considered cost-effective or that adequate
third-party reimbursement will be available to enable the producer or marketer of such product to maintain price levels sufficient
to realize an appropriate return.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 89; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">New laws, regulations
and judicial decisions, or new interpretations of existing laws, regulations and decisions, that relate to healthcare availability,
methods of delivery or payment for products and services, or sales, marketing or pricing, may limit our potential revenue, and
we may need to revise our research and development programs. The pricing and reimbursement environment may change in the future
and become more challenging due to several reasons, including policies advanced by the current executive administration in the
United States, new healthcare legislation or fiscal challenges faced by government health administration authorities. Specifically,
in both the United States and some foreign jurisdictions, there have been a number of legislative and regulatory proposals to
change the health care system in ways that could affect our ability to sell our drugs profitably.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For example, the Patient
Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or the PPACA has substantially
changed the way healthcare is financed by both government health plans and private insurers, and significantly impacts the pharmaceutical
industry. The PPACA contains a number of provisions that are expected to impact our business and operations in ways that may negatively
affect our potential revenues in the future. For example, the PPACA imposes a non-deductible excise tax on pharmaceutical manufacturers
or importers that sell branded prescription drugs to government programs which we believe will increase the cost of our drugs.
In addition, as part of the PPACA&rsquo;s provisions closing a funding gap that currently exists in the Medicare Part D prescription
drug program, we will be required to provide a discount on branded prescription drugs equal to 50% of the government-negotiated
price, for drugs provided to certain beneficiaries who fall within the donut hole. Similarly, PPACA increases the level of Medicaid
rebates payable by manufacturers of brand-name drugs from 15.1% to 23.1% and requires collection of rebates for drugs paid by
Medicaid managed care organizations. The PPACA also includes significant changes to the 340B drug discount program including expansion
of the list of eligible covered entities that may purchase drugs under the program. At the same time, the expansion in eligibility
for health insurance benefits created under PPACA is expected to increase the number of patients with insurance coverage who may
receive our drugs. While it is too early to predict all the specific effects the PPACA or any future healthcare reform legislation
will have on our business, they could have a material adverse effect on our business and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Congress periodically
adopts legislation like the PPACA and the Medicare Prescription Drug, Improvement and Modernization Act of 2003, that modifies
Medicare reimbursement and coverage policies pertaining to prescription drugs. Implementation of these laws is subject to ongoing
revision through regulatory and sub regulatory policies. Congress also may consider additional changes to Medicare policies, potentially
including Medicare prescription drug policies, as part of ongoing budget negotiations. While the scope of any such legislation
is uncertain at this time, there can be no assurances that future legislation or regulations will not decrease the coverage and
price that we may receive for our proposed drugs. Other third-party payors are increasingly challenging the prices charged for
medical products and services. It will be time consuming and expensive for us to go through the process of seeking coverage and
reimbursement from Medicare and private payors. Our proposed drugs may not be considered cost-effective, and coverage and reimbursement
may not be available or sufficient to allow us to sell our proposed drugs on a profitable basis. Further federal and state proposals
and health care reforms are likely which could limit the prices that can be charged for the drug candidates that we develop and
may further limit our commercial opportunities. Our results of operations could be materially adversely affected by proposed healthcare
reforms, by the Medicare prescription drug coverage legislation, by the possible effect of such current or future legislation
on amounts that private insurers will pay and by other health care reforms that may be enacted or adopted in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2007,
the Food and Drug Administration Amendments Act of 2007 was enacted, giving the FDA enhanced post-marketing authority, including
the authority to require post-marketing studies and clinical trials, labeling changes based on new safety information, and compliance
with risk evaluations and mitigation strategies approved by the FDA. The FDA&rsquo;s exercise of this authority could result in
delays or increased costs during drug development, clinical trials and regulatory review, increased costs to assure compliance
with post-approval regulatory requirements, and potential restrictions on the sale and/or distribution of approved drugs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our relationships with healthcare
providers, physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse, false claims, transparency,
health information privacy and security, and other healthcare laws and regulations, which, in the event of a violation, could
expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished
profits and future earnings.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Healthcare providers,
physicians and third-party payors will play a primary role in the recommendation and prescription of any drug candidates for which
we obtain marketing approval. Our future arrangements with healthcare providers, physicians and third-party payors may expose
us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial
arrangements and relationships through which we market, sell and distribute any drugs for which we obtain marketing approval.
In addition, we may be subject to transparency laws and patient privacy regulation by U.S. federal and state governments and by
governments in foreign jurisdictions in which we conduct our business. Restrictions under applicable federal and state healthcare
laws and regulations include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the federal Anti-Kickback
Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration,
directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or
the purchase, order or recommendation or arranging of, any good or service, for which payment may be made under a federal healthcare
program such as Medicare and Medicaid;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the federal False Claims
Act imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities
for, among other things, knowingly presenting, or causing to be presented, false or fraudulent claims for payment by a federal
healthcare program or making a false statement or record material to payment of a false claim or avoiding, decreasing or concealing
an obligation to pay money to the federal government, with potential liability including mandatory treble damages and significant
per-claim penalties, currently set at $5,500 to $11,000 per false claim;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the federal Health Insurance
Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any
healthcare benefit program or making false statements relating to healthcare matters;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">HIPAA, as amended by
the Health Information Technology for Economic and Clinical Health Act of 2009, and their respective implementing regulations,
also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission
of individually identifiable health information;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the federal Physician
Payments Sunshine Act requires applicable manufacturers of covered drugs to report payments and other transfers of value to physicians
and teaching hospitals; and</FONT></TD>
</TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">analogous state and foreign
laws and regulations, such as state anti-kickback and false claims laws and transparency statutes, may apply to sales or marketing
arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private
insurers.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Some state laws require
pharmaceutical companies to comply with the pharmaceutical industry&rsquo;s voluntary compliance guidelines and the relevant compliance
guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and
other transfers of value to physicians and other healthcare providers or marketing expenditures. Additionally, some state and
local laws require the registration of pharmaceutical sales representatives in the jurisdiction. State and foreign laws also govern
the privacy and security of health information in some circumstances, many of which differ from each other in significant ways
and often are not preempted by HIPAA, thus complicating compliance efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Efforts to ensure
that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial
costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future
statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations
are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject
to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of drugs from government
funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the
physicians or other healthcare providers or entities with whom we expect to do business is found to be not in compliance with
applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from participation in
government funded healthcare programs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Recently enacted and future legislation
may increase the difficulty and cost for us to obtain marketing approval of and commercialize our drug candidates and affect the
prices we may obtain for any drugs that are approved in the United States or foreign jurisdictions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States
and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding
the healthcare system that could prevent or delay marketing approval of our drug candidates, restrict or regulate post-approval
activities and affect our ability to profitably sell any drug candidates for which we obtain marketing approval. The pharmaceutical
industry has been a particular focus of these efforts and has been significantly affected by legislative initiatives. Current
laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria
and in additional downward pressure on the price that we receive for any FDA approved drug.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States,
the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, changed the way Medicare covers and pays
for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and introduced a new
reimbursement methodology based on average sales prices for physician-administered drugs. In addition, this legislation provided
authority for limiting the number of drugs that will be covered in any therapeutic class. Cost reduction initiatives and other
provisions of this legislation could decrease the coverage and price that we receive for any approved drugs. While the MMA applies
only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations
in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the MMA may result in a
similar reduction in payments from private payors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;In March 2010,
President Obama signed into law the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation
Act of 2010, or collectively the ACA. Among the provisions of the ACA of potential importance to our business, including, without
limitation, our ability to commercialize and the prices we may obtain for any of our drug candidates that are approved for sale,
are the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">an annual, non-deductible
fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">an increase in the statutory
minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">expansion of healthcare
fraud and abuse laws, including the civil False Claims Act and the federal Anti-Kickback Statute, new government investigative
powers and enhanced penalties for noncompliance;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a new Medicare Part D
coverage gap discount program, in which manufacturers must agree to offer 50% (and 70% starting January 1, 2019) point-of-sale
discounts off negotiated prices;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">extension of manufacturers&rsquo;
Medicaid rebate liability;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">expansion of eligibility
criteria for Medicaid programs;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">expansion of the entities
eligible for discounts under the Public Health Service pharmaceutical pricing program;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">new requirements to report
certain financial arrangements with physicians and teaching hospitals;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a new requirement to
annually report drug samples that manufacturers and distributors provide to physicians; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a new Patient-Centered
Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along
with funding for such research.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, other
legislative changes have been proposed and adopted since the ACA was enacted. These changes include the Budget Control Act of
2011, which, among other things, led to aggregate reductions to Medicare payments to providers of up to 2% per fiscal year that
started in 2013 and, due to subsequent legislative amendments to the statute, will stay in effect through 2027 unless additional
congressional action is taken, and the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments
to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers
from three to five years. These new laws may result in additional reductions in Medicare and other healthcare funding and otherwise
affect the prices we may obtain for any of our drug candidates for which we may obtain regulatory approval or the frequency with
which any such drug candidate is prescribed or used. Further, there have been several recent U.S. congressional inquiries and
proposed state and federal legislation designed to, among other things, bring more transparency to drug pricing, review the relationship
between pricing and manufacturer patient programs, reduce the costs of drugs under Medicare and reform government program reimbursement
methodologies for drug products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that these
healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions
in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure
on the price that we receive for any approved drug and/or the level of reimbursement physicians receive for administering any
approved drug we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the
frequency with which our drugs are prescribed or administered. Any reduction in reimbursement from Medicare or other government
programs may result in a similar reduction in payments from private payors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The costs of prescription
pharmaceuticals have also been the subject of considerable discussion in the United States, and members of Congress have stated
that they will address such costs through new legislative and administrative measures. To date, there have been several recent
U.S. congressional inquiries and proposed and enacted state and federal legislation designed to, among other things, bring more
transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the costs of drugs
under Medicare and reform government program reimbursement methodologies for drug products. While any proposed measures will require
authorization through additional legislation to become effective, Congress has indicated that it will continue to seek new legislative
and/or administrative measures to control drug costs. At the state level, legislatures are increasingly passing legislation and
implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement
constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in
some cases, designed to encourage importation from other countries and bulk purchasing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Legislative and regulatory
proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical
products. We cannot be sure whether additional legislative changes will be enacted, or whether FDA regulations, guidance or interpretations
will be changed, or what the impact of such changes on the marketing approvals of our drug candidates, if any, may be. Increased
scrutiny by the U.S. Congress of the FDA&rsquo;s approval process may significantly delay or prevent marketing approval, as well
as subject us to more stringent product labeling and post-marketing testing and other requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Governments outside of the United
States tend to impose strict price controls, which may adversely affect our revenues, if any.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In some countries,
particularly the countries of the European Union and Canada, the pricing of prescription pharmaceuticals is subject to governmental
control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of
marketing approval for a drug. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a
clinical trial that compares the cost-effectiveness of our drug candidate to other available therapies. In the European Union,
a member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls
on the profitability of the company placing the medicinal product on the market. If reimbursement of our drugs is unavailable
or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed, possibly materially.
Historically, products launched in the European Union do not follow price structures of the United States and generally prices
tend to be significantly lower.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we or any third-party manufacturers
or contractors we engage now or in the future fail to comply with environmental, health and safety laws and regulations, we could
become subject to fines or penalties or incur costs or liabilities that could harm our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We and third-party
manufacturers we engage now are, and any third-party manufacturers we may engage in the future will be, subject to numerous environmental,
health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment
and disposal of hazardous materials and wastes. Our operations, including work conducted through third-party manufacturers or
contractors, involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations
also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes.
We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting
from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources.
Liability under certain environmental laws governing the release and cleanup of hazardous materials is joint and several and could
be imposed without regard to fault. We also could incur significant costs associated with civil or criminal fines and penalties
or become subject to injunctions limiting or prohibiting our activities for failure to comply with such laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we maintain
general liability insurance as well as workers&rsquo; compensation insurance to cover us for costs and expenses we may incur due
to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against
potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against
us in connection with our, or our contractors, storage or disposal of biological, hazardous or radioactive materials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we may
incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These
current or future laws and regulations may impair our research, development or production efforts. Our failure to comply with
these laws and regulations also may result in substantial fines, penalties or other sanctions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, with respect
to the operations of our current and any future third-party contract manufacturers or other contractors, it is possible that if
they fail to operate in compliance with applicable environmental, health and safety laws and regulations or properly dispose of
wastes associated with our drugs, we could be held liable for any resulting damages, suffer reputational harm or experience a
disruption in the manufacture and supply of our drug candidates or drugs. In addition, our supply chain may be adversely impacted
if any of our third-party contract manufacturers become subject to injunctions or other sanctions as a result of their non-compliance
with environmental, health and safety laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may experience challenges with
the acquisition, development, enhancement or deployment of technology necessary for our </I>RADR<SUP>&reg;</SUP> <I>platform. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We operate in businesses
that require sophisticated computer systems and software for data collection, data processing, cloud-based platforms, analytics,
statistical projections and forecasting, mobile computing, social media analytics and other applications and technologies. We
seek, in part, to address our technology risks by increasing our reliance on the use of innovations by cross-industry technology
leaders and adapting these for our applicable needs and applications. Some of the technologies supporting our industry are changing
rapidly and we must continue to adapt to these changes in a timely and effective manner at an acceptable cost. We also must continue
to obtain and utilize data to in forms that are easy to use while simultaneously providing clear answers to complex questions.
There can be no guarantee that we will be able to develop, acquire or integrate new technologies, that these new technologies
will meet our needs or achieve our expected goals, or that we will be able to do so as quickly or cost-effectively as our competitors.
Significant technological change could render our RADR<SUP>&reg;</SUP> platform obsolete. Our continued success will depend on
our ability to adapt to changing technologies, manage and process ever-increasing amounts of data and information and improve
the performance, features and reliability of our platform and capabilities in response to changing internal and industry demands.
We may experience difficulties that could delay or prevent the successful design, development, testing, and introduction of advanced
versions of our RADR<SUP>&reg;</SUP>platform, limiting our ability to identify new drug candidates. New services, or enhancements
to existing services using our RADR<SUP>&reg;</SUP> platform, may not adequately meet our requirements. Any of these failures
could have a material adverse effect on our operating results and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Reliance on Third
Parties </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We rely on third parties to conduct
our preclinical studies and clinical trials. If these third parties do not successfully perform their contractual legal and regulatory
duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug candidates and
our business could be substantially harmed. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have relied upon
and plan to continue to rely upon third-party medical institutions, clinical investigators, contract laboratories and other third
party CROs to monitor and manage data for our ongoing preclinical and clinical programs. We also rely on these parties for execution
of our preclinical studies and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible
for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific
standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and our CROs are required to
comply with cGCPs, which are regulations and guidelines enforced by the FDA, the Competent Authorities of the Member States of
the European Economic Area, or EEA, and comparable foreign regulatory authorities for all of our drugs in clinical development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Regulatory authorities
enforce these cGCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our
CROs fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable and the
FDA, the EMA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving
our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority
will determine that any of our clinical trials comply with cGCP regulations. In addition, our clinical trials must be conducted
with product produced under current good manufacturing practices, or cGMP, regulations. Our failure to comply with these regulations
may require us to repeat clinical trials, which would delay the regulatory approval process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of our relationships
with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or to do so on commercially
reasonable terms. In addition, our CROs are not our employees, and except for remedies available to us under our agreements with
such CROs, we cannot control whether or not they devote sufficient time and resources to our on-going clinical, nonclinical and
preclinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines,
if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to
adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or
terminated and we may not be able to obtain regulatory approval for or successfully commercialize our drug candidates. As a result,
our results of operations and the commercial prospects for our drug candidates would be harmed, our costs could increase and our
ability to generate revenues could be delayed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many of the third
parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom
they may also be conducting clinical trials or other drug development activities that could harm our competitive position. If
the third parties conducting our GLP preclinical studies or our clinical trials do not perform their contractual duties or obligations,
experience work stoppages, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the
quality or accuracy of the clinical data they obtain is compromised due to their failure to adhere to our clinical trial protocols
or to GCPs, or for any other reason, we may need to enter into new arrangements with alternative third parties. Switching or adding
additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition period
when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical
development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not
encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact
on our business, financial condition and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are substantially dependent on
third parties for the manufacture of our clinical supplies of our drug candidates, and we intend to rely on third parties to produce
commercial supplies of any approved drug candidate. Therefore, our development of our drugs could be stopped or delayed, and our
commercialization of any future drug could be stopped or delayed or made less profitable if third party manufacturers fail to
obtain approval of the FDA or comparable regulatory authorities or fail to provide us with drug products in sufficient quantities
or at acceptable prices. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The manufacture of
pharmaceutical products is complex and requires significant expertise, capital investment, process controls and know-how. Common
difficulties in pharmaceutical manufacturing may include: sourcing and producing raw materials, transferring technology from chemistry
and development activities to production activities, validating initial production designs, scaling manufacturing techniques,
improving costs and yields, establishing and maintaining quality controls and stability requirements, eliminating contaminations
and operator errors, and maintaining compliance with regulatory requirements. We do not currently have nor do we plan to acquire
the infrastructure or capability internally in accordance with cGMP prescribed by the FDA or to produce an adequate supply of
compounds to meet future requirements for clinical trials and commercialization of our drugs. Drug manufacturing facilities are
subject to inspection before the FDA will issue an approval to market a new drug product, and all of the manufacturers that we
intend to use must adhere to the cGMP regulations prescribed by the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect therefore
to rely on third-party manufacturers for clinical supplies of our drug candidates that we may develop. These third-party manufacturers
will be required to comply with current good manufacturing practices, or GMPs, and other applicable laws and regulations. We will
have no control over the ability of these third parties to comply with these requirements, or to maintain adequate quality control,
quality assurance and qualified personnel. If the FDA or any other applicable regulatory authorities do not approve the facilities
of these third parties for the manufacture of our other drug candidates or any drugs that we may successfully develop, or if it
withdraws any such approval, or if our suppliers or contract manufacturers decide they no longer want to supply or manufacture
for us, we may need to find alternative manufacturing facilities, in which case we might not be able to identify manufacturers
for clinical or commercial supply on acceptable terms, or at all. Any of these factors would significantly impact our ability
to develop, obtain regulatory approval for or market our drug candidates and adversely affect our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We and/or our third-party
manufacturers may be adversely affected by developments outside of our control, and these developments may delay or prevent further
manufacturing of our drugs. Adverse developments may include labor disputes, resource constraints, shipment delays, inventory
shortages, lot failures, unexpected sources of contamination, lawsuits related to our manufacturing techniques, equipment used
during manufacturing, or composition of matter, unstable political environments, acts of terrorism, war, natural disasters, and
other natural and man-made disasters. If we or our third-party manufacturers were to encounter any of the above difficulties,
or otherwise fail to comply with contractual obligations, our ability to provide any drug for clinical trial or commercial purposes
would be jeopardized. This may increase the costs associated with completing our clinical trials and commercial production. Further,
production disruptions may cause us to terminate ongoing clinical trials and/or commence new clinical trials at additional expense.
We may also have to take inventory write-offs and incur other charges and expenses for drugs that fail to meet specifications
or pass safety inspections. If production difficulties cannot be solved with acceptable costs, expenses, and timeframes, we may
be forced to abandon our clinical development and commercialization plans, which could have a material adverse effect on our business,
prospects, financial condition, and the value of our securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We, or third-party manufacturers
on whom we rely, may be unable to successfully scale-up manufacturing of our drug candidates in sufficient quality and quantity,
which would delay or prevent us from developing our drug candidates and commercializing approved drugs, if any. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to conduct
clinical trials of our drug candidates and commercialize any approved drug candidates, we, or our manufacturers, will need to
manufacture them in large quantities. We, or our manufacturers, may be unable to successfully increase the manufacturing capacity
for any of our drug candidates in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up
activities. If we, or any of our manufacturers, are unable to successfully scale up the manufacture of our drug candidates in
sufficient quality and quantity, the development, testing, and clinical trials of that drug candidate may be delayed or infeasible,
and regulatory approval or commercial launch of any resulting drug may be delayed or not obtained, which could significantly harm
our business. If we are unable to obtain or maintain third-party manufacturing for commercial supply of our drug candidates, or
to do so on commercially reasonable terms, we may not be able to develop and commercialize our drug candidates successfully.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our failure to find third party
collaborators to assist or share in the costs of drug development could materially harm our business, financial condition and
results of operations. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our strategy for the
development and commercialization of our proprietary drug candidates may include the formation of collaborative arrangements with
third parties. Existing and future collaborators have significant discretion in determining the efforts and resources they apply
and may not perform their obligations as expected. Potential third-party collaborators include biopharmaceutical, pharmaceutical
and biotechnology companies, academic institutions and other entities. Third-party collaborators may assist us in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">funding research, preclinical
development, clinical trials and manufacturing;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">seeking and obtaining
regulatory approvals; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">successfully commercializing
any future drug candidates.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are not able
to establish further collaboration agreements, we may be required to undertake drug development and commercialization at our own
expense. Such an undertaking may limit the number of drug candidates that we will be able to develop, significantly increase our
capital requirements and place additional strain on our internal resources. Our failure to enter into additional collaborations
could materially harm our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our dependence
on licensing, collaboration and other agreements with third parties may subject us to a number of risks. These agreements may
not be on terms that prove favorable to us and may require us to relinquish certain rights in our drug candidates. To the extent
we agree to work exclusively with one collaborator in a given area, our opportunities to collaborate with other entities could
be curtailed. Lengthy negotiations with potential new collaborators may lead to delays in the research, development or commercialization
of drug candidates. The decision by our collaborators to pursue alternative technologies or the failure of our collaborators to
develop or commercialize successfully any drug candidate to which they have obtained rights from us could materially harm our
business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Business and Industry
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may face future business disruption
and related risks resulting from the outbreak of the novel coronavirus 2019 (COVID-19) or from another pandemic, epidemic or outbreak
of an infectious disease, any of which could have a material adverse effect on our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The development of
our drug candidates could be disrupted and materially adversely affected in the future by a pandemic, epidemic or outbreak of
an infectious disease like the outbreak of COVID-19. The spread of COVID-19 from China to other countries has resulted in the
Director General of the World Health Organization declaring the outbreak of COVID-19 as a global pandemic. In response, national,
state and local governments around the world, including in the U.S., Canada and Europe, have implemented measures to reduce the
spread of COVID-19, including international travel restrictions. Additionally, numerous national, state and local jurisdictions
have imposed, and in the future may impose, shelter-in-place orders, quarantines, shut-downs of non-essential businesses, and
similar government orders and restrictions on their residents all of varying durations to control the spread of COVID-19.&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Measures adopted to
slow the spread of COVID-19 have adversely affected workforces, customers, supply chains, consumer sentiment, economies, and financial
markets, and, along with decreased consumer spending, have led to an economic downturn across many global economies. In particular,
the measures may result in the inability of our suppliers to deliver components or raw materials on a timely basis or materially
and adversely affect our collaborators and out-license partners&rsquo; ability to perform and advance preclinical studies and
clinical trials. For example, Allarity Therapeutics has informed us that continuing enrollment for the Phase II clinical trial
for LP-100 (Irofulven) has slowed during the pandemic. The timing of non-clinical research studies for our drug candidates by
collaborators and service providers also slowed during 2020 in connection with the pandemic. In addition, hospitals may reduce
staffing and reduce or postpone certain treatments in response to the spread of an infectious disease. Such events may result
in a period of business and manufacturing disruption, and in reduced operations, any of which could materially affect our business,
financial condition and results of operations. The extent to which COVID-19 impacts our business will depend on future developments,
which are highly uncertain and cannot be predicted, including new information which may emerge concerning the severity of the
coronavirus and the actions to contain the coronavirus or treat its impact, among others. While some of the measures were allowed
to lapse in many parts of the world with the fall in cases during the summer season in the Northern Hemisphere, the return of
colder weather in the Northern Hemisphere has resulted in an increase in cases in that region, which has increased forecasts of
a &ldquo;second wave&rdquo; of infections that could result in the reimposition of many governmental measures to stem the spread
of COVID-19.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">International stock
markets continue to reflect the uncertainty associated with the slow-down in the worldwide economy and the reduced levels of international
travel which has resulted. Domestic and international stock indices initially suffered large declines in the Spring of 2020. While
stock indexes have since recovered, the return of additional waves and infections and new virus variants could result in further
disruption in domestic and international capital markets. Disruption in the capital markets could adversely impact our ability
to raise the capital we need to further our business on favorable terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are still assessing
our business plans and the impact COVID-19 may have on our ability to advance the development of our drug candidates or to raise
financing to support the development of our drug candidates, but no assurances can be given that this analysis will enable us
to avoid part or all of any impact from the spread of COVID-19 or its consequences, including downturns in business sentiment
generally or in our sector in particular.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We will need to increase the size
of our organization and the scope of our outside vendor relationships, and we may experience difficulties in managing growth.
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of
this report, we employed a total of 11 full-time and four part-time employees. Our current internal departments include research
and development, finance and administration. We intend to expand our management team to include an operation ramp up of additional
scientific development and technical staff required to achieve our business objectives. We will need to expand our managerial,
operational, technical and scientific, financial and other resources in order to manage our operations and clinical trials, establish
independent manufacturing, continue our research and development activities, and commercialize our drug candidate. Our management
and scientific personnel, systems and facilities currently in place may not be adequate to support our future growth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our need to effectively
manage our operations, growth and various projects requires that we:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">manage our clinical trials
effectively, including our planned clinical trials of LP-184 and LP-300 and our other drug candidates;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">manage our internal development
efforts effectively while carrying out our contractual obligations to licensors, contractors and other third parties;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">continue to improve our
operational, financial and management controls and reporting systems and procedures; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">attract and retain sufficient
numbers of talented employees.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may utilize the
services of vendors and research partners or collaborators to perform tasks including preclinical studies and clinical trial management,
statistics and analysis, regulatory affairs, medical advisory, market research, formulation development, chemistry, manufacturing
and control activities, other drug development functions, legal, auditing, financial advisory, and investor relations. Our growth
strategy may also entail expanding our group of contractors or consultants to implement these and other tasks going forward. Because
we rely on numerous consultants to outsource many key functions of our business, we will need to be able to effectively manage
these consultants to ensure that they successfully carry out their contractual obligations and meet expected deadlines. However,
if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants
is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory
approval for our drug candidate or otherwise advance our business. There can be no assurance that we will be able to manage our
existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.
If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and
contractors, we may be unable to successfully implement the tasks necessary to further develop and commercialize our drug candidates
and, accordingly, may not achieve our research, development and commercialization goals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We depend on our senior management
team, and the loss of one or more of our executive officers or key employees or an inability to attract and retain highly skilled
employees could adversely affect our business. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success depends
largely upon the continued services of Panna Sharma, our Chief Executive Officer, President and Director. We do not maintain &ldquo;key
person&rdquo; insurance for Mr. Sharma or any of our other key employees. We also rely on employees in the areas of research and
development, artificial intelligence and machine learning services and general and administrative functions, some of which are
in the US on H-1B work visas. From time to time, there may be changes in our executive management and employees resulting from
the hiring or departure of executives or other key employees or the expiration or termination of H-1B work visas, which could
disrupt our business. The replacement of one or more of our executive officers or other key employees would likely involve significant
time and costs and may significantly delay or prevent the achievement of our business objectives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To continue to execute
our growth strategy, we also must attract and retain highly skilled personnel. We might not be successful in maintaining our unique
culture and continuing to attract and retain qualified personnel. We have from time to time in the past experienced, and we expect
to continue to experience in the future, difficulty in hiring and retaining highly skilled personnel with appropriate qualifications.
The pool of qualified personnel with experience in artificial intelligence, machine learning, and genomics, or experience working
with the pharma market is limited overall. In addition, many of the companies with which we compete for experienced personnel
have greater resources than we have.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, in making
employment decisions, particularly in the biotechnology and pharmaceutical industries, job candidates often consider the value
of the stock options or other equity instruments they are to receive in connection with their employment. Volatility in the price
of our stock might, therefore, adversely affect our ability to attract or retain highly skilled personnel. Furthermore, the requirement
to expense stock options and other equity instruments might discourage us from granting the size or type of stock option or equity
awards that job candidates require to join our company. If we fail to attract new personnel or fail to retain and motivate our
current personnel, our business and future growth prospects could be severely harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our employees may engage in misconduct
or other improper activities, including noncompliance with regulatory standards and requirements and insider trading. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are exposed to
the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with any
regulations applicable to us, to provide accurate information to regulatory authorities, to comply with manufacturing standards
we have established, to comply with federal and state healthcare fraud and abuse laws and regulations, or to report financial
information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements
in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing
and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing
and promotion, sales commission, customer incentive programs and other business arrangements. Employee misconduct could also involve
the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious
harm to our reputation. We have adopted a Code of Business Conduct, but it is not always possible to identify and deter employee
misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged
risk. If our employees engage in any such misconduct, we could face criminal penalties, fines, revocation of regulatory approvals
and harm to our reputation, any of which could form a material adverse effect on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Business interruptions could adversely
affect future operations, revenues, and financial conditions, and may increase our costs and expenses. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operations, and
those of our directors, advisors, contractors, consultants, CROs, and collaborators, could be adversely affected by earthquakes,
floods, hurricanes, typhoons, extreme weather conditions, fires, water shortages, power failures, business systems failures, medical
epidemics and other natural and man-made disaster or business interruptions. Our phones, electronic devices and computer systems
and those of our directors, advisors, contractors, consultants, CROs, and collaborators are vulnerable to damages, theft and accidental
loss, negligence, unauthorized access, terrorism, war, electronic and telecommunications failures, and other natural and man-made
disasters. Operating as a virtual company, our employees conduct business outside of our headquarters and leased or owned facilities.
These locations may be subject to additional security and other risk factors due to the limited control of our employees. If such
an event as described above were to occur in the future, it may cause interruptions in our operations, delay research and development
programs, clinical trials, regulatory activities, manufacturing and quality assurance activities, sales and marketing activities,
hiring, training of employees and persons within associated third parties, and other business activities. For example, the loss
of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and
significantly increase our costs to recover or reproduce the data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Likewise, we will
rely on third parties to manufacture LP-100, LP-184 and LP-300 and conduct clinical trials, and similar events as those described
in the prior paragraph relating to their business systems, equipment and facilities could also have a material adverse effect
on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications,
or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and
commercialization of our drug candidates could be delayed or altogether terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Disruptions to our information technology
systems, including future cyber-attacks and security breaches, and the costs of maintaining secure and effective information technology
systems could negatively affect our business and results of operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The efficient operation
of our businesses is highly dependent on computer hardware and software systems, including our customized information technology
systems that form our RADR<SUP>&reg;</SUP> platform. Information systems are vulnerable to security breaches by computer hackers
and cyber terrorists. We rely on industry accepted security measures and technology to securely maintain confidential and proprietary
information maintained on our information systems, and continue to invest in maintaining and upgrading these systems and applications
to ensure risk is controlled. Regardless of our efforts to maintain and upgrade our cyber security systems, there can be no assurance
that we will not suffer an intrusion, that unauthorized parties will not gain access to confidential or personal information,
or that any such incident will be discovered promptly. The techniques used by criminals to obtain unauthorized access to sensitive
data change frequently and often are not recognized until launched against a target, and we may be unable to anticipate these
techniques or implement adequate preventative measures. The failure to promptly detect, determine the extent of and appropriately
respond to a significant data security breach could have a material adverse impact on our business, financial condition and results
of operations. In addition, the unavailability of the information systems or failure of these systems to perform as anticipated
for any reason, including a major disaster or business interruption resulting in an inability to access data stored in these systems
or sustain the data center systems necessary to support functions to meet our needs, and any inability to respond to, or recover
from, such an event, could disrupt our business and could result in decreased performance and increased overhead costs, causing
our business and results of operations to suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, our
operations involve the receipt and storage of sensitive data, including personal information about our employees and proprietary
business information of ours and our vendors. We may also share information with vendors that assist us in conducting our business,
as required by law, with the permission of the individual or as permitted under applicable privacy policies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Despite the utilization
of information security measures, we cannot be certain that all of our IT systems or the IT systems of our vendors are or will
be able to prevent, contain or detect any future cyber-attacks or security breaches from known malware, malware that may be developed
in the future or otherwise. Cyber-attacks are rapidly evolving and becoming increasingly sophisticated and difficult to detect,
and therefore, we may be unable to anticipate these attacks or implement adequate preventive measures. Additionally, unauthorized
parties may attempt to gain access to our or a vendor&rsquo;s systems or facilities through fraud, trickery or other forms of
deception involving our employees or vendors. To the extent that any attack or breach results in the loss, damage or misappropriation
of information, we may be adversely affected by claims from persons participating in our clinical trials, stockholders and others
and by costly inquiries or enforcement actions on the part of regulatory authorities. Our operations could also be significantly
disrupted by these claims, as well as by the need to spend significant time and expense to upgrade, fix or replace our systems.
We could also lose credibility with persons participating in our clinical trials and suffer damage to our reputation and future
sales, if any. In addition, the cost of complying with stricter privacy and information security laws and standards and developing,
maintaining and upgrading technology systems to address future advances in technology, could be significant and we could experience
problems and interruptions associated with the implementation of new or upgraded systems and technology or with maintenance or
adequate support of existing systems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our failure to successfully acquire,
develop and market additional drug candidates could impair our ability to grow. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of our growth
strategy, we may evaluate, acquire, license, develop and/or market additional drug candidates and technologies. Our internal research
capabilities are limited and we may be dependent upon pharmaceutical and biopharmaceutical companies, academic scientists and
other researchers to sell or license drug candidates or technologies to us. The success of this strategy depends partly upon our
ability to identify, select and acquire promising pharmaceutical drug candidates and technologies. The process of proposing, negotiating
and implementing a license or acquisition of a drug candidate is lengthy and complex. Other companies, including some with substantially
greater financial, marketing and sales resources, may compete with us for the license or acquisition of drug candidates and technologies.
We have limited resources to identify and execute the acquisition or in-licensing of potential drug candidates and technologies
and to integrate them into our current infrastructure. Moreover, we may devote resources to potential acquisitions or in-licensing
opportunities that are never completed, or we may fail to realize the anticipated benefits of such efforts. Furthermore, we may
not be able to acquire the rights to additional drug candidates on terms that we find acceptable, or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, future
acquisitions of intellectual property rights may entail numerous operational and financial risks, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">exposure to unknown liabilities;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">disruption of our business
and diversion of our management&rsquo;s and technical personnel&rsquo;s time and attention to develop acquired drug candidates
or technologies;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">incurrence of substantial
debt or dilutive issuances of securities to pay for acquisition costs;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">higher than expected
acquisition costs; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">increased amortization
expenses.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any drug candidate
that we acquire may require additional development efforts prior to commercial sale or out-licensing, including extensive clinical
testing and approval by the FDA and applicable foreign regulatory authorities. All drug candidates are prone to risks of failure
typical of pharmaceutical drug development, including the possibility that a drug candidate will not be shown to be sufficiently
safe and effective for approval by regulatory authorities. In addition, we cannot provide assurance that any drugs that we may
develop or approved drugs that we may acquire will be manufactured profitably or achieve market acceptance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>We have obtained statistical data,
market data and other industry data and forecasts used throughout this report from market research, publicly available information
and industry publications which we believe are reliable but have not been verified by any third party.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This report contains
estimates, projections and other information concerning our industry, our business and the markets for our drug candidates, including
data regarding the estimated size of such markets and the incidence of certain medical conditions. We obtained the industry, market
and similar data set forth in this report from our internal estimates and research and from academic and industry research, publications,
surveys and studies conducted by third parties, including governmental agencies. In some cases, we do not expressly refer to the
sources from which this data is derived. Information that is based on estimates, forecasts, projections, market research or similar
methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and
circumstances that are assumed in this information. While we believe our internal research is reliable, such research has not
been verified by any third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Our Intellectual Property
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we do not obtain patent term
extension for any drug candidates we may develop, our business may be materially harmed. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States,
depending upon the timing, duration, and specifics of any FDA marketing approval of a drug candidate, the patent term of a patent
that covers an FDA-approved drug may be eligible for limited patent term extension, which permits patent term restoration as compensation
for the patent term lost during the FDA regulatory review process. The Drug Price Competition and Patent Term Restoration Act
of 1984, also known as the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration of the
patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent term
extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of drug approval, and only one
patent applicable to an approved drug may be extended and only those claims covering the approved drug, a method for using it,
or a method for manufacturing it may be extended. Similar provisions are available in Europe and other non-United States jurisdictions
to extend the term of a patent that covers an approved drug. While, in the future, if and when our drug candidates receive FDA
approval, we expect to apply for patent term extensions on patents directed to those drug candidates, there is no guarantee that
the applicable authorities will agree with our assessment of whether such extensions should be granted, and even if granted, the
length of such extensions. We may not be granted an extension because of, for example, failing to exercise due diligence during
the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration
of the relevant patents, or otherwise failing to satisfy applicable requirements. If we are unable to obtain any patent term extension
or the term of any such extension is less than we request, our competitors may obtain approval of competing drugs following the
expiration of our patent rights, and our business, financial condition, results of operations, and prospects could be materially
harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Changes to patent laws in the United
States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our drugs.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Changes in either
the patent laws or interpretation of patent laws in the United States, including patent reform legislation such as the Leahy-Smith
America Invents Act, or the Leahy-Smith Act, could increase the uncertainties and costs surrounding the prosecution of our owned
and in-licensed patent applications and the maintenance, enforcement or defense of our owned and in-licensed issued patents. The
Leahy-Smith Act includes a number of significant changes to United States patent law. These changes include provisions that affect
the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors
to challenge the validity of patents, and enable third-party submission of prior art to the USPTO during patent prosecution and
additional procedures to attack the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review,
inter parties review, and derivation proceedings. Assuming that other requirements for patentability are met, prior to March 2013,
in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the
first to file a patent application was entitled to the patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">After March 2013,
under the Leahy-Smith Act, the United States transitioned to a first-to-file system in which, assuming that the other statutory
requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention
regardless of whether a third party was the first to invent the claimed invention. As such, the Leahy-Smith Act and its implementation
could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense
of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations,
and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the patent
positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent
U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights
of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability
of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations
governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and our ability
to protect, defend and enforce our patent rights in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We or our licensors may become involved
in lawsuits to protect or enforce our patent or other intellectual property rights, which could be expensive, time-consuming and
unsuccessful.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Competitors and other
third parties may infringe, misappropriate or otherwise violate our or our licensor&rsquo;s issued patents or other intellectual
property. As a result, we or our licensors may need to file infringement, misappropriation or other intellectual property related
claims, which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke such parties
to assert counterclaims against us alleging that we infringe, misappropriate or otherwise violate their intellectual property.
In addition, in a patent infringement proceeding, such parties could counterclaim that the patents we or our licensors have asserted
are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability
are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including
lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone
connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during
prosecution. Third parties may institute such claims before administrative bodies in the United States or abroad, even outside
the context of litigation. Such mechanisms include re-examination, post-grant review, inter parties review, interference proceedings,
derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An adverse result
in any such proceeding could put one or more of our owned or in-licensed patents at risk of being invalidated or interpreted narrowly,
and could put any of our owned or in-licensed patent applications at risk of not yielding an issued patent. A court may also refuse
to stop the third party from using the technology at issue in a proceeding on the grounds that our owned or in-licensed patents
do not cover such technology. Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation, there is a risk that some of our confidential information or trade secrets could be compromised by disclosure
during this type of litigation. Any of the foregoing could allow such third parties to develop and commercialize competing technologies
and products and have a material adverse impact on our business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Third parties may initiate legal
proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome
of which would be uncertain and could have a material adverse effect on the success of our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial success
depends upon our ability, and the ability of our collaborators, to develop, manufacture, market and sell our drug candidates and
use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and proprietary
rights of third parties. There is considerable patent and other intellectual property litigation in the pharmaceutical and biotechnology
industries. We may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property
rights with respect to our technology and drug candidates, including interference proceedings, post grant review, inter parties
review, and derivation proceedings before the USPTO and similar proceedings in foreign jurisdictions such as oppositions before
the European Patent Office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The legal threshold
for initiating litigation or contested proceedings is low, so that even lawsuits or proceedings with a low probability of success
might be initiated and require significant resources to defend. Litigation and contested proceedings can also be expensive and
time-consuming, and our adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting
these legal actions than we can. The risks of being involved in such litigation and proceedings may increase if and as our drug
candidates near commercialization and as we gain the greater visibility associated with being a public company. Third parties
may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of
merit. We may not be aware of all such intellectual property rights potentially relating to our technology and drug candidates
and their uses. Thus, we do not know with certainty that our technology and drug candidates, or our development and commercialization
thereof, do not and will not infringe, misappropriate or otherwise violate any third party&rsquo;s intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we believe
that third party intellectual property claims are without merit, there is no assurance that a court would find in our favor on
questions of misappropriation, infringement, validity, enforceability, or priority. A court of competent jurisdiction could hold
these third-party patents are valid, enforceable, and infringed, which could materially and adversely affect our ability to commercialize
any technology or drug candidate covered by the asserted third-party patents. In order to successfully challenge the validity
of any such U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring
us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court
of competent jurisdiction would invalidate the claims of any such U.S. patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are found to
infringe, misappropriate or otherwise violate a third party&rsquo;s intellectual property rights, we could be required to obtain
a license from such third party to continue developing, manufacturing and marketing our technology and drug candidates. However,
we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a
license, it could be non-exclusive; thereby giving our competitors and other third parties access to the same technologies licensed
to us and could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to
cease developing, manufacturing and commercializing the infringing technology or drug. In addition, we could be found liable for
significant monetary damages, including treble damages and attorneys&rsquo; fees, if we are found to have willfully infringed
a patent or other intellectual property right and could be forced to indemnify our collaborators or others. A finding of infringement
could prevent us from commercializing our drug candidates or force us to cease some of our business operations, which could materially
harm our business. In addition, we may be forced to redesign our drug candidates, seek new regulatory approvals and indemnify
third parties pursuant to contractual agreements. Claims that we have misappropriated the confidential information or trade secrets
of third parties could have a similar material adverse effect on our business, financial condition, results of operations, and
prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Intellectual property litigation
or other legal proceedings relating to intellectual property could cause us to spend substantial resources and distract our personnel
from their normal responsibilities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if resolved in
our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses,
and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public
announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors
perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation
or proceedings could substantially increase our operating losses and reduce the resources available for development activities
or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct
such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings
more effectively than we can because of their greater financial resources and may also have an advantage in such proceedings due
to their more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation
of intellectual property litigation or other proceedings could compromise our ability to compete in the marketplace.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Obtaining and maintaining patent
protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental
patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Periodic maintenance,
renewal and annuity fees and various other government fees on any issued patent and pending patent application must be paid to
the USPTO and foreign patent agencies in several stages or annually over the lifetime of our owned and in-licensed patents and
patent applications. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural,
documentary, fee payment and other similar provisions during the patent application process. In certain circumstances, we rely
on our licensing partners to pay these fees to, or comply with the procedural and documentary rules of, the relevant patent agency.
With respect to our patents, we rely on an annuity service to remind us of the due dates and to make payment after we instruct
them to do so. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance
with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent
application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could
result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed
time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, potential competitors
might be able to enter the market with similar or identical products or technology. If we or our licensors fail to maintain the
patents and patent applications directed to our drug candidates, it would have a material adverse effect on our business, financial
condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If we fail to comply with our obligations
in our intellectual property licenses and funding arrangements with third parties, we could lose rights that are important to
our business.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are party to license
and funding agreements that impose, and we may enter into additional licensing and funding arrangements with third parties that
may impose, diligence, development and commercialization timelines, milestone payment, royalty, insurance and other obligations
on us. Under our existing licensing and funding agreements, we are obligated to pay certain specified milestone payments and royalties
on net drug sales of drug candidates or related technologies to the extent they are covered by the agreements. If we fail to comply
with such obligations under current or future license and funding agreements, our counterparties may have the right to terminate
these agreements or require us to grant them certain rights. Such an occurrence could materially adversely affect the value of
any drug candidate being developed under any such agreement. For example, under the AF Agreement, we are required to use commercially
reasonable efforts to research, develop and commercialize LP-184. If we fail to meet the foregoing obligation, then, under certain
circumstances, AF may terminate the AF Agreement and may exercise the exclusive, sub-licensable and worldwide license we granted
AF in and to certain of our intellectual property to develop and commercialize LP-184. Termination of these agreements or reduction
or elimination of our rights under these agreements may result in our having to negotiate new or reinstated agreements with less
favorable terms, or cause us to lose our rights under these agreements, including our rights to important intellectual property
or technology, which would have a material adverse effect on our business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, these
and other license agreements may not provide exclusive rights to use the licensed intellectual property and technology in all
relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and drugs in the
future. As a result, we may not be able to prevent competitors from developing and commercializing competitive products and technology
in fields of use and territories not included in such agreements. In addition, we may not have the right to control the preparation,
filing, prosecution, maintenance, enforcement, and defense of patents and patent applications directed to the technology that
we license from third parties. Therefore, we cannot be certain that these patents and patent applications will be prepared, filed,
prosecuted, maintained, and defended in a manner consistent with the best interests of our business. If our licensors fail to
prosecute, maintain, enforce, and defend such patents, or lose rights to those patents or patent applications, the rights we have
licensed may be reduced or eliminated, and our right to develop and commercialize any of our drugs that are the subject of such
licensed rights could be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may need to obtain
additional licenses from others to advance our research or allow commercialization of our drug candidates. It is possible that
we may be unable to obtain additional licenses at a reasonable cost or on reasonable terms, if at all, or such licenses may be
non-exclusive. The licensing or acquisition of third-party intellectual property rights is a competitive area, and several more
established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider
attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources
and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor
may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property
rights on terms that would allow us to make an appropriate return on our investment or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unable to
obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have,
we may be required to expend significant time and resources to redesign our technology, drug candidates, or the methods for manufacturing
them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If
we are unable to do so, we may be unable to develop or commercialize the affected technology and drug candidates, which could
harm our business, financial condition, results of operations, and prospects significantly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Disputes may arise
regarding intellectual property subject to a licensing agreement, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the scope of rights granted
under the license agreement and other interpretation related issues;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the extent to which our
technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the sublicensing of patent
and other rights under our collaborative development relationships;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our diligence obligations
under the license agreement and what activities satisfy those diligence obligations;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the inventorship and
ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us
and our partners; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the priority of invention
of patented technology.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the agreements
under which we currently license intellectual property or technology from third parties are complex, and certain provisions in
such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that
may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase
what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse
effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property
that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable
terms, we may be unable to successfully develop and commercialize the affected technology and drug candidates, which could have
a material adverse effect on our business, financial conditions, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our licensors may have relied on
third-party consultants or collaborators or on funds from third parties such that our licensors are not the sole and exclusive
owners of the patents and patent applications we in-licensed. If other third parties have ownership rights to our in-licensed
patents, they may be able to license such patents to our competitors, and our competitors could market competing products and
technology. This could have a material adverse effect on our competitive position, business, financial conditions, results of
operations, and prospects.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In spite of our best
efforts, our licensors might conclude that we have materially breached our license agreements and might therefore terminate the
license agreements, thereby removing our ability to develop and commercialize drug candidates and technology covered by these
license agreements. If these in-licenses are terminated, or if the underlying intellectual property fails to provide the intended
exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products and technologies identical
to ours. This could have a material adverse effect on our competitive position, business, financial conditions, results of operations,
and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may not be able to protect our
intellectual property and proprietary rights throughout the world.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Filing, prosecuting,
and defending patents on drug candidates in all countries throughout the world would be prohibitively expensive, and the laws
of foreign countries may not protect our rights to the same extent as the laws of the United States. Consequently, we may not
be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or
importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies
in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise
infringing products to territories where we have patent protection or licenses but enforcement is not as strong as that in the
United States. These products may compete with our products, and our patents or other intellectual property rights may not be
effective or sufficient to prevent them from competing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many companies have
encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal
systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets,
and other intellectual property protection, particularly those relating to pharmaceutical products, which could make it difficult
for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and
proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions
could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents
at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke
third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies
awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary
rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we
develop or license.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many countries have
compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries
limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner
may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced
to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired,
and our business, financial condition, results of operations, and prospects may be adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be subject to claims by third
parties asserting that our employees, consultants, contractors or advisors have wrongfully used or disclosed alleged trade secrets
of their current or former employers or claims asserting we have misappropriated their intellectual property, or claiming ownership
of what we regard as our own intellectual property.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many of our employees,
consultants, contractors and advisors were previously employed, or may currently be employed, at universities or other pharmaceutical
or biotechnology companies, including our competitors or potential competitors. Although we try to ensure that our employees,
contractors and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject
to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary
information, of any such individual&rsquo;s current or former employer. Litigation may be necessary to defend against these claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, while
it is our policy to require our employees, consultants, contractors and advisors who may be involved in the development of intellectual
property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement
with each party who in fact develops intellectual property that we regard as our own. Our intellectual property assignment agreements
with them may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend
claims they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could
have a material adverse effect on our business, financial conditions, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we fail in prosecuting
or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel,
which could have a material adverse effect on our competitive business position and prospects. Such intellectual property rights
could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology
or products, which license may not be available on commercially reasonable terms, or at all, or such license may be non-exclusive.
Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be
a distraction to our management and employees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to seeking
patents for some of our technology and drug candidates, we also rely on trade secrets and confidentiality agreements relating
to the development of our RADR<SUP>&reg;</SUP> platform to protect our unpatented know-how, technology and other proprietary information,
in order to maintain our competitive position. We seek to protect our trade secrets and other proprietary technology, in part,
by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate
collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors
and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and
consultants. We cannot guarantee that we have entered into such agreements with each party that may have or has had access to
our trade secrets or proprietary technology. Despite these efforts, any of these parties may breach the agreements and disclose
our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches.
Detecting the disclosure or misappropriation of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated
a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and
outside of the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully
obtained or independently developed by a competitor or other third party, we would have no right to prevent them, or those to
whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be
disclosed to or independently developed by a competitor or other third party, our competitive position would be materially and
adversely harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Intellectual property rights do
not necessarily address all potential threats.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The degree of future
protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and
may not adequately protect our business or permit us to maintain our competitive advantage. For example:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our RADR<SUP>&reg; </SUP>platform
is not protected by any issued patents, and we may not be able to obtain, develop, acquire or in-license any patentable technologies
or other intellectual property related to such platform;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">we, or our license partners
or current or future collaborators, might not have been the first to make the inventions covered by the issued patent or pending
patent applications that we license or may own in the future;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">we, or our license partners
or current or future collaborators, might not have been the first to file patent applications covering certain of our or their
inventions;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">others may independently
    develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or in-licensed
    intellectual property rights;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">it is possible that our
owned and in-licensed pending patent applications or those we may own or in-license in the future will not lead to issued patents;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">issued patents that we
hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our competitors might
conduct research and development activities in countries where we do not have patent rights and then use the information learned
from such activities to develop competitive products for sale in our major commercial markets;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">we may not develop additional
proprietary technologies that are patentable;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the patents of others
may harm our business; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">we may choose not to
file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering
such intellectual property.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Should any of these
events occur, they could have a material adverse effect on our business, financial condition, results of operations, and prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to Owning our Common
Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our stock price has been volatile
and thinly traded which may impair your ability to sell your shares. </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock
has traded on the Nasdaq Capital Market since June 11, 2020. Since then, our common stock has been relatively thinly traded,
with an average daily trading volume of approximately 96,000 shares and prices ranging from a low of $10.40 to a high of
$24.84 per share. There can be no assurance that the market for our common shares will become more liquid. The stock market
in general, and early stage public companies in particular, has experienced extreme price and volume fluctuations that have
often been unrelated or disproportionate to the operating performance of such companies. If we are unable to increase the
trading volume for our common shares, you may not be able to sell your common shares at prices you consider to be fair or at
times that are convenient for you, or at all.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Shares eligible for future sale
may adversely affect the market for our common stock</I></B><I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Of the 11,169,665 shares
of our common stock outstanding as of the date of this report, approximately 7,750,558 shares are held by &ldquo;non-affiliates&rdquo;
and are freely tradable without restriction pursuant to Rule 144 under the Securities Act. The market price of our common stock
could decline as a result of sales of a large number of shares of our common stock in the market or the perception that these sales
could occur. Such sales or offerings could lower the market price for our common stock and may make it more difficult for us to
sell equity securities in the future at a time and at a price that we deem appropriate. We may in the future sell additional shares
of our common stock or equity-linked securities to raise capital. A substantial number of shares of our common stock could be registered
and issued. Furthermore, there are substantial amounts of vested stock options which are &ldquo;in the money&rdquo; which could
be exercised and sold in public markets. We continue to expect to issue stock options as part of compensation. There may be further
effect on our stock price upon the vesting and settlement of restricted stock units and performance units. We cannot predict the
size of future issuances or the effect, if any, that they may have on the market price for our common stock. The issuance and sale
of substantial amounts of common stock or equity-linked securities, or the perception that such issuances and sales may occur,
could adversely affect the trading price of our common stock and impair our ability to raise capital through the sale of additional
equity or equity-linked securities. Additional dilution may also result as a consequence of shares of common stock sold pursuant
to potential future offerings as well as if outstanding options to acquire shares of our common stock are exercised.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, holders
of up to approximately 3,192,345 shares of our common stock, including shares of common stock issuable under outstanding options
and warrants, have the right to require us to register these shares under the Securities Act pursuant to an Amended and Restated
Investors&rsquo; Rights Agreement and the terms of warrants issued to the underwriters in connection with our IPO. If our existing
stockholders sell substantial amounts of our common stock in the public market, or if the public perceives that such sales could
occur, this could have an adverse impact on the market price of our common stock, even if there is no relationship between such
sales and the performance of our business.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The price of our common stock may
fluctuate substantially.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should consider
an investment in our common stock to be risky, and you should invest in our common stock only if you can withstand a significant
loss and wide fluctuations in the market value of your investment. Some factors that may cause the market price of our common
stock to fluctuate, in addition to the other risks mentioned in this &ldquo;Risk Factors&rdquo; section and elsewhere in this
report, are:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">sale of our common stock
by our stockholders, executives, and directors;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">volatility and limitations
in trading volumes of our shares of common stock;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to obtain
financings to conduct and complete research and development activities including, but not limited to, our proposed clinical trials,
and other business activities;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">possible delays in the
expected recognition of revenue due to lengthy and sometimes unpredictable product development and sales timelines;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the timing and success
of introductions of new technologies, therapeutic approaches, product candidates and product marketing applications by us or our
competitors or any other change in the competitive dynamics of our industry, including consolidation among competitors, customers
or strategic partners;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">network outages or security
breaches;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the lack of market acceptance
and sales growth for our drug candidates, if any, that receive marketing approval;</FONT></TD>
</TR></TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to secure
resources and the necessary personnel to conduct clinical trials on our desired schedule;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">commencement, enrollment
or results of our clinical trials for our drug candidates or any future clinical trials we may conduct;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">changes in the development
status of our drug candidates;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></P>

<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any delays or adverse
developments or perceived adverse developments with respect to the FDA&rsquo;s review of our planned preclinical studies and clinical
trials;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any delay in our submission
for studies or drug approvals or adverse regulatory decisions, including failure to receive regulatory approval for our drug candidates;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">unanticipated safety
concerns related to the use of our drug candidates;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">failures to meet external
expectations or management guidance;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">changes in our capital
structure or dividend policy, future issuances of securities, sales of large blocks of common stock by our stockholders;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our cash position;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">announcements and events
surrounding financing efforts, including debt and equity securities;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our inability to enter
into new markets or develop new drugs;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">reputational issues;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">competition from existing
technologies and drugs or new technologies and drugs that may emerge;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font: 12pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">announcements of acquisitions,
    partnerships, collaborations, joint ventures, new drugs, capital commitments, or other events by us or our competitors;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">changes in general economic,
political and market conditions in or any of the regions in which we conduct our business;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">changes in industry conditions
or perceptions;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">changes in valuations
of similar companies or groups of companies;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">analyst research reports,
recommendations and changes in recommendations, price targets, and withdrawals of coverage;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">departures and additions
of key personnel;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">disputes and litigations
related to intellectual properties, proprietary rights, and contractual obligations;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">changes in applicable
laws, rules, regulations, or accounting practices and other dynamics; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">other events or factors,
many of which may be out of our control.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, if the
market for stocks in our industry or industries related to our industry, or the stock market in general, experiences a loss of
investor confidence, the trading price of our common stock could decline for reasons unrelated to our business, financial condition
and results of operations. If any of the foregoing occurs, it could cause our stock price to fall and may expose us to lawsuits
that, even if unsuccessful, could be costly to defend and a distraction to management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have broad discretion in the
use of our financial resources and may not use them effectively.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management will
have broad discretion in the application of our financial resources. Because of the number and variability of factors that will
determine our use of our financial resources, their ultimate use may vary substantially from their currently intended use. Our
management may not apply our financial resources in ways that ultimately increase the value of any investment in our securities
or enhance stockholder value. The failure by our management to apply these funds effectively could harm our business. We have
invested and may in the future invest our cash in short-term, interest-bearing securities. These investments may not yield a favorable
return to our stockholders. If we do not invest or apply our cash in ways that enhance stockholder value, we may fail to achieve
expected financial results, which may result in a decline in the price of our shares of common stock, and, therefore, may negatively
impact our ability to raise capital, invest in or expand our business, acquire additional drugs or licenses, commercialize our
drugs, or continue our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may acquire other companies or
technologies, which could divert our management&rsquo;s attention, result in dilution to our stockholders and otherwise disrupt
our operations and adversely affect our operating results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may in the future
seek to acquire or invest in businesses, product applications and services or technologies that we believe could complement or
expand our existing product candidates and business, enhance our technical capabilities or otherwise offer growth opportunities.
The pursuit of potential acquisitions may divert the attention of management and cause us to incur various expenses in identifying,
investigating and pursuing suitable acquisitions, whether or not they are consummated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we do
not have any experience in acquiring other businesses. If we acquire additional businesses, we may not be able to integrate the
acquired personnel, operations and technologies successfully or effectively manage the combined business following the acquisition.
We also may not achieve the anticipated benefits from the acquired business due to a number of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">inability to integrate
or benefit from acquired businesses, products, technologies or services in a profitable manner;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">unanticipated costs or
liabilities associated with the acquisition;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">difficulty integrating
the accounting systems, operations and personnel of the acquired business;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">difficulties and additional
expenses associated with supporting legacy drugs and hosting infrastructure of the acquired business;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">difficulty maintaining
the customers, if any, of the acquired business, including disparities in the revenue, licensing, support or business model of
the acquired company;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">diversion of management&rsquo;s
attention from other business concerns;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">adverse effects to our
existing business relationships with business partners and customers, if any, as a result of the acquisition;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the potential loss of
key employees;</FONT></TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">use of resources that
are needed in other parts of our business; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">use of substantial portions
of our available cash to consummate the acquisition.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, a significant
portion of the purchase price of companies we acquire may be allocated to acquired goodwill and other intangible assets, which
must be assessed for impairment at least annually. In the future, if our acquisitions do not yield expected returns, we may be
required to take charges to our operating results based on this impairment assessment process, which could adversely affect our
results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Acquisitions could
also result in dilutive issuances of equity securities or the incurrence of debt, which could adversely affect our operating results.
In addition, if an acquired business fails to meet our expectations, our operating results, business and financial position may
suffer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Market and economic conditions may
negatively impact our business, financial condition and share price.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Concerns over inflation,
energy costs, geopolitical issues, the U.S. mortgage market and a declining real estate market, unstable global credit markets
and financial conditions, and volatile oil prices have led to periods of significant economic instability, diminished liquidity
and credit availability, declines in consumer confidence and discretionary spending, diminished expectations for the global economy
and expectations of slower global economic growth going forward, increased unemployment rates, and increased credit defaults in
recent years. Our general business strategy may be adversely affected by any such economic downturns, volatile business environments
and continued unstable or unpredictable economic and market conditions. If these conditions continue to deteriorate or do not
improve, it may make any necessary debt or equity financing more difficult to complete, more costly, and more dilutive. Failure
to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth
strategy, financial performance, and share price and could require us to delay or abandon development or commercialization plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If securities or industry analysts
do not publish research or reports, or publish unfavorable research or reports about our business, our stock price and trading
volume may decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The trading market
for our common stock will rely in part on the research and reports that industry or financial analysts publish about us, our business,
our markets and our competitors. We do not control these analysts. If securities analysts do not cover our common stock, the lack
of research coverage may adversely affect the market price of our common stock. Furthermore, if one or more of the analysts who
do cover us downgrade our stock or if those analysts issue other unfavorable commentary about us or our business, our stock price
would likely decline. If one or more of these analysts cease coverage of us or fails to regularly publish reports on us, we could
lose visibility in the market and interest in our stock could decrease, which in turn could cause our stock price or trading volume
to decline and may also impair our ability to expand our business with existing customers and attract new customers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Because certain of our stockholders
control a significant number of shares of our common stock, they may have effective control over actions requiring stockholder
approval.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our directors, executive
officers, and their respective affiliates, beneficially own approximately 30.3% of our outstanding shares of common stock. As a
result, these stockholders, acting together, would have the ability to control the outcome of matters submitted to our stockholders
for approval, including the election of directors and any merger, consolidation or sale of all or substantially all of our assets.
In addition, these stockholders, acting together, would have the ability to control the management and affairs of our company.
Accordingly, this concentration of ownership might harm the market price of our common stock by:</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">delaying, deferring or
preventing a change in corporate control;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">impeding a merger, consolidation,
takeover or other business combination involving us; or</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">discouraging a potential
acquirer from making a tender offer or otherwise attempting to obtain control of us.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Future sales and issuances of our
common stock could result in additional dilution of the percentage ownership of our stockholders and could cause our share price
to fall.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect that significant
additional capital will be needed in the future to continue our planned operations, including increased marketing, hiring new
personnel, commercializing our drugs, and continuing activities as an operating public company. To the extent we raise additional
capital by issuing equity securities; our stockholders may experience substantial dilution. We may sell common stock, convertible
securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If
we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially
diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could
gain rights superior to our existing stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We do not intend to pay cash dividends
on our shares of common stock so any returns will be limited to the value of our shares.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently anticipate
that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring
or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the increase,
if any, of our share price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are an &ldquo;emerging growth
company&rdquo; and will be able to avail ourselves of reduced disclosure requirements applicable to emerging growth companies,
which could make our common stock less attractive to investors.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are an &ldquo;emerging
growth company,&rdquo; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and we intend to take advantage
of certain exemptions from various reporting requirements that are applicable to other public companies that are not &ldquo;emerging
growth companies&rdquo; including not being required to comply with the auditor attestation requirements of Section 404(b) of
the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements,
and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval
of any golden parachute payments not previously approved. In addition, Section 107 of the JOBS Act also provides that an &ldquo;emerging
growth company&rdquo; can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act,
for complying with new or revised accounting standards. In other words, an &ldquo;emerging growth company&rdquo; can delay the
adoption of certain accounting standards until those standards would otherwise apply to private companies. We are not electing
to delay such adoption of new or revised accounting standards, and as a result, we will comply with new or revised accounting
standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies. We cannot predict
if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common
stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more
volatile. We may take advantage of these reporting exemptions until we are no longer an &ldquo;emerging growth company.&rdquo;
We will remain an &ldquo;emerging growth company&rdquo; until the earliest of (i) the last day of the fiscal year in which we
have total annual gross revenues of $1.07 billion or more; (ii) the last day of our fiscal year following the fifth anniversary
of the date of the completion of our initial public offering, or December 31, 2025; (iii) the date on which we have issued more
than $1 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large
accelerated filer under the rules of the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be at risk of securities
class action litigation.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be at risk
of securities class action litigation. In the past, biotechnology and pharmaceutical companies have experienced significant stock
price volatility, particularly when associated with binary events such as clinical trials and drug approvals. If we face such
litigation, it could result in substantial costs and a diversion of management&rsquo;s attention and resources, which could harm
our business and result in a decline in the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our certificate of incorporation
and our by-laws, and Delaware law may have anti-takeover effects that could discourage, delay or prevent a change in control,
which may cause our stock price to decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our certificate of
incorporation, and our by-laws, and Delaware law could make it more difficult for a third party to acquire us, even if closing
such a transaction would be beneficial to our stockholders. We are authorized to issue up to 1,000,000 shares of preferred stock.
This preferred stock may be issued in one or more series, the terms of which may be determined at the time of issuance by our
board of directors without further action by stockholders. The terms of any series of preferred stock may include voting rights
(including the right to vote as a series on particular matters), preferences as to dividend, liquidation, conversion and redemption
rights and sinking fund provisions. None of our preferred stock is currently outstanding. The issuance of any preferred stock
could materially adversely affect the rights of the holders of our common stock, and therefore, reduce the value of our common
stock. In particular, specific rights granted to future holders of preferred stock could be used to restrict our ability to merge
with, or sell our assets to, a third party and thereby preserve control by the present management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 114; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provisions of our
certificate of incorporation, by-laws and Delaware law also could have the effect of discouraging potential acquisition proposals
or making a tender offer or delaying or preventing a change in control, including changes a stockholder might consider favorable.
Such provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management. In particular,
our certificate of incorporation and by-laws and Delaware law, as applicable, among other things:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">provide the board of
directors with the ability to alter the by-laws without stockholder approval;</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">establishing advance
notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at
stockholder meetings; and</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">provide that vacancies
on the board of directors may be filled by a majority of directors in office, although less than a quorum.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our by-laws designate the Court
of Chancery of the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for
the District of Delaware) as the exclusive forum for certain types of claims, which may limit a stockholder&rsquo;s ability to
bring a claim in a judicial forum that it finds favorable.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 7.06 of our
by-laws specifies that unless we consent in writing to the selection of an alternative forum, the court of Chancery of the State
of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware)
shall, to the fullest extent permitted by law, be the sole and exclusive forum for: (a) any derivative action or proceeding brought
on our behalf; any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers or other employees
to us or to our stockholders; (b) any action asserting a claim against us arising pursuant to the Delaware General Corporation
Law (&ldquo;DGCL&rdquo;) or certificate of incorporation or our by-laws; or (c) or any action asserting a claim against us that
is governed by the internal affairs doctrine. There is uncertainty as to whether a court would enforce this provision with respect
to claims under the Securities Act and our stockholders cannot waive compliance with the federal securities laws and the rules
and regulations thereunder. The exclusive forum provision may limit a stockholder&rsquo;s ability to bring a claim in a judicial
forum that it finds favorable for disputes against us and our directors, officers and other employees, which may discourage such
lawsuits, or may require increased costs to bring a claim.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Financial reporting obligations
of being a public company in the United States require well defined disclosure and financial controls and procedures that are
expensive and time-consuming requiring our management to devote substantial time to compliance matters.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a publicly traded
company, we incur significant additional legal, accounting and other expenses that a privately held company is not required to
incur. For example, a privately held company is not required to have well defined disclosure and financial controls and procedures
or systems of internal controls over financial reporting that are generally required of publicly held companies. In connection
with our review of our previously existing internal controls as part of our preparations for becoming a publicly traded company,
we determined that our internal controls over financial reporting for prior periods were inadequate and included material weaknesses
that needed to be remedied. Although we have taken, and are continuing to take, additional steps to remedy these material weaknesses
in order to assure compliance with our future financial reporting obligations, there can be no assurance that we will be able
to do so in a timely manner or at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These reporting obligations
associated with being a public company in the United States require significant expenditures and will place significant demands
on our management and other personnel, including costs resulting from our reporting obligations under the Securities Exchange
Act of 1934, as amended, (the &ldquo;Exchange Act&rdquo;), and the rules and regulations regarding corporate governance practices,
including those under the Sarbanes-Oxley Act of 2002, as amended, (the &ldquo;Sarbanes-Oxley Act&rdquo;), the Dodd-Frank Wall
Street Reform and Consumer Protection Act, as amended, (the &ldquo;Dodd-Frank Act&rdquo;), and the listing requirements of the
stock exchange on which our securities are to be listed. These rules require the establishment and maintenance of effective disclosure
and financial controls and procedures, internal control over financial reporting and changes in corporate governance practices,
among many other complex rules that are often difficult to implement, monitor and maintain compliance with. Moreover, despite
recent reforms made possible by the JOBS Act, the reporting requirements, rules, and regulations make some activities more time-consuming
and costly, which will be particularly true after we are no longer an &ldquo;emerging growth company.&rdquo; In addition, we expect
these rules and regulations will make it more difficult and more expensive for us to obtain director and officer liability insurance.
Our management and other personnel have to devote a substantial amount of time to ensure that we comply with all of these requirements
and to keep pace with new regulations, otherwise we may fall out of compliance and risk becoming subject to litigation or being
delisted, among other potential problems.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 115; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we fail to comply
with the rules under the Sarbanes-Oxley Act related to accounting controls and procedures in the future, or, if we discover additional
material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly
and raising capital could be more difficult.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Section 404 of the
Sarbanes-Oxley Act requires annual management assessments of the effectiveness of our internal control over financial reporting
after a transition period ending with our second annual report on Form 10-K filed under Section 13(a) of the Exchange Act. If
we fail to comply with the rules under the Sarbanes-Oxley Act related to disclosure controls and procedures in the future, or,
if in the future we discover additional material weaknesses and other deficiencies in our internal control and accounting procedures,
our stock price could decline significantly and raising capital could be more difficult.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Comprehensive tax reform bills could
adversely affect our business and financial condition.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The U.S. government
recently enacted comprehensive federal income tax legislation that includes significant changes to the taxation of business entities.
These changes include, among others, a permanent reduction to the corporate income tax rate. Notwithstanding the reduction in
the corporate income tax rate, the overall impact of this tax reform is uncertain, and our business and financial condition could
be adversely affected. This report does not discuss any such tax legislation or the manner in which it might affect purchasers
of our common stock. We urge our stockholders to consult with their legal and tax advisors with respect to any such legislation
and the potential tax consequences of investing in our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #211D1E"><B><A NAME="aa_005"></A>Item 1B. Unresolved
Staff Comments.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #211D1E"><B><A NAME="aa_006"></A>Item 2. Properties</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our principal executive
office is located at 1920 McKinney Avenue, 7<SUP>th</SUP> Floor, Dallas, Texas 75201. During 2020, we leased office space and
access to meeting facilities at this location under month-to-month lease arrangements. In connection with our employees working
remotely due to COVID-19, in August 2020 we reduced our monthly lease commitment and costs to minimal levels. We are continuing
to monitor the COVID-19 conditions and intend to increase our lease of office space following an improvement in the COVID-19 situation.
We intend to add new facilities, add to existing space, or replace with larger facilities, as needed, as we add employees and
expand operations. We believe that suitable additional or substitute space will be available in the future on commercially reasonable
terms to support this expansion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #211D1E"><B><A NAME="aa_007"></A>Item 3. Legal Proceedings.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time
in the future, we may become involved in litigation or other legal proceedings that arise in the ordinary course of business.
We are not currently a party to any legal proceedings, and we are not aware of any pending or threatened litigation against us
that we believe could have a material adverse effect on our business, operating results or financial condition. In the event we
are subject to a legal proceeding, it could have a material adverse impact on us because of litigation costs and diversion of
management resources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #211D1E"><B><A NAME="aa_008"></A>Item 4. Mine Safety
Disclosures.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 116; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="aa_009"></A>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="aa_010"></A>Item 5. <FONT STYLE="color: #211D1E">Market for Registrant&rsquo;s
Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Market Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our common stock began
trading on the Nasdaq Capital Market under the symbol &ldquo;LTRN&rdquo; on June 11, 2020. Prior to that date, there was no public
trading market for our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stockholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 8, 2021,
there were 26 stockholders of record of our common stock. The actual number of holders of our common stock is greater than this
number of record holders, and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers
or held by other nominees.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Dividend Policy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never paid
or declared any cash dividends on our common stock, and we do not anticipate declaring or paying, in the foreseeable future, any
cash dividends on our capital stock. We intend to retain all available funds and future earnings, if any, to fund the development
and expansion of our business, and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination
regarding the declaration and payment of dividends, if any, will be at the discretion of our board of directors and will depend
on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements,
business prospects and other factors our board of directors may deem relevant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Unregistered Sales of Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Options</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt TimesNewRomanPSStd-Regular,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2020,
an option holder exercised options to purchase 50,460 shares of common stock in cash at an exercise price of $1.03 per share of
common stock for an aggregate purchase price of $51,910.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Exercise of Warrants</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2020, a
warrant holder acquired 3,350 shares of common stock pursuant to the cashless exercise of a warrant to purchase 4,022 shares.
In January 2021, a warrant holder acquired 800 shares of common stock pursuant to the cashless exercise of a warrant to purchase
957 shares. In January 2021, three warrant holders acquired an aggregate of 19,367 shares pursuant to the cash exercise of warrants.
All of such warrants were exercisable at an exercise price of $3.13 per share of common stock. The aggregate cash proceeds received
by the Company from the exercise of such warrants was $60,619.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of the foregoing
transactions involved any underwriters, underwriting discounts or commissions, or any public offering. We believe the offers,
sales and issuances of the above securities were exempt from registration under the Securities Act (or Regulation D promulgated
thereunder) by virtue of Section 4(a)(2) of the Securities Act because the issuance of securities to the recipients did not involve
a public offering. The recipients of the securities in each of these transactions represented their intentions to acquire the
securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate
legends were placed upon the stock certificates issued in these transactions. The sales of these securities were made without
any general solicitation or advertising.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 117; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="background-color: white"><B>Securities Authorized
for Issuance under </B></FONT><B>Equity Compensation Plans</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The table below contains information as
of December 31, 2020 regarding the Amended and Restated Lantern Pharma Inc. 2018 Equity Incentive Plan (the &ldquo;Plan&rdquo;).
Additional information regarding the Plan is contained in Note 6 to our consolidated financial statements included as part of this
report. The Company does not have any equity compensation plans that have not been approved by stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: center; width: 25%; border: Black 1pt solid; vertical-align: bottom; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Plan category</B></P></TD>
    <TD STYLE="padding: 0; text-align: center; width: 25%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Number of securities to be issued upon exercise
of outstanding options, warrants and rights</B></P></TD>
    <TD STYLE="padding: 0; text-align: center; width: 25%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; vertical-align: bottom; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Weighted-average exercise price of outstanding
options, warrants and rights</B></P></TD>
    <TD STYLE="padding: 0; text-align: center; width: 25%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt; vertical-align: bottom; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a))</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="padding: 0; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="padding: 0; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; padding: 0 0 0 10pt; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-size: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity compensation plans approved by security holders</FONT></TD>
    <TD STYLE="padding: 0; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">835,608 shares of Common
Stock</P></TD>
    <TD STYLE="padding: 0; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">$6.41 per share</P></TD>
    <TD STYLE="padding: 0; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">535,099 shares of Common Stock</P></TD></TR>
<TR STYLE="vertical-align: top; background-color: #B4C6E7">
    <TD STYLE="padding: 0; background-color: White; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; background-color: White; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; background-color: White; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; background-color: White; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 0 0 0 10pt; font-size: 10pt; text-indent: -10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity compensation plans not approved by security holders</FONT></TD>
    <TD STYLE="padding: 0; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N/A</P></TD>
    <TD STYLE="padding: 0; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N/A</P></TD>
    <TD STYLE="padding: 0; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">N/A</P></TD></TR>
<TR STYLE="vertical-align: top; background-color: #B4C6E7">
    <TD STYLE="padding: 0; background-color: White; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; background-color: White; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; background-color: White; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; background-color: White; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font-size: 10pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total:</FONT></TD>
    <TD STYLE="padding: 0; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">835,608 shares of Common Stock</FONT></TD>
    <TD STYLE="padding: 0; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center; font-size: 10pt; text-indent: 0">$6.41 per share</FONT></TD>
    <TD STYLE="padding: 0; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-indent: 0">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">535,099 shares of Common Stock</P></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Use of proceeds from our initial public offering of common
stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 10, 2020,
our registration statement on Form S-1, as amended (File No. <B>333-237714) </B>was declared effective by the SEC in connection
with our initial public offering of common stock, pursuant to which we issued and sold, on June 15, 2020, 1,750,000 shares of
common stock at a public offering price of $15.00 per share for total gross proceeds of $26,250,000. On June 15, 2020 we received
net proceeds of $23,419,721, after deducting underwriting discounts and commissions of $1,968,750 and other offering expenses
of $861,529 borne by us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As of December 31,
2020, we estimate that we have used approximately $4,569,000 of the net proceeds from our IPO for advancing and developing
our drug candidates and RADR&reg; platform, and for working capital and other general corporate purposes, including payment of
director and officer liability insurance premium amounts of approximately $1,810,000, approximately $1,009,000 of which
have been expensed through December 31, 2020 and approximately $801,000 of which are included as part of prepaid expenses
and other current assets on the Company&rsquo;s condensed consolidated balance sheet at December 31, 2020. Substantially all of
the unused net proceeds from the offering are held in interest bearing accounts. There has been no material change in our use
of the net proceeds from the IPO as described in our final prospectus filed pursuant to Rule 424(b)(4) under the Securities Act
with the SEC on June 10, 2020. Other than payments in the ordinary course of business for compensation of officers and to non-employee
directors as compensation for board or board committee service, none of the net proceeds from our IPO used by us were direct or
indirect payments to any of (i) our directors or officers or their associates, (ii) persons owning 10 percent or more of our common
stock, or (iii) our affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #211D1E"><B><A NAME="aa_011"></A>Item 6. Selected Financial
Data.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt TimesNewRomanPSMT; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a Smaller Reporting Company
we are exempt from the requirements of Item 6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 118; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #211D1E"><B><A NAME="aa_012"></A>Item 7. Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><I>You
should read the following discussion and analysis of our financial condition and plan of operations together with our financial
statements and the related notes appearing elsewhere in this Annual Report on Form 10-K. In addition to historical information,
this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual
results may differ materially from those discussed below. Factors that could cause or contribute to such differences include,
but are not limited to, those identified below, and those discussed in Item 1A titled &ldquo;Risk Factors&rdquo; included elsewhere
in this Annual Report on Form 10-K. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Overview </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
are a clinical stage biotechnology company, focused on leveraging artificial intelligence (&ldquo;A.I.&rdquo;), machine learning
and genomic data to streamline the drug development process and to identify the patients that will benefit from our targeted oncology
therapies. Our portfolio of therapies consists of small molecules that others have tried, but failed, to develop into an approved
commercialized drug, as well as new compounds that we are developing with the assistance of our proprietary A.I. platform and
our biomarker driven approach. Our A.I. platform, known as RADR<SUP>&reg; </SUP>, currently includes more than 1.2 billion data
points, and uses big data analytics (combining molecular data, drug efficacy data, data from historical studies, data from scientific
literature, phenotypic data from trials and publications, and mechanistic pathway data) and machine learning to rapidly uncover
biologically relevant genomic signatures correlated to drug response, and then identify the cancer patients that we believe may
benefit most from our compounds. This data-driven, genomically-targeted and biomarker-driven approach allows us to pursue a transformational
drug development strategy that identifies, rescues or develops, and advances potential small molecule drug candidates at what
we believe is a fraction of the time and cost associated with traditional cancer drug development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
strategy is to both develop new drug candidates using our RADR<SUP>&reg;</SUP> platform, and other machine learning driven methodologies,
and to pursue the development of drug candidates that have undergone previous clinical trial testing or that may have been halted
in development or deprioritized because of insufficient clinical trial efficacy (i.e., a meaningful treatment benefit relevant
for the disease or condition under study as measured against the comparator treatment used in the relevant clinical testing) or
for strategic reasons by the owner or development team responsible for the compound. Importantly, these historical drug candidates
appear to have been well-tolerated in many instances, and often have considerable data from previous toxicity, tolerability and
ADME (absorption, distribution, metabolism, and excretion) studies that have been completed. Additionally, these drug candidates
may also have a body of existing data supporting the potential mechanism(s) by which they achieve their intended biologic effect,
but often require more targeted trials in a stratified group of patients to demonstrate statistically meaningful results. Our
dual approach to both develop de-novo, biomarker-guided drug candidates and &ldquo;rescue&rdquo; historical drug-candidates by
leveraging A.I., recent advances in genomics, computational biology and cloud computing is emblematic of a new era in drug development
that is being driven by data-intensive approaches meant to de-risk development and accelerate the clinical trial process. In this
context, we intend to create a diverse portfolio of oncology drug candidates for further development towards regulatory and marketing
approval with the objective of establishing a leading A.I.-driven, methodology for treating the right patient with the right oncology
therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">A
key component of our strategy is to target specific cancer patient populations and treatment indications identified by leveraging
our RADR<SUP>&reg;</SUP>platform, a proprietary A.I. enabled engine created and owned by us. We believe the combination of our
therapeutic area expertise, our A.I. expertise, and our ability to identify and develop promising drug candidates through our
collaborative relationships with research institutions in selected areas of oncology gives us a significant competitive advantage.
Our RADR<SUP>&reg;</SUP> platform was developed and refined over the last four years and integrates millions of data points immediately
relevant for oncology drug development and patient response prediction using artificial intelligence and proprietary machine learning
algorithms. By identifying clinical candidates, together with relevant genomic and phenotypic data, we believe our approach will
help us design more efficient pre-clinical studies, and more targeted clinical trials, thereby accelerating our drug candidates&rsquo;
time to approval and eventually to market. Although we have not yet applied for or received regulatory or marketing approval for
any of our drug candidates, we believe our RADR<SUP>&reg;</SUP> platform has the ability to reduce the cost and time to bring
drug candidates to specifically targeted patient groups. We believe we have developed a sustainable and scalable biopharma business
model by combining a unique, oncology-focused big-data platform that leverages artificial intelligence along with active clinical
and preclinical programs that are being advanced in targeted cancer therapeutic areas to address today&rsquo;s treatment needs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 119; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
current portfolio consists of four compounds in active development: two drug candidates in clinical phases, one in preclinical
studies and one in research optimization. All of these drug candidates are leveraging precision oncology, A.I. and genomic driven
approaches to accelerate and direct development efforts. We currently have two drug candidates in clinical development, LP-100
and LP-300, where we are leveraging data from prior preclinical studies and clinical trials, along with insights generated from
our A.I. platform, to target the types of tumors and patient groups that would be most responsive to the drug. Both LP-100 and
LP-300 showed promise in important patient subgroups, but failed pivotal Phase III trials when the overall results did not meet
the predefined clinical endpoints. We believe that this was due to a lack of biomarker-driven patient stratification. Additionally,
we have one new drug candidate, LP-184, in preclinical development for two potentially distinct indications where we are leveraging
machine learning and genomic data to streamline the drug development process and to identify the patients and cancer subtypes that
will best benefit from the drug, if approved. As part of our antibody drug conjugate (ADC) program commenced in early 2021, we
have initiated the optimization and evaluation of an antibody drug conjugate aimed at leveraging our LP-184 molecule in combination
with an antibody for select solid tumors.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
development strategy is to pursue an increasing number of oncology focused, molecularly targeted therapies where artificial intelligence
and genomic data can help us provide biological insights, reduce the risk associated with development efforts and help clarify
potential patient response. We plan on strategically evaluating these on a program-by-program basis as they advance into clinical
development, either to be done entirely by us or with our licensing partners to maximize the commercial opportunity and reduce
the time it takes to bring the right drug to the right patient</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">To
date, except for a research grant in 2017, we have not generated any revenue, we have incurred net losses and our operations have
been financed primarily by sales of our equity securities. Our net losses were approximately $5,908,000 and $2,428,000 for the
years ended December 31, 2020 and 2019, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
net losses have primarily resulted from costs incurred in licensing and developing the drug candidates in our pipeline, planning,
preparing and conducting preclinical studies, early stage clinical testing and general and administrative activities associated
with our operations. We expect to continue to incur significant expenses and corresponding increased operating losses for the
foreseeable future as we continue to develop our pipeline. Our costs may further increase as we conduct preclinical studies and
clinical trials and potentially seek regulatory clearance for and prepare to commercialize our drug candidates. We expect to incur
significant expenses to continue to build the infrastructure necessary to support our expanded operations, preclinical studies,
clinical trials, commercialization, including manufacturing, marketing, sales and distribution functions. We have experienced
and will continue to experience increased costs associated with operating as a public company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
operations, including the development of our drug candidates, could be disrupted and materially adversely affected in the future
by a pandemic, epidemic or outbreak of an infectious disease like the outbreak of COVID-19. For example, as a result of measures
imposed by the governments in regions affected by COVID-19, businesses and schools have been suspended due to quarantines or &ldquo;stay
at home&rdquo; orders intended to contain this outbreak. The spread of COVID-19 from China to other countries has resulted in the
Director General of the World Health Organization declaring the outbreak of COVID-19 as a Public Health Emergency of International
Concern (PHEIC), based on the advice of the Emergency Committee under the International Health Regulations (2005). On March 12,
2020, the President of the United States imposed international travel restrictions between the U.S. and Europe to supplement the
existing international travel restrictions between the US and certain Asian countries and, on March 13, 2020, declared a national
emergency in response to the likely spread of COVID-19. COVID-19 continues to spread globally and, as of December 31, 2020, has
spread to over 150 countries, including the United States. U.S. and international stock markets continue to experience fluctuations
and to be impacted from time to time by uncertainty associated with the impact of COVID-19 on the U.S., Chinese, European and other
economies and the reduced levels of international travel experienced since early 2020. The Dow Industrial Average and other domestic
and international stock indices experienced substantial fluctuations during 2020 largely attributed to assessments and expectations
regarding the adverse effects of the pandemic on the world&rsquo;s economies. We are continuing to assess our business plans and
the impact COVID-19 may have on our operations and plans, including the ability to advance the development of our drug candidates,
but no assurances can be given that this analysis will enable us to avoid part or all of any impact from the spread of COVID-19
or its consequences, including downturns in business sentiment generally or in our sector in particular. The extent to which COVID-19
impacts our operations and plans will depend on future developments, which are highly uncertain and cannot be predicted with confidence,
including the duration of the outbreak, new information which may emerge concerning the severity and treatment of COVID-19, and
preventative or protective actions that governments, businesses, and organizations performing research and clinical trials may
take in respect of COVID-19, among others. The existence and spread of an infectious disease, including COVID-19, may also result
in the inability of our suppliers to deliver components or raw materials on a timely basis or materially and adversely affect our
collaborators and out-license partner&rsquo;s ability to perform and advance preclinical and nonclinical studies and clinical trials.
For example, Allarity Therapeutics (formerly known as Oncology Venture) has informed us that continuing enrollment in the Phase
II clinical trial for LP-100 (Irofulven) has slowed during the pandemic. The timing of non-clinical research studies for our drug
candidates by collaborators and service providers also slowed during the second and third quarters of 2020 in connection with the
pandemic.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 120; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Components of Our Results of Operations
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Revenues </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
did not recognize revenues for the years ended December 31, 2020 and 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>General and Administrative </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">General
and administrative expenses consist of our operating expenses that are not included in the direct costs of production or cost
of goods sold which include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">corporate office overhead expenses such as salaries
of administrative staff and corporate officers;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">legal expenses;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">accounting
                                         expenses; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">rent, utilities
                                         and supplies.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Research and Development </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Research
and development expenses consist primarily of costs incurred for the research and development of our preclinical and clinical
candidates, which include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">expenses
                                         incurred towards consultants, laboratories and investigators that conduct our preclinical
                                         or clinical research activities; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the cost
                                         of acquiring and developing preclinical study materials and lab supplies. We expense
                                         research and development costs to operations as incurred.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">For
the years ended December 31, 2020 and 2019, we incurred an aggregate of approximately $2,243,000 and $953,000, respectively, in
research and development expenses related to the development of LP-100, LP- 184, LP 300 and our RADR<SUP>&reg;</SUP>platform.
We expect that our research and development expenses will increase as we plan for and commence our clinical trials of LP-184 and
LP-300.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white"></P>

<!-- Field: Page; Sequence: 121; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our research and development costs
by project category for the year ended December 31, 2020 are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <BR> December&nbsp;31, <BR> 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 88%">LP-300</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">455,914</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>LP-184</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">939,093</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD>RADR<SUP>&reg;</SUP>platform</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">443,152</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Other</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">267,962</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Unallocated*</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">137,104</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Total Research &amp; Development Expenses</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,243,225</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in; background-color: white">*As
a private company, we did not track our research and development costs by project category primarily because research and development
salary expenses were not further allocated to each project. As a result, our tracking of research and development costs by project
category commenced during the three months ended June 30, 2020 in connection with the Company&rsquo;s IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We expect that
our research and development expenses will increase as we plan for and commence our clinical trials of LP-184 and LP-300.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Because
of the numerous risks and uncertainties associated with product development, we cannot determine with certainty the duration and
completion costs of these or other current or future clinical trials of LP-184 and LP-300 or our other therapeutic candidates.
We may never succeed in achieving regulatory approval for LP-184 and LP-300 or any of our other drug candidates. The duration,
costs and timing of clinical trials and development of our therapeutic candidates will depend on a variety of factors, including
the uncertainties of future clinical and preclinical studies, uncertainties in clinical trial enrollment rate and significant
and changing government regulation. In addition, the probability of success for each drug candidate will depend on numerous factors,
including competition, manufacturing capability and commercial viability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>General and Administrative </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">General
and administrative expenses consist primarily of salaries and related costs for employees in executive, finance and administration,
corporate development and administrative support functions, including stock-based compensation expenses and benefits. Other significant
general and administrative expenses include accounting and legal services, the cost of various consultants, occupancy costs and
information systems costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
expect that our general and administrative expenses will increase as we continue to operate as a public company. We expect increased
administrative costs resulting from our anticipated clinical trials and the potential commercialization of our drug candidates.
We believe that these increases will likely include increased costs for director and officer liability insurance, hiring additional
personnel to support future market research and future product commercialization efforts and increased fees for outside consultants,
attorneys and accountants. We also expect to continue to incur increased costs to comply with corporate governance, internal controls,
investor relations and disclosures and similar requirements applicable to a public company.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 122; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white"><B>Financial
Operations Overview and Analysis for the Years Ended December 31, 2020 and 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center">Year Ended</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">December
    31,</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Revenue</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Expenses</TD><TD STYLE="font: 12pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 12pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 12pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">General and administrative</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">3,664,965</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">1,475,000</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Research and development</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,243,225</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">953,185</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><P STYLE="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">Total operating expenses</P></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">5,908,190</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,428,185</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">Net loss</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,908,190</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,428,185</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
</TABLE>

<P STYLE="font: 9pt Sans-Serif; margin: 0pt 0; background-color: white; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Revenues</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">To date, except
for a research grant in 2017, we have not generated any revenue since our inception.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>General and Administrative Expenses
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">General
and administrative expenses increased $2,189,965 or 149%, from $1,475,000 for the year ended December 31, 2019 to $3,664,965 for
the year ended December 31, 2020. The increase was primarily attributable to an increase in corporate insurance expense of approximately
$1,077,000, an increase in general and administrative related stock option compensation expense of approximately $604,000, an
increase in general and administrative labor expense of $512,000, an increase in business development expense of $128,000, increases
in NASDAQ and othering filing fees of $73,000, and an increase in other professional services of $70,000. These increases were
partially offset by a decrease in travel and relocation expense of approximately $147,000 and a decrease in legal and patent fees
of approximately $146,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Research and Development Expenses
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Research
and development expenses increased $1,290,040, or 135%, from $953,185 for the year ended December 31, 2019 to $2,243,225 for the
year ended December 31, 2020. The increase was primarily attributable to an increase in research and development labor expense
of approximately $489,000, an increase in research and development related stock option compensation expense of approximately
$470,000, an increase in research study expenses of approximately $194,000, an increase in product candidate manufacturing expense
of approximately $70,000, and an increase in non-manufacturing consulting expense of approximately $43,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
September 3, 2018, Lantern Pharma Limited, our wholly owned subsidiary, was awarded a grant by the UK government in the form of
state aid under the Commission Regulations (EU) No. 651/2014 of 17 June 2014 (the &ldquo;General Block Exemption&rdquo;), Article
25 Aid for research and development projects, state aid notification no. SA.40154. The grant was awarded to conduct research and
development activities for the prostate cancer biomarker analysis of our LP-184 drug candidate. Following our research and development
activities in Northern Ireland, the grant will reimburse 50% of our research and development expenses not exceeding GBP 24,215
of vouched and approved expenditures within specific categories and will remain in force for a period of five years. No revenue
has been recognized from this grant through December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 123; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Liquidity and Capital Resources
</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Since
our inception, our operations have been financed primarily through the sale of equity securities, and, to a lesser extent, a grant
received by us from Massachusetts Life Sciences Center in 2017. We have not yet generated any revenues from operations, other than
revenues from a research grant in 2017, and we have not yet achieved profitability. We expect that general and administrative expenses
and our research and development expenses will continue to increase and, as a result, we will need to generate significant product
revenues to achieve profitability.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
incurred net losses of $5,908,190 and $2,428,185 for the years ended December 31, 2020 and 2019, respectively. As of December 31,
2020 and 2019, we had working capital of approximately $19,685,000 and $744,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
May 1, 2020 (the &ldquo;Origination Date&rdquo;), we received $108,500 in aggregate loan proceeds (the &ldquo;PPP Loan&rdquo;)
from JPMorgan Chase Bank (the &ldquo;Lender&rdquo;) pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief,
and Economic Security (CARES) Act. As of December 31, 2020, we expect to meet the requirements of loan forgiveness under the stipulations
of the program. We plan to file for forgiveness under this loan within the first half of 2021. In the event we do not meet the
requirements of loan forgiveness, the PPP Loan bears interest at a fixed rate of 1.0% per annum. Payments of principal and interest
were deferred for the first six months following the Origination Date, with the PPP Loan to mature two years after the Origination
Date. The guidance under the Paycheck Protection Program was later updated so that deferral of payments of principal and interest
were extended to ten months after completion of the covered period of 24 weeks and maturity was extended past two years. We continue
to monitor further development and guidance related to the Paycheck Protection Program terms.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
June 15, 2020, we completed an initial public offering of 1,750,000 shares of our common stock at $15.00 per share, for gross proceeds
of $26,250,000, before deducting underwriting discounts, commissions and offering expenses, which substantially contributed to
our liquidity.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
of the years ended December 31, 2020 and 2019, we had cash and cash equivalents of approximately $19,229,000 and $1,232,000, respectively.
In January of 2021, we completed an additional offering with gross proceeds of approximately $69,000,000. We believe that proceeds
from this offering, based on the sale of 4,928,571 shares of common stock at the public offering price of $14.00 per share, together
with our existing cash and cash equivalents as of December 31, 2020, and our anticipated expenditures and capital commitments
for the calendar year 2021 and the first half of 2022, will enable us to fund our operating expenses and capital expenditure requirements
for at least 12 months from the date of this report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 124; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Cash Flows </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">The following
table summarizes our cash flow for the periods indicated:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">Year
    Ended <BR>
    December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left">Net cash flows used in operating activities</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,651,621</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,127,923</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net cash flows (used in) provided by investing activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(16,137</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(5,717</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">Net cash flows provided by financing activities</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">23,664,960</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,920,507</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Net increase in cash and cash equivalents</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">17,997,202</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">786,867</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Operating Activities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">For
the year ended December 31, 2020, net cash used in operating activities was $5,651,621 compared to $2,127,923 for the year ended
December 31, 2019. The increase in net cash used in operating activities was primarily the result of the increase in the net loss
together with increases in prepaid expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Investing Activities </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">For
the year ended December 31, 2020, net cash used in investing activities was $16,137, compared to $5,717 used in investing activities
during the year ended December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Financing Activities </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Net
cash provided by financing activities was $23,664,960 during the year ended December 31, 2020, attributable primarily to net proceeds
from our initial public offering. Net cash provided by financing activities during the year ended December 31, 2019 was $2,920,507,
attributable to the sale of 658,571 shares of Series A preferred stock and warrants to purchase Series A preferred stock for proceeds
of approximately $3,455,000, of which approximately $2,920,000 consisted of cash and $535,000 consisted of the conversion of Simple
Agreement for Future Equity (&ldquo;SAFE&rdquo;) agreements to Series A Preferred Stock.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Operating Capital and Capital Expenditure
Requirements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
expect to continue to incur significant and increasing operating losses at least for the next several years as we commence our
clinical trials of LP-184 and LP-300, pursue development of our other drug candidates, and seek potential future marketing approval
for our drug candidates which could be several years in the future, if at all. We do not expect to generate revenue, other than
possible license revenue, unless and until we successfully complete development and obtain regulatory approval for our therapeutic
candidates. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our
planned clinical trials and our expenditures on other research and development activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all
of our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research,
development and commercialization of pharmaceutical products, we are unable to estimate the exact amount of our operating capital
requirements. We anticipate that our expenses will increase substantially as we:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">continue
                                         the development of our drug candidates;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">initiate
                                         preclinical studies and clinical trials for any additional indications for our current
                                         drug candidates and any future drug candidates that we may pursue;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 125; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">continue
                                         to build our portfolio of drug candidates through the acquisition or in-license of additional
                                         drug candidates or technologies;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">continue
                                         to develop, maintain, expand and protect our intellectual property portfolio;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">pursue regulatory
                                         approvals for those of our current and future drug candidates that successfully complete
                                         clinical trials;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">ultimately
                                         establish a sales, marketing, distribution and other commercial infrastructure to commercialize
                                         any drug candidate for which we may obtain marketing approval;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">hire additional clinical, regulatory, scientific and accounting personnel;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">incur additional legal, accounting and other expenses in operating as a public company; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
    to develop, maintain, and expand our RADR<SUP>&reg;</SUP> platform.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
expect that we will need to obtain substantial additional funding in order to complete our clinical trials. To the extent that
we raise additional capital through the sale of common stock, convertible securities or other equity securities, the ownership
interests of our existing stockholders may be materially diluted and the terms of these securities could include liquidation or
other preferences that could adversely affect the rights of our existing stockholders. In addition, debt financing, if available,
would result in increased fixed payment obligations and may involve agreements that include restrictive covenants that limit our
ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends, that
could adversely impact our ability to conduct our business. If we are unable to raise capital when needed or on attractive terms,
we could be forced to significantly delay, scale back or discontinue the development or commercialization of LP-184 and LP-300
and/or other drug candidates, seek collaborators at an earlier stage than otherwise would be desirable or on terms that are less
favorable than might otherwise be available, and relinquish or license, potentially on unfavorable terms, our rights to LP-184
and LP-300 or other drug candidates that we otherwise would seek to develop or commercialize ourselves.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Off-Balance Sheet Arrangements
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">We did not have
during the periods presented, and we do not currently have, any off-balance sheet arrangements as defined under SEC rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Critical Accounting Policies </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
prepare our consolidated financial statements in accordance with generally accepted accounting standards in the United States of
America. Our significant accounting policies are described in Note 3 to our consolidated financial statements included as part
of this report. We believe the following critical accounting policies involve the most significant judgments and estimates used
in the preparation of the consolidated financial statements.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Use of Estimates </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
preparation of financial statements in conformity with accounting principles generally accepted in the United States of America
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures
of contingent liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the
reporting periods. Significant areas of estimation include determining the deferred tax asset valuation allowance and the inputs
in determining the fair value of equity-based awards and warrants issued. Actual results could differ from these estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 126; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Research and Development </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Research
and development expenses are expensed as incurred. Costs to acquire technologies, including licenses, that are utilized in research
and development and that have no alternative future use are expensed when incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Stock-based Compensation </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
have granted stock options to our employees under our equity incentive plan. Stock-based compensation expense from awards granted
under our plan is allocated over the required service period over which those stock option awards vest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
stock option awards are valued at fair value on the date of grant and that fair value is recognized over the requisite service
period. The estimated fair value of these stock option awards was determined using the Black Scholes option pricing model on the
date of grant. Some of these grants occurred at a time when we were not a public company. Significant judgment and estimates were
used to estimate the fair value of these awards, as they occurred when our stock was not publicly traded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
estimation of fair value of the awards considered our recent transactions, relevant industry and comparable public company data.
Since, at the time of many of the grants, we were a non-public entity, the majority of the inputs used to estimate the fair value
of the common stock option awards are considered level 3 due to their unobservable nature. Each option award is subject to specified
vesting schedules and requirements. Compensation expense is charged to us over the required service period to earn the award which
is expected to be up to four years, subject to the achievement of time and event-based vesting requirements. For the years ended
December 31, 2020 and 2019, we have incurred share-based compensation expense related to equity awards totaling approximately
$1,192,000 and $118,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Accounting Pronouncements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>New Accounting Pronouncements Not
Yet Adopted </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Current Expected Credit Loss</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2016 the FASB
issued Accounting Standard Update (ASU) 2016-13, Measurement of Credit Losses on Financial Instruments (Topic 326). This introduces
new methodology for recognition of credit losses - the current expected credit loss (&ldquo;CECL&rdquo;) method. The CECL method
requires the recognition of all losses expected over the life of a financial instrument upon origination or purchase of the instrument,
unless the company elects to recognize such instruments at fair value with changes in profit and loss. CECL is effective for the
Company on January 1, 2023. The Company does not anticipate a material impact from the adoption of this new standard on its financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>Income Taxes </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
December 2019, the FASB issued ASU 2019-12: Income Taxes (Topic 740) &ndash; Simplifying the Accounting for Income Taxes. This
ASU simplifies accounting for income taxes by removing the exception to the incremental approach for intraperiod tax allocation
when there is a loss from continuing operations and income or gain for other items, the exception to the requirement to recognize
a deferred tax liability for equity method investments when a foreign subsidiary becomes an equity method investment, exception
to the ability not to recognize a deferred tax liability for a foreign subsidiary when a foreign equity method investment becomes
a subsidiary, and the exception to the general methodology for calculating income taxes in an interim period when a year-to-date
loss exceeds the anticipated loss for the year. This ASU also includes other requirements related to franchise tax, goodwill as
part of a business combination, consolidations, changes in tax laws, and affordable housing projects. ASU 2019-12 is effective
for fiscal years beginning after December 15, 2020, including interim periods within that fiscal year. Early adoption is permitted
for periods in which financial statements have not yet been issued. We do not anticipate a material impact from the adoption of
this new standard on our financial statements.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 127; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->123<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Recently Adopted Accounting Standards
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>Leases </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
February 2016 the FASB issued ASU 2016-02: Leases. The ASU introduces a lessee model that results in most leases impacting the
balance sheet. The ASU addresses other concerns related to the current lease model. Under ASU 2016-02, lessees will be required
to recognize for all leases with terms longer than 12 months, at the commencement date of the lease, a lease liability, which
is a lessee&rsquo;s obligation to make lease payments arising from a lease measured on a discounted basis, and a right-to-use
(ROU) asset, which is an asset that represents the lessee&rsquo;s right to use or control the use of a specified asset for the
lease term. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
July 2018, the FASB issued ASU 2018-10 &ldquo;Codification Improvements to Topic 842, Leases.&rdquo; This ASU affects narrow aspects
of the guidance issued in the amendments in ASU 2016-02 including those regarding residual value guarantees, rate implicit in
the lease, lessee reassessment of lease classification, lessor reassessment of lease term and purchase option, variable lease
payments that depend on an index or a rate, investment tax credits, lease term and purchase option, transition guidance for amounts
previously recognized in business combinations, certain transition adjustments, transition guidance for leases previously classified
as capital leases under Topic 840, transition guidance for modifications to leases previously classified as direct financing or
sales-type leases under Topic 840, transition guidance for sale and leaseback transactions, impairment of net investment in the
lease, unguaranteed residual asset, effect of initial direct costs on rate implicit in the lease, and failed sale and leaseback
transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
adopted ASC 2018-10 Topic 842 effective January 1, 2019 and elected the short-term lease recognition exemption for all leases
that qualify. For those leases that qualify, the Company will not recognize ROU assets or lease liabilities, and this includes
not recognizing ROU assets or lease liabilities for existing short-term leases of those assets in transition. This practical expedient
was elected to not separate lease and non-lease components for its office space leases. The adoption of this new standard did
not have a material impact on the Company&rsquo;s financial statements as the Company did not have any leases that have terms
of longer than 12 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>Compensation &ndash; Stock Compensation
</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
June 2018, the FASB issued ASU 2018-07: Compensation &ndash; Stock Compensation (Topic 718): Improvements to Nonemployee Share-
Based Payment Accounting. This ASU expands the scope of Topic 718 to include share-based payment transactions for acquiring goods
and services from non-employees, and as a result, the accounting for share-based payments to non-employees will be substantially
aligned. ASU 2018-07 is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal
year, early adoption is permitted but no earlier than an entity&rsquo;s adoption date of Topic 606. We do not believe there has
been a material impact from the adoption of this new accounting guidance on our consolidated financial statements and related footnote
disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Quantitative and Qualitative Disclosure
About Market Risk </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Our
primary exposure to market risk is interest expense sensitivity, which is affected by changes in the general level of U.S. interest
rates. Historically, we have raised capital through the issuance of equity securities. As of December 31, 2020 and 2019, we had
no long-term debt outstanding, other than our PPP Loan Agreement entered into in May 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
do not believe that our cash has significant risk of default or illiquidity. While we believe our cash does not contain excessive
risk, we cannot provide absolute assurance that in the future our investments will not be subject to adverse changes in market
value. In addition, we maintain significant amounts of cash at one or more financial institutions that are in excess of federally
insured limits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 128; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->124<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
do not participate in any foreign currency hedging activities and we do not have any other derivative financial instruments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Inflation
generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation has had a material
effect on our results of operations during the periods presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>JOBS Act </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
April 5, 2012, the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, was enacted. Section 107 of the JOBS Act provides
that an &ldquo;emerging growth company&rdquo; can take advantage of the extended transition period provided in Section 7(a)(2)(B)
of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. In other
words, an &ldquo;emerging growth company&rdquo; can delay the adoption of certain accounting standards until those standards would
otherwise apply to private companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">We
have chosen to opt out of the extended transition periods available to emerging growth companies under the JOBS Act for complying
with new or revised accounting standards. Section 107 of the JOBS Act provides that our decision to opt out of the extended transition
periods for complying with new or revised accounting standards is irrevocable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">Subject
to certain conditions set forth in the JOBS Act, as an &ldquo;emerging growth company,&rdquo; we have elected to rely on the other
exemptions available under the JOBS Act, including without limitation, (i) providing an auditor&rsquo;s attestation report on
our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and (ii) complying
with any requirement that may be adopted by the PCAOB regarding mandatory audit firm rotation or a supplement to the auditor&rsquo;s
report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis.
We will remain an &ldquo;emerging growth company&rdquo; until the earliest of (i) the last day of the fiscal year in which we
have total annual gross revenues of $1.07 billion or more; (ii) the last day of our fiscal year following the fifth anniversary
of the date of the completion of our initial public offering, or December 31, 2025; (iii) the date on which we have issued more
than $1 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large
accelerated filer under the rules of the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #211D1E"><B><A NAME="aa_013"></A>Item 7A. Quantitative
and Qualitative Disclosures About Market Risk.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt TimesNewRomanPSMT; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a Smaller Reporting Company
we are exempt from the requirements of Item 7A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 129; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->125<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #211D1E"><B><A NAME="aa_014"></A>Item 8. Financial Statements
and Supplementary Data.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>LANTERN PHARMA
INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>INDEX TO FINANCIAL
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%"><A HREF="#fin_001">Report of Independent Registered Public Accounting Firm</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center">F-2</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#fin_002">Consolidated Balance Sheets &ndash; December 31, 2020 and 2019</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">F-3</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#fin_003">Consolidated Statements of Operations for the Years Ended December 31, 2020 and 2019</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">F-4</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#fin_004">Consolidated Statements of Stockholders&rsquo; Equity for the Years Ended December 31, 2020 and 2019</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">F-5</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#fin_005">Consolidated Statements of Cash Flow for the Years Ended December 31, 2020 and 2019</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">F-6</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#fin_006">Notes to Consolidated Financial Statements</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">F-7</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 130; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="fin_001"></A>REPORT OF INDEPENDENT
REGISTERED PUBLIC ACCOUNTING FIRM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">To the Board of Directors and Stockholders
of</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Lantern Pharma Inc. and Subsidiary</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Opinion on the Financial Statements
</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have audited the accompanying
consolidated balance sheets of Lantern Pharma Inc. and Subsidiary (the &ldquo;Company&rdquo;) as of December 31, 2020 and
2019, and the related consolidated statements of operations, stockholders&rsquo; equity, and cash flows for each of the years
then ended, and the related notes (collectively referred to as the &ldquo;financial statements&rdquo;). In our opinion, the
financial statements present fairly, in all material respects, the consolidated financial position of the Company as of
December 31, 2020 and 2019 and the consolidated results of its operations and its cash flows for each of the years then
ended, in conformity with accounting principles generally accepted in the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Basis for Opinion </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">These financial statements are the responsibility
of the Company&rsquo;s management. Our responsibility is to express an opinion on the Company&rsquo;s financial statements based
on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&ldquo;PCAOB&rdquo;)
and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We conducted our audits in accordance with
the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether
the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have,
nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required
to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the
effectiveness of the Company&rsquo;s internal control over financial reporting. Accordingly, we express no such opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our audits included performing procedures
to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made
by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a
reasonable basis for our opinion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">/s/ EisnerAmper LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have served as the Company&rsquo;s auditor
since 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">EISNERAMPER LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Iselin, New Jersey</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">March 10, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 131; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="fin_002"></A>Lantern Pharma
Inc. and Subsidiary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Consolidated Balance Sheets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 11pt Calibri, Helvetica, Sans-Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: justify">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font: bold 9pt Times New Roman, Times, Serif; text-align: center">December
    31,</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 9pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 9pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 9pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 9pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 9pt Times New Roman, Times, Serif">CURRENT ASSETS</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font: 9pt Times New Roman, Times, Serif; text-indent: -9pt; padding-left: 0.25in">Cash</TD><TD STYLE="width: 1%; font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 9pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 9pt Times New Roman, Times, Serif; text-align: right">19,229,232</TD><TD STYLE="width: 1%; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 9pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 9pt Times New Roman, Times, Serif; text-align: right">1,232,030</TD><TD STYLE="width: 1%; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Prepaid
    expenses &amp; other current assets</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right">1,007,690</TD><TD STYLE="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right">788</TD><TD STYLE="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 0.25in">Total
    current assets</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">20,236,922</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">1,232,818</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 0.25in">Property and
    equipment, net</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">21,507</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">8,758</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Deferred
    offering costs</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right">101,205</TD><TD STYLE="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right">191,000</TD><TD STYLE="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">TOTAL
    ASSETS</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: right">20,359,634</TD><TD STYLE="padding-bottom: 4pt; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: right">1,432,576</TD><TD STYLE="padding-bottom: 4pt; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt">CURRENT LIABILITIES</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Accounts
    payable and accrued expenses</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right">552,339</TD><TD STYLE="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right">489,292</TD><TD STYLE="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 0.25in">Total
    Current Liabilities</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">552,339</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">489,292</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">PPP
    loan payable</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right">108,500</TD><TD STYLE="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">TOTAL
    LIABILITIES</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right">660,839</TD><TD STYLE="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 9pt Times New Roman, Times, Serif; text-align: right">489,292</TD><TD STYLE="padding-bottom: 1.5pt; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt">COMMITMENTS AND
    CONTINGENCIES (NOTE 5)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 9pt">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt">STOCKHOLDERS&rsquo;
    EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; font: 9pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in">Series A Preferred Stock (1,000,000
    authorized at December 31, 2020; 3,480,000 authorized at December 31, 2019; $.0001 par value) (Zero shares issued and outstanding
    at December 31, 2020; 2,438,866 shares issued and outstanding at December 31, 2019)</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">244</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; font: 9pt Times New Roman, Times, Serif; padding-left: 0.25in">Common Stock
    (25,000,000 authorized at December 31, 2020; 12,180,000 authorized at December 31, 2019; $.0001 par value) (6,220,927 shares
    issued and outstanding at December 31, 2020; 1,978,269 shares issued and outstanding at December 31, 2019)</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">622</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">198</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt">Additional paid-in
    capital</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">32,358,068</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">7,694,547</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left; text-indent: -9pt; padding-left: 9pt">Accumulated deficit</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">(12,659,895</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">(6,751,705</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 9pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: left; text-indent: -0.25in; padding-left: 0.25in">Total
    stockholders&rsquo; equity</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">19,698,795</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: right">943,284</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 9pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 9pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">TOTAL
    LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY </TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: right">20,359,634</TD><TD STYLE="padding-bottom: 4pt; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 9pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 9pt Times New Roman, Times, Serif; text-align: right">1,432,576</TD><TD STYLE="padding-bottom: 4pt; font: 9pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">See accompanying
Notes to Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 132; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="fin_003"></A>Lantern Pharma
Inc. and Subsidiary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Consolidated Statements
of Operations </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; font-weight: bold; text-align: center">For the Year
    Ended <BR> December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt; text-align: justify">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font-size: 10pt; text-align: justify; padding-left: 9pt">General and administrative</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">3,664,965</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">1,475,000</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Research and development</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">2,243,225</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">953,185</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify">Total operating expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,908,190</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">2,428,185</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 4pt">NET LOSS</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">(5,908,190</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">(2,428,185</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify">Net loss per share of common shares, basic and diluted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1.37</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(1.23</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify">Weighted-average number of common shares outstanding, basic and diluted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">4,304,918</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,978,269</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">See accompanying
Notes to Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>


<!-- Field: Page; Sequence: 133; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="fin_004"></A>Lantern Pharma
Inc. and Subsidiary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Consolidated Statements
of Stockholders&rsquo; Equity (Deficit)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-size: 11pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8.5pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 8.5pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">Preferred
    <BR>
    Stock <BR>
    Number <BR>
    of Shares</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 8.5pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8.5pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 8.5pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">Preferred
    <BR>
    Stock <BR>
    Amount</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 8.5pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8.5pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 8.5pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">Common
    <BR>
    Stock <BR>
    Number <BR>
    of Shares</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 8.5pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8.5pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 8.5pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">Common
    <BR>
    Stock <BR>
    Amount</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 8.5pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8.5pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 8.5pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">Additional
    <BR>
    Paid-in <BR>
    Capital</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 8.5pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8.5pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 8.5pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">Accumulated
    <BR>
    Deficit</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 8.5pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 8.5pt; font-weight: bold; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-size: 8.5pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">Total
    <BR>
    Stockholders&rsquo; <BR>
    Equity <BR>
    (Deficit)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 8.5pt; font-weight: bold"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 30%; font-size: 8.5pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Balance,
    January 1, 2019</FONT></TD><TD STYLE="width: 1%; font-size: 9pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 7%; border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">1,292,952</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 9pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="width: 7%; border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">129</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 9pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 7%; border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">1,978,269</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 9pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="width: 7%; border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">198</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 1%; font-size: 9pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="width: 7%; border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">4,121,395</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="width: 1%; font-size: 9pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="width: 7%; border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">(4,323,520</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD><TD STYLE="width: 1%; font-size: 11pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="width: 7%; border-bottom: Black 1.5pt solid; font-size: 11pt; text-align: right"><FONT STYLE="font-size: 10pt">(201,798</FONT></TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; font-size: 11pt; text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-size: 11pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-size: 8.5pt; text-align: left"><FONT STYLE="font-size: 10pt">Preferred
    stock and warrants issued</FONT></TD><TD STYLE="font-size: 9pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">1,145,914</FONT></TD><TD STYLE="font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">115</FONT></TD><TD STYLE="font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">3,455,392</FONT></TD><TD STYLE="font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">3,455,507</FONT></TD><TD STYLE="font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-size: 8.5pt; text-align: left"><FONT STYLE="font-size: 10pt">Stock-based
    compensation</FONT></TD><TD STYLE="font-size: 9pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">117,760</FONT></TD><TD STYLE="font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">117,760</FONT></TD><TD STYLE="font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-size: 8.5pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Net
    Loss</FONT></TD><TD STYLE="font-size: 9pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">(2,428,185</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD><TD STYLE="font-size: 9pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">(2,428,185</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-size: 8.5pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Balance,
    December 31, 2019</FONT></TD><TD STYLE="font-size: 9pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">2,438,866</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">244</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">1,978,269</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">198</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">7,694,547</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 9pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">(6,751,705</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD><TD STYLE="font-size: 9pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 9pt; text-align: right"><FONT STYLE="font-size: 10pt">943,284</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-size: 9pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-size: 11pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font-size: 11pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt; text-align: right"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="font-size: 11pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-size: 8.5pt; text-align: left"><FONT STYLE="font-size: 10pt">Common
    stock issued from offering, net of issuance costs</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,750,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">175</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">23,419,546</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">23,419,721</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-size: 8.5pt; text-align: left"><FONT STYLE="font-size: 10pt">Preferred
    Stock Converted to Common, net of fractional shares adjustment</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(2,438,866</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(244</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">2,438,848</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">244</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(261</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">(261</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-size: 8.5pt; text-align: left"><FONT STYLE="font-size: 10pt">Common
    stock issued from option exercise</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">50,460</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">5</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">51,995</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">52,000</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-size: 8.5pt"><FONT STYLE="font-size: 10pt">Cashless exercise
    of warrant</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">3,350</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-size: 8.5pt; text-align: left"><FONT STYLE="font-size: 10pt">Stock-based
    compensation</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,192,241</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1,192,241</FONT></TD><TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-size: 8.5pt; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Net
    Loss</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(5,908,190</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(5,908,190</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-size: 8.5pt; padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">Balance,
    December 31, 2020</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">6,220,927</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">622</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">32,358,068</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">(12,659,895</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">19,698,795</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">See accompanying
Notes to Consolidated Financial Statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 134; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="fin_005"></A>Lantern Pharma
Inc. and Subsidiary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Consolidated Statements
of Cash Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">CASH FLOWS FROM OPERATING ACTIVITIES</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Net loss</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,908,190</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,428,185</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-left: 9pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Adjustments to reconcile net loss to cash used in operating activities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in">Depreciation and amortization</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">3,388</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,627</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in">Stock based compensation</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">1,192,241</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">117,760</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Changes in assets and liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in">Accounts receivable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in">Prepaid expenses &amp; other current assets</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(1,006,902</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(788</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 0.25in">Deferred offering costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(49,325</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(191,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">Accounts payable and accrued expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">117,167</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">372,663</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net cash flows used in operating activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,651,621</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(2,127,923</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">INVESTING ACTIVITIES</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in">(Purchase) sale of property and equipment</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(16,137</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,717</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net cash flows (used in) provided by investing activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(16,137</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">(5,717</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">FINANCING ACTIVITIES</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Proceeds from issuance of common and preferred stock</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">26,250,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">2,920,507</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Issuance costs</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(2,745,279</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Proceeds from stock option exercise</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">52,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Preferred stock converted to common stock net of fractional shares adjustment</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(261</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Borrowings on notes payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">169,049</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-left: 9pt">Payments on notes payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(169,049</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Borrowings on PPP loan payable</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">108,500</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">Net cash flows provided by financing activities</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">23,664,960</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">2,920,507</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">CHANGE IN CASH FOR THE YEAR</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">17,997,202</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">786,867</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt">CASH, BEGINNING OF YEAR</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">1,232,030</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">445,163</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt">CASH, END OF YEAR</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">19,229,232</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">1,232,030</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Non-cash financing activities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Conversion of SAFE agreements to Series A preferred stock</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">535,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred offering costs applied to net offering proceeds</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">(85,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">)</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">-</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">Deferred offering costs recorded in AP and accrued expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">51,880</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>See accompanying Notes to Consolidated
Financial Statements</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 135; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I><A NAME="fin_006"></A>NOTES TO FINANCIAL STATEMENTS</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 1. Organization, Principal Activities,
and Basis of Presentation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt TimesNewRoman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Lantern Pharma Inc., and Subsidiary
(the &ldquo;Company&rdquo;) is a clinical stage biopharmaceutical company, focused on leveraging artificial intelligence (&ldquo;A.I.&rdquo;),
machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from
its targeted oncology therapies. The Company&rsquo;s portfolio of therapies consists of small molecule drug candidates that others
have tried, but failed, to develop into an approved commercialized drug, as well as new compounds that it is developing with the
assistance of its A.I. platform and its biomarker driven approach. The Company&rsquo;s A.I. platform, known as RADR<SUP>&reg;</SUP>,
uses big data analytics (combining molecular data, drug efficacy data, data from historical studies, data from scientific literature,
phenotypic data from trials and publications, and mechanistic pathway data) and machine learning. The Company&rsquo;s data-driven,
genomically-targeted and biomarker-driven approach allows it to pursue a transformational drug development strategy that identifies,
rescues or develops, and advances potential small molecule drug candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Lantern Pharma Inc.
was incorporated under the laws of the state of Texas on November 7, 2013, and thereafter reincorporated in the state of Delaware
on January 15, 2020. The Company&rsquo;s principal operations are located in Texas. The Company formed a wholly owned subsidiary,
Lantern Pharma Limited, in the United Kingdom in July 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since inception, the
Company has devoted substantially all its activity to advancing research and development, including efforts in connection with
preclinical studies, clinical trials and development of its RADR platform. This includes research and development for three drug
candidates in development in targeted areas identified with the assistance of the RADR platform:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">LP-100 (irofulven),
                                         out-licensed to Allarity Therapeutics (formerly known as Oncology Venture), in a phase
                                         II trial for the treatment of prostate cancer;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">LP-300 (Tavocept)
                                         in planning stages for phase II trial for the treatment of non-small cell lung cancer;
                                         and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">LP-184 in
                                         preclinical studies for treatment of solid tumors including prostate, liver and pancreatic
                                         cancers and glioblastoma.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the Company&rsquo;s reincorporation in the state of Delaware on January 15, 2020, the par value of the Company&rsquo;s Common
Stock and Series A Preferred Stock was changed from $0.01 per share to $0.0001 per share. The change in the par value has been
retroactively reflected in the accompanying consolidated financial statements. Additional funds have been reclassified from Common
Stock and Series A Preferred Stock to additional paid-in capital to reflect the change in par value associated with the reincorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying consolidated
financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America
(&ldquo;GAAP&rdquo;) and include all adjustments necessary for the fair presentation of the Company&rsquo;s financial position,
results of operations, and cash flows for each period presented. The preparation of financial statements in conformity with GAAP
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses
during the reporting periods. Actual results could differ from these estimates.</P>

<P STYLE="font: 8pt TimesNewRomanPSMT; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any reference in these
notes to applicable guidance refers to Accounting Standards Codification (&ldquo;ASC&rdquo;) and Accounting Standards Update (&ldquo;ASU&rdquo;)
of the Financial Accounting Standards Board (&ldquo;FASB&rdquo;). To date, the Company has operated its business as one segment.
The Company&rsquo;s consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Lantern
Pharma Limited. All intercompany balances and transactions have been eliminated in consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 136; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective June 11,
2020, in connection with the Company&rsquo;s initial public offering (&ldquo;IPO&rdquo;), the Company completed a forward stock
split of its common stock at a ratio of 1.74 for 1 shares. In addition, all of the Company&rsquo;s preferred stock converted into
common stock effective June 15, 2020 in connection with the IPO. All data on common stock and equivalents in the accompanying
consolidated financial statements and in these notes are shown herein reflective of this stock split and the conversion of the
preferred stock. In addition, the number of shares of preferred stock in the accompanying consolidated financial statements and
in these notes is presented to reflect the number of shares into which the preferred stock would convert as a result of the forward
stock split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 2. Liquidity </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company incurred
a net loss of approximately $5,908,000 and $2,428,000 during the years ended December 31, 2020 and 2019, respectively. As of December
31, 2020, the Company had working capital of approximately $19,685,000, primarily as a result of the net proceeds raised in the
IPO of approximately $23,420,000 (see Note 6). As of December 31, 2019, the Company had working capital of approximately $744,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 20, 2021,
the Company closed a public offering of 4,928,571 shares of its common stock at a public offering price of $14.00 per share, which
amount included 642,856 shares sold upon full exercise of the underwriter&rsquo;s over-allotment option. Total gross proceeds from
the offering were $68,999,994, and net proceeds from the offering were approximately $64,200,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">The Company has received
funding in the form of periodic capital raises and also plans to apply for grant funding in the future to assist in supporting
its capital needs. We may also explore the possibility of entering into commercial credit facilities as an additional source of
liquidity.</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our
existing cash and cash equivalents as of December 31, 2020, and our anticipated expenditures and capital commitments for the calendar
year 2021 and the first half of 2022, will enable us to fund our operating expenses and capital expenditure requirements for at
least 12 months from the date of filing this Form 10-K for the year ended December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 3. Summary of Significant Accounting
Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Use of Estimates and Assumptions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of
financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. The significant areas of estimation include determining
deferred tax asset valuation allowance and the inputs in determining the fair value of equity-based awards and warrants issued.
Actual results could differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks and Uncertainties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company operates
in an industry that is subject to intense competition, government regulation and rapid technological change. Operations are subject
to significant risk and uncertainties including financial, operational, technological, regulatory, and other risks, including
the potential risk of business failure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The extent of the impact
and effects of the coronavirus (COVID-19) on the operation and financial performance of the Company&rsquo;s business will depend
on future developments, including the duration and spread of the outbreak, related travel advisories and restrictions, the recovery
time of disrupted research services, the consequential staff shortages, and research and development delays, or the uncertainty
with respect to the accessibility of additional liquidity or capital markets, all of which are highly uncertain and cannot be
predicted. If the Company&rsquo;s operations are impacted by this outbreak for an extended period, the Company&rsquo;s results
of operations or liquidity may be materially adversely affected.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Deferred Offering Costs</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Costs incurred related
to equity offerings are capitalized as deferred equity issuance costs in other non-current assets until the offering is completed
or abandoned. If the Company completes an offering, these costs will be offset against proceeds received; or if the offering does
not occur, they will be expensed. Offering costs include direct and incremental costs related to the offering such as legal fees
and related costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #222222"></P>

<!-- Field: Page; Sequence: 137; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recorded
deferred offering costs of $101,205 and $191,000 as of December 31, 2020 and 2019, respectively. During the year ended December
31, 2020, the Company has applied deferred offering costs of $456,437 as a reduction to additional paid-in capital upon completion
of the Company&rsquo;s initial public offering (&ldquo;IPO&rdquo;) on June 15, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #222222">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Research and Development</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development
costs are expensed as incurred. These expenses primarily consist of payroll, contractor expenses, research study expenses, costs
for manufacturing and supplies, and technical infrastructure on the cloud for the purposes of developing the Company&rsquo;s RADR
platform and identifying, developing, and testing drug candidates. Development costs incurred by third parties are expensed as
the work is performed. Costs to acquire technologies, including licenses, that are utilized in research and development and that
have no alternative future use are expensed when incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Cash and Cash Equivalents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Highly liquid investments
with original maturities of three months or less when purchased are considered to be cash equivalents. Financial instruments which
potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains
cash and cash equivalents with high-credit quality financial institutions. At times, such amounts may exceed insured limits. The
Company has not experienced any losses in such accounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Prepaid Expenses and Other Current Assets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prepaid expenses and
other current assets as of December 31, 2020 totaled approximately $1,008,000 and included approximately $187,000 of upfront payments
for contractor and academic research studies and services, approximately $15,000 of licensing and other fees, and approximately
$806,000 of prepaid annual insurance fees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Loan Pursuant to Paycheck Protection
Program</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 1, 2020, the
Company received $108,500 in aggregate loan proceeds (the &ldquo;PPP Loan&rdquo;) from JPMorgan Chase Bank (the &ldquo;Lender&rdquo;)
pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The PPP Loan
is evidenced by a loan application and payment agreement (the &ldquo;PPP Loan Agreement&rdquo;) by and between the Company and
the Lender. This amount is recorded as a loan payable on the Company&rsquo;s consolidated balance sheet at December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Income Taxes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Deferred tax assets
and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities
using enacted tax rates which will be in effect when the differences reverse. The Company provides a full valuation allowance
against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset
will be realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Stock-based Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stock-based awards
have been accounted for as required by ASC 718 &ldquo;Compensation - Stock Compensation.&rdquo; Under ASC 718, awards are valued
at fair value on the date of grant, and that fair value is recognized over the requisite service period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 138; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Reclassification</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain prior period information has been
reclassified to conform to the current period presentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 4. New Accounting Pronouncements
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>New Accounting Pronouncements, Not
Yet Adopted</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Current Expected Credit Loss</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2016 the FASB
issued Accounting Standard Update (ASU) 2016-13, Measurement of Credit Losses on Financial Instruments (Topic 326). This introduces
new methodology for recognition of credit losses - the current expected credit loss (&ldquo;CECL&rdquo;) method. The CECL method
requires the recognition of all losses expected over the life of a financial instrument upon origination or purchase of the instrument,
unless the company elects to recognize such instruments at fair value with changes in profit and loss. CECL is effective for the
Company on January 1, 2023. The Company does not anticipate a material impact from the adoption of this new standard on its financial
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Income Taxes</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2019,
the FASB issued ASU 2019-12: Income Taxes (Topic 740) &ndash; Simplifying the Accounting for Income Taxes. This ASU simplifies
accounting for income taxes by removing the exception to the incremental approach for intraperiod tax allocation when there is
a loss from continuing operations and income or gain for other items, the exception to the requirement to recognize a deferred
tax liability for equity method investments when a foreign subsidiary becomes an equity method investment, the exception to the
ability not to recognize a deferred tax liability for a foreign subsidiary when a foreign equity method investment becomes a subsidiary,
and the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds
the anticipated loss for the year. This ASU also includes other requirements related to franchise tax, goodwill as part of a business
combination, consolidations, changes in tax laws, and affordable housing projects. ASU 2019-12 is effective for fiscal years beginning
after December 15, 2020, including interim periods within that fiscal year. Early adoption is permitted for periods in which financial
statements have not yet been issued. The Company does not anticipate a material impact from the adoption of this new standard
on its financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Recently Adopted Accounting Standards</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Leases </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2016 the
FASB issued ASU 2016-02: Leases. The ASU introduces a lessee model that results in most leases impacting the balance sheet. The
ASU addresses other concerns related to the current lease model. Under ASU 2016-02, lessees will be required to recognize for
all leases with terms longer than 12 months, at the commencement date of the lease, a lease liability, which is a lessee&rsquo;s
obligation to make lease payments arising from a lease measured on a discounted basis, and a right-to-use (ROU) asset, which is
an asset that represents the lessee&rsquo;s right to use or control the use of a specified asset for the lease term. Leases will
be classified as either finance or operating, with classification affecting the pattern of expense recognition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2018, the
FASB issued ASU 2018-10 &ldquo;Codification Improvements to Topic 842, Leases.&rdquo; This ASU affects narrow aspects of the guidance
issued in the amendments in ASU 2016-02 including those regarding residual value guarantees, rate implicit in the lease, lessee
reassessment of lease classification, lessor reassessment of lease term and purchase option, variable lease payments that depend
on an index or a rate, investment tax credits, lease term and purchase option, transition guidance for amounts previously recognized
in business combinations, certain transition adjustments, transition guidance for leases previously classified as capital leases
under Topic 840, transition guidance for modifications to leases previously classified as direct financing or sales-type leases
under Topic 840, transition guidance for sale and leaseback transactions, impairment of net investment in the lease, unguaranteed
residual asset, effect of initial direct costs on rate implicit in the lease, and failed sale and leaseback transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 139; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company adopted
ASC 2018-10 Topic 842 effective January 1, 2019 and elected the short-term lease recognition exemption for all leases that qualify.
For those leases that qualify, the Company will not recognize ROU assets or lease liabilities, and this includes not recognizing
ROU assets or lease liabilities for existing short-term leases of those assets in transition. This practical expedient was elected
to not separate lease and non-lease components for its office space leases. The adoption of this new standard did not have a material
impact on the Company&rsquo;s financial statements as the Company did not have any leases that have terms of longer than 12 months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Compensation &ndash; Stock Compensation</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2018, the
FASB issued ASU 2018-07: Compensation &ndash; Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment
Accounting. This ASU expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services
from non-employees, and as a result, the accounting for share-based payments to non-employees will be substantially aligned. ASU
2018-07 is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early
adoption is permitted but no earlier than an entity&rsquo;s adoption date of Topic 606. The Company adopted ASU Topic 718 effective
January 1, 2019. The adoption of this new accounting guidance did not have a material impact on the Company&rsquo;s consolidated
financial statements and related footnote disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 5: Commitments and Contingencies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><B><I>General.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has entered
into, and expects to enter into from time to time in the future, license agreements, strategic alliance agreements, assignment
agreements, and similar agreements related to the advancement of its product candidates and research and development efforts (collectively,
&ldquo;License and Strategic Alliance Agreements&rdquo;). As of the date of filing this report on Form 10-K, the Company has obligations
relating to License and Strategic Alliance Agreements that are expected to result in total payments of approximately $600,000 for
2021.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>BioNumerik
Pharmaceuticals.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
January 2018, the Company entered into an Assignment Agreement (the &ldquo;Assignment Agreement&rdquo;) with BioNumerik Pharmaceuticals,
Inc. (&ldquo;BioNumerik&rdquo;), pursuant to which the Company acquired rights to domestic and international patents, trademarks
and related technology and data relating to LP-300 (Tavocept) for human therapeutic treatment indications. The Assignment Agreement
replaced a License Agreement that was entered into between the Company and BioNumerik in May 2016. The Company made upfront payments
totaling $25,000 in connection with entry into the Assignment Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
the event the Company develops and commercializes LP-300 internally, the Company is required to pay to the BioNumerik-related
payment recipients designated in the Assignment Agreement a percentage royalty in the low double digits on cumulative net revenue
up to $100 million, with incremental increases in the percentage royalty for net cumulative revenue between $100 million and $250
million, $250 million and $500 million, and $500 million and $1 billion, with a percentage royalty payment that could exceed $200
million for net cumulative revenue in excess of $1 billion. The Company has the right to first recover certain designated portions
of patent costs and development and regulatory costs before the payment of royalties described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">If
the Company enters into a third party transaction for LP-300, the Company is required to pay the BioNumerik-related payment recipients
a specified percentage of any upfront, milestone, and royalty amounts received by the Company from the transaction, after first
recovering specified direct costs incurred by the Company for the development of LP-300 that are not otherwise reimbursed from
such third party transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition, the Assignment Agreement provides that the Company will use commercially diligent efforts to develop LP-300 and make
specified regulatory filings and pay specified development and regulatory costs related to LP-300. The Assignment Agreement also
provides that the Company will provide TriviumVet DAC (&ldquo;TriviumVet&rdquo;) with (i) specified data and information generated
by the Company with respect to LP-300, and (ii) an exclusive license to use specified LP-300-related patent rights, trademark
rights and related intellectual property to support LP-300 development in non-human (animal) treatment indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 140; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
Company is also required to pay all patent costs on covered patents related to LP-300. Patent costs paid by the Company to BioNumerik
with respect to LP-300 related patents amounted to $0 and approximately $74,000 for the years ended December 31, 2020 and 2019,
respectively. These patent costs are included in general and administrative expenses in the accompanying consolidated statement
of operations. These patent costs are fully recoverable at the time of any net revenue from LP-300, with up to 50% of net revenue
amounts to be applied towards repayment of patent costs until such costs are fully recovered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition to the recovery of patent costs, the Company has the right to recover the $25,000 upfront payments made in connection
with entry into the Assignment Agreement, which payments are recoverable prior to making any royalty or third party transaction
sharing payments. The Company also has the right to recover previously incurred LP-300 development and regulatory costs, with
up to a mid-single digit percentage of net revenue amounts to be applied towards repayment of development and regulatory costs
until such costs are fully recovered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">No
amounts are owed to BioNumerik as of December 31, 2020. Approximately $11,000 is owed and recorded in accounts payable to BioNumerik
as of December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>AF Chemicals.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2015, the
Company entered into a Technology License Agreement to exclusively license domestic and international patent rights from AF Chemicals,
LLC (&ldquo;AF Chemicals&rdquo;) for the treatment of cancer in humans for the compounds LP-100 (Irofulven) and LP-184. In February
2016, the Company and AF Chemicals entered into an Addendum (the &ldquo;Addendum&rdquo;) providing for additions and amendments
to the Technology License Agreement. In December 2020, the Company and AF Chemicals entered into a Second Addendum (the &ldquo;Second
Addendum&rdquo;) providing for further additions and amendments to the Technology License Agreement. The Technology License Agreement,
Addendum and Second Addendum are collectively referred to as the &ldquo;AFC License Agreement&rdquo;.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Second Addendum
provides for us to make specified payments to AF Chemicals within 10 days after signing and by March 31, 2021. The Second Addendum
also provides that, from December 30, 2020 until January 15, 2025, we will have no obligation to pay annual licensing fees, development
diligence extension payments, or patent maintenance fee payments to AFC under the AFC License Agreement. Nothing was expensed
in the year ended December 31, 2020 relating to entering into the Second Addendum.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of the Second
Addendum, we have agreed to apply for specified orphan drug designations for LP-184 in the US and EU. The Second Addendum also
amends and clarifies other provisions of the Technology License Agreement, and provides us with the ability to recover a portion
of initial payments made under the Second Addendum from sublicense fees or royalty payments that may be made to AFC by us or third
parties prior to January 15, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the AFC
License Agreement the Company made annual licensing fee payments to AF Chemicals in the amount of $30,000 during each of the years
ended December 31, 2020 and 2019 relating to LP-184. Such amounts are included in research and development expenses in the accompanying
consolidated statement of operations. In addition, the Company is obligated to make milestone payments to AF Chemicals at the time
of an Investigational New Drug Application (&ldquo;IND&rdquo;) filing relating to LP-184 and also upon reaching additional specified
milestones in connection with the development and potential marketing approval of LP-184 in the United States, specified countries
in Europe, and other countries.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 141; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The AFC License Agreement
also provides that the Company will pay AF Chemicals a royalty of at least a very small single digit percentage of specified net
sales of LP-184 and other analogs. In addition, the AFC License Agreement contains specified time requirements for the Company
to file an IND, enroll patients in clinical trials, and file a potential NDA with respect to LP-184, with the ability for the
Company to pay AF Chemicals additional amounts ranging up to an amount in the low hundreds of thousands of dollars for each one,
two, three and four year extension to such development time requirements, with additional extensions beyond four years to be negotiated
by the Company and AF Chemicals. The Company paid $50,000 and $37,500 during the years ended December 31, 2020 and 2019, respectively
in connection with the extension of the IND filing milestone for LP-184, which amounts are included under research and development
in the accompanying consolidated statements of operations. Pursuant to the Second Addendum, no additional payments of annual licensing
fees or development diligence extension payments are required to be made by the Company until January 15, 2025, at which time
these obligations will resume. The Company will also be obligated to make annual licensing fee payments to AF Chemicals relating
to LP-100 beginning January 15, 2025, as described below under Allarity Therapeutics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of a
sublicense of the LP-184 rights, the Company is obligated to pay AF Chemicals (a) a low double digit percentage of the gross income
and fees received by the Company with respect to the United States in connection with such sublicense, and (b) a lower double
digit percentage of the gross income and fees received by the Company with respect to Europe and Japan in connection with such
sublicense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">No
amounts are payable to AF Chemicals as of December 31, 2020 and 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Allarity Therapeutics (formerly
known as Oncology Venture)</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2015, the Company
licensed various rights to LP-100 to Oncology Venture (now known as Allarity Therapeutics) pursuant to a Drug License and Development
Agreement. In February 2016, the Company and Allarity Therapeutics entered into an addendum and an amendment providing for additions
and amendments to the Drug License and Development Agreement. In connection with the Drug License and Development Agreement, as
amended (collectively, the &ldquo;Allarity License and Development Agreement&rdquo;), Allarity Therapeutics agreed to directly
pay to AF Chemicals on behalf of the Company certain amounts to satisfy the Company&rsquo;s milestone obligations to AF Chemicals
with respect to LP-100 under the AFC License Agreement. Amounts paid by Allarity Therapeutics to AF Chemicals on behalf of the
Company are then deducted from amounts owed by Allarity Therapeutics to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amounts to be paid
to AF Chemicals with respect to LP-100 under the AFC License Agreement are in many ways similar to the amounts to be paid with
respect to LP-184 as described above under &ldquo;AF Chemicals&rdquo;. In the event any such amounts relating to LP-100 are not
paid to AF Chemicals by Allarity Therapeutics, the Company is obligated to pay such unpaid amounts. In addition to the payments
to be made by Allarity Therapeutics, the Company is obligated to make annual licensing fee payments to AF Chemicals relating to
LP-100. The Company paid $30,000 to AF Chemicals during each of the years ended December 31, 2020 and 2019 relating to LP-100.
Such amounts are included in research and development expenses in the accompanying consolidated statement of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the AFC
License Agreement contains specified time requirements for the Company to file an IND, enroll patients in clinical trials, and
file a potential NDA with respect to LP-100. During the year ended December 31, 2020, the Company paid AF Chemicals $25,000 relating
to a one-year milestone extension fee for LP-100 commencing in August 2020, approximately $10,000 of which was expensed during
the year ended December 31, 2020 and included under research and development expenses in the accompanying consolidated statements
of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No amounts are payable
under the Allarity License and Development Agreement as of December 31, 2020 and 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>EU Grant</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2018,
Lantern Pharma Limited, a wholly owned subsidiary of Lantern Pharma Inc., was awarded a grant by the UK government in the form
of state aid under the Commission Regulations (EU) No. 651/2014 of 17 June 2014 (the &ldquo;General Block Exemption&rdquo;), Article
25 Aid for research and development projects, state aid notification no. SA.40154. The grant was awarded to conduct research and
development activities for the prostate cancer biomarker analysis of the LP-184&nbsp;drug candidate. Following the Company&rsquo;s
research and development activities in Northern Ireland, the grant will reimburse the Company 50% of its research and development
expenses not exceeding GBP 24,215 of vouched and approved expenditures within specific categories. The grant contains some reporting
and consent requirements. The grant will remain in force for a period of five years. No payments to the Company have been made
under the grant as of December 31, 2020 and December 31, 2019. No revenue has been recognized from this grant through December
31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></P>

<!-- Field: Page; Sequence: 142; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Patheon API Services</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2020, the
Company entered into an agreement with Patheon API Services, Inc. (&ldquo;Patheon&rdquo;) for the manufacture and supply of cGMP
material to support the Company&rsquo;s planned Phase II clinical trial for its product candidate LP-300. In addition to producing
LP-300 API (active pharmaceutical ingredient) under cGMP (current Good Manufacturing Practices) conditions, Patheon will transfer
previously validated manufacturing processes and analytical methods for LP-300 and will produce non-GMP material that can be used
to support non-clinical studies for LP-300. The agreement provides for payments in stages as specified process and manufacturing
milestones are achieved. Patheon, a part of Thermo Fisher Scientific, has previously developed and/or manufactured more than 700
pharmaceuticals for biopharma clients and has more than 55 locations around the world, providing access to a fully integrated
global network of facilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company paid approximately
$203,000 to Patheon during the twelve months ended December 31, 2020 pursuant to the Patheon agreement. Approximately $227,000
was expensed with respect to the Patheon agreement during the twelve months ended December 31, 2020, which relates to the services
received by the Company through December 31, 2020. This amount is included in research and development expenses in the accompanying
consolidated statements of operations. Approximately $24,000 relating to the Patheon agreement is included under accounts payable
and accrued expenses on the Company&rsquo;s consolidated balance sheet for the period ended December 31, 2020. The Company expects
to pay additional amounts to Patheon in future periods in accordance with specified process and manufacturing milestones under
the Patheon agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>Southwest Research Institute</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">As
part of the Company&rsquo;s research and development activities, the Company has engaged Southwest Research Institute (&ldquo;SwRI&rdquo;)
from time to time to assist with compound synthesis and manufacturing related activities for the Company&rsquo;s product candidates.
Approximately $71,000 and $234,000 was expensed with respect to SwRI during the twelve months ended December 31, 2020 and December
31, 2019, respectively. All of such expensed amounts are included in research and development expenses in the accompanying consolidated
statements of operations. Approximately $82,000 was payable to SwRI as of December 31, 2020, and approximately $13,000 was payable
to SwRI as of December 31, 2019. In September 2020, the Company entered into an agreement with SwRI for the non-GMP synthesis
of LP-184 material and related analytical development to assist with preclinical studies. Approximately $97,000 relating to the
SwRI agreement is included under prepaid expenses on the Company&rsquo;s consolidated balance sheet for the period ended December
31, 2020. There were no prepaid expenses relating to SwRI as of December 31, 2019. The Company expects to pay additional amounts
to SwRI in future periods as synthesis and analytical work is conducted by SwRI under the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>The Research
Institute of Fox Chase Cancer Center</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
September 2020, the Company entered into a research agreement with the Research Institute of Fox Chase Cancer Center (&ldquo;FCCC&rdquo;)
as part of the Company&rsquo;s research and development activities, with a focus on advancing the targeted use of LP-184 in molecularly-defined
sub-types of pancreatic cancer. Approximately $85,000 was expensed with respect to the FCCC agreement during the twelve months
ended December 31, 2020, which amount is included in research and development expenses in the accompanying consolidated statements
of operations. As of December 31, 2020, approximately $14,000 was recorded as accrued with respect to FCCC. The Company expects
to pay additional amounts to FCCC in future periods in accordance with the payment schedule specified under the FCCC agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Other Research
and Service Provider Agreements</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">In
addition to the agreements described above, the Company has entered into other research and service provider agreements for the
advancement of its product candidates and research and development efforts. The Company expects to pay additional amounts in future
periods in connection with existing and future research and service provider agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 143; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Operating Leases</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company leased
office space in Dallas, Texas under month-to-month lease arrangements during the years ended December 31, 2020 and 2019. In connection
with the Company&rsquo;s employees working remotely due to COVID-19, the Company in August 2020 reduced its monthly lease commitment
and costs to minimal levels. The Company is continuing to monitor the COVID-19 conditions and intends to increase its lease of
office space following an improvement in the COVID-19 pandemic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2019, the
Company entered into a leasing agreement for office space in New Jersey. Monthly rent was $2,106, plus electrical utilities. The
lease expired on July 31, 2020 and was not renewed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 6. Shareholders&rsquo; Equity</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preferred Stock </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31,
2019, the Company had 3,480,000 authorized shares of preferred stock, of which 2,438,866 shares designated as Series A Preferred
Stock (the &ldquo;Series A Preferred Stock&rdquo;) were issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the Company&rsquo;s
IPO, all shares of the Company&rsquo;s Series A preferred stock were converted into 2,438,851 shares of common stock effective
June 15, 2020, with fractional share adjustments made in connection with the conversion as discussed below. As of December 31,
2020, the Company had 1,000,000 authorized shares of preferred stock, with zero shares of preferred stock issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holders of Series
A Preferred Stock were entitled to receive dividends when, as and if declared by the Company&rsquo;s Board of Directors, payable
in preference and priority to any declaration or payment of dividends on Common Stock. No dividends on any Series A Preferred
Stock were declared and no dividends on Common Stock have been declared to date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2019, the
Company sold 590,643 shares of Series A preferred stock for aggregate proceeds of approximately $1,850,000. The Company also issued
213,510 shares of Series A preferred stock in March 2019, in connection with the conversion of the Simple Agreement for Future
Equity (SAFE) agreements. See Note 7. In connection with the sale and issuance of the Series A preferred stock in March 2019,
the Company issued warrants to purchase an aggregate of 96,499 shares of Series A preferred stock at an initial exercise price
of $3.13 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2019, the
Company sold 341,761 shares of Series A preferred stock for aggregate proceeds of approximately $1,070,000. In connection with
the issuance of the Series A preferred stock, the Company issued warrants to purchase an aggregate of 41,015 shares of Series
A preferred stock at an initial exercise price of $3.13 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each share of Series
A Preferred Stock was convertible into one share of Common Stock, subject to adjustments for anti-dilution. In addition, the terms
of the Series A Preferred Stock provided that it would automatically convert into Common Stock upon the closing of an initial
public offering meeting certain specified conditions, and also that it would convert into Common Stock in the event holders of
at least 75% of the Series A Preferred Stock approved a mandatory conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holders of the
Series A Preferred Stock, exclusively and as a separate class, had the right to elect two directors of the Company, and two directors
of the Company were elected by the holders of Series A Preferred Stock in accordance with such provision. The Series A Preferred
Stock also had the right to vote together with holders of Common Stock on any matter presented to the shareholders of the Company
for their action or consideration. In addition, the separate approval of a majority of the Series A Preferred Stock was required
in connection with specified Company activities and transactions, including a merger or consolidation of the Company, and the
liquidation, dissolution or winding-up the business and affairs of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 144; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of a
voluntary or involuntary liquidation, dissolution or winding up of the Company or a deemed liquidation event, the terms of the
Series A Preferred Stock provided that holders of Series A Preferred Stock would be entitled to be paid, out of the assets of
the Company available for distribution, an amount equal to $3.13 per share, plus any dividends declared but unpaid thereon, before
any payment was made to the holders of Common Stock. The liquidation preference of the Series A Preferred Stock was approximately
$7,639,000 at December 31, 2019. The terms of the Series A Preferred Stock provided that, if upon any liquidation, dissolution
or winding up of the Company or deemed liquidation event, the assets of the Company available for distribution to its shareholders
should be insufficient to pay holders of Series A Preferred Stock the full amount to which they would otherwise be entitled, the
holders of Series A Preferred Stock would share ratably in any distribution of the assets available for distribution in proportion
to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all
amounts payable on or with respect to such shares were paid in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective January
15, 2020, as a result of the Company&rsquo;s reincorporation in the state of Delaware, the par value of the Company&rsquo;s preferred
stock was changed from $0.01 to $0.0001 per share, and all data on preferred stock was retroactively adjusted to be shown herein
as reflective of this change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 15, 2020,
the Company received net proceeds of $23,419,721 in its IPO, after deducting underwriting discounts and commissions of $1,968,750
and other offering expenses of $861,529 borne by the Company. The Company issued and sold 1,750,000 shares of common stock in
its IPO at a price of $15.00 per share. In connection with the IPO, all shares of the Company&rsquo;s Series A Preferred Stock
were converted into 2,438,851 shares of common stock, after giving effect to the 1.74 for 1 forward stock split of the common
stock and net of the fractional shares adjustments that occurred in connection with the IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company made payments
of approximately $261 in the aggregate in connection with fractional shares resulting from the stock split and the conversion
of the preferred stock that took place in connection with the IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
December 31, 2020, the Company issued 50,460 shares of common stock, relating to the exercise of stock options. The shares were
issued at a purchase price of $1.03 for total proceeds of $52,000.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
December 31, 2020, the Company issued 3,350 shares of common stock related to a cashless exercise of a warrant to purchase 4,022
shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31,
2020, the Company had 25,000,000 authorized shares of Common Stock, of which 6,220,927 shares were issued and outstanding. As
of December 31, 2019, the Company had 12,180,000 authorized shares of Common Stock, of which 1,978,269 shares were issued and
outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Options</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 29, 2018,
the Board of Directors of the Company adopted the Lantern Pharma Inc. 2018 Equity Incentive Plan, which was subsequently amended
on December 17, 2018 and February 26, 2020. The Lantern Pharma Inc. 2018 Equity Incentive Plan, as amended and restated, is referred
to herein as the &ldquo;Plan&rdquo;. The Company reserved 1,489,680 shares of its common stock for issuance under the Plan. The
Plan is designed to provide additional incentives to employees, directors and consultants to remain in the service of the Company
as well as to encourage stock acquisition by members of these targeted groups, which in the opinion of the management will support
the alignment of the interests of the members of these groups and stockholders. Options granted under the Plan are generally exercisable
for up to 10 years from grant date. 535,099 shares remain available for future awards under the Plan at December 31, 2020, following
the grant of options and the award of restricted stock grants through December 31, 2020. The Company recorded stock-based compensation
of approximately $1,192,000 and $118,000 related to stock options during the years ended December 31, 2020 and 2019, respectively.
Total remaining unrecognized compensation expense for non-vested options is $2,480,912 as of December 31, 2020, and is expected
to be recognized over a weighted average period of 1.3 years. The weighted average remaining contractual term of outstanding options
at December 31, 2020 is 8.5 years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 145; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A summary of stock
option activity under the Plan during the years ended December 31, 2020 and 2019 is presented below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options Outstanding</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options Exercisable</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="white-space: nowrap; text-align: justify">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number
    of<BR> Shares</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-Average<BR>
    Exercise Price</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number
    of<BR> Options</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD><TD STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-Average<BR>
    Exercise Price</TD><TD STYLE="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; font-size: 10pt; text-align: justify">Outstanding December 31, 2018</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">629,060</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">1.03</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">194,479</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 9%; font-size: 10pt; text-align: right">1.03</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Granted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,342</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1.03</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify">Exercised</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 1.5pt">Cancelled or expired</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(22,911</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">1.03</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt">-</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify">Outstanding December 31, 2019</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">607,491</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1.03</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">393,413</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1.03</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Granted</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">321,743</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">15.01</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify">Exercised</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(50,460</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1.03</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: justify">Cancelled or expired</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">(43,166</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1.03</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: justify; padding-bottom: 4pt">Outstanding December 31, 2020</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">835,608</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">6.41</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">610,633</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">3.24</TD><TD STYLE="padding-bottom: 4pt; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For 2020 and 2019,
the fair value of each option granted was estimated using the Black-Scholes option-pricing model, using the following weighted
average assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">Term (in years)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">7.00</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">5.94</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Risk Free Rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt">0.54% - 0.67&nbsp;</FONT></TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.79</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">83.2% - 84.37%</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">60.1</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Dividend Yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.0</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.0</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Grant Date Fair Value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="white-space: nowrap; text-align: right"><FONT STYLE="font-size: 10pt"></FONT><FONT STYLE="font-size: 10pt">11.01 &ndash; 11.28 </FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">0.59</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value of
options is recognized as an expense over the vesting period and forfeitures are accounted for as they occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The total intrinsic
value of options outstanding at December 31, 2020 was $10,726,878, and the total intrinsic value of options exercisable at December
31, 2020 was $9,773,797. The total intrinsic value of options exercised during the year ended December 31, 2020 was $20,590. The
intrinsic value of options outstanding at December 31, 2019 was $0. No options were exercised during the year ended December 31,
2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; text-align: justify"><FONT STYLE="font-size: 10pt">Expected Term -</FONT></TD>
    <TD STYLE="width: 80%; text-align: justify"><FONT STYLE="font-size: 10pt">The Company used a weighted average of time to vesting
    and maturity date.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Expected Volatility-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Due to the Company&rsquo;s limited operating history and a lack
    of company-specific historical and implied volatility data, the Company has based its estimate of expected volatility on the
    historical volatility of a group of similar companies that are publicly traded commensurate with expected term as of grant
    date. The historical volatility data was computed using the daily closing prices for the selected comparable companies&rsquo;
    shares.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Risk-Free Interest Rate-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Company used the U.S. treasury bill rate commensurate with
    the expected term as of grant date.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Expected Dividend-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">As the Company has not issued any dividends and does not expect
    to issue dividends over the life of the options, the Company has estimated the dividend yield to be zero.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company had warrants
to purchase 325,618 shares of common stock outstanding and exercisable as of December 31, 2020 at a weighted average exercise
price of $6.49 per share. The Company had warrants to purchase 262,003 shares of Series A Preferred Stock outstanding and exercisable
as of December 31, 2019 at a weighted average exercise price of $3.13 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 146; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the Series A Preferred Stock financing transactions discussed above, in 2019 the Company issued warrants to purchase an aggregate
of 137,513 shares of Series A Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the IPO and the conversion of the Series A Preferred Stock into common stock, all outstanding warrants to purchase Series A Preferred
Stock converted into warrants to purchase common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the IPO, the Company granted the underwriters warrants (the &ldquo;Underwriters&rsquo; Warrants&rdquo;) to purchase an aggregate
of 70,000 shares of common stock at an exercise price of $18.75 per share, which is 125% of the initial public offering price.
The Underwriters&rsquo; Warrants have a five-year term and were not exercisable prior to December 7, 2020. All of the Underwriters&rsquo;
Warrants were outstanding at December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2020, the Company
issued 3,350 shares of common stock related to a cashless exercise of a warrant to purchase 4,022 shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2019, warrants to
purchase an aggregate of 39,651 shares of Series A Preferred Stock were modified to become warrants to purchase an aggregate of
27,754 shares of Series A Preferred Stock. As part of the modification, the term of these warrants was extended from .02 to 1.02
years. The fair value of the modified warrants was approximately $21,000 and is recorded in additional paid in capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2020, a warrant
to purchase an aggregate of 23,734 shares of Common Stock was modified to become a warrant to purchase an aggregate of 21,360
shares of Common Stock. As part of the modification, the term of the warrant was extended from .003 to 1.003 years. The fair value
of the modified warrant was approximately $36,000 and is recorded in additional paid in capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>Note 7. SAFE Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2018,
the Company entered into Simple Agreement for Future Equity (SAFE) agreements (the &ldquo;SAFE Financing&rdquo;) with five investors
pursuant to which the Company received funding of $535,000 in exchange for agreement to issue the investors shares of preferred
stock upon occurrence of a subsequent financing of preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The number of shares
to be received by the SAFE agreement investors was based on 80% of the pricing in the triggering equity financing. In a liquidity
or dissolution event, the investors&rsquo; right to receive cash out was junior to payment of outstanding indebtedness and creditor
claims, on par for other SAFEs and preferred stock, and senior to common stock. The SAFE agreements had no interest rate or maturity
date, and the SAFE investors had no voting right prior to conversion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31,
2018, the Company had received $535,000 of proceeds related to the SAFE agreements. The SAFE agreements had not yet converted
as a qualifying financing had not yet occurred as of December 31, 2018. Pursuant to the guidance under ASC 480, the Company determined
that the Purchase Amount (a term defined in the SAFE agreements denoting the amount in exchange for which an investor received
the rights to receive the shares) should be recorded as a liability on the Company&rsquo;s balance sheet. Due to a short period
where the Company expected these to be converted, the Company recorded the entire amount of $535,000 as a short-term liability.
The SAFE agreements were converted to equity in March 2019 and the Company issued 213,510 shares of Series A Preferred Stock in
full satisfaction of these agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 8. Notes and Loan Payable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2020, the
Company entered into a financing arrangement for commercial insurance with First Insurance Funding. The total amount financed
was approximately $66,000 with an annual interest rate of 6.64%, to be paid over a period of ten months. In June 2020, the insurance
policy was canceled, and the remaining loan balance was repaid. As of December 31, 2020, there is no remaining loan balance on
the Company&rsquo;s consolidated balance sheet related to the First Insurance financing arrangement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></P>

<!-- Field: Page; Sequence: 147; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 1, 2020 (the
&ldquo;Origination Date&rdquo;), the Company received $108,500 in aggregate loan proceeds (the &ldquo;PPP Loan&rdquo;) from JPMorgan
Chase Bank (the &ldquo;Lender&rdquo;) pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic
Security (CARES) Act. The PPP Loan is evidenced by a loan application and payment agreement (the &ldquo;PPP Loan Agreement&rdquo;)
by and between the Company and the Lender. Subject to the terms of the PPP Loan Agreement, the PPP Loan bears interest at a fixed
rate of one percent (1.0%) per annum. Payments of principal and interest are deferred for the first six months following the Origination
Date, and the PPP Loan will mature two years after the Origination Date. The guidance under the Paycheck Protection Program was
later updated so that deferral of payments of principal and interest were extended to ten months after completion of the covered
period of 24 weeks and maturity was extended past two years. The Company is continuing to monitor further development and guidance
related to the Paycheck Protection Program terms.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the deferral
period, unless the loan is forgiven, the Company will be required to make payments of principal plus interest accrued under the
PPP Loan to the Lender in monthly installments based upon an amortization schedule to be determined by the Lender based on the
principal balance of the PPP Loan outstanding following the deferral period and taking into consideration any portion of the PPP
Loan that may be forgiven prior to that time. The PPP Loan is unsecured and guaranteed by the U.S. Small Business Administration.
The Company plans to file for forgiveness under this loan within the first half of 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the twelve months
ended December 31, 2020, the Company received approximately $103,000 in funding resulting from a loan that was funded incorrectly.
All of the funds from the loan were repaid by the Company in July 2020, and no loan funds were expended prior to the repayment.
There are no amounts outstanding under this loan as of December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 9. Related Party Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has obtained
preclinical services from Biological Mimetics, Inc., which is also a stockholder in the Company. No expenses related to Biological
Mimetics, Inc. were recorded during the year ended December 31, 2020 and nothing was owed to Biological Mimetics, Inc. at December
31, 2020. The Company recorded expenses of approximately $23,000 related to Biological Mimetics, Inc. during the year ended December
31, 2019, all of which is included in research and development. Approximately $2,000 was owed to Biological Mimetics, Inc. at December
31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has previously
engaged Intuition Systems (&ldquo;Intuition&rdquo;) to provide services relating to development of the Company&rsquo;s technology
infrastructure and artificial intelligence platform, cloud computing, and computational biology. The chief executive officer of
Intuition is the brother of Arun Asaithambi, the Company&rsquo;s former Chief Executive Officer, President and Director. Nothing
was expensed related to Intuition during the years ended December 31, 2020 and 2019. At December 31, 2020 and 2019, approximately
$9,000 remained unpaid relating to Intuition and is included in accounts payable and accrued expenses in the accompanying consolidated
balance sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2018, the
Company entered into an Assignment Agreement (the &ldquo;Assignment Agreement&rdquo;) with BioNumerik Pharmaceuticals, Inc. (&ldquo;BioNumerik&rdquo;),
pursuant to which the Company acquired rights to domestic and international patents, trademarks and related technology and data
relating to LP-300 for human therapeutic treatment indications. Mr. Margrave, the Company&rsquo;s Chief Financial Officer and Secretary,
formerly served as the President, Chief Administrative Officer, General Counsel and Secretary of BioNumerik and has a minority
ownership interest in BioNumerik. Nothing was expensed related to BioNumerik during the year ended December 31, 2020. The Company
expensed less than $1,000 related to BioNumerik during the year ended December 31, 2019, which amount is included in general and
administrative expenses in the accompanying consolidated statement of operations. No amounts are owed to BioNumerik as of December
31, 2020. Approximately $11,000 was owed and recorded in accounts payable to BioNumerik as of December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 10. Loss Per Share of Common Shares</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Basic loss per share
is derived by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding
during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities,
such as warrants, and stock options, which would result in the issuance of incremental shares of common stock unless such effect
is anti-dilutive. In calculating the basic and diluted net loss per share applicable to common stockholders, the weighted average
number of shares remained the same for both calculations due to the fact that when a net loss exists, dilutive shares are not
included in the calculation. Potentially dilutive securities outstanding that have been excluded from diluted loss per share due
to being anti-dilutive include the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 12pt; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended <BR> December 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 12pt; text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">Warrants</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">325,618</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">262,003</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Stock options</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">835,608</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">607,491</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt">Series A preferred stock</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,438,866</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 12pt; text-align: justify; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,161,226</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,308,360</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 148; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 11. Income Taxes</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our effective tax rate
differs from the statutory federal tax rate as presented in the following table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify">U.S. federal statutory tax rate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">21</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">21</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Permanent differences</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Valuation allowance</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(22</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(20</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Total:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">-</FONT></TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31,
2020 and 2019, the Company was domiciled in Texas, and due to the losses generated and no revenues, it incurred no federal or state
tax.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The tax effect of the
temporary differences that give rise to the significant portions of the deferred tax assets and liabilities is presented below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid">2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify">Deferred tax assets</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: justify; padding-left: 9pt">Depreciation</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">502</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 9pt">Research and development credits</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">180,889</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">93,102</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 9pt">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">257,941</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,695</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Net operating loss carryforwards</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,417,169</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,366,040</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 9pt">Deferred tax asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,855,999</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,484,340</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Less: valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(2,849,762</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,484,340</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Net deferred tax asset</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,237</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">Deferred tax liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Fixed assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(6,237</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 4pt">Net deferred tax assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Due to a history
of losses we have generated since inception, we believe it is more-likely-than-not that all of the deferred tax assets will
not be realized as of December 31, 2020 and 2019. Therefore, we have recorded a full valuation allowance on our deferred tax
assets. At December 31, 2020 and 2019, we have net operating loss (&ldquo;NOL&rdquo;) carryforwards for federal income tax
purposes of approximately $11.5 million and $6.5 million, respectively. The NOL carryforwards generated prior to 2018 of
approximately $3.1 million could expire over time beginning in 2035, if not used. The NOL carryforwards generated in 2018 to
2020 of $8.4 million do not expire and are carried forward indefinitely. We also have state NOLs of approximately $71,000 at
December 31, 2020. The Company also has approximately $181,000 of research and development tax credit carryforwards for
federal purposes. These credits begin expiring in 2034. Due to the change in ownership provisions of the Internal Revenue
Code, the availability of the Company&rsquo;s NOL carryforwards and research and development credit carryforwards may be
subject to annual limitations under Section 382 of the Internal Revenue Code against taxable income in the future period,
which could substantially limit the eventual utilization of such carryforwards.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Entities are also required
to evaluate, measure, recognize and disclose any uncertain income tax provisions taken on their income tax returns. The Company
has analyzed its tax positions and has concluded that as of December 31, 2020, there were no uncertain positions. In addition,
interest and penalties, if any, as they relate to income taxes assessed, are included in the income tax provision, for which there
were none. The Company&rsquo;s U.S. federal operating losses have occurred since its inception and as such, tax years subject to
potential tax examination could apply from that date because the utilization of net operating losses from prior years opens the
relevant year to audit by the IRS and/or state taxing authorities.</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Note 12. Subsequent Events</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 20, 2021,
the Company closed a public offering of 4,928,571 shares of its common stock at a public offering price of $14.00 per share, which
amount included 642,856 shares sold upon full exercise of the underwriter&rsquo;s over-allotment option. Total gross proceeds from
the offering were $68,999,994, and net proceeds from the offering were approximately $64,200,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 149; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #211D1E"><B><A NAME="aa_015"></A>Item 9. Changes in
and Disagreements with Accountants on Accounting and Financial Disclosure.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #211D1E"><B><A NAME="aa_016"></A>Item 9A. Controls and
Procedures.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management, with
the participation of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial
officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2020. The term
&ldquo;disclosure controls and procedures,&rdquo; as defined in Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)&nbsp;under the Securities
Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure
that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded,
processed, summarized and reported, within the time periods specified in the SEC&rsquo;s rules and forms. Disclosure controls
and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed
by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&rsquo;s
management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding
required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide
only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit
relationship of possible controls and procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The closing of our
initial public offering occurred on June 15, 2020. Consequently, as a newly reporting company under the Exchange Act, we are not
required to evaluate the effectiveness of our internal controls over financial reporting until the end of the fiscal year after
we file our first annual report on Form 10-K, which will occur on December 31, 2021. However, in connection with the audit of
our financial statements for the years ended December 31, 2019 and 2018, prior to our initial public offering, we observed material
weaknesses in our internal controls over financial reporting during those periods because we did not have a formal process for
period end financial closing and reporting, and also because we historically had insufficient resources to conduct an effective
monitoring and oversight function independent from our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During 2020, we have
taking several measures to address these weaknesses, including implementation of additional internal control processes and procedures
regarding the financial close and reporting process, the recruitment of a full time Chief Financial Officer, the allocation of
additional personnel and resources to support our finance function, and the conduct of additional monitoring and evaluation processes.
Following the implementation of these remedial actions, and based on the monitoring and evaluation we have conducted, our management
has determined that, as of December 31, 2020, the previously identified material weaknesses have been remediated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the evaluation
of our disclosure controls and procedures as of December 31, 2020, our Chief Executive Officer and Chief Financial Officer have
concluded that, as of such date, our disclosure controls and procedures, as defined above, are effective.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Annual Report
on Form 10-K does not include a report of management&rsquo;s assessment regarding internal control over financial reporting or
an attestation report of the Company&rsquo;s registered public accounting firm due to a transition period established by rules
of the Securities and Exchange Commission for newly public companies. In accordance with such rules, the report of management&rsquo;s
assessment and the attestation report will be included as part of our Annual Report on Form 10-K for the year ending December
31, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #211D1E"><B><A NAME="aa_017"></A>Item 9B. Other Information.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 150; Options: NewSection; Value: 126 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->126<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="aa_018"></A>PART III</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #211D1E"><B><A NAME="aa_019"></A>Item 10. Directors, Executive Officers and
Corporate Governance.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information required
by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to our
annual meeting of stockholders to be held in 2021 (the &ldquo;2021 Annual Meeting of Stockholders&rdquo;), which we intend to
file with the SEC within 120 days of the year ended December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #211D1E"><B><A NAME="aa_020"></A>Item 11. Executive
Compensation.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information required
by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the
2021 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days of the year ended December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #211D1E"><B><A NAME="aa_021"></A>Item 12. Security Ownership
of Certain Beneficial Owners and Management and Related Stockholder Matters.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information required
by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the
2021 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days of the year ended December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #211D1E"><B><A NAME="aa_022"></A>Item 13. Certain Relationships
and Related Transactions, and Director Independence.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information required
by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the
2021 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days of the year ended December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #211D1E"><B><A NAME="aa_023"></A>Item 14. Principal
Accountant Fees and Services.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information required
by this Item is incorporated herein by reference to the information that will be contained in our proxy statement related to the
2021 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days of the year ended December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 151; Value: 126 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->127<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="aa_024"></A>PART IV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #211D1E"><B><A NAME="aa_025"></A>Item 15. Exhibit and Financial Statement
Schedules.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(a) The following documents are filed as part of this report:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(1)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Financial
                                         Statements</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 90%"><A HREF="#fin_001">Report of Independent Registered Public Accounting Firm</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: center">F-2</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#fin_002">Consolidated Balance Sheets &ndash; December 31, 2020 and 2019</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">F-3</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#fin_003">Consolidated Statements of Operations for the Years Ended December 31, 2020 and 2019</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">F-4</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#fin_004">Consolidated Statements of Stockholders&rsquo; Equity
    (Deficit) for the Years Ended December 31, 2020 and 2019</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">F-5</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#fin_005">Consolidated Statements of Cash Flow for the Years Ended December 31, 2020 and 2019</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">F-6</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><A HREF="#fin_006">Notes to Consolidated Financial Statements</A></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">F-7</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(2)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Financial
                                         Statement Schedules</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">All financial statement schedules are
omitted because the information called for is not required or is shown either in the consolidated financial statements or in the
notes thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">(3)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Exhibits</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following exhibits
are filed herewith or incorporated by reference herein:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: justify">Exhibit
    No.</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 86%; text-align: justify">Description</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">3.1.(i)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">(a)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1763950/000121390020009332/ea120601fs1ex3-1i_lantern.htm">Certificate of Conversion (Texas)</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">3.1.(ii)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">(a)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1763950/000121390020009332/ea120601fs1ex3-1ii_lantern.htm">Certificate of Conversion (Delaware)</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">3.1(iii)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">(a)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1763950/000121390020009332/ea120601fs1ex3-1iii_lantern.htm">Certificate of Incorporation</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">3.1.(iv)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">(b)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1763950/000121390020015132/ea123112ex3-1iv_lantern.htm">Certificate of Amendment to Certificate of Incorporation</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">3.1(v)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">(b)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1763950/000121390020015132/ea123112ex3-1v_lantern.htm">Amended and Restated Certificate of Incorporation</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">3.1.(vi)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">(a)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1763950/000121390020009332/ea120601fs1ex3-1iv_lantern.htm">By-laws</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">4.1.(i)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">(a)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1763950/000121390020009332/ea120601fs1ex4-1i_lantern.htm">Form of Warrant (2014)</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">4.1.(ii)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">(a)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1763950/000121390020009332/ea120601fs1ex4-1ii_lantern.htm">Form of Warrant (2017)</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">4.1.(iii)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">(a)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1763950/000121390020009332/ea120601fs1ex4-1iii_lantern.htm">Form of Warrant (2019)</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">4.1.(iv)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">(c)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1763950/000121390020012863/ea122016ex4-1iv_lantern.htm">Form of Amendment to Series A Preferred Stock Warrant</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">4.1 (v)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">(i)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1763950/000121390020012863/ea122016ex1-1_lantern.htm" STYLE="-sec-extract: exhibit">Form of Underwriters&rsquo; Warrant (2020)</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">4.2</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">(d)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1763950/000121390020011747/ea121606ex4-2_lanternpharma.htm">Specimen Stock Certificate evidencing shares of common stock</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">4.3*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="f10k2020ex4-3_lantern.htm">Description of Capital Stock</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.1+</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">(e)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1763950/000121390020023177/ea125821ex99-1_lanternpha.htm">Amended and Restated 2018 Equity Incentive Plan dated August 19, 2020</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.2+</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">(a)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1763950/000121390020009332/ea120601fs1ex10-2_lantern.htm">Employment Agreement dated July 23, 2018 with Panna Sharma</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.3+</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">(f)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1763950/000121390020014351/ea122762ex10-3_lanternpharma.htm">Amendment to Employment Agreement dated May 18, 2020 with Panna Sharma</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.4+</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">(c)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1763950/000121390020012863/ea122016ex10-4_lantern.htm">Employment Agreement dated May 18, 2020 with David Margrave</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.5+</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">(a)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1763950/000121390020009332/ea120601fs1ex10-3_lantern.htm">Form of Indemnification Agreement</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.6</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">(a)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1763950/000121390020009332/ea120601fs1ex10-4_lantern.htm">Amended and Restated Investors&rsquo; Rights Agreement</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.7#</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">(a)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1763950/000121390020009332/ea120601fs1ex10-7_lantern.htm">Technology License Agreement dated January 15, 2015, with AF Chemicals, LLC</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.8#</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">(a)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1763950/000121390020009332/ea120601fs1ex10-8_lantern.htm">Drug License and Development Agreement dated as of May 23, 2015 with Allarity Therapeutics A/S (f/k/a Oncology Venture A/S)</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.9#</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">(a)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1763950/000121390020009332/ea120601fs1ex10-9_lantern.htm">Addendum to Drug License and Development Agreement with Allarity Therapeutics A/S (f/k/a Oncology Venture A/S dated February 8, 2016)</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.10#</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">(a)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1763950/000121390020009332/ea120601fs1ex10-10_lantern.htm">Amendment No. 2 to Drug License and Development Agreement with Allarity Therapeutics A/S (f/k/a Oncology Venture A/S) dated February 11, 2016</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.11#</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">(a)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1763950/000121390020009332/ea120601fs1ex10-11_lantern.htm">Assignment Agreement dated as of January 5, 2018 with BioNumerik Pharmaceuticals, Inc.</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.12#</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">(a)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1763950/000121390020009332/ea120601fs1ex10-12_lantern.htm">Addendum to Technology License Agreement dated February 8, 2016, with AF Chemicals, LLC</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.14+</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">(c)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1763950/000121390020012863/ea122016ex10-16_lantern.htm">Employment Agreement dated May 18, 2020 with Kishor G Bhatia</A></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 152; Value: 126 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->128<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 10%">10.15</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 4%">(g)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 86%"><A HREF="http://www.sec.gov/Archives/edgar/data/1763950/000121390020033954/f10q0920ex10-1_lantern.htm">API Services Project Agreement dated July 10, 2020 with Patheon API Service</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.16#</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">(h)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1763950/000121390021001239/ea132545ex10-16_lanternpharm.htm" STYLE="-sec-extract: exhibit">Second Addendum to Technology License Agreement dated December 30, 2020 with AF Chemicals, LLC</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">10.17*</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="f10k2020ex10-17_lantern.htm">Amendment to Employment Agreement dated February
    18, 2021 with Kishor G. Bhatia</A></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">21.1</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">(a)</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="https://www.sec.gov/Archives/edgar/data/1763950/000121390020009332/ea120601fs1ex21-1_lantern.htm">List of Subsidiaries</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">31.1*</FONT></TD>
    <TD STYLE="width: 94%; text-align: justify"><A HREF="f10k2020ex31-1_lantern.htm"><FONT STYLE="font-size: 10pt">Certification of Principal Executive Officer Pursuant
    to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley
    Act of 2002.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">31.2*</FONT></TD>
    <TD STYLE="text-align: justify"><A HREF="f10k2020ex31-2_lantern.htm"><FONT STYLE="font-size: 10pt">Certification of Principal Financial Officer Pursuant to Rules
    13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley
    Act of 2002.</FONT></A></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-size: 10pt">32.1**</FONT></TD>
    <TD STYLE="text-align: justify"><A HREF="f10k2020ex32-1_lantern.htm"><FONT STYLE="font-size: 10pt">Certifications of Principal Executive Officer and Principal
    Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of
    2002.</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">101.INS*</FONT></TD>
    <TD STYLE="text-align: justify; width: 90%"><FONT STYLE="font-size: 10pt">XBRL Instance Document</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">101.SCH*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">XBRL Taxonomy Extension Schema</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">101.CAL*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">XBRL Taxonomy Extension Calculation Linkbase</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">101.DEF*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">XBRL Taxonomy Extension Definition Linkbase</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">101.LAB*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">XBRL Taxonomy Extension Label Linkbase</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">101.PRE*</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">XBRL Taxonomy Extension Presentation Linkbase</FONT></TD></TR>
</TABLE>
<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 12pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">(a)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated
                                         by reference from the Registration Statement on Form S-1 filed April 16, 2020.</FONT></TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">(b)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated
                                         by reference from Current Report on Form 8-K filed June 17, 2020.</FONT></TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">(c)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated
                                         by reference from the Registration Statement on Form S-1/A filed May 19, 2020.</FONT></TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">(d)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated
                                         by reference from the Registration Statement on Form S-1/A filed May 12, 2020.</FONT></TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">(e)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated
                                         by reference from Current Report on Form 8-K filed August 21, 2020.</FONT></TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">(f)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated
                                         by reference from the Registration Statement on Form S-1/A filed June 8, 2020.</FONT></TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">(g)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated
                                         by reference from Quarterly Report on Form 10-Q for the period ending September 30, 2020.</FONT></TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
                                         by reference from the Registration Statement on Form S-1 filed January 8, 2021.</FONT></TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
                                     by reference from Exhibit 1.1 of the Registration Statement on Form S-1/A filed May 19, 2020.</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">+</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
                                         a management control or any compensatory plan, contract or arrangement.</FONT></TD>
</TR>
<TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">#</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Certain
                                         confidential portions of this Exhibit were omitted by means of marking such portions
                                         with an asterisk (the Mark) because the identified confidential portions (i) are not
                                         material and (ii) are of the type that the Registrant treats as private and confidential.</FONT></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">Filed herewith.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">**</TD><TD STYLE="text-align: justify">Furnished with
                                         this report</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; color: #211D1E"><B><A NAME="aa_026"></A>Item 16. Form 10&ndash;K
Summary.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 153; Value: 126 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->129<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #211D1E">Pursuant to <FONT STYLE="color: #211D1E">the
requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly authorized</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; color: #211D1E">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">Lantern Pharma Inc.,</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 60%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 4%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 36%">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">A Delaware Corporation</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Dated:&nbsp;&nbsp;March 10, 2021</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">By:</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">/s/ Panna Sharma</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Panna Sharma, Chief Executive Officer</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Dated:&nbsp;&nbsp;March 10, 2021</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">By:</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">/s/ David R. Margrave</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">David R. Margrave, Chief Financial Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: #211D1E">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; color: #211D1E">Pursuant to the requirements
of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant
and in the capacities and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%">
<TR>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-top: 0; padding-right: 0; padding-left: 0; vertical-align: bottom; width: 38%; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name</B></FONT></TD>
    <TD STYLE="padding: 0 0 1.5pt; vertical-align: top; width: 2%; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-top: 0; padding-right: 0; padding-left: 0; vertical-align: top; width: 38%; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="padding: 0 0 1.5pt; vertical-align: top; width: 2%; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-top: 0; padding-right: 0; padding-left: 0; vertical-align: top; width: 20%; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
<TR>
    <TD STYLE="padding: 0; vertical-align: bottom; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="padding: 0; vertical-align: bottom; border-bottom: black 1.5pt solid; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Panna Sharma</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President,
Chief Executive Officer and Director</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: bottom; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    10, 2021</FONT></TD></TR>
<TR>
    <TD STYLE="padding: 0; vertical-align: bottom; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Panna Sharma</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Principal
    Executive Officer)</I></FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="padding: 0; vertical-align: bottom; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="padding: 0; vertical-align: bottom; border-bottom: black 1.5pt solid; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
David R. Margrave</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: bottom; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: bottom; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    10, 2021</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David R. Margrave</FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<I>Principal Financial and Principal Accounting
    Officer</I>)</FONT></TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="padding: 0; vertical-align: bottom; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="padding: 0; border-bottom: black 1.5pt solid; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Donald J. Keyser</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="padding: 0; vertical-align: bottom; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Donald J. Keyser</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
    of the Board</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: bottom; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: bottom; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    10, 2021</FONT></TD></TR>
<TR>
    <TD STYLE="padding: 0; vertical-align: bottom; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="padding: 0; border-bottom: black 1.5pt solid; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Leslie W. Kreis, Jr.</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="padding: 0; vertical-align: bottom; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leslie W. Kreis,
    Jr.</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: bottom; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: bottom; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    10, 2021</FONT></TD></TR>
<TR>
    <TD STYLE="padding: 0; vertical-align: bottom; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: bottom; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: bottom; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="padding: 0; border-bottom: black 1.5pt solid; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
David S. Silberstein</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: bottom; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: bottom; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="padding: 0; vertical-align: bottom; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David S. Silberstein</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: bottom; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    10, 2021</FONT></TD></TR>
<TR>
    <TD STYLE="padding: 0; vertical-align: bottom; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: bottom; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: bottom; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: bottom; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="padding: 0; border-bottom: black 1.5pt solid; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Vijay Chandru</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: bottom; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: bottom; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: bottom; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="padding: 0; vertical-align: bottom; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vijay Chandru</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: bottom; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: bottom; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    10, 2021</FONT></TD></TR>
<TR>
    <TD STYLE="padding: 0; vertical-align: bottom; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: bottom; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: bottom; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="padding: 0; border-bottom: black 1.5pt solid; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Franklyn Prendergast</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: bottom; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: bottom; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="padding: 0; vertical-align: bottom; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Franklyn Prendergast</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: bottom; text-align: justify; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; vertical-align: bottom; text-align: center; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    10, 2021</FONT></TD></TR>
</TABLE>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">130</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>f10k2020ex4-3_lantern.htm
<DESCRIPTION>DESCRIPTION OF CAPITAL STOCK
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 4.3</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DESCRIPTION OF CAPITAL STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Lantern Pharma (&ldquo;Company&rdquo;,
&ldquo;we&rdquo;, &ldquo;us&rdquo; and &ldquo;our&rdquo;) has one class of securities registered under Section 12 of the Securities
Exchange Act of 1934, as amended, namely our common stock, par value $0.0001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">The following is a
summary of the rights of our common and of certain provisions of our Amended and Restated Certificate of Incorporation (&ldquo;Certificate
of Incorporation&rdquo;) and Bylaws (&ldquo;Bylaws&rdquo;). For more detailed information, please see our Certificate of Incorporation
and Bylaws, which are incorporated by reference as exhibits to the Annual Report on Form 10-K to which this description is an exhibit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Our Certificate of Incorporation
authorizes us to issue up to 25,000,000 shares of common stock, $0.0001 par value per share. As of March 8, 2021, we had 11,169,665
shares of common stock outstanding, held by  26 stockholders of record.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Holders of shares of
common stock are entitled to one vote per share on all matters to be voted upon by the stockholders generally. Stockholders are
entitled to receive such dividends as may be declared from time to time by the Board out of funds legally available therefore,
and in the event of liquidation, dissolution or winding up of the company to share ratably in all assets remaining after payment
of liabilities. The holders of shares of common stock have no preemptive, conversion, subscription rights or cumulative voting
rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">Our Certificate of Incorporation
authorizes us to issue up to 1,000,000 shares of preferred stock, $0.0001 par value per share, of which no shares were issued or
outstanding as of March 8, 2021, Our board of directors is authorized to issue from time to time, without stockholder authorization,
in one or more designated series or classes, any or all of the authorized but unissued shares of preferred stock with such dividend,
redemption, conversion and exchange provisions as may be provided in the particular series. Any series of preferred stock may possess
voting, dividend, liquidation and redemption rights superior to that of the common stock. The rights of the holders of common stock
will be subject to and may be adversely affected by the rights of the holders of any preferred stock that may be issued in the
future. Issuance of a new series of preferred stock, while providing desirable flexibility in connection with possible acquisition
and other corporate purposes, could make it more difficult for a third party to acquire, or discourage a third party from acquiring,
a majority of the outstanding voting stock of our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Dividends</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">We have never paid cash
dividends on our common stock and we do not anticipate the payment of cash dividends on our common stock in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Anti-Takeover Effects of Certain Provisions of Delaware Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">We are subject to the
provisions of Section 203 of the Delaware General Corporation Law, or DGCL, an anti-takeover law. In general, Section 203 prohibits
a publicly held Delaware corporation from engaging in a &ldquo;business combination&rsquo;&rsquo; with an &ldquo;interested stockholder&rsquo;&rsquo;
for a period of three years after the date of the transaction in which such stockholder became an interested stockholder, unless
the business combination is approved in a prescribed manner. For purposes of Section 203, a &ldquo;business combination&rsquo;&rsquo;
includes a merger, asset sale or other transaction resulting in a financial benefit to the interested stockholder, and an &ldquo;interested
stockholder&rsquo;&rsquo; is a stockholder who, together with affiliates and associates, owns, or within three years prior, did
own, 15% or more of the voting stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The transfer agent
and registrar for our common stock is VStock Transfer, LLC, 18 Lafayette Place Woodmere, New York 11598.</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>3
<FILENAME>f10k2020ex10-17_lantern.htm
<DESCRIPTION>AMENDMENT TO EMPLOYMENT AGREEMENT DATED FEBRUARY 18, 2021 WITH KISHOR G. BHATIA
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: right"><B>Exhibit 10.17</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 112.9pt 0pt 112pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 112.9pt 0pt 112pt; text-align: center">AMENDMENT TO EMPLOYMENT
AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This AMENDMENT TO EMPLOYMENT AGREEMENT
(this &ldquo;Amendment&rdquo;), is entered into as of March 4, 2021 and amends the Employment Agreement, dated as of June 16, 2020
(the &ldquo;<B><I>Employment Agreement</I></B>&rdquo;), between Lantern Pharma Inc. (the &ldquo;<B><I>Company</I></B>&rdquo;) and
Kishor G. Bhatia (&ldquo;<B><I>Executive</I></B>&rdquo;). The Company and Executive may be referred to herein individually as a
&ldquo;<B><I>Party</I></B>&rdquo; or collectively as the &ldquo;<B><I>Parties</I></B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 112.85pt 0pt 112pt; text-align: center"><I>RECITALS</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 5pt; text-align: justify; text-indent: 0.5in"><I>WHEREAS</I>,
the Company and Executive have entered into the Employment Agreement, dated as of June 16, 2020, wherein the Company employed Executive
as the Company&rsquo;s Chief Scientific Officer; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="margin: 0pt 0pt 0pt 5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify; text-indent: 0.5in"><I>WHEREAS, </I>the
Company and Executive wish to amend the Employment Agreement to increase the minimum number of hours devoted by Executive per week
to the scientific, clinical and therapeutic development operations, and affairs of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5pt; text-indent: 0.5in">NOW THEREFORE, in consideration
of the mutual covenants set forth herein and other legal and valuable consideration, the Parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 41pt"></TD><TD STYLE="width: 36pt"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD>Section 1.3 of the Employment Agreement is hereby amended to read in its entirety as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 41pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 41pt; text-align: justify">&ldquo;<U>Duties</U>. Executive
shall have such authority and duties as are usual and customary for the position described in Section 1.1. Executive shall perform
such other services and duties as the Company may from time to time designate, provided that such services and duties are consistent
with Executive&rsquo;s present duties. Prior to March 4, 2021, Executive shall devote a minimum of 20 hours per week to the scientific,
clinical and therapeutic development operations, and affairs of the Company. Commencing March 4, 2021, Executive shall devote a
minimum of 26.67 hours per week to the scientific, clinical and therapeutic development operations, and affairs of the Company.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.5pt"></TD><TD STYLE="width: 31.5pt"><FONT STYLE="font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify; padding-right: 15.35pt">Section I of Exhibit A to the Employment Agreement is hereby amended to
read in its entirety as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 40.5pt; text-align: justify">&ldquo;<U>Initial Base Salary</U>.
The Company shall pay Executive an initial pre-tax base salary (&ldquo;<B><I>Initial Base Salary</I></B>&rdquo;) of $100,000 (One
Hundred Thousand U.S. Dollars) per annum, less all applicable withholdings, with such Initial Base Salary to be paid in accordance
with the Company&rsquo;s standard payroll practices. Commencing March 4, 2021, the Initial Base Salary shall be increased to $133,333
(One Hundred Thirty Three Thousand Three Hundred Thirty Three U.S. Dollars) per annum, less all applicable withholdings, with such
increased Initial Base Salary to be paid in accordance with the Company&rsquo;s standard payroll practices with respect to pay
periods (or applicable portions thereof) during the Term of this Agreement that occur on or after March 4, 2021.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 40.5pt"></TD><TD STYLE="width: 31.5pt"><FONT STYLE="font-size: 10pt">3.</FONT></TD><TD STYLE="padding-right: 10.95pt">All other terms of and conditions to the Employment Agreement shall continue in full force and
effect.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: left; width: 100%"><PAGE></PAGE></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; margin-left: 5pt; text-indent: 0.5in">IN WITNESS WHEREOF, the Parties
have executed this Amendment to be effective as of March 4, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><U>COMPANY:</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>Lantern Pharma Inc.</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">/s/ Panna Sharma</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Panna Sharma</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt">Chief Executive Officer</P>
</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><U>EXECUTIVE</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">/s/ Kishor G. Bhatia</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Kishor
G. Bhatia</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>f10k2020ex31-1_lantern.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Panna Sharma, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">I have reviewed this annual report on Form 10-K of Lantern Pharma Inc.;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or
omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this
report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant
as of, and for, the periods presented in this report;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(4)</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)&nbsp;and 15d-15(e)) and internal control over financial
reporting (as defined in Exchange Act Rules&nbsp;13a-15(f) and 15d-15(f)) for the company and have:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">designed such disclosure controls and procedures, or caused such disclosure controls and procedures
to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
prepared;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented
in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the period covered by this
report based on such evaluation; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting
that occurred during the registrant&rsquo;s most recent quarter (the registrant&rsquo;s fourth quarter in the case of an annual
report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over
financial reporting; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(5)</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of registrant&rsquo;s
board of directors (or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">all significant deficiencies and material weaknesses in the design or operation of internal control
over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize
and report financial information; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">any fraud, whether or not material, that involves management or other employees who have a significant
role in the registrant&rsquo;s internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>LANTERN PHARMA INC.</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Date:&nbsp;March 10, 2021</FONT></TD>
    <TD STYLE="width: 4%; font-size: 10pt"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><I>/s/&nbsp;Panna Sharma</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Panna Sharma, Chief Executive Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Principal Executive Officer)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>f10k2020ex31-2_lantern.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, David R. Margrave, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">I have reviewed this annual report on Form 10-K of Lantern Pharma Inc.;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue statement of a material fact or
omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this report;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial information included in this
report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant
as of, and for, the periods presented in this report;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(4)</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) and internal control over
financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f)) for the company and have:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">designed such disclosure controls and procedures, or caused such disclosure controls and procedures
to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
prepared;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: justify">evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented
in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the period covered by this
report based on such evaluation; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: justify">disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting
that occurred during the registrant&rsquo;s most recent quarter (the registrant&rsquo;s fourth quarter in the case of an annual
report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over
financial reporting; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(5)</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s)&nbsp;and I have disclosed, based on our most
recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of registrant&rsquo;s
board of directors (or persons performing the equivalent functions):</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">all significant deficiencies and material weaknesses in the design or operation of internal control
over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize
and report financial information; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">any fraud, whether or not material, that involves management or other employees who have a significant
role in the registrant&rsquo;s internal control over financial reporting.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>LANTERN PHARMA INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-size: 10pt">Date:&nbsp;March 10, 2021</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%"><FONT STYLE="font-size: 10pt">/s/&nbsp;<I>David R. Margrave</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">David R. Margrave, Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">(Principal Financial Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>f10k2020ex32-1_lantern.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>18 U.S.C. ss.1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AS ADOPTED PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECTION&nbsp;906 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Annual Report of
Lantern Pharma Inc. (the &ldquo;Company&rdquo;) on Form&nbsp;10-K for the period ended December&nbsp;31, 2020 as filed with the
Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Panna Sharma, the Chief Executive Officer,
and David R. Margrave, the Chief Financial Officer, of the Company, respectively, certify, pursuant to 18 U.S.C. &sect;1350, as
adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">The Report fully complies with the requirements of Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the
Securities Exchange Act of 1934; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">The information contained in the Report fairly presents, in all material respects, the financial
condition and results of operations of the Company.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 4%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top; width: 36%"><FONT STYLE="font-size: 10pt">/s/ <I>Panna Sharma</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 20%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 40%"><FONT STYLE="font-size: 10pt">Dated:&nbsp;March 10, 2021</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Panna Sharma</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Title:&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Principal Executive Officer)</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: top"><FONT STYLE="font-size: 10pt">/s/ <I>David R. Margrave</I></FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Dated:&nbsp;March 10, 2021</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">David R. Margrave</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="vertical-align: top">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Financial Officer</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(Principal Financial and<BR>
Accounting Officer)</P></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This certification is made solely for the
purposes of 18 U.S.C. Section&nbsp;1350, subject to the knowledge standard contained therein, and not for any other purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>ltrn-20201231.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Mar 10 03:43:46 EST 2021 -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ltrn="http://laternpharma.com/20201231" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:compsci="http://compsciresources.com" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="ltrn-20201231.xsd"/>
  <context id="c0_From1Jan2020To31Dec2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c1_AsOf8Mar2021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <instant>2021-03-08</instant>
    </period>
  </context>
  <context id="c2_AsOf30Jun2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="c3_AsOf31Dec2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c4_AsOf31Dec2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c5_AsOf31Dec2020_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c6_AsOf31Dec2019_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c7_From1Jan2019To31Dec2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c8_AsOf31Dec2018_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c9_AsOf31Dec2018_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c10_AsOf31Dec2018_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c11_AsOf31Dec2018_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c12_AsOf31Dec2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c13_From1Jan2019To31Dec2019_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c14_From1Jan2019To31Dec2019_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c15_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c16_From1Jan2019To31Dec2019_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c17_AsOf31Dec2019_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c18_AsOf31Dec2019_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c19_AsOf31Dec2019_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c20_AsOf31Dec2019_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c21_From1Jan2020To31Dec2020_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c22_From1Jan2020To31Dec2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c23_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c24_From1Jan2020To31Dec2020_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c25_AsOf31Dec2020_PreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c26_AsOf31Dec2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c27_AsOf31Dec2020_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c28_AsOf31Dec2020_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c29_AsOf15Jan2020_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-01-15</instant>
    </period>
  </context>
  <context id="c30_AsOf15Jan2020_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-01-15</instant>
    </period>
  </context>
  <context id="c31_From1Jan2021To20Jan2021_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-01-20</endDate>
    </period>
  </context>
  <context id="c32_AsOf20Jan2021_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-01-20</instant>
    </period>
  </context>
  <context id="c33_From1Jan2021To20Jan2021_SubsequentEventMember_OverAllotmentOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-01-20</endDate>
    </period>
  </context>
  <context id="c34_AsOf31Dec2020_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c35_From28Apr2020To1May2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <startDate>2020-04-28</startDate>
      <endDate>2020-05-01</endDate>
    </period>
  </context>
  <context id="c36_From4Jan2021To31Jan2021_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-04</startDate>
      <endDate>2021-01-31</endDate>
    </period>
  </context>
  <context id="c37_AsOf31Jan2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <instant>2018-01-31</instant>
    </period>
  </context>
  <context id="c38_From1Jan2020To31Dec2020_BioNumerikPharmaceuticalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ltrn:BioNumerikPharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c39_AsOf31Dec2020_PatentsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c40_AsOf31Dec2019_PatentsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c41_From1Jan2020To31Dec2020_PatentsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c42_AsOf31Dec2020_BioNumerikPharmaceuticalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ltrn:BioNumerikPharmaceuticalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c43_From1Jan2020To31Dec2020_LP184Member_AFChemicalsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ltrn:LP184Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ltrn:AFChemicalsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c44_From1Jan2020To31Dec2020_AFChemicalsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ltrn:AFChemicalsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c45_From1Jan2020To31Dec2020_AFChemicalsMember_LP100Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ltrn:AFChemicalsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ltrn:LP100Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c46_From1Jan2019To31Dec2019_AFChemicalsMember_LP100Member">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ltrn:AFChemicalsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ltrn:LP100Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c47_From1Jan2020To31Dec2020_EUGrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ltrn:EUGrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c48_From1Jan2020To31Dec2020_PatheonAPIServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ltrn:PatheonAPIServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c49_From1Jan2020To31Dec2020_SouthwestResearchInstituteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ltrn:SouthwestResearchInstituteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c50_From1Jan2019To31Dec2019_SouthwestResearchInstituteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ltrn:SouthwestResearchInstituteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c51_AsOf31Dec2020_SouthwestResearchInstituteMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">ltrn:SouthwestResearchInstituteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c52_From1Aug2019To31Aug2019_PropertySubjectToOperatingLeaseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:PropertySubjectToOperatingLeaseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-08-01</startDate>
      <endDate>2019-08-31</endDate>
    </period>
  </context>
  <context id="c53_From1Jun2020To15Jun2020_SeriesAPreferredStockMember_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2020-06-15</endDate>
    </period>
  </context>
  <context id="c54_From1Mar2019To31Mar2019_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-03-01</startDate>
      <endDate>2019-03-31</endDate>
    </period>
  </context>
  <context id="c55_AsOf31Mar2019_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-03-31</instant>
    </period>
  </context>
  <context id="c56_From1Jul2019To31Jul2019_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-07-01</startDate>
      <endDate>2019-07-31</endDate>
    </period>
  </context>
  <context id="c57_AsOf31Jul2019_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-07-31</instant>
    </period>
  </context>
  <context id="c58_AsOf15Jun2020_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-06-15</instant>
    </period>
  </context>
  <context id="c59_From1Jun2020To15Jun2020_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2020-06-15</endDate>
    </period>
  </context>
  <context id="c60_From1Jun2020To15Jun2020_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-06-01</startDate>
      <endDate>2020-06-15</endDate>
    </period>
  </context>
  <context id="c61_From1Jan2020To31Dec2020_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c62_AsOf31Dec2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c63_AsOf31Dec2019_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c64_From1Aug2018To29Aug2018_OptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ltrn:OptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-08-01</startDate>
      <endDate>2018-08-29</endDate>
    </period>
  </context>
  <context id="c65_From1Jan2020To31Dec2020_OptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ltrn:OptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c66_From1Jan2019To31Dec2019_OptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ltrn:OptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c67_AsOf31Dec2020_OptionsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ltrn:OptionsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c68_From1Jan2020To31Dec2020_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c69_AsOf31Dec2020_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c70_From1Jan2019To31Dec2019_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c71_AsOf31Dec2019_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c72_From1Jan2019To31Dec2019_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c73_From1Jan2020To31Dec2020_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c74_From1Jan2019To31Dec2019_SeriesAPreferredStockMember_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c75_From1Jan2019To31Dec2019_MaximumMember_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c76_From1Jan2020To31Dec2020_CommonStockMember_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c77_From1Jan2020To31Dec2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c78_From1Jan2020To31Dec2020_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c79_From1Jan2020To31Dec2020_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c80_From1Dec2018To31Dec2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <startDate>2018-12-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="c81_From1Jan2020To31Jan2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-01-31</endDate>
    </period>
  </context>
  <context id="c82_AsOf31Jan2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <instant>2020-01-31</instant>
    </period>
  </context>
  <context id="c83_From25Apr2020To1May2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
    </entity>
    <period>
      <startDate>2020-04-25</startDate>
      <endDate>2020-05-01</endDate>
    </period>
  </context>
  <context id="c84_From1Jan2019To31Dec2019_BiologicalMimeticsIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ltrn:BiologicalMimeticsIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c85_AsOf31Dec2020_IntuitionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ltrn:IntuitionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c86_From1Jan2019To31Dec2019_BioNumerikMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ltrn:BioNumerikMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c87_AsOf31Dec2019_BioNumerikMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ltrn:BioNumerikMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c88_AsOf31Dec2019_IntuitionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ltrn:IntuitionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c89_From1Jan2020To31Dec2020_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c90_From1Jan2019To31Dec2019_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c91_From1Jan2020To31Dec2020_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c92_From1Jan2019To31Dec2019_EmployeeStockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c93_From1Jan2020To31Dec2020_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c94_From1Jan2019To31Dec2019_SeriesAPreferredStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c95_AsOf31Dec2020_StateAndLocalJurisdictionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001763950</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <unit id="shares">
    <measure>xbrli:shares</measure>
  </unit>
  <unit id="usd">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="usdPershares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="pure">
    <measure>xbrli:pure</measure>
  </unit>
  <dei:AmendmentFlag contextRef="c0_From1Jan2020To31Dec2020">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="c0_From1Jan2020To31Dec2020">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="c0_From1Jan2020To31Dec2020">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="c0_From1Jan2020To31Dec2020">2020</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="c0_From1Jan2020To31Dec2020">2020-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="c0_From1Jan2020To31Dec2020">10-K</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="c0_From1Jan2020To31Dec2020">0001763950</dei:EntityCentralIndexKey>
  <dei:EntityCurrentReportingStatus contextRef="c0_From1Jan2020To31Dec2020">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityEmergingGrowthCompany contextRef="c0_From1Jan2020To31Dec2020">true</dei:EntityEmergingGrowthCompany>
  <dei:EntityExTransitionPeriod contextRef="c0_From1Jan2020To31Dec2020">false</dei:EntityExTransitionPeriod>
  <dei:EntityFileNumber contextRef="c0_From1Jan2020To31Dec2020">001-39318</dei:EntityFileNumber>
  <dei:EntityFilerCategory contextRef="c0_From1Jan2020To31Dec2020">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityIncorporationStateCountryCode contextRef="c0_From1Jan2020To31Dec2020">TX</dei:EntityIncorporationStateCountryCode>
  <dei:EntityInteractiveDataCurrent contextRef="c0_From1Jan2020To31Dec2020">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntityRegistrantName contextRef="c0_From1Jan2020To31Dec2020">Lantern Pharma Inc.</dei:EntityRegistrantName>
  <dei:EntityShellCompany contextRef="c0_From1Jan2020To31Dec2020">false</dei:EntityShellCompany>
  <dei:EntitySmallBusiness contextRef="c0_From1Jan2020To31Dec2020">true</dei:EntitySmallBusiness>
  <dei:EntityVoluntaryFilers contextRef="c0_From1Jan2020To31Dec2020">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="c0_From1Jan2020To31Dec2020">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityCommonStockSharesOutstanding unitRef="shares" contextRef="c1_AsOf8Mar2021" decimals="INF">11169665</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityPublicFloat unitRef="usd" contextRef="c2_AsOf30Jun2020" decimals="0">34733370</dei:EntityPublicFloat>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">19229232</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">1232030</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">1007690</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">788</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">20236922</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">1232818</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">21507</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">8758</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:DepositsAssetsNoncurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">101205</us-gaap:DepositsAssetsNoncurrent>
  <us-gaap:DepositsAssetsNoncurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">191000</us-gaap:DepositsAssetsNoncurrent>
  <us-gaap:Assets unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">20359634</us-gaap:Assets>
  <us-gaap:Assets unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">1432576</us-gaap:Assets>
  <us-gaap:AccountsPayableAndOtherAccruedLiabilities unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">552339</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
  <us-gaap:AccountsPayableAndOtherAccruedLiabilities unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">489292</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">552339</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">489292</us-gaap:LiabilitiesCurrent>
  <us-gaap:AccountsPayableCurrentAndNoncurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">108500</us-gaap:AccountsPayableCurrentAndNoncurrent>
  <us-gaap:AccountsPayableCurrentAndNoncurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:Liabilities unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">660839</us-gaap:Liabilities>
  <us-gaap:Liabilities unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">489292</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies unitRef="usd" contextRef="c3_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:CommitmentsAndContingencies unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:PreferredStockValue unitRef="usd" contextRef="c3_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:PreferredStockValue unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">244</us-gaap:PreferredStockValue>
  <us-gaap:CommonStockValue unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">622</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">198</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapital unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">32358068</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">7694547</us-gaap:AdditionalPaidInCapital>
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">-12659895</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">-6751705</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">19698795</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">943284</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">20359634</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">1432576</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:PreferredStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c5_AsOf31Dec2020_SeriesAPreferredStockMember" decimals="4">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c6_AsOf31Dec2019_SeriesAPreferredStockMember" decimals="4">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c5_AsOf31Dec2020_SeriesAPreferredStockMember" decimals="INF">1000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c6_AsOf31Dec2019_SeriesAPreferredStockMember" decimals="INF">3480000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c6_AsOf31Dec2019_SeriesAPreferredStockMember" decimals="INF">2438866</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding unitRef="shares" contextRef="c6_AsOf31Dec2019_SeriesAPreferredStockMember" decimals="INF">2438866</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c3_AsOf31Dec2020" decimals="4">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c4_AsOf31Dec2019" decimals="4">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">25000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c4_AsOf31Dec2019" decimals="INF">12180000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">6220927</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c4_AsOf31Dec2019" decimals="INF">1978269</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">6220927</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding unitRef="shares" contextRef="c4_AsOf31Dec2019" decimals="INF">1978269</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">3664965</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c7_From1Jan2019To31Dec2019" decimals="0">1475000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:ResearchAndDevelopmentInProcess unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">2243225</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:ResearchAndDevelopmentInProcess unitRef="usd" contextRef="c7_From1Jan2019To31Dec2019" decimals="0">953185</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">5908190</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c7_From1Jan2019To31Dec2019" decimals="0">2428185</us-gaap:OperatingExpenses>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-5908190</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c7_From1Jan2019To31Dec2019" decimals="0">-2428185</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">-1.37</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted unitRef="usdPershares" contextRef="c7_From1Jan2019To31Dec2019" decimals="2">-1.23</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">4304918</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted unitRef="shares" contextRef="c7_From1Jan2019To31Dec2019" decimals="INF">1978269</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c8_AsOf31Dec2018_PreferredStockMember" decimals="INF">1292952</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c8_AsOf31Dec2018_PreferredStockMember" decimals="0">129</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c9_AsOf31Dec2018_CommonStockMember" decimals="INF">1978269</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c9_AsOf31Dec2018_CommonStockMember" decimals="0">198</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c10_AsOf31Dec2018_AdditionalPaidInCapitalMember" decimals="0">4121395</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c11_AsOf31Dec2018_RetainedEarningsMember" decimals="0">-4323520</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c12_AsOf31Dec2018" decimals="0">-201798</us-gaap:StockholdersEquity>
  <ltrn:StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants unitRef="shares" contextRef="c13_From1Jan2019To31Dec2019_PreferredStockMember" decimals="INF">1145914</ltrn:StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants>
  <ltrn:StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants unitRef="usd" contextRef="c13_From1Jan2019To31Dec2019_PreferredStockMember" decimals="0">115</ltrn:StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants>
  <ltrn:StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants unitRef="usd" contextRef="c14_From1Jan2019To31Dec2019_CommonStockMember" xs:nil="true"/>
  <ltrn:StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants unitRef="usd" contextRef="c15_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" decimals="0">3455392</ltrn:StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants>
  <ltrn:StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants unitRef="usd" contextRef="c16_From1Jan2019To31Dec2019_RetainedEarningsMember" xs:nil="true"/>
  <ltrn:StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants unitRef="usd" contextRef="c7_From1Jan2019To31Dec2019" decimals="0">3455507</ltrn:StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c13_From1Jan2019To31Dec2019_PreferredStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c14_From1Jan2019To31Dec2019_CommonStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c15_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" decimals="0">117760</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c16_From1Jan2019To31Dec2019_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c7_From1Jan2019To31Dec2019" decimals="0">117760</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c13_From1Jan2019To31Dec2019_PreferredStockMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c14_From1Jan2019To31Dec2019_CommonStockMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c15_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c16_From1Jan2019To31Dec2019_RetainedEarningsMember" decimals="0">-2428185</us-gaap:NetIncomeLoss>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c17_AsOf31Dec2019_PreferredStockMember" decimals="INF">2438866</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c17_AsOf31Dec2019_PreferredStockMember" decimals="0">244</us-gaap:StockholdersEquity>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c18_AsOf31Dec2019_CommonStockMember" decimals="INF">1978269</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c18_AsOf31Dec2019_CommonStockMember" decimals="0">198</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c19_AsOf31Dec2019_AdditionalPaidInCapitalMember" decimals="0">7694547</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c20_AsOf31Dec2019_RetainedEarningsMember" decimals="0">-6751705</us-gaap:StockholdersEquity>
  <ltrn:CommonStockIssuedFromOfferingNetOfIssuanceCosts unitRef="usd" contextRef="c21_From1Jan2020To31Dec2020_PreferredStockMember" xs:nil="true"/>
  <ltrn:CommonStockIssuedFromOfferingNetOfIssuanceCostsinShares unitRef="shares" contextRef="c22_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">1750000</ltrn:CommonStockIssuedFromOfferingNetOfIssuanceCostsinShares>
  <ltrn:CommonStockIssuedFromOfferingNetOfIssuanceCosts unitRef="usd" contextRef="c22_From1Jan2020To31Dec2020_CommonStockMember" decimals="0">175</ltrn:CommonStockIssuedFromOfferingNetOfIssuanceCosts>
  <ltrn:CommonStockIssuedFromOfferingNetOfIssuanceCosts unitRef="usd" contextRef="c23_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="0">23419546</ltrn:CommonStockIssuedFromOfferingNetOfIssuanceCosts>
  <ltrn:CommonStockIssuedFromOfferingNetOfIssuanceCosts unitRef="usd" contextRef="c24_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <ltrn:CommonStockIssuedFromOfferingNetOfIssuanceCosts unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">23419721</ltrn:CommonStockIssuedFromOfferingNetOfIssuanceCosts>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross unitRef="shares" contextRef="c21_From1Jan2020To31Dec2020_PreferredStockMember" decimals="INF">-2438866</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
  <ltrn:StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment unitRef="usd" contextRef="c21_From1Jan2020To31Dec2020_PreferredStockMember" decimals="0">-244</ltrn:StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross unitRef="shares" contextRef="c22_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">2438848</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationGross>
  <ltrn:StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment unitRef="usd" contextRef="c22_From1Jan2020To31Dec2020_CommonStockMember" decimals="0">244</ltrn:StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment>
  <ltrn:StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment unitRef="usd" contextRef="c23_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="0">-261</ltrn:StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment>
  <ltrn:StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment unitRef="usd" contextRef="c24_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <ltrn:StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-261</ltrn:StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c21_From1Jan2020To31Dec2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c22_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">50460</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c22_From1Jan2020To31Dec2020_CommonStockMember" decimals="0">5</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c23_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="0">51995</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c24_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">52000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
  <ltrn:CashlessExerciseOfWarrantinShares unitRef="shares" contextRef="c21_From1Jan2020To31Dec2020_PreferredStockMember" xs:nil="true"/>
  <ltrn:CashlessExerciseOfWarrant unitRef="usd" contextRef="c21_From1Jan2020To31Dec2020_PreferredStockMember" xs:nil="true"/>
  <ltrn:CashlessExerciseOfWarrantinShares unitRef="shares" contextRef="c22_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">3350</ltrn:CashlessExerciseOfWarrantinShares>
  <ltrn:CashlessExerciseOfWarrant unitRef="usd" contextRef="c22_From1Jan2020To31Dec2020_CommonStockMember" xs:nil="true"/>
  <ltrn:CashlessExerciseOfWarrant unitRef="usd" contextRef="c23_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <ltrn:CashlessExerciseOfWarrant unitRef="usd" contextRef="c24_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <ltrn:CashlessExerciseOfWarrant unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c21_From1Jan2020To31Dec2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c22_From1Jan2020To31Dec2020_CommonStockMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c23_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="0">1192241</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c24_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">1192241</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensationGross>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c21_From1Jan2020To31Dec2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c22_From1Jan2020To31Dec2020_CommonStockMember" xs:nil="true"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbBx2uhymvyVLDa+1t8Zs6OCx+D0Bcy6Dt/X9wfJ64eyeWWDp4AwLD4hnV42U8gMPb6ZmoZskqs/VGWXFAW+VCwrstTEwsw9mBsjnLef0gxwD31/7ddIjxiai89b27Ur3wVtqpWYQb962vnZqopmU1PbSobqhOErLV5kQmlf1KTTNwUf5Cat3VqbECnqtaDVc/RdmuBuY2ba9Yw22yE5sq0] CSR-->
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c23_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c24_From1Jan2020To31Dec2020_RetainedEarningsMember" decimals="0">-5908190</us-gaap:NetIncomeLoss>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c25_AsOf31Dec2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c25_AsOf31Dec2020_PreferredStockMember" xs:nil="true"/>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c26_AsOf31Dec2020_CommonStockMember" decimals="INF">6220927</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c26_AsOf31Dec2020_CommonStockMember" decimals="0">622</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c27_AsOf31Dec2020_AdditionalPaidInCapitalMember" decimals="0">32358068</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c28_AsOf31Dec2020_RetainedEarningsMember" decimals="0">-12659895</us-gaap:StockholdersEquity>
  <us-gaap:DepreciationDepletionAndAmortization unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">3388</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization unitRef="usd" contextRef="c7_From1Jan2019To31Dec2019" decimals="0">1627</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">1192241</us-gaap:StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount>
  <us-gaap:StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount unitRef="usd" contextRef="c7_From1Jan2019To31Dec2019" decimals="0">117760</us-gaap:StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount>
  <us-gaap:IncreaseDecreaseInAccountsReceivable unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:IncreaseDecreaseInAccountsReceivable unitRef="usd" contextRef="c7_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:IncreaseDecreaseInPrepaidExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">1006902</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInPrepaidExpense unitRef="usd" contextRef="c7_From1Jan2019To31Dec2019" decimals="0">788</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInDeferredCharges unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">49325</us-gaap:IncreaseDecreaseInDeferredCharges>
  <us-gaap:IncreaseDecreaseInDeferredCharges unitRef="usd" contextRef="c7_From1Jan2019To31Dec2019" decimals="0">191000</us-gaap:IncreaseDecreaseInDeferredCharges>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">117167</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities unitRef="usd" contextRef="c7_From1Jan2019To31Dec2019" decimals="0">372663</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-5651621</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c7_From1Jan2019To31Dec2019" decimals="0">-2127923</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <ltrn:IncreaseDecreasePurchaseOfPropertyAndEquipment unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">16137</ltrn:IncreaseDecreasePurchaseOfPropertyAndEquipment>
  <ltrn:IncreaseDecreasePurchaseOfPropertyAndEquipment unitRef="usd" contextRef="c7_From1Jan2019To31Dec2019" decimals="0">5717</ltrn:IncreaseDecreasePurchaseOfPropertyAndEquipment>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-16137</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" contextRef="c7_From1Jan2019To31Dec2019" decimals="0">-5717</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">26250000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock unitRef="usd" contextRef="c7_From1Jan2019To31Dec2019" decimals="0">2920507</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <ltrn:IncreaseDecreaseIssuanceCosts unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">2745279</ltrn:IncreaseDecreaseIssuanceCosts>
  <ltrn:IncreaseDecreaseIssuanceCosts unitRef="usd" contextRef="c7_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:ProceedsFromStockPlans unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">52000</us-gaap:ProceedsFromStockPlans>
  <us-gaap:ProceedsFromStockPlans unitRef="usd" contextRef="c7_From1Jan2019To31Dec2019" xs:nil="true"/>
  <ltrn:ProceedsFromPreferredStockConvertedToCommonStockNetOfFractionalSharesAdjustment unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">261</ltrn:ProceedsFromPreferredStockConvertedToCommonStockNetOfFractionalSharesAdjustment>
  <us-gaap:ProceedsFromNotesPayable unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">169049</us-gaap:ProceedsFromNotesPayable>
  <us-gaap:ProceedsFromNotesPayable unitRef="usd" contextRef="c7_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:IncreaseDecreaseInAccountsPayable unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-169049</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable unitRef="usd" contextRef="c7_From1Jan2019To31Dec2019" xs:nil="true"/>
  <ltrn:IncreaseDecreaseInBorrowingsOnLoanPayable unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">108500</ltrn:IncreaseDecreaseInBorrowingsOnLoanPayable>
  <ltrn:IncreaseDecreaseInBorrowingsOnLoanPayable unitRef="usd" contextRef="c7_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">23664960</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c7_From1Jan2019To31Dec2019" decimals="0">2920507</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">17997202</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease unitRef="usd" contextRef="c7_From1Jan2019To31Dec2019" decimals="0">786867</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c12_AsOf31Dec2018" decimals="0">445163</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <ltrn:ConversionOfSafeAgreementsToSeriesPreferredStock unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <ltrn:ConversionOfSafeAgreementsToSeriesPreferredStock unitRef="usd" contextRef="c7_From1Jan2019To31Dec2019" decimals="0">535000</ltrn:ConversionOfSafeAgreementsToSeriesPreferredStock>
  <ltrn:ApplicationOfDeferredOfferingCosts unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-85000</ltrn:ApplicationOfDeferredOfferingCosts>
  <ltrn:ApplicationOfDeferredOfferingCosts unitRef="usd" contextRef="c7_From1Jan2019To31Dec2019" xs:nil="true"/>
  <ltrn:DeferredOfferingCostsRecordedInAPAndAccruedExpenses unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">51880</ltrn:DeferredOfferingCostsRecordedInAPAndAccruedExpenses>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Note 1. Organization, Principal Activities,
and Basis of Presentation&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt TimesNewRoman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Lantern Pharma Inc., and Subsidiary
(the &amp;#x201c;Company&amp;#x201d;) is a clinical stage biopharmaceutical company, focused on leveraging artificial intelligence (&amp;#x201c;A.I.&amp;#x201d;),
machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from
its targeted oncology therapies. The Company&amp;#x2019;s portfolio of therapies consists of small molecule drug candidates that others
have tried, but failed, to develop into an approved commercialized drug, as well as new compounds that it is developing with the
assistance of its A.I. platform and its biomarker driven approach. The Company&amp;#x2019;s A.I. platform, known as RADR&lt;sup&gt;&amp;#xae;&lt;/sup&gt;,
uses big data analytics (combining molecular data, drug efficacy data, data from historical studies, data from scientific literature,
phenotypic data from trials and publications, and mechanistic pathway data) and machine learning. The Company&amp;#x2019;s data-driven,
genomically-targeted and biomarker-driven approach allows it to pursue a transformational drug development strategy that identifies,
rescues or develops, and advances potential small molecule drug candidates.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Lantern Pharma Inc.
was incorporated under the laws of the state of Texas on November 7, 2013, and thereafter reincorporated in the state of Delaware
on January 15, 2020. The Company&amp;#x2019;s principal operations are located in Texas. The Company formed a wholly owned subsidiary,
Lantern Pharma Limited, in the United Kingdom in July 2017.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Since inception, the
Company has devoted substantially all its activity to advancing research and development, including efforts in connection with
preclinical studies, clinical trials and development of its RADR platform. This includes research and development for three drug
candidates in development in targeted areas identified with the assistance of the RADR platform:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%&quot;&gt;&lt;tr style=&quot;vertical-align: top; text-align: justify&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in; text-align: left&quot;&gt;&amp;#x25cf;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;LP-100 (irofulven),
                                         out-licensed to Allarity Therapeutics (formerly known as Oncology Venture), in a phase
                                         II trial for the treatment of prostate cancer;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%&quot;&gt;&lt;tr style=&quot;vertical-align: top; text-align: justify&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in; text-align: left&quot;&gt;&amp;#x25cf;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;LP-300 (Tavocept)
                                         in planning stages for phase II trial for the treatment of non-small cell lung cancer;
                                         and&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%&quot;&gt;&lt;tr style=&quot;vertical-align: top; text-align: justify&quot;&gt;
&lt;td style=&quot;width: 0.5in&quot;&gt;&lt;/td&gt;&lt;td style=&quot;width: 0.25in; text-align: left&quot;&gt;&amp;#x25cf;&lt;/td&gt;&lt;td style=&quot;text-align: justify&quot;&gt;LP-184 in
                                         preclinical studies for treatment of solid tumors including prostate, liver and pancreatic
                                         cancers and glioblastoma.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In connection with
the Company&amp;#x2019;s reincorporation in the state of Delaware on January 15, 2020, the par value of the Company&amp;#x2019;s Common
Stock and Series A Preferred Stock was changed from $0.01 per share to $0.0001 per share. The change in the par value has been
retroactively reflected in the accompanying consolidated financial statements. Additional funds have been reclassified from Common
Stock and Series A Preferred Stock to additional paid-in capital to reflect the change in par value associated with the reincorporation.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The accompanying consolidated
financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America
(&amp;#x201c;GAAP&amp;#x201d;) and include all adjustments necessary for the fair presentation of the Company&amp;#x2019;s financial position,
results of operations, and cash flows for each period presented. The preparation of financial statements in conformity with GAAP
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses
during the reporting periods. Actual results could differ from these estimates.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Any reference in these
notes to applicable guidance refers to Accounting Standards Codification (&amp;#x201c;ASC&amp;#x201d;) and Accounting Standards Update (&amp;#x201c;ASU&amp;#x201d;)
of the Financial Accounting Standards Board (&amp;#x201c;FASB&amp;#x201d;). To date, the Company has operated its business as one segment.
The Company&amp;#x2019;s consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Lantern
Pharma Limited. All intercompany balances and transactions have been eliminated in consolidation.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Effective June 11,
2020, in connection with the Company&amp;#x2019;s initial public offering (&amp;#x201c;IPO&amp;#x201d;), the Company completed a forward stock
split of its common stock at a ratio of 1.74 for 1 shares. In addition, all of the Company&amp;#x2019;s preferred stock converted into
common stock effective June 15, 2020 in connection with the IPO. All data on common stock and equivalents in the accompanying
consolidated financial statements and in these notes are shown herein reflective of this stock split and the conversion of the
preferred stock. In addition, the number of shares of preferred stock in the accompanying consolidated financial statements and
in these notes is presented to reflect the number of shares into which the preferred stock would convert as a result of the forward
stock split.&lt;/p&gt;&lt;br/&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
  <us-gaap:PreferredStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c29_AsOf15Jan2020_MinimumMember" decimals="2">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c30_AsOf15Jan2020_MaximumMember" decimals="4">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Note 2. Liquidity &lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Company incurred
a net loss of approximately $5,908,000 and $2,428,000 during the years ended December 31, 2020 and 2019, respectively. As of December
31, 2020, the Company had working capital of approximately $19,685,000, primarily as a result of the net proceeds raised in the
IPO of approximately $23,420,000 (see Note 6). As of December 31, 2019, the Company had working capital of approximately $744,000.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;On January 20, 2021,
the Company closed a public offering of 4,928,571 shares of its common stock at a public offering price of $14.00 per share, which
amount included 642,856 shares sold upon full exercise of the underwriter&amp;#x2019;s over-allotment option. Total gross proceeds from
the offering were $68,999,994, and net proceeds from the offering were approximately $64,200,000.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in&quot;&gt;The Company has received
funding in the form of periodic capital raises and also plans to apply for grant funding in the future to assist in supporting
its capital needs. We may also explore the possibility of entering into commercial credit facilities as an additional source of
liquidity.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;We believe that our
existing cash and cash equivalents as of December 31, 2020, and our anticipated expenditures and capital commitments for the calendar
year 2021 and the first half of 2022, will enable us to fund our operating expenses and capital expenditure requirements for at
least 12 months from the date of filing this Form 10-K for the year ended December 31, 2020.&lt;/p&gt;&lt;br/&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">5908000</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c7_From1Jan2019To31Dec2019" decimals="0">2428000</us-gaap:ProfitLoss>
  <ltrn:WorkingCapital unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">19685000</ltrn:WorkingCapital>
  <ltrn:NetProceed unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">23420000</ltrn:NetProceed>
  <ltrn:WorkingCapital unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">744000</ltrn:WorkingCapital>
  <us-gaap:PartnersCapitalAccountUnitsSoldInPublicOffering unitRef="shares" contextRef="c31_From1Jan2021To20Jan2021_SubsequentEventMember" decimals="INF">4928571</us-gaap:PartnersCapitalAccountUnitsSoldInPublicOffering>
  <us-gaap:SharesIssuedPricePerShare unitRef="usdPershares" contextRef="c32_AsOf20Jan2021_SubsequentEventMember" decimals="2">14.00</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:PartnersCapitalAccountUnitsSoldInPublicOffering unitRef="shares" contextRef="c33_From1Jan2021To20Jan2021_SubsequentEventMember_OverAllotmentOptionMember" decimals="INF">642856</us-gaap:PartnersCapitalAccountUnitsSoldInPublicOffering>
  <ltrn:TotalGrossProceeds unitRef="usd" contextRef="c31_From1Jan2021To20Jan2021_SubsequentEventMember" decimals="0">68999994</ltrn:TotalGrossProceeds>
  <ltrn:NetProceed unitRef="usd" contextRef="c32_AsOf20Jan2021_SubsequentEventMember" decimals="0">64200000</ltrn:NetProceed>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Note 3. Summary of Significant Accounting
Policies&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Use of Estimates and Assumptions&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The preparation of
financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. The significant areas of estimation include determining
deferred tax asset valuation allowance and the inputs in determining the fair value of equity-based awards and warrants issued.
Actual results could differ from those estimates.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Risks and Uncertainties&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Company operates
in an industry that is subject to intense competition, government regulation and rapid technological change. Operations are subject
to significant risk and uncertainties including financial, operational, technological, regulatory, and other risks, including
the potential risk of business failure.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The extent of the impact
and effects of the coronavirus (COVID-19) on the operation and financial performance of the Company&amp;#x2019;s business will depend
on future developments, including the duration and spread of the outbreak, related travel advisories and restrictions, the recovery
time of disrupted research services, the consequential staff shortages, and research and development delays, or the uncertainty
with respect to the accessibility of additional liquidity or capital markets, all of which are highly uncertain and cannot be
predicted. If the Company&amp;#x2019;s operations are impacted by this outbreak for an extended period, the Company&amp;#x2019;s results
of operations or liquidity may be materially adversely affected.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Deferred Offering Costs&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Costs incurred related
to equity offerings are capitalized as deferred equity issuance costs in other non-current assets until the offering is completed
or abandoned. If the Company completes an offering, these costs will be offset against proceeds received; or if the offering does
not occur, they will be expensed. Offering costs include direct and incremental costs related to the offering such as legal fees
and related costs.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Company recorded
deferred offering costs of $101,205 and $191,000 as of December 31, 2020 and 2019, respectively. During the year ended December
31, 2020, the Company has applied deferred offering costs of $456,437 as a reduction to additional paid-in capital upon completion
of the Company&amp;#x2019;s initial public offering (&amp;#x201c;IPO&amp;#x201d;) on June 15, 2020.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Research and Development&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Research and development
costs are expensed as incurred. These expenses primarily consist of payroll, contractor expenses, research study expenses, costs
for manufacturing and supplies, and technical infrastructure on the cloud for the purposes of developing the Company&amp;#x2019;s RADR
platform and identifying, developing, and testing drug candidates. Development costs incurred by third parties are expensed as
the work is performed. Costs to acquire technologies, including licenses, that are utilized in research and development and that
have no alternative future use are expensed when incurred.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Highly liquid investments
with original maturities of three months or less when purchased are considered to be cash equivalents. Financial instruments which
potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains
cash and cash equivalents with high-credit quality financial institutions. At times, such amounts may exceed insured limits. The
Company has not experienced any losses in such accounts.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;b&gt;Prepaid Expenses and Other Current Assets&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Prepaid expenses and
other current assets as of December 31, 2020 totaled approximately $1,008,000 and included approximately $187,000 of upfront payments
for contractor and academic research studies and services, approximately $15,000 of licensing and other fees, and approximately
$806,000 of prepaid annual insurance fees.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Loan Pursuant to Paycheck Protection
Program&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;On May 1, 2020, the
Company received $108,500 in aggregate loan proceeds (the &amp;#x201c;PPP Loan&amp;#x201d;) from JPMorgan Chase Bank (the &amp;#x201c;Lender&amp;#x201d;)
pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The PPP Loan
is evidenced by a loan application and payment agreement (the &amp;#x201c;PPP Loan Agreement&amp;#x201d;) by and between the Company and
the Lender. This amount is recorded as a loan payable on the Company&amp;#x2019;s consolidated balance sheet at December 31, 2020.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Deferred tax assets
and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities
using enacted tax rates which will be in effect when the differences reverse. The Company provides a full valuation allowance
against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset
will be realized.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Stock-based Compensation&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Stock-based awards
have been accounted for as required by ASC 718 &amp;#x201c;Compensation - Stock Compensation.&amp;#x201d; Under ASC 718, awards are valued
at fair value on the date of grant, and that fair value is recognized over the requisite service period.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;b&gt;Reclassification&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Certain prior period information has been
reclassified to conform to the current period presentation.&lt;/p&gt;&lt;br/&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:UseOfEstimates contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Use of Estimates and Assumptions&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The preparation of
financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. The significant areas of estimation include determining
deferred tax asset valuation allowance and the inputs in determining the fair value of equity-based awards and warrants issued.
Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
  <us-gaap:ConcentrationRiskCreditRisk contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Risks and Uncertainties&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Company operates
in an industry that is subject to intense competition, government regulation and rapid technological change. Operations are subject
to significant risk and uncertainties including financial, operational, technological, regulatory, and other risks, including
the potential risk of business failure.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The extent of the impact
and effects of the coronavirus (COVID-19) on the operation and financial performance of the Company&amp;#x2019;s business will depend
on future developments, including the duration and spread of the outbreak, related travel advisories and restrictions, the recovery
time of disrupted research services, the consequential staff shortages, and research and development delays, or the uncertainty
with respect to the accessibility of additional liquidity or capital markets, all of which are highly uncertain and cannot be
predicted. If the Company&amp;#x2019;s operations are impacted by this outbreak for an extended period, the Company&amp;#x2019;s results
of operations or liquidity may be materially adversely affected.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
  <us-gaap:DeferredChargesPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Deferred Offering Costs&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Costs incurred related
to equity offerings are capitalized as deferred equity issuance costs in other non-current assets until the offering is completed
or abandoned. If the Company completes an offering, these costs will be offset against proceeds received; or if the offering does
not occur, they will be expensed. Offering costs include direct and incremental costs related to the offering such as legal fees
and related costs.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Company recorded
deferred offering costs of $101,205 and $191,000 as of December 31, 2020 and 2019, respectively. During the year ended December
31, 2020, the Company has applied deferred offering costs of $456,437 as a reduction to additional paid-in capital upon completion
of the Company&amp;#x2019;s initial public offering (&amp;#x201c;IPO&amp;#x201d;) on June 15, 2020.&lt;/p&gt;</us-gaap:DeferredChargesPolicyTextBlock>
  <us-gaap:DeferredOfferingCosts unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">101205</us-gaap:DeferredOfferingCosts>
  <us-gaap:DeferredOfferingCosts unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">191000</us-gaap:DeferredOfferingCosts>
  <us-gaap:DeferredOfferingCosts unitRef="usd" contextRef="c34_AsOf31Dec2020_IPOMember" decimals="0">456437</us-gaap:DeferredOfferingCosts>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Research and Development&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Research and development
costs are expensed as incurred. These expenses primarily consist of payroll, contractor expenses, research study expenses, costs
for manufacturing and supplies, and technical infrastructure on the cloud for the purposes of developing the Company&amp;#x2019;s RADR
platform and identifying, developing, and testing drug candidates. Development costs incurred by third parties are expensed as
the work is performed. Costs to acquire technologies, including licenses, that are utilized in research and development and that
have no alternative future use are expensed when incurred.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Cash and Cash Equivalents&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Highly liquid investments
with original maturities of three months or less when purchased are considered to be cash equivalents. Financial instruments which
potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains
cash and cash equivalents with high-credit quality financial institutions. At times, such amounts may exceed insured limits. The
Company has not experienced any losses in such accounts.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <ltrn:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;b&gt;Prepaid Expenses and Other Current Assets&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Prepaid expenses and
other current assets as of December 31, 2020 totaled approximately $1,008,000 and included approximately $187,000 of upfront payments
for contractor and academic research studies and services, approximately $15,000 of licensing and other fees, and approximately
$806,000 of prepaid annual insurance fees.&lt;/p&gt;</ltrn:PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock>
  <us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">1008000</us-gaap:PrepaidExpenseAndOtherAssetsNoncurrent>
  <ltrn:UpfrontContractorFees unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">187000</ltrn:UpfrontContractorFees>
  <ltrn:PatentLicenseFees unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">15000</ltrn:PatentLicenseFees>
  <ltrn:UndepositedFunds unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">806000</ltrn:UndepositedFunds>
  <ltrn:LoanPursuantToPaycheckProtectionProgramTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Loan Pursuant to Paycheck Protection
Program&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;On May 1, 2020, the
Company received $108,500 in aggregate loan proceeds (the &amp;#x201c;PPP Loan&amp;#x201d;) from JPMorgan Chase Bank (the &amp;#x201c;Lender&amp;#x201d;)
pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The PPP Loan
is evidenced by a loan application and payment agreement (the &amp;#x201c;PPP Loan Agreement&amp;#x201d;) by and between the Company and
the Lender. This amount is recorded as a loan payable on the Company&amp;#x2019;s consolidated balance sheet at December 31, 2020.&lt;/p&gt;</ltrn:LoanPursuantToPaycheckProtectionProgramTextBlock>
  <us-gaap:ProceedsFromLoans unitRef="usd" contextRef="c35_From28Apr2020To1May2020" decimals="0">108500</us-gaap:ProceedsFromLoans>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Deferred tax assets
and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities
using enacted tax rates which will be in effect when the differences reverse. The Company provides a full valuation allowance
against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset
will be realized.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Stock-based Compensation&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Stock-based awards
have been accounted for as required by ASC 718 &amp;#x201c;Compensation - Stock Compensation.&amp;#x201d; Under ASC 718, awards are valued
at fair value on the date of grant, and that fair value is recognized over the requisite service period.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;b&gt;Reclassification&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Certain prior period information has been
reclassified to conform to the current period presentation.&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
  <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Note 4. New Accounting Pronouncements
&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;New Accounting Pronouncements, Not
Yet Adopted&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;i&gt;Current Expected Credit Loss&lt;/i&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In June 2016 the FASB
issued Accounting Standard Update (ASU) 2016-13, Measurement of Credit Losses on Financial Instruments (Topic 326). This introduces
new methodology for recognition of credit losses - the current expected credit loss (&amp;#x201c;CECL&amp;#x201d;) method. The CECL method
requires the recognition of all losses expected over the life of a financial instrument upon origination or purchase of the instrument,
unless the company elects to recognize such instruments at fair value with changes in profit and loss. CECL is effective for the
Company on January 1, 2023. The Company does not anticipate a material impact from the adoption of this new standard on its financial
statements.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In December 2019,
the FASB issued ASU 2019-12: Income Taxes (Topic 740) &amp;#x2013; Simplifying the Accounting for Income Taxes. This ASU simplifies
accounting for income taxes by removing the exception to the incremental approach for intraperiod tax allocation when there is
a loss from continuing operations and income or gain for other items, the exception to the requirement to recognize a deferred
tax liability for equity method investments when a foreign subsidiary becomes an equity method investment, the exception to the
ability not to recognize a deferred tax liability for a foreign subsidiary when a foreign equity method investment becomes a subsidiary,
and the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds
the anticipated loss for the year. This ASU also includes other requirements related to franchise tax, goodwill as part of a business
combination, consolidations, changes in tax laws, and affordable housing projects. ASU 2019-12 is effective for fiscal years beginning
after December 15, 2020, including interim periods within that fiscal year. Early adoption is permitted for periods in which financial
statements have not yet been issued. The Company does not anticipate a material impact from the adoption of this new standard
on its financial statements.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Recently Adopted Accounting Standards&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;i&gt;Leases &lt;/i&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In February 2016 the
FASB issued ASU 2016-02: Leases. The ASU introduces a lessee model that results in most leases impacting the balance sheet. The
ASU addresses other concerns related to the current lease model. Under ASU 2016-02, lessees will be required to recognize for
all leases with terms longer than 12 months, at the commencement date of the lease, a lease liability, which is a lessee&amp;#x2019;s
obligation to make lease payments arising from a lease measured on a discounted basis, and a right-to-use (ROU) asset, which is
an asset that represents the lessee&amp;#x2019;s right to use or control the use of a specified asset for the lease term. Leases will
be classified as either finance or operating, with classification affecting the pattern of expense recognition.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In July 2018, the
FASB issued ASU 2018-10 &amp;#x201c;Codification Improvements to Topic 842, Leases.&amp;#x201d; This ASU affects narrow aspects of the guidance
issued in the amendments in ASU 2016-02 including those regarding residual value guarantees, rate implicit in the lease, lessee
reassessment of lease classification, lessor reassessment of lease term and purchase option, variable lease payments that depend
on an index or a rate, investment tax credits, lease term and purchase option, transition guidance for amounts previously recognized
in business combinations, certain transition adjustments, transition guidance for leases previously classified as capital leases
under Topic 840, transition guidance for modifications to leases previously classified as direct financing or sales-type leases
under Topic 840, transition guidance for sale and leaseback transactions, impairment of net investment in the lease, unguaranteed
residual asset, effect of initial direct costs on rate implicit in the lease, and failed sale and leaseback transactions.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Company adopted
ASC 2018-10 Topic 842 effective January 1, 2019 and elected the short-term lease recognition exemption for all leases that qualify.
For those leases that qualify, the Company will not recognize ROU assets or lease liabilities, and this includes not recognizing
ROU assets or lease liabilities for existing short-term leases of those assets in transition. This practical expedient was elected
to not separate lease and non-lease components for its office space leases. The adoption of this new standard did not have a material
impact on the Company&amp;#x2019;s financial statements as the Company did not have any leases that have terms of longer than 12 months.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;i&gt;Compensation &amp;#x2013; Stock Compensation&lt;/i&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In June 2018, the
FASB issued ASU 2018-07: Compensation &amp;#x2013; Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment
Accounting. This ASU expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services
from non-employees, and as a result, the accounting for share-based payments to non-employees will be substantially aligned. ASU
2018-07 is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early
adoption is permitted but no earlier than an entity&amp;#x2019;s adoption date of Topic 606. The Company adopted ASU Topic 718 effective
January 1, 2019. The adoption of this new accounting guidance did not have a material impact on the Company&amp;#x2019;s consolidated
financial statements and related footnote disclosures.&lt;/p&gt;&lt;br/&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Note 5: Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; &quot;&gt;&lt;b&gt;&lt;i&gt;General.&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Company has entered
into, and expects to enter into from time to time in the future, license agreements, strategic alliance agreements, assignment
agreements, and similar agreements related to the advancement of its product candidates and research and development efforts (collectively,
&amp;#x201c;License and Strategic Alliance Agreements&amp;#x201d;). As of the date of filing this report on Form 10-K, the Company has obligations
relating to License and Strategic Alliance Agreements that are expected to result in total payments of approximately $600,000 for
2021.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;&lt;b&gt;&lt;i&gt;BioNumerik
Pharmaceuticals.&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; &quot;&gt;In
January 2018, the Company entered into an Assignment Agreement (the &amp;#x201c;Assignment Agreement&amp;#x201d;) with BioNumerik Pharmaceuticals,
Inc. (&amp;#x201c;BioNumerik&amp;#x201d;), pursuant to which the Company acquired rights to domestic and international patents, trademarks
and related technology and data relating to LP-300 (Tavocept) for human therapeutic treatment indications. The Assignment Agreement
replaced a License Agreement that was entered into between the Company and BioNumerik in May 2016. The Company made upfront payments
totaling $25,000 in connection with entry into the Assignment Agreement.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; &quot;&gt;In
the event the Company develops and commercializes LP-300 internally, the Company is required to pay to the BioNumerik-related
payment recipients designated in the Assignment Agreement a percentage royalty in the low double digits on cumulative net revenue
up to $100 million, with incremental increases in the percentage royalty for net cumulative revenue between $100 million and $250
million, $250 million and $500 million, and $500 million and $1 billion, with a percentage royalty payment that could exceed $200
million for net cumulative revenue in excess of $1 billion. The Company has the right to first recover certain designated portions
of patent costs and development and regulatory costs before the payment of royalties described above.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; &quot;&gt;If
the Company enters into a third party transaction for LP-300, the Company is required to pay the BioNumerik-related payment recipients
a specified percentage of any upfront, milestone, and royalty amounts received by the Company from the transaction, after first
recovering specified direct costs incurred by the Company for the development of LP-300 that are not otherwise reimbursed from
such third party transaction.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; &quot;&gt;In
addition, the Assignment Agreement provides that the Company will use commercially diligent efforts to develop LP-300 and make
specified regulatory filings and pay specified development and regulatory costs related to LP-300. The Assignment Agreement also
provides that the Company will provide TriviumVet DAC (&amp;#x201c;TriviumVet&amp;#x201d;) with (i) specified data and information generated
by the Company with respect to LP-300, and (ii) an exclusive license to use specified LP-300-related patent rights, trademark
rights and related intellectual property to support LP-300 development in non-human (animal) treatment indications.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; &quot;&gt;The
Company is also required to pay all patent costs on covered patents related to LP-300. Patent costs paid by the Company to BioNumerik
with respect to LP-300 related patents amounted to $0 and approximately $74,000 for the years ended December 31, 2020 and 2019,
respectively. These patent costs are included in general and administrative expenses in the accompanying consolidated statement
of operations. These patent costs are fully recoverable at the time of any net revenue from LP-300, with up to 50% of net revenue
amounts to be applied towards repayment of patent costs until such costs are fully recovered.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; &quot;&gt;In
addition to the recovery of patent costs, the Company has the right to recover the $25,000 upfront payments made in connection
with entry into the Assignment Agreement, which payments are recoverable prior to making any royalty or third party transaction
sharing payments. The Company also has the right to recover previously incurred LP-300 development and regulatory costs, with
up to a mid-single digit percentage of net revenue amounts to be applied towards repayment of development and regulatory costs
until such costs are fully recovered.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; &quot;&gt;No
amounts are owed to BioNumerik as of December 31, 2020. Approximately $11,000 is owed and recorded in accounts payable to BioNumerik
as of December 31, 2019.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;AF Chemicals.&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In January 2015, the
Company entered into a Technology License Agreement to exclusively license domestic and international patent rights from AF Chemicals,
LLC (&amp;#x201c;AF Chemicals&amp;#x201d;) for the treatment of cancer in humans for the compounds LP-100 (Irofulven) and LP-184. In February
2016, the Company and AF Chemicals entered into an Addendum (the &amp;#x201c;Addendum&amp;#x201d;) providing for additions and amendments
to the Technology License Agreement. In December 2020, the Company and AF Chemicals entered into a Second Addendum (the &amp;#x201c;Second
Addendum&amp;#x201d;) providing for further additions and amendments to the Technology License Agreement. The Technology License Agreement,
Addendum and Second Addendum are collectively referred to as the &amp;#x201c;AFC License Agreement&amp;#x201d;.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Second Addendum
provides for us to make specified payments to AF Chemicals within 10 days after signing and by March 31, 2021. The Second Addendum
also provides that, from December 30, 2020 until January 15, 2025, we will have no obligation to pay annual licensing fees, development
diligence extension payments, or patent maintenance fee payments to AFC under the AFC License Agreement. Nothing was expensed
in the year ended December 31, 2020 relating to entering into the Second Addendum.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;As part of the Second
Addendum, we have agreed to apply for specified orphan drug designations for LP-184 in the US and EU. The Second Addendum also
amends and clarifies other provisions of the Technology License Agreement, and provides us with the ability to recover a portion
of initial payments made under the Second Addendum from sublicense fees or royalty payments that may be made to AFC by us or third
parties prior to January 15, 2025.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Pursuant to the AFC
License Agreement the Company made annual licensing fee payments to AF Chemicals in the amount of $30,000 during each of the years
ended December 31, 2020 and 2019 relating to LP-184. Such amounts are included in research and development expenses in the accompanying
consolidated statement of operations. In addition, the Company is obligated to make milestone payments to AF Chemicals at the time
of an Investigational New Drug Application (&amp;#x201c;IND&amp;#x201d;) filing relating to LP-184 and also upon reaching additional specified
milestones in connection with the development and potential marketing approval of LP-184 in the United States, specified countries
in Europe, and other countries.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The AFC License Agreement
also provides that the Company will pay AF Chemicals a royalty of at least a very small single digit percentage of specified net
sales of LP-184 and other analogs. In addition, the AFC License Agreement contains specified time requirements for the Company
to file an IND, enroll patients in clinical trials, and file a potential NDA with respect to LP-184, with the ability for the
Company to pay AF Chemicals additional amounts ranging up to an amount in the low hundreds of thousands of dollars for each one,
two, three and four year extension to such development time requirements, with additional extensions beyond four years to be negotiated
by the Company and AF Chemicals. The Company paid $50,000 and $37,500 during the years ended December 31, 2020 and 2019, respectively
in connection with the extension of the IND filing milestone for LP-184, which amounts are included under research and development
in the accompanying consolidated statements of operations. Pursuant to the Second Addendum, no additional payments of annual licensing
fees or development diligence extension payments are required to be made by the Company until January 15, 2025, at which time
these obligations will resume. The Company will also be obligated to make annual licensing fee payments to AF Chemicals relating
to LP-100 beginning January 15, 2025, as described below under Allarity Therapeutics.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In the event of a
sublicense of the LP-184 rights, the Company is obligated to pay AF Chemicals (a) a low double digit percentage of the gross income
and fees received by the Company with respect to the United States in connection with such sublicense, and (b) a lower double
digit percentage of the gross income and fees received by the Company with respect to Europe and Japan in connection with such
sublicense.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; &quot;&gt;No
amounts are payable to AF Chemicals as of December 31, 2020 and 2019.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Allarity Therapeutics (formerly
known as Oncology Venture)&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In May 2015, the Company
licensed various rights to LP-100 to Oncology Venture (now known as Allarity Therapeutics) pursuant to a Drug License and Development
Agreement. In February 2016, the Company and Allarity Therapeutics entered into an addendum and an amendment providing for additions
and amendments to the Drug License and Development Agreement. In connection with the Drug License and Development Agreement, as
amended (collectively, the &amp;#x201c;Allarity License and Development Agreement&amp;#x201d;), Allarity Therapeutics agreed to directly
pay to AF Chemicals on behalf of the Company certain amounts to satisfy the Company&amp;#x2019;s milestone obligations to AF Chemicals
with respect to LP-100 under the AFC License Agreement. Amounts paid by Allarity Therapeutics to AF Chemicals on behalf of the
Company are then deducted from amounts owed by Allarity Therapeutics to the Company.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The amounts to be paid
to AF Chemicals with respect to LP-100 under the AFC License Agreement are in many ways similar to the amounts to be paid with
respect to LP-184 as described above under &amp;#x201c;AF Chemicals&amp;#x201d;. In the event any such amounts relating to LP-100 are not
paid to AF Chemicals by Allarity Therapeutics, the Company is obligated to pay such unpaid amounts. In addition to the payments
to be made by Allarity Therapeutics, the Company is obligated to make annual licensing fee payments to AF Chemicals relating to
LP-100. The Company paid $30,000 to AF Chemicals during each of the years ended December 31, 2020 and 2019 relating to LP-100.
Such amounts are included in research and development expenses in the accompanying consolidated statement of operations.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In addition, the AFC
License Agreement contains specified time requirements for the Company to file an IND, enroll patients in clinical trials, and
file a potential NDA with respect to LP-100. During the year ended December 31, 2020, the Company paid AF Chemicals $25,000 relating
to a one-year milestone extension fee for LP-100 commencing in August 2020, approximately $10,000 of which was expensed during
the year ended December 31, 2020 and included under research and development expenses in the accompanying consolidated statements
of operations.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;No amounts are payable
under the Allarity License and Development Agreement as of December 31, 2020 and 2019.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;EU Grant&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In September 2018,
Lantern Pharma Limited, a wholly owned subsidiary of Lantern Pharma Inc., was awarded a grant by the UK government in the form
of state aid under the Commission Regulations (EU) No. 651/2014 of 17 June 2014 (the &amp;#x201c;General Block Exemption&amp;#x201d;), Article
25 Aid for research and development projects, state aid notification no. SA.40154. The grant was awarded to conduct research and
development activities for the prostate cancer biomarker analysis of the LP-184&amp;#xa0;drug candidate. Following the Company&amp;#x2019;s
research and development activities in Northern Ireland, the grant will reimburse the Company 50% of its research and development
expenses not exceeding GBP 24,215 of vouched and approved expenditures within specific categories. The grant contains some reporting
and consent requirements. The grant will remain in force for a period of five years. No payments to the Company have been made
under the grant as of December 31, 2020 and December 31, 2019. No revenue has been recognized from this grant through December
31, 2020.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0&quot;&gt;&lt;b&gt;&lt;i&gt;Patheon API Services&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In July 2020, the
Company entered into an agreement with Patheon API Services, Inc. (&amp;#x201c;Patheon&amp;#x201d;) for the manufacture and supply of cGMP
material to support the Company&amp;#x2019;s planned Phase II clinical trial for its product candidate LP-300. In addition to producing
LP-300 API (active pharmaceutical ingredient) under cGMP (current Good Manufacturing Practices) conditions, Patheon will transfer
previously validated manufacturing processes and analytical methods for LP-300 and will produce non-GMP material that can be used
to support non-clinical studies for LP-300. The agreement provides for payments in stages as specified process and manufacturing
milestones are achieved. Patheon, a part of Thermo Fisher Scientific, has previously developed and/or manufactured more than 700
pharmaceuticals for biopharma clients and has more than 55 locations around the world, providing access to a fully integrated
global network of facilities.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Company paid approximately
$203,000 to Patheon during the twelve months ended December 31, 2020 pursuant to the Patheon agreement. Approximately $227,000
was expensed with respect to the Patheon agreement during the twelve months ended December 31, 2020, which relates to the services
received by the Company through December 31, 2020. This amount is included in research and development expenses in the accompanying
consolidated statements of operations. Approximately $24,000 relating to the Patheon agreement is included under accounts payable
and accrued expenses on the Company&amp;#x2019;s consolidated balance sheet for the period ended December 31, 2020. The Company expects
to pay additional amounts to Patheon in future periods in accordance with specified process and manufacturing milestones under
the Patheon agreement.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; &quot;&gt;&lt;b&gt;&lt;i&gt;Southwest Research Institute&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; &quot;&gt;As
part of the Company&amp;#x2019;s research and development activities, the Company has engaged Southwest Research Institute (&amp;#x201c;SwRI&amp;#x201d;)
from time to time to assist with compound synthesis and manufacturing related activities for the Company&amp;#x2019;s product candidates.
Approximately $71,000 and $234,000 was expensed with respect to SwRI during the twelve months ended December 31, 2020 and December
31, 2019, respectively. All of such expensed amounts are included in research and development expenses in the accompanying consolidated
statements of operations. Approximately $82,000 was payable to SwRI as of December 31, 2020, and approximately $13,000 was payable
to SwRI as of December 31, 2019. In September 2020, the Company entered into an agreement with SwRI for the non-GMP synthesis
of LP-184 material and related analytical development to assist with preclinical studies. Approximately $97,000 relating to the
SwRI agreement is included under prepaid expenses on the Company&amp;#x2019;s consolidated balance sheet for the period ended December
31, 2020. There were no prepaid expenses relating to SwRI as of December 31, 2019. The Company expects to pay additional amounts
to SwRI in future periods as synthesis and analytical work is conducted by SwRI under the agreement.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;&lt;b&gt;&lt;i&gt;The Research
Institute of Fox Chase Cancer Center&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; &quot;&gt;In
September 2020, the Company entered into a research agreement with the Research Institute of Fox Chase Cancer Center (&amp;#x201c;FCCC&amp;#x201d;)
as part of the Company&amp;#x2019;s research and development activities, with a focus on advancing the targeted use of LP-184 in molecularly-defined
sub-types of pancreatic cancer. Approximately $85,000 was expensed with respect to the FCCC agreement during the twelve months
ended December 31, 2020, which amount is included in research and development expenses in the accompanying consolidated statements
of operations. As of December 31, 2020, approximately $14,000 was recorded as accrued with respect to FCCC. The Company expects
to pay additional amounts to FCCC in future periods in accordance with the payment schedule specified under the FCCC agreement.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; &quot;&gt;&lt;b&gt;&lt;i&gt;Other Research
and Service Provider Agreements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; &quot;&gt;In
addition to the agreements described above, the Company has entered into other research and service provider agreements for the
advancement of its product candidates and research and development efforts. The Company expects to pay additional amounts in future
periods in connection with existing and future research and service provider agreements.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Operating Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Company leased
office space in Dallas, Texas under month-to-month lease arrangements during the years ended December 31, 2020 and 2019. In connection
with the Company&amp;#x2019;s employees working remotely due to COVID-19, the Company in August 2020 reduced its monthly lease commitment
and costs to minimal levels. The Company is continuing to monitor the COVID-19 conditions and intends to increase its lease of
office space following an improvement in the COVID-19 pandemic.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In August 2019, the
Company entered into a leasing agreement for office space in New Jersey. Monthly rent was $2,106, plus electrical utilities. The
lease expired on July 31, 2020 and was not renewed.&lt;/p&gt;&lt;br/&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:PaymentsForOtherOperatingActivities unitRef="usd" contextRef="c36_From4Jan2021To31Jan2021_SubsequentEventMember" decimals="0">600000</us-gaap:PaymentsForOtherOperatingActivities>
  <ltrn:UpfrontPayments unitRef="usd" contextRef="c37_AsOf31Jan2018" decimals="0">25000</ltrn:UpfrontPayments>
  <us-gaap:OtherCommitmentsDescription contextRef="c38_From1Jan2020To31Dec2020_BioNumerikPharmaceuticalMember">In the event the Company develops and commercializes LP-300 internally, the Company is required to pay to the BioNumerik-related payment recipients designated in the Assignment Agreement a percentage royalty in the low double digits on cumulative net revenue up to $100 million, with incremental increases in the percentage royalty for net cumulative revenue between $100 million and $250 million, $250 million and $500 million, and $500 million and $1 billion, with a percentage royalty payment that could exceed $200 million for net cumulative revenue in excess of $1 billion.</us-gaap:OtherCommitmentsDescription>
  <us-gaap:FiniteLivedPatentsGross unitRef="usd" contextRef="c39_AsOf31Dec2020_PatentsMember" decimals="0">0</us-gaap:FiniteLivedPatentsGross>
  <us-gaap:FiniteLivedPatentsGross unitRef="usd" contextRef="c40_AsOf31Dec2019_PatentsMember" decimals="0">74000</us-gaap:FiniteLivedPatentsGross>
  <ltrn:NetRevenuePercentage unitRef="pure" contextRef="c41_From1Jan2020To31Dec2020_PatentsMember" decimals="2">0.50</ltrn:NetRevenuePercentage>
  <ltrn:UpfrontPayments unitRef="usd" contextRef="c42_AsOf31Dec2020_BioNumerikPharmaceuticalMember" decimals="0">25000</ltrn:UpfrontPayments>
  <us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent unitRef="usd" contextRef="c42_AsOf31Dec2020_BioNumerikPharmaceuticalMember" decimals="0">11000</us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent>
  <ltrn:Annualfees unitRef="usd" contextRef="c43_From1Jan2020To31Dec2020_LP184Member_AFChemicalsMember" decimals="0">30000</ltrn:Annualfees>
  <us-gaap:OtherCommitmentsDescription contextRef="c44_From1Jan2020To31Dec2020_AFChemicalsMember">the ability for the Company to pay AF Chemicals additional amounts ranging up to an amount in the low hundreds of thousands of dollars for each one, two, three and four year extension to such development time requirements, with additional extensions beyond four years to be negotiated by the Company and AF Chemicals. The Company paid $50,000 and $37,500 during the years ended December 31, 2020 and 2019, respectively in connection with the extension of the IND filing milestone for LP-184, which amounts are included under research and development in the accompanying consolidated statements of operations.</us-gaap:OtherCommitmentsDescription>
  <us-gaap:OtherExpenses unitRef="usd" contextRef="c45_From1Jan2020To31Dec2020_AFChemicalsMember_LP100Member" decimals="0">30000</us-gaap:OtherExpenses>
  <us-gaap:OtherExpenses unitRef="usd" contextRef="c46_From1Jan2019To31Dec2019_AFChemicalsMember_LP100Member" decimals="0">30000</us-gaap:OtherExpenses>
  <ltrn:MilestoneExtensionPaid unitRef="usd" contextRef="c44_From1Jan2020To31Dec2020_AFChemicalsMember" decimals="0">25000</ltrn:MilestoneExtensionPaid>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">10000</us-gaap:ResearchAndDevelopmentExpense>
  <ltrn:ResearchAndDevelopmentExpensesPercentage unitRef="pure" contextRef="c47_From1Jan2020To31Dec2020_EUGrantMember" decimals="2">0.50</ltrn:ResearchAndDevelopmentExpensesPercentage>
  <ltrn:GrantedPeriod contextRef="c0_From1Jan2020To31Dec2020">P5Y</ltrn:GrantedPeriod>
  <ltrn:ManufacturingAgreementDescription contextRef="c48_From1Jan2020To31Dec2020_PatheonAPIServicesMember">The Company paid approximately $203,000 to Patheon during the twelve months ended December 31, 2020 pursuant to the Patheon agreement. Approximately $227,000 was expensed with respect to the Patheon agreement during the twelve months ended December 31, 2020, which relates to the services received by the Company through December 31, 2020. This amount is included in research and development expenses in the accompanying consolidated statements of operations. Approximately $24,000 relating to the Patheon agreement is included under accounts payable and accrued expenses on the Company&amp;#x2019;s consolidated balance sheet for the period ended December 31, 2020. The Company expects to pay additional amounts to Patheon in future periods in accordance with specified process and manufacturing milestones under the Patheon agreement.</ltrn:ManufacturingAgreementDescription>
  <ltrn:ProductCandidates unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">71000</ltrn:ProductCandidates>
  <ltrn:ProductCandidates unitRef="usd" contextRef="c7_From1Jan2019To31Dec2019" decimals="0">234000</ltrn:ProductCandidates>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c49_From1Jan2020To31Dec2020_SouthwestResearchInstituteMember" decimals="0">82000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c50_From1Jan2019To31Dec2019_SouthwestResearchInstituteMember" decimals="0">13000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:PrepaidExpenseCurrentAndNoncurrent unitRef="usd" contextRef="c51_AsOf31Dec2020_SouthwestResearchInstituteMember" decimals="0">97000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
  <us-gaap:PrepaidExpenseCurrentAndNoncurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">85000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
  <us-gaap:LesseeOperatingLeaseDescription contextRef="c52_From1Aug2019To31Aug2019_PropertySubjectToOperatingLeaseMember">the Company entered into a leasing agreement for office space in New Jersey. Monthly rent was $2,106, plus electrical utilities. The lease expired on July 31, 2020 and was not renewed.</us-gaap:LesseeOperatingLeaseDescription>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Note 6. Shareholders&amp;#x2019; Equity&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Preferred Stock &lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;As of December 31,
2019, the Company had 3,480,000 authorized shares of preferred stock, of which 2,438,866 shares designated as Series A Preferred
Stock (the &amp;#x201c;Series A Preferred Stock&amp;#x201d;) were issued and outstanding.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Upon the Company&amp;#x2019;s
IPO, all shares of the Company&amp;#x2019;s Series A preferred stock were converted into 2,438,851 shares of common stock effective
June 15, 2020, with fractional share adjustments made in connection with the conversion as discussed below. As of December 31,
2020, the Company had 1,000,000 authorized shares of preferred stock, with zero shares of preferred stock issued and outstanding.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The holders of Series
A Preferred Stock were entitled to receive dividends when, as and if declared by the Company&amp;#x2019;s Board of Directors, payable
in preference and priority to any declaration or payment of dividends on Common Stock. No dividends on any Series A Preferred
Stock were declared and no dividends on Common Stock have been declared to date.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In March 2019, the
Company sold 590,643 shares of Series A preferred stock for aggregate proceeds of approximately $1,850,000. The Company also issued
213,510 shares of Series A preferred stock in March 2019, in connection with the conversion of the Simple Agreement for Future
Equity (SAFE) agreements. See Note 7. In connection with the sale and issuance of the Series A preferred stock in March 2019,
the Company issued warrants to purchase an aggregate of 96,499 shares of Series A preferred stock at an initial exercise price
of $3.13 per share.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In July 2019, the
Company sold 341,761 shares of Series A preferred stock for aggregate proceeds of approximately $1,070,000. In connection with
the issuance of the Series A preferred stock, the Company issued warrants to purchase an aggregate of 41,015 shares of Series
A preferred stock at an initial exercise price of $3.13 per share.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Each share of Series
A Preferred Stock was convertible into one share of Common Stock, subject to adjustments for anti-dilution. In addition, the terms
of the Series A Preferred Stock provided that it would automatically convert into Common Stock upon the closing of an initial
public offering meeting certain specified conditions, and also that it would convert into Common Stock in the event holders of
at least 75% of the Series A Preferred Stock approved a mandatory conversion.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The holders of the
Series A Preferred Stock, exclusively and as a separate class, had the right to elect two directors of the Company, and two directors
of the Company were elected by the holders of Series A Preferred Stock in accordance with such provision. The Series A Preferred
Stock also had the right to vote together with holders of Common Stock on any matter presented to the shareholders of the Company
for their action or consideration. In addition, the separate approval of a majority of the Series A Preferred Stock was required
in connection with specified Company activities and transactions, including a merger or consolidation of the Company, and the
liquidation, dissolution or winding-up the business and affairs of the Company.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In the event of a
voluntary or involuntary liquidation, dissolution or winding up of the Company or a deemed liquidation event, the terms of the
Series A Preferred Stock provided that holders of Series A Preferred Stock would be entitled to be paid, out of the assets of
the Company available for distribution, an amount equal to $3.13 per share, plus any dividends declared but unpaid thereon, before
any payment was made to the holders of Common Stock. The liquidation preference of the Series A Preferred Stock was approximately
$7,639,000 at December 31, 2019. The terms of the Series A Preferred Stock provided that, if upon any liquidation, dissolution
or winding up of the Company or deemed liquidation event, the assets of the Company available for distribution to its shareholders
should be insufficient to pay holders of Series A Preferred Stock the full amount to which they would otherwise be entitled, the
holders of Series A Preferred Stock would share ratably in any distribution of the assets available for distribution in proportion
to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all
amounts payable on or with respect to such shares were paid in full.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Effective January
15, 2020, as a result of the Company&amp;#x2019;s reincorporation in the state of Delaware, the par value of the Company&amp;#x2019;s preferred
stock was changed from $0.01 to $0.0001 per share, and all data on preferred stock was retroactively adjusted to be shown herein
as reflective of this change.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Common Stock&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;On June 15, 2020,
the Company received net proceeds of $23,419,721 in its IPO, after deducting underwriting discounts and commissions of $1,968,750
and other offering expenses of $861,529 borne by the Company. The Company issued and sold 1,750,000 shares of common stock in
its IPO at a price of $15.00 per share. In connection with the IPO, all shares of the Company&amp;#x2019;s Series A Preferred Stock
were converted into 2,438,851 shares of common stock, after giving effect to the 1.74 for 1 forward stock split of the common
stock and net of the fractional shares adjustments that occurred in connection with the IPO.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Company made payments
of approximately $261 in the aggregate in connection with fractional shares resulting from the stock split and the conversion
of the preferred stock that took place in connection with the IPO.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;During the year ended
December 31, 2020, the Company issued 50,460 shares of common stock, relating to the exercise of stock options. The shares were
issued at a purchase price of $1.03 for total proceeds of $52,000.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;During the year ended
December 31, 2020, the Company issued 3,350 shares of common stock related to a cashless exercise of a warrant to purchase 4,022
shares.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;As of December 31,
2020, the Company had 25,000,000 authorized shares of Common Stock, of which 6,220,927 shares were issued and outstanding. As
of December 31, 2019, the Company had 12,180,000 authorized shares of Common Stock, of which 1,978,269 shares were issued and
outstanding.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;On August 29, 2018,
the Board of Directors of the Company adopted the Lantern Pharma Inc. 2018 Equity Incentive Plan, which was subsequently amended
on December 17, 2018 and February 26, 2020. The Lantern Pharma Inc. 2018 Equity Incentive Plan, as amended and restated, is referred
to herein as the &amp;#x201c;Plan&amp;#x201d;. The Company reserved 1,489,680 shares of its common stock for issuance under the Plan. The
Plan is designed to provide additional incentives to employees, directors and consultants to remain in the service of the Company
as well as to encourage stock acquisition by members of these targeted groups, which in the opinion of the management will support
the alignment of the interests of the members of these groups and stockholders. Options granted under the Plan are generally exercisable
for up to 10 years from grant date. 535,099 shares remain available for future awards under the Plan at December 31, 2020, following
the grant of options and the award of restricted stock grants through December 31, 2020. The Company recorded stock-based compensation
of approximately $1,192,000 and $118,000 related to stock options during the years ended December 31, 2020 and 2019, respectively.
Total remaining unrecognized compensation expense for non-vested options is $2,480,912 as of December 31, 2020, and is expected
to be recognized over a weighted average period of 1.3 years. The weighted average remaining contractual term of outstanding options
at December 31, 2020 is 8.5 years.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;A summary of stock
option activity under the Plan during the years ended December 31, 2020 and 2019 is presented below:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Options Outstanding&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Options Exercisable&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;white-space: nowrap; text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Number
    of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted-Average&lt;br/&gt;
    Exercise Price&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Number
    of&lt;br/&gt; Options&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted-Average&lt;br/&gt;
    Exercise Price&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 52%; font-size: 10pt; text-align: justify&quot;&gt;Outstanding December 31, 2018&lt;/td&gt;&lt;td style=&quot;width: 1%; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-size: 10pt; text-align: right&quot;&gt;629,060&lt;/td&gt;&lt;td style=&quot;width: 1%; font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-size: 10pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; font-size: 10pt; text-align: right&quot;&gt;1.03&lt;/td&gt;&lt;td style=&quot;width: 1%; font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-size: 10pt; text-align: right&quot;&gt;194,479&lt;/td&gt;&lt;td style=&quot;width: 1%; font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-size: 10pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; font-size: 10pt; text-align: right&quot;&gt;1.03&lt;/td&gt;&lt;td style=&quot;width: 1%; font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: justify&quot;&gt;Granted&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;1,342&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;1.03&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: justify&quot;&gt;Exercised&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: justify; padding-bottom: 1.5pt&quot;&gt;Cancelled or expired&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right&quot;&gt;(22,911&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-size: 10pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right&quot;&gt;1.03&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-size: 10pt&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: justify&quot;&gt;Outstanding December 31, 2019&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;607,491&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;1.03&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;393,413&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;1.03&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: justify&quot;&gt;Granted&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;321,743&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;15.01&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: justify&quot;&gt;Exercised&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;(50,460&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;1.03&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: justify&quot;&gt;Cancelled or expired&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;(43,166&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;1.03&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: justify; padding-bottom: 4pt&quot;&gt;Outstanding December 31, 2020&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-size: 10pt; text-align: right&quot;&gt;835,608&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-size: 10pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-size: 10pt; text-align: right&quot;&gt;6.41&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-size: 10pt; text-align: right&quot;&gt;610,633&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-size: 10pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-size: 10pt; text-align: right&quot;&gt;3.24&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;For 2020 and 2019,
the fair value of each option granted was estimated using the Black-Scholes option-pricing model, using the following weighted
average assumptions:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: justify&quot;&gt;Term (in years)&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;7.00&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;5.94&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Risk Free Rate&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;0.54% - 0.67&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.79&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Volatility&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;83.2% - 84.37%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;60.1&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Dividend Yield&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;0.0&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;0.0&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Grant Date Fair Value&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&lt;/font&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;11.01 &amp;#x2013; 11.28 &lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;0.59&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The fair value of
options is recognized as an expense over the vesting period and forfeitures are accounted for as they occur.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The total intrinsic
value of options outstanding at December 31, 2020 was $10,726,878, and the total intrinsic value of options exercisable at December
31, 2020 was $9,773,797. The total intrinsic value of options exercised during the year ended December 31, 2020 was $20,590. The
intrinsic value of options outstanding at December 31, 2019 was $0. No options were exercised during the year ended December 31,
2019.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse&quot;&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;width: 20%; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Expected Term -&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;width: 80%; text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;The Company used a weighted average of time to vesting
    and maturity date.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Expected Volatility-&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Due to the Company&amp;#x2019;s limited operating history and a lack
    of company-specific historical and implied volatility data, the Company has based its estimate of expected volatility on the
    historical volatility of a group of similar companies that are publicly traded commensurate with expected term as of grant
    date. The historical volatility data was computed using the daily closing prices for the selected comparable companies&amp;#x2019;
    shares.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Risk-Free Interest Rate-&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;The Company used the U.S. treasury bill rate commensurate with
    the expected term as of grant date.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: top&quot;&gt;
    &lt;td&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Expected Dividend-&lt;/font&gt;&lt;/td&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;As the Company has not issued any dividends and does not expect
    to issue dividends over the life of the options, the Company has estimated the dividend yield to be zero.&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Warrants&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Company had warrants
to purchase 325,618 shares of common stock outstanding and exercisable as of December 31, 2020 at a weighted average exercise
price of $6.49 per share. The Company had warrants to purchase 262,003 shares of Series A Preferred Stock outstanding and exercisable
as of December 31, 2019 at a weighted average exercise price of $3.13 per share.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In connection with
the Series A Preferred Stock financing transactions discussed above, in 2019 the Company issued warrants to purchase an aggregate
of 137,513 shares of Series A Preferred Stock.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In connection with
the IPO and the conversion of the Series A Preferred Stock into common stock, all outstanding warrants to purchase Series A Preferred
Stock converted into warrants to purchase common stock.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In connection with
the IPO, the Company granted the underwriters warrants (the &amp;#x201c;Underwriters&amp;#x2019; Warrants&amp;#x201d;) to purchase an aggregate
of 70,000 shares of common stock at an exercise price of $18.75 per share, which is 125% of the initial public offering price.
The Underwriters&amp;#x2019; Warrants have a five-year term and were not exercisable prior to December 7, 2020. All of the Underwriters&amp;#x2019;
Warrants were outstanding at December 31, 2020.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In 2020, the Company
issued 3,350 shares of common stock related to a cashless exercise of a warrant to purchase 4,022 shares.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In 2019, warrants to
purchase an aggregate of 39,651 shares of Series A Preferred Stock were modified to become warrants to purchase an aggregate of
27,754 shares of Series A Preferred Stock. As part of the modification, the term of these warrants was extended from .02 to 1.02
years. The fair value of the modified warrants was approximately $21,000 and is recorded in additional paid in capital.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In 2020, a warrant
to purchase an aggregate of 23,734 shares of Common Stock was modified to become a warrant to purchase an aggregate of 21,360
shares of Common Stock. As part of the modification, the term of the warrant was extended from .003 to 1.003 years. The fair value
of the modified warrant was approximately $36,000 and is recorded in additional paid in capital.&lt;/p&gt;&lt;br/&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:ConversionOfStockSharesConverted1 unitRef="shares" contextRef="c53_From1Jun2020To15Jun2020_SeriesAPreferredStockMember_IPOMember" decimals="INF">2438851</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c5_AsOf31Dec2020_SeriesAPreferredStockMember" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesOutstanding unitRef="shares" contextRef="c5_AsOf31Dec2020_SeriesAPreferredStockMember" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction unitRef="shares" contextRef="c54_From1Mar2019To31Mar2019_SeriesAPreferredStockMember" decimals="INF">590643</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SaleOfStockConsiderationReceivedOnTransaction unitRef="usd" contextRef="c54_From1Mar2019To31Mar2019_SeriesAPreferredStockMember" decimals="0">1850000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c55_AsOf31Mar2019_SeriesAPreferredStockMember" decimals="INF">213510</us-gaap:PreferredStockSharesIssued>
  <ltrn:WarrantsToPurchaseShares unitRef="shares" contextRef="c54_From1Mar2019To31Mar2019_SeriesAPreferredStockMember" decimals="INF">96499</ltrn:WarrantsToPurchaseShares>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 unitRef="usdPershares" contextRef="c55_AsOf31Mar2019_SeriesAPreferredStockMember" decimals="2">3.13</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction unitRef="shares" contextRef="c56_From1Jul2019To31Jul2019_SeriesAPreferredStockMember" decimals="INF">341761</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SaleOfStockConsiderationReceivedOnTransaction unitRef="usd" contextRef="c56_From1Jul2019To31Jul2019_SeriesAPreferredStockMember" decimals="0">1070000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
  <ltrn:WarrantsToPurchaseShares unitRef="shares" contextRef="c56_From1Jul2019To31Jul2019_SeriesAPreferredStockMember" decimals="INF">41015</ltrn:WarrantsToPurchaseShares>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 unitRef="usdPershares" contextRef="c57_AsOf31Jul2019_SeriesAPreferredStockMember" decimals="2">3.13</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <ltrn:CommonStockPercentage unitRef="pure" contextRef="c57_AsOf31Jul2019_SeriesAPreferredStockMember" decimals="2">0.75</ltrn:CommonStockPercentage>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 unitRef="usdPershares" contextRef="c5_AsOf31Dec2020_SeriesAPreferredStockMember" decimals="2">3.13</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:TemporaryEquityLiquidationPreference unitRef="usd" contextRef="c6_AsOf31Dec2019_SeriesAPreferredStockMember" decimals="0">7639000</us-gaap:TemporaryEquityLiquidationPreference>
  <ltrn:CommonStockTotalProceedsValue unitRef="usd" contextRef="c58_AsOf15Jun2020_IPOMember" decimals="0">23419721</ltrn:CommonStockTotalProceedsValue>
  <us-gaap:OtherUnderwritingExpense unitRef="usd" contextRef="c59_From1Jun2020To15Jun2020_IPOMember" decimals="0">1968750</us-gaap:OtherUnderwritingExpense>
  <ltrn:OtherOfferingExpenses unitRef="usd" contextRef="c59_From1Jun2020To15Jun2020_IPOMember" decimals="0">861529</ltrn:OtherOfferingExpenses>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction unitRef="shares" contextRef="c59_From1Jun2020To15Jun2020_IPOMember" decimals="INF">1750000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
  <us-gaap:SharesIssuedPricePerShare unitRef="usdPershares" contextRef="c58_AsOf15Jun2020_IPOMember" decimals="2">15.00</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:StockholdersEquityNoteStockSplit contextRef="c60_From1Jun2020To15Jun2020_SeriesAPreferredStockMember">In connection with the IPO, all shares of the Company&amp;#x2019;s Series A Preferred Stock were converted into 2,438,851 shares of common stock, after giving effect to the 1.74 for 1 forward stock split of the common stock and net of the fractional shares adjustments that occurred in connection with the IPO.</us-gaap:StockholdersEquityNoteStockSplit>
  <us-gaap:ConversionOfStockSharesConverted1 unitRef="shares" contextRef="c60_From1Jun2020To15Jun2020_SeriesAPreferredStockMember" decimals="INF">2438851</us-gaap:ConversionOfStockSharesConverted1>
  <us-gaap:SaleOfStockConsiderationReceivedOnTransaction unitRef="usd" contextRef="c61_From1Jan2020To31Dec2020_SeriesAPreferredStockMember" decimals="0">261</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c22_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">50460</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharesIssuedPricePerShare unitRef="usdPershares" contextRef="c3_AsOf31Dec2020" decimals="2">1.03</us-gaap:SharesIssuedPricePerShare>
  <ltrn:CommonStockTotalProceedsValue unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">52000</ltrn:CommonStockTotalProceedsValue>
  <us-gaap:SharesIssued unitRef="shares" contextRef="c62_AsOf31Dec2020_CommonStockMember" decimals="INF">3350</us-gaap:SharesIssued>
  <ltrn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRight unitRef="shares" contextRef="c62_AsOf31Dec2020_CommonStockMember" decimals="INF">4022</ltrn:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRight>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c62_AsOf31Dec2020_CommonStockMember" decimals="INF">25000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c62_AsOf31Dec2020_CommonStockMember" decimals="INF">6220927</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding unitRef="shares" contextRef="c62_AsOf31Dec2020_CommonStockMember" decimals="INF">6220927</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c63_AsOf31Dec2019_CommonStockMember" decimals="INF">12180000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c63_AsOf31Dec2019_CommonStockMember" decimals="INF">1978269</us-gaap:CommonStockSharesIssued>
  <ltrn:CommonStockForIssuanceReservedShares unitRef="shares" contextRef="c64_From1Aug2018To29Aug2018_OptionsMember" decimals="INF">1489680</ltrn:CommonStockForIssuanceReservedShares>
  <ltrn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTerm contextRef="c65_From1Jan2020To31Dec2020_OptionsMember">P10Y</ltrn:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTerm>
  <ltrn:SharesRemainAvailableForFutureAwards unitRef="shares" contextRef="c65_From1Jan2020To31Dec2020_OptionsMember" decimals="INF">535099</ltrn:SharesRemainAvailableForFutureAwards>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c65_From1Jan2020To31Dec2020_OptionsMember" decimals="0">1192000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation unitRef="usd" contextRef="c66_From1Jan2019To31Dec2019_OptionsMember" decimals="0">118000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions unitRef="usd" contextRef="c62_AsOf31Dec2020_CommonStockMember" decimals="0">2480912</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c65_From1Jan2020To31Dec2020_OptionsMember">P1Y109D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c65_From1Jan2020To31Dec2020_OptionsMember">P8Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue unitRef="usd" contextRef="c67_AsOf31Dec2020_OptionsMember" decimals="0">10726878</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 unitRef="usd" contextRef="c67_AsOf31Dec2020_OptionsMember" decimals="0">9773797</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">20590</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend unitRef="usd" contextRef="c65_From1Jan2020To31Dec2020_OptionsMember" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
  <ltrn:WarrantsToPurchaseShares unitRef="shares" contextRef="c68_From1Jan2020To31Dec2020_WarrantMember" decimals="INF">325618</ltrn:WarrantsToPurchaseShares>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 unitRef="usdPershares" contextRef="c69_AsOf31Dec2020_WarrantMember" decimals="2">6.49</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <ltrn:WarrantsToPurchaseShares unitRef="shares" contextRef="c70_From1Jan2019To31Dec2019_WarrantMember" decimals="INF">262003</ltrn:WarrantsToPurchaseShares>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 unitRef="usdPershares" contextRef="c71_AsOf31Dec2019_WarrantMember" decimals="2">3.13</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:StockIssuedDuringPeriodSharesOther unitRef="shares" contextRef="c72_From1Jan2019To31Dec2019_SeriesAPreferredStockMember" decimals="INF">137513</us-gaap:StockIssuedDuringPeriodSharesOther>
  <ltrn:WarrantsToPurchaseShares unitRef="shares" contextRef="c73_From1Jan2020To31Dec2020_IPOMember" decimals="INF">70000</ltrn:WarrantsToPurchaseShares>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 unitRef="usdPershares" contextRef="c34_AsOf31Dec2020_IPOMember" decimals="2">18.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <ltrn:WarrantsToPurchasePercentage unitRef="pure" contextRef="c73_From1Jan2020To31Dec2020_IPOMember" decimals="2">1.25</ltrn:WarrantsToPurchasePercentage>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c69_AsOf31Dec2020_WarrantMember" decimals="INF">3350</us-gaap:CommonStockSharesIssued>
  <ltrn:PurchaseOfWarrantsShares unitRef="shares" contextRef="c68_From1Jan2020To31Dec2020_WarrantMember" decimals="INF">4022</ltrn:PurchaseOfWarrantsShares>
  <ltrn:WarrantsToPurchaseShares unitRef="shares" contextRef="c74_From1Jan2019To31Dec2019_SeriesAPreferredStockMember_WarrantMember" decimals="INF">39651</ltrn:WarrantsToPurchaseShares>
  <ltrn:WarrantsToPurchaseShares unitRef="shares" contextRef="c72_From1Jan2019To31Dec2019_SeriesAPreferredStockMember" decimals="INF">27754</ltrn:WarrantsToPurchaseShares>
  <ltrn:ClassOfWarrantTerm contextRef="c75_From1Jan2019To31Dec2019_MaximumMember_WarrantMember">P1Y7D</ltrn:ClassOfWarrantTerm>
  <us-gaap:OtherAdditionalCapital unitRef="usd" contextRef="c71_AsOf31Dec2019_WarrantMember" decimals="0">21000</us-gaap:OtherAdditionalCapital>
  <ltrn:WarrantsToPurchaseShares unitRef="shares" contextRef="c76_From1Jan2020To31Dec2020_CommonStockMember_WarrantMember" decimals="INF">23734</ltrn:WarrantsToPurchaseShares>
  <ltrn:WarrantsToPurchaseShares unitRef="shares" contextRef="c77_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">21360</ltrn:WarrantsToPurchaseShares>
  <ltrn:WarrantTerm contextRef="c68_From1Jan2020To31Dec2020_WarrantMember">003 to 1.003 years.</ltrn:WarrantTerm>
  <us-gaap:OtherAdditionalCapital unitRef="usd" contextRef="c69_AsOf31Dec2020_WarrantMember" decimals="0">36000</us-gaap:OtherAdditionalCapital>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Options Outstanding&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Options Exercisable&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;white-space: nowrap; text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Number
    of&lt;br/&gt; Shares&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted-Average&lt;br/&gt;
    Exercise Price&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Number
    of&lt;br/&gt; Options&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted-Average&lt;br/&gt;
    Exercise Price&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 52%; font-size: 10pt; text-align: justify&quot;&gt;Outstanding December 31, 2018&lt;/td&gt;&lt;td style=&quot;width: 1%; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-size: 10pt; text-align: right&quot;&gt;629,060&lt;/td&gt;&lt;td style=&quot;width: 1%; font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-size: 10pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; font-size: 10pt; text-align: right&quot;&gt;1.03&lt;/td&gt;&lt;td style=&quot;width: 1%; font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; font-size: 10pt; text-align: right&quot;&gt;194,479&lt;/td&gt;&lt;td style=&quot;width: 1%; font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%; font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; font-size: 10pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; font-size: 10pt; text-align: right&quot;&gt;1.03&lt;/td&gt;&lt;td style=&quot;width: 1%; font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: justify&quot;&gt;Granted&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;1,342&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;1.03&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: justify&quot;&gt;Exercised&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: justify; padding-bottom: 1.5pt&quot;&gt;Cancelled or expired&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right&quot;&gt;(22,911&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-size: 10pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right&quot;&gt;1.03&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-size: 10pt&quot;&gt;-&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: justify&quot;&gt;Outstanding December 31, 2019&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;607,491&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;1.03&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;393,413&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;1.03&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: justify&quot;&gt;Granted&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;321,743&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;15.01&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: justify&quot;&gt;Exercised&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;(50,460&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;1.03&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: justify&quot;&gt;Cancelled or expired&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;(43,166&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;1.03&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;font-size: 10pt; text-align: justify; padding-bottom: 4pt&quot;&gt;Outstanding December 31, 2020&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-size: 10pt; text-align: right&quot;&gt;835,608&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-size: 10pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-size: 10pt; text-align: right&quot;&gt;6.41&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-size: 10pt; text-align: right&quot;&gt;610,633&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-size: 10pt; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; font-size: 10pt; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; font-size: 10pt; text-align: right&quot;&gt;3.24&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; font-size: 10pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c12_AsOf31Dec2018" decimals="INF">629060</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c12_AsOf31Dec2018" decimals="2">1.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <ltrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber unitRef="shares" contextRef="c12_AsOf31Dec2018" decimals="INF">194479</ltrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber>
  <ltrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c12_AsOf31Dec2018" decimals="2">1.03</ltrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c7_From1Jan2019To31Dec2019" decimals="INF">1342</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c7_From1Jan2019To31Dec2019" decimals="2">1.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <ltrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross unitRef="shares" contextRef="c7_From1Jan2019To31Dec2019" xs:nil="true"/>
  <ltrn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c7_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c7_From1Jan2019To31Dec2019" xs:nil="true"/>
  <ltrn:StockIssuedDuringPeriodSharesStockOptionExercised unitRef="shares" contextRef="c7_From1Jan2019To31Dec2019" xs:nil="true"/>
  <ltrn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c7_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod unitRef="shares" contextRef="c7_From1Jan2019To31Dec2019" decimals="INF">22911</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c7_From1Jan2019To31Dec2019" decimals="2">1.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
  <ltrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiratiosInPeriod unitRef="shares" contextRef="c7_From1Jan2019To31Dec2019" xs:nil="true"/>
  <ltrn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c7_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c4_AsOf31Dec2019" decimals="INF">607491</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c4_AsOf31Dec2019" decimals="2">1.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <ltrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber unitRef="shares" contextRef="c4_AsOf31Dec2019" decimals="INF">393413</ltrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber>
  <ltrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c4_AsOf31Dec2019" decimals="2">1.03</ltrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">321743</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">15.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <ltrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <ltrn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <ltrn:StockIssuedDuringPeriodSharesOutstandingExcercised unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">50460</ltrn:StockIssuedDuringPeriodSharesOutstandingExcercised>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">1.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <ltrn:StockIssuedDuringPeriodSharesStockOptionExercised unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <ltrn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">43166</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">1.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
  <ltrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiratiosInPeriod unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <ltrn:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">835608</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c3_AsOf31Dec2020" decimals="2">6.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <ltrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">610633</ltrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber>
  <ltrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c3_AsOf31Dec2020" decimals="2">3.24</ltrn:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: justify&quot;&gt;Term (in years)&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;7.00&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;5.94&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Risk Free Rate&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;0.54% - 0.67&amp;#xa0;&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.79&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Volatility&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;83.2% - 84.37%&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;60.1&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Dividend Yield&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;0.0&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;0.0&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Grant Date Fair Value&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;white-space: nowrap; text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;&lt;/font&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;11.01 &amp;#x2013; 11.28 &lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;0.59&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c0_From1Jan2020To31Dec2020">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c7_From1Jan2019To31Dec2019">P5Y343D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c78_From1Jan2020To31Dec2020_MinimumMember" decimals="4">0.0054</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c79_From1Jan2020To31Dec2020_MaximumMember" decimals="4">0.0067</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c7_From1Jan2019To31Dec2019" decimals="4">0.0279</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c78_From1Jan2020To31Dec2020_MinimumMember" decimals="3">0.832</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c79_From1Jan2020To31Dec2020_MaximumMember" decimals="4">0.8437</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c7_From1Jan2019To31Dec2019" decimals="3">0.601</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c7_From1Jan2019To31Dec2019" decimals="3">0.000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c78_From1Jan2020To31Dec2020_MinimumMember" decimals="2">11.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c79_From1Jan2020To31Dec2020_MaximumMember" decimals="2">11.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c7_From1Jan2019To31Dec2019" decimals="2">0.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <ltrn:SafeAgreementsDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;&lt;b&gt;Note 7. SAFE Agreements&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In December 2018,
the Company entered into Simple Agreement for Future Equity (SAFE) agreements (the &amp;#x201c;SAFE Financing&amp;#x201d;) with five investors
pursuant to which the Company received funding of $535,000 in exchange for agreement to issue the investors shares of preferred
stock upon occurrence of a subsequent financing of preferred stock.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The number of shares
to be received by the SAFE agreement investors was based on 80% of the pricing in the triggering equity financing. In a liquidity
or dissolution event, the investors&amp;#x2019; right to receive cash out was junior to payment of outstanding indebtedness and creditor
claims, on par for other SAFEs and preferred stock, and senior to common stock. The SAFE agreements had no interest rate or maturity
date, and the SAFE investors had no voting right prior to conversion.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;As of December 31,
2018, the Company had received $535,000 of proceeds related to the SAFE agreements. The SAFE agreements had not yet converted
as a qualifying financing had not yet occurred as of December 31, 2018. Pursuant to the guidance under ASC 480, the Company determined
that the Purchase Amount (a term defined in the SAFE agreements denoting the amount in exchange for which an investor received
the rights to receive the shares) should be recorded as a liability on the Company&amp;#x2019;s balance sheet. Due to a short period
where the Company expected these to be converted, the Company recorded the entire amount of $535,000 as a short-term liability.
The SAFE agreements were converted to equity in March 2019 and the Company issued 213,510 shares of Series A Preferred Stock in
full satisfaction of these agreements.&lt;/p&gt;&lt;br/&gt;</ltrn:SafeAgreementsDisclosureTextBlock>
  <ltrn:AgreementDescription contextRef="c80_From1Dec2018To31Dec2018">the Company entered into Simple Agreement for Future Equity (SAFE) agreements (the &amp;#x201c;SAFE Financing&amp;#x201d;) with five investors pursuant to which the Company received funding of $535,000 in exchange for agreement to issue the investors shares of preferred stock upon occurrence of a subsequent financing of preferred stock.</ltrn:AgreementDescription>
  <us-gaap:InvestmentOwnedPercentOfNetAssets unitRef="pure" contextRef="c3_AsOf31Dec2020" decimals="2">0.80</us-gaap:InvestmentOwnedPercentOfNetAssets>
  <ltrn:NetProceeds unitRef="usd" contextRef="c12_AsOf31Dec2018" decimals="0">535000</ltrn:NetProceeds>
  <us-gaap:ShortTermLeasePayments unitRef="usd" contextRef="c80_From1Dec2018To31Dec2018" decimals="0">535000</us-gaap:ShortTermLeasePayments>
  <us-gaap:StockIssuedDuringPeriodSharesAcquisitions unitRef="shares" contextRef="c54_From1Mar2019To31Mar2019_SeriesAPreferredStockMember" decimals="INF">213510</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
  <us-gaap:DebtDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Note 8. Notes and Loan Payable&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In January 2020, the
Company entered into a financing arrangement for commercial insurance with First Insurance Funding. The total amount financed
was approximately $66,000 with an annual interest rate of 6.64%, to be paid over a period of ten months. In June 2020, the insurance
policy was canceled, and the remaining loan balance was repaid. As of December 31, 2020, there is no remaining loan balance on
the Company&amp;#x2019;s consolidated balance sheet related to the First Insurance financing arrangement.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;On May 1, 2020 (the
&amp;#x201c;Origination Date&amp;#x201d;), the Company received $108,500 in aggregate loan proceeds (the &amp;#x201c;PPP Loan&amp;#x201d;) from JPMorgan
Chase Bank (the &amp;#x201c;Lender&amp;#x201d;) pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic
Security (CARES) Act. The PPP Loan is evidenced by a loan application and payment agreement (the &amp;#x201c;PPP Loan Agreement&amp;#x201d;)
by and between the Company and the Lender. Subject to the terms of the PPP Loan Agreement, the PPP Loan bears interest at a fixed
rate of one percent (1.0%) per annum. Payments of principal and interest are deferred for the first six months following the Origination
Date, and the PPP Loan will mature two years after the Origination Date. The guidance under the Paycheck Protection Program was
later updated so that deferral of payments of principal and interest were extended to ten months after completion of the covered
period of 24 weeks and maturity was extended past two years. The Company is continuing to monitor further development and guidance
related to the Paycheck Protection Program terms.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Following the deferral
period, unless the loan is forgiven, the Company will be required to make payments of principal plus interest accrued under the
PPP Loan to the Lender in monthly installments based upon an amortization schedule to be determined by the Lender based on the
principal balance of the PPP Loan outstanding following the deferral period and taking into consideration any portion of the PPP
Loan that may be forgiven prior to that time. The PPP Loan is unsecured and guaranteed by the U.S. Small Business Administration.
The Company plans to file for forgiveness under this loan within the first half of 2021.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;During the twelve months
ended December 31, 2020, the Company received approximately $103,000 in funding resulting from a loan that was funded incorrectly.
All of the funds from the loan were repaid by the Company in July 2020, and no loan funds were expended prior to the repayment.
There are no amounts outstanding under this loan as of December 31, 2020.&lt;/p&gt;&lt;br/&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:DebtInstrumentMaturityDateDescription contextRef="c81_From1Jan2020To31Jan2020">The total amount financed was approximately $66,000 with an annual interest rate of 6.64%, to be paid over a period of ten months.</us-gaap:DebtInstrumentMaturityDateDescription>
  <us-gaap:DebtInstrumentAnnualPrincipalPayment unitRef="usd" contextRef="c82_AsOf31Jan2020" decimals="0">66000</us-gaap:DebtInstrumentAnnualPrincipalPayment>
  <us-gaap:DebtInstrumentInterestRateDuringPeriod unitRef="pure" contextRef="c81_From1Jan2020To31Jan2020" decimals="4">0.0664</us-gaap:DebtInstrumentInterestRateDuringPeriod>
  <us-gaap:ProceedsFromLoanOriginations1 unitRef="usd" contextRef="c83_From25Apr2020To1May2020" decimals="0">108500</us-gaap:ProceedsFromLoanOriginations1>
  <us-gaap:DebtInstrumentDescription contextRef="c83_From25Apr2020To1May2020">the PPP Loan bears interest at a fixed rate of one percent (1.0%) per annum. Payments of principal and interest are deferred for the first six months following the Origination Date, and the PPP Loan will mature two years after the Origination Date. The guidance under the Paycheck Protection Program was later updated so that deferral of payments of principal and interest were extended to ten months after completion of the covered period of 24 weeks and maturity was extended past two years.</us-gaap:DebtInstrumentDescription>
  <us-gaap:DebtInstrumentFaceAmount unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">103000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Note 9. Related Party Transactions&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Company has obtained
preclinical services from Biological Mimetics, Inc., which is also a stockholder in the Company. No expenses related to Biological
Mimetics, Inc. were recorded during the year ended December 31, 2020 and nothing was owed to Biological Mimetics, Inc. at December
31, 2020. The Company recorded expenses of approximately $23,000 related to Biological Mimetics, Inc. during the year ended December
31, 2019, all of which is included in research and development. Approximately $2,000 was owed to Biological Mimetics, Inc. at December
31, 2019.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The Company has previously
engaged Intuition Systems (&amp;#x201c;Intuition&amp;#x201d;) to provide services relating to development of the Company&amp;#x2019;s technology
infrastructure and artificial intelligence platform, cloud computing, and computational biology. The chief executive officer of
Intuition is the brother of Arun Asaithambi, the Company&amp;#x2019;s former Chief Executive Officer, President and Director. Nothing
was expensed related to Intuition during the years ended December 31, 2020 and 2019. At December 31, 2020 and 2019, approximately
$9,000 remained unpaid relating to Intuition and is included in accounts payable and accrued expenses in the accompanying consolidated
balance sheet.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;In January 2018, the
Company entered into an Assignment Agreement (the &amp;#x201c;Assignment Agreement&amp;#x201d;) with BioNumerik Pharmaceuticals, Inc. (&amp;#x201c;BioNumerik&amp;#x201d;),
pursuant to which the Company acquired rights to domestic and international patents, trademarks and related technology and data
relating to LP-300 for human therapeutic treatment indications. Mr. Margrave, the Company&amp;#x2019;s Chief Financial Officer and Secretary,
formerly served as the President, Chief Administrative Officer, General Counsel and Secretary of BioNumerik and has a minority
ownership interest in BioNumerik. Nothing was expensed related to BioNumerik during the year ended December 31, 2020. The Company
expensed less than $1,000 related to BioNumerik during the year ended December 31, 2019, which amount is included in general and
administrative expenses in the accompanying consolidated statement of operations. No amounts are owed to BioNumerik as of December
31, 2020. Approximately $11,000 was owed and recorded in accounts payable to BioNumerik as of December 31, 2019.&lt;/p&gt;&lt;br/&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty unitRef="usd" contextRef="c84_From1Jan2019To31Dec2019_BiologicalMimeticsIncMember" decimals="0">23000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
  <us-gaap:RelatedPartyTransactionAmountsOfTransaction unitRef="usd" contextRef="c84_From1Jan2019To31Dec2019_BiologicalMimeticsIncMember" decimals="0">2000</us-gaap:RelatedPartyTransactionAmountsOfTransaction>
  <us-gaap:DueToRelatedPartiesCurrent unitRef="usd" contextRef="c85_AsOf31Dec2020_IntuitionMember" decimals="0">9000</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:OtherGeneralAndAdministrativeExpense unitRef="usd" contextRef="c86_From1Jan2019To31Dec2019_BioNumerikMember" decimals="0">1000</us-gaap:OtherGeneralAndAdministrativeExpense>
  <us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent unitRef="usd" contextRef="c87_AsOf31Dec2019_BioNumerikMember" decimals="0">11000</us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent>
  <us-gaap:DueToRelatedPartiesCurrent unitRef="usd" contextRef="c88_AsOf31Dec2019_IntuitionMember" decimals="0">9000</us-gaap:DueToRelatedPartiesCurrent>
  <us-gaap:EarningsPerShareTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Note 10. Loss Per Share of Common Shares&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Basic loss per share
is derived by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding
during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities,
such as warrants, and stock options, which would result in the issuance of incremental shares of common stock unless such effect
is anti-dilutive. In calculating the basic and diluted net loss per share applicable to common stockholders, the weighted average
number of shares remained the same for both calculations due to the fact that when a net loss exists, dilutive shares are not
included in the calculation. Potentially dilutive securities outstanding that have been excluded from diluted loss per share due
to being anti-dilutive include the following:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-size: 12pt; text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;For the year ended &lt;br/&gt; December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-size: 12pt; text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: justify&quot;&gt;Warrants&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;325,618&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;262,003&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Stock options&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;835,608&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;607,491&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt&quot;&gt;Series A preferred stock&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2,438,866&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;font-size: 12pt; text-align: justify; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,161,226&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;3,308,360&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-size: 12pt; text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;For the year ended &lt;br/&gt; December 31,&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;font-size: 12pt; text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: justify&quot;&gt;Warrants&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;325,618&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;262,003&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Stock options&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;835,608&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;607,491&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt&quot;&gt;Series A preferred stock&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2,438,866&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;font-size: 12pt; text-align: justify; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;1,161,226&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;3,308,360&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c89_From1Jan2020To31Dec2020_WarrantMember" decimals="INF">325618</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c90_From1Jan2019To31Dec2019_WarrantMember" decimals="INF">262003</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c91_From1Jan2020To31Dec2020_EmployeeStockOptionMember" decimals="INF">835608</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c92_From1Jan2019To31Dec2019_EmployeeStockOptionMember" decimals="INF">607491</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c93_From1Jan2020To31Dec2020_SeriesAPreferredStockMember" xs:nil="true"/>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c94_From1Jan2019To31Dec2019_SeriesAPreferredStockMember" decimals="INF">2438866</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">1161226</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c7_From1Jan2019To31Dec2019" decimals="INF">3308360</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Note 11. Income Taxes&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Our effective tax rate
differs from the statutory federal tax rate as presented in the following table:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: justify&quot;&gt;U.S. federal statutory tax rate&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;21&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;%&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;21&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(1&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Valuation allowance&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(22&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(20&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Total:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;As of December 31,
2020 and 2019, the Company was domiciled in Texas, and due to the losses generated and no revenues, it incurred no federal or state
tax.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;The tax effect of the
temporary differences that give rise to the significant portions of the deferred tax assets and liabilities is presented below.&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;December 31,&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Deferred tax assets&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: justify; padding-left: 9pt&quot;&gt;Depreciation&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;502&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 9pt&quot;&gt;Research and development credits&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;180,889&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;93,102&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 9pt&quot;&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;257,941&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;24,695&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt&quot;&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2,417,169&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;1,366,040&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 9pt&quot;&gt;Deferred tax asset&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,855,999&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,484,340&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt&quot;&gt;Less: valuation allowance&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(2,849,762&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(1,484,340&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Net deferred tax asset&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6,237&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Deferred tax liabilities&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt&quot;&gt;Fixed assets&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(6,237&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 4pt&quot;&gt;Net deferred tax assets&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Due to a history
of losses we have generated since inception, we believe it is more-likely-than-not that all of the deferred tax assets will
not be realized as of December 31, 2020 and 2019. Therefore, we have recorded a full valuation allowance on our deferred tax
assets. At December 31, 2020 and 2019, we have net operating loss (&amp;#x201c;NOL&amp;#x201d;) carryforwards for federal income tax
purposes of approximately $11.5 million and $6.5 million, respectively. The NOL carryforwards generated prior to 2018 of
approximately $3.1 million could expire over time beginning in 2035, if not used. The NOL carryforwards generated in 2018 to
2020 of $8.4 million do not expire and are carried forward indefinitely. We also have state NOLs of approximately $71,000 at
December 31, 2020. The Company also has approximately $181,000 of research and development tax credit carryforwards for
federal purposes. These credits begin expiring in 2034. Due to the change in ownership provisions of the Internal Revenue
Code, the availability of the Company&amp;#x2019;s NOL carryforwards and research and development credit carryforwards may be
subject to annual limitations under Section 382 of the Internal Revenue Code against taxable income in the future period,
which could substantially limit the eventual utilization of such carryforwards.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;Entities are also required
to evaluate, measure, recognize and disclose any uncertain income tax provisions taken on their income tax returns. The Company
has analyzed its tax positions and has concluded that as of December 31, 2020, there were no uncertain positions. In addition,
interest and penalties, if any, as they relate to income taxes assessed, are included in the income tax provision, for which there
were none. The Company&amp;#x2019;s U.S. federal operating losses have occurred since its inception and as such, tax years subject to
potential tax examination could apply from that date because the utilization of net operating losses from prior years opens the
relevant year to audit by the IRS and/or state taxing authorities.&lt;/p&gt;&lt;br/&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-5">11500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="-5">6500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="-5">3100000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness unitRef="usd" contextRef="c95_AsOf31Dec2020_StateAndLocalJurisdictionMember" decimals="-5">8400000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">71000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">181000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsForeign>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: justify&quot;&gt;U.S. federal statutory tax rate&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;21&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;%&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;21&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Permanent differences&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(1&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Valuation allowance&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(22&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(20&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Total:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;-&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate unitRef="pure" contextRef="c7_From1Jan2019To31Dec2019" decimals="2">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
  <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions unitRef="pure" contextRef="c7_From1Jan2019To31Dec2019" decimals="2">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">-0.22</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance unitRef="pure" contextRef="c7_From1Jan2019To31Dec2019" decimals="2">-0.20</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:EffectiveIncomeTaxRateContinuingOperations unitRef="pure" contextRef="c7_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;6&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;December 31,&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid&quot;&gt;2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Deferred tax assets&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: justify; padding-left: 9pt&quot;&gt;Depreciation&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;502&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 9pt&quot;&gt;Research and development credits&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;180,889&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;93,102&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 9pt&quot;&gt;Stock-based compensation&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;257,941&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;24,695&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt&quot;&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2,417,169&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;1,366,040&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-left: 9pt&quot;&gt;Deferred tax asset&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,855,999&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,484,340&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt&quot;&gt;Less: valuation allowance&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(2,849,762&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(1,484,340&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Net deferred tax asset&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6,237&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify&quot;&gt;Deferred tax liabilities&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt&quot;&gt;Fixed assets&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(6,237&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: justify; padding-bottom: 4pt&quot;&gt;Net deferred tax assets&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <ltrn:DeferredTaxAssetsDepreciation unitRef="usd" contextRef="c3_AsOf31Dec2020" xs:nil="true"/>
  <ltrn:DeferredTaxAssetsDepreciation unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">502</ltrn:DeferredTaxAssetsDepreciation>
  <ltrn:DeferredTaxAssetsResearchAndDevelopmentCredits unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">180889</ltrn:DeferredTaxAssetsResearchAndDevelopmentCredits>
  <ltrn:DeferredTaxAssetsResearchAndDevelopmentCredits unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">93102</ltrn:DeferredTaxAssetsResearchAndDevelopmentCredits>
  <ltrn:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockBasedCompensation unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">257941</ltrn:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockBasedCompensation>
  <ltrn:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockBasedCompensation unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">24695</ltrn:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockBasedCompensation>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">2417169</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">1366040</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsGross unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">2855999</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">1484340</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsValuationAllowance unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">2849762</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">1484340</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsNet unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">6237</us-gaap:DeferredTaxAssetsNet>
  <us-gaap:DeferredTaxAssetsNet unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">6237</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets>
  <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssets unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet unitRef="usd" contextRef="c3_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:DeferredTaxAssetsLiabilitiesNet unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:SubsequentEventsTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;&lt;b&gt;Note 12. Subsequent Events&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in&quot;&gt;On January 20, 2021,
the Company closed a public offering of 4,928,571 shares of its common stock at a public offering price of $14.00 per share, which
amount included 642,856 shares sold upon full exercise of the underwriter&amp;#x2019;s over-allotment option. Total gross proceeds from
the offering were $68,999,994, and net proceeds from the offering were approximately $64,200,000.&lt;/p&gt;&lt;br/&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesOther unitRef="shares" contextRef="c31_From1Jan2021To20Jan2021_SubsequentEventMember" decimals="INF">4928571</us-gaap:StockIssuedDuringPeriodSharesOther>
  <ltrn:PublicOfferingPerShare unitRef="usdPershares" contextRef="c31_From1Jan2021To20Jan2021_SubsequentEventMember" decimals="2">14.00</ltrn:PublicOfferingPerShare>
  <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction unitRef="shares" contextRef="c31_From1Jan2021To20Jan2021_SubsequentEventMember" decimals="INF">642856</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>ltrn-20201231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Mar 10 03:43:46 EST 2021 -->
<xs:schema elementFormDefault="qualified" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" targetNamespace="http://laternpharma.com/20201231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ltrn="http://laternpharma.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="ltrn-20201231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="ltrn-20201231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="ltrn-20201231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="ltrn-20201231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://laternpharma.com/role/ConsolidatedBalanceSheet" id="ltrn_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/ConsolidatedBalanceSheet_Parentheticals" id="ltrn_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/ConsolidatedIncomeStatement" id="ltrn_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/ShareholdersEquityType2or3" id="ltrn_r_ShareholdersEquityType2or3">
        <link:definition>004 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/ConsolidatedCashFlow" id="ltrn_r_ConsolidatedCashFlow">
        <link:definition>005 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/OrganizationPrincipalActivitiesandBasisofPresentation" id="ltrn_r_OrganizationPrincipalActivitiesandBasisofPresentation">
        <link:definition>006 - Disclosure - Organization, Principal Activities, and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/Liquidity" id="ltrn_r_Liquidity">
        <link:definition>007 - Disclosure - Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/SummaryofSignificantAccountingPolicies" id="ltrn_r_SummaryofSignificantAccountingPolicies">
        <link:definition>008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/NewAccountingPronouncements" id="ltrn_r_NewAccountingPronouncements">
        <link:definition>009 - Disclosure - New Accounting Pronouncements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/CommitmentsandContingencies" id="ltrn_r_CommitmentsandContingencies">
        <link:definition>010 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/ShareholdersEquity" id="ltrn_r_ShareholdersEquity">
        <link:definition>011 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/SafeAgreements" id="ltrn_r_SafeAgreements">
        <link:definition>012 - Disclosure - Safe Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/NotesandLoanPayable" id="ltrn_r_NotesandLoanPayable">
        <link:definition>013 - Disclosure - Notes and Loan Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/RelatedPartyTransactions" id="ltrn_r_RelatedPartyTransactions">
        <link:definition>014 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/LossPerShareofCommonShares" id="ltrn_r_LossPerShareofCommonShares">
        <link:definition>015 - Disclosure - Loss Per Share of Common Shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/IncomeTaxes" id="ltrn_r_IncomeTaxes">
        <link:definition>016 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/SubsequentEvents" id="ltrn_r_SubsequentEvents">
        <link:definition>017 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/AccountingPoliciesByPolicy" id="ltrn_r_AccountingPoliciesByPolicy">
        <link:definition>018 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/ShareholdersEquityTables" id="ltrn_r_ShareholdersEquityTables">
        <link:definition>019 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/LossPerShareofCommonSharesTables" id="ltrn_r_LossPerShareofCommonSharesTables">
        <link:definition>020 - Disclosure - Loss Per Share of Common Shares (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/IncomeTaxesTables" id="ltrn_r_IncomeTaxesTables">
        <link:definition>021 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/OrganizationPrincipalActivitiesandBasisofPresentationDetails" id="ltrn_r_OrganizationPrincipalActivitiesandBasisofPresentationDetails">
        <link:definition>022 - Disclosure - Organization, Principal Activities, and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/LiquidityDetails" id="ltrn_r_LiquidityDetails">
        <link:definition>023 - Disclosure - Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" id="ltrn_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>024 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/CommitmentsandContingenciesDetails" id="ltrn_r_CommitmentsandContingenciesDetails">
        <link:definition>025 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/ShareholdersEquityDetails" id="ltrn_r_ShareholdersEquityDetails">
        <link:definition>026 - Disclosure - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbBx2uhymvyVLDa+1t8Zs6OCx+D0Bcy6Dt/X9wfJ64eyeWWDp4AwLD4hnV42U8gMPb6ZmoZskqs/VGWXFAW+VCwrstTEwsw9mBsjnLef0gxwD31/7ddIjxiai89b27Ur3wVtqpWYQb962vnZqopmU1PbSobqhOErLV5kQmlf1KTTNwUf5Cat3VqHfqB6p65LVdPfDJ1d07i200IN7uX6KRu] CSR-->
      <link:roleType roleURI="http://laternpharma.com/role/ScheduleofstockoptionactivityTable" id="ltrn_r_ScheduleofstockoptionactivityTable">
        <link:definition>027 - Disclosure - Shareholders' Equity (Details) - Schedule of stock option activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/ScheduleofweightedaverageassumptionsTable" id="ltrn_r_ScheduleofweightedaverageassumptionsTable">
        <link:definition>028 - Disclosure - Shareholders' Equity (Details) - Schedule of weighted average assumptions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/SafeAgreementsDetails" id="ltrn_r_SafeAgreementsDetails">
        <link:definition>029 - Disclosure - Safe Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/NotesandLoanPayableDetails" id="ltrn_r_NotesandLoanPayableDetails">
        <link:definition>030 - Disclosure - Notes and Loan Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/RelatedPartyTransactionsDetails" id="ltrn_r_RelatedPartyTransactionsDetails">
        <link:definition>031 - Disclosure - Related Party Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/ScheduleofdilutedlosspershareduetobeingantidilutiveTable" id="ltrn_r_ScheduleofdilutedlosspershareduetobeingantidilutiveTable">
        <link:definition>032 - Disclosure - Loss Per Share of Common Shares (Details) - Schedule of diluted loss per share due to being anti-dilutive</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/IncomeTaxesDetails" id="ltrn_r_IncomeTaxesDetails">
        <link:definition>033 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/ScheduleofEffectivetaxratediffersfromthestatutoryfederaltaxrateaspresentedTable" id="ltrn_r_ScheduleofEffectivetaxratediffersfromthestatutoryfederaltaxrateaspresentedTable">
        <link:definition>034 - Disclosure - Income Taxes (Details) - Schedule of Effective tax rate differs from the statutory federal tax rate as presented</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/ScheduleofEffectofthetemporarydifferencesthatgiverisetothesignificantportionsofthedeferredtaxassetsandliabilitiesTable" id="ltrn_r_ScheduleofEffectofthetemporarydifferencesthatgiverisetothesignificantportionsofthedeferredtaxassetsandliabilitiesTable">
        <link:definition>035 - Disclosure - Income Taxes (Details) - Schedule of Effect of the temporary differences that give rise to the significant portions of the deferred tax assets and liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/SubsequentEventsDetails" id="ltrn_r_SubsequentEventsDetails">
        <link:definition>036 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://laternpharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd"/>
  <xs:element name="ScheduleOfStockOptionActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ScheduleOfStockOptionActivityAbstract"/>
  <xs:element name="ScheduleOfWeightedAverageAssumptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ScheduleOfWeightedAverageAssumptionsAbstract"/>
  <xs:element name="SafeAgreementsDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_SafeAgreementsDisclosureAbstract"/>
  <xs:element name="ScheduleOfDilutedLossPerShareDueToBeingAntiDilutiveAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ScheduleOfDilutedLossPerShareDueToBeingAntiDilutiveAbstract"/>
  <xs:element name="ScheduleOfEffectiveTaxRateDiffersFromTheStatutoryFederalTaxRateAsPresentedAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ScheduleOfEffectiveTaxRateDiffersFromTheStatutoryFederalTaxRateAsPresentedAbstract"/>
  <xs:element name="ScheduleOfEffectOfTheTemporaryDifferencesThatGiveRiseToTheSignificantPortionsOfTheDeferredTaxAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ScheduleOfEffectOfTheTemporaryDifferencesThatGiveRiseToTheSignificantPortionsOfTheDeferredTaxAssetsAndLiabilitiesAbstract"/>
  <xs:element name="DeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_DeferredTaxAssetsAbstract"/>
  <xs:element name="StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants"/>
  <xs:element name="StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants"/>
  <xs:element name="CommonStockIssuedFromOfferingNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCosts"/>
  <xs:element name="CommonStockIssuedFromOfferingNetOfIssuanceCostsinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCostsinShares"/>
  <xs:element name="StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment"/>
  <xs:element name="CashlessExerciseOfWarrant" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_CashlessExerciseOfWarrant"/>
  <xs:element name="CashlessExerciseOfWarrantinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_CashlessExerciseOfWarrantinShares"/>
  <xs:element name="IncreaseDecreasePurchaseOfPropertyAndEquipment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment"/>
  <xs:element name="IncreaseDecreaseIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_IncreaseDecreaseIssuanceCosts"/>
  <xs:element name="ProceedsFromPreferredStockConvertedToCommonStockNetOfFractionalSharesAdjustment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ProceedsFromPreferredStockConvertedToCommonStockNetOfFractionalSharesAdjustment"/>
  <xs:element name="IncreaseDecreaseInBorrowingsOnLoanPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable"/>
  <xs:element name="ConversionOfSafeAgreementsToSeriesPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock"/>
  <xs:element name="ApplicationOfDeferredOfferingCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ApplicationOfDeferredOfferingCosts"/>
  <xs:element name="DeferredOfferingCostsRecordedInAPAndAccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_DeferredOfferingCostsRecordedInAPAndAccruedExpenses"/>
  <xs:element name="SafeAgreementsDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_SafeAgreementsDisclosureTextBlock"/>
  <xs:element name="PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock"/>
  <xs:element name="LoanPursuantToPaycheckProtectionProgramTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_LoanPursuantToPaycheckProtectionProgramTextBlock"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross"/>
  <xs:element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageExercisePrice"/>
  <xs:element name="StockIssuedDuringPeriodSharesOutstandingExcercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_StockIssuedDuringPeriodSharesOutstandingExcercised"/>
  <xs:element name="StockIssuedDuringPeriodSharesStockOptionExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_StockIssuedDuringPeriodSharesStockOptionExercised"/>
  <xs:element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExercisesInPeriodWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExercisesInPeriodWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiratiosInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiratiosInPeriod"/>
  <xs:element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationInPeriodWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationInPeriodWeightedAverageExercisePrice"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofweightedaverageassumptionsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ltrn_ShareholdersEquityDetailsScheduleofweightedaverageassumptionsTable"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofweightedaverageassumptionsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ShareholdersEquityDetailsScheduleofweightedaverageassumptionsLineItems"/>
  <xs:element name="LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable"/>
  <xs:element name="LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems"/>
  <xs:element name="DeferredTaxAssetsDepreciation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_DeferredTaxAssetsDepreciation"/>
  <xs:element name="DeferredTaxAssetsResearchAndDevelopmentCredits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_DeferredTaxAssetsResearchAndDevelopmentCredits"/>
  <xs:element name="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockBasedCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockBasedCompensation"/>
  <xs:element name="OrganizationPrincipalActivitiesandBasisofPresentationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsTable"/>
  <xs:element name="OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems"/>
  <xs:element name="LiquidityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ltrn_LiquidityDetailsTable"/>
  <xs:element name="LiquidityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_LiquidityDetailsLineItems"/>
  <xs:element name="WorkingCapital" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_WorkingCapital"/>
  <xs:element name="NetProceed" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_NetProceed"/>
  <xs:element name="TotalGrossProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_TotalGrossProceeds"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ltrn_SummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
  <xs:element name="UpfrontContractorFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_UpfrontContractorFees"/>
  <xs:element name="PatentLicenseFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_PatentLicenseFees"/>
  <xs:element name="UndepositedFunds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_UndepositedFunds"/>
  <xs:element name="CommitmentsandContingenciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ltrn_CommitmentsandContingenciesDetailsTable"/>
  <xs:element name="CommitmentsandContingenciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_CommitmentsandContingenciesDetailsLineItems"/>
  <xs:element name="UpfrontPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_UpfrontPayments"/>
  <xs:element name="NetRevenuePercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_NetRevenuePercentage"/>
  <xs:element name="Annualfees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_Annualfees"/>
  <xs:element name="MilestoneExtensionPaid" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_MilestoneExtensionPaid"/>
  <xs:element name="ResearchAndDevelopmentExpensesPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ResearchAndDevelopmentExpensesPercentage"/>
  <xs:element name="GrantedPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_GrantedPeriod"/>
  <xs:element name="ManufacturingAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ManufacturingAgreementDescription"/>
  <xs:element name="ProductCandidates" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ProductCandidates"/>
  <xs:element name="ShareholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ltrn_ShareholdersEquityDetailsTable"/>
  <xs:element name="ShareholdersEquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ShareholdersEquityDetailsLineItems"/>
  <xs:element name="WarrantsToPurchaseShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_WarrantsToPurchaseShares"/>
  <xs:element name="CommonStockPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ltrn_CommonStockPercentage"/>
  <xs:element name="CommonStockTotalProceedsValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_CommonStockTotalProceedsValue"/>
  <xs:element name="OtherOfferingExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_OtherOfferingExpenses"/>
  <xs:element name="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRight" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRight"/>
  <xs:element name="CommonStockForIssuanceReservedShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_CommonStockForIssuanceReservedShares"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTerm"/>
  <xs:element name="SharesRemainAvailableForFutureAwards" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_SharesRemainAvailableForFutureAwards"/>
  <xs:element name="WarrantsToPurchasePercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_WarrantsToPurchasePercentage"/>
  <xs:element name="PurchaseOfWarrantsShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_PurchaseOfWarrantsShares"/>
  <xs:element name="ClassOfWarrantTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_ClassOfWarrantTerm"/>
  <xs:element name="WarrantTerm" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_WarrantTerm"/>
  <xs:element name="SafeAgreementsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ltrn_SafeAgreementsDetailsTable"/>
  <xs:element name="SafeAgreementsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_SafeAgreementsDetailsLineItems"/>
  <xs:element name="AgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_AgreementDescription"/>
  <xs:element name="NetProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="ltrn_NetProceeds"/>
  <xs:element name="RelatedPartyTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ltrn_RelatedPartyTransactionsDetailsTable"/>
  <xs:element name="RelatedPartyTransactionsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_RelatedPartyTransactionsDetailsLineItems"/>
  <xs:element name="IncomeTaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ltrn_IncomeTaxesDetailsTable"/>
  <xs:element name="IncomeTaxesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_IncomeTaxesDetailsLineItems"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="ltrn_SubsequentEventsDetailsTable"/>
  <xs:element name="SubsequentEventsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_SubsequentEventsDetailsLineItems"/>
  <xs:element name="PublicOfferingPerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_PublicOfferingPerShare"/>
  <xs:element name="AFChemicalsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_AFChemicalsMember"/>
  <xs:element name="BioNumerikMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_BioNumerikMember"/>
  <xs:element name="BioNumerikPharmaceuticalMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_BioNumerikPharmaceuticalMember"/>
  <xs:element name="BiologicalMimeticsIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_BiologicalMimeticsIncMember"/>
  <xs:element name="EUGrantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_EUGrantMember"/>
  <xs:element name="IntuitionMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_IntuitionMember"/>
  <xs:element name="LP100Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_LP100Member"/>
  <xs:element name="LP184Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_LP184Member"/>
  <xs:element name="OptionsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_OptionsMember"/>
  <xs:element name="PatheonAPIServicesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_PatheonAPIServicesMember"/>
  <xs:element name="SouthwestResearchInstituteMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_SouthwestResearchInstituteMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="ltrn_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>ltrn-20201231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Mar 10 03:43:46 EST 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_ConsolidatedBalanceSheet" roleURI="http://laternpharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_ConsolidatedIncomeStatement" roleURI="http://laternpharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_ConsolidatedCashFlow" roleURI="http://laternpharma.com/role/ConsolidatedCashFlow"/>
  <calculationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbBx2uhymvyVLDa+1t8Zs6OCx+D0Bcy6Dt/X9wfJ64eyeWWDp4AwLD4hnV42U8gMPb6ZmoZskqs/VGWXFAW+VCwrstTEwsw9mBsjnLef0gxwD31/7ddIjxiai89b27Ur3wVtqpWYQb962vnZqopmU1PbSobqhOErLV5kQmlf1KTTNwUf5Cat3VqbECnqtaDVc9TFYG6Dbh/ypzGAKrU8xwU] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment" xlink:href="ltrn-20201231.xsd#ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromNotesPayable" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable" xlink:href="ltrn-20201231.xsd#ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="ltrn_IncreaseDecreaseIssuanceCosts" xlink:href="ltrn-20201231.xsd#ltrn_IncreaseDecreaseIssuanceCosts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="ltrn_IncreaseDecreaseIssuanceCosts" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="ltrn_ProceedsFromPreferredStockConvertedToCommonStockNetOfFractionalSharesAdjustment" xlink:href="ltrn-20201231.xsd#ltrn_ProceedsFromPreferredStockConvertedToCommonStockNetOfFractionalSharesAdjustment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="ltrn_ProceedsFromPreferredStockConvertedToCommonStockNetOfFractionalSharesAdjustment" order="7" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>ltrn-20201231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Mar 10 03:43:46 EST 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_ConsolidatedBalanceSheet" roleURI="http://laternpharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://laternpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_ConsolidatedIncomeStatement" roleURI="http://laternpharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_ShareholdersEquityType2or3" roleURI="http://laternpharma.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_ConsolidatedCashFlow" roleURI="http://laternpharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_OrganizationPrincipalActivitiesandBasisofPresentation" roleURI="http://laternpharma.com/role/OrganizationPrincipalActivitiesandBasisofPresentation"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_Liquidity" roleURI="http://laternpharma.com/role/Liquidity"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_SummaryofSignificantAccountingPolicies" roleURI="http://laternpharma.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_NewAccountingPronouncements" roleURI="http://laternpharma.com/role/NewAccountingPronouncements"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_CommitmentsandContingencies" roleURI="http://laternpharma.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_ShareholdersEquity" roleURI="http://laternpharma.com/role/ShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_SafeAgreements" roleURI="http://laternpharma.com/role/SafeAgreements"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_NotesandLoanPayable" roleURI="http://laternpharma.com/role/NotesandLoanPayable"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_RelatedPartyTransactions" roleURI="http://laternpharma.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_LossPerShareofCommonShares" roleURI="http://laternpharma.com/role/LossPerShareofCommonShares"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_IncomeTaxes" roleURI="http://laternpharma.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_SubsequentEvents" roleURI="http://laternpharma.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_AccountingPoliciesByPolicy" roleURI="http://laternpharma.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_ShareholdersEquityTables" roleURI="http://laternpharma.com/role/ShareholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_LossPerShareofCommonSharesTables" roleURI="http://laternpharma.com/role/LossPerShareofCommonSharesTables"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_IncomeTaxesTables" roleURI="http://laternpharma.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_ScheduleofstockoptionactivityTable" roleURI="http://laternpharma.com/role/ScheduleofstockoptionactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_ScheduleofweightedaverageassumptionsTable" roleURI="http://laternpharma.com/role/ScheduleofweightedaverageassumptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_ScheduleofdilutedlosspershareduetobeingantidilutiveTable" roleURI="http://laternpharma.com/role/ScheduleofdilutedlosspershareduetobeingantidilutiveTable"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_ScheduleofEffectivetaxratediffersfromthestatutoryfederaltaxrateaspresentedTable" roleURI="http://laternpharma.com/role/ScheduleofEffectivetaxratediffersfromthestatutoryfederaltaxrateaspresentedTable"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_ScheduleofEffectofthetemporarydifferencesthatgiverisetothesignificantportionsofthedeferredtaxassetsandliabilitiesTable" roleURI="http://laternpharma.com/role/ScheduleofEffectofthetemporarydifferencesthatgiverisetothesignificantportionsofthedeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_OrganizationPrincipalActivitiesandBasisofPresentationDetails" roleURI="http://laternpharma.com/role/OrganizationPrincipalActivitiesandBasisofPresentationDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_LiquidityDetails" roleURI="http://laternpharma.com/role/LiquidityDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://laternpharma.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_CommitmentsandContingenciesDetails" roleURI="http://laternpharma.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_ShareholdersEquityDetails" roleURI="http://laternpharma.com/role/ShareholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_SafeAgreementsDetails" roleURI="http://laternpharma.com/role/SafeAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_NotesandLoanPayableDetails" roleURI="http://laternpharma.com/role/NotesandLoanPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_RelatedPartyTransactionsDetails" roleURI="http://laternpharma.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_IncomeTaxesDetails" roleURI="http://laternpharma.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_SubsequentEventsDetails" roleURI="http://laternpharma.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#DocumentAndEntityInformation" roleURI="http://laternpharma.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants" xlink:href="ltrn-20201231.xsd#ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants" xlink:href="ltrn-20201231.xsd#ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCosts" xlink:href="ltrn-20201231.xsd#ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCosts" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCostsinShares" xlink:href="ltrn-20201231.xsd#ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCostsinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCostsinShares" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment" xlink:href="ltrn-20201231.xsd#ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_CashlessExerciseOfWarrant" xlink:href="ltrn-20201231.xsd#ltrn_CashlessExerciseOfWarrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ltrn_CashlessExerciseOfWarrant" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_CashlessExerciseOfWarrantinShares" xlink:href="ltrn-20201231.xsd#ltrn_CashlessExerciseOfWarrantinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="ltrn_CashlessExerciseOfWarrantinShares" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment" xlink:href="ltrn-20201231.xsd#ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_IncreaseDecreaseIssuanceCosts" xlink:href="ltrn-20201231.xsd#ltrn_IncreaseDecreaseIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ltrn_IncreaseDecreaseIssuanceCosts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_ProceedsFromPreferredStockConvertedToCommonStockNetOfFractionalSharesAdjustment" xlink:href="ltrn-20201231.xsd#ltrn_ProceedsFromPreferredStockConvertedToCommonStockNetOfFractionalSharesAdjustment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ltrn_ProceedsFromPreferredStockConvertedToCommonStockNetOfFractionalSharesAdjustment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable" xlink:href="ltrn-20201231.xsd#ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock" xlink:href="ltrn-20201231.xsd#ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_ApplicationOfDeferredOfferingCosts" xlink:href="ltrn-20201231.xsd#ltrn_ApplicationOfDeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ltrn_ApplicationOfDeferredOfferingCosts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_DeferredOfferingCostsRecordedInAPAndAccruedExpenses" xlink:href="ltrn-20201231.xsd#ltrn_DeferredOfferingCostsRecordedInAPAndAccruedExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ltrn_DeferredOfferingCostsRecordedInAPAndAccruedExpenses" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/OrganizationPrincipalActivitiesandBasisofPresentation">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/Liquidity">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/NewAccountingPronouncements">
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ShareholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/SafeAgreements">
    <loc xlink:type="locator" xlink:label="ltrn_SafeAgreementsDisclosureAbstract" xlink:href="ltrn-20201231.xsd#ltrn_SafeAgreementsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ltrn_SafeAgreementsDisclosureTextBlock" xlink:href="ltrn-20201231.xsd#ltrn_SafeAgreementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_SafeAgreementsDisclosureAbstract" xlink:to="ltrn_SafeAgreementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/NotesandLoanPayable">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/LossPerShareofCommonShares">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:href="ltrn-20201231.xsd#ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_LoanPursuantToPaycheckProtectionProgramTextBlock" xlink:href="ltrn-20201231.xsd#ltrn_LoanPursuantToPaycheckProtectionProgramTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ltrn_LoanPursuantToPaycheckProtectionProgramTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ShareholdersEquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/LossPerShareofCommonSharesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ScheduleofstockoptionactivityTable">
    <loc xlink:type="locator" xlink:label="ltrn_ScheduleOfStockOptionActivityAbstract" xlink:href="ltrn-20201231.xsd#ltrn_ScheduleOfStockOptionActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" xlink:href="ltrn-20201231.xsd#ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ScheduleOfStockOptionActivityAbstract" xlink:to="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:href="ltrn-20201231.xsd#ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ScheduleOfStockOptionActivityAbstract" xlink:to="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross" xlink:href="ltrn-20201231.xsd#ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ScheduleOfStockOptionActivityAbstract" xlink:to="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageExercisePrice" xlink:href="ltrn-20201231.xsd#ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ScheduleOfStockOptionActivityAbstract" xlink:to="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_StockIssuedDuringPeriodSharesOutstandingExcercised" xlink:href="ltrn-20201231.xsd#ltrn_StockIssuedDuringPeriodSharesOutstandingExcercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ScheduleOfStockOptionActivityAbstract" xlink:to="ltrn_StockIssuedDuringPeriodSharesOutstandingExcercised" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_StockIssuedDuringPeriodSharesStockOptionExercised" xlink:href="ltrn-20201231.xsd#ltrn_StockIssuedDuringPeriodSharesStockOptionExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ScheduleOfStockOptionActivityAbstract" xlink:to="ltrn_StockIssuedDuringPeriodSharesStockOptionExercised" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExercisesInPeriodWeightedAverageExercisePrice" xlink:href="ltrn-20201231.xsd#ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ScheduleOfStockOptionActivityAbstract" xlink:to="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExercisesInPeriodWeightedAverageExercisePrice" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiratiosInPeriod" xlink:href="ltrn-20201231.xsd#ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiratiosInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ScheduleOfStockOptionActivityAbstract" xlink:to="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiratiosInPeriod" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationInPeriodWeightedAverageExercisePrice" xlink:href="ltrn-20201231.xsd#ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ScheduleOfStockOptionActivityAbstract" xlink:to="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationInPeriodWeightedAverageExercisePrice" order="15" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ScheduleofweightedaverageassumptionsTable">
    <loc xlink:type="locator" xlink:label="ltrn_ShareholdersEquityDetailsScheduleofweightedaverageassumptionsLineItems" xlink:href="ltrn-20201231.xsd#ltrn_ShareholdersEquityDetailsScheduleofweightedaverageassumptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="ltrn_ShareholdersEquityDetailsScheduleofweightedaverageassumptionsTable" xlink:href="ltrn-20201231.xsd#ltrn_ShareholdersEquityDetailsScheduleofweightedaverageassumptionsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ltrn_ShareholdersEquityDetailsScheduleofweightedaverageassumptionsLineItems" xlink:to="ltrn_ShareholdersEquityDetailsScheduleofweightedaverageassumptionsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_ShareholdersEquityDetailsScheduleofweightedaverageassumptionsTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsScheduleofweightedaverageassumptionsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsScheduleofweightedaverageassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsScheduleofweightedaverageassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsScheduleofweightedaverageassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsScheduleofweightedaverageassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ScheduleofdilutedlosspershareduetobeingantidilutiveTable">
    <loc xlink:type="locator" xlink:label="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems" xlink:href="ltrn-20201231.xsd#ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems"/>
    <loc xlink:type="locator" xlink:label="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable" xlink:href="ltrn-20201231.xsd#ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems" xlink:to="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ScheduleofEffectivetaxratediffersfromthestatutoryfederaltaxrateaspresentedTable">
    <loc xlink:type="locator" xlink:label="ltrn_ScheduleOfEffectiveTaxRateDiffersFromTheStatutoryFederalTaxRateAsPresentedAbstract" xlink:href="ltrn-20201231.xsd#ltrn_ScheduleOfEffectiveTaxRateDiffersFromTheStatutoryFederalTaxRateAsPresentedAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ScheduleOfEffectiveTaxRateDiffersFromTheStatutoryFederalTaxRateAsPresentedAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ScheduleOfEffectiveTaxRateDiffersFromTheStatutoryFederalTaxRateAsPresentedAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ScheduleOfEffectiveTaxRateDiffersFromTheStatutoryFederalTaxRateAsPresentedAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ScheduleOfEffectiveTaxRateDiffersFromTheStatutoryFederalTaxRateAsPresentedAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ScheduleofEffectofthetemporarydifferencesthatgiverisetothesignificantportionsofthedeferredtaxassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ltrn_ScheduleOfEffectOfTheTemporaryDifferencesThatGiveRiseToTheSignificantPortionsOfTheDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="ltrn-20201231.xsd#ltrn_ScheduleOfEffectOfTheTemporaryDifferencesThatGiveRiseToTheSignificantPortionsOfTheDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="ltrn_DeferredTaxAssetsAbstract" xlink:href="ltrn-20201231.xsd#ltrn_DeferredTaxAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ScheduleOfEffectOfTheTemporaryDifferencesThatGiveRiseToTheSignificantPortionsOfTheDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="ltrn_DeferredTaxAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_DeferredTaxAssetsDepreciation" xlink:href="ltrn-20201231.xsd#ltrn_DeferredTaxAssetsDepreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_DeferredTaxAssetsAbstract" xlink:to="ltrn_DeferredTaxAssetsDepreciation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_DeferredTaxAssetsResearchAndDevelopmentCredits" xlink:href="ltrn-20201231.xsd#ltrn_DeferredTaxAssetsResearchAndDevelopmentCredits"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_DeferredTaxAssetsAbstract" xlink:to="ltrn_DeferredTaxAssetsResearchAndDevelopmentCredits" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockBasedCompensation" xlink:href="ltrn-20201231.xsd#ltrn_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_DeferredTaxAssetsAbstract" xlink:to="ltrn_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockBasedCompensation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ScheduleOfEffectOfTheTemporaryDifferencesThatGiveRiseToTheSignificantPortionsOfTheDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbBx2uhymvyVLDa+1t8Zs6OCx+D0Bcy6Dt/X9wfJ64eyeWWDp4AwLD4hnV42U8gMPb6ZmoZskqs/VGWXFAW+VCwrstTEwsw9mBsjnLef0gxwD31/7ddIjxiai89b27Ur3wVtqpWYQb962vnZqopmU1PbSobqhOErLV5kQmlf1KTTNwUf5Cat3VqKMh+/aoU9/9g+1luMIMW+6gYCXYobSB6] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ScheduleOfEffectOfTheTemporaryDifferencesThatGiveRiseToTheSignificantPortionsOfTheDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ScheduleOfEffectOfTheTemporaryDifferencesThatGiveRiseToTheSignificantPortionsOfTheDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/OrganizationPrincipalActivitiesandBasisofPresentationDetails">
    <loc xlink:type="locator" xlink:label="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems" xlink:href="ltrn-20201231.xsd#ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsTable" xlink:href="ltrn-20201231.xsd#ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems" xlink:to="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/LiquidityDetails">
    <loc xlink:type="locator" xlink:label="ltrn_LiquidityDetailsLineItems" xlink:href="ltrn-20201231.xsd#ltrn_LiquidityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ltrn_LiquidityDetailsTable" xlink:href="ltrn-20201231.xsd#ltrn_LiquidityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ltrn_LiquidityDetailsLineItems" xlink:to="ltrn_LiquidityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_LiquidityDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_LiquidityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_LiquidityDetailsLineItems" xlink:to="us-gaap_ProfitLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_WorkingCapital" xlink:href="ltrn-20201231.xsd#ltrn_WorkingCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_LiquidityDetailsLineItems" xlink:to="ltrn_WorkingCapital" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_NetProceed" xlink:href="ltrn-20201231.xsd#ltrn_NetProceed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_LiquidityDetailsLineItems" xlink:to="ltrn_NetProceed" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_LiquidityDetailsLineItems" xlink:to="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_LiquidityDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_TotalGrossProceeds" xlink:href="ltrn-20201231.xsd#ltrn_TotalGrossProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_LiquidityDetailsLineItems" xlink:to="ltrn_TotalGrossProceeds" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="ltrn-20201231.xsd#ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ltrn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="ltrn-20201231.xsd#ltrn_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="ltrn_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_UpfrontContractorFees" xlink:href="ltrn-20201231.xsd#ltrn_UpfrontContractorFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="ltrn_UpfrontContractorFees" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_PatentLicenseFees" xlink:href="ltrn-20201231.xsd#ltrn_PatentLicenseFees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="ltrn_PatentLicenseFees" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_UndepositedFunds" xlink:href="ltrn-20201231.xsd#ltrn_UndepositedFunds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="ltrn_UndepositedFunds" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLoans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLoans"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ProceedsFromLoans" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:href="ltrn-20201231.xsd#ltrn_CommitmentsandContingenciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ltrn_CommitmentsandContingenciesDetailsTable" xlink:href="ltrn-20201231.xsd#ltrn_CommitmentsandContingenciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="ltrn_CommitmentsandContingenciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_CommitmentsandContingenciesDetailsTable" xlink:to="dei_LegalEntityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain_0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_CommitmentsandContingenciesDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_BioNumerikPharmaceuticalMember" xlink:href="ltrn-20201231.xsd#ltrn_BioNumerikPharmaceuticalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="ltrn_BioNumerikPharmaceuticalMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_LP184Member" xlink:href="ltrn-20201231.xsd#ltrn_LP184Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ltrn_LP184Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_AFChemicalsMember" xlink:href="ltrn-20201231.xsd#ltrn_AFChemicalsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ltrn_AFChemicalsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ltrn_AFChemicalsMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ltrn_AFChemicalsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_LP100Member" xlink:href="ltrn-20201231.xsd#ltrn_LP100Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ltrn_LP100Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_EUGrantMember" xlink:href="ltrn-20201231.xsd#ltrn_EUGrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ltrn_EUGrantMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_PatheonAPIServicesMember" xlink:href="ltrn-20201231.xsd#ltrn_PatheonAPIServicesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ltrn_PatheonAPIServicesMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_SouthwestResearchInstituteMember" xlink:href="ltrn-20201231.xsd#ltrn_SouthwestResearchInstituteMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="ltrn_SouthwestResearchInstituteMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOperatingLeaseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOperatingLeaseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_PropertySubjectToOperatingLeaseMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForOtherOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForOtherOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_PaymentsForOtherOperatingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_UpfrontPayments" xlink:href="ltrn-20201231.xsd#ltrn_UpfrontPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="ltrn_UpfrontPayments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OtherCommitmentsDescription" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedPatentsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedPatentsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_FiniteLivedPatentsGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_NetRevenuePercentage" xlink:href="ltrn-20201231.xsd#ltrn_NetRevenuePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="ltrn_NetRevenuePercentage" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_Annualfees" xlink:href="ltrn-20201231.xsd#ltrn_Annualfees"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="ltrn_Annualfees" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OtherExpenses" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_MilestoneExtensionPaid" xlink:href="ltrn-20201231.xsd#ltrn_MilestoneExtensionPaid"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="ltrn_MilestoneExtensionPaid" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_ResearchAndDevelopmentExpensesPercentage" xlink:href="ltrn-20201231.xsd#ltrn_ResearchAndDevelopmentExpensesPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="ltrn_ResearchAndDevelopmentExpensesPercentage" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_GrantedPeriod" xlink:href="ltrn-20201231.xsd#ltrn_GrantedPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="ltrn_GrantedPeriod" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_ManufacturingAgreementDescription" xlink:href="ltrn-20201231.xsd#ltrn_ManufacturingAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="ltrn_ManufacturingAgreementDescription" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_ProductCandidates" xlink:href="ltrn-20201231.xsd#ltrn_ProductCandidates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="ltrn_ProductCandidates" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ShareholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="ltrn_ShareholdersEquityDetailsLineItems" xlink:href="ltrn-20201231.xsd#ltrn_ShareholdersEquityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ltrn_ShareholdersEquityDetailsTable" xlink:href="ltrn-20201231.xsd#ltrn_ShareholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="ltrn_ShareholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_ShareholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_ShareholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_OptionsMember" xlink:href="ltrn-20201231.xsd#ltrn_OptionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ltrn_OptionsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_WarrantsToPurchaseShares" xlink:href="ltrn-20201231.xsd#ltrn_WarrantsToPurchaseShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="ltrn_WarrantsToPurchaseShares" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_CommonStockPercentage" xlink:href="ltrn-20201231.xsd#ltrn_CommonStockPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="ltrn_CommonStockPercentage" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_CommonStockTotalProceedsValue" xlink:href="ltrn-20201231.xsd#ltrn_CommonStockTotalProceedsValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="ltrn_CommonStockTotalProceedsValue" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherUnderwritingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherUnderwritingExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_OtherUnderwritingExpense" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_OtherOfferingExpenses" xlink:href="ltrn-20201231.xsd#ltrn_OtherOfferingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="ltrn_OtherOfferingExpenses" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplit" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRight" xlink:href="ltrn-20201231.xsd#ltrn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRight"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="ltrn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRight" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_CommonStockForIssuanceReservedShares" xlink:href="ltrn-20201231.xsd#ltrn_CommonStockForIssuanceReservedShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="ltrn_CommonStockForIssuanceReservedShares" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTerm" xlink:href="ltrn-20201231.xsd#ltrn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="ltrn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTerm" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_SharesRemainAvailableForFutureAwards" xlink:href="ltrn-20201231.xsd#ltrn_SharesRemainAvailableForFutureAwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="ltrn_SharesRemainAvailableForFutureAwards" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_WarrantsToPurchasePercentage" xlink:href="ltrn-20201231.xsd#ltrn_WarrantsToPurchasePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="ltrn_WarrantsToPurchasePercentage" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_PurchaseOfWarrantsShares" xlink:href="ltrn-20201231.xsd#ltrn_PurchaseOfWarrantsShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="ltrn_PurchaseOfWarrantsShares" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_ClassOfWarrantTerm" xlink:href="ltrn-20201231.xsd#ltrn_ClassOfWarrantTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="ltrn_ClassOfWarrantTerm" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAdditionalCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAdditionalCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_OtherAdditionalCapital" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_WarrantTerm" xlink:href="ltrn-20201231.xsd#ltrn_WarrantTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="ltrn_WarrantTerm" order="38" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/SafeAgreementsDetails">
    <loc xlink:type="locator" xlink:label="ltrn_SafeAgreementsDetailsLineItems" xlink:href="ltrn-20201231.xsd#ltrn_SafeAgreementsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ltrn_SafeAgreementsDetailsTable" xlink:href="ltrn-20201231.xsd#ltrn_SafeAgreementsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ltrn_SafeAgreementsDetailsLineItems" xlink:to="ltrn_SafeAgreementsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_SafeAgreementsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_AgreementDescription" xlink:href="ltrn-20201231.xsd#ltrn_AgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_SafeAgreementsDetailsLineItems" xlink:to="ltrn_AgreementDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedPercentOfNetAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_SafeAgreementsDetailsLineItems" xlink:to="us-gaap_InvestmentOwnedPercentOfNetAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_NetProceeds" xlink:href="ltrn-20201231.xsd#ltrn_NetProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_SafeAgreementsDetailsLineItems" xlink:to="ltrn_NetProceeds" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeasePayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_SafeAgreementsDetailsLineItems" xlink:to="us-gaap_ShortTermLeasePayments" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_SafeAgreementsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/NotesandLoanPayableDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLoanOriginations1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLoanOriginations1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ProceedsFromLoanOriginations1" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentDescription" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="ltrn_RelatedPartyTransactionsDetailsLineItems" xlink:href="ltrn-20201231.xsd#ltrn_RelatedPartyTransactionsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ltrn_RelatedPartyTransactionsDetailsTable" xlink:href="ltrn-20201231.xsd#ltrn_RelatedPartyTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ltrn_RelatedPartyTransactionsDetailsLineItems" xlink:to="ltrn_RelatedPartyTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_BiologicalMimeticsIncMember" xlink:href="ltrn-20201231.xsd#ltrn_BiologicalMimeticsIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ltrn_BiologicalMimeticsIncMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_IntuitionMember" xlink:href="ltrn-20201231.xsd#ltrn_IntuitionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ltrn_IntuitionMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_BioNumerikMember" xlink:href="ltrn-20201231.xsd#ltrn_BioNumerikMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="ltrn_BioNumerikMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="ltrn_IncomeTaxesDetailsLineItems" xlink:href="ltrn-20201231.xsd#ltrn_IncomeTaxesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ltrn_IncomeTaxesDetailsTable" xlink:href="ltrn-20201231.xsd#ltrn_IncomeTaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ltrn_IncomeTaxesDetailsLineItems" xlink:to="ltrn_IncomeTaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="ltrn_SubsequentEventsDetailsLineItems" xlink:href="ltrn-20201231.xsd#ltrn_SubsequentEventsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="ltrn_SubsequentEventsDetailsTable" xlink:href="ltrn-20201231.xsd#ltrn_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ltrn_SubsequentEventsDetailsLineItems" xlink:to="ltrn_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ltrn_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_PublicOfferingPerShare" xlink:href="ltrn-20201231.xsd#ltrn_PublicOfferingPerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_SubsequentEventsDetailsLineItems" xlink:to="ltrn_PublicOfferingPerShare" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_TotalGrossProceeds" xlink:href="ltrn-20201231.xsd#ltrn_TotalGrossProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_SubsequentEventsDetailsLineItems" xlink:to="ltrn_TotalGrossProceeds" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="ltrn_NetProceed" xlink:href="ltrn-20201231.xsd#ltrn_NetProceed"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ltrn_SubsequentEventsDetailsLineItems" xlink:to="ltrn_NetProceed" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://laternpharma.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="21" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>ltrn-20201231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Mar 10 03:43:46 EST 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">TOTAL ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">TOTAL LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash flows used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash flows (used in) provided by investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash flows provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xml:lang="en-US">CHANGE IN CASH FOR THE YEAR</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">CASH, BEGINNING OF YEAR</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">CASH, END OF YEAR</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ScheduleOfStockOptionActivityAbstract" xlink:href="ltrn-20201231.xsd#ltrn_ScheduleOfStockOptionActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ScheduleOfStockOptionActivityAbstract_lbl" xml:lang="en-US">Schedule of stock option activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ScheduleOfStockOptionActivityAbstract" xlink:to="ltrn_ScheduleOfStockOptionActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Options Outstanding, Beginning Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Number of Options Outstanding, Ending Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Number of Options, Weighted-Average Exercise Price, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Number of Options, Weighted-Average Exercise Price, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" xlink:href="ltrn-20201231.xsd#ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_lbl" xml:lang="en-US">Number of Options Exercisable, Beginning Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" xlink:to="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_lbl0" xml:lang="en-US">Number of Options Exercisable, Ending Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" xlink:to="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:href="ltrn-20201231.xsd#ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Number of Options Exercisable, Weighted-Average Exercise Price, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:to="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Number of Options Exercisable, Weighted-Average Exercise Price, Ending Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:to="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="ltrn_ScheduleOfWeightedAverageAssumptionsAbstract" xlink:href="ltrn-20201231.xsd#ltrn_ScheduleOfWeightedAverageAssumptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ScheduleOfWeightedAverageAssumptionsAbstract_lbl" xml:lang="en-US">Schedule of weighted average assumptions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ScheduleOfWeightedAverageAssumptionsAbstract" xlink:to="ltrn_ScheduleOfWeightedAverageAssumptionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_SafeAgreementsDisclosureAbstract" xlink:href="ltrn-20201231.xsd#ltrn_SafeAgreementsDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_SafeAgreementsDisclosureAbstract_lbl" xml:lang="en-US">Safe Agreements Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_SafeAgreementsDisclosureAbstract" xlink:to="ltrn_SafeAgreementsDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ScheduleOfDilutedLossPerShareDueToBeingAntiDilutiveAbstract" xlink:href="ltrn-20201231.xsd#ltrn_ScheduleOfDilutedLossPerShareDueToBeingAntiDilutiveAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ScheduleOfDilutedLossPerShareDueToBeingAntiDilutiveAbstract_lbl" xml:lang="en-US">Schedule of diluted loss per share due to being anti-dilutive [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ScheduleOfDilutedLossPerShareDueToBeingAntiDilutiveAbstract" xlink:to="ltrn_ScheduleOfDilutedLossPerShareDueToBeingAntiDilutiveAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ScheduleOfEffectiveTaxRateDiffersFromTheStatutoryFederalTaxRateAsPresentedAbstract" xlink:href="ltrn-20201231.xsd#ltrn_ScheduleOfEffectiveTaxRateDiffersFromTheStatutoryFederalTaxRateAsPresentedAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ScheduleOfEffectiveTaxRateDiffersFromTheStatutoryFederalTaxRateAsPresentedAbstract_lbl" xml:lang="en-US">Schedule of Effective tax rate differs from the statutory federal tax rate as presented [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ScheduleOfEffectiveTaxRateDiffersFromTheStatutoryFederalTaxRateAsPresentedAbstract" xlink:to="ltrn_ScheduleOfEffectiveTaxRateDiffersFromTheStatutoryFederalTaxRateAsPresentedAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ScheduleOfEffectOfTheTemporaryDifferencesThatGiveRiseToTheSignificantPortionsOfTheDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="ltrn-20201231.xsd#ltrn_ScheduleOfEffectOfTheTemporaryDifferencesThatGiveRiseToTheSignificantPortionsOfTheDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ScheduleOfEffectOfTheTemporaryDifferencesThatGiveRiseToTheSignificantPortionsOfTheDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of Effect of the temporary differences that give rise to the significant portions of the deferred tax assets and liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ScheduleOfEffectOfTheTemporaryDifferencesThatGiveRiseToTheSignificantPortionsOfTheDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="ltrn_ScheduleOfEffectOfTheTemporaryDifferencesThatGiveRiseToTheSignificantPortionsOfTheDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses &amp; other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl" xml:lang="en-US">Deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl" xml:lang="en-US">PPP loan payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES (NOTE 5)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Series A Preferred Stock (1,000,000 authorized at December 31, 2020; 3,480,000 authorized at December 31, 2019; $.0001 par value) (Zero shares issued and outstanding at December 31, 2020; 2,438,866 shares issued and outstanding at December 31, 2019)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, shares par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Series A preferred stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Preferred stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl0" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock (25,000,000 authorized at December 31, 2020; 12,180,000 authorized at December 31, 2019; $.0001 par value) (6,220,927 shares issued and outstanding at December 31, 2020; 1,978,269 shares issued and outstanding at December 31, 2019)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common shares par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share of common shares, basic and diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted-average number of common shares outstanding, basic and diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants" xlink:href="ltrn-20201231.xsd#ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants_lbl" xml:lang="en-US">Preferred stock and warrants issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants" xlink:to="ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants" xlink:href="ltrn-20201231.xsd#ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants_lbl" xml:lang="en-US">Preferred stock and warrants issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants" xlink:to="ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCosts" xlink:href="ltrn-20201231.xsd#ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCosts_lbl" xml:lang="en-US">Common stock issued from offering, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCosts" xlink:to="ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCostsinShares" xlink:href="ltrn-20201231.xsd#ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCostsinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCostsinShares_lbl" xml:lang="en-US">Common stock issued from offering, net of issuance costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCostsinShares" xlink:to="ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCostsinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment" xlink:href="ltrn-20201231.xsd#ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment_lbl" xml:lang="en-US">Preferred Stock Converted to Common, net of fractional shares adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment" xlink:to="ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl" xml:lang="en-US">Preferred Stock Converted to Common, net of fractional shares adjustment (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Common stock issued from option exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Common stock issued from option exercise (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_CashlessExerciseOfWarrant" xlink:href="ltrn-20201231.xsd#ltrn_CashlessExerciseOfWarrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_CashlessExerciseOfWarrant_lbl" xml:lang="en-US">Cashless exercise of warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_CashlessExerciseOfWarrant" xlink:to="ltrn_CashlessExerciseOfWarrant_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_CashlessExerciseOfWarrantinShares" xlink:href="ltrn-20201231.xsd#ltrn_CashlessExerciseOfWarrantinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_CashlessExerciseOfWarrantinShares_lbl" xml:lang="en-US">Cashless exercise of warrant (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_CashlessExerciseOfWarrantinShares" xlink:to="ltrn_CashlessExerciseOfWarrantinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount_lbl" xml:lang="en-US">Stock based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:to="us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accounts payable and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">INVESTING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">FINANCING ACTIVITIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Proceeds from issuance of common and preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US">Proceeds from stock option exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Borrowings on notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Payments on notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable" xlink:href="ltrn-20201231.xsd#ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable_lbl" xml:lang="en-US">Borrowings on PPP loan payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable" xlink:to="ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Non-cash financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock" xlink:href="ltrn-20201231.xsd#ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock_lbl" xml:lang="en-US">Conversion of SAFE agreements to Series A preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock" xlink:to="ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ApplicationOfDeferredOfferingCosts" xlink:href="ltrn-20201231.xsd#ltrn_ApplicationOfDeferredOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_ApplicationOfDeferredOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs applied to net offering proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ApplicationOfDeferredOfferingCosts" xlink:to="ltrn_ApplicationOfDeferredOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_DeferredOfferingCostsRecordedInAPAndAccruedExpenses" xlink:href="ltrn-20201231.xsd#ltrn_DeferredOfferingCostsRecordedInAPAndAccruedExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_DeferredOfferingCostsRecordedInAPAndAccruedExpenses_lbl" xml:lang="en-US">Deferred offering costs recorded in AP and accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_DeferredOfferingCostsRecordedInAPAndAccruedExpenses" xlink:to="ltrn_DeferredOfferingCostsRecordedInAPAndAccruedExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses &amp; other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges_lbl" xml:lang="en-US">Deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment" xlink:href="ltrn-20201231.xsd#ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment_lbl" xml:lang="en-US">(Purchase) sale of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment" xlink:to="ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_IncreaseDecreaseIssuanceCosts" xlink:href="ltrn-20201231.xsd#ltrn_IncreaseDecreaseIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ltrn_IncreaseDecreaseIssuanceCosts_lbl" xml:lang="en-US">Issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_IncreaseDecreaseIssuanceCosts" xlink:to="ltrn_IncreaseDecreaseIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ProceedsFromPreferredStockConvertedToCommonStockNetOfFractionalSharesAdjustment" xlink:href="ltrn-20201231.xsd#ltrn_ProceedsFromPreferredStockConvertedToCommonStockNetOfFractionalSharesAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ltrn_ProceedsFromPreferredStockConvertedToCommonStockNetOfFractionalSharesAdjustment_lbl" xml:lang="en-US">Preferred stock converted to common stock net of fractional shares adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ProceedsFromPreferredStockConvertedToCommonStockNetOfFractionalSharesAdjustment" xlink:to="ltrn_ProceedsFromPreferredStockConvertedToCommonStockNetOfFractionalSharesAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl0" xml:lang="en-US">Series A preferred stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl1" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization, Principal Activities, and Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">Liquidity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Shareholders&apos; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of stock option activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Options Outstanding, Granted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Number of Options, Weighted-Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross" xlink:href="ltrn-20201231.xsd#ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross_lbl" xml:lang="en-US">Number of Options Exercisable, Granted	(in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross" xlink:to="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageExercisePrice" xlink:href="ltrn-20201231.xsd#ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Number of Options Exercisable, Weighted-Average Exercise Price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageExercisePrice" xlink:to="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Number of Options, Weighted-Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_StockIssuedDuringPeriodSharesStockOptionExercised" xlink:href="ltrn-20201231.xsd#ltrn_StockIssuedDuringPeriodSharesStockOptionExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_StockIssuedDuringPeriodSharesStockOptionExercised_lbl" xml:lang="en-US">Number of Options Exercisable, Exercised (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_StockIssuedDuringPeriodSharesStockOptionExercised" xlink:to="ltrn_StockIssuedDuringPeriodSharesStockOptionExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExercisesInPeriodWeightedAverageExercisePrice" xlink:href="ltrn-20201231.xsd#ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Number of Options Exercisable, Weighted-Average Exercise Price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExercisesInPeriodWeightedAverageExercisePrice" xlink:to="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Number of Options, Weighted-Average Exercise Price, Cancelled or expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiratiosInPeriod" xlink:href="ltrn-20201231.xsd#ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiratiosInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiratiosInPeriod_lbl" xml:lang="en-US">Number of Options Exercisable, Cancelled or expired (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiratiosInPeriod" xlink:to="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiratiosInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationInPeriodWeightedAverageExercisePrice" xlink:href="ltrn-20201231.xsd#ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Number of Options Exercisable, Weighted-Average Exercise Price, Cancelled or expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationInPeriodWeightedAverageExercisePrice" xlink:to="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average assumptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Term (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk Free Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend Yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Grant Date Fair Value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_SafeAgreementsDisclosureTextBlock" xlink:href="ltrn-20201231.xsd#ltrn_SafeAgreementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_SafeAgreementsDisclosureTextBlock_lbl" xml:lang="en-US">SAFE Agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_SafeAgreementsDisclosureTextBlock" xlink:to="ltrn_SafeAgreementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Notes and Loan Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Loss Per Share of Common Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of diluted loss per share due to being anti-dilutive</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Anti-diluted loss share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective tax rate differs from the statutory federal tax rate as presented</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">U.S. federal statutory tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl" xml:lang="en-US">Permanent differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Effect of the temporary differences that give rise to the significant portions of the deferred tax assets and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_DeferredTaxAssetsAbstract" xlink:href="ltrn-20201231.xsd#ltrn_DeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_DeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_DeferredTaxAssetsAbstract" xlink:to="ltrn_DeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_DeferredTaxAssetsDepreciation" xlink:href="ltrn-20201231.xsd#ltrn_DeferredTaxAssetsDepreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_DeferredTaxAssetsDepreciation_lbl" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_DeferredTaxAssetsDepreciation" xlink:to="ltrn_DeferredTaxAssetsDepreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_DeferredTaxAssetsResearchAndDevelopmentCredits" xlink:href="ltrn-20201231.xsd#ltrn_DeferredTaxAssetsResearchAndDevelopmentCredits"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_DeferredTaxAssetsResearchAndDevelopmentCredits_lbl" xml:lang="en-US">Research and development credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_DeferredTaxAssetsResearchAndDevelopmentCredits" xlink:to="ltrn_DeferredTaxAssetsResearchAndDevelopmentCredits_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockBasedCompensation" xlink:href="ltrn-20201231.xsd#ltrn_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockBasedCompensation" xlink:to="ltrn_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred tax asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl" xml:lang="en-US">Deferred tax liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US">Net deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl" xml:lang="en-US">Number of Options Outstanding, Cancelled or expired	(in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_StockIssuedDuringPeriodSharesOutstandingExcercised" xlink:href="ltrn-20201231.xsd#ltrn_StockIssuedDuringPeriodSharesOutstandingExcercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ltrn_StockIssuedDuringPeriodSharesOutstandingExcercised_lbl" xml:lang="en-US">Number of Options Outstanding, Exercised (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_StockIssuedDuringPeriodSharesOutstandingExcercised" xlink:to="ltrn_StockIssuedDuringPeriodSharesOutstandingExcercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Less: valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Fixed assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_WorkingCapital" xlink:href="ltrn-20201231.xsd#ltrn_WorkingCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_WorkingCapital_lbl" xml:lang="en-US">Working capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_WorkingCapital" xlink:to="ltrn_WorkingCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_NetProceed" xlink:href="ltrn-20201231.xsd#ltrn_NetProceed"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_NetProceed_lbl" xml:lang="en-US">Net proceed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_NetProceed" xlink:to="ltrn_NetProceed_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering_lbl" xml:lang="en-US">Public offering shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering" xlink:to="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Public offering price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl0" xml:lang="en-US">Price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="ltrn_TotalGrossProceeds" xlink:href="ltrn-20201231.xsd#ltrn_TotalGrossProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_TotalGrossProceeds_lbl" xml:lang="en-US">Total gross proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_TotalGrossProceeds" xlink:to="ltrn_TotalGrossProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOfferingCosts_lbl" xml:lang="en-US">Deferred offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl" xml:lang="en-US">Prepaid expense and other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_UpfrontContractorFees" xlink:href="ltrn-20201231.xsd#ltrn_UpfrontContractorFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_UpfrontContractorFees_lbl" xml:lang="en-US">Contract fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_UpfrontContractorFees" xlink:to="ltrn_UpfrontContractorFees_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_PatentLicenseFees" xlink:href="ltrn-20201231.xsd#ltrn_PatentLicenseFees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_PatentLicenseFees_lbl" xml:lang="en-US">Licensing and other fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_PatentLicenseFees" xlink:to="ltrn_PatentLicenseFees_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_UndepositedFunds" xlink:href="ltrn-20201231.xsd#ltrn_UndepositedFunds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_UndepositedFunds_lbl" xml:lang="en-US">Prepaid annual insurance fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_UndepositedFunds" xlink:to="ltrn_UndepositedFunds_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLoans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLoans"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLoans_lbl" xml:lang="en-US">Aggregate loan proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLoans" xlink:to="us-gaap_ProceedsFromLoans_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForOtherOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForOtherOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForOtherOperatingActivities_lbl" xml:lang="en-US">Total Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForOtherOperatingActivities" xlink:to="us-gaap_PaymentsForOtherOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_UpfrontPayments" xlink:href="ltrn-20201231.xsd#ltrn_UpfrontPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_UpfrontPayments_lbl" xml:lang="en-US">Upfront payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_UpfrontPayments" xlink:to="ltrn_UpfrontPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherCommitmentsDescription_lbl" xml:lang="en-US">Commitments and contingencies, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDescription" xlink:to="us-gaap_OtherCommitmentsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedPatentsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedPatentsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedPatentsGross_lbl" xml:lang="en-US">Related patents costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedPatentsGross" xlink:to="us-gaap_FiniteLivedPatentsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_NetRevenuePercentage" xlink:href="ltrn-20201231.xsd#ltrn_NetRevenuePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_NetRevenuePercentage_lbl" xml:lang="en-US">Net revenue, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_NetRevenuePercentage" xlink:to="ltrn_NetRevenuePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent_lbl" xml:lang="en-US">Amounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent_lbl0" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent_lbl0"/>
    <loc xlink:type="locator" xlink:label="ltrn_Annualfees" xlink:href="ltrn-20201231.xsd#ltrn_Annualfees"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_Annualfees_lbl" xml:lang="en-US">Annual fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_Annualfees" xlink:to="ltrn_Annualfees_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_MilestoneExtensionPaid" xlink:href="ltrn-20201231.xsd#ltrn_MilestoneExtensionPaid"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_MilestoneExtensionPaid_lbl" xml:lang="en-US">Milestone extension paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_MilestoneExtensionPaid" xlink:to="ltrn_MilestoneExtensionPaid_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ResearchAndDevelopmentExpensesPercentage" xlink:href="ltrn-20201231.xsd#ltrn_ResearchAndDevelopmentExpensesPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_ResearchAndDevelopmentExpensesPercentage_lbl" xml:lang="en-US">Research and development expenses percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ResearchAndDevelopmentExpensesPercentage" xlink:to="ltrn_ResearchAndDevelopmentExpensesPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_GrantedPeriod" xlink:href="ltrn-20201231.xsd#ltrn_GrantedPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_GrantedPeriod_lbl" xml:lang="en-US">Granted period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_GrantedPeriod" xlink:to="ltrn_GrantedPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ManufacturingAgreementDescription" xlink:href="ltrn-20201231.xsd#ltrn_ManufacturingAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_ManufacturingAgreementDescription_lbl" xml:lang="en-US">Manufacturing agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ManufacturingAgreementDescription" xlink:to="ltrn_ManufacturingAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ProductCandidates" xlink:href="ltrn-20201231.xsd#ltrn_ProductCandidates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_ProductCandidates_lbl" xml:lang="en-US">Product candidates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ProductCandidates" xlink:to="ltrn_ProductCandidates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xml:lang="en-US">Prepaid expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl" xml:lang="en-US">Lease term, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Converted into shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Aggregate proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_WarrantsToPurchaseShares" xlink:href="ltrn-20201231.xsd#ltrn_WarrantsToPurchaseShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_WarrantsToPurchaseShares_lbl" xml:lang="en-US">Warrants to purchase shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_WarrantsToPurchaseShares" xlink:to="ltrn_WarrantsToPurchaseShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrants exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_CommonStockPercentage" xlink:href="ltrn-20201231.xsd#ltrn_CommonStockPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_CommonStockPercentage_lbl" xml:lang="en-US">Common stock, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_CommonStockPercentage" xlink:to="ltrn_CommonStockPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl" xml:lang="en-US">Liquidation preference amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_CommonStockTotalProceedsValue" xlink:href="ltrn-20201231.xsd#ltrn_CommonStockTotalProceedsValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_CommonStockTotalProceedsValue_lbl" xml:lang="en-US">Total proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_CommonStockTotalProceedsValue" xlink:to="ltrn_CommonStockTotalProceedsValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherUnderwritingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherUnderwritingExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherUnderwritingExpense_lbl" xml:lang="en-US">Underwriting discounts and commissions (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherUnderwritingExpense" xlink:to="us-gaap_OtherUnderwritingExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_OtherOfferingExpenses" xlink:href="ltrn-20201231.xsd#ltrn_OtherOfferingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_OtherOfferingExpenses_lbl" xml:lang="en-US">Other offering expenses (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_OtherOfferingExpenses" xlink:to="ltrn_OtherOfferingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl" xml:lang="en-US">Stockholders&apos; equity stock split, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplit" xlink:to="us-gaap_StockholdersEquityNoteStockSplit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Common stock issued relating to stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Common stock issued relating to stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRight" xlink:href="ltrn-20201231.xsd#ltrn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRight"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRight_lbl" xml:lang="en-US">Purchase of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRight" xlink:to="ltrn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRight_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_CommonStockForIssuanceReservedShares" xlink:href="ltrn-20201231.xsd#ltrn_CommonStockForIssuanceReservedShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_CommonStockForIssuanceReservedShares_lbl" xml:lang="en-US">Common stock for issuance reserved, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_CommonStockForIssuanceReservedShares" xlink:to="ltrn_CommonStockForIssuanceReservedShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTerm" xlink:href="ltrn-20201231.xsd#ltrn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTerm_lbl" xml:lang="en-US">Options term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTerm" xlink:to="ltrn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_SharesRemainAvailableForFutureAwards" xlink:href="ltrn-20201231.xsd#ltrn_SharesRemainAvailableForFutureAwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_SharesRemainAvailableForFutureAwards_lbl" xml:lang="en-US">Shares remain available for future awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_SharesRemainAvailableForFutureAwards" xlink:to="ltrn_SharesRemainAvailableForFutureAwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Stock based Compensation (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized compensation expense (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Recognized weighted average period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Total intrinsic value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Intrinsic value, exercisable (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_lbl" xml:lang="en-US">Expected dividend (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Aggregate of common stock, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <loc xlink:type="locator" xlink:label="ltrn_WarrantsToPurchasePercentage" xlink:href="ltrn-20201231.xsd#ltrn_WarrantsToPurchasePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_WarrantsToPurchasePercentage_lbl" xml:lang="en-US">Warrants to purchase percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_WarrantsToPurchasePercentage" xlink:to="ltrn_WarrantsToPurchasePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_PurchaseOfWarrantsShares" xlink:href="ltrn-20201231.xsd#ltrn_PurchaseOfWarrantsShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_PurchaseOfWarrantsShares_lbl" xml:lang="en-US">Purchase of warrants, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_PurchaseOfWarrantsShares" xlink:to="ltrn_PurchaseOfWarrantsShares_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ClassOfWarrantTerm" xlink:href="ltrn-20201231.xsd#ltrn_ClassOfWarrantTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_ClassOfWarrantTerm_lbl" xml:lang="en-US">Warrants term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ClassOfWarrantTerm" xlink:to="ltrn_ClassOfWarrantTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAdditionalCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAdditionalCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAdditionalCapital_lbl" xml:lang="en-US">Additional paid in capital (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAdditionalCapital" xlink:to="us-gaap_OtherAdditionalCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_WarrantTerm" xlink:href="ltrn-20201231.xsd#ltrn_WarrantTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_WarrantTerm_lbl" xml:lang="en-US">Warrant term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_WarrantTerm" xlink:to="ltrn_WarrantTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_AgreementDescription" xlink:href="ltrn-20201231.xsd#ltrn_AgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_AgreementDescription_lbl" xml:lang="en-US">Agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_AgreementDescription" xlink:to="ltrn_AgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedPercentOfNetAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets_lbl" xml:lang="en-US">Triggering equity financing, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:to="us-gaap_InvestmentOwnedPercentOfNetAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_NetProceeds" xlink:href="ltrn-20201231.xsd#ltrn_NetProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_NetProceeds_lbl" xml:lang="en-US">Net proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_NetProceeds" xlink:to="ltrn_NetProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeasePayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermLeasePayments_lbl" xml:lang="en-US">Short-term liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeasePayments" xlink:to="us-gaap_ShortTermLeasePayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Series A Preferred Stock, shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription_lbl" xml:lang="en-US">Description of maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl" xml:lang="en-US">Annual amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl" xml:lang="en-US">Interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLoanOriginations1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLoanOriginations1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLoanOriginations1_lbl" xml:lang="en-US">Aggregate loan amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLoanOriginations1" xlink:to="us-gaap_ProceedsFromLoanOriginations1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentDescription_lbl" xml:lang="en-US">Description of notes payable and loan payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbBx2uhymvyVLDa+1t8Zs6OCx+D0Bcy6Dt/X9wfJ64eyeWWDp4AwLD4hnV42U8gMPb6ZmoZskqs/VGWXFAW+VCwrstTEwsw9mBsjnLef0gxwD31/7ddIjxiai89b27Ur3wVtqpWYQb962vnZqopmU1PbSobqhOErLV5kQmlf1KTTNwUf5Cat3Vqgk9yemuTfMdt5Py2CR2hT4O/mO3pKtYi] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Loan amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US">Related party transactions expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl" xml:lang="en-US">Amounts owed to related parties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl" xml:lang="en-US">Remaining unpaid expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US">Federal net operating loss carry forwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_lbl" xml:lang="en-US">Carryforwards generated</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US">State net operating loss carry forwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_lbl" xml:lang="en-US">Credit carryforwards for federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_PublicOfferingPerShare" xlink:href="ltrn-20201231.xsd#ltrn_PublicOfferingPerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_PublicOfferingPerShare_lbl" xml:lang="en-US">Public offering, per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_PublicOfferingPerShare" xlink:to="ltrn_PublicOfferingPerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates and Assumptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Risks and Uncertainties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl" xml:lang="en-US">Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:href="ltrn-20201231.xsd#ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl" xml:lang="en-US">Prepaid Expenses and Other Current Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:to="ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_LoanPursuantToPaycheckProtectionProgramTextBlock" xlink:href="ltrn-20201231.xsd#ltrn_LoanPursuantToPaycheckProtectionProgramTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_LoanPursuantToPaycheckProtectionProgramTextBlock_lbl" xml:lang="en-US">Loan Pursuant to Paycheck Protection Program</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_LoanPursuantToPaycheckProtectionProgramTextBlock" xlink:to="ltrn_LoanPursuantToPaycheckProtectionProgramTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl" xml:lang="en-US">Reclassification</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_BioNumerikPharmaceuticalMember" xlink:href="ltrn-20201231.xsd#ltrn_BioNumerikPharmaceuticalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_BioNumerikPharmaceuticalMember_lbl" xml:lang="en-US">BioNumerik Pharmaceutical [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_BioNumerikPharmaceuticalMember" xlink:to="ltrn_BioNumerikPharmaceuticalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_LP184Member" xlink:href="ltrn-20201231.xsd#ltrn_LP184Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_LP184Member_lbl" xml:lang="en-US">LP-184 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_LP184Member" xlink:to="ltrn_LP184Member_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_AFChemicalsMember" xlink:href="ltrn-20201231.xsd#ltrn_AFChemicalsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_AFChemicalsMember_lbl" xml:lang="en-US">AF Chemicals [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_AFChemicalsMember" xlink:to="ltrn_AFChemicalsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_LP100Member" xlink:href="ltrn-20201231.xsd#ltrn_LP100Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_LP100Member_lbl" xml:lang="en-US">LP-100 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_LP100Member" xlink:to="ltrn_LP100Member_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_EUGrantMember" xlink:href="ltrn-20201231.xsd#ltrn_EUGrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_EUGrantMember_lbl" xml:lang="en-US">EU Grant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_EUGrantMember" xlink:to="ltrn_EUGrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_PatheonAPIServicesMember" xlink:href="ltrn-20201231.xsd#ltrn_PatheonAPIServicesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_PatheonAPIServicesMember_lbl" xml:lang="en-US">Patheon API Services [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_PatheonAPIServicesMember" xlink:to="ltrn_PatheonAPIServicesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_SouthwestResearchInstituteMember" xlink:href="ltrn-20201231.xsd#ltrn_SouthwestResearchInstituteMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_SouthwestResearchInstituteMember_lbl" xml:lang="en-US">Southwest Research Institute [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_SouthwestResearchInstituteMember" xlink:to="ltrn_SouthwestResearchInstituteMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOperatingLeaseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOperatingLeaseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertySubjectToOperatingLeaseMember_lbl" xml:lang="en-US">Operating Lease [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertySubjectToOperatingLeaseMember" xlink:to="us-gaap_PropertySubjectToOperatingLeaseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_OptionsMember" xlink:href="ltrn-20201231.xsd#ltrn_OptionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_OptionsMember_lbl" xml:lang="en-US">Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_OptionsMember" xlink:to="ltrn_OptionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_BiologicalMimeticsIncMember" xlink:href="ltrn-20201231.xsd#ltrn_BiologicalMimeticsIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_BiologicalMimeticsIncMember_lbl" xml:lang="en-US">Biological Mimetics, Inc., [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_BiologicalMimeticsIncMember" xlink:to="ltrn_BiologicalMimeticsIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_IntuitionMember" xlink:href="ltrn-20201231.xsd#ltrn_IntuitionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_IntuitionMember_lbl" xml:lang="en-US">Intuition [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_IntuitionMember" xlink:to="ltrn_IntuitionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_BioNumerikMember" xlink:href="ltrn-20201231.xsd#ltrn_BioNumerikMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ltrn_BioNumerikMember_lbl" xml:lang="en-US">BioNumerik [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_BioNumerikMember" xlink:to="ltrn_BioNumerikMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xml:lang="en-US">State [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ShareholdersEquityDetailsScheduleofweightedaverageassumptionsTable" xlink:href="ltrn-20201231.xsd#ltrn_ShareholdersEquityDetailsScheduleofweightedaverageassumptionsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ShareholdersEquityDetailsScheduleofweightedaverageassumptionsTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of weighted average assumptions [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ShareholdersEquityDetailsScheduleofweightedaverageassumptionsTable" xlink:to="ltrn_ShareholdersEquityDetailsScheduleofweightedaverageassumptionsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ShareholdersEquityDetailsScheduleofweightedaverageassumptionsLineItems" xlink:href="ltrn-20201231.xsd#ltrn_ShareholdersEquityDetailsScheduleofweightedaverageassumptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ShareholdersEquityDetailsScheduleofweightedaverageassumptionsLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of weighted average assumptions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ShareholdersEquityDetailsScheduleofweightedaverageassumptionsLineItems" xlink:to="ltrn_ShareholdersEquityDetailsScheduleofweightedaverageassumptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable" xlink:href="ltrn-20201231.xsd#ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable_lbl" xml:lang="en-US">Loss Per Share of Common Shares (Details) - Schedule of diluted loss per share due to being anti-dilutive [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable" xlink:to="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems" xlink:href="ltrn-20201231.xsd#ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems_lbl" xml:lang="en-US">Loss Per Share of Common Shares (Details) - Schedule of diluted loss per share due to being anti-dilutive [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems" xlink:to="ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsTable" xlink:href="ltrn-20201231.xsd#ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsTable_lbl" xml:lang="en-US">Organization, Principal Activities, and Basis of Presentation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsTable" xlink:to="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems" xlink:href="ltrn-20201231.xsd#ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems_lbl" xml:lang="en-US">Organization, Principal Activities, and Basis of Presentation (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems" xlink:to="ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_LiquidityDetailsTable" xlink:href="ltrn-20201231.xsd#ltrn_LiquidityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_LiquidityDetailsTable_lbl" xml:lang="en-US">Liquidity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_LiquidityDetailsTable" xlink:to="ltrn_LiquidityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_LiquidityDetailsLineItems" xlink:href="ltrn-20201231.xsd#ltrn_LiquidityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_LiquidityDetailsLineItems_lbl" xml:lang="en-US">Liquidity (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_LiquidityDetailsLineItems" xlink:to="ltrn_LiquidityDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="ltrn-20201231.xsd#ltrn_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="ltrn_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="ltrn-20201231.xsd#ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US">Related Party [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_CommitmentsandContingenciesDetailsTable" xlink:href="ltrn-20201231.xsd#ltrn_CommitmentsandContingenciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_CommitmentsandContingenciesDetailsTable_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_CommitmentsandContingenciesDetailsTable" xlink:to="ltrn_CommitmentsandContingenciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:href="ltrn-20201231.xsd#ltrn_CommitmentsandContingenciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_CommitmentsandContingenciesDetailsLineItems_lbl" xml:lang="en-US">Commitments and Contingencies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_CommitmentsandContingenciesDetailsLineItems" xlink:to="ltrn_CommitmentsandContingenciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ShareholdersEquityDetailsTable" xlink:href="ltrn-20201231.xsd#ltrn_ShareholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ShareholdersEquityDetailsTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ShareholdersEquityDetailsTable" xlink:to="ltrn_ShareholdersEquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_ShareholdersEquityDetailsLineItems" xlink:href="ltrn-20201231.xsd#ltrn_ShareholdersEquityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ShareholdersEquityDetailsLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ShareholdersEquityDetailsLineItems" xlink:to="ltrn_ShareholdersEquityDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_SafeAgreementsDetailsTable" xlink:href="ltrn-20201231.xsd#ltrn_SafeAgreementsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_SafeAgreementsDetailsTable_lbl" xml:lang="en-US">Safe Agreements (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_SafeAgreementsDetailsTable" xlink:to="ltrn_SafeAgreementsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_SafeAgreementsDetailsLineItems" xlink:href="ltrn-20201231.xsd#ltrn_SafeAgreementsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_SafeAgreementsDetailsLineItems_lbl" xml:lang="en-US">Safe Agreements (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_SafeAgreementsDetailsLineItems" xlink:to="ltrn_SafeAgreementsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_RelatedPartyTransactionsDetailsTable" xlink:href="ltrn-20201231.xsd#ltrn_RelatedPartyTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_RelatedPartyTransactionsDetailsTable_lbl" xml:lang="en-US">Related Party Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_RelatedPartyTransactionsDetailsTable" xlink:to="ltrn_RelatedPartyTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_RelatedPartyTransactionsDetailsLineItems" xlink:href="ltrn-20201231.xsd#ltrn_RelatedPartyTransactionsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_RelatedPartyTransactionsDetailsLineItems_lbl" xml:lang="en-US">Related Party Transactions (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_RelatedPartyTransactionsDetailsLineItems" xlink:to="ltrn_RelatedPartyTransactionsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_IncomeTaxesDetailsTable" xlink:href="ltrn-20201231.xsd#ltrn_IncomeTaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_IncomeTaxesDetailsTable_lbl" xml:lang="en-US">Income Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_IncomeTaxesDetailsTable" xlink:to="ltrn_IncomeTaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_IncomeTaxesDetailsLineItems" xlink:href="ltrn-20201231.xsd#ltrn_IncomeTaxesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_IncomeTaxesDetailsLineItems_lbl" xml:lang="en-US">Income Taxes (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_IncomeTaxesDetailsLineItems" xlink:to="ltrn_IncomeTaxesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_SubsequentEventsDetailsTable" xlink:href="ltrn-20201231.xsd#ltrn_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_SubsequentEventsDetailsTable" xlink:to="ltrn_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="ltrn_SubsequentEventsDetailsLineItems" xlink:href="ltrn-20201231.xsd#ltrn_SubsequentEventsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_SubsequentEventsDetailsLineItems_lbl" xml:lang="en-US">Subsequent Events (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_SubsequentEventsDetailsLineItems" xlink:to="ltrn_SubsequentEventsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_Annualfees_lbl0" xml:lang="en-US">Annual fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_Annualfees" xlink:to="ltrn_Annualfees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_ApplicationOfDeferredOfferingCosts_lbl0" xml:lang="en-US">Amount of application of deferred offering costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ApplicationOfDeferredOfferingCosts" xlink:to="ltrn_ApplicationOfDeferredOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_CashlessExerciseOfWarrant_lbl0" xml:lang="en-US">Cashless exercise of warrant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_CashlessExerciseOfWarrant" xlink:to="ltrn_CashlessExerciseOfWarrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_CashlessExerciseOfWarrantinShares_lbl0" xml:lang="en-US">It represents of cashless exercise of warrant in shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_CashlessExerciseOfWarrantinShares" xlink:to="ltrn_CashlessExerciseOfWarrantinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRight_lbl0" xml:lang="en-US">Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRight" xlink:to="ltrn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRight_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_ClassOfWarrantTerm_lbl0" xml:lang="en-US">Warrants term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ClassOfWarrantTerm" xlink:to="ltrn_ClassOfWarrantTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_CommonStockForIssuanceReservedShares_lbl0" xml:lang="en-US">Common stock for issuance reserved, shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_CommonStockForIssuanceReservedShares" xlink:to="ltrn_CommonStockForIssuanceReservedShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCosts_lbl0" xml:lang="en-US">It represents of common stock issued from option exercise.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCosts" xlink:to="ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCostsinShares_lbl0" xml:lang="en-US">It represents of common stock issued from offering net of issuance costs in shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCostsinShares" xlink:to="ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCostsinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_CommonStockPercentage_lbl0" xml:lang="en-US">Common Stock, percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_CommonStockPercentage" xlink:to="ltrn_CommonStockPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock_lbl0" xml:lang="en-US">Conversion of SAFE agreements to Series A preferred stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock" xlink:to="ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_DeferredOfferingCostsRecordedInAPAndAccruedExpenses_lbl0" xml:lang="en-US">Deferred offering costs recorded in AP and accrued expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_DeferredOfferingCostsRecordedInAPAndAccruedExpenses" xlink:to="ltrn_DeferredOfferingCostsRecordedInAPAndAccruedExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_DeferredTaxAssetsDepreciation_lbl0" xml:lang="en-US">Depreciation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_DeferredTaxAssetsDepreciation" xlink:to="ltrn_DeferredTaxAssetsDepreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_DeferredTaxAssetsResearchAndDevelopmentCredits_lbl0" xml:lang="en-US">Research and development credits.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_DeferredTaxAssetsResearchAndDevelopmentCredits" xlink:to="ltrn_DeferredTaxAssetsResearchAndDevelopmentCredits_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockBasedCompensation_lbl0" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from stock-based compensation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockBasedCompensation" xlink:to="ltrn_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_GrantedPeriod_lbl0" xml:lang="en-US">Granted period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_GrantedPeriod" xlink:to="ltrn_GrantedPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable_lbl0" xml:lang="en-US">IncreaseDecreaseInBorrowingsOnLoanPayable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable" xlink:to="ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_NetProceeds_lbl0" xml:lang="en-US">The amount of net proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_NetProceeds" xlink:to="ltrn_NetProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_NetRevenuePercentage_lbl0" xml:lang="en-US">Percentage of net revenue.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_NetRevenuePercentage" xlink:to="ltrn_NetRevenuePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_PatentLicenseFees_lbl0" xml:lang="en-US">Patent license fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_PatentLicenseFees" xlink:to="ltrn_PatentLicenseFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl0" xml:lang="en-US">The entire policy of prepaid expenses and other current assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:to="ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_ProceedsFromPreferredStockConvertedToCommonStockNetOfFractionalSharesAdjustment_lbl0" xml:lang="en-US">It represents of proceeds from preferred stock converted to common stock net of fractional shares adjustment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ProceedsFromPreferredStockConvertedToCommonStockNetOfFractionalSharesAdjustment" xlink:to="ltrn_ProceedsFromPreferredStockConvertedToCommonStockNetOfFractionalSharesAdjustment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_ProductCandidates_lbl0" xml:lang="en-US">Product candidates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ProductCandidates" xlink:to="ltrn_ProductCandidates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_PublicOfferingPerShare_lbl0" xml:lang="en-US">Public offering, per share.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_PublicOfferingPerShare" xlink:to="ltrn_PublicOfferingPerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_PurchaseOfWarrantsShares_lbl0" xml:lang="en-US">Purchase of warrants, shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_PurchaseOfWarrantsShares" xlink:to="ltrn_PurchaseOfWarrantsShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_ResearchAndDevelopmentExpensesPercentage_lbl0" xml:lang="en-US">Research and development expenses percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ResearchAndDevelopmentExpensesPercentage" xlink:to="ltrn_ResearchAndDevelopmentExpensesPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_lbl1" xml:lang="en-US">Number of options outstanding, including both vested and non-vested options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" xlink:to="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiratiosInPeriod_lbl0" xml:lang="en-US">Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiratiosInPeriod" xlink:to="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiratiosInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross_lbl0" xml:lang="en-US">Gross number of share options (or share units) granted during the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross" xlink:to="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted average price at which option holders acquired shares when converting their stock options into shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExercisesInPeriodWeightedAverageExercisePrice" xlink:to="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationInPeriodWeightedAverageExercisePrice" xlink:to="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTerm_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTerm" xlink:to="ltrn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_SharesRemainAvailableForFutureAwards_lbl0" xml:lang="en-US">Shares remain available for future awards.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_SharesRemainAvailableForFutureAwards" xlink:to="ltrn_SharesRemainAvailableForFutureAwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_StockIssuedDuringPeriodSharesOutstandingExcercised_lbl0" xml:lang="en-US">Number of options outstanding, excercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_StockIssuedDuringPeriodSharesOutstandingExcercised" xlink:to="ltrn_StockIssuedDuringPeriodSharesOutstandingExcercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_StockIssuedDuringPeriodSharesStockOptionExercised_lbl0" xml:lang="en-US">Number of share options (or share units) exercised during the current period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_StockIssuedDuringPeriodSharesStockOptionExercised" xlink:to="ltrn_StockIssuedDuringPeriodSharesStockOptionExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment_lbl0" xml:lang="en-US">Stock issued value preferred stock conversion to common stock net of fractional shares adjustment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment" xlink:to="ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_TotalGrossProceeds_lbl0" xml:lang="en-US">Total gross proceeds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_TotalGrossProceeds" xlink:to="ltrn_TotalGrossProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_UndepositedFunds_lbl0" xml:lang="en-US">The amount represents uneposited funds.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_UndepositedFunds" xlink:to="ltrn_UndepositedFunds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_UpfrontContractorFees_lbl0" xml:lang="en-US">The amount represents upfron contractor fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_UpfrontContractorFees" xlink:to="ltrn_UpfrontContractorFees_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_UpfrontPayments_lbl0" xml:lang="en-US">Upfront payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_UpfrontPayments" xlink:to="ltrn_UpfrontPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_WarrantTerm_lbl0" xml:lang="en-US">Warrant term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_WarrantTerm" xlink:to="ltrn_WarrantTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ltrn_WarrantsToPurchaseShares_lbl0" xml:lang="en-US">Warrants to purchase shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_WarrantsToPurchaseShares" xlink:to="ltrn_WarrantsToPurchaseShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCostsinShares_lbl1" xml:lang="en-US">CommonStockIssuedFromOfferingNetOfIssuanceCostsinShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCostsinShares" xlink:to="ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCostsinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_UpfrontPayments_lbl1" xml:lang="en-US">UpfrontPayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_UpfrontPayments" xlink:to="ltrn_UpfrontPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl1" xml:lang="en-US">PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:to="ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants_lbl0" xml:lang="en-US">StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants" xlink:to="ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockBasedCompensation_lbl1" xml:lang="en-US">DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockBasedCompensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockBasedCompensation" xlink:to="ltrn_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockBasedCompensation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_AFChemicalsMember_lbl0" xml:lang="en-US">AFChemicalsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_AFChemicalsMember" xlink:to="ltrn_AFChemicalsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_OtherOfferingExpenses_lbl0" xml:lang="en-US">OtherOfferingExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_OtherOfferingExpenses" xlink:to="ltrn_OtherOfferingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_SafeAgreementsDisclosureTextBlock_lbl0" xml:lang="en-US">SafeAgreementsDisclosureTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_SafeAgreementsDisclosureTextBlock" xlink:to="ltrn_SafeAgreementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_PatentLicenseFees_lbl1" xml:lang="en-US">PatentLicenseFees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_PatentLicenseFees" xlink:to="ltrn_PatentLicenseFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_DeferredTaxAssetsResearchAndDevelopmentCredits_lbl1" xml:lang="en-US">DeferredTaxAssetsResearchAndDevelopmentCredits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_DeferredTaxAssetsResearchAndDevelopmentCredits" xlink:to="ltrn_DeferredTaxAssetsResearchAndDevelopmentCredits_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment_lbl1" xml:lang="en-US">StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment" xlink:to="ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_PatheonAPIServicesMember_lbl0" xml:lang="en-US">PatheonAPIServicesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_PatheonAPIServicesMember" xlink:to="ltrn_PatheonAPIServicesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_NetProceeds_lbl1" xml:lang="en-US">NetProceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_NetProceeds" xlink:to="ltrn_NetProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_TotalGrossProceeds_lbl1" xml:lang="en-US">TotalGrossProceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_TotalGrossProceeds" xlink:to="ltrn_TotalGrossProceeds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_WorkingCapital_lbl0" xml:lang="en-US">WorkingCapital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_WorkingCapital" xlink:to="ltrn_WorkingCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExercisesInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExercisesInPeriodWeightedAverageExercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExercisesInPeriodWeightedAverageExercisePrice" xlink:to="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExercisesInPeriodWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_AgreementDescription_lbl0" xml:lang="en-US">AgreementDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_AgreementDescription" xlink:to="ltrn_AgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_NetRevenuePercentage_lbl1" xml:lang="en-US">NetRevenuePercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_NetRevenuePercentage" xlink:to="ltrn_NetRevenuePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_CommonStockPercentage_lbl1" xml:lang="en-US">CommonStockPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_CommonStockPercentage" xlink:to="ltrn_CommonStockPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_Annualfees_lbl1" xml:lang="en-US">Annualfees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_Annualfees" xlink:to="ltrn_Annualfees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_DeferredOfferingCostsRecordedInAPAndAccruedExpenses_lbl1" xml:lang="en-US">DeferredOfferingCostsRecordedInAPAndAccruedExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_DeferredOfferingCostsRecordedInAPAndAccruedExpenses" xlink:to="ltrn_DeferredOfferingCostsRecordedInAPAndAccruedExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_BioNumerikPharmaceuticalMember_lbl0" xml:lang="en-US">BioNumerikPharmaceuticalMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_BioNumerikPharmaceuticalMember" xlink:to="ltrn_BioNumerikPharmaceuticalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_DeferredTaxAssetsAbstract_lbl0" xml:lang="en-US">DeferredTaxAssetsAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_DeferredTaxAssetsAbstract" xlink:to="ltrn_DeferredTaxAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_UndepositedFunds_lbl1" xml:lang="en-US">UndepositedFunds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_UndepositedFunds" xlink:to="ltrn_UndepositedFunds_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_GrantedPeriod_lbl1" xml:lang="en-US">GrantedPeriod</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_GrantedPeriod" xlink:to="ltrn_GrantedPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationInPeriodWeightedAverageExercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationInPeriodWeightedAverageExercisePrice" xlink:to="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationInPeriodWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_LP100Member_lbl0" xml:lang="en-US">LP100Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_LP100Member" xlink:to="ltrn_LP100Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_EUGrantMember_lbl0" xml:lang="en-US">EUGrantMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_EUGrantMember" xlink:to="ltrn_EUGrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_LoanPursuantToPaycheckProtectionProgramTextBlock_lbl0" xml:lang="en-US">LoanPursuantToPaycheckProtectionProgramTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_LoanPursuantToPaycheckProtectionProgramTextBlock" xlink:to="ltrn_LoanPursuantToPaycheckProtectionProgramTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_PublicOfferingPerShare_lbl1" xml:lang="en-US">PublicOfferingPerShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_PublicOfferingPerShare" xlink:to="ltrn_PublicOfferingPerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_WarrantsToPurchaseShares_lbl1" xml:lang="en-US">WarrantsToPurchaseShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_WarrantsToPurchaseShares" xlink:to="ltrn_WarrantsToPurchaseShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ClassOfWarrantTerm_lbl1" xml:lang="en-US">ClassOfWarrantTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ClassOfWarrantTerm" xlink:to="ltrn_ClassOfWarrantTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross" xlink:to="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ApplicationOfDeferredOfferingCosts_lbl1" xml:lang="en-US">ApplicationOfDeferredOfferingCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ApplicationOfDeferredOfferingCosts" xlink:to="ltrn_ApplicationOfDeferredOfferingCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_UpfrontContractorFees_lbl1" xml:lang="en-US">UpfrontContractorFees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_UpfrontContractorFees" xlink:to="ltrn_UpfrontContractorFees_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_CommonStockTotalProceedsValue_lbl0" xml:lang="en-US">CommonStockTotalProceedsValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_CommonStockTotalProceedsValue" xlink:to="ltrn_CommonStockTotalProceedsValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_IncreaseDecreaseIssuanceCosts_lbl0" xml:lang="en-US">IncreaseDecreaseIssuanceCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_IncreaseDecreaseIssuanceCosts" xlink:to="ltrn_IncreaseDecreaseIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageExercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageExercisePrice" xlink:to="ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiratiosInPeriod_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiratiosInPeriod</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiratiosInPeriod" xlink:to="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiratiosInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ProceedsFromPreferredStockConvertedToCommonStockNetOfFractionalSharesAdjustment_lbl1" xml:lang="en-US">ProceedsFromPreferredStockConvertedToCommonStockNetOfFractionalSharesAdjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ProceedsFromPreferredStockConvertedToCommonStockNetOfFractionalSharesAdjustment" xlink:to="ltrn_ProceedsFromPreferredStockConvertedToCommonStockNetOfFractionalSharesAdjustment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_WarrantsToPurchasePercentage_lbl0" xml:lang="en-US">WarrantsToPurchasePercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_WarrantsToPurchasePercentage" xlink:to="ltrn_WarrantsToPurchasePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCosts_lbl1" xml:lang="en-US">CommonStockIssuedFromOfferingNetOfIssuanceCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCosts" xlink:to="ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_IntuitionMember_lbl0" xml:lang="en-US">IntuitionMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_IntuitionMember" xlink:to="ltrn_IntuitionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:to="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock_lbl1" xml:lang="en-US">ConversionOfSafeAgreementsToSeriesPreferredStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock" xlink:to="ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_LP184Member_lbl0" xml:lang="en-US">LP184Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_LP184Member" xlink:to="ltrn_LP184Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_MilestoneExtensionPaid_lbl0" xml:lang="en-US">MilestoneExtensionPaid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_MilestoneExtensionPaid" xlink:to="ltrn_MilestoneExtensionPaid_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants_lbl0" xml:lang="en-US">StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants" xlink:to="ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_BioNumerikMember_lbl0" xml:lang="en-US">BioNumerikMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_BioNumerikMember" xlink:to="ltrn_BioNumerikMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable_lbl1" xml:lang="en-US">IncreaseDecreaseInBorrowingsOnLoanPayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable" xlink:to="ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_CashlessExerciseOfWarrantinShares_lbl1" xml:lang="en-US">CashlessExerciseOfWarrantinShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_CashlessExerciseOfWarrantinShares" xlink:to="ltrn_CashlessExerciseOfWarrantinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment_lbl0" xml:lang="en-US">IncreaseDecreasePurchaseOfPropertyAndEquipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment" xlink:to="ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_DeferredTaxAssetsDepreciation_lbl1" xml:lang="en-US">DeferredTaxAssetsDepreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_DeferredTaxAssetsDepreciation" xlink:to="ltrn_DeferredTaxAssetsDepreciation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ManufacturingAgreementDescription_lbl0" xml:lang="en-US">ManufacturingAgreementDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ManufacturingAgreementDescription" xlink:to="ltrn_ManufacturingAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRight_lbl1" xml:lang="en-US">ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRight</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRight" xlink:to="ltrn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRight_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_WarrantTerm_lbl1" xml:lang="en-US">WarrantTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_WarrantTerm" xlink:to="ltrn_WarrantTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTerm_lbl1" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTerm" xlink:to="ltrn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_SouthwestResearchInstituteMember_lbl0" xml:lang="en-US">SouthwestResearchInstituteMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_SouthwestResearchInstituteMember" xlink:to="ltrn_SouthwestResearchInstituteMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_BiologicalMimeticsIncMember_lbl0" xml:lang="en-US">BiologicalMimeticsIncMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_BiologicalMimeticsIncMember" xlink:to="ltrn_BiologicalMimeticsIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ProductCandidates_lbl1" xml:lang="en-US">ProductCandidates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ProductCandidates" xlink:to="ltrn_ProductCandidates_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ResearchAndDevelopmentExpensesPercentage_lbl1" xml:lang="en-US">ResearchAndDevelopmentExpensesPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ResearchAndDevelopmentExpensesPercentage" xlink:to="ltrn_ResearchAndDevelopmentExpensesPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_CommonStockForIssuanceReservedShares_lbl1" xml:lang="en-US">CommonStockForIssuanceReservedShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_CommonStockForIssuanceReservedShares" xlink:to="ltrn_CommonStockForIssuanceReservedShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_PurchaseOfWarrantsShares_lbl1" xml:lang="en-US">PurchaseOfWarrantsShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_PurchaseOfWarrantsShares" xlink:to="ltrn_PurchaseOfWarrantsShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_CashlessExerciseOfWarrant_lbl1" xml:lang="en-US">CashlessExerciseOfWarrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_CashlessExerciseOfWarrant" xlink:to="ltrn_CashlessExerciseOfWarrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_StockIssuedDuringPeriodSharesStockOptionExercised_lbl1" xml:lang="en-US">StockIssuedDuringPeriodSharesStockOptionExercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_StockIssuedDuringPeriodSharesStockOptionExercised" xlink:to="ltrn_StockIssuedDuringPeriodSharesStockOptionExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_NetProceed_lbl0" xml:lang="en-US">NetProceed</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_NetProceed" xlink:to="ltrn_NetProceed_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_lbl2" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" xlink:to="ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_StockIssuedDuringPeriodSharesOutstandingExcercised_lbl1" xml:lang="en-US">StockIssuedDuringPeriodSharesOutstandingExcercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_StockIssuedDuringPeriodSharesOutstandingExcercised" xlink:to="ltrn_StockIssuedDuringPeriodSharesOutstandingExcercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_OptionsMember_lbl0" xml:lang="en-US">OptionsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_OptionsMember" xlink:to="ltrn_OptionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ltrn_SharesRemainAvailableForFutureAwards_lbl1" xml:lang="en-US">SharesRemainAvailableForFutureAwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ltrn_SharesRemainAvailableForFutureAwards" xlink:to="ltrn_SharesRemainAvailableForFutureAwards_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl0" xml:lang="en-US">Prepaid Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl0" xml:lang="en-US">Debt Instrument, Annual Principal Payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl0" xml:lang="en-US">Patents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl0" xml:lang="en-US">Research and Development in Process</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLoanOriginations1_lbl0" xml:lang="en-US">Proceeds from Loan Originations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLoanOriginations1" xlink:to="us-gaap_ProceedsFromLoanOriginations1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl0" xml:lang="en-US">Over-Allotment Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl0" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges_lbl0" xml:lang="en-US">Increase (Decrease) in Deferred Charges</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl1" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentDescription_lbl0" xml:lang="en-US">Debt Instrument, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentDescription" xlink:to="us-gaap_DebtInstrumentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering_lbl0" xml:lang="en-US">Partners&apos; Capital Account, Units, Sold in Public Offering</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering" xlink:to="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription_lbl0" xml:lang="en-US">Debt Instrument, Maturity Date, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount_lbl0" xml:lang="en-US">Stock Option, Down Round Feature, (Increase) Decrease in Equity, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:to="us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl0" xml:lang="en-US">Other Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl0" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DueToRelatedPartiesCurrent_lbl0" xml:lang="en-US">Due to Related Parties, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DueToRelatedPartiesCurrent" xlink:to="us-gaap_DueToRelatedPartiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl0" xml:lang="en-US">Substantial Doubt about Going Concern [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent_lbl1" xml:lang="en-US">Related Party Transaction, Due from (to) Related Party, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherCommitmentsDescription_lbl0" xml:lang="en-US">Other Commitments, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDescription" xlink:to="us-gaap_OtherCommitmentsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl0" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate During Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedPatentsGross_lbl0" xml:lang="en-US">Finite-Lived Patents, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedPatentsGross" xlink:to="us-gaap_FiniteLivedPatentsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForOtherOperatingActivities_lbl0" xml:lang="en-US">Payments for Other Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForOtherOperatingActivities" xlink:to="us-gaap_PaymentsForOtherOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Expected Dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl0" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsNoncurrent_lbl0" xml:lang="en-US">Deposits Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsNoncurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl2" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl2" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOfferingCosts_lbl0" xml:lang="en-US">Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOfferingCosts" xlink:to="us-gaap_DeferredOfferingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets_lbl0" xml:lang="en-US">Investment Owned, Percent of Net Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:to="us-gaap_InvestmentOwnedPercentOfNetAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherUnderwritingExpense_lbl0" xml:lang="en-US">Other Underwriting Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherUnderwritingExpense" xlink:to="us-gaap_OtherUnderwritingExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeasePayments_lbl0" xml:lang="en-US">Short-term Lease Payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeasePayments" xlink:to="us-gaap_ShortTermLeasePayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl0" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl0" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLoans_lbl0" xml:lang="en-US">Proceeds from Loans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLoans" xlink:to="us-gaap_ProceedsFromLoans_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl0" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseDescription_lbl0" xml:lang="en-US">Lessee, Operating Lease, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseDescription" xlink:to="us-gaap_LesseeOperatingLeaseDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplit_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note, Stock Split</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplit" xlink:to="us-gaap_StockholdersEquityNoteStockSplit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl2" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquityLiquidationPreference_lbl0" xml:lang="en-US">Temporary Equity, Liquidation Preference</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityLiquidationPreference" xlink:to="us-gaap_TemporaryEquityLiquidationPreference_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl1" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl0" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl0" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl1" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl0" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, before Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl0" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, General Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl0" xml:lang="en-US">Related Party Transaction, Amounts of Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertySubjectToOperatingLeaseMember_lbl0" xml:lang="en-US">Property Subject to Operating Lease [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertySubjectToOperatingLeaseMember" xlink:to="us-gaap_PropertySubjectToOperatingLeaseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl0" xml:lang="en-US">Conversion of Stock, Shares Converted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl1" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl0" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl0" xml:lang="en-US">Proceeds from Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl0" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl1" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockPlans_lbl0" xml:lang="en-US">Proceeds from Stock Plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredChargesPolicyTextBlock_lbl0" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredChargesPolicyTextBlock" xlink:to="us-gaap_DeferredChargesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Other General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAdditionalCapital_lbl0" xml:lang="en-US">Other Additional Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAdditionalCapital" xlink:to="us-gaap_OtherAdditionalCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl1" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_lbl0" xml:lang="en-US">Deferred Tax Liabilities, Goodwill and Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl0" xml:lang="en-US">Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>ltrn-20201231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed Mar 10 03:43:46 EST 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_ConsolidatedBalanceSheet" roleURI="http://laternpharma.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://laternpharma.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_ConsolidatedIncomeStatement" roleURI="http://laternpharma.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_ShareholdersEquityType2or3" roleURI="http://laternpharma.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_ConsolidatedCashFlow" roleURI="http://laternpharma.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_OrganizationPrincipalActivitiesandBasisofPresentation" roleURI="http://laternpharma.com/role/OrganizationPrincipalActivitiesandBasisofPresentation"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_Liquidity" roleURI="http://laternpharma.com/role/Liquidity"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_SummaryofSignificantAccountingPolicies" roleURI="http://laternpharma.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_NewAccountingPronouncements" roleURI="http://laternpharma.com/role/NewAccountingPronouncements"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_CommitmentsandContingencies" roleURI="http://laternpharma.com/role/CommitmentsandContingencies"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_ShareholdersEquity" roleURI="http://laternpharma.com/role/ShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_SafeAgreements" roleURI="http://laternpharma.com/role/SafeAgreements"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_NotesandLoanPayable" roleURI="http://laternpharma.com/role/NotesandLoanPayable"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_RelatedPartyTransactions" roleURI="http://laternpharma.com/role/RelatedPartyTransactions"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_LossPerShareofCommonShares" roleURI="http://laternpharma.com/role/LossPerShareofCommonShares"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_IncomeTaxes" roleURI="http://laternpharma.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_SubsequentEvents" roleURI="http://laternpharma.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_AccountingPoliciesByPolicy" roleURI="http://laternpharma.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_ShareholdersEquityTables" roleURI="http://laternpharma.com/role/ShareholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_LossPerShareofCommonSharesTables" roleURI="http://laternpharma.com/role/LossPerShareofCommonSharesTables"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_IncomeTaxesTables" roleURI="http://laternpharma.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_ScheduleofstockoptionactivityTable" roleURI="http://laternpharma.com/role/ScheduleofstockoptionactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_ScheduleofweightedaverageassumptionsTable" roleURI="http://laternpharma.com/role/ScheduleofweightedaverageassumptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_ScheduleofdilutedlosspershareduetobeingantidilutiveTable" roleURI="http://laternpharma.com/role/ScheduleofdilutedlosspershareduetobeingantidilutiveTable"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_ScheduleofEffectivetaxratediffersfromthestatutoryfederaltaxrateaspresentedTable" roleURI="http://laternpharma.com/role/ScheduleofEffectivetaxratediffersfromthestatutoryfederaltaxrateaspresentedTable"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_ScheduleofEffectofthetemporarydifferencesthatgiverisetothesignificantportionsofthedeferredtaxassetsandliabilitiesTable" roleURI="http://laternpharma.com/role/ScheduleofEffectofthetemporarydifferencesthatgiverisetothesignificantportionsofthedeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_OrganizationPrincipalActivitiesandBasisofPresentationDetails" roleURI="http://laternpharma.com/role/OrganizationPrincipalActivitiesandBasisofPresentationDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_LiquidityDetails" roleURI="http://laternpharma.com/role/LiquidityDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://laternpharma.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_CommitmentsandContingenciesDetails" roleURI="http://laternpharma.com/role/CommitmentsandContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_ShareholdersEquityDetails" roleURI="http://laternpharma.com/role/ShareholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_SafeAgreementsDetails" roleURI="http://laternpharma.com/role/SafeAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_NotesandLoanPayableDetails" roleURI="http://laternpharma.com/role/NotesandLoanPayableDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_RelatedPartyTransactionsDetails" roleURI="http://laternpharma.com/role/RelatedPartyTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_IncomeTaxesDetails" roleURI="http://laternpharma.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#ltrn_r_SubsequentEventsDetails" roleURI="http://laternpharma.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="ltrn-20201231.xsd#DocumentAndEntityInformation" roleURI="http://laternpharma.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepositsAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Assets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrentAndNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_Liabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquity" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_PreferredStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="4.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants" xlink:href="ltrn-20201231.xsd#ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants" xlink:href="ltrn-20201231.xsd#ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedFromOfferingNetOfIssuanceCosts" xlink:href="ltrn-20201231.xsd#ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="CommonStockIssuedFromOfferingNetOfIssuanceCosts" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockIssuedFromOfferingNetOfIssuanceCostsinShares" xlink:href="ltrn-20201231.xsd#ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCostsinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="CommonStockIssuedFromOfferingNetOfIssuanceCostsinShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment" xlink:href="ltrn-20201231.xsd#ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashlessExerciseOfWarrant" xlink:href="ltrn-20201231.xsd#ltrn_CashlessExerciseOfWarrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="CashlessExerciseOfWarrant" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashlessExerciseOfWarrantinShares" xlink:href="ltrn-20201231.xsd#ltrn_CashlessExerciseOfWarrantinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="CashlessExerciseOfWarrantinShares" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredCharges" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredCharges"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredCharges" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreasePurchaseOfPropertyAndEquipment" xlink:href="ltrn-20201231.xsd#ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="IncreaseDecreasePurchaseOfPropertyAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseIssuanceCosts" xlink:href="ltrn-20201231.xsd#ltrn_IncreaseDecreaseIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="IncreaseDecreaseIssuanceCosts" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockPlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockPlans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromPreferredStockConvertedToCommonStockNetOfFractionalSharesAdjustment" xlink:href="ltrn-20201231.xsd#ltrn_ProceedsFromPreferredStockConvertedToCommonStockNetOfFractionalSharesAdjustment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromPreferredStockConvertedToCommonStockNetOfFractionalSharesAdjustment" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromNotesPayable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInBorrowingsOnLoanPayable" xlink:href="ltrn-20201231.xsd#ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="IncreaseDecreaseInBorrowingsOnLoanPayable" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfSafeAgreementsToSeriesPreferredStock" xlink:href="ltrn-20201231.xsd#ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ConversionOfSafeAgreementsToSeriesPreferredStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ApplicationOfDeferredOfferingCosts" xlink:href="ltrn-20201231.xsd#ltrn_ApplicationOfDeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="ApplicationOfDeferredOfferingCosts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredOfferingCostsRecordedInAPAndAccruedExpenses" xlink:href="ltrn-20201231.xsd#ltrn_DeferredOfferingCostsRecordedInAPAndAccruedExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="DeferredOfferingCostsRecordedInAPAndAccruedExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/OrganizationPrincipalActivitiesandBasisofPresentation">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/Liquidity">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/NewAccountingPronouncements">
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/CommitmentsandContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ShareholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/SafeAgreements">
    <loc xlink:type="locator" xlink:label="SafeAgreementsDisclosureAbstract" xlink:href="ltrn-20201231.xsd#ltrn_SafeAgreementsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="SafeAgreementsDisclosureTextBlock" xlink:href="ltrn-20201231.xsd#ltrn_SafeAgreementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SafeAgreementsDisclosureAbstract" xlink:to="SafeAgreementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/NotesandLoanPayable">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/RelatedPartyTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/LossPerShareofCommonShares">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredChargesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DeferredChargesPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" xlink:href="ltrn-20201231.xsd#ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LoanPursuantToPaycheckProtectionProgramTextBlock" xlink:href="ltrn-20201231.xsd#ltrn_LoanPursuantToPaycheckProtectionProgramTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="LoanPursuantToPaycheckProtectionProgramTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ShareholdersEquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/LossPerShareofCommonSharesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ScheduleofstockoptionactivityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockOptionActivityAbstract" xlink:href="ltrn-20201231.xsd#ltrn_ScheduleOfStockOptionActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" xlink:href="ltrn-20201231.xsd#ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:href="ltrn-20201231.xsd#ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross" xlink:href="ltrn-20201231.xsd#ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageExercisePrice" xlink:href="ltrn-20201231.xsd#ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesOutstandingExcercised" xlink:href="ltrn-20201231.xsd#ltrn_StockIssuedDuringPeriodSharesOutstandingExcercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="StockIssuedDuringPeriodSharesOutstandingExcercised" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesStockOptionExercised" xlink:href="ltrn-20201231.xsd#ltrn_StockIssuedDuringPeriodSharesStockOptionExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="StockIssuedDuringPeriodSharesStockOptionExercised" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExercisesInPeriodWeightedAverageExercisePrice" xlink:href="ltrn-20201231.xsd#ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExercisesInPeriodWeightedAverageExercisePrice" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" order="12.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiratiosInPeriod" xlink:href="ltrn-20201231.xsd#ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiratiosInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiratiosInPeriod" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationInPeriodWeightedAverageExercisePrice" xlink:href="ltrn-20201231.xsd#ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationInPeriodWeightedAverageExercisePrice" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_0" xlink:href="ltrn-20201231.xsd#ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_0" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_0" xlink:href="ltrn-20201231.xsd#ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_0" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ScheduleofweightedaverageassumptionsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageAssumptionsAbstract" xlink:href="ltrn-20201231.xsd#ltrn_ScheduleOfWeightedAverageAssumptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofweightedaverageassumptionsTable" xlink:href="ltrn-20201231.xsd#ltrn_ShareholdersEquityDetailsScheduleofweightedaverageassumptionsTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofweightedaverageassumptionsLineItems" xlink:href="ltrn-20201231.xsd#ltrn_ShareholdersEquityDetailsScheduleofweightedaverageassumptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageAssumptionsAbstract" xlink:to="ShareholdersEquityDetailsScheduleofweightedaverageassumptionsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofweightedaverageassumptionsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofweightedaverageassumptionsTable" xlink:to="ShareholdersEquityDetailsScheduleofweightedaverageassumptionsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofweightedaverageassumptionsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofweightedaverageassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofweightedaverageassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofweightedaverageassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofweightedaverageassumptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ScheduleofdilutedlosspershareduetobeingantidilutiveTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDilutedLossPerShareDueToBeingAntiDilutiveAbstract" xlink:href="ltrn-20201231.xsd#ltrn_ScheduleOfDilutedLossPerShareDueToBeingAntiDilutiveAbstract"/>
    <loc xlink:type="locator" xlink:label="LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable" xlink:href="ltrn-20201231.xsd#ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable"/>
    <loc xlink:type="locator" xlink:label="LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems" xlink:href="ltrn-20201231.xsd#ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDilutedLossPerShareDueToBeingAntiDilutiveAbstract" xlink:to="LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveTable" xlink:to="LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ScheduleofEffectivetaxratediffersfromthestatutoryfederaltaxrateaspresentedTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfEffectiveTaxRateDiffersFromTheStatutoryFederalTaxRateAsPresentedAbstract" xlink:href="ltrn-20201231.xsd#ltrn_ScheduleOfEffectiveTaxRateDiffersFromTheStatutoryFederalTaxRateAsPresentedAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveTaxRateDiffersFromTheStatutoryFederalTaxRateAsPresentedAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveTaxRateDiffersFromTheStatutoryFederalTaxRateAsPresentedAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveTaxRateDiffersFromTheStatutoryFederalTaxRateAsPresentedAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectiveTaxRateDiffersFromTheStatutoryFederalTaxRateAsPresentedAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ScheduleofEffectofthetemporarydifferencesthatgiverisetothesignificantportionsofthedeferredtaxassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfEffectOfTheTemporaryDifferencesThatGiveRiseToTheSignificantPortionsOfTheDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="ltrn-20201231.xsd#ltrn_ScheduleOfEffectOfTheTemporaryDifferencesThatGiveRiseToTheSignificantPortionsOfTheDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsAbstract" xlink:href="ltrn-20201231.xsd#ltrn_DeferredTaxAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectOfTheTemporaryDifferencesThatGiveRiseToTheSignificantPortionsOfTheDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsDepreciation" xlink:href="ltrn-20201231.xsd#ltrn_DeferredTaxAssetsDepreciation"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbBx2uhymvyVLDa+1t8Zs6OCx+D0Bcy6Dt/X9wfJ64eyeWWDp4AwLD4hnV42U8gMPb6ZmoZskqs/VGWXFAW+VCwrstTEwsw9mBsjnLef0gxwD31/7ddIjxiai89b27Ur3wVtqpWYQb962vnZqopmU1PbSobqhOErLV5kQmlf1KTTNwUf5Cat3VqQ2EYrVSNQgTFtI+RYIDfXpsGsMS0CrNt] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsDepreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsResearchAndDevelopmentCredits" xlink:href="ltrn-20201231.xsd#ltrn_DeferredTaxAssetsResearchAndDevelopmentCredits"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsResearchAndDevelopmentCredits" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockBasedCompensation" xlink:href="ltrn-20201231.xsd#ltrn_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectOfTheTemporaryDifferencesThatGiveRiseToTheSignificantPortionsOfTheDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectOfTheTemporaryDifferencesThatGiveRiseToTheSignificantPortionsOfTheDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEffectOfTheTemporaryDifferencesThatGiveRiseToTheSignificantPortionsOfTheDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/OrganizationPrincipalActivitiesandBasisofPresentationDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="OrganizationPrincipalActivitiesandBasisofPresentationDetailsTable" xlink:href="ltrn-20201231.xsd#ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems" xlink:href="ltrn-20201231.xsd#ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="OrganizationPrincipalActivitiesandBasisofPresentationDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationPrincipalActivitiesandBasisofPresentationDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationPrincipalActivitiesandBasisofPresentationDetailsTable" xlink:to="OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/LiquidityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <loc xlink:type="locator" xlink:label="LiquidityDetailsTable" xlink:href="ltrn-20201231.xsd#ltrn_LiquidityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LiquidityDetailsLineItems" xlink:href="ltrn-20201231.xsd#ltrn_LiquidityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="LiquidityDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_OverAllotmentOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityDetailsTable" xlink:to="LiquidityDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityDetailsLineItems" xlink:to="us-gaap_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WorkingCapital" xlink:href="ltrn-20201231.xsd#ltrn_WorkingCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityDetailsLineItems" xlink:to="WorkingCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetProceed" xlink:href="ltrn-20201231.xsd#ltrn_NetProceed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityDetailsLineItems" xlink:to="NetProceed" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityDetailsLineItems" xlink:to="us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalGrossProceeds" xlink:href="ltrn-20201231.xsd#ltrn_TotalGrossProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityDetailsLineItems" xlink:to="TotalGrossProceeds" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="ltrn-20201231.xsd#ltrn_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="ltrn-20201231.xsd#ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOfferingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DeferredOfferingCosts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UpfrontContractorFees" xlink:href="ltrn-20201231.xsd#ltrn_UpfrontContractorFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="UpfrontContractorFees" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PatentLicenseFees" xlink:href="ltrn-20201231.xsd#ltrn_PatentLicenseFees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="PatentLicenseFees" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UndepositedFunds" xlink:href="ltrn-20201231.xsd#ltrn_UndepositedFunds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="UndepositedFunds" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLoans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLoans"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ProceedsFromLoans" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/CommitmentsandContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsTable" xlink:href="ltrn-20201231.xsd#ltrn_CommitmentsandContingenciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="CommitmentsandContingenciesDetailsLineItems" xlink:href="ltrn-20201231.xsd#ltrn_CommitmentsandContingenciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsandContingenciesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="dei_LegalEntityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="BioNumerikPharmaceuticalMember" xlink:href="ltrn-20201231.xsd#ltrn_BioNumerikPharmaceuticalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="BioNumerikPharmaceuticalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AFChemicalsMember" xlink:href="ltrn-20201231.xsd#ltrn_AFChemicalsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="AFChemicalsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="AFChemicalsMember_0" xlink:href="ltrn-20201231.xsd#ltrn_AFChemicalsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="AFChemicalsMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LP100Member" xlink:href="ltrn-20201231.xsd#ltrn_LP100Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="LP100Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EUGrantMember" xlink:href="ltrn-20201231.xsd#ltrn_EUGrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="EUGrantMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PatheonAPIServicesMember" xlink:href="ltrn-20201231.xsd#ltrn_PatheonAPIServicesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="PatheonAPIServicesMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SouthwestResearchInstituteMember" xlink:href="ltrn-20201231.xsd#ltrn_SouthwestResearchInstituteMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="SouthwestResearchInstituteMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOperatingLeaseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertySubjectToOperatingLeaseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_PropertySubjectToOperatingLeaseMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LP184Member" xlink:href="ltrn-20201231.xsd#ltrn_LP184Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="LP184Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AFChemicalsMember_1" xlink:href="ltrn-20201231.xsd#ltrn_AFChemicalsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="AFChemicalsMember_1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PatentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PatentsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_PatentsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsTable" xlink:to="CommitmentsandContingenciesDetailsLineItems" order="7.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsForOtherOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForOtherOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_PaymentsForOtherOperatingActivities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UpfrontPayments" xlink:href="ltrn-20201231.xsd#ltrn_UpfrontPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="UpfrontPayments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OtherCommitmentsDescription" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FiniteLivedPatentsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedPatentsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_FiniteLivedPatentsGross" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetRevenuePercentage" xlink:href="ltrn-20201231.xsd#ltrn_NetRevenuePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="NetRevenuePercentage" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Annualfees" xlink:href="ltrn-20201231.xsd#ltrn_Annualfees"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="Annualfees" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_OtherExpenses" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestoneExtensionPaid" xlink:href="ltrn-20201231.xsd#ltrn_MilestoneExtensionPaid"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="MilestoneExtensionPaid" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentExpensesPercentage" xlink:href="ltrn-20201231.xsd#ltrn_ResearchAndDevelopmentExpensesPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="ResearchAndDevelopmentExpensesPercentage" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GrantedPeriod" xlink:href="ltrn-20201231.xsd#ltrn_GrantedPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="GrantedPeriod" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ManufacturingAgreementDescription" xlink:href="ltrn-20201231.xsd#ltrn_ManufacturingAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="ManufacturingAgreementDescription" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProductCandidates" xlink:href="ltrn-20201231.xsd#ltrn_ProductCandidates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="ProductCandidates" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsandContingenciesDetailsLineItems" xlink:to="us-gaap_LesseeOperatingLeaseDescription" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/ShareholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsTable" xlink:href="ltrn-20201231.xsd#ltrn_ShareholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsLineItems" xlink:href="ltrn-20201231.xsd#ltrn_ShareholdersEquityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ShareholdersEquityDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember_0" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OptionsMember" xlink:href="ltrn-20201231.xsd#ltrn_OptionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="OptionsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="ShareholdersEquityDetailsLineItems" order="5.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockSharesConverted1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ConversionOfStockSharesConverted1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsToPurchaseShares" xlink:href="ltrn-20201231.xsd#ltrn_WarrantsToPurchaseShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="WarrantsToPurchaseShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockPercentage" xlink:href="ltrn-20201231.xsd#ltrn_CommonStockPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="CommonStockPercentage" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquityLiquidationPreference" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_TemporaryEquityLiquidationPreference" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockTotalProceedsValue" xlink:href="ltrn-20201231.xsd#ltrn_CommonStockTotalProceedsValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="CommonStockTotalProceedsValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherUnderwritingExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherUnderwritingExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_OtherUnderwritingExpense" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherOfferingExpenses" xlink:href="ltrn-20201231.xsd#ltrn_OtherOfferingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="OtherOfferingExpenses" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplit" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRight" xlink:href="ltrn-20201231.xsd#ltrn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRight"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRight" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockForIssuanceReservedShares" xlink:href="ltrn-20201231.xsd#ltrn_CommonStockForIssuanceReservedShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="CommonStockForIssuanceReservedShares" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTerm" xlink:href="ltrn-20201231.xsd#ltrn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTerm" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharesRemainAvailableForFutureAwards" xlink:href="ltrn-20201231.xsd#ltrn_SharesRemainAvailableForFutureAwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="SharesRemainAvailableForFutureAwards" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsToPurchasePercentage" xlink:href="ltrn-20201231.xsd#ltrn_WarrantsToPurchasePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="WarrantsToPurchasePercentage" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseOfWarrantsShares" xlink:href="ltrn-20201231.xsd#ltrn_PurchaseOfWarrantsShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="PurchaseOfWarrantsShares" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClassOfWarrantTerm" xlink:href="ltrn-20201231.xsd#ltrn_ClassOfWarrantTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="ClassOfWarrantTerm" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAdditionalCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAdditionalCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_OtherAdditionalCapital" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantTerm" xlink:href="ltrn-20201231.xsd#ltrn_WarrantTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="WarrantTerm" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/SafeAgreementsDetails">
    <loc xlink:type="locator" xlink:label="SafeAgreementsDisclosureAbstract" xlink:href="ltrn-20201231.xsd#ltrn_SafeAgreementsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="SafeAgreementsDetailsTable" xlink:href="ltrn-20201231.xsd#ltrn_SafeAgreementsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SafeAgreementsDetailsLineItems" xlink:href="ltrn-20201231.xsd#ltrn_SafeAgreementsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SafeAgreementsDisclosureAbstract" xlink:to="SafeAgreementsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SafeAgreementsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SafeAgreementsDetailsTable" xlink:to="SafeAgreementsDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="AgreementDescription" xlink:href="ltrn-20201231.xsd#ltrn_AgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SafeAgreementsDetailsLineItems" xlink:to="AgreementDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentOwnedPercentOfNetAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentOwnedPercentOfNetAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SafeAgreementsDetailsLineItems" xlink:to="us-gaap_InvestmentOwnedPercentOfNetAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetProceeds" xlink:href="ltrn-20201231.xsd#ltrn_NetProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SafeAgreementsDetailsLineItems" xlink:to="NetProceeds" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermLeasePayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SafeAgreementsDetailsLineItems" xlink:to="us-gaap_ShortTermLeasePayments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SafeAgreementsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/NotesandLoanPayableDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentMaturityDateDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentMaturityDateDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentAnnualPrincipalPayment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAnnualPrincipalPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentAnnualPrincipalPayment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentInterestRateDuringPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromLoanOriginations1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLoanOriginations1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_ProceedsFromLoanOriginations1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentDescription" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/RelatedPartyTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsTable" xlink:href="ltrn-20201231.xsd#ltrn_RelatedPartyTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="RelatedPartyTransactionsDetailsLineItems" xlink:href="ltrn-20201231.xsd#ltrn_RelatedPartyTransactionsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="BiologicalMimeticsIncMember" xlink:href="ltrn-20201231.xsd#ltrn_BiologicalMimeticsIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BiologicalMimeticsIncMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IntuitionMember" xlink:href="ltrn-20201231.xsd#ltrn_IntuitionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="IntuitionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BioNumerikMember" xlink:href="ltrn-20201231.xsd#ltrn_BioNumerikMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="BioNumerikMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsTable" xlink:to="RelatedPartyTransactionsDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAmountsOfTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAmountsOfTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionAmountsOfTransaction" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_DueToRelatedPartiesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsDetailsLineItems" xlink:to="us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsTable" xlink:href="ltrn-20201231.xsd#ltrn_IncomeTaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsLineItems" xlink:href="ltrn-20201231.xsd#ltrn_IncomeTaxesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="IncomeTaxesDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="ltrn-20201231.xsd#ltrn_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsLineItems" xlink:href="ltrn-20201231.xsd#ltrn_SubsequentEventsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="SubsequentEventsDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="PublicOfferingPerShare" xlink:href="ltrn-20201231.xsd#ltrn_PublicOfferingPerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="PublicOfferingPerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalGrossProceeds" xlink:href="ltrn-20201231.xsd#ltrn_TotalGrossProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="TotalGrossProceeds" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetProceed" xlink:href="ltrn-20201231.xsd#ltrn_NetProceed"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="NetProceed" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://laternpharma.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="ltrn-20201231.xsd#ltrn_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" )V!! # 2(  A$! Q$!_\0
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MZ5IMUJE[%::596GCGPZ6L_#.EI9:9]JO9+Q+>W>92#ET7?\ X-@/UD,@! .
M2VU5.X%C@G@;<D_*Q.W< BL^2%-,$ZG.!DA=P4,FYANVJ5W,H*RDCRG!V-R&
M*,-M?SD_LA?M;?'#X-_LG?MW:G^T9X\\7^,_B;\-_AYX$_:"\ ZEXUUO6M8N
MX--_:<^%EOKWPX\&^&]6UB_U"\.EZ1XX,&@V6D65X(-,O;L):6-A-.]L?5;J
M#]J3Q5KW[&W_  3KTO\ : ^*/PZU_4OV7O\ AHG]J[XX1Z]K&N_'/4[2YU)-
M F\%^%?&6NW=UJ'ABX?QO>W6B)KR7PN-+L5TL69 TTZ3K4M6=@/WC,H )&&P
M0.#@$M@JH8@)EPPV9< LRKD9R R\D*I8CMG!(Y((&" K!) C.45G4 ':P<?C
MM\-X_C-^Q5^VE\$/V;]<_: ^+G[2/P'_ &K/#'Q1O/!^H_M :Y%XT^*OPY^)
M/PKT&'Q9J5O#\0XK339/$7AOQ#HK+;C1KBQL;'3Q]C>S2VEMIKKQ#Y%^PW\-
M/CA^U%XV^-/Q.^(W[7?[3&B^"_@'^VI\8?"'PY^&W@+XGZEI/ASQ9H_AOX@6
M_B'5].^)U]J#:YK7C+P7<V]];^"_#WA..70K'PIHVB7MOI%Q$-0NS.U'2]_Z
MO8#]8OV>OVF/ G[2FD?$76? NE>*M)M_AE\7_&_P6UR/Q99Z/8SW_B;P#=6=
MKK&IZ(NC:YKR77AV[-];MI-]>2:?>7>[RYM.M)"JM]#(^\9QM(X*DJ64]<-M
M+*"1@C#'@BOY7OV=_P!K[7/#NJ_&[]B'X(>(K#P/^T%^T-_P4+_:-TJ7XM^*
M-.U&3P;\&/"_B2[N4M?$%FZ0G3O&/Q(\36WAK6M,^&/A22^%I<^)K7[?XBN]
M-1-+M=1_I:^$7P_M?A5\//#'P^M/%7C_ ,<1>%],CLIO&7Q2\9ZYX_\ '_B>
M^F>2^U#7?$WBCQ#>7FHWNH:G>7<UTUJOV#3-*C>/2]"T?1M!M-,TVV4E9M(#
MT9WV8 &2?J/XT7&=I7<=_P H9EW' R%WNB><N2#@'<%'S+U8*0I.=H<L=JJ"
M=Q^Z2 Q7\UO^"@OQ8^-=IXI_9=_97_9^\:Q_"WX@?M8^/_%OA[5/BM'I,>MZ
MOX!^'?P[\-0>*?'>I>%M/N%%H?%-SIEW#%I=W/+&UK%'>- ^GRR#Q!H7SIXC
M\)?&G_@G=\9?V7];T?\ :C_:#_:,^!_[0WQM\*_L]_$[P7^TIXH;XF:WX;\4
M^.K+4?\ A%/'?@#Q5%I=C?>%$L+ZQNH=1\,G3Q87T$4L>IRW=Y=Q:A8THW7F
M[V^0'V=\<OV_?AS\%/C5HW[/UA\(OVC_ (Y_%&_\/:9XNUO0?V?_ (5'Q^/
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M/\5_^%,^"_\ A,C\-OBO\52==T'0AX3^#/@]O'7C0G7M2BT[^UQH0O\ 3/\
MB1:,LK:AK^HFZ T[389KGRIBHC;U3S.0#L&7*$;\MG#,,*JDEBFR3;D;8V9R
M0$&[\S_^"LOCOQQ\._V2#XB^'WC3Q7X$\0_\+H^".EG7O!OB'5_#&M'2=7^(
M.DV6J:9_:FBW=C>G3]3M))+/4+4RFWOK-Y8)D9'(7Y__ &B-/_: ^,?_  5
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MO!K?&WX8IXGC\4QZ@VB/X8E\.7'BF/5XM?\ [52729-%>UBNQJ!>Q$8U$[2
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M[O\ M5_#/]KS]D;6_P!G+XS?#W]MWXT_$3XM?';X\^#?@#\0/!?Q:O=/U_\
M9Y3Q!\8])U2TM/$/P^^#>FIHNE> M)\(ZUI,E_I&E0:QJLYC6QMKW7)K9-=B
M\12U9M(#]_/-ZX4G;CIR6RH8; !\P;(VG@?+)N*;#E&GVKD*'(;:RHZ$EQN#
M(A8JK.C+\X<Q!4W.2"C+7XC>(_ _QD_8J_;&_8]EM?VN?VB_CGX&_:A\>>-?
MAK\5_ OQU\5Z9XO\/1Z\?#TGB71/$?PWT>UT/2M$^&^F6&N3+<1Z/X?L([BU
MMK.TTA=4O=(6:TKY3^.O[;_P9^+/[4G[1/@#]HO]OKX_?L;_  R^!GCJ?X5?
M"_X:?LS67Q!\.>-?%6M>$XDTOQU\0/'OQ(\$_"_Q[9W&F2^*TUG2?#WA26ZA
M2*/3[>[:WAGL?MFNG*WJE_6P'],XE!SC:2&"G:X8 X!*GH0V&7 (&=Z<@L0I
MYA&<KG!8DJP8;0SKD #<6&U=R;1@L50R%"*_GH_9]_;3\3?%7]D'_@I!X,\-
M?'_Q#\<3^R_\,/$FH?!S]I:WTSQ7\./B+XJ\&^+OAUXQUCPQ=>(H[ZR\->)+
M+QSX#U?P]J.B2>+HUTO5M:GTR/5HV:9WU?5ZUG^S_P#M1>*/V"=+_;2\0_M_
M_M3Z7\;?#_[-UI\;?"WA?PEXTT_2_@HFB^&? H\:>&M!\7^ ?[-FE\?>(=1T
M6TMX?$_B_P 4ZY=7VLZK?G4-8T_4OL<=I*-6T8'[6_'K]HKX?_LY^%?#'BWX
M@KK<UCXQ^(O@[X6>'[7P[IZ:M>WGB[QQJ#Z?H]O(&N+2UM;*$PW-WJ=[<W42
M6EG:7,JK.Z1Q2^ZQR+(H92"/52&7/<!E)5L'K@G'?!XK^;K]O72-?_:;_8L_
MX)V_M#>+_BE\5?"OBGX@^/?V8-#\3^&OAUXO3PSX#NM>^)R6MWJWQ$A\.)I5
MRMIX^\-7ME-<>!=;M;J"'PS_ &A?10V%S'<3^;_0=\,_ _\ PK7P%X4\!GQ?
MXY\?GPIHECHA\:_$O7SXI\?>)_L,(B_MCQ;X@%I8)J^NWGW[^_2QM!<2?-Y"
M  ! =U1110 4444 %%%% !1110 4444 %%%% !1110 44A./IW/I_CFFANY&
M!ZYZ].@QGO\ 3WIV=K]"7))I7U?1)O[[;?.P^BH7E*X.T%<,20QR, 8X"'()
M/.2"!R%;D"%+L/\ P84 DN'W)@#/#!<;O56VD<#&3BI;LDW>SG&FK)N\Y*Z6
MB>C[_"MF[[/F5XJS]YM)\LN527V9246H3E]F,^5S6L6RY144<OFY( V8!5@V
M=V<Y!! *E2.0<YR".*EI]_)M.ZMJG9[^8_DTTVFFG%IIV=TTG_GNKIW"BBB@
M HHHH **** "BBB@ HII;!48)W' P&.#C(SM4A5P#EF( .%Y+"A6#9QGC'.#
M@Y&1@D!6&,<J2,\9H =112%L8'J<#D#GTY(R<9( R3@T +140ESR%/? (=';
M"[\*KHNYMI7@'ABZD@QM3MY&,CJQ&1N88R2"2$P 4&XDX4,0FXY!( ^BF;_]
MENV.#WR/F&-PY!R0&&,-G!X XYR0-O#'<N ?3)(/_?07/:@!]%1><A&X$;1]
MYMRE4P1G<R%@, DD_=4#YV0$$ADPI(5C@D8*L,D#)P K,X(Z-&L@.#SP30!+
M147F@D@ D L"00V&4C(VIO8$#)P0.2JG!;A2Y!QM&<C!RP3& 6W-LX8 28&"
M/E4.T9D44 245&),X.T@%0^3@ *>Y;.TGJ<(6P,%BNY<J9% SU& W +$*<X.
M%#'! /.,<'!."0 ? ?\ P4_^"GQ-_:&_8K^+'PF^#WAMO%WQ!\27?@*?1- 3
M6_#OAU[V/0_B#X7UW4V75_%>J:+H-J;;2]-O+C%]J=L)Q&;> O<S0HWKO[4'
M[,_@S]JWX ^*?@?XZC6P76-,L[CPUXAMH4?4/ WCG18%F\,>+-#='2>*;1=4
M_P!>L5];7&H:7<:GHK7GV#5W,GTZ0SDX^1D!')<@L<-G:K(&4$(02<D;TPF6
MS',I.P#)!=SU;'*2#:5!V2YWL%28&!,"4C?"@>E)I)=OU _!?]D?_@GO^T'K
MO[%O[:_[.?[7DI\-?$']H;XP>*?%5CX\AUCPUXTAUV_.F>#K[1?B48_#NJSL
M4G\<^&O[8GTK5CH'B-HK>606&G7DT5^_JND>,O\ @L$?A]I/P M_V>/@]X0\
M=66E6/@M_P!MAOC5X0\2^ [&RTZ!+)OB#IWP+N]'OO&6H:^^EVXNH8/$23:/
M-XJENIK[PZ-$G71D_9,Q+*2<E660MRB,&=<KOQ(K,00 FX$,JILA=4R7?(%X
MWD'))"X)R%RY"Q_-O? (.T;B,LH&,4.38'Y7_MJ?!#]IF\US]B?XT_!SPCI_
M[2_Q!_97\:ZUJ_C3PCK'B_PG\'M>^)K>)O 5IX3U#Q/IVKZK91^ _"\LFH65
MSK.IZ3#%#!9IJ2QZ)ID^Y[:W\U_X*.?LJ?M"_M+C]GKQM\&?"TOASQ;XL\/W
MOP-_:7T5_$_@M)_"7P&^*=]X1\1>.H+G6;[7]"AU^3P;K7AJ]T\IX1GU+4=7
M35M1.F:?Y,S3Q_LS&H.>5+QG83E9"AV*60,29 #NW 2,'^;D;-H*^3P!N;Y<
M[<DL5X"*P9V:0.(P5+!P'+.S*2YH4FK;: ?B-^V%^P?\7?BQ^VC\!/$WPZ\/
M:</V<?%'AOX5^#_VG)Y-8\+PQVF@_ 3XF?\ "R?!.G'P]K6LP:KJ9UZX&DZ-
M9RZ#I&M-:0VDO]I"PBE@CN?H3]K[X%?M#Z9\>_A+^VQ^R=HOA;X@?$[X;>#-
M;^%'C[X)^+M7L?!L'Q3^%/B'6TUQ[/PYXRU"ZM-,\.>+?#^JR7=]:2^(KF+2
M)&9KV1I&TU=%UO\ 37RB,*KD+T<9<$J$"@1E'00D%8S^[4)CS!Y8:7>J^4.3
MD!BV[<JJK;BH4G(^;=M 4-G.Q55]X#;DW=W _)[X0?"']JW]H3]K+P#^UK^U
M9\,O"W[/&@_ 'P9XU\*?!CX#:+\0M&^+7BF;Q3\0;9=)\6>-?&GCCPS;6_AQ
MK"301':Z/IMA;_;GC-K<3VMG-;7,FJ>M?\$]_@G\4/@9X4_:0T_XI^&3X9OO
M'_[87QV^*?A*(:SX<U?^U_ OC+4M*F\+ZVTGAK4M32R758;260Z5>"VU6&9'
MDO=-LVF*2?H.8@V<DC*LHQT!.X;MC%HBP#'.Z,AFY(QA0&+Y2H.W( !0%=H7
M.P+M8$!<+N4'RVPPV .PHN[6OH!^)'PY_P""=WBWQS^RU^U]\(?BUH"?#7Q]
MX^_;%^,W[0?P'\:P:WH&H:OX=UU]5LK[X0_$F/6/".IZM)HY$L%YI^H::\EC
MKEGHFI:VBV.G7^H)(GZ:_LKZ]\=/$/P+\!S?M*^!)/A_\;=-TI-"^(&FC7O"
M'B.PUS6=%_XES^,=(U'P1K&LZ+#I_BN.!=9_LII;&]T>]NKS39M.B@MK6ZO/
MH-H@QW$MD$D8=Q@D!<?*P.S !,8(0M\Y7< 0J+L!&<\YS@ G@9+;0 26RW 4
M#.   *3=]P/SY_;S_9S^+?Q2;X&_'+]G34O#5O\ M!?LN>.=4\=^!/#_ (T$
ML/A'Q_HGB'2H=&\;> -6U.WDAN=&F\2:;:V4%AJ"W$,+212V,UQI1O(O$6A_
M.L7PS_;:_;7^,_[._BC]I[X%>$/V4/@M^S3\1=-^,9\$V7Q:\*_&OQI\5_BK
MX=@\GPG/;:GX-@&A^%O"?AR[N;VXO+&_F.J">.:U4ZW%=17VF?LBZEAD'# '
M:3DJ&(X+*&7< <9 925W+N 9LM"8/#$@$D;BS,"3GARV[;RV%.0-V 0BJHI2
M:5M-+V?74#\]_AM\%/B9X=_X*.?M)?'C5O"[6?PI\?? GX0>#/"WBH:SX>N5
MU3Q1X7O)/[<T]-!L]9NO$FF0V4*VYCGU31;"UNI))&L[BZ"S&'[3^(O@O1_B
M5X#\:_#O7Q(-$\=^$_$O@O5VB%NTJZ9XIT6\T2_>U^TQ7%L;DV>IRK;K<1O&
MY9_-AFB#PR=EY:H4/!*AL!448#$;R@12PY.?DVDY_>,V%PR0*%.&(490E [;
M<C;\R .C;(R06F5D#*A8 "DW<#\8?@U<_P#!3;]CGX;^&OV<M-_9%\ ?M=^$
M_AY!)X6^'7QG\,?M&^$/@Q/)X"L[J2S\+VGCGPA\1-*U#5)=>TG3!;PW#:+<
MS0?8(=/L([G6[^SN=:OOHS]C+]FGXO\ PVN?VC/CC^T)K'A/5_V@_P!JCQ#I
M.M>+] \!+.O@WP!X>\(:%J&A>!? .C:IJ>+W49=*T>]VZG=RQ"W2[D6"*;5#
M;7WB+4?T41%<=F7:H'RC:WW7#C  ;(V#<"5ROR"/# R"/!;#'#-NYZKE=IV'
M/RY(#'@Y8R$YWC:@/S__ ."9OP6^)O[//[$?PI^$?Q<\-?\ "*_$/PY/\2YM
M<\/'6?#VO_8TUWXG^,M>T9VU?POJNN>'YOMWA_5=)OF2TU6<02W,L5T\<T5P
ML'Y[P?L1_M.)_P $@K']EM_AFO\ PO6'XO67B=_ 8\:?#HNFAQ_M!Q>/I;H>
M(QXO_P"$+,Z>$5EU1;,>)O/9E-F!]M80#^@<Q!CEB3T/#2 AAW7$F$SR#M&6
M4E6)4L"HC&T GZ]=K9!# J25VMEOE((&> " 0 ?$_P"W-^S1XE_:D^!%CX1\
M ^)-/\&?%CX?^./ _P 8_A+K^LVR7V@VGQ"^'MU)>Z+#K<<<%Y(-*U"&ZO-+
MN;VTANWLI+J&Z>UU"QCFL;[YMLO'/_!6+XQ3^#/AS?? 7X9?L?0V.L^'Y_B;
M^TK;_%?X=_&>/7?#6D7D3>(+'X4_"*71=6GT'5/%D"LFF+X^&I0Z'I=[>6TE
M_:ZO]FU ?K.;=#U)]<Y)._/$@+ER)% ")(/G5/E#<)M/);@B5E; 4LJCA0N,
M(&W+]\;P9A,R[I%!^92E*32MH[;7Z ?D-\=O"WQF^$?[;FK_ +07[(FF_"S]
MH'QYXR^#7AWPO^TA^R?K7Q@\(_#CXF7>@^'-7,?P]^+WAR^\0/>:?H=M;+YG
MAO5+[Q!8_P!F2Q1/:Z7;7U_KCZGX:\>^$NN_M'^-/^"L?PM\3?M%^%O"?PW\
M37?['7Q'U/1O@;X+\2P_$"X^$W@N7QUHUA92^.?'FF1VNC^(?$?BS7SJ<EU<
M:7;1:)##8:196-S=2ER?T!_:/_8%^#_[2'CK0?BW=>+_ (S_  5^-'AW0$\(
MZ?\ &3]GKXE:G\,OB(_@X7=U?2>%;K5([?6-.GTFXN;Z]:XD_LE-6>*X:V34
MX[;,+=#^S1^Q)\'OV7=4\7^+O"VI?$/XB_%7XA1V-OX^^-?QJ\977Q%^+/BV
MRTN-8M.L-1\47=M80VEE;+'#YMMHVF:9%J+VUE-JJW]QIVFS6=*2MKO9K9_Y
M@?"?@'P!^WI^QS\8?VE?#'P4_9L\ _M&_!S]H3XY>*OCCX2^(VK?'#PO\)[O
MX9:[\0K32U\1:=X\T/5-)UC6_$NG:7J=G;0V=AX3TEI[RPTU[@WRW.J&QTV?
M]GW]E#]IWP3^R_\ \%*O 'Q6T;2]=^+?[1WCC]H#Q)X+O?#]_P"&-+T/XAZA
M\2/A;;:59ZKHEG+XLU&#P?HVI>+I[NQM+'QCJFCZA80H;O4HK:*6):_9ORS$
MN0X 7#$;2J*,C> JG:D:Q JB8*J0)7\R3+EL:JKD8;:Q"*I((4["^1MVJ\>$
M#)*XDF,CN&90-HAN[; _"CXL_L:?M':C^S'_ ,$V[2S^"W@'XX:S^R9X?T8_
M&7]D3XD^*_#5AX8^(NI7/P[T[PCD>)+ZZU3X<7^K>!K@:ZNEMKDFJ:!<+K%S
M?+#JT%K<Z/?5=7_9]_;4^*7QQ_8G^,VI?LK_  A_9W^&/P,^-5O>:E^SY\,_
M'7P]\1>*O"6B>(])N++QA\4/&/C'38/ _@K5+/1Y].T.#P[X'\!66NZQ<6%_
M>7]U+)-;BW/[RJ X#!R=R(V<,5()RKJK?NU8@;N$!5L$Y'!:T2IMPV,,-H.T
M)YAD+@[2NU6D8E79<'#%8PI8;6I-*VG_  X'Y:Q?##]I/X5_\%)/B'\:O"GP
M3TSXJ_ O]I;P=\(_!?C'QM8?$[PKX2UKX,1?#ZQGTO4-8U?P7XAB36/'5M=S
M,DPTWPG))Y]@3.\[7,(TV[\=^%O@+]O_ /8$B\9?!#X&?LV>!_VN/V?]5\;^
M+_&7P;\11?&CP;\%/%7PPT[QMJ]_KVH>$_'NC^+[:6#Q3;Z;K-]+?0?\(E%;
MR7UFU]J#ZE;W%_!X9T3]J20% &204DXS(QV,Q5G5B\S;UCV@>4\B,N0Y,0=)
M50DN#N51A0%&S((+,=Q'F%R[$LZN5.%*MO\ -RF[Z@?EG\0_V3/VFOVAOV+=
M1^'?QZ^,OA"Z_:ED\=V'QO\ A[XJ\+>'M*TGX<?";QMX8UNWUWP%X$TR+3M!
M34/$?@WPLL/_  CU_P"*O$&DZ]XA;^U9=7NI]?;2;**3YJ_:>T__ (*M_M;?
MLU_$O]G_ %+]D[X:?!F\OO#4*^+?'&G_ !U\$>.)/C3=Z;?6%S'X8^%7A=[S
M3(?AW#X@U6UM9]0U;XG>*E.C^&8M1M;%YM9@T^.Y_>)HM^-Q!PRLH9 X&UD9
M6PY;]ZFT['! 5F+%&(II@#*H9ON&-E^16 :)D92!)YAQ\F =WF+OD9)%=E9$
M!R7@32[[2?!/@W1]4A>UU+1_"_AS3=0MC+#+]GU#3]'L;>ZB$MG*]K)LGA,4
MC6TCVLT;-Y+[990?S5\1_ #]J_\ 99^,?Q;^+_[&.D_#SXP?"KXY>)I/B+\3
MOV6_'WB2;P!J]A\5K^QMK?Q%XW^%OQ'ECO\ 1],G\7G3[2;Q)HOBBV71A*L?
MV*&<2PR:5^K/DJ.G=!&V=S;D#9 8EMQ906VL22&=W.2QI9,*"3@ACD[BJJH"
MY8LQ4@+L5LE@><#*YW  _%CXR:!_P4L_;H^'GB+]G_Q9^SI\)OV)/A3X\MH-
M*^)7C;QO\8=(_:-\>7GATZII-]<6OP]T7X=Q:+X?BUBX:!K2>S\774%E<::U
MQ!9:YI5V(F3T_P#:(_9@^/GP^^*/[/O[4G[(UCX7^(OQ(^!GPAE_9_\ &OPG
M\=ZK8^$$^+_P<$MM>VT&B>,Y8K/2_#/C+3-6M3?6[ZI):Z&;FZC<R6]I8/I^
ML?JBP4N-K>4%^[R8\%PR*,,V1E@"BF)X7*,61W"&*3:NX[0H^8YYX,K?."1C
M'F<1OO9"4SM0MD@.[74#\]_@9KW_  4!^+7QCT_Q[\=OA]X4_9-^!_A;PYK.
MEM\!-,\:>!/CEXY^*7B[6(X8[3Q'XA^).@:%;6OA7P]X453?Z+IOA/4-,UJ^
MO+>XM_$%CJEE/8W%H_\ X)__  3^*/P2@_:[C^*'A=_#!^*?[:GQJ^+?@.-M
M<\/ZV=;^'WB^#PPOA_7D;0-7UE-,&H'2[V3^RM7FL]=MV1I-0TZT>:)&_0@)
MG)#,.P8$G()!8,KEU(R"!E?D5F5-N22GDK\V<$.Q9A@@$[-F" P5E"A1M<,#
M@D@D@J7>U] /QM^'_P"PAX^\?_!?_@I?\$_B_I[_  ^T[]J/]J7XM?$3X7^(
MTU#P[XH6?PYJM[X=USP%XV?3] UJ]>VCM?$6A6E[+H6KRZ+XDCBLI@MKI\[V
MMVK-'\:?\%@?^%?:5^S[!^SQ\'O"'CNTTJP\&M^VS)\:_!_B/P!96>EPQV7_
M  GMC\#+G1M1\<ZAKUQI\,<T-OKMO<:/)XJGN[O4= CT0Q:*?V2DB7"9)RKE
MQD*_13RQE#\  *TA9' PJ2(&"%ZXD&[)!!(^YM(&_< 5E3<K$*I;Y5SD,,X1
M@7;W8'YR?'NS_;X^''B+X=>*O@EI_A;]KWX=V_PR_P"%>_&KX ^.+[X;_!_7
MO&GBY1: ?&'P[XVN?#T6B:7>Z] +VW\2>!]1U&;PQ;:7</#IWAB\GU2UN?"_
MD/[$'[*/Q3T']J#XF_M<_$/]GSX6_L;6'BGX5V/PE\/?LX_"?Q)X8\6Q7ERG
MBBV\4:W\3/'^L>!],T?P-_PDEU+IUCIVFCPO9P3:C87M^VOP6=Y8+<Z_^O0C
M[L=Q8?-RVTD@ X4NP"G'W6WXZ9P!3P@4 9) Z<X'&,<#"@#'   ]J0'Y[_\
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M09&&/W9+;68JN_&U1P%=HTC,C,4 1VCX+/NPAR 2T4U6SGC&"1U]&8#J <X
M)XQS\K,.:&8C@#)/0$GU YP&(&2,G:0HY)'&0!U%1>:OS <E>BX;<V<@$*%+
M%"0<.JLI 8_PFG(X?)'(&,, VU@P#*RL5"N"I!W(64'*[LJ: 'T444 %%%%
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M^&7P\OOBSX]\=^%O"_PVT_3;75IO&FIZU91:#+8ZA%#/ILUA>K(R:G_:L=Q
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M1F=1>VR>A@LJQN8SRN>*Q"IK,)<&4:%#(>(YX>I6IYUD6-P.7>YF.68*HO\
M1!M&+*_WCEBVXL&!9F=6"@<H%*?</*YP0#D"W69IJ%!)OVF1DA,CJQ8.P\U=
MV=J[@=I82<EE81_=B6M.O[XIJ2A!2FZKY(?O9+EG47+&U2<4HJ%22UG!)*,U
M));G^-J;=W)WES3YE:*Y6ISCRI0T2BHQY4_?4)04TIJ044458PHHHH ****
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MR0  ,Y)SQW.>3T.,@#FG444 KVUU?]6_ ****!A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%+QC_P %P?V?-)O;RT\'?#3XG^,8+9WCM]6N4T'POIFH%20LL"WU_?:Q! X
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 0RD
M<#&XE7P.QQMR#[$?RJOO6((S *@&2#@!,?>)9BJJ@ZDDDXZ D$5--(R/& FX
M/O&>>&!0@9"G *>8^<J"8PF<N"/QN_X*T?MBZM\%_!&E?!'X=:PVF?$3XGZ?
M>W7B#5K&3&H>%_AVZW6GSSVDP4II^J^);J.YTW2[P^;-;6UGJLD,$5X]G=VW
MM\.\/XWBC.L!DV7PYL3BZLE&K=<E"C3CSXBI5O)+EA24YZI<SY81?-)(^%\1
MN/<D\,^#LYXTS]U)8+*E2IT</0?)B\?CL74AAL%EN'NES2Q.+K4[S5Z=*DJ]
M>K*%*A5G#QG]O?\ X*PS^'+[7O@W^S!?P-KVFWEWHOC#XMI%#>V6DW=M((M0
MT7P-%<PS6.H:I XDM[WQ)<I/9Z<__()M+RXDM]5L?YZ/$/B3Q%XNUG4/$7BO
M7=8\2Z_J]S)>:MK>O:E>ZOJVI74VT2S7M]J$]Q+.[QI#!O;]X8;>!6=W0R-B
M <+D 82-5 9V*QB)#M8R.S!UE:7>&RV\LV\HT<4*U_>W!_!&1\%9;2PN487!
MSQ]:A3EBLSKTU+$8R<TJE2I.O./M<+[.<I0I4Z"C3<(0;3;<G_AYXJ^,7&'B
M]G5;-.*<?4GE4,15Q62Y!5E5>49+@G>G06'PM*KAZ=6M[*G!XO$5*.)KU,7*
MO+Z_]3E3PD%.#C!88&%)\MF11T5&:,L%'.%9F _AQELISD'J1GDEPS#^ZS1N
MCA#_ !I$T0D^7S-VU<%%?7RJ\J2J9C7BH*[O.A&4DJ=2I)N$;N-&"I5(QJS2
M4E"/._:3L_RQ2F[6E[+GJ3H\CHX>BZLH4?K$84J5'"SITU/#^_0:<57CK%JJ
MY0$/( !P P< @$*_.=A 5D5?^66&\R/+?O&+&OJS]FK]LGXW_LNZY9W7@3Q3
M>WGA);D2:Q\/-:O+R^\)ZC:N7-Y)#:2M<W.CWT@;9_:FCD7IEDA\^VO($9K?
MY4HQSGD':Z[E8JP#J5.UARC9Q^\0K(%#(K*KOGAS/+<NSK#5<NS+"8/'8'$P
ME"MA\73A5E5DTU"M0QE*$JF&<5:4?92C"=E*3O)L]KAKB3/^$<XP>?\ ">:8
MG(<SP->%2EC,#BL3'$5(Q?M)T\9/#KZOBZ=3DG&.'QN'Q&6^R<85J?M>9G]K
M_P"R=^V3\./VI?!L>N^%Y6T[7;#R++Q+X2OG2/5= U%HPRVLB[F%S!<,)1I]
M_ 19WA18@L-QYJ5]B*ZR,.<' VL&#*XQG<I&25YV@X&2K8& "W\)7[/OQT\7
M?L]_$C1O'WA.\FACMKBW3Q%I$<CI8Z[H9DACN[&XA&\(8QMN=/E57^P7JBXC
MCDWRI)_9]\!/C%H/QD\!Z%XMT.Z2[BU+2[>]A;>N]HKJ-9@9<<)-$9'BFCP-
MKP$?*6('\0>*/A[+@G-L/6P-:K4R3,I5OJD:J@YT94Z:E5I3G&_+&E.4E3E5
MY74HP4W=QFU_LS]&?Q[7C1PSBJ6:PPN#XUR"6#AF="E3=*.997C'4C1SF%-?
M[/3?[I4\;3I2A&AB9)^PPU*M0IOZ 3!+$9YQG)^O3V_GG\3)4,((W<Y&% XQ
MG&[+=?XL].V.IS4U?E:::O&_*]5>^J>SLTFKK5)I631_3BMKRJRO)+SLVN;_
M +>W[]PHHHIC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'ZTO:4^9P4XN:W@G[RTOJK7U6H[.U^A2O98X=LDC!%CCF=V8A4$2M")&=CP
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M)5YW4)0PT,=CZT83NYU:L'3C*5%N(I5L$NN2H9I'958EFQF21S&GS,2ZR2"
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M$/@/3_B3I'AO4],N;?P1IMDOCQ++XHZUIUQK-YIMWHTHTS0(HO#T+V6H2:B
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M;W%_I_U7K/\ P3;\":W;6WAZ[_:$_:B@^%^C?'"S_:+\!_!O3?%_PST7P5X
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M).1A0"3N&,J0 <A@/3.[( !)13$?>,[67U#8R&YW*<$@LA&&*EDS]UVP</H
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MEI=12P03075M<126\\,T$30F)(SO<2%:&1D@$Y4E2&!5@1U..1M/\+ G=@Y
MQ7]4O[>O_!.#P[\=!?\ Q!\!K9^%?B5';AKC4DA,>F>)$MTA1%\006\D;W%W
M'!%%:6NH1QS7=O;A;?R;FVBMH;7^:_XI_!7XE_!K6;G1OB!X7U#0W@E=(;V0
MI/HUU$A11+8ZH-ELZ2;U*PW#P7B;E6:VB)7=_=G WB;DG&="E!XC"X'.*M-R
MK997FL/5E63M.6&==TJ6*525ZG^SU9N+FX22E%I_XL>,GT<_$#P?S:4ZV&S'
MB/A"M5K?4^),)@:N*PKPK;E1CF$L+3Q%7 XC#TW#"UY8RC0C6K8>K6I.5&K"
M<O*J*""I 8%"0&PX*L%;[K8(VE7Y*LC,I )!IP [D#I_%&/_ $)U/Y ^^.,_
MHL8MJ3O%<K=TY)-6;W6OX-^K/YZY7!-<C2YIV7-3NESRLW%UX5$GNKTDVFG:
MUAM'^0.[-V51W)YQR.E2PP2W$BQ01RRNW"+%#+*SMV51&C@L2<#D#WKZ$^&/
M[.GC+QU?6+WNG7ECIT\B?Z.$87MRA)R%13F D ;)#YC .W[OM7SN?<5\/\,8
M.>99UF>"H4*,)\N'JUHJM5JJ[A"GAXN5>KS-)7A2<5?5Z7/N^ O##CCQ,S2&
M2\%</YKF57%5Z4,=F&&PM9X'"T+PC../S*I&AA\#@8P3G46'Q,\9.HI<E-II
M'(?"/X9ZC\1->M(4@F?1X;F WQC5A]K!=@;&)L AR5S+*-P@_=@I)YGR_P!6
M/[$?P(7P3X;@UK4;007D\ D0O$$$>58CRQR$C"E<( 0H&<\XKP']D+]B>+1(
M=+U;6M,2T@M8U:WM&1>$SNWSY*[[A]BF27:"YQE1MP?V+TS2+?2[*WL;15CM
MX$55C"#;MV!2F05XRH)XY'&!UK^'O$+CK%\>9RL=*$\'EV$4L-@L#S<T*M"2
M4EBVDW&,I2=U&:C42>L4?[0^ O@ED_@KPG/*J+6-XDSBK'$\2YU.E&-3$2AA
MW1PN7T6TJGU+)J,\1A<NFVIU*^(JXRJFY<YH0!AG)W#9'@^X#!CZ\X!Y_P#U
MV*:JA>!TP!CW&>>IZY'';%.KX)_E9=KV5KZ=S]SC\,5:W+%12\HKEC?SY4N9
M]9784444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% #)$$@()(R",@L",XR058%3@$!U(=<DHZ'FA$V%R3N+M
MDG:BX   'R@%NA8EBQ+LVW:FU$4M@@ 9R">H&,8YY_A&?F(R1QA3GC,U36=.
MT33[O5M7O+/3-+L+6:\OM1OKN&UL[2UMXS+/<7%Q.4BB@BB5I'DD=0J*68!
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ML[;R3O=) 1GG"@Y&, G:!C"*SL\IC7'RJ\C[-S!2%(4+@=0.3UYZX_E11[\
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MK^)97DU]]*U"_>ZO[)]6\QX[YH;A&N(7:!V: ^77H D4N00,J!D;CT)+?,"
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M /$T>TI_\_(?^!?\ +/^FA]%,WCV_,__ !-&\>WYG_XFCVE/_GY#_P "_P"
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M$1/\-!Y@$/A01)Y>U0EW&59C-%\)#&(6/Q+^*W[GXFR?$YXY?%KS-*\P8?\
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M+S6*2CDTXQ[+,</IM?>,GNVT[N]M-TDN>IUH\VWO*=.VMK]>EVOD[;H]<E8
MJ=H8@,5+MP/NYX]3Z8.0.G:FF0E..6XQ\K'JV%SM1B@W'!X^50S$;5)'D!^#
MNSR%;XF?%25D^)TWQ- ;Q9\T@D# _#YQ]A(_X5=&SH(_"GRK$1&/[0)*U\G?
MM>_&+X9?L7?"6Y^)GQ!^)?Q:U*]E^++^,/!7@O3_ !K;+X@\=^)+V"5T^%>G
MQ2Z?(L/PFTVW,E_J>D2H]KH^G6[W:7=Y>#3;*^Z<"N(\SQN&P.!X=GBL=7Q-
M'#8/#T\UI\U1UY1C*I-1I.GRTG*3DV_=A3<Y<L=5Y.=YYE_#N4YGGN=UL/E6
M397@JN/S+,*E6/-3IT(KW%&%ZDZM1\M*C3I0J5:LY0A2ISG.,3[E\9>/?!OP
MY\-:KXO^('B;P_X*\+Z/ ;G4_$/B?5[#1=(L8E;86N;^_GAME=W9(HX_,)EG
MDC@B,DSJI_#7X_?\%]/@=X)N]5T'X"_#GQ'\9KZPFEM(_%NLZA'X \"W$JG8
M;G2I+FRU7Q3J<5O,LB/;W_A_PW]M,0-C=S6TJW:_S;?M-?M9_&3]JGQCJGB3
MXD>+->O_  S+XAU[5_"7@"\US4M5\+>"+35M0>Y?3-$T^^G>W$MM&+;3Y+VZ
MLQ-);6D4)MK8PPI;_,I93R%<-SAG<2E>%4%/-1RA15"( 2B1JJHBG>S_ -E\
M$?1^RW"X2CC>-:V*Q^/G'VDLGPF)A2PF$J.;?LL1CJ3E6Q\+.-_J\\-"*;I)
MU%'VDO\ -WQ2^FMQ+F.*Q&6>&V!P_#^ IR]E'.\?2_M',<5#D2=2G@L5"GAL
MMDI\W*JM'%8B*Y935*I>G']C_&__  7-_;E\2WD\OAZ]^%_P^M6G9K2V\-^
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M /BWLG^A\_"]-_[KPB,!-J_Z><"A/@XZ>5_Q<_XJMY7Q/D^)IW>*R?,\S?\
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MQG%&[K]_H2/F],=>.#SP.2<9Q7CR?!QT\K_BY_Q5;ROB?)\33N\5D^9YF_\
MXM[)_H?/PO3?^Z\(C 3:O^GG H3X..GE?\7/^*K>5\3Y/B:=WBLGS/,W_P#%
MO9/]#Y^%Z;_W7A$8";5_T\X%'UO-_P#H3RZ?\S+#>5_L=+O[O,.>I_T#OI_R
M\I:;7ZZ]?N\T>P[NOW^A(^;TQUXX// Y)QG%&[K]_H2/F],=>.#SP.2<9Q7C
MR?!QT\K_ (N?\56\KXGR?$T[O%9/F>9O_P"+>R?Z'S\+TW_NO"(P$VK_ *><
M"A/@XZ>5_P 7/^*K>5\3Y/B:=WBLGS/,W_\ %O9/]#Y^%Z;_ -UX1& FU?\
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M>R?Z'S\+TW_NO"(P$VK_ *><"A/@XZ>5_P 7/^*K>5\3Y/B:=WBLGS/,W_\
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MB?\ %4ZG)I_Q-^)%BS>*3)F[N/"&L1V_@$QBT0M\-8+B:)[3PJCQM"Z(!J#
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M5K<TG)KLV]5Z)JRZ=M#_ %XNVH\S4GR03:V;44FU]U_F%%%%( HHHH ****
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M.C+$V247B\PH2EB'=)*5+ 5L%&2;AB9UH<T'^<?[6W[)VAZW\-X=7^'6C?\
M%6>%;BXU*1Y)'N=3\365W"QU2RN[Z=VFN+N5X89=/21S:P71D@AMX#?S3U^)
MI#*P63(D(4'Y655$:B'R]KJCK)&T;K,LBI(L@*NBD M_61<V44\;Q2K')%)%
M)%)"Z?)(C@@HW.=ISEL%6)5"&#*#7Y"?M=_L?W2:EJOQ%^'=D7FOI)+[7-"A
M0!+ZZD,9DO\ 3Q&5CBNY0LDE["L 2YN&,J& $H/XR^D=X+8SBJM/COAJC5Q&
M>5*5N(LIP[I1Q&9PITHTEF.!A*4.?,:-*E"C5G"\I82"@KS3B?-<5\'TZ]".
M)RJC&E[!)SP]"-.BHQA%))0BTIR<8WE*-Y5)N4Y+GDS\LB/R['UHJ:XM[BSN
M);.]AFM;JWE,4]O<Q/#/;R D%)HR#M;(/"%^F21D9AQZ^I'&<''<9 //NHQ[
MU_ D\/7H5:F&J8:OAZN&E*C4HUJ-2E.G.DW"491J1C+F3B[W2N[M-IIO\QFI
M1ERSA*E)>XXU(RIR3C[KNIJ+5VKIVLT[JZ:;.V/FP2,@.\9P#N4AXFCE5ED5
M&!60*5#HZ.'!0Z\G:6/S.^Q%>21B2S,R*N5R?D5@S(,@R.3FBC_.._X#O6/*
MU)MTL))RTC>G5>+@[6O424HQUU@WRWARONR')IN,ZD5%?!%24MU?:+=M?S"C
MG!(!; X *@EB0JC,C1QJI)Y9G!'&U6Y 7'3/R@Y^9N .G7CCK^E86L76O_8Y
M/^$2\.ZIXJU<3VL,-AHRVCW:FYNH;4W,<=])'#+]E\W[24\N0%8'5FBW!C]/
MPOP?Q-QGF-+)LAP&,S#&2FZKQ-+"U)Y?@,%2=.6+EFE;E]@JD(5.:BO;.7LW
M&*CS1DH]F!P&+S.HZ&'P]2<5.+J32M%1T=U*5HRTZ1;::MNK&M%X+G^)MY#X
M'M'U-%U.[LEO+W1;R\L;E(X+F&\2V@U*PQ*HN)H85FC1MDL8\M@P/'[R_LX>
M"/'?P6\,:1I^JZ"/&-GXM\;?8M/N_#%IINDOX&\#SZ<MQ9ZEXG;5=66YU/R-
M1M/[.O3I\0N[@2S7!MYKF6UL)?C;]@/X/6.D:YJNA>-KO4_$GB7P+::'9^(_
M&U_;:?IFBW/B+5)YY(/#D2P:G*T>N6BK8[8[.WO49II(O,R$9_VMM846.)40
M(L:[%4JZE/F8/@DJ.2"0Z[@0VY"8V5W_ -,_##@;(>%>$,)E/#V+JT\9&O/$
M9OCL)54JV*S>A5K4\5+&8/$Q>'KX>"C++,,\73='"X>C.ME\)8G$O$4_V[(\
MJPN"P%.E2F^:4?WTJ+]E5E44GIB%/EE42M:/+=<B5G>QY#;Z#\*OB[HMKXA\
M-W%C?Z7/XJTSQ:WB'P9J-QIK:QXE\*7[VL+ZM?Z)(@UR")X)K"ZL[][ZVFMB
MN8FC2VG%B#3OBKX=O((;?6=+\?6&M?$74-0U276[9/#EQX.^'NH6S26VB^'T
MTM;EM=NM*O03;ZCJUW'<7D,\MJT:IY365[Q#\-X9=2MO$GA*Z?P]XIT/PWXI
MT;PQ%%->+X+@OO$31W9U'7?"-A<V-AJ;IJ<,=U++$(+JX\V0RF62.":VQHOB
M7=^"H[RT^*EO'HVG>&?#?A6\UKXJ3FSTCP)K?B+6KC^R+JPTJVN-1N-1M'74
MOLYCBO?-VI=(DTMOBT-W]95C3P5>I4S6D\GQ7M:4Y9]DCJ4<'C(4F\95J8^C
MI1PT*JCC^>GFE'&4Z&'G7J1S"6)Q]"E#T6HTFE4@J::4:=6"?LY6T3Y$G.#T
M:DYQBG)N<6^9-Z/AWXN^&=8E\/Z=K-MK/@CQ!XNU7Q5IWACPMXRLH=)\1:W_
M ,(E<%=1N["QMIKJW?31:*MW8SSSQS7-@8;DQ$JX'5:OX,\(^)'FO=4T73K^
MYN_#VH>&UUJ."./6%\.:RP-]I-IXAM_*U>UM+]L23165_%&9HHKIC'*(F&W+
MIMAJ?DS75O!<26\<ZVUP\:O-:)?P&VN#9W))FMFN[-O)E>*2.26-R6$8EPWE
M5M\*;CP39Z3!\,=;N="T7PIX3\2Z1X=^']_)/>^$+W7M5E-YI.J^(+Z8W_B-
MX+34)9X[I(;R5OL<ZF PBV:&Z[ITLTI4?98^AA,^P4XT82Q2]G@\3)Q>'@L1
MB,+*4L'BJ')B,;C.6E4I4Z-.GEE#ZOBJM:OB\/H_:))S@L13:U=-1BVK:OE;
MO=+3>[VW%3X1#0(HD^'OC3Q+X/32_AO-\/O#&CO=C7/!^ASHXETCQC-X;OR%
MUSQ/I<P6%[K4=1D74;(M;W7S2&=62W7QJ\,I=2/I_AOXCV.C_#BT-M#I\W_"
M,>-/%_Q1M,K>J5NY4\*>'_#6L6Z^9"D;7=UIUR\[QM<PK%"S&^)>K^"[-F^*
M7A]M*T_0?AY9^+O%OQ!T&*XO? MMK4-RMGKGA[2K6,7'B.4VIWZC8@V$CW6G
M!FD,,\>)?5=(UK2M8@BN-,O;*]62UL[]5AG)GCM=3M8KS3I;BVN/])LVN[65
M9X8[F&-_*8'Y!Q7/A*&2UOW>58G-,EQE&$(RP>&K?5YX+FHXFG1HULJQ52>
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M"0I:7Z2T2WT=FL31>S:\G3FK;:6Y?/H^_9V]EHKRS2?C1\-M:33WLO$]DO\
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M_"6[N/#2,TLO]B6\4VIZ*K!E>,VEM)=1SZ?'(7E^T1K<S648$7V"PM )Q/\
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MU8R247S<K=G:-G)J)NFGLXOTE%OMM>^Z):*C\SDC'0XYW?0_P'&#Z\$$'/.
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M_+.)<R\*\QQ#GD^>SQ&:</PJ5:E6."S/+\/4Q&,HTIMU'3H9M@^6,M8QPU3
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M10 444A.,<9R<=0/J>< X&21G. 2 <8H :[A.H)SZ=OF5<GN%&[<S8(506/
MIGG#;NVD#G.2AV[06R[(SHH>,;T9F"$$*[1L0#\->)/BO^T?\7_C-\5?A5^S
M3J7P9^&GA;X 7GA?PU\1_BW\9_A]XR^-!\2_%#Q5X3T'X@GX?>"?AKX&^,OP
M"FT?2?!_@+Q7X2USQ-\1=<^(^HR7NL>)X?".D?#V:/2]7\218D_Q^_:3\ M^
MS7X5^,GP\^'VA^-?B3^U=K/P'\5:[X;O;O5/"GC[X>Z7\#OC#\4-'^+WPNT7
M_A*KKQ5\.I_%6H^ =+MKCX?^/YO%FH>#+AO$OA:35/%>F-X?\?ZF ?H LI8
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M=:DU'\_\_7UJLUR!(8PNY@N3R1MXS\Q*[0 ,Y(8MQPI) KF_%'C7PYX/T_\
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M\0SWNF:I]@>&< _47S,YPI.TL#GY#D$JH4.%)+L,(W$;#+"0C&0'S"059=A
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MTV[D.37-)QDX1:3Y82F[M)JT8IR:[M)I=6C@_'WA4ZW%HNK63:G+KO@^\O\
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MJ-;!4U).680FJ#GR<SJY?0Q&&I4YXFI2C+Q,TS:EEF.RO#0P^)QF*S65>%+
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M\MV6- R.1(S%-@1G*-+&C!A8$J?OAS'@ LOF>6)50E-SY="-KB,Q;CL\S<&
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M'JWQ8UX^++F)A+;>&+$/8>"M.N-P)VV",MSJ4B!(@TE[)Y#LA+VLN3C\\O\
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M ., Y.<XQ@>XYY]\\^U-W'..3QQD;L<D?,2.X&>%_/LUI<9 9"!U 8#G'0\
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M/;JWF+,,>65KP;X=?!3X[:-XPT?Q9\2OVG-;\>V.ERWTLW@[2? /ACP7X8U
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MO42@AO\ 6!2Q1R#)DEE53R02-JA< HVT&E:Z4Y"D;D^\@8[QDA1N3 D7YL
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M*&!P-.I5QF-Q-##8>G3@ZE2I5KU(4H1A%<R7O-J3DU""C.I4:ITYR7GYKF>
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MC'-1LVR,LW. 1MS][ R,GGC'4]N!3BS;T(VA0&W<GO@C.5'H>F>OMS!.W!;
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M^3XW%9/D&&I5'["EEF&F\-5K*":B\3C<51KUZLY1YEA:L**:G'E2TUG5.6(
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M"<'N(3""1EV^4DJ"[MABKY))<EP=Y.R0M'E8F78R FX1D@^F>/7--*#/ITR
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MX>AAJ5*C"") &<A<Y*OE<*226&'5,%N%!S("6W'! %3*K;LG))(R2,< D@<
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M8[%9W.A*5*M7RC(*,:^'P$:L>14UBLTJT:U5R<8SI825*5TXQ>(!@ #L /Q
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M6T\())$;A],L_,U3SOT \/\ C'PKXW_X*H^'[S0-0T#Q!X@T/X,^(O"GQ/\
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ML/JO_?+?_%T?6W_T"Y?_ .$\O_DP_L5_]#7./_"__P"]CP?_ (R3_P"J+_\
MEZ4?\9)_]47_ /+TKWC8?5?^^6_^+HV'U7_OEO\ XNCZV_\ H%R__P )Y?\
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MY.3ES575J5'4K-752KB%-<S7-.]2I*3E+GE)M.;<IN5W*3;;6 "K[Y)_3_\
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MO+J7+W$SL3GNPC1+(-R 8!!,>,#.YB^U<,2S,0JJ% ( 4%68RQ6[1-GS V0
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M?D=%:DNAZW"2)='U2-AC<K6%R",\#/[O'ZU/;>'->NV58=*OOFZ>9;RQY/H
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M>4\+8'&3C4QM;"-NKA\TXLQ="CFF-CB8K$4,%@LEH3IX2K0Q-#$O  8*0(V
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M;V&BZ1!X<L(+_0KM[75;*QTT6.F1M%I\@*236T,D3Q(LL,D_+MZC]F?>&\U
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M<'N",]QT_P D5%+&&506''3()!YSGCG/XU([$$'. ,DYX!X'?GISD]JC#'
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M!<J2<:22IQ=FW&"YFY-L_I6ZLK2E--Q2;;G+WDG'F?--O1KWK\G6-DTE)12
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M4P6-R[-,/4<FY.5/%T,?552,FV_>:E!MTYQC*,HKY))Q]/4_='U/;/T/0TX
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MI<J<4VKJ/-K*R25M$[M.=X?&G%1S6XD"JVT@AMR[6PYRHY ;!&P$,KAE;H0
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M[+J4(TZ."P&"HX.CAZ45:%+#K"*DJ4()).//5Y=O:32N$2X+'!W$*"3C)VY
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MHVB*NKQEE8.&C:1"&.;K?AC1?$6D7V@^(M-L-;T35K:6RU+2-3LH[S3-0MI
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M())0BRSI9Z;%:V[3S+$OG7#1&>1\,\A "UU?V1CDO(&;)8'8RC=P 6 ER3M
M#;63<1G@U^"5JF']K55"G)TE4C+#5<5&#QT(1=^>I*DG1C5JOWZBINT6U%2E
MR<\O[+R_#9G5H8#%9K6PLL=2PU:CC\NRV5=Y#B<1BJ]*K.K3CF,<1CDLO]G6
MI8:I*K&=1XG%U*M.I0Q-/"X;P'X*_LR? O\ 9[TV;3OA3\.= \,O<[A>:P]O
M_:'B?57W-),^J>)]6DU#7-05[B22>.*>_-K"TK"&WB7K[T<*@#8^?(,;R@QE
M>,$'!4XQ].<X/%3K"Z[-[[R-V60&-><<E6>4GO\ QC//.:<4SCHHY.&)P>_
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M4Z=/#Q224*<(4Z<81TNHTX1BNBL5984F4K($D1N"DB!D(.?E9&^]Q@')"MM
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MRP,J,[-'Y)<O''(\95<*2P%?P<#E4<)L61%D P<989PO& JJ44+G>""SI'N
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M==\/^%/"GB#XA^#=:T+6+N#PF/&/@F\TO2^.U#X-^,/BE\<_!7QFT[X&^/\
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MPMWXK> _AHWB*'2A9'59?#Z>-->T4ZT-+_M/36U(:?Y_V*.]MC.4EN+:*?\
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MYL0_\$_(_B)/%J/[5'[0OQG_ &A9P/,E\*2ZP_PR^&3%&!C:V\">"9K<6LT
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M_P!H9?$\]]JVI+X:TKXE^*]+TG7I_#O;_M5?#3XJ_M6^*/CM\??@!\./VB/
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MNYU?5-.T$_#G]IKXC_$WXA6_C30O%WC_ $P2Z;XS\1>$?9?V#M(\?>%/C/\
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MI.I*VD>,?#6AZN(5O!;7YL%M-3@O;2>YBF]!\D@?(P7E>2&8L$4;=Y+[G8N
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M*L,*H!51E6(8#"E#&BY18P'?<CHJ!9"RADWG 7:NQV+NN"SN <!BH93*\:=
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MM6U.UN[DNHB-Q;6L6=HDN(US(O)_"K]JSXB?&;Q[H5CX6_9:^+OA?X17)O\
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MGKZ#'/K3JOMOHDE=WTBDE^"5O(=V]W*3VO*U[+1+32R5DO)*^H4444 %%%%
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ME<GYMQ;?GKU04444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHPTRC+!W#*"?G#S.[AE_>?R9XX^).'Q]'_4W)*GUK#SK1KYOC</[2*4Z&M'
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MK,;4XANP =N<@OAN!T/R%0<Y&-W3:<\D+$FLV\C%1L5@.C3*!D\#)"GC.-Q
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MHF.5[..)_P!$M?\ ASXH\8W'Q.D_:E_9X\*?#0^&/AUXJU9?VGO!&A:Q\/\
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M?V;-;\'7EZ8?$'B/X<>*_'>FZEIEB(I&6[@T3Q=IMT;RX2;RECA6[*'9(3)
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M)*2:TDI73:=PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/!O@/7-1T^>4G#BSU:\TW3=%O,E0?M-KJ$L$@(;SB-A/SMI_[9W_  3HU+4
MD^E_$K1P&VK-?^ [::+YR<N5T36-1N, ("08?,((\I'(?;_/H.,X.-V"Q4*I
M9N<EMJ@2?[(D5]G.TC<Q(V& 4J",C.X"0;><@1RB2!6/&'6$,N#CKQ^U4? '
M@N%)PJXO/J\VN655XG+Z+J-:75-8*IR*VT>>5E;7M_'N(^G5XQSK^UP^7\&8
M;#NK)QP%#A[$VA24WRJMC,5G&(Q%:4XI3J2@X-2E*,9629_7;\!?B?\ L&_$
MR[LX?A]\2/!]UK4TJ06WA_Q%+-X2\13W3,X6"VT+Q1%IFH71!0AS90W P8]P
M&^/=^B^F:/H6DVZIIMI:P1A"H>$850H);D;C@ J#Y>YCO!*!02/\_DJIQP,
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7<]Q<PV\P/V>W3)\RX/ QZE_P5"\,2.UYH7[(_Q(L8A$L2Z-J7Q/\':S<LH
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M2%3&&=@HC1UF78HD1HV:.1?G5R8W2OZ$O^"1OQ]NYM#D^&>K:E).?#NHM96
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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-%% "T444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (H!%8# 2(  A$! Q$!_\0
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MQ?:SXET3Q;X?GU#0+L:?HFCZ?X.UO4;;Q'%=Z7XKM/#US;SSV_Z(^;&.?,&
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M*\3_ /!)#P%_P56_;;\2_LJ?'+]CJP_;$\:_%_XR_$'1_BS^VQ\,]%\.^/\
M5_@QK_@+X'?'WQ3H#V'P_O?'7B>30M5;Q3I?@>2;PKH2N-!TBQ\5VMQXKU(
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MOX<\%6UAX3T,P:?,SPQ?";_@I)^W/^V+_P $_/\ @C]^SCI?[05_\*/VK/\
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M20HR2 8Y)$VD;L;LJI),88A=_P KD8P%RQ=-VU5=ER8VQ^(7['_QK\<_ /\
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MZYU[XD>'_BAJWQ=\.:/=_#6/3K&XUI/&&JV^E6$&E07=_=FUMXY)$I_L[?\
M!=SP9^T[XB^$NE^#/^"8?_!8KPWX"^-$OAN?PK\?/'W[%NDZ-^S[8^&/%-I%
MJ>C?$36_BGI/QAUW2+;X?2:9+#K"^+M+35+%M-DAO[1IX7C<_=G_  4^C;_A
MVO\ \%!&(5"G[$O[4F0BH_"? _QR0%:5224!9(FQ%AV>0JN0*\\_X)BK,?\
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M)'B>_P!"$\%EX1U#4?B O@J:YGO%U?Q7ID<-O.E]W'BK]K+_ (*/?ML^-/\
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MQIX \42>/QXE^'_BF;PMJ>CS^)?!OBAK73QKGA;49+O2-:2R@6YTR5K>.2(
M_0K3/VW_ (/^(_VFOVDOV2_#.D^/?$OQ<_9<^$'@;XL_$S3-)\,1W6G7>E_$
M;3M5U?PEX2\&M)JD5QXH\:ZIIFF_:3I%II]M8LVI:7I\NL1WPEMH/7OV=/C2
MO[0_P7\ ?&O_ (51\:?@<GCS2KK55^%?[1?@4?#3XS^"EM]2OM,^P>/?!/\
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M(M(A_+;]@G]H'P#\2_C!^S%XH_8?_P""^7[2OQ3_ &G=2^*/P\M/VN?V*_\
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MMA:>!="@\-Z??^'/"7B^'7K[7]1&G#5$DT'6?$EYK^B_#G[8O_!:OX&?M/\
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MWA+XK_"O_@L%^P+\(/VZ/B=_P4@_9E\.?\$K?VE_VAO@)^T!^T'X1^(/A_\
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M8 !)#_=*@'E@=HPP)RK8571@"K!E;[K+\RG R2&&1CMG.,_+G=Q7\(_[-_\
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)
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M3Z;X4\0^(-/\8:KIOB?XE:CXAM]!TOPCIGB;4M TR&TN/$]U',%U>?F_@/\
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M%7AOPQHW]K:_?Z7H6E_VGK6I65E_:&LZGIVE67G?:=0OK2TCEGCXW]A3X/\
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MXM^._#=RJ>'[WXP^/M \*:3XBD^UZI9^'?"T=CX1T?Y8U+X$_P#!0?\ 9O\
MB]_P;6?!;X;^!_ ?P[_;C_9^_9I_;GM;GX0_%[QOH&N> /%">$M-TRZ\0_#O
MQ!X]^%>I^+=$M(_BC\+DOK3P]K>FZC?V.@>(-3TBYU;^SVT;4[JV_O:<,5^7
MKE?XMO&X;N=KX^7/09/0,A.]?CCXH_L1?"SXM?M??LL_MI^)/$'Q!LOBE^R1
MX8^-'A7X=:!H6J^'+3X>ZW8?'7P]8>'/&,WC?2-0\+:KXFU.^LK73K>Z\.S:
M)XN\/16E\9)=5BUF(K;D _(W3?@-_P %+_\ @I[^T]^RI\1OV_\ ]DWX;?L!
M?LH_L4_%RR_:(\/_  ,LOVB_!G[3GQI^//[1/A#3+FV^%OB/4?&'PTT>'X?^
M&/A/X,N=:U/4[C1KV>S\7R:U:2VB0:M8:Q8Z[X5\N^ ?P@_X+"_\$A8OBA^R
MQ^RA^Q'\+/\ @HQ^Q_K?Q4\?_$O]FCQK%^U-\-OV7_B-\!M'^)_B'4O$^K_#
MWXMZ)\2M)OK/Q[8>&]>U6YN-,O/ 5C;7%_:M?WKZG:#6++PEX3_J+ .?^^OU
M.12T ?S6?M8?\$_/^"J?[1/[ 7P$\1?$KXS?!KXT_P#!1_\ 9O\ VWOAW^WM
MX%\!V>A:!\._V?M/?P'K=]-H7[+?A[Q!I6B>&]4U;PYX2T#4Y#I7COQM<1^(
M/$>N076D^)/&#Z?<V?BRT\3_ &N?A1_P6N_X*3?\,3:S\4OV#_AA^R%\._V:
M?V]/V7_CAXV^"MI^U)\)/C[\5_B+#X)\4WA\3_%J7Q]I%[X&^'O@GX:_#GP?
M?ZYO\ :3>>-OBOXWUS7;8:;;K9Z*!=_U?T4 ?S@?%W]F3]OSX2?\%6OVN_CO
M\'/V5M$_:0_9O_X*!_LS_"[X)>*?B7I/Q\^&?PT\1_LVZM\-? WB+PC)K'B3
MX>_$6?3M;^*$&L7^I0WEGI/@W4([:#2)HI+O5H]1LCI[_&7[.G_!,S_@I3^Q
M)\#_ /@EO^UQ\ O@1X)^(/[9'[)W[-WQ9_99_:A_8T\<_&7X>^#9_BG\'/B'
M\8/&7Q0T6P\%?'32=0\2?#?2/&GA;Q+K%MXC@GU;Q)JWA8P7P189KVSU72->
M_L,HH _!/PGX4_X+P?M'?#C]L+XE^+_'_P +/^"<WQ!\9_#OPIX<_8=_9BTN
M;X(_M,VWP>\=>%M577/$_C?X\_&&3X3>+M*\5-\48;2/P)]D\-1>)?#_ (-\
M+:YJ?B#3O R>+]$TRYU+\U_VM/V._P#@I_\ \%:=+\#_  *_:8_X)$_LC?L<
M?$&#Q;\-;OXC_P#!4*']H[X._%?Q_HOA7P!XFT;4?&,G[/'@_P"'.A'X\^&-
M<\<V>F.?"/AGQSXXO?"\6ENWA[QAJNCW4]MXCT?^Q2B@"E';RPP0Q+(\S0(J
M>9/+NGG,6!&\\QB8,\HC03D1##2/+'\Z)G\D;G]ESXZ2?\%U-'_;)C\#*?V<
M;+_@EOJG[.5Q\2?^$C\&B3_A<EU^U):?$>#P</"3Z^WQ 8R>"HO[5G\0IH"^
M$'FACM7U,:K_ *$_Z]T4 0JK(<D*J\L2 ,=]Q9@4^>0D.Q$>P!&!.2K5_##_
M ,%?OV3/V@_@Y^R]_P %\/BI\1?"$G@;P)^UG^W%_P $]?%O[/GC.+Q%X0\0
MR^*M \-^,O!7A36/$2:%X:\1ZIX@\.-HOB&>&&+3O&.F^&]1U%U633K:YMF%
MP/[HV&5(QG(Q^!X)[=!SCO7QU^W5^Q-\+O\ @H-^SMX@_9G^,VN^/O#/@3Q+
MXJ^'GB^]U;X::KX?T?Q?;:G\-?&VB>/-#@L[_P 3>&_%^B)8W6L:!96^JQW.
M@7DT^E37T-C/INHR6FI68!^(OQIT3_@OI^V5\#-=_P""<WQ(_9+_ &:O@5X5
M^(?A>/X0_'__ (*4:9^TKX:\;^ _B/\ !Z^AM-&^)&L?!+]F+1= L?BQX(\>
M?$?PK<7EOH^F>.T;PQ8W;:[8O=>$[2\\/ZWI/2>./V"/VVO^":'[5]A^UC_P
M2O\ @EX _:V^$7CS]F#X"?LN?'O]CSQ[\6?"WP%^(>H1_LR^$K'X?_!GXG_#
MKXP^(]/A\!V]_IW@K3;+1_$UCXDLW_=_VQ'I^D:LNLZ/+X)_I2MH#;QP0*28
MX(EB3A  D:*BY"A 9.."D<<03*K%'PM6J /Y_O\ A7G_  6%_:V_9Z_X*+>(
M?VJO!GP\^ .D_'+]C+XQ? S]E;_@G+X#\9_"?XI:WH'Q)\4_#WQ5I$/Q!^*O
M[4,&E^'M+U#Q?XHU2\LO"^D:+I7C*U^%ECH.IIK&MZ=X=UO2I[Z\^=OV=_\
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MI6G6MKIL$LZVWG/]25_I[X<\.X_A3@[)LAS*N\1B\%1J3J-U95EA_KE66,6
MA.<YS=/+O;O!4Y.5JD:3J4X4J4Z=*'^4OTE/$WA_Q@\:N-O$'AC*(9/DV=XK
M PPL/84\+B<S66Y;ALMEGN/PU&,*6'QN=/"QQ]2BE*K2HSPE/%UL1C8XJO,H
MHHK[<_"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1/HUS)Z6:[K7;SV\Q]6M;IJ+5I7YI)RBOAW<4VK-W75:)RT5$\\4:AW?"D@
MX8Y)( X )QDCG&.<YQ3?M,.0 S$E-XQ'(WR\>B'YN1\OWL<XP#1=::K5J*U6
MLGLEKJWTMOT8KJS?11<V[.R@KWDWRVLK.^K:MJD3T5'YL> <G!) RK DCD\$
M9Z9.<8P">QPGGQ8)W' (&2K@') &TE<,,D<J2.^<4/W4W+11^)O1*^BNWHM_
M^"NCZI=6VEH]6E=K:UTM7JM/N):*C2:.3[A)Y*\JXP5R"#N48P01SCGBI*+J
M[5U=6NK[72DK[[Q::[IIK1H/ZUT_.P4444 %%(S!1D\#*CH3RQ"@8 )Y) ]N
MIXJ(W$04,6.#T(5SGDCH%)ZCT_F*.E^BW?1$N48IN4DDN5-MI)<U^6_;FL[=
M[.VQ-14 N8#D>8!ABIR&4;AC(RP .,CD9'OP:<)XBVP-\V 2-K @$[1G*C&3
MP,]3P.:'HW%Z2BKR75)J]VM[6U]"F[.ST=^6SOO9.ST=G:479VW7=7EHJ 7,
M)XWG.0-NQPYR0 0A7>5)(^<#;CG. 33_ #8P"2V #@Y5AS^7_P!:E=7E&ZYH
M*+FKJ\5--Q<ENE))N+>C2=F[.R33Y;:\ZO&R?O+76/NJZT>W9DE%,,B* 2P
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M&YT3XG'Q#\-M+TS2O#9UW4;[5M('@S58Y_$&F#0X[^\E2WU>SM8?Y%?V _\
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MT7T]S<QV.CWGB+6+32=.:9[;2-*2UTK31!I]A##7]+U !1110 4444 %%%%
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MD<,&W *5)#$[1D\4I=%(#,%+$A03@L5!+8SUP 6..B@L> 2/Y"/^"PMU"?\
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M'>A2ZI=Z=KYF\6-XCUV5+N2Q@34;RV\+ROX6D^(46AV'ZG_\%1?VLI?VV?\
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MFGQ6:'QCX2\(R>%#XS/@42GQ'<W=O_:'_"01^$?&$H;3TL\K;G19/M#F-!)
M TH_)W2/^"__ ,3_  -XD\"7O[6G_!,W]HG]F7X-^,?$&G>'A\8?$NI>,KW3
MK6XU1)98;NUL?&GP*^&&F^(K:VLXWU*]@T;Q3<:S_8L%Y>Z?IVI3006=W[=_
MP<A&0?\ !./5FC!:6+XQ_#.55$9D/[NZUF9-J#)9F"'8%#L&QA'.(V^1+_\
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M4O%_@G0/&WBKP8GC[1-!L/#6G:1X3\3:OX4UC2/$%_X8MO$%]I'BBYL;35[
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MA@2-R' ZY#J5_P#'@*H@E8@O+,6R#,%C/W@1@$.& (^48SUP 0#5V;'EG(+
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MU*RM/LC:Z=$\0_V4RFY$WG_V/>DO&L6R+S3/']53%EC8J"6RH&-IQEE!8AB
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M_P &Z?[#/PB_9Z_;L_9C\!^./VFM+^%__!0'4_!>H_%1-0^)'@OQ%XF\#1^
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M%%CK.F:?_0#4*QG<I.!M+,,8;EAA@2X9\%BSAD9"1A6&!@S4 %%%% !1110
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MU03WY8Q4=>MVXMKRL^H4444#&N2%)'7(_F*B<9!&,[MI&#C![9/903SP3MZ
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M8[,<WA/&8CZQ/^U<ZCET<ZQ=_8T;UL?3RG+J=:JXRE56$HK1028@.5)]@?\
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M# XJE+DJX;&8'%T<;A,12G:7)4H5\/"<)I/EFHNSV?B_P'^#6B?L^_!+X6_
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M"]<\67_B2[TK0]:\/ZMJB6-SHWB#6+;7-,B>WMKY%G\\3 'V02%!). /QZ\
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MMSI%GH5EXXN_$_\ 9=M':&SCLOC7]G;PW!X&_P"#;S]M+XQ?"KP7X=T#XO\
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MH3W6N^(?$T<NGZ8]IXGU75]0\4P3:7HTEEJPDT^REB /P7_8Q_8W_:"^"_\
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M .2 2< GH2I&0",@JPVYW9!XX-)YB<'<"""VX<K@!3DL/E'#!ADC*Y894$@
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M_P#XJCCT_P#'G_\ BJ**/:2_Y_8C_P %/_YK#GJ_]!-7_P "?^8<>G_CS_\
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M'_@I_P#S6'/5_P"@FK_X$_\ ,./3_P >?_XJCCT_\>?_ .*HHH]I+_G]B/\
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M?^8<>G_CS_\ Q5''I_X\_P#\5111[27_ #^Q'_@I_P#S6'/5_P"@FK_X$_\
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M)('!'3KU IU?1W5VKZIV:ZIV3L^SLT[=FCK:MOH%%%% !1110 4444 %%%%
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M&I?#>7PQX'^%8TKQ);Z/XQ\1Q>*=?TW3IHN=^"O_  32\<_".[_9=T5_VA/
M5Q\+OV0=1\47_P *O ?@?]FC3OAYJ/BK4=7^%'Q#^%ND>./C7XM_X6MXI/C[
MXH>'X?'/]N2^*O#^@> /#NMZF_B:ZU3P1+K_ (@TC7_"H SXO?MG?M3:_P#
MO6?'/P'^!GPY\-2^,OV@]*_9I^#7BOXD?&C4+/6?$6OZU^T/K/P);XF6W@O1
M?@-X^TNT\%-IME8>--,OM5UFZU=+>;Q%=7G@O4=)\,:3_P +![CQY^WC\3_
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MO%6I61U/4_L>H>)=4BGUVZMFU'54M9[RXMTNY@(YP >YT444 %%%% !1110
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MBE\"?#GPV^K^%O"?_"N9(H-3TZW\_5;>_P!2?4%N5BTB\&D1?I#JW[2/P/\
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MM?E3XAI\,++3=/T_P+?VY\:Z=\3-0^'$4VJZ1JEWXOL]#EU;6=*X;XE?MO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 2FX[]K;$C4CI\JHBS444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\!G_ /*PL^PE%+@^A_(T8/H?R-'RE_X#/_Y6%GV$HI<'T/Y&C!]#^1H^4O\
MP&?_ ,K"S["44N#Z'\C1@^A_(T?*7_@,_P#Y6%GV$HI<'T/Y&C!]#^1H^4O_
M  &?_P K"S["44N#Z'\C1@^A_(T?*7_@,_\ Y6%GV$HI<'T/Y&C!]#^1H^4O
M_ 9__*PL^PE%+@^A_(T8/H?R-'RE_P" S_\ E86?82BEP?0_D:,'T/Y&CY2_
M\!G_ /*PL^PE%+@^A_(T8/H?R-'RE_X#/_Y6%GV$HI<'T/Y&C!]#^1H^4O\
MP&?_ ,K"S["44N#Z'\C1@^A_(T?*7_@,_P#Y6%GV$HI<'T/Y&C!]#^1H^4O_
M  &?_P K"S["44N#Z'\C1@^A_(T?*7_@,_\ Y6%GV$HI<'T/Y&C!]#^1H^4O
M_ 9__*PL^PE%+@^A_(T8/H?R-'RE_P" S_\ E86?82BEP?0_D:,'T/Y&CY2_
M\!G_ /*PL^PE%+@^A_(T8/H?R-'RE_X#/_Y6%GV$HI<'T/Y&C!]#^1H^4O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M .BW+_X;5/\ YNJXS_A][^S%_P!$Y^/?_@A^'_\ \\VC_A][^S%_T3GX]_\
M@A^'_P#\\VC_ (DBX:_Z-'FW_AWXC_\ H@#_ (B]]&;_ *+CA'_PX8[_ #.S
M_P"'73_]%N7_ ,-JG_S=4?\ #KI_^BW+_P"&U3_YNJXS_A][^S%_T3GX]_\
M@A^'_P#\\VC_ (?>_LQ?]$Y^/?\ X(?A_P#_ #S:/^)(N&O^C1YM_P"'?B/_
M .B /^(O?1F_Z+CA'_PX8[_,[/\ X==/_P!%N7_PVJ?_ #=4?\.NG_Z+<O\
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M_P#\\VC_ (?>_LQ?]$Y^/?\ X(?A_P#_ #S:/^)(N&O^C1YM_P"'?B/_ .B
M/^(O?1F_Z+CA'_PX8[_,[/\ X==/_P!%N7_PVJ?_ #=4?\.NG_Z+<O\ X;5/
M_FZKC/\ A][^S%_T3GX]_P#@A^'_ /\ /-H_X?>_LQ?]$Y^/?_@A^'__ ,\V
MC_B2+AK_ *-'FW_AWXC_ /H@#_B+WT9O^BXX1_\ #ACO\SL_^'73_P#1;E_\
M-JG_ ,W5'_#KI_\ HMR_^&U3_P";JN,_X?>_LQ?]$Y^/?_@A^'__ ,\VC_A]
M[^S%_P!$Y^/?_@A^'_\ \\VC_B2+AK_HT>;?^'?B/_Z( _XB]]&;_HN.$?\
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MB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M EL $T .HII91U/\\$], ]"3V7J>P-!=0<$XZ#G@9)"J,GCYF("_WCD+D@X
M'44P2(>0P(^;)YP-IVL&/12&!4JQ!W*PQE6P[<,[><]L@@'KP#C!. 20"2 ,
MD8H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $/3\5_F*
MC'3_ ( W\S4AZ?BO\Q48Z?\  &_F:C_EXO6/_I,R9_"_Z[G\\'_!=O\ UO[+
MO^[\;/\ WD%?SYU_09_P7;_UO[+O^[\;/_>05_/G7]Y>"_\ R;7A[_K[G?\
MZN\6?XB_2^_Y2(X__P"O/"/_ *Q^4A1117ZB?S6%%%% !1110 4444 %%%%
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M=Y>3ZK8PH$+R'PYXIEN97.[RH;/Q3I%E;;HK0!?W($T;#*L"!CH#W!(QQR"
M<$<'M7^=G%_#]3A3B7-^'ZLG)9;BI+#U6M*V!Q,YUL!64EI+GH3C2DUMB*%>
MD_?A)+_?[PGX[P?B5X>\,\9X/EA_:V68>IF&'4U*6!S6G2IT\TP=1)W@J6-A
M5G0YK<^%Q%"K'W)Q;DHIGF)D#)R3M VMUP3@\<< GG XKY_^+'[6W[*GP%UZ
MR\+?'/\ :9_9^^#'B?4M(B\0:=X;^*_QD^'7P[U_4-!GNKVP@UJQT;Q?XCT?
M4;O2I[[3=0LX-0M[:2TFN["]MXY6FM9T3YO_ (/X.S^YJWJ?HNZ36SU3Z/II
M\SZ#HKR[X4?'#X+?'G0+WQ9\#?B]\+_C-X6TW5IM!U'Q-\*/'WA3XB>'K#7+
M>SLM0N-&O-:\(:MK&FVVJP6&I:=>S:=-<I=Q6E]:7#PK%<0N_IPD1NASC.>#
MD88K@@C(.Y2H!&200 <4 /HIN]><G&WKD$ =>Y ' 4L<=%PY^5E)0R(H)9@
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MBI=;L;/5$U_Q);ZKJ":C86M_%<)=P6\R?T[?&2]O=-^$7Q3U/3KRXTW4=/\
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M2^#/V;_C+\,OVEO$GC[PUXQ^(VOZGJ7PR\'?#+5_"\J^*O$]]KUC965]XO\
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MH;]!+Q-^HYUQ!X68ZO4K8#,X?V[PNJTFG#&X+#PEF>604GJ\1AJ5'&PBM5'
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M=9\3ZD/ ]MK\>N^$_ *YE_:=LOV$/#OQ6^)_C_Q'X7T[]J7]O+X\^$=1T/\
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MH-'\4>-O$7ACQSJEK_PJGP]\,M"^'\+^%ET?PI\3+6SOK_Q']L>!_C!\0/\
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M_P ,W^"_A:OQ2T7XN:!X;T#2O"S:'X%\;1>'?!3^"U\//=MKMKI.OW7BIM0
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M[Q7K'B'7=.L?#7ZB_$C]B/\ 9E^+-[X7N_&GPO@>#PMX.TCX=P:!X8\5^.?
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MQ"\:ZNWBN3Q%)XVTK5-1\9ZYJ>O:5?:#XBTN?PM<-:Q^%I=#M])T:&S^BZ*
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MUKJ:$-,3Q+X@74?'_"W[ _[+OA#P]XN\,:=X"\0:MI?C3P!<_";4I/'GQ?\
MC9\3M9TKX57HA-W\,/!7B3XB?$;Q+XB^&GPVN'M; S?#_P"&^J^%?"3?V=8#
M^R_]#LC:?9-% 'SY\9_V8O@_\?;WPEJ_Q$T3Q3!XE\!QZW!X0\:_#GXJ?%7X
M+?$'0K#Q-;6EMXCT&T^(?P:\:> _&TOA7Q"EE8MKWA:YUU_#FKW.DZ3>:CHU
MY=:7IMQ:<5\./V7=#\'?%O0O')TGPEH'@;X*_#H_"#]E_P"&7A"UG@T/X:^$
M=?BT>^^(OBR_CEM;.%_'/C.^T;0_#,"Q+J</AGP?X8D_LO6Y+_XA^-X9?KBB
M@!,8Z>N3[YS_ "XI:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH 0]/Q7^8J,=/\ @#?S-2-T_$?S%0[U4<G'RXZ'JV6'
M0>G.>@[XJ4O?3Z)Q;\ERSU?9$SV];V\[1E)_<DV_)-[(_GB_X+M_ZW]EW_=^
M-G_O(*_GSK^@O_@NVP\[]ET<@F/XVMR",*&^$"Y)( ')&,D9R",@@G^?3C^\
MO_?2_P"-?W?X,3A_Q#?((<\%*%;.E.+G!2@Y9SBIQ4HN2<7*$HS5TKQ:DKII
MG^(WTOHR_P")AN/9<D^6='A)QDH3<9)<(95%N+5.2:4DXMINS33U5@HHX_O+
M_P!]+_C1Q_>7_OI?\:_4>>'\\/\ P.'_ ,F?S7RR_EG_ ."ZG_RH**./[R_]
M]+_C1Q_>7_OI?\:.>'\\/_ X?_)ARR_EG_X+J?\ RH**./[R_P#?2_XT<?WE
M_P"^E_QHYX?SP_\  X?_ "8<LOY9_P#@NI_\J"BCC^\O_?2_XT<?WE_[Z7_&
MCGA_/#_P.'_R8<LOY9_^"ZG_ ,J"BCC^\O\ WTO^-'']Y?\ OI?\:.>'\\/_
M  .'_P F'++^6?\ X+J?_*@HHX_O+_WTO^-'']Y?^^E_QHYX?SP_\#A_\F'+
M+^6?_@NI_P#*@HHX_O+_ -]+_C1Q_>7_ +Z7_&CGA_/#_P #A_\ )ARR_EG_
M ."ZG_RH**./[R_]]+_C1Q_>7_OI?\:.>'\\/_ X?_)ARR_EG_X+J?\ RH**
M./[R_P#?2_XT<?WE_P"^E_QHYX?SP_\  X?_ "8<LOY9_P#@NI_\J"BCC^\O
M_?2_XT<?WE_[Z7_&CGA_/#_P.'_R8<LOY9_^"ZG_ ,J"BCC^\O\ WTO^-'']
MY?\ OI?\:.>'\\/_  .'_P F'++^6?\ X+J?_*@HHX_O+_WTO^-'']Y?^^E_
MQHYX?SP_\#A_\F'++^6?_@NI_P#*@HHX_O+_ -]+_C1Q_>7_ +Z7_&CGA_/#
M_P #A_\ )ARR_EG_ ."ZG_RH**./[R_]]+_C1Q_>7_OI?\:.>'\\/_ X?_)A
MRR_EG_X+J?\ RH**./[R_P#?2_XT<?WE_P"^E_QJDT]4XM=U*#_]O'&$Y/EC
M3J2DTVHQI56VHJ\G94F[16K?1:L**./[R_\ ?2_XT<?WE_[Z7_&G;T_\"C_\
MF2DY14E&;C)-QDJ=5J23<6T_8V:4DT[=4UN@HHX_O+_WTO\ C1Q_>7_OI?\
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M_?2_XT6]/_ H_P#R8<LOY)_^"ZO_ ,I"CL3R< G _BP"2I[@,/E8CY@"2OS
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M  T?@3_Y1T?\,??LH?\ 1M'P$_\ #1^!/_E'7X#?\/#?VP?^BOM_X0/PM_\
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M_17V_P#"!^%O_P P]'U_-O\ H:9E_P"''$__ #:'_$R/@3_T;K-?_$'X+_\
MGF?OS_PQ]^RA_P!&T? 3_P -'X$_^4='_#'W[*'_ $;1\!/_  T?@3_Y1U^
MW_#PW]L'_HK[?^$#\+?_ )AZ/^'AO[8/_17V_P#"!^%O_P P]'U_-O\ H:9E
M_P"''$__ #:'_$R/@3_T;K-?_$'X+_\ GF?OS_PQ]^RA_P!&T? 3_P -'X$_
M^4='_#'W[*'_ $;1\!/_  T?@3_Y1U^ W_#PW]L'_HK[?^$#\+?_ )AZ/^'A
MO[8/_17V_P#"!^%O_P P]'U_-O\ H:9E_P"''$__ #:'_$R/@3_T;K-?_$'X
M+_\ GF?OS_PQ]^RA_P!&T? 3_P -'X$_^4='_#'W[*'_ $;1\!/_  T?@3_Y
M1U^ W_#PW]L'_HK[?^$#\+?_ )AZ/^'AO[8/_17V_P#"!^%O_P P]'U_-O\
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MT?Y"_P#Q-&T?Y"__ !-']KYK_P!#7-__  XXK_YJ#_5#A;_HF.&?_#!EO_S
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MO_S ?-/_  QW^RC_ -&U? /_ ,-'X#_^9ZC_ (8[_91_Z-J^ ?\ X:/P'_\
M,]7TMM'^0O\ \31M'^0O_P 31_:^:_\ 0US?_P ..*_^:@_U0X6_Z)CAG_PP
M9;_\P'S4/V//V400W_#-?P$!5E92OPD\!AE92&1U/_"/<,C ,I&"" 00<&NQ
M\ _ ;X)_"W5KK6_AM\(?AEX!UF]LCIMUJO@OP/X:\-:G=Z>TT5S]@N[[1=-L
MKJXL?M5O#<FUN'DB%S%'*%S&I7V)X]RD D'(Y 4'@@^@ZXP1GD<4FS.3T;&
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MR"!_$U^Q[\3?V>_ /[!__! K2OC9^S /C]XL\;_MA?%#0/@SXN'QD\:_"T_
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M];_,0YP<[0"< GJNX#@'+%<':,M@J<?,N6B:,]&R,N"0K%08V"L&8#:I&X,
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MT/8Y)'!Z'D<XZ<9X(RWS8^/FQD@#<"N6)P%Y ^;=\I7[P8A2 Q /X"?LF_\
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M;5;2"^MDNX;74M&U6VLM0T?4((YE2^T[4+2VU&RN0]C?V\%Q:E*V* "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@!&Z'Z'^50GK^"_P A4S=#]#_*H3U_!?Y"J77T(E\4?^WO_3<S\L/^"MW_
M "0'P+_V631/_4)^(-?SVU_0E_P5N_Y(#X%_[+)HG_J$_$&OY[:ZZ?P0_P *
M_.9_F+]*W_D[-?\ [)_)?_2<6%%%%6?S8%%%% !1110 4444 %%%% !1110
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M6\UCQ+X9\5HL_H",B ;BP"X)SSC"D@G/3 (Z].1_>7*>='M9@V50,6(#'&T
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M,,I<LS+O 3&0#^7S]H7]DG]K7]CC]H/_ ()>_MR^%OAQXW_;5'[)?[*?A_\
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MU)&OQ*_L/QG\1OB7K#V#Z'X4\.ZI>WL,]Q>V5NNLZ?!IVDV%KH?M0:'\+?\
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MWX^\!7N@?!W5] MM3TIO']C)X&74/%?BOXHVGC8W_BKQC#HUAIVF(VH-J%M
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M_A7YS/\ ,7Z5O_)V:_\ V3^2_P#I.+"BBBK/YL"BBB@ HHHH **** "BBB@
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M_ [XR_#W0=3LM,UCQ)X@OXSJ.D3SM=:G*\S/L0+OZ]^R'^SWXC^%.F_!6_\
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MQ_KWCCXD^+Y-%^(]K\.[C1]-\0^,=.T[PQX;LM;O?#E]!JMI8Z?J7RY\&O\
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MOXAV/C'2_AEX&\0^#/C6_BE?#>G?V_X[\&2^*WDT$ _0[X6?!+X<?!=O'O\
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MXDZ=\/;'QI-K5_?ZS>:T=6U.YFFZ6/\ 93_9[_LO4=$E^&6D:AH^L> OB/\
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M VN^'/"T#)%<1:<DZQ[._P#C-^S)\&OC]>>$M8^(6B^)?[>\#VVO6?A?Q7X
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MB@"%4?<C.!D%F.'9@K-N^7#YX53C>FUB3A52,LIFHHH **** "BBB@ HHHH
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MCYX^\:_M'_%3X;?%?XQ?M?\ BW]@OX/?"[P9\7M>\-^#_#OAZ3]HN3]F6_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)Z, 0< G!'3G&*S/ISR'XV_!3P/\?/ -[\/?'L&M1Z;)JWA[Q-HNM^&=<O\
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MXHE\4:#=37GBG5KKQGXH(\601W\*6_JGCC]D[X:^/_ W[2'PY\0:IXRDT/\
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MT*^2$1O)18T546+,2 1((CY<)($=NNX!(0]PL;2*-X*@FSYB9VY(.,\JPR,
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MY.D6WA?QCITUW]J\2:KH]E+LO-5L(?L\-Q)=-Y_F)"T44TD?XY_\.Z/VR?\
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MO^+M]^SQ^TYI?P?\ _';Q9=>/O'/A?Q)\$X/BKXM\#^-]7T+1]!\4>)/V?\
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MCX.>^UO]8:* /SUT7]C7XM_"WQCXXF_9X_:5M?A3\,?BQ=^ M;^).A:W\%=
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M&I2C*K&<J;53V:ISA*7[:[3_ )#?_$T;3_D-_P#$U^)7_#X5O^C>S_X=A?\
MYV='_#X5O^C>S_X=A?\ YV='L9_S+[O_ +4\+_B93P4_Z+B/_AEXH_\ H?/V
MUVG_ "&_^)HVG_(;_P")K\2O^'PK?]&]G_P["_\ SLZ/^'PK?]&]G_P["_\
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MVG_(;_XFC:?\AO\ XFOQ*_X?"M_T;V?_  ["_P#SLZ/^'PK?]&]G_P .PO\
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MUB_T_0;S7_#6IWVFVM[JNL2:3IMUIUE?:KJ+0RWTOT#\*?\ @DA_P5B_9_\
M@I^UI\&/@M^T;^QWI7AC]LKXL?$Z^\?:5XKL?BKKM_\ #CX<>.M-_L:7QA\,
M/&MIX&TV8_%77] U/4_#7B/PQXF\&ZCX/TRRT70M8\+>)=-U:\OH[7Z2^(W_
M  1C\>Z1X(_X)#_"KX#^/?A]+X/_ .">/QSTWXI_%37_ ![>^*?"&M_$2*Z\
M?>#/B%XVU/P3X<\,^'?'.GC5_$/B#2?$NI6NB>)/$EC#9'4--T]_%,IBFU9
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MO(;W5=.O]4O?F?\ X.)?%>A>+[C]C;X#?!BP\<^//^"@&C?%^V^/W[-_PT\
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MGPBN&N].\$>-]5FTG6$O-)\?^+],BTS6-4L9#H5_HUI)--:>#_#UO:^H6/\
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 5"O7\O\ T):FJ%>OY?\
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M)'8<T!E)QGD\8.0<D;L8.#G;R1U Y(% #J*** "BBB@ HHHH **** "BBB@
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MW>%?V9/AK^T-_P %!/CA^RA\9?@#XE\86#?\%#Y=7U7QSJ?B7P[I?B+6-/\
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M$'(^5@>"K8;(88^5L?QB?\%)?''[5G[,'[4[^"_VB_C5_P %6?!G_!/GX>_
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MS^7YDO=?XX?^WGXD?\%A?]9^SW]?BS_Z!\,*_%2OVK_X+"_ZS]GOZ_%G_P!
M^&%?BI7='X8_X5^2/\I?I*_\GKXR_P"O/#'_ *R^7!1113/PL**** "BBB@
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M@E756!%=%(H9"&Z JW8?<8,.2"%(*@AAAE/S*R, P_+G_@EA\5-6\9?!?5/
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M;F">SL/BQ8VT5UK=I]"7O[.WQP^(/@^;P_\ 'C]HWP_XVU&]^*OP.\?2:?\
M#[X&V?PO^&NG:%\%/B?X;^)S^%M"\+ZO\0OB5\0TU+XBW'A^UTWQCK'BSXR^
M,M*1%CF\-^#=&TUM8T+5N(_: _8:U'XU:O\ M$^*=-^+$?A/Q9\;](_9@\/^
M'KR]\%7OB70?"'AS]FCXDZE\5;?PMXCT6S\?^$KGQSX7^)/B36=;M?&EAI>L
M^!=5?PWJ"Z1'JUTMLDZ@'T)H_COQ%\(?V:X_B9^U#J/AK1/$WPV^$UWXL^-N
MN>$M4F\1>'DG\$>')M1\5:WHVH7'@KX<W-\MW;:9>ZM;:</!^BBSOKU]+L+*
MYMK6WN9OEN?]NWXC?#OPZ/&_Q\_95\6?#?P1XM^&MC\1/A+<>"?&%Y\5O$.N
M>(/$'BOP-X,\&_ OXHVL_@#P)X&^$?Q[\>:]\1?"VG^%/"MM\1_'W@W4KS_A
M*9Y/B MIX4U>]?Z\^-GP;T7]H+X$?$OX#_$74+O^P_BU\-?%'P[\7:SX69M#
MO((O$>C3Z)J6L>'DU"Y\0G2;BUENVO\ 3+74Y=?MK*:&*'4/[0CBGCOODSQ!
M^Q7\8/BGX'\3Z?\ '/\ :JN?&/Q!%Q\%M4^$NJ?#[X31_#KX3_"_Q/\ L^?$
M/2?BOX*\;O\ !/7_ (E?$A/&GC7Q/X[T;3$^*FM:QX^L+?6?"MG:^$? NG_"
MR"?5KR^ .>^(?[9'QP\#>$?CWX+^)?P9\-?!SX]Z3^SGK'Q9^ [>!_BL/C?X
M/\3WFJ:VGPU\,Z)K6L>(_A?\-)O#WCOP_P#%'Q-X(L->T ^#O%W@Z_TW7K/4
MO#?B_P :6]GJVDZ=?O/VI?BUX$T_XW^)IE\ ^/\ P[X=^/=A\"_!?B+XN?%G
MX;_LW_"?PS#X#^"W@K4/B1XX^(OQ*N?#WB#7;:Q\0_%Y?'GARTT;P)\./BGX
MAAOH--^S>'?#WART\0:AHF\G[#OB[QIXNO/BK\=_C=HWQ&^+^K>(/@=:ZEJG
MA#X4W_P_^&NE?!_X)?%6T^,EE\*O!'PYU;XI_$35]"3Q]XYT^PU3Q_XO\4?$
M+QY?ZT=)TBRCLK72=$T?2K'F?$7_  3^\3MKOP;^(_@3XO?#^W^+/PKU+]IV
M]G\1_%WX"2_&;P7K$7[4WQ(L_B/XPU_0_ UO\6O %]X6^)WAJ72K#PUX3\?+
MXNUQ3X3?6M USPUJFFZVMCIH!P=G^WK\4OCM\+/@5J_P \ ^&[CXI^/OVM?&
MOP0UWP]X<^*7A[QI\)]?T'X':9\0/$7Q'\4^$?CW-X&O;34/@IKDW@_0='N/
MB+;?"=O&]MI/B>^T_P ,> 9/&/\ 9UM%Z-X7_;Y\3^.K+1?AMX8^!NFWG[6^
MI?%7XS_"75_@S+\7'B^&'A&^^ D^CR^/_B3K'QW_ .%;7FKO\(SHOC/X>S^'
M=;TWX)7_ (WU?7/'^A>%[GX:VL]IXIF\/8/@K]@/XT?"?2?A+>_"K]K73H?B
M)\+;[]J+4]4\5_$GX#1^,O"/Q3US]JGXO1?%/QCXE\?^!/!WQ:^%<P\2>'39
MZ=I?AO4/!WC+PMI]E>I?S6ND:?X;NW\%VW36O[!/B7X=ZE\,OB)\!/C?I?A#
MX^>#8/CQ:>.?B9\6OA)%\7]#^,LW[2OBWP;\1?BSK/B[P1X9^('P9U/0_$+>
M-_ OA[4_ K>$O'NF:%X2T*P'ARZT'7M"^SVED 7[/]N'Q[J^E^"/"VA_L]PW
MO[0?B+X^_$[]G+QA\,)?BW#!X!\"^+/A=\./$7Q'UKQT?BS'X$FO]:^$5SI\
M/@EH?%,'PRT_QC;Z?\0+!;KX?#QEI'_" 7_&_M _\%$/$?[.GC2WT7QS\+O@
MA!H.G^,/A7X)UO1;O]K_ ,%VGQ\\4:K\1[_P3HLNM? /X!V_P\U2]^(WAGP[
MKOC5;&*/XB>,_@A\0/$=OH'B#5]/^'\&ECP\^N^V? O]B[2/@IXY\&>/E^(6
MM^./$&D:#\?[SQSK/B'38XM<^)7Q9_:+\:?"OQAXX^*&IWMCJ@TW2([&W^&%
MCX/\+^$].T22U\.>$GTS1M'U&VM=*O/[;^<#_P $T?%Z:I>:%I?[0/A#2_@O
M??M=67[7VL^&+?\ 9ZLI?BY\0_%"?'W2OCWJ7@[XN?'6Y^*DT_C7PC%XBTR'
M3_"\VB^ O!GB/1M+T;P58:WKWB[P]X9N/#FN &FG[4W[0>H_$_\ :<TO6]&\
M(Z!\,/#_ .TY\&OV2?@=JO@3XAV5WXY?Q/J*>!/%WQ1^(6J6OC?X :OX4@@T
M+X<^/=3\5ZW8WNJ^(M.T_4OAEK_@'2M.LG1_BQJW>^%OVY_&'BB[^$7Q*3X#
MVNG_ +)OQX^)>C_##X5_&2X^*(/Q2UB]\9ZC?Z5\.?'^L_ =?A_;Z?HOPC^)
M&M65I'X5\10_&+5_B!::1XBT#Q#XL^%/AZRFU8Z-M> OV)-8\->(XIO&7Q8T
MSQOX,T_]JCX[_M1:3X>_X5[J>BZ_?:C\:?"OQ%\-0>$O&_C*Z^)?B"S\3Q>
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M ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ I"0HRQ &0,DXY8A5'U9B !U)( Y-+37^Z>O;.&VG&1D!N,$CC
MJO\ O+]X ""1",AAC 8GI@'IG/0GT.#UXX-.W#(7/)!('KC&>>F1GIUKY)^,
MG[8'PP^">C_'#7-8TWQEXHT_]G?P#9>+_B>_@BP\,W9TG5M<72KGPC\,[-]?
M\0^';.Z^*'B+3-8L=;T_PT;U;#0_#^I^&M5\:ZKX=M_''@>7Q'S?AW]LB['Q
M/^%GPQ^+/[+7[1_[.MS\9=9UWPE\./%/Q3O?V:/$7@_7?&NA>$M9\=-X,N+O
MX"_M'?&S7/#VNW_A+PWXCU;1I?$VAZ%X>OAI-WIB:S_;=SI.FWP!]MT5Y-X*
M^/?P,^)7C'QA\//AU\9_A3X^\?\ P\D6+Q_X&\%_$/PEXI\8>!I6N);1(_&/
MAG0]7OM:\,.]W#+;(NMV5B6N$:%<R?+65X2_:8_9P\?)\0)/ O[0'P3\:1_"
M9KI?BH_A/XJ>!?$:_#-K(:DUZOQ!;1]=O!X,:S&C:P;M?$?]FFV&DZF9@@T^
M[\D ]NHKROX??'7X(_%N3Q9#\*OC%\+?B;-X"U%](\<Q?#[X@>%/&<G@S5HV
MND?2_%<?AS5M2;P]J*M8WBM9:N+.Y!M;C,7[I]N/X,_:6_9R^(_ACQOXV^'G
MQ^^"OCSP9\,_[1_X61XN\&?%/P-XI\+_  ^_LBQFU/5AXW\0:'KM]I/A,Z9I
MEM<ZC?C7KNP-I86]Q>3B.WAED0 ]LHKRKPK\=O@AXZN_']AX)^,?PK\8WWPH
MG>U^*5GX5^(/A+Q#<_#6ZC2^EDMO'\&D:O=R>#;A(M,U*5H/$2Z=*L>G7TA3
M9:7#1\?I?[4OP"\:_#K5?B;\)_BW\+OC3X2T[Q%H'@PZK\*_BU\*M?T>Z\8^
M*M=T;PWX?\(Q>+;GQMIG@NU\2:UK/B#2-,TO1]0\2V.I:IJ.HV.E:/;WVM:A
MINGW8!]!+)&Y*JP9E^\!U7TW#L&ZH3@.OS)E>:?7G^F?$[X<:M;^";S3?B'X
M)U*T^(VB7/B/X?75CXHT2[M?'N@VNF0ZY>Z_X+G@U.>+Q)HMIHMW::Q<:AHS
MZA9V>D7EI>3W$=K<PRMR7@S]I?\ 9Q^(_A?QOXW^'GQ_^"GCSP7\,QJ#?$?Q
M?X,^*G@7Q1X6^'PTFQGU35#XW\0:'KM]I/A/^S=,MKG4=0_MZ[L/L=A;W%Y<
M>7;PR2* >VU6O+6&]M;BSN88;FVNHGM[FVN(EF@N;:4%+BWEB=E1TGA9XF5R
M8\/\ZNFY&\X\%?&_X,?$G5?&VA?#KXN?#+Q]K?PUOH],^(VC^"O'GA;Q3JG@
M#49C?"&P\;:?H>JW]WX5O93INH^7:Z[%83.+&[*H1;R[<[X>_M#_  !^+FC^
M*_$/PI^./P?^)N@>!+B>S\<:Y\/OB7X,\9Z1X-N[:TFO[FV\5:EX<UK4K/P]
M/;V-O<7L\.KS6<D5I!-<R*L,4CJ ?SX?$C_@W'NK3Q+\0=/_ &/_ /@H9^T;
M^QY^SW\5]0O]4\?_ +-GA6/Q3XG\"ZD^L&:UU?1;-]&^,7PWL;CPQ/H4D>B6
MNF^-=!\<:I#;PB/4O$.LVC&WKZ=^)?\ P0B^ &M?L,?"S]C'X,_$CQO\&=3^
M"_Q@L?C]X(^.,VEZ/XX\4ZA\78$U*VO/%/CKPY%/X-TGQ)!-8:H+73=)TZ\\
M-0Z+'HGAZWMKB2STV[AUC]7?#G[4?[,WC'X;^*?C)X0_:)^!?BOX0^!A>GQK
M\5/#7Q:\ Z]\./" TZV@O=0_X2?QOI6OW?AG0/L-G<VUW>#5=3M#;6UQ#/-L
MBE1F[_X>_$WX;_%OPKIOCKX4_$#P3\3?!&LM<+I'C'X?>*M"\9^%=5:UFDMK
MH:;XA\.7^I:1?&WN(9H9Q:WDOE2Q2))M9&  /QW^"?\ P2.^+?@#]NKX1?M_
M_&3]NSQ=^TI\9/!/P[\9?#WX@1^,?@=X)\%Z1XOTK7-"\0Z%X<MOAWIG@#Q/
MH>C_  CTOP_%K45_J.DRZ7X\BU[5HM8O8;K0V\23C3.K_9Q_X))M^S]^R3^W
M1^RPO[0'_"5+^VCXM^-'BA/'D?PL?P\_PW7XP>";?P>^GR>&$^)6KIXQ303"
M^HF>#7O!QU3S6MHXM*<B[C_2_7_VC/V>_"GCO1OA;XH^.WP;\-_$[Q%JZ^'_
M  _\.=>^)W@G2/'FNZ^^GZ9JZ:'HWA#4-;M_$&J:Q)I6M:-J::98Z=/?/I^K
M:9>K ;:^M99=^3XP_"2+QNOPSE^*/P[B^)#Q:M.GP^D\:^&X_'#0Z#I.BZ_K
MLP\)OJ0U[R]$T+Q)X=UK6'_L_;IFDZ_HNHWQ@L]5L9IP#\B/$?\ P17\&^*/
MV#OV6_V2;WX\^*_#_P 7/V.-8;QC\!_VJ/ GA*/PUX@\*^.X_$.K:]9ZF? -
MQXOUM9?#HGU"P-]X=@\<6=Y+<Z!I-_8>)-*GBEW]I^S_ /\ !+/QEX=^(OQT
M^+/[9G[9WQ2_;7\9_'SX.:C\ O%VB7?A72/@+\(7^&NIVQTZYLIOA1X U_4=
M!OM?L[.[U'3=)UT3P)I<.M^(KJ'3#K>K/?Q_I=\,?CW\"_CCI_B'4_@M\9_A
M/\7]-\)ZE_8WBG4/AA\1/"'CZP\-ZR(VG_L?Q!>>%-6U>WT;4_*1I&T_4'M[
MQ8@9/)VX-?/TO[?O[*]WXST#P?X(^+/@;XL#7/ _QQ\?:MXI^&/Q&^%?BKP#
MX#\/_L\V?A&Y\?GXC^-9/']EH?@V2-_'7A[3[%M5F@LK:>YO+CQ1=Z%80S:E
M$ ?G?\#/^"-WQR^"M[\-?A?I7_!4W]J6+]B_X/>.KWQEX&_9O\":-I/PC\=2
MVUQJ-QK#>"/&_P"TIX \2:=XX\5>";_5KZ^EUOPHWA_2-(NM.U":W\/6/A?6
M(+7Q%;?7_A__ ()Z_P!C_P#!3GQK_P %&S\6$NCXO^ -I\#6^#?_  K]+9+!
MK2Z\,W?_  E#_$#_ (3.Y\_SY- <QZ&/ MO/#'?M)+KKR(4N/L ?M _!JV\;
M>$_A7XB^*'PY\*?&;QKX?MO$>A_!/Q%\2? -O\5KRPN+#[;.MIX,L?%.HWNM
M"SBAN8KG4/#*ZSH+-8WEU9ZM<6KQW#^6?#[]NC]DSXA>&?C/\0-#^/?PHM?A
MQ\!O']W\./B1\1M<^(_@#1_ VA:];6NF32W=QX@F\0K8Z9H5_JE_<Z3INK>(
M9M)AUW5=+U"703J6DBRU"Z /FC]HW]@[]K/QS\;?$/QM_97_ ."F?QU_95G\
M;Z)!H/C3X8^*? ^@?M2?!8"VMM.MH=4^&WPR^*WBFR\.?"K4[S^SX)=6NO#5
MM]IN;R34'LIK*'5=5CU3VG_@GI^PC\-_^"=W[/\ %\#O /B;Q'XVN=6\6:U\
M1OB%X_\ %JV=MJGC3Q_XBM-(T[6-:33;$+9:!I8L]#TG3]$\/Q3:BVCZ586U
MK=ZKJM^;K4[SZ3O_ (]_ VP^%4/QRO?C-\*+/X*76FV>L6WQ?O/B'X1MOA;<
MZ1?W2V5EJ<'C^;6(_"<]A>WC"SL[I-7-M=7;+:Q2M*VVN/\ @M^TM\*_V@/$
MOQ=T+X4:HWBO2_@[KG@KPYK7CS1K_0=:^'WBK4O'7PT\,?%+37\#^*O#^O:M
M_;UOIWA3QAX;?5K^XM;%;2ZOQ:V9O4WS( ?1(=2<!AGCC/(SNQD=1G:W4#E2
M.H-.KY6^"G[9G[-?QUTG5=0\$?%OX?IJOAOP_J?C+Q=X)U/Q[X 3QYX)\"VU
M_=)IWCKQMX3TCQ7JNH^"_"7B'1H[+Q9H^I>)8=.;_A&]9TBYUJ/2]2>ZTZU]
M_C\;>#KN3PQ:VGBOPY<W/CG3;C6/!MM!K>G2W'BS1;.VL;V_U?PW#'=B;6M,
MLK'4]/N[O4=,%S;6EOJ%C/-(%NK<2@'4*ZN RG<IZ, 2I]P<8(.>&!(/8\&C
M>O/S 8&XYX&W .[)QE0",L,J#D$Y! ^1?C!^U1)\,/BSX6^!OA#X"?&O]H#X
ME>*/ASXD^*\NA_"&^^ VEP>&?!OASQ+H'A&34?$&K?'3XX? _2!+?:_K]I8:
M+I^BW&LW]Q%I^HSWL%M'#),)?AG^U[\.?''@+XU^./%^B>+O@,_[.'B'7M!^
M._A'XT/X(T_7_A=/X<\'^'OB)/?:OJO@'QA\0OA]J6AWW@'Q#H?BNRUCPKXS
M\0Z;/;ZO%:&^MM2@O+:S /K4.I&<GCKD$$<!N00",!@3G&.^"#@+J!GD@9^Z
MK,> 3T4$\@<<?-E0,EES\!^&?^"@GPF\3?L<Z_\ MH1^!/C+HW@OPQJ&N:/J
M7PO\1>&?#6D?&Y/$VB>/$^'EOX6;PK/XZ?PM!K_B+7+C2[G0K>]\:V]O=VFN
M:5>:E/I\QFM8O2?AY^U(?%'Q#T3X5?$WX!_'+]F_QMXRTO7M:^'.G_&4?!76
M]+^(:^%4BOO%.F^&/%'P%^-7QP\*6OB/0]/N(=<D\+^*_$'AKQ'J6B)>ZYX=
MTG5M)\/>(;O20#ZS+H!N++MP6+9& H&XL3T"@<EB0.1SR*-Z[MN?F R1@Y S
M@'IT)!VGHVUL9VMC\RIO^"E.FI\,O%/Q[B_9&_:NO?V<?!VH^.VUWX^64G[*
M]UX.M/"/PR\8:WX.\9_$:'P3'^U//\;]2\'Z->^'=?UEVT_X3GQ9?Z!917^G
M^&+N&>!GH?#_ /X*2Z%\1OVEO$OP2\/> =(OO"?AK3_ 6M:KXHT_Q+\1[WXA
M:/X6^+&KZ7H'PH^(WB/P7<_ VQ^#MC\/_B'+J^DZMX>FT;]I+Q/\5+?PMJFG
MZSXF^$GARWM/%D7A( _40.I.W/S=<$$'&,YP0#M[;NF<KG<,4ZO/_'_Q,^&W
MPA\*ZAX[^+'Q \#?"[P/HI@CU;QE\0?%6@^"/">DR7DHAA34/$'B34--TBQ^
MUSO EO'=WD1EDEB2,N[HIP8/V@O@+=>!O#WQ0MOC=\(KCX:>+EU)O"GQ$@^)
M/@V7P+XG71M%USQ)K#>'O%T>LMX?UI=*\/>&/$NO:DVFZA<BQT;P]KNIW1BL
MM(U">W /7B0.I Y YXY)P!]22 /4G%-#*3@9R1D9!'L>2 ,CNO4=P*\;?]HG
MX 'X21_'I/CC\'G^!EQ;O=P?&?\ X67X,/PEN+6/57T.2>'XC#6O^$.FA&LQ
M3:.'76O+?58I=.W_ &F.2-><^"?[2OPK_:!\4?%O0OA1JC>*],^#NN^"?#NM
M>/-'O= UWX?^*M2\=?#3PO\ %+36\#^)]!U[5E\00:?X4\8>&VU6]NK6Q2VN
M]06SM#>(7FC /HFBBB@ HHHH **** "D89&/<'J1G!!QP5ZXP03@@X8,I(*T
MASC@X/'( ) R,]>.F>N<=<'H0#^9?5/C7\3OV)_^"O\ _P %#?C/XB_8;_;]
M_: ^&/QP\ ?LR^&O ?C']F#]FCQ#\5?#=[>> OA7X97Q)(VNWVH>#_#36T5]
M=2:',FBZCK-Q#JFE75G/Y,\4WEXW[;GP_C_X*N?'+_@D_JWCK]B?]K_PW^SP
M/BU^U+X<^/O@/XY_"7XA?!_Q1X.T$^$_ALOAO7/B%>?#_P 07-WX \,>,-:T
MX?\ "+ZU=^,-"EURZTF6TLY+B$7,+?T\K"R[@#@&3> -X /F;A@),BA H =%
M"B4AI) [.Z%$B;+,R ,R[0S$,P0E\(Q0KN*Y+;<!(#-(D$CH2* /SU^#'_!-
M#]F7]D7P!\6]&_85\!^&OV7OBI\2O!>K^'-*^,ZZ?K?QF\3^$]6N;28:#J./
MB_XJ\3WNN>'?#FM)::Y%X!EUFQ\)ZC<:?;+>6,A2&6.E?_!3]J?P3^PC^U%\
M.?CQ^T=JG[:7Q@\2_"OXYIX9\9Z'\"/"7P7U>]L=?^&E[IGASX?:/\-_A==:
MO#JVJ1:O%<KI^HP75WJNM3ZX-/?3I5LK&VN/T;C1U(R% "[3M4+G'W %#.%C
MC4E0 Q);G  RTISCC@Y'\QGL>HR.F?0J?F !_*E\4OV>?VI]4_X(4?L)?!O3
M/@7\8/$VG^%?$7P=O/VTOV;M \-WOAW]H3Q9^SYX>\5:_J_CWP'X:\/:];Z9
MXIL/%M]J"^&KU-)TBVL_%,P1+BU^S:5'J=S!Y#^S_P#L._MG_%;]F_\ X*)?
M!/\ 8J^$_B_]A']DOX__ !)^#"? SX(_MUW/Q+\#_$*VT'3_  Y;6/[3-G>2
M:9%\3OBSX:\-?$^WT?0O#4UGJ6I>(%UOPS=ZG8:'XITX+J=_??V"E9"2W(XP
M5/WCAB2%"R!!N4E58E74X+NP!6D,1YVA1A-@&%<,JY*(ZD1DJC?=!<\/)RK$
M.H!_-)_P3"^!/_!1SX2?\%.OVM=5^.'PJ_9M\"_"+5?A7^S?X0\<^)/A+X0_
M:%T7X5^)-.^&_P ';CPS\&]$_9(\1_$&VCTGQ#;>#[6*TT?XUV7B:^O1H%[%
M%8^&4C<_NOZ8ZKQQN&R<* [G:&)##,F'(41KYDI??)N#(@5$52P\T6* "BBB
M@ J%>OY?^A+4U0KU_+_T)::V?R_,E[K_ !P_]O/Q(_X+"_ZS]GOZ_%G_ - ^
M&%?BI7[5_P#!87_6?L]_7XL_^@?#"OQ4KNC\,?\ "OR1_E+])7_D]?&7_7GA
MC_UE\N"BBBF?A84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 !. 2>B@L?HH))QU. "<#D]N:>D4LKI#%%)/-+(((K>%&DGGE=S$D$
M$*!I)9IY 8H$53YTK(B;MPRS.""2 -RYR0 5) 923P-PRN3P,Y/&:^\O^"=_
MP/?XO?'[2M:U"T-SX3^%B67C37!,BE;C6(;Z:/P;ITN_E&FU2VN=6,,B 3VF
MBW2MM62,N2:Y&FTKM[M+IYGT?"/#F8<7\39)PUET;U\UQL,*IQ@ZDJ-*I*$L
M5B)1BI/V>#PD*^,4VN7VM*%%M.HD_P!T_P!D'X)1_ 3X'>#?!EQ!%%XBO+=O
M$7C"6(JWG>*=<C6\U"(.LDB/#I4/V?0[62-BLEMID4H):65F^HB0 2<X ).
M6. ,\*H+$^@ ))X )JI"6=U;RU !9<]PJ A6 )R,EG& .A[ &IKB%+B"6"6-
M)8YD,<D<J)+&Z/\ *ZO'*KQR*5)W(ZE7'RD<UQ3^+7IIO>VNBZ]S_97A_)L!
MP[D>4Y#EE*%+ 9/E^$R[#1II<DJ>&H4Z?M$TDISK252M6GJYUJM1MR:;.$^'
M7Q:^%?Q@TO5-<^$OQ+\ ?%#1-#\0:CX3UK6/AYXQ\/>-=*TGQ3I"02:MX;U+
M4?#>HZE9V.O:6EU;-J.D7,T>H60N(3<V\7F)GT D 9/ ]?\ /\^W>OF;]F']
MCS]F[]C3PSXK\&?LS_"O2/A3X8\;^,]2^('BC2]+U3Q'K']J>*]6MK2UN[YK
MSQ/K>O7UK806EE:6>E:!87%EH.AV\,L.CZ;9PW$J2?3#@E6"@$X. QPI/8,<
M-A3T8A6."< GBH/8/G/]KGXX7?[.7[,?QW^.&CZ=9:WXB^&?PU\3>(O"NAZD
MDSZ=KGC6.PEM?!.A:@D-]I=P]EK?BNYT?3+I+74;.Z>VO&-K.DSPL?#=3_;O
M\)^#)]0M?$_PZ^*'B_PQ\--<\._#S]HG]H3X:^&_##_ +X1_%&]A\/6?B71]
M1C\2?$2P^+NO:'X:UGQ%8P^+=7^'OP^^*&A?#87<EG\0_$WA_4/#WB5='Y'X
MN_L[_M?_ !J\6^(?A9X\\;?"#6OV5=9_:&^%/QGL_$9O]<L?C!I?PR^&&J>!
MO')_9JF^%UA\.;7P1XHT+Q-\0O!+G5?BIXG^,-YJ]QX0\4ZWHU_X$OY;72[B
M#SU_V*/VC;WP5XW_ &3[G7/@YI?[*GCS]H+XA?&3Q/\ %71O$_CR;]H37_ G
MQ+^.FK?'[Q-\%Y?AUJ?@>7P7H]]J&MZU=^ KSXP1?%_5IG\%0QW5G\+K#7;A
M9M. /4_%G[>=K\./B7\<['Q5\-O'/B#X/?"'XI_"WX2:U\3? .A:&="^'>K>
M./#7@&\U+7?B+J'B_P >>&[[Q'IR>)/B;X8T2'0?@SX8\=>,] M-,U#6_$'A
MZ'3=1TZYN.G\>_MZ_#KP%XC^)NE7?PK^-_B#PI\%_B[X%^#7QA^*>A^&/ *?
M#CP%K/Q(T+X7ZIX;\23W'B#XB>'?%7C/P[&_Q:T#P[JUA\,/#/CKQUH5_8:F
M^K^#8M&N?#NMZ]RGBW]C_P")WC'X.:3\,]3\0>"OMOB_]N2Q_:6^-VH)JFOQ
MP:M\-_#G[2$WQM\+^%/#,D?AL37GB&S\/>#_ (2^ Y+75(-)T^+2M)UGR]>E
MO[73M7O9_$_['WQ#\9?!*R^%VNZ[X/;4/%?[;=K^TE\6]034M1N+?5OAWH_[
M3S_'71/".DW$G@^W?5-<M_"WAGX<_#UH=5TW3;&VTS2KV*WUF2*QL'O #NHO
MVY/ ^H_'GQK\!_"GPL^.GQ!G^&'CGP1\,_BO\2_ 7AKP7XF\&?#/QW\0]'T[
M7?#6E>+?"ECXZ3X[1:')I6LZ)/JWQ/TKX)ZM\'_#L=[<OK_Q TN+PWXSN/#T
MG[;?[5NG?LG>'?@;K>K>*_A=X"TOXJ_M(?#?X2:]XX^,.LPZ!X#\(>#M4@\1
M>,?B%KMYK-WX@\+:=IVL+X%\'>(K7PS=:QKEOI%IXFN=)N=2L-;L(9]&U'YY
M'[&_[0_BG]JCX9_&?QZ/@#9:A\(_BOXW\4:?^U+X"U;Q-X;_ &C_ (J? G7E
M\4#PM^RW\4_A7X<^&/A#X?W?@SP];^(=$TS4_%>L?&#XAP:I'\/]+U_3OA]H
M_B[Q%=Z[H7UQ\2O@?XM\?_M1_LR_%QK[P]#\./@'X<^.NJ7>ESWFHOXJU3XF
M_$;1?"G@CP=/INEII7]AQZ!H?@R;XDG4]4O-=&H+J>IZ':V.B2PW&HZG9@'S
M%K__  4[_9\NOC;H/ASX3_'/X!?%/X(>#_@5\6_C3^T-\0/AKXRTSXP:CX13
M0O%WPR\!_"/P=X8;X6^*?$)E\9_$#Q5XVUR#3?!\GA[6M:\4'1+72/"]JFLZ
ME:VL_IMU^W[X \*>&_C%KGQD^$/QW^ FJ?![X.7GQYNO!7Q*T#X>7_BKQY\*
M[*YET_\ X2'X<-\,/B9\1O"^KZBFOK9^&)_!?B#7?#7CO0=:UOPS#XM\-Z!:
M^(=+NKSS/]H/]B#XF?&?XH?M _%JU\3?#_3M<UK3_P!BN/X"Z=KT_B6\T=3^
MR5\;==_:)U+1?BE_9>G:;=:3H_Q+\<:X?"-S/X>F\72^'O#VGV/BF&SU75E_
MX1R/P']IKX._M.>*]<T+XA?$6Z^#VA?'?X[^/?@'^S/\'OA3X*\6>*O'?PC\
M _#_ .'_ ,3[G]J[XIZGXN\=>)OAY\-_%?Q USXEZ-\'Y+#Q&EK\.?"UKX8\
M*Z#8:?HUGXCO)]5U'4P#Z\U_]O/P_H_A;X_S>(/A#\7/A%XX^#W[/GB[]HGP
MQH?QH\/^%;6Q^*/P^T"UU.UL/$GA:7P!X^\;+&)?$%KINB:GX%\7WO@KXK:.
MWB#0DUCP?I8UFPN7O:U^V]X2T30OBAIG]B^(/B#XG^ _PCOO$?Q\\8_#'P[H
M?B+X4> _BK;>';:\M?@G%-K_ ,2O#5UXH^*_BK4KAHM(^%_A?7M=U/0+:?1+
M7XE^)/ R^*?".J:UXY\1_P!C'XZ?M,_\+(\7?M WGPN\,^)/B=X;^$GP'/PS
M^%WQ#^).M>$/ 7[.>B_&W0_B5\?S9?%B?P/\,O%WC'XI?&C0M,&B:=?0?#SX
M;6/@9O#_ (7T_2=8D1_$6O:O%X4_X)\>,OA7=?'GX4?"K7O!NF?LJ_&;]H_X
M"_M':5X'UC6O%USXD^'NHZ)X\\->+/VD_ .AVUYINN:3<>"_B8?A[X9U3PQ8
MRZG#;V&K^-_B-975EI=E9Z#?7X!Z_P"*?V]_!O@*^\>:1XB^&?QE\6Z1\%?B
M=\./@Q\>/C#X2\&^"])^$_@GQ;\1O#/PLU32_$45GXK^+,7BWQ+X7%_\6-&T
M77/#WPOL_BC\0/!^IV5Y%KOA^71+SPSXE\5]'%^W)X%U'X\^-?@/X6^%OQS^
M($OPP\<^"/AG\6/B9X#\,^#?$_@SX9>._B%H^G:]X:TOQ;X3T[QW'\>HM#?2
MM9T2?5?B?HWP3U?X1^'8[VY?6_'VG)X;\92^'^$\3?L??$/QC\$;#X7:]KGA
M%M3\5_MLV?[1_P 7M2CU35;NWUGX=Z'^U%=?'/P]X3TJ[N?"4-UJFM6W@SPU
M\,OAX]GK%A9:=9V&F7\%MKEU'I>G7FH><K^QO^T/XH_:I^&7QH\?#X!V5_\
M"+XL>-_%.G_M2> -8\2^&?VDOBK\"=<7Q1_PBW[+7Q0^%OAWX8>$?A]<>#]
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M]-A^(B?&KX;_ !E_9FU3X?\ P]L?BD_A_P",6@>#=0UGQG\/-3UM/#&FZWX
MB^#'C[XLV7B35;KQ7/I_A"/X;&YT_P"+\6OZ[X9TJY\#6E[XGT!=1^=/&?\
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M<\7>'/LFDW6F>&?&5_X?\(>)N1^#G[/'[7_P3U+4OAIX+\7?!;2_@=I_QO\
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M_A /A98ZWX/U75?AAXR^(7Q.UGX]ZY\'K?PMX<:^\9W/P=^'OB/PCJ^E^!_
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MH\B+T_7_ .SKXQ_X>&?L=_\ 18?_ #'WQ1_^8JC_ (>&?L=_]%A_\Q]\4?\
MYBJ\C_B._@K_ -'B\,__ !.N&O\ YYGJ_P#$$_&#_HT_B#_X@_$?_P Z3[.\
MB+T_7_[.CR(O3]?_ +.OC'_AX9^QW_T6'_S'WQ1_^8JNR\ _MF_LT?$_Q;I7
M@7P/\34UGQ5K;W,>EZ7)X1\=Z0+N2TLKC4)T6^UOPQINFQ.MK;32(L]Y$TSJ
ML$(DN)(HG[,#XT>$F:8S"9=EOBKX>YAF&/Q%'"8' X+C/A_%8O&8O$5(TJ&&
MPN'HYC.K7Q%:K.-.E1I1E4J5)1A&+DTGR8[PB\4LLPF)Q^9>&?&^ P."P]?%
MXS&8S@[/\-A<+A,-3E6Q.)Q%>ME<:=&A0HQE5K5JDHPITXN<VHIM?3GD1>GZ
M_P#V='D1>GZ__9TX%"0 Q)8X'R-CHQ.3C P%.<D8. >64&3R_?\ 3_Z]?I"J
M2:NJC:>S5[/5KOW37JGV/SY1BTFHT6GL^1V?_E'S1#Y$7I^O_P!G1Y$7I^O_
M -G4WE^_Z?\ UZ/+]_T_^O3YY?SO\?\ ,.1?RTO_  !__*2'R(O3]?\ [.CR
M(O3]?_LZF\OW_3_Z]'E^_P"G_P!>CGE_._Q_S#D7\M+_ , ?_P I(?(B]/U_
M^SH\B+T_7_[.IO+]_P!/_KT>7[_I_P#7HYY?SO\ '_,.1?RTO_ '_P#*2'R(
MO3]?_LZ/(B]/U_\ LZF\OW_3_P"O1Y?O^G_UZ.>7\[_'_,.1?RTO_ '_ /*2
M'R(O3]?_ +.CR(O3]?\ [.IO+]_T_P#KT>7[_I_]>CGE_._Q_P PY%_+2_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.,HRJ9;[25?*<2U-)VQ668C!U^9>[.3E*+:U'T4TNH#,2 %!+$\   DDYZ
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M +#D,%ZGNI4D JC$@!\#.1B@!X92=N?F')7HP&2,D'G:2I ;&&QP33J_._\
MX)R_\%(O@;_P4R^&'Q2^+GP(\,?%?PEX9^$?QL\7? 7Q3:?%[0_!WA_6;SQC
MX+T'PKK^HZGH=GX)\=^/=.F\,2Z?XLT]+*]U"_T[6)YX;B.;2X+:"VFN?T.W
MIG&X9XR.<C/3(Z@'IDX&?ESGB@!U)N'/.<'!P"3GTP,G([CL.3@4P2QL<*P)
MPK8'968JC'IA696V$D"3:VS=@U\G?M"_MJ_LZ_LR?$#]G7X3?%SQW%H_Q/\
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MF_NM@ 6BFJZ. 58,&&Y2#D,IZ,O]Y3D8894@@@D$4Z@ HHHH **** "BBB@
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MAW0]3UOP!X]^&VK37>J^+-$U+Q)IUK:VNLV^DZ#/,XU:_@FAAN-+G\$^)?\
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MY??LI)R32=_=3:IMZO65-1D^[;9_GTGK)+9-)?.$7)>JDVFNCT9^*W[06H?
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M@SPKX<M)$O-8739]?\0:]K.H^[#< X=MT3@!<NK*Z!"01([ LTJ!O-("(I9
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MOB1^TU^R_P##7]K>']J_Q/X7^%W@2[_9*^+OQ5_;6_9U^'?P_P#B-]G^"8^
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MP[8Q2WFN^'KJWBU?2+6-[C4+.WB4N/60P+%<\CJ,$<'&#R.0<X!&02&&<JP
M M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&O>);SQ+I7C;QS!:Z%XW6\^W:QX?\-/=Z/K/A1=9M;BQ^E_A[KG[3W_!)_\
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MHSQR1Q6J,]S#]&_ KX(?ML^//^"O/_!0+_@C_)_P5Q_X**6?[,/PJ^$'@?\
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M=_;&^"7[='[8>F_\%%/VHO\ @L;^Q7\+(?B;:>'?^">_QO\ V)[E;S]CW3/
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MGC_&#0O^"_?[.%YX=\"?$7QU^R5_P46^#/P+\>7WARPT?]I?XL_LQZ3H_P
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MMY_L?^$_VH=<\8_$73O%/_!"'X1?$7XARZ+\1?&GA1_B=XJDUP7=U<>.=?\
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M&<CK3I22J9;EM.GC,RKX:<DE5H5<VKX:A*K2O!5\OJTY2<Z,E'_*?Z?O'O\
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M'5H_#+61FTI;?1K^[U&WM89*^V:* /"/%_[,/[./Q!\92_$7Q[^S]\$O''Q
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MWQ+HT_1IWU/]O/H9M0^CIP,I>ZWB^+I).^L7Q;FUGHGH[.VWH.HIN]/[R_\
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M1]%TG3[=+:UT^QL[4K%'%#'&@#N)I9&$DDT\LTK2GKZ "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M&/\ =/..@]>I QCWZ5"RJ05XZ# &,C.,C@@@#OGL,8.<$HJ)14I0@[VJ<\7[
MS5DH..BVNXU))O>S\B*DG"*DM^=*SU5U[R=NZ>S\SPGXQ?LY_"+X]2>'#\5?
M"?\ PE(\+-K']A@:YXBT9;)=;&GG4XV?0-6TIYQ<MI.G2 7/F"-K7*%2[!O&
M/^'=G[(7_1(E_P#"Z^)'_P U]%%?$9OX5>&O$F/K9OQ#P#P9GF;8A4Z6(S/-
MN&<IS#'5Z>$IQPN&C5Q6)H3JS5'#TZ=&FI2:C""2LM%]7E7B/X@\-X..39!Q
MSQEDN586<YX?+LGXHSO*\#1EBI/%5Y4\)@<91H*56O5J5)S5-3FY>^Y-)A_P
M[L_9"_Z)$O\ X77Q(_\ FOH_X=V?LA?]$B7_ ,+KXD?_ #7T45YG_$#?!K_H
MU7AU_P"(9D/_ ,RGI?\ $9/%G_HY_B+_ .)SQ-_\\11_P3L_9"R,_"/'NOCK
MXCEO; /B_')X/H,FNO\  ?[%'[-/PS\6Z1XU\&?#E=*\4:#)<7&DWTOBGQIJ
MD-K/<V=S822&QU?Q#?V$[_9;N=$-S:RF"1EGA,5Q%%*A16^"\&_"; 8VAB\#
MX:< X+%X&OAL=A,5A>#\AHXG#XJA.4Z-:A7C@W5HU:4XQG3J4YQE"45)+F2:
MY\;XM>)^-P=3 XWQ$X[QV#S%3P&,PF-XPXAQ>&Q&%KQY*M*K0KYA*G5IU(2<
M9TZD)0E%N,HR3:?U;&OSJQ'/;@80&, J,'&00,\8^8X)Y-6:**_0J:M#I9RJ
M-))144ZDWRJVZ7=Z]]CXVR6W7=]6U97D]Y-I:MZ_(****T **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
&*** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" *V SP# 2(  A$! Q$!_\0
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MX0T5DM-6\2ZS=QW<MD^K8N&M'NQ906EK& ?U@^;'\N6 WDJH.02X&2@! .\
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M7VM4_/'_ (+._#[QE^V;^U5\5O"G@+4=;TV7_@E]^PAK7[5NC:OH,0^V:?\
MM(>,?&V@^,_#FA)<W$UF;L7GPM^%$^IZ6F!$=74O]F-Q"3& ?UF>8G=@#\F0
M3AAYK;8PRG#*7;Y5# $MD=0:!(A) 8%E ++SO7(R-R8W#(Z @$]!S7X=?\%
M/VB+G]H7_@E=\*O^%2WYL/&G_!2-?V;_ (&?#JULKM6O(7_:/U'PY-X^L4:T
MA>(1:+\._P#A.XO$$PBAM].BM+V:YG@EM8XF]1^/G[=4'[*?Q ^%_P"P3^QC
M^RMXR_:__:(\.?"KP[J=I\&O!7C3PY\+/!?PF^#/ANVL?#7A[5OB'\6O%FFZ
MEX6\'27=M:6D.A6%WI0M;]QIMIJM]I,^N^&%UL _70R(#C<,[0W'/#':IXS]
M]LA!U<@A02#@,B!0Y=0A"D/GY"'.%(;[I#$C&#W'J,_F;^R7_P %$XOVA+OX
MU_"KXJ_ CQE^R_\ M;?L[^'AXJ^)W[.7COQ#IGB61O"NH6DUSH?CCX=_$G0-
M/CT;XA^ M8N(H-.F\3:9HEO'::E)"\FF75M=:5<ZK\N_LI?\%1/CS^WQX/T#
MQA\//V ?%OA;]FGQK\/_ !O8_$']I3Q'\<?!,&@^ /'VB^$/$^H:OX4\*_#_
M %#PKHGQ!^+7A_2]5MK3P=<^/=$L= TP^++W5[&/3(=/T:?5YP#]U"Z*"S-M
M 4,2V5 4]SN QC^+.-O\6*#(@QE@,L%&3@%B2H4$\%LJ1M&3QTK^9S_@FY^V
MMX<_92_X) ?L$^'/#_@O5/CK^TK\;?\ A8'A']GC]F3PCK5EI7CCXJ^)V^,7
MQ!DU2^O-=O[?4['P/\/?!UC.^L_$/XKZ_IJ^'/".C02S:@DUU)8V-SP'_!<7
MQG^U/\2_B!^P#^RYXF_8X_X6;\*?BU\1?"^O^,O!'@/]KW3O _A?]HSXI:;X
M;U>X\1_LVGQ3>Z%X"\5:!X5\%&6W\2:/\6/%GA[1]/\ $]S=Z;+I^B^$M<TQ
MKJV /ZI-PX.<@XP1R#GISTY_G@=2*0NJ@EF"@ $LW"C.<?,<#/'3.1D9ZC/\
MU?[,GPI\.? [_@K[^R9\,O#7P<@_9ULO#G_!&N>XG^!W_"Q+OXLK\*O$.O\
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M?%.I_"_X7> _ 6J>)%>>2[<>(=0\+:!IMUK<C7DK7K#49KE'O1]I>1I'E:8
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MEMI^CZ#H.D6]KI>CZ586T:6]EIUA;06=I B0P1)&BJ.C QP* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MO@+1]:\$?"#6X_&^G_LH7]_:SZ_XUTT?$K5K'2]2M?"P!_0*'0YPP.#M)!R
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M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "FD'J,9]3D8&!D CGJHY/KW
MQBG44 <!H7PW\)>&KOX@7NA:0VG7'Q3\0OXN\>2KJ6IW+ZWXDD\)^&O [:C&
MEW>SV^EL/"WA#PYI/V?28;&R<Z<U^;>/4[O4+W4/(->_9\_9N\,>'? >J^*_
M#'AS0_!_[/OPI\3_  ST"]\1^*M6L_"N@_!C7?"NE>'_ !AX(\>RZUKT6B>-
M?A]J'A[PWHK:YHWQ5_X2G0FN-!T7Q+<QQZ]IUOK%M]/5\I_MPZ/K/B3]C_\
M:@\/>&]$UOQ1KNL? GXFZ9I?ASPUHFI>)?$&MZC<^$=32ST?1/#^DP7M_K6L
M7TDRQ6>BV5A=7>JR216B02>:H8 YO3OV-?V4?AWX-^)D=_H.J7/@_P :?#/5
M?A]XV\0?%'XX_&'Q\WAWX*_8;R]U?P/X3\9_%/XF>)M6^$GPUL[#S=5O/#WP
M]UWP7X6L%L;+6$LH9-&TZ6Q]G\4#X+Z_K/P-\3^*?$'A2XU9?%,VJ? 34+KQ
ME!9GQ)XKU_X:^--/F'@^*'5[:'X@W>I_"_5_&^H+I036X7\.Q:CXDL[!)-(.
MIV?Q'\=/BWXW_:F^'7A[X2_LP_";XB^(=3\1>._![?%P?M+?"_\ :A_8P\#K
M\(?"%Y;>,_&>@7?CGXO?LRZCK&K)\3+G2M*^%,VB^%O 'C&_O-"\<>*+E[73
M+;0=4UC1/G2X^"7[0'C_ $K]G[]G_P"+7PR7X?:Y\"OVI/&OC+X9>-_AM=^+
M_BO\+_AIX#U3]G7X\>)?V>O%&E?$[6OA1\*+*]F^"'Q!O-#^&,EOJ_@W0K^S
M;PUX4TSQ#9W.G^/-'O\ Q4 >_?$U_P#@D_X!O?B!X$^+'QZ_9Q^'.I?$+3OC
M5H?BWP?XQ_;"7P!J5OIWQI\>Z;>_'#3O#NB7WQCT.Z\ P^*/B1\.WO-7/@BU
M\,3:+X\TOQ9>Z<EEXCUOQD=1]$^#/Q1_X)ZZ>=4^ 7PU_;"\ ?%36_BM927B
M^ O&?[>WBS]I#XB^(-&\0>!VU4_\(;)\5?CI\2_B#INC:GX!G/B>&'P1>:;I
M3Z#./%EM MO<_P!JR^#_  J\/_&'Q+\"/A;J'C/X0>.? ?CRX_X*4^*/B'XP
M\#WNAZM)>>%M"NOVA_'VIZGXHB>UL[A+[X?7%M-_:F@>-D$6C:SX9U/3=;34
MUCOVFFL_"VZUWPE^UM^U3HNL^.OVS=#_ .$]^.OBG5_!_P )=,_90\0:S^RM
MXTT[4OV=OACHUEXSU#]HRR_9,UI])NQK?A_5+1K>#]JG0-#3Q#X7L-*N]$@D
MO[K1]4 /I;X5?&__ ()]:OJ.J^)O@[^T;^S-XOO_ (,_!2R\-ZWJ_A3]H'P+
MXZ_X5;\"?".H)//<:W/#X\UF'P?X0M]2BTN7QEXLOO[,'B.31?#47C/6=9;P
M[X?73?8?"?PK^ FB?$[4O$OA2TT./XFWVB^*_%6J:=9>-]9U:>'P_P#'#7_#
M&I>+-;@\%S^()M)TWPW\0O%?PKL-2_M*UT&RTK4/%&E^*-5L@NJZ_P"-9]6_
M#K5?@C^U4W[.OPX\)?&_PO-\0+$?\$MOBS\,/@5X;^"G[,'Q-\+^*_!_Q!\8
M_#3X>6OC+X._M)1:E\1/BY>G6V\+^#?#%G\-;FRTGX9^#_&GC33O'VA>*O!^
MA^)-,^%/AW5_T7_9>^'/Q%^&O[67QB\%:UX,\26GPP^'O[/'P4\"_!CXC3Z;
M,WA/Q'X%'Q%^-GB;0/!&EZYY1$NN?!S2]?LOAYJNC7EXNK2^&=#\(^+;^(R^
M+954 ^O/#?[.'P>\)>!OA5\-_#GA:[MO!/P0\1V'BCX5Z)/XN\8ZI'X,U71(
M-;T_1+;3K_5_$6HZK/H7AO3?$.J:)X;\(ZA?77A3P_H,6G>&]*TC3]#T31K&
MR]V0$*H/! &1Z>W&!QTX 'HJC #82#&A  R.@.Y5Y/RJ=J':OW5!1&"@!E5@
M5$E !7RM\8/B[^R%X<^+OPC\(?&OXV_ WP5\:-#U^#Q=\&O _CKXS^$_ WCV
M]\1^,=%\4_"JQU'P]X&U'Q3H>L^,(O$6F^*O$OA'3;273]9TW4-4O&ATZR.N
M6%K<VGU37Y7_ !U_9P^.?QY_:1_:3\(>'_&_A?X9? OXK_LV?L]?#CXE:OXF
M^!/BCQ]XA\:Z5'XN_:-/BG1_A#\1(?BWX!\'>"O&GAK0]?@DDOM>\"?%^'2+
MWQ3X?U2[\,Q0I';ZH ?9_B?X9? ?QOXM^)_A'Q;IWAG7O%_QH^#^E^#_ (G^
M#;_Q+<3:QXK^#&D7GC72]+6X\)'5XKG3-!M=5\?^+=+D\6:/INGSW>HZG%:7
M6KW%]8:;'I7R)K>H_P#!+'Q;X8^,O[,GB;X]?L[^([?5;X>*_CS\/M<_:YM=
M5^(UCJGP0\/>%M&U;Q)XYUJ]^*TOQ5\.:E\/=%^$VA3>,M<U/5M'OK6XT#5=
M8\8WIU*_\2W5[X1'H7[:>G?&.?\ ;#;]GWP0_A>\^+1F>$?%GXC7W[247[&D
MND6'PSM? ,7[-EM^S+<0VVKK'I]E^TY>^ X_C3?>)(_'=S?>'Y-!37I6\(V-
M;X=?#']IS0O'/[.][\4;.RU+]G+1/VYOVK/'6A>&? 7[//Q$M_CG\.?''B7X
MH?M$Z-\(/%7Q)\:77C_Q?I^K_ 'QQI?C_P 1ZAX@^('A'X2^ 9M$MM=^&5SK
M&J77PMUWQ_XHB /M/P1^U+_P3P\9_$*+Q!\._P!JO]DWQE\2+7P;X>^'%BOA
M+]HGX7^*=6TGP??^,=-T_2/#FDZ%IGCS4(M$M?$GCO6_"^E7W]D:=I]SXTUI
M/!&@:O+K=QHWA*QT_5^).N_L._!NSOI_C!\5?@M\(]/MOCWIOQ)OU^(7QRT_
MP#H^F_M!7NDV7CJT9/\ A(_&NB6FF^(-5TUH?']WX-MXK+3/$%KJUUXVU/PU
M?/KM[J]Y\L_%/X&ZU\2/@K\?OAKXM^&_BO7O#_C[_@H[\*=<U/P^/#FN+)K?
MPH/QL^ %SK_B[3X8+)9I?"6G:/I6LZR_B>WSINCVFC:EJRZQ;?V/<7]G\F>)
M/#GQ_P!%^*S^)/BHW[6WPOO? W[9;Z3K7QZ_9T_9QO\ XZ^+_&?AK0/V!(_A
MAH_Q?\->!++]GO\ :0T*Z\$?%;66LK'Q%J7_  K'5;'P5XWU/Q#X,74=-O\
M03JH /O74/$__!-7X<_&K1_C)?\ [7?@+P#\0/C9)HGQDT'1[G_@HAX[\'_#
M7XM0^)]$L_ _A_XB:3\ 5_:#TGX)?$+1/$^F^%K32=,URT^'6L:3K5[H4$EK
M+=ZC9>?8_IK&244GJ1G).<Y).<@D<]<*2@Z(S* 3^&OQW\"_M2_$E_VEO$?P
M*O;KQ!\,_B'^Q%^SUX-\<6_QU_96\>VGQP^._A[^T?VC-)^*&G?#RSU'Q%\
M/!O@G]H*S^'GB?4]9L_AYX\^!>L>'=7^(7B#P'H&N>&?AIX2U-KQ_P!G_ $N
MES>!?!LNB1>((=&D\+:"VE1>+='UGP]XJCT\Z7:_8T\3:#XBTW1]?T7Q"MOY
M8UK2M;TG3-6T_4A<VNHV%I=Q30( ==1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 -+J"0<\=?E;'0'KC'0\<\G('((#//BR5W<J0"-K=3CH=
MN#U&<$XR,XS4,TD:2%68@E-[?+D !D4\Y') 'RGH2&!&<-^07_!4W_@HSIO[
M)'@:3X;_  VU2RU']H+QOI5Q'H\*1V]X/AYH]V)+8^-M6M)P;<WR;9%\-V5_
MBT:[1]7OX+RSL8[&_P#%XBS[+N&LHQF<9IB(X7"X6ES*<USRJUIWCA\-0I*4
M9XC%8NM'ZOA<-3:G4GS2<H0IR9]IX=^'W%7BCQCD_ _!^62S#/,ZKPA0C*I[
M'"8'"JK".*S3,\3[.I#!Y7@\/[7$XC%U>2,536'A&IB*V'I5_&_^"HW_  5A
ME_9QUL_ S]G2\T+6?C $63QQXHN8HM6M/A]'=0(+30M,L9%GM;OQI.DD5Y>&
M]M;[3]%L)$M+C2M1U*^F?0/G/_@F_P#\%D_&7B_XAZ;\'OVO-=T2_B\67$&G
M>#?BY'H^E>&I;7Q%>3LUGH_BJUT6UL- CT35HVM[>PUC3["U>SO9K*359+W2
M]1FOO#_Q]_P3#_8"3]J;Q%XD_::_:9:]D^ WAC5-2U.^F\3ZEJ-M_P +2\9K
M++>7US?:E<W N[K0M'N6GN?%&LS3,^IZD(-$CN;F];Q%!IWN_P#P5!_X)J?#
MK1_ ;?M5_L?:/:Q^"]#MFA^*/@KP[+<7-CI%K;2B&3QMHL,_^GV5KIX$=MXM
MT=6CM[*%(-;$%I"->GF_EV?&GB1CL9#CG+\XR^.#E2Q>;8#P^_M;#4<TS#@S
M 8[ZKC.)%E,XRQ^(P>7NI&CB*E*"J5:E#$3H1Y9X6-3_ %%_XA]]#_AET?HI
MYUA99QQMF&!>69YXX4<DHQI9)XK8ZA"KDF2PXJQ57ZQDM?VZE@GPAA/;Y'4H
MXC+L#FN+Q.=X[$XC+_ZMK::$1!5P I<@(LC(06+YC;;AP58.=F0%.<*O F:X
MB4 DL 2H_P!7(3ENF0$R!V8D *>&(/%?SM?\$?/^"E(^)FFZ5^RQ\>/$ ?XA
M:+9K8?"?QGK-P7N?&^D6AN63P9KE[<N\DOBW1;&V,>D3RSW%[XATVTN;:]>+
M6M)74/$']"V4"H[$!HF\L$>;M[J Q5<EBH4D8VMG>"Z%6/\ 3'"W%66<89/A
MLWRBI&K&JH1Q=",XSJY?7]G%U*->FFI*?/?V--VE4I2A54K*2/\ -/Q>\).+
M?!3CG-N ^*\-36*P,Y5,GS3+Z56ME'$.33G..6YWE&(<:4*^#QRI5*4Z49<V
M QE#&Y?B90QF!JTJNFCK(NY22,L,D%>58JW# 'A@1G&#U&00:=4<3*Z!EZ$M
M^89@3[Y(//0]1P:DKZ3TT7K?\5H_5'YBFI)2C\+5U?>S^2\^B] HHHH&%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH'+\QDJX8GY5/S;(SYB N*<'4 #.,'!ST!)  +8P&)9<*<$@@@$<TI=  2V
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M$8( X.63;*O_ "S=2SY?YB8R&!! (QSE6QAAC.4Y&7'R@9)( .%WKD G!)P
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MOA9XVT'Q%\._$/A3]A::.\GO&\":[=>*]!F^%/@:SMM:\1K-;:QXA>WGOKD
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ME&6)U;H"W!RIQ^BW_!4;_D%?"/\ [#'BO_TB\.U^=7[-?_)P'P=_[*'X:_\
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MDT@MMK+>3>OQ<S4G?S4HP<9*THJ"C%\DIQE&@*Q@!2I ("D@D<G!)R0>.?\
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M* LDD@W[@#\JOV-OAW^U/^SI\3])\#?&+X9_#^Q\!?%+X;:7%XA\=?"OXO\
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MVW2YVSKT:5.5:M6ITJ,;N=7$3IX:$+;ZUJM/F2_F]U/=+6QK;USC//T)'KU
MQ^M!=1U8#MSQU&>,]?P^G6OF/Q3^U[^SAX3=HM5^*?AR^E4L!#X?-[XLE>1
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX6^-GQ*^!NM^*]<\<Z!H'AG2/&.@:QXEE>Y\0:?:ZG+H27.DW-[OGGEA4:O
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MMRY;&W:$8D':-KC/(PW*M[X[ _7YT^$_[4_P;^+ZPP^&_%MO9:PX7/AO6_\
MB3:[%(6(\I;:Y8PZ@  &\[2KB^@"LH=XY=\,?T6CQ2$/')G()&Q]RD#@Y !S
MW&?E&>.O%?"XG"XK!3='$86K1K1DU*,J<HJ,HNTHRG-<DM;IRC==G:S/Z6RG
M.\IS_!TL?DF;Y?G>#<G?$9=BL-BJ"C42<:-5T76INI24HQ46J-6+6LKWM91A
M@ DDY/4<\D^G'X]^IYJ2H(@H3=AN"Q(PQ()8G[N-Q/.1QT.0.E3@YZ?Y_P ]
MZYW>[NK/JM[/JK]3U[65E=65DI7OIT=W)W[WDWYO<****0_7<**** "BBB@
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &>8FYER=R %OE; !
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP50S$L$0':$K]UP.$PV74%AL#16&PW(HRI)13J)*UZS44Y3EJYM.-Y-NR/\
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M3\0WFISZ<MM>ZU:MH^EQJ+F.R&LWB7VL>)+G3-<C%OHEW!IMS=-)]Q1KL14
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M--J<>5J:;3M<_!/XT_L/>*_!TESJ7@U3J&FQM)(-/;<[L0N\+#*SKM.,D[B
M&RHX&*^$=2TS4=+O)M/U2SN;.^A8B6"ZA=)$9<;U1YWD,RC/#10( I !< .W
M]9-W:07@DCN(5E084*^TJ2R\G!Z8YZYY]B2/D/XW_LD^!_B?937"Z=%;:H@D
M:WO8$\FXADV<M&\84RJ6&2),8Z<@"OT+A_C_ !>$C2P>=.6-H4YQ4,55AS8J
M-.-E&FJBFJ;IQBDDI4F[;NY_*OBC]%KAGBE8G-^!XX?A'/J="O.K@H153(<Y
MJ5*DJO*J5/#QQ&2XRS^KT7@<3+"*+4JV'C4YJA_/)VWC+!0%4;Y&(#.5F6)1
ME4)7+NSE1N++D'Y0I !(!!4$JF,#Y <)G'&X(%#?[6>E>_?&+]G;QS\(;^=[
MZSN-3T)79(M7@@9C;[@'07JQ;EB #[?-<*A50S/N)QX ?EQGIP-V,*3@<AON
MG.<@@D-G(R"*_9,OS'!9Q26,RNM3G2<8SJ4$XJK#F2DX**:2<;\MN7H?P#Q5
MPEQ#P5FM3).)LLQ.3XRG.;5:?-6HU80G**A0Q<54I8R$E'2&&E6G"+7MI1?,
MT5HZ3JVIZ#J5EK&C7]WI>IZ=.MU97]E,]O>6=TA&R:UDA=-Q*@)(974%1LDC
MNH L(SOS'U!!_(X//;U'(XHKMG&-:E.E4BY4ZT7&I3J*,N:FU_"E&47%67NN
M48QGUYKZGA8?$XC"UJ.(P>(J8>K0JJO1J46HN,XR4X25G9)22FHQDDYI3<G)
M6/V1_9;_ &Y;?Q+)9^!?BK/;6&O2%;;3O$)*P:=K+Y8K%>L$$=EJ;QLBF15M
MK:=E\U8X1((D_4:RN[:\MX9[>9)HG"D,K;@ ZJZ*6R0<HP93DJZL'4E6!K^2
MCG*DD$#=@\K(G&5$;IADR^6\]3YR$[5!0"OT<_96_;4U7P5<:;X)^)M_-?\
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M/(((YY'/0X/Y'@^] !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M-M0^9;>WU2_N/[-TLS':UIHN@Z:MAH^BV@927L]+TVV4R[YW@$DCLWDR[E)
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M #]"?-CYPP."RD+ECN5=S)M7)\P+SY>-^ <+P:%EB8X616( )VD' 9BJDD9
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MLUX^&/!;_#M]0DU"YMO%7AK2M3U^S /T9WKSST)'0]00I XY.XA0!DD\#)!
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M12T44%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<6UQ9:'+#;&TD26X5KC#@'PW^RI\/OVB?@%^VI^TKX;^+,V@?$3P9^U!X/\
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M\;0> /'=I^T=IWBG4?%=WX(\/P:3^Q+^VIXITCQGXIT[3M4UF?1OA_XG\)?
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MLM.NV32=6GT[5\6% 'MX.1GUYHKSCX6_%KX?_&?PM+XS^&NOCQ)X:A\6>/?
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MSF@!#U/.?< *#[A1PH/4*.%&%[4444 ?H!_SBP_[R ?^^Z5^?P("C)QQWXZ
M$GZ8(YZ$Y )(('Z _P#.+#_O(!_[[I7Y_+C='G:0RH'#=##'YCN#Z R-$C2'
M"J74,1D4 +@G&.=S!!CG+,P55&,Y)=HT'J\L*#YIX0Y_B0?4$'!!'4$$$$'D
M$$$ @BOJ/P9\/]#U"/X5:%<?#>Y\4:?\1;!;CQ)\3UN_%"77A3'B&]T_6VT
M:;JFE^$-/TOP!86B:GXDM?'NFZG%&8M>U&ZOM.T2_P!/FM_EUD".8P\<A#.@
M:(DJQ3DJH:*!U(!PL3P12 AHQ$&1E  8.5'\3YV+D;G X)5<[F /&5!&0PSE
M6P@^;&,?,5 !(#$L5 PI(;&77)QA<Y8@ X]:^'V@Z=+X8\<^,[GPDWC^\\)7
M/A6&/PC+=:U;:.NGZZ==.H>+?$<7A=K3Q-<Z-H$ND:=I$QT_5=,@BU7Q7X>:
MXNF02:=J=+XI>&-/\-:MI'V*QO\ PZVM^$]$\1ZCX1U*5[B\\&:AK+W"MIDK
MW ^W0:=J]A:V'BGPS;W\MW?V_AG7=(M[S4=3O(;B^G /,E.<$="J,.W#21$'
M!Y&00>>:_0#_ (*E ']NOXZ!BQ7;\-?E&7(9O@Y\/DDV1EXX]TL;)&KNX*-\
M^0!FO@'&&8;=N,87KM'FQ;0#W 7 !'!'()!!K[^_X*D_\GV?'/\ [IG_ .J@
M^'- &?\ \%,B6_;9^,3'&6L?A0S8! W-\%OATS  LVU020J[B%&%!P!7P?7W
M?_P4Q_Y/7^,/_7A\)_\ U2WPZKX0H ^T?V%?C->_";XV:1;_ &J2'1O%L\.E
MWB L4BU&,JUA?!%R2P226RP%)=KE,9$;%?[ _!FOP^(] T[4X9/,2YM8GSN#
M$,5^897@CNK*2I&"":_@WT^^N=,O['4K.=K>]TZ[@OK25"0T<UC(EQ;R9'($
M=R49AG++P <$#^PG]AOXC)XX^%VA3B7S%.GV$D 9F++!<6RR1 [@#E58*<_-
ME>0* /NH8(!'(P,'U%+2#H/;C\N#2T %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4A('4@?7^7N?:EIAR6_P!D9'0$@[20ZYSR/N[<$]\;30!^;O\ P4\_:5N/
MV?OV?;W2?#5]]C^(7Q:N;KP;X9F@=%O-+T9;19/&/B.!2"QDL-+GBT>RE0K/
M::MKVGWT?RV<CI_)& 0 #C*@+P" =HQD!OF (&1GG!YK])/^"J?QDF^*G[6'
MB70+>>5O#WPCTVT^'FF6ZNK0MJMJ#JOBZ:5 Q%O>R^([Z?1M1>W#"6V\-:8
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MFDTWPCJ5J+=88(TC1YISX;XB^)W[%WA+4'\2R+\7?VJ_'T4;M#K?Q1\03_\
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M_$,WAK2=6T#PKK^KZ;M>%_VZO@]XOM/A1#:Z#\1M*U[XI?'7Q3^S/JO@G6-
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M/B#PWK M$U/PYKFL:/>66H7'M0((R#D<_F#@CV((((Z@@@\T +1110 4444
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M^_3BOZE/^"S<<[_LH^&WB8A+;XU^#IKC X,<GACQU;1 CJP%S-$^!DJ55B
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MX4M?%'C2ST^>UEB,UEKO@OQ;X(UW1?GU"&\M[TV&IZ< ;'[7G@_Q;\1?C_\
MLW_#6SM]"LU\3_#+X9_#;X8O;W%Y-;Q:=J7Q(\<:%;QZW)?16M[:FT\:R^)]
M$@NKRVMM??0])T6ZUS2=+\1ZMK&BZ9-\0_V-?@R-'^-&A_ ;XR^)?B'\7OV:
M=-O-4^)OA+Q'X'M/#NG^)-(\.7ZZ7\0-;^&M[9W,M]'%X*OUM?[8T^]A:WU
MQ3'3+BYBN(0T7[=^N7VA?$3]ECQAX?6S\+:\G[-WP^\=VD^AVPTZ&Q\5ZO\
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MXGF^&>M>$IM8EM-(?4;BYN=(TV6Q]E\<?L]?!WXE?!.^_9S\7^"[+5?@M?\
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MNT?PZQ)9FQ@.Q=0>-J2$O&IS_=1E'X4 ?HI\(F?]I/\ 9#^)'P)OI$O?B/\
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MP(*V%N"#[*:_DY_8*\*S:S\08[K8=DVLZ=9A\ A8[ /<OMY&X2/>.&*Y&;<
MG)7/]<?A:T-EH.F0=UM(/R**?7MD]>>* .AKY<_;9\+^._&G[('[4G@_X76^
MH7GQ&\6?L_?%_P /^";'2IQ;ZSJ'B?5_A_K]AH^GZ'<22Q):ZQ>WDL5IIL_G
M6ZVM[<17GG1^7(7^HZKS1%SD .O&Z/.TN <XST;:,E(W(A9MPD!WB2( _/\
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MD]-O3T)4ESPYVHTXQK5:S?2G24FH1=[1J3LIQ<DX\B=UJFOXP>. .@  /J
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ME_TCK_\ -N_C%_\ *2@#\_PRC<2R@*H8DD#"B1"7.3]Q0IWO]Q.-S D9^_\
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M^-OQI^PS\;/"4\B)I]IJEO$S*K(EU9SNH (W1[/L\9'1525U"@9;.37BEW\
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MX"L21D EHI%8, RG(.>Q!!!P00<$,""&4@%2"" 012T %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444W<N=N?FZXP<XQG
M.,?=[;NF[Y<[N* '4QI$0@,P7(8\Y "HNYF)Z*B@C<Y(4,54G<R@AD13AF53
ME!\QP"SDA%!. 68@@*"6Z<<C/GWQ)\<VWP]\+WGBB3PSXU\8SB;3[#3O#7P_
M\,7WBKQ3K&H7]RMGIUI9:? BV.FP&\NHQ>Z_XBN](\-Z- [W6OZQIME']H !
MZ 98P=N]=V&.T$%L(55R .2(RRB0C[FY=^-PSY%;?&?P1K7Q*UWX2>%KV_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !D9(].OXT4$X!/H,U%YASC [=C_$<#]?R[X% M7M;SO<_-;_@I
MCXR.E?"WPIX,@G:"Y\7>+EN[D $+-I/ANQ$\ZL2-K;-5U319@H;<WDG:K!&*
M?B,=N?D!5.-BD %4 ^1>./E7 R.H&>]?HY_P4P\3RZI\9/"WAA)%DMO"W@FW
MNFA))6/4O$6JS-<#;CB7[#9:6Y;[I210&RCA?SC. <*2RCA2>I X!^F.@[#
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M?ZI?6FFV%LADN;W4+B*RL[>,=7GNKEHH(5'K)(H[]* +FX9(SDC (')&1D9
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M$I83&:N4G[M:C97;:=^:Y<!!&1TY_0X/ZTM-3[H_'^9S3J\@^_5^N_4****
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ME\25GZWE_P  ****"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M (1?B3_Y6UK_ /"^_CG_ -%H^+/_ (<CQG_\NZ/^%]_'/_HM'Q9_\.1XS_\
MEW0!D?\ "H_BM_T3'XA?^$7XD_\ E;1_PJ/XK?\ 1,?B%_X1?B3_ .5M:_\
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M-V3O'/((;(((!!!! ((IU !1110 4444 %%%% !1110 4444 %%%% !1110
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M)!J-E9WUQ?\ _"/Z?<6URB20A(+J[U:*SE6-K)/$%S:/#&\"Q)]Z'D$992>
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M2U?1M7\/ZC=Z1KNF7VDZK83-!?:?J%M+;WMO, &8W*2(K2LX82/?*HM[TO\
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4TJ#VIU%
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ME6/IC.!@G))X&*]W.<73P.4X_&<RYH86O0HJ7P-U(2BW*UFY*^C4EKT9^?<
MY#4XHXUX4X>IJM*6:<0Y11Q$J=N>%*-?"8J<XMPE&*674*DZCG&2]HN;2-XG
M[>?\$_O"HTOP3'J#Q[6N$2125&3N5B2",\$D]<?2OT@7H/H/Y5\Z_LS>&%\-
M_#70X @1C9P%A@ _ZLYSC_;R/?&02"*^BAP!]!7\K*3E[SU<KR;[MMM_F?[3
M2MS-1C&$5[L8P5HQC!1IQ45T2C3C9>;Z6LM%%% @HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3M/ R>G'(RZJLSJN\LVWRU+[G12J'&0T9;:FY51RVYB8\AY L3 L 3F1!G+
M8*J2> &<J$0DX =BZA4)W$LN!\PR\'(!YY&>00>?4'!!]B 1WK\T/#O[:OQY
M\6>"M(_:#\+_ +)-AXT_9<U[Q)+!I.K^ ?C-K_C3]J:[\"'Q;<>!Q\2M/_9E
MT+X&77A75-.CU"-?%FH^%]&_:&O/'MC\-9)]6N/#"^/[6Y^& ^Q_&?[1G[/W
MPS\:^#?AE\2_CK\'OA]\3/B$^F1>!/A[XY^)?@KPAXY\:W&M:K_86DP>$?"&
MO:Y8Z]XAEU+72-#TZ#1[*_DN]6VZ9 9[TB-@#VBBO(O%G[0/P&\ ^/\ P?\
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M0C(/8FOP=*R2NW9+5N[>F[>EWKKH?Z8;]GZ;?KMMONF+129'OW/((Z<=Q_\
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MY'/:W4,<\3H #8HJ/S8\;MZA=C2;B=JF-?O2!C@%!D$N"5 93G#*3)_G_/\
MGGM0 4444 %%%-+*#C//'RCEL$@9P,G&2,MC ')( )H =29'/?'! !)&>>0,
MGIS]*@N+NUM()KF[N(+6VMHGGN+FYE2"W@@C4O)/--*4BCA106>5V5% )+
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M_B%Q8)( ?AQ^WZOC[XJ_&#]J_P"-VAZQX>\$?!;]BCPGX ^!G[8?P+FUG_A
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M_:'XEW=G(P7Q)XUM)!,/#EXR;#+HO@B;RY[BT#F2;QE%)'<1K_8EM*GXI#D
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M'@J0"I!! ((H&<G)X[#TX_J>M'K]T<G.TY&[)W=55@Q;.Y759%;*RJL@8 H
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M7*X'0 $D  'D&K] !1110 45X'\6OVK?V7?@%K&F>'OCM^TE\ _@KK^M:?\
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MB2**)0$1$14C"X4+B@"U13#(@)4M@A2Q# K\JMM9@2 "%.-Q&0H9&;"NA9]
M!7RE^VC\?(_V;OV>?'_Q(@N(X?$BV,?AKP)&Z+,TWC;Q&);'1YC!*#!/!I ,
MWB*X@E*">UT6ZA!9Y$1_JW/]/U.!_GMU/%?SJ?\ !;3XKW-]XU^$GP2LKG%A
MH.@77Q,UF%3NAFUG7;^\\/>&1<#[OG:;8Z-KLB!SA;;7RYVAT9@#\,KR\N]1
MO+O4;^>:ZO\ 4;JYU"_NKB5I[BYO;V=[J[N+BXD)EN;B:XEDEGNI\7%S*SSW
M(6>2117I %&0F_8"P3S,&38&(7S""09-H'F,"0SY8$@YI: /LW_@GQ:Z9/\
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M?^'L_:"_^;VC_A>O[,G_ $8Q\//_  ]G[07_ ,WE>?\ _#)_[4W_ $;5\?\
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M%E_XH\4VUA92QZ?'HWA2VTC0?#>DV.GM;V,%E'$=0FECO]90:A&]U< 'B/\
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MWM[IC);H1;J'!(!\P?M/_M)?M&? ;]C;X^?$WXH?#GX6?#_XOQZ1;>!?V?\
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MBF_\5_%WQK^)'[5EQ)X'_9E\*_'SQ]8?%OX)_P#!3+P7\(_"GQHO)K'P_?\
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M\)3?"R3XGV7[!=[/X\\0^(]!\.WME<^/+VR@U'PA:^-;G6+F[E2*99I/U.\
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M;/P_XKT>VT_P-'XY'AO_ (3W5+:TT:V^R<C^S%XR^%,7Q^^&&A^ /BU^VQ\
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M\:Z'JFL:#IMTEKJG@?XD6%K\/_CMX T758Y_[.M-?\,37*VNOZ&7M?6_%7[
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MU.Q\.Z?9>$?"FA^#=)@TRUUG6-?U.*,:1X?L6F^UZM=O)<M/*GD1.EM#Y90
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MC!^S/&=IPR_==0X*C^C*%/+BC0'(5% XQP!QQ[#BORG_ ."=WPY;1/#G]K/
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M:?#OP;\9/AOXATK0[2_O_A9<_$OXV?'#2=*L[.+1?B)%X[OKO_A.]-XO2?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN\2?LL?L0^,KQHU$NI>)OV?+:[NII\ W,P^R>(;"-5NI]]PP\I?GD.8EZ#X
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M/_;9LT_:"TN2'P%<^,[#Q\OA.6U^"*Z5;^#D@MY?'UA?^3^L\0Q&JX VY4@
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MW2)+K0Q/);Z9XLTVU;^R;Q0%: W)5YCIU[+$R&6PNBC)-Y@M6N;3R+B7YXR
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MM[H_3.9:6YI)_:]G*,5?K?6+7FG9[JZ)****I:I.S7D]UY/S*"BBB@ HHHH
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M@LWFS#2A_P 3+1FRH(A6VF\MK*,L"52T\V* '9"J(JHO]#_3)Y/3C/\ +/\
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M\!3R%E14.>0"&XP,?-A<Y S]T8SCMDW=-_8"^'UK('FC#*".%QN< ]'&P#'
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M+2Q"<8R^3OA_\+/%_P 3-2@L=(TZ>.SG*!KGRGY+-@ DE0,KR#V_B(-?LO\
ML\_L:Z!X(MK75-=M([G4=L;G> 65@[$LV20.@ YR>" 1@U]2?"_X(>$?AQIT
M$&F:?;K.JH'E"J3E"<E3M.#GCKZY]_;54* % 51Q@?ISGZ=J_$\XS?'9YB7B
M,PK.LE.4J5%.2H4HMMQITX.3:IP348*4I-123;>I_H=P7P)PSP!E$,GX9R^E
M@Z?[N6)Q[ITYYIF-6,(QG6S'&2H4ZV*E5:E*-*K"%#"*;IX/#8>G&$8YUA80
MV,*06UN((XE"( 5^ZG ^[[<#IC'XU>"D8(7&.V1C'/0YX]A_.I:*\W3I%+TT
MLNR\O(^N4(QT@N2/6$;\K;W;NV[O=N^O6XT<#&,?D?ZY]O\ &JUU9V]XC17$
M*RH_)W '!QCH?:K=%(I*RLMEL?-?Q*_9E^'OQ"MKB/4-'LG:XW"0R01LK!U"
MDLJ^7N&>TC2#T  "C\U_B;_P2G\#ZI+/=Z#I4%G)N9T-A,^G<E1\R0V:F$$G
MJ"@+L2TA9V8M^W>.2<GGMV%(5!/('UR<_E_]>@#^9#7_ /@E9KMI*_V.?7BB
MDX5;K3Y, @-C=-I4LC#)P-\C$#@;0 HY*'_@F)XL\T KKTR X*27-G&.3SS%
MIJ#!YX"CWSR3_4N]O$Y):)6SC.2W.!@<=*8+.W'2WB'^?I0!_.%X2_X)@7[2
MQFYTK<Q8'=>W,\[$!NK1NRV@P. %M(\@ L'<M(_VS\-?^"<_A_1!;MJ4=M"B
ME6,-M!%;CAR2"UO%&7R<D[HD!)/+?>;]:5B1/NQHOT__ &:E/T)_+^I% 'AO
M@+X"^!O D40T[1[5940 R;%+9#$Y&5SDDY)/).2:]LA@BMT$<*[$' 50 !^E
M344 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110!&4R>XR0201@X&.1^GZ_6C<V$5XKQW,1EC;.4D
M*,#G.0.3CKCISW/2M*BC1JS2EV;W6O1JS7KOYBLTVTVN96FM&II*R3NFU9:)
MQ<7YL^./C/\ LE>!OB7:3S_V;%::B!(R742K#<HVWY3')"<,.%R)&X QTQ7Y
M$?%G]D[XA?#BYGGL[:77-+21C&88P)HX=JL3(N\(S [ON%F./F&XFOZ.R 6(
MR>1R/IC'U/<8'_U\;5-#TO6()+>^M(+B.1&0K*B\JPQQD8Z?0^W:OH<FXFS7
M))Q6&Q51X713PM1RE0FK+2:4E.UM/C5S\O\ $#PBX)\1\+.EGF5TJ&914EAL
MWP*IX',H2UY95,=0I+$XE7U=/$SKTY._/!IZ_P G$T,]O.]O<Q30SH7WQ3Q-
M#(NTD$,KA2,?PY^\N&7(()A!!Y'/(7@$\GD#]?H.]?OU\8?V+O OCJ"XNK"Q
MAL=0&YDEB41.C;% ;,>&?)' D^F, $_EW\3OV0_B/X#DGGL;9]8L(R[+MA43
M[%P5#$/L;"G"E26V@;\-N _5LE\0\IS"4<-C(/+\191527NX5RLDW!2;DJ;>
ML$ZC:C:[;U/X?X_^BQQOPPZ^.X8JT.+<GI<]25*BX87.</3O*4*,Z55PP6-G
M3A:$JF$J1KU9)RC@:;DJ2^2O_KC\N#15R]TW4-+E:WU&RGL9U)W17$;QD'.3
MCS ,YSN&">"".,54P>.#STX/?U]/QQ7WE"='$15:%6C6H))N<*D:RJ)ZJ<*=
M*2E&,EK&,KR2T;;U/YHQF"Q^ KSPV8X/$9=B:=25*>$QF$JTJT*E.3A.G*GC
M*%).<))QE=1U3T0E!YQN (0'!Y63!SF.,@;2I/S,)2!DD#BEVG./7I@@C\P<
M?K25O*2@DZ<Y^RGJDTKPC+5)1DFXVO;EE=K9ZIG-*%XVISI*,)-U:5.E"E5<
MT_?3Y-$[WNHIQ3V%C/ELK1D1$,)"8HQ QP<A-\4GF"53@K)%); $<DG+GW7P
M7^TS\=_  CB\-_$[Q0MI"%6+3=8NU\1:7'$I)$$5AXA36(;5!G:?L LV8Y<R
M-(S2-X317%B<!@,:K8K"4,1'?][3C)N_5V2]YWU:2W>QZ^4Y_GF18J..R3.,
MWR;%1MR5<LS+'8&:2U4:D:&(]C72LKQK8>2?4_2+P=_P4L^*FE&&+QEX1\*^
M++:/"M-ISWOAK4W!8EI))"^LV$KC=A5AL[%-JJ"-Q9C],>&_^"F/PFOQ'%XE
M\(>-O#TTA DEM(=+UVQA))Y,W]HVM\Z*NTMLT[<&W*B,%5F_$6BOF<7P'PSB
MVY+ ?59R;;GA*DZ;O)W;M+VD=^G+9;)6T/V')/I)^,&3N"K<30SRE",8QHYW
MEN Q,>2"2BIU<-1P>(J.R7-4J595)N\IR<FV?T=^&_VU/V:/$2HMO\3=)TZ;
MCS(=?LM8T)H68G"R3:IIEK:9Q@YBN)$"D'?7L^A_%_X4^)BJ^'OB1X'UMW^Y
M'I?BC1KV5CDC"PV]X\K'(*X"$Y&#S7\KIS@8)R.!\[A0"22"OS(<^R#KSS0<
M'*@84]1D,N<#/RA8^"<GCGWSR? Q'AEE4V_JN<5L.[N\<7"-2,=?A4H4J;=M
MN:[ON?I^6?3&XMP\8?VOPAD&:)1BG_9^,QF33DTE>5\5/'44WO:$5!;1T2/Z
MWEOK1L;9T;/3:&.<],8'>I1/"W1P<=>O'UXX_&OY+['6=7TSG3=4U'3F4Y1K
M&]N+,KSG*_9Y%9<GYC^].6)(QG [.R^,'Q;TQ!'IOQ2^(VGH!@1V'C;Q+9QX
MSDX6WU6+;\Q).T_>.X<FO-J^%U>*?LL\P4OY7*A6L^ST:T:['V.$^F;EM3E6
M+X#QT)67M(9?GV"QTX2M[T+5<+A(N47=-J;B[:/J?U/":-ONMO'/*!G'!P>5
M!'!X/H>.M*)$.1N (Z@Y4CZAL$9R,9Z@Y'%?RY0_'GXX02K+'\8?B@'')\[Q
MYXJN5..F?M>L70;C^]&0,[0-H%6KK]H/X[WC1M-\8/B>N,@"Q\<>(K5I".S"
MVOH(RP4 [4B#E<,P8DNW*_##,GK3S;+ZJ7Q*-'$73ZK?H>A_Q.9PDERSX/X@
MC6<W"-.&/RBHUK9*M::C1FMIPE4DX2NG)VN?U!&6,=6 ^N1_3K[=:C-W;KUD
MX]0KD<<=0I'ZU_+;/\;?C/=*8I_B]\3[E,++]GG\?>+)N6:14F,9U5W>)6B=
M&VPD!T8'/!;EM0\:>,=5+#5/%OB74MQ;S3>Z[JE\DC9(+>9<7SM(&/()BP%P
MJEE 8]%+PNQ/-&-;.J"<];4LOQ,U%/9.;JZM;-V2>Z2OIRXSZ963TY3A@N!L
MPQ,XPYO9XG/LMPLG*VUZ='%)KI=7^X_JCU7Q9X7T& W.N>(=&T:W ):;5M2M
M-.B4!68EGO)85 "HS$D@8&>XSY-K7[4'[/.@HTFH?&#P(YC+ Q:;KEMK5QN7
M[P%KHQO[@L,'@1$YX )K^9 DLV]R7D).6<[V(+("3(^YF/EO)U&1MP,Y7* 8
MP<*K-R75064D9(W@1,>?PQQGC->C2\+L%3E_M>>^T2=G##4'"HGV:G&IRM=4
MT[/2Y\CC_IH9U5IM9;P3E66U'M+,<VQ.;*/E*E@*&";:V=IK;0_>[Q3_ ,%$
MOV>M%DD&CW?BKQCEMH?P[X>GLT!50K!I?%,F@94,"I:*&494E-RD,WSIXI_X
M*=W.)K?P+\+H(L[C!JGBS7FF8$@8\S2=(TZ-D8,6!"ZU,KJ%.Z(DHGY._B3[
MG.?QR[G_ ,>/X#@%>WA?#WAG#M2G0K8Y:/\ VJJ^2>GQ2A2A2^+>S>CZ:6/S
MC.OI1^+6;*<<)FV5Y+0FY-1RK)L,ZBA)MI4\3FCQV,HI)I1]G.G.*2V:/L7Q
M?^W?^T?XK$T4/BO3_"-I<#;):^#]"M+%]NU4P=6U.XU7786(7>7L=1M?F8[5
M50JCY6\1>*/$_BR^.I^*?$>N^)=1^9!?:]J=WK5VD3]5M[C4)FE@"C"*(9+?
M:BA"9-OF-AT5]1A,HRG V^IY9@Z%DDG"EK9:*[DY-VMU;/QS/^,N+>*)\_$'
M$V>YNE)RC1Q^:8W$8>GS-MQI89UJ5"E35[1IPIN,8VBFTD*,#/0AEVG:&$C+
MT&]G>3D  -B1BQ!.[FDR3U ' ''3 &!^. ,^^:**].SG!QBHQCL[)*WDK6LE
MLKW/FU-)RJPE##<L>27,O<G96<G2;]G/FW]^,[]6];E%+CUX]"> ?H3P?P)I
M.@W'Y5]6^4?ANQGIVK']U3IRJ<T/<NI3F_8SNMW"I4ER-76DDFGNBJ<95U22
MPZQ&(J34,.Z%"A4KS3=H.CAZ%.A*3>C5*BJU974>1RW4#/3D^@Y(^H'(_*DP
M1G((QU)! _/I4EM;W6H2)!I]I=7\KN$"VT?RHS$;2SC!<$GG;G&<=J^DOAQ^
MRG\1OB!<0-<6LUA9.R,P:-E4QDD8!9@22,ENG)(]*^3SCC7)<H@TZTL;B=4J
M.#<<1&$E=.&)Q$+0IU(O2I:#2:?0_=> OH[^(G'$Z.*J8%<.Y+.4'5S//*>(
MPE3V,[25:AEDZ4<TG*4)<RCB,+0PZ;2>(M>1\SQ[[B9;:TAFNKE^%CMU+8)(
M WG&T@\< DX]"#7T=\*OV8?'_P 2;N!I[&:QL&VEMT>Q6C+D<8<<D DD=^O-
M?J=\'?V(?"/@^."[UJ"*[O!M=@Z"3:0Q8X8[AG@<$_\ UONG0O#&BZ!;K;:9
M86]ND:!5V1JIPO3H.,]?Q[5^2YUQMG.;\].E6_L_"2E*U#!RFN>FV^7V\YRF
MJE3E:YYPC3C*5W&,4[+^X/#GZ// 7 $J>85,'3XESZC&')G.<TZ&+HQK02YJ
M^6Y9*$\!A*<YISH2E#$8F$'%3Q56:=1_'WP4_8\\(> +>VO+ZQBN;Y45CYBH
MQW;F8GYB67#$#G'J 5Y/VE8:7::;;K;6=NEO$H"A(ML:A1Q_".A!)(QU/TQI
M]L=.,>N* ,#&<^]?(W:OR^[SMRJ6N_:2>LI3<G)MR=Y2M9-O:VA^[**?+)I.
MHMJKC%U(IV:IQERKEI0MRTZ27LZ<4HTXPBDDBC:H&,=>/J2?\_K3J**10444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 PCDD=>/
M3![8_P <_A3=I)^X1]&&/RY(J6BA.U^M^XFHR^**EVO?3TLT1!.2<-R.>0>?
M;MT'7&>V<5G7^CV6IQF*^@2XB92I1T0\'/J"!U/0D^M:U%)I25I>]O:Z6B[*
MR6W1WOYE)N+NG;3EZ/1*RW3L[=4D_.^I\I?$G]E3X>^.XI'FTJVBN#D!_*C!
M.5QN#H-X(Q_%WY' %?G?\3?V -<TAIKSPG<EX5+.MNY\P%< A1E^F0<#MG'8
MU^WM1O$DF0Z*X(QR,Y'?/]/PZ5Z67YOF6534\!C*^&:M[L9RE!V[QJ2FODK+
ML?)\3\#<'\:85X7BKAS*,[2CRTL5C,'2_M+#QM9+#9G1C0QU#E7PN-64E9/F
MDU<_EM\5?!KX@^$YG75/#]T\<3$>9#"^S'!W#:Q(Z\\9SDBO,)(Y(7,<T<D,
M@)!CE5T=2#C!615?Z$CD$$9!!K^J_7? GAC7HI8=3TNUG1E(&]!_$.<G:2?0
M5\L>/?V+_ASXN62:VL(+.?DKY2(A)*X!+##<8/TX'3FOO<N\2\9026:86&*C
M9*53#PJ1JS=M9R;J2ASR>LN6"CS-VBEH?S1Q7]$'A;,>>MPIGF8\-U^>;HX7
M&4/[9R]Q<FX1JXY?5L;1BDTKU_KE;E5ZE:K-.<OY]#QU!].A^OI1Z#!YZ<'_
M  XZ=Z_3[QQ_P3TU2S\V?P[>N0I+*C$NA^4' RW0'.>,#IUZ?*7BC]ECXI^&
MY'9M(:\1">84/S*%ZX#\<=A[]^GU^!\1>&L8U&=>M@Y67-&O1F^276+DE%-Q
M>C:T=C^?^(OHN>*>2^UJ9=A\HXLH0G-<^09C"-514FDZN$S2&!Q;J-).4<'2
MQ4%*ZIU*BM)_-W^>>**ZK5/!'BO1G=-1T'4+?82&/V>1EY&[C&Y@,'N/ID8K
MF'BEC.)(I(STQ)&Z'CUWJ,?C7U.'SC*<4HNAF>$<9)2C*;Y;IJ\79R35TT[/
M5;,_'<WX$XUX?YWG?"'$F6QIRE&53%91F-*@W%M-TZZPE=5:=U[M102G&TDD
MFD,HI0,],'Z$8./0YP?P]#Z4 $]!USCMTZ]:]&,_;64,1]:C:T51PD9+EZ<L
MO:7DK;2>ZUZGRKIKK&O!WUC-8AI/JN2M/#\MGI;V=.VSA'X1**3(R1W':EQW
M_J/Y=:M1JWY51J::6:I1M;2W*XMQ:[-MK:[)E&35I1J3BMN>A>-EM9J>UMO>
MEI]I[C))8X8WFF=(88TDDDFF810QQPQ^;-))-(5B2.*,&21W8*B LQ !-?"?
MQ1_X*$_ WP;JK>#/AU'X@_:!^)%Q*;.R\&_"&QF\26XU !CY6H>(;6VGTJ)Y
M0!:2KI$GB._M9$:.;15E0FOMW6M'L]?T76-#U"-WT_6]+O\ 2+Y83''-)::G
M;FTNQ&QMY,.8&VQW!E6:)QA4**,_EKI/[%?Q[_9:U74_$G[&7Q0T#5]&U*[C
MNM7^$_QAT+3)4U1HLNMI:^.+%;2\61<1-:VK2>&$,4:1S:Y)+N:7P,[Q.<TJ
M%-96H*A*LZ>/KT*+KXG#14K5%&C'D<JD/>NTI1;6B:/TGP^P7 N+GG7^M^<4
MZ&)PF'P7^KO#^:8V61<-9GCJ\8<]/.^(L!A<TQ.7PE-I8>A/#X>,TU&OC</>
M52/IGPY'[?'Q@\?>$/&OQ)'A#]G3X1:1K5EK$_PLTTOK_CSQ3IMH\T]O8:_J
M*SSO:!&*VTY>_P!&$"L(KGPLLD4JC]$,8X], 9(/ X'(2,-QCYA&@;[P5<X'
MP!\+?VWM7NO'OAKX,_M!_ SQ[\$/B=XKU.QT/0)TM?\ A(_A[XIU&YD-K"FG
M^(X%MU@EEEC"6Z"/Q+8648$%[K4\D3W,OZ '&?E(*]5(4*=IY4,H50L@7 D7
M8FV0,"B$;1MDLL+*%987,:V/GS2]L\?#'8:O&I]M*/U>-.FU*_N+GC%Z*32N
M<WB-ALYP6.PE+->'LEX:PT:<*644^'(8#&8#$8",5'!SIYQ0S/&U<=1G0]G*
MGCJM:53%0<:\Y.4W9**,@ DE1CKEAD?AG/Z4=1GL._;\^E>QS1HI2<ZM#1/G
MEAE5B_-5).#J)[J;C%R6KBF['P2]NM']:FEHE",;67:=*<Y27:3NWHV%%-9U
M7JRCID9!(SC&0,GN.U/17D.(XYI#D#Y(97Y/3[J&N*OF>64+RK9EAF]Y;0E?
MKS1YVHROO%:)Z'M95PSQ)GU3V>3</9WFDV](X'+<QQE1WVORX.G%MWO=59I]
M)RNFS!/0$T8/ [GMU/?J!R.G?&:Z'3?"/BG5Y FFZ%J%SN*C<8'6/G&,8PY
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M;-+MK2\MW5[>[M5O8KE(+FW:,!&7=@MF-U&,;]C^Q)\5+EUCE7R1P,>5D =
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+ "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>image_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" ($!(8# 2(  A$! Q$!_\0
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M"\.>&O$FBW-EJ^O^+EL[B]L8WG;P[.FIV-[X:]=D^)__  4>_8S_ &X?V/\
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MXLM-!^%VC>)+;PEIGA:'4]&\(:6NLWFH/*B>(=<DM;>TUO7[&&XN=?T[S?\
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M+_X*#?\ !;30O&'@[QQX/^%7[3_[/?[-?PK\%_%'5_"7B&U\%^*A?_L^>)O
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M!O@W7]0O;:*Y\5:-9>)YX_"VH7JE-=DT[4KC2_#^IW^JZ9X6O@#,_:P\?_\
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MF3:IH'B2PT_6+1M0TC4+#5+4W%I%;WMC>6UYI[3:;<V<\O-_L9_#7XD>&/\
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MO$GBF7PQH7AX)X<@T2]O+6RU+XKT/]G!=0_:X_X)H?&K]E3_ ())_%O]C?\
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M@)_P4.^)W[9OQ&_X)VVW_!23]F7]ICX:?#OPOXR\/^#?@MX&^/OQT^ OQ/\
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MM;TSZ1^,/Q(_X*N?\$UO"O@G]K/]J#]K7X4?MB_ 6;QEX&\,?M(?!C2/V?\
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M>2_S=_MY_%_X^^*?V\_VDO@AX;_:[_;(^&/[5W@[3?A#KG_!-7]FG]F<Q/\
M OXPZ%K_ (.CU_Q+K_Q^TK3=$USP]X@BTGQII/B>;QE??&G4O"6B^$/!EI%K
M=@OC3PY'+I6F ']9E%8.A+K!T/1?^$D-E)XB_LG3UUTZ8LHTM]9^QVZZM_9H
MNMLATU[U+A[5)_WYMRCYW?-7YJ_!+QSX\^'W_!2#]MKX(?$'Q[XFUWX>>./A
M1\$/VJ/@?IOBOQ5K-_IO@'PR;/7?A+\7]!\+0>(7\C2=&M?&OA72?%^HV6CW
M']AZ5)XE%TUG!JFH7D]X ?J17PQ^W7^Q!X:_;=\#^ ]%G^)GC_X)?$OX,_$;
M2OB_\%?C)\,YK)/%'P_^(FA6%]9Z=J;V&IV\ECK^AW$=^RZOH+SZ?+J(M;06
MNLZ<UO<";\L_^";7Q[_:(\1?M:P?%?XS?%#X@^*O@?\ \%+/!_Q_^*/[-7@#
MQ'K&L:KX+^$MO^SW\6[G3_ /A_P!I6I:H]KX:A^(?P UJW^(UU9Z3H=@?$36
M$&MWEM#>6MP@]\^"7[9>A_"?P?\ M\_MX_M,?$GXB)\$O$?[7NN?!G]G[P='
M?^,/'.FR>#_@G+IWP)TC3?@O\-+1/(M/%'Q3^+>E>/[O4$\/:;9_VTMA;^(?
M$=XMOHVK:G:@'1^ /^"8OQP\7?&'X0_%O]OG]O[XA?MK1?L^^,;/XF?!GX96
M/P2^'/[-?PLT/XCZ;%*N@>._&7A7X<7.J#QUX@\*7)DU#PM?7]_I3Z+/+<Z?
M,M]H6H7FDWOKO[3/[!'Q$_:L^/O@7Q!\5OVK?%,_['/@KQ'\/OB#<_L5:1\*
M_ ^FZ#XS^(_PYOYM8T+4O&GQB&H2>,_$/@.;7X=.UG5_AQJ^CSZ3<7>GV4FE
MZM975GI4VFV/V7_^"GGPB_:4^+#? G6?@M^U7^RU\:-1\+ZKXV\%?#G]KOX)
MWOP5U[XG^$/#ES:1:SX@^&S?VUXDLO%%IH[WT3:G8QWUOKD-G!?ZJ-!73;'5
M9[3\_/VIO^"KV@_M)?L5?M,:G^RWX$_;&^&L_@KP5H&MQ_M*S^#G^&/PV\/^
M*='^/WP^\#^(/AAHGQG\.>/)X;SXHRV6IS7&I:#X1FU:R7PW>W4>I:O;ZC#?
MZ):@']&"?=';DYX YR<YQQNSG<1P6R1P:=7P;J'[>?P^_P"$M_:)\$?#GX5_
M'[X]S_LJ> YM;^+.O_!/P%I?B[0Q\1+>QBU'_AF[P<]_XMT/6?'O[0\FB/:Z
MQJ?@GPCINM:7X3^WZ?I'C#Q;H7B6Y&@K_.M^R+\?OCS\2_AO\&OVDO$WQC_X
M*0V'Q"^-?_!3K]G#P1\0;'XW^)]>\#_LQZMX&\1?%KXQF\\&_LN^$M"U&SL#
MX*A\/Z=H_@_XUZ#))=^'++Q'H<>AVNDM;6D8H _L;HK\G/CK_P %<_@/\%_B
MK\0/@]X:^!G[8_[2>J_!FZM=*^./BO\ 9=_9\U;XK?#WX'ZC<Z7'K;V7Q)\6
M)KF@0Z1)INBO+K&I+H%MK3646G:C8*PU;1K[2K?Z/^&/[=OP"^,GQ!^!_@?X
M<:EK?B6R_:+_ &?O$'[1GPE\?VEII_\ PA'B;P;X2\0^'/#GBOPX\LFK+XNT
MGX@>%KGQ3I,^LZ!J/A:"STII=0TN^U>W\06-YI4 !]J45^;'A+_@J'^SIXZ_
M9O\ B3^TYX2T?XF:WX0^&WQZA_9MN/"=EH7AA/B+XO\ B/JGCGP9X$\)VW@K
MPY>>-[73M2TSQQ=?$#PCXA\)/J6O:/J%YX5UE=2FTZQE#02?I% _F1(^QDW@
ML49MQ4DDD%@2K8/\2,\9',3O&58@$M%%% $;8W#H.<'G&[".0F/X_O%MN0.O
M<<_#W[/'['3? ?\ :>_;6_:0'Q%_X2H?MC>*/A+XG'@__A$?[!_X5Z?A9X$N
M_!PLO^$@'B/4O^$O;Q$UX=5:5M$\,'3$C33BFH-:MJ%Q]RT4 <YXBL]9U/P_
MK>F:#K<OA?7-0T?4;/1O$L>G66L/X?UB\LYX+'64TJ^,]AJ+:)=-%?G3M2#Z
M=?-''9S2B*1MGP)^Q?\ L,>,/V<_'WQ;^/W[07[1_B3]K_\ :E^,.D^&/!VO
M?&KQ#\//"GPJT[0?AAX$6[F\-?#OP+\./"5_J6A>#M%;5=0N?$7B<Z?K$</B
MWQ%)%K5QI&FWMM<W-Y^CU% #5&% SD8XR ..W "@<<8P,4ZBB@ HHHH ****
M "BBB@ HHHH ^'M,_8Y&E_\ !0GQ9^W@?B+YY\3_ +,7A_\ 9M'PM/A+R1IY
MT;X@MXX'C/\ X3C_ (2C_2S<^8=('AT^$X_*\QKO^V)B5LZ^WTSL7. =HR <
M@<=,\9QTW8&>N!G =10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %>"?M%_ ;P'^TQ\*?&7P8^(]G+<>&_%UFD8N;&5;;5='U:V1;C2=?TFZDBG
MCCU31KZ""Z@66":WEA62WOH+NQN)K27WNJDSE2^W82H.-SJN"5CP,'G^+)YQ
MC']X5ABL-1QF'K83$PC5PV)ISHXFC.*E"O1J1<*E*I%Z2I2C.7M8V=Z:>UKK
MNRO-<QR+,\OSO*,;C,NS7*,9A\RRW'X"K*AB\'C\%4AB,)B</5@U*->CB*5.
MI0Y6I2JI0C?GDG_ U\0_ '[1/_!+G]JVPN+2^?3?$_@S5'UWP3XL@@GA\.?$
M;P=.]TLA:&YG(N=$UO3DGTGQ#HDEXUQ97\EYI\NHP3Q-JH_=KXR_&7X"_M/_
M ++UK^U=X2ELK;5=66#PC\3?AE)<1QZS:_$)[%)Q91S1QP3">V@L9-82_M8E
M2_\ #48\36\=K=6NLQM^FG[<O[%_@']M/X1WW@;Q.\&C>,]&@NM3^&_CF.W$
M]WX1\0O;Y)G1 DMSX:UB2VMK7Q'IB2Q&]M88)X7@U33=(N[/^5S]C_\ 9F_:
ME\,?M7>+_P!ENY^'FH3V5O<6NF_&FRU*XGM/#WA71(Y';0?B1::[)&=,GO-%
M@GE\0>"9X(%G\66U[JUA90R66NZS_9_\+>+'@Y2^JYAX;8K)IY_P-QEF-/&<
M&2H.4LRX7XJA&K6PF/P6)A>OA\5A?]JI8['P][-LBQ$\OJ4JU/#5:4_]=^$/
M%3@;Z27!F4^*'$.;Y;P+XV>!. H9CQK.&)P608/C+P]PM2CB,RH^UQ4Z=&M0
MQM:C"KE:I585>%N-L74P^%FL#Q)AN7ZO_P""?WAK0OB)\4$\!>*=1M-'U'5I
M+F\7Q%<PI;QMHMC"M_JOA:TMY"!'J*6VGW-VDLQ,T9A1KE?+M=05O ?^"I7[
M=UG\?_%.F_LV_ 2[E'[/?PMOX=/M6T>215^)WBNU%Q9R:PT]LYN[CP]I<\LZ
M>'YBR6VI_:)?%5\^I37NB)HOV?\ \%!/V/?B=^RE\"=;\5_ FUO_ !YHNK6-
MSI7Q.\906EK9Z]\.?"LEM9VFJ3Z;HNGEUDTCQ>;F>R\2^*6DDN/#GARWN-)N
ME@T[Q'?:U8VO^".W_!-2)3X?_:[^/>A>8S/%JWP2\$:M!"P99&WV'Q'UZPG)
MC6=ID,_A&SG$BQRQKXA+.!H$T/R/AIX%YWP+B\QX)PN5TZ'&7%\J&(XTXRKN
M.*P]+A# N&&RKA[+ZVM*EEN$JSJ8NIAL(^3,\?6I8?$3G4PGL<+])7\2?!"$
M<Q^F#G^?4^)LGX>C3R+PSX"AB</#$XWQ&CA:RS',L1E]>/U[*\Q>$E@,)@(X
M_#4J?#N54\PXIPE#$8/,<DK5_JW_ ()'_P#!.&?]F;PP/CO\7M-D'QO\>Z E
MCI_A^ZAB1_AQX0U)[:Z-I=VB%%_X2S6C;1SZF)$\WP];2_V)'Y4]SKL;?N/;
M#$*_=Y:1OE(8?/*[9RORDG.6( &[.!BH%P$#;E"\C!4*5^;<H;/1U/#9(RV>
MC5:A 5 %  W/P,\$R,3G)/.2=W;=G  P!_?_  QPYEG">38/(LJI2A0P=*$:
MM6;YJV+Q"7[S$8F;47*I.3?LYV:=)1H)VPZO_DKXI>)O%?B_QSG?'G&F-EBL
MZS?$35.A24HX#+LMHRDL!E&74YRG.G@<KP\X8?#JI.>)KU98S,,?4KX['UL5
M4DHHHKWSX **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** /RB_X*5_L_I^T-\3_ /@G#X:U_P"$M]\7OAGX>_;3LO&'Q3TB3PCJ
M7B_PAHOAC0/@E\7;G2M<^(,<%M/I&D>$X_&+>'[2>;Q!MT;6M1NM.\/ZD;RS
MU"72;WAOB#\//B9^P%^UU9?'_P#9Z^&7CKXC_LE_M;>,]*T']K?X'?";PKKO
MC'7_ (1_&K61#IN@_M>^!/ /AJPU;4;G0=;T_3X- ^/NE>']+AGNS'I?CE[/
M7-92:/3_ -EJ* /XVOBG^RY\9_V<_P!H7]IOP]XOTW_@O7/IWQB_:)^*/QD^
M$.M_\$KOBGHP_9K\4:-\5?$"^(+*3QYH<^D6]_\ !SQSH]]J=IX6\77_ (DU
M37[?4!HDOBFR>/1X";K]&O'W[.WB+]F+_@D1\$?'C>&/&/A3XP_L :MI'[9W
MAOPE\4_BYX9^)/C?0+WPQXS\4>-?BA\,O%_Q7\%?#_X;>&/%%QXL^%'CCXB>
M M5.@^";"QDO]6MK"V?Q)=Z19:W>_P!!=?&O[67[%?P[_;&N_A9:_%;QW\;-
M,\"_#3Q.?$NL_"?X=_$N[\%_#'XV)<7FBW4'A?XZ^&8+.Z'COPIIFH:!8:CI
M-E;W6AZGI5T^HM8:HXU6[MB <'_P3&^$WB/X7?L<_#?5/B##*OQ>^.E]XI_:
M;^,\EW$+6_E^)W[0OB"\^)_B'3-1ME:1(KKPI8Z]I7@HP+)*D$?AF* 22)'Y
MC_(_PC_8$^!OQV_:<_X*?Z_^U=^R+X#\>6?CWX_^"+3X9?$/XM_!?3;G7=7\
M"?\ #-?PJT;4[[X4_$36M!76K;1[+Q);ZO;_ -M_#_Q'8W>C^++758UGT[6M
M,DG3]NXP @ &%&0HV[-JAB%4+M3 50 HV] .6^\7T ?S[?![5/VA_P#@F1\)
M_P!K_P#9(\*?L_?%7XP>%O@SX U_XP_L"?$7X8? GQ1XNLOB3X>\<W"Z%H7P
M4^*6H?"CP:^BZG\;_AKX^O=,CU[6M6N+7Q'X[^'G]H?$34#IVCZ+>S+YOX2_
MX-\=$U7]ES3/A+XZ_;T_X**:9J/B_P "PZO\2/A1I'[0>@K^S>WQ;\1VT?B[
MQE>/\(I/AP-/O_##?$^YN];_ +.O=6?6M0FB:_GUU=5>368/Z4:* /YI/B3\
M6_VHF_9J_P""5'QO^,'[)?[6OQ'^+O[+G[5&I:1^T3\/?A3\#O&'C+XL:Q<?
M#[X.?&GX22_%'0_#]_/:?VEX1\?75_H'B;3_ !A?:YI7AS4&\2I%IVLW3E+<
M^E_'+X__ +0/_!4_P1IO[(GPF_80_;2_9J^%WQ*\:^"(?VD_C?\ MD_"S1?@
M38^$/@EH'B/2_%OBFP^'OAV_\7^)=8\?^,/&4>B0^#(]-L+2%["/6KJZU'[/
MI7VO6+'^A"B@#\;==_8Z^&GQR_X*C?M ^*_VA/V7?!GQ:^$\/[&_[.7AGX?>
M*OB_\%]'\;>!K3Q9:_$;XX-XJT3P1XD\9>%-4\/VWB73-(U#P]/K%CX8U>VU
MK3[.^TB2\M)8;NUN(,?]DKX">)/^";_[77B[]F3X:?"+7=6_8>_:?CUGXL_!
MSQMX*^'UWJ[?L[?%K08FD\>_!WXT^.-"T::Y_P"$"\4Z==VVK?!3QI\2/$#R
MZ=/;R?#2RN;Y[!;F7]JJ* /#]*_9Q_9Y\/\ Q5U;X[Z)\"/@WH_QNUR*YBUS
MXPZ1\,/!6G?%36H[VVM[._@U/Q_8:''XPU*.:RL[2WEBO-3F,L%O! [-#&$3
MX_\ ^"FG@;QQX\\$?LH6G@;P?XL\:W/A_P#X*%?L8^,_$-IX2\-ZKXCN=!\&
M^%/BW8:IXG\5:Q!H]A?/I'AGP[8*=0U_Q'J*P:=H=E;Q7=U()(PS?IA10!_/
MM\&OV;OC=I7_  4:^*OP\\3?#WQ</V3?V?/%G[2'[7_P(\;3:'J=CX-\1_%O
M]L/PKX*L7\!^%;F;3UT?6=<^%VL:S^TOJ#V^CW5Y=>'?^%@VL5TD0U*SMX_$
M?AC\,?VD?V;?V:/^"0/[4UM^RW\7?C'J'[(GPU^-W@+X\_LY^&?!C6_[0/A?
M0/C=I5MITOCCX>_#7Q0/#VL:CXQ\-3>%[:RO_!\DBZYJVA^(;:SL5M[6?5];
MM_Z=Z* /YU;_ .'_ ,>/^"H/Q=_:$^,$?[-/QC_8W^%MW_P3V^-O[&OPWN_V
MIO!^F_#_ .+WQ/\ B1\;-;T[6;S5/$?PYT_6=:U73?A=\/QX>*:9<:A>7,NI
MW_B&?7?#XG,^I6UC\X?M/_'+]KCX\_L":-^Q)I__  2]_:T\)_%+X7P_LP>'
MOBUXH\1_#BTU;X.Z?8_"SXE?#))M7_9W\5>"KCQ3/\9]4U2YT&TGEBT/1=,T
MCP7X.G\0>(=3U>XMO#CIJ?\ 5S10!^&'C3X@?M!_LC?\%'?VG_$^B?L8_M"?
MM+>"_P!M'X=_L]_\*?\ &7P,T/P]J'A#PC\2/A)X;\5^#=4\,?'3QKXBUO1=
M ^$WAB_FU/1=3'CG67N;;2],^T7-AI/B6Y26&#YP_8W^ OQZTSPY_P $9[3Q
M[\'OB#X3UGP#J?\ P46D^,(OO ?C2UTOX877Q#L?B!'X:D\7GQ!I>GZCX;TG
MQ/=:K;CP-+XBDT^[\2"^TYM.6Y,Z7$O]+U% '\-7A_\ 8]^/?P6\!ZE^R%XU
M\%?\'"GB+XF:;:^,/!&@>&_V5_VAO!&C?\$Z_B!I&NZOKXTBYL/B1K/AK5/#
MWPA\ ^.]-O+R]\4Z#XR\-^*I/"<NLW-KKD%W=3063_I-_P % /V:/#?@?3/V
M1[/Q=^R)_P %&O%&J_"']FCP'\'_  A^UW_P30^)5CX__:F\"ZOX5M;>RU+X
M.?$'PEI'A'X=:;KO@>>UTU]5@^+=OX=MK;4;W5-=L]-\,_#V;4"&_IOHH _*
MO_@DU9_M>67[.?B>']JJ\^-=W:)\3M?'[/#_ +33>''_ &FT^ 46A:#%X9'Q
MU?PE)J$4GCF77O[?E)UN^N?&;6I2367^S'3X9?PTUOX4_&?0?A!=?LM:U_P3
MJ_;%O?\ @I]X+^//C'XP?"W_ (*,_!GP!X.N?A=XV^-%UXS\0^)O WQK\=?M
M5^)O$5GI[>!]>\+ZI9^&_'_PW\>V-QI$7A>&S\+SZ9X>UO3='T_P[_8_10!^
M8W_!*:#]I;2?V9]6\(_M?>&_C+I'[1/A;XO?%6V^)OB'XL^(;+Q7X<\=:OXC
M\57OC/3O$_P1U?3]>U"T/P77P[XAT;1?#6D6NG:%9^'=3TW7/#MI:2QZ8;NX
M^5O^"T/PR_:3E7X._%O]E'X?^._'_P 1O&/@OX\_L2^-+/X=Z%KNNZ[X=^'_
M .U1X6TU--^).J+I-G<VNC^'OAAXU\!:+J-YXAU4Z9H^DG6W.J:YIXN+>]A_
M>*B@#\5/V_O@/XQ_9\_9)_97\;?LE?#'QC\1_B-_P3Z\3?#_ /X5C\/OA[X2
MNO%/C/Q5X$U3X=:O^SOXP\/Z?X>TA5U>]BO/#OC:S\4Z[;Z.L;V\7AZ;5=1C
M\BWEV\5\8?V._C/\%?V /^"?VC_"/X;M\<_BE^PK\5_@-\?OB!\(+2\LK75/
MC%K>@Z!XKMOC5<:!<ZO=6ME>?$&;Q7X_\1?$/1;FZDNI+S4]/D33=(U+5KW3
M[2;]X** /P>\+?%#XR_\%$/VSOV/OB3H_P"Q5^U)^RQ\%_V0M8^,/Q&\;_$?
M]KSX;:9\'?'OBKQ9X[^%6N?#;PS\,OASX-37O$>L:UX;U'_A)'U[Q5KT:OH<
MD>@QZ=<R6FKPZ5'K7BMU\ /C'<?\&^_B_P"!\'PB^*EA\7-8F\:$_#'3? GB
MC3OBJ)=;_;$U#Q.U[8^$H]%@\1+J\WARY_X2H:K)IX"6$SZ]-,L*R2V_])=%
M 'XX?L*?"CXD_L-_M"?&/]B5/#'Q1\7?LE^-++4/VC/V7/B[?:5XL\8:3\/M
M3\5ZI(OQF^ 'Q&^(%UHUT+;Q OC"6]^(/@:]\9:VVM:_H6OWT=QJ.N>(7N9'
M^3/AO\$/C79?\$_?^"8_@R^^#WQ3M/&/@3_@I)X'\<^.O!UWX#\86_B#P;X'
MMOVC/C5KUWXQ\8Z)=Z(FI>%_"=GH.J:5J;^)M3T_3M.@T_4K7427CU-)7_I"
MHH _GM\ _'?X\?\ !-[XA_M8_!KQ+_P3Z_:^_:6TWXS?M2?&/]HOX%_&+]EK
MX;:/\2?!GCK3OC5>V7B7^Q/C1KDGB/3+KX5ZYX5UNY3P?>ZMK]M?I>Z#IS:E
MIVB?V3HZ2ZIXOXX_97_:X_9J_P""=?[+GQ9\!?!O4/$?[9/P4^(/[2/C#4_@
MQ\,-.N/&.K^"="_;M_X6SI&O^ _"J>&KF_?4M)^$'BGXE?"WQ9XI/A^6?0KA
M?AKJ]]:W]GHD$MS7]/5% '\WG@S]A/XA_##]M_\ 9S_9=T7X=:[-^QYX1T#]
MFO\ :^\9_$>TT+7IO -W\>?V6/@SXG_9ZTOP=J?B"YLI=%'B_P 1>(M*^"WQ
M?.CZGJ^IRW8\(W^N&U;6;RZU6;^C^( 1J 20N5!)9FPK%1O9V=V? ^=G8N7W
M%P&) DHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K/\ L5M%>W%^EO#'
M=7<5M!<7:HHEGAM&D^RPROC+>7)=S^7GD*[#.,;="D)P"?2@.9K;KH_3?7RT
MV*<]O#<P20RQ0S03Q-'+%*BR121LK9CF1E*F,J<$$;>2".>9[>)(((H(HTBC
MA011Q1H$CC1/E5(T  6-% 5 !C:!C(YIZODX(^G^'_UZ?0'-+X7M\7S6FWHP
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'-!/!(DD4J,5D1@ZG#"KE !1110 4444 %%%% !1110 4444 %%%% !1110
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MIT:\<7]QHFBV4]Q-:1:5I=K;0NGCO["MIJEW^U+\,SI.I:IIMS86GQ$UB?\
ML:R6^U75-,\/?#+Q?XBUWPWIUM-/;1RW'B[0M+U+PL&2]M7A.KK>*;2\L+"[
MG^V_C!^RO^SU=:SJNI?$'P5^T=^S)K%W?7-W=^,]$\&CXW_ '5C<2&6W\1VV
MI^#+5?$6BW^K*TNJZMHR0^&8?#UO=P6">%K2+9;Q@'S:?V3/V<;L;](_;Q^%
M!@R&@GU_P9J^@_:8&.1)):0ZUX@OH[DJ<R17FDQ@.&\F]N(3'=SG_#,O[(FA
M_P"D>+?VZO#;VR\?8O"?PG\5>)K_ %$#EX;:[TK7O$+Z7 YRJ7=YIEE!<O\
MZ-);6 4ZI8L_X92_9CU#/_"-_M\?#:XBWMMD\3_##QQX#>.V496&>PU"YO=2
M%Q(  UE'I:V4,I,4]_;7RV=C=Z6E_LM_LB1WL=MJ?[;;^*+QA^Z\*_#+]GWQ
MUXFUJ_8-]GN([+4M+O+[1;65I;BPBMKR2?4+:X 6T) 3RP ?0O[/5]^RO%X8
M_:U\&_L]Z3\5]2U>P_8R_:!\1>(OBA\2+W1;*36['3O#]CH\?A+2_!F@QM;0
M>&9+[Q#;>([6:ZDT;Q%9ZGH-M;W4NH6:(Q_&K)."2#E5((VX*E05(V'9RN#\
M@1/[D<:XC7]X?!WP&\(_#[X+_M'ZE\*/A3\?/AS;7W[./QABU/XN_&NWT73?
M&'BZQM?";^(]3\'P_#2 VMQX?^'NOQZ5%YWB0Z;X>N%OI-*TC_B<7UU8^(M!
M_![ 4!1P  !RK'  QED 1V_ONF4=LLC,I#$ *.!U177*NXD5Y%:)1(DR/# /
M-:#9+N+G[CDX. *** /W>_X)._MLWFG:KI7[*_Q/U66\TK5%E@^#WB'4KEC+
MIFIPQ37<W@>]NKMO.GT[6$9I?"P:,M9:PJ:(JWLFOZ7'9?T/QG=&C'@NH<CY
M."XW$?(SH<9QE7<'J'?[Q_@/TW5-0T34;#6=(O+K3]5TB]L]5T_4+3_7V5]I
M]PEY:3VG!_TVVN((;B,8Z;/Q_MC_ &4?CA#^T3\ OAO\50L4.JZ[H_V/Q+:V
M\@,=KXLT&XN='\0PJ@ "6EUJ-C<WVGC!SI]U:.2210!](44B@   8 X QC '
M  &!@ <#CICKUI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH @D8 DE2X4%BNTN3MV_*D8ZN2R8;&!G&1S7\^G_!5_]MZ[
M-]JO[*OPQU&2WMK>&)/C+XCLIY_-OWN(X9[?P#8SPAO*L+9'AO\ Q:X#RW[L
MOANWC:.#7;2__8_]J7XU6G[//P&^)'Q;EC@N;[PSH930+&9]J:CXKU.>'2_"
MUC+AE/V>36]0LY;X#)&G1W3X(''\=GP@\#Z_^T5\?/!O@G4M9O+C6?BCX]A?
MQ/XEGV2W<,.IZC<ZMXN\572OE&NK+3X]8UR9)9+6.[^S26LC>4LK$ ]C^%'P
M]\"?"?X;V?[27QY\.MXJ@UB^N]/^ WP9O+A[*+XIZSH[M!J_C?Q9/:.-1?X7
M^#[F5[62VM9]WC[7I(])$]KHT&JS7WS_ /%CXP_$/XU>)Y/%7Q#\23ZU=01F
MVT33XE2V\.^&-*5$AM-"\*^'D5='\+>'[6TCAA@L-,2-%"%VCCF>1%^F_P!I
MWP_XG^+'Q%U[5M!G\'Z;H?@;PI;:)\-_@G;^*XSXW\(_!'P'I:W'A^-=$D-U
M!+K*>%HG\9^*-"BUW6_%^D->:M>>(]%T^[T^[:/XKT71-:\1ZG9:+X>TK5_$
M.MZE(T%CI>CV%YJ&IZE,6.T66FZ7%<RWEU<#]^@2WVHL@1"ZJ&8 ]7\':9X4
M\/?#C5/B5XA\*6_CN]'C#3?!6C^'-8O]>T_PQIRR:/=ZW=:IX@?POK?AKQ5?
MS7B0M#X1M+#Q%H=E)<:9KL\UQ?BU:R.3\6/#'A_0K[PAK'AFSO-'T7X@^!]-
M\90>&M5OWU6]\,O<ZMKFA7.FR:E+8Z?/J%I/=^&Y_$_A>[NH);RX\,ZYI,MY
M?:I=--J=WZU8#Q_^S;\-M<&MZ)?^%/B!\5-;L]$M_!WCWPG"XT_P+X/E@U+5
M-?USP)XVT2:SN+OQ#XGO])TCP;XAO-,^T6J>&?B!9VDPANH7/)ZC\*_B9X\N
M+7Q-XB\4^'=1\?\ C#2=/U_1/!VO^*K.7XB^(="FTR*XT>?2M(:8V<45]H,-
MO'X+\-W.K:3X@\0Z(^COX=\/W>GWGAZ'4P#RWP'\1/&_PN\4Z;XX^'GBC6O"
M'BC2)UN+/5]'O?L5VJL?EL+CK#J&GS9:'5M)N6DAU*U+6]YI\UILE?Z\\6^&
M_"'[5/@'Q/\ %_X;>&])\&_';X?V%SX@^-_PO\/1M9>%O''@^!8FU3XQ^ ]%
MB&-'O=,NI(C\0_#-C&+<12V_B+0K=;9);&]^$L8)7&-K,I&9" 58J=K3)'(Z
MY!V.X8NN'\V8'S7]*^#OQ0\0_!?XH>"_B?X:,<FH^$M9@OGLI_\ CQUC2Y ]
MKK7AO4_^H;XET>XU+1]1_P"H;=7M 'FHW8RV=S?,2R+&[;OFW21QEHTE;.Z5
M(F>)9"ZQ.\85B5]&_M7?#70?AC\8]8M_ \<@^''CC1O#GQ3^%4TW$4O@7XAZ
M)%XDT.Q7!/[SPW)<77AV;G_7:5)S7SF55"4085"57W"DJ#]"!D>QH _5_P#X
M)D?MM7/P,\<V/P5^(FI2R_!SX@ZS!;65U=NDD'@'Q;K#FTM=2\R0B.S\*ZS<
MK%;^)HY&"6US+9ZV7M+:VOXM9_J=C!$: C!"@,-Q?YA][YV"L^6R=[*K/]YE
M!) _@"QGY25",R%P>AX?$DG/^J 0HW^R6[5_7[_P3;_:"NOV@/V9?"]WK]V;
MGQO\.IW^''BZXNI5-[J,^BV>GOHNM7,0Y$NKZ!>Z:=2R5#>(+34_O=$ /T#H
MIJ8*@C(SSR,'.>=P_O9SN]\TZ@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** *\IW!U4!B /E4_,64JVS(93&[!P4;*^22LV
M<=/Y>/\ @I_^V[??&SQG?_ KX?:I+#\)? 6M-:>)+_3IXVC^('C+3+AX);T7
M*%XI?"_AV[CE@T*%"\-W<QW/B>X%VXT&?1?V@_X*,?M!W/[//[,OBS6=$O#9
M>,_'$B_#OP==1R;+C3;[Q!9WC:KKUN 0WVC0_#]KJU]88R#K$>EAN&P?X[R2
M2<YW9(8,=TBN.'68_P#/=6!6?TF$@[4 )R<%MNX@%MBE$WD OY88EO*W$^6S
MLSO'M=V9F+&:&WENYK>UMX+FYN+F1;:WM;:%YYKJ:22.-;:"UBBNKB[FO9)[
M>U1(( Q(V@%ADPU]5?LVV-OX%M/&_P"TQK=K!-8?!JVL+/X>V]\D9L-;^//B
MI+Z'X<0-!<_)?0^"8;+6/BCJZV_S&'P=I.E-\^M&@#E?^&3OVJ!D']FG]H %
M25('P;^(KJ&0E66-QX697A4@K"ZDJ\01E.TBC_AD_P#:G_Z-I_: _P##,_$7
M_P"96O(Y_&7C"XFEN+GQ3XHGN;B1Y[B>YUK4FN)YYF,DL\["[B#33.S2R,$4
M,[DC(()B_P"$L\4_]#+XA_\ !SJ?_P GT >P_P##)_[4_P#T;3^T!_X9GXB_
M_,K2-^R?^U* N_\ 9I_: V[N2/@W\2%90!DA#'H$4RR8&[S418E4X<,0Q/C_
M /PEGBG_ *&7Q#_X.=3_ /D^G+XN\5(4=?$_B1"A,BM'JVH !XT>1@?/O_)G
MF=(T"@=(X@IZ4 8UW:7=A=W5C?VL]E?65S/:7EE=12P7=G=6TKPW%K=PSP6T
M\-W;RH\-U%-"DL=PDB2;F4NU?@=45URKN)%>16B42),CPP#S6@V2[BY^XY.#
M@"OJK]HB+_A8FC?#_P#:6T]89)/BA:OX<^*!M B"R^.G@*WTV#Q9=7BK)*(X
M/'VA7.@?%"&0.W]JZIX@\01'!T3 ^5!T7@#Y5X7@#@<;?X2.Z?P'*]J /W?_
M ."3O[;-YIVJZ5^RO\3]5EO-*U198/@]XAU*Y8RZ9J<,4UW-X'O;J[;SI].U
MA&:7PL&C+66L*FB*M[)K^EQV7]#\9W1HQX+J'(^3@N-Q'R,Z'&<95W!ZAW^\
M?X#]-U34-$U&PUG2+RZT_5=(O;/5=/U"T_U]E?:?<)>6D]IP?]-MKB"&XC&.
MFS\?[8_V4?CA#^T3\ OAO\50L4.JZ[H_V/Q+:V\@,=KXLT&XN='\0PJ@ "6E
MUJ-C<WVGC!SI]U:.2210!](44B@   8 X QC '  &!@ <#CICKUI: "BBB@
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M'H&2-W'[2WQU& WS 8349$4@$ J'.",'!!4'_#0'['G_ $8'H/\ XDO\>/\
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M\(_C;X)EG_X6G^PCX]M=,\1Z/;NCGQ)^S]\3]=NKZVU&\B2YMVNDM/$$^N>
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MO<_4XH _IP0 *  0 , $8P!P!CT X'J!FG4@X  ! ''/MQ^N,CU%+0 4444
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M2_\ EQ1_PT1\!O\ HLOPI_\ #@>$O_EQ1_K%D'_109/_ .'3+O\ Y>'MZ/\
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M1FU'6T\:7FGI>QQ_:]-B@NX"\<JD9U*M*DH^UWG-4Z7_ %]:;7_DJD!^S8
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M .&[,O\ Y2'^MW"?_14<.?\ AXRK_P":#Z5PWH/R6C#>@_):^:O^&ROV4/\
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MQ.!?_$JX:_\ GL?;N7]_R_\ K49?W_+_ .M7Q%_P\7_8\_Z*ZO\ X0/Q/_\
MF'H_X>+_ +'G_175_P#"!^)__P P]'LI_P L?P_S#_B)_AK_ -'$X%_\2KAK
M_P">Q]NY?W_+_P"M1E_?\O\ ZU?$7_#Q?]CS_HKJ_P#A _$__P"8>C_AXO\
ML>?]%=7_ ,('XG__ ##T>RG_ "Q_#_,/^(G^&O\ T<3@7_Q*N&O_ )['V[E_
M?\O_ *U&7]_R_P#K5\1?\/%_V//^BNK_ .$#\3__ )AZ/^'B_P"QY_T5U?\
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M'BR_O<,Y\Y27,ITLGS;WH_\ A/=K5:JZ>GD3]<PMM,1&_777SOTW1^\^UO\
M9_(?_$T;6_V?R'_Q-?@Q_P 1-/\ P1&_Z/5/_B.'[6W_ ,X:C_B)I_X(C?\
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M@E?/Y_U_F?6OVX_X)=?ZSXV^H7X:*P[AEE\>JP/N&!!]P:_CBAXJT/$+Z1'
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M:+JO@[QK>S3R.-3\*:!J9")X@"#Y-_:CTO4?$/AW]F?XC:!;7&K> =4_9_\
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MIHM%TW0_VAX-2U>X6UGD_LZREU;X#Z-H;W.J/_HD9U74XK R2AI-2MH<F/\
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M E*_,^2PF1T\1E>19A5K7EGW$V+RB='V=2?+0PV79!7<O80_?RL\V4?K$?\
M9XWO+22-!OV?/CV%;?\ !+XMIEBAGE^&GC PK(%D4SL[^'K<F/$DY:>XN6CR
M2T1$1C6O/?#_ (5\4^+KZ?3?"OAG7_$>H6ME<:E<:7H6D:IJM]:6%J-]U<ZA
M96=HQM[;3%(-Q=7#$VLZM;8#1[1]+_'[2O@O_P +H^+LMWX_^)L6K_\ "PO'
M3WEG;_"3PE/I%MJQUW46>T@UV3XWZ3>W5G'>EXX;\^'H9YH@)6TV!\PCU?\
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M*/P'?WG[8N@7UWX.CMT$5LGA&ZG_ &7IY_#NR%5V1:7%9HXQ*[.\C2-\@44
M?7X^/_PHL]:\:^-K3X?_ !X\0?$;Q=\/OB9X&E\4?$[]I3P]X[@_XN3\.?$'
MPYN=8UZ&V_9[T76];DT2PUM[FRLH?$^F+]NBM(74*NT?(!SDY+'!(RQ!8@'
MS@G:< ?NR=T?^K?YU:BI(XY))(TCC\R5V"QK_P ],G!A].3\WXGZTU'F=NVN
MO0.>$%*523A2C3JSJRC\4:-.E4J5IK^Y"G"<ZS^Q0C5J?\NRSI^GS:I>V]C
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MC_M4?'?]O;X>_%7]I[]GNPOM"\.^*]'^*O@S]G3QG\.O'_QMT#P8MU'KE_\
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MU(Q?+B)1A57P&;\88[-E*C3I>SPO-S.7>*4HM?=*_P @(QV([X+[R >0"WJ
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M (*:?LV_'+X<>/\ P/\ LB^$-(^!W[4?[)?QB^$VK#Q5^S+XB\.ZWXB_9?\
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MI($O=$\2^&/B9\;=&UC39RJK'*;6]LYHDN8 UM=Q*EU:R2V\T4C_ )9?LZ?
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MOUF_X)=?ZSXV_P"[\-/_ $;X]K]N^CC_ ,GHX-].(/\ UG,>?4<&?\E'@/\
M#B__ %$JGZU]U_W'_F:_G>_X+MDF]_9CSV'QE5?]S_BT+#_Q]WK^B'NO^X_\
MS7\[W_!=O/VW]F//=?C)CTQGX1#^8:O]GO!NW_$2^&UR<[<<]48^?]BYIM^O
MD?+_ $O7)?1WX[<(U)5$N$^3V7\52_UNR76'FE?F_N<Y^#7@WQ;KG@+Q5X9\
M;^&;I+/Q%X1US2O$>C7$@WPQZEHUW%J6GF\03%);1+FU+/;RV;R9.V.95O%D
MM?J.Q_:3^&&@_$J7XW^%?@+>:)\68[M?$5BDOQ3N[WX1:/\ $"Z\MM4\96'P
M]M?!-KXQDA&JR7_B+2/"5[\7+[2M/FO'@$>J>&K#^SKCYO\ AEX;L?&7Q%^'
MOA#4Y[JVTWQ5XV\+>&]1N+&5(;Z"PU_7=,TR\ET]Y4EMTO[>T>YFBFN(Y5C#
M*3;2J &^QQ\#/V?->^,OQ?\ @1H]G\7_  7JWPYC^+@A^*?B7XB>$/%/@ZR'
MPLLM>N;C5?&7AJP^#G@_4-$\/:_#HC::U_!XSC_L[4-1TL22ZM+>-!J/]@\2
M3R/Z[[''9=CZ]=96IXWZEB\5AX0RQ8[#0Q3QU#"X_!U,RPG-4HJ> Y,7.?/*
MI2P[E&<G_DWP'_K=2RFIB>'\YRC#4GQ%AH9=A\QPV%Q%&KQ2\-F<L%2R6MCL
MJS7!Y9F,\/#,(QS;$0PE+ XE1J3QN&DZ-6'E\OQ[^'GBGX/?##X8?$[X:>/_
M !%=_#/6?B/K&G^)O!GQ8\.>#I->G^(VM66N:Q;W^E>(/A+X^A<6[VMCY<T&
MJVZ7 B-ZD8BNDMX8OAG\</A9\*?%GBG4_#OPO\>W_A3QQ\)?&OPE\2:+X@^,
M?AZ\UQ;?QQY,-WKNC>*M)^!^D:;H\VFZ9:D1V6J>%-=C>>=+A;Z*("V/<V?[
M*WAC6--^"VN1>)]<T'P[XD^ WC/X[_&37+RQLO$2^%M \%^*-<T+48O"VA6M
MGH#WJZA;V6D:7HVA7.I7<SZYK$;W5_:6)6:/DM#^&?P7^,FG_$*Q^#L7Q0\(
M>._ WA;6_B%HNE?$7Q-X9\<:?\1_"7A+R]2\2Z;;W_ACP-X"U#PIXTMM)#:_
M!I+6OB_2-:2SFL9-9T=[=IY?+A7X0J1Q5*$<XCE4\7CZ>=TL-F6;4<LHT*V9
M^PK2KX.&986&"J/,(<].-'"57"4J==5*>$E13^CJX3Q,P6)R^IB<9PO5SG"8
M;*(<.QJ9)PEB\TS^AE60PQ<\HPV-J9+#'8K#87)<SH86<LUS:C_;=2>,R##?
MVOF*]@X/A9\<OA-\%_BS\//BSX ^$WQ(EU'P5KFHZCJ6C^-?C3X:URTUZQU7
M0M5T-=,LKO0_@=X0&B7OVC45G34KI]56>WMKRT-A,"M[8<!JOB/]G:ZMKR72
M_A7\:[349H;W['-??'KP+J=A!.\1-B][8Q_LT:;/-;PW<R3FRCO=,9EM KW=
MK*6BBU?CU\)_#GPNT_X%7.@WFL7;_$OX#>#OB;XDCU>XTV]@L]>\1ZCK=EJ&
MGZ.FFZ5ID<6DI#I-NJ?VE_;#* !%*D815T](^&/P^\&?"/PI\7/C/#XZUD_$
M_4?$^G_#+P%X#USP_P"%+O4=+\&:EI>D>*O&&O\ C3Q!X8\;VNF:5:ZI=W6A
M:3I-CX0N-3N[O3Y[]M=T33K!(9O0E2R"-#"9O0_U@K8W'TZN587#T\[SN./Q
M?]GYAF5.I0JUHYK&G&HH0QD\.\5.&&>%IU*4G>K!2\2OB.-)8G..&<7+@FAA
M,MBN(LQK8GA7ANEE^0K&Y?EF7U\;1G0R2>(P4L7AIY7E'+D^ Y*^8^RGA<M>
M/5:3K6OQI\'^)/ _A;P5\9OA[KOCB;X?V4.@^!/&?@OQ_;?#WQ?I_@LWVL:O
M<^#/$DVJ?#_XF:#XLT.PU#49-3T$_P!@:3K>@R3ZDD&MW-I=6%I:97Q=^.=Y
M\4O%/A'48?"^F>"O _PUTG3/#/PX^'FB7M[>V/A3PKHM]-J$5K/K>I2_VAK'
MB;5KN\GNO$'B:]03^(]<N=0O7@C\L:-:^J0?LM67Q'\0_ N]^#>O7LGP_P#C
MYJVNZ-!+XWAL#K7PTUSP+*MS\0=)\5WFCVEMH&M:9I7AVXM_&>B^(=#TW0KK
MQ9X:EELY_#OAV>QGT^/%T/PG^RGXN\0:K\/;#Q/\3/!E^NBZG;^%_C7XX\1^
M%E\ :[XJT>S6^CN?$/PXLO!$'B;P7X7\=_8]2TS29K/XF>-=5T*6_P!!2;3O
M$INGCN9HXCAFGC*V-P.69GFK4ZV98FG.OBJ\,E_M'&XC!9Q/%8"..JX? XV.
M+H8R,GE]*IFN)INK7H/V4JCJ]6+P/'];"QP.8YQP_E^!QF,R_!8''8N>48;%
M\4X_!91@LYR;#3SS!8!8_-\HHY=B,MS#!8KBO'?V7A\-4P.&SO&TL5A,#E]&
M2V_:C^S_ +1/Q5^/7_"")_Q<S3?BCI3>$%\2B)-#_P"%F^'-4\. S^(/[ 47
M47AT:A<73H-%M_MLJFW74X/+$8YJU^-G@?Q1X+\&>%?C1\.==\=7GPUL(-!\
M&>,/!GQ!L_AWXM;P9]NO;R'P;XJ;4/ GQ+L_%&B:=?WQC\++;Z=HVM:*MQ<Z
M9'?7MO+:I8>F6O[*>A:_IGP-U33_ !-JN@Z3XQ_9_P#&OQT^+GB+5+.UUVP\
M)>'/!.O^(M,U8^&]#ME\.75TDUCIVG6FC:;J7B*.^O=<U&)=2UG3+5O]'\XN
M-(_9@\4:+\08_"^I_%#X9>(_#&E3:[X+U#XD>)/#?C_0_B/]GO&L&\+3:;X/
M^&WA34/!GC35Q=V&M:9J7]H>*](ACM[NPUJ[M[&#3]>M^2G/AC%JG++,%F^)
MJX/"99AGC<H^N1Q>6T,LQ.8Y/@JE65.:S*.&]E]8C6>!A4<\/*-3.8QG*A)=
M5;_B(N70K2S?/>'8/%SS/.88?-I93F>"SC,<\RO*>+LZ=#+\?P_5P,J>'R_#
MY)+"K-,/EV H8ZG1P>35)YG2G0ATMO\ M9ZF/$?Q'U*Y\!Z1#H/BG]GKQ#^S
M;X&\%>']6?3] ^&/@S4X;9-'%G=ZG9^)-;\4W.ESV^I:EJ4NH7T=SXIU._O-
M0.J6R[;:#/\ "7[4^M>'OV7OB;^S+J7ABS\0Z9XVU30+_P ,^,9=2:SUGP9#
M;>)](\2:[HT%NUE<'6]#UC4='CU:VLOM>C_V1J%_KOB'S]375 C>B_LR?LH^
M$?C/\/\ 7=>\8>)M?\/>+O&GB'7/AY^SUI&GOHZ:9XL^(?AOP%XA\=7=OX@C
MU;2;ZXN_#/G6^@>&(9=%>..+7M=MK>:^OK@%:\9^'/P@T+Q9\&?VEO'WB";Q
M!8^(_@OI?PUFT'2X;NQ@M+F[\8>.G\+:[:^);*>PDU&ZELK,O/ -/ET )>>8
MKQW#JUHFM2GP0ZN88*G0J0669QP[+$49RQGML5F];%T</EV,A*K4=*<*.(Q#
MHYA["4KX^IB(XIRJ<R>5/_B*]/"Y1FO]K0ITN(N&_$6IAZDLPRQ49Y.\IPV?
M\9Y%F^7XW!.I3^O93/#9ED675<)3D\%C,'4X;E"C2P$7QWP2^+.I?!+XCZ+\
M0=,TNQUZ+38-7T[6= U:2>VL-=\,^)-)O/#?B719-2M4CU'3?MFBZI<Q0W^F
MQQW5G<&UU6VB(M+^RNOICP;^V#X+^'?PH\?? /PG\%_$=U\)OBNNLMX_T[QC
M\<=9U3QBVNMIEI!X9NO!?B+P[X0\%>$/"EEX>N])MM2U2UU3P+XEUGQREN^A
M:W??8;.UL[/X/)W$L226)=F(<.[L=SR2"5(Y!+(Y9Y5>.,K(SCRT^Z$KZ#->
M%\GSK%K%YK@)U\7AZT*2A"K5IQ4<NKU7EM62ISAS3I598ITI-W@W))24G$^(
MX;\0N+.%<)# 9%C?JE)1SVCR5\DR7-U76;8>GEN8+#RSC*G7H4,TR:EA<JS;
M+\$XX'&QIT:&82C7544D$EMV_)W;R HDSR7VJL>P2$[@A&Y P5G=@9&2BBO=
M2C%QA\#A!1C2_E@K)/Y62/BKJU**O.-.A&E1K2C"FYX>,ZDXTY0I8ATI5</.
MK4PLZZPL*M;#T<+*4XX:GA8R****H84444 %%%% !1110 4444 %%%% !111
M0 4444 %?H'_ ,$L_P#D_'X$?[_Q+_\ 5/\ Q!K\_*_0/_@EG_R?C\"/]_XE
M_P#JG_B#7R_''_)%<8_]DIQ#_P"JV9^D^#?_ "=WPK_[.1P1_P"KZF?V1K]Y
MO]T_^C!7XE_\%A#_ *3^SZ.P7XH_GGX9?TQ7[:+]YO\ =/\ Z,%?B7_P6$&+
MG]GWW7XHM^OPR7_V4U_G70^)^G_S.?['_23M_P 03XTO+EBZ61J7G#_6++^=
M?.',?BU;20Q36TL\!N(DFB\RW+&-+A5E@E2*8G+BWGVRVQGB'EAY/+?]VM[7
MZCV'[1_P@F\?^+/$_P 0?'L/Q!^ GBO2/"#6/[.DO@CQ1JWB/PAJ7AZ+1E\.
M:/HVGW-CH?PU\.Z5X$G.L/?7GAGQMK5CXGT:74=-7PKJT^NK=:5^6&TE1C8J
M[6&]@CA7E58Y'<R 0PQJJVV\O'<RE03&OW4'T[K_ .S9)X7\;VOPZ\0_&GX.
M:/XRO'T)$TB_;XL10Q77B/3[/5M%@N=?MOA-+X9LI9H]6T^:\FN=9DL8[:00
M7M_IMM&3'VP;YFDHOW>;5I;-]Y1YM&_=UONE=)G^>7 .=<3Y5]?GD&59=6HP
MQ.5K%RS3%RP^"JXZOA\^PN44*U#^U<JH9D\3@*V.HTLNQU3%X"K6J4ZV*P=3
MV-&K2YC2-9\%^&?VD=#\26?B/2=5^'^D?%[P]XE3Q'HGAG5O"^ECPY!XMMM:
MGN]-\(S6=M>Z5I]GI"O:1Z1;6&H0P/ =,LH+JU@@O)OHW3/VI&\5^._C=\._
MBG\3/&^L? #XQ:KXPL]-URYU/Q5J%YX&C&L:AJW@+Q!X>TJ?SM<31XOLVF66
MJ^!;-;;3[G3)D2_TN6TL[33D\$3]G7Q%I?AOQ!XF\?\ C+P/\+[;PI\1KSX6
MZG9^+I/'&J:J?&6G:9!K-Y:6UO\ #SP)XSAN;&2P6:Z:[,CV,IMVFBNI('BE
M>QIO[,WC+6O%_P +?"7A_P 2^"-<T_XR6NM77@CQO87OBJ+P5<2Z"=3M=?L[
M][_PWI7B72[K1GT[[/+#/X5@>22[TAT2:(K<2O5.[6E]4WOJ]&KJ5M&KV\[I
MI,]'*\3XAY9!PRK+'AZN?9IB<PS')*F9J&,QCSCZWPY4RK,,KJ9X\RCD-:&*
MK99&AG.#PWO8K#5)9E2E"A"MUOB"_P#AQXP^!GP9^'L/QA\%Z!K_ ,-?$7Q8
M?6$UKP]\6Q87MCXB\3:7>:)J>C/H'PMU[;93Z?I,ES#%J<-K>P0W,,-Q;6EU
M%<V=KYYX/T/X,:'XEO/#_P 1/&.D>+O#GB;PS?:=I_CSP%IOQ*NG^&7B6>\M
MXM&\5ZKX?\5Z3X"O/%%A9K'>'4- L;/4C<6%W<SV FU*&RL%Y[5?ASX4TZQO
MKNV^.WPJU>]M(+R>+2-.TGXUMJ=]/:Q22PV-A-JGP<L-(\^YFB6#S=1OM)LG
MDNVFGO5#F1NJO_@'#H&F>!K[Q?\ &'X4^#F^(7@_1?&N@Z?JZ?%6YO(O#VMR
MW]M97&I7WAWX5Z[H5DI^P3Q7T":NR6UOMO;J:WC?3KYZ71*$>9*[ES[K6]TY
M\BNG;371./O')6GFF/Q^'QE/AS@VIB<JPN5T'F-//,NEDF'P^5X:EPKEV68]
M5N,<RRO!UL=A\-0RV&'I?5\PIUJ\*N&J8:<958]JOCCP]X'^"'Q%^%]Y\5[;
MXNP>+$TBS\#>"M#M?'C^$?A_J=CXFAU74/&7VOQ_H?@]?#NNWUF^K:;86'AK
M1;]]4N=0N1K6I6MM/;6^JZO[1?[3?C/Q'\4=>N?A=\9OB(OP\ET;PA9:58:5
MXH\;^%_#KRVG@_1-+\064'ANYDLH[:.35H]2:6*72H8YYB]Q%)=0RI=S^27_
M .S_ ./])O/BA9:N-"TZ?X5>%])\9Z[B_FN[76_#OB"_TVPTG4/"6HZ38:CI
M^HV-W%KNGZHLL!MH_P"R;M[9G,V68L_@?J$=GX>N/&OC_P"'?POO_%D%M>^'
M/#OC>Y\7#6[W2-4BMULO$=W;^$_"?B.V\*:3K4=TD=M-XTU70Y)=.AEUA(X-
M&N[6\8]YOW4XZ-)*35E>S3E*47J[KWI>25M#HQ.9<?U,"LEPF6U<AIPR[ X?
MVE*OC\JP]+#Y!F_$5*>6U\SS+,9UY83$YIG>8X3+\#B:;>)Q-#"97E^'CR4J
M^+U/ WBCP9XA^$^L?!;QMX@'@N6#QD/'_@?QK<Z7?:EI%KKQT&30_$6D^*Y-
M!M;[Q)!I>LV%II;0ZEHFBZD]CJEK!-JELVGS7]S;^B^"?B/\.?A19?#;P1H_
MB\>)K:]^-_P]^)_Q6\;Z7H6N:3X9TG1? VI0MI7AWPUINL:1IOBO6A9VU_JN
MKZUJL_A;1+:SEAM-&TS2KIH([R;SG1/V=?$-[X[_ .%5^(_&7@;X>_$U_%%C
MX4LO!OBZ'QY<75[=WZ65SI&K6FK>%_!?BWPQ-I&KQWBI9W5]K=M'>VJVUS=2
MVD4MH]Q5G^!4SZ5XWU7PY\2OAYXPC^'&B/XA\66NA1?$JRNM,M$US2_#Z0V9
M\9?#[P;I^I7DE_J4$=A+_:3P".ROX;R2RC%KYJ:?*KQ6S2ES+FLD[QMSM723
M^SS**VLTV\)4XVP%".*PF2X)8_!86MEO]HXC$<N;RPV30_M+&Y?7R)9Y0K0K
MTL+5JX?,J%#)H9C2RNO6EB\7AU5C5?TQ\"_VB?AGX7_:%\?WWQ U:[3X6:M\
M4O&GQ.\%>)+73-;F.B^*99O$-KI.LMI8L;O5?[,\6>%?$%UHNJ6(TYKYIW\-
MF_6P@TV6&/YZTB'X2:[X0\*:EHGCVV^"OQ@\%:Q=SZGK7B"T^(MWHOC*V;5I
M]6\,>+M"U;P;HOC?4/"?BCPO)%9Z5J.DRZ3X?L[YWTS5]*NQJ.FF&LBR^!-^
MMKX9_P"$K^('PR^'NM>*K&UO]"\*>,]9\0VVNWFFZG;PMIFJZI<:3X6\1^'/
M"=KKJW$?]F2^/-6\++<IYM_J=I%IUM97S7O#O[,OQ9\16/QEDAT6UL]7^!%G
M9WWCWPO?W4L'B":"Y^WR7,OAZ!X]1L=7F@LM'OM38'4M/L;[3EMKWP_<ZG-/
MI9,I6:O&^G5O;=)V=XV6J3Y79[6L:SS'C?,:.7Y=CN%,GSB@JO$.98'!N6*=
M2EB,PPF%XAQ<ZU7*LW_M'+<;DN&R>C7P6&]K1S"K@)1IRQ&8895H4_H^Q^.O
MPZUGQOK$7B+Q\UW=R_LK>,_@OJ'Q@\4:!XL+^/O'&JO/'I&K:S;Z;IWB'QC?
MZ98:>++3(M?\1Z=;>*;W3;&>\NK&WGG:T3XXUWP+X5TNPO[^P^,_PU\37$$*
MSVNE:-I7Q@M[[5$,@=+&V?Q!\*M T5FB#_:-]UJ]JY<.T[/(QDEJ1_#G7F^%
MUU\6#<Z4?#=GX\MOA_<6(FO!KAUNYT5]>:6*VNK""RBLXK*SF26*;4X-1B:-
MXXM):+R#)P'/=E8@ %E&%) P2 >>H_B 8GEE5B5%.2UO"+;5T[R5E9)62=G;
ME^UJ]6[WN_F^(.*LQS*A@X<09%A*TJOUO&Y-F,I9I#'5<%F%/!JO5YL/FT</
MCL/*MA*<7BJTLPK59T88K%8FK5Q+Q6)/?+'/S$N26);YB22J=220 " #A6=0
M'8HHJ#X5M:\ON1;O[+_9O=WUTPZQ6E[>_BIP_FA*7+*)1110(**** "BBB@
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MHJJJG&0NQ"H.UD1@5'I8'$Y=GV)]G4P>&<J>49)C)RQ44X4,/G>+Q&'GEO\
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M &57XA_^I=K%?T^2?<D^C_\ LM?S!_';_DM_QD_[*K\0_P#U+M8K^/?I@_\
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M\,^(+NZL-$U""WL]09K::]N=-N%%IJ]M9:Y$+8)>:6URDTC<&&X<RR-/%X+
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M_M"O_:&%P]#-IX7'8CV=!PC9*K>353CSG.L56S'.ZF8\!\28>OGF%P'"O&&
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MO1M \):G-;> _!T]I:7F@+\,;_6C8SQK9V>IVMOXXCO=4\N40W>EV\T,5O\
MGJN ,_=&U]K@A&C>00B29-P+O)&L%L4DM_FC( /S*:UM:UW6_$NI3ZMXEUC5
M->U:=+6.YU+6;ZZU+49ULK6"RM8IKN]_TEXK.SM[>RM4DXM[.W@M8LQ11YZG
M\5M/AZQ4NO2^S[-:G^9V2<3?V%E6:X##Y;@Y5L;FV29@Z^,P&$S%1?#M+/G1
MK8>CCL/B,-3Q-#$YK1Q%/$3IIT84ZDZ<E44$_NO4?'^B^/?V8_$GCSXNZ'X@
MUVX\6_M:WFKWEOX \3Z3X*GT[4[CX;0SS26EWJWA'Q];OI-C8M-I]OIUU)I]
MXJ-923^(9)XGGG]O\(16>E?M!_L8Z'\/[)IO@!!H?BS7/A7K\][=W>L^(;_Q
M%HNL7WCV+Q;?6EMI]K8>+M$\16B:5>Z%96C'PY#!9&+SWE:&Q_*4:[K7]B_\
M(V-7U1/#W]K?VY_8(OKG^PX]7CLTM!KHTQO^)4^O"V1;+[=+_P 3*+3DA6W_
M '03.UI/Q#\>Z'::+8:)XY\8Z+9>']0FUKP_9:3XFU73;?1=3O(7LKW4O#\,
M&J6\-C=W5I>WT=WJ=G FI74$LEN S,SM44EOKUO9<S;=W=MZIZZ/K9]S[C*O
M$ZGAZV6ULTP&*KU\'3X8Q']H9;# +,\9B<JSVKF^.H8W.(X/#XG&Y3F$\1#%
M5<+B9MTL1@\-3H1=!5&NJ\0^/_"=[;:O86GP0^%>D75P]^D.M:9J?QIDU*RE
M>6,1S6-OK/Q8O]#2[ARI1;_0]2TP,BAF\K]T/5/VFTDFT[]F:%=\TK?LS?#J
M(;D4NTW]J^)Q&GDHJQ7@NI)&22VB40M="!HOW96O)[KX[_&^_M+FPO\ XR_%
M:[L=0M[FUOK&Z^(?BV6RN+6YA87$$EI>:P'O8[E7>&XLY,2I9, QWE@8M,^.
M/QJT;3+#1='^+WQ.TO2=-M8;;3])TOXA^+M/TG3;:*,+%!96MIK)MH;*%0$B
MMY.B@9(8FKGR3W<[/KR4DTT[Z1BU'5>C]5<\-YYD&(H9M@,37S6-+,H0PJK9
M7POD^"G@*F69L\VAA:]+)L3A,+F$:JG4ISQV-G/'0DXU/9RC&HX_?7BO?I_@
M7XA>$]19U\4> ?V)_A9X;\;V4Z+/>Z-JZ?$C2M9MO#&J1L [:MI6EZYIME<6
MD!:*-UDC=MX 7YI_:STG5/$OQTD\4>&M,O=6\,?%/3_!.H_#&;1[9KJ#7M.F
M\,>&="LM"\/FWM+FRO=4T74;,>%;S3;1YY;+4;1-,N(K:YGEO'^9(/$WB2S&
MMFTU_7K4>)8?*\1/;ZI?P_\ "1)+J*7\EOKBQ37,^L6S7P&IP0W4[M-J@A8[
M4?RQT/AGXH?$OP1IL^C>"_B%X[\(:1<7+WDVE^%O%GB#P[87-X\=I:27$FGZ
M=>V-DEZ]O9VB7-TQN UI:#3Y5$T4@$KETO=))I<L8WWNM6U=6WVUU29Z.>\>
MY3Q1EU/*LPPV;9?A*BP56&*P=:&+QN$CEF9X^IE&'KX!TL,J]#-,@S?$4JN.
M_M*#K5:L,Y5+&>R^J5_?_AMX!UWX:?M>_"?P=XLUK0]9\2V'Q%\!OXCDT;4=
M0U2RTG4[NYL+^YT*\O=2 A;6=->Z_L^\@M3(;*[MI[(S3-;F1]'X7/$GA_\
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M]%^G]317\&+;[_\ TJ1^AK9>B_)"/RDA]5;^G^-?S"?';GXW_&0^OQ5^(?\
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MZ%6:_P#AK_\ MCY0HKZO_P"&(/VHO^B8'_PL_A[_ /-+1_PQ!^U%_P!$P/\
MX6?P]_\ FEH_XAMXC_\ 1"\<?^(WC_\ Y@#^Q,\_Z%6:_P#AK_\ MCY0HKZO
M_P"&(/VHO^B8'_PL_A[_ /-+1_PQ!^U%_P!$P/\ X6?P]_\ FEH_XAMXC_\
M1"\<?^(WC_\ Y@#^Q,\_Z%6:_P#AK_\ MCY0HKZO_P"&(/VHO^B8'_PL_A[_
M /-+1_PQ!^U%_P!$P/\ X6?P]_\ FEH_XAMXC_\ 1"\<?^(WC_\ Y@#^Q,\_
MZ%6:_P#AK_\ MCY0HKZO_P"&(/VHO^B8'_PL_A[_ /-+1_PQ!^U%_P!$P/\
MX6?P]_\ FEH_XAMXC_\ 1"\<?^(WC_\ Y@#^Q,\_Z%6:_P#AK_\ MCY0HKZO
M_P"&(/VHO^B8'_PL_A[_ /-+1_PQ!^U%_P!$P/\ X6?P]_\ FEH_XAMXC_\
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M$8''8>E%8J]3$8)X>G=X2LE'GN[R;VB[)I-WT/T:P&&>>01^OZ?K^O'\\/\
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M_P#\T'X_45^P/_#E#]K#_H=/@)_X5?CS_P"=M1_PY0_:P_Z'3X"?^%7X\_\
MG;4?\15\.O\ HKLN_P#!5;_Y2'_$M?CK_P!&OXC_ /!N'_\ F@_'ZBOV!_X<
MH?M8?]#I\!/_  J_'G_SMJ/^'*'[6'_0Z? 3_P *OQY_\[:C_B*OAU_T5V7?
M^"JW_P I#_B6OQU_Z-?Q'_X-P_\ \T'X_5^@7_!+3_D^_P"!)_NM\2W_  3X
M/?$%R,=\XKW_ /X<H?M8?]#I\!/_  J_'G_SMJ^H_P!BW_@ES^T%^SO^TU\,
MOC#XY\4?"&_\*^#SXP?5K3PSX@\97^MS'7_ GBCPG8I866I^"=)TZ607VNVT
MMY+<:C:>5IT4XC2:4!7^<XO\3. \;PIQ+@<'Q-@\3B<=D.;86A2HPJ1E*K5P
MC5--NDE:4H\FK2YFKM)-GWOA;]'OQERGQ,\.\US;PZSW Y7E?'7">:9EC*]2
MBZ>&P.79S#%XFM)1KMM0IT^9V3T3T9^_P?,?4(1M0$D@$[5(.>>OY=L=:_$O
M_@K^H2X_9_"@!<_%0D>DC-\,G8=^"K(X]V/U/[99 7# <@M&AQC<JLY'& ,
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M?:?_ ("P_P"(9>)'_1NN-_\ Q'>(?_F(^,**^S_^'?'[7O\ T2(?^%[\-/\
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M[7O_ $2(?^%[\-/_ )M*.:?:?_@+#_B&7B1_T;KC?_Q'>(?_ )B/C"BOL_\
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M (7OPT_^;2C_ (=\?M>_]$B'_A>_#3_YM*.:?:?_ ("P_P"(9>)'_1NN-_\
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MM7O;2:&9+B#ZS3_@S?\ ^"G<BJW_  N_]A-21C9_PM+X^90+\H4JO[+81 H
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M .PNHI1<;.VEVG>Z2T]VUFWN?)?[$/\ P3D\=?#+XZ:9X3_;I_X)]_"[QO\
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MLM_\$8C_ .9B/[-S#_H%C]Z_S/Y+J*_K1_X@VO\ @IW_ -%R_82_\.E\?O\
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M^'2^/W_T+='_ !!M?\%._P#HN7["7_ATOC]_]"W1_P 1)X&_Z*;+?_!&(_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_%30A!\-M \0:QJUCX?UKX3:-XGLUTRZBN_'VK&@#^F^BOYVO!_[.'C7XK>
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M7O-"N]0\"Z#XUOWT>:UA\3WMS<0?LSVWAOX^_$+]CKX'_M!WK?&;]CR;7O\
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ML/CII%IJ_@C1]93]GCPM=_"W7Y?%'C?4?!OAJXNO MOXR\:_$NP\,SZC=8<
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MX,\%?%B37]*\9_";P9)X$7X=:OX;TCPMXD\,Z#X]A\9:A>7]IXC3QKJ]QXE
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MKW[-GP4UGP!\0/V$?BC\+O!/[ /[-FC^.]/O;?Q1\0OAG^V9XS^)/Q9_;O\
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M/!&B:GHEM<ZX ?JWX<^ OP0\%>&/ G@CP5\&?A/X2\&?"[Q%/XM^&OA+PO\
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MU2]T?03,-%TZ_P!1U2>SB2ZN'9_P!\$?MNVO[.C:U\#]+^*_[.GP+\3?&_\
M;O\ ^"F/BZ]^-W[5^I16OP?\ ^!?AA^T3J\&K10^&Y/BG\'KSXA^.O&VO>,_
M#NB^%?"FD?%3PT=/TU?$WBZ^EGL?#$?A_6OI;P-_P4JU/QS\#OB5K.F_%?\
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MZV_:>^#/BGX]?#)O GA3QAX!\-I=ZM87'B+0/C%\$O#/[0WP:^(WA@F6+5/
MOQ5^$_B+6_!FJZ[X;OQ.FI67_",?$#P#K6E>)M%T2^GU+5=&LM1\+ZWY%^RG
M^Q-X4_9PG^)6NZE!\*=0U_XK^'_"G@G7O"WP6^!^E? #]GWPU\/O USX^U#0
M?!GP^^!EOXH^(#Z%8ZGKGQ.\=>*?&U]XA\=>.=4\7^+O&FKW$<FC^'X-*\/Z
M7^:'QN%IX6_9_P#VUO@?HGPR_9V^'$'P&_:F_P""8_@M=1^ /P7;X+:#XVOM
M6\5?L8>-M1UK6_"6F>*_$J+:Z=JGB6?P]X)T.VUZ]G\+^#-.T;0+C6?$-S8R
MZU>4/AO^V-\9/V5/@E\2M1^+OQJ_9VU'QG\<?^"FG[1?P ^'_P 2OBKX>\2_
M"?X2_"FYT#XE?%:\^(OQ*^*&O>+/CWXEM=<^'V@^$O 'V/X4?"#2_&'P]U&Q
M>S\)_"^#XA>(H]13QGHX!^TG@#]DW]E;X3Z'X\\*_"[]F;]GWX;^&?BAI2^'
M_B5X;\ ?!GX<>#M!^(NA16>HZ>N@^-M)\.^'-,L/%6E)9Z[K=K'I7B.'4[(6
M6MZI;!5M[^]BKU9O G@?^UO"WB$>#?"[>(/ VB:GX<\%ZU_PCNC)J_A/P_XA
M32;76]#\+:A/9&Z\/:/J\6@:)'J.D:3<6=CJ":-I45Y;RQ65EL_%"^_X*H>-
M+/P#^TEX<\ _$7]D']JCXO\ P3U7]E/4?!?Q0^ >K:G)\!?B%X0_:3^/7A[X
M,7NA^(=$T?XO?%?5/AA\2O MX_B**\TR7XQ>-1-9:IX'\=+I\EGJE]X*M/9?
MB1^T#\:?@/XW_:WF\7:)^SAX^^,WP'_X)I#]HA/BWX/^"OBWX;W7C'7=+\;_
M +3%YX8^'^LZ?J?QC^)'BVV^$_AZ#P7IMW_PC*_$2[NI_$.K>-M=TG7?#TGB
M.VTKP^ ?H=X$_9T_9]^%GBKQGXX^&GP(^#?PY\:?$66\N/B'XP\#_#+P/X1\
M1^/+G4[^YU359?%_B30M%L]9\3RWNJ7$VKWK:Y<W9NKRX>ZD\R[>\8[UC\'?
MA/I.C?#SP]IWPM^'6FZ!\(;VWU3X4:%IW@7PW:Z/\,]2L])U71;._P#AYI%I
MH_V'P/?6.AZKJNCV=WX<M[*:/3-4U'28W>&[D,WY6^*_V_/VBOV8X= \;?M6
M:#\$O%W@;XB?L<_&K]J;PSH/P0T7Q?X.\2?#WQ!\%-/^&^MZI\']:\7>.OB'
MXYT7XL6_BJS^*&A:1IGQ!TCPA\)H[75M/>=O!%[!J-D++L[[]H+]O_X1_'+]
MAKP;\;$_95\3>!/VN?'FL>#/&T7PV^'WQ4\*>*O@MKNB?!;X@?%5? ^F:QXB
M^./C72OBB;^7PY]CM_B8/"WP\MK:#PMJJ7'PNEG\;:/<>"@#]('^$'PFG\13
M^+)_A9\.I/%5SXPT_P"(]QXC;P/X8/B"?XB:+X7N/ NF?$"7Q!_9_P#:5QXO
MTOP3,_@W2?$S7 U[3?"\\OAX7\.E7*VD?->(/V:OV=_%WQ/T/XV^+O@%\$?%
M'QG\+II#>'?BOK_PH\!:Q\3-"?0WG?0_[&\>ZIH=]XITC^R)9[E]&_L[6K4Z
M9-+,()/WI=_-_P!M_P#:CL/V._V;_&_QTO+'1M3OM*O?"/A/PQ8^*]?C\&^#
M_P#A,OB1XST#P'X6O?&_C.X@:T\&^ M*UGQ'::QXU\3Z@=FB^&M/U&XC9;R)
M(G^'_A3^W[\1?B)\3?$W[-'@']I;_@G_ /M3_&7Q?^S[X]^*_P $?B/^SA%K
M=W\.?#/C_P"'5WX;TG5_AG\=/AMH_P"T9\8/$-EHFO2^+]%UCPC\0+#XL>%3
MK%E9>*M*D\+6VI:'8/X@ /UQ\8>#/!_Q%\,ZWX)^('A/PYXX\'>*+"YTKQ+X
M2\6Z'I_B3PSXATFZ$?VG3-<T+6[*]TK4;*Z"Q"6PU*WD3Y HWJ@QY'H/[)_[
M+'A738=!\+_LT? +PUHMMX)\5?#.#1O#_P &_ASHNC1_#CQW?SZGXZ\!1:=I
M?AV"T3P1XQU*634O%?A)HQX>U[49TOM:TZ[NSYQ_&G]HW]KC]HW]J_\ 9(^(
MOQ1^"T_ACX!_"/PG\8/V1_@[K5G\0_A_X_UOXL:S\;G_ &B?AAX;_:"\)R:O
MH7Q<^&^AZ9\-?AKXU\1Z)\)O%"RZ%XMM?BG-X1^,OAZPURQ\.^)/#WBK3ON+
MPA^T)^UQK?QI_:V\-7)^ FN^ _V-+/PE8ZGH^D>"/$_@SQC^T#XQ\3?LN>$_
MBNVEZ!XS\8_M"+X&_9^TW3/B'KC%M1\;Z3\5M&N_!^OZ;H&JZQX=OO".I?$'
MQ$ ?H4_@;P6VK^%_$@\%^%6\1>!M%U;P[X,UYO#VC'6_"F@>((](37=$\+ZC
M]EBO- TG75T#0X-5TJPFT^PU!M%TLWMO(FDV07R7PK^R5^RIX%\7R_$#P-^S
M-^S]X,\?2^)IO&5SX[\+?!CX<:!XOD\6RVOB&PD\52^)]+\-0ZO)XDGLO%/B
MFRN==DOI-9-GXH\11RS+%KNI>;^?'[-/_!0WQ+\1OVHO!WP&USXO?LL?M$^%
M/B%\#?B%\3SXX_9/\,>/+;P?\&?&OPWN_ DNM_"?5/BW=?%GXO?#3XYZJFB>
M/;22XNO MU\/_&/A==+TOQ!XJ^'.A:9\2/"5O#Z=\!?C#^WE^TS\+OA_^T=X
M%U/]E7P+\)/C/9ZSK_A+X8^-OAC\7M5^)WPZ^&6O:1X@3X<>/M=^(FC_ !BT
MWPS\4?%<=Y;^$?%'B/X3:;\.OA)I.I:1K6M^%]-^-.E:GX>LO$?B  _42(L8
MU+?>8;B/0M\V!E$;:N<*717*@&0;]U25^:__  2;O?B=JW_!/W]FS7OBGXUT
MGX@:]XF\ :?XAL==L/#FOZ#K,NE:LCWL5OXTO_$GC_QY?^-?&MUJDFK:MK?C
MR*]\/VOB)[[;<^'[.ZMKC5-4_26-MR*V0<YY&<'D_=)"EE_NN%"NN'4;6% #
MZ*** "BBB@ HHHH **** "BBB@ HHHH I7")*)HI(EECEC,<D<RJT+QLC!BR
MNDL3)EE1PT1;!S,# $KGO"7A'PIX!\-:+X(\">&/#G@OPAX:T^#2?#OA3PEH
MNG^&O#V@Z3"VR+3-$T+1;6RT_1M.MT9!;6VG6L%O!)&RMM(+MTLP!W[B(R0
MDA*D#?M!/SJ0C90 *X>%F\MBDK;HQ^5^M?MN_%C3_P!ESXU_&Z'P]X /BKX;
M?MT:O^S+H6ESZ1XC70I_A_8_MH^&_P!G&#5=7L8_%<&I2>-SX+U>>\N+RTU:
MRTZ/Q/';7L/AZWTUY-"G /T T;X,_"'PYXMO/'OA_P"$_P .-%\=7^K>*=>N
M_&NB^!/"6E>*[O7_ !M:^'-.\9^(+[Q)::9'J=QK/BRP\&^$++Q-JK7CWGB&
MQ\,^'+/5$NX?#FGPV?6>&O"'A;P;:ZG8>#_#'A[PK9:QX@U_Q5J]GX:T;3-
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M\2?'D>HMX9?Q/8ZEIVGZU::/8 'Z1_$K]G7]GSXQ:_X6\5_%[X$_!WXJ>+/
M<K3^!O$WQ'^&/@SQOX@\&R&[@O\ S_"NL>*=!UC4=!F%[;6EX6TF>W)O;6UN
M/DN8K<)T</PM^&D'PV_X4W%\.O D?PA3PH? T7PM3P?X?7X<#P.+%=)?P8/
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MM,^.'[.'@3P/XD^%=AI^@ZUXHTC7_'7BKQ[XDT[XB:-J?ASP'9:!X5UW6=7
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M$TGXTZ)<:3JFJPQ_$W2/"WP;6VOO!S72>"9(_&T-GX? /W?HJ.$,(P&QG+\
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M<T[X@?$M?BM\1?&C?#)/A/J_@SQSJ_Q(T6'XJ>+9/%'A#0M)NO!DD7B+Q&-
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MLO:#XTDT+XC?LG^#KCX)_"7P'XQ\,?L[^/+76_C!^TA^U+I4'P]MO&_C?4O
M_AKX-_&?2_%?P&\&Z+IMEK7A>+Q_XU^#OQ7TG2_^$4\8_$_Q1;Z!\*]#77+]
MOCC]HSXE_"3]LO\ :%_:2\6^./#]U^SO\*_^"8GPV_:*N?A#;?#WQA<>,E\.
M7OB3XWZH- \-^)[GXP)X2TGQYJ?B[PFD_B+QR_PQ.G>)?"<7@WP)/X9T6[\%
M2^-=2 /U9\ ?LX?L\_"B[\.7OPL^ WP9^&=[X/T#7/"7A:Z^'OPM\">#KCPY
MX2\1ZT/$GB/PUX?D\.:#93:+X;\0^) OB#6-%TR2SL]3UZ&/4[ZWN+LR3G6?
MX*_!J3P+XF^&#_";X:/\-?'-[XAU3QM\/SX"\+R>!?&6J>-=4N-8\5W_ (J\
M)C1WT#Q!=>*M;N;S6_$^HZE827&M:K<3:GJ$ES<W<TS_ )2? ;_@II>>(?C'
M^S9X!\>_M'_L!_'-?VH[W5?"\GPV_9+\:)K7Q/\ V<OB O@K6?B-H>D>-+J#
MXU?%6/XQ^"!I_AW6?A_XE^(]AX'^"T6D>,%\,:A)X7;1?%%Q:Z!^V<>=B@DD
MC()889B"06(V1@%B"WRHJ\_(-N* /GC0_P!D[]E?PIIT6A>%OV:?@%X;T6#P
M5XK^&T.C:!\&_AWHVD)\._'^H3ZMX]\!II^F^'(+8>"_&6JSS:GXM\*/$/#W
MB'4YQJ&LZ?>73"=NPU_X)?!SQ9!KMKXI^$7PS\36?BGP-IGPQ\46WB'P)X3U
M>T\2_#72;O4-1TSX?:[;ZEI5Q'JO@W2M2U+4[ZV\*W]NVA6DVIWT]KIWVF61
MCZU10!\WZ-^R1^ROX>T=?#_A_P#9E_9YT3P]'X*\4_#:VT'1_@O\.M*T:#X>
M>.M3EUOQQX!&GVGAJ&UB\%^,M9=M4\5^%8K1=&UW5#-JVN6-Y=R_NN@^&_[.
M_P  /@YKOBSQ1\)/@5\'/A7XJ\>N)/'/B/X<_"_P7X%U[QBT=S<:@H\4ZQX=
MT:QOO$#+?7E[<J=3NKZ-;J[O;R)O/DN6;W"B@#YZ\5_LL_LQ_$3P+X3^&/Q
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M/V'?"6E:'^UMX.\>^*KCQSX+_:W\-^"O"7BK0;30_P#A%+O0O#7AS]G+P/\
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M5K'C74?B'X3^(BWWQ2?1/C/\-O$.F?$+Q5X4DTC0=(^#NMZ9X;UB\2Q\5?\
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M(?%&GMX?U6\\)^(O!OQ%\.>,_AI9>'/$.A^/=&GU+PU<P^(=)UGPDFN&W-B
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MT7PMX:\&^'?$46E>+8EN/"OB3Q3< 'S3H_\ P2^\&3?"W]F/X0?$/XA2^.O
M?P'_ &6/V@OV7/%VGVOA&;PQ<_$_P]\?=(^'&D:GXCTR]M_%VL-X N- LO $
MGV#1K-O$D5X^N*Z:AIO]D)#>Z-K^P[^TAXC^+G[)_C[XT?MDZ+\2O"G[(/C+
M6?$O@[PKI'[.</@CQ#\1/[4^&7C?X9)K7Q@\:M\9O$\>M_$33]-\46-U#XF\
M&^$O G@F:5/$[WWPNN[KQ/H^I>!OKCX*_M2_!3]H/5/%WAWX;^(O$9\5^!XM
M O/%G@SX@?##XJ?!OQOI>D^*K>ZNO"OB8^!_C#X,\!>+[WP/XG%CJ,7AOQA8
MZ-/X4\0W6EZK8Z;K=W>6&H01P_&O]JCX*_L_7VEZ1\1]7\9W>O:AX?U/Q:GA
MGX;?"#XP?'7Q;8>$M!GBM]5\=^)?"?P*\!_$3Q#X7\$:??SPZ?-XP\0Z-I'A
M1=9D73X=5>]010@'9_ 3Q%\2O%GPJ\-^(/BYIFFZ1XZU&[\4M?6FE>%=>\#6
MLFBV_B_7[3P;J4G@WQ/X@\5>(/"^H:SX+@\/:QJVA:OK^HWNF:K?7MI*\!B%
MK![#7Q]XY_;E_9>\ Z;\&-4U;XG3:XG[0_A?6?&/P&M/AMX!^)/QGUKXO>'?
M#]MX3O\ 5KKP!X:^#_@[QSK?BF[M-/\ &'A_6AHFC::^O7.BG5]9LK)](\,>
M)K_3?:_@[\9/AO\ 'SP!HWQ,^$_B6'Q5X*U^34;2SU!M/UK2-0L]4T/5+_1O
M$&@>(?#?B33M'\2>%_$GA_6=.U'0O$7AOQ'I.EZ_H&MZ??:3K&GVFH6<UNH!
MZM135  &.AR1WX)) ^@!P!V  YQ3J "BBB@ HHHH _,+_@HW\,_C)\2?%?[!
MT?P2U+Q1X:\4>$_VR])\6WOQ T#P+J7Q"T;X<:39? ?XY6*:]\1/#UC)IT$W
MPVUO5+ZP\&^+UU'Q5X)CU+3O$+>']&\5^'O$6L:?JT%3Q1_P3L\2_$GPO\:_
M$'Q2^.>B^(_VE/C%XQ^ 'C"/XI:)\'IM#^$_@FT_9:\<V/Q"^"GPXT#X&ZO\
M3O%6LWWPOLO%%OJFM>/M"USXU7NO>/\ 5O%_B>Z@\4>%+=/#%GX8]6_;>_:]
M?]D;4?V6]3U#_A'X? _Q=_:-T[X2?$;4-4\/^+/%6OV7AG4?A9\4/%ME!\//
M#O@VZ.NZY\0=:\5>$O#FA>'M"TO0/&.I:Y-J0T#2/"VI^(-;T/R=?4OVT?@M
MXE^%GC'X@^"?BQ!X'/P_^(_PL^'?CI/BQ\!_C58^*O GB3X@^.?!.A:#X4\<
M? ?Q';?"3XS^&M1^(UKXQTNR\!>(-;TW2M#TV3Q!I'Q!N5\1^#+"^TO4@#P/
M4?\ @GQ\6/'_ (X_:3^(GQD_:?T?Q;JW[5?[(.O_ +)OQ$T'P;\!SX&\*>$M
M+<^+;;P3XI^$=CJ?Q@\=>(O#L6AV'CCQ-J/C+PYX]\4?%*[\8^*]6EU/0_%O
M@G0K;3/"-CVWAS]@J;Q ?'+_ +07Q-\/?%NS^)_[%7A']C#Q]I7@[X8:E\+]
M+UGP[X5\3_%?4O\ A.=(BU?XF_$Z\T36-6T#XD6^F-:OJ&JI9:_X?_X2_3=7
MAMM2L_#VB^Y?&/\ ;._9U^ _BN;P3\2/&7B.#Q1I_A'_ (6#XGL/!OPL^+OQ
M3A^''@"2[N;&+Q[\7-6^$_@#QKIOP9\ 3SV.LO#XU^*]]X/\/26>B>)-2BU.
M2S\-:[<Z5S7Q(_X* ?LH_"[Q=#X$USXDZSK_ (RG^%^A_&NT\,?"GX2?&CX[
M:QJ7P?\ $CZ]%H_Q0TJT^!_@#XAM??#U9?#NH+K'BNQBO-&T%+GP^VOWNE?\
M)-X5;60"I\)?@9^UMX/UGP'IWQ(_;"\.^.?A3\.-"U'1++POX/\ V:]"^'WQ
M#^):+I\&B>%6^-WQ'\1?$SXGZ-K0T#3 VI7Y^#'PQ^ 5_P")?&IM=5>\T;PI
M'=>!]2XWP9^P>/"7P1_82^#K?%(ZF/V*?B-X5\>OXA'@<V?_  LK_A&OAI\4
M/ATVC'1U\8W \(F]_P"%F2ZR;]M0\6^2ND-I_P!CG;45O['T7X:?M[_LH_&/
MQ?X$\&_#3XGWGBF?XH6VIW?PL\50?#CXI6/PG^)MQX?T67Q!XBT'X;_&[5/!
M5A\&O'7BSPSI=IJ,WB?P-X9\<:KXP\,7>@^*=/UG1=/U;PAXCL-'T?"_[;_[
M-/C/XEZ%\)M!\=Z]-XH\7:SXL\.^!=:U'X5?%_PY\*OB7XA\#I>S>*] ^%/Q
MQ\2_#_2_@C\5/$.BPZ7J\]QH?P]\?>)M5QH'B+RHKB+P[KLEB 6_V./@#XK_
M &6?V??!7P \1?$?1?BGI_PS@G\.^!/$6F^ KWX=ZG#\/[61&T#2?%EM-XZ\
M=6OB/Q?I4+7":IXQL)?"=EKC/9R2>$]&NVN+F[^./CA_P3@^,'CKX1_M#_LU
M?"#]K32O@]^S3^T7JWQ%\3ZWX-U7]G^'XF_$7P)X@^*]_JGBKXBZ)X$^)4GQ
M>\%Z%8_"SQKXZU74?%7B#PAXF^&OB?Q8D7B;QCH?A/XI>#M.U?PU+X+ZK]I;
M_@I)X&\&?"CXQ:S^SM>/\0OB5\'?BCX'^&'C"?Q%\'?C>?A#H/B>7]I;X??
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MOX>^!?V@-7\"V?P)\>>/M+?1M;LKCP?X3^)6K>(CJ.A^(]/DTK^T_#FIV5H
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M&>*?AGXE\86\?B;QEX?\+?%#P;8ZIX;D\%;_ ,?O^"K/P/\ AO\ "GQ)XO\
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M#X(\,^"_$WBR;6/B7:>.]8^'*^)OA)\8_ =G\0_#OPSM/!%]XJ\7>!]9\=^
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MZTNH^&?$EKI?B32M5TNR /HZBF1\HISG(W9XY+').5^4Y)R64!6/S* I #Z
M"BBB@ HHHH **** "BBB@ HHHH **** /B?_ (*!_P#"S%_9D\52_"KPK<^*
M_$D'C7X.7E^-(^&6C?&;Q?X6\':;\6?!VH^-OB/\/?A7K^A>*-)\=_$WX7>&
M;;5/B%\--#N?#'BF>3QQX>T2YTSPQKFJVMAI=]^-M_X"^)GB/QS_ ,%+=9\/
M^$/VZ_B[HGQZ_P""7/BOP9\-OC#^T-\&_&>@>*OC'\1_")^-,6M>"_#GPRL?
MA?\ #'3_ (0:A91>/O"GA7P'\-9?@E\'-1^)4VC:S\0?!GA3QG<Z]JWQ-\9?
MTU44 ?A%^VW^RW\7OCQI7[.?PS^&_A'6=&UG4_\ @G+^VM\&9O$4FAW^F>%/
M"/C+QIX#_9GTSPAX.\:>(?[&N+'P4=?NM&UO2K"TU*6U>[M[#Q%'IJB[T:9[
M;1\=?$_7OVA?VD?^"7EMX,_9._:B\$-\$?C+XL\1?&+7/'O[.?Q!\!^#/@3;
MW/[,WQ=\$)X%E\?:[X8TWPIXTL=6\2R6NF1>+_A-K'BGX5RMHOAN&]\4V]QX
MH\$0:S^YE% 'P=^V;X.\5^*/'?[!%UX6\+>(O$5IX+_;<\,>*O%=[H6B:AK5
MKX5\)6OP _:&T:X\1^)9K6VN(M%\/QZOKFA::^NWMQ9VL>KZCI-B;H7UY9QG
MX0\2?!?XGS_L,_M,^%4^$_CJ;QCX@_X*D:W\2=%\/6O@CQ#-XEUOP</^"D7@
M;QG:>/\ 1=*CTTZEJ/AQO EA<>*K'Q9#;:CH0\%V4GB">]N/#\-Q,?W@HH _
MFW\6_![XS:GX7OIM,\/?M/> -0_9<_X*U_M$_M(>-?\ A67P0&M>.]4^#_QF
MUWXZV7@KXL_L\6'Q=^%OC_X1?'RY\*6?Q%T/Q/>^'/!/@[XD^)+#0AXCA\/Z
M%;?$JW\/:->=!X\^!'BCXLZ!\=/CO\-E_P""@O[1?C;PSXO_ &)M;U]/VI_@
MM\(/V;[7X]> _P!E3X\6GQ]UKX9?"+X/#X$?LN_$37?%.G:#XC\6VO\ PD'Q
M&^%%EX7\6ZY>Z=X'\(^,M>ETO6=/T_\ HHKS#XN?"3X??''P+KOPR^*/AN'Q
M/X*\0K8OJ%@=0U31=0MM0TS4;+5-#UOP_P"(- OM*\1>%_%7AW6;#3]<\,>+
M_#6KZ1XI\+:[I^GZQX:U:PU>UM[NS /P _;)\>S?M1_M(^/8?A)\%?CQ#=_\
M.A/^"BW@W1+_ .(?P'^)7P=\8_$WQ5XCG^"5M:^!_!GPZ^*W@KP;\8O$']AZ
MAK>BPQWDG@^R\):UJ?C5]%\*:KJ6I:?XJ31OL7]HM?B=X3U?]BFTM9/CU\'_
M (7:9\!/'OACQQ\8OV7OV6;3]H+]H'P/XTGT3X1Q>&OA)'H\_P"SY^TCXC^%
M/PX\;V6D^(=8\7ZYI'PV2+_A(OAKX(T34?$WANY&C+JWW]\(?V9?@_\ !'6]
M;\4^"M+\9ZQXR\3:;8Z%JGQ"^*_Q:^,/Q\^(TGAK3;R74M,\(V/Q$^.WCGXE
M^.=+\#6.JW=[K=EX-TKQ!9^$[/7M1U37TT>/5=4N[N;Z(C!"+G.<9^8DGDYY
M+/(>_P#?;'0''  /YI?@9X+^)WPR^!'[.]QXI_9^_:F\/CX'_P#!8+XN?%;Q
MSX7\0_#KXI?&GXJ:/\*?B5X=_:';P?\ $2ZU/PO'\1?%7QOLHHOBQX*B\:?$
M#P5K/Q')U>Y\02:YK-U=Z5K-U:NO?@-XU\&^#?VL?V6/C/XY_P""G,UI\:_C
M[\?M0L/A9^RW^S%\"_B!\)_CI\.?VFOB5K?B'1M6TC]I'QQ^R/XV\-?#O7'\
M/>+(="^(NH?'O]IOX7WWPZU+POK.J6VI^'/!D7AC5Y_Z6Z* /Q2LKKQ%^R5X
ME_;I\$^._@/^T9\:E_:;UC1?B)\%/$'P\^#OBSXW#XFV-Y^SI\-?@G<_!GXE
M>,? F@ZQX)^%OBCPSXA^'MW)/K'QEUOP/\+KW1/&T.NZ'XMU Q^,K73/J/\
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M=TA[/5B^KZ43@/\ "?XM>&? /@_XIW/PB^(GB33/@+_P6-_:<_:,\9^ -/\
M!/B:_P#'_B#X-^*/'_[07A;3_B;\-_ <446N?$9=)MOB1H/Q+\.V?A2Q\0ZO
MXJ\+V$]]X"L-9N6T[2]2_?>B@#\A/VG_ (]>-_B[X;^$GBCX3_"W]JSX=?#/
MP9^TIX;L_'WQV/[&5_XF^/G@[PO=_"#XDPWGQ#_9[_9T^,OP?^)'Q>M9]/\
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MK3]*\66'@K3KKQ_IFB6VH?T21@!% &T 8"C@#'& ,+@#& -J@#&% X#Z /S
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M^O\ G^>: /RZ_;FU#XDZ9\;?V=KS3M4^.WPU^$[>!?C?I7C+X[_LL_LRZ?\
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MB+2;"^M[?[;X>U[3+F#4-'U*!7L]2TRYM;^SNKJTNH;NX^^** &H %  ('.
M<<#)P %X  P% Z* #S3J** "BBB@ HHHH _+[_@I"OBO2?$_[!WQ%T#X/_$O
MXRZ#\)OVT- \>?$+1_A;X%\1_$;Q!X6\$P?!'XUZ%J?CI_#?A>UO]6N;?PI=
MZWIFJ0V5G93ZAK&J)IFA>'K+6_%FM:%H>H?&_P >_ 'Q'_:#U#]KG]HWX?\
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M>N],\00:?$QO[32-3TS4V"Z=J=F\O>I]Q>=W&=PZ-G^)<,P"MU4 G"D#C&*
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M5\0O$WBGQ->ZUXR\>^)6O-;T>]\=^/\ QGKNN>(M6U3Q!H+:]KU[J&MZ9]K
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MQ3IFJ_K;\6_V//V?OCCXWC^(OQ$\(>(+[Q4_A6'P'KL_AKXH_%GX=Z1X_P#
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MPMX=T^UTG0O#^A:1;1V6FZ1I.FV4<-K96-C;0QP06\$2)&B !<YH Z:BBB@
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M?LL3Q#XBZGI^C7/P8^+?@.^N+Z\\0Z)<?"SP'9>!_ NKZ]YC^Q;X)UT?!O\
MX)A? WP7\6?C?X#\._M!?L+?MGZGXJO-)^-OQ<O[BQ\:W&@_L]:)X6\8^%EU
M3QQ<#PI=^ !JVKZOX#TKPDVDZ3X2O=6UN_\ ".G:)=ZOK%U=_K_X&_8%_9:^
M'/C[P!\5O#G@WQQJ'Q1^%UGJ>G>!_B3X[^//[0/Q/\::3X:U31I=#OOA^WBW
MXG?%/Q=K^J?"V.SGGU#3OA=KNI7_ ,.-(UR[F\5:)X:@\17%YJ;]-\)OV+?V
M</@9?_#[4/AIX+U_19/A3;_$RQ^&L&J?%#XM>,M-\":1\7)/"<_Q!\/^%-&\
M:^._$NEZ)X2U>?P7X7FT[PI8V%OX:\+3:;/-X7L-%.L:M_:H!^*WB7]MO]HW
MQ;\*/#_B/PAXAUV7XF_\$^/V)_VE?B[^UQHVC:UJ5EI_BS]J+X=0_$']FOX;
M^%O'VC:7>Y\2>#]1\<?"WXY_&]?#'B&VU#1;RQ\-^$=5OIHWGTNX;Z2_9NT+
M]JSPY\3?V5_$O@SX3_M[R^&_%,=Q8_M>>.?VK?VG_@%\4OA5X]\+>(?A[JFL
MV7Q1\"^ -(_;&^->J?"[QG8_%.W\.7_ACPW\"?AOX \#_P#"'>(/$^@ZEH+V
MVGZ ^D?J;X#_ &;_ ((?#+Q1\<?&7@GX<:'HWB']H_Q%;>+OCA?2G4M2MOB+
MK]IX<B\+1W&KV.L7VJ:?9VCZ)"UO>Z5IEA;:'J%S>:EJT]G/K6L:Q>W?EOPW
M_8._9>^$?B_PEXZ\'^ O%$VJ_#6WU6Q^%.D^.?C1\;?BAX ^#EOKT266ICX*
M?"[XF?$GQ=\-/@M-%HL7_"-V5U\+_"'A.YT/P=+?>%M%GA\,WU_H]R >'?\
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M]2TKX@R^ [./PU9^*KZUFBMM='A&T'AZR\03L^AVQTR&XC>U_)[]G+QA\9_
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MMUH?QO\ &/Q!L/">N>&_%NL?#O3I;SQ+HWA[G_V;_P!@+XD_!KQ-^R=J>O\
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MZU+-J7@CP[XHL/",_B76[_P?YK\%?VU?V@_A3H_QR\8?$3X1:C\1OV>_#O\
MP4A^-GP$U7XP^(/CGJMS\4?#=GXX_:JU+X7^!6^'/P?O/AYXATC6/A!\.=4\
M6>#O!MRNO_&'X>ZWI-E;ZY9^'/!6JZ)X:TJ37/C=/'?C#XF?!C]C_P#8+^#W
MQH_92^-6@?!_]I3]EO2;4?#7QAX^UC]L#4/@]^SY\=_!NKQ-\;_V1M<^'7A"
MY_90O_A-X%\++/\ %WQQ\1OB3XAM9/$WA*S\*V_@[PKXG^*VAZ9X;_4C6OV(
MOBO?_LL_&SX)6VO?#U/%7Q*_;GU+]I[1+U]8\0GPY8_#^^_;:\,?M'C2+^Z'
MA-KU/&,?@'1KK0XK&#29/#D'B@Z?:V^LVVD)+K=L ?JHF-H & "1UW'@D9).
M26/5LDG<3DDY-.IJ#"@9)QD9.<\$]R 2!T#')888LQ)8NH **** "BBB@ HH
MHH **** "BBB@#Q'XY_$CQQ\.?#VA-\-/A1JOQ?\>^,_&.D^"?#'AZ#4M1\-
M^#](N]1L=4U:Z\6?%CQ]I_A/QQ+\./AIHNF:'J)UOQ7%X/\ %6HR:A+HGAOP
M_P"'M=\3^(=%TF?\_P"Q_P""I?A^P^!7[3?Q*\9>!?!%EXU_9;^//AK]G+QU
MIG@7X]:+X\^!+^/O'.J^!]#\)^(+G]HW5O!7@N#PG\-]%U'Q]IEC\9/$7B_X
M9:7K/PIO=&\7VE]X6UW5="CMM9]^_;O_ &:O%_[2/AGX/67AOPU\)OBII7PR
M^,^E?$KQK^S_ /'O5=:T3X+?'3PW;>#?&/A:'PGXZU/1_ 7Q8:W/AGQ!XDT?
MXE>&8]3^&?C+P[<^*?!FD0:QHT)>WUS2OG#X$?L@_M4_!G3_ -L@VOAG]BHV
MO[1.K?"CQ/X%^#D%EX^G^"GACPWX4^&/ASX2>*/V9-9TV#P!H<%OX#L/A[X)
MTGPGX1^,=AX:U:WU&[U?5?%VM?LPZ7I%E:?#"\ /O'X,>._VB/$FM^)]!^//
MP$\(_"U-*T[1-5\,>./A7\=+7XW_  T\7VVI?;X=0T-;[Q-\-O@A\3=$\6^'
MI[)+K5+34/A3<^#[K2=7T:ZT+Q]JNHOKFA:/\Z:[^W-K_AOXJ_M;:/KWPH\-
MZ'\ ?V(]/LM7^._QOU[XKZK8Z_=Z1J7[/^B_''3V^%OPJTGX5^(K?Q9J]G-J
MMQX;\1Z3X@^(_@1M-L1H6N:'JGBW4]5N?"FC9W[%G[(7B7]G_P"*WQN^)LWP
MO^ ?[,GA'XI^'?AUX?T_]F;]ESQ1XC\7?"&V\0^")?$7]K_&74+W4?A+\!M!
MTGQ[XXTW7-#\):MHWAWX2VB0Z/X#T_6]3\9>*]4UN[AT#7US]B>[^(C?\%(_
M"_Q+UK2D^'W[<YT#1]'E\-7&I7/B/PSX=M/V9? _P5US4=<L]4L;73;?6H/$
MOAK4-:T#3[6]\3::VE_V8U^8GNM4TFT *_@C]M+XLV'BOX)V'[1W[-6G_!+P
MA^TW;ZU'\$M<\-?&3_A:WBV/QEIO@G6?BAI7PP^,_@=OA=\/K+X??$3Q/\/=
M!UZ_T:V\ ^,/C3X1?Q/X<U3P3<^-O[3NO"]QXGJ?LY?MH_&[]HGPI\,?C5X>
M_9N^'VH?LT?%W3=>UCP[\0_ /[3^C^,OB9X%TO3[;59](O/C5\*-;^%'@7PM
MX6NH+_2)O"'Q#\,_#;XR_&?QC\,O'-S;Z!J/A_6;2QU[7M"\>_9P_85\6?"W
MXA?"K5]3_8P_X)1_"%_A;I>KKJ_[0'P9^%5SXD^-?Q#\0V^BKX;T+7?!WAL?
M!WX(Q?L[WVL27.H^*?&EV_QC^/L]K:K/X#TM]376+GQYHF9;?L5_&#4_CY\/
MOC_XP^"W[%/P!\;?#?7/B3XN^*O[1'[+.N>/;/XI_M66?B?P+XC\(7?A'XB?
M#F^^"O@"S\,>$_&.M:KHWQ)\1Q^//CA^TAJ'@G5?".DZ3H&N:S>W]Q\1+  Z
M'X)_\%)_BK\0OAO^SC^T1\3_ -E'2?@U^S/^T=XI\$^ ]"\=2?M!6'C3X@^"
M/$WQ'GM/"W@36/&'PTM/A5H7A]/AKXR^),R>"?#WBO0_BAJWBV#3]9\+>*/%
MGPX\'V&KZU#X<[GQ]_P4"\;^&M+^/?QE\%?L[6/C[]DO]F'Q1XD\(_%[XKQ_
M&6WT7XJ:E=?#2^:P^-^L_"'X(O\ #K5?#WC7PQ\(9X[NTUFX\7?&OX5Z]XEU
M'PQXRL_!GAGQ#'I?ARX\6_$7["GP4_:B_:9_85_X)^?#WXHR_ _1OV:? L?P
M)^.5UXV\,>)?&]W\:/B%I'P?UJS\=_"WX47GPPOOAQI?@KX>II'BS1/#-OXN
M^)^F_&_QM?\ B;0O"KBV\#>&9/&\X\._3OC?]C']J"U^'_[4W[*?PGU;X'6/
M[-O[5_C#XH^)[SXM>*_%GQ)MOC=\%M,_:*U'5-3^.WA;2?A9I/P^UGP9\6[N
M2]U/Q)<_#3Q5J/QL^%G_  C4GBRULM?\,>);7P="OC< V_B?_P %%_B?X8UO
M]KO4OAK^R[H_Q'^$/[%>D>#/&/Q.^).I_'F7P5J/C#P)XI^"W@_XXW4_PD\%
MVOP>\9?V]XV\/>%M?U:74?#'C#Q'\/\ PS/I]IX5N4^(!N?$VJZ3X)Z;XB?M
MK_%?QA;_ ![M_P!EK]GP?%GPG\ ?"&EO\5_&7B7XN3?"3Q6_B3Q5\+])^*Z>
M#?@-X1TWX8_$"T^)/Q%\*?#WQ+X=U;6-,\=^-/@?H,'B3Q'X;\/:3XGU1YM=
MU+PVFL_L1^/CX _X*7^!/#FN^#4L_P!K[X?V/@CX,_VKJVL$^'DTS]CWPE^S
MQ9'XDRP>&+J+3HD\2>'Y=7:3PS9>*;B\T0P7]TAO)YM"@Y:P_99_:[^!"?&W
M1/V:)_V<O$OAK]I;1O#&N^+[[XQ>*/B%X5O_ (+_ !JL/A!X,^"OBSQIX7T3
MP7\+O%D?QT\%>)O#G@CPUXCB\$^)?%OP9U72_%.F:R)?'5Y:>+KFX\- 'FO[
M&G[8WQR\4?LZ?L9?![X4> ++]I/]HJ\_8C^#GQ[^-WC'XZ_'CQ'\-= \/:/X
MQTYO#WABX\6?$FS^%OQ[\9^+/BC\3?%/ASQ9<:=HK>%5LI-/\,:[KGB?QEID
MESH5MKGLEI_P40\9?$74OV:_"7P)_9]TWQ/\2OCY9_M+Z?XC\+?%CXQCX8Z-
M\$/B#^RIXH\'>#OBOX*\?^(_ WPR^.-UJL,6M:[KVEZ%KGA3PYJ5IK.KZ5X6
MN5LXO#'C2X\4>$/E;PK_ ,$G-?\ A_H'[-'B+7?@!^P[^U_XZ^'G['_P@_9<
M^+'P^_::.IP^"[#5_@\=9O-!^)7P2^)VI?L[?&W5M'>[G\2:]H'B;P[J/P7T
M0^+=)'AK7(]?\-7_ (;FTW7_ +"^#W[&WCKX??$S]C[Q]-X5_96^%VD_!3X;
M_M2:+\0OAS^S)X$UWX4_#?3_ !1^T#K7P>UK0K#X>>&?L5W9>(K+P^_P^U>U
M\7^//$5QX(U/Q?J\MEXKT[X?>&VUN[\+Z, :?PW_ &S/CA\:?$7C'6?@[^S5
MX#^('P:^'/[0GBW]GKQS=6?[3.DZ/^TEX9UOX?>+8O _CKQ#J7P%\1?"C2/A
MSHNF:1JB2^+-+T#Q#^TSH/CCQ#\(I]'\<Z3X6O/$7B'0_ %[^D$3%D5B,$Y.
M./4\\<$GJ2I923E'D7#M^0'QI_8E^,_QQ^-&A>-=<^#W[%'@SQAX8^-_P^^(
MF@_MV?#;4_'OA/\ :VM/AW\/_%5AK>G^ 9OAW#\))9[S4]>\"6MW\#_%%UJO
M[7%_X&UO1M:U;QTWP\M+%-/^$EE^C'PC^)6L_$F7XK+J?AG3_#T'P_\ B_XL
M^&VDZAI'B6Y\36'C#3/#5AH5W%XEBGN?#'A.32M2CU'5M0\+>)/#*VVKP:)X
MD\-ZQI<7BK7(;9;F4 ^7OBI^UU\<M/\ VKO$/[)OP%_9G\,?%;Q-X8^!W@KX
MZZQX]^(/QYF^#G@/2]$\6>)OB'X47P[=RZ9\&?BUX@?Q3<:IX-L!X9AT[0=5
MTC5(+_7+KQ)J?@FW\.6,OBEWA[]M#QM\6?A3\(O&WP%^ <OB;QI\11\2H/'.
MA?%CXA7?PO\ A;^S]KGP1U(^%?C!X5^,/QJ\(?#SXT6^F>)=$\?03^#/"&D>
M&_ NMKX[GTW7/$]E+I_AC0]4URR^<?&&K_M+Z7_P5:^-C_LY^'_@SXWED_85
M_9X'BCP=\9?'/C'X5Z7+))\8?VCHO#OB+2?'?@OX6_&+4(;GPO.UW!JO@VZ\
M$K%XHL?$27A\2>'+GPYI\.M\GJG_  3*\<>'_#G[,]M=>#_V:?VR(?AHO[2G
MB3XR?"+]IRZ\0> /@SXL^-/[2?C[1_BAK?QQ\!Z59_"']HK2]/\ $/@CQ(OB
M_P &^"M \3> M5,/@#QMJ:67B33=14M= 'K'AK_@IK>?$/\ 9[_9Y^+?PH^"
MVC>/_&?Q[_:@UW]DBR\'VGQLLW^'.B?$/PI8_%M[WQCIGQGT3P!XQ7QQ\))-
M4^%DM[#XZTKP';:O>>!-93Q9;^%)-=TZW\'ZMX,?VJ_VG]!\4?MZ7O[2/PV\
M*3^!OA=\??V)_AUH'A+X.?M>?%K3[SP-J_Q3NOV9(K#2/"7B[1/V>O@CXAU;
MPE-=_%"]^*/CK5+ZYTC6_%5V]U\$-;\+>)/A]J*^(;?TSX*?L%_M(>!_#GP;
MT#X@^+/@IKMY\*O^"D/Q+_;,O_$?@^?QEX>L/%'P^^*7@SXU-JFA6'@6_P#"
M^N1^&/%&@^/?B]]ATGP^/&GB+2'\):)!K4WCN/5[NX\-5O?&7]B;]H/QWXT_
M;(M/#5]\&_\ A7?[27Q>_8S^-GAC7]<\9>,[#QKX;U_]G'Q#^SQ:^,O!OB#P
M98_"[6]$U#3-;\)_"#7=6T#Q?;?$&[U$^(K_ $G0M5\+66G37OB2R /4/VO/
MVX_B'^R[HOQB^)9^ 7AO4/@7^SO9>%;OXC_$CXN?&V7X#ZIXRO?$.GZ9K$NA
M?LS^'[KX5>-_#'QM\1V&FZM8:*EKKWQ#^$.EZ]\2+]?A=H.IWNN6VOS:9T/P
M_P#B9KWB_P#X*%>.-*LO$WB5_AIJ'[!7[.GQ(\.^#KW5-37P]IVL>+/C/\?H
MKOQ-_P (J-1;2--\2:EHFF^']+U;5#:1ZO=V>DV>F2R2:=ID,K?(7[3W_!./
MXS?&+QU^V?J7ASPA^R/XCU7]J3PM>^'?AQ^U5\8W\3ZY^T#^S%X7UOX(6OPE
M\1_"GX>>"-/^$>JV]YX)UJ2Q\1WNGZYX<^/7P[N-,O?B[XQU_6_!/C.?1T\/
M>+_L_P"!'[._Q:\&_'RQ^-?Q%E^']NEQ^Q-\ OV>-=T'P3XD\2^(&L?B/\,/
M&OQ/\3>*[[1+[5_!/A/^T?!-Y;>-M*M= U:_CTGQ(]Q97R7WAS3(4COM0 -G
MQC^T_P#$>P_:W'[+_@3X.>%=?T[0O@U\/OCY\2?BGXY^+^J_#W0_"GP^\4?$
M7Q[X#UVSTC1M(^$/Q!G\2>.M,'@IM=\,:%J.L^$O"?BVR'B6WUOQKX%DT73)
MO%?AWA+_ (*&>,]:\,?"[]H7Q#^SSI_AG]BWXV?$7PEX ^'OQJ_X6_/??%RW
MTOXD>+XO OPG^)_Q#^ LWPLTK0_"WPP^(OB^^T2WT^^TCXW^-O&OA_P]XP\.
M>(?%G@?1+:3Q5%X=^DH_@!X@N?VP?B7\>M6O- N/AUXZ_93^&_P%&CQ7FM#Q
M6WB'PG\2?C'XM\07EW:1Z59:9!X>N='^(&DP:5?:?K=QJMSJ46JM+INFV]OI
MUY>_G3\"O^"7U]\#9/A-\--+_8Z_X):^(_"WPG\::5-8?M;^,OA>WBC]I+Q)
M\//#-Y<ZEX>N=4^$UI\$?#-G:?'9X8="\.ZA\9F_:GUNR@URVN_BL? NIS71
M^',0!]8_#?\ ;.^-OQI\2>-=9^#G[-?@CQ_\%?A[^T!XI_9X\<75K^TQH^A_
MM)^&?$'P_P#%?_"$>.?$6H_ /Q#\+K#X<:1I&F:EYGC#2=%\1?M,:!X\\3?"
M&?1?&FC^#I->\0:)X&U#R.T_X*4_%V;PC\:/CG=_LCZ9IO[,'[.OQR^)GPB^
M+_Q-NOVA[1_B)%H7PF^)FM>!O&?Q;^'WPIB^$CZ1XL\#^$-%L+?Q?XQL?$'Q
M1^'WB.U\KQ1HW@C2/B =%TO5?%#?C-^Q3\:?CE\9?#OC77/@Y^Q-X+\:>%OC
M?X!^(?A_]NWX;:GX[\)_M96GPZ^'WB:PUK3? -Q\.)?A#?M>7WB+P-!?_ GQ
M=_;G[5VO>!=3\,ZSJOC8> (EELOA;8_*WP"^$'[5/[37[.?[77[-.E7/P0TC
M]FSXP?ML?MH>"_%GQ-U/Q/XZL_C7X"^&NI?M+>-K?XG^"/"OPLB^'>L>"O'.
MN>+;*'6[;PQX[UOXQ>#'\%CQFQU+P?XGD\'6W_"4@'Z4>//VO?BG??$OXJ^!
M?V8_@#X:^/6G_L_>&M UOXT>(_$OQR'PD*^(?%7AN+QUX<^&/PBTFR^&'Q,A
M^('Q&O? TMAXBU >-M6^$/@+2D\3^#=.F\>2R:EXD?PGY39?\%$OB#\8O&?A
M/PM^R%^SGI?QFL/&7[(/PV_;!TGQ;\3_ (SS_ _1K;PK\1?$GQ!\,6OP^UFS
MT/X/_&S7['XGG4/!=O'X?TB+2;WPWJ,\WBZ+7O$?A8>%=(D\6=/KG[//[37P
M:^+7Q\\6_LEVGP#UOPM^TYHOA*\\50?&KQQ\2_!.O_!OXI>!O 6D_"C2O'/A
M>U\%?#;XDV?Q>\)WO@G0?"]U<?#76M6^$>LC7/"]Z;7XI7-AXPDE\)6OV5?V
M'=:_9<^)WAR]TKQ=IGBKX<>#OV&?@/\ LMZ;JMU_:%KXWUWQK\+?'WQ;\6>)
MO&&I>'4L[C0=.T/7K?Q_I]SID%OXGU&^@O/M6F3P26VF6.HWX!@>!?\ @H+X
MN_:)LOAM9_LD? '3?B-XQ\6?LZ^ _P!I3QQ8?&CXOW'P3\(?#+PE\1;_ ,0:
M-X'\$W_B_P +_##XZ:UXA^)_B+6?"7C(6&D6_@W3_"$.D>$M2UK6?'.@WU_H
MFE:K\P_L4?MO_&'5?@?\*_!=C\/_ !1\7?VI?C]^T7^W/J_A_P  ?''XMW_A
M*T^$?PL^$7[1/C"SUY_BW\2M/\+?%_6O#NC?#&R\1>"_A9X:T'P5X(\;VMUK
MUSI'A72CIGA2RU#7=(]#_9S_ &*?VKOV-=$^%_B3X*C]G?XC_$*Y_9B^%G[.
M_P ?/ OQ$^('Q#^'/@6\UCX+ZMX[UCX:?$_X<_$SPY\%/B3XJOGTS_A97BOP
MWXF\$>)/AWI%OXITR7P_J6G>,_"M]X;O++7?(/#7_!*'XEZ9\/\ X%>)_BSX
M$_8U_:I^.'PF^*'[7FM^+OAI\8=%U[_AG;XD>#/VJOC-=_%6YU/0M1\2?"_X
MJ:W\*?B1X.U&Q\.ZAH.I'X:_$6UM+>[\6>"9-2N]-U*T\:6 !]5:U_P40\9Z
M=HOA?PQI_P"SO87?[2MY^UQI_P"QAXZ^#-U\8H[/PAX(^(FM?"#Q7\9/"GCF
MV^+5A\-=8U'Q/\'?$'@[3?#OB.UU_P#X57HOBK2O#>OZW>7_ ($7QMX1N/AS
M?[]M^V=^T7XO^(WQG^&7PC_9A^$?Q!\8?LR0_#G3OC[X)NOVM&\&?$:7Q=XZ
M\ Z/\0I+7X$>$M;_ &>Y-(\?>!;_ $C6AH?PT^)GQI\8?LV:5\1_%NB>*M+.
MG>&=(\-:GK1XCP3^PWXYT^P_9YO]+^$'[$?[-[_#C]M2#]HKQ1\,OV5O!VM>
M#_!=E\/M+^#?Q>^%&EV+^,(OA_X13XV?%B>7QEH.J7GBO4OA5\&-%AT+[3X>
ML[&2WT*WU;Q@S]MO]CKXO?M5:KXVT"?X$?L-^,?[9T6PT3X*_M6^,=4^('@+
M]J3]E4,+>ZAUSPG9Z)\*?B/>^/O$WP]\9K<?$?PG>^%OC]^SYH_B*XO;3PGK
M6B:3#:7OBKQ: ?K'IMQ-=Z?975Q976FSW-K#/+IU\]C)>V#RQK(UG>2:9?:G
MITEU:EO(N)+#4+VRDF1WM;J: H[7:R/#^GW&E:#HFEW>I7>LW>FZ3IUA=:O?
MH([[5;BTLX;>;4;R,!1'=7LD;7,Z!0$EE90!C%:] !1110 4444 %%%% !17
MYM?\%9=(A\0_L2>-M N;K5;&VUOXP?LE:3<WNAZIJ>@:U9V^J?M;_ O39[G1
M]=T>>RU/2-4ABNC+I>J:?>VVH:=J"1:A8W"75C$E?FO^U3X,TC]D?XC_ +9O
M@/\ 9<T.P^ 'PF\0_LI?L3^.?BEX<^%._P"''AKPAX:\1?M7?$/X6?'_ .,M
MA!X1N]!M_"_C&W^ .E7A\6?$K19K?Q-::9X=MO$NJ:M/+I-IJ%J ?TFT5_-[
M^V-\-_@Q^SGX@^+WPO\ V0/"_A'X7_#SQW_P2+_;I\:?'#X8_![3]-T+P#JV
MD^&?#/@[2O@%\8/$OAKPS<1: ?&FH:CJ/Q'\+Z1\3=2TM?%_C+0H=;TFZUGQ
M-IGALIX;ZZ]_8\_9GO?VJ_\ @FE\,+[X,?#R]^'_ (A_93_:C^)7Q \)3>']
M-F\/_&3XA?V+^RI%>^,OC9I36SZ=\9=9U>^BTSQ/KFL?$G3?$NH>(/%6@^&O
M$NL#4-4T'2);4 _H4I,XZ^N!^6?Y\5_*EH7P1^%?PU_8Y\7_ !T\&^"M(T[X
MR_!7_@JT/AS\%?B7):/J'C;X.?";0?\ @H1X>^$^F?!;X7>(M6EU+5? ?P9M
M? M]XAT.;X/:#?Z9\-YK7Q/XHO-0\+O+XDOWU&K^U'JUAJ6E7/[6GAKP'\$_
MAY?:=_P4S\*_#SPK^U=\6OB3<^,OVZO%7B/PM^U;I?PD\2?!?X?6.A?#CX?6
MOP%^#VD^$]#^(MII_A2;XO\ Q.BU'X#^&M5T[Q+\,/[3^(7B+QMH !_19X<_
M:)T?QG\4_BI\*/"?@/X@Z[K7P8^)?@CX:_$?5X%\"V'AS0F\<?"/3/C'IOC-
M)]8\<Z?K&J^$;31]>T#PMK"Z7H=YXMB\4ZE'#IOA74O#UO?^([/Z*7.T9!!Q
MR#@D>QVY7/KM)7.=IQBOYYO'A9?^"@GB%F5T'_#W/]E(L&";TW_\$J_%(0E8
MY&A<CRGCEN'N=\BAG:&62U(/I'PC_9P_9]^/W[9WC+]J+X(_LU? #P7\-?V2
MM4^(WA3X7^//!7PB\"^$_$?[2'[8>H6]]HWQ0^(^L^,M \/Z'KGB7P!\%YKC
M4OA[I4VK:C=:3XD^,&K^,?&<]XFK?#_PIJEH ?NG7B_[0OQJ\+?LY_!/XK?'
MCQO8>(M3\'_"'P+XC\?^)]/\)V]A>>);W1?#>F2:E>6FA6NK:MH.GRZG=Q0/
M#9+=:M869FSYVHV7SSQ_SA?LS_#3XJ^(_@!^RA^U ?!O["OP<_:$UOXU_#;7
M/B-^V[\0?VP?'6B_M'_$+XDZY\3K;3OC;^S]\3M#D_9,TBW\1Z]XXM[;QG\#
MH?V:M<^.'B;0O E[;>'-$\+QPW_@OPSJ&E0?M._#']GKXE?\$T_^"DG[0'[1
MUGX2D_;#\'?%7]K'PGJ?Q-\6:C!8_&+X6>(='^)WB7P[^S[\"?!?C#5H+/Q=
MX.^&/C;X/W'PTT[P_P#"719K#P=\1O!WQ)UC5;G2[V#XE:M<W !_4;I.KP:M
MH^E:S$MU'::OIEGJMNDZQ"XCMKRS%_$+PVTDL5O.8I"':.<6B7"-!%,RF%KC
MP/\ 9>_:3TK]JCX=6OQ;\)_#+XH^!OAWKTK7?P]\1_$J'X<6"_$_PT\T\%OX
MX\,Z/X+^(?CG7="T"_>WDN+:R^(FF?#_ ,8&*6*6?PG$')KT6Q\,^&_&?P<T
MWPGXM\.:)XL\*^)/ASIFA^(?"_B32=-U_P .^(]$U;P[;VFI:+K.C:M!+H^J
M:5JUE//8:E::C;&SGM9I4NXOLKDC^=W]DOX.?!S4/@U_P2"^"OC;X8?#*R_9
MF^.OPO\ BO\ $3XG>";GP]X<T;X?_'S]J?PUX1\$R_"G3_BYH4-OIFB?%SQ9
M/X4L?'7BS3/#_CO3]9MM=U3P#I^M"PN[WP1IDFF@'].R$E>01RP&1C(5B ?O
M-D, ""3D@@D*3M'GOQ5^(7AKX1_#CXA_%;QI/=VG@WX9>!O%7Q$\57EC:3WU
MY;>'_!6@:CXCUR6VLK9A+>7$.E:==306ZM#+).L*6[O,R&'^=+6O 7@/Q9\4
M;+]G*QTZV\2_LC^"_P#@M#X,^'?P[^'C,-3^%NAZ//\ L+_$#Q1\:_@AX<TJ
M6XU305^$ND_%74?%GA;6_@]IB6'@K0K?6O$?PZ?PSI^@/=>'=/\ UM_X*"_"
M_P"&L7_!-S]K/X=)\.O J> /!7[)GQ8_X0[P,G@_P^O@GPHW@#X8Z[J7@(^'
M/#/V)?#^A_\ "%ZCHFC7?A&32],M6\+7^C:;>Z3! ;6RB4 ^G_@G\4=1^,?P
MY\._$:^^%7Q(^#T?BJS@U32_!OQ2N/AJ_BY="N;&WU+1]8OHOA9\1?BGX;MK
M?5[.[A*V1\3-X@M=JV^L:)ILJ21K[&IR!SD\@G!4$@D$@,20I.2O)&W&"1@G
M^;:\^!J>*/VG_A/^SGHG[(W['?Q<^!?@C]@3X7_$3X&?L[?'KXA2_!'X*V_C
M#QSXU\:)\?/BIX!^&/@[]F/]H+PQXZ^)5E>3> [+Q'XMO="\-ZMX$L_&L-WI
MEX]]\2-9NI=/PQH/B7QEX2_9'_97\5>'/V9OVX?$,2?MF^+O O@3Q9^U?J7C
M[]BO3OAA\+OB-X7\*>"]#^*'C?6?V<?B1XQ_:-^,O[/>G^.]"^&/A33+[X9^
M&;?04LO&?BCQ5+:>*]'T&^M #]W_ (F_&+P5\*-2^%VE>+;O48-1^,?Q-TKX
M1^ [?3["2^^W^,M7\.^)_%,5O=S86STJRMO#O@[Q)JTM]?2QK.VFC3+$7NK7
MVGZ7>>K1C"*,8P, 88!0#@*-X#$ < D#<!D*H( _E#^ _@?X0?&7]GK_ ()Z
M:?\ $?1/@3\=_#G@K_@KQ\?_ (+>"M8;P1X?UGX>6OPIM[/]J#4="\!?#31/
M%NH_$"[\,?!V[F\.^!-2\%?#Q_%6NZ58Z7X?\ 6T>J:S%I?AJX3WWQKXO\*Z
M5^P9^U%X>U#7]*T[5[O_ (+(ZIX,L-)O;I=/O+KQ3J?_  4B\ ^/-+\/VMK<
MR.T^K2^"/^*SBLHGEA_X1_.O6K-8PP-0!_2%17\PGCGP39>!OV*_V]/C[\-O
M"OAO3OC-XK_X*$?'WX5?$;XTWVKM\/\ QWX:_9BU[]O*PT/XM^#8?COHGASQ
M#XZ^$?PBMO"IU?7_ !AJOAJRU32/ \NK>*?BA;:#>>)[>Y9_N#]EOX(^)?@A
M^V1X5M_"GPZ_8._9&\!^+_V>_%LWC7]FK]F7]I'Q-XYUGXPS:7XE\&)\-_CM
MI?P9OOV:_P!G;0;!_ :MXG\(^)/BQIT>MZGXDTOQC8>'=?N]4.G: VC '[-T
M5\3?M]?#V3XI?LR>+?A_:_%;X??!O4?$OB#X<Z?HNK?%B^N+3X4^.=<@^(?A
MJZTCX&?$R#3M=\*ZEKGPY^.\\+_!_P 3^'])URVU?5]*\9SZ7I^D>(;V^B\/
MW_XQ_M :E-\!/A/^V9\&OAE^RE\(?V,/BOI^B?L<^(OC"_[+G[0OB.P_9KU_
M]F;XO?&QOA_XY\?W-_X9^$'PI@^!?CG3/#VA_$?P_P#$_P")TW[-MQX[TKX6
MVUOXOL/$?C#1_#>A0:  ?T2?&CXGZ#\$?A+\4_C/XKM=8OO"_P )OAUXR^)7
MB&Q\.P6-SX@OM$\">&M6\5:Q8Z%;ZCJ.E6-WJ]YIVES0Z?;7^IZ59-<M&9M2
MLD+74/9>%->LO%7ACP[XHTU+J/3O$FAZ5K]A'?+"EXEEK-C!J-JMU';SW-O'
M.L%S&)8H+B:"-PR0R-&JFOYP?C%\$?$OP0\&?M71>%?AU^PE^R-X!\9_\$Q?
MVN)?&?[-O[-'[2GB7QYJGQGNM+\$6X^'_P =M/\ @W??LW?L[Z+:W'@B&3Q1
MX2\7?%^P77]9\3:+XUT?0=?O=7DT_03HV5I'PO\ &7[17QC_ &M+#XI_L^?L
ME_'-/A)\-OV>]%^%VM?M/_M/>-O@OXH_9[^".K?LW>#_ !/!\4_@CIWA?]E?
MXT-\-E\2?$6?X@:[K/Q^\)^.?!'C.;Q9X*E\/-<Z2/AKHUW; '].5>':]\=?
M"VF_$KQG\'-&T;Q-XU^*G@WX-6GQPN?!'AZ#1K"^UGPUJVN>(_#7A31-#USQ
MCKOA3P>_B;Q9X@\'^(M-TJ+5O$FBZ!I,UE'=^+]?\,Z7>VVHS_CS\$OAYHW[
M1O[1WP+^%'[=&L_!7]L&S\*_\$V?@]X_^&4MP^D_&/\ 9U^+_P 3]4\?^,O#
M/QL^/G@&/Q;8#0_B+XND\.Z=\*[8>-X_!J7&BZ!XNEO=!C\,6?B^[MM9^?OC
M5\$OV0M%\;?MWZ]\!_"OPD\2Z+X9_P"")FN7?PP^(^C7^E?$SQ(KVMQ^U;\)
MM4UC0_B_JVH>)?%FN:E8^$O#6C?"N^\4GQ?J6I67A+PYHG@34+V30=!TC2K8
M _ILT^>:YL;.YN;.ZT^XN+:&>?3[YK%[RQFFC622SNGTRZOM.>XM78P3-8WU
MY:M)&Q@N[F,K,]ROQ4MOA[\-?V@OVP/@W\'_ -J;P1X$^)WP@\/?L"?#;XA_
M 'X7?%O2-%\2_#_Q-\4)O$FK^'?C;XRM?AUXH6_\->+/&7@7P</AKIT&IZAH
M5QJW@+0O&]^VG_V<?$^HO)\:_L\?#WP-^TI\4/V"_!'Q;M9_CQ\"?#>K_P#!
M6W1OA'I_Q+OK[QUX:^)7P)^'?QW^$7AGX'VOC"/Q)>:YIWQ;\(:)H5AIDG@^
M+QI>^)= OG\*^&/$Z3WVH^'M"U"4 _IUHK\X/^"8NGQ>&O@3\4_ &E2W:^$?
MA3^V!^V#\+_AWHDTTDMKX3^''@;]H#QYH_@KP=H*2DBS\/>&]'@M]%T#2XO*
MM-(T:SL]*L[6SM+."VB_1U!M4#   PH&>%'"CGN%P#[YQQ0 ZBBB@ HHHH *
M*^8/VR_AC\9_C-^S%\;OA?\ L]_%:7X)_&;QKX$U'1?AW\38KW6=*/A7Q#*\
M4@E;7?#:3>)/#J:K8I<:(?$WAV%_$/A7^TAXC\/V]YK.GVD!QOV&/A+\??@7
M^RI\'/A5^U#\8_\ A??QT\'^'KK3_'GQ1^V:QJ__  D%]/KFJZAIUJ?$?B.U
ML?$GBG^PM"O-*\-GQ9XDL;+Q#XI.D'Q!K=K!JFI74:@'UC*6P0N=W\(4#>#@
M@L P9''SJ '"1AL[Y!D8_.OX;?M]>*/C7X1@^(/PA_8*_;%^(7P]U#6_%NA:
M-XPL/$'["NA:5K,W@OQ/KG@G7+NTTCQE^VKX8\7PV(US0M3M+9M3\,V]S=6U
MM'<P:>\<\+R_HG(00<[B.A"-L? 9<[9A)$%"-D.N\D@8]5/XC_\ !+;PM^U_
M=_LI?#74O!OQR_9NT'X4GXF_'62'P=XG_94^(_BSX@IH\'[2'Q2CUO3V^)>B
M?MF>#/#LUYJ,ZZE<:5J4GPH6+1%O[:*ZTOQ))8RW>H@'[9Z;/-<Z?97-S9WF
MG7%Q;0SSZ?J$EE+?V,TR"26SO9--NK[37N[9V:&X.FWMYIWFH_V"[N;3R9GN
MU_.I\3/A=XR_:*_; _X*$V'Q3_9]_9+^.D?PE_X5KH_PLUG]I[]IWQO\%?$_
M[._P/UCX+Z'XIMOB=\$-.\,_LL_&M_ANFO?$.X\?:OK/[0'A7QYX+\:W'BSP
M/+H+W>E_\*VT>\ML+Q;IE]\==#\(?#SXQZ;^R+^U]XS^#/\ P3N^%?Q ^+G[
M0O[1'Q9D\=?L>>"-,\<ZA\0;#4OVG_@+\.;;X17E]\;_ !YK.B> -9\0>//B
M+J7Q'_9]TB'0=(\&:%X3^(7P]@\9^*;Z  _>WQ1\8/!OA;XL_##X,:E=W_\
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M=H.=O8+@  8%>4?&GXO^"_@5X!U'XD^/KG4;;P_IVM^"_#:?V78R:G?7.O\
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M^DQ^'_B;\1D&D:S=^$;:34-4UW47T6SN+0 _IHHK\,_#'P-_9@^ _P#P6/\
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M+^'7PI\&_LP?'[PMXS^(FESMX!TW7_%%UX?\-:EX L/&5O<Z3>RW?Q'UB]F
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M_1Y-VT;NH+#L> Q .03G( .3@GJ50DHH ZBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@#E?%OA/PMXWTL^'O&GACP]XQ\/2ZAHNIS:
M%XGT72_$.CMJ/A_6+#Q'H.J2Z9J]G>V1O=!U[1M.UO2+UTCETS5K"RU.P=-3
ML[21()? _@^;Q+JWC*7PAX7E\5ZQX7LO!&K^)I?#^E/XDUKP=IE[JVIZ;X3U
M;7?L;ZC?^%++4M?UO4+/0)Y+C3;.^UG4[V&W2XO[T'SG]I7XFZ[\&_@IX]^)
M/AJU\%3ZQX9T[3I(;KXE^.=$^&WPY\/6FI:WIND:GXT\=^,O$6I:3INF>#_
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MNYM+'43HVEKJ$#K96VW\DO%O[?G[1O[,=OX>\;?M5Z%\$_%7@7XD_L>_&_\
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M >%_%'BG0O'GBGXCZ1H*/X8N=GXB?\%#_%OPB^!/@7Q7K_Q[_8!^(>H_'/\
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MK>G>);#Q&/!ND:)9^&_^$@L_$>C:-KUEJMII;ZA8^(;#3M6MY1=VEG*GN%%
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M"\9_+OA?^RM^S)\$-4M]8^#'[-WP)^$>KVMMK%O#JWPR^#WPY\!:E#;^(?[
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M&_1FB@#\ZOB!^QM\85\9?&[7?V=?VF+'X)Z%^TW;Z;-\=-$\4?!:W^+FM?\
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MC7OA?X9\63?"[XPV/P1\4_$WPU;:O<ZS\/?"7[0]_P" X?@/XL\;Z:_AO7[
M^%_#OQ%U'76USP_K/AZ'3TUW3K[380#'^$_P*_:W\):UX'T[XA_MDZ)XS^&'
MP_\ #VK:'I^@^!OV;?#?P_\ B-\1473K71O".H?&;XA^+OB-\7_#VN7GANQ$
MNJWI^#WPM^!">)?%QT[4]5GA\*6-UX"U;S;5OV0OCEX[\;_!WQG^T%^T3X'^
M,&C_ +,OB'Q?X]^%$WA']FB+X8?&O7_%6J> O$?P]LF^*'Q+M/B_XQ\$Z[97
MWAOQ5>7/BSP]\*/@G\$-*\9^+K/P_K.GVGASP]HT?A:\[K]B/]L32OVE_A%\
M'KOQC>:!IOQ]\8_L\^ /C_XX\$^%?#GBO3/#VA^%?'WB#Q;X3T74]*O=<FUB
MR6UF\0^#?$NGC0/^$OU?Q)8FP>2[C:VN["\OMK4_V_/V6++PG\-?&FG^/?%/
MC#3?B_X%N?B;X#T;X8_!?XX_%SX@:K\-+"2WM;GXC:C\*OA?\./%WQ0\*> [
M+4;F'1[WQ9XL\*:#X:L]7O+?3)]7M]9O+.UN@#\^_P!@[]B;]H7Q7^R1^PWX
M0_:;^+5Y%\)O@[;?##XM#]G+Q'\!K_P/\9+;X@^ +D:[X%\!_%[XBZ[X_N[#
M6/AM\-O& CUSP]X)M/@1X#\6NOAWP3IOB;QKJW]B:U=>*OIGQ[_P3]\<>)=+
M^/7P:\&?M$V'@']DW]I[Q1XD\6_&#X31?!VVUWXJ:7>_$J^:^^.6A_"#XXO\
M0]'\/^#/"_Q;N7O+G68/&/P2^*?B/PUJ/B;QE>>$O$^@-JGA^'PI%^S;_P %
M(OAY\0/V;=#^/WQ<\2:#Y/Q$_:$^/GPA^#VE? _P)\2/B?KGQ7T3X<_%GX@>
M&?!5UX ^&_P]A^*/Q$\;ZOJ/PY\)VGC3Q/J7A/3=2TFUTU-5\3W-GX?\/6V+
M'Z<'[9?[-4OP9B^/<?Q.C7X=R^*V\ QF3POXUM_B!/\ $N/7#X?F^$4?P=N/
M"Z_%^7XSOKL$NBQ?!R#P#_PM2;6(VTJU\+I?%(  >5ZW^PY8W_A']OOP=I'Q
M!71=*_;=\'Q^#M/2'P8]];?"&Q@_9F\,_LX63"V/BN*7QY%:VOAV+Q-%;&Y\
M&;X+L:))/++;MXBDY/XS?L;_ !Z^+WPW\8_L]WG[37@&Y_9N^)_@+0/ASXT\
M$?$']EW3?&OQ'\,Z"GA?2?"?B>S^$?Q'T/XS> _"7AB:_CTQ_$_@W5?B?\*/
MCCKG@?XA7EWK"^(O$NCVFA^$M-T/V;_VYK/]I;]K;]H?X+>!TA?X<_!;X1?
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M1ZO)X9A;6(0!WPI^!!^&'Q@_:>^+!\4'7#^T?X\\ >./[!71CII\'GP+\'/
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M*MH-,\/V4MS;Z=#=:I)?ZM<7M_=_<U% #4^[WY+'DMSEB<C<20#U"YPH(4<
M5\)_$OPAXKO_ /@H?^RWXUL?#7B*Z\'>'OV9_P!K30=?\7VNCZM-X7T#6?$O
MC']F6YT#1-4URUMVTNRUWQ);Z!K5SI&FW5[::CJ=GH&HW.G1R1Z3=E_NP[2<
M$#KP"!RP4$'Z@#K['TKY%\1?MN? ;P_\3?%WPC1?CCXM\:^ ]<\/>&/&\?PP
M_9._:P^,'A7PIKWB;P]H/BW2=*U[X@_"CX*^,OA_I%W<>&?%/A_7+G[3XH":
M5I]_'-K)TX1SE #X9^*OPC^(.K>$?^"ZL%O\-/&-_>?&3P0VG_"Z&#P7K%U<
M?%*:/]@;P5X0@L? 9M=%DNO'36GC6._\,6L'ARWU+[+XHAN]'2<:FVI&N&T7
MX)?;_!O[?MC\<_@?^TKK'@?Q3XW_ &*_$GAVY^#6@>)]"^,NF:A\.OV9/V<+
M=/B_\%[BSO/#/B?5O%'P+^(GAF?Q%=6OPP3Q3XHCUWP5JWA30O!7C+Q$&\"Z
MQ^E_Q@_;+_9U^!7BS_A#_B;XVU72]<M?#]CXQ\3'0?AS\5?'>C?#/P9J-_=6
M&E^-OC=XH^'W@7Q)X7^!?@*\EM-6DM/''QEUOP3X3$6A^)=035)+/PMKU]I_
MTU%.EQ;PWEG,EU;3QI<6TT,JRPW%M<,DL$\<L.$DC:/]Y&S;O-5ES=1H]Q(0
M#\Y/V*?&WQ\\2_%+XT:7XA\<_M"_&/\ 9KTWPW\.+SX8_%/]JG]FR']F/XRP
M?$VZF\31?$[X=VO@V;X)_LX:MXS\!:7HUEX$\4:3\0;OX*Z58_VKXFUCP?IG
MB_QAJ/A_4CH>U\7O OBS5_\ @I#^Q;X]L_!WB34?!G@_X ?M@Z;X@\8VOAV_
MU#PYX7U_Q-J7P!'AW3-<\10P7%AH^JZW9V.OQ:#93W\%SJL5AKPTJ.1+:Z4]
MEX/_ ."BG['WCOQ]X=^'?ACXMRW&H^-/&OB#X:?#[Q9?_#GXL>'_ (._$SX@
M>%+V]TW7/!?PO^/6O> M.^!7Q-\36EY87EO9:'X ^)/B#4-6NK6^M;"UGEL)
MU3K_ !)^V?\ LX>$_BM+\'=>^(5[:>++3Q-X6\$:UJUI\/?B7J_PL\'?$'QG
M':W/A'X>_$+XZZ9X/OO@I\/?B+XJCU'08_"_P_\ ''C_ ,/^,=8N_%7A#['H
M-W<>-O"$.J@'Y0:Q\%/BX/V!?C;X.M_A+\1!XS\0_P#!5O4_B39^&[;P)XID
M\4:OX$D_X*-^&?&L/Q L='BT>[UF[\*/X T\^*D\40V4FA2>#8)=4-P_AJ"2
M4Z?C_0?B5X*_9J_X*"?L.WGP+^.?Q(^-O[27Q*_:=U#X+^(=$^$?CW7?@S\0
M?#_[56NZOJ7@GQ1K_P ?]+TRY^$OPPL/A);>))].\=:5\6_'/@GQ#I<?@=I/
M"N@:U8:QX.L=7_5'XO\ [9?[.OP)\6'P=\3?&^IZ9KEGH%GXO\3OX?\ AU\5
M?'VA_#7P;?ZA=Z?IOC?XU>*OA[X'\3>%?@=\/KV:SU:6Q\=_&+7O!?@]K?1/
M$>I0:M+I_A?7+^P^I+.>"ZMH+FVFCN;:YC%Q;7$4B313V\_[V":*6/Y)(Y(G
M1XW!;<A#%W8EV /Q-\/CQ;^QYJG[;7P\^)7P-^.WQSO/VD+SPYX[^$/BCX._
M!+QU\8-"^*JR_LW?#+X':E\(/&/B/POX:O\ PY\(-4\/^)_AU?7%O>?';5?
MGP]?PUXXM-6T_P 6ZE=0>-H-.\3_ &+8OB?^R=_PRMXM^)W[/7[0U]9^,/\
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M-'C^)UMH&E7WZ$_L4^#=-U3XW?'?X[0>*_V\_B/K?B+P+\+_ (5ZA\2?VO\
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M;AT6TT^UN(-*T"QM=-TGPW;Z-I>G:/;V]3X0_L=_ ;X)>,9_B-X+T'QOKGQ
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MO:G\,]8L+_PA%XA\0>(_B%K>OZ=86&K:A\4/&UQ>2>*-3=?_ +"7[+UUX<\
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MUG\$O'WC[PK!IF@R^&_''B[X:ZUXLT[4/"GA'5;;6K;4/"WA6ZTP ^-_@/\
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MA7XP^/-;UC7?%OCSP1\4/!_C30?B;\/]5UV[\0^(;?4(?!GBOPUITFAZS?\
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M1110 4444 %%%% !1110 4444 ?GK^W[XL\86W_#*'P@\-^-_$?PUT']I/\
M:N\)?!OXE^-?!>MZIX1\<P> (OAQ\3_B7J/A?P;XUT66UUWP9KGCK4?A_IO@
MY?%GAK4-,\4:/I^MZE_PC&I:7K<L&K:?XY^T;\/?$?P T;X*_ OX:?&W]INV
M\!?M<?M;>!_A;XO\2^*OCAXT^(WC_P"#?@6[^&'C+Q)XLT3X3_&SQ_+XF^-G
MA5?B?J7PRT_1)];U_P")'B#5?!^J^-M6N?A/JW@+7=0\-SZ7^B_QB^#GP[^/
M'@J_^'?Q3\,1>*/"EW?:3K,=N-2UGP_K&D>(/#>H6NN>&O%7A3Q9X5O]*\7>
M#O%GAO6[2TU7PUXM\)ZYH'BKP[JUI'J6BZI;W,4,B^*V_P"PU^S'%\/OB#\-
M;_X?:[XJT3XK:IX?\0>/O$/Q!^*?Q;^(WQ:U[Q#X-%J? NMGX\>._'WB;XW:
M=KWPUGTVQO/AOJND>/[2_P#AQ?VZ:K\/[C0M2-U=2@'X]_MB^,?C#\ M9_:<
M_9F^#?[0_P =M%\&VEI_P3D^)O@#Q9JOQ3\<?$KXM?!GQ%\:_P!L.7X1_$/P
MSI_Q9^)VK^)OB#XB\+^,]"\*VGB*'P=\1_$OCG0XY[_Q/X:CL8O FI7WAVT]
MRM/@!/<_MN_M!?LVO^T5^V:/@=X8_9!^%/QMTCP>O[8G[2;^)+#XQ>*_&?Q<
M\#7GC.Q^,+?$Q/C/;Z=;Z'X-MVMOA;)XSN/@MK&L:I-KU_\ #VXU72]#NK#]
M$K/]AO\ 9@L_!7BKP-<?#W5_$-AX[\<?#_XC^.-=\:?%'XL^._B5XW\8?";7
MM"\2_#/4_&?QB\:>.?$'Q9\3VG@74_"^B+X7T/7O&.HZ3HVDZ?)H5EI*Z+<Z
MAIMQ[)%\%OAM%\4?%'QJ3PZX^)?C;X<^'/A7XF\2?VOKX_M'P%X4UKQ%X@T3
M0?[!.K'PY8FQU3QCX@G&JZ?I=IK\_P!N\BZU*[@M+)+8 _!7]BN_^*'[=/Q&
M^$Z?'/\ :6_:$LM$?_@F3^RM\4]:\"?"/X^?$?X&?\)G\6O%?C7XY>#=0^+&
MI7GPA\1^#O%*:G:V&BP3^*+/0=3TKP;XBU?5/#=QXOT3Q#'X=\)V&@]EX'_:
M!^(/QF^$O[,?PS\2:C^U;\>?%W]M_ME:1/X"_9L\<^'?@G\3OVA_ W[+OQBC
M^"O@/X^_$;]I>T^.?[,UCX \(6*7'AJY\3:#\,_%5P_Q3^(?CC2;ZUT^_P#"
M^@ZYH.H?46G_ /!*?X1VO[1TGBV+2+[PM\!?"?[)WPI_9S^$.D?#/X\_M#_#
M'XO>%%\(>-_BIKOBG1;[X@_#OQEX0\<7_P /M?TCQAX<$^E:M\3?$5EXDU?1
MXI=<\-1W.A:+J\GUYXM_8G_9K\6:%\*O#@\"ZSX!L?@=H6H^%?A+>? [XE_%
MO]GKQ'X%\):Q86-AJOA31_%GP'\;?#CQ9'X6UB+1M(FU3PK+K$NA:EJND:=J
ME[9SZM:VMQ& ?C7\-_B!\?\ XI_LS?L<?#OQI\<OBQX0UR]_X*K_ !C_ &8O
M''B;X??&SQ;KGC76/@]\.[#]J;2Q\+=2^.DFG^#_ !K\0XSHWA+2_#L7Q4\0
MV&D?$>^N]&T7XAV\^C_$*QT[Q!9>DV'C3XH_"S]I>Q_9\T+XR_&'6?AG\/\
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MB?$+7/B9XO\ AM?ZGK/B[5?"WB#QUX:M/B/\5-*^$GQ1\2>"C92>%O$GQ;^
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MZ[U33'\1W!33& -[X7?MN>.=6_:=\-_LI_'/X1> /A7\1OB%\%-?^._@G1O
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M!>!-9^%GPV^*?[.VG^-_AG\8+GX<_"[X66%QXYM/"VEW'Q*^$VB:3;^%M?\
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M$R3QC.23M4 +DL6P=D:AB6ER-I&.>%/YZZ#^US\<?BIXO\?WOP%_9>T/XG_
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ME?#_ .)_AO7;7PI-XO\ #[>'_AJDGQB\,+]IL-:U?XC_ !'31O$-[]NAU>\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MNQ;5_"EEK_\ 8YU/1K'4;'X%^('_  ENG>%=9^ ?PETKP/XK_8BO?^"N%O\
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M.H3:!I-]JFIO+I-I>60!_4M17X#6/[#O[(DW_!07]I3X./\ L\?"N3X*:?\
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M]FOXG_M5:;X/_:)AO[DVO@[Q5HTGPH^)^I?"?X;_ !++P2:=J'PY^(OQQLO
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MXC%O<6T\+C[/(LD>T,EU'<"X@,]L4\IR!\5>#OV#O@5\)/V@OAK\:O@5\/\
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M7]A\.[J*WTN"&7P#I]YXCU^[L_!TL$FC65YKVLWPTOS-5N7?R*#]E7PMI7Q
M^",_A73?A9X"^ ?[.SZUXK^$WP)^'?P?L/! \/\ Q;\1Z1XR\)ZGXT?Q-HOB
M-/#<'A2'PM\0/$T-AX)\.?"KPU>P^*M5O_%.M^-M9@-MHMG]>44 <;X8\&>$
M?!8U[_A$?"OAWPI_PE7B75?&GB<>'="TO0CXE\7ZW'$=;\6Z^=+M[)-2\4ZV
M]E:OK.O:I'->Z@;98[B>X*B5NOC "  8"Y4#;M VDK\JY.$X^09(V8P<8I]%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MRLO$OQ?_ &B?VIK"X\#1^/O&FK>!/"_PC^,^E>-?@!\/M(L;?7?#,/C[QO\
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M"WB.XUN2]\,Z[X4UX _5/PM\#_@QX%F\.S>"?A'\,/!]SX3_ .$S/A6[\+^
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M[@<@'-?AO^Q9XGU[]GG]I[]K3XBZSK.J77P#_:8_X*0_'GX%^-[?4+\OX?\
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M)XOU7Q)9:CH&M:Z((HW2RU2P[CPW^V_\?OC%K'@+X;_"6V^#/A[QG\??C?\
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MP_M+5!:WEU:Z=)=VMF(9S9WLNGVPEA3S9[*SC/V:, ZJBOPT\0_MM?MWZ?\
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M+XEZI\5=&^&^@:3XMURYUS7?#MC\5_V?OC-%X'UWQ)J4KV7B+PRFB^%-&?\
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M"6J^*OC#XM\2_##1=+NO /A'0?&&N^$=9\51_##6?!5KXXN=*D< ^A?V?_\
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M/"6I>*/$<ND7TEG)H6G:"G[3?[;=K^S1^U+^S-\(_%D"M\._C?\ #GX\:[J
M\,?#CXI_%GXMZIXU^&][\*X_"'A_X9^!_A/IWBKQ/XBEN;#Q=XJUKQ!8:?\
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M\:>.-#B^%7AGQ-)\0M<TO2K@ ^M/VC_V>I/VA#\ Y3XN7P<WP0_:1^%W[09
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M:AX:O/VR/AEH'A+PC;6O@Q9U_9Z\>6FB^';/Q%\2_#EQ%XLTFY\6WWBWQ3X
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M_9I^-?ASX8^#= ?PE\+K3]F?2U\6?$?7+7X8>(T\8>,/!^D^.]>U3]/?%?[
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\8^+M0T4^ KW6?$?B'3/"FH_#JUOM7T73=&\7Z[KDTEAH7[UU7D.'RQP%PP
M.,*H^=B&9<8W;/-C<#]\%F0QH20#\GOV7-,U[Q=^U6GQ8N/AK\4?#G@S6/\
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M2\.B^(]+U#3&O;*S;2[T6XO-*NK[39;6[D],7[HSU/)SGJ3D_>Y R>!T X'
M% 'X??LU? ;5/!OQU_8.\3^&/ G[5">"%\(_\%%OB1XD\0_M.>$/ ^G?$'PS
MXK_: ^(/P6\:6<WC73OA)H6G?#OX377Q!U"]\9>(O!WPWOM*\#>+=,TR?7]&
M\2>$O#_B71]9\/V/[?PC$:@'(7*C[Q^520HW/\S@  "0_P"L \S)# UQ7C/Q
M]X.\"W'@^U\6>(]/T&\\?>,=,\!^"[2]G>.X\2^,-2L=4U>ST#2;6,F>_OWT
MG0M:U>ZCME/V/1M(U/4[_9I=C>RIVT9W(K<_,H;G:#\PR,[25SSSM)!.2.*
M'T5EZEJ=GI%I?ZEJ#M!9:;:37UY<")Y?+M+:"6>YE*QH\C"WACDD*0@S,2(T
MA>2: 3\E\)_BAX&^-GPS\"_%[X9:Z?$_P\^)?A?1_&O@KQ"=*UO0SK/AGQ%9
MQ:GH^HG1_$EAI>O:8;JRN(938ZOINGW]MN\JXL[:13"@!Z#1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:!\+O#?Q#L-'\27$GAS19=?75:7[0GPZ_: LO@A^U_X>A^#?[=OPX_93UO\
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MUCTJY\37>G3+"P![?13(\[$W<MM&XY!RW\1R$C!W')W!$#9R%4' ?0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/%%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>image_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" )D!%(# 2(  A$! Q$!_\0
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M6^/=&^%?Q-_:/^ WPZ^)_B,:0WA[X<>.OB_\/O"7CW75\0:@^D:"VC>#]?\
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M[S_5G/3:Y^5&SM9_W:DO\M*9$&><XVYP&;&YB@S@' #*P8GA,$N5 )K^4?\
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M 87G&"S$9"1CS7*Q_/2++&QP&YP3@@C"[R@8Y PKLK>6WW90"T9=037X5_\
M!4K0?B!\6?VU?^"7'[,WAC]I3]IK]G#P-\=M4_:_C^(>M_LN_%_6/@_XPUI/
MA_\ "KPEXW\)"ZU:SAU;1K\:?K-FT%NNM^&-=5+#6M;CL1I]WJ8U"#R?]JS]
M@KXS?L3?L\?%[]J_X"?\%5O^"C&J_$CX!^!_$'Q0TSPW^U/^T-HOQT^#?BS3
M_"=LVIZQX0U_X?ZYX#TK3+J?Q)%%_8VEZK.VH76G:AJ,$-M:M++&B@']%VY?
M7!X.""#@XYP1G R,GH.<D8. NH(4G#,2 N#N..I QDJ.[8VXYSCFORQ\1_\
M!4CX0_"+]F_]DCXJ_%;PG\2_$GQG_:R^%?@7QU\.?V8_@'\/]6^)?QF\7ZUK
MW@70O%OBW3_!/@>SGMIVTOPY/KJ6UQJ'B36]-L_,V6ZWDMVI0]'^R7_P5%^
MW[6?Q:\3?L]P?#G]HO\ 9P_:"\+^%SXYN/@9^U9\(KOX._$;4O!8NK2Q_P"$
MJTK3$USQ#I6H:;)-?VK1V,FK6VL36AFOXM->PM;JYMP#]*RZ X+#.0#UX)X4
M'T+'A<XW-\HR>*-Z$D!@Q&,A?F(RQ09"Y(&]64DX */DC8V/QPTW_@M)\ ?&
M/Q"U;X7_  N_9V_;=^-/C'PC\5?&WPG^(D'P:^ MAX^TOX4ZSX.\>ZA\/]/U
MSXD:[IGCR30O#'ASXAZOI-_=^![J749M>G\-+'K6NZ/X5MKVS>?YO_X)&_\
M!0;XG?M.?M0_MR^ /B-\)?VSK33+[X_>+==^'NK?&'X6R:'\._V??!GASPYX
M<TNP^ OCJX.O7=G\,/BM#)=75Y_PKZWL=2N;^$WFIZIK][=3QEP#^A_<N"<X
M .,D$ _3(&X'L1D'L32"1&^Z=W(' )&3C'(!'((;K]PA_N'=69J=^=,L+[4!
M:W=Y]BLKV\-G8Q^?>W*V*EA;6=N3M>:?[J*""S%1G)!7^=SP-^U9^W7\7/\
M@K!^Q3#\7_A_XN_97_9D^*?PL_:DU'X8?LY>(/%%S!\2O%UMX,\&64C_ ! _
M:7\*:!=-X6L]:O[K4]"G\ > K^ZUW4/ ,FGZ]*\%A?:B^IZP ?T<T444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGQ;IWPHUZ\U.>26^U6?6O!>HG6-7N)M6UD:A?22W+_='Q0^"OPU^,GPF\7_
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MQF:'_@HQXV=D!5I;>.X\'>'XS(L<:P+;HWD2P?:%CB1IX)U,6Z-U/ZF? _\
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M>-K :!8:Y9>%]936+?3[*,W&O:)J-U8I;C^RGL7)9P#VVBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKQJ2Y7&FUNIR4HVB[-\R[DU%%% PHHHH **** "BBB@ HHHH **** "BBB@
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MI:>)[F$P7T:S_9-0L+J\TN[FL[^TM;VXN+"^CM_JLD%CF1MJEE"("&R%<G(
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MYM/73<?1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MI 0<$=_8_P!:S=7UK1] TO4M<UW5+#1=%T:QN]3U?5]6NX-.TO2M,L()+J^U
M'4M0NWAM+&PL[:&6YN;RZEBMH((WFDE6-2P$G)J,4W)OE22;;E_*DDVWY)-^
M3$VENTO5I?F74<')WJ0.N&#$9 (/!. 1@@G@@Y'!!K#\3^+/"_@W1K[Q%XO\
M2:'X4\/Z9&)M2UWQ+JMEH6BV$/\ SVO=4U.:UL;:($C=+-.D:\[F&#CXS'Q4
M_:!_:, B_9VT33_@Y\'KWF#]IOXJ:,-9\2>,=,<!VU;X#? V6:RDGTB\Q,=$
M^)WQIU3PYI!>VM-?T3X3?%GP7J^EZS>=%X:_8/\ V=[#5[/QG\1_"M[^T;\3
M[-VNHOBA^TKJ(^-/BW3]1D8FYN_!&G>+H[GP)\(;>[R=WA[X+^$/AQX30X9=
M 5@2W3+#T8+_ &NJU*VM.@E*I=;\UI*,.UGS376,=ES\\[?N(3W_ .7ZE%+_
M ,"5_P!/S,:7_@HY^Q7-++%X5^.VC?%?R)98;F?X">&_'?[0]E9O;R>1=?;=
M0^!GA'XA6-DEG<_Z+?275Q#'97G^B7;PW/[JH6_X*&_L][C]G\)_MDZE"<>7
M?:+_ ,$Y/^"AVNZ7<J>DEGJVC?LKWVF7T)[3V=W/">SU]MQ6,4$4=O;PPP6\
M$8BMX8;>"&&"&-%CABCCA,8C6!$6.#RA&(X0(QM8"2IC"21A47"D$[(V/_7,
MAER8\\\.AX   IRJ9=RI0P.-YEO*ICL)RM6U:C3R].+;UMS22VUT9DJ.-ZU,
M%Z*AC/S>._0^'?\ AX9\ O\ H1OVW/\ Q6?_ ,%(/_H3:/\ AX9\ O\ H1OV
MW/\ Q6?_ ,%(/_H3:^YO+'I^B_\ Q5'ECT_1?_BJR]IA/^@'$?\ A92_^8B_
M9XG^;"_^",5_\VGPS_P\,^ 7_0C?MN?^*S_^"D'_ -";1_P\,^ 7_0C?MN?^
M*S_^"D'_ -";7W-Y8]/T7_XJCRQZ?HO_ ,51[3"?] .(_P#"RE_\Q![/$_S8
M7_P1BO\ YM/AG_AX9\ O^A&_;<_\5G_\%(/_ *$VC_AX9\ O^A&_;<_\5G_\
M%(/_ *$VON;RQZ?HO_Q5'ECT_1?_ (JCVF$_Z <1_P"%E+_YB#V>)_FPO_@C
M%?\ S:?#/_#PSX!?]"-^VY_XK/\ ^"D'_P!";1_P\,^ 7_0C?MN?^*S_ /@I
M!_\ 0FU]S>6/3]%_^*H\L>GZ+_\ %4>TPG_0#B/_  LI?_,0>SQ/\V%_\$8K
M_P";3X9_X>&? +_H1OVW/_%9_P#P4@_^A-H_X>&? +_H1OVW/_%9_P#P4@_^
MA-K[F\L>GZ+_ /%4>6/3]%_^*H]IA/\ H!Q'_A92_P#F(/9XG^;"_P#@C%?_
M #:?#/\ P\,^ 7_0C?MN?^*S_P#@I!_]";1_P\,^ 7_0C?MN?^*S_P#@I!_]
M";7W-Y8]/T7_ .*H\L>GZ+_\51[3"?\ 0#B/_"RE_P#,0>SQ/\V%_P#!&*_^
M;3X9_P"'AGP"_P"A&_;<_P#%9_\ P4@_^A-H_P"'AGP"_P"A&_;<_P#%9_\
MP4@_^A-K[F\L>GZ+_P#%4>6/3]%_^*H]IA/^@'$?^%E+_P"8@]GB?YL+_P""
M,5_\VGPS_P /#/@%_P!"-^VY_P"*S_\ @I!_]";1_P /#/@%_P!"-^VY_P"*
MS_\ @I!_]";7W-Y8]/T7_P"*H\L>GZ+_ /%4>TPG_0#B/_"RE_\ ,0>SQ/\
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M $)M?<WECT_1?_BJ/+'I^B__ !5'M,)_T XC_P +*7_S$'L\3_-A?_!&*_\
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M_P#FT^&?^'AGP"_Z$;]MS_Q6?_P4@_\ H3:/^'AGP"_Z$;]MS_Q6?_P4@_\
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M+BNS>:GJ>IWZQPK9O9V4,FM^*O%RV\=Y,UM(EM;2V:Z)H,']&26OPY_X)V?
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M$-=\#:WJEU+9)X0\:1>-]2TC3=$\00ZM!)8V< U"YM-9B6&]T2?4=.NK6]F
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M_P"&*=?TB"WO;[_AC;Q/J.GZ"VG:E>7.H0_LH^+-7O/L?A^73=0U![B^T_\
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M=@J<HRQ5&AC(2SW!PJQJ97PEFN'QV Q=>CALWRVJ_#?@-^UOX8_8X_9R\?\
MQ'\;>'?[<^)>CPV7@[X%VE[E[75-6U.WNVDM)2JK)%;^#+!;#4/$5^ZVQBT6
M\TCPS:36VMZS#:W'YA?LH?LS_&G_ (*7?M-:YJ_B;6]:GTZ[U=O&'QJ^*-Z#
M/+H^G:I=W8EM-.DE'V=-=UA8)M!\)Z" ^EZ79QW44.E#0M$FMH/UK_X**_\
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M<IU)SJ3G.51RDY2E*3DVQ]%%%:F04444 %%%% !1110 4444 %%%% !1110
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MGX\_9(^&L&IPQP6=O-X?_:+\9>*=/M-.E^T7K:%^S5;Q0Q_8M0>6+]6_AO\
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M&P %D9AOE0,AV;T$C+F.9WE.<.P42JV08\*,@$;OF#X\T$"0$.4 54WM&DQ
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M@@?*,GD@#H"PYY4,PR%8A[7OTM?ROM?U ?1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 ,;O]3_Z!7PK_ ,%._P#E&U_P4%_[,B_:M_\ 5$^.Z^ZF[_4_^@5\*_\
M!3O_ )1M?\%!?^S(OVK?_5$^.ZWR[_D8X+_L89=_Z?PYS8W_ '3$?]>Y?DS[
MMHHHK Z0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM_\ 5$^.ZWR[_D8X+_L89=_Z?PYS8W_=,1_U[E^3/NVBBBL#I"BBB@ HHHH
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M=1553I8K$3K8',7A\)!8=3=:,,)F2QWZ_P"%O#WAAQ7PSQ-F_%?$M#)*G"N
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MBZ:XD:^>8R7$ES,)VN)IKV:XO+XSO?SS,\ZFOVY20DYXY /XE"W\QSTSWKY
M_8<_9$T#]B;]G3P7\ _#NO:IXN.AS:OKGB3Q-JQBM_[<\7>)KU]6U^_L-+A+
MPZ/H@OIY+;1M(CEN)-/TZ"UBN;G4[L2ZA)]BJ@'.!GICC@ 8&?7CKQWZ#FNN
MC&I"E0IUINM7HX+!8?$5[-JOB*>#I4YU5)[I3A-.2ONMME\)G>*P>.SK.L;E
MU#ZK@,9FV9XO 8:W+]7P6*S&>)P>'Y;+E=#"2C1<;>ZX\N@^BBBMSS0HHHH
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M.?\ ]+.H^J3_ .?E'_PXX?\ ^0#ZU3_Y\XO_ ,$2/N3>OI_Y#/\ C1O7T_\
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M,L+@@AMQ&UB%."R@_P 2=7ZO]3^JSZ[HKD_!7CWP-\2O#&C^-OAUXR\+>/\
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MT'V_38HF-_%<Q[D7?7N7@/3++5/!OB_X+>*6FNAX/6Z\$2N\Q-UJ/@C4M/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?@R/1[&UT;1/%<]_J/B:S\*^&M T%XM'O]-\4:X^IM=ZX-/TG6%EU23Q!?\
M@ZXN+C4=/]6O_P!OK]HG3HO$C#_@FS^T[JDWA=HH"=,N]%N8-8U&]T30-0L;
M;0[F^TZRN-3L;:XUK5-*UG6+"SN;33KG0WDLYM>3493:?9?[,7PE\?\ P/\
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MG?7&2(X-7@?2D@A@B62YN;ZZENHX=/L;:*:\U&^G@L;&WN+J>*%_YU/V@/\
M@G_\+_VH=/C^*OBGPMI7PN\?7EAX6\2Z39>'O#6BW.IZ]X:U/0=>U/Q_/\1!
M.8Y)O%<OB;X9>+O%-S;VSE]+N-9-GX@EU2]UB]BL_K_#O,_[7PD*'$U..+R#
M!9O7=>K5A>KF#S3+ZE"&6Q<HQIXJ<\1"EFV98ZM&EC\OPV"H8NOF4(PA"IY6
M>4(X=N>"]K&I%)S5/F<HQN[:)\V_5ZVT2LVU\[?LW?\ !1SX^_'_ /:1\0?%
M*QCD\&C6=2\-1'P5H.K0SVE_I.DW=QI%AX:US1X(F:6XTL1ZN#J.L/=/J FE
M:Q>X2VLV?^LOPYJ>J:IH^GW6L:.=%U2:VMY;_35OK'45LKI@//@^U65S/'((
MR#\\;NC@X#MC-?!WPY_X)\_LS? ?P+X&M_AC\/=&T_QAX6_LZ%?BG';6]A\0
MO$=W?WUU=76J^)M>L+>"\UI;S5]3FN['3)WMK+2%N%LK"?3=&BFMQ]V^'8A_
M9L$J,JO(CI*KVFGPR1SQ.8I$8Z;';(2KJ060,K9#*V"&KXSC',LCS:C@*^38
M2IAJ.#GB<OI3Q%%83'5,/AZW)EWUR&&]HX^PP"5#][\#BXRY4TST,FP^*PL%
M2KS]IS7:=[IOJT^N^MO.W4ZVBBBOACVPHHHH **** &-W^I_] KX5_X*=_\
M*-K_ (*"_P#9D7[5O_JB?'=?=3=_J?\ T"OA7_@IW_RC:_X*"_\ 9D7[5O\
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M,.+)\)\.2KTE'+\RRN%&=_KL\GGD^=8&%/ T%:6&I8B7UK2\6[6/MSP_X/\
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M)C*T:N"<J,Z^,HYA3J\EI*4(3C7<8S<\3#6)_'?#N.Q6.XG7M<)Q8Z&">6O
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M.V887\M3EK?Q,%_BJ?\ J!/_ .1?_@+[,^Y%^^/]P?\ HROAG]F@G5?VFO\
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M7$-A903'4;;Q'\/?V-[*X2YM+J]F6P^(GQ%\$E?-\4ZEX/AF62N0^)2?!O\
MX)D7$/[:'[?OQ&M_VZO^"I_Q#T2^7X8V=S:#3O!?P<TO4II&G\"_LO> -4^W
M6_P#^!WAV^N9-*UGXI7]M/\ $CXB&#4?M][J>LZG>^%K7\8_BWX>^,'[9WQ
M\4?'/]M?XU+X!UFV\/W5UK'@:;PQJ\$?P)\ :_J=YH7@"YMO"VJ7UK#9?#C3
M_B##K?@;XHV>EW6I?$?PAXGM_#UIX\A&I>.M)O\ 2O'S7/</E*J0?+6Q%*DZ
MU6A3DIU:=!1YG5J4X<\X4^5.3DTDHIO5)W_5O#WPLS+C#VF;8[&5LAX:HN5*
MOFKP,\16QTXS]B\'D^$DKXUPJR5.6*H0J1C-J+J*337]C_[)O_!/K]DK]BJV
MUF]^ 'PETG1_'OBQ67XA?&OQ9>ZM\1OCQ\3KJ62.YO[SXC_&?QO>:[\0_%"W
M>IQ'4&TB\\1?V!I]ZJII&E:; D5I;_QI7'%WJ[_P/XA\1!)/^6;!->U9V99/
MN% C!_,#>64#N&*QR%?Z&O\ @AE^TO\ M$_%C]G;Q+X<^.?A[5]3^%?P<*:#
M\)OVDO$UP-,M/&WAG1I[NPG\)W[:U):ZKKC>!+2TA">-9+1[%].EMM#\0WT'
MBW0]2EF^,?A1^R]^Q+J/@O\ 9"D^,WC/]HE/C%^VM>?$=_ =CX"UWX>67A/4
M-8\,?$G2-+UK3H+W7-"M6TU(=#\5:?XDL8[S5K\ZQH?A[7[O2!?:_;:1I>I_
MNO@MQUD?"-/-\YS?!XVK1S>GE/U*%#!8:I.C99I-RFO:Q45R.+33N[J\8IH_
MF[QH\/L_Q6>4.&L-BLKKYEPW6SFABZM'$4:V7UJM">6TJM)5H2E2E.G-.%6"
M;=.:<97>_LG@TK_PXG^*8;Y67X@ZR<."C?\ )SWAH8 ;:3DG:  <N"@RXVU^
M&VN,HTC5P70$Z=>H!O7+,]JR@*,Y;F-PQ (38Q<J%)']&D'PETO1_P#@F1\<
M_@%I&K:Q!X>LOVS]<^"VF^(;M;#4M>M?#M[^W?X9\"0:M,L5AI6E:OKEAI-X
MM\VZS@M)-1BRQ4J=OPW\9_V%/V;_  ]\/?VP_P#A6'[2_P 4_'/Q,_9-^'_C
M35?B)X0OOAWH=CH&A:[I'A>UUG1O#'B+6+/P]IMI OBZUU.._P!#%I>R76J:
M=IGB'4-/^TVNG7;Q_I? _B9PODV(XL6:8K,(RXCXVQV9Y3&E@:C:G5AE/L_K
MD8P?LW*]ES74FKIRO=_F_$_ N?9G0X7EE\L-..2\-Y91QLJTX<M>HF_<3<K2
M>[2O=_,_HS^,WP"TS]I3X#:?\+-6^)7QK^$]IJEMX)U7_A-_V?OBGXA^#OQ)
MT^;0CI^KI!HOC?PR4U6QL=0^S_8=4MXC,EW822P_+)EE_,[P;^P!\0+E?%.H
M_L;?\%M/VZX-:\&>+-;\#Z]:?%7XA_!']MGP)X7\9^'IE76?"/B?PS\3OAM_
MPDT&H:6NT7VAR>/-$U5(I5G%\L;QRKD?\%C/VX?C'^RG^S!X"\-_!+PQXDTR
M]^,^CMX8U']H?38(IO#7PTTJVTZTBFTC1-3LC=BR^)7BF.6Y@\*3ZA;V]CI^
MFVNKZMH\^H^)K'3--B_G^_9LUWX^_L3WFD_'S]E#Q1J7Q \2^&-'\#VG[6WP
MBM)[SQK\+O$5YX\&H>*O#'A33?%/AV--*\?>.H/!"SZ[XGT_PA;^(?$GP7FG
MU74XO%'B'P\GB_3+?^/\TSS"Y7CEE]:E7G6H0E5E-0D_J5%2E3=6\E_M,%.$
MXMIS2E"49-:L_M7A+PES7B_A/'<0X?-,%@U*=2EDF6U<10@\UJTJE&.:TZV)
M5;FX<G7K8C#4<NAC_95,PQ]>E'V66Y?..;O^C;4/VC/^"L_[%437_P"U1^SI
M\/?^"@?P'TM&.L?';]@S2]:\"_M%^&M'MQ_I'B7QC^QYX^\0ZW!\09V#">YL
M?@7\3K_4[6UCEN;3PC-!;S21_I/^RY^UI^SQ^V;\,+/XO?LW_%#0/B=X,FNI
MM+U-M.>ZL/$?A#Q% Y75/"'C_P &:S:Z9XL\!^+=)?:-0\+^,=#T77K-&CDG
MT](9(Y)?,OV(OV[_ (#_ +>7POMOB%\*=72R\1:9%8P?$#X9ZU<6C>,/ &M7
M*1W,$&I6\$A@U/0[B82_\(MXNL(Y=(UN*-_LDMMJ%MJNEV?S1^V/^P=XST?X
MB:G^WM_P3Q.@?"?]NWP]90W/CGPL[MHGP>_;I\$:*@N+CX,_M&Z/#):Z1-XI
MU"R2XTOX8_'"1;?QA\/M9NK0W^NOX:55T3UHSA.FJL)QG2E#VD:D9*4)0_G4
MTW%Q_O)V/S;&8/%Y=C,3E^887$8''X.M4P^+P6+HU,-BL+B*3M4H5\/6C"K2
MJTW\=.<>9>9^NVY<XSGKG ) VXR"0" >1@$@GG .#AU?*/[%_P"UI\/_ -MC
M]GGP/^T!\/K+5_#\/B,:KH7C/X>^*8#8^._A)\3O!^HW/ASXC?"+Q_I4RQ7&
MF>-O 'B_3=7T/5[::&..Y2UM]8L&N-&U/3;Z[^KJHY@HHHH **** &KT_+_T
M%:\B\;R>;\1O@_:#DKJGC7567'1;'P3JNF-(2<#"2:Y''@?,3,&4%0Y'K@(&
M 3C.W'X@ ?K7DVOA;GXO> $[V7@CXF7P'H\FK?#K3XG/;+)/<(,<X9LX&371
MELHPJ8AR5U#+<[NNL76RW'4Z,FNG-*JG#^:SY;DU/AMUE9+SM9V7?9['KE%-
MWKZ^G4$=?<C'^<5&]Q!&CR22I''$K/))(=D<:*"69Y&PBJH!+$D  $DXKE<X
M*,I.<5&/-S2<HQC'D=I\TI.,8J#^)R<5'[32U&VERW:7-\.OQ?X>_P CQ7P5
M=V^BZW\<TF;9!I7CQ-<?Y7;R[?4/ASX)U>9PD:LY5[D7P&Q2SR!T4%^#VW@&
MVGM?!GA5+CS'NGT'3Y;IY;@W<C75S:)>3A[Z2TLI[I5EEE"3RV5M/<!5EN(D
MD9@?EV[UKQ%I?C+]IF\UW6_A_'X#\8:?\-+#X77/AV]\2W?B:>]NO#Y\*^,W
M\:KIETBV[6.K76EIH$WAMK4)HG^EZA<)<PS21?8]I=6+VEK):303614):2VT
MB302PK&$B\F2$NDB^5N;*%@J([,0$8ASSS(\WIU'E&;Y?F,WBJ5/&0R_'X'&
MRP^)RC+,-2QE#$4L)B\14HRC6Q%6#A4A%MJ<7>4'R\V'G%QD[JT=&W=*-G+=
MM)7=^OZEX2 Y^8=2,9!Y&>@./ND$''\2LI&4;'R5\0=:O_BIXB\.>'/"]_J6
ME_#G0_'L>D_$'Q?HL^LV]QXHN[G2_$&D:E\/_"-_H<+7$=I!>7<)\=>,96M-
M-T,VUWH^CZG;>*[?4-2\*]KK&JZI\5=9U/P3X+O+S2O!>DW,NG^/_'>G,;6X
MU.[AEC6Z\!>";V/"M>QQPSV'BKQA:LX\+CSM T2<>+_MUUX7ZSQ7HNE:!X,T
M+3]&TV'3-(\.:YX'72].TFPN9+33[*P\3:'$L5II^F7^FHEO%IYN(O.EGFM+
M0'[;+IVK)$=.N_>R]0RBKAZM:FZV;XB--T,/\4,MIXR$Z$,74C>T\9*,Z=7!
M86;Y\/"4<?BJ7UAT,.IJS]O&T-*;LO:?86J5^9::+Y=.YZ)IVDV>CV.GZ7I5
ME::;IFF65OI]G86<*6]K:6%I$L%G:VD,0$<$%I @CBMT0*BE$CE2-7674)R,
MJ,GH?7'X?THY51C))^IP/Z=OUIA8 @KG)[ ,>_8 =,C'![@#J,_/3;FZDZDI
MRF[MSM*]FW+W=V[MMO=MMW;W.E*,;1BU%>;_  U\OZ[P$8Y4=-@7)!SD@L.0
M>F,YSSD8Y%>"? "U\9Q:)\1+SQGXHL?&%]J/QN^,D_AV_MO#-OX;&E>"8/'>
MJZ?X5\(RI!?:@=7;PEI5C%HK^(9#!)K?V7[9-:V]R[*WO:LH!;##:0@&U\%<
M*V. =Q&1@C*[OER6XK^>+]J;_@LIX4_9%O= ^"'@'PS:^-/BSK&J_$7Q7XJ'
MBRU\0:9H6@6.J^.M9UZ"6%[?3XY-6>[TS5O[<@U)9$T)],@EG6_98Y/*]GA_
MAK&\4.6&RO+Z&/S:6.P]++O:T\-0<)5X9M5Q=JV,KK#*5:AEUM<5AE)14M/>
M<.?%XNE@4JT_:RA_S[C&4[V2TY%KU6Z[ZO8_:WPEHVD_$#5OBGXAUNRL-5\/
M>(;Z7X;Z=87MK%=6E_X6\%B]TO7([F,RRBYBU#QC?>,()5"PK<:;;:6DT,D4
M43'Y@U=_#G@+7?BE-\5=3URX^&>C>*_"/AGP'\6;>^E?QI\,_$.F^%M/N= T
M&]OHHIM3NI;W5?&]YH/A#Q?+;ZK/XINM2G\(?$*/5)-4MM0\6Y_[&G[='[/_
M ,8/V+_#7Q_T?6+GPQX'\,:0GA[Q0_B*WOHU'BO3["TN-1M-(U6^MK6W\7W>
MMW=ZEY;W&ERW,UW?ZE-97HM]4M+^TMM_]GSQ#\-OBEHVH?%/Q9XI\.>-I_%'
MC'QWJ7AOP#X=O-/\?:+X*TSQ!K7B#1K1-4L_"KZY;^(?&VL:!I,^GWWB*Z66
MUTS2YG\&^&ECL1K&H^*/LLM^L8*KQ%7QE'&RRO+L?EV2X>AAJ%9YG66&Q3IJ
MIETXTJM#"Y@L!E-;$8_'XCGR_#4,=]6Q]/'U\1]3/)K8C#UEA(1K4:>)Q%/Z
M[4E*<%*%9)>[)73536W([2O&Z2Y3M?!%[XKU#QAX9E_:.M(;/5XYXA\'(F@M
MH?!]W>-&(X-3\5+;/=Z=I?QWN862"717N+KPWHUN_P!G^&5YJ-]<>)9U\]UJ
MPB;XY>"/!MV[1PV'BC]H?PSJ)B> 0C3OB/X>T;QMX7N=725Q<*MK?^-+[P[H
M$I5K6XFU2ZMG=)KE4D\O_:1^*OQ.^"GA=O#_ (&\(^ /'GP3U*PUVWG/[0VO
MQ_#>V^'=R]MX4N/!>CZWK_BKQ#HWB"/X:WMWJ>JV.F^+9?#^I:]X UG3K+2-
M:N++3M,BOK;P*3XB_M6:IX)M?&>F_"[X5Z]+%X,LO&WP^U'P1XAO?B+K?B'Q
M?H6GZQXE\'W=W=:CXHTVZUOPY+#;>&'\17&G?\)+K4ITOQ7=1Z;JEI<VDD'X
MAXS>.7_$&<Z\-W6X#S7B3!>+.99EP/E53)L9'*<HRNOB\%#+XRRG+JV'Q]:7
M$E:GQ)]:K\+U*LZ.+S'+\SQ6&SN.%E3>']#!9=''4\12IXRA'%Y;3=6L\96I
MTYXR"M>I2]K43K12;7,HM*]K:7?[%>!9Y->^#O@^YEF(N;OP#H,LSM)<Q,M]
M'H=MYSF6VEM;@>7=J69HV0Y 8$96NZTJZM;J-9[.830WB17*&%WDAC66WCGE
M9G$0CC)>5?E9E<Y/&0RC\O/V0K/]IWQ;\.M+U+XN>%+*74K/Q#KME9V)O[6/
MPY:Z;8:KKJ6DUMIM_J3VEDKI-;P1RMX$FO&ADNY!J+0+IS2_H1X1EO[A+.<W
MEA=Z9!#]CMWT>ZM;S2XIK:XDMIX8I],LK&.Y=$2(!9&._GR]^U\?K?%.0T<D
MS',\##,L%C90S+,5;"XBG6M^\J6C[LI-M^ZK^ZFXR<8N+N&78F6+H8:K"C4C
M?O![6MU2[/N>O @\BBD4$  _YYI:^,/1"BBB@ HHHH 8W?ZG_P! KX5_X*=_
M\HVO^"@O_9D7[5O_ *HGQW7W4W?ZG_T"OA7_ (*=_P#*-K_@H+_V9%^U;_ZH
MGQW6^7?\C'!?]C#+O_3^'.;&_P"Z8C_KW+\F?=M%%%8'2%%%% !1110 4444
M %%%% !1110 4444 %%%% !130ZGO^8(_F!2D@<DTFTMW8!:*B,T0_BR< X5
M68A3NPQ"@D*2K ,0 2K '((!YT>,[C^"N3^("D_I2YHW:YE>*O);M+N[)V%=
M6OTT=U=JSV=TFK/H[ZDM%1^;&>0V1V(!P<^AQ@GV!)I%FC;H6[\E' R#M(R5
M R#QCKP3T!JE[U^76SY7;H^SVL_*Q23=[)NV_EZ]ON):*C$J, 03@@$$JPR#
MT89 ^7_:Z8YSBE,BCJ3^ 8G\  23[#)IV?9_<0I1:34DU+9W5GZ7M<?14/GQ
M<<M\VW;^[D^8,< J-G*]V895%!=BJ L'^8G/S=,YX/;J>G3WHL^S*>C46TI/
M9-J[]%=MCZ*C,T:G!8Y_W6/OV!I^X$9&<'V/^%#32NTTN[T0VFK-II/:ZM?T
M%HHHI""BBB@ HHHH **** (C]W\5_P#0!7PK_P $P?\ E&U_P3\_[,B_95_]
M4;X#K[J/W?Q7_P! %?"O_!,'_E&U_P $_/\ LR+]E7_U1O@.MH?[E6_[#L+_
M .FL8<%3_?<+_P!@.._]+P1]WT445B=Y67C/)&!&..I^09!SZ$#Z9K\H?^"W
MG@K4O'__  2[_:O\':-IMAJ^HZWX9\!Q6NG:G,;:QN#:_%SP!JDOG3)?Z<RF
M.WLI9(]M];[Y42,&0MY;_JXPRR'D;&+'MD%1CW/MZ5^:/_!7GPW=^-?^"=_[
M2?AO3]1GTF^U?0_!B6M_%K$?AR:W:R^(_@_46V:S<F*.Q6;[&;9I)S&DJRM$
M2 ]?+<88K^S^%.+,Q]I'!/ \.9I56-DOK"I^SR^I-3EAE+F:BX:Q]V4DFU*+
MM*/R_&F,A@>#N+<;.K&BL%PQG6)52;Y8PIX?*ZE6I6<FXKDI*"J3ESQ45&UU
MHU_DN_M5?#O4_@5\3=%\'^*/AYX9TR]U+PKIVN1QZ)?7EZ19WFJZK9!Q*NL:
MF[W+&SN%-CE0=J'RU$D9?V_]F33OA9HVO>*Y=?\ B7\<?!5O=:'916EUX6AT
M_P /2ZE=G40WV>[E\0^!IXY4"?O1:6+33B,><8C%N8=%^V]\']/\!_&/PY!X
MT\1ZSJFH+X+T74X;IO'-IXJ:*VBUS77ALXKJ'S&$IF@G!MD)E4.Q,8W)4T_Q
M[NO$$A7X3S>$_$FJ0Q^9JT/QOT>*RTNVL,(MK=:%)XNN-,CNM7>Z#0NUJUP_
MV,8.,-7\W?VSC^*/#OA:GE[Q>(GG631EF7$U#$/!9?0EAYMTJDO[1PG$V&I4
M\1R)4(U:51NUN>4N6:_+,_GF..\(?"^ME^<Y3GF*XOX8QV)SS-<DX@P$GPYC
M*>/P$\!1SO"9UD^?ULMK8R,)RP=#%XOVE=1?LHR47)?&_BW0_MG[2_BR;P?J
M'B37[:;QIXBN='\3^/+=;Z]U:T6UN1%?>()=+MK5+F5P 6ET^VT]0PS\H!!]
MVT_3_A-I6G78^-.K?"^Q\;JLTNC1:AX6^)5Y?S67V>1=.DL[K2(1IC"34(+B
M%&U$Q&&2)Y9S%;AI!=N'CEUJ3Q/\0;3X@:.+JYO+_7;KX7:/K7_"'P7LZ7,;
M3>"[CP_;26!\/,\\*17%EJ.HPR1O'Y4KQD5\_?&*QMM;\107_P .M=\276@V
M^BQ6]\?B+K-QI^O)J=I<:A>3BSM-96QOS81P3QLI2V9'EDOH(G>Y#0C[7"8B
MIGV)RG+Z^+S'+(Y=E6 I5\XRU86G'$3RN%/VL(9W4IQH.6,O)QH+)X1K;PA"
M*C26]7'OBJKD>#Q.*QW#L\OR7+LGEG64.FHJME%O;X>>>5\!/#*>-O:G0>50
ME6BM()-V]H^!_P"U+\2/A]JFOWWQ,\!>&?BC::EIUO9Z=9Z[-'=1:5?170O)
M;RV2PU^Q6.Y;!@,X=X9-VT.< 5Y9\3K70_%GB?Q7\8?#NDZWX(\5^(=6N?$=
MEIUK=::/".BG5KYXYK*PT]8)-06RM[&2:VTD?VOC<\1"E8W)\*^%?CB[\$WV
ML7+:!HWB!M0L8+<0:UX=C\3Q6;6]VMUYT$;!&MY)!^Z8-ARK$D8)-?4&H:7X
M>U#P7_PGFK:=X_B34HH];NM%32M93P)']NNB4M[30AIGV'^SD,JG2@244 $[
M0G'3CLDP/"W$M7-,%EO]FULV> RFI/*:DZF!S"G"*:P']E5\Q> PU.,D_:8M
M3BI-MRG*+L?0<1<%Y5P/F5+B#+,'E&#GGM2CDF+J976Q-?%X_#SC&I1R_'<+
MXC-IX2EA*M.]2%7"N.)G&TW*<9:=/\$O!7COQMX'U+6[G7M+U"2WU74;=[V?
M6](M+M62SM9'V:??7=A), GS;K>*1 ?ESN K_:6B^8,2<9=V!["/>&7'L 1Q
MG/3TK_(#_9>;X)W?P7\6MJ^F?#RTU634?$T-G_PF%IHNF:D%/AJS%G+:6NOR
M03&UFO'\J&<1_9FG$R+*7@G"?Z_-NW[J-2#N"*KG&?NJ%D.0",A@>0?F R,Y
MS7I^&&:5L=Q)XCX>>6U\!2R[,<L6$>(P&%P5&K3E3QDG+#2PM2K&K3C)VG**
M482:6KMS<OAGFE;'9WQ_"6 J8&EA\VRV%*5:C&A"HY0S&_LVI.,I*RNDTTWM
M=R2T****_:3]>"BBB@"!?OC_ '!_Z,KX9_92_P"2]_\ !3?_ +/=^'O_ *[=
M_P""?M?<R_?'^X/_ $97PS^RE_R7O_@IO_V>[\/?_7;O_!/VMZ/\/'?]>*7_
M *L,,<=?^+@?\<__ %!QA]S+]\?[@_\ 1E?#/[*7_)>_^"F__9[OP]_]=N_\
M$_:^YE^^/]P?^C*^&?V4O^2]_P#!3?\ [/=^'O\ Z[=_X)^T4?X>._Z\4O\
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M/VDL \5^\?YU?\$Q_A]^T1_P4%\46WQQ_:TM=7M?V/?AFEI%^SE\"_"1\/\
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MB/J4<%3E##8J=0^MX2P&%S#'XFIB'3JT\O\ BI-I\DGLZD;MPLHM^^HZ=QR
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M6V#GG[)IQL;$X]K#MQUX_IGA'Z)?B7Q-E.'S;&8C)N%L/BXQG@<#G?\ :O\
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M^&BR2>%XM*NG34&\_A;QZS#*:F$PG'5*.:X?$IQJ5,)RT,WA"_-^\J14</\
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MC'.:[[H^4_K=?YCJ*8)$(R#G'/1L_EC)Z&E+*._Y G^0-)M)V;2?;K]V_P"
M/W?BT]=/S'44A(')I<C&>V,_A3Z7Z=Q75[75^U]?N"BBB@9$?N_BO_H KX5_
MX)@_\HVO^"?G_9D7[*O_ *HWP'7W4?N_BO\ Z *^%?\ @F#_ ,HVO^"?G_9D
M7[*O_JC? =;0_P!RK?\ 8=A?_36,."I_ON%_[ <=_P"EX(^[Z***Q.\IJ6V
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M,A(D0<9XGL-;\006*Z-J>EZT]N[2W*6MOH-D]NKPX5@KVD+2 D$(@64@!BR
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MT\1V%W:W4D/B'Q3&;5;V\672KY]'UA+'$^'/CG]LOX2> ?BW\*?AU^Q=\/\
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M_P""9U?<XZ?\ 3^2U\,?$#_E)-^R;_V9#_P4)_\ 5[_\$SJVH?%BO^P'&?\
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M\3-?UG2+OP9XR^(OA?7/ ^LZ+X-TCQ&D42?"_P"%&F^,/#_P[O)O&$.DM?\
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M//C2;PUI)U"_NM132M=\%>*-=UGQ/-#9:1J^N>(=1UG1-7U35=<^VZ:+F_\
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MPQJ>LSS-?7.BZ1I<3VNJ:H([EO=[)FFL[>9[I;M)HUE65[0V^4*JP8HS(T9
M895E5P<JRAE8+Y%8?"72M.\&:%I]^L&I>)= T721>:UIMO%H)U?6=*T*QT>_
MO+;3-'ET71=,_M:RM+JW^R6UG::78+?L;.TM+1/LI]*\,HD5A&D=U+*AP\3&
MZBN5(8G*)( RR!I?-GW(2 DR(Q.W:OZ]B\1A\3@L*H574K8310GEN%RZHH.\
MDVL+.?,^9RNVE;:VR.FG&5*I=II==&DK^;_X??6^IU=%%%>2=(4444 %%%%
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M<5SI^I?$+X@7&FZJ=(CU#1M%T'0/%OCCQ'X(\">*?/\ P5^RQ9ZOXHT;XO\
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M2V_2Q\+9MV2N^QS^DO\ V=K6KZ,Y*PW\L_B33"PP)IIIEB\06D74!K&^:WU
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MB[#_ (3:V8'S8[A8:RG<9$Q]PX&?<<>OX>U<;X$>U_X1JTN4N[K4-2U2YO\
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M[2?P+^!W@P>/OBKX_P!%\#V?A/PBVO\ A?PRNM3Z1\3O _B+44.N>,=;\/\
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MHS84$[49E$C8VQ@[I"J\T@EC8X# MP=HSN&69.5QN&&1PV0-I5MV-IP >#?
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MN1\NZZ_9312W]U7D=8T8X5Y#Y:DN"H_9/(_IR"#^1Y_'I0!^&OPS_:%^.O\
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M0/VI_@'^VOX5\:)^S]K&I^"M7\'QV%KXM^&/BBTTGQ+X?AL-6M-7L?#VJ?\
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MX8GVCT/T/,>"\AXIX3EPAF^!]OEN84(*GA73YL7@\5.?M(8G!8IQ<_[0G/\
MVR$:<O:RE_L:O\!\AV&JP_%+QS?_ !%CF%_X-\&3ZUX1^% C#/:W]\MT^D_$
M3XCQ(V")]1U"#4OAUH5\(Q<:;I.A>([RP5KGQ7,Z>B@$810PS]QF4CS3S\HR
M  _'W#A\?PUR]GX)MO!6F:=IW@2WC.DZ/IUEIQ\.37"PP:C!IUH+2/5+65W2
M'3O$=[;V\9UG4Y)8K+Q!>W=S<WR6=_=76O+@>)_B?X2\*6"W.H2WEQK%S))%
M8>#K6U2+QE>W<./.B&G7;Q'2+2#_ )>/$VK"Q\-P=)M6CK_)?Q2\*.+N ,]A
M2Q^%EC,KQ[^K9-GF"P]6O@L91YN>^-C1IU,/@,?S^]R594JGUS_:+_5=#^)/
M%3P5XK\*<U^I9AA98CAK&0E3RKB7"4*E2GB<).7/4JX]4Z<J.78V53WL9&K.
ME/$8S_:,+;"Z'M6B>/-,\%V-]+XAN9[?26\J33Q;P37>IW.L23?9[+0-#T^&
M*66_U#Q!<!HM.L;&&>YGUA)%CB/EOLS],M=7U75Y_&OBZW@M_$%Y8M8Z/H,4
MR7=AX%\+R3VS/H-M<1/+'=>(=72PL+SQ?KME)<)?7MEI>E65Q/HVAV4LGPS<
M^(_$VL^(]+\;:_/;)J^B7)O/"VAZ?),V@>#A<2;;IK!7 ?7/$VHVV(O$GBK4
M5M[B]MWN].T"#0+&2.-OT!L+Z#4[&PU.W(:#4;.&^@5>=JSB-H5(^]AA*F00
M"N2'"E6 _E3Q<X4Q?"=7+\7*-.E_K'*<,VEA^6V&E@(.>8QP[BU:52#<Y15G
MR\\FK*N\QPX'Q.#K8?$86=24\52ASX:7,N:M#W_?I)R4IP_=5/>BFOW<]?=9
M+H-P-*\4SV3$"Q\3V,FJPI@[(?$&A06MOJKQ8&(_[6T9K>^$;;2=2TF2YV[;
MFZ9?2D&-[L0I<@C<0&"=%RI(89Y/(X_"O(M7.RX\+3H0LD?C#1HXY%(^<7L6
MJ:-J.&!P(1I=]>+<<A8Y(%\PJT7'HFOZ_IGA;1[_ %[59IH].TVTM%=;6VFO
MKZ]O+^[@T[2M-T^QMHI[[4]8UC4KJSTO1=&TZVNM6UK5+NRTO2K.[O[NWMI?
MU?PAS.OG7!F!I5Y2Q&,PN,J9-"4;U&W@9_6</1C:[]I4PS>%A37O3DN2,6U9
M_P"]OT'>.,3Q!X%SH9UC7.?!'$>>\-PS',*T:5"GDN'I9=Q%@8U*]>4*4*&$
MHYU6PO/*K&%/"9?1;E"E33CZ!\)_ABW[07QX^$_P1BA6Y\/ZEK5O\1OBKM42
M06/P?^&6JZ=K.JZ;J*[U\F#XA>,V\'_#BT1BT]UI6O>++F*%VTF[>V_J'*.6
M4H0J!T*J2.5V%&W XW  C*Y)/49K\_/^"?O[,6M?!#X>:M\0/B9I<5G\<?C2
MVC>(/&FFK>1W_P#PKOPI8V]W'X#^#]E?(&BN(_"-KJ&H:EXIO+.:XL-7^)'B
M3QG?V%Y=>&VT+ROT+\OA25.00<97Y3C'KR.^ >OKUK^Q.&<GAD^6PHR3^L8A
M.59N*<D[/E4KV::[RMJ[=C^2O'CQ'_XB7X@8_-L#5JRR/*U#+.':51R499?A
MXNEB<343<E[;&8N>*Q*:NYPAA9W:E%D]%%%?0'XX%%%% 'E/Q:^%'AOXR^"-
M2\$>+H[^"VO);"^TO7="OFTOQ+X/\2Z/=0:MX<\:^#M;B#W.B>*?"NN6UGJ^
M@ZI#'OBO[*%+F&YL7F@F\P_99^*?B?XB> =2\-?$YM.C^.OP4\377PA^-UKI
M=DNFZ=?>-=!T[3+_ $KQYH>E1O/'IGA/XO>!M9\*_%OPAIT-U>G1?#?C>T\.
MZC<+K>CZO;6?T^3S[87//L/_ -7<@\_3X5U8/\,?V_\ PAJD*I%HG[5OP"\0
M^#=;$(V^7\1_V8O$B>+_  )<M"I(FN/$_P .OC)\6K?5M3F'FQVOPZ\'Z-YG
MEQV+P].%YL1A\7A))N<:<JV$G=MT/JU-O%N[LO9U\)&I6D[K]]24TVXR4N:K
M*-&<:B27MYPIU&[)*4I<D%+M*4VH1C]J3Y4KGWA1117,=)$?N_BO_H KX5_X
M)@_\HVO^"?G_ &9%^RK_ .J-\!U]U'[OXK_Z *^%?^"8/_*-K_@GY_V9%^RK
M_P"J-\!UM#_<JW_8=A?_ $UC#@J?[[A?^P''?^EX(^[Z***Q.\***:75069@
M% )+'A5 7<6+= H7DL2%'<T (9$!P6 XW#/ *@X)!. 0#@$YP-R9^^N5WKD#
M."Q(7/&2N<@$\$@*QP.2%+ 8!(_+3X9?'?\ ;1_; \*>*_CC^S'J?[,OPF^!
MLVL^+O#GP-LOC9\-/B5\8?%_QU3P/KGB+PSJ'Q)U3Q7\-_CO\)M*^"_@KQ9K
MNC2Z5X-TR#PA\6_%<.@VC^,M;2VGU2Q\#:=] 6/[8/AGPA\%/A-\3_VD?"'C
M+X$?$3XGW\WA6U^!%CX5\=_&?XHS^/\ 3AKDFJ>&? O@SX5^!M:^(WQ*TY=,
M\/:GXKM-6T'X>V\K>"$MO%>MZ+X85;ZWLP#[-HKY(O/V[/V4].^%GA;XSZC\
M6+?3OA_XP^(P^#VD7M_X0\?V7B*V^+/VG5;!_ACXE\!77A2+Q_X*\?P:IHU[
MHEUX/\9>&-!\06GB!M/\/W6GPZUJ^D6%]H^$?VU/V:/&/@KXM^/X?B-/X/\
M#_P$,1^-5O\ %[P-\1O@7XL^%L-UX?M?%.F7GCCX?_&GPCX!\>^'=.UW0+VW
MU+PUJ>H^&H-/\3Q-)'X>N=3N()X8P#ZD+J,;F"Y8*-QVY8D  9QDDD 8SDD
M9I/,08W-MW;-N\%,F0D(HWA<N2"/+^^#C<HR,_G)\3?^"DWP+\/_  $_:.^*
M?P[;X@ZWXZ^ 7P8U3XL-\)?'?P&_:)^%WC[4])NM(UAO!/B:;X;^/?A1X;^(
M\OPDUKQ!I1TS4_BYI?A>[^'WAN.TUF[\1>*M'LM%U>YM.P^!/[7OA;XNWGPC
MDU'QYI/A&_\ &_[+4OQXUSX8^+O@3\9?A5XMM[72_$V@^'/%7Q%M_%WQ,O\
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M-U#Q$]F^N7%M;7-R(*^S1+&20&Y&TD8/1CM0C(Y5VR(V&0Y#!"Q5L $E%%%
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MHPC*<HUL6G*M7E&,-%!I0E+5Q]B^:PZ<HN,9WC[ZM'56G;6T==5VMW+YEB4
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M^)\D>@P?#!O@EXS\._#VW\%?#1?!]MHOB;6H(OAYXBUNW /Z8/B%^U7^R_\
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MHJ:/XO\ VT/$6DK-)+:7%GJ7QFCT#X3:9JFF0P0?8/@]>_V;<RQ:A<(W[/4
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ME6PF'KQHX%U_D<?F<L4IX/"2=.$[K%XQ/]S2>B:P=57A*2MJH2MTOH>O^%_
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M?@]K6L>,H=0^/?Q-NX?'L5AK.D7VA:QX:GT7P-H=A:>)]#MOAE*WBNTU?PP
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M-4?'JST;2O$=[X,N]7UCXL?%G0M7OM;L-/DU26;POH;^-S<ZWX4N/,MFTOQ
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M=4^#R%XKNSL[*:QN8%\<_8Y+$V]K%##'/%J!0-J+$"&ZFM-2_KA\MO\ :'_
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M1Q>'I8##9AE^9>5FV!Q-?#4*.#K*E#%W68XF+_VS#1T_W9)\]WW6SU]/E?\
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M&>55V'".5\S?PSXD;.[4M<E)3 SXIMH^?LVD6V/W?AH8)-K=S;AG$D]^W)U
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M>&_"LT*2/\--,BF;8D\8T;PN[0S"+4U:,M+)\ZQ_VKJ2K(A:,_VQ>G.V\O\
M?>GTOP_8V]U<_P#"#0!88I)&C32/#Z><OV>Q10H$\ASY<%O:%6Z_V6I=/)2R
M:7XC).&>'N&\!A,ER3*<-DN58"/L\NRG)L+EF795@8MRER8/+Z%2=#!1O.RC
M3G-6MK)^\_0E4K5*CJ5&VV[Z7;?KO;YW;9^$_P#P4=_X)H_"_P#X*"_%VX^,
MOA?QUX*\&_%[X56^A_"S3];\2^,-4&C>*-(MX;K6=5T_;IU_J2>'QX7\0ZG'
M8Z,=,TJXMY-?@\>6NJZ=<:GMN[3Z]_X)M_L@_!7_ ()]_!WQ#X:T[XC>%O$O
MCKXD>()O&WQ.\6:?KTDNB7VH&"XUJQTW0;"YU*6*RTG1=$UNXOHIRD.HZK%J
M#ZU=Q&*:TM[?]#?!N@Q>'=#M+1]#D&ISW5YK6K7(M+"-I=<UK5=1UC5;DM;S
MR*Q74-2O[A&4O\MUYB%KF6X\OJTNP <Z5J*@#<L:P*HW>6DA0HMQLR99Y5R6
M*^?"\I;:EK/+]QF'$>*JY52X3ISQ$N&\)BEBJ>#C/*XU7C8TZ=!XF.+A@GB&
MIXBKCL2FL;:"K\RYDVWY=#+4L4\PDTJKWBV^;7?1_P!6^9P]YXK\.ZIXGT"P
MM=:AG73?[:U*Z$4&H,#?P7'_  BMM:2WEI(EG',;J^U1!:WD=U,PM9+F*-$M
MFGC] L$T\@/9Q*D<R[@(8)X$90[2Y:-T102\DA(*AOWGKC&59*O]L:QJ36US
M&9([+38I&L88I%@LFGN2$N(97DF@FNM1NY"DL4<JRK,YD8/;YZ9<. RJ5(RJ
MJNWY1TW?+Q^'4'&,@ U\IBO8T5AZ&&IUU[*&&C.^-LIJJI.?MI*BJV)>$<_W
M;J3GRZ*,E$]6+U=[)/6]MG=>2?W;:Z%JBBBH&%%%% !1111N%[;Z$6" #Z _
MSQD?]]9!KX8_;,9?'.K?LO?L[VN;B?XN_M)_#[QGXGMXU+RV'PR_9DU.W_:.
M\2:S>Q8'_$AU'QM\/_AC\,=2E)*->?$S2+%@PO2%^XA*"=JG+*IW#D@$' RW
MW3@Y Y^\CJ/FC<+\-?LWN?CM\5/'O[85Z$NO".H6&H?!3]EU3F>W_P"%*:!X
MD2Z\=_%G2W.Y4/[1/Q&TJQU>QO[(3Z5X@^#_ ,,/@?XAMIX9=5OR>G -49U<
M=*3C'"0EB(-OD7UBM"='#14M&Y4*W-B9<K4J<:?M+Q]V2Y<3^]4<-:ZKW52V
MKC'1OF72][6=KWT/N^BBBN8ZB( $<_[WX#([\#G-?Y&W_!9OX4-\%O\ @J3^
MW'X)%I]DM[WX[^)?B+8V^#%&NG?&&+3_ (Q:?';!?W9MX[?QK#!&(SB)8_)E
M6.6*2-/]<=0P!)Z;5';KD$_IBO\ -O\ ^#KSX3MX&_X*8^'_ (@VEJ5L_C9^
MSM\/?%-Q>!!BX\0^$M9\7_#G4K/=G_76WA[PGX3G=Y%176^BCB>1HY G[3X#
MX]87C'$X)2M#,,HQ3Y7*W,\M2Q47%;2M3YI7>J@FT[-GP/B%AW5R>GB4FW@\
M=&=TFTH23BVWK:-^7WGI<]#_ .#1[XKGPM^W?\;/A-=W8MM/^+/[-NJ:G:VY
M(07WB;X:>.O"=_I<;)G#>3X<\4^-;J(D<0&=00V17^B44&/4E2OIGM^?3\_I
M7^3_ /\ !!;XL1_!S_@K3^QGKMS<M;V/BKQ_K?PHO8C)Y<=Z?BUX(\3?#K0+
M:0,P+F/7O$VA75O%@^?=6L!0-MW+_K!+C!!..68>Z\$GIV&>O//M6/CK@%@N
M-*.*2=LSR7 8[FZ.K0E5R^M%.UN:%'!4)3BFW%5(2E925[\/L1[;):M&35\)
MCY\J>_))*2DNO+?9[=/(L4445^.'W9 .G_ $_DM?#'Q _P"4DW[)O_9D/_!0
MG_U>_P#P3.K[G'3_ ( G\EKX8^('_*2;]DW_ +,A_P""A/\ ZO?_ ()G5M0^
M+%?]@.,_]0ZQQ8S^'#_L/P/_ *G(^[J^$O&/[3_Q6U_]H#X@_L[?LR_!7P%\
M4?%GP5\+>"/$_P 9_$_QD^.&J? KP-X?G^*%G?WWP_\ "?AB\\%_!+]H/Q5X
MR\5:MI.BZIK?B9;[P;X5\+^']&;P_P#8_$.N:SJDNFZ/]VU^)/[3^L?L5Z[^
MU3\3_#_[7^H^(OV#?B[IOPMM_"/[/G[:&@_M2^/?V5KKX[_"7Q!I^@ZMXG@\
M-?%SPMK/PV\!^(/$_P %_B9J=M;-\"OBEJOQ,?2KM=-\=:=X-N/!WB[53<8G
M:?HG\*OVC;/Q-\%-;^+_ ,<_!>L?LIS?#_4/%.B?%[2_C1J%GX9\+>#-3\"W
MGV3Q'XHT;XDZW!X>\,^./@U?S(-;\#_%^UBTS1?$GAJZM=3O=/T"^;6?#ND\
M!\8?VXOA3X*_9\@_:)^#?B#X=?M(^"9?BW\)OA5;ZA\,?BSX>U7PW-J?Q&^+
MO@GX6:Q+%XO\)VWC32I=0\&IXR77KWPVEOYU[)8C2+J?0DF&L0_C'\5_'?[2
MOQ!^#?P7^(7BGXLP^/\ ]E_X'?\ !2NUU/PM^U7\</@7<>)O"_CS]FC0_A1?
MW_PF_:$^./PX^%WB;]GWP_X^^%'PY^/^NI;VOQN\.7WPS\"ZEHW@WP=\=M32
M^\/Z;>ZEXBX_XO7J?$#3/VN_C5X<^/GPS_:!\,^+?C3_ ,$MO"OB[XA_LU_
MJ[^&'[*_BWXG^%_VJ? ]Q%?>#?'M_P#M4_M$_P#"T?BWX;\":UX6\.?%;4_#
M,>E^&]'TE?A]X4U'5=4\1Z7JNA^'@#^D37?VD_V=O#'Q2T3X&^)?CU\&/#WQ
MK\2K8OX=^#VN?%#P3I/Q3UY-3CGFTUM'^'M_KD'B[4EU"*UN7L39Z1,+M8)O
ML_F>6V+?C_\ :$^ ?PG\4>#O _Q3^-_PA^&GC7XB745E\/\ PA\0/B5X,\&^
M*?'-[/?6^F0V?@_P_P"(]:TW5O$UU+J5Y::=%;Z+:7LSW]U;V:H;B>*-OY@_
M%%WXITCX+?MU?LS_ !H_:-^!WP^^,7Q/_:E^-6I_\*!U']D_Q[\2_P!O#XPZ
M[XN^*D5[^SO\2?V:YKC]N/X4)\3Y(]!@^&#?!+QGX=^'MOX*^&B^#[;1?$VM
M01?#SQ%K=O\ ;&L>*?V?_A!\;_\ @I=X+_;\1]9U+]HCX>_ /3/AQX>\3RVE
MGXT_:J^#^C_ /3?"-W\(/V:=%TOQ%I^I^+?B7;_&G_A/H;KX8?"C5H_$NC_$
M3Q[X;US1]0:?Q1H6MQ 'Z56W[<7P2F_;<U+]AG_A,/ T?Q0TWX2Z?\2V@G^(
MW@V#6+CQ#J5_K-P?A?I?@D7;^)[SQQIG@32IOB?XEM69+[2_ ^HZ#XD&FOHV
MM-?VWM_PZ_:2_9V^,'B;Q9X*^$OQZ^#/Q2\9> I9H/'7A'X=?%#P3XW\4>"Y
M[?49M'N(/%OA_P ,ZWJ>K>')X-7MKC2IH=8M+.2+4X9;!U6[1H1^(?[84GC.
MY_:%_:)\&_"Z?Q%\.OC1\;/^"+5IX(_9R\&>*_%2VOQ:\6^/O#/CSXV>*->^
M''A'4CXJU._\8_%OPIX9O5NM>C\*^)O%6JZ;=7%MXDOM>FTZZCU"?SWX3ZW+
M\9?'?[ GA3X)_M0?LY^,?B%\$/!'Q''A/X9?LJ?LC>)?A]\0/V=_!B? +5_!
M'B#X>?M6^(/&'[;7Q/7X"^"_^$IU'P+X?N_"/BWX0WOC37/C-X=\*IIOA/[3
MH7B&^T, _7/XX_\ !0'X'?"OQEX%^&'A#QU\)_BW\6_$'[0_PE^!'C;X4^%_
MC)X0_P"%C_"ZW^)OBJU\,7/C#Q5X)TQO$GB:R7PS+?Z?Y^D:KI6@#4;C4;*U
MEUK19;NW\S[UK^67PG\3OV8C^R5_P2U_9QN;GPE'^U[\%_VP_P!E;3_B3\([
MK3[*7XY?"7XOV?Q?MK/]HCQU\0_#:Z?;>)O!.F^./&>IZU<WOQ+\0Z7!X>^)
M>K>./#TFG:QXAN?%NF:G=?U-4 ?G/K'[67[1'BG]JSX]_LO? 7]GCX,>-3^S
MSX/^!_BSQ5XW^+W[3WCKX1#5U^-NG>+]3T.ST'P]X,_95^.[32:0? NK1:C+
MJ^OZ:MWOLWME<272P_35Q\9K'X5?">T^)/[77B#X$_LY36]S+8^*;R?XXQ:E
M\)="O;[7+JP\/6EK\6?B;X(^!9U.[UVP;3KJXM]0\#>&Y;76KRXT6Q378K*S
MUJ__ "]\'_ ;P/\ &_\ X*M_\%$_^$SU[XT:*OAGX/?L,+8-\(OVD?VB?V>Q
M,^K^&?C+]JC\0-\"/B=\-U\5R V5D=+3Q0VKMI:RWHTM+#^T-1_M"G^WC8>+
M/@G^U+^P'X^A^+'P]^#WP ^$_P /OCCX+LOC;^U9X7^)G[0OPI^&?QBU32?
M&G>!?$/Q0\9ZK^T9\']6TGQGXO\ A]I_C_P7X7^,WQ2^)&I7']I:KXI\.7L^
MN:_\0+*[T\ _7EOCG\$U^%@^.C?&#X7+\$CHW_"1K\86\?\ A0?"UO#WVE;+
M^WE^(!U8>$VT8WCI:KJ@U8V+7#K"LYD95/R3\?\ _@I'^RC\&/V:]6_:=\.?
M&?X*_&'P18>/?"GPQT>\\#?&[X;7N@>(/&_BWQ+X=TR^\.VWBZSU?6=&2_\
M#7A_6I_B!XKTZUAO]7TGP)HNLZ\-/&G6C7"_C;<^,D^'W@%?B[;>/?@IXO\
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MOA=/$T?@'PUIWAB+6CX>&LZ^ND'5;;3H[EM,?6]6BMV<QM=MC)][INX>C?\
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M:?J-G;WMC>0-OM[NSO8(I[6Y@EQLDAN8IXI(74D2*W'(8#_$/Q\I/OC\./\
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M@_\ %@WQV_\ I9U?<NU_5O\ OL__ !5&U_5O^^S_ /%4>UH_]"_!?^"\3_\
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M_P"&2_C]_P!)-?VW?_#>_P#!-[_Z "C_ (9+^/W_ $DU_;=_\-[_ ,$WO_H
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M^/W_ $DU_;=_\-[_ ,$WO_H *^Z=T?I_XXW_ ,31NC]/_'&_^)H^OXCO0_\
M"++_ /YA#ZEA_P"6O_X<,P_^;3X6_P"&2_C]_P!)-?VW?_#>_P#!-[_Z "C_
M (9+^/W_ $DU_;=_\-[_ ,$WO_H *^Z=T?I_XXW_ ,31NC]/_'&_^)H^OXCO
M0_\ "++_ /YA#ZEA_P"6O_X<,P_^;3X6_P"&2_C]_P!)-?VW?_#>_P#!-[_Z
M "C_ (9+^/W_ $DU_;=_\-[_ ,$WO_H *^Z=T?I_XXW_ ,31NC]/_'&_^)H^
MOXCO0_\ "++_ /YA#ZEA_P"6O_X<,P_^;3X6_P"&2_C]_P!)-?VW?_#>_P#!
M-[_Z "C_ (9+^/W_ $DU_;=_\-[_ ,$WO_H *^Z=T?I_XXW_ ,31NC]/_'&_
M^)H^OXCO0_\ "++_ /YA#ZEA_P"6O_X<,P_^;3X6_P"&2_C]_P!)-?VW?_#>
M_P#!-[_Z "C_ (9+^/W_ $DU_;=_\-[_ ,$WO_H *^Z=T?I_XXW_ ,31NC]/
M_'&_^)H^OXCO0_\ "++_ /YA#ZEA_P"6O_X<,P_^;3X6_P"&2_C]_P!)-?VW
M?_#>_P#!-[_Z "C_ (9+^/W_ $DU_;=_\-[_ ,$WO_H *^Z=T?I_XXW_ ,31
MNC]/_'&_^)H^OXCO0_\ "++_ /YA#ZEA_P"6O_X<,P_^;3X6_P"&2_C]_P!)
M-?VW?_#>_P#!-[_Z "C_ (9+^/W_ $DU_;=_\-[_ ,$WO_H *^Z=T?I_XXW_
M ,31NC]/_'&_^)H^OXCO0_\ "++_ /YA#ZEA_P"6O_X<,P_^;3X6_P"&2_C]
M_P!)-?VW?_#>_P#!-[_Z "C_ (9+^/W_ $DU_;=_\-[_ ,$WO_H *^Z=T?I_
MXXW_ ,31NC]/_'&_^)H^OXCO0_\ "++_ /YA#ZEA_P"6O_X<,P_^;3X6_P"&
M2_C]_P!)-?VW?_#>_P#!-[_Z "C_ (9+^/W_ $DU_;=_\-[_ ,$WO_H *^Z=
MT?I_XXW_ ,31NC]/_'&_^)H^OXCO0_\ "++_ /YA#ZEA_P"6O_X<,P_^;3X6
M_P"&2_C]_P!)-?VW?_#>_P#!-[_Z "C_ (9+^/W_ $DU_;=_\-[_ ,$WO_H
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MI.W(W8R*@!5<*I#* LAV[&4Y*L'VH,DS$2LC*J(TBG"AR"P!^6]_^R]^U/\
M!#Q[^T[=?LF2? 36_ 7[5$7AO6+I/C+XQ\>^!O$/P ^(OA[X4>&/@NWBCPMI
M7@WX5_$NP^-?A:[\,^$O#6O6_@35O$?P=ETW5]$O-%C\675GXDDOO#VQ^S'^
MPAK7[,'QH^#6M:%XQT?Q+\,O@_\ L">$/V2+:\U6?4K3Q]X@\8^&OB;!XTO/
M&=]H<-A)H.G>'-2LUGE\F#Q+=7\6I7*Z3Y#6$:7S?5'Q[_:0\)? )/ FDWOA
MKQY\2OB/\6?%-SX.^$_PB^&&EZ#JOCSXB:]ING2^(M<6RN_%?B'P5X \-:1X
M4\)65]XI\0^)_B)X_P#!GAC3]!L9([G6CKE_I&FZASWP6_:N\._%KXC^-O@K
MXD^&WQ3^ ?QR\!>'=$\=ZE\'/C/;_#Y/%&J?#?Q1=W&D:!\3?"GB/X0_$GXM
M?#'Q9X-O?$-IKGA74)-$\<ZAX@T#Q3HMY9>)-"T<W.@-J@!\'_"/]@7]I/\
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M2^_\$R?^SVOB'_Z[?_X*!U]SCI_P!/Y+7PQ^UA_R7W_@F3_V>U\0_P#UV_\
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M[>I][\O+S7WH/J.!U?U##6BDW[BT3O9O]]HG9V]'V/AG_AWG\ _^AY_;;_\
M%F?_  4A_P#HK*/^'>?P#_Z'G]MO_P 69_\ !2'_ .BLK[H)P 3GGI]X_P G
M-)O'J>H'\74YQ_'[&A8['.]J]1VWLWIZZ:!]1P.B^H8:\FU%<BU:3;2_?:M)
M-NW1'PQ_P[S^ ?\ T//[;?\ XLS_ ."D/_T5E'_#O/X!_P#0\_MM_P#BS/\
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M - &&_\ !:_^7'PK_P .\_@'_P!#S^VW_P"+,_\ @I#_ /164?\ #O/X!_\
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M )G_ .+H^O8[_G_4^]_Y!]1P/_0!AO\ P6O_ )<?"O\ P[S^ ?\ T//[;?\
MXLS_ ."D/_T5E'_#O/X!_P#0\_MM_P#BS/\ X*0__165]U8/O^9_^+HP??\
M,_\ Q='U['?\_P"I][_R#ZC@?^@##?\ @M?_ "X^%?\ AWG\ _\ H>?VV_\
MQ9G_ ,%(?_HK*/\ AWG\ _\ H>?VV_\ Q9G_ ,%(?_HK*^ZL'W_,_P#Q=&#[
M_F?_ (NCZ]CO^?\ 4^]_Y!]1P/\ T 8;_P %K_Y<?"O_  [S^ ?_ $//[;?_
M (LS_P""D/\ ]%91_P .\_@'_P!#S^VW_P"+,_\ @I#_ /165]U8/O\ F?\
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M ,-_X+7_ ,N/A7_AWG\ _P#H>?VV_P#Q9G_P4A_^BLH_X=Y_ /\ Z'G]MO\
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M (LS_P""D/\ ]%97W5@^_P"9_P#BZ,'W_,__ !='U['?\_ZGWO\ R#ZC@?\
MH PW_@M?_+CX5_X=Y_ /_H>?VV__ !9G_P %(?\ Z*RC_AWG\ _^AY_;;_\
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MWCBX&G+-XRT[3]$NKK0H;#Q ]^EII%_<:9;O:VDBV[@'\X'@Z/XJ_M0_'/\
M9P\ _%KX,_L^_M=Z)#_P2U_9B^+'P[^'7[9/QJ\4>"O!.O\ C+QJ-2M?CK\9
M-&TFT_9=_:*TSXF_%"R>/P)H>K>*-=L]-UWP/I&L_P!H:%>QR>.]?:+]:?\
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M .Q3XE_8 ^+OBKQGXPN/VK/#=IXMO_B=^QD/@'<V/QZ^*_Q5U[PQK_B:_?\
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MU;2]/_)[Q1^QGXDM?$'[7$'Q&_8H?]IWX3?$#]IOX >-/AQI'@WXP^!OAO\
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M;5D"M)&"Y<J720-M9AM"2-Y,;,%3<.2Z+7YLZIXQ\0? _P#;,^.OC36_@_\
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M@WQAX5^%&EQ>8SI8_P#"L?A_X2\%>(+5-P!C,WC#3/$FHO !E)[R0#+#<?\
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MA^X2SU[PIJE_H%_J%K8>)=#NY([76-!NY8M5TRXD2"]M()'53VV],@%L%C@
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M9]4M;6+5+>RNY[%YXK:9TZ(.I.!G()4_*PP1N)R2, 87()(!#(02)$W?C/\
M'#]H7]L23XD_\%#/ _P%'B3QA>_!;PY^Q5JO@#PKX(\(?#+7?B3X0\(_$R3Q
M/??M&>*/A?I7C:+P]HGQ&^*NG^ M&U;Q!\-_ _Q"UO7- O/'^AZ)HEMI.H6M
M_=>&K_F8_P!KCQ#H?[*'_!0S7OA_^V#\4?BC\8_@5\#/$?Q1\'^%/VE?V6]
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M#KHPO\:K_P!@N,_]5V8G%C/X2_[#L#_ZGP/NZBBBN<[0HHHH **** "BBB@
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M*H22DYFZ$-C8<=<9(P,#G@X. <]AU[5\Q?M2?#!/B3X,\"RVT7D^(O 'QZ^
M?Q"\.WZ/MGLKGPY\7_",>NA&#AL:GX*U#Q3HUVH)$]OJMS& ZR 'Z<=68 87
M:5)SN3Y6'3'S=">.X&>W;%UG8;=&\L3&/4]$)3<N%,6LZ>XD8$_+Y?E"Y#G"
MA$,N=B[AZ]>DJU&M2J+FC>,HIWY96E"2B]4FI<O+*]]-+:GP>5XZK@,?A<7A
M9VJ8:4*V%<'>I+VOMZ-;#U%&\E2K4*TZ%=6M[#27NW.HHHHK4Y@HHHH @7[X
M_P!P?^C*^&?V4O\ DO?_  4W_P"SW?A[_P"NW?\ @G[7W,OWQ_N#_P!&5\,_
MLI?\E[_X*;_]GN_#W_UV[_P3]K>C_#QW_7BE_P"K##''7_BX'_'/_P!0<8?=
MM%%%8'8%%%% !1110 4444 %%%% !1110!7(' YR$ Y[YY_K]:_SB/\ @[-^
M*G_"9_\ !1WP'\.K:YWZ?\'?V;?!.E7=J')>#Q/XS\4^./%FK3$;0B1W7AK4
M/!T3("TCI;,W/FP*?]'8[AG@X)0_@ 1T_P DX[U_F0_\%HOV1_V^OVF/^"G_
M .V!\6?!/[$?[8'C/P7J'Q)L?"/@WQ3X6_9K^-7B+PKX@\.?#7P?X5^&VFZW
MX;UW2_!5WI6J:'JX\'G6+#4].NI]-U(74MQ8W%RDZM)^M^"=3+J/%KQ^8XS!
MX"CA,KS!4JN-Q-#"TYU*_+@H1A4Q%6E3E)T93DHJ3DX^\HM)M?$\=+$5,GAA
ML-1JUYU\=%U(T:<ZLHTXW?-*-.,FHMV]YI+579YK_P &WGPK;XG?\%<_V<[J
M:W^UZ5\+M(^*GQ4U5657,8T+X=>)]#T&Y<G(!MO&OB?PW=Q2 -M@A> F.2XA
M+?ZE)ZCV#GC_ &AM&?3GGH<U_#?_ ,&L/["?[2'P-_:C_:2^-'[0W[.WQO\
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M (C]W\5_] %?"O\ P3!_Y1M?\$_/^S(OV5?_ %1O@.ONH_=_%?\ T 5\*_\
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M !1110!$ Q[Y'?D$?SJ%[<ESM "$[CN8D@@Q_*BD$H#&)%5TEC$;,2(GR"+
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MVER,\\/P_P#C!X?_ +.^)WPXEF5E7PYXBM]'OGAU_1M;TW3_ *=#@<,P!8$
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MW_U1/CNM\N_Y&."_[&&7?^G\.<V-_P!TQ'_7N7Y,^[:***P.D**** "BBB@
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M7_X/P?\ \Q'PU_PL#_@I)_T:?^Q!_P"+!OCM_P#2SJ/^%@?\%)/^C3_V(/\
MQ8-\=O\ Z6=7W+M?U;_OL_\ Q5&U_5O^^S_\51[6C_T+\%_X+Q/_ ,\0^KU?
M^@G%_P#@_!__ #$?#7_"P/\ @I)_T:?^Q!_XL&^.W_TLZC_A8'_!23_HT_\
M8@_\6#?';_Z6=7W+M?U;_OL__%4;7]6_[[/_ ,51[6C_ -"_!?\ @O$__/$/
MJ]7_ *"<7_X/P?\ \Q'PU_PL#_@I)_T:?^Q!_P"+!OCM_P#2SJ/^%@?\%)/^
MC3_V(/\ Q8-\=O\ Z6=7W+M?U;_OL_\ Q5&U_5O^^S_\51[6C_T+\%_X+Q/_
M ,\0^KU?^@G%_P#@_!__ #$?#7_"P/\ @I)_T:?^Q!_XL&^.W_TLZC_A8'_!
M23_HT_\ 8@_\6#?';_Z6=7W+M?U;_OL__%4;7]6_[[/_ ,51[6C_ -"_!?\
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MW!_Z,KX9_92_Y+W_ ,%-_P#L]WX>_P#KMW_@G[7W,OWQ_N#_ -&5\,_LI?\
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MNK]8*_)__@N#_P HM_VJO^P7\+O_ %>_PNH _6"BBB@ HHHH **** "BBB@
MHHHH ;O7U(Y"\@@9.,#) '4A?3?\GWN*7<,XR,GL3@_EUK\^OC)^VIKWPA^,
MWBCX+7GP7-]K=_X'\->*?@;XJOOB-IV@^"/C)KEQJ]S;^-_AA>:U<>%=2N/A
M[\2O"GA^RU3QSH_A6\M?$J>/?!>BZ[J/AFY%QH6LVUCWNJ_M\_LE:!>_$_1M
M8^-GAAO$7P2U'2]&^+NA>'[/Q1XLO/ 5]JK^(H4N=:@\-^'M5O4T33;CPAXK
MM?$GB:VAG\.^$KKPWKEKXIU32+C2[Q(EI;FMK;;K_P N_P#Y;3Z?\O(?SQO7
M)+^67W/_ "/L;S$.3N& 2">@# A=K$\*V2!M)#$G@4N]<@;AR2H]V') /0D<
MYQG&UL_=;'AO@7X_?#?XN7GQ7T#X2Z]_PF?B?X.^(M3\#>-M.ETKQ3X<T_2/
M'6F02E_"]QXAUKP_::?<W8<07-Q<:!+K:0:7J.D:P[G2]9TBXO?@VY_X*?6,
MGP!^$WQ5L?@QJ6E_$CXC?%KQ;\&_&?PJ\5^-+>SL/@AXE^'VE>*]=\;>(/B'
MXNT#PWXIGU#PAHVC>'M*U;3K_P &>$-:UGQAI?C#PO?Z+I4-O>3RV[?NKFEI
M'DA4YGHO9U?X=2[TY*GV);2^RV2?JZ9(R< J<@.".ZC 8@\@A6(W$$A"1N(R
M*X[QSX\\-?#W0IO$'B:ZN8+3[3:6%E9Z9IVH:UKFM:I?R&*RT/0M!TBTO]9U
MO5[ILO#IVDV-W>M DUSY8MX)I4^=$_;6_9ZTW1+F]\0_$&W:_P!"TGX?W'B+
M_A$_"7Q.\8Z/+K/Q T'P_KOAG0?".I:;X*FN?&FMZGIGB71-:M/#VAVM[XR3
MP]J%KK>L^'M.TTR3Q>/_ /!1&R\7^*_@>-/^&>F>)-0\4:[X=\12:'J&D65S
M+;-:70\/C7?#UO(CV]YIWC7QAX%O/$FE^%F@DM-3U#3/^$K\)Z;<)J7B6UTO
M5/.S?$5LKP&:8^GAJ^*J8/+JV)IX.E2G5K5,3A8RG2HPI13J2JU+I0IQBYR:
MT3>W5EV&ACL=A,#*O3PRQ,DJF(JSC3I0\YU)-1BM.K70]CT']LWX0:[J>EZ/
M$VL0W\R3#Q'!!J'@7Q'=> 6BNX+1Y/&ECX&\:>)KVPL?,N5N-2\1:1:ZMX;T
M&Q675=?U?2M+M;J\A^NUEBE5'1PR.BLDBD,DBR8V%77Y7#@@KM;D$8!W#/\
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M4;7_  4%_P"S(OVK?_5$^.Z^ZF[_ %/_ *!7PK_P4[_Y1M?\%!?^S(OVK?\
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MT:RL+"*]UW6]0U+6]7F6$-=ZKJ=Y=W3W=S*]TX!^"GQ0_9^\ Q_'[P7^P_\
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MZ)?VAAEKVU:7S1R5D_:8/1^[.=]-O]CQ<=>WO2C'7K)+=H^[J***Q.L****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!C=_J?_ $"OA7_@IW_RC:_X
M*"_]F1?M6_\ JB?'=?=3=_J?_0*^%?\ @IW_ ,HVO^"@O_9D7[5O_JB?'=;Y
M=_R,<%_V,,N_]/X<YL;_ +IB/^O<OR9]VT445@=(4444 %%%% !1110 4444
M %%%% !1110 5^3_ /P7!_Y1;_M5?]@OX7?^KW^%U?K!7Y/_ /!<'_E%O^U5
M_P!@OX7?^KW^%U 'ZP4444 %%%% #0RMG!!P=IQR0W'# <J1D9!P1WQ2>9&
M"77!"$'<,8<[4.>F'/"<_,>!DU^)'[:G_!;KX*_LJ_&'7?V>/AA\'OB;^UC\
M:? D6F/\6-&^&%_X0\*^!?A'<ZS80:OI'AWQI\2?'FKZ?H<?CC5=+N+>_L/
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MJE2=2#IRC*,6WAFFG_"PVM*6J7N-I<CV;U38FK=4S\NOA3^QM^R7^U+\&?\
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M_P!/X<YL;_NF(_Z]R_)GW;1116!TA1110 4444 %%%% !1110 4444 %%%%
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M[7N@:OH7QM\1:OJ.GWNF^&O%=OH%SX >[BNH[9?"5CHNGZ#:^$K)W6U274/
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MM/%-Y#;[9I[/PK<Z5-XI-K;Q75Q>Q:)<P6>F:K?2PZ5/^>'_  4.\3I^SO\
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M+_Z*RC_AW?\  7_H>_VV?_%F7_!2+_Z*RCV."_Z"\1_X;G_\\ Y\;_T!T/\
MPY2_^8#[F\P>_P#WP?\ &CS![_\ ?!_QKX9_X=W_  %_Z'O]MG_Q9E_P4B_^
MBLH_X=W_  %_Z'O]MG_Q9E_P4B_^BLH]C@O^@O$?^&Y__/ .?&_] =#_ ,.4
MO_F ^YO,'O\ ]\'_ !H\P>__ 'P?\:^&?^'=_P !?^A[_;9_\69?\%(O_HK*
M/^'=_P !?^A[_;9_\69?\%(O_HK*/8X+_H+Q'_AN?_SP#GQO_0'0_P##E+_Y
M@/N;S![_ /?!_P :/,'O_P!\'_&OAG_AW?\  7_H>_VV?_%F7_!2+_Z*RC_A
MW?\  7_H>_VV?_%F7_!2+_Z*RCV."_Z"\1_X;G_\\ Y\;_T!T/\ PY2_^8#[
M?\Z,G!9LY Q@DY)Z8SGC.3Q@#).!S7S-\4OVL_@]\,/$"?#^'4]2^*/QFN5C
M;3?@1\';"+X@?%W4DF;9;7FI^'-/O;6Q\!^'G; O/'GQ.U/P5\.=+)"ZOXKL
M%V,WFR_\$[?V='++J][^U!XRM&V*VE?$+]O;]NKXC:&RY?<#X?\ '_[1_B71
M") [0WP-A_I=B[6D_P!JMR;0_37PP^"GPD^"7AYO"7P;^%_@'X5>&7G^US:'
M\//">@>#]+NKTKL?4+VQT"PT^VN]2E 'GZA=)/=W39>XF9CFG&EED(J;C7QM
M17O&MA*&7)OI[RK8^=G=7LD[W2=K,MO&3^'V=->;>GR:2_KY'DGPP^$_COQ-
MXWLOC[^T+'HJ_$/3M-U72_A=\,=!NSJ_A'X#^'?$(BCUL6VL3QH/&'Q>\56$
M<.F^-OB+#;Z?I^E:(C^ ?A[9V'AV\\8^(/B']7#D=,>U Z=,>V<_K2UC.I*L
MU)I1A9KDY'&RZ))W:7JVWJVW=F\*:A>WYA1112+"BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH 8W?ZG_ - KX5_X*=_\HVO^"@O_ &9%^U;_ .J)
M\=U]U-W^I_\ 0*^%?^"G?_*-K_@H+_V9%^U;_P"J)\=UOEW_ ",<%_V,,N_]
M/X<YL;_NF(_Z]R_)GW;1116!TA1110 4444 %%%% !1110 4444 %%%% !7Y
M/_\ !<'_ )1;_M5?]@OX7?\ J]_A=7ZP5^3_ /P7!_Y1;_M5?]@OX7?^KW^%
MU 'ZO$=#QN'<=^,#]<?AGH*_)#_@H=_P5H^%O["WB?PY\'/#OPS\5?M'?M+>
M+?#LGCBS^#?@?6=%\)Z?X1\!B]NM,@^('Q8^)'B"*?1/ 'AG4=4LKVRT1%L=
M=\4:])8:A-HWAR^M[&YEC_6X.,XZ*. <'J,?Y_K7\-O_  4]\-:[\*O^"L'[
M3LGQ(BDTH?M->'?@C\3/@#XFU25K/3?&G@7X>_"70OA?XN\ >'-2E8Q3:W\.
MO'.@^(O$?B#PO#+)J%I8?$?3O$EMHDT&J?:W^LX#R++.)^)\KRO-<?3P."Q4
MFJE>5:%*BO>4$G4G*$%[[Y%=_%:.[/FN*\WQ^19%C,RR[!3QN)PL;PH\DYSE
MTO&$4Y2U?17?Y?O#^P3_ ,%FOAY^U_\ %N#]G#XL?!+Q7^RQ^T#K>BZUXE^'
M?A;Q!XLT'XE?#GXN^'O#D?G^(8/AW\3_  W::+:7WB[PW8,^IZ]X&\0>'-"U
MRVT>"YUG1H-<TNSO;VV_;#D+@$'@Y[\'!^N/\?3D?P$?LQ^&/$7Q?_X*%?L*
M?"WX8)+JOQ$^'7[1WA+]HOQO=:=,\C?#3X)?##3-;F^(OB'Q=<6Y*Z%8_$72
M-7T[X9>&ENI+3_A,=6\4+8+;7D,$QA_OS+'!/'*X!XQV]>.P[YY^F>GQ$X9R
MWA/B;%9/E6*CBJ4:4<9*]2%7DJSTY9RC.:3=M4Y7TN^YS<&9YF'$.04<SS+#
M_5JE2_*HQE'G2WE!-1;UVLEJ]+K4_!_]M#_@N-X(_9T^-GC#]G7X!?L_>*/V
MK_BA\,+JRL/C-J>F?$+PY\)?A-\,M>U'3K'5K#P/??$CQ!H_B"?Q-\1%T2^M
M=1UGPOX8\.ZG%X9\Z*Q\1ZYI6H":Q@^LO^">?_!33X2?\% =(\<:+I'A/Q9\
M%_CM\)QHK_%GX"_$2?3+SQ!X9T[Q +T>'O&/A?Q+HD]QX<^(?P[UZ33+VVT[
MQ;X<=!9ZA;MIWB32-&U"6VM+C^.*\\*^(?@S\?\ ]J7]GGXI!]+^.G@_]I?X
MY^._%EA?NMMK7Q#\.?%SXD>)?B=X'^-.E/._VKQ-X<\:>%O%/A];/7XXKF72
M;G3;CPWJ*Z=JFF(T?Z,?\$2O#>M?$K_@IIXF^*WP\!U'X=_L^?LM_$7X5_&?
MQUI<ROX<N?'GQ6^(OPV\0_#GX2R:Q:R36FJ^)/".E^ ?&/C/5=!$MRGA&VUF
MT2^;3Y/$%K#=_89WX<\,X'PTPG&&'S6I5S6I3RK%QP].O2GEU2OBV_K5*-"-
M3ZU*KAV[U8I-TV[SBNOS^6<9YWC..<7P[5RUT\HIK,^;%SI5(5H?57'ZK*;<
M%&*Q-[4.9I35N1RUO_9W3#(@.-W(!)&#E0!G+#&5&.[  G ') IV1C/;UP:X
M7Q[XJ@\#>#/$GBV[N?#MLGA_2K[4XCXK\46/@GPY-/;0--;VFK>*]3M[W3]!
MMKBZ*VSZU<6CI;,RO+'M^8_C+:3LVD^W4_3MU=;=^GWG=%@#@G'3&> 220 "
M>"21]T'/3CD90N@(!8!B"0IX8A?O':><#N<8Y'/(SX'\ OVCOA-^TC\.+/XF
M_"[Q1IFM:!+OBU5;6^T^[FT2^C1Q<PWUYI=U>:;>6<AB:\TKQ-HUU?>&O$.C
MM;Z]X>U;4]$N[;4)?.OVAOVA/ 7A?X(^*O&WA7X@:GK$=L^J:5IZ_!.S_P"%
MA>+O$7BNW\*Z_P"(]*\ :!=>'](\8Z;X<\5^*9M&33M)U;Q#IDU@^HWNG:<&
M:_UC3()ZLU)Q:?,MXV=UZJVGS:OTN.SM>VFNO33?[O1GV"748R>""<X.,*,D
MDXP%Q_$2 <C!.13J_-S]E#XQ>+-,\#_LU^'?BU\5_&GQ3^,7[16C:?XAU6_\
M6_#Z/PWH&D>(/!_P1\-:[\6_#_@MO!_A72+'2M'LO&$.H7MG;^*Y[IK?6;CQ
M-X477V-GX<T.+](Z0@HIN]<E<@L!DJ.6 / )49.#ZXQ2%U'<\YQA6.<8XX'4
MY!4=7'*!AS0!&2N%;^' &>@)(SD$\'(/!&1G@'@@?-_[2?P$L_CUX,&@3K92
M2PVNK:9/I>KW#V>D:_X?UZW@75]%O-0ATW5KW0KQ=0L=#\2Z'XHTFRO-1T#Q
M/X7T*Y%MJFCR:YHNK:GQ*_:9^"GPKU>+PKXD\;VEYX\NEA73_AGX,L=6^('Q
M0U*212]E#9?#GP1IWB+Q?Y5X?DBO)-&BLLM^\N8Q\Z>;0_$+]JWXHB%/AM\'
M] ^!7AB=P?\ A.?VB[Q==\:R6A4J;W2/@;\,];5'DW?.(O&/Q6\%7JG'F: R
M-BN;$T*&*P]7#8FBZF'Q4GA*E/ENE1E=.4DDVH=Y<O*E9IMJQI0KUL+5I8C#
M3=/$X9\U.IMK;H]+^=C\XO"__!+_ ,,_"3QO\./%GBGXF0:K!JWC/1],\(^&
MO%L5AIUEHWBQ\WVDZ;K>IZ9)>6GCW6;0:?J,NA:%8Z7X/T;Q/K6AV&G:KJ-E
MIU^=,D_<#PWX>M?"N@Z5H%D]W<6FC6-M807%W)&]]<K;P+'Y]W+#!;QO=2E?
MWCJBAR=YP3BOR2^'W_!)+0]+_:V^+'[5?Q/_ &AOC-X]UKQSH_PTF\)^"]%\
M23^!/AUX0^)_@[6=.\4Z]\:[/X8:!"OP[LO&^I:KHF@:+H$ T#4(=)T&RUS5
M-<U'Q1XO\8ZGK=K^N.I>*?#6E7$EIJWB'1]*NHM/GU>2WU#5;&TGCTJVP+G4
MVAN9XI5TZV)Q<7K*+:$C$DJD&O%X=X6R+ABC6H9%E=/*U72=>,*SQ#C?X>:\
MGRI:J]VG?5I;^EGF?YIQ!.C5SC%2S&6'BY47*]'FCHW**LKQU6MK'R?^U_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #&[_4_^@5\*_\ !3O_
M )1M?\%!?^S(OVK?_5$^.Z^ZF[_4_P#H%?"O_!3O_E&U_P %!?\ LR+]JW_U
M1/CNM\N_Y&."_P"QAEW_ *?PYS8W_=,1_P!>Y?DS[MHHHK Z0HHHH **** "
MBBB@ HHHH **** "BBB@ K\G_P#@N#_RBW_:J_[!?PN_]7O\+J_6"OR?_P""
MX/\ RBW_ &JO^P7\+O\ U>_PNH _5HX.=O)7[W/ XSQ^O?&:_C+_ ."\'CJX
M_:=_;;T_]C[XBVEO<_L\_LO_  L^&OQFG\"R VD/Q*^-GQGO?'VG:3XI\0ZA
M;&WU27PY\.?!7A/5-.TC1K*YCM)?$'BS5M8U=-3&E:?;6_\ 9L ZG &1Z\#'
M'?G)Z^_MZU^&/_!5W_@E-\0?VO\ Q9X(_:4_95\7^ ?AU^U3X(\/1_#'7+#X
MJ/K%O\'OC3\';GQ-!KT?ACQ_>>$M"U[Q5H?B'P#?W&N>(OAQXLT+2[V[T_4=
M;UG1M6MM0TC4+632OI>!LSRC)^*<IS+B"A/$9=1FW6HU*4\1&'-3=&+FL/U5
M=PQ$GJDHN5E%67SW%6"S/,\CQV#R>K3HXRI&U*=:3AK>]XO?NDU9J^COJ_PI
M_P""0?B-?V+?^"A7P9^&WP6TJQT#X-_MOWGC#X5_%WX:6P>>P@\;_#WX8>.O
MBK\-?B[X:EU*74M4TF_TF'P;XF\"Z[90ZB_AO6K'Q1!+)80ZKHMC,?[FY'PJ
M\JIQTD&['/ XX)//N>>*_E-^&G[(EE_P2(\/>)/^"G/_  43\;>$?BS\7?AQ
MI-S\*_V9OV>OV<;+6KWPIH_CKXSW&F>&8M,\'>(O'MEH'BGXD?&[XHR"#P<G
MB?6='\+>&_ /@%?$$MIIDEE+JNHV_G^E?\%^?V]O">OGQ[\4OV2OV>M?^#EO
M<3:IXH^#OP>\>>/M4_:'\*^$D>1[FZT'QIXFBL/AK\2_%_AO2XC?:EX7@\+>
M"M/\3/;7%IH/B:RGN;6(_2\397+CCB'/\YX X;Q=7AW#U.:L\-AJ5.C2EUQ,
M\/7K2Q,)RT?U1J4UTBM4>)D6/CPMDV59;Q7GE"&;U8VC'&>S=.;[0=)14N5:
M-JZNDD[6/Z//VE_V$/V.?VRO^$??]J7]G#X4_&^^\(B>'POJ_CGPQ:7VNZ%;
M7+B6ZT_3/$5J\&NVNF7$I+W.F#4!8RS&222V;>K'UWX+? OX0_LZ?#W1OA1\
M"?AGX(^$WPU\.1RKH?@CP#H&G>&O#ME-/(LUQ>)I^F6T44VH7TX:XU/5KO[1
MJFH7>;B^N;R55DJY\&?B]\/_ (_?";X<_&[X4>(;3Q;\-OBKX.\/^._ _B*S
M<FWU?PUXELK?4+*\,+!)8+B.&X1+VUNH8;O3KL36=]#;W$$T0]4*-MP 1GJ%
MP/Q))_S^=?F4FZD::JWG"A\$/:8GZNM+OEPO/R_+V<M;I,^YBK2G.'LHJO>]
M7ZNHUU>WQ+E4ELG[R3OOL03WMK:6\]U>7,%M;6T4L\]Q<2)%!!# C23S32.5
M2.*WC1Y)Y'(6&(-)*40%J_'WQU<_ W_@M3\&V^&_@]- \<_L2>)_#T.I_$7X
MHW.E:==ZSXI\57^ES'1_AK\*Y;IIIO#&L>!=1N%N_BG\1;2%)]-FMI?AGX-O
MKO6+SQIJOA/]#/C_ / KP_\ '7P/JN@:KKVM>"M<&B>(])T;QYX9NWT_6=%T
M_P 2:3<Z5KMA>2"XC&J>&-9TR86GB'0[N6W$WE1ZGI-]HWB+3= \0Z-_(U\-
M?^"HFM_LWZ3>?"S_ ()/?L;_ +%GPH_9>\%:QJ/A]_&WC#_A9EJO[2WC#PE>
MR^&/%GQ)\ VOA"ZC\2:/\.-3U;2;S3O!7C?XI:]XZ\::_911>(-8L(HI8[:^
M]C)\BS?/\14P61X2KBZ]*BZ]6<:<ZD:5!;U9RC&2A3O9.I*T4W9M'G9IFV5Y
M3AXXO-<3##4:DE3IQE4C#GJ-JT()RCSRM?W8W:LW:R9ZA_P6)67X9Z[^R)_P
M2L^&=[JW@G]F;X??L>>&?%_Q3MO#-[-X8U_XY^#OAOKL/P5^#?PE\9^(?#:Z
M=J4WPVT*:P\6^,/%WA2UNH])\4:_K>@V]]';6RW$-]^2O@?Q1+_P3Y\:^'/V
ML?V7+*+X4>(/AMX@\%R_$SP)X*EN="\!?'CX3ZCXIT;1_&?PP^(W@NQ>+0M>
MU*]TZ\O-4\$^(_[*3Q#X8\;:7I-WI$][<V\MI!^__BGP+X3_ ."^?P \&_M
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@!C=_J?_0*^%?\ @IW_ ,HVO^"@O_9D7[5O_JB?'=?=3=_J?_0*^%?^"G?_
M "C:_P""@O\ V9%^U;_ZHGQW6^7?\C'!?]C#+O\ T_ASFQO^Z8C_ *]R_)GW
M;1116!TA1110 4444 %%%% !1110 4444 %%%% !7Y/_ /!<'_E%O^U5_P!@
MOX7?^KW^%U?K!7Y/_P#!<'_E%O\ M5?]@OX7?^KW^%U 'ZP4444 ?B%_P7B_
M9Z^*WQM_8Z\&^,_@[X6U?XB>*_V7/V@? '[1VK?#'PW:RZCXM\>^!O#N@>+_
M  /X]TWP=ID<6=6\6^'O#7Q!OO'VBZ(=EWK5SX5.GZ3YVM7>F6-S_(O:_M,?
M"#5UTVS^'/BFQ^+?Q!UJZ33/ WP5^'D4_BKXR^,?%TBR6FF^#K#X6:?&_C/2
M]=O[\P66I6^N:1IPTE+AYM9^PVT<LJ?Z3GEN%P QR <;]N""2%X88P#L9@Y+
MX&05Z>>:7\(_AEHGBV]\>Z/\,_ >E>.=1-VVH^-=-\(>&;#Q;J+WK;KQ[[Q%
M::;#J]P]ZRK)=/)>-YK8#(<,3^C<#^*6<<#9?F. P.!PU>.+?UZFZM/F^IXS
M6V)5HVQ<TE_NDG);77O)/XCBK@3+.+<7@<5CJ]>D\$_<]C+EOJGO>Z5M--=[
M>7R#_P $J_V:O'7[(O\ P3Y_9:_9\^)YLQ\1_ GP[FNO'-IIUTMW8:)XN\;>
M(==\>^(?#-E?1$P7]CX2U/Q3/X6LKZU!M+BVTB&;3S)8O#*WZ%5 )(\;E8X)
MX.6)8YQL'F#:N6^4#(&[Y>&J3S$! R<MG "L2<<'@#/!X^M?G/EUT_';[^G<
M^VNN53NN5VM*_NN^UGL[].YRGC3PZ?%W@[Q9X5%]/IK>)O#.N: FH6[,MQ8/
MK&FW=@MY"RG<LEL;D3Q[<89!@\U_F\:?J>F?L=6\G[*?[46N^'/@A\9OV=[9
M/AUXFT3Q]JEOX2T_QCHWA>>[TOPI\4/AC=Z__9D'C?P)\1-%LK7Q3HVI>'#J
M%TUSJ<EG>64.IQSVJ?Z5I1S\V.2F,9'!_/K[CIZU^<O_  4X^(>D_ O]E+XF
M_'O1OV:O#O[3OQP\!^'YK'X'^ ];\ :;XVFN/B'K9C_L66_O;NSDG\.>"_#C
MI-XT\=:C)JNB)8^%- U9TU&UFDL]_P!IP+QMF' F95\PP.'H8F&+P+P%6C52
M;Y);O5-6T^6C9\KQ5PKA.+,)0PN-JU:,<+CE5IRI.S:[V6\;/67=.SZGYQ_\
M&\_P:^(6D>!OVIOVK?%GAOQ%X*\$?M5^//AA;_!+0?%NF:EX?U_7_AA\%O!.
MH>'+7XM2>'=7L[/4=)TGXE:YXEUJY\+-J<-MJFL^#= T+7);.UL+O3&N/Z-0
MIR,_W""/IG_ _3K7B/[._P 4[CXX_!+X7_%K4/!GB7X;:UXY\'Z-K7B3X=>-
M-)NO#_B[P!XH6V@L_%O@GQ#I=Y%;75IJ?A3Q':ZGH%TV)[6[:PBN[*[N=.GM
MGE]S(;L,\MW'0_CUY/\ 6OF,WS/$YOF>/S;%4X1Q&.QN.QU2-+5*564G&R2U
ME)-VZO3Y^[EN7X;+,!@LNPTJDZ."PD<#!U;ZTX;/7H]=M-?DOQ>_8^^&?[3/
M[$7Q[^*_A?\ :A_:6^)/Q<^ 7[2?QY^*D_[)MCXMO],\4^%?@A#K?CK7=<^'
MOP;\3^,-7L9_']MKWBCPK(DG@.:X\62^![RXMK[P NA:#XEB\-OXL^U/!W[5
M%S=_'OXA?!7XE^ T^']CIGQ+E^'/PJ\>6WB$ZYH'CS7A\.?!_P 2I/#/B:+^
MR=+_ .$'\9ZUX<\42Z_X+TBXN-5T?QIHFF:P;#5O^$HT#6_#]C]->/OA[X2^
M)_@W7_A]X[T'3O$G@_Q5IL^E:[HU_'(T=Q;3L)O,ANHI8;NSOK6[BM-0TW5+
M&2WU+3=4LK;4[&ZMM0AM[NU^+?"'[''BZ_O?V@?"OQT\<:;\3OAS\2?#'PG\
M-^#/%=H=8T7XUBZ^&%SXHNM!\>>,M;C==&M?BUX5_M'PFNA?$CPB]C<ZOK'@
MS1?%EUH/A_4K>:QON([C]!A(AZ.IY(R"",C)(R.,@ DCJ!R<#FGU\M_ 'XD^
M*;N\\2? [XP75M-\;?A1::6^HZY%;II]I\7OA_?/-8>$?C7X?L8QY,,7B8:?
M=Z3XWT"V)3P=X_TW6M%B,GA[4/#&JZM]0B1" <\'..". <9Y'3G@]".1QS1T
MOT[] Z<W3OT^_8?13#(@&23U P%8G+,%!*@$@9.2Q&T+ER0H) 9$!VEL'T(/
M/*CCCGEE''<XI75TKJ[T2ZO?9=?AE_X"^S#OY;^7KV'T4FX9QSGW!&>2."1@
M]"3C.!AC\I!+6D1?O''('0]3G@<<X +-_=0%VPGS4Q-I;NP^BF>8G'/7&#AL
M?,,CG&,D'IG-'F+@G)XSG(8=.O4<CT(X/;-*Z[K[_P"[S_\ I/O?X==AW_\
M;?\ R;X?_ OL]^@^BBBF 4444 %%%% !1110 4444 %%%% !1110 4444 ,;
MO]3_ .@5\*_\%._^4;7_  4%_P"S(OVK?_5$^.Z^ZF[_ %/_ *!7PK_P4[_Y
M1M?\%!?^S(OVK?\ U1/CNM\N_P"1C@O^QAEW_I_#G-C?]TQ'_7N7Y,^[:***
MP.D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG[)6UDDOL+>5V]HW/T+HIJ[MOS##<]P<^G^<_C3JJZ[C"BBBBZ[@%%%%%UW
M****+KN 444477< HI-P'7CZ@C^G/X4W>H[G_OEC_(4)J2NG==U_2 ?129'J
M/SIHD0XPP(()!!RIP2#AA\IQ@Y .0!DX%-:JZU7=:K[]OQ#;?0A\Z,DJI&\(
MK,N#N".&VL%QNVOL<!L8+*Z EU8#X9\/G_A?_P"U_J7C:(K<_"W]CS3?$7PZ
M\*W3D2VGB?\ :2^)FD:'=?$77; LVR6W^"OPL%C\.-*\062/;7GB#XP?&7PI
M>L-:\$W(A]-^/'Q5\1Z3?Z%\%_@TFG7_ ,>_B58W=SH5QJEJU_X;^%?@ZVFB
MTS7OC5\1+59;8WFA>')KF#3?"?A+[7;:C\4/'4VE>$M.NM*T6#QAXQ\&^E_!
MOX3>'?@=\-O"_P ,?"+ZG=:-X9M+OSM7\07W]I^)O%&OZOJ5YKWB?QGXLU<1
MQMK'B[QGXHU/6/%7BW5V@A_M;Q%K6IZ@L%LDJ6Z]-%+!X>M6E9UL2_JV%II>
M]1H.T95912O&#5X0D[)J525FHIG+4_?U?96O36KET?7XMNVW^:/5Z***YCJ"
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  # QZ5\Z?%_X")\0-
M7T?XD>!O$DWPL^/'@ZQ;3O!_Q3TS3AJL%YHPNY;UO 'Q/\)KJ6E6_P 3OA+J
MM[//=:OX,U35]/U+3+N=O%'P[\3^ ?B'!I7C'2?HH9QR,&@DCH,_B!54YSIS
MYHM?=\FFMFFMT]'^42@I[GQQX+_:NTVQ\3Z/\)?VC?#K_ #XQ:Q=QZ+X<MM?
MNY[OX1_%K5FE,$7_  HWXPRVNF^&_&%YJ>Q[ZP^&VL?\(K\:].TI7U36OAS8
MZ5'_ &B_U]YBMC#X+DXQD'C!)STVC(#'. QV$[L"N5\9^ _"'Q&\+:SX(\?^
M$?#?C;P?XBLY-/UWPMXMT;3?$/AW6;&15$MIJNBZI;W>G7MO*PYAN+::)>'V
MY58Z^1V_9#^(/P[3'[,G[4'Q5^%6D0[OL?PN^*L=O^TW\&[="=T5I9Z;\3-4
MA^,WAG2-.CQ8:-X7\ ?'GP;X,T;2S_9FG^&8K2STE-.Z?98"O*,J3>75W=5(
MSC4KY8]$N=3@IX^#?O-PJT\:E=>SGHD<[GBJ*]Z,:VNG)J[=GW2]/5'W.7V_
M>RO(&3@ D] "5P3["G9)_O#ZJ"/T KX8.J?\%*/#&+5/A[^Q+\:PH2(:Y_PN
M/XZ?LOY"D9NO^$37X'_M<_,RY T__A-1$IY-Z>07?\)Y_P %*/\ HTW]B'_Q
M8-\=O_I9U8O!2Z5,#ZK&1M_Z3%_A\P^M+_GQBO\ P34_R/N+>OI_Y#/^-&]?
M3_R&?\:^&_\ A//^"E/_ $:;^Q'_ .+!OCG_ /2SJ/\ A//^"E/_ $:;^Q'_
M .+!OCG_ /2SJ/JD_P#GY1_\..'_ /D"_K5/_GSB_P#P1(^Y-Z^G_D,_XT;U
M]/\ R&?\:^&_^$\_X*4_]&F_L1_^+!OCG_\ 2SJ/^$\_X*4_]&F_L1_^+!OC
MG_\ 2SJ/JD_^?E'_ ,..'_\ D ^M4_\ GSB__!$C[DWKZ?\ D,_XT;U]/_(9
M_P :^&_^$\_X*4_]&F_L1_\ BP;XY_\ TLZC_A//^"E/_1IO[$?_ (L&^.?_
M -+.H^J3_P"?E'_PXX?_ .0#ZU3_ .?.+_\ !$C[DWKZ?^0S_C1O7T_\AG_&
MOAO_ (3S_@I3_P!&F_L1_P#BP;XY_P#TLZC_ (3S_@I3_P!&F_L1_P#BP;XY
M_P#TLZCZI/\ Y^4?_#CA_P#Y /K5/_GSB_\ P1(^Y-Z^G_D,_P"-?%/[<7[#
MWP]_;Y^%5I\&/BM\2?CW\/O  UE-6\0Z5\"?B9-\-)O',5N\-W9:-XTN8M'U
M<ZYH6GZQ9Z?KFGZ;BS\C5["TOVN"8C;FC_PGG_!2G_HTW]B/_P 6#?'/_P"E
MG4?\)Y_P4I_Z--_8C_\ %@WQS_\ I9U'U2:VJT5Z9C0_^0']:I_\^,7_ .")
MGSM_PZ:@_P"DE/\ P5M_\3/O?_F"H_X=-0?])*?^"MO_ (F?>_\ S!5]$_\
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M?_TLZC_A//\ @I3_ -&F_L1_^+!OCG_]+.I_5:EK>UI6_P"QE0_^0']:I_\
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MS2B;_@I/XM"0-HG[%/[/Z%?+EU"U\6?'#]K.:$#&)+33+CP9^QI;.>P2>]
MX.0!0\"ZJM7G@$E_/C(UE;_N#!-OR2U)^M*+TH8I_P#<*I_7XGW"\J(,%P"
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=%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" **!"X# 2(  A$! Q$!_\0
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MK(!L<C*2*"8S+ 7:,%HW*_SP_&?]LGXV_M*?LY?!?Q]INL^+O@!I/B/]G_\
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M&^J?$RS\$^$K7XD:YH&G>%-:^(%OX<T>'QMJ_A?2+RZU#2?#>I^*H[-==O\
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MO_Z:-_G\*-__ $T;_/X4>]_-3_\  :__ ,B'/3_Y^TO_  -?YEC=_N_]]?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4TXXNI3GA\WHPI1G3Q^"QWU/#0IX:?,XQJSP[J59J7,H\EG_ +#@_P""9?\
MP3:(;'_!/W]B$D<*&_95^! R01V_X0-<YZ?>QW!ZTQ?^"9__  37.U#^P!^Q
M")2N1&_[*GP'64GH"UN/ A8+U+'S%)"C  W-7^3)\2-/\4VOAB&/6!XAUG3H
MM0L+=-/TJ_U6^990LA@8P&6)2EOY+9)0[C*!)N*J1Z5X"U6"7X.-X:N/!?Q
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC_9TGC\/0HX.ODM7,:E'FJPG*C]>GFF%Q].4HSC*>*QOUZE5C4A"E&U&I?\
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MM?@5JWA/6?@E\== ^/$/QLOO[-N=+^#\'[,&N?#*Q_:3OOB?KNEZMI^NZ!X
ML?A-<^+/$/A:\A\6Z)I=SX9DBUEP#[@HKP[X%_M#_"S]I#PA>>,_A)KFLZII
MVC^)-:\%^*-'\8>!/'WPK\?^!O&6@^4VI^$_B'\*/BGX8\%_$[X>^)K>VO-+
MU>WT#QSX5\.ZCJ'AC6=$\4V"WN@ZYH^I7_Q'\&O^"E'@YOA+?>-OVC;HZ1XS
MUO\ :R_; _9^^%_PY^!/P9^.?QF^)'COP[^S?\<?B/X"L]9T'X,_"C0/B_\
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MOA+_ (*>HH_X)L_\%!3@Y'[$?[50')/#? GQVQ&"<$$J.HZ#'0D5]VU\*?\
M!3W_ )1L?\%!O^S)/VJ/_5$>/:VPFF/R]K1K'81I]4XXBE*+3Z-22DNTDFM4
M<V-;6#Q+3::HS::W32C9KS5W9]+GW$O' ]#^K./Y 59JL/Z'_P!#>K-8))7L
MDM5LK=)?YO[V=*^TNBJU$ET27)9+LET70****8!1110 4444 %%%% !1110
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M;;3!^[!D+L&4G!0L!\A=0Q5 %P HWE6$+M,P>1F8))$@:.V40DG:,G@\=00
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\
M)?\ !0K_ )('X"_[/;_X)F_^O(?V4*^[:^$O^"A7_) _ 7_9[?\ P3-_]>0_
MLH5]VUT3_P!UH?\ 7_&_^E84YX?[WBO\.'_])J!1117.= 4444 %5&52<+PR
MX+=]RX P2><CU&3SU(%6ZK(<@,5(;:H*\< <<]3R .3V..G5K1W:35^J3M)Z
M+=.UU=7]-=B91;Y+*,DJBYHSLTXN,[V3>K[:.WD?Y_G_  =PV.N:C^V3^S&^
MEWT=LL7[-VIVTD=QX4E\0^:[_$[Q-,72ZM9;1+<#;$/*D+2?*7#[9&2OX^/!
MGBW31J\[:K<1^,X%M)-NG:?J$/P^F@GBGMXH[Y]9U>&]M[IU1Y%;3(8OM+Y)
M^U!@#7]=/_!WWXXLO"?[9_[+=C<V6K7;7W[-&H76-,N[^VCD!^*?BR(^9;Z?
M=11S.H3:SS(&&5P, -7\E_B?X46_P^TV#7;#2O'OB4WLT,)L=9\-Z+I6GVT%
MS;?;#=17MEKDY7RVMS$4\A(P)#C&1G\CX@5"GG&9T<QA"@LRG1_LY1AAJ%7'
M5*4&JS^N5)4JE.5*,Z24XXC"KEFHN=1M(_585O#?$<+<-\)97C<T\.\SXPI9
MAA_%#.GCL+B\JXOI4))Y+_:N%P/$699W3P664GBZ4Z>!RW*,=5>,A"BL13A-
MTLGQ9\3/ \1U>QM? 6MZ3J:I+%;ZA;?%33=1^QW,D&Z*8^7X?CCN"C$%?(VE
M/E"%=J$=;\$/C#\:-$T[78/A?H-WXJL;B_LI=7FUWPUJGQ%EM;Z"VNA"@NK*
M"%-.BEME$?V:9I96V!OF8%A\SZR-"N]0NH'MM7TCQ,[1QPZ'>:7:S0VL\<&4
MCEO#.\T84#&];8'@%]Q6O=?@7\5?BW\)-+U^P\.:CI]C;ZIJ>F:C=*UO9E#<
MVUFZ12?+8W.V<)*Z[TVR2$DR%W (Y<\R/!TN%:GU/*LOS+&UJV"BLOXDQ&*6
M6U*;G%59_6/99@JCIP_>4*=&M*E4G%<\91<9Q_)>*?!K+\33H\*>'V&R'C7,
M<:J6.P65XS.74P.*P>'JS=;'5*N;5H8S+%2H0J8G"956C5J2G3I0K5(5)J+U
M?$OCJ3QK%-HWB#6M.U*X:\>_O=,U:==/M(;F*1H9AY5_=1L9+=I&2.U'SP1,
M88A'$!&O/Z#ITFC:KINNZ1HND3V^E:G;7\5R/AW>>*?#!FMI(II#<^);0V^D
MMI,4D<;3%IF^S!+J.X78BYT_@_<^)(/B%?ZRU[I,EY>V6LSS-IO@WPOXWN1-
M?7QGN)6T7Q58IHJ;W^9+V.YCO81D0SQ\@^P^*OB)\3/#E_?ZEI'B_6K"+2X4
MOXO#\_PF^'5CH#O:PAVM[W0M-/\ 9,-A?OG[;#)8W::EYCB^CNFDD#>56G7R
MQQR')\-EL95,/2JU*6+S'%X7"3EB*2C6HT<#@\FJ48\OP4ZTZ+C*#7MIK5KC
MS?PJ\3\HR"G3X2\.\ZXCX*;INKQ1_JCFV"P\<TK4JU#,\KJULJX<S^<HX)TJ
MRIUZU6.&^K4'BZWLOW4E3U[X[?%.>2'^P$^"OA\P@321>']"T?PZMT)MWD&Z
MC;64^T;"\WW0P@)'3S.?U]_X-UK#PS<_\%B/V0M7EBB@\37S_M 7LTVG>.]-
MU&WO-:NOV8OC3_:D<6BVMK#<C3IHKB]N8DAE"VB6B1SA80J#^?KXA_&;Q9\9
MY=&N/'=IX/O7\.I>Q:=_PBWA/0?A[L.H&V%T+O\ X0W1-&&HD_8X!"=0%ZUI
MMD%F;837'G?U9_\ ! KX3?#[PQ_P44_8<\66/P(^&'A'Q%=Z3\26L_'6B_&#
MXJ>)?%4E_J?[*'QE^U33^$==B;PI$_B&P&J1ZPF(H=/GG5]&5Y%C)QC]4X2S
M#A2E7RW#97C\\S_+\+6HY/4R2$9SAB8U*2Q&.QF9Y=C<PH-5E.5'#9=B:]%R
MG;#1BX3EEPW0R3PHR?)UQ+P50K\1>(N'Q63Y51R'B"& PO"M>E7FGG&=8S'?
MZLT<]H5J%6$L-EN'EF.8PKQQ5.665JDJ5&K_ *.6 ,@$@ *3L+ @[3UP@))V
M\G=GC!*[N;E9I!*90N<)(A;<%7<JEMV6Z9?(5NG&& 7)K2K]^CMS+2-Y1L]9
M\\9U%)W3:Y):."2@UK>$;Z^K!1O)K6[O&2UA.FM(RBTE%7DI^X_?BK.3J1E&
MHRBBBJ+"BBB@ KX4_P""GO\ RC8_X*#?]F2?M4?^J(\>U]UU\*?\%/?^4;'_
M  4&_P"S)/VJ/_5$>/:VPG^_8#_L-PO_ *>IG+C?]SQ7_7BI^43[B']#_P"A
MO5FJP_H?_0WJS6"Z^J_)G5UG_P!?:G_M@4444P"BBB@ HHHH **** "BBB@
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MC?UZA$ VX^4YR"20=P((()(*X. IRJJ J@!0 "*,'<$4-_> PW.S(W#G!$:
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M9+\1_M$Z?\8]*7P9X6M+CX6^(]/N_B!X8LK+4O!=[):3_P!;ZQ1J %7: 6;
M+ %GW%RP!PQ=F9W+9WR'S&RX#!?+0L&(^90X#9;< [*[J#G(5F1,KG&%"@;1
MB@#\E_\ @FCX*\'?"#XM_P#!3CX'?"OPMHGP\^#/PM_;/\*P_##X4^"]+MO#
MOP]^'%EXW_9"_9G^('B?2O /A#2[>VT7P=H^M>,/$^N>,-2T#P[I^G:4GB+Q
M%K.KQZ;%>ZK>W=]^M=,\N,DDJ"2026^8G:YD0$MDD([%HP>(R?D"T^@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#%_/VZY!P!]I^)7P"E ]"N_P#9DR#Z% /K7U9^Q+_P;=_L+_L%?M._#/\
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M[#N>F#GMT[#V^/?AO\7OCK-<^%O"_C+]F;XSV0*6NFZS\2?%7BC]GJ'383#
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M\%_CG^V%XE_:K3]A#3O^"B'@CX=?$']AK]KSP+XZU#]K'XG?MI?!/X9_$/\
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M5_M:S^'_ (NZ]^RWKWPV\6_"C]AW]LW]HOP/XJT[PI^SWH7AK7Y-+\;?L\_
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M-8+KZK\F=76?_7VI_P"V!1113 *A4D,!G@J#CWW[<_EQ_P#7J:H%^^/]P?\
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M,'3_ ( G\EJ>H!T_X G\EKNE\+]/UB9R22NDDV]6DE?W9[V2/AC]K#_DOO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_D@?@+_L]O\ X)F_^O(?V4*^[:ZI_P"ZT/\ K_C?_2L*8P_WO%?X</\ ^DU
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M_#^,:P^'QV(;5/!1<OZ /A\[M_P4A_:U>3:A_P"&(/\ @GT05.]<#X[?\%-
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MT:[\>^(]/FBQ+%<V>DR6VBP2IMDAN-?MY[62&ZBBF7^"%2 %5,A%+%!]U 7
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M*(V?ABTOH@$FTW1+0[FR[-]I+'$)?GCR^SF0G_6DH=^%W#,B*@0N5(0@!2,
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M!DY/\_\ .:3VOU6R[W$V[I6T=[OM;_AQU?"/_!/55_X4%X[4YVK^VW_P4S
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MW?Q7_P! %1))--))RDW*W5VB]>^J3]4@?Q7Z\N_7W%+EUWO&_NMW:Z,^%O\
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MT6A\,?M8?\E]_P""9/\ V>U\0_\ UV__ ,% Z^[-B_W1Z>_?OU[U\)_M8?\
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M[@!@I."<G9^[W@=LA995BSW\TGCIZTVOTGNOB!^R9JZZ!I7QS_X)_>(_V=_
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M;W27OA&\>.VGO_#4MU,\EEK&EIIEG]Y_\%./^"?&@?MG_#7^W_"MI8Z;\??
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M&,PU>$<91R2I.HJ'&?$>&Y<MPF-5+$8#!\,X+-<ZK9EA%&C4P_UA_P $=_\
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MC*Y(4@$@HT4;8#*&"X*[B3L9<[63)^5UR<.N''9N!0!\/_!']LN7QEXX\ _
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M*^?CG_\ 3,:^Y-B^O_D0_P"%&Q?7_P B'_"CZW/_ )]T?_#=A_\ Y,/JM/\
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M &<G/6F^5%@#8A )."Q().<D@\$L6)).222223FF;_\ IHW^?PHW_P#31O\
M/X4)-.ZE33244U"NFHK9745HKNRV5W:UW=\]/_G[2U=W[\=7W]28!1TVCDG
M<@9)))QTY)/YFG;O]W_OK_ZU5]__ $T;_/X4;_\ IHW^?PH2:O:5-7W]ROK^
M <]/_G[2_P# T6-W^[_WU_\ 6JL6;Y<!@&0= "5QQW'J![].>M+O_P"FC?Y_
M"OF3XG_M=?!/X9:^GP_F\5)X^^,]Y&3HGP$^% M/'_QMUN59/+5U\ Z->27G
MAO0$N&AM=6\?^.KCPE\-O#!G6^\7>,?#FEA[]-(4:V(52G3BZKY&VJ?M8.*3
M3]HZC2Y5!)RW2DHM-ZZY5:E*,82=:*2JP3E&U6R?,K2IJ[E&2T<N5\BU=CS3
M]H@'Q3^UG_P3]\#:<_VC6/ _Q-^.O[2VLPH K6O@/P7^S'\6/V=-2O)V&Y8T
MD\<?M8> ;.W5]DER);IX"RZ?=LOW7N]SGZ+_ "_^O7QAX T'_A7&K>-/VG/V
MFO$?@_P?\1_B?:>$? Z6&I>([-/!_P '?AYINL7:^ O@WH/B>_.FV>M:]J'B
MGQ7J6M^/?%,<5K-\0/'.M6FEV)F\'^#? &GZ5]CK.L@#1D2)QN*J 1T;&.3@
MCC(SW&0>F^)KX65:E@X8BG5JX;"TE4]G)1DIUI5*LE*&LHKVG.HRDH1JN$YQ
MTM=TZ.(I49X^MA\4\)BL56C1Q2PLZ6$JRHJE"?L:_LU#$3IPE2]O&,YSPZE3
M4U!3@Y6<G!);Z<?7@C'^?YR5"!]X'L#^8/'^?>IJR=KV72SZ6LUI\^_F:).+
M:O>.CBWJ]=7=_=;L%%%%(84444 %%%% !1110 5\6_M[^&O$'B[]C/\ :1\*
M^%="UCQ3XDUOX4^(=-T+PUH&DWNNZSJ]^]E&(].TW1[&.YO]2N+DC8D-E#+)
M)Z'YJ^TJ^3/VUOB'XQ^$G[)GQZ^(_P /M97P_P"-?!OPW\0:]X;UIM-TO4WT
MW5[*U,EK=_V=K-EJ.DW<D6T[8K^QNK:0[?,A?&VO$XDCAI</Y['%^U>&EDF:
MPQ2P]WB_JLL'5]N\+!_NY5DE[KFM'RI-7=_KO#YY@N/^!?['C@IYQ+C+A:&5
MT\QJ5J. GF"XARFI@5C<1AZ.(Q%#"?7:>&^MU,/1K8B&%]O.A0JU81B><_\
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M\0FMO.G#1 VZ?:93;+,<Q*SJC(@55\W_ &+A\3-0^,7_  3UM?VD/%W@33O
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M[LX9IY3F&?SGPRLNCDG"V%IUJ.,RNC]6RW-LZSK+\'BLQI8>@I^QC3P.3X#
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M>,OA]=:AX/U2RU?POJ.I:?=]'UO%_P#05BO_  IQ'_R\GZO0?_+BC_X+A_\
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M\6:%\6?C3\5O"WP\;PC\0-0\5'UO%_\ 05BO_"G$?_+P^KX?_GQ1_P#!4/\
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M^?%'_P %0_\ D3^AW_AV/_P3;VY'_!/K]B4X#$%?V4_@7\P0J<$'P#O/F!6
M,4;[AO>/G8%#_P $R/\ @FZ%R/\ @GM^Q)G<@PW[*GP,Y7!9F0?\($CL21Y9
M38)%VF18I!L27\(O$'@SX+?!SXI_'7X&^,_"/AWP%_P2Y^&/_!7+PC#\?OA/
M9Z=H6@?LH?#7X<^.O^"<OP\\<^#=.^,'@\16'@WP5^S/JG[7^O\ @OQCXO\
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M2+*RU"[*7/BDV>G76FS6?BZ&VN%ODU#^P/$'V#Q?HFH6]U^JCI&R[?*!WY.
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MNZ8S_,?YZ=NM/KAB^:\M=?=<;Z)Q;O;S=]>^ATA1115@%%%% !1110!\)?\
M!0K_ )('X"_[/;_X)F_^O(?V4*^[:^$O^"A7_) _ 7_9[?\ P3-_]>0_LH5]
MVUT3_P!UH?\ 7_&_^E84YX?[WBO\.'_])J!1117.= 4444 %%%% 'Q1^W/\
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M_/-X_P#VO/\ @I)\<?C#^U[_ ,,E>%?VC_&-O^ROXX\)_"OX-^'/V?\ 3/\
M@F7;?LS?&/QWI_P=^''QBU+4/VI;[]KGXY:3^U?HOA+XIZK\1[#1-/3]GVY\
M KX(^#W]C^)] \8?$?QSJ6H2Z3YU^W[XU_:J_:S_ &*?^"R'B^Y^.>H_L[>$
MOV8/!7C7X%#]E:T\,_!/Q1X)\2Z=IO[+7PS^+_QDU7XV_$/4?!'B?XNW/Q&U
MX?&'7="^$^H_!_XG_"_P-IVF>%OAIXEO_#7Q#CU?Q5'X@ /ZAXWCD598F61'
M1959.LB28,9W Y(*HHR2=P4 Y J;8I&""1D'!9B,CD'KU!^;/7=AL[@#7P1^
MW-\;OB%\"_V9/#&K?"K7?#7@SQ[\3?BS^S)^SYH'Q"\76$.K:3\-&_:%^,7@
M#X077Q(_L"](TWQ'KO@FR\8WFO>&?#NLO_8.K^*+?1-.U^&\T>YO+2X_,G]I
M7]J']M3]F>^_:=_9I\(_M.ZI\3O''@/Q3_P2]\6_"3]HSXO?"SX&W?CG0]"_
M;,_:ZU#]G_XD_"SXJ>%/A7\.OA!\)/$^D6>G> -3U;PGJWA;P!X+\<?V'XVU
MJW&M3ZQX=T/Q'  ?T6&.,D$HI*D,I(R58;L.,YP_S-\XPQR<FLZ&[M)[JZL8
M;BW:\LA:/=6T4B/<6UO=1S?86N;?$<MLLABFDA#J5+1R&-B5<)^;'[+_ (U^
M.G@?]M?]IS]DKXI_M"^./VE/!O@GX _LT_'_ , >/?BKX.^"/A7XD^'=2^+7
MB_X_>!/&7@6YD_9_^$GP7\"Z_P"%$;X1^'_$7A:2\\#'Q=I5]K&N6.K>(?$%
MA/I,.F?E+XJ^+?QY_8]\7?\ !8?XF?"CXE_%'XG?$'XC_P#!1_\ 9*_9Y\#>
M%M>T+]FF32/ FN?M"?!W]DCPU:_$;P_9:WX;^ ^AZMXS\#^$O&EMX&^&>D?%
M7XR:'\+O$+^%OA[#\2KF_P!6OO&OCOQ$ ?U)"- 6..6^]DDY]>"2.1@'U554
M_*B@9MW<6=K;2W5Y=6MI9PJ9[FXGE2V@$:F(&66>0I%''RD+>89DD@:./?LE
M)/X9>%O&?_!7BS\#?M'>%M%^%W[5&K6?]C_!37_@Q\4_VJ+K_@E7!^U#!>:M
M\1HO"_[2OP^^&?A[]E/XJ6G[*OB#Q#X=^$$4'Q'_ &=O$GQ\\.>"/# ^+%WK
MOA?XK3>+?!46AV<?PE^U3\0?B+\8O@)XN^#_ (A_;/\ VX?#_P 1_A]^U5_P
M3B\3>*O@K^U=^R3^R_\ "+]J#X9S^)OV[_#WPFLO%&F?%KP#\ M-_9#^/GP+
MN=?\-+X_^'GB#X$>&/B5I=GX^\#V\OC'X^>-OASXRU#X4( ?U,Z'XV\&>*=7
M\7^'O#7BSPOXBU[P!K=MX>\?:!H>NZ9K&K^!/$5_H>D^*=-T'Q=INEWMS<>&
MM;O_  WXBT/7X]'UQ+"^U#0-<L-9@$FC7EI-/V(AB7D(H(&,_P 70KG=][.T
MD!LY ) .#7\ZOQ%_:;_;+U']J+4/V:/ W[2VL>#-*F_X*B_#_P#90'CJ?X7_
M  /U_P 9:3\"M4_X)=VO[1/C"/0X]2^%Y\)GX@ZA\4+74_'.@:_JWAW7+/2/
M&SZ?#J/AKQ!\+-.O?A7>6]+_ &GOVP/^%UZE^P!)^U#XHNM<OO\ @HIK'[.M
ME^V7J?PU_9[7X]:3\$-$_83T?]M:ZT*P\+:5\*;+]FB]^,.H^)KB;X8:-XIU
M+]GZ?P^/ALFOZA+\/=0\>Z3#XFB.M^JV?5!UOULU?K9[KT=E=;.VI_1 T2.&
M# D, #\S#@=,$$$?ABJ+1! S(IZ(0 X1-R@_. 1\F1]\$;7SA@> /SJ_X)[?
M$']H#Q!XD_;K^&7Q_P#C5#\=[W]G7]L23X,_#?QL_@_P%X.UR3X8K^S-^SA\
M3O#MGXQLOAOX=\+>&=3^(<M[\1=<U+XA:IIVAZ+I5UXRO=:/A;PSX(\&CP]X
M$\,?HZ<-@NN1W7 )'/WB<YYY]NV>U2Y:J'(YRGT^RHQ:NYO9I/E:@W[[225U
M=1*"G>+NG.*AS14?:6BU**BYOD:BTVH24XW:DH2<4C^8C_@LI_P43UG3KZ7]
ME/X*77Q"\$ZOI&LZ;J_Q+^(-C)KG@R\U*+38+N[LO"GA65['3M6UG19;IK76
M-7\0Z3J,&G21:986UD=0TRYGD3\S?^"1?QI;X/\ [=OPLGO;U[71_BF=6^$W
MB"Y,BNUT?&$,;^%DG)!\VZO_ (@:-X865Y")!)=R,9 LLP?^U#XK_!?X2?&G
MP[+X9^+/PW\)_$G0F,CQ:;XMT;3=52UED4HUUI5S>1-=:9>;3\MYIES:7D9P
MR2JRJ1^-/QD_X(7_  DE\1Z9\1/V7/B'XB^!OC;P[J^E>(]#T3Q"UQXX\"VF
MM:%>1ZAI;VL]]=V_C/1[M[^&*Z6^O-=\21P,B&/29-@2OYXXT\/_ ! Q7&67
M<<93GE#.J>69G@,1A<M=)X9T<-@YS5;!.DING5A.&(JQ<TOWC3<KNT8_Z4>"
M7TC_ */&!\#N(_ KB;A#-/#W$\6Y!GF4YMQG4C2XPP&=9UF648G#X7-<YQ.7
MX+#\39>J>9X;*\5EV7QR[%97E=2A&IA:E!T7B'^]4OFB,!3N)&&;S(XR"!@D
M&16&<]!P".,<5?K"TXWO]GV0U$P+?"RMEO?LTGGVT=V(!]H\F1XHI'A$@9DD
MD4%PP''%;M?T2FW!-J-G*3BX?"XM0:DM7;F;F[??JF?YL*$83G&/))0_=>UB
MYR]KR2FN:\I.%O=324*=5<[]M%.22****"@HHHH **** "ODW]M3XA^+_A%^
MR=\?/B7\/M:_L#QMX-^''B#7_#.MM8Z;JG]GZS8VFZUO?[+UJRU'2+PI(21;
MZA875JX7$D#K@5]95Y7\8/AQX>^,/PS\<?#'Q7"\_A_QQX>O_#VJPK)<1%K3
M4K<P,/-LYK>ZC".X9C!<12X4;'7(SYN<4,7B<HS7#X"I.ECJV6X^EA*E.3A5
MAB*N%K4Z$Z<XM3A.G6E"I"<6G&<827O)->_PICLIROBKAC,\_P -#&9#E_$6
M18W/<-5I0Q%'$9-@\WR_%YGAZF$JIT\3&O@Z->C*E.,HSISJ4YIPJ23^?OV"
M?BEXY^-/[(?P,^)_Q,US_A)/'7BWPM<ZIXAUQ=+T;11>WW]LZS8"X72O#VG:
M3HMIMMH+=!#8Z=:PG87,9>21V^T3$A&TCC.<;FZC\:^>_P!F/X(V/[.'P+^&
MOP4TW7+OQ/:_#OP]!H!UZ]LH],GU68W,MY>7[Z;#/>'3Q<W5S//%8R7%P]HK
MK \[A%<_1%5D]+%8?*,IH8VK*KC:.69?2Q=2I-U*E3$TL)1IUZE2<FY3G4K1
MJ5)3DVYSE.3;DVWT<<XW)LUXUXTS'A["T\)PYF'%O$N,X?P=.A'"4,-D6+SG
M%XS*<+3P,(QIX2GAL'B:-&G0A",*5.$:<(QA",56FL[6XBF@N((YH+B-HIX9
M5\R*:-@5=)(VRCJZL5<,I#J2KY4XKYON/V-_V8;GQ#_PD\_P:\)OJOF";8%U
M)-',@&-Q\-QZ@GAPGU!TK!/)!/-?3-%>DIR6BE)+R;/@<UX?R'/'0>=9+E.;
MO"S53#/,\NP>/>'FK)3H/%4:KI222LX-;+31&=!I.F6UI#I]O96\%C;VZVD-
MG$@2UCM4C$2VRVZXB\A8@(A%MV"("/&SY:+#1]*TN-HM,TVQTV)BA:+3[6&R
MB8Q@*I:.V2)"0H"$E26151LHH4:-%#G)WO*3OO=O7UU/5C"$(4Z4(1A3I0C3
MI4X1C&%.G%*,84X148PA&*2C&*44DDDDBD--T\0QVXLK400SI<PP>1%Y,-S'
M,UQ'<11;=D<Z7#&=)D59%EQ(K!P"%CT^PBNI;Z*RM(KV:,0S7D=M"EU-$NS;
M%+.J"62-?+3".S*-B8'RKBY12;;U;;>N[;W=WNWN]7W>KNRK(****0!1110
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M-];*]E?LKNRZ79Z:5E9:*[=EM=[OU?5]0HHHI@%%%% !1110 4@4#H/YTM%
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MXZ?";PUXV\(V)U[PYXA_:$^!_P +-"LI[W0O#7CFX\'>,M>T;PKJGYP_#_\
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M-_&GB;1OV4=(\?Q>-OV4OV@M&^$K^$? \7A[XP_#?3YOA5X#U"[U;0-+?6/
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M"VD^+-7N9OA%^UUXN2TM_AE=?$#P?XG^(_P]\1Z]X&^*DO@Q]6_X07PUXO\
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MQ>\*_!+XX7FK^%=%T3PAXNO?BWX \:7?CGP9HNC>#_&<^O>&M*T_2K?\F_\
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MKAIZ12YG+EM!MZMR@E&3;>K;:N_/S.KJWWZ?\ ****L HHHH **** "BBB@
MHHHH **** "O@_X>QHO_  4F_:R 1<#]B/\ X)]+R 25/QX_X*:N%8G)=4;_
M %2L2(066((K,#]X5\)?#[_E)-^UG_V9)_P3X_\ 5Z_\%-:Z,/OB5T6$E*W3
MF6*PD5+U4922>]I-7LV<U?\ B87SJU4_-+"UY)/R4HQEZI/=(^YHW9NISP.P
M[OCL/2N#^(]A\2M0\&:]I_PA\6>"_!7Q#NK>&+PQXH^)'@#7OBIX(T:^6[LG
MGNO$'@7PQ\2_A!K_ (@LWL!>VL=AI_Q'\+74>H7%GJ+7S6-A=V%[W47]%_\
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MSX7_ /!0#]E+XS_$C3_A3\._B)XFU?7O$5SXUL_ 7BG4O@[\;?"?P;^+=_\
M#NZO+;QMIGP._:%\7_#G0?@-\=M1\.)I^KZC<:=\'?B-XXOWT+P[XD\16UO>
MZ)X8\27VF_FWX/\ V%OVA/\ ACG_ ((Q_ _5O TWA'Q/^S)J.D6_[1RZ?XJ\
M RS_  GLI?V(OVB/@[J>NP7MIXF_LSQA/8_$3XAZ'9QIX&N_%5^UWJCZS$QT
MRTU+5++Q7]D__@G'XR\->&?V9OV>OC%^R'^U#9^)_P!FK0KWPU<?M1>,/^"G
M_P :_&W[(NAZIX%^&'BWX0^"?C!^RM^S+=_M:_%75)_%'B[1M<MFT/X3?$G]
MF?X > ?AIX-\2^-?"]MXQ"Z#X>T'QW-E?FMKWZ@TFFFDT]TTK/\ (^ZM9_X*
MK?"KQK^TU^Q)\"?V<]?@\=:'^T?\<?BUX"\5>+_%7P?^.?A?PKXP^'WPT_9]
M^.7Q"NO'/[+WQ9\4:!X*^$OQR\/:7\2/AUX*T'Q+\1/A-XC^,?@.TT?Q9I=I
M-=:7=>.?!>MR_H/\<_VB/A7^SAX1TGQG\6==UK2]/\0^*=+\$>%-$\*> /B'
M\5/B%XY\9:U;W^H:=X2^'OPG^%'A;QI\3_B'XDDT?2M8UVXT3P5X2UK4].\.
M:!XB\3:G:6>A>']:O;'\6?@/\%_VUK76?^"/OP5\??L71^ _#/\ P3M\5>(O
M"GQD_:&'Q9^ NM_#WQ7HOA7]C7X[?LU^!/&G[.OAG1_'M]\9-2^'WQ,U'5_#
M>M>(-(^)/P\^%7C_ ,#RZUX,TY_!/C33['Q=XJ\%_?W_  40\-?M-^)_!7P>
ML?V?-(^,WB#PE)\88K;]IGPU^S!\1/@U\(_VE_%/P'O/!/C*"[\-?"+XH_''
M7_ _AGP0U_\ $5/ 1\<ZGX-^*7PC^,$/@^WU2]^%?Q*\*>+8(7D>X))))*R6
MR6R+Y_X*D?L3Q^"]+\>7GQ5\7:1IVK_&[5?V:K/PGXA_9\_:,\._%R+]H+2_
M M[\2$^#FI_ W7OA/I?QJT7XA:WX+LAK/@WPAK'P]L-;^(-QJGAW2? D7B'5
M_%'AO2]6Z"#_ (*._LC7?PEU/XRP?$?Q;!H&E?%Z+X 77@G4?@1\?M-^/W_"
M\Y8++4(O@Y:_LNZA\+[7]I?4OB==^';Z#QI9^"M+^$=]XCF\ F?XBP:7=^!K
M2XUI/QY_9J_8-_:PT#X]>$/B'XK_ &>_'G@/P)#_ ,%7-)_:MT^Q^+7[5%E^
MU%\2_"WP'F_X)M^(_@/H^M_$+XH_$CXR?$CX@^*/'FB_%&XT;PSXK\)VOBGQ
MK'X1U^>72_AGX@^(?PJ\.Z/\1;WV[QS^R3^U7X(_:]^)/[8_@OX'S_%;3_ 7
M_!1G0?CUX6^$6D^/OA=X=\:?&CX%^-/^"=?@?]D#QEXJ^&%]XT\8>&_ FA_$
MGX:>.[S5]8TKPC\8/%WPNM/%/A+PSXUAT_Q#::AKW@^3609]Z?L&_MJS_MGZ
MK^V/J&EQZ.W@3X$_M53_  +^&MW!X/\ '?@#Q=<>'--^ 'P(^(^O0?%/P?\
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M\.A_V'Y=_P"IL#[L3H?K_04^F)T/U_H*?7)'KZ_I Z8]?7]9A1115EA1110
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MY-Q\$<^A^-UPN?\ OKX:Y'7O^=/'Q5U<C(G^"9]A\;+@G\G^&L?Y_P"-8/\
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M[XJ>'? &E?"W0?V@7@6X\26^BZ-X=T_Q.-0TG3-#N;;WOXT?LR? GXD_ /\
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MPUF 3ZI\6_BE;:KX_P#'-\GQ+\?WGB/X@7MWXV\3R7WB">37=2^W3?M2:O\
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MH;MK[3X+!+*\>XM[2VM)7N8)6>RA2R)^R9A.A_PD%Y_T#K;_ ,&,O_RMI/\
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MU![$=?3T/.;"L=W( :-5#.I/3.>@'<GIZ>OPM\//^"D/[%_Q4\<^'?AW\/\
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M9;F.,P.89?FF"JY?CL'BL/AL1"K0KX2M&%:C.$U*+5:$*FGO12M?[DB_HO\
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M?''Q!U+Q: ?T\9#KNXW*6658V5CN>/!1G89*>5LD4R*OF9@D;RHQ@/!P=H5
M5)*JF\*H,C('#>45+X+&947]TS".7=&PEK^;[]JS5_BYI.L_M%?M8^./%/QW
M^._P!^&.CZ9KFN>)/V!O^"DGBOX#_'G]A/2_!O[-_A/XI>(M(\3_ +#^L>(O
MA/\ L>_&[4/#OB^>[^*>K7'QV^(/Q)^*7C3PG\8O GA:^^!7CKX;^'](\+7'
MD7Q3\:_MI?M!_%O_ (*$^+_"/Q?\#_#2']DC6OAOI?P1^)?QJ_X*5_M,_L*>
M%OV>? K? ?P%\4_!7Q_^-7[*_P *_P!E+Q3\ /V@_"'Q*\<:]XJ\4>-]:_:(
MU[4/!VOZ%H&K_!K3_"OP[T+P=JDNJ ']"O[0W[6/[/O[*0^$+_'SXA1?#Q/C
MU\9?!'[/GPJFG\->,O$,'B;XM>/WU%O"/A2>7PEX?UR+PS%J<>FZ@S^)O%C:
M%X/TI()&UK7;*%5K5\>?M*_!3X:?&SX'?L\>-/',&C?&+]I"#XDWGP;\'-HG
MB74'\8V_PCT"T\2?$28ZYI>C7GAGPW_PC^B:A870;Q?K6A'6@\VG^&AJ.I03
M62?DG_P5P^'NJ?'CP_\ \$NOAEXJO_#]OXD^*/[8#^%=7UGP?>3W_A_3?%_B
M+]AO]JRS'B7PCJ5W8F[DT[P[XFNSK?AG7[FSAU2Q%E8:S!:17*&2U^9O#'QQ
MU3]JS]L/]C/]L?3=*6;7O"WQ)\1?LU:-X:M;R77]*T[XG?##_@F]^TY\7/V@
M=%TF"PC6]:;2OC9\6)/A)XGBN3'J-WK/P0:-DMGLM/#@']//"[RN J[>S!&S
MM*-\JL%!'R2LP)1 )<(A^;RSQ[\9_AM\./&7P?\ A]XR\1_V1XP^/GC?6_A]
M\)=%.B:[JK^*O&7A?P#XL^*NL:6U[I6FWNFZ%#IW@#P'XL\3&^\2W>BZ7,FD
MK86FJ'6M1TG3[W^?'X(?%;XF^$O"/_!*;]ICX;?M ?&[X[_'C]NW0?B_>?M*
M?#7QY\7/B1XQ^'/CZ]T_]E?XI?'#QR? OP#\5^(KSX?_ +,\7[/_ .T!X#\)
M?#"QMO@MX#^'\^FZ?J0^&WC]?%FJZ[;W$_CO@(V6JO\ \$'OVLM-_:8^*_Q_
M_:,_:,OOC=\:?&/P]\<_''QU\0O!GQ7^,!_X)V?M)>)_&^H_#WX.>(/%&M^"
MOV?=(^$?Q+UO4/A4?A_\ O!?PL\)^'E\=:=X-^(&GW6O>'O!UQI !_5M<WD-
MC;W5_=LL-I:V\][/+M=FAAMTDGFGDCCC(4I&CQAHS<O<QJ)8R8TDW<-\(/BU
M\/\ X\_"WP!\:OA-KX\4?#;XI>$=#\<> _$QT?7-"?7?"?B/3X]5T34AHWB?
M2]&\1:8M_83Q7*6&KZ-IVH6A;;<V"-N2OYI_V']<_;8\=^%/V'OVL/%7QH^"
MM@O[2ECXG?XY:G\0_P#@J)^U!\4C^T<OB+X:>./$7Q(^#_PB_8#^('[+_@K]
MGKX#?%[X2>/?#L.HZ7X2^ OB73=:^%VA_"KQS\/_ !7KOC_1-0\9:UJO["?\
M$@B/^'6W_!/]2HV']DOX'$C#  2^!=%D."Z1,T,K,4A1(I=X4+)-(S,P /T@
M,49.XKEN><MGGOG.=R\A&^]&"P0J&(((HU 4 A5!"KN;:H)! 5<X79M CP!Y
M0&V/:I(J2B@!NQ!C"J,=, <<J>!CU53]5'H*^$OB%_RDH_9._P"S)/\ @H5_
MZO7_ ()G5]WU\(?$+_E)1^R=_P!F2?\ !0K_ -7K_P $SJZ,+_$K?]@.8_\
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M7Z#5XCS:&/>)CC<:X4\1&E]7CB:OL*BC*SFJ?/R.$TTTN5IIZ'^O='P;\/\
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M%66%%%% !1110!\)?\%"O^2!^ O^SV_^"9O_ *\A_90K[MKX2_X*%?\ ) _
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M1X_(\VRFK2A@<RGD\(YEE&(IU,LCC,MQ&&PRRVG*CBVFJE.E1I4?BKQ^"?\
M@I)^R8&R&'[$7_!0<9R"V_\ X7K_ ,$S 2P4!03Z8VCH!D5]Y5\%?$(O)_P4
MC_9/4$)+_P ,1?\ !08GC[H;X[_\$S"JY[D*.3SU'.<X^]:_9:]W]3;LY/+J
M;;5TFOKV8V:3T2?2W;IH?Q5AK^TQ3<:B<ZE&JY5%",FZF&IZ.,+6LHII2C%Q
MC.,+6BK?G!^VWX)\9>*OCS_P3'U?PIX4\4>)-*\!_MNZMXL\=ZGH/A_5M6T[
MP3X1N/V1/VI?#<'B7Q3J%A:75AH/A[_A(_$.@^&$U?59[72UUWQ'H>EK,NH:
MM9I/\"_M@?#/XD^!O^"AWQ5^.WC/XA?MY^ O@G\9?V0OAA\*?AWXP_8G_90^
M&O[9A74/AUXT^)&I_$_X%_$3P'XF_8D_;,\9?#BR\?'Q[X2\9:+KNE:1X&^%
MOQ%?3]1TOQQXEU+5/ 7A?3]-_H5,49R2HR6W$\[BW(Y;.2-I*8)QY9,>/+)4
MN**>HR<$9.2<$J2N3SM;:NY>C8Y!K$ZS^;6\^%*_LB:'\$+KX.^*?^"G'[/7
MQ.T']DC]GKX5:;J_Q!_85T#_ (*6_#[XQ?#WX1^*/'7BC3_@7^U)X._8Q^'O
MQ(\:^$_'?PXT'QSXB\':N?AK\:?V1O#OB.#QGX/U+P'X\^+UK\-/$-EX<\1^
M)?PO_:%L_A/^UKX6\8?L<^)/A=\1OVE/^""WPT^%_A'X2?LN_ 3QQXD^!'A+
MX\_"RP_:XU?X@? 7PI<_##1?''@#X9ZO8M\0_#%Q\._A]XA\9FYUO^WM/\*^
M!]:\>>(X+K/]7 11R!S@C/.0"<X!ZA<] #@8& ,#">7'Q\H!7(##(8!F5W&X
M?,1(ZJT@)(D(^?=0!_-;XR_9D\>WO[,/_!P&%_9^\9:AX\^/7@G1/#_PWM3\
M,?$-QXH^,%EX-_X)T_!#0/!VF^!=/FT"74/',/ACXHOXVTCP_;^&[>^_LGQV
MNNZ3ISV_B-+U+/YX_;@M9O@W^QK_ ,%I_A=^T'^S1\>/B7XX_:HT33?C9\*/
M'&A? OXD?$#X;^,O!&A_LN_!+POX!U/QS\=-(T#4/AC\%_$?[,'Q.^%'BS6=
M2\"?%SQQX,\:2'POI7B'X7^&_'_BSXD^%].\0_UM!%&,*."Q'U9MS?@6PQ'0
MD XR!7Q+X^_X)T_LA_$WXF^)/BMXR^'/BB^USQSXD\)>,?B3X0TSXV_'GPO\
M#OBUXM\#0Z);>%_$_P 9OV;?"OQ-T7]GGXR:_IUGX8\+V,NK_%'X8>+;_4]/
M\+^&=/U:>^L_#VC060!V?[3,VKV?[,7C<V'[-.G?M=V<_A72-+\7?LUZE=>$
M+8_%7X?:C<Z1IGQ"T#3M-^(VDW7@;Q9K\'@NXUW4M$\!>,5T#0_B%J6G6?@B
M_P!;\/QZU%KEE^0'PC^&^DZ?\6?@7X6_X);^'?V^_P!GWX81:;\:-)_:.^'G
M[2O@3]N_X5_LH_#SX7^,OACXMO/ $7PJ^&'[<^@:9H?@SXF>$/C[<>")OAWX
M;_8DTO0M(T?PO/\ $+3_ (C):^ CX7M)?Z)1&@_A&<LV3DG+9!Y.3C!V@9PJ
M@*H"@ *40XRH) (!QR WW@#U&[ S@\]Z /Y8?V$_V:/$MOHO[!_P)^*/B/\
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M82:C'+8)'&GZ'A$!)"@$C&<#I_='HN>=HXR2<9))-B$@E02#D$CD$@ G/7D
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M<;[5:J3>[M@\1_D?=$7]%_\ 0S5FJT7]%_\ 0S5FN6/Z1_*1T1^"G_U[I_\
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MC6NL+;V_X'^(+:_\':I<^'O&VCZ[X!URPF\F^\-?$'0=9\!:]ITW_/"Z\/\
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M-MW?4ZE^6GR6W_#= HHHJAA1110 4444 %%%% !1110 4444 %%%% !1110
M4F/KZ=3_ (_KUI:* &[%QC!_-O\ &G444=;]>_IL))+96"OA#XHNO[.'[1B?
MM+ZJ\5A\%?B]X)\(_"#]H+6IYHX=,^&/B'P!K?B75/@I\8]:+%8M+\&WQ^('
MC#X9?%7Q*[W,.A0W'PA\2Z]/HG@/PAXRU_1?N^J5W865];75E>VL-W:7\$]K
M>6=R@GM;NVN4>.X@N+:8-#/#/'(\4\4D;)+$S1.&0[:UHU_82ES:TZL'1JJ[
M7-"4HR47JMJD85(W32J4XNW4SJT^=)IVG!N4'U3:<6UU3<6XMK>,G%Z,C\]1
M&'C<;3M(D_=LAC8[DE#^8D;($S.VQF80+N8*2H-O<_HW_?!_^)KX7/[)_P 0
M_A>TO_#)O[1.O_!CP^',]G\%_B;X-M?V@/@!H9W@+9^$O"FH>)? ?Q:^'_AR
M%0L%MX%^'?QQ\*_#/P]9K':>$_!6B1 @O_X5_P#\%)/^CL/V(/\ Q7S\=O\
MZ9C5RH8>+O'&4*?,W*U>5:+\DHPP^(24==I*.ONWV62K5H1C!T*LN56O2IT9
MZ+;F=6O1M9;<O-UO:RO]R[G]&_[X/_Q-&Y_1O^^#_P#$U\-?\*__ ."DG_1V
M'[$'_BOGX[?_ $S&C_A7_P#P4D_Z.P_8@_\ %?/QV_\ IF-+V5'_ *&&"_\
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MZ-_WP?\ XFDRWH__ 'RW^%?#?_"O_P#@I)_T=A^Q!_XKY^.W_P!,QH_X5_\
M\%)/^CL/V(/_ !7S\=O_ *9C1[*C_P!##!?^#,3_ /.X/K%7_H&Q?_@C!?\
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MR3]JC_U1'CVONNOA3_@I[_RC8_X*#?\ 9DG[5'_JB/'M;83_ '[ ?]AN%_\
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MW>M_Q;_0$E'X4EZ*WY";1SQUSGKWZTM%%-)+;084444 %%%% !1110 4444
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M_P#@G[^V%^R+J]A\)_B)\8?BM\0/B?\ %C]H#3_AY=>&OCU^T%^T[XZ_9O\
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MHFK_ !1^*5G^T9\?X-1O-&\4V>E^ HA\0+?6_ 99=@_K9?Y'W_\ LX_MX?\
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M'?AO\:OA)X@\,Z!?^*8_B#X*USPYXVT"WN'^?/\ @G]_P3'^-_[)7Q$_9O\
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M-O8P:KJWW7L3^Z.2Q(YQ\PPPQTVMU9<;2WS$%N:IK'MR%RH)!P, ?+TX#<
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MBCQ;XH^,GQK\2:7%I'B'XP_$%M&;7H]$^V?VB/!G@GP_X>TW1_"GPR^'4-_
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MRV%)-<^%KU*LY+XVL3&FDY/=KFP[5[V;DKV=K\E_98N;>V(C34;_ /3OFO\
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MS:^$M'T?P3!X7/Q&T'QQ^VEIGQXT"'P=XE^ W@3PCK&G7?@'P!K(!^VWPO\
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MDV>MW5EX*\:0ZI?>%_"*P;]E#]IS_@ESXN^//[-OQ<;3K#P5_P %BOBU\/\
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MUHVK6[*GX<_ N7XL2_"S_@BK^S5!^R]^U9!\5OV)/B@FC?M*R^+_ -GWXK>
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M5O716_$0J",<X]B1_(BEHHK1))MI)-VN^KMM?T ****8!1110 4444 %%%%
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M  "0H 4+M"YVA2H *@;254D$J"#RH^/EZ%3U.<HYD4DYY.\EB3DLW+9-244
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MK5OV8?@AX9^$_P"TO\$O#7[4>AZA<S?'3XBZSH&A3^#/&6GO'JQ@M?#5I<?
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M7A2YU6[GT+3;QF_9&UIA>Z=I9M;)I9]8U^2<QF:YN+BX9Y&NGPGAJF85,O\
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MRIPO*-U);-M+]@#(1GK]=I./Q  /O_2F>8^ <D<9.5!8>W0*,=S^E?@GX\^
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M4;MPY%>ZC\2M>[2_?#S".K#Z#&[\B ,_B:02,1D?J,9Y_$?E^-?E7\5OA/\
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M\/?&+X2>+M<^&GQ5TK1I+B22XF\.0^.?"NNR^%[ZXD>75/"\^AZH"RW\;O\
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M.">G3)QU.5\M/]KKG[[_ )?>X'? XSSC-/HI679:^0N6.W*O^'WZC/+3&,'
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MY(+,1VXZ\#@<#C/.,\U&%08&20",<MV((X(/.0.A'04%R"!OYW;=O +97+#
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MQ\._B5',_@OQ9I6MW-J6%_IT4SV6NZ80 -NIZ!?K;ZSIQ.XA?MUC:@ MM/+
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MQJ)M33T;M<;L7&,?J>WOG-.HHIF@4444 %%%% !1110 4444 %%%% !7P?\
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MY\4=!\,_$7QU\1[KPA=^ +7QU^T1^T-^T7^U=XJ\-^!]3D,VO>$O ^N?M/\
MQ7^+^H?#[P[XJE%L_C32? T_AZR\:MINC'Q9#K/]AZ/]A^Q:* /SA\"_\$IO
MV$_ASXJ^%/B_PU\*?&DVM? K59M0^!'_  EO[17[2_Q#T;X&V]UX7\1>$-0\
M*_ _PU\0?C%XF\-_"+X?ZUX4\3ZAH^N_"[X;:3X=^&^O:5I?A6/6O"M[)X"\
M"OX=]\\/?L@_LZ^%O"/[,_@30OAW]@\*?L=:GI>K_LX:4_BSQY=2_#K4M&^'
MGBGX5:5<K>7OB.[UCQAY/P[\9^(_#\D?CR^\4V[K??VC<6LFL:?97]I\U?\
M!7SQIXD^'O\ P3V^/'BOPQXK^(O@?6-/O?@O:R^)?A!KGQ \-_$NQT36OC[\
M,=#\26G@S6OA3-9_$Z'6-1T#4-4T:U7P1-;>([R#4IH=)2\O91:2_%/@?4_#
MVD_M,_LQ:M^Q-_P].A\,:-XN^(6N_MBZE^VBW_!5?_AG>U_9?TSX7>+EU*.>
MT_X*874>BW?Q?E^,,_PKO/AK!^S]8ZG\4O*L?&,OBPI\,(_&<MR ?J-\*/V
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MNSL?X/\ @/\ ,4ZF_P '_ ?Z4ZOE5LO1?DCR5L%%%%, HHHH **** "BBB@
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M?M8XX/\ A'/"^H#1-/MDCBANM5:V_L[P[H-M9H@MC!J'B*_TW2Q9K"81>7<
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M9CAJ5*$*5&C3SK T<T]A1ITHQITZ5&5>=.$*<8QA%**BDK!1117N'Y*%%%%
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MT+1M+T?[4T+VYN%TBP@T_P"T%)'E1/,,"3E4.SDXWJQ)Z(HK?>&1@@@DD$$
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M?(_P*_84_9?_ &;?&=SX^^$?@/Q#I/B0>&+_ ,"^&W\5?%SXS?%'1/A?\/\
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M/AW0]$>\M%.X6US-IMC:R7-MG.;6Z:6(\D*<FMU0XJ>.6+>?94LF=%TY8/\
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M^=YYFU:4I5<?FF<XR3E)R?M*N)Q]5U+MM\\ZBG-RO=R;=[GJOP-_Y+;\'_\
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M-XFFC?1]:TR"/%P?[!FOIM20AM*M-0!K^T;X(?#+2?@G\(OAK\)=&N3?Z?\
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M=VNIE&O1<W3=>C*LK?NH23E%W^U'5IO9726CL;O..O/K@?RZ>U0K]\?[@_\
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MQJ00<X/7YG'Y8;C\,=3ZFGT5*C%;)+6^B2U>[]?1H;2>K5WMUV^]?U]XP1J
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MMEV"OL+]BK3Y+OXK02C=MMY%4L!D )]WH.<#G)!]^O'QZS*JLQ'3H,],Y_\
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MGC(X#%8J%2%>I3ITX3K5$ZKC"*7)KS?F^/\ '_PWR^C'*ZG$]:OAZ%2=2%+
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M.7_AT1_\H:0_L\ 8_P"+Y_LYG/I\41Q]?^)#57[/^RU_T&_V@/\ PF?AW_\
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MXMK#0G6J5Z="@EB4J-"A.M*&&I12A2ITTJ:BD[_]L7AQX+^%_A9P?D_ G!_
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MF^)+"1$BCEBS^E:_?'^X/_1E?Q _\&@?[4PE@_:E_8SUG423$="_:.^'%BS
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MMR=&4:JH13DJ%."<D_X'XHXSXGXRQCS'B',:N(<IU'0P=.O5C@L'S./M*5'
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M\30^!++2=3\8W4'A']G;X5_%;Q'8V/AZSUS2WO\ 4-7TZPTU%NDVWI8/MM?
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M^ O^SV_^"9O_ *\A_90K[MKX2_X*%?\ ) _ 7_9[?_!,W_UY#^RA7W;79/\
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M%B,EP63YAEN)X7XUR_,*^(Q='$X"3Q&4\0/"T\#0QCQ$L;2E4]A*G>I]@M'
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M.?\ @EW\>OVP?%^A7=NGQ[^./PI_9%^"$VH6\MO'?:9I-UJGQY^,/C/2!=I
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M#$8#&T:_!'#="6%Q5/$4JU&4:M"I5I1CB*-7"NG*I&I3=7V#7^@I_P $BO\
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M?^%/#_AG3]!O/&'A76?#/AK5O#?B6XL)-9T+4_#N@W^EWMK=:/ITMM]'T44
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MU1M0%_\ #'XGWWPOUCQOX<2RU2\TZV.L7_P6^)?Q>^&TK:Q:V]OKNG_\(_\
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MM]H'@;4_"?BNUTC4M?N=(TZP%]J&LOXCLVUB[L0UEIAM2T<\H0^L_P#!*?\
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M$G^,0D!(,:_";4Y,-_=(^UQO]1E32_\ $2-_P32_Z&/XP?\ AJM5_P#DJO\
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ML<;22D0#)5%4$L9 ,JH&>>/4<D?TC^4CHC\%/_KW3_\ 24/#R-T(5B75<A"
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M_%_Q'\&-XSN-;TK6-$\/VVH^*/%K)X7CMYM(L='^[Z_'C6/V^[KP=\<OCO\
M [X2?!'5OB-^T+XB_;.\'?LX_#?PQXZ_:3\<:7\+_&6L0?L=?#;]I+QI\3]<
MU;6_"OQ-'[,GPJ\$_"]-:L;CPC\(/AG\0(_'?Q&LM'U-?#Y\2?$[QAKVA\>G
M_!5KXY_VI%\-I_V)+6W^/3_\% ;C_@GR? D_[1EM'X'?Q?;_ +)4'[3Q^-4/
MQ";X++K+_!6Y>=-,TZ]/P\'CZ?X8'_A93^ CX\'_  HT@'[;U#N+9VN,K\_#
MH<J<[=_R';&^,AA\W'!X./RDL?\ @H7\:9/A=^T3>ZY^S;\)?"/QP_96^.\?
MP?\ CGIOB[]KO3/"/[)/P[\)-\*?"7QR;X]>)_VL/&7P2\-^*++X60?#;QKH
M,.HVFG_LWZO\1])\=7B:1>>!5\$6FK?$?3OA*V_X*P_M%?M,^//V3=)_9N\-
M?LOW-C!_P4?\0?LN_'R^^&G[9)^,GP-^*FB:7^R7XK^/WA5OA/\ '7PO^RAJ
M,GB?P5J.EW8UG7=1A\,_#KQEX9^*WPPTOX3ZKH&L>%/'7B#QKX< /Z3J*_,"
M7_@H^T7[,6L?M''X-9_LG]N67]B\^#E^(8"SNG[;D/[&H^(H\0GP,Q3,LZ?$
M#_A#_P"PV;S ?"!\2\CQ+7@^K?\ !7CQ-X*^"?Q^_:@^*/[/7P^^'7[//PF^
M/7Q2_95\!>(_$/[3=OI'C/XL?'KP;^TC<?LZ^#I;W3/%7P8\*_"CX4_ ;Q)J
M$$_B/QU\9O&/QNN+SX60:)XQ^W_#[Q%X6\/6?C?7 #]MZ*_+K]A/_@IAX&_;
M)^)7Q?\ @?\ VY^S!JGQ4^$WA?P3\1I=2_8]_:RT?]M'X'^(?ASX\O=9T#3;
MBV^+=A\,/@OJ.@_$71/%'AO5K'Q=\//$?PZLCI6BZMX$\2Z1KWB2T\4WEKX?
M_46@ KX2^'W_ "DF_:S_ .S)/^"?'_J]?^"FM?=M?"7P^_Y23?M9_P#9DG_!
M/C_U>O\ P4UKHPV^)_[ Y_\ J7@CFK_Q<)_U^J_^HF(/N2+^B_\ H9JS5:+^
MB_\ H9JS7+'](_E(Z(_!3_Z]T_\ TE!4 Z?\ 3^2U/4 Z?\  $_DM.7POT_6
M(I[+U_\ ;)'PQ^UA_P E]_X)D_\ 9[7Q#_\ 7;__  4#K[NKX1_:P_Y+[_P3
M)_[/:^(?_KM__@H'7W=75B/X>"_[!:W_ *L,0<V'_C9A_P!AL?\ U#PH4445
MS'6-"J.0.>.<G)P,#)SEOQ)R>3SS7 ?$7XF_#OX/^"_$'Q+^+'C_ ,%_"WX<
M^%+2&]\4^/\ XC>)]"\&>"_#=K<7EO817/B/Q9XBU'3=#T:U&HWD%IYNHWUG
M:O=7=I:13H[NC>@U^8W_  44\+^*)/$7[#'QFA\!>,_BE\*?V:?VO=,^+?QR
M\"?#OP1X@^)_C6'PI?\ P5^,GPX\&_$'P_\ "WPAIFM^/_B+=?"?XL^.O ?C
MU?#?@/PMXF\66]KHUSXMT;0+V^\)QH0#U#XA?MO_  YT:?\ 8YU/X37OP^^.
MWPZ_;*^-VM_";PM\5O GQ5T+4? .F6.A_!?XS_%6Y\;Z3XB\+Z;XPTGQU8VF
MH_!J?P=>P:9JNG6VFOJ5UK!UUI=!?P]>7Q^WQ^R=X*^'7@7QG\>_VK?V+_@]
MJ'BWP5X#\873K^U?\-=6^&T]M\1[;7[CPMJG@3XE>,T^%TWCWP9XO?P;XTB\
M">-)_"'A>/QE%X2UV]L-#4Z7J-M9_"_QDT\_&W4_V ?'_P "/V4_C/\ "OP-
MIO\ P4&^-7Q$\86>O? +4/A+KNJZ9K?[*_[5^DZS^T+XY^',-K:>,_A_I/Q/
M\?\ B.PAM-8^/OACX<_$;Q#XGUK2)_%'@BSNO%?AJ35/F[_@E;^S+\0/"'B/
MPOX@^+/P"\<^&-7TS_@B=^PU\!(]1^(WPW\2:%<6GBBT\4?M(:O\4_A$C^(]
M!LPGB.PEE\%7'CKP8%&L:,;[PF-:T6);ZQ\X _=B/XW^%HO&_C_2-8\;? ZP
M\">!?A#X1^,6I>(4^-&GR>-M)\(^(9_&TM[XQ\>^ +KPQIVB^"?@_P#V3X1F
MU#PM\5Y/B1K6F^+[NQ\;V<^C>';/P;)?:U%X,_:F_9D^)'PI\2?'?X>?M&?
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M_P!M+X5?MG^!=0\6?#XZCI'B#PW<66F^-/!&NM:)KWAJ]O$F-I<!K29K?4M
MU>2TOCH6KPK FHR6-[;75MIE_9ZAIMC_  @$YR3\V>#N^;]#D5^HG_!(;XZO
M\&OVR/"&AZC?O:>&/C39R_"_6D::3[,^L:BQNO EW/$K>7<ZG)XLM++28+F<
M-/9VOB'4(()([>[N8I/NN*^%,/B,OQ./H+%+&86DI*>(Q=3$U*U*$6W",JDY
MR4:<8.R32U21_/WA)XKY]EG$63Y!F6)P+R'-L;#!5)PRO)\LP^$Q&*]W#UJ2
MRVA05252O&E"K/$*4HTDE%I2DC^T)LL0OF,H+8V@XZ@[5R"&QD;CCM]2*_//
M]O;_ (*(?!G]@#P%HOB'XC+K'B7QIXTDN[;P'\-?#1B_X2'Q))ILFGQZOJL]
MY> Z?HN@:&E]9R:IJ5XD\P,T=CI>EZC>SB*OT,.%.< LS,P.1\NQ6P.>PX'I
MT'6O\]O_ (+5_M$S?M ?MZ?$VTM-3.H>$/@Q!9_!SPMLG=[1IO#!EN?&MR;?
M(AAN6\=WOB323( TLD.E:8PE$:QJO\D^*?&M?@CA6>89>J/]IXK%T\!@*=6*
MJ<M6:FZM>%)Q<9NC"TFI7OS05G&3O_N#] +Z,F4_2G\>L-P?Q;#,EP#PUD>/
MXOXW>68R>78O%X'"8C"8+)LAI9A"%2I@EG&:XO#K&U,-&GCEE^$S!X'$8;%.
M-6&W\<_^"E'[-O[0/Q.U7XI>.O\ @FE\"M5\4:G?1WSZO-\5OBKH6M:K<I";
M<W_B<> KWP-H_BO69D.;BYU7P[</<2!9)F=E4C]J?^">G_!<C]GSQEXC\!?L
MT>+/@3H7[*F@74MGX2^&=UX,UF#6OA?:ZG?W;QV.BZI:Q>&- F\()J^IW0L[
M+53_ &OI-UJ=U)=ZO>::&5S_ !JGD$$GGY.VTY&,L< %O5S\X]<C-/BEE@D2
M:*22&>-XY8IHY&26.6-V=)4D4AU97(;<IR6"MR54C^1,D\4N*,BS>.:PEETY
MUL9%YC%Y%EN!GBZ:J+ZQAZF)P6'HUZJ4:\YM5JD_9SC"HHN4FY?]$_BI^SX^
MCSXG>'$/#V>7<8Y72X=R6OA.!,5#Q)\0L]PG!F9X; +!97BLKR;B;B_B#()0
MHSAAJ4L)B<!3A6P5;%TISP]1MT_]8),.G!^1ESA% 7#C.Y6(7(&0%(&,_K_.
M[_P<7_'-_ ?[+WPV^!6E7\EMJ?QL^("ZIKL$<R[[GP)\,(+;5;VV="#(9)_%
M^M^"KRW*E?.?3KQ3(\=N\8_5W]@?]H6/]J#]DCX$_&AYXKC6O%7@:PA\5M;
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M^#[/PD=!'PZ?Q]+ T*6>N:\VI/J0\=RB13)!%$;!<"02D+_*M_P7"T>?1?\
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M36/$KN;+4K!M/MT1/@,1XK8G'Y5QW#"97B\ES7(</F]:.*S1QPV H1PV94L
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M/7P^"I02Q&5JE@Z\N27/#\V?VP?V9-0_9>^,4G@BPUO_ (3CX=>*M!T7Q_\
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M2G//LYS"K2E4P^6Y1@/:PGC:]:4(PKK]W2P6'G/'8O$8?"X>I[;Y?_X))_\
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M<EO=MM\S;YM_L77N):):+0]A24E&R:O"$[-6:4E=)A7PE^RA_P E\_X*;?\
M9[_P^_\ 7;W_  3^K[MKX2_90_Y+Y_P4V_[/?^'W_KM[_@G]75A_@QG_ &#T
M/_5C0.>O_%PG_7VO_P"H=<^Y(OZ+_P"AFK!4''7@@\,PR1TR006'J&R#W!JO
M%_1?_0S5FN2/Z1_*1T1^"G_U[I_^DH_+#3_V(/VF_A)X6\3?!+]DO]LGP?\
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MW:WD'*?#>\_X*%^!?C#X6\/?':7]FK]H+X+>-="UN/5_BK\!/A?XR_9G\5?
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M/^"57_!/SX_>"?B_I.GZUH7A^#P%\4OVH]6\#_M7?M5>*K3]K/X+Z\?$%_\
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MGM_\$S?_ %Y#^RA7W;79/_=:'_7_ !O_ *5A3GA_O>*_PX?_ -)J!1117.=
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M' G .-XHXCSS-LEI.AGN!RK,L:\SP6 Q$:L,%B<XQ.5T\0H2A7PE+\HRPVL
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MFL+'PY+HUK]I&B7.DZS#=/%$D>K37*N5>MXZ^"/P:_9/^!_P]^(7_!27X/\
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MS_@IM_V>_P##[_UV]_P3^KIP_P &,_[!Z'_JQH'-7_BX3_K[7_\ 4.N?)?\
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MWW\TXOSB]XOR=E=;.PWK&47K&:M*+VDDT[26S5TG9Z729_5A^S?\8=&_:%^
M_P )_C9H_EI;_$?P+H/B2[M89&EBTO6KRTBA\1:(K;MQET3Q#;:GHLPC*DW6
MGRA@3MQ_)?\ \%D+N*Y_;N^(,,9S)9>$_AG:S^TK^$M)O&^F;6]MQ@<#@@!F
M)/ZK?\&_/Q-USQ7^RO\ $3X<:M;:A)I?PK^*=^?"VJ2*S:<-'\9Z;!J]YX=L
M)D=UDO=#\06NL:MJ/V=\0MXJM;52+B&YK\@?^"N5R9O^"@7QSC*8%I#\,8 <
MG]]_Q9[X<W>/]D'[1Y8QCYHSCYB<_>>'B?\ ;E>:T=/+*\KK1\D:V'3C?^7E
M<HVVM)KJS^??I)5+<$Y/S:WXLRYJ^NM/+\TFGKU5E9]+*VR/SPU'2-0TI=.:
M_M9;<:KI=OK-CO*C[1I]Q)=P0W"%ARDTMA.5(XZ@' Q7]NG_  2W<7?[!?[.
MKR/YX'AC7[4DDNH-CX^\4V850Q*J(_LP5%  38 H&T ?RQ?MP?#=/AY9_L>O
M'!Y?_"7?L8?!GQ+=DQF/.K:KJ/C.ZU&-LG_76L=W8"8#:,NN5YRW]/W_  21
MGDN?^"?'P =VPT2_$ZU 7&42V^,OQ&MXE/'\,*0D;LD@!FR22WO\>8BGC.&L
MJQ%-1Y?[6<(N*2M*E'-(W6UG>$5=?RQZ)'YI]'[+:N2>(^>Y57<O:X;A"A-<
MS?,GB\9D^8)K6Z?L\PB[[V=]+GZ-&UA4, G4,"VYMQ5D=RN[=NV;N=F=@/(4
M5_#Q_P '"\GCGQ5^V;!>GPCXKB^'_P ._@_X%\,IXF/A[5QX235-;UOQ/XAO
M;@>(%L/[-\^^/B#1--E4W#*;VU6T11>O(6_N.D.-WX_^BV']:_&C_@NOY;_\
M$T?CHS( _P#;?P=>)VQC/_"X/ Z+;@$'$RHQN"!C*0[B"V:_EWQ7R1Y]P'G-
M)XF=!991_MYQC)J.(_LC"U\:\/4AHIPJS4924KZP4E%R2M_L[^SU\4:7A/\
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M%%4,**** "BBB@ HHHH **** "BBB@ HHHH *^$OA]_RDF_:S_[,D_X)\?\
MJ]?^"FM?=M?"'PPSJ'_!0S]L37+=MUKIO[,W["OPYN,#.S6_#_CG]N+X@7D3
M, 0'&C_%GPY*\9.](IDD*JLL;-U86$I+&22NJ>!;F[K13QV!IQ];S:6FV^QS
M5OXN$75UJUOE@\0W^"/N:+^B_P#H9JS5:+^B_P#H9JS7''](_E(Z(_!3_P"O
M=/\ ])05!@@GTV*,>_R_T]ZGJ-N>1UP,_EN_I_\ 7J*J;]G9M<M6G.23MS04
MN647W3YHW3T=E?9#5KJZNM?OT_2Z^9\+?M9C'Q\_X)ED?]'N?$,#O_SC?_X*
M"?\ UJ^[:^$OVQ2=.^(/[ _C21O]&\&?MNZ.9MX"IGXE_LR?M.? FU3)(7+:
ME\6;,0QRLLK7(6. W%PUM9S_ ';7=4B_JN J-WO2Q-.][N\,;4D[_.HOQ.:C
M;VV(LK7E3E+SDXRCS/N^6,8W>O+&*V2"BBBN8Z0HHHH **** "BBB@ HHHH
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M[5=671SX@@U/3?#VHRZC_8ESIQU71Y6MWO4M-84Q72,+G2;6'YK<R*/Y-?\
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MOVR[+X;_ +57P1\.W7@WQ+X"TSX:^/?BSX=F\(:GK%MXAL=)\3:UX(TR[L?
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MN:;2Y^9:NVF\*E.HKPDG;=)WMV\M==F]B>BBBF6%%%% !1110 4444 %%%%
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M (H_L]WEGLW33'5-79E$-O9F?KPT%4HYG3NU.IE\72E%V<9X;,<#C*DD]_\
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M:9J]C/I]^(+B%EGA::UN9(A+#*D\)826\B3*L@ /\OS_ ((/^!F^('_!6/\
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ME+M&3_"_Z'PM\.MTW_!1[]K6Y3YX(OV-/^"?VDS2@<+J%M\9?^"CVIW%HV
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MF++P5+XAT?PF+'P7>G3KOK_BCXZ^,/Q+E^*7COPO\=OCAX+UGXH_\%2_AO\
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MK":I<NFI6%G(S%_Z16PV2>R;BO(!&,#)[@9S@Y&<$8(S7Y?_ /!7G]E'X_\
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MFW[;G_AO_P#@FY_]+\K[EVCU'_?0_P#B:-H]1_WT/_B:?]H8CO#_ ,-F _\
MF4/JM+_G]BO_  ?4_P#DSX:_X93_ &@/^DFW[;G_ (;_ /X)N?\ TORC_AE/
M]H#_ *2;?MN?^&__ .";G_TORON7:/4?]]#_ .)HVCU'_?0_^)H_M#$=X?\
MALP'_P RA]5I?\_L5_X/J?\ R9\-?\,I_M ?])-OVW/_  W_ /P3<_\ I?E'
M_#*?[0'_ $DV_;<_\-__ ,$W/_I?E?<NT>H_[Z'_ ,31M'J/^^A_\31_:&([
MP_\ #9@/_F4/JM+_ )_8K_P?4_\ DSX:_P"&4_V@/^DFW[;G_AO_ /@FY_\
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M_P#$T?VAB.\/_#9@/_F4/JM+_G]BO_!]3_Y,^&O^&4_V@/\ I)M^VY_X;_\
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M77?AQ^SGX:^!O@'QG97.^;=X>\<>&O$?AV$77^BZ5 ;6S6U^Q?"/@OPA\/\
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ME9=@"BBBBR[ %%%%%EV ****++L 4444678 HHHI@-VKZ?J?\:=110 4444
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M,QH_X0/_ (*4_P#1V7[$?_BOGXY__3,:^V\GU/YFC)]3^9H]K5[87_PAP_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
*444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image_007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %O G # 2(  A$! Q$!_\0
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M&GQ]^!7PWU<Z!\1/C5\)? 6NBVBO#HOC3XC^#O"VKBSG!,-T=-US6;&\^S3
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MGV<,UW?7UW-#:VEM#+<7$L<4;N/Y7_VIO^"TW[9&@>*/VOG^ 6@_ ?PG\/\
MX!?\$S/V?_\ @HYX-C^*?PZ\=>*_B!J:?%23PO<ZE\'_ !-_8WQ/\):#;QM9
M:OJ$3>)[;3(+_1;F&WA72=4W37,'H6B?\%-OVG_B3XO_ &\?@=\7/!O[-WC+
MPGX>_P""/_A3_@H5X!\.3_#;Q5?>%;=?B'\.[S4O$W[/_P 5-+UOQY>I\6/
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MAO\ 9[Y[&T@^P>$/"6F:'>Z5\0]>@UJ]L)D!)_ET/Z;J*_DP_:*_X+9?MO\
MPA^)_P"V99Z-X;_9PO?AQ^QI_P %&_V3?V49--NO WQ /C3XJ_#G]HN'5I=9
M>[UH?$L:+X.\2>&8+2VETOQ!8Z'K-IJ5U(\=UX>MK>WS?>__ +:__!7C]I;]
MF7]KW3OAIX=T/X(^)_AWIG[=/[('[+FL>"M!CUCQ]K9^%W[3OAG4&O\ QK\4
M/B/H6NZ?IGP.^-5IXML+V?X;?";6-$UF_P#$G@C2[SQ)J6C3Z/):Z[< 77<_
MI0HK^2O6O^"B/[</P.U#_@X>_:3F^)OPZ^)%I^PE\1OA;X+^#GPH\8_#CQ)%
MX*TW0[+1-+OM)T[3Y=$^*.GW.DVSV/BK79/%T@BO]8\6^++BTU]M9T72[&U\
M,1^K^*?^"SG[5>DM_P %&X;'P5\#%?\ 9&_X)E_LV_MU?#>2Y\->.+C^U?&?
MQ8^%NB?$+Q?X&\:1Q^/K;^T?"\%W+JVF^'[K1WT'5]/M)K&?4+G5I[6?[0!=
M']/M9FLZUH_AW2K_ %WQ!JNFZ%HFE6LM[JFL:Q?VNF:7IME N^>[O]0OI8+.
MSM84!:6XN)HXHU!+N!7\XWC[_@IA^WU\(_A;^POXO^)NC?L[W^O?\%0_BO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1-$N[1+75=*M$/V*_AEEFDD^V**!GE'P0^"/PT_9S^%WA#X,?!_0+GPO\./
M>DVVA>%="O/$?BCQ;=:;I5E&L%G9/XA\9ZSX@\2ZA%9VT<-G9#4M8O#9V%O:
MV%J8;*UMK>+U>BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBO,_&7QI^#OPZBG
MG\?_ !6^&_@B*V5GG?Q9XW\,^'O*"9+;UU;4[1@1@_+MW$\ $\4 >F45^??B
M?_@JK_P3T\(O/%JG[5/PUO)H-P>'PU+K?C!V9<Y6,^%-'UE)"2, JY4\'=CF
MOF_Q!_P7?_X)^:+++%8>)OBGXK\MBHE\._"KQ"D$N"1F*7Q$WA]74XX;@<\D
M<X /V4HK\&-4_P"#A?\ 8ZM68:5\-_VA-84'"O\ \(KX,TT-SP0+SQX&4'K\
MP!'<5Q5W_P '%O[.J%_L7[/OQUN0$!C-S=?#RSWOW5]GBN[\M1_?&\^J"@#^
MARBOYU[?_@XP^ C%_M7[.OQK@ V[##J_@"Y#==V[=KMOLQQC[^[_ &<#/5Z?
M_P '$/[*$[ :C\'OV@]-4G#,ND> +\*,?> M_'BLPZX  ;ID#.* /W]HK\2=
M'_X+\_L':B8UU"W^./AXOC>^I?#*.[BB'JS:#XBUB1AU^Y$Q.#@9P#[_ .$_
M^"Q7_!.GQ9%$Z_M%:5X;GE('V3QGX2\=^&)HR?\ GK-J7AF.PC]#NO..IX()
M /TWHKYS\!_M?_LJ_$]4/@#]HOX+^*99-I6STSXC^%'U+Y_N[M+FU2+44STP
M]JISQUXKZ%MKFVO((KFTN(+JVF7?#<6TJ3P2H>CQS1,T;J>S*Q!YP>* )Z**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH_I0 4444 %%%% !11
M10 445Y9\8?C/\/O@3X.'C;XC:O+INF7?B#PWX-\/Z=86-WK'B3QEXY\::Q:
M^'?!?@7P9X>TV*XU3Q)XN\6:_?6>DZ)HVGP233W$S7%P]MI]K>WEL >IT5XK
MX.^-5OXH\=:[\/-7^'/Q0^'FOZ%X0TGQP;OQQH&DP^%M7T'5K^\TXC1/&/AG
MQ#XF\,7VLZ-=6>WQ'X?;58=:T**[TZZOK%+/4;*YG]=&I:>8+2Z6^LVM;\6Q
ML;D75N;>\%XT2VAM9O,\NX%TT\*VQA9Q.TT0B+&1,@%VBJRWEHUTUB+FW-ZE
MNEV]F)HC=):RR2117+VX<S+;R2PRQ1S%!$\D;HK%D8#Y_P!:_:4\'V/QEN/@
M7X<T7Q#X_P#''AVU^'6K_$JU\(3>&)1\*_"_Q4OO&NF>#O%_B^UUKQ'HNI3:
M!)>^ =>.N-X:LM>U3P]8/I>J:CI:6&IVT[ 'T316>FK:7(FG21ZC8O'J^/[*
MD2\MF34]T#72_P!G.LI6^W6J/<C[*9<P(TH_=J6'%^%?BW\+_'/_  D?_"'?
M$#PAXE_X1#7M>\+^)SHWB#3+X:%XA\*S"V\2Z3J30W+"WN] N2;75T8[=/NH
MYK:Y:.>":., ]$HJF-0L2]M&MW;,]Z@DLT6X@9[N(QM,);5!)NN(S"CRAX@Z
M^4K29V*S")-8TF6&SN8M3T^6WU"8VVGSQWMJ\-_< 3,T%G*LICNIE%O<%HH6
M>0""8E<1O@ T:*\#^-O[1'@SX(WG@+PYJ5CJWBSXB?%;4O$VC?"[X9^&)] A
M\6>/-5\(>"]?\?Z[I^B-XGUKP[H45Q%X>\-WZ6;:KK.G6U]K5UI&BQW*W>J0
M$>MZ=XFTV^TO3]2NF;0Y+Z#26FTK7)K&RU;2;[6(()K71-7MDO+B*UUI7G6T
MDL8[B<M=J\5M)<*%=@#H:*KR7=M%+#!+/#%/<LR6T$DL237#K%+,R01,X>5E
MAMYYBJ*Q$4,LF-D;D+;75O>017-I/#<VTZ++!<6\L<\$T;C*R0S1,\<B,.5=
M&*GL30!/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%<QXQ\;>#OAWX>U#Q;X]\5>'?!?A?2HC-J7B'Q3K.GZ#HMC&%9@;G
M4M3N+:TB+!6$:-*'D8;8U9L"OP\_:7_X+Z?LV_#7^T- _9\\-ZW^T)XJ@$L,
M?B!&F\&?"ZVN  J2#7M3M)=?\01QR;BRZ)X>^PW"*I@UD+()% /WJKYM^-W[
M8/[,/[.-N\WQJ^-_P^\"7*$A=#U#78+WQ3.P7=MM?"6D#4/$MT2,#,&E2("5
MW,,BOXN/VA_^"M/[<7[1,E_8ZA\5KGX5>#KR279X*^#*7'@FU6UE&W['?^*(
MKFY\;:M&$P)!<>((K:9LM]BC4B-?S:G>2[NKB_O)IKV_O)&FO-0O9I;N_O)G
M)9YKN]N7EN;F:1B6>6>621V)9F))- ']>/QF_P"#A?\ 9U\,?;+#X(_"CXD?
M%S4(FEB@UGQ UE\-/"4CJS*ES%+J*ZQXIN;9B%=4D\,V$DJ'&^+AC^7'Q4_X
M+U?MO^.)IXO %O\ "WX+:5(CQ11Z!X5;QEKR(VX"276O&MSJ&GM.%(VR6WAR
MT52 RH3S7XIT4 ?2GQ&_;+_:W^+BW,7Q'_:4^,WB>SNR_GZ4WCG5]%T-TD)+
M1#0?#<VC:.D!SCR%L1%@#Y*^:)XUNIC<W0-W<LQ9KF[9KJY9B22S7$YDF9B2
M269R23DDFGT4 ( !T 'T '\J6BB@ HHHH **** "BBB@"![:VE8-);PR,IRK
M/$C,I]58J2#[@@UZEX!^-/QE^%5RMW\,/BY\3?A[.I4@^#_'?B;08<J<KOL]
M/U.&RE .=JRV\BC)XZY\THH _4?X7?\ !9?_ (*#_#!+:UE^,6G?$W2[>5';
M3_BOX/T3Q)<3HN-T,OB#2H_#WB=D=1M+R:Q)(#EMQ<EJ_3CX/?\ !Q?&TMM8
M_'[]G">VC=D6Y\2_!_Q3'?)$,$/+_P (AXQ%C-L8D,$B\6S.@!4)*2IK^8"B
M@#^^SX&_\%6?V%/CY)I^G>&OCEH7A#Q-J.5B\(?%6&?X<ZZ)L<6\<WB(6_A^
M_N&Y$<>DZYJ/G$8B9^,_H9:W=K?6T%Y97-O>6=U%'/;7=K-'<6UQ#*H:*:">
M)GBFBD4ADDC=D92"I((-?Y@CQI(I21$D0]4=0ZGZJP(/XBOI;X$_MB?M0?LS
MWEM/\$OC9XX\&:?;S"5O"C:FVO\ @6Z(.2EWX)\0KJ?AMD;)W/!I]O<#),<Z
M,=U '^C;17\L_P"S?_P<-ZM:-I^@?M6_!^+4;95@M[CXD?!QO(O%"_++>ZM\
M/->O3%*S9$LK:#XDCQM86VCDLL:_T#?L]_M>?LX?M3:,-8^!GQ9\*^-Y(H1-
MJ/A^"[;3/&&B_*A==:\'ZNEEXCTP1,XC:>XTX6<C\V]S,A5V /I*BD!!Z?Y_
MSZ4M !1110 4444 %%%% !1110!\O_MI>%]3\6?LJ_'W3]&^(7Q&^%^JV7PF
M^(6N:=XR^%/BB3P9XVTO4-#\(:UJ6GR:5XFMK:XU#2ME];VT\DVFO:7D@@6$
M7:023Q2_$7_! [Q!K_BS_@CY^PCXE\5:[K/B?Q'KOPCO]4USQ!XBU6_US7-8
MU*\\>^,9KO4-4U?5+BZU#4+RYE9I)KF[N)978\O@ #]"OVH)$B_9I_:'DD=(
MXT^!GQ;=Y'8(B(G@#Q SN[L0J(J@EF8A5 R2!7YM_P#!O;)&_P#P1@_X)^%)
M$=3\%KF/*,' >/QWXPCE0E20'CE5HY%/*.K(P#*0 77Y?U^I^//PV_:1^!OC
MSX>_\%+?A!^V];_$\?\ !8'X;_%?]H6W^'G@^#5/&D'[0'B*W\5Z_J]E^Q</
MV +7P[>PW>E^%['2[WX>:7H=C\-!;6]O?VNH_$_XFM-X=\1:MXDN?ZDOV0;+
MX^:;^RK^SGI_[5%_IVJ?M)V?P4^&MM\==0TIK1[.[^*L7A+2D\;2K+IRQZ9/
M<'7Q>B^N=*CBTFYOA<W&EQ1:?);1K_,OHG[(6B_\%<OV.?CK^WY\7OBUK'[.
MG_!2SX+?M#?M+S?"WXY:!XI?P3JW[!B_LN>.O&WASX<?L[ZS#9W.GIHWPPM/
M!^E0^//B:?$T0\2ZSJ?Q+\0?$-]6^SW6DVL?[/?L/_\ !0#1=<_8/_X)\_%W
M]NWXC?#;X"_'W]K;X>^!M-T?P_\ $#7-%^'-W\4/B5JUC"MH_A#P]K5W9.]_
MXWL9-&\5P:+I\7D6+^+-+TVW2+[9IMO* G_FCYLU/XA_\-S_ /!9SXV_L;>.
MKJ76_P!EC]@;]F'X>>-?&/PD2[O8?#'Q2_:6_:%OK/5_#NM_$^SM;B"V\8^'
M/AM\+(9%\(>#]8BN]%LO%^NZAXJNK>ZU73M%?2_D"Z_X*2_$#_@G?X5_X+N_
M ?4[Z\\>)_P3=TSX??&;]CRY\<ZMJ?B6]T[X>?M9>%-/NOAG\)M?UG5KJ[UW
M7_!WP;^+.O6>A^'SK&H7NMCP)J%AX8;56L]'TMH?IG]GOP)/^SG_ ,'#_P"W
M@?%,5QIND_\ !0/]D7X#_&GX,:Q>KY>E^)M<_9I%C\*?BYX)T:_DQ#>>)O#<
M6MZ!XQU+0HF:^MO#6MVNK-#]A5ID_+3]H[]D3XH_M]7O_!T)\9?A'HE[XJT3
MXB>'_@#^S1\!!I"M<_\ "T_'W[$&A>$O'OQ@T/PC*&\G6KFT\=^$;7X=V!L&
MEL[KQ8NI:$ER=0L-1M[4$V_Q?_ /LO\ :E\+>.?V!/\ @DK\%_\ @I7X*\7>
M,?$/[:/P*TG]FC]H3]H[XE>(?%.M7FK_ +4%C\5-?\$:5^T1\*_BM!=7DNEZ
MOX UBR^(FL/\/O#/V&VT_P"%5WX8\%M\/5\,KH<2O]'_ !$_: MOV[/^"M?P
M3_8:M=4U2[_91^$_[$#?MT_&KP;:WEYI6F?&WQM\4=?T/P?\$/ /Q(CT^Z@N
M=;\ >"O#WB'_ (6;<>#YKG_A'?$GBJ\\/_\ "36&MV>A6UK'X'_P4W^+6G?M
M5?\ !O1\(/"'P7EM_%GQ$_;^\#?L6? KX&^$M-E$NJ>(OB1XW\7?#34_$?AN
M.R@WW"7G@'2O"'CG4/&UNT8/AFT\'^()=8^QQZ7=M%VOPO\ @C<?L9?\%]OA
MK?Z_,[_#S]K;_@EGX>_9Y^&/B^ZB>#3]7^-O[)FM^"[KQ'\/X;B0"&/6]0^$
M?AV#Q[I]@TWVB_L++7I+>*1=(NFC N]-_L_B>_\ [$/Q@\2?!K_@J9^W;_P3
M*FU35-6^"OA+X5?"#]L+]EW3=;U:_P!:OOA;X+^(D>G^#OBU\)M*U'5;B[OF
M^'VF_$SR_$7P\T![E[?P78:WJ_AW2O*\/V^BZ=I?V=^WS^SO\3/CAHW[-/CO
MX/-I&J?$/]E#]J[X9_M.:1\/O$>J#1?#_P 5M)\*Z%XT\"^,_ $VMS6U[9>'
MO$=_X*^(?B'5/ /B#4K2;2M+\=:3X>.JO8Z9/>ZE9_GE^R?X-U?XM_\ !P!_
MP4L_:ET.$WWPI^!O[-'P"_8AM_%MN_G:+K7Q=NCX>^-/Q%\*Z3>(6AN]5^&L
M+:1I?C.U@+?V'J^O6>G7A2_%U!!^Q/Q^_:4^&'[-=C\--0^)U]J]I%\6OB_X
M%^"/@R/1M U?79+KQOX_O)K?28[_ /LNTNETS3+:UL[_ %"]U&],, BM/LEL
M;C4;FSL[@&C\ROVF_A#^W/\ %_XI_%GXN?!O0/B9H?P[L/A%^S!_PCW[.?Q
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ML_X)_?M1VW@;XSQGX&:3\-_V@[;_ ()G?L&_!7X,_$SQ+XU\$:MI-O\ M ?
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M:BL;JSL+JTOYHEL[JWGE^,O _P#P49^#_B#XX_M*_#GQ3XC\ >$_AY\$=.^
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M^MSDAR,CI175^4F"-HP>HPO_ ,33&M8'&&C0]/\ EF@P >@PJ_XYZ]ZWH_2
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M /N^BOA#_AD3XV_])!?VI_\ P3?L^?\ SF*/^&1/C;_TD%_:G_\ !-^SY_\
M.8H ^Q/&W@3P9\2?#6I^#/B#X6T'QIX1UN![36O#'B?3+36M!U>SE1HY;/5-
M*OXI[+4+.:-WBGM+N&:WGB=XIHGC=E/._"OX+?"'X&>&4\%_!?X8^ _A-X-B
MGDN8/"7PX\*Z+X+\,6L\KR2S26F@>'K+3])LVFFFFGF^RVD(FGEEFD#2R.[?
M+O\ PR)\;?\ I(+^U/\ ^";]GS_YS%'_  R)\;?^D@O[4_\ X)OV?/\ YS%
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MD%^-(\0:;YPTWQ#H5VX6^T'Q!IZW%RECKFC7-CJMI'<W,5O=QQW$RO\ +?\
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MH\6WOAC5-1U#4ON'_AD3XV_])!?VI_\ P3?L^?\ SF*/^&1/C;_TD%_:G_\
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M-W!#%J?B35_*+K!&RPQV6C:3%)):Z)H]M9Z=;O,T4UU<@'U91110 5P7Q/\
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MHX9'M]0\8ZE:LWD6Y:>R\+6,[:9ICR7,NI:C?_G3110 4444 %%%% !1110
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M+AK@+(J&7TI0I2S3-\1&GBL_X@Q=."4L;G>;3HQQ&+J.7/*CA8.AEV!A/V.
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M$TZ,_P#!6J8:%&=[JW)5E>Z-.BBBM#G ]#WK^,3_ (+K?M82_&?]I:R_9_\
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M?!/BJ[U6WE?29?#>N1ZU:7L]A9ZA-:>B?#S]JG]G_P"*WQ$O_A1\/OB;X?\
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MI/AR'QMX0O;K6;K3!I=SIWB32=0TVZO;*[2XKA]*_;P^&?B_Q[<>!=/UF_\
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M%2"#^TK^VZ<YS_QE1\1AG/4\7( SDG   Z  8 7US.?^A'!>N>9?^F"8WD'
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M_:I^-V6)ZD_\5>!D^P ]J/\ AWA\#2,-XT_:9;C!+?M3?'DECW+8\= 9/4X
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M<7D^FO,\.KVDZE%^:?@=\(O&W[0?Q6^'?P:^'EG!=^,_B3K]CH&D?:C,FG6
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M&K2^%=(GQ8:>DRVEG970O)]2EM4>(VJW3Q@'PG17V=HW[/\ \._AO^SU\/\
M]I+]H\_$>_TCXW>)O$_A_P""/PN^%FI>&?#GB;Q#X>\$-!;>,?BCXF\5>*]*
M\0V&D^'+'5+F#1/"^@VF@7&H>)-19KR[U'2M(59)N&_:9_9Y?X":[X U'0/$
M4_CCX1?&SX=Z)\6_@KX\NM.CTC4M>\&:VHCN-(\3:3;SW=II/C?PAJ0?1?%.
MG6=Y<VGV@6NHV;)::A##$ <#\"O'<OPS^,/P]\:)+)';:9XCLK75EC8J)]"U
MA_[)UF"0#AHS8WDLI4@@O#&<;E7'[8_MD>'8?$?[-WQ0@,:W#Z/IECXGM& W
M%9=!U6SNS*F0<!K(W2L1UBD93P2*_GRGW>3*4.UPC%&'574$J1[A@"/?%?T:
M:A<?\)S^S/>WET?,;Q1\"I[N<L=Q>XO/ C32.Q&,M]I!DR.C#/:O\SOIT9;3
MX9\4_HS^*^#@J6.P?&>#X>QU:G[DZU#*N(^&>(,!"<HI-JGA<SSS#J[TH5ZE
M))QG**_K7Z.F,EFO"/BKP;7DYX:MD6(S&A"7O1IRQ^4YQE>*<4WHIU</@:TK
M+^)34W>2B?HG_P $X/V//V4_CY^Q3^SK\5/B3\+H_B/XIU?P4++6W\=^,O'?
MC#1UU3PKK>J^&)TL_"^M^)KOPOI=F'T97M]+T_1K:QLHC'!;P)&@%?JWX/\
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MF+Q7U[$4<'1_S>?B9:&P^)WQ/L&W;K'XE_$"R8N%#$VGB_68"6"_*&)CRV.
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MT_8SUJTU*2=Q';&ZO=/\=+81.7_=F61HY%A!!8LVQ<E\5#^WM+#/_P $W_\
M@D7)I)!T!/AI\0+:8H%,8\46MAX.MM95]@&V<7\.KB3=R)$E#$R"0U\I:E\?
M?AU\'/V9OB5^S)^SWKWBOQU>?'[Q+X<UCXZ_&7Q3X/@^'D-_X0\%EYO"OPO\
M">"VUSQ+K-KITFH376J^+?$6MZO#)J374VCZ=I0L6:[,7@O]H#P%X_\ V6K+
M]D7]H#5_%/A?1_AW\0[GXG? 'XO>&O#0\>S> [K7H+NV\<_#SQ7X*.N>'[[5
M/!?B0WMQK6DZAH6J)J>AZ^2)[2\T]XUA /M#P-/I>G?\$0Q)XC,8L=2_X*&^
M#SIPF90&AL]4\(SZP\2N,$+I&EZ^9MH.(H[AW&Q7-<3_ ,%SI))/^"@'BJ<N
MK:;+\'_A+-HKQX^SOI3:3JS![<K\K0->?;"I7CJ!QBODC]H?]HCPQXQ^#GP5
M_98^#UEXBLO@1\##XCUUM;\6VUEI?B[XN_%+QE=7=SXF^(WB/0M*O=1T[PYI
M]O%?7>C^#_#::CJM[I>DS3RZEJD]W<+#:^B?$7X[? S]K7PI\$+_ /:6\7?$
MWX=_%SX+^!K+X2^+_%'@?P#IOQ#MOCI\+_#MT]SX1N+9I_%'A5O!7Q2TNTN]
M2T74=6UX:QX<U=;F'6))()H&L" ?1G_!3EK>U_94_P""46E710>([?\ 9>OM
M0N5=PURNC7NE_#D:=O!^=89)8Y1$6^0E)%0?(U?DS$P:*,C_ )YQCH1SL7.,
MU[G^UQ^TQJ7[4WQ5MO&2^'O^$)\!>"_!OAGX6?"#X>+?G4T\#?#+P99FST+2
MKB_V117VLWS//JFO7EO##;2W]R;:UC^QV=L3X-9MNMXFSG,:8Z=LJ>GN#[^N
M#P/P+Q^HREDO#U=*\:.;XRE*6MDZ^7*<$UM>3H2UTVL?Z=_LP,?2I>(?BIEL
MI)5L;P-D>+HQ;BG..7<5SC7Y5\4N2.84I2M=14HWW1:HHIK;L?+@$D#)!(7)
MP6(!!8*,G:""V, C.1_+FY_L[_P?79_CV\['I7PE^%FH_%SQA!X4M-3LO"WA
M^RLY_$'Q \>ZL&B\.?#;X?Z:\9\1^-O$$ZC"6NFV\@ATS3XMU_X@UZXTS0-*
MAN=1U&"%O5/VM/C[:?M!?$_3-2\+V%[H?PG^%_@?PQ\&O@CX=U(*-2TKX7>
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M$#YC*4"G=BO._C=;ZM/^W]\3+2X28ZU<?MCZQ;E"#YQNYOC$%ME'<,5>#9W
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MCRRZAK7A/QAX(T_PEK%W\3-$\%:_=7^N^!Y_#6OZ+>:VMV=)\1'3 'U!O4_
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MM;ZSX-\36NO3'0YEDTO4='N=/:.5>"_:>_:'3X]Z[\/-+\->'+OP1\(/@?\
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MJ%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME_&6&S;@;%SJ22I^WSW"PK9,YN34%_PN93@:,7*Z<L9"*3E.!OT4=:*_BO\
M _Z&MM.P5+!-+;3V]S RI/:SPW,+/%#.BS02++$SP7$<MO,BR(K-#/%+#(!L
MEC="RF*BC_A_N:?EV[B<8R3C)*49)QE&2O&49)QE&2ZQE&4HR6SC*2>C9KZ]
MK^N>*-7O=?\ $NL:AKVMZBT3WNJ:I<O=W<PAACM[>'S'.(K:TMXHK:SLX%BM
M+*VBCMK2"&"-(UR***<I2G)RG*4Y2;E*4I.4I2>KE*4FVVW=MMN[;?4BC1HX
M>E2P^'HTL/AZ%.%*C0H4J="A1I4XJ%.E1HT:=*E2IPC%1A3ITX0BM(Q2"BBB
MD:!1110 5-;7D^FW=IJ5J2MUIMW;:A;,,Y%Q8W$=W#C!!!\V%,$<CM4-!Y!'
MK4SA"I"=.HE*G4A.%2+VE3G&5.<6K.ZE"I.+35FI-/1L4HQG&4)I2A4C*G.+
MM:4)QE"<7?2TH3G%IZ-2:>ES^E3PQK]KXL\->'O%-DP>T\1Z'I>MVY!!Q'J=
ME!=[25)7=&TK1O@\.C"MROBW]A;X@IXK^#?_  BEU<&35OAOJ<NBLKL"S:!J
M32ZEH4R<EC%%OOM/!("I]B5 2-M?:5?Y$\;</5^%.+N(N':\91>5YMC</1<D
MU[3!NM*M@:T6[\T:N"Q&$DI)M-J2O>+2_P WN)\EJ\/<0YSDM523R[,,30IN
M2?OX;VLJF$JIO>-3"UL-)-:-\RZ!1117RYX(4444 %%%% ".D<J/%-&DL,J/
M%-%(H:.6&52DL4BGADDC9D8'(*L0<CBOYN_CM\-+KX0_%GQGX&EC=;"RU274
M/#TQ0HEWX8U=FO\ 1)HL@!EBMI/L$NPL$NK*XC)!0BOZ1:^(OVVOV?KCXL>"
M;?QKX4L?M/C_ , 6EU)'9P(3<^)?"KG[5J6C1*OS3:AI\BOJNDQ#+S.;VRC&
M^[C _M3Z#?C9@O";Q7GDO$6,A@^$/$;#X/A_,<77J*GA<JSW#XGVG#6;8F=2
M2I4L-+%8FODV,KS2C0PV:8>O.I"EAJDH_@OTA. ,1QIP8L?E="5?/.%JE;,\
M)1IQ<JV,R^I24,UP-)1BY3J>QHTL;AZ24G.OA)P@G4K14OP\HI%(89&0.1A@
M58$=0RL RL#P0P!# @@$$!:_WL6RLTU96::::LFFFFTTU9IIM----IH_SA_K
M[M+>JV:W75(**** "BBB@ HHK0TG2=4U_5=-T+0["YU76M8O;?3=*TRSC:6Z
MO[^ZD$5O;0HH)W.[99CA(XU>61EC1F&5>O1PU&MB<36I8?#X:C6Q&(Q%>I"C
M0P^'P]*I7KUZU:K*%*E1H4:56M5JU)PITZ=.=2<HPA)JZ=.I5J4Z-*$ZM:K.
M%*E2IQE4JU:M2<:=.G3IP4IU*DZDX0A"$92E.<8QBW))_8'["?PQE\=_&RS\
M47=NS^'_ (86W_"27<S*/)D\0W*RVGABQRP(>07)N-59%&Y8]-!) <9^X_\
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M/<-C.6CQ#Q+0C2S!*2YX9GQ'*C@:> 4TVY/+,FH8FE52NE76*E%N"O+^O/\
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MY!P017^H$P!4A@&4@@J0"&!&""#P01P0>#TK_/W_ ."E_P"RY-^R7^U]\2O
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M\BQ%L/E>/Q$W*57$8"O"$HY;BJ\FYU:%2D\!6JR=2,L).I43_GMHK[X\<_\
M!/+XQZ#/))X)U?PQX_TX!FB4W?\ PB^M@ G;'+8ZJ[Z:\A4#YK?5F0MQM0<G
MY]O_ -E_]HG39F@N?@UXY=E?8'LM.@U.%R2 #'/IUU=1.K9^5E;#=J_TYX8^
MD!X(\882GC.'_%3@;$PG",WA\9Q%EN2YA14K)1Q&6Y]B,DQV'J)^[.$J-3DF
MG%5)JTG_ "3FWAIX@Y'6E0S/@WB*E*,I1]KA\KQ688:IR_:I8K+:>84*D6K2
MBXR3<7?E5I*/A-%>U^"_V<?CE\0K=+WPG\-]<O\ 36O;[3FU2ZETW2M-@OM,
MNI;'4K2YN=3OK7R+FPO(9K:[@=/-AEC9"F< _67P^_X)R>.M4F@N?B;XPT7P
MGIQD4S:5X9SXBUZ:' +I]OF6UT6P=\E!(/[3V'+^4W KGXV^D1X)>'E/%/BG
MQ*X5PV+P?-&KD^7YG2SS/75C'F^KPR?)'F>-6(E>"C3K_4TG.'/.G&<9O7A_
MPP\0.)YT/['X3SFM0KN+ACL3A)Y?ERA)M>T>.S#ZK0=-6D^:E[=MQ<8QE)<J
M_/C0= USQ5K.G^'/#.D:AK^OZK.MOIVD:5;O=7UW*Q .R)/N11@[I[B4QV]O
M&#+/+'&K,/VQ_91_9+LO@K;CQIXU%EJ_Q1U"U:)/(87.F>"K*YC"SZ=I4Q&R
MZU:X4F+5-810GEAK+3B+8S3W7OOPF^!GPR^"FFO8> ?#D-C>7,21:GXBOG_M
M#Q+K 7)/V_5IE65869BWV&R2TT]#C;:[AN/KJJ68*.I( ]\D>_\ /I]*_P H
MOI.?3=SGQ;P6.X%\.\)F'"OA]BN:CFV/Q<U2XEXLP\9IK#8N&%J3IY-D=5PC
M4JY50Q&(QF814*>:XQ8=3R^?]E>$OT?L#P5B,/Q%Q17PV<\34?WF"P]!2EE.
M2U;?QJ+JQC4Q^/IIM0QE2E3H8:TY82A[22Q$?._BO\1=)^$_P]\3^/=793#H
M6G226%HS!&U/6;C_ $?2-,AR>9+R^>)&P"5@6>4C;$V*O_!OY\%=7\>_%SX]
M_M>^,(I;N72+>7X=>&M2NX9&%[XO\:7-OXI\=:A9W#*$+Z5H]OH.ELJ$M%#K
M\T!VA=M?GM^UEXLL/VB-:T[X:_#'XH^#6O/"6LW%BW@+7KF_\.3^-?%\LYT^
MVE\-^)KFWE\,Z[)'(PTG2M.DO+*X:\N+J2W-PT\1']7_ /P3A^%WPZ^ /[*W
MPP^"_A+Q+X?USQ5H.C-K?Q,_LV]B_M&;XC^)96U?Q?+>Z?+Y.H0QV>IS/HVG
MO<VD!.EZ59)M^0BOZL^@%P!D/A]PCF.=<08W"Y=XC>(,L-5H9%FT*V4YSA^$
MLO3K953P&%S?#9;4S&EFE>O4SBO6R>IFM'V:P4*CI2IS4?S[Z5F>YAC<?E/"
MF!PN*K95PTZN/XBQE&#KX;#\2XRFL/1RG&/#SK_5*^294Z:K0QM+!-8_-ZD:
M:FZ,I1^]Z*:K;O\ /Y^WTIU?Z,'\=!1110!^:WQ;_P""='_!/6?P+^U1X^_:
M5^"?PK^(MO\ &6'X@?$G]HGXS_&+P_H/B#QM%X6LM&NI8H[3X@ZS:/K?@3PE
M\)/ ^F66C> ++POJ6B67@O3?#]OJ]AY6O3ZGJ][_ #6:]XI_::_8K_X-2OA3
MX$U?Q'XV\*_$3]I'Q;X=^!_PRO=8N]0M?'?PR_9X_::^-NM7OA#1KBXF^SZA
MI>JW/P GN;.RLSY4_A6#Q7::3 ELVBQ6\/Z*_MG_ /!4SX-?$G]H3Q'^S9\4
MOV;?V^?%_P"R5\']>TU_B"/A;^Q3\:_''AO]K/XAZ#JD]PO@BYUDZ+I5HW[/
M'@#6]*M;SQ5:K!=P_'37QI^E13'X4Z3K$7Q(]'_;?T7QC_P6R_X)2?'\_ ?X
M$_&'X/\ C'P7\2O#GC[]EOPS^T/X3F^%/Q"^)OCG]GO5O#?C(SW'@/6Q'<^#
M-"\<72^+/ACX.GUS4H9+VY">(K_^QM,FBC4%Z6O;0R?^"Y^GZ5^Q/^Q?^PI\
M=_@586/@+Q!^P9^V!^RKIGPJ'A^VAT]+'X5ZU;W7P3\>_"F)(%C)\$^.?A_J
MT>A^)-"7_1M0M=.T^:2,76G65Q;=C^P3XNU;]I'_ (+7?\%??BSXQG_M*T_9
M&T+]FO\ 8S^!%C=AIH_!'A/7= U_XF?&!M%1_P!U97/COXB:1INI:]=P+'=Z
MA:Z1H-E=3SV>E6,5OYW^WWK]K_P6!^%O[#?[)WP1T+QDFH^,OVF?@3\>?VRK
M+7O!WB+P]<?LL?"+X-V.J>,/B)X)^, US3=.B\*_%S5_&QT?X>>#?A_=2G7M
M=U<:CKUI9S>$-(O];C]4^&^@6W_!./\ X*N?M\_%7XOW,OA3]E?_ (*)>"_@
ME\9_ OQ<NM,U*X\&>$OV@/@KH>J?#[XC?![Q7K.G6-U%H'BKQOHVL67Q"\!0
M:J+6V\86\.MZ+H%WJ7B'2IM*#TMY_/\ X877RT_)E+_@C=XYNO"'[7?_  6=
M_8ETRYG7X7?LU?MH:7\3?@_X<+;M+\!>'?VJ_#>J_$_Q9X&\+PK^ZTGPIIOC
MZR\0:YI6@6H2RTRZ\2ZF+2&".8QK]Y_%CX%?%7PS^W]\(OVV/AWH\?Q(\)-^
MS=XX_9/^,GPXBU33=)\7>&?#VM?$7P[\6_!GQ9^'#:Y=Z=H6O2V7B+0=1\*_
M$7PE>ZOI&I:GH>I^'-=\/RZE?>%I-$U'YC_X)$?L]>/_  ]XZ_X*'_MP_$_P
M;K?P\UG_ (*!_M8ZG\1OAMX)\6:5>Z%XVTC]G+X7Z=<> _@AJ_C?P]J<%MJG
MA7Q-XWTE]9\:3>%M3MX=3T71]:T.#5H;35FO-/L_N3]I']J34/A!\3?@;\!O
M WA;2?$_QB_:(MOBI<?#Q?%^IZ[X=^'MDWPI\)P>)[^+Q;XD\/\ AOQ5J6EQ
M:[<WNFZ':75GHM^=*%W<ZY?6L]IIPLKY%+S/S6\<_LZ?MW23^(/'/B#PC\1/
MVBOACJG[:OQW\4R?LL:U^T#X6M?&US^RC\3/@7H'P\^&\.@ZK\1=>E^%FGWW
MPS^(?_"<^*5^&&M>++9)/#WC&34K?Q)%XHT'2-"@\OTG]@3XU^"OBQ!XE^'_
M .S[XJ\/V7AG]L+_ ()\>,_ GBS5_BWX7^(7C3PW\%/A!^S7H_PG^-^HS^._
M%7CAO%WBB?3K^#4-!\4VVJ)!K_Q;M56^EL=?LIHKB/\ ;F+]JO\ 9_BMKT:K
M\7/A]9:OI%QX&T[5]$@\1QWNHKJ_Q(@OIO EIH-@;:UUCQ5:^-SH^N_\(+J>
MA:1=6WC*#0=:N-#%R-)U-+/S@?\ !0+]D[_A)?%FA/\ %K18M(\&?#+X+?%O
M6OB%)!?GX8'P7^T'K^O^'/A1J6F^/DM'\.:I'XGU'P[=1Q7%E?2V-N]YI]M/
M=K>RW%M:@'Y;_#+]BW]HO4?@UJ6@_$[X0?&CX7?M)>'= ^!_PL\5?M%?#W]H
MKX4_$GP_\9[[X-_$'5/&FC?'S1O@UXTFF\(?$30;[6'N/$/CKP?\?/#7ASXB
MZYX9\9ZK\,K"[U./2[+5K;ZC_:5_9]_:$^)W_!*K2_@+K/PB\ ^+/VBY=$^!
MMKK7P]^&DF@:/\/+37?!OQ6\#^)?$MYX8_X6!XB?2?#^E6WAG0=6N[?26\1Z
MLFG7$Y\.:-J6KVHM;RX^SM>_;:_9-\+^(9_"'B']H#X9:/XOM_&/B;X?R>$[
M[Q%!#XH/C/P8OA:3Q9X?A\/%3K%S?>'K?QOX0O=6%M9RPV>G>(])U&69;"\B
MN3ZQX8^,WPK\9^+]9^'_ (7\>^&M:\;>']'M_$6J>%[+4HGUF/PY=:MJ&@0^
M)+2R?9)J?APZ]I.IZ$^OZ6+W2(M:L+K29KU-0@>W !^,NG_L8_&'2_B!\=_B
MGX7^ &DZ/_:G_!3#P#\<Y?#.HZCX!MM=^-W[&S_ _P"%/@7QG\/-"O+77[^Q
M\/VVB_%[PO+\9_\ A5GBF\\-Z!XPUCX>Z-!>Q1W7B.WNK;Q_XI_\$[_C;J*^
M-]+M_@G<?$3PYKO[-7_!6+PS\+]"N_$G@7^S?A+J?[3GQ)^&'C+]DKX-VL6N
M^+[..W;P=/X6\;^(](UBPANO#7P9U#Q1:Z'X=UVSL;"PGM_WC@_:#^"]W<:Y
M:6?Q&\-7MUX=:!=3MK*[EO+@O<^(-5\)VR:9!:P2R:[)/XIT+6_#4,>A+J3R
M:_I&IZ.BMJ%A=6\7SYX>_;@\$>*OVD].^$_AZ[\#:Y\&M:_9&OOVI]'^/FD>
M/;:_T6[M=*^+%M\,=5\.S6":6FEVUG8R7(O9=9'B2>ZAU"WOM$OM%L;NT9G!
M;'A_[!'P$^+7P7^-G[0FL>+/ACJ7PZ\#?$7X"?L26^EWDFN>$]3LO$'QM^'/
MP]\?^'/CUK>IZ9H/B36;Z3Q;<7FI^!K36O&FKVPE\>KHT-Q_;&JQZ/#<-\,>
M-O\ @G5^UG\1_P!F@?#O5=(T>W^-WAO]D']M+X&_%[Q?J7BW2;G0OVOOBA\1
M/$_A37O@#XVN-5:[O+_<-<\-ZA\2;3Q)X^T[1]>^$OB+Q#/X8T=387>K7B_M
MM?\ [6G[->E^'-3\6ZG\:_A]IGA_0=7\3:%XEO\ 4=>@L3X3U3P5<:9;>,[7
MQA:70BO_  @/",NN:$WB>Y\36NE6F@6VNZ%>:M/:6FM:9-=><:=^VW\&O%WC
M>?P#X.\=>#M,\0^'OVI-0_99\0:7\3+C7O NH>*?'_A[X>#Q_P")O#OP?MKS
M1I6\?>)M-L;W3Y;>WA-IH]YI=AXCU9-4%C::5<:L#M_7SN?GEIO[+/QU\0?M
MDZ=^T1XM_97T_3/A[=_MEZ!\9YM/UWQC\&M8\4Z3X"\7_P#!-I?V9_%6O:QI
M]KKUW866H^%/C'I.G:AXQT[1M=UB_P!9L);/Q'X=3Q%<Z=(L?YX_L\?L4_$K
MX^_L*?LI?%[X _"^PLM2\._LQ^#+/Q1&_C#PG::C^TQXJ\!?MJ? [XV>!I;'
M5)==NK#^V? O@?X4?%.+P=XQ\>:CH.HZ-?\ Q2B\"0WFFZ)=>*#I_P#2AXJ_
M:_\ V4/#6F>*Y_&WQZ^$F@:+X:LK*7Q/<^*/%FCZ9H\>D:[XK_X5Y:WHN=6E
M@L-8T6[\:S)X,FU#3I+[2T\1SQZ#=W$6H3QVS]S\#_&7P0\9>"IG_9_U/P)?
M>!/#'B3Q%X-N;#X>VNFZ9HOAKQ7X>U&2W\3>&[S1-,MK)-#UG3]0D,M_IUS9
M6EUBZ@O6C>"]M[B8 _'GX/\ ['W[07AW]J[X;_&_Q7^SSI%EX4T#]NW]N7XI
M1QGQ?\+]8U[PU\+_ -I7X6^!8? OCY8(]5\O319^,_#.HV_BWPSH-[?^)++7
M9XM8L;/6K*1M5;V']JS]E3]H[XN?$W]J6ST6!=3T[XP^"_V79?V5_C-:^(=+
MTG4_V3?B%\(O&VJZCXYG%O<7L'B72XWO+BR^*6GZOX,M=2'CZ5]5^'/BRVAT
M^TTH:C^PU% 'Y_\ [$WP>\6?"WXC?MWZYXL^%,?P]M_C!^V#X@^*7P]UP#P5
M(_C3X<W_ ,(O@]X/L]49O"VJ:AJ6G2-XN\$>+[UM%\20Z?J,46H6^KM;"?5[
ME8_T HHH#8**** "D)QV)^GXG^E+63KVLZ=X>T;5->U>X6TTK1K"[U/4;IR-
MD%G8V\ES<2$$C<5CC;8HY=]JCDBL<1B*&$P^(Q6)K4\/AL+0K8G$XBM.-.C0
MP^&HU<1B*]:I-QA3I4:%"M5JU)-1A3I3G)I19=.G4K5*=&C"=6K6J4Z5*G3B
MYU*E6K.%.G3A"*<ISJ5*E.$(Q3E*<XQBFVD^,^)WQ3\&_";PY+XF\8ZD+.VW
M&"PL8 L^JZS>[=Z6&EV0=6N)R/FD<LEM;1_OKF>&(;J_*_XE_MK_ !5\87-Q
M;>#Y8OAYH!9T@CTY8;[Q%/"?NR7NL7,<D5O*PY\O2[:V$9.#<3%0Y\-^,GQ9
MU[XQ^-[_ ,6:O)+%8*TMGX9T=G)M]$T-)";>WCCSM%Y=+MNM3N,;[BZD92?)
MBAC3RJO\./I'?3;X\\0,_P TX>\,<\S+@SP]P.(KX+"X[)ZL\NXBXKA0J5*4
MLUQV:TG''Y;E^+<)5<ORG+ZN"G'!RH5LPQ=;%8BIA\-_H-X6?1^X<X:RW!YI
MQ?EV%SWB?$4J>(K8;'0CBLKR:52$9QP5#!3OAL5BZ"FHXK&8J&(@\0JE/"T(
M4:*JUNMO_B!X]U2=KG4O'/C"^N'8N\USXFUEW9B<D_\ 'Z%!)_NJ .@ & .G
M\,?''XP>#YDFT'XC>*H$0@FSOM4FUG3I-O19;#6#?6S+@X.V-&QT<'FO*Z*_
MC;!<=\<9;CXYKE_&O&&"S.%3VL<?AN*N)*6+55._.ZZSV=2;NVVJKK0E=J=.
M<6XG[MB.'.'<7AI8/%</Y%B,)*/(\-6R7*9T.7:RIO+8J-NG(Z;7243]3?@G
M^W'I^NWEEX:^+MG8Z!?W+I;VGC'3A)%H%Q.Q5(TUNSD>1]%>9R1]MAEFTU6*
MB9;*/+U^A\<J2HDD;*\<BAXW1E=)$8!E='4E65U(964D,I# D$$_S1$ @@@$
M$8((!!!Z@CN"."#Q7Z>_L/?'.\U+S/@YXIOGNI]/LIM0\#WMU*TEQ)IUJ-VH
M>'7D<L\O]G1-]MTS<2R6*W-MGRK6!5_U'^AY],WB#BCB++/"?Q<S"&:9AG#6
M$X/XTKQHT,=BLRA3E*CP_P 12I4\/A\97Q].E4AE.;JCAL54QE)8#,88BIBL
M)C)?R#XY>!&69-E>+XTX(PT\'A,#^^SW(*<JE7#T,+*:C/,\K4Y5:M"EAYSC
M+'8%U:M&GAY_6<+*E"CB*,?TDK\>/^"S_P"QK/\ M.?LS3?$#P5I)O\ XN_L
M^KJOC;PY;VD(?4/$W@N6VB?Q_P"$(@B&:YN9M-L+?Q#HEL&9I=8T.&QMX_,U
M24G]AZ0C((]?;/Z5_J>?Q\?Y?R.LB+(A#(ZAU8=&5@""/J"#3J_7G_@L#^PC
M-^R7\>)OB/X#T=H/@)\<=5U+6O#:V<.+#P+X]F9]1\3^ 9=BA+2QNW>?Q'X0
M1Q'&VF3:AI%OO_L!V;\AJ "BBB@ HHHH **** "BBB@!59D970X92&4_0\@^
MQ&01W!([UTUO<)<(KJ>3D%?[K X*GW';.,C!ZYKF*GM[E[60/UB.!(H&3Z!P
M.FY?S89!K\N\4.!5Q?E,<3@816?95"I4P+]V/UW#RM.OEU2;LDZDH^UPLYRY
M:>)BXN4(8J?+_9'T-OI)S\!^.:F4\1XBK+PTXTKX7#<207/5609E!K#Y=Q;A
MZ$5.;C@XU5@\\I4(^TQ633=:,*F)RN@JG4T4R.1)%5D8,K $,,?,"!R/\.H/
M! -/K^,ZE.I1J5*-:G.E6I3G2JTJD90J4ZE.4H3IU(2490G"491E"48RC)-2
M2:/^@C"8O"9AA,+C\!BL/C<#C<-0QF"QN$K4L3A<7A,51IXC#8G#8BC.I1KT
M*]"M2K4:M*I.G4IU(3A)J6A1114'0%%%% !1110 4444 %=-X,\8^(?A_P"*
M=&\9^%+UM/U[0;H7-G*<M!.C#9=6%]""!<:??P%[6\MVXDAD8J5D5'7F:*PQ
M6%PV-PV(P>,HTL3A,71JX;%8>O3C5HU\/7IRI5J56G*\9TZE.<XRB]&GO%I2
MCEB,/0Q="OA<51IXC#8FC4H8BA6A&I2K4:L)TZE*I"2:E"<)RC)-;.Z::37]
M"/P4^,WACXW>#8/$^@NEIJ5J(;3Q1X=DE#WOAW6&3=);R#AYM.N<&?2]0"^7
M=VQ 8K<13Q)Z_7\Y_P ,OB=XN^$?BRS\8>#;X6U_;J+>^L+@N^EZ[ICN&GTK
M5[9&'GVLV"T4HQ<6<X2ZM9$E3YOW!^"7Q]\$?'+0OMWA^<:;XCL84;Q%X/O9
MHSJND2GY7GMP-O\ :>CO(&^S:G;KM((BNHK:X!B/^<WC-X)YCP#C,1G>1T*^
M.X-Q5:4Z=6*G7KY#.M4O' 9BXQE4>%C*?)@<QG'V=6')A\5.EBH1GB?XE\3O
M"S&\'8JKFF54J^,X8Q%5RI5DG5K91*K)\N#Q[BG)45)\F$QLE[.I3Y*6(E3Q
M,5+$>WT445_/Y^/!1110 4444 %%%% "Y_S_ )^@_*@$C@$CZ$C'OD<]O?VY
MI**+?Y:ZV6FU[VT5O^ K#N[I]K?A:WW67Z6/G&/'PB^-C0C%O\._C_?M+#G"
M6GASXU6%D#-&.0EM:_$C0[4S $!9O$VD. ?,O_F^CSP2,=_?C^OY\\?6N$^)
M7@.P^)?@G7/!U_</8/J,$5QI&L0\7?A_Q'ID\>H^'?$-DX!:.ZT?5[:TO$*<
MR1)+ ?DF<'&^#GCN_P#'WA!)/$%LEAX\\+:C=^#/B+HT8(_L_P 9:$4@U"6&
M/:K#3M<@:W\0:/(%"3:;J<!C)V-C],XA_P",NX3R[C*G^\SSAV.6\)<;12<J
MV*PJH_5N"^+*J5YR>-R_!2X1SG$RYG/-L@R3$5Y^US.,ZGRF6+^Q,XQ&12]W
M+\U^M9SD-W[E*JZJJY]D\7:,4J&)Q$<ZP-))6P>8YC&E!0P<HQ]3K\_/VS?V
MGX? >E:C\+/ FHAO&NJ6IM_%.KV<N6\)Z7>1[6TRWFC;]WXDU2%]I*L)-'L'
M>X?;=3P".?\ :>_;&TWP+%J7@/X6:A::IXUVR6FM>*(#%=:3X.R&2:&QE&^#
M4O$:9*@1[[/2)"))VFO$6WC_ "U^%'PL^(W[2GQA\'_";X>65SXA\??$?Q"-
M/TY[MY[A89+AWO-=\5>([PB62+2M&L$O-:UW4)BQBL[64;FFDCC?^M/H@_10
MS#Q!X@R_C?CS+ZV%X/R>MA\PPV68JC.G5S>K!T\1A'B:5:$90PU9PA6H8>K"
M-2O22Q=>E2PJPL,9T>+''&"\#^"Z7$F;QH5...(\-7AX;\)XJ,9UY5+>SEQQ
MG^"J6G1X?R.I4C6RS"XNE!\0YW3P&&C3EEV$S!U?UK_X(;_L<S?'7]H2?]HS
MQGI;2_#/]GJ_MKG0OM4+&S\1_&&[M_.\/VMN6 2XM_ VG2'Q-?%"YM]7N/"R
MR@^9(!_7EXQ^$?PZ\=2I>>(O"^GS:O'N^S>(+#SM&\26;M@B2T\0:1)9:M#(
MC*KIB[*!ER489!X+]E?]G#P-^RA\"O 7P-\ PA]+\(:6!JFLRPQQ:AXK\4W[
M?;/$OBS53&/GO]=U62>[*LT@L[4VNG0/]ELH$7Z&K_:K,<@R/-\MCD^:Y-E>
M995"G2IPR['X#"8S!4XT(1IT'2H5Z%2%"=&$(1HU<.\-7H<D'1Q%*<5,_P G
M/[:SEYGBLZ_M7,%F^-Q.)QF,S-8W$QQV+Q6-KUL3C*^)Q,:RJUZF*KUZU7$>
MV=6%:56?M*4HOD7S[_P@?Q>\&$R> /B9'XLTV/#)X5^+5JVJ2!%&#!9^.-%2
MVUNWRHQ$VJ6.M;7PTC,I8%P^.%WX980?%KX?>*?A^%=4?Q'90GQIX&<%1B8^
M(?#\,MUIL3G)/]LZ18"$8$DG!->_X'I[_P"?\_RI"JL"I (8%2" 001@@@\$
M8XP01C(Z$U\E_J/CLI][@SBW.L@A'6&2YO*?&/##6MJ-/+\^Q<LZRNCM&*R7
MBNDJ,;*EA;1C!>A_;U#&:9YD^ S%OXL=@DLCS;I[\L3EU%8#%35KOZ]DLG-W
M4ZUI2D\'P[XJ\.>+=/CU7POKVD^(M-E *7NC7]KJ$'.?E=[6641R#!#1R;)%
M8%752#6^.1US7CGB+X%_#K7-1?7;+2[GP;XF9_,_X2GP'J%UX1UUI"/F>YGT
MAHK74L]7CU6SO8V(4LAR<X0TCX^^"<'1O$7ASXO:-$"!I?B^!/!WC)8U)V1V
M_B71K>XT'4I]@VO)J>BV!D9=SW*G<:%Q+Q?DGN\3\'5<QPT-)YYP#7J9]1LK
M7JXGA;,GEG%>$37OSAE]7B.$+N--5E%.8LKR;'.^59W#"U97:P'$=..75+ZV
MITLXPJQ>35V]HO$PRIOW>9PO[OT!CZ_F?\:   !UQZG)^O->!P_M!>&=+D%G
M\1=!\9?#'5 F[[/XG\/WM[I=VR@B0:5XB\.1:OHNHJIR<+<07!4;S;)R!:_X
M:2^"O_0\1?\ @E\1_P#RFK:'BCX<RC^]XUX<P-5-QJ83-<RI9+F.'J1TE2Q>
M5YW2RC,\'5B])4\3@*4MG&56#524RX3XG37)D&:XB#5X5L%A)X_"U8O:=#%Y
M?/&X2O!])T<3-=&H2O!>YT5X;_PTE\%?^AWA_P#!+XC_ /E-1_PTE\%<_P#(
M[P_3^Q?$>/\ TS9_6K_XBAX;?]%_P9_XD^2__-I/^JG%/_1-Y]M?_D48_P#^
M9]O,]RQC_P#63_.OA/\ :;_9=\>?';]H+]FGXA:5XA\,Z)\.OA/X2_:4\(?$
M"TFOM?L/'VIVG[0'PZT_X?1WW@6\T[3KK2-.U#PO%9RZLDVK2-]KN)(88!9&
M W,GO7_#27P5_P"AWA_\$OB/_P"4U)_PTE\%?^AWB_\ !+XC_P#E-1_Q%#PV
M_P"B_P"#/_$GR7_YM#_53BG_ *)O/NG_ #*,?U_[E_N[GYC?"W_@G;^T7\/?
MAG\-/"1UO]CZS\;?#/Q=\$O#.O\ Q*\"_"7QIX/\8_M"? #X.Z9XNT6RT?XE
M>*WU[6/%/@#QE*/$MMXKM--^'&K-X>L_$L?C#3[+5=/\,_$35--TKS3P;_P2
M0^-WAS]G#QS\!+SXP?"627Q;^Q)^S1^S;:^(-.\,>,X;33OB%^RA\7OBA\1_
M OB%M)N=5F>7P-XXT[X@6NF^+K%;Y=?T"[TVY;19M4@NU>/]A/\ AI+X*_\
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MIM#T#Q#\.OAEX&B\/^(VUBRM$N=:M9?AZ^H27VFC[#-#J<=LL,3V3377I/\
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MB^TH5J-*<7Y2A$^*J4ZE*3A5IU*4XZ2A5IU*4XOM*%2%.47ZQ1%12LI09?\
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M$U+4-&UBTET_5M)O;G3M3L9U*36E]:2M#<0N&&2%=24;I(A61<JZDT:_8?\
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M&XTK6M/>2UNXB5)BN8I[>'_2RKXM_;5_84^"7[</P^'A/XF::^D^*]&AN7\
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M&V.$_0JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC&,8QC&,8QC&,8Q2C&*22^1;;;;;;;;;;;;;;;;;;;;;;;;;;;;;>K****H
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M:?T?XL^,=0T/XM7GQ<FM/V]_VUOV=?A[\#)_"OP[TK0_&GP^\ ?L0^*?CO\
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MJ_P[\7?%&\4JQN/B3\0/$-_"74#/_$I\-S^%]%*%@6\N33I ,E267(/Z[44
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MX)U>!Q+'J&B^'[YIKOQ1K%G*B/8:[XG"16D@6ZL/#^GWL45TG[B@8KWC\O\
(Z_KTZ=D?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" *4!($# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **:6(.  3\N?F VJ2<L1C., [< [FX.T L$#$J"%(R2 ""N ">2&
M4%00,C*]P.F#2EMNUYK5_DP'T4PR* "3QG&01C..!U!8GH% +9_AZ4Y3NSQC
M!Q^@/3J.".& /MC!,QW^*3\FK+\D M%%%6 4444 %%-+8./;)/8=>O<< \D
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M$?\ \]F@#O=_L?\ OE__ (BC?['_ +Y?_P"(K@O[-^*G_0Y?#_\ \-IXC_\
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MP_\ _!5XC_\ FKH _3W?['_OE_\ XBC?['_OE_\ XBOS"_X;6^*G_0 ^'_\
MX*O$?_S5T?\ #:WQ4_Z 'P__ /!5XC_^:N@#]/=_L?\ OE__ (BC?['_ +Y?
M_P"(K\PO^&UOBI_T /A__P""KQ'_ /-71_PVM\5/^@!\/_\ P5>(_P#YJZ /
MT]W^Q_[Y?_XBC?['_OE__B*_,+_AM;XJ?] #X?\ _@J\1_\ S5T?\-K?%3_H
M ?#_ /\ !5XC_P#FKH _3PR ;L@X52S8!)"X)R4*AL':0NT-N.X8^6EWYS@'
M@D'A^"#@_P !Z]0?XE(8?*P)_, _MJ_%$D;_  _X!*@.<+I?B $$#AE+^)Y
M& S@E77D$H<<_=6B7GQ'\1V^HZCIWB'P5I5C#XF\8Z):65_X'U[6+U+?PQXL
MUKPS#-=:E#\1M'BNIKJ/2%NG9-.MA&9O)Q)Y?FR 'JN_V/\ WR__ ,11O]C_
M -\O_P#$5P7]F_%3_H<OA_\ ^&T\1_\ SV:/[-^*G_0Y?#__ ,-IXC_^>S0!
MWN_V/_?+_P#Q%&_V/_?+_P#Q%<%_9OQ4_P"AR^'_ /X;3Q'_ //9H_LWXJ?]
M#E\/_P#PVGB/_P">S0!WN_V/_?+_ /Q%&_V/_?+_ /Q%<%_9OQ4_Z'+X?_\
MAM/$?_SV:/[-^*G_ $.7P_\ _#:>(_\ Y[- '>[_ &/_ 'R__P 11O\ 8_\
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M?_XBC?['_OE__B*_,+_AM;XJ?] #X?\ _@J\1_\ S5T?\-K?%3_H ?#_ /\
M!5XC_P#FKH _3W?['_OE_P#XBC?['_OE_P#XBOS"_P"&UOBI_P! #X?_ /@J
M\1__ #5T?\-K?%3_ * 'P_\ _!5XC_\ FKH _3W?['_OE_\ XBC?['_OE_\
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M&E$3N&A9(2DDCPJ"N 2P7<6VA\JS$2K'&GEX,L<LJR+,(Y8T"Q99GW/;K/\
ME7X-\;_$OQUI6@_LPZ=XS\=?\)CH/QZ^..K?%[QN/%FO#QOIWP(^%'QHU;4=
M#T^Q\63ZHVJ6VM?$M-1\'_#WPVRZO UEX1;QO'#<6$NC2VLGD'A[XH_M ^-?
MAAX7_:#3PY^T3IGQ1^)GCWPKK'PRUR[^/7P(\(?LU-X2\2^-K2R\*?!Z'X5Z
MC^TI:PZZOB#P/<)H&H:GKOPGU'XM:GXQO9KK2;F"_6!+  _;/(P'8E48AO,
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M\78(_B!J_P#:VM^(],MX]7E\0>;?7M[J(!^^?Q*;=X:L#@#'CWX5C"L&&/\
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MX =P6TNO$$NIZK=*%(5A]ICGV!6W*26/Y;_\%*O^"D_[;_[:F@?"WX1?M?\
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M#EM"\4W-Q:LFX:.TDTVN573NA2=US;/R7R/[*OVJOVJ/@C^QQ\&?$OQ\^/\
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MM7&EZ2EY:NNEV"P?I[_PQ3\5/^@_\/\ _P &OB/_ .92C_ABGXJ?]!_X?_\
M@U\1_P#S*4 ?F?X%_9N^"WPZNM9O?#W@V6YN==T >$;Q_&'BKQE\1DMO!4C,
M]QX!T*/XB^(/%2>%OA].[JY\$>%AHOAMC;V0N-/N4M(4$'P]_9I^#'POUFQ\
M0^$?"^HKK.C:5>Z'X:O?$WC;QYX]7P5HNI>4+_0_A_9^.O$_B.Q^'>@W"PQQ
MOH?@:U\/:;]FBM+/[.;*V6W;]-_^&*?BI_T'_A__ .#7Q'_\RE'_  Q3\5/^
M@_\ #_\ \&OB/_YE* /SR\&_!KX8_#_QK\2_B)X1\)6.C^,OC#JNCZO\2->A
MN-2FN_%%UH%@-)TA;A;B^E@L;:VT_>'L])AT^RN-0N+S5Y[5]0OKV:XXWP]^
MR[\#/"WBZU\;:-X*D35],U36-=T#3M0\5^-]:\%>$==\0^>^N:YX%^&NK^)+
MWX<^ ]7U*6ZNVGU#P;X4T.X,=[?P!_+O9PWZ?_\ #%/Q4_Z#_P /_P#P:^(_
M_F4H_P"&*?BI_P!!_P"'_P#X-?$?_P RE 'Y@:_\-?$/@;X8ZSX$_9Q\-^![
M/5O%&N^*+NZN?B-XJ\5-I^E7_P 1M1\0^(/%OC60OH/CC5_&^KMXNUDZK#X%
MO=4\):5K)OY-*L/$_A?3=/LX+?I_@3\'/"7[/GPC\ _!_P #1-'X?\"Z#!I5
MO=S0VL%[JUY*\E]K&M:I%:Q0Q)J>N:U<W6KZN@C4"^N+B%,0K&5_1G_ABGXI
MD8;7OA^5Y!4ZKXB*NCE"Z/&_A1XG!V*49D+1NH=6X(*?\,4?%3@?\)!\/R %
M _XFGB$'A1N)">$TC&6W%0D:*JE5(9@TC@'R .C<D\$\G(!+ D+P,+N)VKSM
M!QDXK]O_  ;_ ,C'\6?^R@:;_P"JK^&E?G]_PQ7\45.&\0>  "%&1JGB(G+.
MH PWA9 20&V98!G 0E=VX?>$%CX^T37O&5[HFA^$-7TWQ/K]CKL$NJ^,=;T&
M^M6@\(>%O#<]I+96O@+Q!"ZBX\/2W,-RM\IEAN45K:)HR7 )?B+\'OAU\6+W
MX<W_ ,0/#J>(Y_A-\0]'^*_@&.XU+6;.ST7X@^'M.UC3-"\1SZ?IFHV-CKDV
MCPZ[?W.FV6OV^J:99ZH++6H+*/6-+TR_L^YU/2K75].O]*OFN?L6I6=S87:V
M=[>Z9=?9[J*2&0VNI:9<6FJ6-V$D9H;ZQO;>\MYB+BVFAG6*2/DO[2^*G_0F
M_#__ ,.7XC_^=-1_:7Q4_P"A-^'_ /X<OQ'_ /.FH \QU+]DOX!:O\"/!W[-
M5]X$'_"G?AYI7@_2? &@6/B7QCI.O^!T\ 06MMX-U7PC\1=+\0VGQ(\.^+/#
MT-JBZ?XXTGQ;:>-$D>>[?Q ]_=WUW=Y_AW]C7]FSPW\-/'WPDMOAC8:UX*^*
MVHSZU\45\;ZYXI^(_BWXDZ_,ULUOXD\>_$GX@Z[XG^)'B[Q)I L=-C\.>(=>
M\67^M^&H=*TB+0M0L(])TQ;3U[^TOBI_T)OP_P#_  Y?B/\ ^=-1_:7Q4_Z$
MWX?_ /AR_$?_ ,Z:@#Y]TO\ 8+_9:TSPEKO@V;X?:WXDL?%?COX;_$KQAKOC
MSXJ_&+XC?$+QIXP^#_B;2O&'PNN_&GQ4\>_$#Q)\3?%^C^!-?T:QN/#?A3Q-
MXNU7PKIUG]LTB+1O[(U35;&]Z_Q!^R+\ /%(^):Z]X)O-1'QA^*7PT^,WQ*\
MWQM\04/BOXA?![_A _\ A7&I7Q@\5PF+1O#)^&?@IH?!EG]G\$:B^D2-K/AS
M4AJVLC4/4_[2^*G_ $)OP_\ _#E^(_\ YTU']I?%3_H3?A__ .'+\1__ #IJ
M /._B1^RS\#?BWJ_Q$U_Q_X,?7-:^*_P1OOV<?'FIQ>*/&FAWNK_  5U34=>
MU;5/ UI/X<\2:._A^UU74/$FIR:MJWAPZ3XAU2V-E8ZAJUS:Z5I$=A@?%;]C
M/]G;XTR^'+GQYX*U=KSPQX27X?V6H>#?B/\ %'X7ZIJWP\6:TN&^''C35OA?
MXU\':K\0_AK-=64-W=?#OQ[>^)/!E[=O<75[H=Q<7$TC>Q_VE\5/^A-^'_\
MX<OQ'_\ .FH_M+XJ?]";\/\ _P .7XC_ /G34 >)^//V)OV;/B)JW@W6M8\!
MZIX>OO O@2U^%>B+\*_B-\4/@C87GPIL;J"\T_X5>+](^#/C7P%I/C[X7:9-
M#<1Z3\-_'%CXA\#Z79:KK^FV'A^#3_$.O6VHVO@+^QE^S=^S)J,VJ? _X;P^
M!;J7P-I'PT1+?Q/XUUVQL? .@>,/''C[1O"FD:7XJ\2Z[IFAZ1IOB[XD>,=5
MMHM%L]/D\K4K32Y99=)T71K&Q]B_M+XJ?]";\/\ _P .7XC_ /G34?VE\5/^
MA-^'_P#X<OQ'_P#.FH C^):[?#>GC))/CWX5$L>K$_%'P9DGM]  %4850% %
M? 7[:O\ R5/0/^Q TO\ ]23Q97W+K]I\2/$=OIVF7_ASP1I=E%XF\'ZS>7MG
MX[UW5;J.U\-^+=$\2W$=II\_PXTB*[N)X-'E@2.34;14:59#(^TQGQ']H3]G
MKQI\6_&>F>)/#FI^&+*PLO#-GHDD6N7FKVEXUU;:OK=])(D5EH>HQ&W,>I0K
M&[3J[NDA\H)L>0 _,FN>\6^%M#\<^%O$7@OQ/:3:AX;\6:%K'AK7K"#4M5TB
M:[T;7K&33M4MH=4T.^TW5["2>TE9%NM/O[:XB<)-%(EQ#;S0_</_  Q3\5/^
M@_\ #_\ \&OB/_YE*/\ ABGXJ?\ 0?\ A_\ ^#7Q'_\ ,I0!\6Z+I&F>&]&T
MGP[H%E#I6AZ#I>GZ+H^G6H"V^FZ9I5K!8V%K9Q_ZF);>TMT@W>2SOR[$N2S>
M<7GP-^%NH:=\8M*NO#+O8_'[[:OQ91=?\3K<^*4OO!EE\/IP-0.M-J&C!O!^
MF6.B"#1+K3[%8%O)$LDGOYI1^C/_  Q3\5/^@_\ #_\ \&OB/_YE*/\ ABGX
MJ?\ 0?\ A_\ ^#7Q'_\ ,I0!^9/BC]FKX.>,-1\.ZOJWAS6;'4O#'A6#P)87
M'@_Q]\1/A_\ VAX&M9X9H/!7BQ? OBSPZ?'?A*-HI67PWXX?Q%HT4]_JT]M9
M0-JNH"XQ_P#ADKX P^$O!'@K2_!.H>&=(^&KZX?A_>^"O'OQ&\"^+?!UMXGN
M[C4/$6F^'O'_ (,\7:#X[TK1=7O;C?<Z%9^)(-%-M;65BVG26EE9QP?J=_PQ
M3\5/^@_\/_\ P:^(_P#YE*/^&*?BI_T'_A__ .#7Q'_\RE 'YBZE^S)\$M3\
M(>&/!)\'W>DZ3X,U?5O$/AC4_"OC'QQX-\;:-X@\137UQXFUVS^)'A3Q+H_Q
M"76O%<VIZE<>+M:?Q.VM>+;N]NKKQ)J.J2WE^UYZ/\/_ (=^"OA;X9L?!W@#
MP[9>&?#MA+=W,=C9&>YFNM2O[C[7J&MZKJ.J2ZAJ>K^(-3NVEO-6U_4[R[UC
M5[Z:6\U*]NII9S+]Y_\ #%/Q4_Z#_P /_P#P:^(__F4H_P"&*?BI_P!!_P"'
M_P#X-?$?_P RE 'P1X%^''@KX:6GB*R\$:''H5OXL\8>)?'WB)4OM5U*75?&
M'C&_.I^)=;N;K6;_ %*\,^HWC?N[=+A++3[6.WL;"VM[2UAA'<'MQ@ 8'T'"
MC/? P,]\9KZ__P"&*?BI_P!!_P"'_P#X-?$?_P RE'_#%/Q4_P"@_P##_P#\
M&OB/_P"92@#X^/4_[C_RK]P?AI_R+FI?]E ^+/\ ZM3QE7Y^-^Q5\4P0/^$@
M^'V65U_Y"WB$-DJ2@53X5&XL5/&0 JLV>,'[JT.S^)'ARWU'3M/\.^"=4L9O
M$_C'6[.]O?'6OZ1>/;>*/%FM>)H(KO38?AQJ\=I<6L6KI:RHFHW2NT)E#)YG
ME1@'JLD>\$$C##:P*Y#*3R&!.&&"0 P*?,=R.#BO,O!_P:^'?@+QS\4OB7X6
MT :?XY^-6J>&M8^)WB.XU37M5O/$][X,\.VWA+PHGDZMJU]8Z)IVA^'[<V=G
MHOAVTTG1ENKB]U06 U'4-1N+O1_M+XJ?]";\/_\ PY?B/_YTU']I?%3_ *$W
MX?\ _AR_$?\ \Z:@#-\=_!GX>?$W7_A?XG\<:')KNM?!CQPWQ(^&MX^L:Y81
M^'?&S>%_$G@P:]+I^EZE8Z5KLT/ASQ=X@L;:T\0V.J:;;S7D6HQV(U/3].O;
M7@/$?[(W[/?B^R^/5AXE^'EMJ\'[36I>%M8^-3W.O^+5N_%6K^!M \.^'/!>
MKZ9?1>(([WP)J_A&R\)^';SPOJGP]G\*7WA[Q!I-GXLT>>R\61#7:]1_M+XJ
M?]";\/\ _P .7XC_ /G34?VE\5/^A-^'_P#X<OQ'_P#.FH ^>?"/[ W[*O@W
MQ!XI\6P?#G4O%_BGQY\,=9^#'Q!\2_%WXE?%;XYZ_P#$/X6:]?0ZAJ'@GX@Z
MQ\:/''CZ_P#'.C)-;PP:6GBJ?5YM!TK[1H&A3:;X?O;S2Y];X8_L1_LV_"6_
MN=2\,^"=<UV[E\%W_P -K)OBQ\4/BW\>(O#7PWU=;--:^'7@6V^./CSXB6WP
M]\ Z[%INE0Z]X+\#0^'O#6MP:5I4.J:9>)I6EBR]P_M+XJ?]";\/_P#PY?B/
M_P"=-1_:7Q4_Z$WX?_\ AR_$?_SIJ /%/@Y^Q3^SA\!O$\'C/X=>!]6A\3Z;
MX>O/!GA?5_&?Q)^*OQ4F^'G@:_O(+Z\\"?">+XK>-_&T'PC\$74]GIS7?@[X
M8Q>$O#-S_9FEQR:2;?2M,M[/U+Q1\#_ACXS^)WP[^,GB;PTFJ?$GX2Z)\0/#
MWPX\2R:IKEM)X1T[XI6>B:?X\.EZ99:G:Z*=1\0V/AW2+.;6KW3;O6;&S@GM
M-)O]/MM0U&*[V?[2^*G_ $)OP_\ _#E^(_\ YTU']I?%3_H3?A__ .'+\1__
M #IJ *7P;^#GPV_9^^&/@_X-_"#PQ;^#/AMX"TPZ/X4\-6U_J^J1Z98/=7%]
M,KZGK^H:MK>I75U?7EW?7NH:KJ5]J%]>W-Q=WEU/<322-Z;7G_\ :7Q4_P"A
M-^'_ /X<OQ'_ /.FH_M+XJ?]";\/_P#PY?B/_P"=-0 GC/\ Y&/X2_\ 90=2
M_P#55?$VOQ '0?\  O\ T-J_:Z:Q\>ZWXA\%W>N:'X1T?3?#'B"]UZXETGQA
MK6OW]R)_!_BKPS%;06-WX#\.P ?:/$4-Q-.VH$QQ6[J()&D4K\(+^Q5\4F&5
M\0> " 2.=5\19SDD@[?"S+E22K!68 @C=Z 'P_XM\+:'XY\+>(O!?B>TFU#P
MWXLT+6/#6O6$&I:KI$UWHVO6,FG:I;0ZIH=]INKV$D]I*R+=:??VUQ$X2:*1
M+B&WFAOZ+I&F>&]&TGP[H%E#I6AZ#I>GZ+H^G6H"V^FZ9I5K!8V%K9Q_ZF);
M>TMT@W>2SOR[$N2S?:7_  Q3\5/^@_\ #_\ \&OB/_YE*/\ ABGXJ?\ 0?\
MA_\ ^#7Q'_\ ,I0!^<UY\#?A;J&G?&+2KKPR[V/Q^^VK\6477_$ZW/BE+[P9
M9?#Z<#4#K3:AHP;P?IECH@@T2ZT^Q6!;R1+))[^:487BC]FKX.>,-1\.ZOJW
MAS6;'4O#'A6#P)87'@_Q]\1/A_\ VAX&M9X9H/!7BQ? OBSPZ?'?A*-HI67P
MWXX?Q%HT4]_JT]M90-JNH"X_3;_ABGXJ?]!_X?\ _@U\1_\ S*4?\,4_%3_H
M/_#_ /\ !KXC_P#F4H _+'_ADKX P^$O!'@K2_!.H>&=(^&KZX?A_>^"O'OQ
M&\"^+?!UMXGN[C4/$6F^'O'_ (,\7:#X[TK1=7O;C?<Z%9^)(-%-M;65BVG2
M6EE9QP:FI?LR?!+4_"'ACP2?!]WI.D^#-7U;Q#X8U/PKXQ\<>#?&VC>(/$4U
M]<>)M=L_B1X4\2Z/\0EUKQ7-J>I7'B[6G\3MK7BV[O;JZ\2:CJDMY?M>?IU_
MPQ3\5/\ H/\ P_\ _!KXC_\ F4H_X8I^*G_0?^'_ /X-?$?_ ,RE 'P9\/\
MX=^"OA;X9L?!W@#P[9>&?#MA+=W,=C9&>YFNM2O[C[7J&MZKJ.J2ZAJ>K^(-
M3NVEO-6U_4[R[UC5[Z:6\U*]NII9S+P=O^S?\%;7^RO(\#6J_P!B_&+6?V@+
M 2ZWXJND_P"%O^((=9AU;QI?+=Z]/_:EVZZ]J7]G:?J1N='T<-:?V9I]L=-T
M]K7]+_\ ABGXJ?\ 0?\ A_\ ^#7Q'_\ ,I1_PQ3\5/\ H/\ P_\ _!KXC_\
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M]]2U_6]0-P8;2!0T<44%O:V]Q=ZA?W=P]O9:?IEA;7&H:C?W5K8Z?:W5Y/%
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M9-2OK&RN?U!2Y9T+>4<,_P"Z^<$R(Q(61MH(CC8 M\Q!"E=P5B57^&?]I?\
MX)7?M+_LF_"7P_\ '#7KSPUX@TNVELO^$OM/!U[J=QJWP]O+Z2(65YJ[W6EZ
M;I]S8Q2_\2^75[266TL=1N;>-HOLS/J(_>;_ ()+?\%'(?VFO!]M\$_BWJ<0
M^._@[3]VFZO=2QQGXF^$],ABABU6%WD#7/BW1XE'_"26XYO[-4UZP%R@UF/2
M?BN!?$C/L3G,N%_$/+*>0<0UZ-+&9+RX:K@,)FU&I17/02Q4ZC=6-=\T98>K
M)4I<V"Q'^TPYI_N'T@/HQ^'N5\#R\8?HU\5XKQ$\-,AQ5?)^-H5<QI9OFF0X
MW"XB.#>;RJ8?+\!B:F5K$2A0S%/+:=+#3JX7-,!B,5D6/IXG#?ML)P<<(0RL
M0"S %DY; *?=&02>IZXJPC!AQCC X.1T!]!V(Z9X[YR!GAAEBZDLJY1?+(*G
M.TMDA3R!EEV_*,[=R ,;5N,*^&W*9"4 Z*NQ!M' XR">_7K7[CJ[-)))>_[W
M-:;2O"-DKJ-VW)VOLKZV_A!<RY/MJ7-&I**LJ=2*YG%IMM*S4.6\FJB;52<&
MF6****"PHHHH **** "BBB@ HHHH **** $)QCWX'U/0=#QU)/8#H:_DT_X.
MI/VK=1\%?!GX)?LB>&=2GM9OC5K.H_$[XG6]E+)'=7W@'X9W=E#X4\.SB-3Y
MUCXE^(6I6>H-"Q$DMUX,MXK<J9)98_ZR6'.X'! Y)!/ #@>V07S[]/>OX0_^
M"\P'Q(_X+;_LN?#?Q+OD\-)H?[(_@X02$&V;1_&?QW\17FO$(P"%YDO9(  2
M'DA0LW(1.W 1C+$>\K\E*M.*Z<T()QNK.^K?SL^AE6?N+SG!?B_\C^GO_@D%
M^Q'HG[#G[#OPH^'LNE6]I\4O'6C:?\4_CCJP@,6I:C\1_&6F6%]>:-<7!8W7
MV#P'I TSP'H-N9O*@T_0!=^6MU?WAD_0[QY\0/!/PG\&^)/B#\2?%>@^"/ G
M@_2;K7_%7C'Q5J=EH?A_0](LU'VK4=5U2]DM[*U1&:,8E>(SR2K#:I--B)NS
M0$ @ ?>8@ 8498\# _$GG+$]!@#^,;_@Z8_:+^(FL_$;]F+]AWPA?W-EX3\6
M:+!\7/%NEQ7<MG:^-_&.L^.)_A]\*M$U9H6#W.C^'=0TCQ-K=Q:.LMJVI7>D
M7LUO-/IUIY>5*B\9B;RFTVISE*[=H12<M+V;:LH[6Z/2SNZC%?+\3[>^*O\
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MW%O,AY3GW[]C7]D/P9^W1_P;_P#[.7[-'C;49]!MO'?P*M;GPWXLM+:*]O\
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M+S3=&OO$$4$>IWFDV-S<7$]KIUU<RVD4T\DL<*%WW>1_M4_%2[^ O[-'Q_\
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M;QZ'_OHT;QZ'_OHT?\2\X+_HK,=_X:*'_P T!_Q$C&_] &!_\**O^1_L,_\
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M (V#_L0GG@+^U=\"4  Z  >/^2 !DDLS-DY5=JK_ (\^\>A_[Z-(6&,_-W&
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M:Q2U]1W\I?\ @+=_F/\ E_O'\Y/_ (NC&<8W')Y.Y\#_ ,>_SQ4/VE, F,
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M]'LM=L]?O%71M*U2YMO)_P#@W@_X*B:9\/;5?^";7[4&H3> ];\/>*-9TO\
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MHQG7AB8N+=TU\+:T=M=$]&G=BG&*4I6]Y1=G=^OI_D>W_P#!./X">'?VH_\
M@@9\%_V?/%$<7]C_ !<_9H\>^"?/EP1IVK:IXM\<)X=UF/)3_2= \0KIFN6!
M#H8]0TZV</QQ^1/_  :I_&#Q9H7Q6_:[_97UO=<Z,OAS0_C-&8YF>QTGQMX/
M\20?"SQP^FQD$-'KMOJ/AJ2>16B8R:)M$<RS[K?]^/\ @AF,_P#!)[]BGKQ\
M,M5Z?]E!\89R""#C (.,C!P>37\W/_!L+_RD4_;$P%#-\$?'A)P2 X_:%\+
M%5R JEI9'=0/G8J<@H*5W*EG<&[QIU54@K)\M1U91;75]-&[(F3Y70<=')I2
M\_=O^I+_ ,'4#!?VS/V/"Q48^!MX203M41_&(+(7/1(X@S&25PL:JFXX'RK_
M &9V'[1W[/,5C9QO\>?@NK):6RY/Q2\$ .%A0;E#ZVCA201\\<;@@@H,#/\
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MX\3ZD9UTF+Q;/HL"/+/JVOL8M/T+2IX);JRTJ6PT=K33]5DUF'4OZ.OVMO\
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MG)O7U_"F_P#$7=_P3AX_XL?^VYR 1_Q;;X&C@C*D9_:.&0RD,#SP1SG-*/\
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M /!.#_HAW[;G_AM_@5_]$;1S>-_;CC[Z_P#\B'+P'_/DG_@0[_B$-_X)P_\
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M5RK>.E32H^.IWTY9RK2279)P=EMI'D>FXVN!9*4'6RCEDFI+V\]4]]IZ"?\
M$(;_ ,$Y<?\ )<?VVMW_ &47X&8/T'_#.F?S(H;_ (-#O^"<G4?'+]MD  9S
M\1O@:<G)S@_\,YK@8QP1P>Y[+_Q%W_\ !.$]/@=^V[^'PW^!7_T1M'_$7?\
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MWM=;==^GY]W=W_$(;_P3A_Z+C^VY_P"''^!G_P!#C1_Q"&_\$X?^BX_MN?\
MAQ_@9_\ 0XTW_B+O_P""<'_1#OVW/_#;_ K_ .B-H_XB[_\ @G!_T0[]MS_P
MV_P*_P#HC:?-XW]N./OK_P#R(^7@/^?)/_ AW_$(;_P3A_Z+C^VY_P"''^!G
M_P!#C33_ ,&A_P#P3A!_Y+A^VY_X<CX%C]#^SC1_Q%W_ /!.#_HAW[;G_AM_
M@5_]$;2'_@[O_P""<)_YH?\ MN?^&W^!?]/VCA1S>-W5\<15][U]?+X>HFN
MTM\FEY0?-+Y+MW%_XA#_ /@G!_T7']MO'_92/@9_+_AG#^M*/^#0[_@G"?\
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M ,8KDZ7XC\,_#WPYHNM:=]KL_AU<6-V;/4[.ZM))[&YN;4S0RI%.Y0X_4_\
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M]+A_;;_8S&<?M:_LRMG<<_\ "^?A65VHFYV^7Q66("JVXJIVD'< N"?Y_/\
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MA:9XEFC9)([_ ,<ZC;MKWCW5'93F1=3\::IKFH)F5V$5Q&AE<+O/X2?LT?\
M!L%\'_V>_P!H+X-_''5/VHO&'Q,L/A%\0M ^(\7P^U/X1>$- TCQ-J_A>X_M
M+0K?4]2M?$&HS16MIKEOI>J2#[#<B<:>MMLC\XSQ_P!1:,L8(SD_>).X$[N2
M-S*5)X9L @( H(5>:C&5\/[##T</.<Z<5*4IN'*Y3;;3<5>^_71V124^;FE"
M*T>MVWMZV_ ^0/VY_P!M'X2_L"?L\>+OVB/C'+?7NBZ++::'X8\(Z.;4>(/B
M#X[UXSQ^&_!/AT7\B6<=[JDL5U->W]Y+'9:-HEIJ6L7@>UTV1*_D 3_@L/\
M\%S_ -O+7?$&H_L4?!K4/"?P_L]0?3OLOP6^#6D_$:#0#$ 8M.\3?&#XH66L
M^&+KQ%Y4\!U0Z9'H<-NIMYK?3[>VECDE])_X.C/BSXA^*O[4/[(O['_@ZZ:X
MFT?PJ/&3Z3"TKI-\0_CEXRB^&7@E;N.!C'<75EI&BW\EAY3.T5MXENBD\)N)
M ?[!?V9O@)X)_9A^ GPI^ ?PZTRSTSPI\+O!6A^%;1;&"*%=2U"PLXFUGQ'=
ME JW.L^)=;DU'7]=U"6-KK4M8U*\OKF1[B61GTC[##8:C5G2CB*]1W5.::@H
MK12Y5;5*WS?9$/FG*R=HZ]$]MO,_C#O?VF?^#HSX%++XH\6_#WXX^*M#M(Q?
M:A8ZK\!/@_\ %+2H+.S#3W+WEM\)-/N/$MI;&/Y+A[+4(72-2=UN2&/T]^RQ
M_P '2\-K<:CX,_;H_9\N/!^O:1:7L;>.?@M;:BL":WIMA-=1Z%XK^%7C.]?Q
M3X6N]7F0VL&H6&O:[%9W-XGVW2K*R2YOH/[$3'N'S?-G!(VH%)&"#C.[Y7'F
M(=^]7)(?& /S*_X*#?\ !*7]E+_@H-X1O8OB+X4M? WQAM;-H_!OQ_\  ^FV
M5A\1O#^H(PEL(-;GC$,/CWPU]LBB-QX7\5R7$&6D?0[W1=8E@U*&XXW#5IPC
MB,#1A#FCS3I7A**NNL7S-=][I;,MJ:C;GNNW+'5>I_,I_P $!?A)\0_VWO\
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M$H16&:^&--13Y+I)MJ^O-=O1W[$+)6UOJWOW+=%%%>>:!1110 4444 %%%%
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MMZ_H/\*;11>?_/RK_P"#9_\ R0<W]V'_ (!$=O;U_0?X4;V]?T'^%-HHO/\
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MM\):-96_PIUSP3H/B[5'^'6JR\K^S-^R]\!-;L?^"??]K?#'PGKT/Q0_8?\
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M/,EEV$,D/S!F_KT_9\?_ (L)\$.F&^$/PT(RSKU\$Z,<$,N_)QN.\LVS<[$
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M IXR^,]Y'=3Z3KUG>0:;$?$D&CQ+?P1&9RS0<*W/RZ/VT_\ @Z3  'P1^,V
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M_P#!,&G_  0\-7FJ^ /#T%AIL-OHNGR7OB;2_#UK!:P0,;N]O+_4)ADM$_\
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MQKM_J/B#56OM:U'4+ZZ_TSO^(<?_ ((T @?\,<N3QDC]H3]JH'DXX)^.@7@
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M(_[S_P#?M?\ XY7^I]_Q#@?\$9?^C.'_ /$A?VJ?_GWT?\0X'_!&7_HSA_\
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MP\S:3LL3EZZ_[QBY;>7U*'W\VG9WT_RP ,YP<X!;;CYF QE@ 2JK'E3(TK1
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MNR0I4MO=FDR5920Q;..A<F5_,EVNH;)6D5V;)4$ !!RI+'!+,T@Y*%@C*&9
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M"YW[97QE_8'_ &!?V:OA-\(?B)J7PP^/?Q-N_"7@;4?%7A&:QN=4T3P3\,O
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M7='>_OSXMGF\*_;#XMTO2;/3?'EGX2UW4K]X;S2-)U#PYK'AK7=;M^,/C_\
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MQX*^#LVGZ==Z;,D^E7-E9-\4UM[673)XXY;*2V6*6W=0\,D3C?3S_P '0_\
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M(IX-TR]T.T^U:DDKFYBF6:Y;=+.F_!;\^C_P0]_X+L;A_P 9<6B9. 6_;/\
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M9H]G;W5SJM_J%YY<%K8VEK=W-X\\<-K S7*>;]5^0I&T-@[E;<-JEBKHS*P
M 9'"!' 490LH()R0P@[E\QU8CB1>)%89((8G:VS+_NW1HV&-Z,"P;R,7FE3$
MXO+\7"FJ-3+OJ<*4)OV\6L!B*F)I.;Q,:C:E+$U(\L4HQ2;@HMR<^#$XR>(K
M4JJII.A&FH>_.Z=&I*I3:::;7-4G?FO=-)W5C\_?VD-,\0Z#IW[&_P 18O"7
MC;Q+X=^#'QJTCQ5\0K#P-X/\1^-_&6B>&=7^#'Q0^' UFQ\ >%=-UKQWXDAT
MWQ+XU\/6VNZ5X7T#7M9L-.O+G6+C26TW2]5U32_D33/!GBCXK?M$Z9\1;GX+
M?$^P\#:K_P %'/"?Q5T:3Q_\,?%/AV5?"'AS]@X^']#^(VHZ5K&FK?>&=)@^
M(>F:=#I<_B>W\/ZGHOBB:QT/Q)9:3XK@.A6_[?+$JKM5W("[1YC&1A]XY#R;
MW=CGK(SXP N,XI5AC!X"C R"5W,-VW)W,2"Q9$8MCD@%AORU>G@N**N$]IR8
M*C4K<^92I5)5*T''^TL;F6*Q#C&FU&;ISS.KA8.:O&E%224[S.JGFTX1K+V*
M<J_M>=MO_E[7J8F5EM%^UFY1:LDO=2BDK?CU\1?@AJ\WPZ_X+ -IGPDUJ[U_
MXO3:C_PB$<'@:[FU#XE_V;^RO\/+/P^_A> :<$\9FV^($OB:'2WTI=3SXG.H
M632'7/M=HO#_ !6\(>,;+P-^VU\'-3^"7Q(\5?%/]J6/PK>_!#Q=H7@CQEXL
M\,ZY%=?!WP#X#\'P>+OBCI^@7GA;X-2?!CXC^&O$/BF6R^(FO^%(M'BO'\4>
M$/[5O-285^WNU=V0V.0" "<@ 8W#<5Z#&2"2N%&T@$M>!#E2%;AE *@J2W=D
M!"G&2"!MR&?G<Q:JCQ3CIQY*V&ISC]9R_%-RJ3E-SR[ 8; TESU>::HMX6E4
MJ4824*T4J;3IQ5E3S>=)+VE&+M.G4322?/3BHP>D;M:>\FN22;NM6W^8/A#X
M,/>_\/*;7QW\-O'OB>P^,&NZ/X?N%\-:=9^'?&?Q6\&6?[*_PR\+7$7@'7/%
M-UX8\,:K*=9N/&6EZ+<2>(8O"^G^(I-2TJYOH)(=4A-?]FS4_B/J_P ?M(C2
M7QI\:_A3X9\"^,S8_%K]HC]C_P 4_LV?';X1ZIK;_#F#1OA[X?\ '/B+P#\&
M?"OQ/\)^./[(\6WNJ:7\.?@MH=QX:CT#PW'XW\7:G<IH"ZW^HZP+N7*_<8NA
M<!L$A@Q#'YP2KLHV% JMM"E,J6B)5^0 H&WAMI9,AU&2-KJ$<L 3(JA^'QM)
MWCAJYY6KO&N5*E/ZTU%0FYTJ,:GLO9*=*+BI0J1BK1=&4*<H\M*4*E*$::57
M,YU7B&Z=.7UCXXI1C'9KFC:SBXK90<4]I1E:-ORR^-'@+Q9\;?&O[?WAG16@
MU#QG:?L\_#GX2?#K0I[J/3S)X=\7^'?&_B_Q'I,=_?WCPZ6?B3K][+X<U/67
MCL+.XA\,:);:C<W">&HI+#Y:^.%I/^TU\:/%.D?L^?"WX@_#7Q=X@_X)H?M$
M_"S3]0\>?#7Q#\!-<U?5W^(/P1FT3X9::GQ!T+PYJ<UKX9M=1N]+M/%.DV6J
M?#;3Y_&5R-!\57O]F:U!:_M3XH^"_P ,_&<OC:3Q1X5T_75^)'@73OAMX\M-
M4-S=Z5XJ\%Z3+XFGT[1-7T5KE='D2UF\9>)62\@L(-2*ZK) ;W[/#;PQ<S\*
M?V<?A;\&;[5=7\&V7BV_UW6-.LM#N_$WQ&^)OQ/^,7BJ+P_I\DMS9>'-,\4?
M%SQEXXU[1?#<-Y++J+>'='U&QT*;4YYM3GTZ;4)6N3Z>6\14<OA.M3I2J588
M58?"4I1YL/2KJ675)U:BUA72GETK4:L90_>W@E.,5#HPF;4\+!-PYZM.FX4*
M4HIPC&:@IMMI<SBH>[S7^)M/5W_)+7/A[J7Q'^&7QCU/P_J?[>_Q%\;>'/V(
M/C_\/=*\-_%[]G#X;?!?PSH<OC/P'%8V/PCM;#PC^SI\#_%7Q6\1ZAK>C61\
M-:;\)KGXG?#[3-4\.&YAUC28]8\,2>(?3_C/\ OB+K.H^$_"?PJ\!:EHWF_\
M$OOVB?@WIC:1I$WACPOI/BK4-:^ $?@GX;3ZW;VMAI/A&_O;"R\4Z?X>L9KC
M3;G3M.BUV\TG[#'IM]/!^QP@CV!6&2/,Q@!-ID5D+1LA5XV"N563<9 I;YRS
M%J5HE)4A@I5@P #>66YW956&XX+;225#E9&1VC0CF_UIQD80A##*<'7J8AQG
M*IS6]A&G"A[JHQ4/:T8U(V2J0G+G4URQE'-9Q5]I*?LH--WC%QARJTXR6D8+
MX7%-:.UGYW_#G]HW1M:_:#\+>(]6^!WP(^+W@[3/AQ^P=^TS\+/$VC>(O@CX
MZ^%FKZKJ7CKP9X<T[X:? 7P/X5\0>&M#OOB/-HNL^&M5OX9_ ,'B#P#HIL[.
MT\/>);ZX\3VMM>>@?&#X$ZGL_:UG\+_"C59;F_\ ^"6OACX3>!Y='\&ZI<-J
MVMVK_M(BY^'?AZ:UTX-JVOV23>"C)X8MI&U^!+OP\@L)(KJU2+]AA"B@*I'4
MX&U6'15Z8^Z5RK!2&VD*&48 3RP&R<9R1D*N7.7VJW'W%)4D+L9RJ9) *MI#
MB[&X>%&C3PJ=&E*K*E&=2I5:4_9.5ZDI.<N=4IQ@Y-^S@JD$DJL_:-9O4248
M4H:6L];\JE)Z^CG-*VR;LS\1[;P-\0_"'Q4TKXN^*_AW\3M8^'OP]_:E^'GC
MGQ9I^D> ?&_BSQ#<Z7?_ /!/KPK\)=)\?^'_  1X;T/5_%/Q"3PA\4-57PYK
M%GX2T+Q)JNA:E/JVN7EA9Q^#]7N]+]>^,_BC7;!?V<]0^&OPO^(7[._PPO?
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M/BWX;L[6Z!ANY-9^'?QY\.R>([%%D <3M K:C/; LPCL+F5VD6V=Q_=N^<\
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MU\9!=1_9/*G_ ";^->!_P=2^$LDG_C(WX+8&0J[I/V<-"7>50)N==OWGW9&
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M&*<:4DE=I24GS:*.SBVU%IWBVG>76VC7X.R]-?DBQCC[REB"!SW(QUY)^A_
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M..3Q=\&O' M[J3X5_%"\MQ;MXB\(7FDW$E_*EL-?\*>(HHM-\4IF_P#!7?\
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M+>WCDU'^R?#MM')\3O#X>5F8V?B#X?V^H231,MQNUGP_X=O(X?.LHMGYI?\
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M<_ABEHKS4K&H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-+:]G<_8O]NCQ#XC^*_[/7_!2VSNOCS!^VW9>"_VE/AE=_"GX8>'H;O4[_\
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MWP^^(FJ:!J5YH&MWW@G2_AG\4/B)/X.T[Q%I#6VL^'#XUUCP+I'A>\O]%O\
M3M6ET+4-5TRWU*SDU%KFWZOPA^RVVG>,/"'C7XE?';XT_'W4?AS<WVI?#RQ^
M*8^$>E:+X.\0:IHE]X;U#Q-::;\&_A-\)8?$'B"X\/:GJFC6]_XW;Q4FC6FI
MZD^@P:3=ZA=W4WKOQ:^$?A#XU>"[[P/XS35(K&>[TO5M+UC0]3N]#\4>%?$N
M@7]OJ_AKQ;X2\0V#Q:AH?B?PWK-I:ZKH^I6[LJ7$#07MO>6-Q=VESY=7-<%5
MS/+\=.H\73HK%2K<U.M4PM.:JXZ&"J8)YC4JXN,\%'$TJCIXNO5DJJ?LIVC!
MKDK8K#>VH5.9RTFIM*7+SN_)**G>7NIJ35VKJR;3L_!]"_9@_9F^!/Q$\&>/
M_A=H7@S]GKQ!>C5_!2>$?A?!X1^%GA#XUW%WH&M:QI_A?Q;X/L-/L-*\:>(/
M#EMIFM>+O">H6%K%XTT*#3-?GL=83PI?>+]+U+Y'\)_MS_%*_P#B_P#"3P^W
MC7X,_%/P'\6_&GCKP5-+\'_@1^T+%X#\':EH7PZ\=^.]+C\(_M@Z]X@O?@3\
M=VT2[\%R>$/$UKX9\,>!-=N]1GU"_M=$T230-;T:R^Q] _9-TV/QQI?Q$^*O
MQA^+O[0OB/POI>LZ5X!/Q7F^&&DZ1\/F\2V-WI/B75O"_A[X-?##X2:"WBG6
MM#O;G0)/%VOZ?KWB?3=#GO\ 2=$U?2[#6=<@U+SSPU_P3]\(Z!J'P7N=2^.'
MQ]\:Z3^SMJ G^"_A'Q7KGPV3PKX'TAO!'B/X>3>'#9>%OAAX9N_&=A)X3\1+
MI<.M_$6_\8>-]&CT:R/AWQ9HPU7Q@OBGKR[&9+[6E_;&-JYC6HPI4JBJ4/:U
M*>']AB*D:<:_M5B()XB4)?OHTH2C*7L:DJ=/V)UX*ME\*U&>8REBJ2G%5(N'
M+^ZM)RC&45&=^9QM?E:O92:T?C/PC_:Q_:7O/"O['GQ:^+ ^"A^'W[5<,NDS
M^ O O@[QUIGC'X=ZP/A!XQ^*.F^(E\<:K\2O%>D>*]+U2+X?ZC#?>#1\/_"U
M]X17Q)96:>*O%LOA>ZO_ !![E\ _C#^T+\0? GA/]HOQX_P:A^!'Q%^%&H?%
M73/ _AW0?'>G?%3X=:3J5GIGBCP%8:EXIU#Q+X@\+_%:[U+PC<7A\7M;^#_A
M"?#WB"*TBT6/Q78M+/'Z;H_[)GP^T3P+^S/\/K77/&5UH_[*MWIEY\/[C4+[
M09[[7Y-,^&?BWX40Q>-Y4\.0VNIV[^&?&>JW$L>BV?AYFU>&PNPZP6QLY:/P
MJ_9*\._"34=,ATGXK_&;6_ASX3T?6]!^'GP2\0^)O#A^%?@#1-=:*$Z196V@
M^$="\9^.]-T738VT7PKI_P 9/&WQ,L_"FF2&'P]#IKVNG26.%?'9#4PO/2H*
MG6AB\3*N_9+DG@%7BZ=&"<DJ5;V-T\3*=EIS<SC[V$J^7RH)1@XUOK5=RDZ:
M?-A7/]S22NDFHNSFK2Z2;>K^+_@I^W=\;/B-KGPH\2WW@'7=7\ _&J.^G_X0
M[2OV1?VK_!MU\#])U?0[SQ/X*\5>+OVD?'UNGP7^*V@1K9:=X<\52>%?#O@6
MUO=4\46?B/P;J_B+PSX=OI=6W_"G[2W[8&K_ ++WP?\ V@=8L/AW+-\=(O &
MH)#\.OV=OCK\8_\ A0_AW6/!WB3Q)J7BWQ-X"^'?Q0UGX@_'"R\7:KI_ACP]
MHNE^#K/X8)\-9O&0O_$NO>,])\/W5[>_3OPU_8ZT?X77?A_3M#^-OQXN/A5X
M'CU>#X<_ V]\5>%K;X;^!K+4[6[L--TBUO\ P_X&T/XG>,_#OA/2]0O-.\'^
M$_BK\1_B!X5T"W_LR>WT9]0\,^%;W0^HL/V7](\-?!;X6?!CP!\5?B]\.H?@
MWI&A:'X-\>>$];\*+XMDL=#T"7PRD?BG1-;\%ZW\*_&MM?:3<7"W.E^+/AMJ
M^AV>JR6WB/0M*T?Q+I6B:QINM;'Y$W)8;#48U'BXOFE3J3?U"=*HZ5&3<XN%
M2,W!*=.G.55QYW.K%.,M*N)RY>SC1I14O:ISDXRDI4>6W(VU[LD];QCS;)RG
M8S_V2OC7J/QK\!ZQXFNOBI\!?C1I]EKL5GI?CWX"2ZWI6GW=M>:#HNO2:1XY
M^'&O^(O'>J_"OQKH7]LI8WWA74_B%XIU.?31I6NZC#X8O=6F\+:1]9(Q;=D8
M(8KW[ =,]CV]O3I7AWP9^!^D?!V'Q=>#Q9XN^(7C+XB>(H/%/C_XA>.W\+Q>
M)/%VKV&AZ7X5T>6\TGP#X8\"> ](MM&\*Z%HF@6EIX6\&:#:W4&F)JFKQZEX
MBO=5UK4/<47:",DY8G)QGL "03D@  DG)QS7AXJ6'GBZSPTFZ2Y5"/*H<MX1
ME+FC&4M;W2<U3;2YE%.;C'R<2X2Q%:5))4FU[-)6LEH_Z;^2NTGT445B8!11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !28^;.>V,4M
M% $;XX!SAMRG'7!5C_[*1]37\''[;-Y%^QQ_P<K_  \^,/B-GT?P3XS^+O[/
M_P 1[C5)D\NW7PG\6?!=K\$?&FJ;V+1R6NE:_;:^=0E+(%BB\QUB4/(O]Y1&
M<$'!!';/0_ID;A^/?I7\L?\ P<\?L-:M\8/@1X%_;(\ Z3-J'BC]F^'5/#OQ
M3BTY)1J4_P $/%=];7DOB,/ 7G*?#?Q7&-6GE@MKF33O#_B3Q-JC1Q6NGW5R
MG7@)PIUI1;Y8U:56D^W-4A[NO36^JV;[LRJQ;5X[J46_\*>OX,_J57."&7G)
MPJXQP0Q)PS'YF)D1<[MC*" =P'\,O_!8;]F?]I3_ ()M?\%%;#_@JA^S5H]]
MJ/PY\8>-(/B5JWB2VTS4-;T'P%\2M0TE/"WQ(\%_%&UL9T?3_ 'Q;T6YOKBQ
MUN5M&LAJ6O:[HLNHP:Q8:%=:M^^/_!$#_@H]H7[=/[*/A_PQXM\06[?M*_ +
M1-"\$?&70KN>.+5_$-A90?V?X/\ BO8VS2-]HTKQSIUD8];F65Y-)\:6&NZ7
M?+' ^DWFH_LYJ6E:?KNFWNEZM96FIZ7J5K/9:CIFHV<-W8:C8W<3Q7%CJ-E>
M0O#=VEQ;R^5<6D\1BF0O!<+)$TD9FC4EE]><904HSYH3A)>[*,K/3?XM&GMN
MGU*:YXJSM9II]FOP/Y))O^#L+X/+\*CJ$7[)7Q/?XQC3C$-"F\<^#/\ A52Z
MY-"3%<MXWE*>+)=(>\1KE+1/AU%JHAA,$D5LICNC\??\$A/V-?C7_P %0?VY
M?%W_  4K_;'\$V/B+X*_\)!K'B]8_%_A=[CP#\9?']UH$OACP=X.\">'/$L=
M_;ZS\*?A+HB6C?VE=&ZTI=7\.>%]%@N=0OAK:Z=_6%'_ ,$P?^"=T?C$^/5_
M8F_9F7Q0UU)??V@/@[X&6W%Y-*T\US_92Z,-):6:X9KF5Y+%V:X)G!$I9C]M
M6VGV6F6MGINFVEKI^G6%K#:VEA90);6EG86L7D0VMK:VRQPV]O;1"-+.WCC:
M&(!HXXE5$:/:IC:--26%HNA.:LY\SE*S3YE%.3LG?LDE9ZM)*7"3:<I7:NEH
MEN_)(^75_8+_ &'=F?\ AC3]E=/F)P?@!\*54!I"SD[?"F Y9V=E"@>864,1
M^\*+^P;^PYC)_8U_99'&0!\ /A7SDY49/A,99A]Y>2ISN/1C]-ZWKNC>%]$U
M;Q+XCU6PT/P[H&E:AKNOZ]K%U;:7I&C:-I-J][JFIZK?7LEO!9:=I]C'/>7-
MW<N(+6UMYYKB950!OY9?V2_^"VW[4G[:?_!5K5?@1^S?X \%^.OV,M7O;F.+
M4/$&CZGH7BGP1\+? -NEIXG^/$?C'3(Y(C)X\UZZ@'A+P+XJTZZMKU-8\-Z7
M:W>F7TVN:A;X48XNNJDH3J<L(N<KU9I1BE=W?,DW97M>_P K%I15EIS6U_4_
MH#7]@O\ 8;/'_#&O[+ VNK;7_9]^$[X95#*5+^$F QN^]$>H*EMP*K<GG_8T
M_8DT-(GF_9L_9+\*^.=:>?RS)\,/@7X=\6^(K2SABN)Q&Q\,Z9KFM6NGK:+<
MS'S]0BTZ.W#2_9K>.-?J" _NV!V#YY,*HV@*6)  +'L<[MV'SO"QJPBC_D=_
MX.U(;>7X*?L:&6*%UB^+OQ0):=%984?X<1I)(L@S)'N!&[:6$BQ%-JEA*IA8
M3Q>(IX2I5J?O>923E-Q:492=KZ72M9]VNY,WRKF6_-%7\F[,^JO^#E;7]"\6
M_P#!*W0O$WAC6M+\2>&?$?Q]^!VK:%K^B7]IJVC:YHNJ1^([FQU/3=3L)9K+
M4=+U"TE2YLKNUFDM[B"2WN(Y"HPWP=HO[%WQ_P#V[/\ @W7_ &$_@[^SCX>\
M-^(O'&E?&37/'^I:?XE\4V/A'3U\+Z-\1OVB-*OIUU#4XKBTNY;:\\1Z7$NG
MRQL)86=QM$;9[;_@JR/*_P"#<?\ 8@.W:L>A_L/L0&)&V+X8.JJF<L45$CCC
MR20@4L25.[]</^"!B[O^"2O[(YY&-&^***>#G;\;/B4A.ULJ,.6!'.XHI8X
M6O0C*6%RZFX*,ZE#,*L8<RT48.R33T=K*777JM;S9.HELG%MK;6R?7U/YM?
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M'D9I,I_8/^S6-_[.WP D&X,/@E\*\-D;2K>!= 89ZC!'WL'#8&<E4*_RT_\
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M%_#>O6GB;Q+8P!=^E'Q_XYOYV\,6$X>XCDETWPMJ-];6\B1Z1?:9<10W=O\
MV9;@^7"N2K;=JML?>/O JSJC #!!;(D7#J&0HS!/SL,L#M7Y@<\= =F6 8'<
M3((2A  +C;A>:&98R--4^=*,$XPO3I2DHO\ ON#D[+JVVM+:I%J$%M'?S?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY\URLC$M)G:KOM9F,C+N9FP&EE;RXBZJ7E=/D9=C3RK*:_U//^(<'_@C,/\
MFSF3_P 2%_:I[_\ =;ZAD_X-O_\ @C0S C]CR50I60?\9$_M6+B1#E711\<@
M%<<_.%+L#C=A0*WH^/?!.%ITJ-#AWB6E0IVIT:%+#9)0HT(-2BH4(8?%5/J]
M-1=N6E3C&VDI133)? .<U7/VN+P4W*,GS_6*]>JY>[_S^PE+65DI2]JGM9.U
MC\ O^#2C]A@>(_'?Q=_;^\:Z2&TKP%%?_!#X&RW<,G[SQAKMC9W_ ,5/%=FL
MD<#I)HOA*\T7PAIU_']JMKN/QCXML5:WN=/D$O\ =Z(?-#%V^\6!P0P9"P8!
M@1L8,@53N1G56<*^YBY\/_9N_9H^"G[(_P '/"OP"_9X\"V7PY^$_@HZRWAO
MPM9ZGK^NFP?Q%KNI>)=9FN-;\5:KKOB35KF^UK5K^[DNM7U>_N526.U2=+2W
MMX8O>4Q@X&.?Z >@_P ^V /YXXQXEJ\6\28_-I4ZL,-*-##8&G7:]K0P>$4H
MX2BXP2I2J0A4G*K52;G4DFYS<(S/TO(LJCE&5X?!:>T2;Q$E>]6<E=N3>K5]
M$E9)+57=SYK^(_[)GP7^)GC&X^(.MZ?XZ\.>-]1TRPT;7/%/PG^,OQH^!NM^
M)],TEI#HUMXNOO@O\0/ 4OB]="6>YAT"3Q,VK3:';WE]:Z5):6][>1SR^)/V
M2O@/XF\(> O \O@VX\-:)\+9+V7X>7?PV\6^-_A-XK\(-JL%Q;Z\-$\>_#'Q
M)X3\<647B=+J>3Q?;Q>(1;^+KM_M_B6+5+Y([A/I'].>_P#]8]_Q^E+_ )_S
M^=>%'&XZ/LTL=C+4%%4+XFI+V*C"=-0I73Y8*$YTU!NI!4YR@H1BW%^_'$5X
MJG&-6<515J24FO9WWY'O'Y,^8]4_8[_9TU?POHW@RZ^&NG1>&O#_ ,*_'OP5
MTG2M/U;Q)I4%M\.OBB^AR_$#2)7TW6K6;4-3\477AW2;_4/%>IRWOBW^U([[
M58=;AU'6=<N=2YGXH?L(_LQ?&'4?$&H>/? 6IW__  F/AW1?#'C?3=&^(_Q5
M\&^'?'VG>&K2XL/#-U\0/"G@SQOH'A7QWXB\+VL\2>%_%_B[1=9\6^&WTW09
MM$UNPE\-^'WTW["HK2&8YC25)4\QQ\/8R<J3CBZZ=.4T^>4'SOEE)OFDUKSJ
M,TXRC&2J&+Q4+<F(KPY9.<5&K.*4G\4DE*R<M.9I>]I?9%"WL(K6!+6 !((E
M2-(QNVK&FW:@.=_RA>I<ABSEP0VT<5X6^%O@SP9K?Q!\1>'-)&GZW\4_$EGX
MM\>7QO\ 5[QM=UW3_#6A^#K*]-OJ&HW=IIJP>&?#6BZ6+/1X-.L6^Q&\-M]N
MNKJXF]$HKD4IJ-2*JU>6MR^V2JS2K2A4=>$ZMFO:5(5Y.M"<O>C5;J+W]3)U
M*C<W[2?-4FISES/FE*+<DY/5O5MO75MMZZGR!X<_84_9F\)^)_#/BO0_ FL1
M7_@;7M7\1_#[3;_XE_%76?"'PVU#7],\1Z-K5K\,O 6L>.+_ ,#_  V\/:KI
M7BO6;#4/"?@CP]H'A:[MET6.;1R/#/AP:7Z;I7[.GPCT'P]\&/"NC^%?L>@_
ML]W=CJ'PAL/[>\53GPG>Z=X0UWP%9S27D^NRZAXC$7A+Q)K>D/%XIN]:BNA?
M-?7J7.HP6MW![E1GK[''Z _UKJGF&85>55<?C:L8J:A&>*K2C#VD90J\L.:*
MBZD9U(U&E>I[2;E)\\W+66+Q<TD\5B+)22Y:U2-N>+A.W+))<T).,G:[BVFV
MCYT\3_LJ_ WQ?:^.;;7/!LCR?$;QSX?^)WB;5M,\4>,_#_B./X@^%= T3PMX
M>\8>%/%.@>(M,\1> ?$&D>'?#NEZ78ZEX$U/PY=QPI>2O++<:GJDUY+X;_9:
M^"'A6P\$6&C>#Y\?#[X@ZM\5_#VHZGXK\;:[X@N/B1KWA[7_  IK/C3Q;XIU
MWQ)J/B;XA>(-3\/^)M7TV^U'X@ZOXHGN(9K61_W^F:5-9_0U)U_GUZ_KT]J'
MC\?9KZ[B^5RE*WUFO9.48QDU^\T3C&*LO=T7N[MJ6+Q<ERRQ>)DFV[/$57JU
M%?S=H15E962/E[QI^QU\!_B!XFUKQ5XD\/\ BQ+KQ3<6MUXV\/\ AKXL_%[P
M3\._B)<VMI9::UU\2_A3X,\>Z!\,OB1=ZCHNF:9X<UVZ\<^$O$$WB+POING>
M%M?;4O#FGV>F0?3-G:6]A;Q6EK#%;VT$<<4$$$2PP0Q11I%%%#$@"1Q1QHJ1
MHH"HBJHX%6:*QE7KSITZ-2O6JTZ5W3A5JSJ*#:46X\\GKRQC#FLY<D8PYN2,
M8J)UZU6,8U*M2<8?#&4W)+1+9MZV26M[))+30****S,PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHI-)Z,!"#G@X'ICK^-
M'/8C\L_U%+13 3GU'Y'_ !HYQUY]<?\ US2T4K (,]SG\,4M%%%E>_5: %%%
M%-J_]6 *3GL1^6?ZBEHI6Z:_>_SW 3GU'Y'_ !I>>_\ +']3111:W?[VP"BB
MBF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !43Q[V# X(&
M.^#UZX8>M2T4FDU9ZIB:3T:3U3U[K8@,9;[P'7^$LO'_ 'VU2*FT8X/U!)_,
ML?Z#VI^,>OXDG^=%#2>Z3^2_R$HQ3NDD^KMK^8W;_N_]\_\ UZ-O^[_WS_\
M7IU%+EC_ "Q^Y?Y%#=O^[_WS_P#7I"@.<XY] 1_(T^BCECT5O./NO[U9V[KJ
M&PP*1@ @#Z?XD^_ ]:<!C/N<TM%-*W?YMM_>PZM]7NPHHHI@%%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 023^7NPA?:I; 8 G!QCG !;G
M9D@-M;)4#-?RPR?\'=W_  3>2::-?@G^VS<)'*R1W$'PX^":0W"+@+/$EU^T
M/:W212CYXQ=6UO.4*L\*9"C^I:\3,<A!.0K #DK\Q7<2N=N=H9 Q!90S 8#,
M&_Q!P#@8 .0#G8F3D _-M502!@9P. , # 'ZYX3<#91QKB<\I9P\;R9?0P=6
M@\%B8X>I&5>K4IS4^>G.$XOD32=G'>+=VE\-QAQ!C<D>#6"]E&=93Y_;14J;
MY4NKU3[).SZG^B__ ,1>/_!-_P#Z(=^V]_X;OX&?_1'4A_X.\?\ @G#GCX'?
MMNXQW^'?P-SGZ?\ #1O3WS^%?YT7S?W?_'1_A2@-QD!0S !F\M5 ',A8L05V
MJ5*DCRSD[WC5&8?M+\">"8*[>?-;6EFF'@KO16:PTW*7:"C>3T31\0^/<_>G
M/@%JMJ<6WY).ZUV/]%T_\'>/_!.#M\#OVWOQ^'7P-_\ HCJ0?\'>/_!.#O\
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M %3CX&<_E^T?D?F<^U-'_!WC_P $XO\ HAW[;G_ANO@:?T_X:.K_ #ILG&0
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M0D!G"E 'P0^TL&4*JL4"NVXHOF1D%PQVU_Q W@1.TJF;M--J:SS#**>\8.V
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MOVC?\:_SI%5RP4!59@XVL@+>8NU=H2,2,^7.X>0)G:W,<T:.Q>&-&;:2,KG
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M?W?_ !T?X4?-_=_\='^%:?\ $!^"N^?_ /AQPW_R@?\ K]G_ /-E_P#X O\
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M7C_P3A/7X'?MN?A\.?@9_P#1'"C_ (B\?^"<.?\ DAW[;F/7_A77P-SU]/\
MAH['3WY/&.]?YTA9R,C!&!D@1L#N'8QLZL/<'(.<A2"*%1Y&"A0<Y_Y9NQ !
M7<Q"Q,615R["/S)55&8Q! 7J8>"' 4GRRJYW[1OEC2IYDY2=].=-Y>KQANTK
MW36I/^OF?RN^? 0Y=7%4HWER[Q2?5[73NNA_HN'_ (.\?^"<.1CX'?MND=_^
M+<_ Q3^0_:/.>/4CT]R#_@[Q_P""<'?X'?MO?A\.O@;_ /1'5_G0M\A5?E)8
M1G \LD!RH.X*S!<!BRARI*@;@A. NU@%.PC>H<910"K$E"",@ADVD^C%DYVY
M.D? S@6;E"G//YRINU22S"G9-[+W\%3BGZRN^BOH'^OV?-\ZE@HJ7PPE2BK]
MW?1NVZWT[[G^B[_Q%X_\$W_^B'?MO?\ AN_@9_\ 1'4?\1>/_!-__HAW[;W_
M (;OX&?_ $1U?YT/S?W?_'1_A1\W]W_QT?X57_$!^"N^?_\ AQPW_P H'_K]
MG_\ -E__ ( O\S_1>_XB\?\ @F__ -$._;>_\-W\#/\ Z(ZC_B+Q_P"";_\
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M.\?^"<!Z? []MWW_ .+<_ S^G[1P_P ]J/\ B+Q_X)P9_P"2'?MO8]/^%=?
MS\\_\-'?F.G]/\Z1I"0 FV0#)(C6+>J[7 RDC(SM)*JPQI%YO.]Y&A0)YK2
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M5.5*D\RPW-*$?BEK0N[)IOU0X\><0/VDD\#R1DDG[.*2NVM&K-IM.Q_HM?\
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M_E_PT< /J#2#_@[Q_P""<'?X'?MN^V/AU\#>GO\ \9&]>OK]:_SHU"OEAM*
M@%Q&& R./G4&$G.(]HDW&<K",N3A"NWA2K#G)1> <D$'(X92,,O\+ KVJ_\
MB!? LIM4ZN:N+C&,(0SRA5K^TA_'?LY8*%X*ZO[WN:6YKF;X\S^+]YX2,OY9
MX25)>?O.R3[*^NRON?Z+W_$7C_P3?_Z(=^V]_P"&[^!G_P!$=1_Q%X_\$W_^
MB'?MO?\ AN_@9_\ 1'5_G0_-_=_\='^%'S?W?_'1_A5?\0'X*[Y__P"''#?_
M "@/]?L__FR__P  7^9_HO?\1>/_  3?_P"B'?MO?^&[^!G_ -$=1_Q%X_\
M!-__ *(=^V]_X;OX&?\ T1U?YT/S?W?_ !T?X4?-_=_\='^%'_$!^"N^?_\
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MN\>7&BZ7I6GZ3K/AW2OB-XQM;CPIHGACQ?X3_MS5]1_<#QMX6_:[\"?L(_\
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MXHZCXATKQ_I$QL/#GPLG^#^N^"-&U>VT[2?#30Q:)X=U0?F[_P $Y6@DL/\
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M^'7P@^%__!"KQ+\2_&VA_"^QUBZ_X*Q^ ?"OQ8\1O:Q:!\,/B%\2/$5UX+\
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MC7I<M"I*IA5B</AE4I255TI_5YXB$5;]_"3O+]M/"'P$_P"#;_XW_MN>,?\
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MSX=_#OQEKOARYU&PC\>:Y%K>I>*+NRM[B2*"R@(6"XM9='U*\_2K]H7_ (.
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M"(0P545F9OWB[1MV]2S(H+#^@+PY_P %)M%^#'_!$+X6?LQ?L\?M/?%'X/\
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MY_P2]_8&T?\ :0_:._94_:8^,/[0W[1?QS^$GQ/^"/P8_9S\7_ S7OALW[,
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M@\6376H>/];T/Q_X8TFX^*FH>%?%MH?$7P\L=.G\,:%9:CK$K?;/L\_MY_\
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M5:-RA*[XR58*X&-VPI&45B8UV$>7B682?MY_Q#C?\%EST_8X8_\ =PG[*_\
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M?\,5_M;_  4_:F?P'_PLT?!_Q/J'B0^!#XH/@S_A)&U#PYKN@26[>*?^$?\
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MHU_'<6RWT5C?R7_AK6A;7,WAKQ-9Z/XCAM;R\TBRCC_1WXQ_\%-?V<8/@?\
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MM^WO_$.-_P %E^G_  QP_/(_XR#_ &5__GWT?\0XW_!9?_HSAO\ Q(3]E?\
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M<;_@LO\ ]&<-_P")"?LK_P#S[Z/^(<;_ (++_P#1G#?^)"?LK_\ S[Z?^N_
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MC!1=J* %V*41%5%. &8.DD;NBDQA0R-^WG_$.+_P67Z_\,;OCU_X:#_97_\
MGWT?\0XO_!9<]/V-W/\ W<'^RO\ _/OI_P"N_ O*XKBKA*,7)-\N=93&2<8\
ML9*<*4)J:5]5.*4G*7)>3$LESZR3R?,6DH*TL!6FKTXRA"5I0=YQC.2YF[M;
MMM*WXA;L C:OS*Z.0B#>&\OEB%W.?W:Y5RZ;B76-9&=V0LS<N=S<Y;H#R=H
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M%?$%UX<2XM?$NLPS7_A"Y\/ZL([QS:W]K/!93VOZ1?\ $.-_P67_ .C.'_\
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MM!:*[TM;RV9^(C,A14V_=RI;*EI S!F9V9&?S5V!XI%D4+( 94GA,L$BAP
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MW_!9?./^&-W_ /$@_P!E?]/^+W\_A2_\0XO_  67Z?\ #&[Y]/\ AH/]E?\
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MB:6J9^(:L #N,F2#DI*T>[<KHY^4%DR)&(,<B2?\]))-T@D3<H4*$7;A59
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M"HZ$ _H*_AU_X-X/^"<W[9G_  3\_P""DOB(_M<?!D_"7_A;7[$GQY'@$_\
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MWQ1)X=MM3LK+7O&.@ZUX:B\1V%TU_<6&FQ:=-K#Y(?R0_P#!</\ Y$++LO\
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M8*S!Y%.UMHP%W298!D4@X4A02"HQZ[9AU ( _O,<@!5R2<C[PVGY>_:Z^/\
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ME>R?^/\ _P 54V![_F?\:,#W_,_XT<D/Y(?^"X?_ "(6]/Q_^2(?*]D_\?\
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M -I*XATK[;<I+!'[;YHP&*N%.P9_>9#,0-KJ55DSD$%P !S)Y>5R<D/Y(?\
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M ,?_ /BJ<'! )W#+E!CS#G&6'!4'[H^?C",&7)*DU&)LGA&QMW'YSN!V*_\
MJCB88W*K@QB12\6(CO;8<D/Y(?\ @N'_ ,B%O3\?_DAWE>R?^/\ _P 51Y7L
MG_C_ /\ %4H;+,I5Q@Y7EB2J[ Q)("#!<$!7=B < .K1J>8-Q7#9')^?D#AN
M4!+AF3<R+MW-L<$+@$G)#^2'_@N'_P B%O3\?_DA/*]D_P#'_P#XJCRO9/\
MQ_\ ^*I3( "2#CV9F(P<,&"[COS\J(N]G;Y< YP>8N>AP"1DEQ\RLRD#(&2=
MIV$<,01D?+N.2'\D/_!</_D0MZ?C_P#)">5[)_X__P#%4>5[)_X__P#%5)D?
M[6,[<Y.,[MOKGK[8]SQGS&Q^,7P\U'XN>(/@39Z^9OBKX5\ ^&?B?XA\*)IN
MM[M-\#^,-<\1^&O#NN/K3Z<GAV9=1USPEXCL8]-M]6EUN/\ LN6ZN-+ALI[.
MYN3DA_)#_P %P_\ D0MZ?C_\D>E>5[)_X_\ _%4>5[)_X_\ _%4T3J=F.?,
M*$.0K HCDJYPCC$BA#&SAV.,@+(R\EXN^(?@OP'/X1M?%OB&PT.\\?>,-/\
M /@JSOIV2Z\4>,M4L-5U:Q\.:+!&LDE]J<ND:%K>L20Q*5M=(T;5=5O9+;3M
M-O[JV.2'\D/_  7#_P"1"WI^/_R1U_E>R?\ C_\ \51Y7LG_ (__ /%5YY\.
MOBW\/_BUIGB75_AYKW_"0V/A#Q_X[^%WB&?[!J^E#3?'/PT\2WWA'QKHKQZU
M8Z?/<QZ-K^FW=H=4L8;O2M0@1-0TJ]OK">WN9?12^,85VR<#EE)(8@\''/&5
M[=2Y1/GHY(?R0_\ !</_ )$+>GX__)#?*]D_\?\ _BJ/*]D_\?\ _BJY'X@^
M/_"GPL\!>-?B=X[U-M"\#_#SPGXB\<^,-<%CJVJC1_"WA+2+S7?$>I_V9HEC
MJ6LW[Z=I.GWETNG:9IUYJ=\\0M+&TGNY8X#%X.^(GAGQXNHR^&SX@FM=,A\/
MW+ZCJO@_QIX:TC5+7Q/X:TSQ9I%[X7UGQ-X?T?2_&-B^CZM:"^OO"MWJ]IHV
MK+?>'-:FT_Q'I6J:39')#^2'_@N'_P B%O3\?_DCL_*]D_\ '_\ XJCRO9/_
M !__ .*KGO%/BO3/!^COKNK6OB*\L4U#1M-,/A;PIXL\<:P9M=UNPT"SG3P[
MX+T77O$$FG6MYJ=I=:WJR:8VD^'=$6^\1Z]?:=X?TK4M4M>@$H\OS-K$!78K
MN(;<G5 7\M!T;/FM&R8(D5"KA#DA_)#_ ,%P_P#D0MZ?C_\ )"^5[)_X_P#_
M !5'E>R?^/\ _P 50[A"HVL2QY )&U>K/EMH*KD%R64#&T$RLD<GGMK\6OA_
M>?%C6/@?!KQ?XH:!\/\ P_\ %#5O#']F:XOV;P/XI\0>(_"VA:XFMR::GARZ
M^W:YX2\068TNTUB?6[=; W5[IEM9W-E<7)R0_DA_X+A_\B%O3\?_ )(]"\KV
M3_Q__P"*H\KV3_Q__P"*HDDV8 5F)R!\^WG:[8R20  C$L^U0 0"SX0GFJ>5
MRPSC(9P ,.=[Y'RQD(=CC<) 5*Y5U).2'\D/_!</_D0MZ?C_ /)!Y7LG_C__
M ,51Y7LG_C__ ,51YGRABC\\$!U)4G)"L2X0,  &^; =E56?.:\T\"_&3X<_
M$KQ%\5/"?@G7WUO7_@IXXMOAS\3=/_L?Q#IQ\,^,;OPMX<\:V^C_ &G5-*L[
M/6FD\+^+- U87_AZXU;24BOUMI]0BOK>\MK<Y(?R0_\ !</_ )$+>GX__)'I
M?E>R?^/_ /Q5'E>R?^/_ /Q5!E0!BQPH4N2'+*$W%0SL#M12.=S,%PLA)"QL
MU)YR[<G .YEVEI=PY 4E?+WJ,,C2ED"Q(QD+-& [')#^2'_@N'_R(6]/Q_\
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M:5.!AL'/1P0RD=L'&"X8-N!5RMN!."!D@9!!.."<$ @9SCCD889!%,>0HP&
M1L9R2P4X4$DKD;2 0 [.T:IN3YF+!: /@_X?_L23^ OV[/VF/VV;;XIB\G_:
M'^$WPY^&,'PX7P.MLO@F?X>6=E;1>(CXMD\67J^)1JLMF+F71Y/"NBI;-)Y+
MZA>0KM?X4_; _P""2W[6O[:?P?\ V>/AE\7O^"E<.L:K\%/&WB;XB^+/$FH_
ML<>!+GPY\9O%UQX@%_\ #R[\9_"/2?BOX=^&<VE_#7PX)?"MGH&L:#XFTCQ+
M#?:KJ6O6LLVIW5N_[M>:-V#P ?E.3\XV[OD7:&D(!!;:"@S@.S*RJ><@8C!&
M-N2-N,L1A2,[@_S A&56;)V*Y!P ?&W[,'[/?[1'P[^&/CCX>?M<_M8P_MEW
M'BJZNK#2-=B_9^^'W[-T'A?P->:%'HL_@N'0/A7JUS9:E&[&[NQK<T]M?P&X
MBM[-+5+.!Z]K^ 7P ^$W[+_PE\'_  ,^!OA5O!'PL\!6^IVOA3PL=?\ $_B8
MZ5#K&M:AXAU%!KGC'7/$/B*^^TZQJNHW@?5-7OI(1=?9K>2&TBB@3V#S!E@0
M1MR#PV!P6'S%0G*C).["DA3R1E48NH8J5R <$@D9 /)4LF1G!V.Z\<,>P!^0
MG[7O_!-C]H#XW_ME>!OVU/V:?VY/^&1_B3X,^ G_  H+8/V9O!/QX;4O#MUX
MU\2^--:NS+XX\=:)HEL-7N=:L+=K63PO?75G)I+W=OJP_M%[>U\RT'_@C[\4
M/%5_^TI\2?VJOVZO%/[37[1'QT_93\<_L?>#_BC+\!O!/PA\(?"'X6>.H;BX
MU!M,^$?P_P#%<>D>(=8M]<N'U)+L>(/#HN;<O97(:[9=63]RZC=RA^[D!2Q.
M0,!>3Q@DX'MG<4 !!=HP#\1Q_P $;<?\W&\?\.GK;_@E\/\ BT+$A;8Z>1\<
M"6^*+$LXL0&^&HP 92?^$^^7#]E\-_\ @D/X2\+^/O!OB+Q[\7)?B+X)T3_@
MF#H/_!-#Q7X#A\!3^$)O%_ARPO-,?7?B?;^*[3Q_J]YX:N];TZPFL+7PE;:;
MJ$NBRW8OT\87\MM%$?V'1]^_C&Q]OW@<_*K X!W*<, R.J,&!P"FQW?0!^$/
MPM_X(O>.M$UO]GKP;\>_V]OBC^TA^R3^R3XX\._$+]G;]F/Q%\(OAYX+'ASQ
M#X#AOK7X:Q_$#XK>'+Z?Q%\3=$\"V=\UII'A^_T;1M(AM+>VTRQM-.T59-+E
M]J\/?\$KSH'P;_X*<_"1?CN9_P#AXU\3OC-\1D\1)\,I+1_@Q_PMK2;C2H=)
M73H_B.\OC^;PSYXN8]6@U7P"VIRQCRK'2&V2)^N#R!&"@ L1D+N"DC<JEANP
M"J!MTI4ED4#",SHK(9> 0K9;:%W)(H)8 C)\LE!DA3O52ISN (P0#Q+]FOX+
MC]GG]G7X&? (^(T\7CX+_"'X>?"G_A*%T./P[%XE3P%X2TOPL-:/AU=2UI='
M75O[,%^VE_VSJIM#,;=M2O2)+B;\M/&?_!(GXO6WQ:^.&M?LV_\ !1GX[_LI
M_L__ +3?Q2NOC5\<_@E\,O _A:7QEJ'Q+UZXMYO&/B#X6_'Y]:TWQA\(E\2"
MPTX/:Z'H6I- ()+*]N-6T-=-T;2OV[1MX)P1@E2#C(*G!!QD=0<8)!&"#@TZ
M@#\8/CE_P2=^(WB_]J#QQ^TA^SC^W5\4OV6F^-OPG\(?!_\ :(\,Z3\-O!_Q
M6UKXF>'/ ^BQ^&-$U+1?'_CO5AJ?@GQ5)X>M;2VU'Q=)I/BGQ5-J,=WJMAK>
MF2:A=V[XW[.O_!''_A06F?\ !,_3A^T8WBL?\$Z_$/[4>OB5?A)_8/\ PM]O
MVE+S4[TVPC?XGZVO@#_A#)=0#&>5O'9\1-$Y6+0!,$A_;BB@#\%_VB_^")_B
M7XR?'3]KKXH?#O\ ;8\7?!/P)^VSX-M] ^./PXLO@/\ "_X@>(M5U32O!-QX
M3T6#1OC#XKNU\:>&OAO).+*Y\4_#WPY#I%]XCT+^U/"EOXVT.RNM(N_#_IFK
M_P#!)[QJ/''["_Q+\$_M;WG@KQO^R=^SOX2_95^*-P?@5X7\5^&_VCO@AHQT
M.+Q3X7G\+^)_&5];?"^[\<V.FZA9WVLV-WXRO-%-_9WFB&VO=(BGNOV9=]A&
M02"5&0"<%B0-W' W;1D;B-VY@J*S@C<2*'7[IY!]1Z@C@KG[K E77#JS*P)
M/Q0_9U_X)(?%C]G/QS\-_#/A?_@HM^T(O[%'P7^(FK_$GX6_LB>'- TSX>W=
MK?WNJ7>N67@[XA_'CP?XEL/&'Q-^%5MK&HZA<ZI\,=9\/6/A/7X)HX;VQCF%
MW=WO ?&__@BAX_\ &OB3]K?2_@3^WW\3/V=?V>?VT]8\3>//C9^S[8_"+PC\
M0M-U/XI^*+*X75->T?QUK7B?1?$?ACP7K.J-:7'BCP-X3A\/W_B'0[=O"I\:
M6&E1Z.=%_>YGP<#YB "5!^;#;@"1C@$K@$D _-SE<%48.#C^%F4XR1E3C@D
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MC1]<T.:\T?4/AI&UQ-?R^7>,OV-M=_92^"/AUD^+'QU^*7C'P3^VUX@_:?\
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M/T=DB\S!#%67E2..G(5BNV387$;NB2)YGE*C'875W1H(T5%^ZH"J  H 50H
M50J( !@*BJH'0"@#\Q?&/[ GQ1^.-C\2M9_:8_:0\,_$#XG>(?V4_C+^RC\,
M=?\ AK\"+[X2^ /AKH?QUT:UL/B!\2]6^'NK?&KXH:SXZ^).LWFC>%S-/'\1
M?"/A*RT'0/[%\.^%/#]]K&L:_=_1O@#]E\>!OCO>?&P^.#J?VK]EKX2_LT#P
MRGALZ<(D^%WBWXA^*F\9+K"^(;Q#_;;>/%L8O#W]CJ^D#2I+E]?U9M1$-A]8
M44 ?E7\$/^"<WQ"^ -W\.YOAW^U$-"'AO]C;PY^R1XMU:Q^".B7/BN]D\"^(
M?B!XO\!?%7X:W?BCQQXI\'>!=<T;Q-\0;^ZUCPMX[\!?&?PSXCTVW&FS0V$L
MT=_:^R_#?]E+XL']H?PA^TK^T3\9_A=\2O'WPV^%/C/X2>!4^#/[/.J? :TN
M- ^(VO>%O$'B^Y^)-UXJ^.?Q]UCQM,E[X+TB3PCINCZEX'T'PS<ZGXOOYM*U
MN^UVSN-%^[Z* &JNT=<Y)/0 #M@ #H,8 )) X).*=110 4444 %%%% !1110
M 4444 %%%% !1110 5#*A<@ X^5@/8D$ _SQ^-35&Y/;V.??YL>_^%9U9<D'
M4_Y]VEWO;1KYJ37JT%KV7FFO5-23^3BG\K=;/X5_X*'*VA_LX7/Q5C!2?]GO
MXM_ ;]H>:[#,AL_"WP?^,G@GQ=\3G9UPT=O??".R\?Z-?3+N\G3M4O)/*FVA
M#]SVX 0D,6#.S@MC.'PP7( RJ@A4R,A H;+ D^7_ !L^'&F?&3X1?%;X0ZZ%
M.A_%+X;>//ASJ_F9*'3/&_A?4_#-]D*0[*MIJDX<*RL PVY+9'G/[%OQ(U;X
MO?LE_LY_$GQ&SCQ;XL^#7P[U#QQ;S?\ 'SIWC^+PMI=CX^TB\&U=M]HWC&UU
MS2KY-HV7=G,F %P.Q6J8&$KN4\)C:]#WMXTL=2I8_FC:RY'6I^S^T^>+^&*L
M^91Y*Z6GO07S]FI6^:527:Z?5I6^G:***YSI"BBB@ HHHH *:?O#\/Y/3J:?
MO#\/Y/4S^'_MZ'_I<"9;??\ ^DR/A#X@?\I*OV4_^S'O^"@'_J^/^":-?=L?
M1O\ >_\ 95KX2^('_*2K]E/_ +,>_P""@'_J^/\ @FC7W;'T;_>_]E6MJNV$
M_P"P&C_Z>Q9QX7^)B_\ L88S_P!-X49, 002.0H.>JDOA&7'S+)DD1,H.U\'
M!P,?BCJGQ0_;4_:F_:-^+O[ 7CSX87WP<^%O@KQ_>^+?BK^U#\+;OQ5I7ASX
M@?LF:[8:/J?PK^#_ ,//%&HWEMK6C_'3XL7UQX@\)?%OQ5X7U&PN_AOX:\)^
M*+KP7Y'B36M%U[1?VQ>(.RL2?E!P!D8+ J6W A@P1F5"I&W>YY)&UHB&_?N8
MD$G!.5(Q@ @C!*@#:?O+C(.7F,N9W&7X=\/:%X3T#1/"WA?2-+\/>&O#6DZ=
MH'A[0-$L8-+T70]%T:SATW2](TC3+1(K33M,TVQMH+.QL+6*.VM;:&.&%%10
M!M#WQGO@8_J?YTU00,%BQR3DX'4Y[=!Z#L,#)QDNH _&S_@X!VG_ ()(_M;H
MV#YFG_!Y55P'A9C^T%\)PH>)DD29P6W01&*56F"231F""1E_F>^,.EZIK.D?
M$?\ X)03Z)=-\._V-/$'[?W[<BVCVL\FC6/P=O/V5M5^+/[-=I"MS8R>'9!9
M?$?XX:Y836]O9+I>GO\ 99]\#7,!U#^X[]H+]GWX1_M2_"/Q=\"OCKX3/CCX
M6>.X=)@\5>%U\0>*/"_]JQ:'K^E>)]+1M<\&:WX<\2V:6VN:)I=\ZZ=K-G]I
M%K]ENC-:33V\ODVN_L%_LG^)/B)\5_BQJ_PCTZ?XA?'#X#7/[,OQ1\30^(O&
MEE>^*?@E>:?::3<>#'ALO$EO8:4\FF:?IVG_ /"3:'9Z9XO^Q6-G;-K[1V=D
M+8 _!3_@G?\ %SXB:'^U]_P2J^$T_P 4?&NC?!KQ1_P12\&>)_\ A7$GC/7[
M+X9^(_B+I&OZHL^OCP9-J*^%]2\;6?AVRW2:OJ6E2:_9>'].=%N[?3[6$5\<
MV7QB\??&[P9\)M:\;_%3QA\6M/T/_@Z!\/\ A3X>:UXE\>:WX^L=$^'5A_9U
MYX5T/P/J^M:QK L_A_I%M?WL^DZ9H$K:=IO]IQRZ5I]O'=2;/Z8/BS_P2@_X
M)]_'/P)\$/AM\5OV<= \7>$OV<O#NF>#_@[;S^+OB3IFL^%?"6CP6\&G^%KO
MQ;HGC33?%_B_P[ +:.=M%\;Z]XETZ>\>XO[FWFO;F>XDO>$/^"6G[!WP_P#"
MWAGP1X*^ =AX:\(^#/VE]-_; \*^'M+\=_%*'2M#_:&T33[72M%\<V=M_P )
MR0+#2-.L[6STSP"Q;X<6%O:VL=IX2A%I:F( _E%\4>!/B#^S7\!O^"Y7QO\
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MG@SQ1I5G?NTEUI4?BSX?>)O"GB6ZT669C<-H5_JMWHHNWDNDT]9I"X /,_\
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M!U+Q)=>)?A#YNA>,]"T'P]XT^&6D>/\ XH>%O@7XUL/"?AJV\(>$9O&O[/\
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M.M? ;]EWP]XS_;L_:+C\00?M!?%&T^#/PT^-=KX0^-?B+PIH6I>$HM#/B_\
M;+\1_';]GCX@:%\(O@_K'CJTT72=#O\ XE^,_BO\19_$7A:+Q5K7BO2? ^KV
MNJ?:.I_L1?LUZG\)_A9\%1X&U;1/ _P/DM)O@W<^#_B/\4? WQ$^%TUIIUYH
MYG\"?&7P9XTT'XQ>&KF]T?4+_1]7N]+\=VUWKNBWUYH>N3ZEHES+IK<U=?\
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M>+=+T_X8V7B/_A8&L7EO(FC^'-7\Z"8 'ZM?&7]M#]F;]G>_\5Z7\:?BE8>
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M,Y/#&JIX9UCQ3I'Q4^/6L:QX0TO7Y[%=,U/Q%IUEJ>@ZAJ/AVUN+B_T^VO\
M2[JZLX?M4<TX!] ^-OVT_P!G/P)H_P *=:N_&>M^,8_CCX<_X3+X3Z-\'/AG
M\5OCUXT\<^"5T>PUV;QUHGP^^"7@?X@>.Y? MCINJZ0^J^,Y?#D/AK2;O6]#
MTS4-3M]1UC3[6?'\0?MY_LK:!HWP<UV'XE7GC6S_ &@]"\2^)/@G:?"'X=_%
M+XX:_P#$K2/!<GAV+QC)X8\+?!SP3XZ\2WE]X4'B?3KCQ'HQTE-8T:PM?$&H
MZA8V]EX1\6SZ'^3/["GAWXA?L=Z9^RM\7/C7\(?V@YO!?B__ ()[?"/]GS4-
M-\"? 7XN_%OQM\$?BI\,?'OCKQS?>'_'/PB^&OA7QE\5/"NG_$#2/&5O-!K\
M'@2?PSIOB'P4=%\9:KH&HW7ATZUZ)^R;\!?C%X/^/W[(/CSQQ\)?%?@S3=>U
MC_@J_P#&*]T2YTR^UJ+X,Z;^TC\;?A3X\^%_@_QYJ^DW/B/PUX3\=ZOX3?4;
MB?0'UM)_[7/B;P]93W]WHFLP6H!^ZZR>>D<JK,F]4E1)(Y()#&QZ.DB)+#(0
M0QAD$,R'8ERD?[V,?%ES^W#\"/AQX&N_'/Q7^,V@7^B:E^TK\3OV<O"^I^$O
MA)\6=.EN?B3X0UGQQ;V7P>M?"\0^(7B3Q;\0+"+P/J_AB/Q+HL&E^&OBKXOL
M[>/X>:);W?BGPMX;U#[18C(?!R9$V%""6SGEMH"R(P4N!\QC1A,QMQB2#\,/
M"_P<^*.WX"K>_"[Q[Y>B_P#!<']IWXN:JMYX'\0O_97PRUBX_:VG\._$[4S<
M:,RV/@?4;OQ!X>&A>-KAXM NI-<T(Z3JMU%JNF7# 'TK\4_^"HOP5T&3X"I\
M-]-^)7CO_A:/[3 _9\^(6F1?LZ_M.+XZ^$MWI/@?7O''B&R\5?#%/@\GQ"\/
M>/;BSL_#O_",^!/%WASPYXB\1^#?$VJ?%+PSIVO^#?!?B*YC^AO%/[=_[+?@
M?XAZK\,_$GQ$U.TUKP_XJ\->!_&'B:U^&OQ8UGX1> /'?C)])C\,>!OB3\>=
M"\#ZK\"_AGXUU@Z[H"V_A/QY\1?#6O&7Q%X;>738AXGT9[W\P/C%X$^(?@_]
MK7X@?&"7X0_%_5O .B?\%0/V8/BA?:QX ^$?CWQ[JE]X M_^">>I?"K5?'_A
MSPWX(\->(_$?BKPWX?\ B+KEGX>\7ZKX4\/ZTVDWT.MQ:K$AL-2QY+>? KQI
MX1\&?M7?LL?&/QW_ ,%/;JV^-OQ^^/\ JEE\+_V7OV7O@=\0/A-\<?AQ^T]\
M3-:\1Z7K&B?M&^/?V3/'_AWX:ZG/I'C.'2?B/=_M!?M1?#O5?AUJ?AO5[^UU
M3P_X/B\+:A<@'[@2?M@_L_I\8/&/P*'B_6I_B-\-PLGQ-AM/AO\ %&^\&?"R
MTD\ 6GQ0M=4^*7Q5LO!=Q\*?AOHNJ^";U=2T#7/&OC70]'\1ZA:ZMX:T.^O_
M !+HFL:18T/A'^VC^SU\</&A^'G@+Q/XKB\8W'A&3X@:#H_Q ^$7QD^#Z^.?
M ,-Y:6$WCKX7ZI\6_A_X(T?XM>"[:XU#2VN_%GPPU#Q?X>M;75]%OIM26TUO
M1YK[X5M_AI\8?"6D_P#!8"Y\#?"'4?''BWQIH7P]M/@SH?Q<\*6^N>'OCE<>
M'_V&_A=X2CT2_.MQ0>%?BAI,WBJQU?PKK^F0W]]X9O-835_"^HS013ZA:+\[
M?!G0OB!KG[>/[)GQ4\W_ (* ?%?PJ?V??V@?A/XO^-_[2/[/_B?X&>%_AQX_
M\6Z'\,/$F@?#W1O@SX;^"OP'\/?#;PWIZ>#/$&IW7QBG^%\7A_Q1KVN^'? %
MO\=?B!J?AC1O"_@H _3RZ_X*(?LHQ^(;KPY;>-?'&K3Q>(_%/@;3/$&@_ 7X
M_>(_AUXQ^('@W3M?U+Q#\-?AI\6M ^%^H_"WXI?$NV'A?Q#I\/P[^'7C7Q/X
MRU77=!U+PUHVB7_B.TFTQ?-?V/OV[](_:G\)?LL^*[C48OAIXD^/'P]^*OBZ
M7X/>(_@G\;M)U?Q#-X 'P]N]3O?AS\3?&$'@KPI)X,\"V7CK1[35O$S>$_$V
MB?$S4-?M5\&:YH-YX2\26$OFO[ OQ%UOX&? /]GK]C#QI^SS^TA:?&SX96:?
M!WQP=*^"'CR'X,6,&@2ZN+_XSQ_M)>)+'1_@5XB\"^)K*WLO&!MO#'Q0\1?$
MV^N?$JZ%9?#0^)[35?"^D_.?[$/@+XE2R?\ !+C1=6^%OQJ\!7_P'_9:_;&^
M"OQ;O/'?PB^)'@:T\"?$*5OV<[+2+>75/%GAK2-#U33/$S:7K-[X#\3>'M2U
M+P[XTM=+U5]#UG5+G0]22S /U!T/]NO]ES7?B-%\+=+^(U_+KMWX\U'X5Z7X
MGNOAS\4--^#6O_%C2XKB34?A7X8_:&O_  3:? 'Q9\3;:YLM5TRX\!^&OB9J
MWBP^(-&U_08](?6M!UK3M.PK;_@HK^R%>^.KCX>VOQ/U676M/^+=Y\!M<UO_
M (53\9Q\-?"GQEL_$UWX/'PS\:_&,?#MOA'X)\9:MX@M([+PKHGBWQOHMUXR
M77/!E_X476-+\=^#+_7/S%T3P;\4]8_8T_9V_P""="_!#XXK^T/\)/CC^SU8
M>./'/B+X1?$'2O@AHGA/X%?'_P )?%KQ5^T'HO[16H:5%\&?%VE^*?"?AF2_
M\+>%_"_Q \2_&'4O$'BVT\/:YX)L==TOQE-H/:^(_@Q\3+G]B#]I3PM'\*?'
MD_C#7_\ @J;KWQ/TCP]#X%\12^)=;\(S_P#!2;P3XQ3XAZ1I*Z:FK:IX>D\
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MP,ET0J%:5"6'(P1P<$$$@#=M(YP&RIW!3E3\H&"?Y,O@U_P4T_:W_9T\9?\
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M\JV]Y%; '[+9$7!#L&);*H[A?N*1\BNQ+,VX!BQQO.X(F TSD%1Y9+%@K '
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MB?XI_#WQC92P>+_#_A;PYXTG\,Z9J/BOVQ_VY=:C^+W[4FB7OPP\'Z)^SO\
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M3+FTU33A<Z;=VUY* ?7WDY9&WR;DW ,2"2&0(V0RE0<JK HJ$,O4J\JRJL6
M,DE@20W (YZX'REVQEV()8LXP$;8/B_]E/\ X*(_L:_MMV'C?4/V9?CCX?\
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M+*K-*$V@LQ0(PP%RS@I@88J&8!@I4@L2%#'86VXW$%@ 20R[ I8LS88)M<H
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MKC6&T_7-*M?$'BFU\0_TP>6HXSC(QP%4_4% K \N001@NQQTPT1#!!8]6Q@
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ME%8?"O3_ -=I59XGC526=98\E9% ,K,"YRIP-X+L.!Y; H7^3?*;==H0;54
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MLQ4$$OAE5B<\C:!M 7&U$"*L052H)!;.7VIN+')+D8V!F9F<@($+LS;/F8,
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MV^@6\EUH>J^%_#OA#2E&E:_#%XOTB^CNO$'](/[.7_!+O]@O]DGXH>(/C/\
ML\?LX>#OAS\3/$D.I6EUXHM]2\6^(9='L=7EFDU*P\$Z5XM\1Z]H/P[L[V.8
MV%W;> ]*\.076C)%HUQ%)IT,$$5+PE_P2O\ ^"?G@+]I.]_:U\(?LO\ @32/
MC]?:W?\ BEO&D5SXJN-+L/%6IR>?<^*-$\!7NOW'PV\/^)&N8Y;Q->\/^%-,
MUBWU*>74DNTU"]FO' /BW_@N8P/AK_@G.VO_ &<_"_\ X>@?LKO\55U%9SHR
M^&C>^(U@D\202E-+ET&.YWM=PZUNLI+J.Q";;M(0/QD_X*/_ /"1?\)/_P '
M%8^&IM3\/PW_  38/CW^R?M?E#Q,UWX8?QDK&U^8Z@D#>(D\5&\6.U*+.=;0
M6)DS_2/\,O\ @FQ\#HO W[9WPU^,/P^\%^-/A=^V#^TGXV^-WB/X81:GXSUK
M0M,75K/PMIEGJ,?B/Q#J<?BNQ\<ZWJOA5_B/J^H>';[1[7P-XKUT>'? #Z=H
MOA'0[EO:?@A^P#^QY^SG\#_%_P"S9\'_ ("^"O#/P0^(2Z['X_\  6HKK7C6
MS\=0^)+)M,UB#QGJ_CS5_$_B+Q/!/I/E:7;1:SJ]W'ING6]MIVFK::=;6]G$
M ?SW_MR_:O\ AN/]I7_AG7^R_LG_ !#S?$__ (27_A#_ +3O_LO_ (2+4?\
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M1TCQ+XAUK0?A_HEY>.AET+P'I?AO1/LUK8V":<FGV%G:P@'\\_P_'_!7H_\
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M;:S<SZ'H%A=I#/'UG@7]E/X#?#7_ (4D?!'@;^PW_9R\!^+OAE\&&7Q)XOU
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M^RWX?\=6OC_3?A_K4=WIOCC5/B;HW@:Y^*?Q>U+X%>'?B3K,NHW6I?$+PO\
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M\ :)X=_9L^&GQ0C^+7Q.@3X@7$G[2GB?Q]XF\:R7FHS?M0M\4]-U+P[X5M+
MV%LWB#QNNM_H_P"'/V/?V=?"6A?#WP]H'P\%I:?##XN7WQ[\+:C<>*?&NJ^*
M+GXTZKHGB;PYK'Q0\;>,]8\1W_B_XH>--:T7QAXAL=<USXG:YXPN]<2]A?5W
MOI=.TQ[/#^,G[#O[-'Q]\4:EXQ^)W@;7-0USQ#X8L_ _C9_"WQ2^+GPTTSXG
M^!].N;RZT_P3\9/#_P ,_'GA#0/C1X0T^34M6CT[PU\5M,\8Z+I]GK.M:9:6
M46F:SJEG=@'XI?L[>!/CO<_LE_L1>.]9\!?M7_'/]F&T_P""=WP=MO#W@_\
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M^(_A6W\9:EX#\0?#[3-<E:]\*:+XR5].\;W7A>6*!M*UGQ=X2DM(KGP)JNM
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M\<_$2R\8:?>W_P '_&&M6^CMXSO?A;IVE6UQKFGZ3=>!--T./5A#/8ZY-/\
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MK1=5\1Z7\ ?$4MAX1U+4-;\.Z"?B/\1? D6JZA%XZ\96E]XEN]2?Q%X:>_\
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MW'B/PSHFN7FN:';S2W,,4%QJMA9Q2R21IN1IH!+_  5Z):Z3I/[#/_!?C3=
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M[$]K* ?VU77[4'[-]C\5;+X%7WQ_^"%A\;=1:"/3_@Y?_%KP#:?%:^GO-/\
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M0WX)?!B\O/V,_P!I?Q5:?!?_ (1:+Q-\:;?7O%/B#0;CPW#X-\8^)_V<M?\
M%&M_M/Z;%IWQ7\-Z!X>^%_QOTOQI%I/@Y_T%_P"">_Q8NOC%;?M&^*+W1_V=
M?$EQ8_')]&C_ &HOV6_"-WX4^$7[6UA9^ ?!\EK\0M,;4O$?C[4M<U_P1;RM
M\(O$]\GQ3^)FCV_B+P#?:;H_BEK/3!I=B =-XZ_X*#_"KPU^V#\$_P!C+PGH
MVN?$3X@?$GQ=XH\*_$CQ1H%OJ:_#_P" ]YH?P=\9?%[1/#WC7QC'HE_X;O\
MXI>-=,\*%] ^%%AK$'B6T\+-J?CCQ%)HNEP>&[7Q?H_M_P#[=7@O]@GX'I\6
M/$/A+5_B/XDUSQ+I'A'P'\,M O)=,UCQ7JUXS7VN7MSJ2Z1K;>'O#/@[PO:Z
MIXG\3>(KO2+JUTZSL8+-XOMVJZ7%<\I^V$<?M2?\$O%; S^U7\6"%!D9F>/]
MBS]IPP ;&'SO&CMND('R.A?RFN$E_.+_ (*N_"O]JNV^&G[;?QN\4?#_ /9Z
M\=_#.;X8^$_AE\&O$-[\>?B)X=\=?"'X2S>*_ >L^-!:_"2+]E_7?#&J^/\
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MX0U3PM\&?!&MZOX3UC1=3_X1WXB?%"_.C7>FRSSJUP-+U,69N+"V= #^A(3
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M@K[NRC5U>]]W;22BBBL#J"BBB@ II^\/P_D].II^\/P_D]3/X?\ MZ'_ *7
MF6WW_P#I,CX0^('_ "DJ_93_ .S'O^"@'_J^/^":-?=L?1O][_V5:^$OB!_R
MDJ_93_[,>_X* ?\ J^/^":-?=L?1O][_ -E6MJNV$_[ :/\ Z>Q9QX7^)B_^
MQAC/_3>%%= _7&.,@C(8#/#="1@DKS\K8;!QBHS"Q(/F$< ="2" 1N4[LA@"
M=N=RY9]XD&P1SU&\BIG/.T!F Y8*VX*0B@LQ=EV(H&7.0N2I%9G<.10BA0
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MK/!)J4UC#/%802QW%T\4<T!EV5E#J&4;@><H=PV\G<,<R*^TF,HK%P1PH)(
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M_9N_81\2_#/XB?"K5-=_8M_X)3?"A?AAI>IC7OCS\$OA?=ZS\=?B/X@AT==
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M!R6 !'W'C.TM\S(20RLT?$9"JOE'&-_!.Y@% !))9@!G&QF)R&W$JS L3M9
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M.)@/!VIC3+'4M!ATK5K+1?'6O7'C+1?$WBJYU+6++59_-6E\'?V OVZ?B?\
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MY@XR2Y8;\9 +.=J''**%'W2-I0&I , #Z=,@=,< DX'H <"@!:*** "BBB@
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ II^\/P_D].II^\/P_D]3/X?\
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M4?#^G)XH\$>(]1D>Z@\/7WBW54NM(N;+PO!8>'VGM/!&H_3GQ_\ @+\0(O\
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MQWIK:YH:/XK\7:)K>@V8U+65T-=1M]#BU$ _?A6#*&&<$ \@@CV96 96'=6
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MVP5P%Y*YRQ+-DG!^8_<$>58JQ<+&(_R]^!W_  5L_9S^+D'QE@\;?#W]I/\
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M4-[!=+DV+V[K<$ _2UY5C8!LC</E."0S#)V+@?-(RABJKEFVD$#Y=RB08).
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MI9<JP,;(65]P %,()!+;FPZLS8#%'R2H";%!R5R2AR%4L&958'E#.0Q'S!F
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M#L"F%B5/F.=K*2<[2<(RY;RS&K DE]C*\6XL?*)VE'&7Y2VTJ!GE\@=6"D[
M^U2 '8L 8T8%PK!E5R.LB[E(9<D!E965L=U*D@C.1S@Y!R!0 P1$'/F,<-N
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M>HD+A," =I R 2<JH+$C@N%9MS?*FU2SED;:$D5RIDY(VDD=%4C><8W':2H
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M2&R&)!(W;R[T;>"<$8)4@XR"IP0<9'4'&"01@@X-.H KF$Y!#E<'HN\ @.K
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M0[=^%R"1,(O+\_+!SL9E*F'T=Q\JIU)^52>6))9W(XW2,X!&0N'E$@!\;?\
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MX0A%I<R6]QJD\>IV.L)X8\.>[?LU?\$YOC5^S1^W]^QCXJLM*/C/X!?L]?\
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M#XXK<-H0T(:.?C-\1M=\>#PJENVL:RMZOAP:VNDC6A-9-K+6[ZA_9>EI.MA
M ?F%\6_V^OVW_&?[:7[0W[-G[#GP)_9[\?>#/V+? _@SQ3^T5K7QQ\;^-_#/
MB'Q]XB\?>%9O%OASX>_!S6/!L>HZ7X>\2KI<$T46I^/-"U?1KS4=,U6&^O\
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M?#%K9-Y=?._[,_\ P1J^*WP,^-G[(/QE\<_MX:K\8X_V0/#7Q*^'/@OX>_\
M#,_PW^%W@EOA?XY\ GP9IVA:+9^!O%$5UH_C'3+V:XUWQ%\1O$UQX_UGQ@MO
MHVFFRT$Z;/J.H@'P9X;_ ."T_P#P4YB_8V\.?\%"/%_[.W[&UQ^R_P"%OC#-
M\,OBQI&@>(/BWHOQD\9V%S\1D\$P>(/AEH=_XAUGPQX M-*O+RW\/WTOC3Q!
MXQU?4M:BN->MO#5AH;>5:>[?MW?\%A_VK/V>_P!M+QC^SQ\-_"G['GPY\#^
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MH&IZ1HB>!8/"MZOB&[TT?V)X@U7P[9K)K6E??FJ_\%,?VWOV;M;_ &E_V?\
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M;_#C7Y?BH;:?5O'>J7\DVG6?B#3+#PUHL>IZ5=S)H#Z;K%AJ!_-/]I/X\_\
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M_B!I7Q8_;,^#G_!5#]K;XT?M0^#?V>;#]HCX._\ !%CXK^/= D^#5]\0=?\
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MT_>'X?R>IG\/_;T/_2X$RV^__P!)D?"'Q _Y25?LI_\ 9CW_  4 _P#5\?\
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M0\-_"OQ#\4OB-X ^%/[8W[-A^)7P/^'WQ\UOX'?$?Q)\"[K]C_X=ZGXJ\#_
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M/AWXL\&ZA^S)K2W5A;V.E^*M,M/&NK^%]2TV9Y/AWHFES>(M"T3SOXM?$?\
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MM!^)/Q6@\,V?B.[^&EB_AS5+&/X?>"Y_"'A.ZEU(3:A807^F1QW'U+9_&?\
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MAUX7\8^)_A6/$VJZ9I-SJ4LNE7>LOHFD6EW9Z?JL6F6,2T ?LS\:?VD_@O\
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MVT\7?&KX#6 NGO\ P3\4/$NA7ED/BK:--Y<GBJT\22:[#X@DNX(KXWVEV-C
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MTK0=;TKXM:5:Z#K>DZ!JRV6F2^'+!/)U/2-;O] UQ%@-J^KZKX1\.]<_:Y^
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M1-%7PKXSB2UG;Q#X-O!KL.J7>A^?9&?5]&\/WAU '3I(+O\ )JT_9"U[7/\
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M/[)N@_MP?\%+OC;\>/VJ/$OCOXU:[X7^"?CSPGI7QU^)UW8?#OP=-/H7@_\
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MC4=&TR#VOXK_ +?WP\'[-W[7WQ.^!MUJMQ\6OV8_@?XN^*%_\-/CK\&_C?\
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M^._A[1+>Y@U*_P!=^#_B/QMI<&AW%EK@N9-'O;6^E /K>BOB#X3?\%&OV/\
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M">)_'$&B7'A'2#I.E^'+O6/$\WB+_A(]'M]+?P79:_'=:E-/I)<ZCIFL6-D
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M+?$.]GO;"RC\$^(?B+IGB5-6U72=(GTN'4]9TFUOL'XD?\%#?V2?A-X\\?\
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MGQ3U36_^%I6NL7/PV\2ZI\+/C)X0^'7CV^T'26U_Q'X7\'?%CQQ\/_#OPO\
M$GCOPOI4.HW'BGX=Z/XQNO''A>31/$.GZSX<LKWPUKUOIL=A_P %%?V4=9O[
M.PTKQ?\ $.Z77[?Q,? .OM^SG^TI!X%^,%QX6TK4=<U'2O@)\0I_A!%X+_:!
MUS4-&TG4M9\,Z!\$=>^(&N>-]'TK4-1\$:;X@MK.XD4 ^WS*0P&P@%@"3N&
M3MX 0[FW \*2@C!D>1 5#2(V]=V, \CD$D8')QTYXQUP!G!R!^77[-/_  4-
M\,?'GX6_L]?%+7YM6\!:G\5_A%\9?B/JOP/7]FW]HOQ'XY\51?"^V^'VIZU-
M\(=:M]#L;CQ9H/@NP\<:5I[MX:^&_CU_C9J?B&V@^&$UKJ'A'Q'ILGHG[&'[
M?/P^_:B^%7[//B'6['7/ /Q3_:#\'>-_&?A_X>ZK\.?BWX=L[BQ^'A\)77C!
M_#_B;QQX+T+3/%6A^&].^('@FSC\=6-[_P (SXRU*[OW\)W5W_9>L6.C 'Z
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M)R<#J<]N@]!V&!DXR74T,#G&#Z$$$'(!!R,X!!&,\GL",$N'OC/?!S_0?RH
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MIMOI,>G>*/$=KJGU*TBJP4GDXP,,>"2"> 1@8.X]%XWE002JDG.1@@XZ@@\
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M8M\4=(N=5U'7-634FT_QI;K>Z5>S>'IU?P\PTI?0?V7OV OV1?V+M3\>ZO\
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M/P]\8_#Z.>'PCK/]JQ^,H]<\62:1!=7$:V7CG4_$VFWWF ZI8WXBB5?K\R@
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M4445F=Q0N_\ 53?[C_S%?%7_  3$_P"4;7_!/O\ [,C_ &4?_5#> *^U;O\
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M &1Y'11\C!F=G0VZ[#&I"AL[R561G!CV!F,FX/*-J'S)A*6VX<,&P #^7O\
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MK7X7?M3^)?A3HDOC:^^'_P 0H?#'@+P#X4\._M)?M5>$O$'@?7)I/"9;X?\
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MXJUFUB;2_#NH6]I]CT*],^HW-G;S?9XI3<1_+_P<T+_@N_X4U+X7>&?'C_\
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M_P""A'Q*\&?L-_&+3?VH_@?\4_V\_P!CKXJ_$+XB-XL^+WP[O_!'P*\3Z/\
M%&*TT?4_!-GHGPD\-_VYIND>%_#NCZ7H>E:O<^&;OQ-XCEDUG7+KQ%X9DDM[
M&( ]&^+7_!8[PS\&-5_X*<6_B[X#>(;W1_\ @G*?V?[,:AX9\:PZKJ'QCUG]
MH.S0:!9/IEWX/TNR^'-EH&LW-I8ZUJDFN>-D.FQZEJ=K:R7EK8Z)JOK_ /P3
MZ_X*%_$C]LN^\5:1\3?V1?%'[/LVF>&]$\;^"_'?A/XK^$/VH/V?/B-X4UN2
M&W\C0OVBOA-I-O\ #&#Q]I<\\5UJWPXDU.X\06NB7%OJRF4QZK9Z5\5?!O\
MX)H?M_Z'>_\ !3;Q]\3/VC_V<]$^.'[=%A\#KOPCXV^'GPMB\>_#S1=1^&FA
M^)[+Q?X&\=_!OXZ>!/$GA>3X<ZWI.M6WP[M+IM0\;^(]2\,-J/C*\M[+6TAT
M1NB_X)I_\$O_ (_?LS_M5?$']J?XVI^Q_P#""7Q-\';;X20? K]@S0?BIX7^
M#GBZY?Q)9^(Y_B?\0-%^(K:79:;XNM&M9=*T[1_"?ARWT6>WOQJ%HNB2Q:G9
M:N ?77[8'_!0_P 9? SXZ>!/V3OV9_V5?&7[9/[4WC/X?ZE\8;[X:Z)\0_"W
MP:\)>"OA'I6KW?AZ7Q?XP^*GCC3]2T'2;K5->LKC2_#NCS:>(]5NHDMI=5L+
M_5/#=EKWRGXY_P""Z'AKPG^RWX;^/5A^R[\0M9^*6G?MDZ/^Q+\<_P!F&X\:
M:/IGQ+^$_P 6KC3]?U#6++0]4M?#VM:'\2+A5T6W@\(6\?\ PB.F>+;G46MK
MK7_#5SIFH00^R_M>?L4_M9S_ +7O@3]O7]@?XA? 'PY\<M/^"&K_ +./Q+^'
MO[4&C>,[[X1>._AQ>^*!XUTK44UOX:6D_C;1O%6B^)OWTTUI&CZI'9Z1:OJ-
MEIB>(=,\2_'^O?\ !&KX^:I\#/!]GJ/Q:^%GC#]I[QU_P4K^'O\ P4'_ &HO
M&FJOXP\)?#VY'A]?$\&H_#KX36&D^&_%6KR6.B6^MQP>&K7Q-9:/;:Q)/JCW
M5]H]K'86%F ?=7[(O_!27Q]\=/VJ/B9^QO\ M#_LA^,/V1_CAX.^%UI\<_"6
MBZQ\4_!OQ?TCQM\(+W7]/\-P>([KQ!X*TW3](\-ZXNHZQI<5QX:@N_$BVLIU
M6UN-8CN=(N(I.%_X*[?$7XHZY9?LG?L5_ +XH>.?@[\9_P!M3]H#2O"Y^(?P
MO\0:AX9^(7@GX-?"W3;CX@?%KQ3H>N:'J.EZO8?9+*'1;.YDL-1@2?3;W5+*
MY:YLKJ]M7]@T[]C;XG6G_!6?Q!^W?-K?@1OA#J_[$UG^S=;^'XK_ %L_$H>.
MK;XKZ5X[?6+C31X53PT?"QTBUN;".\;Q?-JS7DQMH] CM%CNAX3^T[_P2A\-
M_MW_ +=TGQF_;/TWP9\2_P!E#X>_L_Z?\-/@I\(-(^(/Q2\-^+U^)6K^*K?Q
M/XR\?^,7\&#P4NDV=Q;Q3:)I=EH_CC68=:LK32Y]:TVT:R2U(!^?OQ!_;"^/
M.O?\&\WQT\5WOQ3^(GA#]KW]E7Q#HW[,?Q8^(GAKQWXLTCXI:;\3_A5^T1\.
MO!%[JUWXYT[4X/%<VO\ C#P)J.BW>O:K>:GYFO3^(]1FOKB[:6X@DV/VF_@E
M^T?_ ,$TOV4/"O\ P40^"'_!0/\ ;I^-VK?#>?X-^*_B[\#?VM_CC'\:?A-\
M2O 7CW7/#.@^*?"NC:3J'A'2K_P?J<]]XJB^P>)+9]1URQLC/)IMQ::LEKJ4
M?1_$3_@A[\5O"'P@_P""D?[+/[)FO?![P/\ LO?M@:5^SOXA^!W@/XB_$+XN
MZGJGPG^*?PQ\5^#-5^(X\0:G>^#/B'J,GAKQSI6C:G<V6O0>(O$FLV^K0>']
M _L>ST^"#5++U?QI^PG_ ,%5OVROA]X$_9?_ &XOBI^PEX!_9%T;6_AW??$S
M1_V2]&^.FH_%OXK^&OAKJ&CZKIOP^O\ 7/BQ]BTCP?;:M=:/IM[-XH\*RV.J
MZ??V<,IL-1TIKC1KT T/&&J?&[_@I9^WQ^T1^S-H/[3O[0G[)/[,7[(/PQ^!
MFI:^/V8/%^F_#+XS?%3XL?'/PW<>.-&UN^^*D>AZ_JVA^$?"_AR&329O#,%N
MUIJMW9&?4[=8=0+VGZ&?L*_L\_M1_LT^&_B9\/?VB/VIM4_:H\'Q^.;N;X!>
M)O'=C=77QB\/?#J6W"1:%\4/B!=7%L?'&NW-R8)8I);*2>WEBNYAKLME=V&A
M^'_F7X[_ +#?[6WPV_:J\8?MG_\ !-_XD?L_^&?B'\7_ (?>#OAS\<O@K^U%
MX;\=W'P6\;I\/+5--\">.M+UWX2JWC+0O$_A?00FBQ6%I9G3;J,W+K?VL-W=
M:<?IS]A3X)?MB?"?P_\ %'Q+^VK^TMI?QU^*GQ7\=R^,(/"_@72)=-^#/P3T
M=;"*RA\%?">77=+LO%]UH)\FWGO)M933[)A!:2C11X@N/$GB'Q& ?(/QH_X*
MN?M"^%_VO_VE?V._V</^"=GC']J?QE^SEX8^&7C?5?$&@?'[PG\.-*U'PMX\
M\#:1XTU2XU6+QEX$E70M;TIM;M-)\+>%M&OO&6L^.9+;4IK6WT-K6VLKWP'2
MO^"A5Q^V'^V%_P $4/BC\$_%OQ6^'?PC_: M/VY++XJ_!J?Q7J>DZ9J7BSX5
M_#$V\OAOXB^'O#^JMX=\:2^#/%6F7U_X2U"]L[F,17%GK=M'I4UU=VEGXI+H
M?[=6K?\ !:'_ (*I2_L(_$+]G[PGXTM_A3^R5:>)?"'[2WA?QMJOP\\16>N_
M"CPO_9GBNPUWP!/)XM\.^+O $\>L7&D0?V%XA\-:_/XCDM?$%C;VEE:2CZ8^
M$'_!'7XE_ OQ'_P30G\)_%WPUKEA^R+IG[8.J?'7QUJMUKNE^/O%WQ(_:E\%
M:O8?\)'\,=%70-7T>ZM?#/BW5G\BU\4^)_#!CTC3M/U9VO\ 5GU"UN@"_:_\
M%NO$.C_M2?![X)_&G]B#XA_ CX8_M!?%R+X._!_Q_P"/_C'X!T_X[:IJNJ:]
M#X=\)^*/''[&=YI-A\9_AIX'U[6KBP$OBWQ-,-.L=$U*PUO2+K5AJ-E;WGY?
M>/\ _@I/_P %3D^#/_!8'4T^ OC"PTWX;_%CQ3X.@^,EC^TW\)[6]_8OLK#_
M (1CP^/ _A+P5'X=AO\ QY-IVA:Q+XGA\<^#?LTMW<ZJMTUXNHVMM=#U;X*_
M\$'?VQ?AKXM_9EU;6]:_X)]:S_PS7^V%X*^/&H?%+1O"?QAA_:-_:&\)6/C7
M5/%'B:_^,/Q=\2Z/XGOK/Q'ID7V&/P=\-?#MJW@>\U>[?5O$OC275/">@W=]
M]=?%+_@EQ^VKJL?_  51^%?@'X@_LO77[/7[?]WX@^*'@ZX\9O\ $[1?BWX*
M^-&K:GX&%EI>OS:1X4UKP=I_PWT_1M*\0QR7MA8>*O$-YJ5MX<O+33M*6?58
MW .._9=_;E_:1_9F^"G[-_[*_AW]EO\ :K_;._;R^,OP^\1_M-^)_AG\</VS
M_ /C[4O _P %K[6'T71/&_B?]J/7O#D?@_1- \6+IEK>_#_X9MHAN= EU*3P
MSXA\1R>+;S3Y?%'O'C;_ (+E^'_#'[+GAGXZZ5^RWX^UKXKV?[9>C_L0?&S]
MF'4/'6AZ%\1/A1\8+K3O$&HZM9:1KJ>']8T#XAB%-%MX?#8@'A?3O$<^J1P7
MFL>';FRO8(NB^,7_  3_ /VQ/!?QI_9X_:^_8@^)7[.^C_M$_#S]E#0OV1?C
M!X%_:0TSQ_JOP0^(/@C2)-+UNTU32==\!:?_ ,)]HNLZ/XKLFF@DM[.S?4[2
MST6UDN-)T]?$FB^(?%&_X(Z_'9_A'\.I=8^+'PP\9_M,>+/^"G_PN_X*)_M4
M>,KX^*?"7@.\@\*2^)FU+X=?"*QTSPYXEUF6VT"+6+>'PI;>*(="L=1>[UF:
M[U+0K;[%96H!Z#XL_P""O'[6_A'XT^#_ -F.Y_X):^*-<_:5\5_LW:Y^T-=?
M"GPO^UC\,]1A\&V>C?$CQ3X0_L[QAX\O_ >D^"[3PW=>&/#"^)H_&.CZGKER
MWB+Q%X:\!6OA*\OM0FUBSQ/@_P#\%X%^*VI?L<^*;O\ 8F^+7@3]G3]K;XG:
M1^S]I_Q\\1_$3P/<6_A_]H;5I;G3)/!'A[X=Z7:77BOQEX*TCQ%%_8NJ_$[6
M&^'UC&UIKLEGH%[=Z'<Z;+]B>)/V,OBAJG_!4AOVW8]?^'H^%'_##^L_LVCP
MU>:MKZ?$$^.K_P"(\WBU=832AX4N/#\?@]M,N(K.^U"#Q:-;>Z\BU&@W5G!;
M7$OP5X)_X)"_M%>%?V0?^"8/P!N/&7P./C;]BK]NO3/VH?BSJ]CKWC.7PWXB
M\#:=\6/B'XR73_ U[-\+QJ^K>,8] \6:3:V>G>(M$\*Z##?:;<69UZ+3K*UN
M+@ _7G]OKQY\3/AK^Q9^U)\0_@Y)IEO\1/!/P&^*GBO0-2U/Q+J'A;^P5T'P
M;K&HZAXJTG4-/\(^-9KKQ)X5L+>?7O#6B7.B0:=X@UZSTW0M0\1>%;/4I?$V
ME?)GP&^,_P ;_AMX/^"G[,GPN^$&D?&']HW4?@[8_'SXOGXQ?MT_&KQMX%\
M>!_$FH7.@>%=9U7]H'XG?!GXI?&7Q%XN^)NLZ3J%QX>^&VB?!VW\$^$GT?QG
M:2>*-$TO2O#=QXP^\OVI?A?KWQM_9F_:&^#/A.\TC3O%/Q9^"7Q4^''AR_\
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M4445F=Q0N_\ 53?[C_S%?%7_  3$_P"4;7_!/O\ [,C_ &4?_5#> *^U;O\
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M?W7B[QK\%/\ @F)^RK?>*/B;\.?A;\5/#7[9/Q3^(^L_"SQQXN^$?C/QC/\
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MET?Q7IGB_P AM:T&?6QHGBKQ7IFL7O ^B_M8_$#P7X,L[F__ &C_ -IGX#?
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MNL>)_B-XAUK3]-M-1UGXD^/)YV\3W_X:?M0W_CSXI?$K]HW]L:STOX@^'O\
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MM=D#Y<H7(8LX)VL13C'G.YFR5*Y7Y2-V>5*X(*@D1G)9<G+,34E% $8B51M
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MNZJLK1N29/-Q*)Z* (1"%&%9D QM"LP1!A4 2/<4"JBJ%3;Y8;+E"S/E/(7
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M%OP[=> M7DT+XW?$5/B_XXTD?$OXK1V-A\6(M6?Q#'\4/AC!'XY5?@C\2/\
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MHT>P^(OP4\;?#WQRGA[Q-:0VP\0>&I/$$GA[6I;+3KK4=,NKK3=/N+;Z!$0
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MSLKF#U7PE\)? /@;QA\3?'OA70SI7BSXQ:WH/B/XCZL-4UB]/B+6O#'A#0/
M6AWOV+4M0O--TH6/A/PQHND_9M&LM/M9_LC7]Q#+J5W?7EUZ110!X/\ &?\
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M\ ^);N7Q_K.B^(OB7X-T7XP_&OP?\'/BSKN@K81V6K?&+X"^#?B+X?\ @?\
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MBJAV=!MKX/U+_@EO_P $V=4MI[6[_P""?_[%X2Z39)-9?LP_!?3+L9Y)@O\
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MQ?[13XC=&\=FE)ROI:ZL>34X^Q-"ZK<.XJC)/7V^)KTJ:\G*>6Q=W;W5U/\
M;U^TK_D'_&C[2,\8Q[@_T!K_ !!Q&YR-N&4Y96MU&$#,-Q81$!2NUMSE$))&
M\XW%C%452YMUW-@%D0 LQ(2.-RFR5S@EA&6"!@6?!^7J_P")>,1\,>,L%*5_
MAED=>$K=7=YDZ&G;VW,_LJ3N<[\1WLLEBWVCF4V[+1NW]G[:ZOH?[??VD>J_
M^/\ _P 32&Z [ _0.?\ V6O\04G'&V/_ +XA;GN-\>]&P01E'8=B005#<_[*
M?]^T_P#B:I_1XKQDH2XRPRFU>RR&4E9;ZK-_T#_B(^]\F:M_U,I+_P!Y[/\
M;[^UCT_\=?\ PH^UCT_\=?\ PK_$$S_LI_W[3_XFC/\ LI_W[3_XFG_Q+O7_
M .BRP_\ X8)__/8/^(CQ_P"A/+_PY/\ ^=Q_M]_:QZ?^.O\ X4?:QZ?^.O\
MX5_B"9_V4_[]I_\ $T9_V4_[]I_\31_Q+O7_ .BRP_\ X8)__/8/^(CQ_P"A
M/+_PY/\ ^=Q_M]_:QZ?^.O\ X4?:QZ?^.O\ X5_B"9_V4_[]I_\ $T9_V4_[
M]I_\31_Q+O7_ .BRP_\ X8)__/8/^(CQ_P"A/+_PY/\ ^=Q_M]_:QZ?^.O\
MX4?:QZ?^.O\ X5_B"9_V4_[]I_\ $T9_V4_[]I_\31_Q+O7_ .BRP_\ X8)_
M_/8/^(CQ_P"A/+_PY/\ ^=Q_M]_:QZ?^.O\ X4?:QZ?^.O\ X5_B"9_V4_[]
MI_\ $T9_V4_[]I_\31_Q+O7_ .BRP_\ X8)__/8/^(CQ_P"A/+_PY/\ ^=Q_
MM]_:QZ?^.O\ X4?:QZ?^.O\ X5_B"9_V4_[]I_\ $T9_V4_[]I_\31_Q+O7_
M .BRP_\ X8)__/8/^(CQ_P"A/+_PY/\ ^=Q_M]_:QZ?^.O\ X4?:QZ?^.O\
MX5_B"9_V4_[]I_\ $T9_V4_[]I_\31_Q+O7_ .BRP_\ X8)__/8/^(CQ_P"A
M/+_PY/\ ^=Q_M]_:QZ?^.O\ X4?:QZ?^.O\ X5_B"9_V4_[]I_\ $T9_V4_[
M]I_\31_Q+O7_ .BRP_\ X8)__/8/^(CQ_P"A/+_PY/\ ^=Q_M]_:QZ?^.O\
MX4?:QZ?^.O\ X5_B"9_V4_[]I_\ $T9_V4_[]I_\31_Q+O7_ .BRP_\ X8)_
M_/8/^(CQ_P"A/+_PY/\ ^=Q_M]_:QZ?^.O\ X4?:QZ?^.O\ X5_B"9_V4_[]
MI_\ $T9_V4_[]I_\31_Q+O7_ .BRP_\ X8)__/8/^(CQ_P"A/+_PY/\ ^=Q_
MM]_:QZ?^.O\ X4?:QZ?^.O\ X5_B"9_V4_[]I_\ $T9_V4_[]I_\31_Q+O7_
M .BRP_\ X8)__/8/^(CQ_P"A/+_PY/\ ^=Q_M]_:QZ?^.O\ X4?:QZ?^.O\
MX5_B"9_V4_[]I_\ $T9_V4_[]I_\31_Q+O7_ .BRP_\ X8)__/8/^(CQ_P"A
M/+_PY/\ ^=Q_M]_:QZ?^.O\ X4?:QZ?^.O\ X5_B"9_V4_[]I_\ $T9_V4_[
M]I_\31_Q+O7_ .BRP_\ X8)__/8/^(CQ_P"A/+_PY/\ ^=Q_M]_:QZ?^.O\
MX4?:QZ?^.O\ X5_B"9_V4_[]I_\ $T9_V4_[]I_\31_Q+O7_ .BRP_\ X8)_
M_/8/^(CQ_P"A/+_PY/\ ^=Q_M]_:QZ?^.O\ X4?:QZ?^.O\ X5_B"9_V4_[]
MI_\ $T9_V4_[]I_\31_Q+O7_ .BRP_\ X8)__/8/^(CQ_P"A/+_PY/\ ^=Q_
MM]_:QZ?^.O\ X4?:QZ?^.O\ X5_B"9_V4_[]I_\ $T9_V4_[]I_\31_Q+O7_
M .BRP_\ X8)__/8/^(CQ_P"A/+_PY/\ ^=Q_M]_:QZ?^.O\ X4?:QZ?^.O\
MX5_B"9_V4_[]I_\ $T9_V4_[]I_\31_Q+O7_ .BRP_\ X8)__/8/^(CQ_P"A
M/+_PY/\ ^=Q_M]_:QZ?^.O\ X4?:QZ?^.O\ X5_B"9_V4_[]I_\ $T9_V4_[
M]I_\31_Q+O7_ .BRP_\ X8)__/8/^(CQ_P"A/+_PY/\ ^=Q_M]_:QZ?^.O\
MX4?:QZ?^.O\ X5_B"9_V4_[]I_\ $T9_V4_[]I_\31_Q+O7_ .BRP_\ X8)_
M_/8/^(CQ_P"A/+_PY/\ ^=Q_M]_:QZ?^.O\ X4?:QZ?^.O\ X5_B"9_V4_[]
MI_\ $T9_V4_[]I_\31_Q+O7_ .BRP_\ X8)__/8/^(CQ_P"A/+_PY/\ ^=Q_
MM]_:QZ?^.O\ X4?:QZ?^.O\ X5_B"9_V4_[]I_\ $T9_V4_[]I_\31_Q+O7_
M .BRP_\ X8)__/8/^(CQ_P"A/+_PY/\ ^=Q_M]_:QZ?^.O\ X4?:QZ?^.O\
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M!AG'/<"-Y5D(/F(OWH\98G<0V" H.2N2>OW22=H4FOYROA=_P:P_\$J/A_\
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M_P#!+XZQ>$O[7_X16/XR_"GP+\3T\-'7QIHUW^P4\::'K*:.FN#2-)764L!
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MXZ_^%?X@F?\ 93_OVG_Q-&?]E/\ OVG_ ,31_P 2[U_^BRP__A@G_P#/8/\
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MVG_Q-&?]E/\ OVG_ ,31_P 2[U_^BRP__A@G_P#/8/\ B(\?^A/+_P .3_\
MG<?[??VL>G_CK_X4?:QZ?^.O_A7^()G_ &4_[]I_\31G_93_ +]I_P#$T?\
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MY,V_/,I;==LNN_0_V_#<^FS\=X_]E--%R&YPGID[AQP>C*IQ] 1[YR!_B#
M_*3 #DY^53V&U56)'?>W.4=4V  \[B5<L8Y! W##.-@<+&,EI#Y99E(!4J'C
M3>69=R[ 6%]';$3TCQBWN^>/"E=T[+?WI9S#1Z6;LO4%XDPCODU5R[?7^:.N
M^GU*#;_[>TW:U/\ ;[%PG^R!VY/\BHQWIK7*Y"Y3!'\1/7G_ &<=NYK_ !$=
M-TG4=:OK72]&L+G5]3O'\FRTW2;1]0O[R;@B&UL[:.6YN)"K)A(HF<LVQ0S#
M%?<WPH_X);?\%%OC6;=_AW^Q/^TEJ^GW;0BW\0ZO\)?%7@SPI.)RH4P^*O&^
MF^&_#TIPR%@NHGRTECFG\F"2*9_/Q/@/A< G4QOB-E&&C%J,HXG*\+AY)RND
MN2IQ"IW;32C9N][+0Z*'B!6Q,E&CP]BZTFFU'#XB<ZFEM4OJDM%=<VFET?[!
M/V@9YV_@6_GM(%.\]?8XZX.?_917^8]\*?\ @U[_ ."KOQ&,)\5> _@U\#XY
ME5RWQ5^,/AZ_>-"YRLEO\'[;XKW2S&+$@B:%2"3'*8&&3^F'PF_X,\/'-Z+:
MX^./[;'A+0/+D!O-#^%/P@U;Q<+J,QPLR6OBKQ9XQ\&?V>Z2F9!/+X,O_-18
M2T2>88X_D<9P-P/@G..(\6<N<H*2Y,)PKF&82E*+Y>6/U+,IINZ=WS**2YF^
M6S?L4>(,^KM<O"F,I0:NIXO'0P\>C7O5</%)O[*:U=TK/0_NN:Z08 *DG_:Z
M_0 9/UZ9X)ZXC-RH.XE,="?, Q@N><C (R>,\#J#FOYA_A5_P:<_\$W?!?D7
M7Q$\8_M&_&F]V1+=6>O>/O#_ (0\+RR1-ND-MI7@'PCX?UV".4DH\%WXMU)8
M1E[5H)WDE;])?A7_ ,$1/^"4WP>B2+PI^P[\$M8"1M'YGQ/T/5/C1,ZMMR)7
M^,&L^.&EY&\%\A&9_+"!F6OBLQP'#.$E*&#XFS;,[2?+*GPGA\'2GRM27[S&
M<1*K",VDDY4)2CJY4W91?NX7$9M5:=;*:6'BXRNWF=*ORMJR_=TZ$)/=Z^T2
M\GT]P\?%7_X*3_LI,K Y_8>_X* A!DG=_P 7Y_X)G@LI 90%W*7W[3M(:,2@
M2B+[KA)*L<8R[8Y!R =N<@D8;&X<YP1D*<J/FWX/?L;?LE?L^>(;_P 7? 7]
ME_\ 9W^"/BK5-$N?#6J^)_A'\%/AO\-_$.I^'+V]T_4KOP_>ZWX.\-:/JEUH
MEWJ6D:3J-SI4MV]E-J&E:9>26[S6<#+]*H, \YY/4Y]/\]O8 8%>/4G3E.DJ
M?MG&G25.+J0A'W(N4DI>SE4C=.<N6TVW=W;2BEW8>DZ:J2G:-2I5G6G%:QYZ
MB@I23N]U"*M?E5KI)MW?1112.@*0@D]>/3&<TM%'6_7_ # ;C_=_[Y_^O3#$
M"<\''3.<@\Y((*D9!P>3T^M2T<_A]/ZY_I2<4_)]U[K^]6=NZOJ&SO=_>[?=
M>WX$7E]/F(X&1ER#SD'!<CKG)QEA@$X7%,:W#XW%3SD@QJRL1@@D-DC:5!&&
M&" <YQBQ12Y8]8Q?^)*7_I2E_7WCN^[7FG9_^!*S_$KM;J2#GD-N&%7AN1N&
M1PV, 'J H4'!8-Y+\2?V?O@A\9+:2R^+WP>^%OQ5LI+<VLEI\2?A]X5\<VTE
ML9'E:V>W\3:9J<#VYDEE<0M$8E:1ML?)S[%13A*5*?M*-2I1G9Q4Z-6K1DE*
MW,E*E5IM*5E=)V?5=3*=&E5CR5J<*T79\M:$:L;J]GRU%)75W9VNK[GY&?%+
M_@A!_P $E?B[]H?Q+^Q+\)]"GN#.XG^%S^*O@R+>6?.)+>T^$_B3P;IZ"+=E
M(&LY+4E%#0%1L/YR?%+_ (-+_P#@G'XPEN[SX>^/OVEOA!>RPRK:V6B^.?"G
MBWPW$[)L@-W8>,?!&I^)+N"U(#1P0^,+&1VW-+<.TDC-_4=2$9.<D'&.W]0:
M^EP?&G%V7QC#"\39U3I1E&4:%3'U\3A[P5HWP^*>)HM16T7"VB:5]7YE?(,E
MQ*:JY;A-=;TZ2I2O_BHNG+7JKV?5'\*WQ4_X,Z?%UG]IN_@O^W'X>UHR&8VN
MB_%+X+ZCX<:+;$@MDNO%?A/QWXGCO&GN,K-)%X-TT6T.)8[>\E#J?S?^*7_!
MK+_P52\!BYD\'Z-\!OC:D09K:/X<?%NWT6YNQY:21@)\7M ^&%M%*2Q24->-
M'&ZGRIK@?,/],21,D$L1U^[G/0A>=PR &8X8,NX@C:5!-=XUW$Y)!P<%L9(S
MDG );.[&TDH%50JC'/UV \;/$#!J*K8W#8^G#W(K&Y9A*B:EHFW@:>#Q/-%)
MI7FH)-NI&5HGC8G@7(,1K##3PW5SH5*\YIKHHU*LX6;>NFEM+:G^19\4?^"/
M7_!4'X._:F\;?L.?M"2P6.[[7>^!? =Y\5M,MUCC\R::35?A8WC/3?LT>&_T
MI;IK=E4OYH4BO@/Q9X'\:^ ]5DT/QOX1\3>#M9B?RWTOQ9X>U3PY?B3#$H;7
M6+.TE1E"/O\ -$85U,1/G%8V_P!M/RU4*#R5R <X.P\X*IL!'0#*D9P2,\US
M?B3PCX9\86,FD>+/#V@>*-'N-OVC2?$>D6.M:?.P22$&2QU&"YM6 CED4#R<
M8DDQA9) WV6 ^D-FE.2IYED&7XE.]Y8/'XG SLDK6I5</B];W^TH<K2;35WX
M6(\-\)*_U;,*M-]/K5*G[);^ZY0?,I/3EZ731_B3C<3\H#*=N& P-KA\$AE5
M@?D*E"-V[<F-Z,H<RNN05^8; N(I""7"D!OW0:,_-_RT4';API4J6_UY_BA_
MP2/_ ."9WQA$S^.?V'/V<9KRX!^TZOX3^&F@?#S7KES%Y!EN/$'PZMO"NN33
M>2%C65]19XU2-8BGEIM_.+XF_P#!K9_P2C\?>:WA3P=\:/@HSX\H_#3XPZ[J
M7V8^7<1LL*_%^S^*V(7-R[F%RR(ZKY(B48/UV#^D#PO/ECF.5Y]@)N-Y2HTL
M'C\-&5U[JJ4ZU'%2O?1O#*-T^=QLG+Q:WAUF\&W1K8'$0O[O+*4)O?6TU:W?
MKVWT_P S0_>VJ588!!'E*6!&X; S*68J5)7 Y)&3U*$D'M]"@##V88(S]"PP
M1@FO[L?BA_P9U_#RZ:6?X+_MN^./#D<,>ZUTSXI?!_0/'ANY-I7RKG6O"OC#
MX?):AL1YN;?PQ/)&=SK%(NR*+\Y/BA_P:5_\%#?"0N;KX;?%#]F?XKV,(+6]
MBGBWQKX)\4W)WRX1=.\1^!I?#D0:,1,K3>,542.\3%4B$TWV&!\7N L>XI<0
M8?#<S?NXS"XS"U;J*=^>I"5%1ULY-I-KEBTWKXU?@[/Z#?\ PFNO9:JARSE:
M]N9)25TNN_\ E_+3GU_]!4_X4;B. >/H!_C7Z]?%#_@@O_P5K^$@N9O$'[&'
MQ \1V<"M)#<_##7/ OQ8FO8@TBB2UTKX<>*_$^M&0F)V-I-IL%ZD9CDDMXTF
MB+_G7\3OV<?VA/@J\D?QC^ _QF^$KPG;,GQ,^%_C?P*T;[W3:Q\4:)I: ED8
M []I*L 258#[# <29%FEO[,SO*<<W!S5+#XW#NLZ:=G4Y:E>DE&.B=U&[=HQ
MD[I>/7RO'89M8G+L;2<7RVJ8>48)OHI*-NETKN_<\8R?;\A_A2Y]?_05/^%-
M!C.S,D8$F<9>(#IT#,ZQDGK@N-V0(R[959#'A-Y)4#YF+*XVKE5!QM+ LS8V
MNL;  , RNK5ZL*E.<K1EB9RLWRT(1KJRW=J=.<6H]6JVBMI*^G$Z<8O]Y3J0
M7G3Z]%K;=_UJ,R?;\A_A1D^WY#_"EV\D<$@E<#Y\G) .(M[8(&<D+@Y![$MR
M&Y7&!D9!4\@D'HS$<Y&&VMC!*@$9MSZ*23_EG1K4ZOWR_=I+JK7?3J1RK5J'
MN]Y12]-+_DO787)]OR'^%&3[?D/\*2BCFEW?]?(-/Y8_^ K_ #%R?;\A_A1D
M^WY#_"DHHYI=W_7R#3^6/_@*_P Q<GV_(?X49/M^0_PI**.:7=_U\@T_EC_X
M"O\ ,7)]OR'^%&3[?D/\*2BCFEW?]?(-/Y8_^ K_ #%R?;\A_A1D^WY#_"DH
MHYI=W_7R#3^6/_@*_P Q<GV_(?X49/M^0_PI**.:7=_U\@T_EC_X"O\ ,7)]
MOR'^%&3[?D/\*2BCFEW?]?(-/Y8_^ K_ #%R?;\A_A1D^WY#_"DHHYI=W_7R
M#3^6/_@*_P Q<GV_(?X49/M^0_PI**.:7=_U\@T_EC_X"O\ ,7)]OR'^%&3[
M?D/\*2BCFEW?]?(-/Y8_^ K_ #%R?;\A_A1D^WY#_"DHHYVMV]=/F]NC''EO
MK"+6OV?\F+D^WY#_  I1N/09^B@_TI!C*@Y^8XXV\<J#R[(O0G W9+ +QNR!
M>3QU!XPT1!^7)&5E)[G[H.1@YY( U4NE&:G-IM0<93]U?$[0Y9:*W6RZW#E6
MZ4(K7WI1T_!M^@IR.",'T*@?TI,GV_(?X4JAR1EL G;G+'YMI8CE5#'  PC,
MWS [>F9+>&6[DCA@CFN+B4HD=O;133S,SX"K&BQ$N[,=JIPY(X3D;DI6NI5(
MJ23;BHSIM6WDY3DTE'K?H_(M4[J_+"2Z*E"3FWTWOIWT[;$63VQSQT'/MTI<
M-_=_\='^%?87PM_X)Z_MW?&K[))\*_V._P!I7QK97WE&VUK2/@SX['API<*3
M!-/XIO=#L_#%E;3*K,L][K-NKJK-") *_1_X6?\ !MG_ ,%<OB7]GFU'X!^&
M?A5IMSY)CU3XH?%KX<Z</+FD5'>30O"FN^+_ !C9_9E)DGCU+PS83E%_<13L
MRAO Q_%?#^6W^N\0<.8-QDH26)SG RQ"GJU#ZHJT*S;2>K:<?Y9<R1WX;)LU
MQ5I8?+:M9/9NE-?.]XK\3\'\/@G8< 'YM@*@C'#;0SJ.1\VP@]!DC%*JL^-N
MT_>!("L"5 .$*!L]1Q((B.X]?Z__ (6?\&?/[4&M"WD^-'[6_P #/A\#N-S'
M\-?!GC?XNS0A9&"K$WBB+X-+.SQ@,V^:.&&0D(D^#(_Z/_"W_@T)_8WT2*WE
M^+W[2G[1?Q%NX61IX?!UM\/OACHM[(@3>MQI^H>'OB1J,5M(0X\BVUV&5495
M6XWJ9'^-Q_C/X?X&$O\ A=>,K):4<ORO,ZOM$G9NG5G2AA59V:YJT>9.\.;K
M[F'X)S^NHM8&A2NM77FH1C?KI)NZ6W=G^>_G !;"9SPR@$8('.<#'/W@2O;.
M00 %2#\ZG&.GE,%W!RI=@V(U812@,W&8RN2:_P!4+X7?\&Z/_!(OX7FWNE_9
M;A\?:O RL=5^)OQ(^)GBR.X5$C58[GPS-XMM/!,J%T:9P?"_SR32JV81%%%^
MD7PK_8G_ &/O@>UM-\'?V6OV>/A?=6<JRP:AX#^#7P]\,ZH)UB2$74NJZ-X?
MM-0FO&B18Y+R:X>ZE1(UDF9445\?B_I!Y+3YOJ60YSC-6HSJ8K!8&,E;2;A.
MEB*BC>UX:3M=WV1[&'\-\;-J6*Q^#HZ:PHQE5FF]K.32[W>NFS3/\A[X7?LF
M?M4_' 6[?!O]FSX]?%:.Z1)(I_AS\'_'_C2T,,BI(D[W_AWP]J%A%;F.2.1I
M9;I$C5@S[8RKM^COPO\ ^#?'_@KE\4VM)K7]DS6/ ^EW+6[2ZO\ %#QU\,_
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M>#?B!HY2XC&D^-_"^B>*],V7<<<-V/L&M6=Y:J+F*-4E6&*%)%.)DD-?G?\
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M']Y)0-S_ !?PMN4LI.1D%@<D9X!&.,8I4CP#\TBGL2Q)'R@%B#F-F//.S X
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MFFW[:I9+1?RN]^VEM'>]D?YKFQP0"K<C=N"LRA<G#\+N*'&-^S;N!7.0:U]
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M\^21CC(VC.Z3G &.6)<AE9RNR-LLC,67<.0,[HU,9W @;R%(P06!KX \)_\
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M@RQ^,L?P%N/VC?"3?$N;Q"/"0TZVTWQ;>>'(O$[W#V:Z)<_$&T\/3_#VQO\
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MH#:'J4,]Y(=)N?HK]B?QQJ'B7]EWP+\0_%W[1J_M+1:Y:^)O$0^.-U\,-/\
M@?::SH=OK6J".%OAY:6.EP^&K3PQ;64FC,U[;1WEXNFRZC>.SW#$==7A[-L/
ME%+.<7A,5A,/6S6MDE"G5P^+C6K8_#J^)C";P?U5K#N=&%2+K0Q*G-06%DXS
MDKJ9=C*.#EC*]*%*G'&1P,83^LQQ,\3[O/3Y)4%27LG4@K.2G-M1C=ML^QEF
M4L0, _CDGW.WI^!_(TQYR@9L*V I.7P0"6&<;>F0,$?>Y(.1BO@;X7?\%.OV
M%/C)\6X?@C\-/VA?#?BOXCW][=Z=I>D0:1XTL=&UZ\LL_:+7PQXUU?PW8^ O
M%,[A7>PC\,^)=4.I1PSRV!N8H)Y$T_C5_P %$/V._@A\34^!/Q"^/WA/PC\7
MK^WMTMO#EQ#K%[#HNH:K:&YT2W\6>);+2+WP?X(OM0@DMM1L[3QSK>C^=I=U
M9:F;633[N">68\-\1RQ=/ O(\\6,E3==8:64XVG5>&56%.6*JT)4/;K!4I58
MQJXN"]G%1YI.,DHU%#*\RGB*>'C@L3.I4C.:BL/7A/V=*:I5:D81C4DX4YR7
M/4ORPZQ^RON".X=GVA4V@G)#R=!UR# HR%Y^9L=LXP2]K@[FCV' "%7+':V]
MF!RP0JNW:2<X!X^:ORU_9F_;K\*^&/\ @GQ\%OVHOVSOC)H>D7?BO3]7CUSQ
MG?:/;6ESXAUW_A+O$VGZ9INB>#/ F@PW6K:LFD:2K-H_A3PM<70M=,U'4Y[;
M[/:7E\W >$?V]-#^/O[1'QE3X,?M%:2/V;]$_8*O/BOI/B[3? ]CKDGP[^*%
MKX^\3:+K/C74_#>M>'+;QU<:UX:\.VNEZE+\.=?%O;7MI!8S2^&C+K5I>7?9
M2X2S^O5S7EP-583)/;QQ&91H8NIE^(KX;&X/ 5*-#$TL+4IU9RKYC0C"@E"M
MB(QE*G*%5PH5=:>2YC56+]CA\1.E0A)SQ4J=>5*E45?#T5!3AA5[TIUU"$94
MY.4DTW&5D_V)^UKD H022HQN)'*J3]T'8&.&8?=^3CYN'QW 8L"""F X^<]L
MEER@+#G /&X#<!M(-?D'X6_X*5?#;2OVI_V=_P!E36OB]H_CZ+XA?L[>#-9O
MOB3+\,O'7A[6_'GQH\?IX OOAMY.CZ7HY\/^$-(\?^"M3\0^,[VTDB32/#6H
MW&GZ'JNM^'[ZWCT^^^B/!'[7?P8^$?[*'AGXZ_';]J;0O'?@R]UGQ5H\/QKU
MGP!<?"Z;QAJ=IXO\56D7A[1_A98Z<-<FUKPU9Z+=:"--T;1;K5M;LO#-[XI^
MQRVT]W=C#$<-9[@G@:>(R^O/$9K2I8C*Z&'P>8^UQ]#$5L;AZ4J%">&E.4O;
M9?B:?LI3A6E*/+[-5HU*,#$93CJ4Z5-8>K*5>$'1A3A7E4E.I5Q$8/V<Z$;>
M[A*SE&4HMV:B[IM?>K3#Y.BAL[>6^;&?1?8=QU[8Y43@L5V\@<KSP"!TXP1Z
M@?7GD#Y"^"_[=_[*?[0OP^\>_%#X/_%[2?&7@WX5Z9=ZS\0[JWTCQ3I>N>$M
M(M;#4]3_ +1UCP9KVAZ9XSMK.\L=&U:?1YO[!=-;_LV^CT<WLMNZ5Q'PS_X*
M9?L,?&;XHZ#\&_AW^T)X6\2?$3Q3I=AJ?A_0(].\46-GJBZA91:E:Z59Z_J>
MA67AJ3Q6+:XV7G@Y=9_X2VRO+:_TV_T2UU+3-1MK7&60<1..,Y,@S:4\KA.>
M81>78U?4DH*I?,&L/)X&/L.;$<V(4$J<')IPNUSQRW,93KQ6#QG-A.1XI2P]
M1JFJE%XB+DHQ4J*=).:DY58J,&WI=GWH9MK88 9(5/F/S8&6)&T;>> 3@'KC
M X#.>3LR54,RAU#J#G!(;: I((#%@K8;D$$'X&^,?_!3?]A;X"?$P?!WXK?M
M"^%_#7Q#AN;:RU+0K;2?&'B2UT&]N3&([7Q9K'A/PYKNA>%9(ED6>\'B74M)
M^P6G^EWWV>U!EK5M?C3XMUC]O7PY\+-%\56]_P#!W7OV-KGXNV6D6-GH5YIV
MH^+&^+EAX=TWQ58^(H+%M9FL[KPU>-%':1:S)I%Q"]K=Q6D5VLTT[EP]G3HR
MQ-?+\?EV$GE>(S?"XS&8/$4,+CL+@XX:=:>!K5Z$:6*7)B:=13H3G&5.;D_9
MI)RTCE>/24ZV&JT:4\//%4JM2A6ITZE.E3C-JG5FN2JYPG&I=*%HM.*<6F?<
MXDSGCG)Z$X(P"&!*@,"I&2,A2"N25-/4Y'3&#@?D/_U4SY1T.?O>N>1ZXQ[#
MC@'IWIZ]/KC^0KR+R<E;11<KK^:,H)P?=:W?G^!P*VKO=-Z=E;22\]?N'444
M58PHHHH **** "BBB@ HHHH **** "BBB@ J-G"L 3U'J<=3UP#4E5Y/OC[P
M&T?,!\HY;.<\9QTS]:F<E%7;Y>B=G+6SMHDWT>MM/S3O;2+E;5I2C%V6[O+2
MRZK=[(;),P("H3R/F!;;@DY.X(<84$X. ?E&X9J,7!,B@*#N4,1NY ;=QD!H
MR0%W >;G8"P!QBOSD_X*%>+_ -H#3;W]E3X;?L]?&\_L_P#B;XY?'VY^'>L?
M$$?#OP7\3Q8Z'9_"KXB^.#%_PB_C>SGL;EYM0\)61:2SO=)NX+5+EQ>E$,$G
M@E[<_M[_ +'?Q#^!&O?&/]L'PI^UQ\*OB[\=/ GP/\6>$]8_9Z\)_!OQ-X,E
M^(;W^EZ'XJ\%:M\.-5U:;6+RTUPZ;)K6F:_;W%DN@PW3P_8/M-QJ5I[^#X;G
MC,)@L4\XR>ABL=2S.K@<HG/.)9ACO[(56.)ITJU/)IY12J25*;IT\7F6&55Q
MY8U(3Y:<_4PN4U,7!.EB:7M:ZJNAAZG/3<O8PJ5:G+75*=&ZC1FE&3O.348M
M/5_LXLI8] =QRH)8<<X(W(,'.>,'(P0<$4JR'>P*CJ ,'J.01@J#D8''0YZ]
MA\>Z3^W?^RKK?QN@_9RTCXJV>H_&:YUWQUX;/@FT\+^.)[NQU;X:6TUUXUAU
MK44\-?V/H&GZ9#:W1L];UK4-/T/79+.\M_#NHZK+8W20\5\/_P#@IK^PQ\4_
MC)%\!_ W[0_A'7_B5>WSZ+I6F6]IXBMO#^OZI%Y133_#'CJ\T:W\">)]0N7G
M2&QLO#_B;4KV_G+6]E;SRV]PD/$^'^(O8U&LASGFI8&EF-=_4<2_JN"KJ->A
MC,2Y8:FZ6%JTI/EQ$J<J3@G*#J1Y*DL(9=F%6-2K2P=>I1A1CB74AAZTXQP\
MX<T*DIQ=HK23E-P45%)R23N_OEI0!DC'?#''0^_//;CKZTOF#!X'&,\\<CL<
M <?KUKX<_:&_X*)_L9?LL^-]+^'/QV^.>C^!_'&IV=AJ"^&[?0O&OBJ[L;/4
MS+]@N?$+>#O"WB*'PU%>QV\]Q9GQ'/I/VFRB>^C!M TX]2^*/[6/[.GP=^$.
MF?'CXC_%_P '^'/A)K]KI5QX8\:KJ8UC3_%R:W8R:GHT/@RV\/V^L:CXQO=6
MTR";5--T[PQ8ZO?W>G6UQ?16WV:VNI(,EE.;R67UEEV8.CFC5++Y0P.+G2QU
M;GTIX*?U>,\7-QDFUAXSY%&[C9W:>7XY0PTW@\4HXUM8-K"XE_6)*,I-4&X-
M8FRIR;6'YM$[-I77T@),@%0&!XX8$ Y]1DDGT('0XIOG $#& 6"Y!4C)X'<8
M))4*.221Q7R9\&?VW/V8/C[\+O&?QB^$GQ9T?QAX ^'-AJ6K^.]1ATOQ1I6K
M>%-.TC3[[5M0N=;\(:]H&D^,M/4Z7IE_>V"7'AZ.35TM)UTU+AXGQYU\-/\
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M#I'C?PQHWBC3&6[CCANQ]@UNRO;51<11K',L<,4<RC$R28K\\?BK_P $4_\
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M[LL27[L68!2[5^1?B+_@G5^T5XG'B+X3^*/^"C?QK\1?LI^++G5HM;^$&K^
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M@LO[=&B#"10<[E *[596)!W%TW L')9G4G;D[@ Y+M$8(0Q^12V\DY1>2P;
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M 4444 %%%% !1110 4444 %5ILL2I4%0JD>I9F88_# (P.O?I5FF-@G!Z8'
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MUXD\.7;^(KBWDM]Q:YU^?4[FXU9IUO1J]_<"YU!+V\=)3^ZD5O%PZ*@PNS>
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M+^_MO^$1AGM9HKJZU*[TV^M=OVBXL([5EG;YON/^"T'[/$-YH5U)\%?VMH/
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MLTGXL?M"^/-*\"^(]"6XUR[^&G@_P-;Z_P"!;;3H-7U'1I= U_Q!XOGU'1M
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M &/=)_9-M/\ @GQ^T?X5^(?PVNO@)H_Q(US5O!5CJ/PPTZV\!^/_  "UQ=?
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MM]-\+6N@>/K^Z;48E\57\WV/0=0\2^']!TZXN(G-W>V<$]E-=_8?@O\ :8\
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MJU)>RG-^SH3I5*4X3G*,9U8J:<K./V?XO_X*:_!?PQX%TWQEIOPZ^._Q%O\
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M(MKC33X>U?PCXTAT&TN_$_AKQ19R76EZAX4U--+TWP[)IAURQN;K4;Z:TO\
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M<G)ZM\M^B?+'EC=*RNEHNRT(]G!1Y5&T;WM&\?M*71IV<DFU>SZIE0VHP K
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M]F48RONY*[;**6BI@!MWW@=R !MQ5G)$6Q-S,NYL*%#;B$4%]SOLQ)7YU&W
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
JHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !< 2P# 2(  A$! Q$!_\0
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M(;72?$5YHDWAB\U$Q3+I":U_;!AF-@L3_#7Q2_X*)?ML_';]FKQ3^S]\+O\
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MZ\;?%GXK>/-8MO#?P]^&G@^VERCZSXGU^\@BDN62:/2='M]5UN:WN(-,EA<
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7 **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image_010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" #2 G # 2(  A$! Q$!_\0
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MX>\!WNBS>'GDN[>4:3%<QMM5AYGFDD$>F.* +6D^.;4>'+6[U"Z%Y<2B=_\
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MD2/%)&3G8Z,589[]/RHY)_S?@'UG"_\ /G_R9G)?\+)O/^@,?^^V_P#B:/\
MA9-Y_P! 8_\ ?;?_ !-=5!K%S>:3;WMI8;Q.[85I=H6,;L.3@]0!QC^*L_PW
MXQ_M[3+;4I;);.QG$F)9+@$JRMMVD8'7DC&>E')/^;\ ^LX7_GS_ .3,Q?\
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M *!&I?\ ?$?_ ,76I10!E_VS+_T"-2_[XC_^+H_MF7_H$:E_WQ'_ /%UJ44
M9?\ ;,O_ $"-2_[X3_XNC^V9?^@1J7_?$?\ \74%WXFBL?$4NFW,0CAAL#?R
M73/\JH&VD$8_'Z5+%XIT6=]D6I6[O\QVAN?E7>?_ !WGZ4 ._MF7_H$:E_WQ
M'_\ %T?VS+_T"-2_[XC_ /BZ:GBG19+0W2:E;F!612^[@%_N9^N>#0_BG14A
M,K:E;B,1^:6W<;<9_ESCKCGI0 [^V9?^@1J7_?$?_P 71_;,O_0(U+_OB/\
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MO^V9?^@1J7_?$?\ \74<_B VUO)/-I6HI%$I=V*)P ,D_>K8K.\1?\BUJ?\
MUZ2_^@&@#D?AG_Q]ZM_O+_-J[FZN8;.VDN+B18XHUW,QZ 5PWPS_ ./O5O\
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MP8J"PZ$CI0!Q/ASP?J6B:GH,\KP3)::4UE.=Y!5BX?*\<CC':NXHHH ****
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MZ5&T,;/M_P!(#!>2!V^4'GDG]=.]TH7NJ6%ZT[+]B+LD04%69E*Y/T!./J:
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MU#_H.WG_ 'YA_P#B*#I^H#KKEY_WYA_^(JEH5S))9ZS"\Y2.SO9X(IFY\M
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ML4<:6H5$1HP%=AN1CEE8YRP)YP<U+_8"_P#02U/_ ,"31_8*G_F)ZG_X$F@
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M7.U0%&3DX'O6=)IUI#%)++K=ZD<9P[M>X53Z$]JF30T=%=-4U)E89!%T2"*
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M&&?H: )J*:"HX!%+N'J* %HI-P]11N'J* %HI-P]11N'J* %HI-P]11N'J*
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M,G<K]FN8YW40N3)*.44$#'7!)]@/7'2&@#-_X1S1_P#H&6G_ '[%'_".:/\
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M_A0!5_M.P_Y_K3'_ %V3_&@:E8  "^M !T F3_&K/]FV&<?8[;/IY2_X4O\
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MK;_OTO\ A1_9EC_SY6W_ 'Z7_"@"M_:=A_S_ %I_W_7_ !H_M.P_Y_K3_O\
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MK27;S+%;RY@NS:2;BHP0H8MUY'(Z<^U6K?4+2ZACF@N8GCD)5&###'.,#UH
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M%%G;7GV*.XFN[6X1F>WOK<',#@?Q<8PP)&#P>E:E]JD%CIUW>9\Y;6(S.D3
MMM )]?0&IH[N&1$;S%4N@D"LP!VXZXH XW1&U&#7;;5M;C&R6RDM//CB*KN6
M8LKE>J>8I!^H^E5KFPO&\1OXB6VG;35U..4Q!"79%MS$9MG4@,P[9P,UVT.I
M07/DO;LLMM+&T@G5UV #'OGG/7&./I5E)8Y=WENK;3@[3G!]* (+6]@O6+VX
M+J!_K-I ^@)JU110 4E+24 >?S?\E>3\/_15==J/_(8TC_KK)_Z+:N1F_P"2
MO)^'_HJNNU'_ )#&D?\ 763_ -%M6-+[7J>AC]J7^!?J94&DS3^-]6NI1=PP
M/%:^5(C;4D9"Y8'U'(Z^IK$.E7=YH.I)/I^H_P!KK836TA.!'.Y.592,;R2,
M@_PY.<5Z'16QYYP-SH4Z7&I26VG3*1<6,UJ57HP*^:R\\' .?7WIL=G?R7=^
MRZ;>0K/IUY#L*D@R&3*98GYB020>G.!TKT"J>IZE!I5LLT^?GD2%%&/F=B%4
M9/ Y/>@#E+.PN6U*W@U"RU#<GV::UFBP$C"QJ&1FZKA@^5_B#=ZWM<TN'69H
M;*[@D>VDBD#.HQY;94J0W9@1D'VJ[:ZB)_/$\+VS0R>61*1AOE#94@\C!_0U
M82>*1@J2HS%0X 8$[3T/TH XQH-<M;13J=O+>""^"SM;(&:YA$6U9=AX)W$;
ME]02*FA\/RVL^G_8K>X^QW5NUI=K<2 R1QABZ,??&Y,=MR^E=#J6LV^G6!NR
M#/&LJ1-Y1!(+,%'?L6&:N/<0Q@EY8U .TDL!@^E '#7&F7-VNIQ7-AJ!OXEN
MQ%(@ AFCD#;!N'WN-@"D_*5KK-!L8K#1[>..#R&9%>52.2^T;B??BKK3Q*^U
MI$#>A89Z9_E3D=9%#1LK*>A4Y% #J*** "BBB@#&\0Z7)?RZ9<1Q+.+*Z\YX
M&Q^\4HR'&>,C=D9]*Y]?!]Q!%%OMH[I&L[JU\@N,0"27>F">P'RG'(P,5W-%
M %;3;:2STNTMIY3-+#"D;R'JY"@$_C5FBB@ HHHH **** "L7Q/;7%U;6(MH
M7E:._MYG"XX17!8\^PK:HH P-7AN-0U2S6U2]AFL[E)/-SB%XS]\$9^;Y21T
MR#6_110 4444 %%%% !1110 4444 %%%% %35;,ZCI%[9!MAN8'A#>FY2,_K
M7/:79WME>1ZC/93$VNF0V/DIM+.X;+E><;1QSWYKK** ./?0+PWKVHC/DOK2
MZEY^>!& &Q]=R[<>AS2ZIHE]J2^*X(HFC^W1Q+ [$!9=J8*YSQG&.?6NOHH
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MWBO&0VW,$VS"W/7OG:0.< 'UJFFCW5QI)==(N[>_W6D4XDE0J_E2JQ*X."
MQW'!.0*ZC3]<2ZN;R&X$<#PWC6L0WY,N$5\CCKANGM3[GQ#IME?36EU=)#)!
M")Y"YPJH20"3^!H 76],.J:=-"DDB2,A5<2LBY/KBJWB'0FU7PKJ&EV\S"2X
MC(1Y7+?-U&2><9%6UUS372-UO8"DC^6K;N"V[;C/UX^M0W?B72K.UN9Y+R,I
M;+ND"'<0-VW@=_F&/K0 D5[<7]@\,^EW$,IB*RI)M*@[>0ISAN>/\*YS3M'U
M*UDT8"UD#16UM!=PSHCPD(I!96!RCKD^S<?AT[>(=)2;R7U&V63<$VF0 AB,
M@'T)%..MZ7)8&Z-Y UJVY2^[CCAL^F._I0!P6D:')>^&+2XTRP:*0Z-<6TK
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M (!__9T>3K'_ $%+?_P#_P#LZ -BBL?R=8_Z"EO_ . ?_P!G1Y.L?]!2W_\
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M1Y.L?]!2W_\  /\ ^SH V**Q_)UC_H*6_P#X!_\ V='DZQ_T%+?_ , __LZ
M-BBL?R=8_P"@I;_^ ?\ ]G1Y.L?]!2W_ / /_P"SH V*SO$7_(M:G_UZ2_\
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M-% !24M)0!Y_-_R5Y/P_]%5U.K?\AK1O^NLO_HIJY:;_ )*\GX?^BJZG5O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
K!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image_011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" &\ G # 2(  A$! Q$!_\0
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MK,6DZ5IS:-?^;8^(/M4S^3\GEY'S _Q#Z5L7N@:I<WWQ"\O3[@C4(8_LA,9
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M$<TAC19I55LY(4$=B0,X]ZY+1O!\VDZEXAAT 7BZ'=:<Z)!<@J&N6!P$#8.
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M^G65A#J5VA9C<2'R44$X.!DDMQ@=N<U'X9\4:WXE\(274%A:QZLEP]J?,8B
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MI-)$FF3 B1E4XW%L]3@]!@=#ZUT'A?4+C4=!MI+S39=-N44));/'L"D?W?\
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M%_\ LJ/LNJ?]!*'_ ,!?_LJ -&BL[[+JG_02A_\  7_[*C[+JG_02A_\!?\
M[*@#1HK.^RZI_P!!*'_P%_\ LJ/LNJ?]!*'_ ,!?_LJ -&BL[[+JG_02A_\
M 7_[*C[+JG_02A_\!?\ [*@#1HK.^RZI_P!!*'_P%_\ LJ/LNJ?]!*'_ ,!?
M_LJ -&BL[[+JG_02A_\  7_[*C[+JG_02A_\!?\ [*@#1HK.^RZI_P!!*'_P
M%_\ LJ/LNJ?]!*'_ ,!?_LJ -&BL[[+JG_02A_\  7_[*C[+JG_02A_\!?\
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M^RH T:*SOLNJ?]!*'_P%_P#LJ/LNJ?\ 02A_\!?_ +*@#1HK.^RZI_T$H?\
MP%_^RH^RZI_T$H?_  %_^RH T:*SOLNJ?]!*'_P%_P#LJ/LNJ?\ 02A_\!?_
M +*@#1HK.^RZI_T$H?\ P%_^RH^RZI_T$H?_  %_^RH T:*SOLNJ?]!*'_P%
M_P#LJ/LNJ?\ 02A_\!?_ +*@#1HK.^RZI_T$H?\ P%_^RH^RZI_T$H?_  %_
M^RH T:*SOLNJ?]!*'_P%_P#LJ/LNJ?\ 02A_\!?_ +*@#1HK.^RZI_T$H?\
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M<71T'Q+-%'!%?:4X>)#\ZO"P#1L>>XSGT(K3M_$-X(_$[R1QS?V5*P@51M+
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M<D>M6X/!NA6RJL&GK&%>*0;9'^]%GRSU_AS4Z^&-)6P-BMFHM"6/D;VV?-U
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MF15FBG>Q!@Z]I$*V,4EAIL3S17$4FV&-58A7!.#QVJ;^W+K_ * 6H_\ D/\
M^+K8HJN;2S P[CQ)+:6\D\^BZBD48W.Q\O@?]]5M*V] PZ$9JGK5G)J&C7=I
M"5$DT112W3)]:II)XA1%7[)IO Q_Q\/_ /$T[)K0#:HK&\[Q%_SZ:;_X$/\
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M_P *T:* ,[^WM/\ ^>[?]^G_ ,*/[>T__GNW_?I_\*T:* ,[^WM/_P">[?\
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M46C@DJ1SO3UK9K,?_D:(O^O-_P#T-:TZ "BBB@ HHHH X[Q5^\UR)/(L[O;
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MSZX%#$^6VA2?_D:(O^O-_P#T-:TZS'_Y&B+_ *\W_P#0UK3H)"BBB@ HHHH
M888SNS&GSG+?*/F^M/HHH **JSZE:V]W';2RA99,87'J<#/ID@@>M$.HVT]Y
M):Q2AI8\Y&/3 .#WQD9],T 6JS="_P"0<W_7Q/\ ^C6K2K.T+_D'-_U\3_\
MHUZ (YM?AAF>-K34&*,5)2U<@_0XYIO_  DD'_/EJ7_@&_\ A6O157CV S+O
M5&2QM;B!-@GGCB*SH5(#-@\<$&JS:Y,NLS0+"LMG#@R2QJ6* J2#QG)W#& .
M^>U;$L,4ZA9HTD4'(#*",^M)%;PP$F&*.,G .Q0,XZ5('/W_ (EN+&XN(VAB
M<)EXVPP!01L^"?[QVD?7/''-S1]=.HB9IHA$JHL@ R2H9F7:P_O#9S]:U/LT
M."/)CP6WD;1][U^M.2-(RQ1%4L<M@8R?4T 9]WJC)>V5M;A ;H2,))00HV <
M8XR3G\@3VJG)XKMK19!<I(SQLZ-Y8&-R@$@$GGKD=..U;DD4<P E17 .0&&<
M&JUYI5G?6LL$T*A)L[R@VL<]>1]* ,E/%L(O7BEB8(9$B0#&Y6+%6SS@@$#D
M>M,M?&=M+'&TT$L9<*Q7*D("JMR=W/##MZUO?8K;<&^SP[AC!V#(QTIIT^S;
MK:P'/K&/\* ,1_$ES%J,R-;*]K"%=V7Y61&5BI))QDD*,?[7M4A\5PW$<,EE
M&2C2Q(YDP,;L$C&<[L,/;K6V;:$ER88R9  ^5'S8Z9]:9]AM<Y^S0YX_Y9CM
MT_*@#$M_&-O(D9:WES+((XL%?G)16!(S\N=P']:2Y\80_P!GO+:PR&7[.TX$
MBC:@&[&_!XR5(]CUK<^PVA4*;:# Z#RQQ_G H-C:DDFVA)((.8QSGK^= $XZ
M4M(!@8'2EH **** "BBB@ HHHH *HW\MW'<V(M4W1O-MG.W.U-IY]N<5>JEJ
M$EW%)9_9$W*]P%FXSB/!R?;G%)ET_B_S+M%%%,@*RO#'_(NVGT;_ -"-:M97
MAC_D7;3Z-_Z$: -6BBB@ HHHH **** "JNHV,>I6$MK-G9(.HZ@@Y!_,"K5%
M &'-X8BGMUB>X?(,A9PHR3+N\W\]W'I@5M*H10JC  P!3J* ,B6TAB\46MPB
M8FEAE#MD\XV8XJ[?RW<4(:QMH[B3=@J\NP >N<&J6JWD-AJUA/<L4B\N5=VT
MD9.S X'L:=_PDVE?\_7_ )#?_"@<79WM<L7$VH)91/;V<4ER<;XFFVJO'.&Q
MSS[59B,C0(TR!)"H+*IR%/< ]ZSO^$FTK_GZ_P#(;_X4?\)-I/\ S]?^0W_P
MI#;35K&!!<ZY;+9W3M=3I(9/W+1LQ& 1E_E!&3M('MUYJ\/$&KO K_V4R.=@
M9&CD^7<N=V0.1G*D#D=3Q6C_ ,)-I7_/U_Y#?_"C_A)M*_Y^O_(;_P"%,DR[
M/5-:MH&BEL9)F#28D=6SG>^U#]5"X?H,C-=)OD\W;Y7R?W]P_E6?_P )-I/_
M #]?^0W_ ,*/^$FTK_GZ_P#(;_X4 9T-[J,6GV\\R74E\TBI<0%&"(2>JX'W
M1Z\@CKS5:XU_5+N*X@CM9(I8UC9_*1M\>><]^XQCK@YK:_X2;2?^?K_R&_\
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M^?K_ ,AO_A1_PDVE?\_7_D-_\* -6BLK_A)M*_Y^O_(;_P"%'_"3:5_S]?\
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M)#*CO$<.%.=I_P @_D:FK)TG1/[-NY9C-O!4H@ QA2[.<^^7(^@K6H ****
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M_P#"3:7_ ,]I?_ >3_XFC_A)M+_Y[2_^ \G_ ,30!K45D_\ "3:7_P ]I?\
MP'D_^)H_X2;2_P#GM+_X#R?_ !- &M163_PDVE_\]I?_  'D_P#B:/\ A)M+
M_P">TO\ X#R?_$T :U%9/_"3:7_SVE_\!Y/_ (FC_A)M+_Y[2_\ @/)_\30!
MK45D_P#"3:7_ ,]I?_ >3_XFC_A)M+_Y[2_^ \G_ ,30!K45D_\ "3:7_P ]
MI?\ P'D_^)H_X2;2_P#GM+_X#R?_ !- &M163_PDVE_\]I?_  'D_P#B:/\
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MWA'G9*JMN8F'3DY.?I2WWAC5Y?&SZI;LBVQN[:4'[0P(C2-UD&W&.2R\=]M
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MHZTJ "BBB@ HHHH **** &2KNA=<!LJ1@]ZYFYT&_N/#^FV2B-'MK?RW4O\
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M*CK2K-TK_C^U;_K['_HJ.M*@ HHHH **** "BBB@!LDB11M)(P1%&69C@ 5
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M+-%%%,R"N=M+B]TRYU!#I-W.LMV\J21E,%2!ZL#VKHJ*I.P&/_;=Y_T K_\
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MYYKKKBXAM86FN98X8EZO(P51^)KC?#+65QK<5Q;FVCR)?+2*:%Y&YZR!5!'
M]3VSS0!U]]9Q:A936MP"8I5VM@X-9TOAFUFMQ#))(1ODD8\99I-PD/3N'(]L
M#%;-% #401QJB_=4 #Z5G7X']M:6<#.^3G_@!K3K*U42'4]-$!19=TNTN"5!
MV'J 10!JT5F^7K7_ #\Z?_X#O_\ %T>7K7_/SI__ (#O_P#%T :5%9OEZU_S
M\Z?_ . [_P#Q='EZU_S\Z?\ ^ [_ /Q= &E16;Y>M?\ /SI__@.__P 71Y>M
M?\_.G_\ @.__ ,70!I45F^7K7_/SI_\ X#O_ /%T>7K7_/SI_P#X#O\ _%T
M:517,/VBVFBSM\Q"F<=,C%4O+UK_ )^=/_\  =__ (NCR]:_Y^=/_P# =_\
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M< E5SC)],UE>'7D=-1::/RI#>ON3=NVG"]^] &Q1110 4444 %%%% !1110
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MVALO+CEA@DGVW#A0S(FTD'C/!8*,]LUGW>N7VG"X"VS7*0Y_>N"N1Y88$@#
M&<@D>G3K@ Z6BN3GU[5(+IYDM))H_)&R-8VV.0[?,#C()4#@TLGB+5;?=NL?
M-<%B<1R 8!EP,8/)"(,Y_B% '5T5SDUWJC:@\EN[B%(A<&-XS@KN8%0-N2Q
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M_(S:=_U[7'\XJU*R[K_D9M._Z]KC^<5 C4HHHH **** "BBB@ HHHH ****
M"LE=)NX)[E[743$D\IE*&%6P2 #S^%:U% &9]AU/_H+?^2R_XT?8=3_Z"W_D
MLO\ C3K368;O4)+1$<,N_:QQA]C!7_(D5HT 9GV'4_\ H+?^2R_XT?8=3_Z"
MW_DLO^-:=% &9]AU/_H+?^2R_P"-'V'4_P#H+?\ DLO^-:=% &9]AU/_ *"W
M_DLO^-'V'4_^@M_Y++_C5F_O5L(HG9&<231P_+C@NP4'\S4&GZU!J-U+#$K
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M');[H"(7(^IQ@5JQOYD:O@C< <'J* ,W[#JO_063_P !5_QH^PZK_P!!9/\
MP%7_ !K4HH R_L.J_P#063_P%7_&C[#JO_063_P%7_&M2B@#+^PZK_T%D_\
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M44 (    , = *6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\5OO$A4%VB63)!7Y1DE1SUQ47_"=7<MPPAT_;%%-(C,X?YPL+NN.!C++CD4
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MQWYSZ5D6GQ$BDL;5Y;-S<31QN0"$4AD9L@D]!M(Z]:[!X(I) [Q(SJ,!BH)
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M@"\\"-<=O;V'Y4?V=9\_Z);\@J?W:]#U'2@#.\/ZU+K$VI"2(1+;3K&BD8<
MQ(^&Y/(+$?A6N(T$ID"+YA 4MCDCTS^-)'!%"6,4:(6.6VJ!GMS4E !1110
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(* "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image_012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" %V G # 2(  A$! Q$!_\0
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ML[+0(I;6'=8:L][-MG&"A(Z>IZ_E5V3P9>W4GB)-1TL7%MJ=^EQ&(KE5DC4
MC<IZ!AP<'@Y(H Z^;Q=HMNELT][Y0NI&BA#QN"SJ<,N,9R#Q@U6C\>>'I$B8
M:B ))_LWS1.-DG]ULCY3]<5S*^$_$;P>%OMA6ZETR^:XF>25=_E;AM!/\3;>
MI_4U1N? VORZ+J-JMK#YESKO]I)F<8\OT/\ M4 >G7]_;:992WE],D%M"NZ2
M1S@**Q=2\96-OX?U6_LV,T^GQ%WMW1E=6*Y3<I&0#QSTQ3?'?AZY\4>$Y["T
M=8[DLDJ!S\K%3G:3[_SQ6#=^%-6U"X\5:B;<0RZK9)9V]JTJDC" %F(X'/3&
M>* -[P5?ZMJVDIJ.I7%O+#=112PK'"T;1DK\ZG/49Z'TJL?&@3XBQZ!)%MM9
MK=O)G(_UDZG+*#Z <?45>T>VU/2/!%G:+:H^HVMHL(B,@VLZK@'=Z=ZYGQ-X
M&U"]T?2I]):X_MFRG6=#/<@HC9R_YGGB@#L-6\3:5H<FS4+L1,$\Q@%9MB9"
M[FP#A<D#)J@WC2P?Q%<Z/$9#);VWGO-Y3,@)Y X'(QSGI66VC:U#XR;6CIL-
MW;:E9);W=J\Z_N'7Z\,OZ\GBGC0=5M?'FJ:I':Q2VE]IRP*4E"^6ZC&W!]<<
M&@#0T7Q/ OAJPO-4U.UNYKJ1HHY+.)\3MN("HF-Q( YX[5;?QAH<=K:7+ZC$
M(;MS%"^&PS@X*].#GL<&N,T?P1K.EZ9X4ED@22YT.>?S;=)1^]20GYE)P,C/
M0XID/@36K>TT@^5%)+'KC:K<1^:,1*2/D![G ^F: /0-(URPUVWDFTVX$R12
M-#(-I5D<=5((!!K0KD_ ^A:AHMQKSZA$D8OM0DNHML@;Y6['T-=90 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% "4M>&3:WJ@GE U*\ #M_RV;U
M^M,_MO5/^@E>?]_V_P :YOK2['T"X?JM7YU^)[M17A/]MZI_T$KS_O\ M_C1
M_;>J?]!*\_[_ +?XTOK4>P_]7JO\Z_$]VHKPG^V]4_Z"5Y_W_;_&C^V]4_Z"
M5Y_W_;_&CZU'L'^KU7^=?B>[45X3_;>J?]!*\_[_ +?XT?VWJG_02O/^_P"W
M^-'UJ/8/]7JO\Z_$]VHKPG^V]4_Z"5Y_W_;_ !H_MO5/^@E>?]_V_P :/K4>
MP?ZO5?YU^)[M17A/]MZI_P!!*\_[_M_C1_;>J?\ 02O/^_[?XT?6H]@_U>J_
MSK\3W:BO"?[;U3_H)7G_ '_;_&C^V]4_Z"5Y_P!_V_QH^M1[!_J]5_G7XGNU
M%>$_VWJG_02O/^_[?XT?VWJG_02O/^_[?XT?6H]@_P!7JO\ .OQ/=J*\)_MO
M5/\ H)7G_?\ ;_&C^V]4_P"@E>?]_P!O\:/K4>P?ZO5?YU^)[M17A/\ ;>J?
M]!*\_P"_[?XT?VWJG_02O/\ O^W^-'UJ/8/]7JO\Z_$]VHKPG^V]4_Z"5Y_W
M_;_&C^V]4_Z"5Y_W_;_&CZU'L'^KU7^=?B>[45X3_;>J?]!*\_[_ +?XT?VW
MJG_02O/^_P"W^-'UJ/8/]7JO\Z_$]JN])L+^19+RRMYW7A6DB#$#ZFK2(L:*
MB*%51@ #  KPO^V]4_Z"5Y_W_;_&C^V]4_Z"5Y_W_;_&CZU'L'^KU7^=?B>[
M45X3_;>J?]!*\_[_ +?XT?VWJG_02O/^_P"W^-'UJ/8/]7JO\Z_$]VHKPG^V
M]4_Z"5Y_W_;_ !H_MO5/^@E>?]_V_P :/K4>P?ZO5?YU^)[M17A/]MZI_P!!
M*\_[_M_C1_;>J?\ 02O/^_[?XT?6H]@_U>J_SK\3W:BO"?[;U3_H)7G_ '_;
M_&C^V]4_Z"5Y_P!_V_QH^M1[!_J]5_G7XGNU%>$_VWJG_02O/^_[?XT?VWJG
M_02O/^_[?XT?6H]@_P!7JO\ .OQ/=J*\)_MO5/\ H)7G_?\ ;_&C^V]4_P"@
ME>?]_P!O\:/K4>P?ZO5?YU^)[M17A/\ ;>J?]!*\_P"_[?XT?VWJG_02O/\
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M/^_[?XT?VWJG_02O/^_[?XT?6H]@_P!7JO\ .OQ/=J*\)_MO5/\ H)7G_?\
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M(YYBI:>T9E_\(;8?WW_7_&C_ (0VP_OO^O\ C6_2U'U:EV-?[6QO_/QG/_\
M"&V']]_U_P :/^$-L/[[_K_C7044?5J78/[7QG_/QG/_ /"&V']]_P!?\:/^
M$.L/[[_K_C704@H^K4NP?VMC?^?C.2UGPW::?I[SQEBV#C)/I]:Y6O0/$_\
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MA3!7S/,VY). V!D#.!P*TZXC_A+];GBU6YL["V>WM+B.WCC.[SB6",6*Y .
MY^4<DUT7AO5_[;T:.[+Q/)N9)/+1U 9201M89!]0?UH U:*2B@!:**2@!:*2
MD# DC//I0 ZBH9[B*W3=-(J#W-1P7T%SGR95?'4 T"YE>Q/(@DC9&SM8$'%<
M)IOA3Q!9/HUB+F**QTJ4$7$5RZ_:(0V=C0XV[L<$D^OK75SZS#;S^6P9L=2.
MU:$;K(@9>A&10"DGL<%9^!KG3])T<I9:?<7%G-/)=6LAQ'<E]P5BVTY901C(
M]156\^'&IR6>F6L5[$5CM#'=D,1N>,L\&WU57?'/8"H/'&JZI:^(]5^S7&J)
M;VMG ZM:W*QQ6[N7 >12"67(&<#@ UM1^,=3CUL:=]B6[CMC!#=31 Y=GC#F
M13G&WGA>I&<4#*3>!M32SA(2SFNYM,N[>ZD9MI%Q,=^\''(W$CMP:W?#'AN;
M0]7NYO+@BMIK.UB"1=Y(U8,2,>XY[UECQU?Q^&AJ\L&GR"YCB>V@AE8R1^9)
ML'F#N!D9(QSD>]2?\)?K,CZ?;?8[.UNKI[I&>Z+*A$0!#  Y&<\@G(P?2@!^
MC>"[C2O#5TD4@&KSQ3QXEG>6W!=V*_NS\O3&>/7K659>!]6MIFN9+:SG5;Q+
MH64LP*2CR#&02$"@@X8?+BG0>.]2=[S4BL'V5K"RDAM7) CDF<IN9_[H.23C
MICIS6@/%^L3:K#I,$&GM>?;9+628E_)(6(2[E YS@X(]>] %>_\ !%_=F80P
MZ=:BXTN*U(B)"Q.DA?8.,E&!VD]<=J<G@FYNM5M[N\L["*T;4!<R6"'?%&JP
M&,$?* 6+8)X X'6M/P[XIN]3UR;3]2AAM9=CO%"%<LRJ^W<'Y1QC'((()QBN
MJH 0# P.E+110 4444 %%%% !1110!P&@Z9XN\-)?V]IIVEW,-Q?2W*O)=LC
M8<],!#V%6;#X?V=QXEUS4=>TZRNUNYTDMBXWE5"X(((XYKMJ2@#'U'PQ9ZC=
MVMPTUY UJH6*.VN&CCP#D90<'_#BN>3PUXDU'7M*FURXT]H=*N&G6\MU*S7.
M00JE< *,=>3G%:6J^+6T[Q59Z0MMY@N!S)N^[^%=-3:L)23V//M.\"ZK;7NG
M6$TMF=$TS4'U""12WG.2250KC P6.3FC3_ NK6]YIVGSRV9T73-0>_@E4MYT
MA))5"N,#!8Y.?2O0J*0Q:*** "BD)Q3&FC0$LZKCKD]* )**JS:E9P!C)<Q
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MS@(S$]<#M6,>>YV:%[[2^C3M&&%Q:-_K;=CD8/<>AJU&BZ?JT)B.8)@&C/\
MLGH#7)V5M<6436;?Z1-*WRR@Y9\] ?85U&H_N);.U/W[6)4<CUKIOKH<>*44
MDSH",$T4 [@#VP**R$%)2T4 9'B?_D"O]&_E7GU>@>)_^0*_T;^5>?UY.-_B
M'W7#?^ZOU'S_ /'Q+_OM_.O2?AW_ ,>S_P#7%/YFO-IO^/B7_?;^=>D_#O\
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MEP\?)('&/6JT\NM7XE625+6,H)%V<D>V:T/LS1)",1Q!5VENF14K>7$W 9E
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M2H8IG0]0::*UW,&@HQ113$&*,444 &*,4<T46&&*,4E+0 8HQ110(,48HHH
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MK=A@J.H-206,-L0X3=)C!9N]61GN:*]102/B95&PR>AHS1BBJ("BBBD!5O\
M4;72XDDO)1&KMM'UJS$RR".6-A)&?FRIX-5M0T^UU2V,-W$'7'![K]*XR[6]
M\%:A&EG>B>!_F$#]<>XJK71G*?(]38UNROK/5KV\BMFO5NRIB9!G:!_":U?#
M]C<Z7HB0WC!9Y)3,(^T6>U0Z)XHL]5S$CM:W&.8G;&?H:U>0><Y]Z&W:QLJM
MUH9FJ>'K35YI)FN9K1YR#,(QD.1T/M5ZSL[?3[&.SM%984^8[NK,>YJ;% &*
M5WLQ.3>X=ZELPC7:+(H*GCFHJ0G:0W]WFD]A+<Z8P(8#&% !&,"N;=/+D9#U
M4XKIH&\R!&]16%JB;+TG^\,UE3>MC>JM+E6B@45L<X4E+0>U Q&Z<G K0L;$
MH_G2D$$?*N*JVD2S7(1U+*!D^E;6 ,?3M6<F:4X]1.,TM%%0:A1110 4444!
M<*.:*#0,.:#\HW,0!_M'%9>MZK_9UOMC(\]E+;CTC4=6-8=G<Z5J:JUS?W#2
M.AD5IU*AP.NWUICL=BOS_=96/L<TGX].H->>&6PN)0+"[N()&4O&6#(' [KZ
MUM>%?$KWSQV5V_F,ZEH)_P"^!U!]ZKDTN@L=311Z^M%0(,T4F,<G@>_%+D8R
M.:!"TE'':B@#%O\ 9]L?8,'C=[U%4MZ[/=ON4+MX&/2HJV6QSRW"BDI\<$EQ
MD0XR,9)/ H%8:H+R"->6;H*N0:86#&X.W/ "U=AMXX0-JC<!C=CK4IP%W,0H
M]ZSE,UC CAMHX(PB+P.<FI:C^T0C@N,_2G@@@,I!![CD5-[FBLA?2CZU!<74
M=MRYRW916=-?32]#L'H*:C<ESL:Y('WB!]:3S$_O+^=8)8GDL6_&D ;KM;\J
MKE1/.^QT(.1P0:*Y]9'4_*[*?K5R#49(R!*-R^O>CE8U4-2BHXITG0-&21Z=
MQ4A(52S$!0,L3T J"]PZ]*7RV/:N:NO$LETS1Z4JH@/S7,W _ 57&FWE^BR3
M:FTNXX^67 )]!BJ42K'6X(X!'X&@J0/F&/PKA[G1! 2TEXR8[M*1^'UJJ'U3
M3R)+34)-G49;<IJE2OLPL>@48]A7,:5XS2:9+;58A#(_"S)]TGW]*ZCIZ$=B
M*AIQT9-BI)I\#LS8(9AU![U2FL)88RQ;>!_='-;&*.*:DR7!,Y[)P,@KGU%.
MK9GM8[D+Y@Z'@CK6?/82I(QC :/KUYJU),R<&BK00K AQE6ZBD!!_"EJO,E[
M6,2^TAH<R6P+)U*^GTJ.UU>2WQ',OF(..>&%;X.*@N+*"XR9(QD_Q+UJU*_Q
M&$J33O%B07<%S&7CD48'(/!%5;O6(HE*V_[QR/O=A4<FA Y,-QCV84U-!?/S
MSKCO@4THHF3J/0HVD#WEVJC)).YV-=/MV@+V P*AMK6*S7;$.3U8]34Q/Z4I
MOF-*5/D6NYC^)_\ D"O]&_E7G]>@>)_^0*_T;^5>?UXV-_B'WW#?^ZOU'S?\
M?$O^^W\Z[;PI_P >H_ZX+_,UQ4W_ !\2_P"^W\Z[7PG_ ,>J_P#7!?YFG@_X
MK)XB_P!SCZK\F;] HHKU3X<**2B@=A:2EIDDB0QM)*P6-1EF)X H#8KZKJ4&
MCZ<]W/CY1\J]W;L*YSPSILVKWKZYJPWEC^X1O\]!5:,2^,]?WMN&EVS9'N/\
M37:HB1H(XU"H@V@#H!5;(R7O,Q-9\*V>J9EA'V:Z'(E3@$^XK4T^WDM-/BAF
MF::5%PTC=2:LXHJ;EJ*3N HHHH&%(PI:0].] SH=,;=81'VQ6?K8Q/$?45=T
MH?Z!'5/7#^\B^AK"/Q'3/X#.HQ2"EK<Y@I#2TAH$7]*5_P!Z?^69^[ZUHUFZ
M60&E&_D]%K2K&6YT0V#I37=8\!LEC_"*<3MY]!FN7UK6;FSU33;>&Z-O'=*[
M22)#YK9'3CTJ&RCHGGD7_ECQ[FB.ZCE?9RC^AKG]+\2:E*D%K=Z<\UW.9&C8
MKY>Z-?XB#T)I;#7X-<,YM8)$6W.R5VXV2@\I[X]:5Q2NCI>0<'K14=M(9;:-
MV^\1@U)5(:"@]#1R>@/Y4<^E,#D/&(DCO'=5RES:F)">F[' JO9:3;KH4'VJ
M::XO8;4QQ)*^5B<CM787]A;ZE:-;72;XSZ<%?<5S%QX2U"WP+&\26/L).#CZ
MU:Y6K,JYAW\UY?V>EVMQ:FV6P7+R.X)9L8PN*9X2@FDUC38 ,20EGDQ_".:U
ME\&:K<OBXN884]0=QKIM&T*TT.!DM@6D;_63.<LYK1RA&-H@S1)YSVJI?7AM
M8P%QYCYP6Z*!U8U;XQ6%KSF.Y&45UEA:,*YPK'TSVS6,5?0B3LAEI=:?JTX@
M6_>>=@64$,H<=RN>"*6ZTV>S)DM)I(V'HV1^585K]N^SI#86]Y#'';NK)=8;
MRLC@1/UJIJMM=P?84M$N1#%"AO<S',_L/<'DU4;WU1G-1MN=GHVJ-?*T5QA;
MJ+[V.C#UK38A023@ =37*^'R9]?DDC!$:QX)]/0&N@U.5([8HP)+] *4E:5D
M%.3E"[,KDL2S;CDG-':@=!2UHC,:3TP,GT%;5M:I;H=@^9N6)JAI\3/=;\#8
MHYS6MZ>U1)FM-=08@ D]%&:R]4U"33=/>_-K]I1#\XW@;<G'%:; .I5N PQF
MLJ^MQ>:?-IUPYC5\#=[ YK*1I?4J:CX@^QFWAEL0L\T?FX>0*F/0,>-WM5RU
MN2$AE56B2903&W5,U6U73S?*OEW85!'Y;1RQB1",8R >AI-.LTM+6&UC=VM[
M<<R2')/XU*(F^PLJE96#G<V<9/>K5O8$();IO+C].YIUE&LCR7<P^0'(!K,U
MO78[2(7-Z7$!<(BQKDDGH,5O=O8E16[-0WMM!Q;P ^YIO]K2?\\DQ6/8ZO9:
MC;&6"90%8JZ285T(ZY%+<:G9VVW?/&S,P79&02,^HHY4+FD;0OK:88N( /\
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MW3?%>>P$[FT&E[Q!GY=V>N/6O2E+E/C(0YC12"65=T<;,/4"DDC>(XD1D)Z
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M'':FXI:*T1C<!0:**8B]I<A!>+;P/F#?XUHUA12-%,C(Q7! /N*VU<.H96#
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MKHFT^R9@6LX"5SCY>F>M$NG64^?-LX7R=Q)7O]:+,?,ET,&7QIMN)(4MFBQ
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MPJJ+R<GK6^LT.T .N!TYKF>M&*<H7)C4Y3IWD!0[&&<<<USEP9'F;SSN<&F
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M,$ '(_6EU:\M;J9[@3E9B49'4CY&48%:J$KZ&A';>(QHMY%]BNGF@<_/ X/
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MENA/6MB1/-C9-Q7<, CJ#ZURWAFWU4:W?B_G8PP/@\?ZT]C^5%VNHSJ4C6)
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M:8+^*S'B+_<X^J_(WZM:;G[6 ,;2#FJM.AD$,RR'.%]*]1['Q,=S='3VH/\
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M(V]56, *WJ!V/)YJ30X^UUZ\TWX6:1J"2+)<RQ6\;3W!++'O95,C\\@9SUK
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M_P"??XK_ #(O%_ANYL9[S44N(HK29Y)&@B+XD9AU922H;N67&:X>NLUSQO\
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9K%_WT?\ "C^S)_6+_OH_X44460>UEW/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>image_013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "E -0# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH KW=W;6%K<WU[/%:V=G;S75W=
M3NL4%M;6\;37%Q/*Y"1PPQ(\DDCD*B*6)P*_GN^ OQG_ ."HG_!57PWK_P"U
M1^RS^TM\'/V"?V-=7\6>-?#O[+MCKW[,UC^TC\9?CWX3\"^)M5\(2_&#XGR>
M,O'?@W0/A]X6\8:_HFI2>%O"?A6S?7XM#A6>^U63=8ZMJW[Y>-O#,/C3P=XL
M\'7-Q+9VWBSPUKWAJXO( &GM(->TJ[TJ6YA4L@:6!+MI8U+*"RCYAUK^;+_@
ME?\ \%#OV9O^">'[)_@S_@G3_P %#_BOX-_8_P#VG?V+%\7?"_7=$^,DMYX&
M\*_%WX?Z;XR\1:C\.?C1\%?%NL6D'A[XA^#?'?A*_P!-N8UT+4KO7;;6[;5(
M+W2X8I+&:[ /T*_X)V?MG?M"?$OXP_M0?L.?MM>&?AWH7[7O[(D_@/7M1\:?
M"&'6+'X3_M!_ [XKZ??7OPV^,W@G1/$%U?ZOX5U)Y=)O]!^('A&?4-2M= \2
MQQ1:??F*YET_3?UJK\"/^"=FI7/[3G[>O[>/_!5VWT77/!O[*GC;X1_!O]F+
M]EKQ=XUT'6/!NH?&/X9?!4^(O&OQ/^/L.@>)++2]9TWX;ZOXRUP:=\/-:U*P
MMI?$6@Z7?ZDUM9^086_=KPOXH\-^-_#>@^,?!VO:/XJ\)>*=(T[Q!X9\3>'M
M2L]8T'Q#H.L6<.H:3K6BZMI\UQ8:GI>I6-Q!=V-_9SS6UU;RQS0R.C!B ;M%
M%% !163J6O:)HTNGP:OJ^F:7-J][%INDPZA?VEE+JNI3Y\C3M-CN9HGO[^;!
M\JSM5EN)/X8SD4_4M9TG1H8+C5]2L-*M[FZM;&WGU*]M;"&:^O95@L[**6[E
MA22\NYF6*UM49I[B4B.)';B@#3HK,M=:TB^OM0TNSU33[K4M(:V35=/MKVVG
MOM,:\B,]F-1LXI7N;$W<"M-:BZBA^T1*98MZ#=0FMZ/+JL^A1:IITFMVUK%?
M7.D1WMJ^J6UC/(\,%]<:>LIO(;.>:-XH;J2%8)959$<L"  :=%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %<UXA\&>#_%IL3XJ\*>&O$QT
MN<76F'Q!H6EZT=.N@5(N; ZE:W)M+@%5(FM_+D!53NX%=+10!\F?M,W7[1O@
M-_"7QE^ 5M)\2M'^'T>I0?%7]F00:!::E\7O VH26,UWJ_PI\3ZA%9SZ'\;_
M  %'83W_ (&T#6-:MO 7Q&L[[6? _B#^P-7U3PWXY\*_%/@GX@:!^SEX?@_:
MN_97>_\ BE_P3M^*-_K/BKXS_![PGH>KW/C']E#QC<ZM>K\0?B]\*?A\+5/$
M^G>#]+\3IJZ_M1_LQ'1K/Q9\-_%5EXC^(/@3P[;>(K3X@^!/$?[$U^4O[6?A
M[QK^QUXMN/VJ_P!E&R\,ZCXP^.?Q'^&OPI^*G[,OBS6[OPO\.?C_ /%+XJ>(
M]%^&'PX^+&@ZGIFF:Q+\/_C-X,O]4TJ_^(7BC3]$NK#XG_!OPWKFE>,[9O$/
MA;P-XM\- 'Z?>&O$WA[QEX>T/Q;X2US2?$_A7Q/I&FZ_X;\2^']0M-8T#Q#H
M6LV4.HZ3K6B:OI\UQ8:II.IV%S;WEAJ-E/-:7=M-%/!*\;JQY_QA\4OAE\/8
MC/X^^(O@3P/ NTF;QAXO\/>&H@'^Z3)K6HV2C=U7)&<<9K\^O@[_ ,$I?V;O
M"OP\TG0?C'I>L_&3QG=:EXC\7>-KJ;QW\4O"GPAG\9^.==U#Q9XNM_AO^S_H
M7CZ'X4_#'X=P:]K&H6_A/P3H/APIINBI;#6=0U[7IM5US4OI+PM^P?\ L3^"
MGAF\+_LD_LX:3>02)+'JD?P8^'MSK(DCQLD?6K[P_=:M)(I 99)+QG#98,&)
M) /Q9_X.)/V?E_:RU#_@E-\ ['Q_KWPRU/XG_MWW>G>$?B?X0E7^W? GC.Q_
M9Y^+OB+P#XSTJ1)(VD_L#QCI&@:Q*EM<6]S<6EK+'9W=K<O#<Q?-?[3W[8_C
M#]K'_@G/^SKX7^/>CVG@W]LW]EG_ (*U?L ?L[_MD?#J-%@71_C'X._:"\*1
M#QYX?MML7VCX=?&7P\UA\1O .LVD']C7FG:U?:5I=[J"Z'<W!_<#]NK]DSXH
M?M%?'#_@FS\0?AU-X2MO#G[)G[8$?QS^)T/B#5KS2[^;P0GPD^(7@86_A*TL
M](U&'5=;75_%&FNNGWEQI%J+%+F47P>-(9/@_P#X*G_\$B/B_P#M/?M/_LX_
MM2_LF>-/"'@/7F^-'[,]U^VWX%\6ZG>Z)X;^.?PL_9K^+.C?%7X5^-+8Z9X?
MUU;GXO?"F:PU_P )Z!>7D6GW&N>#O%8T"X\0Z?INB1V=^ ?-OPQ_;/T[]D/_
M (+/_P#!;J.[_9>_;._:,E^(&L_\$^;E9_V1_P!GG6_CK!X27PY^RU);M!X]
MGT?5=-'AB[UDZPDOAVWN!,=5M].U6:-D%BRMZ)^P3^T78?M-?\%Y/VQ?BE!\
M&/VA_@%#%_P3<_9]T";P5^U%\)]0^"WQ(7^R?C9XQN9-=3PGJVH:A<MX7OHK
MR./3M::X2&[N;'485C461D?],/V4_P!D;XL?!?\ X*%?\%1_VH/&%SX1E^&?
M[8^K?L?7WPEMM%UB^O?%%I%\"?@AJ7PZ\:?\)EI=QI%C8Z-)-KMW')H2Z=JF
MMB^TXM<7+6$R_9F^0_VN_P!DWQ+X1_:I_P""A7[</Q3\">(OB]^S-\4?^"<'
MPX_9UC^#_P $-8\82?M _$7Q9X/^)GB+Q#K?@S3M%\+:-]ML/#GBZQ\16.A7
MVL:;J]],ND7FMMJ>E)I<-VTH!^Y_AGQCX3\:Z3#K_@SQ+H/B_0;B6X@@USPK
MJ]AXAT>>>TF>WNX(M3TBXO+*2:UN(W@N8DG,D$R-'*JN"**_G>_9\_9U^#GQ
M%TWXC?%#Q1\6/BY^S]XB^)'Q'/B'5?@E^QA\$_VC_@)\"?AG_9?P]^'W@K3/
M#>C6'B_X,^%-8^)OB :'X3TO4O%?Q?'@[P;IOBW6]1NK'2?"NBZ=H-M:(4 ?
MTBT444 %%%% !1110 4444 %%(2!^/3@G^5+UH **** "BBB@ HHHH ****
M"O@+XERI\9OV]/@-\*H7>Y\+?LL_#WQ'^U5X^@$4-Q9CXD_$B+Q'\#?V>=-O
MPV3#<0^'W_:*\7P0RKYL-]H'AK48T7]Q./.;_P#X*Q?LZZ!_P4\@_P""5_B[
M3/%OA/XU:W\+=)^(_@CQUK T./X:^.-3U?2KOQ!;?#C1[Z/5GUNV\;S>'=)\
M0ZS86FI:1:V.JQ>'M2LK"]FU*2PM+SWF[_:O^&VB?M]Z)^P]'X$UR/XL>/\
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M.:)X2\,Z3;?\>^E>'_#>F6NC:-IL R2(;'3K*VMHP3D)$,T =)1110 4444
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MXF\1^'?VC?@3\$;?P;J<'[-_@BWL]$N-+^+FKZ9J.N37]JTE_P#;](6:RMT
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MJFGS$7.F:K:"#4M+NUCO-/NK:ZBCF7Y%_:*MH+']KO\ X)L65K'Y-K:?$/\
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MNB^#H_@5X*&HVWAB'PAX2\9Z/X4TN77I[J:72()-*^T7;2W?V)P_G-\^Q?\
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M'7/!7A3Q>OAV+Q/X=\-:B8OM.DZ1X@7PEX735K"SDB@OAH&D"='^PV^S\L=
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MTG4;^/1]!M[][J_\1>+M>G*BV\->!?!VBVVI>+O'OBJ\W#[%X7\&Z'KGB"\
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$4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>image_014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" %P G # 2(  A$! Q$!_\0
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MT4 )13)IDMX7FE<)'&I9V/10*IVFM6]W<10B.>%YD,D7FIM$BCTI#+]+113
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ME\XN.I?&-WUQ45SHT4UR)4*QHS^9-'CB5^Q)]JTJ2BP7%/7/K2444""BBBF
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MI5U51G[3G_@(JL=3U&UXFCBF0=<C::?)<EU;;E#[)XY_Z"VB?^ S4?9/'/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 5]1_Y!EW_P!<7_\ 037D]M_Q\0?[Z_S%>L:C_P @R[_ZXO\
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M+6>=OGE?OA1P .YSWK!4DI<U]3T)XZI*E[)Q7+:UNUNJ\SHJ***W//"BBB@
MHHHH **** *^H_\ (,N_^N+_ /H)KR>V_P"/B#_?7^8KUC4?^09=_P#7%_\
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M96&01[BL^'P_8P31RQK*!&P9$,Q**PZ$ TG"[&IZ:F5HMT]_<7\TJ[9=ZQN
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M;O(WO711:1:Q0*JH !4/3<7*8O\ PDVGA@)5N81TW.G%:4$\%S%YMM.DT?\
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MS!G(W#N1V/6K5%%( HHHI@+1110,*@N+N.W.'5R?]D9J>DH$S/\ [9@S@QR
M>XJ5]2MT@\U7WCH .I-/N[:":)C*@X&=PX(KG3MSD'Z$^E6HIF,Y2B:#2W&J
M)(FR/R@,D%<BJKZ)"EFLZ(C*<$@CFK^C2KF2(X&>@]:EA4OI,L?=2R_3%-NP
ME%25V9-BL&G3EA:KN/))'(^E5M6TDM=+?V+CR9&#'GE&K;O(5GTV.< >8JCD
M>E9;!E)5LC'4 \&FG<B2458CN[X1;9+IF?)V@BJ+2S3ZLZ[&*%=I"CC;CJ:Z
M/3(89&=)5CE! <$C.*L6L(^RW4(4*0S+P.2.U-RL'LVU<Q+?1O[,LQ-*^^20
MXV#H!VH/W2"<<<FI[FZ,PB0# C7;CU-6Y='>334$3;;I?G4GH3Z&B_<.2^B*
MMK&]W=HKC]W;P-M]R:2V<S27-\RG$.R-?^ ]:@AGDBE 96AF7JI_SR*OVTT;
MZ=-;J565LL<]#ZTF$?,L: &>RDN7)+7$K/R>@[8K3J"QV?8HA& %"@8':IZR
M9TQV"BBB@8IYK)F\1Z?!.T,LCHZG!!0BM;TK"N88Y]9U%945U%L" 1T--$S;
M6QK6UU!=Q[[>59%]CTJ5G6-69V"JO))/ %<&L=SH,MM=POE)4##T;U!%37^I
M7/B&[BM808XV(PF>I[DU7)?4Q]MT>YT,OB;38G*^>7QW5214]IK>GWK!8;A=
MYZ*W!-8*6,=IH%ZH"M(EP$+XY/(JIXGMHK?5(_)0(6B#-CCGU]J.5-V#VDHJ
MYK>*KB%?L;)*IG@8@H#SM-+I_BFWBC5'D*D^U8GAZ*&ZUN-;K$BL"3YASN/O
M4UQHT<ME+=Q3%6-P8O+Q\N,X'OQ56BO=94:TI+F1T%SK*21;ED!4]Q7.7^I?
MO%(Y(8''K52_LI]+NWM9'&[J"O0CUQ3-/L9+^]6WC?+-U;T]ZN,8I7']9TMU
M-,:O##K4UQ$Y:&8A^G()'(KH(/$UO<J%CF^;T/!K$^PQ#01$5#$WGEEP/FQG
M%9>K6$>FZB\$<QE50#N/!^AJ;1EH*5><?>9O:EKD8)7S,MZ"LJ"^CE%Y%*_E
MK/%A'/9AR*J:;ISZK>K;),(206WL,\>E:":/;KHAFRS7#W B\UC]T9QP*;M'
M0%7E)<Q=T'6?+C56;##BM:YUR-(R7E"_6N+N;233K]H)F*E#]Y?XO<4ZVLKG
M5!,Z,"($RY8T2A%NXUB7;E6YH7NM)/G8Q.>^*A\-6[WGB2&8_+%; R,2<9IT
M7AQV:R-S=!8KSD;!\R@#-9]TJV]]/';LPC1RJ_-SCZT[IJR)E6G'5G;W7B'3
M;:0JUP&;T49IL'B/3;A]@N-AZ?.,5S6BPP-8:B[Q[Y%C^1CS@>M7=0TV'4+B
MRCB(BD:VW$D8W$#O6/+%.PE4DUS'5Y'4$$$9R*@N[ZWLDW7,R1@] 3R:Y'2M
M?FTH26URK2HF0HSRI]/I5?[/<:U]KOYY"%B&X_7T'M3Y!^WOMN='<:_8W=C<
MQ0M(S/$X!"''W3WKSFV_X^(/]]?YBO4#"D/AJ01HJ VQ)VC_ &:\OMO^/B#_
M 'U_F*\G'?&CZW(+^QG<C/0U[!;_ /'K#_US7^0KQ\]#7L%O_P >L/\ US7^
M0IX#>0L_^&G\_P!"2BBBO2/F@HHHH **** "BBB@!:***!A1110 E4M5U2#1
M[ W5R'8%@B(@RSL>@%7:I:OI<.LV!M;@N@#!TDC.&C8=&%(#%;6];OHR8+:T
ML(<?,T[>8P'TZ5E:/H/_  D>HW-W<7EW+8!%C:?B/[20>BXZ(/;K6PGA*:;;
M'J>J275J#\T*1B+S/]XCG'MWJ'Q@S0_8897>VT?:5?R?E&\?=5B.BXID*_4W
M[2?3+0I9VMQ9Q[/E6))%!&.WO7(64[1ZA?FXD==2DF+3PLN %Z*5]1CO4L&G
M:3-;^6UK;F(C[Z'M]1TK*AU'^UKJSLX97^WV<S017<HRDD;?=5NY''4=Z?PL
M3]Y6-2]U@6+(+B145ONXY/Y4X7$;P"='$D;C*LISN^E;.B>''L;N6\U)X;F\
MD78NU/DB3^ZN?7N:P]4TI=.\2B"SR+2XC:X:'M$PZE?KZ=JM3U,W3:1'J;7'
MV,_8P3*S#(!PQ7N ?6KVDZ)H.L6TC6_]H6]U"0LJR3'S8V[''0BJEN;Z_07%
MAI\MQ9(<%PP5G/3Y >H'K5IK76;"WO-7@MA%=2HD$< 'F-'&#RY'\3>@J9OL
M7336Z,\0WEKJ\L:W"PZM98VS!?DN(CTWKW'TZ&NFT?Q NHSFTO(3;7X7=Y><
MI(HZE#Z>W6JD^FW^K:5I^I"-(-9@4_(_RK*F>4;TSU]C69J&@:SX@"R+#_9A
MMU;8'D^:5CU7(^ZI'>IO<K5/0ZN'5].N;QK6WOH)+D9S&K9/'7'K5RN/TK0K
MN34[!Y--&GP6!+DL06D)&-JX[>YKL#UI%:]1****8!1110 4444 +1110,*0
MTN:K7-]!; [VRX_@'4T!>Q5UBYV0B%3RWWOI4>F622V\DDRY#\+[57BMY]2N
M3(PPI/+'H!Z"MU%$<:HHPJ\ 5;?*C&*YG=G/W-K)83 @G .5<5?TNY67S4D(
M5G.<'O6@\:R(4=0RGL:SGT9"^Z.5D]L9Q1S70<C3T&&=8M*>-CELL@'XU4L[
M*2\W$' 4?>/<UH+HT6[,CNY^N!5^.-(D"(H51VI<U@Y+O4Y]?M&G7&?+(['C
M((J<W\K>=Y,+@S8YQT-;?U']:!QT  ]A1SH:IV,G3],8.)K@=/NH?YUK=\T4
M5+=RU%1&O$DG$B*P]Q51M(M"V=A'L#5VEHNP<4R&"WBME(B7:#4U)2T#V$HH
MHH 4=16,W_(<U(\_\>HK8/(JK?67VZ+RQ-)#SRT> 6'H30A239R&L7L5Q96%
MK$=SPH-Q'3)[5!ILATS68&ND9-A!((Y />NJL/#EEI\@E"M)(/NE^<?A5J_T
MFTU0!;E#D<!U."*TYUL<_L9-\QAW5RB:+?[63Y[HLG/W^>U4M$TZ?Q'JIGN,
MF%#F1CT/HHK23PK9K.4FEF8(?N9P"/6NHLEM[*V6&W18T7HHK.51+8N%-RE[
MVQQ?B72'T74%O+52L#$,"O1&]/QI()4N- +;E$QN0S*#R,GK7;7+PW,+Q2HK
MHPP0W>N8F\+6/F,8I9X@>RMQ251->\*=+EE>)B^(9_M&KLL;>:<!05Y.?04>
M'I5M-:03_N\94EN,'WK:M=(M;*0?9U:25CA6?DBK^I^'[+4)-SADE  +QG!-
M:*JOA,XTI-\QAW=TMOHS .OF_;"R '/0]:A\/Z8VJ7S7=T"T*MN)/_+1O\*U
MH_"%FL@:66:0#^$M@&MN*)(8U2) JKP HX%'-9:&BI2;O+8X[6K&31-42[M<
MB%FW*1V/=35F"X2;PXA9U#"Z#.,],FNGGMXKF%HYT#HW4&L1O"%H6;9-.BG^
M$-Q_]>A33W!TFFW'8PM8N!JNLL;16DXV@#JV*DT.^BM8K^*;(:6,A,],^E=3
MINC6NEC,"9DQC>W4U!J?AVTO@TR(8YP<G9_$/I3<TU8E4I+W^IC:E>?8].TM
MHW4SI&>"<[01C-6?#'AP7D+7E[&2CJ1&K=3GJU3V7AO3UE625I9RO0.W'T-=
M,MTBH% PH&,"LI5$E:)=.E=WF>=:C:7'AZ_FA&=DBE5)Z.I[?45O^;;M>V$O
MF)Y2VIRV>E;.I0VVHP^5=1AU[$=1]#VKGY/#%FO"SSX_NYXH]HI+WMR90Y&^
M78YN4F:XE\I68%BP*CG'O6KI$\?]B:A S!9&7<H)ZBMO3-,AAE$5M'A>KN>>
M*+WPM8W4[2H9(2QZ(>*T]JI*Q$:,E[Q=E_Y%M_\ KU/_ *#7EEM_Q\0?[Z_S
M%>I2VWV30;F'S'DVPO\ ,_7&T\5Y;;?\?$'^^O\ ,5Y..^-'V60_P9D9Z&O8
M+?\ X]8?^N:_R%>/GH:]@M_^/6'_ *YK_(4\!O(G/_AI_/\ 0DHHHKTCYH**
M** "BBB@ HHHH 6BDHH 6BDHH 6DHHH ,TUT65&CD561A@JPR#^%.HH Q9O!
MF@S2;S9;3W$<C*#^&:OII5A'+;R1VD*26R[8F5?N#T%6F=4*AF52QP,G&3Z"
MEI !Z<<>PK&UW3KJ>YMK_3T26XM]R-"[;1*C=1GL:V:*!O4S/#EA<Z;HD-M>
M%?.5F.U3D("<A0>^*T^ASWHS^E% @_/CWH I-Z[]FY=^,[<\X]<4M, Q2TE%
M !1110 4444 %%->1(EW2.J+ZL0!2A@0"""#T(/6@!U%-9@BEF(51R23@"FF
M:(=98QTZL._3\Z0Q]1F&,N6\M2QZDBI**8GJ'3CM[444UI$5U1G4,WW5) )^
M@H8(?1437$,;['FB5_[K. ?RI^]0X3<-Y&0N><?2D,=13/-CV%_,38O5MPP/
MQIV<C(Z4Q"T4TNH8*64,>0I/)_"EH 6BDHH 6BDHH 6BDHH ***3>N_9N7?C
M.W/./7% #J*2ES0 4E%%(8V2))EP^01T8=13/*G4?(5D'L<&I:1BJ\LP4>I.
M*EQ3%8KE;GIY+?G3?LMQ)]\*B^K'FK0=7.$<,?\ 9;- (;.&#8ZX.<4N1"Y4
M1PVZ0<J=\AXWD=/PJ449&X#(W>F>:0R(.2ZCG'+"K2L-*PM+3/,CP3YB8Z9W
M#%.#!AE2&'J#F@844$A<9(&>F3UHZ4P%I,D<CK2TE(!DD$4K;VRC_P!Y>A^H
MJ-K:8?<>-A]<5.2!R2 /<T8YS4N"8FDRL;:Y;L@_X%0+#G]]-^"5:S28I<@N
M5"*BQH$C7:GH.I/J:6BBK2L5Z$&HG_B57G_7%_\ T$UY-;?\?$'^^O\ ,5ZQ
MJ/\ R#+O_KB__H)KR>V_X^(/]]?YBO-QWQ(^FR)_NID9Z&O8+?\ X]8?^N:_
MR%>/GH:]@M_^/6'_ *YK_(4\!O(G/_AI_/\ 0DHHHKTCYH**** "BBB@ HHH
MH **** "BBB@ HHHH **** .1\2?:=4U1X;.VGG_ +/BW(T1 "3G!!.2.@';
MUHO/$,D[K-%J#6D;Z>)T4(#NFW$;>1ZC&*Z[&*@%E"+XW@3]\8_*SGC;G/3Z
MU-BKG,W^LZA&TA>X:UN4MX7M[41@BX=A\P/&>O&!TI;K6+R+4KQ$O&$\5U$D
M-GL!$@8+N&<9XR?I76?TJ&"SAMIKB6)2'N'#R$G.3C''IP*+!=')Q7<MC)?1
MB^EB5]39;B4@,88R.&Z<;B,9Z<4^?5]0&F02"]PGGRHLIQ$TZ+]U@Q4J._'&
M:Z_ YX'/6@C(P0"/2BP7.2EU.Y=I+F&0PRMID<@DFB 8$R8.< XX_ =:UO#E
M]+?6D_G/)(T4NW>Q5@1@'Y64 ,/?%:_?/>CH,#@4["N%%%%,04444 %%%% '
M/>*$@:XL&GF2$H7*-<0^9;DXZ..Q]#67IL@%WHDA+VD*R7"*L9)CD/&"N[G#
M=,?E7:]>#R*/Z5-BKG"R:S<WD%[$UR\T$]A.Y23;E6'08 ^7CMDU8NG:*[G*
M@9+:>O*@\?C798'H/RHP/0?E18.8Y=+^_P#M'GF\D9/[6-IY)5=ICSZXSFH]
M/U>[FU'3DFOI#-/<2I<VA0 1 !MHZ9[#OS768'H/RJA!HEG;W2W"+*70ED#R
MLRH3U(!/%%@NBEKE]);ZA;PO>O86C0NYG5 =T@/"Y(/;G'>J&D)/?^([:[OR
MXG%@LFPJ  2Q' QD9Z^O-=7UZT=\]Z=A7.3OFTI?$>KC5A 0UM$(Q(N23M/W
M??ITJJEMJ!N-'E0N-0M=.,H5^KX?[C?53CZUVV!G.!GUQ1WSW]:5A\QP<%P=
M1T6UT^*UFF6ZNYKB>&/ ?R@^<<X'4C\JZ'PY>3OH<D$L;?;;'="T;]20,IGZ
MC%;> .P_*C%"0-G%V%^\^J:==37DES.MG.\J>6,PO@94# ].A]*8FO7YM+XQ
MWKOMMHI8W;:S*Q< ]  .#R.<>M=O[X&:,#T'Y46#F.5FO-1M;RY7^T)9$MKR
M"(*R+\ZR8W9P/RQ3?[;NSKZQV\\DB-/+$8) H^ZIVC:!D<C@D\^E=9@>@_*D
M958$, 0>#18+G(V.LWKS6OEWLEW-):32RV[1A0DH&0O3L>W^-7/#&I7=].ZS
MW'GQ^0KMN*EDD)Y' &!['D8K5M-&M+*X$\0E:15*H9)6?8#U R>*O4) VCE[
MB_U*.TUB[BN9&-O<F".,*,(N5RW3)(!-0G6+T::KF^Q%]O2);@;7;RR/F!P,
M''J*Z[I4-S9PW?D^<I(AD$J8.,,.E%@N<NVLW/V4H+Z9HS=O'!=@*GFH%SRQ
M&!SQD#FH5U:\DM/MAD'VD:0\GF! #O$F,]/;I7:8'H,48'H/RHL%RMIR2I8Q
M&>X>>1U#EW &,@' QVJS113)"BBBF 5%<VEO>P^3=0I-'G.QQD9J6BD!Q=G:
M"#P'+=6$(2Z<,LDD0^<QB3YL$>U:%E)HEO>A]"B>>Y%N6,=L_P CCC[Y/&[T
MS71JJH,(H4#LHP*1(TCSL15R<G:H&:5BKG+:I]MO=:TVXMX7M;Z&VEF2!V!+
M;6&5)'J/YBL<S17EG9S.($CFU:=B+K[BY4'#5Z%M7<&VC<!@-CD?C33!"PPT
M,1&<X* C/K18.8X_4(;=M%MHK8:5*6U&(%+7(B8D' ;J?_K5?\-0B#6=322.
M*SG4(ILH<[ !TD!/7-="L$*C"PQ*,YP$ Y]?K3MB[]^U=^,;L<X],T6"YRMY
M_9C:WJG_  D+* JI]E$K$#R]O)3_ &L_C1<ZO)!^YAOFL+>&R6:W-S&&>X;G
MY3N^@&!SS75-&CXWHK;>1N4'%#(CD%T5BIR-P!P:+!<Y2\UC4S]JD6;[*8--
MCO##Y8;YSU!SVI+[6=2LH;P&[5W6VM[A&,0&PNV&&.XQ^-=68T8L61"6&"2H
M.1Z&H+[3K?4+9H)TPC;<E.#\IR!GTR*+,+HY74]0EN(+VU-XE[;QR6SK.J@!
M6:093CCW]:MPZY?RZ^86D55^UM ;9B@Q&/XASNSWSTKIO*CVE?+3:3DC:,9]
M:/+0N7V+O(QNVC./3-%@NCE+37KUKR[C-R+B.WBE>U(CQ]L*^_\ L^W6EL-<
MOYK.[?[7!(5M!,))-F(I">A"9^7Z\C'-=4(HQLQ&@V?=PH^7Z>E"QHF=B*NX
MY.U0,_6BP71B^&]3FOFNHKB5I7BVG)V,H!'9TX/TQD5N4U(TC7;&BHO7"J *
M=30F5]1_Y!EW_P!<7_\ 037D]M_Q\0?[Z_S%>L:C_P @R[_ZXO\ ^@FO)[;_
M (^(/]]?YBO.QWQ1/I<A_AU/D1GH:]:M[NV%M"/M,.?+7_EH/3ZUY3Y4G_/-
M_P#ODTGD/_SR?_ODUST*[HMV5[GH8_ QQBBG*UCUO[9;?\_,'_?Q?\:/MEM_
MS\P?]_%_QKR3R'_YY-_WR:/(?_GDW_?)KH^O2_E/._L&'_/S\/\ @GK?VRV_
MY^8/^_B_XT?;+;_GY@_[^+_C7DGD/_SR;_ODT>0__/)O^^31]>E_*']@P_Y^
M?A_P3UO[9;?\_,'_ '\7_&C[9;?\_,'_ '\7_&O)/(?_ )Y-_P!\FCR'_P">
M3?\ ?)H^O2_E#^P8?\_/P_X)ZW]LMO\ GY@_[^+_ (T?;+;_ )^8/^_B_P"-
M>2>0_P#SR;_ODT>0_P#SR;_ODT?7I?RA_8,/^?GX?\$];^V6W_/S!_W\7_&C
M[9;?\_,'_?Q?\:\D\A_^>3?]\FCR'_YY-_WR:/KTOY0_L&'_ #\_#_@GK?VR
MV_Y^8/\ OXO^-'VRV_Y^8/\ OXO^->2>0_\ SR;_ +Y-'D/_ ,\F_P"^31]>
ME_*']@P_Y^?A_P $];^V6W_/S!_W\7_&C[9;?\_,'_?Q?\:\D\A_^>3?]\FC
MR'_YY-_WR:/KTOY0_L&'_/S\/^">M_;+;_GY@_[^+_C1]LMO^?F#_OXO^->2
M>0__ #R;_ODT>0__ #R;_ODT?7I?RA_8,/\ GY^'_!/6_MEM_P _,'_?Q?\
M&C[9;?\ /S!_W\7_ !KR3R'_ .>3?]\FCR'_ .>3?]\FCZ]+^4/[!A_S\_#_
M ()ZW]LMO^?F#_OXO^-'VRV_Y^8/^_B_XUY)Y#_\\F_[Y-'D/_SR;_ODT?7I
M?RA_8,/^?GX?\$];^V6W_/S!_P!_%_QH^V6W_/S!_P!_%_QKR3R'_P">3?\
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M@_[^+_C7DGD/_P \F_[Y-'D/_P \F_[Y-'UZ7\H?V##_ )^?A_P3UO[9;?\
M/S!_W\7_ !H^V6W_ #\P?]_%_P :\D\A_P#GDW_?)H\A_P#GDW_?)H^O2_E#
M^P8?\_/P_P"">M_;+;_GY@_[^+_C1]LMO^?F#_OXO^->2>0__/)O^^31Y#_\
M\F_[Y-'UZ7\H?V##_GY^'_!/6_MEM_S\P?\ ?Q?\:/MEM_S\P?\ ?Q?\:\D\
MA_\ GDW_ 'R:/(?_ )Y-_P!\FCZ]+^4/[!A_S\_#_@GK?VRV_P"?F#_OXO\
MC1]LMO\ GY@_[^+_ (UY)Y#_ //)O^^31Y#_ //)O^^31]>E_*']@P_Y^?A_
MP3UO[9;?\_,'_?Q?\:/MEM_S\P?]_%_QKR3R'_YY-_WR:/(?_GDW_?)H^O2_
ME#^P8?\ /S\/^">M_;+;_GY@_P"_B_XT?;+;_GY@_P"_B_XUY)Y#_P#/)O\
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M '\7_&O)/(?_ )Y-_P!\FCR'_P">3?\ ?)H^O2_E#^P8?\_/P_X)ZW]LMO\
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%2E>Y_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>image_015.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" #Q G # 2(  A$! Q$!_\0
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MHGRY!!L&Y2W/S=,$ 'GFJUCH6L#4[*^O["ZDF/ATVKREP72Y!/7YLY(QSWH
M]&M+N*^M(KJW8M#,H="5*D@].#R/QJ:O(KO1/$L]A"/(U7[1'H"1 K.R_P"E
MB4'G#<G;GD\5=U2X9_$T_P#:%[J$4$5S92/(()6CA 3+1$I\H#%AG..IX/%
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MZ%17'>"K#6(9GEULWRW<:R13;W4P3YD++(N"3D X[8''I78T %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 57:PM'G,[6T1E."7*#)QTJQ10 4444 %%%%
M!1110 4444 %%%% !5>:PM;B42S6T3R 8W,@)QZ58HH 3&*6BB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HK%TY]7O]-MKLWMFGGQ+)L%JQVY&<9W^]6/L^K?]!"T_\!&_^.4
M:5%9MA<7G]IW5G>2PRB**.17CB*?>+@@@L?[M:5 !1110 4444 %%%% !111
M0 4444 %%%% !16;KSRI81K#-)"TEQ#&7C.&"M(H.#]#33HV.NIZB/\ MN/\
M* -2BLO^Q?\ J)ZC_P!__P#ZU+X>EEFT:)IY7E</(F]^I"R,!G\ * -.BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***S/$<\MMH-U+;R-%(  '
M7J,L!Q^= &G169_8A_Z"6H_]_O\ ZU,72%<D+JNH,5.#B<<'\J -:BLK0'E:
M"[CFFDF\F[DC5I#EMH/ )K5H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBL:]FOYM>6RM+M+:,6WG,3"').['J,4 ;-%97V'5_P#H,1_^ @_^*JKJ
M7]KZ;9FZ_M.*4(Z H;4#<"X!YW>AH WZ*** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH Q])NXK'PA97,[!8XK.-F)./X17/>$M5N[7QAJND:J
M9U:] U"T$_! ("R(HST4CCV!-:NFZA#%H5G97FFW[M% B2(UD[+N 'M@\BK1
MU2R,ZS'2KTRH,*_V!]P^AQ0!/;_\C-?_ /7M!_Z%+6G6/IDS7>M7MR+>YBB:
M"%%,\1CR09"< _4?G6Q0 5'.[16\CH 6520#TZ5)3)(Q+$T;9VL"IP<'!H Y
MCPMXU_X2,@FU6.(6:74DJ2[EA+$_NVX'S8&[Z4T^-_-TFUN[>SVR2ZF--E@F
M?:T+E]N3@'V./0UHV_A#2+18EM[=XA' +8;9G&Z('<%;GY@#Z^I'2EE\(Z1+
M<R3FW=7DN([I@DK*OFI]UL X!&!_6@#"N?B*MN\:R6L,)$]U;7#2S$)%) NX
MX('(8$8/'7I6DWB+4WA\V/2]C&R2Z$$I._<QP8\@8W<?J*N'PGHY:!C9@F%I
M64%F(8RC$A;GYBP)SG-:&GV$&F6,-G:AU@A79&K.6*J.@R<GB@"C::ZK:;/>
MW\36T<=PT2@HV2N["DC'?(]A3(_%VC2VXN([S=!Y0F:4(VU%*EAN./ER >#6
MAJ.G6VJVOV:\0O%N5]H8KRIR.0?45G0^#]%M[>6WCL\036XMI8_,<K)&,X##
M/)&3@]10 LGBW2H;J.VFEFBFD**J/ ZG+N8UZCNP(_\ K5&?&FBK9&[>XD2W
M#%?,:!PN02#SCL0:EG\)Z5<SVT\\,KS6P01R-.^[Y&W)DYYPW/-,G\':-<:?
M%8S6K-;0F0HGG/P9"2W?G))^G:@"63Q1I<62TS^6)EMS*(F,>\N4QNQC[PP>
M>#6G#*L\*2J&"N,@,,'\JR+GPO9R6<]I;HD=M=S>9=12!G5P>6VC=A23@Y'?
MM6T  , 8 H S-?\ ^/.W_P"ORW_]&K7-?$T*1X;!\G+:Q"O[W[A!#9#?[/K7
M3:^'_L^-XXI)?+N89&6-=S;5D4G '7@57N-3L;L 7.E7LP7H)-/=L?F* ,?X
M92?\2;48"2Q@U*="4;=!U!Q"?[@[ ^];OAG_ ) B?]=IO_1KTD6M6T$:QPZ=
MJ$:+P%6Q< ?ABG^'(Y(]$B$L4D3&25MDB[6 ,C$9';@B@#4HHHH **** "N.
M'C*[_P"$IDTA;>!F74%M5'S*6C\H2,^X\;ER/EZGM78UER>&])F>9Y+*-GFF
M6X=B3DR+]U\YX(Z9% &>_BO_ (G.JZ:L2"2UM#<V[ELB;;D.".VU@!^.:P9_
MB+?6^C?:6LK9IWT>/5(P"VT N%9&'7^($'OS77R^'-+F^S^9:*QMD>.(EFRB
MMPPSGOWIG_"+:-]ADL_[/A-O(BQNA!Y1?NKGKM'8=* ,NT\0:IJJRO811&&+
M41:&01DEDP-[%"04*G(YZ]>E7=)OM9GU$PZC:+' D3GS50@2,'^4C).,J1P>
MX-:5KIEI97,]Q;P+'-<;?-<9R^T8!/J<<9ZU:- '+0?$/2YX!*MO>C=Y11&C
M7<ZR2&)6'S=-XQZU9'C73F++Y=TKB9;;:8NLQ95\O.<!@6'4^N,XIVE^#-+T
M[3(K.2(7)C96\V08<E7+KG'H6)%7I= TN<W)DLH6^U,KS<??9<8;Z\#GKP*
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M-T]I;2W$T:B.)"[D,2< 9/ '-+)J%G#(4ENX$<=5:0 C\*@NKW3;NTFMY+^
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M/6O_ #WOO_ N3_&B[#EI_P S^[_@FK165_PCUK_SWOO_  +D_P :/^$>M?\
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MQS]: .VHIDDL<0!D=4!(4%CC)]*C%Y;-(8Q<0F0-L*AQG=Z8]: (=3_U=O\
M]?$?_H0JO#_R-5U_UZ1?^A/5C4_]7;_]?$?_ *$*KP_\C5=?]>D7_H3TGT-:
M>TO3]4:M%%%,R"BBB@ HHHH **Y:;Q<_VS7;2..)9;&S-W:,QW"=0"&R!TPZ
MX^A![U#/XMO+/PS::K-'!(US:V[B, HJRS,%&6R<(-WUXH Z^BJ+7%S8V\\U
MZT,L<2!QY2E2>N>"3[8YJ+2M:BUA)C;1NABQ]_').<="?2@#3HK(\*ZQ+K_A
MRTU*>)(I)PQ9$)(&&(XS]*UZ "BBB@ HHHH 9)-'$4$DB(7;:NY@-S>@]3P:
MYOQW_P @NR_Z_%_] >I?&RPG18I+@W:117,;M+:R,CQ#D;LJK'C/0#GCD5DZ
MVXD\&Z,Z_:]K7"$&[),I&Q\%L\Y/7FLJ_P#"EZ,VP_\ %CZHPZ***^;/J HH
MHH **** "J&M_P#((F^J?^A"K]4-;_Y!$WU3_P!"%:T?XD?5&5?^%+T9A444
M5](?+!1110 4444 %-D_U;?2G4V3_5M]* /H"3'EMN!(P<@=37#_  _G@FU'
M4%C2Z4QQ1K&)[J.0)%EMJJL8  Z\G)/X5W#ML1FQG SBN7\'^+'\2W%R&@LX
MA'&C@03,[#)/#91<=.V>] '1W5JMT(PS$!'WX&.<=,_C@_@*KZ/I$&BV1MK;
M[A8N0 %4$XSA1PHXS@<9)J_10!3BB#WEV2SCYU^ZQ'\(J#68%&F2'=)]Y.KG
M^^*M6_\ Q]W?^^O_ *"*AUK_ )!<G^\G_H8I2V+I_&O4M?9U_OR?]]FJ.D0*
M=/!W2?ZR3HY_OM6G5'1O^0</^NDG_H;4=07P/U7ZEG[.O]^3_OX:/LZ_WY/^
M_AJ6BF01?9U_OR?]_#1]G7^_)_W\-2T4 1?9U_OR?]_#1]G7^_)_W\-2T4 1
M?9U_OR?]_#2I$$;(9S]6)J2B@!",CKCWKB?#+.GBR[A>[N[C8TQ+MIT<*,^X
M DR#ECP!TYQ79SS1VT$DTS!(HU+NQZ  9)KA/#5U9R_$+48[>#2S*?-D:XB"
M^<ZDK\N H/!Y)8G)- '?U#=_\><__7-OY5-4-W_QYS_]<V_E2>Q4=T>+#H**
M!T%%?/'WH4444P.O^'7_ "$[S_KB/_0J] KS_P"'7_(3O/\ KB/_ $*O0*]?
M!_PD?)9M_O4OE^04445U'FA16=>:]I]A<S6]Q,4EAB69EV'[K-L7!Q@DMQBK
M5G>0W]I'<VSAXI!E6H GHHHH **** "BBLNX\1Z;:RW,4LY$ELZ1R*$;(9@6
M4#CG@$\>E &I14<,T=Q!'-"X>.10Z,.A!&0:DH 9,GF0NG/S*1Q7":/##9:^
M\CQWMQJDLP\S=ICQA(U7:D:/]Q$'4G)S7?5S,&L:E)XJ:U1K273WDXE%Q'\H
M"'*!0=Y?=@G/  - &MJVC6VM01171<+%()%V-CD C^M-?0[>2\ANI&=IHG\P
M-P"6P!U X'!X'7)S6E10!2U/_5V__7Q'_P"A"J\/_(U77_7I%_Z$]6-3_P!7
M;_\ 7Q'_ .A"J\/_ "-5U_UZ1?\ H3TGT-:>TO3]4:M%%%,R"BBB@ I&4,I4
M]",&EHH HC1M/$T$OV.'S+>,Q1,5Y1#U4>Q]*>FE6,=DUFMI"+5EV&'8"FWT
MQZ>U6Z* (H+:&V4B&,(#UQWJ1@&4@]",&EHH KV-A;:;:K;64$<$"9VQQC"C
M/)P*L444 %%%% !1110!R/CRRMEM(M1DED6>-A$B?:;B-) <G;B')SWS@]*H
MZH / VAXD,H\]/F._GY'_O\ S?\ ?7-;/CF SZ  (W8I,K;D$Q\OK\Q$)#D<
MXX]>:RM:C:+P9HJ-&\3"=,HY<D?(_7?\W_?7/K65?^%+T9MA_P"+'U1AT445
M\V?4$<\\=M"TLSA(UZL>U16FH6]]9"[A?]Q\WS.-N-I(.<].AJROWA]:Y2)'
MD^'MT(P2<S$@=2!*2?TS6U."DOFE]YC4FX/Y-_<;UIJ]I>S"*%WWE=Z!XV3>
MO]Y<CD5=K&O9([C6=#^S.K8,DF5.?W6S&?IDBMFIJ12LUU'3DY7OT_R"J&M_
M\@B;ZI_Z$*OU0UO_ )!$WU3_ -"%.C_$CZH*_P#"EZ,PJ***^D/E@J&>ZBM]
MHD+%G^ZJ*68^O J:J).W7@7( :VPF?4-S_2@"U#,EQ$LD3!D;H14E4=*YCN7
M7F-[EV0CH1G_ !S5Z@ ILG^K;Z4ZFR?ZMOI0![W=W,=K 7E<HK$(&"%L$G X
M'N:Y+P'=BXN]0 NWFQM8@M<,&))^?,P&W/\ =7@8^E==>0"YLYH6:10Z%<Q/
MM8<=CV-<IX&:,S7,:MK$LL44:3-?2NZ1ODYC3<JY(ZD@=Q0!NZUKD6B"V::&
M5TGD$9D4?+&/5CT'H!WI^BZS!KEFUQ;I(@1]A5QSG:&'Z,*MRVL$\B/-$KM'
MG:6&<9Z_R%+;6L%G%Y=M"D29SM1<#- $,,B)>789U!WKU/\ LBH-9EC.ER 2
M(?F3O_MBK%N,W=W_ +Z_^@BH=: _LN3C^)/_ $,4I;%T_C7J7/.B_P">B?\
M?0JEH\T8T\9D0?O)._\ MM6A@>@JCHX']G#C_EI)_P"AM1U!? _5?J6_/B_Y
MZ)_WT*//B_YZ)_WT*?@>@HP/04R!GGQ?\]$_[Z%'GQ?\]$_[Z%/P/048'H*
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MA"M*/\2/JC.O_"EZ,PJ***^D/E@J.:"*X4+-&LB@YPPS4E% "*H10J@*HX
MP!2T44 %-D_U;?2G4V3_ %;?2@#W+7+>XN=+=;."">X5E=$G=E3(8')*\]JY
M3X>>3]NU 0V=G RQQB1K5YVPV6RC>:!AAZ#UY[5W$G$3\D<'D'!KC?A]=6UT
M+AK?63>$1J1:"+8+8%F;YCSN8DG+9[4 =K15#4M1;3VM0(?-$\PB.) I4'N
M>N.I'IFH]!UAM:L7GDM7M725HVAD)WKC&,\#!((/?KUH M6__'W=_P"^O_H(
MJ'6O^07)_O)_Z&*=%-''>78=PIW+U_W14&LW,+:9(!(I.Y/_ $,4I;%T_C7J
M:E4=&_Y!P_ZZ2?\ H;58^UP?\]%JEI%S"NG@&10?,D_]#:CJ"^!^J_4TZ*A^
MUP?\]5H^UP?\]5ID$U%0_:X/^>JT?:X/^>JT 345#]K@_P">JT?:X/\ GJM
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M0WFDX^8>U53PE6,U*2T1%3&T9P<8RU:\RM15S^QK_/\ RZ_]]M_A2?V-?_\
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M;>YP8FZ%R1V]#67;^,5GN[.#[&P-Q-)$2K[@I61X\].?N9/H"*O:QKK:7=+
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MSM_^_2_X4?4'_,']N1_D_$XCX=$?VG><C_4C_P!"KT#-0I8VL9)CMH4)ZE4
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M$AD$A12X&-V.<>F:<    , = *YU_'.D0P3/+(Y\F-W?8A()159U7U*AU/\
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M%X<30Y)'6[FG\Q0N'Z#Z>WH.PJWINMV.K/*MC/YIBZD*0",D9![C*L/PJ_0
M4444 %%%% '->.KB&VT:!Y[HVBFZCQ/Y?F"-ADABG\0R.GT/:L#Q>8C\/-),
M%X][&;B,BX==IE^5^<=OIVKI_&.IC2] D;,BO.PA1XYDB*,0>=SD =/6N>\=
M7W]I^!].O!&(O.ND;8)%?'RO_$I(/U% 'GM%%%,D*KSV,-PY=PP8KM8HY7</
M0XZBK%% "*H10J@!0, #L*6BB@ H7_70_P#79/\ T(44+_KH?^NR?^A"HJ?
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MR2\NSJ$8M)\GYX!)DR,,#!,98-VX'K0!T3^%=*DGDG:!_.DN5NRXE8$2@8#
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MD5C_ *1'T!!]:B:O%HNGI--]R\>IHJ]_8&M_] N3_O\ 1?\ Q5'_  C^M_\
M0+D_[_1?_%5X'U6M_*?2_6Z'\R*-%7O^$?UO_H%R?]_HO_BJ/^$?UO\ Z!<G
M_?Z+_P"*H^JUOY0^MT/YD4:*O?\ "/ZW_P! N3_O]%_\51_PC^M_] N3_O\
M1?\ Q5'U6M_*'UNA_,BC4-Y_QY3_ .X?Y5J?\(_K?_0+D_[_ $7_ ,54<_AS
M6Y8)(QIC@NI4$SQX_P#0J<<-64E[I,L51<7[R/2J***^@/FPHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I*** "EHHH ****
+"BBB@ I*** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>image_016.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_016.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" )T \@# 2(  A$! Q$!_\0
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M20#DO\RR#@@,6^;&&#O'$)2) "SNA4I_JU1*_&S_ (*H_MC?M(_#?QI^RO\
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M1)I7AAKJ;5+W40#^J2BOB[X*_MO_  H^/'[4_P"V#^R!X0T'X@:;\2_V*O\
MA2Z_%/7?$FE>';7P-KI^.GA+5_&'A-O 6JZ3XIU/7=4.EZ9HUS%XE&O^'O"A
ML+Z2UM=+;4MM_)I^/X#_ &]?@_\ $']J/]LK]DK1/#7Q-LOB7^Q!X1^$OC7X
ML:SJ6C>&V\%^(=-^,?@2[\?>%++X=WUCXNU'Q+K%Y9:':F/6[76_"WA"*#56
M$5C=:G%+/=T ?=-%?B;^QO\ \%S?V</V\_B'\*/!'[-_[.O[<?BGPO\ $S0&
MO=7^/4_P!TV/]G'X,>*8/"FJ^-+KX8_&#XS:;X]UGP;X=^).GZ%IULU]HWA]
M_%FEQ:MKFE>&8]>E\3"^T.Q\V\7_ /!Q/^Q=X?USQ9J?A/X&_M[_ !H_9M^'
M?B35_"_Q*_;H^"/[)WBOQ_\ L7> +SP]>FP\77^O_%R/6K75+_1/"$Y2;7-:
M\+>"?$=I=PR6M]H+ZW:W5O). ?OW17#_  _^(/@CXL^!/"7Q+^&GBK1O&_P]
M\=^'='\7>"O&7AO4H-4\/^)_#.NVEOJ>CZWI.HV\DL5YINI6<R2QRALF(LI4
M$Y/\Q_\ P7@^,_[;'Q;_ &@OAK^P[_P3S^,'Q1^#_P 5?@7^R[\</^"C7QIU
MWX/^(O$NA>*?%&D?#2SN?"/P%^#=ZWAC4[$>(=-^)GCR/7+36O VM)?Z?XD\
M_P +R2Z3J2Z?]FG /ZJ**^.OV*?VL?"?[87[&'P$_:[\,RB30_BW\(= \?:G
MI]AB5M%\2QZ8\'C[PJ@/D^?>^%?&NF>)/"<I=D@GO](=0)%(N)/R*T+_ (.9
M_P!C;QY\--/^*_P9_99_X*0?M ^%-.TO4M8^,EY\#?V5K/XAZ3^S+%8WU['%
MIWQ_\8Z3\3H_ASX6U2]\.:?-XO2W\.^-/&::7X;E@N_$4NA:DSZ.H!_1U17Y
M]-_P4X_8H7]A2V_X*0W7QJTJW_9$O_"J^*(?B)=:1KHOGED\0'P6?"*^#HM+
MN/%,GC5?&<,_@J7PK9Z?<ZNGB/[1:FU>%&NU^'/A_P#\'!?[+>N?%KX2_"WX
MT_LO?\%$_P!C*Q^/WB_3/ GP3^+W[8O[*.H?![X,_%'QAK=S967AO1?#'C*'
MQAXGF2?7C?:?=6M_JVC:3HNGZ??6M[XBO='MWFDA /WHHK\'_%GQ?^+-A_P<
M8_#SX)VGQ(^)#_!BY_X)*>*/B3>?!BS\;>(8?A;J?Q#M/VF]5T&W\93> 9]:
MM?!/_"?KX?2TT.V\5WMA+J:Z4EOIRZCIMC/((_T<_8Z_;1^$O[;G[/\ ;?M%
M?#6R\9^"/"\7BKXC^!_%OA3XK:;H7AWQ]\.O%WPH\5:OX0\<^'O'6EZ)XB\6
M^&]'U#3+_19KYWM/$&I6IT>\L;DSQSWK16X!]B45^+0_X+G?L>-^QY\*/VRH
M?!'[2NH^%/VB?BIXQ^#_ .S/\%_#GPCM/&7[1G[2WB[P9KNO^'KA_@_\,O!G
MC#Q%%JVA:[=>&-3DT'4O$WB+PU&]LMA;ZM%I5WK>A6EWZY^Q#_P5@^ O[;WQ
M,\<? 2R^&'[4/[+W[2GP_P#!UG\1]?\ V;OVR/@IJ/P.^,S?#/4[^#1[/XAZ
M/X=.J>(]+USPM_;%[86#7-KK0O+4ZC8M?:= TZR, ?J317X'_LO?\%&?V-OV
M>_V)/VH?VJ/%'QQ_;1\8_"/X>?MP?''X5:OJG[6^K6'QG^--U\8IO&NA>'(O
M@Y^S_H?P[O\ 7;B_^$RZM?6NG?!CPIYD>HZ#H4VM:GXB&B:)9:C?1^S?LH_\
M%H/V?_VFOCYX:_9<\7_L]?MO_L5_'GXC:#X@\3?"/X;_ +=?[..I? C4OC+H
MO@^PEU#QA/\ #&]A\0^,](UMO#>EVMW>W]K>WVDW,UK87TEI;W+P7$I /V*H
MJ- 5)4DM@(=Q"@GC:=V""SY3);8B$,H0':U24 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M!SOB_P#Y%/Q/_P!B_K/_ *;KBOPK_P"#8;_E"?\ LC_]AS]I3_UJ;XT5^]&H
MVL%]9W5E=Q>?9WEK<VEU#N*>;!<0M%)'N$D9&^-G7.Y=F?,\V+9N/X'3_P#!
MKY_P0QNYI;J7]AL23W$DD\SG]IG]L,>9/+(6G+M_POS"DL[MQ$&W97$/EG(!
MR'_!R%X$_P"%H_!?_@FS\-3XS\>_#D?$+_@K_P#L8^"/^%@_"SQ"?"'Q-\"'
MQ59?%30QXR^'/BP6FH'PWX[\-F^_M/PIK9T^[72-8@MM59-MB5?I;K_@WM^%
M7BVSO?#7QL_X*9?\%G_VDOA;K,)LO%_P3^.7[?VO>)/A;X^T>699;O0/&&@^
M'? OA/5-6T;4H%EL;ZV@UW3Y)K.:X\F:*Y:&ZM_O+P-_P2C_ & _AU\$/@3^
MSEX+^ W]C_!7]FO]H/P[^U3\$O!A^)_QFU./P9\=O"VKZQKWA_QTNNZK\1+_
M ,2>)/L6J:]JM]_PC?BS6-?\)7378;4- G:VM3#^B,)SO]05#'#C+%0^?F&#
M\KJ,H648\L$;-B@'Y9?M%_"[_@H[\$?!?P#^#_\ P1_\)_\ !-SP)\&_AGX,
MOO!7B/P?^V)!^TI!'X=TWP^F@:?\-],^%H^ ZE9].MM'AUR+Q9=^,9[S4KO4
M$TN=+V\O'U>ZF^N?V1_^&Q/^%+Z/_P -V?\ #-G_  T1_:NN_P#"0_\ #)G_
M  M'_A2W]@_VG/\ \(K_ &-_PN3_ (K[^VO[%^S?\)'_ &C_ *#_ &GYG]F_
MN-U?350S9^3T)(8Y<%1M/S_*0,+CG<4V@[ED6155P#\%?^"89(_X*F_\%^<=
M#^T7^Q]NP2'('[+UH<1D*V7)& @VLP)99%*8/P'\/OV1?V2/^"RW_!2[_@I1
MH_\ P4VBO_BM\1/V+/BZGP'_ &</V3[SQ]XE^$>F?#?]F(Z3H'B+0_C=9I\)
M_$/@7X@>.Y_BQXBN=3UK4-?USQ5K&F:(-7M+:_T33K#5O!UGI?\ 31\+OV9/
M@?\ !OXJ?'[XT?#7P0OAWXD_M0>(O!_BOXZ>)3XA\6ZQ_P )WKW@/PHG@[PE
M>OI.OZ[J>@>%UTGPULTT6'@[2="TV\ :]O;2YU&:>>OE3]LS_@D'_P $W?\
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M\:?MN?LW:UX2_8R_91^$_BZT.O'1/%5S'?\ Q2/Q*^+GBK4/BO-X:\$R7O\
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MX!T+1_#C>&M(\*V&D-IE]\2_$FC^)?B'XEUJS:'2-:\:Z VH6FIW']!>@_\
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M3LP>,!-P(D(;. L@*; >#RP+;3T!&#U!%FO*OC1\6? WP,^'GB/XJ_$C6X=
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MM%T[TJ^%QT/9XO!8^BWA\3A*M/$824L-BHLGHHHKT#P HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZYI&JZ&+Z^T#ZM_X*Q'-Q_P33;*G=_P52_93.5QM8'3/B21(.6;#DGJ[ ,&
M)(:20 ^J?V4?^"@?[(G[<.A^/_%'[+_Q>C^)7A_X77&E6OCW5;CP9\1_ EIX
M=EURSU+4K#[4/B1X3\&_:4>ST6^EDN=/%XNFK;F6^>TBFC-Q\V:W_P %Q/\
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MEN=(NTN[6_$:_D[X_L_VJ_VA/VZO^"(OQAT7]IYOA/J/Q=_9*\6?$"?P_/\
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ML$%I;^)_L4_L?^ _V-/@YI'PU\)00ZEXANS#J?Q"\<3VZ6VH>,?%8MO+GO\
MR]HDBT6Q=Y;/P]IKO*;73E-Q=376J7NH7UU]DPY#2@E<Y4D ;2,Y^\.!SC(/
M<=<=!_2/AGP"N$\/B<TS2K/,.*L[C"IG.-Q$\15EAZEUB*^#P<JSE25"%?$M
M8FKAU".,Q$>9<T,-!'\J_2I^D?'QDSW+>$N"*4<A\&. J4,HX*R+"*I@</G,
M<NI_V;0XBS#+G)2IUEA,)]7R#!8I3J97D4E5E;,<TS&:L4445^JG\EA1110
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MSJ_@[QE'\-9[?P:-3U'5]4U+4+=O"T7B*Q\'+<63WL6I:GH;,GG\!K'[$?\
MP4(^#GQ,^.OA']C']H']G;P;^R3^U'\2O%GQ4\::=\5O!GC?4?CE^SMXL^*"
MHWQ2O/V<Y?#;P^!=<_X2?69=2\3:%IWQ(%KH/@W4I;6UT_1M28:E>ZE^W-%
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MA7OA/QI9ZKJ>@ZA9^%[;5M>TB_L+2>_\+V=E=Z=JW[C44 ?D-X\_92_;U_:
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M+;Z/IEQXFU:WU/39_#=QXKO'T1 )[*R>"WTFY_4^B@#\AO&7[!7Q?U_]C?\
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M(45F_;;C_H%ZE^>F_P#R?1]MN/\ H%ZE^>F__)] &E16;]MN/^@7J7YZ;_\
M)]'VVX_Z!>I?GIO_ ,GT :5%9OVVX_Z!>I?GIO\ \GT?;;C_ *!>I?GIO_R?
M0!I45F_;;C_H%ZE^>F__ "?1]MN/^@7J7YZ;_P#)] &E16;]MN/^@7J7YZ;_
M /)]'VVX_P"@7J7YZ;_\GT :5%9OVVX_Z!>I?GIO_P GT?;;C_H%ZE^>F_\
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MT?;;C_H%ZE^>F_\ R?0!I45F_;;C_H%ZE^>F_P#R?1]MN/\ H%ZE^>F__)]
M&E16;]MN/^@7J7YZ;_\ )]'VVX_Z!>I?GIO_ ,GT :5%9OVVX_Z!>I?GIO\
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M7YZ;_P#)] &E16;]MN/^@7J7YZ;_ /)])]MN,C_B6:B,Y^]]@(_'9?']?PH
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M_P!MLAO^"S7_  368'(_X1;Q$,G;\X,_CIUE4J K)(KC+(/+,HF"<J]?K?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#D.M.B@#,WZG_SYVG_ (&-_P#(=&_4_P#GSM/_  ,;_P"0ZTZ* ,S?J?\
MSYVG_@8W_P AT;]3_P"?.T_\#&_^0ZTZ* ,S?J?_ #YVG_@8W_R'1OU/_GSM
M/_ QO_D.M.B@#,WZG_SYVG_@8W_R'1OU/_GSM/\ P,;_ .0ZTZ* ,S?J?_/G
M:?\ @8W_ ,AT;]3_ .?.T_\  QO_ )#K3HH S-^I_P#/G:?^!C?_ "'1OU/_
M )\[3_P,;_Y#K3HH S-^I_\ /G:?^!C?_(=&_4_^?.T_\#&_^0ZTZ* ,S?J?
M_/G:?^!C?_(=&_4_^?.T_P# QO\ Y#K3HH S-^I_\^=I_P"!C?\ R'1OU/\
MY\[3_P #&_\ D.M.B@#,WZG_ ,^=I_X&-_\ (=&_4_\ GSM/_ QO_D.M.B@#
M,WZG_P ^=I_X&-_\AT;]3_Y\[3_P,;_Y#K3HH S-^I_\^=I_X&-_\AT;]3_Y
M\[3_ ,#&_P#D.M.B@#,WZG_SYVG_ (&-_P#(=&_4_P#GSM/_  ,;_P"0ZTZ*
M ,S?J?\ SYVG_@8W_P AT;]3_P"?.T_\#&_^0ZTZ* ,S?J?_ #YVG_@8W_R'
M1OU/_GSM/_ QO_D.M.B@#,WZG_SYVG_@8W_R'1OU/_GSM/\ P,;_ .0ZTZ*
M,S?J?_/G:?\ @8W_ ,AT;]3_ .?.T_\  QO_ )#K3HH S-^I_P#/G:?^!C?_
M "'1OU/_ )\[3_P,;_Y#K3HH S-^I_\ /G:?^!C?_(=&_4_^?.T_\#&_^0ZT
MZ* ,S?J?_/G:?^!C?_(=&_4_^?.T_P# QO\ Y#K3HH S-^I_\^=I_P"!C?\
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M_P"!C?\ R'1OU/\ Y\[3_P #&_\ D.M.B@#,WZG_ ,^=I_X&-_\ (=&_4_\
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M=W4=54L 2@.2N/E^8[>]/J.,DYX(R%.WC"9 !08 .01N;<.K<>@DK, HHHH
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M]H?P_J1'[G7/AGI!B8<ACH^KZ[ Y_*Y3ZYZYK\X0<@'U4-^>?\#7[5_\%6O
M\U[X:^&'Q)L[5I$\.:MJ7A?5KJ/@VUGXEMH+G2)6Q_"FHZ>=.7/4ZLQ'&:_%
M8@*64< /*,'J&$KJ<_7 /XU_G-XV996RWQ,XFEB-\QE@,VH^F88=1_!81I^:
M/]COHQYY1SOP3X)A0=WD^#Q^2XK;^/EN/G]7V;_YEF,PC5[.S5TKH2@9)4 +
MG>I4N/E:3E8XF)X'F,^1GKL]J*4$*02"<?, H.X$# 8GR)D$:[CY@?;N!&,X
M./RFUW%<L)7E&_M(TY4HKF5YU54T5*FKSJ3C^\A&+E3]]'[Y&W/!\W*U.,H^
M]"$92BVX0FZG[MTZDU&%6-3W)TW.,OLGR?X]^+5EXJ\5:K\+]%^('AOX>Z)H
MV+;Q[XXU?Q!IMAK3ERPO/#?@ZVU">&)M1DC+6]UJ;[[;1(;B.\FQ,UJ6ZG5=
M!TWQ!\)=4^'W[/GB;P79O!#;Z:]Q9>(#>VEA973N^HV]UJ&AIJ>I?VKJUO'=
ML+F:W6ZU8/J%UYJ1& UZ9<_"SX87D\UU=_#CP!<WMW.;JYGF\):+<S74KG,L
M\EU+8[YY)."Y)^4CGK6YH7A3POX5CN(?#/AO0?#L=VZ272:'HVGZ3]I,?F>1
M]I^PP0_:!!YLWD>:&\KSIMF/,?/Z/BN*.'L+@<F624,RRV.2XC"8NE@\3#+L
M3E>89S1K4YXG'XNIAM<QJ58*I' 0I_N\DHRAAL+[F(QA^-X3@;BO'YIQ%7XM
MQ7#N/PW%.69SEM;'97/-\-F679%B9U*-# </TY_['EV"I2=-XZ=;]YG=95\3
MB/WN'P1\2_$#1?CCX<LOA#H5Y:?!2PL-)^(/ABP\'6GAM/'2VL&NP6U\--77
MFOH_M$FAR0--/J;V5Q+<M>2Q>7%;])/NK2_[2_LS3_[8^Q_VM]CM_P"TO[.^
MT_V?]M\L?:?L/VS_ $O[)YV_[/\ :_\ 2_*V^?\ P4S4=)TO5?L3:IIVFZBV
MF7T.J:>VHZ?::@--U&V#K!JEHER"]M=6PE=(KR(CR#/E\EDK1ZY)!!)/RDDD
M G=\[#Y))&9FD:1/O!U!Z"O*XEXMGQ+EF3X.OEN R['Y9BLQQ6,=' >QJXFG
MF-252G*-7[.LHR?\T;KJ?0<&\!QX/S7B#&T\YQV:8+.Z>2T\JA5Q_MJ.'P62
MX!8!1]G]J*:M'MAOJ;Z!1117QJ=I0\ZE-?\ @4TOU/T6$93G3A'XI5(17K*5
ME^-A02"I7&Y65T)[2*<+^:-)7[I?\$FM'DM/A5\4M99-L.L?$*SMK=_[\>B^
M&M-M3^(:8Y[\\U^%;.J#>S;5C(=\)N<Q [9MA[%8G>0^NP"OZ<_V%O ,OP[_
M &:/AWI=[;"VU;6[&X\8:O'L"N+SQ3>W&JQ(^.K0V$UE >X,1%?OOT;\KJXS
MC^MF7_+O*,FQ:?\ W-5)X:*];U+_ "9_(WTRL\P^7^$V&RN3_P!JXBXGRK T
M5U:RBAB<QS=[WLL52P:>C5VK[IGU]1117]YG^5P4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !36X(.,X#=%RW;A3VSW&#G
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MF.)A*&$<TJBRK#X-5$L1+$(FHHHK]@/Y\"BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_@)XBT[5K'4XK+QKJ6BZ=XE\'>+M,L#!/8^']9T[4M.U^ZN;^70+N&-KR_\
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MQ!^(_B^XE@\/>&;74-0>/3-$M72VOM3U?7M4D%GI.BZ;J-VL5Y>)9V-U\^?
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M_D^C;JW_ #\:?_X W?\ \GT :5%9NW5O^?C3_P#P!N__ )/HVZM_S\:?_P"
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M5%9NW5O^?C3_ /P!N_\ Y/HVZM_S\:?_ . -W_\ )] &E16;MU;_ )^-/_\
M &[_ /D^C;JW_/QI_P#X W?_ ,GT :5%9NW5O^?C3_\ P!N__D^C;JW_ #\:
M?_X W?\ \GT :5%9NW5O^?C3_P#P!N__ )/HVZM_S\:?_P" -W_\GT :5%9N
MW5O^?C3_ /P!N_\ Y/HVZM_S\:?_ . -W_\ )] &E16;MU;_ )^-/_\  &[_
M /D^C;JW_/QI_P#X W?_ ,GT :5%9NW5O^?C3_\ P!N__D^C;JW_ #\:?_X
MW?\ \GT :5%9NW5O^?C3_P#P!N__ )/HVZM_S\:?_P" -W_\GT :5%9NW5O^
M?C3_ /P!N_\ Y/HVZM_S\:?_ . -W_\ )] &E16;MU;_ )^-/_\  &[_ /D^
MC;JW_/QI_P#X W?_ ,GT :5%9NW5O^?C3_\ P!N__D^C;JW_ #\:?_X W?\
M\GT :5%9NW5O^?C3_P#P!N__ )/HVZM_S\:?_P" -W_\GT :5%9NW5O^?C3_
M /P!N_\ Y/HVZM_S\:?_ . -W_\ )] &E16;MU;_ )^-/_\  &[_ /D^C;JW
M_/QI_P#X W?_ ,GT :5%9NW5O^?C3_\ P!N__D^C;JW_ #\:?_X W?\ \GT
M:5%9NW5O^?C3_P#P!N__ )/HVZM_S\:?_P" -W_\GT :5%9NW5O^?C3_ /P!
MN_\ Y/HVZM_S\:?_ . -W_\ )] &E16;MU;_ )^-/_\  &[_ /D^C;JW_/QI
M_P#X W?_ ,GT :5%9NW5O^?C3_\ P!N__D^C;JW_ #\:?_X W?\ \GT :5%9
MNW5O^?C3_P#P!N__ )/HVZM_S\:?_P" -W_\GT :5%9NW5O^?C3_ /P!N_\
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M16;MU;_GXT__ , ;O_Y/HVZM_P _&G_^ -W_ /)]46:5%9NW5O\ GXT__P
M;O\ ^3Z-NK?\_&G_ /@#=_\ R?0!I45F[=6_Y^-/_P# &[_^3Z-NK?\ /QI_
M_@#=_P#R?0!I45F[=6_Y^-/_ / &[_\ D^C;JW_/QI__ ( W?_R?0!I45F[=
M6_Y^-/\ _ &[_P#D^C;JW_/QI_\ X W?_P GT :5%9NW5O\ GXT__P  ;O\
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M/6*-B $1=NXY50"">!Y<G#@\'E1G[N>@%/!/\0 X]<_E_G/MZ&5!P#R?3O\
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MGQ+X?\(Z1I&M3/<P$P73OJ%G<$W47R7 VR+\K+7M%11-NW8'"D("/ND#)!3
M"E-I7E2</OC)S'@2UF 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M, HHHH **\T^+NO?$7PUX!UW6?A-X#M/B;\1+9+*'PQX+U+Q78^"-)U.[O\
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MHCVY -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\C7OTO>Q_FG:,7RQO:#G2^Z3K6_\J_/0?1116PPHHHH **** "BBB@ HHHH
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M23R/*[RRNSDUZ#0!%%CYO^ CDY;"J$.Y0 D?SJXV19C)!D4Y<@2T44 %%%%
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MC2H4H\U:K4P]6O1BI/E3GB<.ZN&@N9I)S5F[)-2:1Z<+68'G4;Q3[1V7Y_\
M'D#^7X4J6EP2V-1O%/&<)9\]<=++Z_GFK@D#@%"&]0<%E^C>GY8[CFK"GD\<
M87]1T]>/>OW.+?M)1:K*2493E.[I58O9TM6DKM2LDFE9--.[^2Y%%V@O9_\
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MV.Y_Z"=[_P!\6?\ \A4?8[G_ *"=[_WQ9_\ R%6G10!F?8[G_H)WO_?%G_\
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M_P#R%1]CN?\ H)WO_?%G_P#(5:=% &9]CN?^@G>_]\6?_P A4?8[G_H)WO\
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MV.Y_Z"=[_P!\6?\ \A4?8[G_ *"=[_WQ9_\ R%6G10!F?8[G_H)WO_?%G_\
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MJZ;_ -DQ4J==I:NFIV7,E?\ )L+M*Q@X7'&,\>O0'L.I/MBI @ P'( [9/\
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M9:WX"^,_PV^#T$?AG1H9-2^*'P2^-+>-?#R^)W.GWUIX5\4?#OQ3X6\&^/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME&$U_)/X9=EZM_#_ 'K'D7Q-^$OA?XG6,4&L0/::I"K#3=<L1&E]8%S'F/\
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M[-]UIFF:GKMPMKI.DZMJUPY 2&QL;B^=R3@9CMR7 )X$A/EIR9,J*^FOA_\
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M,Y3&<E0TM12C@')!&0",9!8;=WS K\H)(#@H3C<,A2 #\(?VU(O@[\%?VO\
M6_C7XE_X*9:[^R7\2_'GP^\+Z+#\//"_PL\->,C/X&T&)+"RNO$^F0:!XC7Q
M +K7CX@O]%U7QUHUUK=B+[4=)\,7$.D:6$'LG[!O[0G@[XI?&?7_  SX=_X*
M2^+/VQ;ZS^'FIZQ/\.M2_9\TKX<Z/H,2>(O#MK_PE8\::5\.?"L4]UIRW#:3
M'X;FUR>>[&M2ZB=.D&DAD\^_:*_8Z\??$/XY?\%&+9?AI>^*+?\ :O\ V5O
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M&:FM;VYTR^M-4T^ZGLK^PG2YMKBS_P"/R&YB(>&:'L6A92QR,9QFOZ4^C_\
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MO4P6)3WGB*4I*33TYHM+G4K6:DI*U]):***^D.,**** "BBB@ HHHH ****
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MO\E8_-H:QYOYFW][_P K?>+1113*"BBB@ HHHH **** "BBB@ HHHH ****
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M9G]G1?W[_P#\&%Y_\ET?V=%_?O\ _P &%Y_\ET :=%9G]G1?W[__ ,&%Y_\
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M ).>?3/OZ<_YQ44G#( K?-NZ.HQC;T!R6'//I^-47T^( -YE\,$D_P"GWA)
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M#E]E4C2PU6K#2_,Z2HN.FFCI:M7LDD]=7^65I*6)Q%52]K"KB,14IU.>%/\
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M*;I\J<5&#Z\L?+I_706D(R0?3/Y\4M(1D@^F:<92A*,XNTH24XO^647>,O\
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MQ+>?&?PYH-WJ^B&#[7<Z1=>$O'%_/I\HG@G4VDEWIMC<W&U58"U4AN*\C/\
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MVT74O#+Z]X:-YX7M-?\ %M[>:9/J=_J:Z1JD&E1B.]NH=%N)[?>+20#]9Z*
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MUKP=?.&/A^:#4]%4<%--OFN(I[7'))M=0M[EO]VY3IUK[,@(RP QM2,?49D
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M\87<6NZNNBVHT;3?"_C#2;EH;LAMUVMWKEB\,(7#[&+,JJ37ZAUX[\:OC?\
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ME0<C YSC@\]<$CH" .">!Q4B,H=QD#A,C!R/O=3T(/;C/8DX&/\ 4/P7\#>
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M5'#N-7%49.UW"6'56<%?2I"+23<F_P!-@5.-HY*CW^7VXQGZ=OTF7&.G89_
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MP_9WWA;1]5.K_%OXSZ)#<7IU+61H-S?^%M*URQTRZN;:&_C\/!=*)BY#X?\
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M/VRYM/J/ISXE(-Q&6550&1G<<1HN=\J^C*I.\]H#.>F17WU^RI\.[G2=*O\
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M2U#"00<;L':1O149MPW%BH"LNYRVY942191+D%2M35F 4444 %%%% !1110
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *JSJ#)"2%R/,
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^>O\ P4H_8_\
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MZIVB_;UZ[<[=Z'_+HEHHHK084444 %0RC+(",KACGT8%-OIG.3P>#BIJAEX
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"C_:NF_\_MO_ -_!1_:NF_\ /[;_ /?P5>V)_=7_ +Y'^%&Q/[J_]\C_  H
MH_VKIO\ S^V__?P4?VKIO_/[;_\ ?P5>V)_=7_OD?X4;$_NK_P!\C_"@"C_:
MNF_\_MO_ -_!1_:NF_\ /[;_ /?P5>V)_=7_ +Y'^%&Q/[J_]\C_  H H_VK
MIO\ S^V__?P4?VKIO_/[;_\ ?P5>V)_=7_OD?X4;$_NK_P!\C_"@"C_:NF_\
M_MO_ -_!1_:NF_\ /[;_ /?P5>V)_=7_ +Y'^%&Q/[J_]\C_  H H_VKIO\
MS^V__?P4?VKIO_/[;_\ ?P5>V)_=7_OD?X4;$_NK_P!\C_"@"C_:NF_\_MO_
M -_!1_:NF_\ /[;_ /?P5>V)_=7_ +Y'^%&Q/[J_]\C_  H H_VKIO\ S^V_
M_?P4?VKIO_/[;_\ ?P5>V)_=7_OD?X4;$_NK_P!\C_"@"C_:NF_\_MO_ -_!
M1_:NF_\ /[;_ /?P5>V)_=7_ +Y'^%&Q/[J_]\C_  H H_VKIO\ S^V__?P4
M?VKIO_/[;_\ ?P5>V)_=7_OD?X4;$_NK_P!\C_"@"C_:NF_\_MO_ -_!1_:N
MF_\ /[;_ /?P5>V)_=7_ +Y'^%&Q/[J_]\C_  H H_VKIO\ S^V__?P4?VKI
MO_/[;_\ ?P5>V)_=7_OD?X4;$_NK_P!\C_"@"C_:NF_\_MO_ -_!1_:NF_\
M/[;_ /?P5>V)_=7_ +Y'^%&Q/[J_]\C_  H H_VKIO\ S^V__?P4?VKIO_/[
M;_\ ?P5>V)_=7_OD?X4;$_NK_P!\C_"@"C_:NF_\_MO_ -_!1_:NF_\ /[;_
M /?P5>V)_=7_ +Y'^%&Q/[J_]\C_  H H_VKIO\ S^V__?P4?VKIO_/[;_\
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MBBB@ HHHH **** "BBB@ K\_O^"D/Q=T3X>? *V^']_\0]"^%VJ_M(>,] ^
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M*T+PWX<TG3]#T'1M-M"ZVUCI6E:7!;V%A9Q(<PVMM&L<2L 5\PR.X!TE%%%
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M<]<8K\9M;\0ZO\.O^":_Q _9H\9ZGJFJM8_LP_"KXM?!#Q#K%]+>W_BSX/\
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M@UK+6X1INE_$/5O 7P1\!:UXOTJUN['2+KP7)K-TTOHGC+]GWQ/9?$<_&/\
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M*^ _!=KJ'B;7-,TS2T\>:[)J.H^,/B%\0?$>M:C=2W4NO6FGII^A:5])C],
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MS_#_ /9JU75?C;8>#]$TUO$WQ7\=>'/ ^G33:7/\0K^\N+/1/A]J.OV6H_\
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MY S)',511*I(5FGH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'OBKXG^-_'?PC\/?''XI:E\.?#4GC?XX?&3QUXVTNT\7>(V636)[#7?&.O\
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M6&TT8^%-.@6[U2"#YS^(O_!4[X@67[)7[&&L^)/BC\//V=?B9^T]#\1AX_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>image_017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" )B ^P# 2(  A$! Q$!_\0
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M<ZAJ$T-C8V=N]U=W=W-'!;VMM"GFSSW$KG9!%#&)"SS&/YHG4@#:S?*?@/\
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MYN"-RE!@$ER!CY68\C*' 4[@'W* 690F&*K*K#@@G&X ')*DD*X !8HQ! 8
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M^W)XJ_X)Z?L^?L8_M3_LP_"7X3^*/^"8MG>_#G1_VBM \$?"OQ=X7\=_!O\
M9K^(VCZ)!\*OB]\%/#^A^(/"/A;PCX-\&'5M,A\2_#SQ!\*K[49K35M!TC3Q
MX5,>HWVF=+^R=_P4;^)W[;WQY_;(\9_L^6/PDUO_ ()U?LQ>'G^&OP_^-KZ/
MXPUOQ;^T9^TWHVC1^*O'FJ_#SQA:^,-,\$/\"/AU9W%AX7N[BR\':]K/C'6[
MJW\1>&O&<6B7T5K;@'[,K)N.-I'7.2#M*E0P<J64-A@5 9L@'.TC%-\]2> 3
MT/RE7)5MQ#J$+94A'/)5CMVJK,RJ?Y+?V(?^"H/_  7E_P""DO[*/@K]J+]E
M/]E'_@GWX=\/>'5\1Z)\0)OCWXA^./A2Y_:,\;>&M>U9M5T3]E?PQX8\7>)+
M?P)HN@:/;6/@RX\6?&CQU<:7K'CZ]U>>S6TTGP_JEM9_2GQF_P""Z?B#2/\
M@CMXB_X*4?#CX.:5X3^+7PH^.7@WX#_M ?L[?%(ZEXHE^%GQ TCXZ^%/A;\:
MO LM[H.O?#^YU+6['0M5N];\ ZO-J%E;B76/#]SXBT&?[/JVBP@']'YE ."#
MWQR!NY*JJDX4R.PPJ;L@?>VGY:/-^;9@$C8"0VX!F5G9?E!<%47>"Z(KAE"G
M)P/P*UW_ (* _P#!1G]CW]F'XO\ [4G_  4+^ 7[+S7?C77?A!X,_8@_96_9
M/\5_%;6?C;XO^*_QO\1ZAH7ACX%_&KQEXZM;KP4WC?1VN/#*:OXH^&6CW^A7
M%A9^,-2T/2VETK3-#U;S3Q9_P4!_X+"_L--X!^/?_!3;]G;]ANX_8J\;^//
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M6G5%9V5@JC<3L?A<,[$KLWKM123E<%B(U+2?+7X:_M?_ /!0[]LS7_VS9_\
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M-\4/B5JOCK7M<U[4M6\/ZY=6'AJSNK6+6-+CG6YFA /Z<#,0I)3D#A<Y)/\
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M;_9(_99_X*@?!K]AO7O G[;_ (@\9^!/A-\9OV%/%'QR@@\"_$+PGX>EUQ-
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M'(89.&!&:?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!_.;_ ,'(/Q.\"_!/X-_\$W/C
M%\3]?3PQ\-_A9_P5^_8M^(WC_7VT_4M871/!G@:V^*/B7Q9K$NBZ#9:IXDUM
M-,\/6%_>'2?#VE:EJM^(OLUKIVH74MG;'KH_^#HG_@A=P%_;DP">$_X9F_;
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MUM;?TV&W4N'/S$,KKN,CD-G+@;Y& C;;&RQ*JJDL:2_,ZH47R<X!<X48'!W
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M3X@L=6TCP5!H7A#Q:FJ>,+VZU&U;3=.UF7POH5S'#=+<:Y92".2OU,6/(!(
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M=O;'X@W&F6]_X;^%_B'6O%_Q O\ 4-:MI-(\+Z]I?BR72/\ A),;XW_LE?\
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M!8 @\;B-N-H12"$ )&7V.C1 % "LP"A0 S.RD*Q8 J7VY!/#*%;"HF3&HCH
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M)X7O/"FJZ.+^T\(/%!>7_P"4'_!//]E3X-^"OV.?VQ_^"KE]X7\0?%']LO\
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M/CK2- ^(&I?M(6$?A#5= O/B1->>'K^?PGX8\"Z&FL:S9/'/:VWA;03=22P
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ME9X9[>TT+2(M.MQ;G3_[+TR7/^/'P-_:"_X)+?M1>$?%?A3Q+<7FG17+:_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:'IVG:9:?4B+M55X^50/E4*O Q\JC(4>BY.!@9/6G44 %%%% !1110 4444
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M>-;^[6[NI=8,9V6TWB#28M.ATNX*&;.@7*6CK=^6LE3_ ((3?$GX?)X!^/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX@MK>X_O'ECW,26(!P-O(X !R&# ALD@D$94E2.]?,7[6W[+GPY_:T^#VO\
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M@NKQU@/$?\%SO$">$?V,/"?BPZ)XB\2MX8_:W_9$\0MX;\(:4NN>*_$*:/\
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MCO2O"]W<:AX=T[Q</$?A]O$5CH&J7D4&H:CH5OK(O(M)NK]!/<Z8+<S1(24
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MAJ]NDG>RM/%'A+Q%IVB^+?#-UJ26MS-I-MKVAZ=/JUM#+=Z='<VT;RK],&8
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MY^&>C^*-/\&7_B1?$RZ2WA"(Q>)M4L=,31KC7X=?F$KWT.E/IT$UW'ZR;A0
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MA^)O$^E^&O"^C7*:1?\ B*\_X2/5]<M=.TS4I]+L;MK])?W!V\MSPPY'7D@
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M-7[4O[$/PD^#NNVT_AOQG\9?V:?AW\7+O]I?Q?X)GMIM/UJUM=(^(+6?PO\
M 'B#Q?IL[6M[K7A-X;KPM=7\M]X>DD6PAAG_ ')\KK\[<L6YQD$],8 !VX&T
MR"3:% Z"E,>1M9BPQSN"DEL@AL "/.02<QDEB""NW! /R5_:Y_8!\=ZI^S=^
MQ]\,/V$[KX2_#KQ9^P[\9_A#\4O@SH7QN7Q?>?#'7=-^&?AGQ/X7/ASQS?>
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M4< ,I!;.058'<Q0J5V@(4*Y#E@^\X /R^_:E_8L^*6M?M/\ P+_;?_8\\0>
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M\/1?^"=Q *_MI_LT,65&&?C#X+"%78H&$G]JE-A88#9PP^8$C!*)_P %1/\
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M%?\ RDE\9<(IV?%'#Z:T:_M? Z/_ ,''U=17RC_PW)^R)_T<A\$__#D^&/\
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M<\(:1!';R?;]4U?0-'OXM-T=UU!M:NAIUE;:/J5S=C&[\=OVX_@3^US\6?V
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M65;?\?NL?]=[3_TBMZU: "BBB@ IA0'=@E2V<E>#D@#=G^\ J@$YP!C%/HH
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M\\S3B_@C-J#J4WCJ68\/<2XW'XG"/$T>>E0Q&29ME]7+TX5Z=+$5HSC+XO\
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M2;NWK=G?A\'A<)2]AA,-2PE%-R4<)"-&*EOI"*C&.M](Q45T220J !0  .O
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MFWM[I">/M#^'OQN^(NL>&8KR]GT"#QM#H]X]=?\ MJ>!?&?Q%_9O^(GA_P
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M1110 4444 ,,:EM^!NPPW#AAN"@@,N&P=B[@2<E4.1L7#3$I"@X8 @D,"=V
M1\W(#=<C>&PWS8+8*RT4 1")0,$!CMC!)&2QC8NK').3O);/7<22Q/(/) *X
M)VJ00IRV&!R6RQ/S-QN9@S?>92K.S&6B@#YY_:G^ H_:8_9]^*OP*_X2H^"3
M\3?#!\.#Q4-#_P"$B_L,G4-/OC?+HB:QX?;42PL(X6MO[:L%QL=95V.DOMVC
MZ1_9.D:7I:W+S-INGVEC]J$:PM,;6V2W\X6ZL\,9<IYJQ.)DC8L29)&:1MBB
M@"$P@GAB@V[<1A4POR@JK ;E#*J@D$.-JF-H\<@A 7;N/W0O& !V8A2"B[AP
M0JJ "VT#-344 0/ K$\X5L;T"@ X,C[E9-CK)YC[]Y9L$%D5)2)55HMQ^]W8
MX91(#N1E*MOR=A+$E8S'G"J"JEP\U% $?E*<Y .0@RV6/[MRZ9+$D[6.0>N<
MG/0!ODJ"2N 2$4D@DL%9VQ(VX/)D.V [%=S,Y#%B#-10 @& !DG QDY)('3)
M)))QU/<\TM%% &5;?\?NL?\ 7>T_](K>M6LJV_X_=8_Z[VG_ *16]:M !111
M0 4444 %%%% !1110 4G<_0?S:EI.Y^@_FU &7H__'H__7W?_P#I=<UJUE:/
M_P >C_\ 7W?_ /I=<UJT ?'?Q=;^S?VD_@5JR_+]K34M'=N@/V@3P.-W.?W%
M^4"D<F3[W:OKT$85<\<9/'TS^(Q^-?(G[2H%CXW^!6LCA[?Q]%;AL;2%N+G0
M<KO&3@K')@8_B;I@FOK5F*J"!GY<^GW.<?CGKV'UKZ'-TZF5<,5OY\#BL+!]
M9?5,SK.:Z6Y8U+J_317Z_ <,N5#B3Q%PEN6$,ZP.:4TMG''</Y<YS26W-4PM
M>Z^*\&[>]&Y+O/R@D(S(N>GRLI1L>O?COGIQS_.]^RAXA_X4]_P5#^//P\+_
M -GZ3X\\<^/M%BM@OE0-/J%Y/XRT)D3Y@?,E-U#;I\NP3L58B7RZ_HD!XW$9
MR7&WT"G (.#R2F>@QG!]3_-C^T7$OPY_X*V:%KJC[/;:YXI^#?BJ-1^[61M2
MTW2]%NP7&[ DO].O5DEVX(DD0IU8_,XRK.CDN=U(+W\##!8^-K:4\#FV Q>)
MDN[>!GBZ;7Q2BW&*;:B_Z>\&<+0S;.^*>'L6W.AGO O%%*EA]??Q^&R7'?V9
M*+LXJK''QPU:DWM./-]EL_I,@=BB;N7)()'*EL9&">W)'T'%4=4M;?4;.\L;
MN)9;2\AGM+N"5=\<\%U"\$T3J00R2Q.R,C *06!/S#%^V'F0(X(&XE@ ,[<.
M1C((R1@C.!P>G J3R6/60$;B<%/X<@A?O?PXX;KCC&,Y3I1Y&I0]K!0JPE1D
MX\M:$O:M1:E[EJD:[C)3V25]4F?CL;QE&49RY(5*,XN$G"HW2E3]Z,TU*$J=
M;#1K)IIN[2OL? '['4\_@GQ;\8_@/J4Q/_"%^)&UK0(W9_FT35Y660QACO$?
MEMITV [!9;R0CD;I/T!P200."ISQU;_]?;UY]Z_/[QS&?AM^VYX \3%V73?B
MUX=;PU>;%,22ZG9116EM%)@N'(>STIP^U"6DVD;AO;[\#LI4  XWYYQG:FX$
M_7/N>/K7POAVIX'+,QX:JSG4J<+\09ME="I4E>53 3Q$\UR]MMOE4,%F-#"P
MO+X:48KX6E^G^*S_ +0S?)>+XP@EQQPODN=8N5**A"6<TZ,,BSMJ"247/-\M
MKXFI:*CSXAS>D[GQW^TX#H'C/X+>.T0J=)\:0:;=2@[9&MKJ>QE4 K]Z)(DO
M]T;E06?S.50K)^;7[%\1_9(_X*4_M6?L?*!:_#CXXZ0?C_\ "2Q4.;.TNGAN
M=2U/2;)9#MWPZ7<Z[ITJ0L@DMO!]JVP"W4)^IO[6^FR:C\(=3O85/G>'M;T+
M7(W!&1Y=TME)G@$*B7GF-M/(4@@#+5^3_P#P4?U2?X2?'#_@G3^W9I2%(-$\
M3Z9\-?']VF?*;PWXKM1?0I<31A?D32=1\>Q%WB<,DC0@+O#K^4>&T5D7TE/'
MWA9MPI\6\/\ AEXI9;*6E*EB<5@<SX(SJE3IIJTZM?AW+JN(J<B<ZM6E*<F[
M-_/9_&.*X+X,S-M\^49MQ!D6*GJW.BX87-<'AY:7<(4L9B7&UX)1Y5:6A^^^
ME_\ (-L?^O2#'7./+7&<_P 6,;O]K-72O.[C/)Y&?FQM!ZC@ MQW+9R#5/3!
M$NG6(@D:6#[+!Y$K,&:2$QJ8I"R\-OC*MN'#9SQG%7J_I9-R2D]&U=KLWO\
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M#$Q5O9XC"8B.)P>)C)1Y*^#JQLK$M%(#D9^H]>AQ2US[ZGT@4444 %96M_\
M(+NOI%_Z/BK5K*UO_D%W7TB_]'Q4 :M%%% !1110 4444 %%%% !1110 5F:
MA_K]*_["(_\ 2*\K3K,U#_7Z5_V$1_Z17E &DO0?0?RI:1>@^@_E2T %%%%
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M;:S+)M44IB#?>.X$ ,,O@@'<1@N1M8Y#J00Z;4;(04GFG@F-L8).TA\C("%
MFXNLA)()V;5&Z0)D"E$N=HV]1DD;F7&TME&5,."<;2=H92<'>C1@ !%@J00-
MHYV@Y/3*J69MD1(!\M>.!@]<R#( S@G') P">Y R< GG&3CU/6D0L54NH1\?
M,H;<H;H0K%5++G[K%$++@E%)*AU !1110 4444 %%%% !1110 4444 %%%%
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M\>;%?BO\,X54K81ZW%#J.IZK8V*LS+&R1MK^B.$9"T'A?2<1D2K'%^RP;>>
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MA/"5O]D\*^&[7_GVT'2(#@8YBL+>,\9.,E<XR<=,GK70U6LXA!:6T(Z0PQQ
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M2R>+?^"<O[&>N3.9)I_V?_ %G.Y?>1<Z-I$>BW$9.!_JIM/>/H,;-N.*[/\
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MSQ_P51D\O]AKXV\X,MIX20<XS_Q67A^3;]#Y6/\ @6?X<'Z7_9C7[/\ LW_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &5;?\?NL?\
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M%XL97)-JMX?ULUA&^CJ</\2\-9@I6VO3PU7&55]IJ$HQ]Z23^]1@ < #<R@
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MB@ HHHH **** "BBB@ K,U#_ %^E?]A$?^D5Y6G69J'^OTK_ +"(_P#2*\H
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MDV__ "$]5_W;'_TGFK6K)M_^0GJO^[8_^D\U &M1110 4444 %%%% !1110
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M "-J@$;50@C ^ZGR#)&1L_=_W#M*U\0_L]?\$U?V'?V5_'=]\3_@+^SOX'\
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M_&.S/WXO$'@^\*;LE?M.A:A!TP"<_9%^;N>,#;D_MN" I7_:(XZ9&,U^"?\
MP1,U MI_QPM<EMUG\/KQ5W<DQ_\ "4V\K$8SR1&N?8#!XK]Y8FW'&,9V'/\
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M<\Y'Y'])Z*H<-^%6:-6>3_2&\$\2ZF_LUC>-J627LKR?-3S:I%\M[*6NAXG
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M@ X.#C!S@ N<;%1I"$+1*<*64+G/1U<,0C.?+VY9\JNY<JA*?,0I&T_'VN^
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M@#D!::@ 10N-H&%P !M'"X"_*!@#& !CH . Z@ HHHH **** "BBB@ HHHH
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MNIW3NFK---:---:6>B:X3PG\)?AYX)U&XU;PSX:TW3-0NBYDN[>',RB0DO%
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M !1110 4444 %%%% &5;?\?NL?\ 7>T_](K>M6LJV_X_=8_Z[VG_ *16]:M
M!1110 4444 %%%% !1110 4G<_0?S:EI.Y^@_FU &7H__'H__7W?_P#I=<UJ
MUE:/_P >C_\ 7W?_ /I=<UJT 5+O/DS$=?*8#\0W'OGVQ^?-?)W['GF+\._$
M4<AR(_'>M(%QTS;Z<2<^Y);&.IZU]9S@LDB?WAC/ID8Z?CGK_.ODG]D(R)X3
M\;VSG(A^(&L@<8Q_HMDI&.V?)W=?^6F,?+EOHLN_Y)SB7RQ?#E3_ +<C4S&D
MW\IU(1MOK>UDVO@\Y]WCS@B<M(RP/%U%/O4^K9=7Y;+_ *=PG*^VEK\S2?UV
M.,GON;CZ _XU"Q!4C/.UP/KM)P?Q/?UJ7^'<>Y;CZY'],_CBFO'CDGH#VZY&
M#W[ 9]^E?/:<T/*5WZ:K\[?>?<*]G9:NI1MYI2BY/Y*Y_*MX'?\ L/\ X*>:
M[:K\@M?VKM1AW9V[DO=;OXY'P 0H83!BN3G=C=WK^JD'<"3UY].H^48X'OGV
M[5_*;XG_ .))_P %+O'MTQV&#]J?P^X<#8435=7LY0XY/W1)VQOWGE>_]54;
M%D#$8W;'QGH)&WXS@?=#8)P,XSWKS(-1XHXKB]'*KD6*MO\ NL1D&5QIRTO\
M4J55<OQ+EO)*\;_T7XX-U^"?H_8R+YG5\/<[P2=K7J4.+LRKQCK:W^^5_)63
M=N:-YUQYGJ-SC\E0_P C4-[$L]M=0L,I-;RQ,#T*R1,AS^#=.,],CK4@!3YN
MIW.<>[83'?IMSTYSCWI)@2D@')57//&[:C_+GMG')P<#L:[*D4Z=6,MHT:D)
M==7#$-KSO"?2^]MS^>(3LZ$J;NXS]U[?#44KW=K6O%ZV^]'PI^P1.8OAOXTT
M5CNDTCXCZ[;.N-I!DALF)VY.W+;SC)/!&21D>X?M,P_:?@CXY48)6RT^8' .
M/)UO3G8XR.BJ3D'C'X5X+^Q6#9:E^T+I)^]IOQ;U$!,X)C:34D23;SMWK8@@
M9;&_&6V9;Z1^/D!?X-?$)<;MGA>^G P?O1;;E1]08^N.,9P<5_./&&&^N?19
M\0L'45W#PN\1<NY-'[V'RKB/#U(^J=&FNSZ7/V;CF4*/CA7Q--_N\3Q3PCF<
M9:J\,SR_A_,G+OK3Q,9/K[SB_>31T7P>E^U?"OX?3[O]9X2T51CG!2Q$><\9
MSQQ@8(ZFOR!\#2?\(O\ \%W/C/8@F%/B%^S#H.K; N%NI=(TOP):[R0><-H=
MPV/[T;>I-?K/\ )C)\%OANYY*>&[2$G/4V[S6Y/MGR\XYVYVY.,G\E_B,B^&
M?^"[?P+U!@T:^/\ ]F37=*&6V+/)IFF_$2X=0<'>5_LNVRN%.8E.>U?K/A!B
MWCO"OPVQDI<TL7X<\%UW+^9U.%\C;?S<>I^3<54_8Y[FU*UE2SS,H>EL?B]-
M/4_<H=1QC 8 >P( _,#/XU_./^UIC0?^#B#_ ()RZL#L7Q%^SY\2M)E/02E-
M'^,UE'&3SG$M[#( 0.450?GW+_1R,]3_ +0_ GC] *_F[_X*%%M+_P""Y_\
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M23]5%8, >Y&<?0X//<9Z'H>HR*_D-_80_P""5W[6>D_M2_#+QM\6? 5Q\+?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MNQ=V<L$$EK<>; T,10QK[%2 RK;_ (_=8_Z[VG_I%;UJUE6W_'[K'_7>T_\
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M6:_\%N,K[:VO>Z/I@=/Q;^9I::O3/J2?S)_E3JZ+WU74\G^OP05F/_R&8/\
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MDC&X#^]G<>2@4J)"V,, 44E?F(&#2*UZZ/KZB>2-S'?( V-P$DG.#*V,L[;
M#("##Y391%+&)5C5/(&UDW$J^0ZG)4@A5V!22JQA5V[% !5G9B97>1@S;1RI
MSC@@AE/) R4WL VT["4&XX0#S&"4HFR%RC!F 8H"A=%XW%L-M;RR0)!$TN"R
M;=X=20"8?7/N<?T 'Z45 TS*$)CSD%FV,&X _P"68P&E+$Y4*H/E@LVU]D3J
MLZOPN"2%Y4Y4LVXD*Q"E@  ^X*<QND@&QE) )J*0'(!P1GL>OU]L]0#@@'D
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M^/W6/^N]I_Z16]:M95M_Q^ZQ_P!=[3_TBMZU:0!1110 4444 %%%% !1110
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M64:GX9UNPDD &#F#7(5C.2,\RQG'^T!GFONBZ&('7;TCD!R>H,;C'L#NR.X
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MQ8\,Z5!87^J77AF#PMXY\7:UH.K:?HNKZ-X@NO"/Q'TCP-XR31+^:]3P^_\
M8/BF/0H-9_:OM7U7Q;8?"WX&_'+X_P"E^ +_ %'1/&_B[X3Z?\,[;PIHGB;1
M6NH]>\+:5??%?XH?"[4/B+KN@2V<UKK=M\*-*\>0:7JROX8O+F'Q?;W?AZW
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MI^'?COPM(@E7Q#X,\0Z-L9=X=]2T:^LL;<C)9Y5&,C.2"1G-=Y(Q!('IGZ9
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M !69J'^OTK_L(C_TBO*TZS-0_P!?I7_81'_I%>4 :2]!]!_*EI%Z#Z#^5+0
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MT_1?[-EMY+ORD-Q,LU=%XA_9>TG]F+]MO]G'_AISXW_M*_M.?LX^/O%.G0_
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M/<#IVSTX;O\ Q */;;[U"<DE;I*_R;=_P9;ZNW,VEII]E2MO_CD?CK^RP9?
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MP2#C^+ .&(+$(=J97!?E58,I.Y2*:)@0IVL-S!0&PK9)4?=)Y # MM)*X*,
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MX:?PCHDN/4FS\.NWX#>0/I[U]<N,MUZ%1^;(*^0_"P2']KKXA*K9>X\#:2[
M\9VVGA] ._0*#^?O7T.0?P>)8O[>05FEWY,=EDG]UGOYGP7&NF+X'F](PXSP
M,)/LZ^59[0IJV[YJM2$=$[7N[13:^P$Z'_>?_P!#;^72G4U/N_4L?S8G'X9Q
M3J^=6J7]=S[Y[_UV1^+'_!8FT$NE?LP71&!'\;H;,MCHM_IEOO&<C@K9$%?X
ML=1CGWC_ ()77)G_ &8KR$G_ (\OB?X]MER<_(;BUN%XP-H)N,A><8SGYL#R
M;_@L- %^'7[/VI$?+8?M!>&'<] $;0_$!(+9PN]HT[?P]^W<_P#!*"=_^%!^
M-M-8G=8?%KQ,I&?NO<V&C,1C^$@J6Z\[OX<<^;GG_(WX%G]G^RN-:-_^GL*^
M3UY0MOI2DI7MRO9/FNC^DLL;K?19XX@]8X+C_P .ZU->56/&]*LUVM4Q%&/F
MYIJZ3M^ID?*?B_Z.PI],C&%Q_M.?3J[&GUZCW?J?S9MIVLON21\Z?M56 O?@
M'\4XRN_;X;FO-O\ UXS65W_[:XSVW;L'&#<_9POSJ/[/OPSN';<P\$V$#'U:
MSMGM6]^&BP<\\<YKHOCKI[:M\(/B;IRD!KCP3XD5"1N 9-)GD4E<KD[AP-PZ
M?EY=^R!J(U#]F_P!(/F*66MV38;/EF'7M4MP.G(CB5"!QD'@BOS^7[KQ0H22
MM'%\$8FG4?\ -]1SS">QTZ^_F-3:_+>[LM3],BG6\%\7RWE/ >*>":6GNO..
M#,4GJ[64UE5/7:\4F[G,Z"3#^UW? ''VSX7::V.F3!9:$@.><Y".!P" AX/4
M?9;$DX'!VY!/^R47^I_+\OC (;7]K?P[+N_Y"'PK@88&W+16MV"G!.XXM8V)
MPN!@$$#)^S2VX %<97 .>0&*Y/3MN/'!.WWX_(OHVU/8S\>,#/1Y=](WQ2IR
MAJ^1XZ>29PUIH^;^V'47+=/G:OS)H\7C%<]3A.JE:-;@KA^I!_S4Z+Q.$E*W
M2U3#U(\KM)\M[6<6_P /_P#@F,R^'/VX/^"IW@-7&R#XU:)XAM(=GE*8KO5_
M'YFE5,O@/]NM"7W'.5!'((^G/^"Q5E]O_P""8W[94!7?Y/P?OKX\9S_96KZ1
MJ1('^R;3.?X.7P=N#\O?L@1GPS_P6'_X*%>%RH@C\0>!_"/BX)G;YLD[^#KI
M9 N#N+Q^(9Y-^X8"MA3YGR?;/_!4?2FUK_@G5^VEIJ+N>3]G+XHR1K@GY[3P
MS?WL1QD<J]HI'/?/U_J*6E>DWM:+^5D^GD?G=#3!XB+WC.JFNSO+[_D8G_!)
M.];4/^":/[%%R[[W_P"% ^"+:1O^FEE9O92 ^ZO;LI'8C%?HE7Y;?\$5M5&J
M_P#!+G]CNX7YO(^&^HZ>WS9VG2_&?B>P$?0?<$ C QP%'T'ZDC_'^?\ 6HJ_
MQ*G^.7YG9A_]WH?]>:?_ *0@HHHJ#8_'?]NQE\$_MO\ [!/Q05A;K=>+]4\"
M7]U@J$M;Z[TRS*R/D@BX@\67=NJX&U2S9;<0OZ^(X94 Z[F3(YR(\'/OE<$Y
MZ]SUS^1__!7VP?2OA;\&/B?;)_I7PX^.GA/4VF&5:.SNK6\DD E&[R_-O]-T
MTYV/S;K\IW9'ZN:7-'=:=I]]#*)8;VTM[N&1<%7BN[2*2-P<\@K\PR!G=CC%
M?1YI:KDO#>)TTHXW 1=[^_A,94K5(/JN6E5C4UT?-:-VFE_/'AFGEGC5](SA
MY7A2S#-?#KCJA!W37^L'"2R7'U*?V7"I4X:=23C[SJ1DI>^TC>3(49]_R))'
MZ5F:W_R"[KZ1?^CXJTH_N+[C/TR2<?ATS[5FZW_R"[KZ1?\ H^*OG-.FW3^O
MF?T.G=7M:^MNU]5^%C5HHHH **** "BBB@ HHHH **** "LS4/\ 7Z5_V$1_
MZ17E:=9FH?Z_2O\ L(C_ -(KR@#27H/H/Y4M(O0?0?RI: "BBB@ HHHH ^=?
MVI)O*^$NI#KYNK:)%C(&=U_$V.ASPC<8[&O:/#,0M_#?AZWYS!H>F0YVD9\K
M3K9"<<@9(SC)VYQDXS7@W[5TG_%LXH.\_B;1E'/78+F0+C'.3CTQBOR,_;(_
MX(8#]L']HSQ_^T4/VH%^'7_"P;+P&O\ PAI^"(\7_P!C_P#"'_#CPAX"Q_PD
M1^+?A@ZA_:'_  C']J_\@.R^R?;?L/\ I/V;[9<8TN5XJ=W9*G9NS>WDM3U\
M1ID.7Q>CEC\SE'SYJ%&,?_ IQ<==MW9']!BG@=?R/;\*7(]_R/\ A7\K _X-
MEP?^;UUZD?\ )MB]CC_HO-'_ !#+C_H]=?\ Q&Q?_G]5T\E-ZJIH]=I]=3QU
MHDO)?DC^J?(]_P C_A69(2-7MV"L1_9UZK':0 RW6G%1G'.\2,>VWRSUS\O\
MM?\ Q#+C_H]=?_$;%_\ G]55;_@V>'VV*U_X;47+6LMP)?\ AFY00L<T"-%M
M_P"%\<B0RJV[<,>7C:V[*G)3_P"?GX3_ ,QGZ6?$[]__ ,%C?@1",.+/]G;6
M)B%96*L__"PD?<BEGC'E2J=\BA6+1IG]X"/KO]L[]LOX?_L._#;PG\6/B9X=
M\3^(/!_B'XH:!\-M2;PDFGW6KZ&NOZ!XFUF+Q MAJ-Y8PZG:V?\ PC?V:?3X
M[ZUOIEO!+9+=3Q16=W_*[J__  1+_LK]LSPQ^R*/VFOM9U[X;7'Q&_X6 WP9
M:,:?]C35I$T9?"3?%B9)#(UA_P A./Q':NJW<@^QM@F3,_;C_P"")'BO]D;X
M7>$?&W@/XP>(?VB?%?C+XH>'_AGH_P -/"_P+O-"UN_O-=\,^+==_M"VGTSX
MC>.M2U)H4\+?9&LDT48%_)=PZA:S02PW?TW$$ZE6'#%/'X66&AAN&<)[&2J0
MJ?6*$L1FSP]>U*<W%UX24^6:4X)J,XIIH^!X)PF78?%\<U\KS59I4QO'.95,
M=A_J^(H/!YC' 911Q>"Y\12I0J?5J,8KVM*4Z-3EM2J3/Z_OV?/VI?@%^U'X
M1B\8_ GXG>&?B#I:I!_:5GI-U+!X@\/SW$0GBM/$OAC5(-/\1>')Y8F62V37
M-*T_[9"\5Q:>=!-#))[X2'0L1PRG@@A@ I9"5D4;7&>5>,E6.U@=O/\ (O\
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M@B>&PM.L^&>M?MO_ !&O?VD?V0]<_:I\*^$?CU^S_P"(/A'XHT;]J3PK\"_
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M+!*D)QQM&><GIGJ2>>>I)YZD\TU9#V7(&X$9Q@IW''.2,\>O/(Y;O+-D*"V
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MZ%X)\'V"ZGX@U>VTG6==FM+.2[ALU>WT;P[I^K:YJ4S7-U;1);:;IMW<2/,
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M)W9.: 'T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK)\PQSP_*D=@Q.3CG^HVURTG?3GTWUM+^MSX*BTJN*4?A=:-6_\ <5!Q<O\
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MX;"Y@H;^]A,?1C*>ME>.&QDI63NTVHW::/YZ\3H_V1XS?1]XGYO9T\3G?&_
MF,FWI5I<5<*+.<!AI-:RC_:G"M-THN\55J]&VW^Q*#"@>G'Y&LS6_P#D%W7T
MB_\ 1\5:48(10>H&..G7K^/^<UFZW_R"[KZ1?^CXJ^<7]=MV?T(KM)O1M)M=
MFTFU\FVOD:M%%% PHHHH ***C:3:Q4@<!2/F7)W$Y)4D84 $@Y);9(%4E1O
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M_M/_  =T;QK\ /VBI)/ 'Q\\7>)E&H>'O@5\8-"L+G2XUUKPG:^'M:G6VO\
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M,?%.H01_;!I]E;RP6EK;V%MIT+S74ZV#7&H7TT]+EZM]._S ^^/VD?B)XQ\
M_L<_&CXK^$=:.D>.O"/[/_C3QQH.OM8:;?BQ\1Z-X%O]<L-5&GWNGWNDWD4-
M]%'=M9SZ5<6,RK]F33D=S;KZI\!O$FM^,O@=\&_%_B:].I>(_%7PK^'WB37]
M1:UL[(WVM:YX3TG4]4O#9:=!:V%F;F^NIYC:V-O#:6^_R;:-8405^+_[2/\
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MA*ST;0H=*T[PGX'233=,^UR>)-%\0ZUJ^L7(!^S4;!T5N1G)*D@E6R=R-AF
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MA7]IWX&W!D"+)I^IVV.F69[]\YR.O^K _P"FF>,8;[ (RQ'J?Y+_ %S7Q_\
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M1-5L]9T)W(^\UPUS:[2V3G*:B(@FT ^;NW \'[W<')/;&1Q_=&3^>,>W7Z_
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MY0_3%LO1!1110,**** "BBB@ K)M_P#D)ZK_ +MC_P"D\U:U9-O_ ,A/5?\
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MU &7H_\ QZ/_ -?=_P#^EUS6K65H_P#QZ/\ ]?=__P"EUS6K0!&1EL>I;_T
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MO+VK%3[H_'^9IU(!@ >E+61VE5U;S,CIYBGCTV 9)]B#_/M5.:)I(7B8 B6
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M'DS39 /7_4[< C[V[/&#<K,U#_7Z5_V$1_Z17E &D.0#Z\_G2TB]!]!_*EH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM^G^UZ#)^H^OMEORQ_/[WZ5S8?\ AU/[V)K->:<G;T^9ZN=:8NBGTRK*;_\
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M44 %%%% !1110 4444 %%%% !1110 4444 95M_Q^ZQ_UWM/_2*WK5K*MO\
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M2I&].A_;%.=3DA5YI?K1$P>)6& &4XQR.2>G3/KVJ.6-6CD215="C%U(#!E
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M5CPJ35+'RA.48J47&"<EK9Z)J^CZ:VVZ7/Z%!C QTQQ].WZ4M1HY*@[0,9!
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MTG**;=E%R2DWNERW;NUJM-5JKDU%1B0$9X[]R>_LN*7>/;\S_P#$U/RE_P"
ML.9=U\[K\'&X^BF;Q[?F?_B:-X]OS/\ \31\I?<_\PNNZ_'_ "'UDV__ "$]
M5_W;'_TGFK3WCV_,_P#Q-95NW_$RU3IRMCW/_/"8>GJ?:GKVE_X"PNNZ^]_Y
M&Q13-X]OS/\ \31O'M^9_P#B:7RE]S_S"Z[K\?\ (?13-X]OS/\ \31O'M^9
M_P#B:/E+[G_F%UW7X_Y#Z*9O'M^9_P#B:-X]OS/_ ,31\I?<_P#,+KNOQ_R'
MT4S>/;\S_P#$T;Q[?F?_ (FCY2^Y_P"877=?C_D/HJ/S,D@ DCTSCIGKMQ1Y
MF#@X'XG)_ J/U/6JL^W2_G;T#JE:3OJK1;T[Z;+S:2%/7\1_-*S-+^[>_P#8
M4O\ _P!'RUI YY]_ZI6;I?W;W_L*7_\ Z/EI#-5>@^@_E2TB]!]!_*EH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /E?]M;XV>*
M_P!G+]ESXV?&[P-I_A_5?%GPY\'#7M!T_P 4V6HWWAZ[OFU6PL/+U:VT?6-!
MU2>S2.[\R1+/5["52%;SRIV5X9X3_;1U;X@_\$_?B#^U5X=T71=+^*_PW^$W
MQ%OO&WP^UR#5IM(\(_&?X8Z#J+^)_"FNZ6VJ6>M#04US3TU#3[=M5M]1NO"V
MI:;=+J;G4/-&G_P53Q_P[Z_:I+,P'_"M2A&]HQG^WM&(<,5*E%#LTH7/F;$C
M+1D9KX$_;T@N/V3O!OQK^)UA!>?\*,_;<_9O\3_#;XJ6T, FL?!G[3=E\(;O
M3_A%X[EM($#VFD_$W0M.O/ OBJYMH!!_PDUEX<U/6+V*&<>52Y;:O7Y_Y ?L
M%X7^/G@W3?@'\+OC3\:?&?P_^%>F>-O 7@#Q'JVM^+/$NE^"/"%GX@\9>&K+
M7)-(L]1\6ZO%;V^9I[I-/T^YU:[OS!;2(TD[0F:7NH_C!\*9_A_#\6+?XE_#
MZ?X77-O'=6OQ*B\;>&9/A_<6T^H)I5K<P^,HM4D\/2V]UJ4B6,$T5_(LEXRV
M:YNW2!_Q7\$>"_A9\9?VN?V-_AE^TAI.A>-/ NA?\$U/AKXO^"OPS^(JV&J>
M ]?^*U[J6D:9X_U5?"VIF71O%GC?3O!^EZ3%+I6J6E]]DT6S_M5-),MG9ZE:
M?-'[0FA?#_X?_#;_ (+,_"3X%MIUE\ M"\-_LQZZ/!WAFXMYOAYX'^,'BO5H
M$^(VD^$+*V?^R=$N+ZUL/#\OBCPYIQ>+1Y[2TTB>UTJ&V@T^UD#^CKPK\9_A
M%X\\3^)?!/@7XH_#GQIXS\%LJ^,O"/A3QSX7\0^)O"1:9K8?\)-H&CZI>ZOH
M)-TIM]FK65HYF#1JC2(R#9\=ZY=^&_!/C#Q/IZ6\E]X>\+Z_K=I'=K,UD]]H
MFEWM_!#=B":RN)K.6X@6*=([JW=TRJ,H=V7\?_%/[.GP7_9J_;B_X)Q1? /X
M3^%OA]=:W\./VH_#>OVOA.SM?#U[X_M/#7PC\.7F@6/C74EC@7Q'>0ZI>3W+
M:OK8O-1:^N!>W_VFVM,0?07ASX\_MJ?$'3_B)X<^./[ S?L\>!IOA9\0;F;X
MDM^U-\)OBV;;4K3PUJ4FG:0?"/A31[759H=2>9[=M1>X2ULF,LER8;8VTLCY
M7]^VJ \"^"?QA_X+(?'3X/\ P_\ C;X1T;_@FU'X7^(GA2P\;:%H&O0_M/Z/
MXM.G:C9M<V6FZI!'J6I:%8:R[@07*0:K<:=:7>R5[E[=VDC^\/V/OVH#^T7^
MSQ8_%OQIX?L_AKXF\-:GXS\'?%;0[K58)M"\+>+_ (;ZUJ&@>*[BVUQR+9_#
M3-IIUF#5)9&L[33;DA[^\BLI;Z7\/?AW^P=\:=>_X)Q?"'XV? 7]KK]MR;QE
M+\(?"?CR\_9^L_VBM>T+X8>*/"4<,.H>*_AC\/\ 3M'TJVN/!6HZAH!U"W\+
MW-V_BFUDO&M=+GL[VVO?M]CWW[3^I?"S4O\ @F;^Q9H7[)&D_#WPQ^SS\3_C
M]\*M)\7:!\9-=\:R?#FQ76YO%^OZSX:_:,UOPA<?\)<=%M?C%86G_"QM6M=7
MT]+;7=+M&M[I=!!\EVCLWK\]._\ D!^^GPV^-7P@^,MEJ&I_"+XI?#GXI:9I
M-S'9:KJ/PY\=>%/'-CIE_- +F&QU"Y\+:OJT5G=SP>9-#!,RR2Q0RS(IB$;R
M9EA^T'\"=6\>W7PHTKXS_";4OBM8R7<%[\,;+XC^#[KXA65U8*&O;:\\%6^K
MR^*+6XLPT;7<$^D1W%JLB^="C_NZ_'3X#_LU?M _![]L3X*>//B$_P#P2_\
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M0_J.&_Z'&7_^$>8?_*#V+2L_96^Z/],U$<@D_+J%TO\ =(P<9&#W[UI?BO\
MWS_]C7A$?PL^*,0VQ_'G7%3?(^W_ (0_0>LCM(W_ "\=V8GI3S\,/BH3G_A?
M>NCV_P"$/T'_ .2:/:S_ .@27_@RC_\ ) \%AK_\C?+_ )8/'I?<L/9'N18#
M@D L=JL!WP"<@8]0.1WX]X)XDFCE@D1766*1)E(QO#J8V4_WMZN1GC&.^:\2
M_P"%7?%,\GX]:X3G.?\ A#M!Z],_\?/7'%+_ ,*N^*7'_%^=;[$Y\':"<L&+
M _\ 'SQVR.^W.>34^UJISE'"SYHSHSI_O*2<I1<6VGS^ZZ=M&VKM)K5"EE^$
MJ<].>;Y?[.2Y&W@\>TX5:$H5=/J][*4G&2:][6R<7<\H_9KO3X7UWXH_":];
MR;[P]XIN=8TN"1E5Y]+U"<0I+#%DLJ-#!;W6 SC_ $S8"!$9)/L#:>3(,QR$
M&--OS)V&2""/0\X['G&/F#4OV:-=U;Q%'XNO?B[K \3Q0K!'KMEX<M--OU1%
M\M5W6&JV\+H$+C9-#*,LI_@PW6)\(_B;$H5/CYXEXR07\-Z:S$DY.2-07/Y=
M.N>2?7SC'4LPQBQ=&CC*-2K2I2Q/[RBHRQ7LH+$2A[[?+4JPYXWA>-W'F:>G
MS7"W#E;(LMAE6,SC*,10P.-S"KEE;#/-:4XX#$8BM4P>%JTY9>HQGA:%2-%J
M,I4URVBVDF>]HS*FP*HP6R$8_+R2.Y[<]3W)ZUPOQ-\%:;\1_A[XW^'^J%&T
M_P 9>%]<\-WS2()C!!K.F7.G27"1EX@\EL+@3Q;75B\0VLA :O/3\)?B?\V/
MCSXB);J5\.6$1' Q@KJ> ?< 'U]Z:_!KXE J7^/7B@X<MSH]GYBDGAHV-^P1
M^  765/+>1#'E]R^?3Q%:FX5%1ESPG&5G.FF^62:D[2:OIJD^Y]+#"PHRPV*
MIYIESQ%"M&?+*.9N;Y9)J;G]4C"4FU=[7?35G\]-O?\ BSX;>#(_@_XEV:!^
MT?\ L'>/Y?$?@&9W:/\ X3_X1Z[K1U?4+?3T)2[UH:/JM[:>(XK2V+/<^!]8
ME,$2O;WJQ_T7? [XY^ _COX)TGQIX)UZRU+[5I]H-<T2"YAFU#PYK#P*UWIF
MJP;HKF&:UG#QK*85@NXE2[MY'MYHV;YQ^)G_  3[\#_&77[+Q7\4?$4?C+Q-
M86%MIMMK^H^'WM]6CL[:6XE6V%]I>O6%Q) OVNZBMXYWF-I#<SQV[IOW#)\+
M?\$Y_ ?@+4_[9\#>+=7\(ZM@*^I>'KCQ+HUW.F,E;F73_&%O+/N.2S22%F.>
M0#M'EXW"U(Y_C<_RNBJ']KX7 X;-\!*4>6OC\-25)9Q1=^2FU3YH5X)JK6E:
M5I/4_:L]XRX+XNX!RKAK/\5F>"X@X5Q.:8CAG-\#A?[6R_ZAGU7!XW->&<7A
M,<L+BL/EBSN&.SW!8VEB*]?!8G,\RPU+#O#U*<9?HLK!AD%3RPZ9&02#R%(Q
MD=L@=*AN<_9YS\I/DR\ '/\ JWQCY>^?3\^,?+D/[/\ \1;95C@_:"\>^6@P
MHEO=6E;!R>7?Q 7;!) :1GD88,CN^YFG/P)^)C!PW[0'C4A@@QY^J# 5F+?\
MS 2=X8 _[N><XKTI3=VE0DU?1\T%?SMS:7W/QB6!PBD^7.,#**;Y7/!8_F<4
M]')>P:NU:Z^1]&6F6T^QW KBUL]H4XR1;0GJ=HY+NAXR=@[\'XG_ &D?A%XG
MTCQ;9?'KX5:7%J?B#3+(6/CSPH1OB\;^&S$UI=*]GO5;VZ73KF>TO87 %S$M
MK<>9YEBD,OI*_ 7XDJBQCX_^-=JA0 9M3(^4 +UU\] ./3M3O^%$?$K&/^&@
M/&N.>/,OR&!R"K[M<9F4!Y&559,2LKN9$01GYKB;A[#<4Y9B<KQM"4(35*K0
MQ$/9.I0Q=*HG0Q&&;DW&I##U,3@\2II0K8>M4IM5(245]'PGG%3A'.?[8P>9
MY/BHUJ%?!9AEV*H9J\)FF55Z$:6,RS&4HX7E]EBX-_5JD'[3"XF,<4IT:N%P
MU27R_P#LL?'[PIH6I:EX,U+4Y]&\.ZQJ+7/AY-:,T4FB:C=82ZTB_>6*,P1.
M4B"7#B)5N$ED>-3<GR?TRM)4DBCF@DBF1\/N287*LC\JT;P%P8V7#(Q"DA@6
M52=H^&M<_87T;Q+J4VL:YXS?4-4N3NNKZ32ITN+MRH5I+EH]<19)&V@EU1""
M!C XK=T#]D'5O"J+'X;^,?C'0XT&$BTW4O$D$"+DL%2W/BMX(U!8\1QH.23\
MQ)/Y=X.^''&7A/DE3@NKF^5\3<'9;C\QQ7"L*];%X?.,DRW,,;B,4L@J5IT:
MF$S7+<)]8<<MI5:6$KY30A#!4L5B:5.$SZ+CC%^''$>.CG>08O-,GQU>E3^L
MY;F&51Q6%I5_90C4=#,,-7IUG2C*+BJE7#3K58PA5JKVLZE_I[XD_#OPE\7?
M /B[X:>/](@UWP9XXT+4_#WB'2;B+<EUIM_"T$QC9HI/)O+=G6[L;A%$MM?6
M]M<PXD@+#^67X/V^K_\ !$O]NW7M)^*FIZSK?[-'[0WAVZL[;Q7IEL+Z;Q!:
M>$KI)O"GC6ZT2W=6N/&_@"/5KOPQXTM[".>^U+0O$']M6D=TS6%B_P#10O[/
M?Q(4';^T#X]Y&TYU+72, [D8;O$$C"59"Q+B0J\96-D 7)\Q^*_["&D?';0K
M'PS\:?&;_%/0=,U:#7-+T_QOIMYK::3J]N&C34-*DN-9\S3[IK9Y+::2V*"Y
MA*QW"RQ^;'-^Z0Q->*<'A).+5K^TII>J3J2DK^<I/NVS\TKY5@IN,XYUE[J4
M[)3>"Q[E*W5MX5:O?6Q]1?"CX[?![XY:%;>)?A'\1_"'C_2+J%9O-\.:Y9:A
M=V18$^3JFFQ/_:&DS)@AH=2MK692 &CR03ZN&R"W&T8.[<A!!&<C:S9X((SC
M(((XK\F]+_X)"?LZZ#?1ZGH&B:%H>IPN6@U31[+Q+IFIP;EVDP:E8>*H+Z.0
MJ #(+@DD;B.<#Z%T#]C[Q)X4MTLO#7QR^(ND6,2+%%;0^,/B!+&D2G*IB[\8
MW#=>22W))(P#BJ4WI_L\EY<]/_,M8##V7-FN6-V5VZ6:Q;?5M+"N*;>Z3:70
M^XP#CM_WSG]=I_G[4N#[?]\'_P")KX_'[-_Q,48'[0GQ"('3=XC\7NWXL_B5
MV/XL?08& 'C]G;XFJ-O_  T%X\./[VO^*">>>2VO,?S)XZ<<5#JU+M+"RM?1
M\]+5?^!%_4,)9?\ "UEZ?983,6EY)O#7:\VKO=GUY\WI_P".C_"LS6 S:?<+
MC[WD#.!GYKB,'L/N@9Z\C@=#7RO_ ,,\?%#M^T'X[ _[#WB?_P"7PI&_9V^)
MSKM?]H'QRRYR0=<\39/'R_-_;Q/RGD?EQUH]K/\ Z!)/UJ4O_DQ_4,'_ -#O
M ?\ A'F#_!X8^M'CWL_+ [E.8W(/W5ZKN"C 4$$C<!RH&XEOA?\ :S_86\!?
MM)3:=XTT;6M1^%OQK\-E;GPO\3O"^;:^:ZM4'V"/Q%#:7%G/JD5D5 L-0AO+
M+6=-.(K;4!9M<6=WV@_9W^)XS_QD'XYR0 Q&N>)EW # R!K_ #@#'.:!^SM\
M3@ !^T%XZP#N .N^)QAO3*:\C>60/FC+'<Q)W $ =&$Q^.P%=8G!1J4*J5IR
M4Z3E6@TTZ%1<_)*BT^6TKKEZ)ZGRG&/AYP7Q_D&8\-\6_P!F9UE6+5%RP^+P
M^94ZD:M&:G0QF68K#4:>*RS,L!54:V"QF%Q&#Q$)4XMXAQO1G\&V/[4/[:W[
M'QC\-?M3?"'5?C=\.M, MK3XW_#5&O-1328F0QS:Y,MO'8W=RD&V":'6X?#M
M]++ [-=:KA-1N_L#X6_\%'/V0_BC';V^F_%;2_"VKRQAFT+XA03^#;N)CDE/
MM6J1PZ1=;"-ADL-1NHPWR%O,5EKL/^&=/B;M96_:!\<LKAA(C:]XJ:-PQ)8-
M&_B%HPO.U5C5%V@>8)'W2-X7XK_X)I?#CQWJ4FL^,)?#_B+59D*3W]_HNHK<
M3A@ QG>RUNS$[.%!=I59G8%W+,6)]F6:Y/CHWQ_#^+R^L_>E4R/%X>G1J5)+
MWZE?!XF<H3G-MRFJ5:E!MOE45H?D>!\,/%[@>5'"\#^-60\8\+T:BA3X:\7L
MFSC,<VR_"P:C0IY;QSP[@\)F.+ITZ*A25+/LNQN(IQA'GQN)J*52?Z":!XW\
M'^*[1+_PUXK\.:_9RY,=QH>N:?JD# .T99)+.><%"ZL,G !!!QC%=*)%?(4A
MQST*OQ_WR3S^%?EI;?\ !*7X,V4BS6-OH=C,C(\<]C9>(+&YC,8"H(Y[+Q);
MR1A H5"A5@H&69\NWHNF?L!V&C.)=*^)/BRPD  5K?Q9\2-J*HPH1)?',BJ%
M4   ;1C@ 8 \JM+ )M8=9FH7?)&6"R]-0O[JE;,$KI:.S:[,_4\LH\=R26>4
MO#RGHN:>4\5<2XA3:2YI4\/C^ Z4J,9.[C3GB:LH)J$JM1KG?Z&JX "K\I&?
MDP,KR>HP#D]?NCOSW(&SVX]0J'/YD5\5V7[*7C+3$2.P^/7Q$M53.U5\6^.B
M@#,6(V-XNQ@EB?J<UJK^S;\20/E_:$^(6/\ L8_&+#_Q[Q26)]RQ_P .-U'=
MVPU22N[2DZ,)-='*,:DE&36\5*23T4FM3ZFC@O=7M<QRNG*RYHPK9I4A%VU4
M9+*J:DD[I25.":LU"-^5?7Y//0_^.C],TF3Z']/\:^1A^SE\2P,?\-!^/_\
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MUSH5CX=.DZ;X5N;"SN/#-GI,EK"4^C**+ON_O ^0?V=OV"/V1?V4-;UCQ-\
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M/_"GXU>/?AYX3U2]U'7&O;K7M3MO"^AZ);7VNZB]]?ZSJEK=7&KS:C?O<R3
M'V69U !*E<J"-Y"#=@$Q[GVJ7QG"@]58.4 S4J,'4,.,YR,@E2"05;!(#*05
M< G:P(R<9K\9?B!^SK\'_A1\6/V;OAC^SCI.OZW^V#'\6_"/Q5^*'QNDU*XO
M?BO)\$I?&1UKXT>*OVGOB+HMI8Q^*?#GQ+TFSU;P1X8\$>*6AT/6O$=]96G@
M/1-*L?#<WV3]FDSL7/7'."Q&<\X+_,5SG:3P5P1P10 ZBBB@ HHHH **** "
MHFE ;8,$Y*]3_K-GF*GRJ^"4&YMVTJI5@&!XEKX:_;0)\2ZS^RS\&=3BGN?
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M>++3S?'?Q'L]0ENY]#UG7+'P@WFMX4M;R^_8!,;%QD#:, @*0,< J  I'0@
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M2(V;A"H');>5'*@&0;"P,A5' 3E=SY0)YZY7[NUAP2VW.76-2@<*&5G8!6W
M2 H8O,W8'X=>,M!T3Q-^RI^UU^VIJ>BVA_:7^&OQ4_:1\4?##XLWUC+)X\^'
MFD?L]_$GQ-X4\!>!?"VM&]NK_P ,>![_ ,.^"Y-(\4>"-*OM+\*^+3XN\97/
MB/1[H^*-=FO_ +=_;K^)WBGP5^S;IU_X5M/&T?B'XF?$GX#?# V7@>YMM(\?
M?V;\4OB5X3\.^)-)\*WNI:QI.G:)XMU?P]?:SX<T+4[G7M(_LO6[^RN&US3P
MBZI; 'W1YQR!L&&'RDN!EN3MVXW'(!92@?<J2,!@1^=,"&&0<CD?B"00>X((
M((/(((/(K\SO@!X-\(_!S]J3_A&[OX)>"OV7O&?Q&^"7B+5M(\!?L\>/-/\
M$/[//Q-T7P/XV\.C5_$_C#P\_P &O@O=:9\<O ]SXLL[*RUJUT"\M=7\#^*=
M4M)O%.M/I%M9Z/\ I?'MV * %4L@ VX4(Q0*-K,!MV[<9R,8*J05  ^BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>Z3HVMZ;8+J[P?"7PQKWBJTTS3H]8UYYI-?N/$'VK10 BC: "2Q'4D 9/7H
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M (9T3PQJ6K^--;U_Q-XDC_X0_7[/4O[5?3-$@\,0V\-Q7SQX7_8G\8:/X?\
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M<\7ZTWC>Z;2?#NEF_%]X@U**VO#I^E6MY=1Q3;0;CXV^+/@S]I3QY^T#K/\
MP4H\,?"'QBL_[*GCS3_A9\(/@%K?PYCLOB?\8?V?=._X2;0/CAX_TS3M:\.O
MXVM_%WBN?QA?ZA\(!'-:^=X;\/:I)!IU^WB2%[G]\S!]XJVUVP"^&W$(\DD2
MLRNLA1'D),8D6/:7C1(T=A3O)&T*'8'"@OA-Y*8*-PH4,CC<!L,7++Y>PJ%
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M?$#Q0T=A(;RVM1X=O='N]=N[?]SFA#<;FP>3DG))SE@P(92 28]A18W.\ G
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L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>image_018.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_018.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" &, <(# 2(  A$! Q$!_\0
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M;3D"K"A42;47*J1P3]*YO196?Q'X(NHK:XM[*)KB%(C%(WD D@*TA&6)SD]
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MHH **** "BBB@ HHHH **** ,FQT)K35KJ]EU"[NEED,D4$S K;DC!V]\8'
M[<^IK6HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $;.T[<;L<9Z5S
M%IXEN[VRT)$C@CO=561RQ4F.,(N2<9R>=HZ]ZZ<]..M8L/AB&WT_3K>&YE6;
M3MWD7&%+ ,""",8.0?3L* ,6'QU+=Z=-?P6\:PV4,$EU&V2Q9W*LJGMM"DYY
MSD#BI;GQM)9V@U&:"-[&5KI857(?,(;!)Z?-L;MQD=>:T/\ A#=/2)((C)';
M>5%%-""")EC;<FXXSG).2.N:>_A*PE>19S)+;'SBEN2-L9FSYA&.><MCTW&@
M"72=5N9]3N=/OEB\^&&*?=$"%*ON&,'/(*'GN,4YO%>@([(^N:8K*<$&[C!!
M].M2Z9H\>G333F:6XN)E2-Y9<9VH"%' ]R?<DUE>(O#&A+X?U2==&TX3"UE<
M2"U3=NV$YSCKF@#HH9XKF%)H)$EBD 9'1@58>H(ZU)6!X#_Y$/0O^O*+_P!!
M%;] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !6;XD_Y%C5?^O.;_ - -:59OB3_D6-5_
MZ\YO_0#0!2\!_P#(AZ%_UY1?^@BM^L#P'_R(>A?]>47_ *"*WZ "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "LWQ)_P BQJO_ %YS?^@&M*LWQ)_R+&J_]><W_H!H I>
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_(L:K_UYS?\ H!H I> _^1#T+_KRB_\ 016_6!X#_P"1#T+_ *\HO_016_0
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M)?)_WBH4G\*S?$'BW6GTC4[=O!^HK$8)4,QE3:%VD;OIWH W_ ?_ "(>A?\
M7E%_Z"*WZP/ ?_(AZ'_UY1?^@BM^@ HHHH **** "BBB@ HHHH *P=9@E+^5
M9P2[&^:38#M)[<5O45SXF@J]/D;L:4JCIRYC(T.>5$-I<HZ.@W)N&,K6O44T
M"3J ^01RK#@J?8U"MP\#".ZQ@G"RC@'Z^AI48NA!4Y.Z6S_S'-^TDY)?(MT4
M45TF04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4456O[M;*T>4\GHH]3VJ9S4(N4MD.,7)V19I"0.IQ65H>H-=1-%
M,V94YR>XJC\0?+_X0J_,FW \O[W_ %T6LZ%:->FJD-F54ING)Q9T98 9) %'
M6N3\97EE<:;:0P2VTSQZA9G9N&T S* #UP#@_AFK6CVM_H"_9GM)+I+N[DFS
M;NOE6:L1A!N() Y/ [G@<"MB#HZ3(QG(QZUP^IO(EEXN%F[!A>0F3RS\RH4A
M\P^WR[OUJ ,/^$FV.8QX<^W2;<X\G?\ 9E./3;NWX[;L]Z /0**\[TR3QD=*
MLS$"8S FTR?>QM&,YYS10!T?C&66#3H)1--%;I-^_,5TEM\NTXR[$8&<<#K5
MGPN6?2!(?M!5Y"R-/=K<EAQR'4D8]LTFI1/JEP8K5%6XL7#I)<P^9"6*],9!
MR >HZ9J;0H7@LY$FF26X\YC-Y<0B56XX"Y.!C'<YSGO0!IT444 ,:)'96=%9
MD.5)&2#[4"*,2&0(H<C!;')'UI]% #(XDB!$:*@)R0HQD^M4/$G_ "+&J_\
M7G-_Z :TJS?$G_(L:K_UYS?^@&@"EX#_ .1#T+_KRB_]!%;]8'@/_D0]"_Z\
MHO\ T$5OT %%%% !1110 4444 %%%% !1110 4UD5U*L 5/!![TZB@"GMDLN
M4#2P?W>K)]/4>U68Y$EC#QL&4]"*?5:2W9',ML0KGED/W7^OH?>LK.G\.J[?
MY?Y%W4M]RS14,%PLV5P4D7[R-U'_ -;WJ6M(R4E=$M-;BT444Q!1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5!<V<%WM\]-X7H"3
M4]%3*,9KEDKH:;3NBI#IEK;RB2&(*XZ$$U8>))5VR(KKZ,,BGT4H4X4U:"L@
ME)R=V[D(L[<+M%O$!G.-@ZU-115B&+%&C,R(JLW+$#!/UH\J/R_+\M=G]W''
MY4^B@ HHHH Q-2T_64NGGT._M(1,098;NW,B[L8W*58$' '!R..U7-(T^33K
M1EN+EKJYED,LTQ7:&8\<+V    ]!6=XO,(L;<7-\;2)I=IVRR1L_RG&-GS$C
MKCH<<T>#-O\ 8TI21'!N'/RR2R8Z<%I &)_"@#H**** "BBB@ K-\2?\BQJO
M_7G-_P"@&M*LWQ)_R+&J_P#7G-_Z : *7@/_ )$/0O\ KRB_]!%;]8'@/_D0
M]"_Z\HO_ $$5OT %%%% !1110 4444 %%%% !1110 4444 %%%% $,]NLV#D
MK(OW77J/\^E9$VM20:@D4A4QQG;(R_Q>_MBMPC((R1GTK-/A^R)R1*2?]NN'
M%TJ\K/#Z/J;T94U?VAI @@$<@TM4D#:<H0[I+8<!NK(/?U'O5M6#J&4@@\@B
MNN$^;1Z,RE&VVPZBBBK)"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH P/%<=R\=@;1;MF6XY%HT2RXV-
MT:0X ]<<FI_#$KSZ29'>[<-(VUKJ6.1B/9H_EQ57QD(GTV..2.[D:0LH6U>-
M'*E3O^9^!E<CCYN>*F\*/&^FS^5;_9E6X9!#NC(C    \OY<8QZT ;E%%% !
M1110 5F^)/\ D6-5_P"O.;_T UI5F^)/^18U7_KSF_\ 0#0!2\!_\B'H7_7E
M%_Z"*WZP/ ?_ "(>A?\ 7E%_Z"*WZ "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *J- ]LQ>U&5/+0]C[KZ']*MT5,H*0T[$4,Z3IN0]#@@C!!]
M"*EJO-;;W\V)O+F ^]CAO8CN*(;G>_E2KY<PZJ>_N#W%2IM/EG_PXVKZHL44
M45H2%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% ''ZS/>S^(Q9QWETL DCPXTV.6&WD(^4%V.=QZY XW#)%;^B
M:8^DV'V9Y8I<.6!BMUA SVVKQ^-4=6\.Z9-<37U_?7ML)&4L4OY((P0 !P&
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M6EI8'=:0Q*D)W;LJ!QSWXJY6+X1L[BP\-6T-TACEW2/Y9ZHK2,RK^"D"MJ@
MHHHH *@NI8(X"+F18TD^3YFQDGL/>IZY'Q+!J(UQ[JU-R&CT]EL#%&'47&XD
MAA@XW#8,G' ;D4 ;.B6FEZ#:0:'I\RJ+=3LA:3<X!)8^_?-:M<3;Z;?_ -HP
MP/#(MPNM/?23!3L\DQGHWOD)CKQZ5VU !1110 5 +VV+3K]HBW6X!F&\?N\C
M/S>G'/-3USD6RWU[Q%/<VTKVYB@.!"6\W:K9"C'S'IP* +&A?V'I6B'^R[R%
MK 3.QD\X.-[-DC/KD]*V(Y$FC62)U>-QE64Y!'J#7$I&+J\M=6AM+M5&IBYO
M4:U>,@>0T:$*0"VWY<D#J2>U;_A*SN+'P_''=(T;M+-*L;=8T>1F53]%(X[4
M ;5%%% !40NH&N'MQ-&9HU#O&&&Y5/0D=AP:EKG9H7;Q;J+_ &9Y8WTJ., @
MA9&#R$INZ9P1^= $VB0:)I$.HS:==1^5/<M=7+&;< [XR?8''%;$$\5S"LL$
MBR1MRK*<@UY]9Z9J"6\#.EQ<06T]G*S21,LJQH6S 0?OB,D,".3[FNK\,6T\
M%K?23*R+<WTT\2,""$9N,@],\G'O0!M4444 %53J=B-0%@;R 7A7<(/,&\CU
MV]:M5S.H3VUUXAMK5;*X$EK-YZ2"TDV/,4*@F0# 4!CDY]!VH T;.STS2K_5
M)X9D2>X9;F[#RCY>,!B/X1A3^1K0M[F&[B$MO*DL9)&Y#D9'6N#OM'U=[G6!
M)9H[2PV4DCQ.S>>4F9G4949^7(QV&T=ZZ7P]!,+W6;ME>.VN[L20(ZE3@1HI
M;!Y&64]?KWH W**** "JTFH6D-Y':27,*7$OW(F<!F^@[]#5FN?UR.2\U/3X
M[12TEK=QS2QR6Q,;KT+;\8!4$D8/7 Q0!8LK/2+;Q!JE_;3H;^Y5!=#S<X$8
MP..V.]:5K>6][$9+6:.9 <%D8$9KSNYT'5KK1H-/ABE%W:07ZW#L"!*9&R &
M/#;^OMWQ76:%%))KFKWZPR16EP(%B61"A)1"&.T\CJ!_P&@#>HHHH *K3ZA:
M6L\,%Q<PQ2S';&CN 7/H!WJS7/\ B=)KI8K:Q!-TDT,_EO;%HYE5P=I?&!C&
M>N1@?B 75T[3XO$SZB'QJ4UL(2N_K&&)'R_7O5RUO;:]#&UN(I@APQC8-BN+
MEL-8:XU."V:X6[O+FY68NG[HP&-A"ROC@C]V  >N[BM+PW:SG5EN1!+;VT>E
MV]JR2(5S*I8D8/7:#C/3GB@#J:*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **0L%!+$ #J341N[=5+-/$% R27& * )J*** "BD+!>6( ]Z6@ HIB2)(6"
M.K%#M8 YVGK@_F*<&!) ()'4>E "T444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 1SP174#PSQK)$XPR,,@
MCWKSY&MK'0O$]];0V?GVVJR!&>)6 4^6",>A!->BTSRH\$;%P>HQUH XYM<U
M*35FA34H(XFU62Q $2DJGD>8&R3]X$8]#GI5;3O%VHZC%IJ"ZL(+B6WAF/G-
MM%SF1ED"C!).%'"G(+#/%=UY4?\ SS7\J0PQ$H3&F4.5.T?+]/2@#$O[B5O%
ML-NS!(8M/EN$)''F;E7<>QP#_P"/5S#>+-8BTP7;:A;LPTVVORGDJ!N9]KIU
MZ'\Q7?SVD5Q-%*Z_O(2=C#J >H^A]/I4GDQ_\\T_[Y% ''_VQ=G4I;:"\M;?
MS-8>U+K"N=GV;>#UY8$8R:?I&KW-_-X6O6*&74+>5;HQCY6"IN!Q[,/PW$5U
MOE1_W%_*HELX5NQ<[?WH3RU/95)R0/J0,_04 6**** "BBB@ HHHH **** "
FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>image_019.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" &, <(# 2(  A$! Q$!_\0
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M5;TN'Q6FIJVK7>CR6/S;EMX9%DZ<<DXZXKD_#EU _P <_$A6:,A[1%4AA\Q
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MO)$"ZDF1^F6R3M';UYKHYWTU_'GBO2?&3&.WU-(&M'<E0T:'(5&]<D<#J0:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !5'6_\ D!:A_P!>TG_H)J]5
M'6_^0%J'_7M)_P"@F@#E? >EVTWA#0C(I/FV8/#$?,#_ /7K=T6PM;2_OHEM
MH5GADRL@0!C&XR.?KN'X5C>$+E;+X>^'9R,E8%&WN00<U/K7BK3]&U^&4M)*
M7M]LRQ#.!D%#^K?G7%!4*=65DD_\_P#@G;3C6K1Y(W=U^1UE+5;3]0M]4L8[
MNTDWPR#(.,'W!'K5FNU.YQM.+L]PHHHH$%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !169J-KJMY(4L[]-/B7^-81+(__?7
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!SWBR>*SM[>9X[ 9DVM->.T848) #J"0Q.,?C4'AO7C>:A):>89(R\O
MEJS%GC5-@Y)Y.2YZ^E6_$WVV6*U73_M[+YQ$RV+1K)C:2,L_ &<>_2I?#L3Q
M69^U)>K.78#[<Z/,5X[IQMYH V**** "BBB@ JCK?_("U#_KVD_]!-7JHZW_
M ,@+4/\ KVD_]!- &3\._P#DGVB?]>JU=N=2CM=:1,C:R!)#_=.>/YU1^'G_
M "3W1/\ KU6I[K0D$J.]Q(QEDPQ('?-<6.=917L5K?\ K[S>@J;;]HS8N[9+
MRTEMY?N2H4/XUD:1XEL;E8;*>]A_M!<QNF[[S*<'!Z'.,_C6E):R'2Y+59CY
MAB:-9#U!(P#7D=OX8U9=7M[.2UDAD:4!9&X3CDD-T/ )K6=24;-+<Z\%AJ5>
M$U4G:VQ[/12#I2UT'FA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!BZ_9:=L%U>ZE+I9)"&>*[\C=Z Y.#^(J30(-.%LT^G7K
M7^X[&NGN#.S$=MV<?@.*I^+HI9([$V@E>[28F)(K9)68;2#]\A5'/))]N]7/
M#:S+IK+=,YG$K;U>!(F0\<$(2IXQR"<YH UJ*** "BBB@ JCK?\ R M0_P"O
M:3_T$U>JCK?_ " M0_Z]I/\ T$T 9/P[_P"2?:)_UZK6W?\ _'HSCJA#_D<U
MB?#O_DGVB?\ 7JM=#*GF0NA_B4BHJ+FBT.+LTQW6J.LV[3Z<[1D+-"1-$Q.
M&7D?@>A]B:L6;^99Q,>I49^M4_$5C-J6@7EI;,!-+'A<G&><X_'I^-%^:%T7
M35JB3=M1NE^)=+U=ECM+N-IRNXQ=&'K]<>U:M>2^&_#^IIXHLA-;RVIB?S6:
M0;<JO7'KU X]:]:J:,Y35Y(ZL?AJ6'J*-*5TT%%%%:G"%%%% !1110 4444
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MN_$^E=6S(7O1MU7]?\'[S5HHHJC,**** "BBB@ HHHH **** "BBB@ HHHH
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MBU>)8"3A;A.87_'^$^Q_,UJ Y (.0::=R90<=Q:***9(4444 %%%% !1110
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M'?\ R3[1/^O5:Z2N;^'?_)/M$_Z]5KI* "BBB@ HHHH **** "BBB@ HHHH
M:Z+(A5U#*PP01D$5F'3;C3R7TF0"/J;24GRS_NGJGZCVK5HI-7*C-Q*-GJL-
MS*8)%>WNP,F"7AOJ.S#W%7JKWEC;W\0CN8@X!RIZ%3Z@CD'W%4<ZAI?W@^H6
MH[C'GH/IT<?D?K2NUN5RQE\.C[&M16#?^,]&T](S)<F1I.B1H2R_4=OH>:U;
M"_MM3LX[JSE$D+]&'\CZ&A23=DPE1J0BI2BTF6:***HS"BBB@ HHHH ****
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MQ^:YIR:_IC'!O(XSZ2Y0_P#CV*T*1D5QAE##T(S1J%X=OQ&17,,XS#-'(/\
M88'^5252ET739CF2QMR?41@'\Q47]@VJ#]Q+=V__ %RN' _(DBC4+0[O[O\
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MBBBMCSPHHHH **** "BBB@ HHHH **** "BBB@ HHHH RI/#.F2:O+JC0/\
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M=[__ ,!(O\* .QHKCO\ A$?$?_0[W_\ X"1?X4?\(CXC_P"AWO\ _P !(O\
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M^$O$;*#_ ,)O?\C_ )](J7_A$?$?_0[W_P#X"1?X4 =C17'?\(CXC_Z'>_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !13))4B7=(ZH.F6.*8+NW9E59XB6.T ..3C./K@'\J )J*** "BF2S1
MP+NED2-?5F %.W ,%R,GH* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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144 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>image_020.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_020.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" &; B8# 2(  A$! Q$!_\0
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M T1[6/XF^%%A:%4;P^BD(0 258X^M:OPGDAAO/$UI(52Z&J2OY1&'"^N.PH
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MR*3XJ2QQ_#G5E=U4O&JJ"<;CO7@5A>$;_1O#OAG3]:EU%&FETV*V:V\_>[2
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MZN1I\UL]O)?Z>UW;9D#;TP>&Q]U\<X_7B@#JA;PJ$ BC 0Y4!1\I]J7R(O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI"0H)/ ')H 6BJ<6JV4UBE
M[%<QM;.VU9 >&;=MP/4YXQ5B"XBNH5E@D62-NC*<CT- $E%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQY_R(6N?]>4O_H)JO\-?^2=Z+_U[_P!35CQY_P B%KG_ %Y2_P#H)JO\-?\
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M ))WHO\ U[_U-6/'G_(A:Y_UY2_^@FJ_PU_Y)WHO_7O_ %- '44444 %%%%
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MT5% '(^$/">FP:1#=WFB6\>HRO))(\\"F4$NQ&2<X.,5UJJ$4*H  Z "EHH
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MOQ^#_"S11EM,L"< Y.#SCZUJ6>@:3I]D]I9Z=:0V\BE'C2)0'!ZAO7/O5?\
MX0[P[_T ]._\!D_PH YHZ#/!XQN+;PG?VVCQ?8(GFVVPF#DR2 8!. >*TO\
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MJ_PU_P"2=Z+_ ->_]35CQY_R(6N?]>4O_H)JO\-?^2=Z+_U[_P!30!U%%%%
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M8\8[$8[UV=97_"/P?;99_M-V8Y9/->V,N8BW'.,9[#C./:M6@ HHHH ****
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MBB@ HHHH **** "BBB@ HHHH ***X_4_BIX3TJ[:VFU,22H<-Y$;2!3]0,4
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MM?!MQX9O(=/_ +"^U2[$C\@Q;\EU'&.>_:NILM$O;"RBM+;48[>")=J)#:*
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M1I2D[)&S14%OY4B++#(SJ>AW$U/71&7,KF;5G8****H04444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!!?6HO;"XM2[()XFC+KU7(QD>_-?/
M.I?!;Q39W;1VD$-[#GY98Y57(]PQ!'ZU]&T4 >:_"KX=:AX0GNM0U6>,3W$0
MB6WB;<%&<Y8]">.WO72H+ZP\5:Q>KI=S<07$$"1-&T?S,F_/5AC[PYKI:* .
M1C\/OJWB+5)=9LI19W4%J-@E_=R,FXLK ') +#KP>:UY-/OXTU%I-0ENXYHW
M$-L8HU$6<X 8 $^G)K7HH Y.QT6\MHO#%XT#&;3;)K6>WW+G+(@R#G!PR#OT
M.:R[?P5?V&CZA8Q[)7U/34M9'#?+#)NDW'_=Q*<8_N^]>@44 4M.N%?SK18I
MD^QE8MT@&'^48(()_H?:N?O]!N]4A\4VWEF'[<\;6TCD;7*QH.<'(&Y<?2NL
M  Z#%+0!B:9I\_\ ;^HZM<1F+[3##"D1() 3<23CCJY'X>]<O8^%9D?33<:/
ME4:^%T#L.Y'8M$IY^8=,#L?2O0Z* /,KBTF%I#8WJ3,T6EVL-VJRQE[=D8ME
M07') ZC.>/3%;NMZ3J.H6EBVGB2"X>_^T>:%'[A!&R(2"?0KD#GDUT\VGV=Q
M<)<3VEO)/']R1XP67Z$C(JS0!YYJD4LZ6UJU@;21M,EAGM$FB(M]S >8F77)
MRIPV?K@UW6F^5_9EKY"NL7E+L#C# 8XS[T7.GV=ZZ/=6D$[1_<:6,,5^F1Q5
MF@ HHHH **** .>\;1K+H2(\$4ZFYBRD\WEPGYO^6A[K[?2J_A*UBMKVZ,5C
MHEKNC7)TV?S"W)^]\HQ[?C5[Q;Y1T-O/ETR*/S$R^I1[X1S_ '<C)].:R/!4
ML#:I?I;RZ+.JQ1GS-*M/*3DMPQW')XZ=OQH [*BBB@ HHHH Y_QY_P B%KG_
M %Y2_P#H)JO\-?\ DG>B_P#7O_4U8\>?\B%KG_7E+_Z":K_#7_DG>B_]>_\
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M()HVD;<0S[PPR?78#^)JC;^,KRY:V6/24!N_M*Q;KKC?"Q#!OEX! X//T[T
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MK."-'5;)=ENP<[HUQMQGKC''/H*?)I%E+I\=BT %M$R,D:D@ HP9?U -7:*
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M35?X:_\ ).]%_P"O?^IJQX\_Y$+7/^O*7_T$U7^&O_).]%_Z]_ZF@#J****
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M9)41CT#, :DKF"UO?>.+R>X\K[/I-DL):3& \IWMG/HJ)_WU0!T]%<+H5[K
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M:#;S:Q%>R+$T443JEN8AM#NP9G_WC@?KZUS$&J2IXGWW]X(O*MUM3>A %D=
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO1?^O?\ J:L>//\ D0M<_P"O*7_T$U7^&O\ R3O1?^O?^IH ZBBBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G_'G_ "(6
MN?\ 7E+_ .@FJ_PU_P"2=Z+_ ->_]35CQY_R(6N?]>4O_H)JO\-?^2=Z+_U[
M_P!30!U%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>image_021.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_021.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" %] G # 2(  A$! Q$!_\0
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M<0O(=\+%@P9BW4@'OC\*K0^'M3T_QKJM_#%:7FG:J(G<3/AH)(Q@'&#N'Y4
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M>XD\,Z6][G[2UI$9<]=VP9S[UIT %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 E(R*PPR@CT(IU% &.
M_AFUD\5#7VEF-T+;[+Y9*^7LSNZ8SG/.<UKXI:* &E5)!(!(Z$CI0$4,6"@,
M>"<<TZB@!H15SM4#)R<#J:7%+10 @55&  !Z 48%+10!RU]\/-#U*\NKB\@\
MYKJ3S)"Z(6SZ!]NX#CH#Q74    =!2T4 %-"*K%@H!/4@=:=10 U45<[5 R<
MG ZFEP*6B@!H15)(4 GK@4I4,,$ CWI:* $VC.<#/3-&!Z4M% "8I BJ254
ML<G ZTZB@ JIJ6GIJ=A/:O)-")D*&6!]DBC_ &6[5;HH SI-%AET.?2VFG,<
M\31R3%@9&W##,3C&3GTIVBZ1!H>DV^GVS.\5N@C1I,;BHZ9( S5^B@!H1020
MH!;KQUH5%10J*%4=@,"G44 4K;3(+.^N;FWRANB'FC'W6< #?CL<  ^N!5S
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5EWMA:SZU8SRP(\JAMKD<C&"*U*IW'_(3L_I)_
M(4TVA,MTM%%(84444 %%%% !1110 A('4XH+ $ D9/0>M9FM6<MU)IS00^88
M+M)6.0-JC.>OUK.O-/O]5OUN8U:W&50%F&8]CODCUW C^M '1^8F =RX)QU[
M^E*6 (!(!/0>M<:?#6IM:E RKF/RPF\85O*1/,_-2?7FK][I]_J>H+-&&A6-
MDC#LPRNR3<7'^\./PYH Z+S$QG<N,XZ]_2G5QA\-:F;5E##F+RO+W\;_ "=G
MF?\ ?7/K781*R1(K-N8* 6]3ZT /HHHH **** "BBB@ HHHH **** "BBB@
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MX-,M+8SJS6TGF [?E?KP1G_:_,"H+CPK:3Z9); LCLCJKJS!4#,6P%!Q@$\
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MP*V4)!W;B3R.F,>]<_I7C[49TT6YO+>W:'4DO T4",&C:#<0023D,%(QV.*
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MC9@A9'W, "3CL..N!7144 9@\-Z0+:>W_L^#R9X_*D3;P4R2%]ADDX'K2?\
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M^1)I7_(6M/\ KJ*[VN"TK_D+6G_745WM=:.,****8!1110 5YG?_ /(1NO\
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M **** "BBB@ HHHH *IW'_(3L_I)_(5<JG<?\A.S^DG\A30F7****0PHHHH
M**** ,W75>33)8A;3W$,BE)%MG"R@'NN<?SS65X;0Q7,AM[36U1P \FJ3$[0
M,\*"2<\_2K?B?5+K3+6-K:6.W5B=]Q);R3*GH-J<\^IXXIOAC5;O4H93<S1W
M*)C;<1VTD 8]QA^OU'% &]1110 UY$B7=(ZH,XRQQS2/*D94.ZJ6.%!.,GVJ
MAKME+J&GK# B,XFCD&XXP%<,?T%4=2TN\U:[\S"PK&3""6SE=Z/O''7Y2,4
M;9N8 &)FC 4X8[AP?0U)7*#PM>+SYL;% %"DG#\2C<??]X/R-=+90&UL+>W9
MM[11JA;U(&,T 3T444 %%%% '.>,_P#D'V__ %U_H:X^NP\9_P#(/M_^NO\
M0UQ]>%C_ .,SWL!_!1UFC?\ (GW/_;2N>KH=&_Y$^Y_[:5SU>MA_X4?0\C$_
MQI>IN^$_^/\ G_ZY_P!:ZNN4\)_\?\__ %S_ *UU=;F 4444 %%%% %'6O\
MD#7G_7)OY5YU7HNM?\@:\_ZY-_*O.J\?,OCCZ'LY9\$O4Z+P9_R$+G_KD/YU
MGW__ "$;G_KJW\ZT/!G_ "$+G_KD/YUGW_\ R$;G_KJW\Z[,#_ 1Q8_^._D2
M:5_R%K3_ *ZBN]K@M*_Y"UI_UU%=[76CC"BBBF 4444 %>9W_P#R$;K_ *[/
M_,UZ97F=_P#\A&Z_Z[/_ #->;F7PQ/3RSXI$^B?\ANS_ .NHK7\5?\A2/_KD
M/YFLC1?^0W9_]=16OXJ_Y"D?_7(?S-&7?PWZBS+^(O0Q#T->A6/_ !X6_P#U
MR7^5>>GH:]"L?^/"W_ZY+_*O11YI/1113 **** "N(\7_P#(97_KDO\ ,UV]
M<1XO_P"0RO\ UR7^9KBS#^#\SNR_^-\C"/0UV.O?\B]9?5/_ $&N./0UV.O?
M\B]9?5/_ $&N7+=Y?(Z<S^&)S5==X5_Y!+?]=6_I7(UUWA7_ )!+?]=6_I7K
M(\@VJ***8!1110 5SWC+_D&P_P#78?R-=#7/>,O^0;#_ -=A_(USXO\ @R.C
M"?QHG&UUN@_\BG=_]M/_ $&N2KK=!_Y%.[_[:?\ H->7E_\ &^1ZN8_P?F<X
M.E;OA/\ Y",W_7+^HK"'2MWPG_R$9O\ KE_45[9X1UE%%%, HHHH **** "B
MBB@ HHHH **** "J=Q_R$[/Z2?R%7*RK[4+6#6[&"6=$F8-M0]3G@8IQ3;T$
MS5HI*6D,**** "BBB@#G?%5K>W#VATR^6VO0DT<*-N D+)C.1_=Z\BK&AZ<^
MES/:1N/LT<,?#2L[M)SN8YZ9X^O-+KTUY9O;W6G?9I)T#*;>>7R_-0XSM;L0
M0/SIF@W-_?W,]UJ26MN^T)';03"4JN22S,.,D],>E &Y1110 4444 %%%% !
M1110 4444 <YXS_Y!]O_ -=?Z&N/KL/&?_(/M_\ KK_0UQ]>%C_XS/>P'\%'
M6:-_R)]S_P!M*YZNAT;_ )$^Y_[:5SU>MA_X4?0\C$_QI>IN^$_^/^?_ *Y_
MUKJZY3PG_P ?\_\ US_K75UN8!1110 4444 4=:_Y UY_P!<F_E7G5>BZU_R
M!KS_ *Y-_*O.J\?,OCCZ'LY9\$O4Z+P9_P A"Y_ZY#^=9]__ ,A&Y_ZZM_.M
M#P9_R$+G_KD/YUGW_P#R$;G_ *ZM_.NS _P$<6/_ ([^1)I7_(6M/^NHKO:X
M+2O^0M:?]=17>UUHXPHHHI@%%%% !7F=_P#\A&Z_Z[/_ #->F5YG?_\ (1NO
M^NS_ ,S7FYE\,3T\L^*1/HO_ "&[/_KJ*U_%7_(4C_ZY#^9K(T7_ )#=G_UU
M%:_BK_D*1_\ 7(?S-&7?PWZBS+^(O0Q#T->A6/\ QX6__7)?Y5YZ>AKT*Q_X
M\+?_ *Y+_*O11YI/1113 **** "N(\7_ /(97_KDO\S7;UQ'B_\ Y#*_]<E_
MF:XLP_@_,[LO_C?(PCT-=CKW_(O67U3_ -!KCCT-=CKW_(O67U3_ -!KERW>
M7R.G,_AB<U77>%?^02W_ %U;^E<C77>%?^02W_75OZ5ZR/(-JBBBF 4444 %
M<]XR_P"0;#_UV'\C70USWC+_ )!L/_78?R-<^+_@R.C"?QHG&UUN@_\ (IW?
M_;3_ -!KDJZW0?\ D4[O_MI_Z#7EY?\ QOD>KF/\'YG.#I6[X3_Y",W_ %R_
MJ*PATK=\)_\ (1F_ZY?U%>V>$=91113 **** "BN6?P);/(S?;[WYB3RX/\
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M?Q.JHKE?^$"MO^@A>_\ ?0_PH_X0*V_Z"%[_ -]#_"B[[!SU/Y?Q.JHKE?\
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MT8ED(1V4$GDX-<&/47&/,['?@*M=2?+3O\[?H:>B?\ANS_ZZBM?Q5_R%(_\
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MA&Z_Z[/_ #->1F]/V?+$];*9<SDR?1/^0W9_]=16OXJ_Y"D?_7(?S-9&B?\
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M=W_VT_\ 0:Y*NMT'_D4[O_MI_P"@U\WE_P#&^1[V8_P?F<X.E;OA/_D(S?\
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M)P5/B9Z9XC_Y%[3O^ _^@5R]=1XC_P"1>T[_ (#_ .@5R]?$YA_'9]9E_P#
M1UFC?\B?<_\ ;2N>KH=&_P"1/N?^VE<]7JX?^%'T/)Q/\:7J;OA/_C_G_P"N
M?]:ZNN4\)_\ '_/_ -<_ZUU=;F 4444 <=\2?^03:?\ 7?\ ]E->=5Z+\2?^
M03:?]=__ &4UYU7K83^$CCK?&>@^%_\ D0+OZRU@UO>%_P#D0+OZRU@U\MG/
M\<^BRC^$SHO!G_(0N?\ KD/YUGW_ /R$;G_KJW\ZT/!G_(0N?^N0_G6??_\
M(1N?^NK?SK? _P !'+C_ .._D2:5_P A:T_ZZBN]K@M*_P"0M:?]=17>UUHX
MPHHHI@9?B7_D6M1_ZX-_*O':]B\2_P#(M:C_ -<&_E7CM>E@OA9RXC='8_#;
M_D*WO_7 ?^A5!?\ _(1NO^NS_P S4_PV_P"0K>_]<!_Z%4%__P A&Z_Z[/\
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M;>0W'7TILOA&TFE>1Y[C<[%C@KU/X5YN9TWBI)TST,OJQP]^<YG1?^0W9_\
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M*C2JA**[;5)[ GM4]-=%D0I(JLC#!5AD&@# .M7TEF+FU@9V@E(N;66/;*%
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M((]P8C//) _&MEM/M'9F:VA+,P<DH.6'0_7WIPLK92Q%O$"S[V.T<MZGW]Z
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M=O7BF)XATUV8?:E"J4 9AA6+*&&#WX(-1OX8TV2621HY"\A7<QE8D[2"._J
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2G\: +5%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>image_022.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_022.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "B 3\# 2(  A$! Q$!_\0
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M%''_ ,32.;2I;ZYC34=52_U.-;RJ7[//_!%7P3X(_:,\%?MA?M>_M2_M"?\
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M?$'X&>'#-#X"_:V\-:%91)_:/Q<_9;74=2/BPO%=W_B_X(7NLZ;%>Z6_A?\
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M00#R"/Q(./0]*_"_]L/PCXI_X)L?'SQ!_P %/_@EH6L:Q^SAXXL+&V_X*@?
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M#<)*TL:AP\#;'$B%"3D@,H/WD;!*N,JP(*D@T 3T444 %%%% !1110 4444
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M'/C+\+_ OQ4T'1O@;\7?%^B:3XZ\-Z=X@MM"\6>'OAUXDU+0?%'A^>[MWO\
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M?"WB;28=$T#P7X>L-<N-!\.Z9K'B&:[M_P!@J* (HH8X=WE@@.<D9XSR<@#
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MJ8_X(L>"K4Z:+2X.H+=)^R'X=BDMFLA']I6XCD5HY(6B$L;JRNJE6  /VW^
MO_)#O@W_ -DJ^'7_ *ANBUZS7E'P'1X_@?\ !Q)8Y(I5^%7P[66*5&CEBD7P
M?HRO')&X5XY$92KHZJZ,"K $$5ZO0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>M?V?<7-C<R:??6WVC3M3LY3;ZOHM[I>K)%;+?"VA^IOB'X@\:>'/"7B#5?
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; 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092611252920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 08, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lantern Pharma Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,169,665<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,733,370<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001763950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092611307960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 19,229,232<span></span>
</td>
<td class="nump">$ 1,232,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses &amp; other current assets</a></td>
<td class="nump">1,007,690<span></span>
</td>
<td class="nump">788<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">20,236,922<span></span>
</td>
<td class="nump">1,232,818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">21,507<span></span>
</td>
<td class="nump">8,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsNoncurrent', window );">Deferred offering costs</a></td>
<td class="nump">101,205<span></span>
</td>
<td class="nump">191,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">20,359,634<span></span>
</td>
<td class="nump">1,432,576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">552,339<span></span>
</td>
<td class="nump">489,292<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">552,339<span></span>
</td>
<td class="nump">489,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">PPP loan payable</a></td>
<td class="nump">108,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">660,839<span></span>
</td>
<td class="nump">489,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES (NOTE 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Series A Preferred Stock (1,000,000 authorized at December 31, 2020; 3,480,000 authorized at December 31, 2019; $.0001 par value) (Zero shares issued and outstanding at December 31, 2020; 2,438,866 shares issued and outstanding at December 31, 2019)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock (25,000,000 authorized at December 31, 2020; 12,180,000 authorized at December 31, 2019; $.0001 par value) (6,220,927 shares issued and outstanding at December 31, 2020; 1,978,269 shares issued and outstanding at December 31, 2019)</a></td>
<td class="nump">622<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">32,358,068<span></span>
</td>
<td class="nump">7,694,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(12,659,895)<span></span>
</td>
<td class="num">(6,751,705)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">19,698,795<span></span>
</td>
<td class="nump">943,284<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 20,359,634<span></span>
</td>
<td class="nump">$ 1,432,576<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092610959176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common shares par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares authorized</a></td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">12,180,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares issued</a></td>
<td class="nump">6,220,927<span></span>
</td>
<td class="nump">1,978,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding</a></td>
<td class="nump">6,220,927<span></span>
</td>
<td class="nump">1,978,269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, shares par value (in Dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">3,480,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,438,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,438,866<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092611022680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">$ 3,664,965<span></span>
</td>
<td class="nump">$ 1,475,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Research and development</a></td>
<td class="nump">2,243,225<span></span>
</td>
<td class="nump">953,185<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">5,908,190<span></span>
</td>
<td class="nump">2,428,185<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (5,908,190)<span></span>
</td>
<td class="num">$ (2,428,185)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share of common shares, basic and diluted (in Dollars per share)</a></td>
<td class="num">$ (1.37)<span></span>
</td>
<td class="num">$ (1.23)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average number of common shares outstanding, basic and diluted (in Shares)</a></td>
<td class="nump">4,304,918<span></span>
</td>
<td class="nump">1,978,269<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092610639080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)<br></strong></div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 129<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">$ 4,121,395<span></span>
</td>
<td class="num">$ (4,323,520)<span></span>
</td>
<td class="num">$ (201,798)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2018</a></td>
<td class="nump">1,292,952<span></span>
</td>
<td class="nump">1,978,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants', window );">Preferred stock and warrants issued</a></td>
<td class="nump">$ 115<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,455,392<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,455,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants', window );">Preferred stock and warrants issued (in Shares)</a></td>
<td class="nump">1,145,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">117,760<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">117,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,428,185)<span></span>
</td>
<td class="num">(2,428,185)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 244<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">7,694,547<span></span>
</td>
<td class="num">(6,751,705)<span></span>
</td>
<td class="nump">943,284<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2019</a></td>
<td class="nump">2,438,866<span></span>
</td>
<td class="nump">1,978,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCosts', window );">Common stock issued from offering, net of issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">23,419,546<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">23,419,721<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCostsinShares', window );">Common stock issued from offering, net of issuance costs (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment', window );">Preferred Stock Converted to Common, net of fractional shares adjustment</a></td>
<td class="num">$ (244)<span></span>
</td>
<td class="nump">$ 244<span></span>
</td>
<td class="num">(261)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(261)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross', window );">Preferred Stock Converted to Common, net of fractional shares adjustment (in Shares)</a></td>
<td class="num">(2,438,866)<span></span>
</td>
<td class="nump">2,438,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Common stock issued from option exercise</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">51,995<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">52,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock issued from option exercise (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CashlessExerciseOfWarrant', window );">Cashless exercise of warrant</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CashlessExerciseOfWarrantinShares', window );">Cashless exercise of warrant (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">3,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,192,241<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,192,241<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,908,190)<span></span>
</td>
<td class="num">(5,908,190)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 622<span></span>
</td>
<td class="nump">$ 32,358,068<span></span>
</td>
<td class="num">$ (12,659,895)<span></span>
</td>
<td class="nump">$ 19,698,795<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,220,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_CashlessExerciseOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cashless exercise of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_CashlessExerciseOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_CashlessExerciseOfWarrantinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents of cashless exercise of warrant in shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_CashlessExerciseOfWarrantinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents of common stock issued from option exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCostsinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents of common stock issued from offering net of issuance costs in shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_CommonStockIssuedFromOfferingNetOfIssuanceCostsinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_StockIssuedDuringPeriodSharesIssuedPreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued value preferred stock conversion to common stock net of fractional shares adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_StockIssuedValuePreferredStockConversionToCommonStockNetOfFractionalSharesAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_StockissuedDuringPeriodValueIssuedPreferredStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, before forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensationGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092610659352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (5,908,190)<span></span>
</td>
<td class="num">$ (2,428,185)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">3,388<span></span>
</td>
<td class="nump">1,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount', window );">Stock based compensation</a></td>
<td class="nump">1,192,241<span></span>
</td>
<td class="nump">117,760<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses &amp; other current assets</a></td>
<td class="num">(1,006,902)<span></span>
</td>
<td class="num">(788)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCharges', window );">Deferred offering costs</a></td>
<td class="num">(49,325)<span></span>
</td>
<td class="num">(191,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">117,167<span></span>
</td>
<td class="nump">372,663<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows used in operating activities</a></td>
<td class="num">(5,651,621)<span></span>
</td>
<td class="num">(2,127,923)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment', window );">(Purchase) sale of property and equipment</a></td>
<td class="num">(16,137)<span></span>
</td>
<td class="num">(5,717)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flows (used in) provided by investing activities</a></td>
<td class="num">(16,137)<span></span>
</td>
<td class="num">(5,717)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of common and preferred stock</a></td>
<td class="nump">26,250,000<span></span>
</td>
<td class="nump">2,920,507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_IncreaseDecreaseIssuanceCosts', window );">Issuance costs</a></td>
<td class="num">(2,745,279)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from stock option exercise</a></td>
<td class="nump">52,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ProceedsFromPreferredStockConvertedToCommonStockNetOfFractionalSharesAdjustment', window );">Preferred stock converted to common stock net of fractional shares adjustment</a></td>
<td class="num">(261)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Borrowings on notes payable</a></td>
<td class="nump">169,049<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Payments on notes payable</a></td>
<td class="num">(169,049)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable', window );">Borrowings on PPP loan payable</a></td>
<td class="nump">108,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flows provided by financing activities</a></td>
<td class="nump">23,664,960<span></span>
</td>
<td class="nump">2,920,507<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">CHANGE IN CASH FOR THE YEAR</a></td>
<td class="nump">17,997,202<span></span>
</td>
<td class="nump">786,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH, BEGINNING OF YEAR</a></td>
<td class="nump">1,232,030<span></span>
</td>
<td class="nump">445,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">CASH, END OF YEAR</a></td>
<td class="nump">19,229,232<span></span>
</td>
<td class="nump">1,232,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock', window );">Conversion of SAFE agreements to Series A preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">535,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ApplicationOfDeferredOfferingCosts', window );">Deferred offering costs applied to net offering proceeds</a></td>
<td class="num">(85,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_DeferredOfferingCostsRecordedInAPAndAccruedExpenses', window );">Deferred offering costs recorded in AP and accrued expenses</a></td>
<td class="nump">$ 51,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_ApplicationOfDeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of application of deferred offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_ApplicationOfDeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of SAFE agreements to Series A preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_ConversionOfSafeAgreementsToSeriesPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_DeferredOfferingCostsRecordedInAPAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs recorded in AP and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_DeferredOfferingCostsRecordedInAPAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>IncreaseDecreaseInBorrowingsOnLoanPayable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_IncreaseDecreaseInBorrowingsOnLoanPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_IncreaseDecreaseIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_IncreaseDecreaseIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_IncreaseDecreasePurchaseOfPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_ProceedsFromPreferredStockConvertedToCommonStockNetOfFractionalSharesAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents of proceeds from preferred stock converted to common stock net of fractional shares adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_ProceedsFromPreferredStockConvertedToCommonStockNetOfFractionalSharesAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of expenditures made during the current reporting period for benefits that will be received over a period of years. Deferred charges differ from prepaid expenses in that they usually extend over a long period of time and may or may not be regularly recurring costs of operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of (increase) decrease in equity for down round feature triggered for stock option classified as equity. Excludes stock option granted for share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=SL109261905-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12B<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL109261756-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionDownRoundFeatureIncreaseDecreaseInEquityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092697951880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization, Principal Activities, and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization, Principal Activities, and Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 1. Organization, Principal Activities,
and Basis of Presentation</b></p><br/><p style="font: 10pt TimesNewRoman,serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Lantern Pharma Inc., and Subsidiary
(the &#x201c;Company&#x201d;) is a clinical stage biopharmaceutical company, focused on leveraging artificial intelligence (&#x201c;A.I.&#x201d;),
machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from
its targeted oncology therapies. The Company&#x2019;s portfolio of therapies consists of small molecule drug candidates that others
have tried, but failed, to develop into an approved commercialized drug, as well as new compounds that it is developing with the
assistance of its A.I. platform and its biomarker driven approach. The Company&#x2019;s A.I. platform, known as RADR<sup>&#xae;</sup>,
uses big data analytics (combining molecular data, drug efficacy data, data from historical studies, data from scientific literature,
phenotypic data from trials and publications, and mechanistic pathway data) and machine learning. The Company&#x2019;s data-driven,
genomically-targeted and biomarker-driven approach allows it to pursue a transformational drug development strategy that identifies,
rescues or develops, and advances potential small molecule drug candidates.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Lantern Pharma Inc.
was incorporated under the laws of the state of Texas on November 7, 2013, and thereafter reincorporated in the state of Delaware
on January 15, 2020. The Company&#x2019;s principal operations are located in Texas. The Company formed a wholly owned subsidiary,
Lantern Pharma Limited, in the United Kingdom in July 2017.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since inception, the
Company has devoted substantially all its activity to advancing research and development, including efforts in connection with
preclinical studies, clinical trials and development of its RADR platform. This includes research and development for three drug
candidates in development in targeted areas identified with the assistance of the RADR platform:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#x25cf;</td><td style="text-align: justify">LP-100 (irofulven),
                                         out-licensed to Allarity Therapeutics (formerly known as Oncology Venture), in a phase
                                         II trial for the treatment of prostate cancer;</td>
</tr></table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#x25cf;</td><td style="text-align: justify">LP-300 (Tavocept)
                                         in planning stages for phase II trial for the treatment of non-small cell lung cancer;
                                         and</td>
</tr></table><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#x25cf;</td><td style="text-align: justify">LP-184 in
                                         preclinical studies for treatment of solid tumors including prostate, liver and pancreatic
                                         cancers and glioblastoma.</td>
</tr></table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the Company&#x2019;s reincorporation in the state of Delaware on January 15, 2020, the par value of the Company&#x2019;s Common
Stock and Series A Preferred Stock was changed from $0.01 per share to $0.0001 per share. The change in the par value has been
retroactively reflected in the accompanying consolidated financial statements. Additional funds have been reclassified from Common
Stock and Series A Preferred Stock to additional paid-in capital to reflect the change in par value associated with the reincorporation.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The accompanying consolidated
financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America
(&#x201c;GAAP&#x201d;) and include all adjustments necessary for the fair presentation of the Company&#x2019;s financial position,
results of operations, and cash flows for each period presented. The preparation of financial statements in conformity with GAAP
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses
during the reporting periods. Actual results could differ from these estimates.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any reference in these
notes to applicable guidance refers to Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Update (&#x201c;ASU&#x201d;)
of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). To date, the Company has operated its business as one segment.
The Company&#x2019;s consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Lantern
Pharma Limited. All intercompany balances and transactions have been eliminated in consolidation.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective June 11,
2020, in connection with the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;), the Company completed a forward stock
split of its common stock at a ratio of 1.74 for 1 shares. In addition, all of the Company&#x2019;s preferred stock converted into
common stock effective June 15, 2020 in connection with the IPO. All data on common stock and equivalents in the accompanying
consolidated financial statements and in these notes are shown herein reflective of this stock split and the conversion of the
preferred stock. In addition, the number of shares of preferred stock in the accompanying consolidated financial statements and
in these notes is presented to reflect the number of shares into which the preferred stock would convert as a result of the forward
stock split.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092692572648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Liquidity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 2. Liquidity </b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company incurred
a net loss of approximately $5,908,000 and $2,428,000 during the years ended December 31, 2020 and 2019, respectively. As of December
31, 2020, the Company had working capital of approximately $19,685,000, primarily as a result of the net proceeds raised in the
IPO of approximately $23,420,000 (see Note 6). As of December 31, 2019, the Company had working capital of approximately $744,000.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 20, 2021,
the Company closed a public offering of 4,928,571 shares of its common stock at a public offering price of $14.00 per share, which
amount included 642,856 shares sold upon full exercise of the underwriter&#x2019;s over-allotment option. Total gross proceeds from
the offering were $68,999,994, and net proceeds from the offering were approximately $64,200,000.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0; text-indent: 0.5in">The Company has received
funding in the form of periodic capital raises and also plans to apply for grant funding in the future to assist in supporting
its capital needs. We may also explore the possibility of entering into commercial credit facilities as an additional source of
liquidity.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our
existing cash and cash equivalents as of December 31, 2020, and our anticipated expenditures and capital commitments for the calendar
year 2021 and the first half of 2022, will enable us to fund our operating expenses and capital expenditure requirements for at
least 12 months from the date of filing this Form 10-K for the year ended December 31, 2020.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092692555992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 3. Summary of Significant Accounting
Policies</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates and Assumptions</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of
financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. The significant areas of estimation include determining
deferred tax asset valuation allowance and the inputs in determining the fair value of equity-based awards and warrants issued.
Actual results could differ from those estimates.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks and Uncertainties</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company operates
in an industry that is subject to intense competition, government regulation and rapid technological change. Operations are subject
to significant risk and uncertainties including financial, operational, technological, regulatory, and other risks, including
the potential risk of business failure.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The extent of the impact
and effects of the coronavirus (COVID-19) on the operation and financial performance of the Company&#x2019;s business will depend
on future developments, including the duration and spread of the outbreak, related travel advisories and restrictions, the recovery
time of disrupted research services, the consequential staff shortages, and research and development delays, or the uncertainty
with respect to the accessibility of additional liquidity or capital markets, all of which are highly uncertain and cannot be
predicted. If the Company&#x2019;s operations are impacted by this outbreak for an extended period, the Company&#x2019;s results
of operations or liquidity may be materially adversely affected.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Deferred Offering Costs</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Costs incurred related
to equity offerings are capitalized as deferred equity issuance costs in other non-current assets until the offering is completed
or abandoned. If the Company completes an offering, these costs will be offset against proceeds received; or if the offering does
not occur, they will be expensed. Offering costs include direct and incremental costs related to the offering such as legal fees
and related costs.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recorded
deferred offering costs of $101,205 and $191,000 as of December 31, 2020 and 2019, respectively. During the year ended December
31, 2020, the Company has applied deferred offering costs of $456,437 as a reduction to additional paid-in capital upon completion
of the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;) on June 15, 2020.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and Development</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development
costs are expensed as incurred. These expenses primarily consist of payroll, contractor expenses, research study expenses, costs
for manufacturing and supplies, and technical infrastructure on the cloud for the purposes of developing the Company&#x2019;s RADR
platform and identifying, developing, and testing drug candidates. Development costs incurred by third parties are expensed as
the work is performed. Costs to acquire technologies, including licenses, that are utilized in research and development and that
have no alternative future use are expensed when incurred.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cash and Cash Equivalents</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Highly liquid investments
with original maturities of three months or less when purchased are considered to be cash equivalents. Financial instruments which
potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains
cash and cash equivalents with high-credit quality financial institutions. At times, such amounts may exceed insured limits. The
Company has not experienced any losses in such accounts.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Prepaid Expenses and Other Current Assets</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prepaid expenses and
other current assets as of December 31, 2020 totaled approximately $1,008,000 and included approximately $187,000 of upfront payments
for contractor and academic research studies and services, approximately $15,000 of licensing and other fees, and approximately
$806,000 of prepaid annual insurance fees.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Loan Pursuant to Paycheck Protection
Program</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 1, 2020, the
Company received $108,500 in aggregate loan proceeds (the &#x201c;PPP Loan&#x201d;) from JPMorgan Chase Bank (the &#x201c;Lender&#x201d;)
pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The PPP Loan
is evidenced by a loan application and payment agreement (the &#x201c;PPP Loan Agreement&#x201d;) by and between the Company and
the Lender. This amount is recorded as a loan payable on the Company&#x2019;s consolidated balance sheet at December 31, 2020.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Income Taxes</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Deferred tax assets
and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities
using enacted tax rates which will be in effect when the differences reverse. The Company provides a full valuation allowance
against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset
will be realized.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock-based Compensation</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stock-based awards
have been accounted for as required by ASC 718 &#x201c;Compensation - Stock Compensation.&#x201d; Under ASC 718, awards are valued
at fair value on the date of grant, and that fair value is recognized over the requisite service period.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Reclassification</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain prior period information has been
reclassified to conform to the current period presentation.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092692572648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>New Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>Accounting Standards Update and Change in Accounting Principle [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 4. New Accounting Pronouncements
</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>New Accounting Pronouncements, Not
Yet Adopted</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Current Expected Credit Loss</i></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2016 the FASB
issued Accounting Standard Update (ASU) 2016-13, Measurement of Credit Losses on Financial Instruments (Topic 326). This introduces
new methodology for recognition of credit losses - the current expected credit loss (&#x201c;CECL&#x201d;) method. The CECL method
requires the recognition of all losses expected over the life of a financial instrument upon origination or purchase of the instrument,
unless the company elects to recognize such instruments at fair value with changes in profit and loss. CECL is effective for the
Company on January 1, 2023. The Company does not anticipate a material impact from the adoption of this new standard on its financial
statements.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Income Taxes</i></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2019,
the FASB issued ASU 2019-12: Income Taxes (Topic 740) &#x2013; Simplifying the Accounting for Income Taxes. This ASU simplifies
accounting for income taxes by removing the exception to the incremental approach for intraperiod tax allocation when there is
a loss from continuing operations and income or gain for other items, the exception to the requirement to recognize a deferred
tax liability for equity method investments when a foreign subsidiary becomes an equity method investment, the exception to the
ability not to recognize a deferred tax liability for a foreign subsidiary when a foreign equity method investment becomes a subsidiary,
and the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds
the anticipated loss for the year. This ASU also includes other requirements related to franchise tax, goodwill as part of a business
combination, consolidations, changes in tax laws, and affordable housing projects. ASU 2019-12 is effective for fiscal years beginning
after December 15, 2020, including interim periods within that fiscal year. Early adoption is permitted for periods in which financial
statements have not yet been issued. The Company does not anticipate a material impact from the adoption of this new standard
on its financial statements.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Recently Adopted Accounting Standards</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Leases </i></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2016 the
FASB issued ASU 2016-02: Leases. The ASU introduces a lessee model that results in most leases impacting the balance sheet. The
ASU addresses other concerns related to the current lease model. Under ASU 2016-02, lessees will be required to recognize for
all leases with terms longer than 12 months, at the commencement date of the lease, a lease liability, which is a lessee&#x2019;s
obligation to make lease payments arising from a lease measured on a discounted basis, and a right-to-use (ROU) asset, which is
an asset that represents the lessee&#x2019;s right to use or control the use of a specified asset for the lease term. Leases will
be classified as either finance or operating, with classification affecting the pattern of expense recognition.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2018, the
FASB issued ASU 2018-10 &#x201c;Codification Improvements to Topic 842, Leases.&#x201d; This ASU affects narrow aspects of the guidance
issued in the amendments in ASU 2016-02 including those regarding residual value guarantees, rate implicit in the lease, lessee
reassessment of lease classification, lessor reassessment of lease term and purchase option, variable lease payments that depend
on an index or a rate, investment tax credits, lease term and purchase option, transition guidance for amounts previously recognized
in business combinations, certain transition adjustments, transition guidance for leases previously classified as capital leases
under Topic 840, transition guidance for modifications to leases previously classified as direct financing or sales-type leases
under Topic 840, transition guidance for sale and leaseback transactions, impairment of net investment in the lease, unguaranteed
residual asset, effect of initial direct costs on rate implicit in the lease, and failed sale and leaseback transactions.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company adopted
ASC 2018-10 Topic 842 effective January 1, 2019 and elected the short-term lease recognition exemption for all leases that qualify.
For those leases that qualify, the Company will not recognize ROU assets or lease liabilities, and this includes not recognizing
ROU assets or lease liabilities for existing short-term leases of those assets in transition. This practical expedient was elected
to not separate lease and non-lease components for its office space leases. The adoption of this new standard did not have a material
impact on the Company&#x2019;s financial statements as the Company did not have any leases that have terms of longer than 12 months.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Compensation &#x2013; Stock Compensation</i></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2018, the
FASB issued ASU 2018-07: Compensation &#x2013; Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment
Accounting. This ASU expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services
from non-employees, and as a result, the accounting for share-based payments to non-employees will be substantially aligned. ASU
2018-07 is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early
adoption is permitted but no earlier than an entity&#x2019;s adoption date of Topic 606. The Company adopted ASU Topic 718 effective
January 1, 2019. The adoption of this new accounting guidance did not have a material impact on the Company&#x2019;s consolidated
financial statements and related footnote disclosures.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=SL108384541-122693<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=113356391&amp;loc=SL49131195-203048<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=112272810&amp;loc=d3e31137-122693<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092614356040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 5: Commitments and Contingencies</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>General.</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has entered
into, and expects to enter into from time to time in the future, license agreements, strategic alliance agreements, assignment
agreements, and similar agreements related to the advancement of its product candidates and research and development efforts (collectively,
&#x201c;License and Strategic Alliance Agreements&#x201d;). As of the date of filing this report on Form 10-K, the Company has obligations
relating to License and Strategic Alliance Agreements that are expected to result in total payments of approximately $600,000 for
2021.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>BioNumerik
Pharmaceuticals.</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
January 2018, the Company entered into an Assignment Agreement (the &#x201c;Assignment Agreement&#x201d;) with BioNumerik Pharmaceuticals,
Inc. (&#x201c;BioNumerik&#x201d;), pursuant to which the Company acquired rights to domestic and international patents, trademarks
and related technology and data relating to LP-300 (Tavocept) for human therapeutic treatment indications. The Assignment Agreement
replaced a License Agreement that was entered into between the Company and BioNumerik in May 2016. The Company made upfront payments
totaling $25,000 in connection with entry into the Assignment Agreement.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
the event the Company develops and commercializes LP-300 internally, the Company is required to pay to the BioNumerik-related
payment recipients designated in the Assignment Agreement a percentage royalty in the low double digits on cumulative net revenue
up to $100 million, with incremental increases in the percentage royalty for net cumulative revenue between $100 million and $250
million, $250 million and $500 million, and $500 million and $1 billion, with a percentage royalty payment that could exceed $200
million for net cumulative revenue in excess of $1 billion. The Company has the right to first recover certain designated portions
of patent costs and development and regulatory costs before the payment of royalties described above.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">If
the Company enters into a third party transaction for LP-300, the Company is required to pay the BioNumerik-related payment recipients
a specified percentage of any upfront, milestone, and royalty amounts received by the Company from the transaction, after first
recovering specified direct costs incurred by the Company for the development of LP-300 that are not otherwise reimbursed from
such third party transaction.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
addition, the Assignment Agreement provides that the Company will use commercially diligent efforts to develop LP-300 and make
specified regulatory filings and pay specified development and regulatory costs related to LP-300. The Assignment Agreement also
provides that the Company will provide TriviumVet DAC (&#x201c;TriviumVet&#x201d;) with (i) specified data and information generated
by the Company with respect to LP-300, and (ii) an exclusive license to use specified LP-300-related patent rights, trademark
rights and related intellectual property to support LP-300 development in non-human (animal) treatment indications.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">The
Company is also required to pay all patent costs on covered patents related to LP-300. Patent costs paid by the Company to BioNumerik
with respect to LP-300 related patents amounted to $0 and approximately $74,000 for the years ended December 31, 2020 and 2019,
respectively. These patent costs are included in general and administrative expenses in the accompanying consolidated statement
of operations. These patent costs are fully recoverable at the time of any net revenue from LP-300, with up to 50% of net revenue
amounts to be applied towards repayment of patent costs until such costs are fully recovered.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
addition to the recovery of patent costs, the Company has the right to recover the $25,000 upfront payments made in connection
with entry into the Assignment Agreement, which payments are recoverable prior to making any royalty or third party transaction
sharing payments. The Company also has the right to recover previously incurred LP-300 development and regulatory costs, with
up to a mid-single digit percentage of net revenue amounts to be applied towards repayment of development and regulatory costs
until such costs are fully recovered.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">No
amounts are owed to BioNumerik as of December 31, 2020. Approximately $11,000 is owed and recorded in accounts payable to BioNumerik
as of December 31, 2019.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>AF Chemicals.</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2015, the
Company entered into a Technology License Agreement to exclusively license domestic and international patent rights from AF Chemicals,
LLC (&#x201c;AF Chemicals&#x201d;) for the treatment of cancer in humans for the compounds LP-100 (Irofulven) and LP-184. In February
2016, the Company and AF Chemicals entered into an Addendum (the &#x201c;Addendum&#x201d;) providing for additions and amendments
to the Technology License Agreement. In December 2020, the Company and AF Chemicals entered into a Second Addendum (the &#x201c;Second
Addendum&#x201d;) providing for further additions and amendments to the Technology License Agreement. The Technology License Agreement,
Addendum and Second Addendum are collectively referred to as the &#x201c;AFC License Agreement&#x201d;.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Second Addendum
provides for us to make specified payments to AF Chemicals within 10 days after signing and by March 31, 2021. The Second Addendum
also provides that, from December 30, 2020 until January 15, 2025, we will have no obligation to pay annual licensing fees, development
diligence extension payments, or patent maintenance fee payments to AFC under the AFC License Agreement. Nothing was expensed
in the year ended December 31, 2020 relating to entering into the Second Addendum.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of the Second
Addendum, we have agreed to apply for specified orphan drug designations for LP-184 in the US and EU. The Second Addendum also
amends and clarifies other provisions of the Technology License Agreement, and provides us with the ability to recover a portion
of initial payments made under the Second Addendum from sublicense fees or royalty payments that may be made to AFC by us or third
parties prior to January 15, 2025.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the AFC
License Agreement the Company made annual licensing fee payments to AF Chemicals in the amount of $30,000 during each of the years
ended December 31, 2020 and 2019 relating to LP-184. Such amounts are included in research and development expenses in the accompanying
consolidated statement of operations. In addition, the Company is obligated to make milestone payments to AF Chemicals at the time
of an Investigational New Drug Application (&#x201c;IND&#x201d;) filing relating to LP-184 and also upon reaching additional specified
milestones in connection with the development and potential marketing approval of LP-184 in the United States, specified countries
in Europe, and other countries.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The AFC License Agreement
also provides that the Company will pay AF Chemicals a royalty of at least a very small single digit percentage of specified net
sales of LP-184 and other analogs. In addition, the AFC License Agreement contains specified time requirements for the Company
to file an IND, enroll patients in clinical trials, and file a potential NDA with respect to LP-184, with the ability for the
Company to pay AF Chemicals additional amounts ranging up to an amount in the low hundreds of thousands of dollars for each one,
two, three and four year extension to such development time requirements, with additional extensions beyond four years to be negotiated
by the Company and AF Chemicals. The Company paid $50,000 and $37,500 during the years ended December 31, 2020 and 2019, respectively
in connection with the extension of the IND filing milestone for LP-184, which amounts are included under research and development
in the accompanying consolidated statements of operations. Pursuant to the Second Addendum, no additional payments of annual licensing
fees or development diligence extension payments are required to be made by the Company until January 15, 2025, at which time
these obligations will resume. The Company will also be obligated to make annual licensing fee payments to AF Chemicals relating
to LP-100 beginning January 15, 2025, as described below under Allarity Therapeutics.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of a
sublicense of the LP-184 rights, the Company is obligated to pay AF Chemicals (a) a low double digit percentage of the gross income
and fees received by the Company with respect to the United States in connection with such sublicense, and (b) a lower double
digit percentage of the gross income and fees received by the Company with respect to Europe and Japan in connection with such
sublicense.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">No
amounts are payable to AF Chemicals as of December 31, 2020 and 2019.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Allarity Therapeutics (formerly
known as Oncology Venture)</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In May 2015, the Company
licensed various rights to LP-100 to Oncology Venture (now known as Allarity Therapeutics) pursuant to a Drug License and Development
Agreement. In February 2016, the Company and Allarity Therapeutics entered into an addendum and an amendment providing for additions
and amendments to the Drug License and Development Agreement. In connection with the Drug License and Development Agreement, as
amended (collectively, the &#x201c;Allarity License and Development Agreement&#x201d;), Allarity Therapeutics agreed to directly
pay to AF Chemicals on behalf of the Company certain amounts to satisfy the Company&#x2019;s milestone obligations to AF Chemicals
with respect to LP-100 under the AFC License Agreement. Amounts paid by Allarity Therapeutics to AF Chemicals on behalf of the
Company are then deducted from amounts owed by Allarity Therapeutics to the Company.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amounts to be paid
to AF Chemicals with respect to LP-100 under the AFC License Agreement are in many ways similar to the amounts to be paid with
respect to LP-184 as described above under &#x201c;AF Chemicals&#x201d;. In the event any such amounts relating to LP-100 are not
paid to AF Chemicals by Allarity Therapeutics, the Company is obligated to pay such unpaid amounts. In addition to the payments
to be made by Allarity Therapeutics, the Company is obligated to make annual licensing fee payments to AF Chemicals relating to
LP-100. The Company paid $30,000 to AF Chemicals during each of the years ended December 31, 2020 and 2019 relating to LP-100.
Such amounts are included in research and development expenses in the accompanying consolidated statement of operations.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the AFC
License Agreement contains specified time requirements for the Company to file an IND, enroll patients in clinical trials, and
file a potential NDA with respect to LP-100. During the year ended December 31, 2020, the Company paid AF Chemicals $25,000 relating
to a one-year milestone extension fee for LP-100 commencing in August 2020, approximately $10,000 of which was expensed during
the year ended December 31, 2020 and included under research and development expenses in the accompanying consolidated statements
of operations.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">No amounts are payable
under the Allarity License and Development Agreement as of December 31, 2020 and 2019.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>EU Grant</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2018,
Lantern Pharma Limited, a wholly owned subsidiary of Lantern Pharma Inc., was awarded a grant by the UK government in the form
of state aid under the Commission Regulations (EU) No. 651/2014 of 17 June 2014 (the &#x201c;General Block Exemption&#x201d;), Article
25 Aid for research and development projects, state aid notification no. SA.40154. The grant was awarded to conduct research and
development activities for the prostate cancer biomarker analysis of the LP-184&#xa0;drug candidate. Following the Company&#x2019;s
research and development activities in Northern Ireland, the grant will reimburse the Company 50% of its research and development
expenses not exceeding GBP 24,215 of vouched and approved expenditures within specific categories. The grant contains some reporting
and consent requirements. The grant will remain in force for a period of five years. No payments to the Company have been made
under the grant as of December 31, 2020 and December 31, 2019. No revenue has been recognized from this grant through December
31, 2020.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Patheon API Services</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2020, the
Company entered into an agreement with Patheon API Services, Inc. (&#x201c;Patheon&#x201d;) for the manufacture and supply of cGMP
material to support the Company&#x2019;s planned Phase II clinical trial for its product candidate LP-300. In addition to producing
LP-300 API (active pharmaceutical ingredient) under cGMP (current Good Manufacturing Practices) conditions, Patheon will transfer
previously validated manufacturing processes and analytical methods for LP-300 and will produce non-GMP material that can be used
to support non-clinical studies for LP-300. The agreement provides for payments in stages as specified process and manufacturing
milestones are achieved. Patheon, a part of Thermo Fisher Scientific, has previously developed and/or manufactured more than 700
pharmaceuticals for biopharma clients and has more than 55 locations around the world, providing access to a fully integrated
global network of facilities.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company paid approximately
$203,000 to Patheon during the twelve months ended December 31, 2020 pursuant to the Patheon agreement. Approximately $227,000
was expensed with respect to the Patheon agreement during the twelve months ended December 31, 2020, which relates to the services
received by the Company through December 31, 2020. This amount is included in research and development expenses in the accompanying
consolidated statements of operations. Approximately $24,000 relating to the Patheon agreement is included under accounts payable
and accrued expenses on the Company&#x2019;s consolidated balance sheet for the period ended December 31, 2020. The Company expects
to pay additional amounts to Patheon in future periods in accordance with specified process and manufacturing milestones under
the Patheon agreement.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b><i>Southwest Research Institute</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">As
part of the Company&#x2019;s research and development activities, the Company has engaged Southwest Research Institute (&#x201c;SwRI&#x201d;)
from time to time to assist with compound synthesis and manufacturing related activities for the Company&#x2019;s product candidates.
Approximately $71,000 and $234,000 was expensed with respect to SwRI during the twelve months ended December 31, 2020 and December
31, 2019, respectively. All of such expensed amounts are included in research and development expenses in the accompanying consolidated
statements of operations. Approximately $82,000 was payable to SwRI as of December 31, 2020, and approximately $13,000 was payable
to SwRI as of December 31, 2019. In September 2020, the Company entered into an agreement with SwRI for the non-GMP synthesis
of LP-184 material and related analytical development to assist with preclinical studies. Approximately $97,000 relating to the
SwRI agreement is included under prepaid expenses on the Company&#x2019;s consolidated balance sheet for the period ended December
31, 2020. There were no prepaid expenses relating to SwRI as of December 31, 2019. The Company expects to pay additional amounts
to SwRI in future periods as synthesis and analytical work is conducted by SwRI under the agreement.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>The Research
Institute of Fox Chase Cancer Center</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
September 2020, the Company entered into a research agreement with the Research Institute of Fox Chase Cancer Center (&#x201c;FCCC&#x201d;)
as part of the Company&#x2019;s research and development activities, with a focus on advancing the targeted use of LP-184 in molecularly-defined
sub-types of pancreatic cancer. Approximately $85,000 was expensed with respect to the FCCC agreement during the twelve months
ended December 31, 2020, which amount is included in research and development expenses in the accompanying consolidated statements
of operations. As of December 31, 2020, approximately $14,000 was recorded as accrued with respect to FCCC. The Company expects
to pay additional amounts to FCCC in future periods in accordance with the payment schedule specified under the FCCC agreement.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b><i>Other Research
and Service Provider Agreements</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">In
addition to the agreements described above, the Company has entered into other research and service provider agreements for the
advancement of its product candidates and research and development efforts. The Company expects to pay additional amounts in future
periods in connection with existing and future research and service provider agreements.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Operating Leases</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company leased
office space in Dallas, Texas under month-to-month lease arrangements during the years ended December 31, 2020 and 2019. In connection
with the Company&#x2019;s employees working remotely due to COVID-19, the Company in August 2020 reduced its monthly lease commitment
and costs to minimal levels. The Company is continuing to monitor the COVID-19 conditions and intends to increase its lease of
office space following an improvement in the COVID-19 pandemic.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2019, the
Company entered into a leasing agreement for office space in New Jersey. Monthly rent was $2,106, plus electrical utilities. The
lease expired on July 31, 2020 and was not renewed.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092614194328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Shareholders' Equity</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 6. Shareholders&#x2019; Equity</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Preferred Stock </b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31,
2019, the Company had 3,480,000 authorized shares of preferred stock, of which 2,438,866 shares designated as Series A Preferred
Stock (the &#x201c;Series A Preferred Stock&#x201d;) were issued and outstanding.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the Company&#x2019;s
IPO, all shares of the Company&#x2019;s Series A preferred stock were converted into 2,438,851 shares of common stock effective
June 15, 2020, with fractional share adjustments made in connection with the conversion as discussed below. As of December 31,
2020, the Company had 1,000,000 authorized shares of preferred stock, with zero shares of preferred stock issued and outstanding.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holders of Series
A Preferred Stock were entitled to receive dividends when, as and if declared by the Company&#x2019;s Board of Directors, payable
in preference and priority to any declaration or payment of dividends on Common Stock. No dividends on any Series A Preferred
Stock were declared and no dividends on Common Stock have been declared to date.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2019, the
Company sold 590,643 shares of Series A preferred stock for aggregate proceeds of approximately $1,850,000. The Company also issued
213,510 shares of Series A preferred stock in March 2019, in connection with the conversion of the Simple Agreement for Future
Equity (SAFE) agreements. See Note 7. In connection with the sale and issuance of the Series A preferred stock in March 2019,
the Company issued warrants to purchase an aggregate of 96,499 shares of Series A preferred stock at an initial exercise price
of $3.13 per share.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2019, the
Company sold 341,761 shares of Series A preferred stock for aggregate proceeds of approximately $1,070,000. In connection with
the issuance of the Series A preferred stock, the Company issued warrants to purchase an aggregate of 41,015 shares of Series
A preferred stock at an initial exercise price of $3.13 per share.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each share of Series
A Preferred Stock was convertible into one share of Common Stock, subject to adjustments for anti-dilution. In addition, the terms
of the Series A Preferred Stock provided that it would automatically convert into Common Stock upon the closing of an initial
public offering meeting certain specified conditions, and also that it would convert into Common Stock in the event holders of
at least 75% of the Series A Preferred Stock approved a mandatory conversion.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The holders of the
Series A Preferred Stock, exclusively and as a separate class, had the right to elect two directors of the Company, and two directors
of the Company were elected by the holders of Series A Preferred Stock in accordance with such provision. The Series A Preferred
Stock also had the right to vote together with holders of Common Stock on any matter presented to the shareholders of the Company
for their action or consideration. In addition, the separate approval of a majority of the Series A Preferred Stock was required
in connection with specified Company activities and transactions, including a merger or consolidation of the Company, and the
liquidation, dissolution or winding-up the business and affairs of the Company.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of a
voluntary or involuntary liquidation, dissolution or winding up of the Company or a deemed liquidation event, the terms of the
Series A Preferred Stock provided that holders of Series A Preferred Stock would be entitled to be paid, out of the assets of
the Company available for distribution, an amount equal to $3.13 per share, plus any dividends declared but unpaid thereon, before
any payment was made to the holders of Common Stock. The liquidation preference of the Series A Preferred Stock was approximately
$7,639,000 at December 31, 2019. The terms of the Series A Preferred Stock provided that, if upon any liquidation, dissolution
or winding up of the Company or deemed liquidation event, the assets of the Company available for distribution to its shareholders
should be insufficient to pay holders of Series A Preferred Stock the full amount to which they would otherwise be entitled, the
holders of Series A Preferred Stock would share ratably in any distribution of the assets available for distribution in proportion
to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all
amounts payable on or with respect to such shares were paid in full.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective January
15, 2020, as a result of the Company&#x2019;s reincorporation in the state of Delaware, the par value of the Company&#x2019;s preferred
stock was changed from $0.01 to $0.0001 per share, and all data on preferred stock was retroactively adjusted to be shown herein
as reflective of this change.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Common Stock</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 15, 2020,
the Company received net proceeds of $23,419,721 in its IPO, after deducting underwriting discounts and commissions of $1,968,750
and other offering expenses of $861,529 borne by the Company. The Company issued and sold 1,750,000 shares of common stock in
its IPO at a price of $15.00 per share. In connection with the IPO, all shares of the Company&#x2019;s Series A Preferred Stock
were converted into 2,438,851 shares of common stock, after giving effect to the 1.74 for 1 forward stock split of the common
stock and net of the fractional shares adjustments that occurred in connection with the IPO.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company made payments
of approximately $261 in the aggregate in connection with fractional shares resulting from the stock split and the conversion
of the preferred stock that took place in connection with the IPO.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
December 31, 2020, the Company issued 50,460 shares of common stock, relating to the exercise of stock options. The shares were
issued at a purchase price of $1.03 for total proceeds of $52,000.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the year ended
December 31, 2020, the Company issued 3,350 shares of common stock related to a cashless exercise of a warrant to purchase 4,022
shares.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31,
2020, the Company had 25,000,000 authorized shares of Common Stock, of which 6,220,927 shares were issued and outstanding. As
of December 31, 2019, the Company had 12,180,000 authorized shares of Common Stock, of which 1,978,269 shares were issued and
outstanding.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Options</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 29, 2018,
the Board of Directors of the Company adopted the Lantern Pharma Inc. 2018 Equity Incentive Plan, which was subsequently amended
on December 17, 2018 and February 26, 2020. The Lantern Pharma Inc. 2018 Equity Incentive Plan, as amended and restated, is referred
to herein as the &#x201c;Plan&#x201d;. The Company reserved 1,489,680 shares of its common stock for issuance under the Plan. The
Plan is designed to provide additional incentives to employees, directors and consultants to remain in the service of the Company
as well as to encourage stock acquisition by members of these targeted groups, which in the opinion of the management will support
the alignment of the interests of the members of these groups and stockholders. Options granted under the Plan are generally exercisable
for up to 10 years from grant date. 535,099 shares remain available for future awards under the Plan at December 31, 2020, following
the grant of options and the award of restricted stock grants through December 31, 2020. The Company recorded stock-based compensation
of approximately $1,192,000 and $118,000 related to stock options during the years ended December 31, 2020 and 2019, respectively.
Total remaining unrecognized compensation expense for non-vested options is $2,480,912 as of December 31, 2020, and is expected
to be recognized over a weighted average period of 1.3 years. The weighted average remaining contractual term of outstanding options
at December 31, 2020 is 8.5 years.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A summary of stock
option activity under the Plan during the years ended December 31, 2020 and 2019 is presented below:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#xa0;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options Outstanding</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&#xa0;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options Exercisable</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: justify">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number
    of<br/> Shares</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-Average<br/>
    Exercise Price</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number
    of<br/> Options</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-Average<br/>
    Exercise Price</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-size: 10pt; text-align: justify">Outstanding December 31, 2018</td><td style="width: 1%; font-size: 10pt">&#xa0;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#xa0;</td><td style="width: 9%; font-size: 10pt; text-align: right">629,060</td><td style="width: 1%; font-size: 10pt; text-align: left">&#xa0;</td><td style="width: 1%; font-size: 10pt">&#xa0;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 9%; font-size: 10pt; text-align: right">1.03</td><td style="width: 1%; font-size: 10pt; text-align: left">&#xa0;</td><td style="width: 1%; font-size: 10pt">&#xa0;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#xa0;</td><td style="width: 9%; font-size: 10pt; text-align: right">194,479</td><td style="width: 1%; font-size: 10pt; text-align: left">&#xa0;</td><td style="width: 1%; font-size: 10pt">&#xa0;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 9%; font-size: 10pt; text-align: right">1.03</td><td style="width: 1%; font-size: 10pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: justify">Granted</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">1,342</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">1.03</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify">Exercised</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: justify; padding-bottom: 1.5pt">Cancelled or expired</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(22,911</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">1.03</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt">-</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify">Outstanding December 31, 2019</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">607,491</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">1.03</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">393,413</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">1.03</td><td style="font-size: 10pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: justify">Granted</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">321,743</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">15.01</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify">Exercised</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">(50,460</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">1.03</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: justify">Cancelled or expired</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">(43,166</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">1.03</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify; padding-bottom: 4pt">Outstanding December 31, 2020</td><td style="font-size: 10pt; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">835,608</td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">6.41</td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">610,633</td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">3.24</td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For 2020 and 2019,
the fair value of each option granted was estimated using the Black-Scholes option-pricing model, using the following weighted
average assumptions:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Term (in years)</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">7.00</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">5.94</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Risk Free Rate</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="white-space: nowrap; text-align: right"><font style="font-size: 10pt">0.54% - 0.67&#xa0;</font></td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2.79</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Volatility</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right"><font style="font-size: 10pt">83.2% - 84.37%</font></td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">60.1</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Dividend Yield</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">0.0</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Grant Date Fair Value</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="white-space: nowrap; text-align: right"><font style="font-size: 10pt"></font><font style="font-size: 10pt">11.01 &#x2013; 11.28 </font></td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.59</td><td style="text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The fair value of
options is recognized as an expense over the vesting period and forfeitures are accounted for as they occur.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The total intrinsic
value of options outstanding at December 31, 2020 was $10,726,878, and the total intrinsic value of options exercisable at December
31, 2020 was $9,773,797. The total intrinsic value of options exercised during the year ended December 31, 2020 was $20,590. The
intrinsic value of options outstanding at December 31, 2019 was $0. No options were exercised during the year ended December 31,
2019.</p><br/><table cellpadding="0" cellspacing="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 20%; text-align: justify"><font style="font-size: 10pt">Expected Term -</font></td>
    <td style="width: 80%; text-align: justify"><font style="font-size: 10pt">The Company used a weighted average of time to vesting
    and maturity date.</font></td></tr>
<tr style="vertical-align: top">
    <td style="text-align: justify"><font style="font-size: 10pt">Expected Volatility-</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">Due to the Company&#x2019;s limited operating history and a lack
    of company-specific historical and implied volatility data, the Company has based its estimate of expected volatility on the
    historical volatility of a group of similar companies that are publicly traded commensurate with expected term as of grant
    date. The historical volatility data was computed using the daily closing prices for the selected comparable companies&#x2019;
    shares.</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Risk-Free Interest Rate-</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">The Company used the U.S. treasury bill rate commensurate with
    the expected term as of grant date.</font></td></tr>
<tr style="vertical-align: top">
    <td><font style="font-size: 10pt">Expected Dividend-</font></td>
    <td style="text-align: justify"><font style="font-size: 10pt">As the Company has not issued any dividends and does not expect
    to issue dividends over the life of the options, the Company has estimated the dividend yield to be zero.</font></td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Warrants</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company had warrants
to purchase 325,618 shares of common stock outstanding and exercisable as of December 31, 2020 at a weighted average exercise
price of $6.49 per share. The Company had warrants to purchase 262,003 shares of Series A Preferred Stock outstanding and exercisable
as of December 31, 2019 at a weighted average exercise price of $3.13 per share.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the Series A Preferred Stock financing transactions discussed above, in 2019 the Company issued warrants to purchase an aggregate
of 137,513 shares of Series A Preferred Stock.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the IPO and the conversion of the Series A Preferred Stock into common stock, all outstanding warrants to purchase Series A Preferred
Stock converted into warrants to purchase common stock.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with
the IPO, the Company granted the underwriters warrants (the &#x201c;Underwriters&#x2019; Warrants&#x201d;) to purchase an aggregate
of 70,000 shares of common stock at an exercise price of $18.75 per share, which is 125% of the initial public offering price.
The Underwriters&#x2019; Warrants have a five-year term and were not exercisable prior to December 7, 2020. All of the Underwriters&#x2019;
Warrants were outstanding at December 31, 2020.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2020, the Company
issued 3,350 shares of common stock related to a cashless exercise of a warrant to purchase 4,022 shares.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2019, warrants to
purchase an aggregate of 39,651 shares of Series A Preferred Stock were modified to become warrants to purchase an aggregate of
27,754 shares of Series A Preferred Stock. As part of the modification, the term of these warrants was extended from .02 to 1.02
years. The fair value of the modified warrants was approximately $21,000 and is recorded in additional paid in capital.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2020, a warrant
to purchase an aggregate of 23,734 shares of Common Stock was modified to become a warrant to purchase an aggregate of 21,360
shares of Common Stock. As part of the modification, the term of the warrant was extended from .003 to 1.003 years. The fair value
of the modified warrant was approximately $36,000 and is recorded in additional paid in capital.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092692602072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Safe Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_SafeAgreementsDisclosureAbstract', window );"><strong>Safe Agreements Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_SafeAgreementsDisclosureTextBlock', window );">SAFE Agreements</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Note 7. SAFE Agreements</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2018,
the Company entered into Simple Agreement for Future Equity (SAFE) agreements (the &#x201c;SAFE Financing&#x201d;) with five investors
pursuant to which the Company received funding of $535,000 in exchange for agreement to issue the investors shares of preferred
stock upon occurrence of a subsequent financing of preferred stock.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The number of shares
to be received by the SAFE agreement investors was based on 80% of the pricing in the triggering equity financing. In a liquidity
or dissolution event, the investors&#x2019; right to receive cash out was junior to payment of outstanding indebtedness and creditor
claims, on par for other SAFEs and preferred stock, and senior to common stock. The SAFE agreements had no interest rate or maturity
date, and the SAFE investors had no voting right prior to conversion.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31,
2018, the Company had received $535,000 of proceeds related to the SAFE agreements. The SAFE agreements had not yet converted
as a qualifying financing had not yet occurred as of December 31, 2018. Pursuant to the guidance under ASC 480, the Company determined
that the Purchase Amount (a term defined in the SAFE agreements denoting the amount in exchange for which an investor received
the rights to receive the shares) should be recorded as a liability on the Company&#x2019;s balance sheet. Due to a short period
where the Company expected these to be converted, the Company recorded the entire amount of $535,000 as a short-term liability.
The SAFE agreements were converted to equity in March 2019 and the Company issued 213,510 shares of Series A Preferred Stock in
full satisfaction of these agreements.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_SafeAgreementsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_SafeAgreementsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_SafeAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_SafeAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092614354904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes and Loan Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes and Loan Payable</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 8. Notes and Loan Payable</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2020, the
Company entered into a financing arrangement for commercial insurance with First Insurance Funding. The total amount financed
was approximately $66,000 with an annual interest rate of 6.64%, to be paid over a period of ten months. In June 2020, the insurance
policy was canceled, and the remaining loan balance was repaid. As of December 31, 2020, there is no remaining loan balance on
the Company&#x2019;s consolidated balance sheet related to the First Insurance financing arrangement.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 1, 2020 (the
&#x201c;Origination Date&#x201d;), the Company received $108,500 in aggregate loan proceeds (the &#x201c;PPP Loan&#x201d;) from JPMorgan
Chase Bank (the &#x201c;Lender&#x201d;) pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic
Security (CARES) Act. The PPP Loan is evidenced by a loan application and payment agreement (the &#x201c;PPP Loan Agreement&#x201d;)
by and between the Company and the Lender. Subject to the terms of the PPP Loan Agreement, the PPP Loan bears interest at a fixed
rate of one percent (1.0%) per annum. Payments of principal and interest are deferred for the first six months following the Origination
Date, and the PPP Loan will mature two years after the Origination Date. The guidance under the Paycheck Protection Program was
later updated so that deferral of payments of principal and interest were extended to ten months after completion of the covered
period of 24 weeks and maturity was extended past two years. The Company is continuing to monitor further development and guidance
related to the Paycheck Protection Program terms.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the deferral
period, unless the loan is forgiven, the Company will be required to make payments of principal plus interest accrued under the
PPP Loan to the Lender in monthly installments based upon an amortization schedule to be determined by the Lender based on the
principal balance of the PPP Loan outstanding following the deferral period and taking into consideration any portion of the PPP
Loan that may be forgiven prior to that time. The PPP Loan is unsecured and guaranteed by the U.S. Small Business Administration.
The Company plans to file for forgiveness under this loan within the first half of 2021.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During the twelve months
ended December 31, 2020, the Company received approximately $103,000 in funding resulting from a loan that was funded incorrectly.
All of the funds from the loan were repaid by the Company in July 2020, and no loan funds were expended prior to the repayment.
There are no amounts outstanding under this loan as of December 31, 2020.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092614395896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 9. Related Party Transactions</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has obtained
preclinical services from Biological Mimetics, Inc., which is also a stockholder in the Company. No expenses related to Biological
Mimetics, Inc. were recorded during the year ended December 31, 2020 and nothing was owed to Biological Mimetics, Inc. at December
31, 2020. The Company recorded expenses of approximately $23,000 related to Biological Mimetics, Inc. during the year ended December
31, 2019, all of which is included in research and development. Approximately $2,000 was owed to Biological Mimetics, Inc. at December
31, 2019.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company has previously
engaged Intuition Systems (&#x201c;Intuition&#x201d;) to provide services relating to development of the Company&#x2019;s technology
infrastructure and artificial intelligence platform, cloud computing, and computational biology. The chief executive officer of
Intuition is the brother of Arun Asaithambi, the Company&#x2019;s former Chief Executive Officer, President and Director. Nothing
was expensed related to Intuition during the years ended December 31, 2020 and 2019. At December 31, 2020 and 2019, approximately
$9,000 remained unpaid relating to Intuition and is included in accounts payable and accrued expenses in the accompanying consolidated
balance sheet.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2018, the
Company entered into an Assignment Agreement (the &#x201c;Assignment Agreement&#x201d;) with BioNumerik Pharmaceuticals, Inc. (&#x201c;BioNumerik&#x201d;),
pursuant to which the Company acquired rights to domestic and international patents, trademarks and related technology and data
relating to LP-300 for human therapeutic treatment indications. Mr. Margrave, the Company&#x2019;s Chief Financial Officer and Secretary,
formerly served as the President, Chief Administrative Officer, General Counsel and Secretary of BioNumerik and has a minority
ownership interest in BioNumerik. Nothing was expensed related to BioNumerik during the year ended December 31, 2020. The Company
expensed less than $1,000 related to BioNumerik during the year ended December 31, 2019, which amount is included in general and
administrative expenses in the accompanying consolidated statement of operations. No amounts are owed to BioNumerik as of December
31, 2020. Approximately $11,000 was owed and recorded in accounts payable to BioNumerik as of December 31, 2019.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092692537384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share of Common Shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Loss Per Share of Common Shares</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 10. Loss Per Share of Common Shares</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Basic loss per share
is derived by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding
during each period. Diluted loss per share includes the effect, if any, from the potential exercise or conversion of securities,
such as warrants, and stock options, which would result in the issuance of incremental shares of common stock unless such effect
is anti-dilutive. In calculating the basic and diluted net loss per share applicable to common stockholders, the weighted average
number of shares remained the same for both calculations due to the fact that when a net loss exists, dilutive shares are not
included in the calculation. Potentially dilutive securities outstanding that have been excluded from diluted loss per share due
to being anti-dilutive include the following:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt; text-align: justify">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended <br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt; text-align: justify">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Warrants</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">325,618</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">262,003</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Stock options</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">835,608</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">607,491</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Series A preferred stock</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,438,866</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="font-size: 12pt; text-align: justify; padding-bottom: 4pt">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">1,161,226</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">3,308,360</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092699472936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 11. Income Taxes</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our effective tax rate
differs from the statutory federal tax rate as presented in the following table:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">U.S. federal statutory tax rate</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Permanent differences</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(1</td><td style="text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Valuation allowance</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(22</td><td style="text-align: left">)%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(20</td><td style="text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left">%</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31,
2020 and 2019, the Company was domiciled in Texas, and due to the losses generated and no revenues, it incurred no federal or state
tax.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The tax effect of the
temporary differences that give rise to the significant portions of the deferred tax assets and liabilities is presented below.</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">Deferred tax assets</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-left: 9pt">Depreciation</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">502</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Research and development credits</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">180,889</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">93,102</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Stock-based compensation</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">257,941</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">24,695</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Net operating loss carryforwards</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,417,169</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,366,040</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Deferred tax asset</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,855,999</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,484,340</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,849,762</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,484,340</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Net deferred tax asset</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6,237</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Deferred tax liabilities</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Fixed assets</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,237</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Net deferred tax assets</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Due to a history
of losses we have generated since inception, we believe it is more-likely-than-not that all of the deferred tax assets will
not be realized as of December 31, 2020 and 2019. Therefore, we have recorded a full valuation allowance on our deferred tax
assets. At December 31, 2020 and 2019, we have net operating loss (&#x201c;NOL&#x201d;) carryforwards for federal income tax
purposes of approximately $11.5 million and $6.5 million, respectively. The NOL carryforwards generated prior to 2018 of
approximately $3.1 million could expire over time beginning in 2035, if not used. The NOL carryforwards generated in 2018 to
2020 of $8.4 million do not expire and are carried forward indefinitely. We also have state NOLs of approximately $71,000 at
December 31, 2020. The Company also has approximately $181,000 of research and development tax credit carryforwards for
federal purposes. These credits begin expiring in 2034. Due to the change in ownership provisions of the Internal Revenue
Code, the availability of the Company&#x2019;s NOL carryforwards and research and development credit carryforwards may be
subject to annual limitations under Section 382 of the Internal Revenue Code against taxable income in the future period,
which could substantially limit the eventual utilization of such carryforwards.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Entities are also required
to evaluate, measure, recognize and disclose any uncertain income tax provisions taken on their income tax returns. The Company
has analyzed its tax positions and has concluded that as of December 31, 2020, there were no uncertain positions. In addition,
interest and penalties, if any, as they relate to income taxes assessed, are included in the income tax provision, for which there
were none. The Company&#x2019;s U.S. federal operating losses have occurred since its inception and as such, tax years subject to
potential tax examination could apply from that date because the utilization of net operating losses from prior years opens the
relevant year to audit by the IRS and/or state taxing authorities.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092614198072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Note 12. Subsequent Events</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 20, 2021,
the Company closed a public offering of 4,928,571 shares of its common stock at a public offering price of $14.00 per share, which
amount included 642,856 shares sold upon full exercise of the underwriter&#x2019;s over-allotment option. Total gross proceeds from
the offering were $68,999,994, and net proceeds from the offering were approximately $64,200,000.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092611056888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates and Assumptions</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates and Assumptions</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of
financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. The significant areas of estimation include determining
deferred tax asset valuation allowance and the inputs in determining the fair value of equity-based awards and warrants issued.
Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Risks and Uncertainties</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Risks and Uncertainties</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company operates
in an industry that is subject to intense competition, government regulation and rapid technological change. Operations are subject
to significant risk and uncertainties including financial, operational, technological, regulatory, and other risks, including
the potential risk of business failure.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The extent of the impact
and effects of the coronavirus (COVID-19) on the operation and financial performance of the Company&#x2019;s business will depend
on future developments, including the duration and spread of the outbreak, related travel advisories and restrictions, the recovery
time of disrupted research services, the consequential staff shortages, and research and development delays, or the uncertainty
with respect to the accessibility of additional liquidity or capital markets, all of which are highly uncertain and cannot be
predicted. If the Company&#x2019;s operations are impacted by this outbreak for an extended period, the Company&#x2019;s results
of operations or liquidity may be materially adversely affected.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Deferred Offering Costs</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Costs incurred related
to equity offerings are capitalized as deferred equity issuance costs in other non-current assets until the offering is completed
or abandoned. If the Company completes an offering, these costs will be offset against proceeds received; or if the offering does
not occur, they will be expensed. Offering costs include direct and incremental costs related to the offering such as legal fees
and related costs.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company recorded
deferred offering costs of $101,205 and $191,000 as of December 31, 2020 and 2019, respectively. During the year ended December
31, 2020, the Company has applied deferred offering costs of $456,437 as a reduction to additional paid-in capital upon completion
of the Company&#x2019;s initial public offering (&#x201c;IPO&#x201d;) on June 15, 2020.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Research and Development</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development
costs are expensed as incurred. These expenses primarily consist of payroll, contractor expenses, research study expenses, costs
for manufacturing and supplies, and technical infrastructure on the cloud for the purposes of developing the Company&#x2019;s RADR
platform and identifying, developing, and testing drug candidates. Development costs incurred by third parties are expensed as
the work is performed. Costs to acquire technologies, including licenses, that are utilized in research and development and that
have no alternative future use are expensed when incurred.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Cash and Cash Equivalents</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Highly liquid investments
with original maturities of three months or less when purchased are considered to be cash equivalents. Financial instruments which
potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains
cash and cash equivalents with high-credit quality financial institutions. At times, such amounts may exceed insured limits. The
Company has not experienced any losses in such accounts.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Prepaid Expenses and Other Current Assets</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prepaid expenses and
other current assets as of December 31, 2020 totaled approximately $1,008,000 and included approximately $187,000 of upfront payments
for contractor and academic research studies and services, approximately $15,000 of licensing and other fees, and approximately
$806,000 of prepaid annual insurance fees.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_LoanPursuantToPaycheckProtectionProgramTextBlock', window );">Loan Pursuant to Paycheck Protection Program</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Loan Pursuant to Paycheck Protection
Program</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 1, 2020, the
Company received $108,500 in aggregate loan proceeds (the &#x201c;PPP Loan&#x201d;) from JPMorgan Chase Bank (the &#x201c;Lender&#x201d;)
pursuant to the Paycheck Protection Program under the Coronavirus Aid, Relief, and Economic Security (CARES) Act. The PPP Loan
is evidenced by a loan application and payment agreement (the &#x201c;PPP Loan Agreement&#x201d;) by and between the Company and
the Lender. This amount is recorded as a loan payable on the Company&#x2019;s consolidated balance sheet at December 31, 2020.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Income Taxes</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Deferred tax assets
and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities
using enacted tax rates which will be in effect when the differences reverse. The Company provides a full valuation allowance
against net deferred tax assets unless, based upon the available evidence, it is more likely than not that the deferred tax asset
will be realized.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Stock-based Compensation</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Stock-based awards
have been accounted for as required by ASC 718 &#x201c;Compensation - Stock Compensation.&#x201d; Under ASC 718, awards are valued
at fair value on the date of grant, and that fair value is recognized over the requisite service period.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Reclassification</b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain prior period information has been
reclassified to conform to the current period presentation.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_LoanPursuantToPaycheckProtectionProgramTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_LoanPursuantToPaycheckProtectionProgramTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire policy of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_PrepaidExpensesAndOtherCurrentAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6359566&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092692597624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 12pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#xa0;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options Outstanding</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&#xa0;</td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options Exercisable</td><td style="padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: justify">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number
    of<br/> Shares</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-Average<br/>
    Exercise Price</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number
    of<br/> Options</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&#xa0;</td><td style="white-space: nowrap; font-size: 10pt; font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="white-space: nowrap; font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-Average<br/>
    Exercise Price</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-size: 10pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; font-size: 10pt; text-align: justify">Outstanding December 31, 2018</td><td style="width: 1%; font-size: 10pt">&#xa0;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#xa0;</td><td style="width: 9%; font-size: 10pt; text-align: right">629,060</td><td style="width: 1%; font-size: 10pt; text-align: left">&#xa0;</td><td style="width: 1%; font-size: 10pt">&#xa0;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 9%; font-size: 10pt; text-align: right">1.03</td><td style="width: 1%; font-size: 10pt; text-align: left">&#xa0;</td><td style="width: 1%; font-size: 10pt">&#xa0;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">&#xa0;</td><td style="width: 9%; font-size: 10pt; text-align: right">194,479</td><td style="width: 1%; font-size: 10pt; text-align: left">&#xa0;</td><td style="width: 1%; font-size: 10pt">&#xa0;</td>
    <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 9%; font-size: 10pt; text-align: right">1.03</td><td style="width: 1%; font-size: 10pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: justify">Granted</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">1,342</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">1.03</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify">Exercised</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: justify; padding-bottom: 1.5pt">Cancelled or expired</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">(22,911</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">1.03</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#xa0;</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt">-</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify">Outstanding December 31, 2019</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">607,491</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">1.03</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">393,413</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">1.03</td><td style="font-size: 10pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: justify">Granted</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">321,743</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">15.01</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify">Exercised</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">(50,460</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">1.03</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="font-size: 10pt; text-align: justify">Cancelled or expired</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">(43,166</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">$</td><td style="font-size: 10pt; text-align: right">1.03</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt">&#xa0;</td>
    <td style="font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-size: 10pt; text-align: justify; padding-bottom: 4pt">Outstanding December 31, 2020</td><td style="font-size: 10pt; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">835,608</td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">6.41</td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">610,633</td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">&#xa0;</td><td style="font-size: 10pt; padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: left">$</td><td style="border-bottom: Black 4pt double; font-size: 10pt; text-align: right">3.24</td><td style="padding-bottom: 4pt; font-size: 10pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of weighted average assumptions</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Term (in years)</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">7.00</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">5.94</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Risk Free Rate</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="white-space: nowrap; text-align: right"><font style="font-size: 10pt">0.54% - 0.67&#xa0;</font></td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2.79</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Volatility</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right"><font style="font-size: 10pt">83.2% - 84.37%</font></td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">60.1</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Dividend Yield</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">0.0</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">0.0</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Grant Date Fair Value</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="white-space: nowrap; text-align: right"><font style="font-size: 10pt"></font><font style="font-size: 10pt">11.01 &#x2013; 11.28 </font></td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.59</td><td style="text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092692543384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share of Common Shares (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of diluted loss per share due to being anti-dilutive</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt; text-align: justify">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the year ended <br/> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="font-size: 12pt; text-align: justify">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Warrants</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">325,618</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">262,003</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Stock options</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">835,608</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">607,491</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Series A preferred stock</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,438,866</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="font-size: 12pt; text-align: justify; padding-bottom: 4pt">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">1,161,226</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">3,308,360</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092617930264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective tax rate differs from the statutory federal tax rate as presented</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">U.S. federal statutory tax rate</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">21</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Permanent differences</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(1</td><td style="text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Valuation allowance</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(22</td><td style="text-align: left">)%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(20</td><td style="text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Total:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right"><font style="font-size: 10pt">-</font></td><td style="text-align: left">%</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Effect of the temporary differences that give rise to the significant portions of the deferred tax assets and liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: right; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: justify">Deferred tax assets</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: right">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify; padding-left: 9pt">Depreciation</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">502</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Research and development credits</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">180,889</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">93,102</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Stock-based compensation</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">257,941</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">24,695</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Net operating loss carryforwards</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,417,169</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,366,040</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Deferred tax asset</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,855,999</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,484,340</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Less: valuation allowance</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,849,762</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,484,340</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Net deferred tax asset</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6,237</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Deferred tax liabilities</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Fixed assets</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(6,237</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Net deferred tax assets</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092619260472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization, Principal Activities, and Basis of Presentation (Details)<br></strong></div></th>
<th class="th">
<div>Jan. 15, 2020 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems', window );"><strong>Organization, Principal Activities, and Basis of Presentation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Series A preferred stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems', window );"><strong>Organization, Principal Activities, and Basis of Presentation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Series A preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_OrganizationPrincipalActivitiesandBasisofPresentationDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092612728472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 20, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_LiquidityDetailsLineItems', window );"><strong>Liquidity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,908,000<span></span>
</td>
<td class="nump">$ 2,428,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_WorkingCapital', window );">Working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,685,000<span></span>
</td>
<td class="nump">$ 744,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_NetProceed', window );">Net proceed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Public offering price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_LiquidityDetailsLineItems', window );"><strong>Liquidity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_NetProceed', window );">Net proceed</a></td>
<td class="nump">$ 64,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering', window );">Public offering shares (in Shares)</a></td>
<td class="nump">4,928,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Public offering price (in Dollars per share)</a></td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_TotalGrossProceeds', window );">Total gross proceeds</a></td>
<td class="nump">$ 68,999,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_LiquidityDetailsLineItems', window );"><strong>Liquidity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering', window );">Public offering shares (in Shares)</a></td>
<td class="nump">642,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_LiquidityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_LiquidityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_NetProceed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_NetProceed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_TotalGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_TotalGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_WorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_WorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of units sold in a public offering of each class of partners' capital account. Units represent shares of ownership of the general, limited, and preferred partners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 4.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187171-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PartnersCapitalAccountUnitsSoldInPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092610949912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 01, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,205<span></span>
</td>
<td class="nump">$ 191,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent', window );">Prepaid expense and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,008,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_UpfrontContractorFees', window );">Contract fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">187,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_PatentLicenseFees', window );">Licensing and other fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_UndepositedFunds', window );">Prepaid annual insurance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">806,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLoans', window );">Aggregate loan proceeds</a></td>
<td class="nump">$ 108,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 456,437<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_PatentLicenseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patent license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_PatentLicenseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_SummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_UndepositedFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents uneposited funds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_UndepositedFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_UpfrontContractorFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount represents upfron contractor fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_UpfrontContractorFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLoans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from principal payments made on loans related to operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLoans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092607365848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_UpfrontPayments', window );">Upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_GrantedPeriod', window );">Granted period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ProductCandidates', window );">Product candidates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,000<span></span>
</td>
<td class="nump">$ 234,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedPatentsGross', window );">Related patents costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">74,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_NetRevenuePercentage', window );">Net revenue, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForOtherOperatingActivities', window );">Total Payments</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ltrn_AFChemicalsMember', window );">AF Chemicals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Commitments and contingencies, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the ability for the Company to pay AF Chemicals additional amounts ranging up to an amount in the low hundreds of thousands of dollars for each one, two, three and four year extension to such development time requirements, with additional extensions beyond four years to be negotiated by the Company and AF Chemicals. The Company paid $50,000 and $37,500 during the years ended December 31, 2020 and 2019, respectively in connection with the extension of the IND filing milestone for LP-184, which amounts are included under research and development in the accompanying consolidated statements of operations.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_MilestoneExtensionPaid', window );">Milestone extension paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ltrn_LP100Member', window );">LP-100 [Member] | AF Chemicals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ltrn_EUGrantMember', window );">EU Grant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ResearchAndDevelopmentExpensesPercentage', window );">Research and development expenses percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ltrn_PatheonAPIServicesMember', window );">Patheon API Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ManufacturingAgreementDescription', window );">Manufacturing agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company paid approximately $203,000 to Patheon during the twelve months ended December 31, 2020 pursuant to the Patheon agreement. Approximately $227,000 was expensed with respect to the Patheon agreement during the twelve months ended December 31, 2020, which relates to the services received by the Company through December 31, 2020. This amount is included in research and development expenses in the accompanying consolidated statements of operations. Approximately $24,000 relating to the Patheon agreement is included under accounts payable and accrued expenses on the Company&#x2019;s consolidated balance sheet for the period ended December 31, 2020. The Company expects to pay additional amounts to Patheon in future periods in accordance with specified process and manufacturing milestones under the Patheon agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=ltrn_SouthwestResearchInstituteMember', window );">Southwest Research Institute [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,000<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_PropertySubjectToOperatingLeaseMember', window );">Operating Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDescription', window );">Lease term, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company entered into a leasing agreement for office space in New Jersey. Monthly rent was $2,106, plus electrical utilities. The lease expired on July 31, 2020 and was not renewed.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ltrn_AFChemicalsMember', window );">AF Chemicals [Member] | LP-184 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_Annualfees', window );">Annual fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ltrn_BioNumerikPharmaceuticalMember', window );">BioNumerik Pharmaceutical [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CommitmentsandContingenciesDetailsLineItems', window );"><strong>Commitments and Contingencies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_UpfrontPayments', window );">Upfront payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsDescription', window );">Commitments and contingencies, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In the event the Company develops and commercializes LP-300 internally, the Company is required to pay to the BioNumerik-related payment recipients designated in the Assignment Agreement a percentage royalty in the low double digits on cumulative net revenue up to $100 million, with incremental increases in the percentage royalty for net cumulative revenue between $100 million and $250 million, $250 million and $500 million, and $500 million and $1 billion, with a percentage royalty payment that could exceed $200 million for net cumulative revenue in excess of $1 billion.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent', window );">Amounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_Annualfees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_Annualfees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_CommitmentsandContingenciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_CommitmentsandContingenciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_GrantedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Granted period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_GrantedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_ManufacturingAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_ManufacturingAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_MilestoneExtensionPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_MilestoneExtensionPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_NetRevenuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of net revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_NetRevenuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_ProductCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product candidates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_ProductCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_ResearchAndDevelopmentExpensesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expenses percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_ResearchAndDevelopmentExpensesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_UpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_UpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedPatentsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross carrying amount before accumulated amortization as of the balance sheet date of the costs pertaining to the exclusive legal rights granted to the owner of the patent to exploit an invention or a process for a period of time specified by law. Such costs may have been expended to directly apply and receive patent rights, or to acquire such rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedPatentsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of lessee's operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the nature and terms of commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForOtherOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for operating activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForOtherOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date within one year where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ltrn_AFChemicalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ltrn_AFChemicalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ltrn_LP100Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ltrn_LP100Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ltrn_AFChemicalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ltrn_AFChemicalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ltrn_EUGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ltrn_EUGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ltrn_PatheonAPIServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ltrn_PatheonAPIServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=ltrn_SouthwestResearchInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=ltrn_SouthwestResearchInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_PropertySubjectToOperatingLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_PropertySubjectToOperatingLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ltrn_AFChemicalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ltrn_AFChemicalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ltrn_LP184Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ltrn_LP184Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ltrn_BioNumerikPharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ltrn_BioNumerikPharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092605282760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 15, 2020</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Aug. 29, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 15, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CommonStockTotalProceedsValue', window );">Total proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">12,180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,220,927<span></span>
</td>
<td class="nump">1,978,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,220,927<span></span>
</td>
<td class="nump">1,978,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Total intrinsic value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,590<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of shares</a></td>
<td class="nump">1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_WarrantsToPurchaseShares', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CommonStockTotalProceedsValue', window );">Total proceeds (in Dollars)</a></td>
<td class="nump">$ 23,419,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherUnderwritingExpense', window );">Underwriting discounts and commissions (in Dollars)</a></td>
<td class="nump">1,968,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_OtherOfferingExpenses', window );">Other offering expenses (in Dollars)</a></td>
<td class="nump">$ 861,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Price per share (in Dollars per share)</a></td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_WarrantsToPurchasePercentage', window );">Warrants to purchase percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ltrn_OptionsMember', window );">Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CommonStockForIssuanceReservedShares', window );">Common stock for issuance reserved, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,489,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTerm', window );">Options term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_SharesRemainAvailableForFutureAwards', window );">Shares remain available for future awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">535,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Stock based Compensation (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,192,000<span></span>
</td>
<td class="nump">$ 118,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognized weighted average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 109 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Total intrinsic value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,726,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value, exercisable (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,773,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend', window );">Expected dividend (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued relating to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_WarrantsToPurchaseShares', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,618<span></span>
</td>
<td class="nump">262,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.49<span></span>
</td>
<td class="nump">$ 3.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_PurchaseOfWarrantsShares', window );">Purchase of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAdditionalCapital', window );">Additional paid in capital (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_WarrantTerm', window );">Warrant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">003 to 1.003 years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ClassOfWarrantTerm', window );">Warrants term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">3,480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">213,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,438,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,438,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted into shares of common stock</a></td>
<td class="nump">2,438,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">341,761<span></span>
</td>
<td class="nump">590,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,070,000<span></span>
</td>
<td class="nump">$ 1,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_WarrantsToPurchaseShares', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,015<span></span>
</td>
<td class="nump">96,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.13<span></span>
</td>
<td class="nump">$ 3.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_CommonStockPercentage', window );">Common stock, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Liquidation preference amount (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,639,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplit', window );">Stockholders' equity stock split, description</a></td>
<td class="text">In connection with the IPO, all shares of the Company&#x2019;s Series A Preferred Stock were converted into 2,438,851 shares of common stock, after giving effect to the 1.74 for 1 forward stock split of the common stock and net of the fractional shares adjustments that occurred in connection with the IPO.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Aggregate of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Converted into shares of common stock</a></td>
<td class="nump">2,438,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_WarrantsToPurchaseShares', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_WarrantsToPurchaseShares', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Common stock issued relating to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRight', window );">Purchase of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="nump">12,180,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,220,927<span></span>
</td>
<td class="nump">1,978,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,220,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,480,912<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_WarrantsToPurchaseShares', window );">Warrants to purchase shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_ClassOfWarrantTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_ClassOfWarrantTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_CommonStockForIssuanceReservedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock for issuance reserved, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_CommonStockForIssuanceReservedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_CommonStockPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_CommonStockPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_CommonStockTotalProceedsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_CommonStockTotalProceedsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_OtherOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_OtherOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_PurchaseOfWarrantsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase of warrants, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_PurchaseOfWarrantsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_ShareholdersEquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_ShareholdersEquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_SharesRemainAvailableForFutureAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares remain available for future awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_SharesRemainAvailableForFutureAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_WarrantTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_WarrantTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_WarrantsToPurchasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_WarrantsToPurchasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_WarrantsToPurchaseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants to purchase shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_WarrantsToPurchaseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAdditionalCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of additional paid-in capital (APIC) classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 5.T)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868742-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAdditionalCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherUnderwritingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred during the period, such as those relating to general administration and policy maintenance that do not vary with and are not primarily related to the acquisition or renewal of insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 720<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=35755714&amp;loc=d3e28434-158551<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherUnderwritingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the stock split arrangement. Also provide the retroactive effect given by a stock split that occurs after the balance date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ltrn_OptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ltrn_OptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092610617416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - Schedule of stock option activity - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ScheduleOfStockOptionActivityAbstract', window );"><strong>Schedule of stock option activity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Beginning Balance (in Shares)</a></td>
<td class="nump">607,491<span></span>
</td>
<td class="nump">629,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Number of Options, Weighted-Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 1.03<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber', window );">Number of Options Exercisable, Beginning Balance (in Shares)</a></td>
<td class="nump">393,413<span></span>
</td>
<td class="nump">194,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice', window );">Number of Options Exercisable, Weighted-Average Exercise Price, Beginning Balance</a></td>
<td class="nump">$ 1.03<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options Outstanding, Granted (in Shares)</a></td>
<td class="nump">321,743<span></span>
</td>
<td class="nump">1,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Number of Options, Weighted-Average Exercise Price, Granted</a></td>
<td class="nump">$ 15.01<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross', window );">Number of Options Exercisable, Granted (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageExercisePrice', window );">Number of Options Exercisable, Weighted-Average Exercise Price, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_StockIssuedDuringPeriodSharesOutstandingExcercised', window );">Number of Options Outstanding, Exercised (in Shares)</a></td>
<td class="num">(50,460)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Number of Options, Weighted-Average Exercise Price, Exercised</a></td>
<td class="nump">$ 1.03<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_StockIssuedDuringPeriodSharesStockOptionExercised', window );">Number of Options Exercisable, Exercised (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExercisesInPeriodWeightedAverageExercisePrice', window );">Number of Options Exercisable, Weighted-Average Exercise Price, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Number of Options Outstanding, Cancelled or expired (in Shares)</a></td>
<td class="num">(43,166)<span></span>
</td>
<td class="num">(22,911)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Number of Options, Weighted-Average Exercise Price, Cancelled or expired</a></td>
<td class="nump">$ 1.03<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiratiosInPeriod', window );">Number of Options Exercisable, Cancelled or expired (in Shares)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationInPeriodWeightedAverageExercisePrice', window );">Number of Options Exercisable, Weighted-Average Exercise Price, Cancelled or expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options Outstanding, Ending Balance (in Shares)</a></td>
<td class="nump">835,608<span></span>
</td>
<td class="nump">607,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Number of Options, Weighted-Average Exercise Price, Ending Balance</a></td>
<td class="nump">$ 6.41<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber', window );">Number of Options Exercisable, Ending Balance (in Shares)</a></td>
<td class="nump">610,633<span></span>
</td>
<td class="nump">393,413<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice', window );">Number of Options Exercisable, Weighted-Average Exercise Price, Ending Balance</a></td>
<td class="nump">$ 3.24<span></span>
</td>
<td class="nump">$ 1.03<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_ScheduleOfStockOptionActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_ScheduleOfStockOptionActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiratiosInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiratiosInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_StockIssuedDuringPeriodSharesOutstandingExcercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, excercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_StockIssuedDuringPeriodSharesOutstandingExcercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_StockIssuedDuringPeriodSharesStockOptionExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_StockIssuedDuringPeriodSharesStockOptionExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092610890968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - Schedule of weighted average assumptions - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareholdersEquityDetailsScheduleofweightedaverageassumptionsLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of weighted average assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Term (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">5 years 343 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.79%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant Date Fair Value (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.59<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareholdersEquityDetailsScheduleofweightedaverageassumptionsLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of weighted average assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Rate</a></td>
<td class="nump">0.54%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">83.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant Date Fair Value (in Dollars per share)</a></td>
<td class="nump">$ 11.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ShareholdersEquityDetailsScheduleofweightedaverageassumptionsLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of weighted average assumptions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk Free Rate</a></td>
<td class="nump">0.67%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">84.37%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant Date Fair Value (in Dollars per share)</a></td>
<td class="nump">$ 11.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_ShareholdersEquityDetailsScheduleofweightedaverageassumptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_ShareholdersEquityDetailsScheduleofweightedaverageassumptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092691488328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Safe Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_SafeAgreementsDetailsLineItems', window );"><strong>Safe Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_AgreementDescription', window );">Agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company entered into Simple Agreement for Future Equity (SAFE) agreements (the &#x201c;SAFE Financing&#x201d;) with five investors pursuant to which the Company received funding of $535,000 in exchange for agreement to issue the investors shares of preferred stock upon occurrence of a subsequent financing of preferred stock.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentOwnedPercentOfNetAssets', window );">Triggering equity financing, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_NetProceeds', window );">Net proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 535,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeasePayments', window );">Short-term liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 535,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_SafeAgreementsDetailsLineItems', window );"><strong>Safe Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Series A Preferred Stock, shares issued (in Shares)</a></td>
<td class="nump">213,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_AgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_AgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_NetProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_NetProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_SafeAgreementsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_SafeAgreementsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedPercentOfNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percent of net assets at close of period. For schedules of investments that are categorized, each category has a percent of net assets for the aggregated value of the Investments in the category.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column D))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401592&amp;loc=d3e611197-123010<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99383244&amp;loc=d3e12121-115841<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedPercentOfNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for short-term lease payment excluded from lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092619476328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes and Loan Payable (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 01, 2020</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Description of maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The total amount financed was approximately $66,000 with an annual interest rate of 6.64%, to be paid over a period of ten months.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAnnualPrincipalPayment', window );">Annual amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.64%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLoanOriginations1', window );">Aggregate loan amount</a></td>
<td class="nump">$ 108,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescription', window );">Description of notes payable and loan payable</a></td>
<td class="text">the PPP Loan bears interest at a fixed rate of one percent (1.0%) per annum. Payments of principal and interest are deferred for the first six months following the Origination Date, and the PPP Loan will mature two years after the Origination Date. The guidance under the Paycheck Protection Program was later updated so that deferral of payments of principal and interest were extended to ten months after completion of the covered period of 24 weeks and maturity was extended past two years.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Loan amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAnnualPrincipalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the total principal payments made during the annual reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAnnualPrincipalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLoanOriginations1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash inflow associated with loan origination (the process when securing a mortgage for a piece of real property) or lease origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLoanOriginations1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092607330872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ltrn_BiologicalMimeticsIncMember', window );">Biological Mimetics, Inc., [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related party transactions expenses</a></td>
<td class="nump">$ 23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction', window );">Amounts owed to related parties</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ltrn_IntuitionMember', window );">Intuition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Remaining unpaid expense</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ltrn_BioNumerikMember', window );">BioNumerik [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_RelatedPartyTransactionsDetailsLineItems', window );"><strong>Related Party Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_RelatedPartyTransactionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_RelatedPartyTransactionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAmountsOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transactions with related party during the financial reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAmountsOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date within one year where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ltrn_BiologicalMimeticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ltrn_BiologicalMimeticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ltrn_IntuitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ltrn_IntuitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ltrn_BioNumerikMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ltrn_BioNumerikMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092691488264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loss Per Share of Common Shares (Details) - Schedule of diluted loss per share due to being anti-dilutive - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems', window );"><strong>Loss Per Share of Common Shares (Details) - Schedule of diluted loss per share due to being anti-dilutive [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-diluted loss share</a></td>
<td class="nump">1,161,226<span></span>
</td>
<td class="nump">3,308,360<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems', window );"><strong>Loss Per Share of Common Shares (Details) - Schedule of diluted loss per share due to being anti-dilutive [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-diluted loss share</a></td>
<td class="nump">325,618<span></span>
</td>
<td class="nump">262,003<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems', window );"><strong>Loss Per Share of Common Shares (Details) - Schedule of diluted loss per share due to being anti-dilutive [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-diluted loss share</a></td>
<td class="nump">835,608<span></span>
</td>
<td class="nump">607,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A preferred stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems', window );"><strong>Loss Per Share of Common Shares (Details) - Schedule of diluted loss per share due to being anti-dilutive [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-diluted loss share</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,438,866<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_LossPerShareofCommonSharesDetailsScheduleofdilutedlosspershareduetobeingantidilutiveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092619517272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carry forwards</a></td>
<td class="nump">$ 11,500,000<span></span>
</td>
<td class="nump">$ 6,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness', window );">Carryforwards generated</a></td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carry forwards</a></td>
<td class="nump">71,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign', window );">Credit carryforwards for federal</a></td>
<td class="nump">181,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness', window );">Carryforwards generated</a></td>
<td class="nump">$ 8,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_IncomeTaxesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_IncomeTaxesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible general business tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092610614168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of Effective tax rate differs from the statutory federal tax rate as presented<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_ScheduleOfEffectiveTaxRateDiffersFromTheStatutoryFederalTaxRateAsPresentedAbstract', window );"><strong>Schedule of Effective tax rate differs from the statutory federal tax rate as presented [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions', window );">Permanent differences</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(22.00%)<span></span>
</td>
<td class="num">(20.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_ScheduleOfEffectiveTaxRateDiffersFromTheStatutoryFederalTaxRateAsPresentedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_ScheduleOfEffectiveTaxRateDiffersFromTheStatutoryFederalTaxRateAsPresentedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092605221944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of Effect of the temporary differences that give rise to the significant portions of the deferred tax assets and liabilities - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_DeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_DeferredTaxAssetsDepreciation', window );">Depreciation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_DeferredTaxAssetsResearchAndDevelopmentCredits', window );">Research and development credits</a></td>
<td class="nump">180,889<span></span>
</td>
<td class="nump">93,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">257,941<span></span>
</td>
<td class="nump">24,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">2,417,169<span></span>
</td>
<td class="nump">1,366,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax asset</a></td>
<td class="nump">2,855,999<span></span>
</td>
<td class="nump">1,484,340<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(2,849,762)<span></span>
</td>
<td class="num">(1,484,340)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="nump">6,237<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets', window );">Fixed assets</a></td>
<td class="num">(6,237)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_DeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_DeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_DeferredTaxAssetsDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_DeferredTaxAssetsDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_DeferredTaxAssetsResearchAndDevelopmentCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_DeferredTaxAssetsResearchAndDevelopmentCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from stock-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsStockBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140092777400792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event [Member]<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jan. 20, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Stock Issued During Period, Shares, Other | shares</a></td>
<td class="nump">4,928,571<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_PublicOfferingPerShare', window );">Public offering, per share | $ / shares</a></td>
<td class="nump">$ 14.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of shares | shares</a></td>
<td class="nump">642,856<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_TotalGrossProceeds', window );">Total gross proceeds | $</a></td>
<td class="nump">$ 68,999,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ltrn_NetProceed', window );">Net proceed | $</a></td>
<td class="nump">$ 64,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_NetProceed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_NetProceed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_PublicOfferingPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Public offering, per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_PublicOfferingPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_SubsequentEventsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_SubsequentEventsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ltrn_TotalGrossProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total gross proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ltrn_TotalGrossProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ltrn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>72
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MQ$242"-9XS8-><3@?:ORM]M%&D(C=D*;[R81! GVGM!=BCY*ELE6?M%G3$C
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M&(V9T +P?<F!P*L7K:#^;\'9OU!+ P04    " #=@&I2HE=C4MH(   Y%@
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M!&6;FH?;B</X=@28@7K-M=3%$^(63-M(K.$ZQ]GG7<R[>&'8P=DX[.2#'"?
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MUOD(JU&JX2Z$%6T3>L_8S[=]%+YMC1-W(+7(FUYJ(Y,.ALAL+UU;@$L?2&$
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M():J0#0KQ 7]*KX\GS@[+/U8.HC2DGH.#9=3(% !U)%<::#MA%^C9X4F4""
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M1:381_3Z$L0'"_@D@QHPX0,?*!#O5\0+IY$;(FL1D3U==?J.UT!RV^!H G5
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M -]7%@B:7DA!]S><\_\"4$L#!!0    ( -V :E(*Z%3BZ D  &L:   9
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M.#N0X0K_1VTW_!LN"UO7-N>/:Z/A"'0#KB\M[,_]01NT/^KS^O\ 4$L#!!0
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M>)!%(2G*8;A]C4=1,V /3]_88S$-QXO%8W0F*UJL,UUI8(GZHHI$EV0SG:@
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MI((S>>KHW$U*I%H0'"A3NJ"CR$K#;TF9#AY#M1+QH(H-5&"%R%.]LO7'.5^
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M6HT%/N8$Y=:YCL[*>KW6B29S4,4A#X_R/=I\7:,)M6Z"I:9QQHV#]<R<3/]
MU8;GHZ9(>[Q[FW("Z ;I#HSL['&>@&TGOZ )[I#R?5ZP&:S+ 9OWIK.UHI16
MD#,RV%:+"-EE;G-;B&U5ZA+5SG@"YYTV%VMJW@.WF:/I< 9PZVB#0UYNB7,V
MY)#"_J1[U&JN*Q??RZP&B 7'QISS--;5:=7QEJ:=+!2@.B^@$>D4Q,)4MLI\
MJU+YP+%.7R/'".266O61:TK/H#R6B%N9;6#2=9'OQ/5P,(P82_!AB(\>FIA2
M*:7N3XHFPKVI!>>HJLC-9).*$2XC&]2#3S]D@L!&9P$_O$ZM<IA?[9@9M'/U
MC]1!^".-%DC:GAV-K*I:3<%U/ K'Z#EF<41ZHQ S@YDUI7Q 0IUP@5AG</0'
MI&&ZH &',3N)2P,6X (E3:88A8OI/)Q-A@'/'+C,: I.]66OLM(4^]?S:11.
MXH58Y@4X;P\+VKVK-\3@AB@B^@Q]/8,>*,_*PJV#URA$$QBMTWN=:S.?.I_J
MQ'WP9^933N\;I")2%L>%RRK18#9F-(CH_P<:H1A9RWVJF^ PY*SK\NA"-?>Z
M\ZVRU<-PPLZ3I&8A>OI\:*5M&<Y[-A%RY=MI,^-IY +RV/J=(7[*FPEZT@-'
MG0GIH[RVU/(Z E=W=V..!:OR''DNE4GO$(]%>UNSF]+U00$I%(W&@TYR[8[N
MK'?"(\?3/H\,(4\J61QKSZ:)Q9.&T7S/I:=1L >7@7-_]F373'LN/1B.V#.J
MO(+^6O$]B4V/_U<$&X6C26^DL5@&OJ1(9+E-J9CUA9-N&-":!8S#81P'AN@3
M1J3QY/*,M-VN-X/P:1B#VB*>M=)0WVSTCCWYI*0Z,["-P^C29+Z'&T#D;![&
MTT4/-T&+FQ^-6Q#$W]4;Q*N(%\S0W(#\Z3CUI*Y:P;64B9=_P!"JR,1'[+R3
M0+]DP+3<(06^H"('^>9C*E'SV3("J:BLER7J:-REM+4S'@3I&CU%,\,6*_2]
M6A:4RT4\-:YEW/JIVU/^-ULQ52B+TCKJ+\VYT21J^)7)F/2X=W1!).PQ11NU
MJ)4M*!]&X7B^"*=SW[TI<;1<G$*K&89Q)N1-B#J3#>@3,61.5TPPV)JZZ7$1
MF-K)QE,QM=NG^4&I,O2&"R:A9H1\;GI6*#JG;:H:\*V3;O%"E<*#HCK6D$8]
M5!=RXQ!3)E!NR6Q0FMVQN9R7(!;1.&X4.<BFR.M]Z8QNM\SW.O,JU)W,0-DT
M/IKR8[VG8I1=4::0WXWC>89(UH;-&I<\V=ML:5*[=]YW=/L-00=X:RM>4#V]
M49DJ>")F\8:/$,A<U%SG(AHRV)4F@S A.Y>?C( CQV&NU7&[ZE[SL%I0[0@P
M[6Y_TG(16JWS-,W1%FU8&V9#2&J!O<E93))ND&H XU63JS9V:+J%5C;;TRVZ
M;DSC(;?XADZZN1ZC&DM6-B6>S'VC16P0"]Q<1T 1NO!@O)6,Q*J=.$J3.4XY
M8W(&)8_-2'H8!#]S4C(:-J4DL;W)&"I]9EUQR,K/\NP&@4(L.4X08-<QGX0N
MHI@\_12CN6/@HP$F1HH-3%WM[9FC7J"DQ(?_A"NXIEA!3:AS-DLT&!EAC;I/
MGCP*@UCE<VB>+J#79FL?P=OQ'IQS%^)R/IBXG>[<2Q9-01"8U6Y,=>CZX)--
M0SL>QWA\.OEMT*07CVWWW3LOK/Y9$U'RJ-^L/F[NK#[Z;P4^U6Y"G8LI,MD0
M-=.UX!HF6HS#\6QA+X._V\B/PM$X=L_<B)O LH5;-^9?\(:P.:7A$7P'IJ<9
MH'@>QW"52'SCK[W$T$),A[-PO(C<@M&"VJ-1EZ%1C 9DS%]/J!=L\_3<%H*M
M;<\S.!Z%T73Z: 9ARCF :SJ<8\%T,([$-!J&TQ%Q,AK$8_$>Q-O!R$!$0\5C
MTZOH:,2ZE@-7RN^(-D8)0&WI_.HU*N;/-Y\2H#(E1UYT0Y4GGQ[D*Y6&WM,-
M_#4A$[B0D<B?.^-5WW)IQ^P%/U/,/ ?TL@-_(V;4G$T&BW'PDRX_B_>%4N(G
M:AF&@\GX&?0S'$QGXIF(!W"39\&O.=74*<7&' J@!^;CP6CV#(8<1'C@K1WJ
MB?_6--1 PX[%_+\QIGA+Q-^3?GYE_< 0$9F4&[SH.[J*2=O8?\%@T-)EX&&3
MAS!\%-[ &>,-J8?PC)1C@89L!*A;*TUYIN2,1@/_FBW"1TJE&41Q5V8'>HRF
M2*L(_5(G06-5QXF//F=1ATQ]#;>9H3";HPQMLE*'M#@A[259GW30)KT(9[-1
M.%O,SC+<2Q4BK\[U*'T2 .HG"Y,/@PO4+ZL#$<_$AOR&@%MC#FR>P!:_MC,
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MX+"KX1<NERIG6JP=,Y0._GP2 "I;DW0'<-4"S+X!,)W11VM"X>G69)P= TS
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M3BE(;:L,)*%6;#6-:O52L*^DN8Q)VM;1RUSABLJ/LN*C@=PB?**=726[R*E
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MC]RPL:KU#PNU!CU3?EG3[P+4SH"^5XKJ=]DX@NF7QN8_4$L#!!0    ( -V
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MAE-H?/"F#B>_N?$X1X;;%0[NPI( OB\,4MP^D(/N7P&7_P)02P,$%     @
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M?9^O0"FNE+>*EDC*LN3UI8J6O%EOK<LL>;UY2.4!G %)1,/!&,!(FGQ]3C>
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M7-*.5("OJT+1\C2*_!'G<+9K>XS0"%(V\),1WQC$H]A/>/R>4!QQ?Y"X[7[
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MM;(T5WY;T4.&VCG0_48I>S!<@.%IG/T%4$L#!!0    ( -V :E*>(.BO?P,
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M9D[BH"WL2,G4!W[Z'6J'(L.7<B;M+SI5>Z.)@])2*I[58*T@HWGU)%_K0+0
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M\K&/CZCGP^H%I&<HZ)<O/BSWQJ_EKJY;5SR_*YYO_8+/+-[]M79!5PHJ^6>
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M OT\YUP]3\SQU7W?S/X!4$L#!!0    ( -V :E*;V7?GBP@  '(B   9
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M;8Q'*A<\5P!P<S#EG4Z@S<KJ!8?J0HO"_"$_$UJ+S/Q<,@HD&0? \[D0NKE
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MH;=?\XHE8%GD(>=1"=[$&;C.DX05I6Y;W#;*2*U,4L?S.19,(H;]K+$!;VW
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MD[IS+KC[<Q^O"%/.OJ1N./BR%US@) B3S1U8D$V8)/(5+'"$$Y^ #V$"TEG
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M@L;IZY;@@# E(/]?4RI. ^6@N'F>_P=02P,$%     @ W8!J4CN54XUB P
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M!EK/%=U6/W&M>/A4V_X%4$L#!!0    ( -V :E* $,]^[0(  !P)   9
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M*31V0G:XP685I G ]RLA]&YB-FC;W_@?4$L#!!0    ( -V :E)JKT\Z<0(
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MS+JWA>AF;>WO=GOAPB7</NB2/U!+ P04    " #=@&I2EXJ[',     3 @
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M<' N>&UL4$L! A0#%     @ W8!J4MO'.(7N    *P(  !$
M ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ W8!J4IE<G",0
M!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " #=@&I2:RBYJ&<$  #_$   &               @($-"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ W8!J4GQNCHT3
M!0  (A(  !@              ("!J@P  'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    ( -V :E*2,#@$P@(  %X)   8              "
M@?,1  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " #=@&I2
M;Q#_GQP#  "X"   &               @('K%   >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @ W8!J4M(BJKEL!0  Y!L  !@
M     ("!/1@  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M -V :E)29T@?- 8  #D8   8              " @=\=  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    " #=@&I2HE=C4MH(   Y%@  &
M            @(%))   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @ W8!J4A-$4*>S!   *0H  !@              ("!62T  'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( -V :E(/.'$YPPH  ,\9
M   8              " @4(R  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    " #=@&I2"NA4XN@)  !K&@  &0              @($[/0
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( -V :E)4?$&X
M9A4  .!'   9              " @5I'  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @ W8!J4FC*8S[\$   $30  !D
M ("!]UP  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #=
M@&I2SH/<D,0$  #;"@  &0              @($J;@  >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( -V :E*%D"-82P8  )D.   9
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M970Q."YX;6Q02P$"% ,4    " #=@&I2_7)\'%4+  ":'@  &0
M    @(%PC0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M -V :E*]PMGQ:@,  *\'   9              " @?R8  !X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @ W8!J4M 2=A2& @  )@4  !D
M             ("!G9P  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    " #=@&I2GB#HKW\#  "[!P  &0              @(%:GP  >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( -V :E+"BO1^-P(
M /H%   9              " @1"C  !X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @ W8!J4D^G-7QC P  GPL  !D              ("!
M?J4  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " #=@&I2
M%'"QM]<"  #K"   &0              @($8J0  >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    ( -V :E*;V7?GBP@  '(B   9
M      " @2:L  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%
M  @ W8!J4NU'N'H "@  _30  !D              ("!Z+0  'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #=@&I2KB4T5F8$  "%%@
M&0              @($?OP  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M 0(4 Q0    ( -V :E([E5.-8@,  ",-   9              " @;S#  !X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ W8!J4J/S1MZ"
M P  K@D  !D              ("!5<<  'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6Q02P$"% ,4    " #=@&I2[2SRWJ\#  "V"0  &0
M@($.RP  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( -V
M:E* $,]^[0(  !P)   9              " @?3.  !X;"]W;W)K<VAE971S
M+W-H965T,S(N>&UL4$L! A0#%     @ W8!J4D7:-H<" P  "@L  !D
M         ("!&-(  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4
M    " #=@&I2:J]/.G$"  !%!P  &0              @(%1U0  >&PO=V]R
M:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( -V :E+9J'OIK (  ",(
M   9              " @?G7  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL
M4$L! A0#%     @ W8!J4HJ1*,MH P  %PL  !D              ("!W-H
M 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #=@&I2JL>]
M!Z4"  "L!@  &0              @(%[W@  >&PO=V]R:W-H965T<R]S:&5E
M=#,W+GAM;%!+ 0(4 Q0    ( -V :E()]#V!- (  -T)   -
M  "  5?A  !X;"]S='EL97,N>&UL4$L! A0#%     @ W8!J4I>*NQS
M$P(   L              ( !MN,  %]R96QS+RYR96QS4$L! A0#%     @
MW8!J4DG(==:2 P  %!D   \              ( !G^0  'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    ( -V :E*9/J*$? $  )86   :              "
M 5[H  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( -V
M:E*J9Q1AF $   L7   3              "  1+J  !;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@     M "T ,@P  -OK      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>96</ContextCount>
  <ElementCount>302</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>31</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Organization, Principal Activities, and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/OrganizationPrincipalActivitiesandBasisofPresentation</Role>
      <ShortName>Organization, Principal Activities, and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/Liquidity</Role>
      <ShortName>Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - New Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/NewAccountingPronouncements</Role>
      <ShortName>New Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Safe Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/SafeAgreements</Role>
      <ShortName>Safe Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Notes and Loan Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://laternpharma.com/role/NotesandLoanPayable</Role>
      <ShortName>Notes and Loan Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Loss Per Share of Common Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/LossPerShareofCommonShares</Role>
      <ShortName>Loss Per Share of Common Shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://laternpharma.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://laternpharma.com/role/ShareholdersEquity</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Loss Per Share of Common Shares (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/LossPerShareofCommonSharesTables</Role>
      <ShortName>Loss Per Share of Common Shares (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://laternpharma.com/role/LossPerShareofCommonShares</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://laternpharma.com/role/IncomeTaxes</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Organization, Principal Activities, and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/OrganizationPrincipalActivitiesandBasisofPresentationDetails</Role>
      <ShortName>Organization, Principal Activities, and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://laternpharma.com/role/OrganizationPrincipalActivitiesandBasisofPresentation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/LiquidityDetails</Role>
      <ShortName>Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://laternpharma.com/role/Liquidity</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://laternpharma.com/role/CommitmentsandContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://laternpharma.com/role/ShareholdersEquityTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Shareholders' Equity (Details) - Schedule of stock option activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/ScheduleofstockoptionactivityTable</Role>
      <ShortName>Shareholders' Equity (Details) - Schedule of stock option activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://laternpharma.com/role/ShareholdersEquityTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Shareholders' Equity (Details) - Schedule of weighted average assumptions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/ScheduleofweightedaverageassumptionsTable</Role>
      <ShortName>Shareholders' Equity (Details) - Schedule of weighted average assumptions</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://laternpharma.com/role/ShareholdersEquityTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Safe Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/SafeAgreementsDetails</Role>
      <ShortName>Safe Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://laternpharma.com/role/SafeAgreements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Notes and Loan Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://laternpharma.com/role/NotesandLoanPayableDetails</Role>
      <ShortName>Notes and Loan Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://laternpharma.com/role/NotesandLoanPayable</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://laternpharma.com/role/RelatedPartyTransactions</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Loss Per Share of Common Shares (Details) - Schedule of diluted loss per share due to being anti-dilutive</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/ScheduleofdilutedlosspershareduetobeingantidilutiveTable</Role>
      <ShortName>Loss Per Share of Common Shares (Details) - Schedule of diluted loss per share due to being anti-dilutive</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://laternpharma.com/role/LossPerShareofCommonSharesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://laternpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Income Taxes (Details) - Schedule of Effective tax rate differs from the statutory federal tax rate as presented</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/ScheduleofEffectivetaxratediffersfromthestatutoryfederaltaxrateaspresentedTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of Effective tax rate differs from the statutory federal tax rate as presented</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://laternpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Income Taxes (Details) - Schedule of Effect of the temporary differences that give rise to the significant portions of the deferred tax assets and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/ScheduleofEffectofthetemporarydifferencesthatgiverisetothesignificantportionsofthedeferredtaxassetsandliabilitiesTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of Effect of the temporary differences that give rise to the significant portions of the deferred tax assets and liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://laternpharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ltrn-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://laternpharma.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://laternpharma.com/role/SubsequentEvents</ParentRole>
      <Position>37</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ltrn-20201231.xml</File>
    <File>ltrn-20201231.xsd</File>
    <File>ltrn-20201231_cal.xml</File>
    <File>ltrn-20201231_def.xml</File>
    <File>ltrn-20201231_lab.xml</File>
    <File>ltrn-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>77
<FILENAME>0001213900-21-014576-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-21-014576-xbrl.zip
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M4/;D6Q%)/PR^VJ+JT[]# !(]0=>!/_TD93<CZ?:(>M(&44]3&P:+7+K.TQ5
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MH9;HHCQ8F=QW!FGNLP@!?QX)6[R3-HG "76][R3IN N;!10F&$V&"%H7?31
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MLOEY.D#D.0*4D=\L*1PZT@4+"84 MW<7XF27?$TA,V(I@@\4G88FKYHOT;E
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M-_"-",^B;64\!2^=DKU-175SA:!!,8BQ<PH#2ZEK;"G\OI2\R-3)/UI]F"<
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M2GK(::VY5%7#^<A>_3*=:U!KAE*&IZ3%=''WY2S;S#1;_XC2VJEO.RN$S"]
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MQBD<?I<?%5!("7C9NP9<\(6P>+]DO22) RG3M@ 6]E 7O2)X)Q2XN+/("SG
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MZS@'<H%S  _8 HS;+8O8'\?7>(@&Y"*KIP/;0WW.9D)R=6JB&R_\/YT;T)P
MR2WE4^"9%'^<SH WIN=SVCI< \HG9@G,H&#,W+2X/QK2Q*@2%=]#F-WBF@E^
MMB5%=Z];<SJWW9[6O!/!'0]N0AZ9!1Z\4$K !*Y,\L%9%C:DX*C6[8>^?.CB
M@^P'%@7'"!<(.TK;B>H+/T9(VG# 7AB^M>HH1U/+"D4$_^[QKT;GD]0J!Y/A
M'D>*#I&K%>)VE > DO0E/I#0R$NA,F/IX@/2*0[#4!B]@O]@ ([$O<112(M
M;H"RURT*$U5X=1DO&S\':-5W R3QJ[  :.6*PT9:QAD4/[X[+?8R]N5D)%E0
MN;0*ADR)INM0F0F44AJ$",,?(4^2H8?1*!%YJ#-;!8ER I[L^9<&B4KV,)-#
M.!H-B@@NFCN;;!2&>7!65+ 2IO*T4G[VB=+><+IT.:D:>"HYG 5'8RBSMG3&
MTQ*&%@M^,2FG-1%Q8\#PH:'PP7'P<S!PT7%(Z95B$?NL&TQ<!96(?DDDE^2]
M7Z)*XAFR9_$[A][7NNNO?@"H\?AM1(/3.(JB@)..(A:CT&H4>3D-C@3*B/ >
M+?RMK_-K0P#.S+  0QH@[!YS'TR#"9SRR70LYX[^\!6H\4T#"+JTC8XJKD0
M,H!PT/T;!H/O'4M@?@G)8-B4 Q6/)>Y=I=&/DL.'N$A<PLUBD(>G02D =@(D
M(7Z]H\/D/&8F2LT#"B :YB@".@F',Z(B6@+>P21A18]CQ?RUI::L6(P2TJ%-
M0%ER]!CQ&E22%7"0B6B4T84AKEIR>CO*-$4<ASQK\T.1:6D>\D\+-$CQ@^D$
M'BP9D/^=?@=K!; 0T!6$<K/R?+;PE ]R/"OZ<S*,A8D?KH,AL_@XT-:*B(,<
M81 J/C>$"T;HWD9.BRP5TYZ[.FI+@XP=[AMH$'-NBJ@Z;!>LGZ[YP&?SP<0N
M5 748S CHQ+@_-R \G^2341WE[9SQ<76N#?9'&05_$@?+S2=.8S/TW: A)@A
M)H\2W+H\.P7^/'4#6YEZ.F!C?7%KJL4+0\K@.V<TU44TU16?2L6[:/2610#F
MW$1OR''I^H3.)MW/D[&C$S63#TY,8>J@>*7'GF14F?HE?U93IY;(>#\1)W?!
MM6%@$]R7MSNFB)! \A3JAL$=JB6_"^*[*N(CD<80"A$_3.S$D1,!?J(EF=K0
MN .7N$L*$VY*+I-0F#P8GL[)M#BJG/>IG.MY4%K? &>X)@"\>]U= -H(Z$5S
MJ+L21SO^=.K*H"I%4#=$0"Q.8IDYP$:8*D:"=GCTEK![L/O "U>?@0RY M-%
M AVK %+3NJ]3@%H2KR_7QX"J"%#?!PL**#!77]+B8%BF^R*);B:B]5Y'^0J'
MZ2MLIZL_L))SR@^HR'D :L4!)5)NF.$R'S836<(/-)P)U'<\'X<0=7B.53&4
M'&N2#_R?S&:(H<\<C&!9R0E0MTB;AW^[I\09&,OAZ6I'SJ.-:<KF,D;:<&;B
M;\6ZHTAO2#/4A M),T^"' TLHJBP&^^U'-.^UDRH>43*E,BG2JJ0.\$\9 P2
MH2>97%^)>& 16)2ON!312H_P5QCW02=.@@'1IB1#/A(42H$)34NB"2[L B'E
MZ</2><K11>QHK.$^I+V@@J]>"*ZB=R&/^#>H&ODKI7&"05$*_<\8884 "U14
M-JT"O)A>TJ5Z)KFG==;.G33P\Z3?[7Z==9:91UG6F3P/V ]'&L%DWAGE1Y5'
MR89)W_9G9-=SZ9TD/=W"*3.ALBO4WT(A3NU94F6*?2RE<U3&;7&0<DG6$B37
MH:.VHP[K)]&3>;"JP_239*.8RB5H=<2DC)K3;8C*.$7UCD3E0G<Q+<2[9BXE
M3;V4&(@&=N$+MC&YQKSV>[(I<[2DF+?.T[\:' GYI'N K"RD'P.@E#$'SAGF
M/KOA*X89/CU$ VLSGW]4I$L(DR;GZ/.@AQ?>WSR*-TV*SA\U9=]-P$_R]Q-W
M,20B E8P'3 ##QIVP(NR APU1;< $AROL?D</"U5,>=X1:G&=TU+!V$J0D F
M*CPKE-(5)OH3<3R3Q$1.TS.6 !$+OMEPZ<V6>*; *>:/N4)<\T@)W?QZ+(0I
MF.8:7L("D2X!$PPPY?- 7%S3I'P9W&5&..V;QS-</6P.)72!M3&"$$"C#TL;
M2OA:,"G:M9A1E?NGYN\>D9'9PLA?I,1V?<'O56\!H\;485[FC*>G4Z1<QVP7
MNBR\9_B&)2*2/8%>AOG#18:3\"L['P,',5JD@'(\14>Y#O?66DDC1)N9D"Z:
M_AZ6IMQB?@Y[$N.2H,SR)0R7$#WUH:PR>4-" >1+#&/_'PL/_79*>==7%O6*
M?DM%L+9;QENN!-7#<LJ-JNM=7))ZE,/TJF+3.;6BD^LU*#X@9[.X:==)DI:$
MEU#.C\.6KG[-<I!7FGSK<O :JKL?GH>'J._>Z +O?PO@4E$KL'[)\@85+._W
MANI(&]=<VIY+NS>(3[T1WG[U=\FG Q;>O)'!^%HU'P]2_73<!Z'M5@CMMLM;
M'JB$]8DZF&Q<Q;J1C35R_>P*6QF]3DV]3-S 4JUE@-<SM<\7A?7F2 G+\49V
M^_E$OS$V]]0!B/MX--H7NW=K&.IX%-GS.:C<X1HLJ1YD/2F!\929$]Q:;&="
M4C1%2D8T51MI:J^WIHP,=G,@:_"Y1$ :SNJ^VN^.U?YH3<]O4U:'AS%5'3KW
MMK$P+%_8$2_]#0HQ3^V9"-H>O/7=#N-E;:"D#9BU<M &S-J 61LP:W @J V8
MM0&S-F#6!LS:@-G+C^2T ;,V8-8&S!H1Q6D#9F\L8);73FVMZ%<R/W=J^V:8
M2G83Y:Q=B+PTC(R=Q4_=LC.E'S3G5C\<%S<0$!Y/0;U#\!G 98A7O!5BLRG7
M^^#!I%N85%[. _ 'P!UX'3S(%J (Y>!BL;2<%6-2"\ "?@ D!T2^?7[LG1F]
M0H&HSPQ [0#:7P$S^H6245H?]<G[:)O6O]_Y;L#>_9%^>;07RHN?YJQ5V160
M'@"]5W',:W5YHE5K@%T NFQ]U?M><:U.+MRB 80 !+'3%5_:AK-@/_2GEU?;
M0]/P?0&2KP#]C7[$<A6XXIT$E=?7GWB='^5H9L)O7:G.&+X*#7S'72ES-J.'
MIM&G>=4$#R/CT=L"J7X/XK9=9_+7NV_D4?<ZG)5\P>U>2#7J_DE9]_JDUN5(
M=/M;&"]XTU=0.^!A>P65.DA4X#+44['F"C76EFY<FG3?4A'SKD72;UN[B7KU
MK$F$-?9W\02 "4P5/COF]AF+_*QS 7602YF-KV.R\MBT^Z8/&Z_M]R*).HQF
M+94Z;*$H*A8CJ,/GN&M=>AYH;WJ]K6U.Q?H.M< *Z+29].U;IVUVO7PHIF\R
MQ#:NTU_A>C>5N7VHO!]8"?ICTRTK?AI!?.$%95?V7OA]-_XYWH'=&N4WRY3J
M-/%#!GV*NE\FBAPFNCSH'E:O,PW3XA&>'^Q)%Y4\I-(46/$!Z.:%R'Q1U8L:
M%STP.\ %F%C70_2OA#^$'IKCDI.&<2=PT9I7LI!JPX/O*"J*B&*=1SY;+!T7
M2]-):)P7Q\"^"""87L0;K$V()3JQ8*#H^1#UJ8FJ8>,<.N^3AZP+VT!B*H\I
MQ]AN&<"P8C8U/J2V[2SOW035UG'_J[/XU\PKKI^$_[PHSHO8B3:\^6K"FV2L
MFQ_=W..I.,]J_\V]Z^K]V0SK;^RX')RX32)U^PE7Q^<1P>1'92*?Q7.&Y?1-
M"KN4B_]^PM7O:Q%1$8JMR+A]D>\FML*88;<B5K6EIQ)[">V4RO7W@G8#B@$J
MT%Q+]1TFF#WNJN-QA45Z%6\I)GU5JQ++YR:$'CSB4RJKE.ITS-L#8K%L9GOY
M^G@3Y;+3O>L-3]3)8/OO8)HGI;V!.IH,&R&E6U"8*0A;(IO?F!_69J>&T!YV
MGG;=U=QQ'W5W5O'X<AONU$M[A**=J-IH,U?B4&]^7C+'-;6/71('F_F_K^(Z
MH0+@I]V^YNM:=3P<JI/)GM'/@5:KJ8/Q0.U7"?#S)+6]:VWO6O>QWB8KQ_J@
MYPOSO(_*0XUTE"T8WQ=K>3^ GAY,U)-1A?.VMNG]O65S(O>KGH%X-IOW&[U)
MNAC9J\G&HY01J*:3MV$P*N*I+SXZ\U+WI04N!P<N6]!_"0]-RL5X ;Y+*X '
M%\!F(>?/YA/UX\R]77[;H<$/-0!#,Z#RR^7QWDHM'>JF,[=T3#Z 7O/\U2E&
MLX-2-!77VL^I0+.F,!RPR$_+UQK1R\:E-Y_SC&1=N3<]>O9YY,S#W.1'QOO6
MQ3G*GHG=!?%_J$2)BA^Y99;)L"D=-5E>."X[MLQ?S%H=8R_G8VRF1UF^NF65
MY? ^FO!W9!-^X98I+H-E_,/[8F?;%R<ZT/^X9RZ;P\1J1'+4'EE7Y@$,G!,&
M4[ %8^ FB2$*.$65G>W#N>SL[6*B+?JWJR_Q/[&U>N+ND9H8AKG=)B^$P"G!
MINE+Q^.-&_5T2^C.4%D RVA)0-+[4?P+%=M"+GF9 FO%6VX#$:EYXUU=NB86
MN7:HQ3Q.=I2:K=_1HLD,ZCO)GI8F=B %*Z'X()"P8R"&6*<",]Y[W?Z0.F+B
M7@8>FU730-^"V8$*V@/B-9#R?MP91'//'!I13([+QF:).*2)#17YJ-BUG<U-
MV_1I\7_#!RW/X5O%$^>!CCR>GO VV[K/*:CH72X&]3([,^;#P/AN4?H.[B]/
MX<F1!9H\%(A0!&ANCX6)/YS=G!$QSP<=Y3Q^8&# Z;O#PZK$C=Z!T@?3D]/I
M+S%+UX:9OO-W!S#WF3,3#>[U!]VTN"NW"K^0V_0^N[.\1WEI^E+J&PM]A>?^
MR MN_XL/!U KV78 I%GFPO1%<T]P$;#_+>,-M/OC7N%"<!F*?J>;MD<<ISQ_
M<<#"NAN!'X  \7:O*BR=MU;E(@YT8 ]/T>63:. -7V%X'\D*?&#,/URK8)=2
M;*.:6%+SWF9<P'+HA01U9T4)=MG_ A.U'_8:95Q-PNXOF(Y%9%12I'<V*&+1
MZY7*R^ _L$N[ 1@1^"NK+4G"?/T7LU'+ M=,5_Z0RX#OMI<\4,!^.DZPARO4
M^RCF-*+CF7SOD0+\B.&$O5FY8<DW$"3"+G:7I9:N$KG1B-39%BT]-V;8]!6$
MB(&\X%1+!J3PWKQA<U^=>OZN8 '8:AI%-%X5<A7-)J@[59':!$=57O*XI-*1
MYV+'R3T2]-HLP9[D>4N4;$C:'B"#5)UCB*=#PF8#-R.[S54G[_RK$D'8W0#_
M'1T]LC]1!V-ZS_.D+TR;BSL_(=C>=Q46O8&-F"%/;IFA!Q[O39LZ(5E#R43-
M'&Z!.!$.IH[1UX$$8#0():@,:K^ *B% S2':/E]^O\&E_!$]B0(ZJ5MNX-\[
MO*Q2_AF,BS&554Y*544+0USPX2DAA*MP+=B7^TP^^><P)AQ'HZSA>5_N=YZL
ME'4\Q$)9PVXWV>1\_?EWNX)!LF-[>@6CK2R@E'[XX8QL2>++?Q*JL#X%(/K8
MX'KS3>AK54NH14'5-CQ[&9-A<AT_;_ X3.W9%P=<^+\"U_1FII%?51#7.1YL
M:YW*QA*7('G#/>N^.SW1-I6Y! 'IPH(U&?(9O! PQYN3#_!QDXT0\YZF^2\5
MC T+ET4:[SLL]SM#8PI:FI3TP7LF[?(99?MVKWV[5S^"U98F:TN3O9;Z6YL_
M]GKUK&E+DZV1X[OI=7%;FJP9>4%M:;)&YF.TI<E>5Q+,6UMO\Y)^XN^UI<FV
M893?+%/6:<BS=GPE&=NL\_VI_YG[0C>A*Y3X<!QU6@8NVZ1%0^_=:;?3D[J+
M;(&J;%!PUTNMU9NA.4L]!PDRPMO-;6Q@=\U5Q02DHYY;)+_NIAP_E_ZU%W!&
M%^67=B;4&N'E:90SLHT-@A7V>NNM< T2-Y/!;?%@C5WN=0_.@S,@W;0#T[X3
MMP+/.(/9OD0[H:"$P544Q+8JPT*\]8AS]MMK@+:88EM,L;V0>5T7,FTQQ;:8
MXEZ):XLI;N6"K2VFN$O&M,44VV**-2WPWE;:%E-LBRDV7TK;8HIM,<6VF&(#
M.=X64VR+*;;%%-MBBLW,EGAKZVVR<FR+*6[7\K;%%-MBBFTQQ;=@,-IBBLW<
MEQ:X'!RX;$'_M<446P%\+<BY+:98C./:8HIM,<7-;$5;3+'!1?]:ONZ&K\7%
M%/,>9*R5Y,K?8EB^:V<K;L@),6L5]L@FY#Y_DI*:.]UWI\-N[U]_5$]0MMHP
M30*X=1XG29R)NG//J&O2'8\G1<253EK.N(WI+>?DI*\5\[**W&)JL="4^-W%
M$U[KLS/I>A_&^\1L-H=1* /@$R8 R!_8G/^]X<EDH!4MZ)EDE<G3#E=<OH.]
MP6@RW-F"A;W>I-#1,S9QH)UHH\E&U8TR3V.V1''Y)FC]T:@[V*P>4S7%?[K.
MQN6]D)WCX7 R*6,G35!5O:N2B@H6#<:#?BF+:E%1]E!G?<8,)B>C7@E)^6]N
MMDC@<WFV 8$(FC=FV0@\N1)R8.P:.J."@@Q/,@"C8'0)]OSI.#,LM0PJ[M+V
M=?O.!!C$9]_!XNM-7+(SSZ>\DFFE.R+-OZYXY*._+<Q4+0;)9U_!K<?^%P!
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MOB //FA[_IB=[=-?%M"021,L!:! PI8+ Q?9I?[I7'U*QL.&8@7\9%(#.3F
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M--3&="KC4D%CUP.0W(O6B^WE<K$'J\4/ .4&UHH])IM?+A0[X3I156Z'BT2
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MWUE9%YU16I.)0X-TY?4@6C!%D4WE1YD2Z/6](K?\#;$8M^55PZT.#-$MRP)
M]OEL0ER1GEVK98NGJ+-R2K)'9MZI$^L<P6\[''O1\Y>.-0MQFJ(IZ",33!?F
M  -=>R/"SWPN[_ .<@;!E0I5T_LIR'5#@!H[?2[G9Z_'8!2U1L3Z"K.31]14
M Y^&'(^K9H*581L78W(R/85IQ98_/ ,V5>!:,FP=JG*G\V41:$MMJ$\QMX,-
MCFO?DYNP\J=M/OGC/N%KA^'!KNXZ"9]-:V3*F6VLK=0V2K2$Z'!J+8(3Z723
M, ?_=[6I44]#OFT] .*#7(9=ND&:"S0555@O/H-2Z_BJ6*6Y9_77%S#MYI35
MAQ*F)&NL2YS/K$">706?7!UTR5Q?5EQLHSPR:>5-D(MYC7&KP ^C-L0_I-^M
MIN_SS1<07U)EBP60*CCFYI5ZSOEBT9S[#W'>5376SQRZ>Q)6>$'YA?>@;>]X
M!#6YY?<5;6FSKJ>-;@6WEN@KZBJHZ5#P6YQNV(P>AMZLOR NT]*JKP!6Q].>
M3TEM5WV.)BODF,^KGBERS)QA:9,))Q8-%5H[';E8$V\V6V^&7?HLT0T1!'-K
MU'+M-GDD#E/;96<J4[J)9.Q+:6_68R7^X4/T+,S^)69IUSXE+AF 6!6B9Z;Q
MOY'1UM54'Q:O<VEAY4;[]94QS)?K"*_0^+T9-?2S7^I2Q,KY2#Y [89 JG2%
MB-1#,SCQ/>-?Y888GE /.]4= 5,X=?1\(EYX=*"ZJL0PZH?A'@,U5<(V.@I1
MX?,'.6"-&;]5[M^LW'CQ!/2F%,HJTBHTV#P1MW::N)T,.(.P#_Y)Z(Q?D.<]
M4K"FR^?CU0U+'>S!'U?4DI':AC1[IM$I"U7/F6N3"1,@P+[PW4J/4!FH^H-0
M15?'5FY *@M9RV.Q@ H-/*N -4U"80<.4[05[I!IH/J8 0*+&UA!NS[I@*/(
M4'V8SIG+IR^<,L]%99@16Z[K8V=0[>$_!M*@RD?J$.$![O,9#*KR1&('TTU$
MIL^EE@:PWN7RDS?1T:LJN6%II 8^U8X_L?-V^R* +ZQ5$I&>IX_8]0< 1FU6
M+PX%MHFP.)UD<U_Z@?T9=2G&J VO.+-]RSN3YPYLB%\J?18U"[9HAS5OUZ=R
M44@!TJ?H6*&HHP1&;7@5O1798]&;+I5Y'4D+33^2Q%ZZV-SPOO;IPWQ4)5]#
M5>F+*'.A7LM[QFAP@^^<YN#6.J$Z AT=?W^)(_MK1B+Y>+6K-@<+L7B7[IK?
MR(WPX&SN]:!++)A29"[[##L.L4_GD=N'!;_]@>0U\9?JK1>,1R^:R5B(/Q*[
M,N-0*9CFLS#]XD-/?<V9G![AXTI$<QM1I.#$F[@A8TS=UB/,7A(CV/O"]^1]
M-5)0%9RA%,P59MLJK4*,Z(ROXRQ>DHU$5*;S:J$9AJ7$>%>9_I<#2Z^#%OPW
M63RE,9=Y<ZVJ*PD]2NTAO[PJ55H^F/&9LF'57*OKEN=:/9:;GL^9:ETWN(ZC
MU/E:P0]35*X[E<+[1&4KU,5*(S5TMNQ/$E2.31U$4]_+UJD0;R9PAE V_V;M
MRM%EQ&D^(Y%;L4+$%2(T7&3B]QUJ1:O[Z/!P!5[OT  SS<\79R,RIA9@^DCB
M;S>';X#;3"YC7I:9+":# J>4!=<>?ZT,_@PD;4"[+-E1=[];!(2#WA54)1>@
M:02 J@X;JL)T3*"6@*&R2HIIT1F\[?Q6[5A51HTD'OW=6YZO[M.O#.XT(I,C
M774:]7IED,?1Z \-=QIOWU0)\@*-/L$>I. J SJ)QW P;428V^I<=@E_I!:I
MC@)::(:HD/G>:$J$%VWV7[I!4Z0R6A5"- R>IE\KJ=#-PF502G]4/PT2_"J
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MD--1FZL,_#SULB'#:6H;O&MHCYU7_X=NO2:CLSZ_@%:"6UE5<!@8V#=??K;
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M+ [^7[+X_P>'!_=)LOSYZ.CQ\?%;C_V&>@'!-$Z)ARG_BX/#0S9@,>0IP7S
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M:(X1I>E"$*>&_+<-:'.=K8GZ09@RFB'3Q25;-%S]_!0G\1UF2YVYA('X0?"
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M#(K9I'B)SQ@_X# 6#:'R].;<\H.$+MK)#DAZ2BA"=0*0%-S!KSXUP@.RF&I
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M!2WO@C(E,7^@:T)N,'D(/*L-N6K''I[[)X>I]4;,4!J\WV).B"K;-!V1U!"
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M4#FWP*J0"MAG!XOTCN+/*3O9GCUL];#0[Q-1/Y9>D*-U$,.7(.J'U>ABT31
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MW)-OU2,;@2M"0V(+D-@-S74]>:F&Y%5&%N2;]ECKU.0.QULE@1ME(^-IT&-
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MK:5Q%FUQDOKN)#I. PSS,?K>, K$]0)[5%Q#G**H6 0%9!7DPC*H6,?J1>8
MT6AZ3GID&U&FR0^GY-]^VM@M_[!.LL0/<3+)K;PF)!9\>!TX125_ZU/0ALXA
M!^>\9+F72$C%69U4@Z*]RA_1;4JH34Z+*[+@)-GKVK#,6&$W !56O80+B1XZ
MVU94:YBH:.KN-@4G5^ 748S]S407'KT@L"[94O!$>II.8-);JFM:<YB9)W9#
M6WHRH*&IZT32?!>VRNX#WRWZ1JUP3/.UFG(I?!W(G6JXU00?"N'30!A<]OHZ
MJ+KC6DT(EC.A]BY0B.J \_DC/#0\)[;KEFC!24S)O1V,FXC-_45E:]F#T7(8
M=<AKE1YL.N%\%M45!@?% 2)Q"B"%:=X[WD]^9;H'?II"/F3;F4^GE$ CBA22
M/S%Y^4BFQJGCA_L1:1M2H\#%1EOM#KRU<R79479*=-4&)ZN(J+"7._R<GI!Y
MDXA3QXY6TCYD$ ES/_*4\4+A(R@ :_G63HV;/%-&@KONJV=H5T-@?R"F^QE^
MQ$&T@PON/+C(-IKFJJU[6PM"I@"6\*:#S:0JK#;7^I6:,GN;5VEJ=-"5NE,G
M@;7A/]#S\M$)X/6- ;VFMK&% U,%+F' +6%B1W^H3;<:<NO%XL89JDP*G9?Z
MJQC#1621ST VHK<L^7T><Q2E<BARY#36-?JV4P- D0/(5D+%4E3V6 /H?#7$
MEK-:*$:?SY6OJ$DRO5?"D!FWRF+H(I?>12OGQ7W [J^K.$HQS5D@/VUB9]M/
M+'LO:KPR35\(97F%Q3J0VE*LA*JE4+Z63;G4Y7(IE%KTTCVG+T,WVN([Y]G
MT2S<RWBL0P2)\"$,#$=DO-TT@RYF-<L=2% <6N^Z51B4%?,E^O.2NL?^(Z8U
M\Z=S+W3 ,/XPNC^,LGYLA^U^;+:#)P.$H;O8;#>A]"^@5K$?Q>SQUPUVH<R8
MO_9=5N/6^R5C=4(F?G/3&P8;&:E]@11W/VK,M>PTZ[*_^?A+@S+ZA4JR^P3_
MEH&/_@C/M3%TO)Y$L7(W,JXZ>5"(E&,Y%M'!Z"<V_!]6B_#+^-70?4),!V2=
M/N)X$001JW9$I6\Z@1%O9B&\)P1&U B:C#\L)R VHRU EM14)Q\;N:12U+7]
M@]5R.M&I%C?O 11;BTS^U7(6>J1%_X:-WT!"PZBG_N:)'UUG6W*0_;HB=MC6
M<7&6DH,LX/%=$(3H6,)TX40Y. *.5Y-0<Y95.>C!H3* H("^YC7ERDDA5#N=
M1FAN8,7@K4,@BH^R,=QSPH8UR^-*PU1MX:09P%P=?_?['FJA/MYH*+RVL2B:
MN#HD0W@<-!XO;!.U"@7NX:%9!??B] %O00-POUQ1"=S6+,,Y:RT 1$\>+U Y
MT+KI)B=X5?B6BYON"4[$Y.BHWW=9CC?]718;2[[+HZ.9?)?[1*U_EPT\]+[+
M\X_OH<9U#\8U9QB_R6EL+VJJ]1'101P6FN8@E[XE#]O(Z+4.<=(''(6+U67>
MMKJ/CA5.-MPZ1 "&V/R!X8B,1\6$>2C>+F94%[\RC#63Q&^C+'UX@O)B>6X-
ME!/QTRS%/22B<Q'#AW 7/**87#$-E6E3Y43[_I0JITIQ4:+"@$NU50POCM*7
MV^S^%^RF=U'U# >*%T_H;REM;#Y;2@DN44RO?+Q%Q\XBC-.+P7LEYA0)H9,K
ME?=@[:&?FC.,6R"-[87\9Q5\K*L9+G5+G=)&1<O^./&C(-K0\(Z_Q:GO)I>A
MVR]T)YQO^*R1@"*.V>4S4#'E@!PT[E<'MF,SJKRI!^VDR.OZAI=AFOFB&R"!
M3.S/,1V_W=M?7)Z6C9J'[2D@=,E@'E(Z.KN*[FH%Z&VX_?N[=T?@[3N/(C)S
MHNQ# @'E-7#]=?5?L]A//-^=]N*V:TOS?22D\$@?[=O6 #W9V.P(T8VV?BI
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M4;7T :VP0E>'+ZN^?NWSVS_JC.<SC"4R50[$*!37RGP9L'._PVF<G8Q9BJ.
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MZR!K?HP+UMOZ"Q_(D\2"2U7Z-F'@K:I%J1F-D#+!&IE;-F3O+DJ=@ 8B.A/
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M4Z*(&=\H2PXWCK/;:W98]#@,O6M"!/8/87L(-A/E4VVQ1!V1.D_ZHF\@#E2
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M9$T?275-*7616_9#_CYF/W%G#O:"T,,4XFLA'%MT;8'B*MV!UV(T+7)C/3>
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MEP:S=6_.MSC>$.7W/HZ>T@? TPF[*GP4<Q";A/)9UNN?<7'9/W,[T383M*Y
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MXJ!&%T,C/=N[AP"@A6*U!MF-=*?@=\_P4\B&O-BF)VK5'(+L.$:#4G6TNB1
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M#>,Q'$:AR35LVXGSCT.5ZY"V_<B$D4G.T!:YT'='I<PYIK^:96F8];V@8;_
MNA ,B_XX8[/<2V-06JTXA=&%N,QHN*H"Z'P_Q,+%AQMW?/0PI1O&#Q>-&\(
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M35=(L->8(._,CJ(;<IY"'7=U7$$_'PA4]6HS@T^*@R/J>)B&I.9I/3UZ)\>
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MNYM'R#A;7-U!LD4.E/&A:K\\!AM=/W-M]P92N88X#!Z?( W25OM7/F6GX3"
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M$C579.L!T@ Y)K15A0T;&BS@8.23 Q2D:SGP5>*9_3!E_T9!CM_DP'<>4B8
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M.YZIZ*)))5XM$4M7>%GF^3E<XPJ/AK/B2,HBDA> KE."+ Q):N,EH@[P?H>
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M<FXM,C R,#$R,S$N>'-D4$L! A0#%     @ W8!J4OZ800C.!P  )T8  !4
M             ( !E)L  &QT<FXM,C R,#$R,S%?8V%L+GAM;%!+ 0(4 Q0
M   ( -V :E+8 ;!EF#   $+: @ 5              "  96C  !L=')N+3(P
M,C Q,C,Q7V1E9BYX;6Q02P$"% ,4    " #=@&I2K<?(V"]N  #%@04 %0
M            @ %@U   ;'1R;BTR,#(P,3(S,5]L86(N>&UL4$L! A0#%
M  @ X(!J4JW6T*;J,   U/\" !4              ( !PD(! &QT<FXM,C R
C,#$R,S%?<')E+GAM;%!+!08     !@ & (H!  #?<P$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
